sid,nct_id,inclusion_exclusion,criteria_sentences,classification_result,caption,cui,term,negated,uncertain,temporal_constraint,measurement_constraint,dose_constraint
1,NCT00034840,Inclusion,mild-to-moderate hypertension defined as a baseline mean seated dbp of greater than or equal to 95 mm hg and less than or equal to 109 mm hg and a baseline 24 - hour abpm mean dbp of greater than or equal to 85 mm hg .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00034840,Inclusion,mild-to-moderate hypertension defined as a baseline mean seated dbp of greater than or equal to 95 mm hg and less than or equal to 109 mm hg and a baseline 24 - hour abpm mean dbp of greater than or equal to 85 mm hg .,Observation,Observation,C1305849,dbp,FALSE,FALSE,equal 24 hour,greater_equal 95 mm hg; lower_equal 109 mm hg,NA
1,NCT00034840,Inclusion,mild-to-moderate hypertension defined as a baseline mean seated dbp of greater than or equal to 95 mm hg and less than or equal to 109 mm hg and a baseline 24 - hour abpm mean dbp of greater than or equal to 85 mm hg .,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 85 mm hg,NA
1,NCT00034840,Inclusion,mild-to-moderate hypertension defined as a baseline mean seated dbp of greater than or equal to 95 mm hg and less than or equal to 109 mm hg and a baseline 24 - hour abpm mean dbp of greater than or equal to 85 mm hg .,Observation,Other,C1547225,mild,FALSE,FALSE,NA,NA,NA
1,NCT00034840,Inclusion,mild-to-moderate hypertension defined as a baseline mean seated dbp of greater than or equal to 95 mm hg and less than or equal to 109 mm hg and a baseline 24 - hour abpm mean dbp of greater than or equal to 85 mm hg .,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
2,NCT00034840,Exclusion,pre-menopausal women ( last menstruation = 1 year prior to signing informed consent ) who :,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
2,NCT00034840,Exclusion,pre-menopausal women ( last menstruation = 1 year prior to signing informed consent ) who :,Condition Occurrence,Condition,C1096235,pre-menopausal,FALSE,FALSE,NA,NA,NA
2,NCT00034840,Exclusion,pre-menopausal women ( last menstruation = 1 year prior to signing informed consent ) who :,Condition Occurrence,Condition,C0025344;C2129647,menstruation,FALSE,FALSE,equal 1 year,NA,NA
3,NCT00034840,Exclusion,are not surgically sterile .,Other,NA,NA,NA,NA,NA,NA,NA,NA
4,NCT00034840,Exclusion,are nursing .,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
5,NCT00034840,Exclusion,are of child-bearing potential and are not practicing acceptable methods of birth control ; or do not plan to continue practicing an acceptable method throughout the study,Observation,Observation,C3831118,child-bearing potential,FALSE,FALSE,NA,NA,NA
5,NCT00034840,Exclusion,are of child-bearing potential and are not practicing acceptable methods of birth control ; or do not plan to continue practicing an acceptable method throughout the study,Observation,Other,C0025663,methods,TRUE,FALSE,NA,NA,NA
5,NCT00034840,Exclusion,are of child-bearing potential and are not practicing acceptable methods of birth control ; or do not plan to continue practicing an acceptable method throughout the study,Observation,Other,C0700589;C2703065,birth control,TRUE,FALSE,NA,NA,NA
5,NCT00034840,Exclusion,are of child-bearing potential and are not practicing acceptable methods of birth control ; or do not plan to continue practicing an acceptable method throughout the study,Observation,Other,C2827714;C0871511;C2828387,method,FALSE,FALSE,NA,NA,NA
6,NCT00034840,Exclusion,acceptable methods of birth control include iud contraceptives ; oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Drug,C1706306,iud,FALSE,FALSE,NA,NA,NA
6,NCT00034840,Exclusion,acceptable methods of birth control include iud contraceptives ; oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Drug,C0086466;C1272936,injectable,FALSE,FALSE,NA,NA,NA
6,NCT00034840,Exclusion,acceptable methods of birth control include iud contraceptives ; oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Other,C0025663,methods,FALSE,FALSE,NA,NA,NA
6,NCT00034840,Exclusion,acceptable methods of birth control include iud contraceptives ; oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Other,C0700589;C2703065,birth control,FALSE,FALSE,NA,NA,NA
6,NCT00034840,Exclusion,acceptable methods of birth control include iud contraceptives ; oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Other,C0009905;C0274536;C0481121;C1548892,oral contraceptives,FALSE,FALSE,NA,NA,NA
7,NCT00034840,Exclusion,no exceptions will be made .,Other,NA,NA,NA,NA,NA,NA,NA,NA
8,NCT00034840,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 m .,Drug Exposure,Condition,C0555008,night shift workers,FALSE,FALSE,NA,NA,NA
8,NCT00034840,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 m .,Drug Exposure,Drug,C1654656,daytime,FALSE,FALSE,NA,equal 4,equal 00 m
8,NCT00034840,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 m .,Drug Exposure,Other,C0037313;C0723362,sleep,FALSE,FALSE,NA,NA,NA
9,NCT00034840,Exclusion,mean sitting sbp = 180 mm hg or mean sitting dbp = 110 mm hg during any visit of the placebo run-in period .,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
9,NCT00034840,Exclusion,mean sitting sbp = 180 mm hg or mean sitting dbp = 110 mm hg during any visit of the placebo run-in period .,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
9,NCT00034840,Exclusion,mean sitting sbp = 180 mm hg or mean sitting dbp = 110 mm hg during any visit of the placebo run-in period .,Observation,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,NA
9,NCT00034840,Exclusion,mean sitting sbp = 180 mm hg or mean sitting dbp = 110 mm hg during any visit of the placebo run-in period .,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,equal 180 mm hg,NA
9,NCT00034840,Exclusion,mean sitting sbp = 180 mm hg or mean sitting dbp = 110 mm hg during any visit of the placebo run-in period .,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,equal 110 mm hg,NA
10,NCT00034840,Exclusion,known or suspected secondary hypertension ( ie ; pheochromocytoma ) .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
10,NCT00034840,Exclusion,known or suspected secondary hypertension ( ie ; pheochromocytoma ) .,Condition Occurrence,Condition,C0031511;C1706920,pheochromocytoma,FALSE,FALSE,NA,NA,NA
11,NCT00034840,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Condition,C0086565,hepatic dysfunction,FALSE,FALSE,NA,NA,NA
11,NCT00034840,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
11,NCT00034840,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
11,NCT00034840,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
12,NCT00034840,Exclusion,sgpt ( alt ) or sgot ( ast ) > 2 times the upper limit of normal range .,Observation,Observation,C0376147;C0036828,sgpt,FALSE,FALSE,NA,NA,NA
12,NCT00034840,Exclusion,sgpt ( alt ) or sgot ( ast ) > 2 times the upper limit of normal range .,Observation,Observation,C1140170;C2257651,alt,FALSE,FALSE,NA,NA,NA
12,NCT00034840,Exclusion,sgpt ( alt ) or sgot ( ast ) > 2 times the upper limit of normal range .,Observation,Observation,C0242192;C0201899,sgot,FALSE,FALSE,NA,NA,NA
12,NCT00034840,Exclusion,sgpt ( alt ) or sgot ( ast ) > 2 times the upper limit of normal range .,Observation,Observation,C0004002,ast,FALSE,FALSE,NA,NA,NA
12,NCT00034840,Exclusion,sgpt ( alt ) or sgot ( ast ) > 2 times the upper limit of normal range .,Observation,Observation,C3542016,range,FALSE,FALSE,NA,NA,greater 2 times the upper limit of normal
13,NCT00034840,Exclusion,serum creatinine > 2.3 mg / dl ( or > 203 umol / l ) .,Observation,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,greater 203 umol/l,greater 2.3 mg/dl
14,NCT00034840,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney .,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
14,NCT00034840,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney .,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
14,NCT00034840,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney .,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
14,NCT00034840,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney .,Condition Occurrence,Condition,C0478647,transplant,FALSE,FALSE,NA,NA,NA
14,NCT00034840,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney .,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
15,NCT00034840,Exclusion,clinically relevant sodium depletion ; hypokalaemia or hyperkalaemia .,Condition Occurrence,Condition,C0020625,sodium depletion,FALSE,FALSE,NA,NA,NA
16,NCT00034840,Exclusion,uncorrected volume depletion .,Condition Occurrence,Condition,C0546884,volume depletion,FALSE,FALSE,NA,NA,NA
17,NCT00034840,Exclusion,primary aldosteronism .,Condition Occurrence,Condition,C1384514,primary aldosteronism,FALSE,FALSE,NA,NA,NA
18,NCT00034840,Exclusion,hereditary fructose intolerance .,Condition Occurrence,Condition,C0016751,hereditary fructose intolerance,FALSE,FALSE,NA,NA,NA
19,NCT00034840,Exclusion,biliary obstructive disorders .,Other,NA,NA,NA,NA,NA,NA,NA,NA
20,NCT00034840,Exclusion,congestive heart failure ( nyha functional class chf iii- .,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
20,NCT00034840,Exclusion,congestive heart failure ( nyha functional class chf iii- .,Condition Occurrence,Condition,C0018802,chf,FALSE,FALSE,NA,NA,NA
20,NCT00034840,Exclusion,congestive heart failure ( nyha functional class chf iii- .,Condition Occurrence,Other,C0456387;C0489477,class,FALSE,FALSE,NA,NA,NA
20,NCT00034840,Exclusion,congestive heart failure ( nyha functional class chf iii- .,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii-,FALSE,FALSE,NA,NA,NA
21,NCT00034840,Exclusion,unstable angina within the past three months prior to signing the informed consent form .,Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,NA,NA,NA
21,NCT00034840,Exclusion,unstable angina within the past three months prior to signing the informed consent form .,Condition Occurrence,Other,C0009797,informed consent form,FALSE,FALSE,NA,NA,NA
22,NCT00034840,Exclusion,stroke within the past six months prior to signing the informed consent form .,Other,Other,C0009797,informed consent form,FALSE,FALSE,NA,NA,NA
23,NCT00034840,Exclusion,myocardial infarction or cardiac surgery within the past three months prior to signing the informed consent form . ; ptca ( percutaneous transluminal coronary revascularization ) within the past three months prior to signing the informed consent form .,Procedure,Procedure,C0018821,cardiac surgery,FALSE,FALSE,NA,NA,NA
23,NCT00034840,Exclusion,myocardial infarction or cardiac surgery within the past three months prior to signing the informed consent form . ; ptca ( percutaneous transluminal coronary revascularization ) within the past three months prior to signing the informed consent form .,Procedure,Procedure,C2936173;C0002997,ptca,FALSE,FALSE,NA,NA,NA
23,NCT00034840,Exclusion,myocardial infarction or cardiac surgery within the past three months prior to signing the informed consent form . ; ptca ( percutaneous transluminal coronary revascularization ) within the past three months prior to signing the informed consent form .,Procedure,Procedure,C0877341,coronary revascularization,FALSE,FALSE,NA,NA,NA
23,NCT00034840,Exclusion,myocardial infarction or cardiac surgery within the past three months prior to signing the informed consent form . ; ptca ( percutaneous transluminal coronary revascularization ) within the past three months prior to signing the informed consent form .,Procedure,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
23,NCT00034840,Exclusion,myocardial infarction or cardiac surgery within the past three months prior to signing the informed consent form . ; ptca ( percutaneous transluminal coronary revascularization ) within the past three months prior to signing the informed consent form .,Procedure,Other,C0009797,informed consent form,FALSE,FALSE,NA,NA,NA
23,NCT00034840,Exclusion,myocardial infarction or cardiac surgery within the past three months prior to signing the informed consent form . ; ptca ( percutaneous transluminal coronary revascularization ) within the past three months prior to signing the informed consent form .,Procedure,Other,C0009797,informed consent form,FALSE,FALSE,NA,NA,NA
24,NCT00034840,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator .,Condition Occurrence,Condition,C0750197,sustained ventricular tachycardia,FALSE,FALSE,NA,NA,NA
24,NCT00034840,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator .,Condition Occurrence,Condition,C0004239;C1963068,atrial flutter,FALSE,FALSE,NA,NA,NA
24,NCT00034840,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator .,Condition Occurrence,Condition,C0003811,cardiac arrhythmias,FALSE,FALSE,NA,NA,NA
24,NCT00034840,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator .,Condition Occurrence,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
25,NCT00034840,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve .,Condition Occurrence,Condition,C0007194,hypertrophic obstructive cardiomyopathy,FALSE,FALSE,NA,NA,NA
25,NCT00034840,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve .,Condition Occurrence,Condition,C0003507,aortic stenosis,FALSE,FALSE,NA,NA,NA
25,NCT00034840,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve .,Condition Occurrence,Condition,C0003501;C1269005,aortic valve,FALSE,FALSE,NA,NA,NA
25,NCT00034840,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve .,Condition Occurrence,Condition,C0026264;C1269004,mitral valve,FALSE,FALSE,NA,NA,NA
25,NCT00034840,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve .,Condition Occurrence,Observation,C1261287;C0947637;C0009814,stenosis,FALSE,FALSE,NA,NA,NA
26,NCT00034840,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c = 10 % .,Condition Occurrence,Condition,C0011854,insulin-dependent diabetes mellitus,FALSE,FALSE,NA,NA,NA
26,NCT00034840,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c = 10 % .,Condition Occurrence,Condition,C0011849;C0011847,diabetes,FALSE,FALSE,NA,NA,NA
26,NCT00034840,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c = 10 % .,Condition Occurrence,Observation,C0202054,hba1c,FALSE,FALSE,NA,NA,equal 10 %
26,NCT00034840,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c = 10 % .,Condition Occurrence,Other,C1547311,stable,TRUE,FALSE,NA,NA,NA
26,NCT00034840,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c = 10 % .,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
27,NCT00034840,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or angiotensin ii receptor antagonists .,Drug Exposure,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
27,NCT00034840,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or angiotensin ii receptor antagonists .,Drug Exposure,Drug,C0003015,ace inhibitors,FALSE,FALSE,NA,NA,NA
27,NCT00034840,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or angiotensin ii receptor antagonists .,Drug Exposure,Other,C0521942;C2757003,angiotensin ii receptor antagonists,FALSE,FALSE,NA,NA,NA
28,NCT00034840,Exclusion,history of drug or alcohol dependency within 6 months prior to signing the informed consent form .,Condition Occurrence,Condition,C0001973,alcohol dependency,FALSE,FALSE,lower 6 months,NA,NA
28,NCT00034840,Exclusion,history of drug or alcohol dependency within 6 months prior to signing the informed consent form .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,lower 6 months,NA,NA
28,NCT00034840,Exclusion,history of drug or alcohol dependency within 6 months prior to signing the informed consent form .,Condition Occurrence,Other,C0009797,informed consent form,FALSE,FALSE,NA,NA,NA
29,NCT00034840,Exclusion,chronic administration of any medications known to affect blood pressure ; except medication allowed by the protocol .,Observation,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
29,NCT00034840,Exclusion,chronic administration of any medications known to affect blood pressure ; except medication allowed by the protocol .,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
29,NCT00034840,Exclusion,chronic administration of any medications known to affect blood pressure ; except medication allowed by the protocol .,Observation,Other,C1547296;C1555457,chronic,FALSE,FALSE,NA,NA,NA
30,NCT00034840,Exclusion,any investigational therapy within one month of signing the informed consent form .,Procedure,Procedure,C0949266,investigational therapy,FALSE,FALSE,NA,NA,NA
30,NCT00034840,Exclusion,any investigational therapy within one month of signing the informed consent form .,Procedure,Other,C0009797,informed consent form,FALSE,FALSE,NA,NA,NA
31,NCT00034840,Exclusion,known hypersensitivity to any component of the formulations .,Observation,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
32,NCT00034840,Exclusion,any clinical condition which ; in the opinion of the investigator would not allow safe completion of the protocol and safe administration of trial medication .,Other,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
33,NCT00034840,Exclusion,inability to comply with the protocol,Other,NA,NA,NA,NA,NA,NA,NA,NA
1,NCT00095394,Inclusion,men and women ages 18 and older ;,Person,Person,C0025266,men,FALSE,FALSE,NA,NA,NA
1,NCT00095394,Inclusion,men and women ages 18 and older ;,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
2,NCT00095394,Inclusion,willing to provide written informed consent ;,Other,NA,NA,NA,NA,NA,NA,NA,NA
3,NCT00095394,Inclusion,must have uncontrolled hypertension defined as : currently untreated with a diastolic blood pressure greater than 110 mmhg or currently receiving antihypertensive monotherapy with a diastolic blood pressure greater than 100 mmhg,Observation,Condition,C1868885,uncontrolled hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00095394,Inclusion,must have uncontrolled hypertension defined as : currently untreated with a diastolic blood pressure greater than 110 mmhg or currently receiving antihypertensive monotherapy with a diastolic blood pressure greater than 100 mmhg,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
3,NCT00095394,Inclusion,must have uncontrolled hypertension defined as : currently untreated with a diastolic blood pressure greater than 110 mmhg or currently receiving antihypertensive monotherapy with a diastolic blood pressure greater than 100 mmhg,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater 110 mmhg,NA
3,NCT00095394,Inclusion,must have uncontrolled hypertension defined as : currently untreated with a diastolic blood pressure greater than 110 mmhg or currently receiving antihypertensive monotherapy with a diastolic blood pressure greater than 100 mmhg,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater 100 mmhg,NA
3,NCT00095394,Inclusion,must have uncontrolled hypertension defined as : currently untreated with a diastolic blood pressure greater than 110 mmhg or currently receiving antihypertensive monotherapy with a diastolic blood pressure greater than 100 mmhg,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
4,NCT00095394,Inclusion,monotherapy is defined as treatment with one antihypertensive medication for at least four weeks,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
4,NCT00095394,Inclusion,monotherapy is defined as treatment with one antihypertensive medication for at least four weeks,Drug Exposure,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
5,NCT00095394,Inclusion,fixed combination therapy does not represent monotherapy ;,Condition Occurrence,Condition,C2827483,fixed,FALSE,FALSE,NA,NA,NA
5,NCT00095394,Inclusion,fixed combination therapy does not represent monotherapy ;,Condition Occurrence,Procedure,C0009429;C0556895,combination therapy,FALSE,FALSE,NA,NA,NA
6,NCT00095394,Inclusion,must be willing to discontinue antihypertensive medication ; if applicable ;,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
6,NCT00095394,Inclusion,must be willing to discontinue antihypertensive medication ; if applicable ;,Drug Exposure,Other,C1706472,discontinue,FALSE,FALSE,NA,NA,NA
7,NCT00095394,Inclusion,women of childbearing potential ( wocbp ) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to one week after the study in such a manner that the risk of pregnancy is minimized .,Observation,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
7,NCT00095394,Inclusion,women of childbearing potential ( wocbp ) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to one week after the study in such a manner that the risk of pregnancy is minimized .,Observation,Procedure,C0700589,contraception,FALSE,FALSE,NA,NA,NA
7,NCT00095394,Inclusion,women of childbearing potential ( wocbp ) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to one week after the study in such a manner that the risk of pregnancy is minimized .,Observation,Observation,C3831118,childbearing potential,FALSE,FALSE,NA,NA,NA
7,NCT00095394,Inclusion,women of childbearing potential ( wocbp ) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to one week after the study in such a manner that the risk of pregnancy is minimized .,Observation,Other,C2827714;C0871511;C2828387,method,FALSE,FALSE,NA,NA,NA
7,NCT00095394,Inclusion,women of childbearing potential ( wocbp ) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to one week after the study in such a manner that the risk of pregnancy is minimized .,Observation,Other,C0032961;C3484365,pregnancy,FALSE,FALSE,NA,NA,NA
7,NCT00095394,Inclusion,women of childbearing potential ( wocbp ) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to one week after the study in such a manner that the risk of pregnancy is minimized .,Observation,Other,C0032961;C3484365,pregnancy,FALSE,FALSE,NA,NA,NA
8,NCT00095394,Inclusion,wocbp must have a negative serum or urine pregnancy test within 72 hours prior to the start of study medication .,Observation,Observation,C1513916,negative,FALSE,FALSE,NA,NA,NA
8,NCT00095394,Inclusion,wocbp must have a negative serum or urine pregnancy test within 72 hours prior to the start of study medication .,Observation,Observation,C0430056;C0373524,urine pregnancy test,FALSE,FALSE,lower 72 hours,NA,NA
8,NCT00095394,Inclusion,wocbp must have a negative serum or urine pregnancy test within 72 hours prior to the start of study medication .,Observation,Other,C0229671;C1546774;C1550100,serum,FALSE,FALSE,lower 72 hours,NA,NA
9,NCT00095394,Exclusion,women who are pregnant or breastfeeding ;,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
9,NCT00095394,Exclusion,women who are pregnant or breastfeeding ;,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
9,NCT00095394,Exclusion,women who are pregnant or breastfeeding ;,Condition Occurrence,Condition,C0006147;C1623041;C1623040,breastfeeding,FALSE,FALSE,NA,NA,NA
10,NCT00095394,Exclusion,known or suspected secondary hypertension ;,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
11,NCT00095394,Exclusion,hypertension emergencies or stroke within the past 12 months ;,Condition Occurrence,Condition,C2745965,emergencies,FALSE,FALSE,lower 12 past months,NA,NA
11,NCT00095394,Exclusion,hypertension emergencies or stroke within the past 12 months ;,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
12,NCT00095394,Exclusion,heart attack ; angina or bypass surgery within the past 6 months ;,Condition Occurrence,Condition,C0027051,heart attack,FALSE,FALSE,lower 6 past months,NA,NA
12,NCT00095394,Exclusion,heart attack ; angina or bypass surgery within the past 6 months ;,Condition Occurrence,Procedure,C1536078,bypass surgery,FALSE,FALSE,lower 6 past months,NA,NA
12,NCT00095394,Exclusion,heart attack ; angina or bypass surgery within the past 6 months ;,Condition Occurrence,Other,C0002962;C2024883;C2926611,angina,FALSE,FALSE,lower 6 past months,NA,NA
13,NCT00095394,Exclusion,significant kidney disease ;,Condition Occurrence,Condition,C0022658,kidney disease,FALSE,FALSE,NA,NA,NA
14,NCT00095394,Exclusion,significant liver disease ;,Condition Occurrence,Condition,C0023895;C2186532,liver disease,FALSE,FALSE,NA,NA,NA
15,NCT00095394,Exclusion,systemic lupus erythematosus ;,Condition Occurrence,Condition,C0024141,systemic lupus erythematosus,FALSE,FALSE,NA,NA,NA
16,NCT00095394,Exclusion,gastrointestinal disease or surgery that may interfere with drug absorption ;,Condition Occurrence,Condition,C0017178,gastrointestinal disease,FALSE,FALSE,NA,NA,NA
16,NCT00095394,Exclusion,gastrointestinal disease or surgery that may interfere with drug absorption ;,Condition Occurrence,Condition,C0678745,drug absorption,FALSE,FALSE,NA,NA,NA
16,NCT00095394,Exclusion,gastrointestinal disease or surgery that may interfere with drug absorption ;,Condition Occurrence,Other,C0543467;C1457907,surgery,FALSE,FALSE,NA,NA,NA
17,NCT00095394,Exclusion,cancer during the past five years excluding localized squamous cell carcinoma or basal cell carcinoma of the skin ;,Condition Occurrence,Condition,C0007137;C1302853,squamous cell carcinoma,TRUE,FALSE,NA,NA,NA
17,NCT00095394,Exclusion,cancer during the past five years excluding localized squamous cell carcinoma or basal cell carcinoma of the skin ;,Condition Occurrence,Condition,C0007117,basal cell carcinoma of the skin,TRUE,FALSE,NA,NA,NA
17,NCT00095394,Exclusion,cancer during the past five years excluding localized squamous cell carcinoma or basal cell carcinoma of the skin ;,Condition Occurrence,Other,C0260515;C2707253,cancer,FALSE,FALSE,NA,NA,NA
18,NCT00095394,Exclusion,currently pregnant or lactating ;,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
18,NCT00095394,Exclusion,currently pregnant or lactating ;,Condition Occurrence,Condition,C2828358;C3668831,lactating,FALSE,FALSE,NA,NA,NA
19,NCT00095394,Exclusion,mental condition ( psychiatric cerebral disease or organic cerebral disease ) rendering the subject unable to understand the nature ; scope ; and possible consequences of the study ;,Other,Other,C1548428;C1561580,psychiatric,FALSE,FALSE,NA,NA,NA
20,NCT00095394,Exclusion,drug or alcohol abuse within the last five years ;,Condition Occurrence,Condition,C0085762,alcohol abuse,FALSE,FALSE,NA,NA,NA
20,NCT00095394,Exclusion,drug or alcohol abuse within the last five years ;,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
21,NCT00095394,Exclusion,known allergy to irbesartan or diuretics,Drug Exposure,Drug,C0288171,irbesartan,FALSE,FALSE,NA,NA,NA
21,NCT00095394,Exclusion,known allergy to irbesartan or diuretics,Drug Exposure,Drug,C0012798,diuretics,FALSE,FALSE,NA,NA,NA
21,NCT00095394,Exclusion,known allergy to irbesartan or diuretics,Drug Exposure,Other,C0489531;C0718579;C3542994;C3539909;C1314973;C1547315;C1611280,allergy,FALSE,FALSE,NA,NA,NA
1,NCT00095550,Inclusion,willing to provide written informed consent,Other,NA,NA,NA,NA,NA,NA,NA,NA
2,NCT00095550,Inclusion,subjects must have uncontrolled hypertension defined as :,Condition Occurrence,Condition,C1868885,uncontrolled hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00095550,Inclusion,subjects must have uncontrolled hypertension defined as :,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
3,NCT00095550,Inclusion,average systolic blood pressure between 160 mmhg and 180 mmhg ( while diastolic blood pressure is less than 110 mmhg ) or,Observation,Observation,C1282151,average systolic blood pressure,FALSE,FALSE,NA,greater_equal 160 mmhg; lower_equal 180 mmhg,NA
3,NCT00095550,Inclusion,average systolic blood pressure between 160 mmhg and 180 mmhg ( while diastolic blood pressure is less than 110 mmhg ) or,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,lower 110 mmhg,NA
4,NCT00095550,Inclusion,average diastolic blood pressure between 100 mmhg and 110 mmhg ( while systolic blood pressure is between 130 mmhg and 180 mmhg ),Observation,Condition,C1282163,average diastolic blood pressure,FALSE,FALSE,NA,greater_equal 100 mmhg; lower_equal 110 mmhg,NA
4,NCT00095550,Inclusion,average diastolic blood pressure between 100 mmhg and 110 mmhg ( while systolic blood pressure is between 130 mmhg and 180 mmhg ),Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater_equal 130 mmhg; lower_equal 180 mmhg,NA
5,NCT00095550,Inclusion,subjects must be willing to discontinue their antihypertensive medication ; if applicable .,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
5,NCT00095550,Inclusion,subjects must be willing to discontinue their antihypertensive medication ; if applicable .,Drug Exposure,Other,C1706472,discontinue,FALSE,FALSE,NA,NA,NA
6,NCT00095550,Inclusion,men and women ; ages 18 and older will be included .,Person,Person,C0025266,men,FALSE,FALSE,NA,NA,NA
6,NCT00095550,Inclusion,men and women ; ages 18 and older will be included .,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
7,NCT00095550,Inclusion,women of childbearing potential ( wocbp ) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to one week after the study in such a manner that the risk of pregnancy is minimized,Observation,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
7,NCT00095550,Inclusion,women of childbearing potential ( wocbp ) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to one week after the study in such a manner that the risk of pregnancy is minimized,Observation,Procedure,C0700589,contraception,FALSE,FALSE,NA,NA,NA
7,NCT00095550,Inclusion,women of childbearing potential ( wocbp ) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to one week after the study in such a manner that the risk of pregnancy is minimized,Observation,Observation,C3831118,childbearing potential,FALSE,FALSE,NA,NA,NA
7,NCT00095550,Inclusion,women of childbearing potential ( wocbp ) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to one week after the study in such a manner that the risk of pregnancy is minimized,Observation,Other,C2827714;C0871511;C2828387,method,FALSE,FALSE,NA,NA,NA
7,NCT00095550,Inclusion,women of childbearing potential ( wocbp ) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to one week after the study in such a manner that the risk of pregnancy is minimized,Observation,Other,C0032961;C3484365,pregnancy,FALSE,FALSE,NA,NA,NA
7,NCT00095550,Inclusion,women of childbearing potential ( wocbp ) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to one week after the study in such a manner that the risk of pregnancy is minimized,Observation,Other,C0032961;C3484365,pregnancy,FALSE,FALSE,NA,NA,NA
8,NCT00095550,Inclusion,wocbp must have a negative serum or urine pregnancy test within 72 hours prior to the start of study medication .,Observation,Observation,C1513916,negative,FALSE,FALSE,NA,NA,NA
8,NCT00095550,Inclusion,wocbp must have a negative serum or urine pregnancy test within 72 hours prior to the start of study medication .,Observation,Observation,C0430056;C0373524,urine pregnancy test,FALSE,FALSE,lower 72 hours,NA,NA
8,NCT00095550,Inclusion,wocbp must have a negative serum or urine pregnancy test within 72 hours prior to the start of study medication .,Observation,Other,C0229671;C1546774;C1550100,serum,FALSE,FALSE,lower 72 hours,NA,NA
9,NCT00095550,Exclusion,women who are pregnant or breastfeeding,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
9,NCT00095550,Exclusion,women who are pregnant or breastfeeding,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
9,NCT00095550,Exclusion,women who are pregnant or breastfeeding,Condition Occurrence,Condition,C0006147;C1623041;C1623040,breastfeeding,FALSE,FALSE,NA,NA,NA
10,NCT00095550,Exclusion,known or suspected secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
11,NCT00095550,Exclusion,hypertension emergencies or stroke within the past 12 months .,Condition Occurrence,Condition,C2745965,emergencies,FALSE,FALSE,lower 12 past months,NA,NA
11,NCT00095550,Exclusion,hypertension emergencies or stroke within the past 12 months .,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
12,NCT00095550,Exclusion,heart attack ; angina or bypass surgery within the past six months .,Condition Occurrence,Condition,C0027051,heart attack,FALSE,FALSE,NA,NA,NA
12,NCT00095550,Exclusion,heart attack ; angina or bypass surgery within the past six months .,Condition Occurrence,Procedure,C1536078,bypass surgery,FALSE,FALSE,NA,NA,NA
12,NCT00095550,Exclusion,heart attack ; angina or bypass surgery within the past six months .,Condition Occurrence,Other,C0002962;C2024883;C2926611,angina,FALSE,FALSE,NA,NA,NA
13,NCT00095550,Exclusion,significant kidney disease,Condition Occurrence,Condition,C0022658,kidney disease,FALSE,FALSE,NA,NA,NA
14,NCT00095550,Exclusion,significant liver disease,Condition Occurrence,Condition,C0023895;C2186532,liver disease,FALSE,FALSE,NA,NA,NA
15,NCT00095550,Exclusion,systemic lupus erythematosus,Condition Occurrence,Condition,C0024141,systemic lupus erythematosus,FALSE,FALSE,NA,NA,NA
16,NCT00095550,Exclusion,gastrointestinal disease or surgery that interfere with drug absorption,Condition Occurrence,Condition,C0017178,gastrointestinal disease,FALSE,FALSE,NA,NA,NA
16,NCT00095550,Exclusion,gastrointestinal disease or surgery that interfere with drug absorption,Condition Occurrence,Condition,C0678745,drug absorption,FALSE,FALSE,NA,NA,NA
16,NCT00095550,Exclusion,gastrointestinal disease or surgery that interfere with drug absorption,Condition Occurrence,Other,C0543467;C1457907,surgery,FALSE,FALSE,NA,NA,NA
17,NCT00095550,Exclusion,cancer during the past five years excluding localized squamous cell carcinoma or basal cell carcinoma of the skin,Condition Occurrence,Condition,C0007137;C1302853,squamous cell carcinoma,TRUE,FALSE,NA,NA,NA
17,NCT00095550,Exclusion,cancer during the past five years excluding localized squamous cell carcinoma or basal cell carcinoma of the skin,Condition Occurrence,Condition,C0007117,basal cell carcinoma of the skin,TRUE,FALSE,NA,NA,NA
17,NCT00095550,Exclusion,cancer during the past five years excluding localized squamous cell carcinoma or basal cell carcinoma of the skin,Condition Occurrence,Other,C0260515;C2707253,cancer,FALSE,FALSE,NA,NA,NA
18,NCT00095550,Exclusion,currently pregnant or lactating,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
18,NCT00095550,Exclusion,currently pregnant or lactating,Condition Occurrence,Condition,C2828358;C3668831,lactating,FALSE,FALSE,NA,NA,NA
19,NCT00095550,Exclusion,mental condition ( psychiatric cerebral disease or organic cerebral disease ) rendering the subject unable to understand the nature ; scope ; and possible consequences of the study,Other,Other,C1548428;C1561580,psychiatric,FALSE,FALSE,NA,NA,NA
20,NCT00095550,Exclusion,drug or alcohol abuse within the last five years,Condition Occurrence,Condition,C0085762,alcohol abuse,FALSE,FALSE,NA,NA,NA
20,NCT00095550,Exclusion,drug or alcohol abuse within the last five years,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
21,NCT00095550,Exclusion,known allergy to irbesartan or diuretics,Drug Exposure,Drug,C0288171,irbesartan,FALSE,FALSE,NA,NA,NA
21,NCT00095550,Exclusion,known allergy to irbesartan or diuretics,Drug Exposure,Drug,C0012798,diuretics,FALSE,FALSE,NA,NA,NA
21,NCT00095550,Exclusion,known allergy to irbesartan or diuretics,Drug Exposure,Other,C0489531;C0718579;C3542994;C3539909;C1314973;C1547315;C1611280,allergy,FALSE,FALSE,NA,NA,NA
1,NCT00110422,Inclusion,subjects must be willing and able to provide written informed consent,Other,NA,NA,NA,NA,NA,NA,NA,NA
2,NCT00110422,Inclusion,subjects must read ; sign ; and receive a copy of the informed consent prior to any study procedures ; including withdrawal of any antihypertensive medication .,Condition Occurrence,Condition,C2825032,withdrawal,FALSE,FALSE,NA,NA,NA
2,NCT00110422,Inclusion,subjects must read ; sign ; and receive a copy of the informed consent prior to any study procedures ; including withdrawal of any antihypertensive medication .,Condition Occurrence,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
3,NCT00110422,Inclusion,males and females > = 18 years of age .,Person,Person,C0025266,males,FALSE,FALSE,greater_equal 18 years,NA,NA
3,NCT00110422,Inclusion,males and females > = 18 years of age .,Person,Person,C0086287,females,FALSE,FALSE,greater_equal 18 years,NA,NA
4,NCT00110422,Inclusion,uncontrolled hypertension defined as an average systolic blood pressure > = 140 mmhg or an average diastolic blood pressure > = 90 mmhg,Observation,Condition,C1868885,uncontrolled hypertension,FALSE,FALSE,NA,NA,NA
4,NCT00110422,Inclusion,uncontrolled hypertension defined as an average systolic blood pressure > = 140 mmhg or an average diastolic blood pressure > = 90 mmhg,Observation,Condition,C1282163,average diastolic blood pressure,FALSE,FALSE,NA,greater_equal 90 mmhg,NA
4,NCT00110422,Inclusion,uncontrolled hypertension defined as an average systolic blood pressure > = 140 mmhg or an average diastolic blood pressure > = 90 mmhg,Observation,Observation,C1282151,average systolic blood pressure,FALSE,FALSE,NA,greater_equal 140 mmhg; greater_equal 90 mmhg,NA
4,NCT00110422,Inclusion,uncontrolled hypertension defined as an average systolic blood pressure > = 140 mmhg or an average diastolic blood pressure > = 90 mmhg,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
5,NCT00110422,Inclusion,this applies to both people not taking any blood pressure medications and people taking just one blood pressure medication .,Person,Person,C0027361,people,FALSE,FALSE,NA,NA,NA
5,NCT00110422,Inclusion,this applies to both people not taking any blood pressure medications and people taking just one blood pressure medication .,Person,Person,C0027361,people,FALSE,FALSE,NA,NA,NA
5,NCT00110422,Inclusion,this applies to both people not taking any blood pressure medications and people taking just one blood pressure medication .,Person,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,TRUE,FALSE,NA,NA,NA
5,NCT00110422,Inclusion,this applies to both people not taking any blood pressure medications and people taking just one blood pressure medication .,Person,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
6,NCT00110422,Inclusion,presenting at least 2 of the following :,Observation,NA,NA,NA,NA,NA,NA,NA,NA
7,NCT00110422,Inclusion,obesity ;,Condition Occurrence,Condition,C0028754;C1963185,obesity,FALSE,FALSE,NA,NA,NA
8,NCT00110422,Inclusion,high triglycerides ;,Condition Occurrence,Condition,C0020557,high triglycerides,FALSE,FALSE,NA,NA,NA
9,NCT00110422,Inclusion,low hdl cholesterol ;,Condition Occurrence,Condition,C0151691,low hdl cholesterol,FALSE,FALSE,NA,NA,NA
10,NCT00110422,Inclusion,elevated fasting glucose .,Condition Occurrence,Condition,C1260439,elevated fasting glucose,FALSE,FALSE,NA,NA,NA
11,NCT00110422,Exclusion,women of child bearing potential who are not using adequate birth control .,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
11,NCT00110422,Exclusion,women of child bearing potential who are not using adequate birth control .,Person,Observation,C3831118,child bearing potential,FALSE,FALSE,NA,NA,NA
11,NCT00110422,Exclusion,women of child bearing potential who are not using adequate birth control .,Person,Other,C0700589;C2703065,birth control,TRUE,FALSE,NA,NA,NA
12,NCT00110422,Exclusion,women who are pregnant or breastfeeding,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
12,NCT00110422,Exclusion,women who are pregnant or breastfeeding,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
12,NCT00110422,Exclusion,women who are pregnant or breastfeeding,Condition Occurrence,Condition,C0006147;C1623041;C1623040,breastfeeding,FALSE,FALSE,NA,NA,NA
13,NCT00110422,Exclusion,diabetics,Other,NA,NA,NA,NA,NA,NA,NA,NA
14,NCT00110422,Exclusion,systolic blood pressure > = 180 mmhg .,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater_equal 180 mmhg,NA
15,NCT00110422,Exclusion,diastolic blood pressure > = 110 mmhg .,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater_equal 110 mmhg,NA
16,NCT00110422,Exclusion,stroke within past 12 months .,Other,NA,NA,NA,NA,NA,NA,NA,NA
17,NCT00110422,Exclusion,myocardial infarction and heart revascularization procedure or acute angina within past 6 months .,Observation,Procedure,C0027056,heart revascularization,FALSE,FALSE,NA,NA,NA
17,NCT00110422,Exclusion,myocardial infarction and heart revascularization procedure or acute angina within past 6 months .,Observation,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
17,NCT00110422,Exclusion,myocardial infarction and heart revascularization procedure or acute angina within past 6 months .,Observation,Other,C1547229;C1547295,acute,FALSE,FALSE,NA,NA,NA
17,NCT00110422,Exclusion,myocardial infarction and heart revascularization procedure or acute angina within past 6 months .,Observation,Other,C0002962;C2024883;C2926611,angina,FALSE,FALSE,equal 6 months,NA,NA
18,NCT00110422,Exclusion,moderate to severe heart failure .,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
18,NCT00110422,Exclusion,moderate to severe heart failure .,Condition Occurrence,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
18,NCT00110422,Exclusion,moderate to severe heart failure .,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
19,NCT00110422,Exclusion,significant kidney or liver disease .,Condition Occurrence,Condition,C0023895;C2186532,liver disease,FALSE,FALSE,NA,NA,NA
19,NCT00110422,Exclusion,significant kidney or liver disease .,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
20,NCT00110422,Exclusion,cancer in past 5 years .,Observation,Other,C0260515;C2707253,cancer,FALSE,FALSE,lower_equal 5 past years,NA,NA
21,NCT00110422,Exclusion,drug or alcohol abuse .,Condition Occurrence,Condition,C0085762,alcohol abuse,FALSE,FALSE,NA,NA,NA
21,NCT00110422,Exclusion,drug or alcohol abuse .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
22,NCT00110422,Exclusion,gout,Condition Occurrence,Condition,C0018099,gout,FALSE,FALSE,NA,NA,NA
23,NCT00110422,Exclusion,lupus,Condition Occurrence,Condition,C0024131;C0409974,lupus,FALSE,FALSE,NA,NA,NA
1,NCT00129233,Inclusion,clinical diagnosis of hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00129233,Inclusion,clinical diagnosis of hypertension,Observation,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
2,NCT00129233,Inclusion,clinical diagnosis of type 2 diabetes or impaired glucose tolerance,Condition Occurrence,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
2,NCT00129233,Inclusion,clinical diagnosis of type 2 diabetes or impaired glucose tolerance,Condition Occurrence,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
2,NCT00129233,Inclusion,clinical diagnosis of type 2 diabetes or impaired glucose tolerance,Condition Occurrence,Condition,C0271650;C0159069,impaired glucose tolerance,FALSE,FALSE,NA,NA,NA
3,NCT00129233,Exclusion,history of congestive heart failure ; myocardial infarction ; or coronary revascularization in the recent 6 months .,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,lower_equal 6 recent months,NA,NA
3,NCT00129233,Exclusion,history of congestive heart failure ; myocardial infarction ; or coronary revascularization in the recent 6 months .,Condition Occurrence,Procedure,C0877341,coronary revascularization,FALSE,FALSE,lower_equal 6 recent months,NA,NA
3,NCT00129233,Exclusion,history of congestive heart failure ; myocardial infarction ; or coronary revascularization in the recent 6 months .,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,lower_equal 6 recent months,NA,NA
4,NCT00129233,Exclusion,taking calcium channel blocker for the purpose of angina pectoris,Drug Exposure,Condition,C0002962;C0577698;C0235467;C0542052;C0010073;C0541777;C0235462,angina pectoris,FALSE,FALSE,NA,NA,NA
4,NCT00129233,Exclusion,taking calcium channel blocker for the purpose of angina pectoris,Drug Exposure,Drug,C1995603,purpose,FALSE,FALSE,NA,NA,NA
4,NCT00129233,Exclusion,taking calcium channel blocker for the purpose of angina pectoris,Drug Exposure,Other,C0006684;C3536851;C2757014,calcium channel blocker,FALSE,FALSE,NA,NA,NA
5,NCT00129233,Exclusion,reduced ejection fraction ( < 40 % ),Drug Exposure,Other,C2700378;C2020641;C0489482,ejection fraction,FALSE,FALSE,NA,NA,lower 40 %
6,NCT00129233,Exclusion,second or third-degree of atrioventricular block,Observation,Condition,C0004245;C2108077,atrioventricular block,FALSE,FALSE,NA,NA,NA
6,NCT00129233,Exclusion,second or third-degree of atrioventricular block,Observation,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
7,NCT00129233,Exclusion,severe hypertension ( > 200 / 110 mmhg ) or secondary hypertension,Observation,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
7,NCT00129233,Exclusion,severe hypertension ( > 200 / 110 mmhg ) or secondary hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,greater 200 mmhg; greater 110 mmhg,NA
7,NCT00129233,Exclusion,severe hypertension ( > 200 / 110 mmhg ) or secondary hypertension,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
8,NCT00129233,Exclusion,history of stroke in the recent 6 months,Other,NA,NA,NA,NA,NA,NA,NA,NA
9,NCT00129233,Exclusion,serum creatinine > 2.5 mg / dl,Drug Exposure,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,NA,greater 2.5 mg/dl
10,NCT00129233,Exclusion,estimated survival duration less than 3 years due to other conditions,Other,NA,NA,NA,NA,NA,NA,NA,NA
11,NCT00129233,Exclusion,pregnant woman or possibly pregnant woman,Person,Person,C0033011,pregnant woman,FALSE,FALSE,NA,NA,NA
11,NCT00129233,Exclusion,pregnant woman or possibly pregnant woman,Person,Person,C0033011,pregnant woman,FALSE,FALSE,NA,NA,NA
1,NCT00134160,Inclusion,outpatients aged 65 years or older ; and less than 85 years ( at the time of informed consent ) ; regardless of sex,Condition Occurrence,Person,C0001792,aged,FALSE,FALSE,greater_equal 65 years; lower 85 years,NA,NA
2,NCT00134160,Inclusion,current antihypertensive treatment with monotherapy,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
3,NCT00134160,Inclusion,sbp > = 140 mmhg or dbp > = 90 mmhg in a sitting position on two measurements on two clinic visits,Observation,Condition,C0277814,sitting position,FALSE,FALSE,NA,NA,NA
3,NCT00134160,Inclusion,sbp > = 140 mmhg or dbp > = 90 mmhg in a sitting position on two measurements on two clinic visits,Observation,Procedure,C0008952,clinic visits,FALSE,FALSE,NA,NA,NA
3,NCT00134160,Inclusion,sbp > = 140 mmhg or dbp > = 90 mmhg in a sitting position on two measurements on two clinic visits,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 140 mmhg; greater_equal 90 mmhg,NA
3,NCT00134160,Inclusion,sbp > = 140 mmhg or dbp > = 90 mmhg in a sitting position on two measurements on two clinic visits,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 90 mmhg,NA
4,NCT00134160,Inclusion,at least one of the following risk factors :,Condition Occurrence,Condition,C0455624,risk factors,FALSE,FALSE,NA,NA,NA
5,NCT00134160,Inclusion,diabetes mellitus type 2 ;,Condition Occurrence,Condition,C0011849,diabetes mellitus,FALSE,FALSE,NA,NA,NA
5,NCT00134160,Inclusion,diabetes mellitus type 2 ;,Condition Occurrence,Other,C1552651,type,FALSE,FALSE,NA,NA,NA
6,NCT00134160,Inclusion,history of cerebral infarction ; cerebral hemorrhage ; subarachnoid hemorrhage ; or transient ischemic attack ( more than 6 months before giving informed consent ) ;,Condition Occurrence,Condition,C0007785;C0038454,cerebral infarction,FALSE,FALSE,greater 6 months,NA,NA
6,NCT00134160,Inclusion,history of cerebral infarction ; cerebral hemorrhage ; subarachnoid hemorrhage ; or transient ischemic attack ( more than 6 months before giving informed consent ) ;,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,greater 6 months,NA,NA
6,NCT00134160,Inclusion,history of cerebral infarction ; cerebral hemorrhage ; subarachnoid hemorrhage ; or transient ischemic attack ( more than 6 months before giving informed consent ) ;,Condition Occurrence,Condition,C0038525,subarachnoid hemorrhage,FALSE,FALSE,greater 6 months,NA,NA
6,NCT00134160,Inclusion,history of cerebral infarction ; cerebral hemorrhage ; subarachnoid hemorrhage ; or transient ischemic attack ( more than 6 months before giving informed consent ) ;,Condition Occurrence,Condition,C2937358;C0007784,cerebral hemorrhage,FALSE,FALSE,greater 6 months,NA,NA
7,NCT00134160,Inclusion,diagnosis of asymptomatic cerebrovascular disease ;,Condition Occurrence,Condition,C0393970,asymptomatic cerebrovascular disease,FALSE,FALSE,NA,NA,NA
8,NCT00134160,Inclusion,history of myocardial infarction ( more than 6 months before giving informed consent ) ;,Observation,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,greater 6 months,NA,NA
9,NCT00134160,Inclusion,diagnosis of angina pectoris or heart failure ( new york heart association [ nyha ] functional classification i or ;,Condition Occurrence,Condition,C0002962;C0577698;C0235467;C0542052;C0010073;C0541777;C0235462,angina pectoris,FALSE,FALSE,NA,NA,NA
9,NCT00134160,Inclusion,diagnosis of angina pectoris or heart failure ( new york heart association [ nyha ] functional classification i or ;,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
9,NCT00134160,Inclusion,diagnosis of angina pectoris or heart failure ( new york heart association [ nyha ] functional classification i or ;,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
10,NCT00134160,Inclusion,diagnosis of left ventricular hypertrophy ( thickness of the wall of interventricular septum > = 12 mm on echocardiography or sv1+rv5 > = 35 mm on electrocardiography before informed consent ) ;,Observation,Condition,C0225870,interventricular septum,FALSE,FALSE,NA,greater_equal 12 mm,NA
10,NCT00134160,Inclusion,diagnosis of left ventricular hypertrophy ( thickness of the wall of interventricular septum > = 12 mm on echocardiography or sv1+rv5 > = 35 mm on electrocardiography before informed consent ) ;,Observation,Observation,C0013516,echocardiography,FALSE,FALSE,NA,greater_equal 35 mm,NA
10,NCT00134160,Inclusion,diagnosis of left ventricular hypertrophy ( thickness of the wall of interventricular septum > = 12 mm on echocardiography or sv1+rv5 > = 35 mm on electrocardiography before informed consent ) ;,Observation,Observation,C1623258,electrocardiography,FALSE,FALSE,NA,NA,NA
10,NCT00134160,Inclusion,diagnosis of left ventricular hypertrophy ( thickness of the wall of interventricular septum > = 12 mm on echocardiography or sv1+rv5 > = 35 mm on electrocardiography before informed consent ) ;,Observation,Other,C0149721;C0232306;C3484363,left ventricular hypertrophy,FALSE,FALSE,NA,NA,NA
11,NCT00134160,Inclusion,diagnosis of aortic aneurysm ;,Condition Occurrence,Condition,C0003486;C2072946;C0340629,aortic aneurysm,FALSE,FALSE,NA,NA,NA
12,NCT00134160,Inclusion,history of aortic dissection ( more than 6 months before giving informed consent ) ;,Condition Occurrence,Condition,C0340643,aortic dissection,FALSE,FALSE,greater 6 months,NA,NA
13,NCT00134160,Inclusion,diagnosis of arteriosclerotic peripheral arterial obstruction ( fontaine classification from 2 to 4 ) ;,Observation,Condition,C0264995,arterial obstruction,FALSE,FALSE,NA,greater_equal 2 ; lower_equal 4,NA
14,NCT00134160,Inclusion,serum creatinine2-2 . 5 mg / dl ( male ) 0 - 2.55 mg / dl ( female ) ;,Drug Exposure,Person,C0025266,male,FALSE,FALSE,NA,NA,NA
14,NCT00134160,Inclusion,serum creatinine2-2 . 5 mg / dl ( male ) 0 - 2.55 mg / dl ( female ) ;,Drug Exposure,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
14,NCT00134160,Inclusion,serum creatinine2-2 . 5 mg / dl ( male ) 0 - 2.55 mg / dl ( female ) ;,Drug Exposure,Other,C0229671;C1546774;C1550100,serum,FALSE,FALSE,NA,NA,equal 5 mg/dl
15,NCT00134160,Inclusion,proteinuria : > = + 1 ( or > = 0.3 g / g ? cr ;,Observation,Condition,C0033687;C1279888;C1962972,proteinuria,FALSE,FALSE,NA,greater_equal 1 ; greater_equal 0.3 g/g,NA
15,NCT00134160,Inclusion,proteinuria : > = + 1 ( or > = 0.3 g / g ? cr ;,Observation,Other,C2348261;C1707506;C0152369,cr,FALSE,FALSE,NA,NA,NA
16,NCT00134160,Inclusion,estimated from 24 - hour urine collection or random urinary protein corrected by urine creatinine ) .,Observation,Condition,C1325413,urinary protein,FALSE,FALSE,equal 24 hour,NA,NA
16,NCT00134160,Inclusion,estimated from 24 - hour urine collection or random urinary protein corrected by urine creatinine ) .,Observation,Observation,C0200354,urine collection,FALSE,FALSE,equal 24 hour,NA,NA
16,NCT00134160,Inclusion,estimated from 24 - hour urine collection or random urinary protein corrected by urine creatinine ) .,Observation,Observation,C0428283;C1318439,urine creatinine,FALSE,FALSE,NA,NA,NA
17,NCT00134160,Exclusion,secondary hypertension or malignant hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
17,NCT00134160,Exclusion,secondary hypertension or malignant hypertension,Condition Occurrence,Condition,C0020540;C0024588,malignant hypertension,FALSE,FALSE,NA,NA,NA
18,NCT00134160,Exclusion,heart failure ( nyha functional classification iii or,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
18,NCT00134160,Exclusion,heart failure ( nyha functional classification iii or,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii,FALSE,FALSE,NA,NA,NA
19,NCT00134160,Exclusion,required treatment for malignant tumor,Condition Occurrence,Condition,C0006826,malignant tumor,FALSE,FALSE,NA,NA,NA
19,NCT00134160,Exclusion,required treatment for malignant tumor,Condition Occurrence,Other,C3245502;C3245501;C1619636;C1546857,required,FALSE,FALSE,NA,NA,NA
20,NCT00134160,Exclusion,serious liver or renal dysfunction ( serum creatinine > 2.55 mg / dl or with dialysis treatment ),Drug Exposure,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
20,NCT00134160,Exclusion,serious liver or renal dysfunction ( serum creatinine > 2.55 mg / dl or with dialysis treatment ),Drug Exposure,Procedure,C0011946;C0917873,dialysis,FALSE,FALSE,NA,NA,NA
20,NCT00134160,Exclusion,serious liver or renal dysfunction ( serum creatinine > 2.55 mg / dl or with dialysis treatment ),Drug Exposure,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,NA,greater 2.55 mg/dl
20,NCT00134160,Exclusion,serious liver or renal dysfunction ( serum creatinine > 2.55 mg / dl or with dialysis treatment ),Drug Exposure,Other,C0023895;C0496870;C0872387;C0023884;C0721399;C1278929;C0577060;C0023899;C0736268,liver,FALSE,FALSE,NA,NA,NA
21,NCT00134160,Exclusion,not appropriate for change to the test drugs from current therapy for hypertension or coronary diseases ( ie calcium channel blockers ; beta-blockers ; thiazide diuretics ; etc ; ),Drug Exposure,Condition,C0010068,coronary diseases,FALSE,FALSE,NA,NA,NA
21,NCT00134160,Exclusion,not appropriate for change to the test drugs from current therapy for hypertension or coronary diseases ( ie calcium channel blockers ; beta-blockers ; thiazide diuretics ; etc ; ),Drug Exposure,Drug,C0006684,calcium channel blockers,FALSE,FALSE,NA,NA,NA
21,NCT00134160,Exclusion,not appropriate for change to the test drugs from current therapy for hypertension or coronary diseases ( ie calcium channel blockers ; beta-blockers ; thiazide diuretics ; etc ; ),Drug Exposure,Drug,C0012802,thiazide diuretics,FALSE,FALSE,NA,NA,NA
21,NCT00134160,Exclusion,not appropriate for change to the test drugs from current therapy for hypertension or coronary diseases ( ie calcium channel blockers ; beta-blockers ; thiazide diuretics ; etc ; ),Drug Exposure,Drug,C0001645,beta-blockers,FALSE,FALSE,NA,NA,NA
21,NCT00134160,Exclusion,not appropriate for change to the test drugs from current therapy for hypertension or coronary diseases ( ie calcium channel blockers ; beta-blockers ; thiazide diuretics ; etc ; ),Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
21,NCT00134160,Exclusion,not appropriate for change to the test drugs from current therapy for hypertension or coronary diseases ( ie calcium channel blockers ; beta-blockers ; thiazide diuretics ; etc ; ),Drug Exposure,Procedure,C2827774,current therapy,FALSE,FALSE,NA,NA,NA
21,NCT00134160,Exclusion,not appropriate for change to the test drugs from current therapy for hypertension or coronary diseases ( ie calcium channel blockers ; beta-blockers ; thiazide diuretics ; etc ; ),Drug Exposure,Observation,C0022885;C2826273,test,FALSE,FALSE,NA,NA,NA
21,NCT00134160,Exclusion,not appropriate for change to the test drugs from current therapy for hypertension or coronary diseases ( ie calcium channel blockers ; beta-blockers ; thiazide diuretics ; etc ; ),Drug Exposure,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
22,NCT00134160,Exclusion,history of serious adverse drug reactions to angiotensin ii receptor blockers or calcium channel blockers,Drug Exposure,Condition,C0041755,adverse drug reactions,FALSE,FALSE,NA,NA,NA
22,NCT00134160,Exclusion,history of serious adverse drug reactions to angiotensin ii receptor blockers or calcium channel blockers,Drug Exposure,Drug,C0006684,calcium channel blockers,FALSE,FALSE,NA,NA,NA
22,NCT00134160,Exclusion,history of serious adverse drug reactions to angiotensin ii receptor blockers or calcium channel blockers,Drug Exposure,Other,C2757003;C0521942,angiotensin ii receptor blockers,FALSE,FALSE,NA,NA,NA
23,NCT00134160,Exclusion,patients with other serious reasons ( ie illness;significant abnormalities;etc;) that investigators judge inappropriate for the study,Other,NA,NA,NA,NA,NA,NA,NA,NA
1,NCT00134160,Inclusion,outpatients aged 65 years or older ; and less than 85 years ( at the time of informed consent ) ; regardless of sex,Condition Occurrence,Condition,C2024467,time,FALSE,FALSE,NA,NA,NA
1,NCT00134160,Inclusion,outpatients aged 65 years or older ; and less than 85 years ( at the time of informed consent ) ; regardless of sex,Condition Occurrence,Other,C1522384;C1879943,sex,FALSE,FALSE,NA,NA,NA
1,NCT00146341,Inclusion,history of mild-to-moderate hypertension defined by a mean seated dbp > = 95 and < = 109 mmhg before inclusion in the open-label phase,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00146341,Inclusion,history of mild-to-moderate hypertension defined by a mean seated dbp > = 95 and < = 109 mmhg before inclusion in the open-label phase,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 95 mmhg; lower_equal 109 mmhg,NA
1,NCT00146341,Inclusion,history of mild-to-moderate hypertension defined by a mean seated dbp > = 95 and < = 109 mmhg before inclusion in the open-label phase,Observation,Other,C1547225,mild,FALSE,FALSE,NA,NA,NA
1,NCT00146341,Inclusion,history of mild-to-moderate hypertension defined by a mean seated dbp > = 95 and < = 109 mmhg before inclusion in the open-label phase,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00146341,Inclusion,history of mild-to-moderate hypertension defined by a mean seated dbp > = 95 and < = 109 mmhg before inclusion in the open-label phase,Observation,Other,C1705425,label,FALSE,FALSE,NA,NA,NA
2,NCT00146341,Inclusion,patients who fail to respond adequately to telmisartan monotherapy ( mean seated dbp > = 90 mmhg ),Observation,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,NA
2,NCT00146341,Inclusion,patients who fail to respond adequately to telmisartan monotherapy ( mean seated dbp > = 90 mmhg ),Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 90 mmhg,NA
3,NCT00146341,Inclusion,participants between 18 and 80 years of age,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 18 years; lower_equal 80 years,NA,NA
4,NCT00146341,Inclusion,ability to provide written informed consent,Other,NA,NA,NA,NA,NA,NA,NA,NA
5,NCT00146341,Exclusion,patients taking more than three anti-hypertensive medications at the screening visit .,Drug Exposure,Drug,C0003364,anti-hypertensive,FALSE,FALSE,NA,NA,NA
6,NCT00146341,Exclusion,pre-menopausal women ( last menstruation 1 year prior to start of screening ) :,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
6,NCT00146341,Exclusion,pre-menopausal women ( last menstruation 1 year prior to start of screening ) :,Condition Occurrence,Condition,C1096235,pre-menopausal,FALSE,FALSE,NA,NA,NA
6,NCT00146341,Exclusion,pre-menopausal women ( last menstruation 1 year prior to start of screening ) :,Condition Occurrence,Condition,C0025344;C2129647,menstruation,FALSE,FALSE,equal 1 year,NA,NA
7,NCT00146341,Exclusion,who are not surgically sterile ( hysterectomy ; tubal ligation ),Procedure,Procedure,C0020699;C1548863,hysterectomy,TRUE,FALSE,NA,NA,NA
7,NCT00146341,Exclusion,who are not surgically sterile ( hysterectomy ; tubal ligation ),Procedure,Procedure,C0520483,tubal ligation,FALSE,FALSE,NA,NA,NA
8,NCT00146341,Exclusion,who are not practicing acceptable means of birth control or who do not plan to continue using an acceptable method throughout the study ( acceptable methods of birth control include iud contraceptives ; oral contraceptives ; implantable contraceptives or injectable contraceptives ),Drug Exposure,Drug,C1706306,iud,FALSE,FALSE,NA,NA,NA
8,NCT00146341,Exclusion,who are not practicing acceptable means of birth control or who do not plan to continue using an acceptable method throughout the study ( acceptable methods of birth control include iud contraceptives ; oral contraceptives ; implantable contraceptives or injectable contraceptives ),Drug Exposure,Drug,C0086466;C1272936,injectable,FALSE,FALSE,NA,NA,NA
8,NCT00146341,Exclusion,who are not practicing acceptable means of birth control or who do not plan to continue using an acceptable method throughout the study ( acceptable methods of birth control include iud contraceptives ; oral contraceptives ; implantable contraceptives or injectable contraceptives ),Drug Exposure,Other,C0700589;C2703065,birth control,TRUE,FALSE,NA,NA,NA
8,NCT00146341,Exclusion,who are not practicing acceptable means of birth control or who do not plan to continue using an acceptable method throughout the study ( acceptable methods of birth control include iud contraceptives ; oral contraceptives ; implantable contraceptives or injectable contraceptives ),Drug Exposure,Other,C2827714;C0871511;C2828387,method,FALSE,FALSE,NA,NA,NA
8,NCT00146341,Exclusion,who are not practicing acceptable means of birth control or who do not plan to continue using an acceptable method throughout the study ( acceptable methods of birth control include iud contraceptives ; oral contraceptives ; implantable contraceptives or injectable contraceptives ),Drug Exposure,Other,C0025663,methods,FALSE,FALSE,NA,NA,NA
8,NCT00146341,Exclusion,who are not practicing acceptable means of birth control or who do not plan to continue using an acceptable method throughout the study ( acceptable methods of birth control include iud contraceptives ; oral contraceptives ; implantable contraceptives or injectable contraceptives ),Drug Exposure,Other,C0700589;C2703065,birth control,FALSE,FALSE,NA,NA,NA
8,NCT00146341,Exclusion,who are not practicing acceptable means of birth control or who do not plan to continue using an acceptable method throughout the study ( acceptable methods of birth control include iud contraceptives ; oral contraceptives ; implantable contraceptives or injectable contraceptives ),Drug Exposure,Other,C0009905;C0274536;C0481121;C1548892,oral contraceptives,FALSE,FALSE,NA,NA,NA
9,NCT00146341,Exclusion,any woman :,Person,Person,C0086287,woman,FALSE,FALSE,NA,NA,NA
10,NCT00146341,Exclusion,who has a positive urine pregnancy test at screening ( visit 1 ),Observation,Observation,C1514241,positive,FALSE,FALSE,NA,NA,NA
10,NCT00146341,Exclusion,who has a positive urine pregnancy test at screening ( visit 1 ),Observation,Observation,C0430056;C0373524,urine pregnancy test,FALSE,FALSE,NA,NA,NA
11,NCT00146341,Exclusion,who is nursing,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
12,NCT00146341,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Condition,C0086565,hepatic dysfunction,FALSE,FALSE,NA,NA,NA
12,NCT00146341,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
12,NCT00146341,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
12,NCT00146341,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
13,NCT00146341,Exclusion,sgpt ( alt ) or sgot ( ast ) greater than two times the upper limit of normal,Observation,Observation,C0376147;C0036828,sgpt,FALSE,FALSE,NA,NA,NA
13,NCT00146341,Exclusion,sgpt ( alt ) or sgot ( ast ) greater than two times the upper limit of normal,Observation,Observation,C1140170;C2257651,alt,FALSE,FALSE,NA,NA,NA
13,NCT00146341,Exclusion,sgpt ( alt ) or sgot ( ast ) greater than two times the upper limit of normal,Observation,Observation,C0242192;C0201899,sgot,FALSE,FALSE,NA,NA,NA
13,NCT00146341,Exclusion,sgpt ( alt ) or sgot ( ast ) greater than two times the upper limit of normal,Observation,Observation,C0004002,ast,FALSE,FALSE,NA,NA,NA
14,NCT00146341,Exclusion,serum creatinine > 3.0 mg / dl ( or 265 mol / l ) or creatinine clearance < 0.6 ml / sec,Observation,Drug,C0059387,sec,FALSE,FALSE,NA,NA,NA
14,NCT00146341,Exclusion,serum creatinine > 3.0 mg / dl ( or 265 mol / l ) or creatinine clearance < 0.6 ml / sec,Observation,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,equal 265 mol/l,greater 3.0 mg/dl
14,NCT00146341,Exclusion,serum creatinine > 3.0 mg / dl ( or 265 mol / l ) or creatinine clearance < 0.6 ml / sec,Observation,Observation,C0373595;C0812399,creatinine clearance,FALSE,FALSE,NA,NA,lower 0.6 ml
15,NCT00146341,Exclusion,clinically relevant hypokalaemia or hyperkalaemia,Other,NA,NA,NA,NA,NA,NA,NA,NA
16,NCT00146341,Exclusion,uncorrected volume depletion,Condition Occurrence,Condition,C0546884,volume depletion,FALSE,FALSE,NA,NA,NA
17,NCT00146341,Exclusion,uncorrected sodium depletion,Condition Occurrence,Condition,C0020625,sodium depletion,FALSE,FALSE,NA,NA,NA
18,NCT00146341,Exclusion,primary aldosteronism,Condition Occurrence,Condition,C1384514,primary aldosteronism,FALSE,FALSE,NA,NA,NA
19,NCT00146341,Exclusion,hereditary fructose intolerance,Condition Occurrence,Condition,C0016751,hereditary fructose intolerance,FALSE,FALSE,NA,NA,NA
20,NCT00146341,Exclusion,biliary obstructive disorders ; cholestasis or moderate to severe hepatic insufficiency,Condition Occurrence,Condition,C0008370,cholestasis,FALSE,FALSE,NA,NA,NA
20,NCT00146341,Exclusion,biliary obstructive disorders ; cholestasis or moderate to severe hepatic insufficiency,Condition Occurrence,Condition,C1306571,hepatic insufficiency,FALSE,FALSE,NA,NA,NA
20,NCT00146341,Exclusion,biliary obstructive disorders ; cholestasis or moderate to severe hepatic insufficiency,Condition Occurrence,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
20,NCT00146341,Exclusion,biliary obstructive disorders ; cholestasis or moderate to severe hepatic insufficiency,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
21,NCT00146341,Exclusion,known or suspected secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
22,NCT00146341,Exclusion,bilateral renal artery stenosis,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
23,NCT00146341,Exclusion,renal artery stenosis in a solitary kidney,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
23,NCT00146341,Exclusion,renal artery stenosis in a solitary kidney,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
24,NCT00146341,Exclusion,post-renal transplant patients ; presence of only one functioning kidney,Condition Occurrence,Condition,C0478647,transplant,FALSE,FALSE,NA,NA,NA
24,NCT00146341,Exclusion,post-renal transplant patients ; presence of only one functioning kidney,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
25,NCT00146341,Exclusion,congestive heart failure ( nyha functional class chf iii-,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
25,NCT00146341,Exclusion,congestive heart failure ( nyha functional class chf iii-,Condition Occurrence,Condition,C0018802,chf,FALSE,FALSE,NA,NA,NA
25,NCT00146341,Exclusion,congestive heart failure ( nyha functional class chf iii-,Condition Occurrence,Other,C0456387;C0489477,class,FALSE,FALSE,NA,NA,NA
25,NCT00146341,Exclusion,congestive heart failure ( nyha functional class chf iii-,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii-,FALSE,FALSE,NA,NA,NA
26,NCT00146341,Exclusion,unstable angina within the past three months,Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,NA,NA,NA
27,NCT00146341,Exclusion,stroke within the past six months,Other,NA,NA,NA,NA,NA,NA,NA,NA
28,NCT00146341,Exclusion,myocardial infarction or cardiac surgery within the past three months,Condition Occurrence,Procedure,C0018821,cardiac surgery,FALSE,FALSE,NA,NA,NA
28,NCT00146341,Exclusion,myocardial infarction or cardiac surgery within the past three months,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
29,NCT00146341,Exclusion,ptca within the past three months,Procedure,Procedure,C2936173;C0002997,ptca,FALSE,FALSE,NA,NA,NA
1,NCT00149227,Inclusion,clinical diagnosis of hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00149227,Inclusion,clinical diagnosis of hypertension,Observation,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
2,NCT00149227,Inclusion,clinical diagnosis of one or more risk factors ; such as diabetes ; smoking habit ; lipid metabolism abnormality ; history of ischemic heart disease ( ihd ) or cerebrovascular disease ; obesity ( bmi > 25 ) ; chronic heart failure ( nyha ii- ; and electrocardiogram ( ecg ) abnormality ( lvh ),Condition Occurrence,Condition,C0455624,risk factors,FALSE,FALSE,NA,NA,NA
2,NCT00149227,Inclusion,clinical diagnosis of one or more risk factors ; such as diabetes ; smoking habit ; lipid metabolism abnormality ; history of ischemic heart disease ( ihd ) or cerebrovascular disease ; obesity ( bmi > 25 ) ; chronic heart failure ( nyha ii- ; and electrocardiogram ( ecg ) abnormality ( lvh ),Condition Occurrence,Condition,C0011849;C0011847,diabetes,FALSE,FALSE,NA,NA,NA
2,NCT00149227,Inclusion,clinical diagnosis of one or more risk factors ; such as diabetes ; smoking habit ; lipid metabolism abnormality ; history of ischemic heart disease ( ihd ) or cerebrovascular disease ; obesity ( bmi > 25 ) ; chronic heart failure ( nyha ii- ; and electrocardiogram ( ecg ) abnormality ( lvh ),Condition Occurrence,Condition,C0598783;C1517898,lipid metabolism,FALSE,FALSE,NA,NA,NA
2,NCT00149227,Inclusion,clinical diagnosis of one or more risk factors ; such as diabetes ; smoking habit ; lipid metabolism abnormality ; history of ischemic heart disease ( ihd ) or cerebrovascular disease ; obesity ( bmi > 25 ) ; chronic heart failure ( nyha ii- ; and electrocardiogram ( ecg ) abnormality ( lvh ),Condition Occurrence,Condition,C0151744;C1313980,ischemic heart disease,FALSE,FALSE,NA,NA,NA
2,NCT00149227,Inclusion,clinical diagnosis of one or more risk factors ; such as diabetes ; smoking habit ; lipid metabolism abnormality ; history of ischemic heart disease ( ihd ) or cerebrovascular disease ; obesity ( bmi > 25 ) ; chronic heart failure ( nyha ii- ; and electrocardiogram ( ecg ) abnormality ( lvh ),Condition Occurrence,Condition,C0151744,ihd,FALSE,FALSE,NA,NA,NA
2,NCT00149227,Inclusion,clinical diagnosis of one or more risk factors ; such as diabetes ; smoking habit ; lipid metabolism abnormality ; history of ischemic heart disease ( ihd ) or cerebrovascular disease ; obesity ( bmi > 25 ) ; chronic heart failure ( nyha ii- ; and electrocardiogram ( ecg ) abnormality ( lvh ),Condition Occurrence,Condition,C0007820,cerebrovascular disease,FALSE,FALSE,NA,greater 25 bmi,NA
2,NCT00149227,Inclusion,clinical diagnosis of one or more risk factors ; such as diabetes ; smoking habit ; lipid metabolism abnormality ; history of ischemic heart disease ( ihd ) or cerebrovascular disease ; obesity ( bmi > 25 ) ; chronic heart failure ( nyha ii- ; and electrocardiogram ( ecg ) abnormality ( lvh ),Condition Occurrence,Condition,C0028754;C1963185,obesity,FALSE,FALSE,NA,greater 25 bmi,NA
2,NCT00149227,Inclusion,clinical diagnosis of one or more risk factors ; such as diabetes ; smoking habit ; lipid metabolism abnormality ; history of ischemic heart disease ( ihd ) or cerebrovascular disease ; obesity ( bmi > 25 ) ; chronic heart failure ( nyha ii- ; and electrocardiogram ( ecg ) abnormality ( lvh ),Condition Occurrence,Condition,C0264716,chronic heart failure,FALSE,FALSE,NA,NA,NA
2,NCT00149227,Inclusion,clinical diagnosis of one or more risk factors ; such as diabetes ; smoking habit ; lipid metabolism abnormality ; history of ischemic heart disease ( ihd ) or cerebrovascular disease ; obesity ( bmi > 25 ) ; chronic heart failure ( nyha ii- ; and electrocardiogram ( ecg ) abnormality ( lvh ),Condition Occurrence,Condition,C0013798,electrocardiogram,FALSE,FALSE,NA,NA,NA
2,NCT00149227,Inclusion,clinical diagnosis of one or more risk factors ; such as diabetes ; smoking habit ; lipid metabolism abnormality ; history of ischemic heart disease ( ihd ) or cerebrovascular disease ; obesity ( bmi > 25 ) ; chronic heart failure ( nyha ii- ; and electrocardiogram ( ecg ) abnormality ( lvh ),Condition Occurrence,Condition,C0149721,lvh,FALSE,FALSE,NA,NA,NA
2,NCT00149227,Inclusion,clinical diagnosis of one or more risk factors ; such as diabetes ; smoking habit ; lipid metabolism abnormality ; history of ischemic heart disease ( ihd ) or cerebrovascular disease ; obesity ( bmi > 25 ) ; chronic heart failure ( nyha ii- ; and electrocardiogram ( ecg ) abnormality ( lvh ),Condition Occurrence,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
2,NCT00149227,Inclusion,clinical diagnosis of one or more risk factors ; such as diabetes ; smoking habit ; lipid metabolism abnormality ; history of ischemic heart disease ( ihd ) or cerebrovascular disease ; obesity ( bmi > 25 ) ; chronic heart failure ( nyha ii- ; and electrocardiogram ( ecg ) abnormality ( lvh ),Condition Occurrence,Other,C0037369;C1519384;C0453996;C1548578,smoking,FALSE,FALSE,NA,NA,NA
2,NCT00149227,Inclusion,clinical diagnosis of one or more risk factors ; such as diabetes ; smoking habit ; lipid metabolism abnormality ; history of ischemic heart disease ( ihd ) or cerebrovascular disease ; obesity ( bmi > 25 ) ; chronic heart failure ( nyha ii- ; and electrocardiogram ( ecg ) abnormality ( lvh ),Condition Occurrence,Other,C0018464,habit,FALSE,FALSE,NA,NA,NA
2,NCT00149227,Inclusion,clinical diagnosis of one or more risk factors ; such as diabetes ; smoking habit ; lipid metabolism abnormality ; history of ischemic heart disease ( ihd ) or cerebrovascular disease ; obesity ( bmi > 25 ) ; chronic heart failure ( nyha ii- ; and electrocardiogram ( ecg ) abnormality ( lvh ),Condition Occurrence,Other,C1623258;C0018064,ecg,FALSE,FALSE,NA,NA,NA
3,NCT00149227,Exclusion,patients who have already been administered arb,Drug Exposure,Other,C0521942;C2678493,arb,FALSE,FALSE,NA,NA,NA
4,NCT00149227,Exclusion,patients with ihd within 6 months after percutaneous coronary intervention ( pci ) ; and who are stable but are going to implement pci or coronary artery bypass grafting ( cabg ),Procedure,Condition,C0151744,ihd,FALSE,FALSE,lower 6 months,NA,NA
4,NCT00149227,Exclusion,patients with ihd within 6 months after percutaneous coronary intervention ( pci ) ; and who are stable but are going to implement pci or coronary artery bypass grafting ( cabg ),Procedure,Procedure,C1532338,percutaneous coronary intervention,FALSE,FALSE,NA,NA,NA
4,NCT00149227,Exclusion,patients with ihd within 6 months after percutaneous coronary intervention ( pci ) ; and who are stable but are going to implement pci or coronary artery bypass grafting ( cabg ),Procedure,Procedure,C1514496;C1532338,pci,FALSE,FALSE,NA,NA,NA
4,NCT00149227,Exclusion,patients with ihd within 6 months after percutaneous coronary intervention ( pci ) ; and who are stable but are going to implement pci or coronary artery bypass grafting ( cabg ),Procedure,Procedure,C1514496;C1532338,pci,FALSE,FALSE,NA,NA,NA
4,NCT00149227,Exclusion,patients with ihd within 6 months after percutaneous coronary intervention ( pci ) ; and who are stable but are going to implement pci or coronary artery bypass grafting ( cabg ),Procedure,Procedure,C0010055,coronary artery bypass grafting,FALSE,FALSE,NA,NA,NA
4,NCT00149227,Exclusion,patients with ihd within 6 months after percutaneous coronary intervention ( pci ) ; and who are stable but are going to implement pci or coronary artery bypass grafting ( cabg ),Procedure,Procedure,C0010055,cabg,FALSE,FALSE,NA,NA,NA
4,NCT00149227,Exclusion,patients with ihd within 6 months after percutaneous coronary intervention ( pci ) ; and who are stable but are going to implement pci or coronary artery bypass grafting ( cabg ),Procedure,Other,C1547311,stable,FALSE,FALSE,NA,NA,NA
5,NCT00149227,Exclusion,severe / malignant / secondary hypertensive patients,Condition Occurrence,Condition,C0334590;C1533592,malignant,FALSE,FALSE,NA,NA,NA
5,NCT00149227,Exclusion,severe / malignant / secondary hypertensive patients,Condition Occurrence,Condition,C0857121,hypertensive,FALSE,FALSE,NA,NA,NA
5,NCT00149227,Exclusion,severe / malignant / secondary hypertensive patients,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
6,NCT00149227,Exclusion,pregnant women and women of childbearing potential,Person,Person,C0033011,pregnant women,FALSE,FALSE,NA,NA,NA
6,NCT00149227,Exclusion,pregnant women and women of childbearing potential,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
6,NCT00149227,Exclusion,pregnant women and women of childbearing potential,Person,Observation,C3831118,childbearing potential,FALSE,FALSE,NA,NA,NA
7,NCT00149227,Exclusion,history of heart failure ; unstable angina ; myocardial infarction ; ptca ; or cabg within the preceding 6 months,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,lower 6 preceding months,NA,NA
7,NCT00149227,Exclusion,history of heart failure ; unstable angina ; myocardial infarction ; ptca ; or cabg within the preceding 6 months,Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,lower 6 preceding months,NA,NA
7,NCT00149227,Exclusion,history of heart failure ; unstable angina ; myocardial infarction ; ptca ; or cabg within the preceding 6 months,Condition Occurrence,Procedure,C0010055,cabg,FALSE,FALSE,lower 6 preceding months,NA,NA
7,NCT00149227,Exclusion,history of heart failure ; unstable angina ; myocardial infarction ; ptca ; or cabg within the preceding 6 months,Condition Occurrence,Procedure,C2936173;C0002997,ptca,FALSE,FALSE,lower 6 preceding months,NA,NA
7,NCT00149227,Exclusion,history of heart failure ; unstable angina ; myocardial infarction ; ptca ; or cabg within the preceding 6 months,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,lower 6 preceding months,NA,NA
8,NCT00149227,Exclusion,arrhythmia needed to be treated or accompanied with symptoms ; second degree av block or third degree av block,Condition Occurrence,Condition,C0003811,arrhythmia,FALSE,FALSE,NA,NA,NA
8,NCT00149227,Exclusion,arrhythmia needed to be treated or accompanied with symptoms ; second degree av block or third degree av block,Condition Occurrence,Condition,C0004245,av block,FALSE,FALSE,NA,NA,NA
8,NCT00149227,Exclusion,arrhythmia needed to be treated or accompanied with symptoms ; second degree av block or third degree av block,Condition Occurrence,Condition,C0004245,av block,FALSE,FALSE,NA,NA,NA
8,NCT00149227,Exclusion,arrhythmia needed to be treated or accompanied with symptoms ; second degree av block or third degree av block,Condition Occurrence,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
8,NCT00149227,Exclusion,arrhythmia needed to be treated or accompanied with symptoms ; second degree av block or third degree av block,Condition Occurrence,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
9,NCT00149227,Exclusion,severe renal impairment ( serum creatinine > 3.00 mg / dl ),Condition Occurrence,Condition,C1565489;C0035078,renal impairment,FALSE,FALSE,NA,NA,NA
9,NCT00149227,Exclusion,severe renal impairment ( serum creatinine > 3.00 mg / dl ),Condition Occurrence,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,NA,greater 3.00 mg/dl
9,NCT00149227,Exclusion,severe renal impairment ( serum creatinine > 3.00 mg / dl ),Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
10,NCT00149227,Exclusion,severe hepatic impairment ( hepatic failure ; cirrhosis ; etc ; ),Condition Occurrence,Condition,C0948807,hepatic impairment,FALSE,FALSE,NA,NA,NA
10,NCT00149227,Exclusion,severe hepatic impairment ( hepatic failure ; cirrhosis ; etc ; ),Condition Occurrence,Condition,C0085605,hepatic failure,FALSE,FALSE,NA,NA,NA
10,NCT00149227,Exclusion,severe hepatic impairment ( hepatic failure ; cirrhosis ; etc ; ),Condition Occurrence,Condition,C1623038;C0023890,cirrhosis,FALSE,FALSE,NA,NA,NA
10,NCT00149227,Exclusion,severe hepatic impairment ( hepatic failure ; cirrhosis ; etc ; ),Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
1,NCT00151827,Inclusion,mean sitting bp prior to randomization of 140 - 180 / 90 - 109 mmhg ;,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
1,NCT00151827,Inclusion,mean sitting bp prior to randomization of 140 - 180 / 90 - 109 mmhg ;,Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,equal 109 mmhg,NA
2,NCT00151827,Inclusion,renal impairment prior to randomization of mild ( 50 < = clcr > = 80 ml / min ) to moderate ( 30 < = clcr > = 50 ml / min ) severity,Observation,Condition,C1565489;C0035078,renal impairment,FALSE,FALSE,NA,NA,NA
2,NCT00151827,Inclusion,renal impairment prior to randomization of mild ( 50 < = clcr > = 80 ml / min ) to moderate ( 30 < = clcr > = 50 ml / min ) severity,Observation,Other,C1547225,mild,FALSE,FALSE,NA,greater_equal 50 ; greater_equal 80 ml/min,NA
2,NCT00151827,Inclusion,renal impairment prior to randomization of mild ( 50 < = clcr > = 80 ml / min ) to moderate ( 30 < = clcr > = 50 ml / min ) severity,Observation,Other,C1547226,moderate,FALSE,FALSE,NA,greater_equal 30 ; greater_equal 50 ml/min,NA
3,NCT00151827,Exclusion,malignant hypertension or sitting bp greater than 180 / 109 mmhg ;,Observation,Condition,C0020540;C0024588,malignant hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00151827,Exclusion,malignant hypertension or sitting bp greater than 180 / 109 mmhg ;,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
3,NCT00151827,Exclusion,malignant hypertension or sitting bp greater than 180 / 109 mmhg ;,Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,greater 180 mmhg; greater 109 mmhg,NA
4,NCT00151827,Exclusion,severe heart failure ; severe renal disease ;,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
4,NCT00151827,Exclusion,severe heart failure ; severe renal disease ;,Condition Occurrence,Condition,C0022658,renal disease,FALSE,FALSE,NA,NA,NA
4,NCT00151827,Exclusion,severe heart failure ; severe renal disease ;,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
4,NCT00151827,Exclusion,severe heart failure ; severe renal disease ;,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
5,NCT00151827,Exclusion,recent history of myocardial infarction ; stroke or transient ischemic attack ;,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,NA,NA,NA
5,NCT00151827,Exclusion,recent history of myocardial infarction ; stroke or transient ischemic attack ;,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
6,NCT00151827,Exclusion,history ; clinical evidence or current evidence of any significant gastrointestinal ; respiratory ; hematological ; metabolic ; immunological or any other underlying disease which in the opinion of the investigator would interfere with the patient participation in the trial ;,Condition Occurrence,Condition,C1559265,gastrointestinal,FALSE,FALSE,NA,NA,NA
6,NCT00151827,Exclusion,history ; clinical evidence or current evidence of any significant gastrointestinal ; respiratory ; hematological ; metabolic ; immunological or any other underlying disease which in the opinion of the investigator would interfere with the patient participation in the trial ;,Condition Occurrence,Procedure,C0030699,patient participation,FALSE,FALSE,NA,NA,NA
6,NCT00151827,Exclusion,history ; clinical evidence or current evidence of any significant gastrointestinal ; respiratory ; hematological ; metabolic ; immunological or any other underlying disease which in the opinion of the investigator would interfere with the patient participation in the trial ;,Condition Occurrence,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
6,NCT00151827,Exclusion,history ; clinical evidence or current evidence of any significant gastrointestinal ; respiratory ; hematological ; metabolic ; immunological or any other underlying disease which in the opinion of the investigator would interfere with the patient participation in the trial ;,Condition Occurrence,Other,C1546767,respiratory,FALSE,FALSE,NA,NA,NA
6,NCT00151827,Exclusion,history ; clinical evidence or current evidence of any significant gastrointestinal ; respiratory ; hematological ; metabolic ; immunological or any other underlying disease which in the opinion of the investigator would interfere with the patient participation in the trial ;,Condition Occurrence,Other,C1524026;C2707259,metabolic,FALSE,FALSE,NA,NA,NA
7,NCT00151827,Exclusion,hypersensitivity or contraindications to arbs or ace inhibitors or any cross allergy ;,Drug Exposure,Condition,C0268496,cross,FALSE,FALSE,NA,NA,NA
7,NCT00151827,Exclusion,hypersensitivity or contraindications to arbs or ace inhibitors or any cross allergy ;,Drug Exposure,Drug,C0003015,ace inhibitors,FALSE,FALSE,NA,NA,NA
7,NCT00151827,Exclusion,hypersensitivity or contraindications to arbs or ace inhibitors or any cross allergy ;,Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
7,NCT00151827,Exclusion,hypersensitivity or contraindications to arbs or ace inhibitors or any cross allergy ;,Drug Exposure,Other,C0489531;C0718579;C3542994;C3539909;C1314973;C1547315;C1611280,allergy,FALSE,FALSE,NA,NA,NA
8,NCT00151827,Exclusion,treatment with dis-allowed medication ;,Other,Other,C0451119,dis,FALSE,FALSE,NA,NA,NA
9,NCT00151827,Exclusion,pregnant females or breastfeeding females or females of childbearing potential without adequate contraception ;,Person,Person,C0086287,females,FALSE,FALSE,NA,NA,NA
9,NCT00151827,Exclusion,pregnant females or breastfeeding females or females of childbearing potential without adequate contraception ;,Person,Person,C0086287,females,FALSE,FALSE,NA,NA,NA
9,NCT00151827,Exclusion,pregnant females or breastfeeding females or females of childbearing potential without adequate contraception ;,Person,Person,C0086287,females,FALSE,FALSE,NA,NA,NA
9,NCT00151827,Exclusion,pregnant females or breastfeeding females or females of childbearing potential without adequate contraception ;,Person,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
9,NCT00151827,Exclusion,pregnant females or breastfeeding females or females of childbearing potential without adequate contraception ;,Person,Condition,C0006147;C1623041;C1623040,breastfeeding,FALSE,FALSE,NA,NA,NA
9,NCT00151827,Exclusion,pregnant females or breastfeeding females or females of childbearing potential without adequate contraception ;,Person,Procedure,C0700589,contraception,TRUE,FALSE,NA,NA,NA
9,NCT00151827,Exclusion,pregnant females or breastfeeding females or females of childbearing potential without adequate contraception ;,Person,Observation,C3831118,childbearing potential,FALSE,FALSE,NA,NA,NA
10,NCT00151827,Exclusion,history of drug or alcohol abuse,Condition Occurrence,Condition,C0085762,alcohol abuse,FALSE,FALSE,NA,NA,NA
10,NCT00151827,Exclusion,history of drug or alcohol abuse,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
1,NCT00153023,Inclusion,type 2 diabetes mellitus,Condition Occurrence,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
2,NCT00153023,Inclusion,aged 30 - 70 years of age,Person,Person,C0001792,aged,FALSE,FALSE,greater_equal 30 years; lower_equal 70 years,NA,NA
3,NCT00153023,Inclusion,hypertension at screening defined as :,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00153023,Inclusion,hypertension at screening defined as :,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
4,NCT00153023,Inclusion,an average cuff systolic blood pressure > 130 mmhg or diastolic blood pressure > 80 mmhg in untreated patients or,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
4,NCT00153023,Inclusion,an average cuff systolic blood pressure > 130 mmhg or diastolic blood pressure > 80 mmhg in untreated patients or,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater 130 mmhg; greater 80 mmhg,NA
4,NCT00153023,Inclusion,an average cuff systolic blood pressure > 130 mmhg or diastolic blood pressure > 80 mmhg in untreated patients or,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater 80 mmhg,NA
5,NCT00153023,Inclusion,patients receiving antihypertensive therapy ( ie ; medications specifically prescribed to treat hypertension ),Procedure,Procedure,C0585941,antihypertensive therapy,FALSE,FALSE,NA,NA,NA
5,NCT00153023,Inclusion,patients receiving antihypertensive therapy ( ie ; medications specifically prescribed to treat hypertension ),Procedure,Procedure,C0278329,prescribed,FALSE,FALSE,NA,NA,NA
5,NCT00153023,Inclusion,patients receiving antihypertensive therapy ( ie ; medications specifically prescribed to treat hypertension ),Procedure,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
6,NCT00153023,Inclusion,overt nephropathy defined by 24 hour proteinuria > = 900 mg and by serum creatinine below 265 mol / l ( 3.00 mg / dl ),Condition Occurrence,Condition,C0022658,nephropathy,FALSE,FALSE,NA,NA,NA
6,NCT00153023,Inclusion,overt nephropathy defined by 24 hour proteinuria > = 900 mg and by serum creatinine below 265 mol / l ( 3.00 mg / dl ),Condition Occurrence,Condition,C0033687;C1279888;C1962972,proteinuria,FALSE,FALSE,equal 24 hour,NA,greater_equal 900 mg
6,NCT00153023,Inclusion,overt nephropathy defined by 24 hour proteinuria > = 900 mg and by serum creatinine below 265 mol / l ( 3.00 mg / dl ),Condition Occurrence,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,lower 265 mol/l,NA
6,NCT00153023,Inclusion,overt nephropathy defined by 24 hour proteinuria > = 900 mg and by serum creatinine below 265 mol / l ( 3.00 mg / dl ),Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00168779,Inclusion,ability to provide written informed consent .,Other,NA,NA,NA,NA,NA,NA,NA,NA
2,NCT00168779,Inclusion,age 18 years or older,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 18 years,NA,NA
3,NCT00168779,Inclusion,ability to stop current antihypertensive therapy without unacceptable risk to the patient ( investigator discretion ),Drug Exposure,Drug,C0723457,stop,FALSE,FALSE,NA,NA,NA
3,NCT00168779,Inclusion,ability to stop current antihypertensive therapy without unacceptable risk to the patient ( investigator discretion ),Drug Exposure,Procedure,C0585941,antihypertensive therapy,FALSE,FALSE,NA,NA,NA
4,NCT00168779,Inclusion,seated cuff dbp of,Condition Occurrence,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
4,NCT00168779,Inclusion,seated cuff dbp of,Condition Occurrence,Observation,C1305849,dbp,FALSE,FALSE,NA,NA,NA
5,NCT00168779,Inclusion,95 mmhg at visit 2 ( baseline ),Observation,NA,NA,NA,NA,NA,NA,NA,NA
6,NCT00168779,Exclusion,pre-menopausal women ( last menstruation,Condition Occurrence,Condition,C1096235,pre-menopausal,FALSE,FALSE,NA,NA,NA
6,NCT00168779,Exclusion,pre-menopausal women ( last menstruation,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
6,NCT00168779,Exclusion,pre-menopausal women ( last menstruation,Condition Occurrence,Condition,C0025344;C2129647,menstruation,FALSE,FALSE,NA,NA,NA
7,NCT00168779,Exclusion,1 year prior to start of run-in period ) who :,Other,NA,NA,NA,NA,NA,NA,NA,NA
8,NCT00168779,Exclusion,are not surgically sterile or,Other,NA,NA,NA,NA,NA,NA,NA,NA
9,NCT00168779,Exclusion,are nursing or pregnant,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
9,NCT00168779,Exclusion,are nursing or pregnant,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
10,NCT00168779,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control ; do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in studies of > 3 - months duration,Observation,Observation,C3831118,child-bearing potential,FALSE,FALSE,NA,NA,NA
10,NCT00168779,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control ; do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in studies of > 3 - months duration,Observation,Observation,C0032976,pregnancy testing,FALSE,FALSE,NA,NA,NA
10,NCT00168779,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control ; do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in studies of > 3 - months duration,Observation,Observation,C0947630,studies,FALSE,FALSE,greater 3 months,NA,NA
10,NCT00168779,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control ; do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in studies of > 3 - months duration,Observation,Other,C0700589;C2703065,birth control,TRUE,FALSE,NA,NA,NA
10,NCT00168779,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control ; do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in studies of > 3 - months duration,Observation,Other,C2827714;C0871511;C2828387,method,FALSE,FALSE,NA,NA,NA
10,NCT00168779,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control ; do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in studies of > 3 - months duration,Observation,Other,C3641827,agree,FALSE,FALSE,NA,NA,NA
10,NCT00168779,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control ; do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in studies of > 3 - months duration,Observation,Other,C1706381,periodic,FALSE,FALSE,NA,NA,NA
11,NCT00168779,Exclusion,acceptable methods of birth control include oral ; implantable ; transdermal ; or injectable contraceptives ; and intra-uterine device ( iud ) .,Drug Exposure,Drug,C1272919,oral,FALSE,FALSE,NA,NA,NA
11,NCT00168779,Exclusion,acceptable methods of birth control include oral ; implantable ; transdermal ; or injectable contraceptives ; and intra-uterine device ( iud ) .,Drug Exposure,Drug,C0086466;C1272936,injectable,FALSE,FALSE,NA,NA,NA
11,NCT00168779,Exclusion,acceptable methods of birth control include oral ; implantable ; transdermal ; or injectable contraceptives ; and intra-uterine device ( iud ) .,Drug Exposure,Drug,C1706306,iud,FALSE,FALSE,NA,NA,NA
11,NCT00168779,Exclusion,acceptable methods of birth control include oral ; implantable ; transdermal ; or injectable contraceptives ; and intra-uterine device ( iud ) .,Drug Exposure,Other,C0025663,methods,FALSE,FALSE,NA,NA,NA
11,NCT00168779,Exclusion,acceptable methods of birth control include oral ; implantable ; transdermal ; or injectable contraceptives ; and intra-uterine device ( iud ) .,Drug Exposure,Other,C0700589;C2703065,birth control,FALSE,FALSE,NA,NA,NA
12,NCT00168779,Exclusion,known or suspected secondary hypertension .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
13,NCT00168779,Exclusion,mean seated sbp > = 180 mmhg or mean seated dbp > = 120 mmhg during any clinic visit prior to randomization .,Observation,Procedure,C0008952,clinic visit,FALSE,FALSE,NA,NA,NA
13,NCT00168779,Exclusion,mean seated sbp > = 180 mmhg or mean seated dbp > = 120 mmhg during any clinic visit prior to randomization .,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 180 mmhg,NA
13,NCT00168779,Exclusion,mean seated sbp > = 180 mmhg or mean seated dbp > = 120 mmhg during any clinic visit prior to randomization .,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 120 mmhg,NA
14,NCT00168779,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters : ; sgpt ( alt ) or sgot ( ast ) > 2 times the upper limit of normal range ; or,Observation,Condition,C0086565,hepatic dysfunction,FALSE,FALSE,NA,NA,NA
14,NCT00168779,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters : ; sgpt ( alt ) or sgot ( ast ) > 2 times the upper limit of normal range ; or,Observation,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
14,NCT00168779,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters : ; sgpt ( alt ) or sgot ( ast ) > 2 times the upper limit of normal range ; or,Observation,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
14,NCT00168779,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters : ; sgpt ( alt ) or sgot ( ast ) > 2 times the upper limit of normal range ; or,Observation,Observation,C0376147;C0036828,sgpt,FALSE,FALSE,NA,NA,NA
14,NCT00168779,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters : ; sgpt ( alt ) or sgot ( ast ) > 2 times the upper limit of normal range ; or,Observation,Observation,C1140170;C2257651,alt,FALSE,FALSE,NA,NA,NA
14,NCT00168779,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters : ; sgpt ( alt ) or sgot ( ast ) > 2 times the upper limit of normal range ; or,Observation,Observation,C0242192;C0201899,sgot,FALSE,FALSE,NA,NA,NA
14,NCT00168779,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters : ; sgpt ( alt ) or sgot ( ast ) > 2 times the upper limit of normal range ; or,Observation,Observation,C0004002,ast,FALSE,FALSE,NA,NA,NA
14,NCT00168779,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters : ; sgpt ( alt ) or sgot ( ast ) > 2 times the upper limit of normal range ; or,Observation,Observation,C3542016,range,FALSE,FALSE,NA,NA,greater 2 times the upper limit of normal
14,NCT00168779,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters : ; sgpt ( alt ) or sgot ( ast ) > 2 times the upper limit of normal range ; or,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
15,NCT00168779,Exclusion,serum creatinine > 3.0 mg / dl or creatinine clearance < 0.6 ml / sec .,Drug Exposure,Drug,C0059387,sec,FALSE,FALSE,NA,NA,NA
15,NCT00168779,Exclusion,serum creatinine > 3.0 mg / dl or creatinine clearance < 0.6 ml / sec .,Drug Exposure,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,NA,greater 3.0 mg/dl; lower 0.6 ml
15,NCT00168779,Exclusion,serum creatinine > 3.0 mg / dl or creatinine clearance < 0.6 ml / sec .,Drug Exposure,Observation,C0373595;C0812399,creatinine clearance,FALSE,FALSE,NA,NA,lower 0.6 ml
16,NCT00168779,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant or with only one kidney .,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
16,NCT00168779,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant or with only one kidney .,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
16,NCT00168779,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant or with only one kidney .,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
16,NCT00168779,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant or with only one kidney .,Condition Occurrence,Condition,C0478647,transplant,FALSE,FALSE,NA,NA,NA
16,NCT00168779,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant or with only one kidney .,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
17,NCT00168779,Exclusion,clinically relevant hypokalemia or hyperkalemia .,Condition Occurrence,Condition,C0020621,hypokalemia,FALSE,FALSE,NA,NA,NA
17,NCT00168779,Exclusion,clinically relevant hypokalemia or hyperkalemia .,Condition Occurrence,Condition,C0020461,hyperkalemia,FALSE,FALSE,NA,NA,NA
18,NCT00168779,Exclusion,uncorrected volume depletion .,Condition Occurrence,Condition,C0546884,volume depletion,FALSE,FALSE,NA,NA,NA
19,NCT00168779,Exclusion,uncorrected sodium depletion .,Condition Occurrence,Condition,C0020625,sodium depletion,FALSE,FALSE,NA,NA,NA
20,NCT00168779,Exclusion,primary aldosteronism .,Condition Occurrence,Condition,C1384514,primary aldosteronism,FALSE,FALSE,NA,NA,NA
21,NCT00168779,Exclusion,hereditary fructose intolerance .,Condition Occurrence,Condition,C0016751,hereditary fructose intolerance,FALSE,FALSE,NA,NA,NA
22,NCT00168779,Exclusion,biliary obstructive disorders ; cholestatis or moderate to severe hepatic in sufficiency .,Condition Occurrence,Condition,C0205054,hepatic,FALSE,FALSE,NA,NA,NA
22,NCT00168779,Exclusion,biliary obstructive disorders ; cholestatis or moderate to severe hepatic in sufficiency .,Condition Occurrence,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
22,NCT00168779,Exclusion,biliary obstructive disorders ; cholestatis or moderate to severe hepatic in sufficiency .,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
23,NCT00168779,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or angiotensin ii receptor antagonists .,Condition Occurrence,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
23,NCT00168779,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or angiotensin ii receptor antagonists .,Condition Occurrence,Drug,C0003015,ace inhibitors,FALSE,FALSE,NA,NA,NA
23,NCT00168779,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or angiotensin ii receptor antagonists .,Condition Occurrence,Other,C0521942;C2757003,angiotensin ii receptor antagonists,FALSE,FALSE,NA,NA,NA
24,NCT00168779,Exclusion,history of drug or alcohol dependency within six months prior to start of run-in period .,Condition Occurrence,Condition,C0001973,alcohol dependency,FALSE,FALSE,NA,NA,NA
24,NCT00168779,Exclusion,history of drug or alcohol dependency within six months prior to start of run-in period .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
25,NCT00168779,Exclusion,chronic administration of any medications known to affect blood pressure ; exc,Condition Occurrence,Condition,C0152318,exc,FALSE,FALSE,NA,NA,NA
25,NCT00168779,Exclusion,chronic administration of any medications known to affect blood pressure ; exc,Condition Occurrence,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
25,NCT00168779,Exclusion,chronic administration of any medications known to affect blood pressure ; exc,Condition Occurrence,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
25,NCT00168779,Exclusion,chronic administration of any medications known to affect blood pressure ; exc,Condition Occurrence,Other,C1547296;C1555457,chronic,FALSE,FALSE,NA,NA,NA
1,NCT00170924,Inclusion,diagnosis / history of high blood pressure,Condition Occurrence,Other,C0020538;C2926615,high blood pressure,FALSE,FALSE,NA,NA,NA
2,NCT00170924,Inclusion,male or female age 45 years or older,Person,Person,C0025266,male,FALSE,FALSE,NA,NA,NA
2,NCT00170924,Inclusion,male or female age 45 years or older,Person,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
2,NCT00170924,Inclusion,male or female age 45 years or older,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 45 years,NA,NA
3,NCT00170924,Exclusion,history of stroke ; transient ischemic attack or heart attack within the last 6 months,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,lower 6 last months,NA,NA
3,NCT00170924,Exclusion,history of stroke ; transient ischemic attack or heart attack within the last 6 months,Condition Occurrence,Condition,C0027051,heart attack,FALSE,FALSE,lower 6 last months,NA,NA
4,NCT00170924,Exclusion,a hospital admission for congestive heart failure within the last year,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
4,NCT00170924,Exclusion,a hospital admission for congestive heart failure within the last year,Condition Occurrence,Procedure,C0184666,hospital admission,FALSE,FALSE,NA,NA,NA
5,NCT00170924,Exclusion,use of certain high blood pressure medications such as ace inhibitors ; angiotensin receptor blockers or aldosterone antagonists or other agents that may work in the same pathway ( raas ) as valsartan within the past 3 months .,Drug Exposure,Drug,C0003015,ace inhibitors,FALSE,FALSE,lower 3 past months,NA,NA
5,NCT00170924,Exclusion,use of certain high blood pressure medications such as ace inhibitors ; angiotensin receptor blockers or aldosterone antagonists or other agents that may work in the same pathway ( raas ) as valsartan within the past 3 months .,Drug Exposure,Drug,C0521942;C0815017,angiotensin receptor blockers,FALSE,FALSE,lower 3 past months,NA,NA
5,NCT00170924,Exclusion,use of certain high blood pressure medications such as ace inhibitors ; angiotensin receptor blockers or aldosterone antagonists or other agents that may work in the same pathway ( raas ) as valsartan within the past 3 months .,Drug Exposure,Other,C0020538;C2926615,high blood pressure,FALSE,FALSE,NA,NA,NA
5,NCT00170924,Exclusion,use of certain high blood pressure medications such as ace inhibitors ; angiotensin receptor blockers or aldosterone antagonists or other agents that may work in the same pathway ( raas ) as valsartan within the past 3 months .,Drug Exposure,Other,C0002007;C2757004,aldosterone antagonists,FALSE,FALSE,lower 3 past months,NA,NA
6,NCT00170924,Exclusion,other protocol-defined may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00170963,Inclusion,patients with uncomplicated hypertension ; essential hypertension,Condition Occurrence,Condition,C0497248,uncomplicated hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00170963,Inclusion,patients with uncomplicated hypertension ; essential hypertension,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00170963,Exclusion,severe hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00170963,Exclusion,severe hypertension,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
3,NCT00170963,Exclusion,history of stroke ; myocardial infarction ; heart failure ; chest pain ; abnormal heart rhythm,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
3,NCT00170963,Exclusion,history of stroke ; myocardial infarction ; heart failure ; chest pain ; abnormal heart rhythm,Condition Occurrence,Condition,C0232187,heart rhythm,FALSE,FALSE,NA,NA,NA
3,NCT00170963,Exclusion,history of stroke ; myocardial infarction ; heart failure ; chest pain ; abnormal heart rhythm,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
3,NCT00170963,Exclusion,history of stroke ; myocardial infarction ; heart failure ; chest pain ; abnormal heart rhythm,Condition Occurrence,Other,C2699333,abnormal,FALSE,FALSE,NA,NA,NA
3,NCT00170963,Exclusion,history of stroke ; myocardial infarction ; heart failure ; chest pain ; abnormal heart rhythm,Condition Occurrence,Other,C0008031;C2926613,chest pain,FALSE,FALSE,NA,NA,NA
4,NCT00170963,Exclusion,liver ; kidney ; or pancreas disease,Condition Occurrence,Condition,C0545792,liver kidney,FALSE,FALSE,NA,NA,NA
4,NCT00170963,Exclusion,liver ; kidney ; or pancreas disease,Condition Occurrence,Condition,C0030286,pancreas disease,FALSE,FALSE,NA,NA,NA
5,NCT00170963,Exclusion,insulin dependent diabetes,Condition Occurrence,Condition,C0011854,insulin dependent diabetes,FALSE,FALSE,NA,NA,NA
6,NCT00170963,Exclusion,allergy to certain medications used to treat high blood pressure,Condition Occurrence,Other,C0489531;C0718579;C3542994;C3539909;C1314973;C1547315;C1611280,allergy,FALSE,FALSE,NA,NA,NA
6,NCT00170963,Exclusion,allergy to certain medications used to treat high blood pressure,Condition Occurrence,Other,C0020538;C2926615,high blood pressure,FALSE,FALSE,NA,NA,NA
7,NCT00170963,Exclusion,other protocol-defined may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00170989,Inclusion,patients with mild to moderate hypertension,Other,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00170989,Inclusion,patients with mild to moderate hypertension,Other,Other,C1547225,mild,FALSE,FALSE,NA,NA,NA
1,NCT00170989,Inclusion,patients with mild to moderate hypertension,Other,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
2,NCT00170989,Exclusion,severe hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00170989,Exclusion,history of stroke ; myocardial infarction ; heart failure ; chest pain ; abnormal heart rhythm,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
3,NCT00170989,Exclusion,history of stroke ; myocardial infarction ; heart failure ; chest pain ; abnormal heart rhythm,Condition Occurrence,Condition,C0232187,heart rhythm,FALSE,FALSE,NA,NA,NA
3,NCT00170989,Exclusion,history of stroke ; myocardial infarction ; heart failure ; chest pain ; abnormal heart rhythm,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
3,NCT00170989,Exclusion,history of stroke ; myocardial infarction ; heart failure ; chest pain ; abnormal heart rhythm,Condition Occurrence,Other,C2699333,abnormal,FALSE,FALSE,NA,NA,NA
3,NCT00170989,Exclusion,history of stroke ; myocardial infarction ; heart failure ; chest pain ; abnormal heart rhythm,Condition Occurrence,Other,C0008031;C2926613,chest pain,FALSE,FALSE,NA,NA,NA
4,NCT00170989,Exclusion,liver ; kidney ; or pancreas disease,Condition Occurrence,Condition,C0545792,liver kidney,FALSE,FALSE,NA,NA,NA
4,NCT00170989,Exclusion,liver ; kidney ; or pancreas disease,Condition Occurrence,Condition,C0030286,pancreas disease,FALSE,FALSE,NA,NA,NA
5,NCT00170989,Exclusion,insulin dependent diabetes,Condition Occurrence,Condition,C0011854,insulin dependent diabetes,FALSE,FALSE,NA,NA,NA
6,NCT00170989,Exclusion,allergy to certain medications used to treat high blood pressure,Condition Occurrence,Other,C0489531;C0718579;C3542994;C3539909;C1314973;C1547315;C1611280,allergy,FALSE,FALSE,NA,NA,NA
6,NCT00170989,Exclusion,allergy to certain medications used to treat high blood pressure,Condition Occurrence,Other,C0020538;C2926615,high blood pressure,FALSE,FALSE,NA,NA,NA
7,NCT00170989,Exclusion,other protocol-defined may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
2,NCT00170989,Exclusion,severe hypertension,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
1,NCT00171002,Inclusion,patients with uncomplicated hypertension ; essential hypertension,Condition Occurrence,Condition,C0497248,uncomplicated hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00171002,Inclusion,patients with uncomplicated hypertension ; essential hypertension,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00171002,Exclusion,severe hypertension,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
3,NCT00171002,Exclusion,history of stroke ; myocardial infarction ; heart failure ; chest pain ; abnormal heart rhythm,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
3,NCT00171002,Exclusion,history of stroke ; myocardial infarction ; heart failure ; chest pain ; abnormal heart rhythm,Condition Occurrence,Condition,C0232187,heart rhythm,FALSE,FALSE,NA,NA,NA
3,NCT00171002,Exclusion,history of stroke ; myocardial infarction ; heart failure ; chest pain ; abnormal heart rhythm,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
3,NCT00171002,Exclusion,history of stroke ; myocardial infarction ; heart failure ; chest pain ; abnormal heart rhythm,Condition Occurrence,Other,C2699333,abnormal,FALSE,FALSE,NA,NA,NA
3,NCT00171002,Exclusion,history of stroke ; myocardial infarction ; heart failure ; chest pain ; abnormal heart rhythm,Condition Occurrence,Other,C0008031;C2926613,chest pain,FALSE,FALSE,NA,NA,NA
4,NCT00171002,Exclusion,liver ; kidney ; or pancreas disease,Condition Occurrence,Condition,C0545792,liver kidney,FALSE,FALSE,NA,NA,NA
4,NCT00171002,Exclusion,liver ; kidney ; or pancreas disease,Condition Occurrence,Condition,C0030286,pancreas disease,FALSE,FALSE,NA,NA,NA
5,NCT00171002,Exclusion,insulin dependent diabetes,Condition Occurrence,Condition,C0011854,insulin dependent diabetes,FALSE,FALSE,NA,NA,NA
6,NCT00171002,Exclusion,allergy to certain medications used to treat high blood pressure,Condition Occurrence,Other,C0489531;C0718579;C3542994;C3539909;C1314973;C1547315;C1611280,allergy,FALSE,FALSE,NA,NA,NA
6,NCT00171002,Exclusion,allergy to certain medications used to treat high blood pressure,Condition Occurrence,Other,C0020538;C2926615,high blood pressure,FALSE,FALSE,NA,NA,NA
7,NCT00171002,Exclusion,other protocol-defined may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
2,NCT00171002,Exclusion,severe hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00171093,Inclusion,essential hypertension,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00171093,Inclusion,elevated ldl-c cholesterol,Observation,Observation,C0008377;C0201950,cholesterol,FALSE,FALSE,NA,NA,NA
2,NCT00171093,Inclusion,elevated ldl-c cholesterol,Observation,Other,C0202117;C1325353,ldl,FALSE,FALSE,NA,NA,NA
3,NCT00171093,Inclusion,using stable dose of hmg coa reductase inhibitor ( statin ) for 3 + months,Drug Exposure,Drug,C0360714,hmg coa reductase inhibitor,FALSE,FALSE,NA,NA,NA
3,NCT00171093,Inclusion,using stable dose of hmg coa reductase inhibitor ( statin ) for 3 + months,Drug Exposure,Drug,C0360714,statin,FALSE,FALSE,equal 3 + months,NA,NA
3,NCT00171093,Inclusion,using stable dose of hmg coa reductase inhibitor ( statin ) for 3 + months,Drug Exposure,Other,C1547311,stable,FALSE,FALSE,NA,NA,NA
4,NCT00171093,Exclusion,severe hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
4,NCT00171093,Exclusion,severe hypertension,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
5,NCT00171093,Exclusion,evidence of history or current heart disease,Condition Occurrence,Condition,C0018799,heart disease,FALSE,FALSE,NA,NA,NA
6,NCT00171093,Exclusion,history of stroke or myocardial infarction,Observation,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
7,NCT00171093,Exclusion,dislipidemia or hypertension due to secondary causes,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
8,NCT00171093,Exclusion,uncontrolled diabetes or insulin,Observation,Condition,C0011849;C0011847,diabetes,FALSE,FALSE,NA,NA,NA
8,NCT00171093,Exclusion,uncontrolled diabetes or insulin,Observation,Observation,C0021641;C0202098;C1533581;C1145751;C1579433;C2739803,insulin,FALSE,FALSE,NA,NA,NA
9,NCT00171093,Exclusion,other protocol-defined may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00185133,Inclusion,male or female patients,Person,Person,C0025266,male,FALSE,FALSE,NA,NA,NA
1,NCT00185133,Inclusion,male or female patients,Person,Observation,C0150905,female patients,FALSE,FALSE,NA,NA,NA
2,NCT00185133,Inclusion,18 years of age or older ( 20 % equal to or older than 65 years ),Drug Exposure,Person,C0001779,age,FALSE,FALSE,equal 18 years; greater 65 years,NA,NA
2,NCT00185133,Inclusion,18 years of age or older ( 20 % equal to or older than 65 years ),Drug Exposure,Person,C0001779,older,FALSE,FALSE,equal 18 years; greater 65 years,NA,NA
3,NCT00185133,Inclusion,with mild to severe hypertension defined as seated diastolic blood pressure of 95 - 120 mmhg while off any hypertensive medication,Observation,Drug,C0684167,hypertensive medication,FALSE,FALSE,NA,NA,NA
3,NCT00185133,Inclusion,with mild to severe hypertension defined as seated diastolic blood pressure of 95 - 120 mmhg while off any hypertensive medication,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00185133,Inclusion,with mild to severe hypertension defined as seated diastolic blood pressure of 95 - 120 mmhg while off any hypertensive medication,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater_equal 95 mmhg; lower_equal 120 mmhg,NA
3,NCT00185133,Inclusion,with mild to severe hypertension defined as seated diastolic blood pressure of 95 - 120 mmhg while off any hypertensive medication,Observation,Other,C1547225,mild,FALSE,FALSE,NA,NA,NA
3,NCT00185133,Inclusion,with mild to severe hypertension defined as seated diastolic blood pressure of 95 - 120 mmhg while off any hypertensive medication,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
3,NCT00185133,Inclusion,with mild to severe hypertension defined as seated diastolic blood pressure of 95 - 120 mmhg while off any hypertensive medication,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
4,NCT00185133,Exclusion,patients should not have serious concomitant conditions that could interfere with the analysis of the results or that could interfere with the well-being of the patients,Condition Occurrence,Condition,C0243086,concomitant conditions,TRUE,FALSE,NA,NA,NA
4,NCT00185133,Exclusion,patients should not have serious concomitant conditions that could interfere with the analysis of the results or that could interfere with the well-being of the patients,Condition Occurrence,Condition,C0031206,well-being,FALSE,FALSE,NA,NA,NA
4,NCT00185133,Exclusion,patients should not have serious concomitant conditions that could interfere with the analysis of the results or that could interfere with the well-being of the patients,Condition Occurrence,Observation,C0002778,analysis,FALSE,FALSE,NA,NA,NA
1,NCT00185172,Inclusion,age : 18 ( 19 if required by local authorities ) to 75 years,Observation,Other,C3245502;C3245501;C1619636;C1546857,required,FALSE,FALSE,equal 75 years,NA,NA
2,NCT00185172,Inclusion,males and females of any race,Person,Person,C0025266,males,FALSE,FALSE,NA,NA,NA
2,NCT00185172,Inclusion,males and females of any race,Person,Person,C0086287,females,FALSE,FALSE,NA,NA,NA
2,NCT00185172,Inclusion,males and females of any race,Person,Other,C0034510;C2608036;C1315098;C1561446,race,FALSE,FALSE,NA,NA,NA
3,NCT00185172,Inclusion,female participants must take adequate contraceptive measures ( oral contraceptives ; u ) ; be post-menopausal or surgically sterilized,Person,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
3,NCT00185172,Inclusion,female participants must take adequate contraceptive measures ( oral contraceptives ; u ) ; be post-menopausal or surgically sterilized,Person,Other,C0009905;C0274536;C0481121;C1548892,oral contraceptives,FALSE,FALSE,NA,NA,NA
4,NCT00185172,Inclusion,essential hypertension : sitting dbp greater than or equal to 90 and less than 110 mmhg,Observation,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
4,NCT00185172,Inclusion,essential hypertension : sitting dbp greater than or equal to 90 and less than 110 mmhg,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
4,NCT00185172,Inclusion,essential hypertension : sitting dbp greater than or equal to 90 and less than 110 mmhg,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 90 mmhg; lower 110 mmhg,NA
5,NCT00185172,Inclusion,written informed consent,Other,NA,NA,NA,NA,NA,NA,NA,NA
6,NCT00185172,Inclusion,mentally competent,Other,NA,NA,NA,NA,NA,NA,NA,NA
7,NCT00185172,Inclusion,negative pregnancy test in women at a childbearing age at the beginning of the study,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
7,NCT00185172,Inclusion,negative pregnancy test in women at a childbearing age at the beginning of the study,Person,Observation,C0427780,negative pregnancy test,FALSE,FALSE,NA,NA,NA
8,NCT00185172,Exclusion,patients with known severe ( world health organization ( who ) stage iii ; sitting dbp stable at greater than or equal to 110 mmhg ) ; malignant hypertension or secondary hypertension,Observation,Person,C2700280,world,FALSE,FALSE,NA,NA,NA
8,NCT00185172,Exclusion,patients with known severe ( world health organization ( who ) stage iii ; sitting dbp stable at greater than or equal to 110 mmhg ) ; malignant hypertension or secondary hypertension,Observation,Condition,C0029237,organization,FALSE,FALSE,NA,NA,NA
8,NCT00185172,Exclusion,patients with known severe ( world health organization ( who ) stage iii ; sitting dbp stable at greater than or equal to 110 mmhg ) ; malignant hypertension or secondary hypertension,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
8,NCT00185172,Exclusion,patients with known severe ( world health organization ( who ) stage iii ; sitting dbp stable at greater than or equal to 110 mmhg ) ; malignant hypertension or secondary hypertension,Observation,Condition,C0020540;C0024588,malignant hypertension,FALSE,FALSE,NA,NA,NA
8,NCT00185172,Exclusion,patients with known severe ( world health organization ( who ) stage iii ; sitting dbp stable at greater than or equal to 110 mmhg ) ; malignant hypertension or secondary hypertension,Observation,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
8,NCT00185172,Exclusion,patients with known severe ( world health organization ( who ) stage iii ; sitting dbp stable at greater than or equal to 110 mmhg ) ; malignant hypertension or secondary hypertension,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,NA,NA
8,NCT00185172,Exclusion,patients with known severe ( world health organization ( who ) stage iii ; sitting dbp stable at greater than or equal to 110 mmhg ) ; malignant hypertension or secondary hypertension,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
8,NCT00185172,Exclusion,patients with known severe ( world health organization ( who ) stage iii ; sitting dbp stable at greater than or equal to 110 mmhg ) ; malignant hypertension or secondary hypertension,Observation,Other,C0441771,stage iii,FALSE,FALSE,NA,NA,NA
8,NCT00185172,Exclusion,patients with known severe ( world health organization ( who ) stage iii ; sitting dbp stable at greater than or equal to 110 mmhg ) ; malignant hypertension or secondary hypertension,Observation,Other,C1547311,stable,FALSE,FALSE,NA,greater_equal 110 mmhg,NA
9,NCT00185172,Exclusion,patients who have had a myocardial infarction or percutaneous transluminal coronary angioplasty ( ptca ) or coronary artery bypass graft ( cabg ) within the last 6 months,Procedure,Procedure,C2936173,percutaneous transluminal coronary angioplasty,FALSE,FALSE,NA,NA,NA
9,NCT00185172,Exclusion,patients who have had a myocardial infarction or percutaneous transluminal coronary angioplasty ( ptca ) or coronary artery bypass graft ( cabg ) within the last 6 months,Procedure,Procedure,C2936173;C0002997,ptca,FALSE,FALSE,NA,NA,NA
9,NCT00185172,Exclusion,patients who have had a myocardial infarction or percutaneous transluminal coronary angioplasty ( ptca ) or coronary artery bypass graft ( cabg ) within the last 6 months,Procedure,Procedure,C0010055,coronary artery bypass graft,FALSE,FALSE,NA,NA,NA
9,NCT00185172,Exclusion,patients who have had a myocardial infarction or percutaneous transluminal coronary angioplasty ( ptca ) or coronary artery bypass graft ( cabg ) within the last 6 months,Procedure,Procedure,C0010055,cabg,FALSE,FALSE,lower 6 last months,NA,NA
9,NCT00185172,Exclusion,patients who have had a myocardial infarction or percutaneous transluminal coronary angioplasty ( ptca ) or coronary artery bypass graft ( cabg ) within the last 6 months,Procedure,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
10,NCT00185172,Exclusion,patients with a history or current evidence of congestive heart failure,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
11,NCT00185172,Exclusion,bilateral renal artery stenosis,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
12,NCT00185172,Exclusion,severe renal insufficiency ( serum creatinine greater than 200 micro mol / l ),Observation,Condition,C1565489;C0035078,renal insufficiency,FALSE,FALSE,NA,NA,NA
12,NCT00185172,Exclusion,severe renal insufficiency ( serum creatinine greater than 200 micro mol / l ),Observation,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,greater 200 micro mol/l,NA
12,NCT00185172,Exclusion,severe renal insufficiency ( serum creatinine greater than 200 micro mol / l ),Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
13,NCT00185172,Exclusion,severe hepatic impairment or biliary obstruction,Condition Occurrence,Condition,C0948807,hepatic impairment,FALSE,FALSE,NA,NA,NA
13,NCT00185172,Exclusion,severe hepatic impairment or biliary obstruction,Condition Occurrence,Condition,C0400979,biliary obstruction,FALSE,FALSE,NA,NA,NA
13,NCT00185172,Exclusion,severe hepatic impairment or biliary obstruction,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
1,NCT00190580,Inclusion,ckd with serum creatinine more than 2.0 mg / dl,Drug Exposure,Condition,C1561643,ckd,FALSE,FALSE,NA,NA,NA
1,NCT00190580,Inclusion,ckd with serum creatinine more than 2.0 mg / dl,Drug Exposure,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,NA,greater 2.0 mg/dl
2,NCT00190580,Inclusion,blood pressure more than 130 / 85 mmhg,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,greater 130 mmhg; greater 85 mmhg,NA
3,NCT00190580,Inclusion,20 years old or above,Other,NA,NA,NA,NA,NA,NA,NA,NA
4,NCT00190580,Exclusion,end-stage renal disease with maintenance dialysis,Condition Occurrence,Condition,C0022661;C2316810,end-stage renal disease,FALSE,FALSE,NA,NA,NA
4,NCT00190580,Exclusion,end-stage renal disease with maintenance dialysis,Condition Occurrence,Procedure,C0011946;C0917873,dialysis,FALSE,FALSE,NA,NA,NA
5,NCT00190580,Exclusion,polycystic kidney disease,Condition Occurrence,Condition,C0022680,polycystic kidney disease,FALSE,FALSE,NA,NA,NA
6,NCT00190580,Exclusion,collagen disease,Condition Occurrence,Condition,C0009326,collagen disease,FALSE,FALSE,NA,NA,NA
7,NCT00190580,Exclusion,malignant or accelerated hypertension,Condition Occurrence,Condition,C0334590;C1533592,malignant,FALSE,FALSE,NA,NA,NA
7,NCT00190580,Exclusion,malignant or accelerated hypertension,Condition Occurrence,Condition,C0020540,accelerated hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00219024,Inclusion,patients with essential hypertension,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00219024,Inclusion,patients who are eligible and able to participate in the study,Other,NA,NA,NA,NA,NA,NA,NA,NA
3,NCT00219024,Exclusion,severe hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00219024,Exclusion,severe hypertension,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
4,NCT00219024,Exclusion,history or evidence of a secondary form of hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
5,NCT00219024,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
5,NCT00219024,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident,Condition Occurrence,Condition,C0000924;C2046386,accident,FALSE,FALSE,NA,NA,NA
5,NCT00219024,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
6,NCT00219024,Exclusion,other protocol-defined may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00219037,Inclusion,patients with essential hypertension .,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00219037,Exclusion,severe hypertension .,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00219037,Inclusion,patients who are eligible and able to participate in the study .,Other,NA,NA,NA,NA,NA,NA,NA,NA
3,NCT00219037,Exclusion,severe hypertension .,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
4,NCT00219037,Exclusion,history or evidence of a secondary form of hypertension .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
5,NCT00219037,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
5,NCT00219037,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident,Condition Occurrence,Condition,C0000924;C2046386,accident,FALSE,FALSE,NA,NA,NA
5,NCT00219037,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
6,NCT00219037,Exclusion,other protocol-defined may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00219063,Inclusion,patients with essential hypertension,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00219063,Inclusion,patients who are eligible and able to participate in the study,Other,NA,NA,NA,NA,NA,NA,NA,NA
3,NCT00219063,Exclusion,severe hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00219063,Exclusion,severe hypertension,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
4,NCT00219063,Exclusion,history or evidence of a secondary form of hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
5,NCT00219063,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
5,NCT00219063,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident,Condition Occurrence,Condition,C0000924;C2046386,accident,FALSE,FALSE,NA,NA,NA
5,NCT00219063,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
6,NCT00219063,Exclusion,other protocol-defined inclusion also apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00219076,Inclusion,patients with essential hypertension,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00219076,Inclusion,patients who are eligible and able to participate in the study,Other,NA,NA,NA,NA,NA,NA,NA,NA
3,NCT00219076,Exclusion,severe hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00219076,Exclusion,severe hypertension,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
4,NCT00219076,Exclusion,history or evidence of a secondary form of hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
5,NCT00219076,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
5,NCT00219076,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident,Condition Occurrence,Condition,C0000924;C2046386,accident,FALSE,FALSE,NA,NA,NA
5,NCT00219076,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
6,NCT00219076,Exclusion,other protocol-defined may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00219089,Inclusion,patients with essential hypertension,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00219089,Inclusion,patients with a documented diagnosis of type 1 diabetes or type 2 diabetesmellitus .,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
2,NCT00219089,Inclusion,patients with a documented diagnosis of type 1 diabetes or type 2 diabetesmellitus .,Condition Occurrence,Procedure,C1301725,documented,FALSE,FALSE,NA,NA,NA
2,NCT00219089,Inclusion,patients with a documented diagnosis of type 1 diabetes or type 2 diabetesmellitus .,Condition Occurrence,Other,C1552651,type,FALSE,FALSE,NA,NA,NA
3,NCT00219089,Inclusion,patients who are eligible and able to participate in the study,Other,NA,NA,NA,NA,NA,NA,NA,NA
4,NCT00219089,Exclusion,severe hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
4,NCT00219089,Exclusion,severe hypertension,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
5,NCT00219089,Exclusion,history or evidence of a secondary form of hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
6,NCT00219089,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
6,NCT00219089,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident,Condition Occurrence,Condition,C0000924;C2046386,accident,FALSE,FALSE,NA,NA,NA
6,NCT00219089,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
7,NCT00219089,Exclusion,other protocol-defined may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00219102,Inclusion,patients with essential hypertension,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00219102,Inclusion,patients with a documented diagnosis of type 1 diabetes or type 2 diabetesmellitus .,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
2,NCT00219102,Inclusion,patients with a documented diagnosis of type 1 diabetes or type 2 diabetesmellitus .,Condition Occurrence,Procedure,C1301725,documented,FALSE,FALSE,NA,NA,NA
2,NCT00219102,Inclusion,patients with a documented diagnosis of type 1 diabetes or type 2 diabetesmellitus .,Condition Occurrence,Other,C1552651,type,FALSE,FALSE,NA,NA,NA
3,NCT00219102,Inclusion,patients who are eligible and able to participate in the study,Other,NA,NA,NA,NA,NA,NA,NA,NA
4,NCT00219102,Exclusion,severe hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
4,NCT00219102,Exclusion,severe hypertension,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
5,NCT00219102,Exclusion,uncontrolled diabetes type i and diabetes type ii,Condition Occurrence,Condition,C0011854,diabetes type i,FALSE,FALSE,NA,NA,NA
5,NCT00219102,Exclusion,uncontrolled diabetes type i and diabetes type ii,Condition Occurrence,Condition,C0011860,diabetes type ii,FALSE,FALSE,NA,NA,NA
6,NCT00219102,Exclusion,history or evidence of a secondary form of hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
7,NCT00219102,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident .,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
7,NCT00219102,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident .,Condition Occurrence,Condition,C0000924;C2046386,accident,FALSE,FALSE,NA,NA,NA
7,NCT00219102,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident .,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
8,NCT00219102,Exclusion,other protocol-defined may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00219115,Inclusion,patients with essential hypertension,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00219115,Inclusion,patients with body mass index > = 30 kg / m2,Observation,Observation,C0005893;C1305855;C2240399,body mass index,FALSE,FALSE,NA,greater_equal 30 kg/m2,NA
3,NCT00219115,Exclusion,severe hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00219115,Exclusion,severe hypertension,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
4,NCT00219115,Exclusion,history or evidence of a secondary form of hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
5,NCT00219115,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident .,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
5,NCT00219115,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident .,Condition Occurrence,Condition,C0000924;C2046386,accident,FALSE,FALSE,NA,NA,NA
5,NCT00219115,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident .,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
6,NCT00219115,Exclusion,other protocol-defined inclusion also apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00219128,Inclusion,patients with essential hypertension,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00219128,Inclusion,patients who are eligible and able to participate in the study,Other,NA,NA,NA,NA,NA,NA,NA,NA
3,NCT00219128,Exclusion,severe hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00219128,Exclusion,severe hypertension,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
4,NCT00219128,Exclusion,history or evidence of a secondary form of hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
5,NCT00219128,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident .,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
5,NCT00219128,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident .,Condition Occurrence,Condition,C0000924;C2046386,accident,FALSE,FALSE,NA,NA,NA
5,NCT00219128,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident .,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
6,NCT00219128,Exclusion,other protocol-defined may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00219141,Inclusion,patients with essential hypertension,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00219141,Inclusion,patients with a bmi > 25 kg / m2,Observation,Observation,C1305855;C1542867;C0005893,bmi,FALSE,FALSE,NA,greater 25 kg/m2,NA
3,NCT00219141,Inclusion,patients with lvh ( lvwt > = 1.33 cm ) confirmed by the echo,Observation,Condition,C0149721,lvh,FALSE,FALSE,NA,greater_equal 1.33 cm,NA
4,NCT00219141,Exclusion,patients treated with an ace or an arb within 3 months of study entry ( study visit 1 ) who are unable or unwilling to undergo the 3 month washout period .,Drug Exposure,Other,C0050385;C0201888,ace,FALSE,FALSE,lower 3 months,NA,NA
4,NCT00219141,Exclusion,patients treated with an ace or an arb within 3 months of study entry ( study visit 1 ) who are unable or unwilling to undergo the 3 month washout period .,Drug Exposure,Other,C0521942;C2678493,arb,FALSE,FALSE,lower 3 months,NA,NA
4,NCT00219141,Exclusion,patients treated with an ace or an arb within 3 months of study entry ( study visit 1 ) who are unable or unwilling to undergo the 3 month washout period .,Drug Exposure,Other,C1705654,entry,FALSE,FALSE,equal 3 month,NA,NA
5,NCT00219141,Exclusion,patients treated with an ace and arb combination at study entry .,Drug Exposure,Other,C0050385;C0201888,ace,FALSE,FALSE,NA,NA,NA
5,NCT00219141,Exclusion,patients treated with an ace and arb combination at study entry .,Drug Exposure,Other,C0521942;C2678493,arb,FALSE,FALSE,NA,NA,NA
5,NCT00219141,Exclusion,patients treated with an ace and arb combination at study entry .,Drug Exposure,Other,C1705654,entry,FALSE,FALSE,NA,NA,NA
6,NCT00219141,Exclusion,known secondary hypertension of any etiology ( eg ; uncorrected renal artery stenosis ) .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
6,NCT00219141,Exclusion,known secondary hypertension of any etiology ( eg ; uncorrected renal artery stenosis ) .,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
7,NCT00219141,Exclusion,other protocol related inclusiopplied to the study,Condition Occurrence,Condition,C0445223,related,FALSE,FALSE,NA,NA,NA
1,NCT00219154,Inclusion,NA,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00219154,Exclusion,severe hypertension,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
3,NCT00219154,Exclusion,history or evidence of a secondary form of hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
4,NCT00219154,Exclusion,history of myocardial infarction,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
5,NCT00219154,Exclusion,other protocol-defined inclusion also apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
2,NCT00219154,Exclusion,severe hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00219167,Inclusion,patients with at least 65 years-old,Other,NA,NA,NA,NA,NA,NA,NA,NA
2,NCT00219167,Inclusion,patients with essential hypertension,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00219167,Exclusion,severe hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00219167,Exclusion,severe hypertension,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
4,NCT00219167,Exclusion,history or evidence of a secondary form of hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
5,NCT00219167,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
5,NCT00219167,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident,Condition Occurrence,Condition,C0000924;C2046386,accident,FALSE,FALSE,NA,NA,NA
5,NCT00219167,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
6,NCT00219167,Exclusion,other protocol-defined inclusion also apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00219180,Inclusion,patients with essential hypertension,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00219180,Inclusion,patients who are eligible and able to participate in the study,Other,NA,NA,NA,NA,NA,NA,NA,NA
3,NCT00219180,Exclusion,severe hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
4,NCT00219180,Exclusion,history or evidence of a secondary form of hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00219180,Exclusion,severe hypertension,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
5,NCT00219180,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
5,NCT00219180,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident,Condition Occurrence,Condition,C0000924;C2046386,accident,FALSE,FALSE,NA,NA,NA
5,NCT00219180,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
6,NCT00219180,Exclusion,other protocol-defined may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00219193,Inclusion,patients with essential hypertension,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00219193,Inclusion,patients who are eligible and able to participate in the study,Other,NA,NA,NA,NA,NA,NA,NA,NA
3,NCT00219193,Exclusion,severe hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00219193,Exclusion,severe hypertension,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
4,NCT00219193,Exclusion,history or evidence of a secondary form of hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
5,NCT00219193,Exclusion,other protocol-defined may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00220220,Inclusion,mean sitting bp of greater than or equal to 140 / 90 - 115 mmhg and mean 24 h dbp greater than or equal to 80 mmhg with at least 30 % of daytime readings greater than 85 mmhg prior to randomization .,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
1,NCT00220220,Inclusion,mean sitting bp of greater than or equal to 140 / 90 - 115 mmhg and mean 24 h dbp greater than or equal to 80 mmhg with at least 30 % of daytime readings greater than 85 mmhg prior to randomization .,Observation,Drug,C1654656,daytime,FALSE,FALSE,NA,greater 85 mmhg,greater_equal 30 %
1,NCT00220220,Inclusion,mean sitting bp of greater than or equal to 140 / 90 - 115 mmhg and mean 24 h dbp greater than or equal to 80 mmhg with at least 30 % of daytime readings greater than 85 mmhg prior to randomization .,Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,NA,NA
1,NCT00220220,Inclusion,mean sitting bp of greater than or equal to 140 / 90 - 115 mmhg and mean 24 h dbp greater than or equal to 80 mmhg with at least 30 % of daytime readings greater than 85 mmhg prior to randomization .,Observation,Observation,C1305849,dbp,FALSE,FALSE,equal 24 h,greater_equal 80 mmhg,NA
2,NCT00220220,Exclusion,secondary hypertension of any aetiology ;,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00220220,Exclusion,any serious disorders which may limit the ability to evaluate the efficacy or safety of the test drug ( s ) ;,Observation,Observation,C0038577,test drug,FALSE,FALSE,NA,NA,NA
4,NCT00220220,Exclusion,history of myocardial infarction ; unstable angina pectoris ; percutaneous coronary intervention ; congestive heart failure ; hypertensive encephalopathy ; stroke or tia within the last 6 months,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
4,NCT00220220,Exclusion,history of myocardial infarction ; unstable angina pectoris ; percutaneous coronary intervention ; congestive heart failure ; hypertensive encephalopathy ; stroke or tia within the last 6 months,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
4,NCT00220220,Exclusion,history of myocardial infarction ; unstable angina pectoris ; percutaneous coronary intervention ; congestive heart failure ; hypertensive encephalopathy ; stroke or tia within the last 6 months,Condition Occurrence,Condition,C0002965,unstable angina pectoris,FALSE,FALSE,NA,NA,NA
4,NCT00220220,Exclusion,history of myocardial infarction ; unstable angina pectoris ; percutaneous coronary intervention ; congestive heart failure ; hypertensive encephalopathy ; stroke or tia within the last 6 months,Condition Occurrence,Condition,C0917805,tia,FALSE,FALSE,lower 6 last months,NA,NA
4,NCT00220220,Exclusion,history of myocardial infarction ; unstable angina pectoris ; percutaneous coronary intervention ; congestive heart failure ; hypertensive encephalopathy ; stroke or tia within the last 6 months,Condition Occurrence,Procedure,C1532338,percutaneous coronary intervention,FALSE,FALSE,NA,NA,NA
4,NCT00220220,Exclusion,history of myocardial infarction ; unstable angina pectoris ; percutaneous coronary intervention ; congestive heart failure ; hypertensive encephalopathy ; stroke or tia within the last 6 months,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
1,NCT00220233,Inclusion,without antihypertensive pre-treatment mean seated bp greater than 160 / 100 mmhg,Observation,Condition,C2257086,pre,TRUE,FALSE,NA,NA,NA
1,NCT00220233,Inclusion,without antihypertensive pre-treatment mean seated bp greater than 160 / 100 mmhg,Observation,Drug,C0003364,antihypertensive,TRUE,FALSE,NA,NA,NA
1,NCT00220233,Inclusion,without antihypertensive pre-treatment mean seated bp greater than 160 / 100 mmhg,Observation,Observation,C0005824;C0005823,bp,TRUE,FALSE,NA,greater 160 mmhg; greater 100 mmhg,NA
2,NCT00220233,Inclusion,pre-treatment with amlodipine 5 or 10 mg : mean seated bp greater than or equal to 140 / 90 mmhg,Observation,Condition,C2257086,pre,FALSE,FALSE,NA,NA,NA
2,NCT00220233,Inclusion,pre-treatment with amlodipine 5 or 10 mg : mean seated bp greater than or equal to 140 / 90 mmhg,Observation,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,equal 5 mg; equal 10 mg
2,NCT00220233,Inclusion,pre-treatment with amlodipine 5 or 10 mg : mean seated bp greater than or equal to 140 / 90 mmhg,Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,greater_equal 140 mmhg; greater_equal 90 mmhg,NA
3,NCT00220233,Exclusion,secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
4,NCT00220233,Exclusion,any serious disorder which may limit the ability to evaluate the efficacy or safety of the test drugs,Observation,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
4,NCT00220233,Exclusion,any serious disorder which may limit the ability to evaluate the efficacy or safety of the test drugs,Observation,Observation,C0022885;C2826273,test,FALSE,FALSE,NA,NA,NA
1,NCT00239369,Inclusion,essential hypertension .,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00239369,Inclusion,currently taking between one and three antihypertensive medications at a stable dose for at least four weeks before visit 1 .,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
2,NCT00239369,Inclusion,currently taking between one and three antihypertensive medications at a stable dose for at least four weeks before visit 1 .,Drug Exposure,Other,C1547311,stable,FALSE,FALSE,NA,NA,NA
3,NCT00239369,Inclusion,blood pressure not adequately controlled on existing treatment before entry ( inadequate control defined as seated dbp > = 95 mmhg on one current antihypertensive medication or dbp > = 90 mmhg on two or more current antihypertensive medication ( s ) .,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,greater_equal 90 mmhg,NA
3,NCT00239369,Inclusion,blood pressure not adequately controlled on existing treatment before entry ( inadequate control defined as seated dbp > = 95 mmhg on one current antihypertensive medication or dbp > = 90 mmhg on two or more current antihypertensive medication ( s ) .,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
3,NCT00239369,Inclusion,blood pressure not adequately controlled on existing treatment before entry ( inadequate control defined as seated dbp > = 95 mmhg on one current antihypertensive medication or dbp > = 90 mmhg on two or more current antihypertensive medication ( s ) .,Observation,Procedure,C2827950,existing treatment,TRUE,FALSE,NA,NA,NA
3,NCT00239369,Inclusion,blood pressure not adequately controlled on existing treatment before entry ( inadequate control defined as seated dbp > = 95 mmhg on one current antihypertensive medication or dbp > = 90 mmhg on two or more current antihypertensive medication ( s ) .,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
3,NCT00239369,Inclusion,blood pressure not adequately controlled on existing treatment before entry ( inadequate control defined as seated dbp > = 95 mmhg on one current antihypertensive medication or dbp > = 90 mmhg on two or more current antihypertensive medication ( s ) .,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 95 mmhg,NA
3,NCT00239369,Inclusion,blood pressure not adequately controlled on existing treatment before entry ( inadequate control defined as seated dbp > = 95 mmhg on one current antihypertensive medication or dbp > = 90 mmhg on two or more current antihypertensive medication ( s ) .,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 90 mmhg,NA
3,NCT00239369,Inclusion,blood pressure not adequately controlled on existing treatment before entry ( inadequate control defined as seated dbp > = 95 mmhg on one current antihypertensive medication or dbp > = 90 mmhg on two or more current antihypertensive medication ( s ) .,Observation,Other,C1705654,entry,FALSE,FALSE,NA,NA,NA
3,NCT00239369,Inclusion,blood pressure not adequately controlled on existing treatment before entry ( inadequate control defined as seated dbp > = 95 mmhg on one current antihypertensive medication or dbp > = 90 mmhg on two or more current antihypertensive medication ( s ) .,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
4,NCT00239369,Inclusion,failure to respond to six weeks treatment with t80 / h12,Other,NA,NA,NA,NA,NA,NA,NA,NA
5,NCT00239369,Inclusion,( failure to respond defined as seated dbp > = 90 mmhg at six weeks,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 90 mmhg,NA
5,NCT00239369,Inclusion,( failure to respond defined as seated dbp > = 90 mmhg at six weeks,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
6,NCT00239369,Inclusion,this criterion will be assessed at visit 3 ; ),Other,Other,C0243161,criterion,FALSE,FALSE,NA,NA,NA
7,NCT00239369,Inclusion,willing and able to provide written informed consent .,Other,NA,NA,NA,NA,NA,NA,NA,NA
8,NCT00239369,Exclusion,women of child-bearing potential not practising acceptable means of birth control ; positive serum pregnancy test ; breastfeeding .,Observation,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
8,NCT00239369,Exclusion,women of child-bearing potential not practising acceptable means of birth control ; positive serum pregnancy test ; breastfeeding .,Observation,Condition,C0006147;C1623041;C1623040,breastfeeding,FALSE,FALSE,NA,NA,NA
8,NCT00239369,Exclusion,women of child-bearing potential not practising acceptable means of birth control ; positive serum pregnancy test ; breastfeeding .,Observation,Observation,C3831118,child-bearing potential,FALSE,FALSE,NA,NA,NA
8,NCT00239369,Exclusion,women of child-bearing potential not practising acceptable means of birth control ; positive serum pregnancy test ; breastfeeding .,Observation,Observation,C1514241,positive,FALSE,FALSE,NA,NA,NA
8,NCT00239369,Exclusion,women of child-bearing potential not practising acceptable means of birth control ; positive serum pregnancy test ; breastfeeding .,Observation,Observation,C0430064,serum pregnancy test,FALSE,FALSE,NA,NA,NA
8,NCT00239369,Exclusion,women of child-bearing potential not practising acceptable means of birth control ; positive serum pregnancy test ; breastfeeding .,Observation,Other,C0700589;C2703065,birth control,TRUE,FALSE,NA,NA,NA
9,NCT00239369,Exclusion,known or suspected secondary hypertension .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
10,NCT00239369,Exclusion,mean sbp > = 200 mmhg .,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 200 mmhg,NA
11,NCT00239369,Exclusion,severe hepatic impairment or renal impairment .,Condition Occurrence,Condition,C0948807,hepatic impairment,FALSE,FALSE,NA,NA,NA
11,NCT00239369,Exclusion,severe hepatic impairment or renal impairment .,Condition Occurrence,Condition,C1565489;C0035078,renal impairment,FALSE,FALSE,NA,NA,NA
11,NCT00239369,Exclusion,severe hepatic impairment or renal impairment .,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
12,NCT00239369,Exclusion,bilateral renal artery stenosis ( or in a solitary kidney ) ; post-renal transplant or only one functioning kidney .,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
12,NCT00239369,Exclusion,bilateral renal artery stenosis ( or in a solitary kidney ) ; post-renal transplant or only one functioning kidney .,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
12,NCT00239369,Exclusion,bilateral renal artery stenosis ( or in a solitary kidney ) ; post-renal transplant or only one functioning kidney .,Condition Occurrence,Condition,C0478647,transplant,FALSE,FALSE,NA,NA,NA
12,NCT00239369,Exclusion,bilateral renal artery stenosis ( or in a solitary kidney ) ; post-renal transplant or only one functioning kidney .,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
13,NCT00239369,Exclusion,clinically relevant hypokalaemia or hyperkalaemia .,Other,NA,NA,NA,NA,NA,NA,NA,NA
14,NCT00239369,Exclusion,uncorrected volume or sodium depletion ; primary aldosteronism .,Condition Occurrence,Condition,C0020625,sodium depletion,FALSE,FALSE,NA,NA,NA
14,NCT00239369,Exclusion,uncorrected volume or sodium depletion ; primary aldosteronism .,Condition Occurrence,Condition,C1384514,primary aldosteronism,FALSE,FALSE,NA,NA,NA
14,NCT00239369,Exclusion,uncorrected volume or sodium depletion ; primary aldosteronism .,Condition Occurrence,Observation,C1705102;C2700258,volume,FALSE,FALSE,NA,NA,NA
15,NCT00239369,Exclusion,hereditary fructose intolerance .,Condition Occurrence,Condition,C0016751,hereditary fructose intolerance,FALSE,FALSE,NA,NA,NA
16,NCT00239369,Exclusion,previous symptoms of angioedema after ace inhibitors or angiotensin-ii receptor antagonists .,Drug Exposure,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
16,NCT00239369,Exclusion,previous symptoms of angioedema after ace inhibitors or angiotensin-ii receptor antagonists .,Drug Exposure,Drug,C0003015,ace inhibitors,FALSE,FALSE,NA,NA,NA
16,NCT00239369,Exclusion,previous symptoms of angioedema after ace inhibitors or angiotensin-ii receptor antagonists .,Drug Exposure,Other,C0373546;C0003009,angiotensin-ii,FALSE,FALSE,NA,NA,NA
17,NCT00239369,Exclusion,drug or alcohol dependency within the previous six months .,Condition Occurrence,Condition,C0001973,alcohol dependency,FALSE,FALSE,NA,NA,NA
17,NCT00239369,Exclusion,drug or alcohol dependency within the previous six months .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
18,NCT00239369,Exclusion,administration of any medication known to affect blood pressure .,Observation,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
18,NCT00239369,Exclusion,administration of any medication known to affect blood pressure .,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
19,NCT00239369,Exclusion,concurrent participation in another clinical trial or any investigational therapy .,Procedure,Procedure,C0949266,investigational therapy,FALSE,FALSE,NA,NA,NA
19,NCT00239369,Exclusion,concurrent participation in another clinical trial or any investigational therapy .,Procedure,Other,C1096775,clinical trial,FALSE,FALSE,NA,NA,NA
20,NCT00239369,Exclusion,hypertrophic obstructive cardiomyopathy ; hemodynamically relevant stenosis of the aortic valve or mitral valve .,Condition Occurrence,Condition,C0007194,hypertrophic obstructive cardiomyopathy,FALSE,FALSE,NA,NA,NA
20,NCT00239369,Exclusion,hypertrophic obstructive cardiomyopathy ; hemodynamically relevant stenosis of the aortic valve or mitral valve .,Condition Occurrence,Condition,C0003501;C1269005,aortic valve,FALSE,FALSE,NA,NA,NA
20,NCT00239369,Exclusion,hypertrophic obstructive cardiomyopathy ; hemodynamically relevant stenosis of the aortic valve or mitral valve .,Condition Occurrence,Condition,C0026264;C1269004,mitral valve,FALSE,FALSE,NA,NA,NA
20,NCT00239369,Exclusion,hypertrophic obstructive cardiomyopathy ; hemodynamically relevant stenosis of the aortic valve or mitral valve .,Condition Occurrence,Observation,C1261287;C0947637;C0009814,stenosis,FALSE,FALSE,NA,NA,NA
21,NCT00239369,Exclusion,allergic hypersensitivity to any component of the formulations under investigation .,Observation,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
22,NCT00239369,Exclusion,concomitant therapy with lithium ; cholestyramine or colestipol resins,Drug Exposure,Drug,C0009279,colestipol,FALSE,FALSE,NA,NA,NA
22,NCT00239369,Exclusion,concomitant therapy with lithium ; cholestyramine or colestipol resins,Drug Exposure,Drug,C0008402,cholestyramine,FALSE,FALSE,NA,NA,NA
22,NCT00239369,Exclusion,concomitant therapy with lithium ; cholestyramine or colestipol resins,Drug Exposure,Procedure,C1707479,concomitant therapy,FALSE,FALSE,NA,NA,NA
22,NCT00239369,Exclusion,concomitant therapy with lithium ; cholestyramine or colestipol resins,Drug Exposure,Other,C0337452;C0023870;C3540800,lithium,FALSE,FALSE,NA,NA,NA
23,NCT00239369,Exclusion,non-compliance with study medication ( less than 80 % or more than 120 % ) during th e run-in treatment period .,Drug Exposure,Condition,C0376405,non-compliance,FALSE,FALSE,NA,NA,lower 80 %; greater 120 %
24,NCT00239369,Exclusion,any other clinical condition which ; in the opinion of the investigator ; would not allow safe administration of telmisartan or hydrochlorothiazide,Drug Exposure,Drug,C0248719,telmisartan,TRUE,FALSE,NA,NA,NA
24,NCT00239369,Exclusion,any other clinical condition which ; in the opinion of the investigator ; would not allow safe administration of telmisartan or hydrochlorothiazide,Drug Exposure,Drug,C0020261,hydrochlorothiazide,FALSE,FALSE,NA,NA,NA
24,NCT00239369,Exclusion,any other clinical condition which ; in the opinion of the investigator ; would not allow safe administration of telmisartan or hydrochlorothiazide,Drug Exposure,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
1,NCT00240448,Inclusion,ability to provide written informed consent .,Other,NA,NA,NA,NA,NA,NA,NA,NA
2,NCT00240448,Inclusion,age 18 years or older .,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 18 years,NA,NA
3,NCT00240448,Inclusion,ability to stop current antihypertensive therapy without unacceptable risk to the patient ( investigator discretion ) . ;,Drug Exposure,Drug,C0723457,stop,FALSE,FALSE,NA,NA,NA
3,NCT00240448,Inclusion,ability to stop current antihypertensive therapy without unacceptable risk to the patient ( investigator discretion ) . ;,Drug Exposure,Procedure,C0585941,antihypertensive therapy,FALSE,FALSE,NA,NA,NA
4,NCT00240448,Inclusion,seated cuff dbp of 95 mmhg at visit 2 ( baseline ) .,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
4,NCT00240448,Inclusion,seated cuff dbp of 95 mmhg at visit 2 ( baseline ) .,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,equal 95 mmhg,NA
5,NCT00240448,Exclusion,pre-menopausal women ( last menstruation 1 year prior to start of run-in period ) who :,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
5,NCT00240448,Exclusion,pre-menopausal women ( last menstruation 1 year prior to start of run-in period ) who :,Condition Occurrence,Condition,C1096235,pre-menopausal,FALSE,FALSE,NA,NA,NA
5,NCT00240448,Exclusion,pre-menopausal women ( last menstruation 1 year prior to start of run-in period ) who :,Condition Occurrence,Condition,C0025344;C2129647,menstruation,FALSE,FALSE,equal 1 year,NA,NA
6,NCT00240448,Exclusion,are not surgically sterile or,Other,NA,NA,NA,NA,NA,NA,NA,NA
7,NCT00240448,Exclusion,are nursing or pregnant,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
7,NCT00240448,Exclusion,are nursing or pregnant,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
8,NCT00240448,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control ; do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in studies of > 3 - months duration,Observation,Observation,C3831118,child-bearing potential,FALSE,FALSE,NA,NA,NA
8,NCT00240448,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control ; do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in studies of > 3 - months duration,Observation,Observation,C0032976,pregnancy testing,FALSE,FALSE,NA,NA,NA
8,NCT00240448,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control ; do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in studies of > 3 - months duration,Observation,Observation,C0947630,studies,FALSE,FALSE,greater 3 months,NA,NA
8,NCT00240448,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control ; do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in studies of > 3 - months duration,Observation,Other,C0700589;C2703065,birth control,TRUE,FALSE,NA,NA,NA
8,NCT00240448,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control ; do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in studies of > 3 - months duration,Observation,Other,C2827714;C0871511;C2828387,method,FALSE,FALSE,NA,NA,NA
8,NCT00240448,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control ; do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in studies of > 3 - months duration,Observation,Other,C3641827,agree,FALSE,FALSE,NA,NA,NA
8,NCT00240448,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control ; do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in studies of > 3 - months duration,Observation,Other,C1706381,periodic,FALSE,FALSE,NA,NA,NA
9,NCT00240448,Exclusion,acceptable methods of birth control include oral ; implantable ; transdermal ; or injectable contraceptives ; and intra-uterine device ( iud ) .,Drug Exposure,Drug,C1272919,oral,FALSE,FALSE,NA,NA,NA
9,NCT00240448,Exclusion,acceptable methods of birth control include oral ; implantable ; transdermal ; or injectable contraceptives ; and intra-uterine device ( iud ) .,Drug Exposure,Drug,C0086466;C1272936,injectable,FALSE,FALSE,NA,NA,NA
9,NCT00240448,Exclusion,acceptable methods of birth control include oral ; implantable ; transdermal ; or injectable contraceptives ; and intra-uterine device ( iud ) .,Drug Exposure,Drug,C1706306,iud,FALSE,FALSE,NA,NA,NA
9,NCT00240448,Exclusion,acceptable methods of birth control include oral ; implantable ; transdermal ; or injectable contraceptives ; and intra-uterine device ( iud ) .,Drug Exposure,Other,C0025663,methods,FALSE,FALSE,NA,NA,NA
9,NCT00240448,Exclusion,acceptable methods of birth control include oral ; implantable ; transdermal ; or injectable contraceptives ; and intra-uterine device ( iud ) .,Drug Exposure,Other,C0700589;C2703065,birth control,FALSE,FALSE,NA,NA,NA
10,NCT00240448,Exclusion,known or suspected secondary hypertension .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
11,NCT00240448,Exclusion,mean seated sbp > = 180 mmhg or mean seated dbp > = 120 mmhg during any clinic visit prior to randomization .,Observation,Procedure,C0008952,clinic visit,FALSE,FALSE,NA,NA,NA
11,NCT00240448,Exclusion,mean seated sbp > = 180 mmhg or mean seated dbp > = 120 mmhg during any clinic visit prior to randomization .,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 180 mmhg,NA
11,NCT00240448,Exclusion,mean seated sbp > = 180 mmhg or mean seated dbp > = 120 mmhg during any clinic visit prior to randomization .,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 120 mmhg,NA
12,NCT00240448,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Condition,C0086565,hepatic dysfunction,FALSE,FALSE,NA,NA,NA
12,NCT00240448,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
12,NCT00240448,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
12,NCT00240448,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
13,NCT00240448,Exclusion,sgpt ( alt ) or sgot ( ast ) > 2 times the upper limit of normal range ; or,Observation,Observation,C0376147;C0036828,sgpt,FALSE,FALSE,NA,NA,NA
13,NCT00240448,Exclusion,sgpt ( alt ) or sgot ( ast ) > 2 times the upper limit of normal range ; or,Observation,Observation,C1140170;C2257651,alt,FALSE,FALSE,NA,NA,NA
13,NCT00240448,Exclusion,sgpt ( alt ) or sgot ( ast ) > 2 times the upper limit of normal range ; or,Observation,Observation,C0242192;C0201899,sgot,FALSE,FALSE,NA,NA,NA
13,NCT00240448,Exclusion,sgpt ( alt ) or sgot ( ast ) > 2 times the upper limit of normal range ; or,Observation,Observation,C0004002,ast,FALSE,FALSE,NA,NA,NA
13,NCT00240448,Exclusion,sgpt ( alt ) or sgot ( ast ) > 2 times the upper limit of normal range ; or,Observation,Observation,C3542016,range,FALSE,FALSE,NA,NA,greater 2 times the upper limit of normal
14,NCT00240448,Exclusion,serum creatinine > 3.0 mg / dl or creatinine clearance < 0.6 ml / sec .,Drug Exposure,Drug,C0059387,sec,FALSE,FALSE,NA,NA,NA
14,NCT00240448,Exclusion,serum creatinine > 3.0 mg / dl or creatinine clearance < 0.6 ml / sec .,Drug Exposure,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,NA,greater 3.0 mg/dl; lower 0.6 ml
14,NCT00240448,Exclusion,serum creatinine > 3.0 mg / dl or creatinine clearance < 0.6 ml / sec .,Drug Exposure,Observation,C0373595;C0812399,creatinine clearance,FALSE,FALSE,NA,NA,lower 0.6 ml
15,NCT00240448,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant or with only one kidney .,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
15,NCT00240448,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant or with only one kidney .,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
15,NCT00240448,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant or with only one kidney .,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
15,NCT00240448,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant or with only one kidney .,Condition Occurrence,Condition,C0478647,transplant,FALSE,FALSE,NA,NA,NA
15,NCT00240448,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant or with only one kidney .,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
16,NCT00240448,Exclusion,clinically relevant hypokalemia or hyperkalemia .,Condition Occurrence,Condition,C0020621,hypokalemia,FALSE,FALSE,NA,NA,NA
16,NCT00240448,Exclusion,clinically relevant hypokalemia or hyperkalemia .,Condition Occurrence,Condition,C0020461,hyperkalemia,FALSE,FALSE,NA,NA,NA
17,NCT00240448,Exclusion,uncorrected volume depletion .,Condition Occurrence,Condition,C0546884,volume depletion,FALSE,FALSE,NA,NA,NA
18,NCT00240448,Exclusion,uncorrected sodium depletion .,Condition Occurrence,Condition,C0020625,sodium depletion,FALSE,FALSE,NA,NA,NA
19,NCT00240448,Exclusion,primary aldosteronism .,Condition Occurrence,Condition,C1384514,primary aldosteronism,FALSE,FALSE,NA,NA,NA
20,NCT00240448,Exclusion,hereditary fructose intolerance .,Condition Occurrence,Condition,C0016751,hereditary fructose intolerance,FALSE,FALSE,NA,NA,NA
21,NCT00240448,Exclusion,biliary obstructive disorders ; cholestasis or moderate to severe hepatic insufficiency .,Condition Occurrence,Condition,C0008370,cholestasis,FALSE,FALSE,NA,NA,NA
21,NCT00240448,Exclusion,biliary obstructive disorders ; cholestasis or moderate to severe hepatic insufficiency .,Condition Occurrence,Condition,C1306571,hepatic insufficiency,FALSE,FALSE,NA,NA,NA
21,NCT00240448,Exclusion,biliary obstructive disorders ; cholestasis or moderate to severe hepatic insufficiency .,Condition Occurrence,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
21,NCT00240448,Exclusion,biliary obstructive disorders ; cholestasis or moderate to severe hepatic insufficiency .,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
22,NCT00240448,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or angiotensin ii receptor antagonists .,Condition Occurrence,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
22,NCT00240448,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or angiotensin ii receptor antagonists .,Condition Occurrence,Drug,C0003015,ace inhibitors,FALSE,FALSE,NA,NA,NA
22,NCT00240448,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or angiotensin ii receptor antagonists .,Condition Occurrence,Other,C0521942;C2757003,angiotensin ii receptor antagonists,FALSE,FALSE,NA,NA,NA
23,NCT00240448,Exclusion,history of drug or alcohol dependency within six months prior to start of run-in period .,Condition Occurrence,Condition,C0001973,alcohol dependency,FALSE,FALSE,NA,NA,NA
23,NCT00240448,Exclusion,history of drug or alcohol dependency within six months prior to start of run-in period .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
24,NCT00240448,Exclusion,chronic administration of any medications known to affect blood pressure ; etc .,Observation,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
24,NCT00240448,Exclusion,chronic administration of any medications known to affect blood pressure ; etc .,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
24,NCT00240448,Exclusion,chronic administration of any medications known to affect blood pressure ; etc .,Observation,Other,C1547296;C1555457,chronic,FALSE,FALSE,NA,NA,NA
25,NCT00240448,Exclusion,any investigational drug therapy within one month of start of run-in period .,Drug Exposure,Drug,C0013230,investigational drug,FALSE,FALSE,NA,NA,NA
26,NCT00240448,Exclusion,known hypersensitivity to any component of the formulation study drugs ( telmisartan ; valsartan ; hct ) .,Observation,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,NA
26,NCT00240448,Exclusion,known hypersensitivity to any component of the formulation study drugs ( telmisartan ; valsartan ; hct ) .,Observation,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
26,NCT00240448,Exclusion,known hypersensitivity to any component of the formulation study drugs ( telmisartan ; valsartan ; hct ) .,Observation,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
26,NCT00240448,Exclusion,known hypersensitivity to any component of the formulation study drugs ( telmisartan ; valsartan ; hct ) .,Observation,Observation,C0018935;C0472699,hct,FALSE,FALSE,NA,NA,NA
27,NCT00240448,Exclusion,contra-indication to a placebo run-in period ( eg stroke within the past six months ; mi ; cardia surgery ; ptca or angina within the past three months prior to the start of run-in period .,Condition Occurrence,Condition,C0153417;C0007144,cardia,FALSE,FALSE,NA,NA,NA
27,NCT00240448,Exclusion,contra-indication to a placebo run-in period ( eg stroke within the past six months ; mi ; cardia surgery ; ptca or angina within the past three months prior to the start of run-in period .,Condition Occurrence,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,NA
27,NCT00240448,Exclusion,contra-indication to a placebo run-in period ( eg stroke within the past six months ; mi ; cardia surgery ; ptca or angina within the past three months prior to the start of run-in period .,Condition Occurrence,Procedure,C2936173;C0002997,ptca,FALSE,FALSE,NA,NA,NA
27,NCT00240448,Exclusion,contra-indication to a placebo run-in period ( eg stroke within the past six months ; mi ; cardia surgery ; ptca or angina within the past three months prior to the start of run-in period .,Condition Occurrence,Other,C1301624;C1547316,contra-indication,FALSE,FALSE,NA,NA,NA
27,NCT00240448,Exclusion,contra-indication to a placebo run-in period ( eg stroke within the past six months ; mi ; cardia surgery ; ptca or angina within the past three months prior to the start of run-in period .,Condition Occurrence,Other,C0027051;C0025953;C3496280;C0278960,mi,FALSE,FALSE,NA,NA,NA
27,NCT00240448,Exclusion,contra-indication to a placebo run-in period ( eg stroke within the past six months ; mi ; cardia surgery ; ptca or angina within the past three months prior to the start of run-in period .,Condition Occurrence,Other,C0543467;C1457907,surgery,FALSE,FALSE,NA,NA,NA
27,NCT00240448,Exclusion,contra-indication to a placebo run-in period ( eg stroke within the past six months ; mi ; cardia surgery ; ptca or angina within the past three months prior to the start of run-in period .,Condition Occurrence,Other,C0002962;C2024883;C2926611,angina,FALSE,FALSE,NA,NA,NA
28,NCT00240448,Exclusion,any other clinical condition which ; in the opinion of the principal investigator ; would not allow safe completion of the protocol and safe administration of telmisartan ; valsartan ; or hct .,Drug Exposure,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,NA
28,NCT00240448,Exclusion,any other clinical condition which ; in the opinion of the principal investigator ; would not allow safe completion of the protocol and safe administration of telmisartan ; valsartan ; or hct .,Drug Exposure,Observation,C0018935;C0472699,hct,FALSE,FALSE,NA,NA,NA
28,NCT00240448,Exclusion,any other clinical condition which ; in the opinion of the principal investigator ; would not allow safe completion of the protocol and safe administration of telmisartan ; valsartan ; or hct .,Drug Exposure,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
29,NCT00240448,Exclusion,night shift workers .,Condition Occurrence,Condition,C0555008,night shift workers,FALSE,FALSE,NA,NA,NA
30,NCT00240448,Exclusion,clinically significant ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator .,Condition Occurrence,Condition,C0042514;C1963247;C2108113,ventricular tachycardia,FALSE,FALSE,NA,NA,NA
30,NCT00240448,Exclusion,clinically significant ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator .,Condition Occurrence,Condition,C0004239;C1963068,atrial flutter,FALSE,FALSE,NA,NA,NA
30,NCT00240448,Exclusion,clinically significant ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator .,Condition Occurrence,Condition,C0003811,cardiac arrhythmias,FALSE,FALSE,NA,NA,NA
30,NCT00240448,Exclusion,clinically significant ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator .,Condition Occurrence,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
31,NCT00240448,Exclusion,nyha functional class chf iii-iv .,Condition Occurrence,Condition,C0018802,chf,FALSE,FALSE,NA,NA,NA
31,NCT00240448,Exclusion,nyha functional class chf iii-iv .,Condition Occurrence,Other,C0456387;C0489477,class,FALSE,FALSE,NA,NA,NA
31,NCT00240448,Exclusion,nyha functional class chf iii-iv .,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii,FALSE,FALSE,NA,NA,NA
32,NCT00240448,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of aortic valve or mitral valve .,Condition Occurrence,Condition,C0007194,hypertrophic obstructive cardiomyopathy,FALSE,FALSE,NA,NA,NA
32,NCT00240448,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of aortic valve or mitral valve .,Condition Occurrence,Condition,C0003507,aortic stenosis,FALSE,FALSE,NA,NA,NA
32,NCT00240448,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of aortic valve or mitral valve .,Condition Occurrence,Condition,C0003501;C1269005,aortic valve,FALSE,FALSE,NA,NA,NA
32,NCT00240448,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of aortic valve or mitral valve .,Condition Occurrence,Condition,C0026264;C1269004,mitral valve,FALSE,FALSE,NA,NA,NA
32,NCT00240448,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of aortic valve or mitral valve .,Condition Occurrence,Observation,C1261287;C0947637;C0009814,stenosis,FALSE,FALSE,NA,NA,NA
33,NCT00240448,Exclusion,patients whose diabetes has been unstable and uncontrolled for at least the past 3 months as defined by a hba1c > / = 10 % . ;,Condition Occurrence,Condition,C0011849;C0011847,diabetes,FALSE,FALSE,NA,NA,NA
33,NCT00240448,Exclusion,patients whose diabetes has been unstable and uncontrolled for at least the past 3 months as defined by a hba1c > / = 10 % . ;,Condition Occurrence,Condition,C0443343,unstable,FALSE,FALSE,greater_equal 3 past months,NA,NA
33,NCT00240448,Exclusion,patients whose diabetes has been unstable and uncontrolled for at least the past 3 months as defined by a hba1c > / = 10 % . ;,Condition Occurrence,Observation,C0202054,hba1c,FALSE,FALSE,NA,NA,greater_equal 10 %
33,NCT00240448,Exclusion,patients whose diabetes has been unstable and uncontrolled for at least the past 3 months as defined by a hba1c > / = 10 % . ;,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
34,NCT00240448,Exclusion,concomitant use of lithium or cholestyramine or colestipol resins ( potential drug interactions with hct ) .,Drug Exposure,Condition,C0687133,drug interactions,FALSE,FALSE,NA,NA,NA
34,NCT00240448,Exclusion,concomitant use of lithium or cholestyramine or colestipol resins ( potential drug interactions with hct ) .,Drug Exposure,Drug,C0009279,colestipol,FALSE,FALSE,NA,NA,NA
34,NCT00240448,Exclusion,concomitant use of lithium or cholestyramine or colestipol resins ( potential drug interactions with hct ) .,Drug Exposure,Drug,C0008402,cholestyramine,FALSE,FALSE,NA,NA,NA
34,NCT00240448,Exclusion,concomitant use of lithium or cholestyramine or colestipol resins ( potential drug interactions with hct ) .,Drug Exposure,Observation,C0018935;C0472699,hct,FALSE,FALSE,NA,NA,NA
34,NCT00240448,Exclusion,concomitant use of lithium or cholestyramine or colestipol resins ( potential drug interactions with hct ) .,Drug Exposure,Other,C0337452;C0023870;C3540800,lithium,FALSE,FALSE,NA,NA,NA
35,NCT00240448,Exclusion,history of non-compliance with prescribed medication or protocol procedures,Condition Occurrence,Condition,C0376405,non-compliance,FALSE,FALSE,NA,NA,NA
35,NCT00240448,Exclusion,history of non-compliance with prescribed medication or protocol procedures,Condition Occurrence,Procedure,C0278329,prescribed,FALSE,FALSE,NA,NA,NA
1,NCT00240474,Inclusion,aged at least 60 years old,Other,Person,C0001792,aged,FALSE,FALSE,greater_equal 60 years,NA,NA
2,NCT00240474,Inclusion,mean sbp greater than 140 mmhg and mean dbp less than or equal to 95 mmhg,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater 140 mmhg,NA
2,NCT00240474,Inclusion,mean sbp greater than 140 mmhg and mean dbp less than or equal to 95 mmhg,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,lower_equal 95 mmhg,NA
3,NCT00240474,Inclusion,24 - hour mean ambulatory sbp greater than 125 mmhg,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater 125 mmhg,NA
3,NCT00240474,Inclusion,24 - hour mean ambulatory sbp greater than 125 mmhg,Observation,Other,C1561560;C1547135,ambulatory,FALSE,FALSE,equal 24 hour,NA,NA
4,NCT00240474,Inclusion,hypertensive patients not on current antihypertensive therapy or able to stop their current treatment for a period of up to eighteen weeks,Procedure,Condition,C0857121,hypertensive,FALSE,FALSE,NA,NA,NA
4,NCT00240474,Inclusion,hypertensive patients not on current antihypertensive therapy or able to stop their current treatment for a period of up to eighteen weeks,Procedure,Drug,C0723457,stop,FALSE,FALSE,NA,NA,NA
4,NCT00240474,Inclusion,hypertensive patients not on current antihypertensive therapy or able to stop their current treatment for a period of up to eighteen weeks,Procedure,Procedure,C0585941,antihypertensive therapy,TRUE,FALSE,NA,NA,NA
4,NCT00240474,Inclusion,hypertensive patients not on current antihypertensive therapy or able to stop their current treatment for a period of up to eighteen weeks,Procedure,Procedure,C2827774,current treatment,FALSE,FALSE,NA,NA,NA
5,NCT00240474,Inclusion,willing and able to provide written informed consent,Other,NA,NA,NA,NA,NA,NA,NA,NA
6,NCT00240474,Exclusion,women of child-bearing potential who are not practicing acceptable means of birth control,Person,Observation,C3831118,child-bearing potential,FALSE,FALSE,NA,NA,NA
6,NCT00240474,Exclusion,women of child-bearing potential who are not practicing acceptable means of birth control,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
6,NCT00240474,Exclusion,women of child-bearing potential who are not practicing acceptable means of birth control,Person,Other,C0700589;C2703065,birth control,TRUE,FALSE,NA,NA,NA
7,NCT00240474,Exclusion,known or suspected secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
8,NCT00240474,Exclusion,mean sbp equal to or greater than 200 mmhg,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 200 mmhg,NA
9,NCT00240474,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Condition,C0086565,hepatic dysfunction,FALSE,FALSE,NA,NA,NA
9,NCT00240474,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
9,NCT00240474,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
9,NCT00240474,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
10,NCT00240474,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; patients post-renal transplant or with only one functioning kidney,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
10,NCT00240474,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; patients post-renal transplant or with only one functioning kidney,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
10,NCT00240474,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; patients post-renal transplant or with only one functioning kidney,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
10,NCT00240474,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; patients post-renal transplant or with only one functioning kidney,Condition Occurrence,Condition,C0478647,transplant,FALSE,FALSE,NA,NA,NA
10,NCT00240474,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; patients post-renal transplant or with only one functioning kidney,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
11,NCT00240474,Exclusion,clinically relevant hypokalemia or hyperkalemia,Condition Occurrence,Condition,C0020621,hypokalemia,FALSE,FALSE,NA,NA,NA
11,NCT00240474,Exclusion,clinically relevant hypokalemia or hyperkalemia,Condition Occurrence,Condition,C0020461,hyperkalemia,FALSE,FALSE,NA,NA,NA
12,NCT00240474,Exclusion,uncorrected volume or sodium depletion,Condition Occurrence,Condition,C0020625,sodium depletion,FALSE,FALSE,NA,NA,NA
12,NCT00240474,Exclusion,uncorrected volume or sodium depletion,Condition Occurrence,Observation,C1705102;C2700258,volume,FALSE,FALSE,NA,NA,NA
13,NCT00240474,Exclusion,primary aldosteronism,Condition Occurrence,Condition,C1384514,primary aldosteronism,FALSE,FALSE,NA,NA,NA
14,NCT00240474,Exclusion,hereditary fructose intolerance,Condition Occurrence,Condition,C0016751,hereditary fructose intolerance,FALSE,FALSE,NA,NA,NA
15,NCT00240474,Exclusion,biliary obstructive disorders,Other,NA,NA,NA,NA,NA,NA,NA,NA
16,NCT00240474,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or angiotensin-ii receptor antagonists,Drug Exposure,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
16,NCT00240474,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or angiotensin-ii receptor antagonists,Drug Exposure,Drug,C0003015,ace inhibitors,FALSE,FALSE,NA,NA,NA
16,NCT00240474,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or angiotensin-ii receptor antagonists,Drug Exposure,Other,C0373546;C0003009,angiotensin-ii,FALSE,FALSE,NA,NA,NA
17,NCT00240474,Exclusion,history of drug or alcohol dependency within the previous six months,Condition Occurrence,Condition,C0001973,alcohol dependency,FALSE,FALSE,NA,NA,NA
17,NCT00240474,Exclusion,history of drug or alcohol dependency within the previous six months,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
18,NCT00240474,Exclusion,chronic administration of any medication known to affect blood pressure ; other than the trial medication,Observation,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
18,NCT00240474,Exclusion,chronic administration of any medication known to affect blood pressure ; other than the trial medication,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
18,NCT00240474,Exclusion,chronic administration of any medication known to affect blood pressure ; other than the trial medication,Observation,Other,C1547296;C1555457,chronic,FALSE,FALSE,NA,NA,NA
19,NCT00240474,Exclusion,concurrent participation in another clinical trial or any investigational therapy within thirty days prior to signing the consent form .,Other,Procedure,C0949266,investigational therapy,FALSE,FALSE,NA,NA,NA
19,NCT00240474,Exclusion,concurrent participation in another clinical trial or any investigational therapy within thirty days prior to signing the consent form .,Other,Other,C1096775,clinical trial,FALSE,FALSE,NA,NA,NA
19,NCT00240474,Exclusion,concurrent participation in another clinical trial or any investigational therapy within thirty days prior to signing the consent form .,Other,Other,C0009797,consent form,FALSE,FALSE,NA,NA,NA
20,NCT00240474,Exclusion,symptomatic congestive heart failure ( new york heart academy ( nyha ) functional class chf ii-,Condition Occurrence,Condition,C0742758,symptomatic congestive heart failure,FALSE,FALSE,NA,NA,NA
20,NCT00240474,Exclusion,symptomatic congestive heart failure ( new york heart academy ( nyha ) functional class chf ii-,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
20,NCT00240474,Exclusion,symptomatic congestive heart failure ( new york heart academy ( nyha ) functional class chf ii-,Condition Occurrence,Condition,C0018802,chf,FALSE,FALSE,NA,NA,NA
20,NCT00240474,Exclusion,symptomatic congestive heart failure ( new york heart academy ( nyha ) functional class chf ii-,Condition Occurrence,Other,C0456387;C0489477,class,FALSE,FALSE,NA,NA,NA
21,NCT00240474,Exclusion,unstable angina pectoris ; myocardial infarction ; percutaneous transluminal coronary angioplasty ( ptca ) or coronary artery bypass graft ( cabg ) surgery less than three months prior to informed consent,Procedure,Condition,C0002965,unstable angina pectoris,FALSE,FALSE,NA,NA,NA
21,NCT00240474,Exclusion,unstable angina pectoris ; myocardial infarction ; percutaneous transluminal coronary angioplasty ( ptca ) or coronary artery bypass graft ( cabg ) surgery less than three months prior to informed consent,Procedure,Procedure,C2936173,percutaneous transluminal coronary angioplasty,FALSE,FALSE,NA,NA,NA
21,NCT00240474,Exclusion,unstable angina pectoris ; myocardial infarction ; percutaneous transluminal coronary angioplasty ( ptca ) or coronary artery bypass graft ( cabg ) surgery less than three months prior to informed consent,Procedure,Procedure,C2936173;C0002997,ptca,FALSE,FALSE,NA,NA,NA
21,NCT00240474,Exclusion,unstable angina pectoris ; myocardial infarction ; percutaneous transluminal coronary angioplasty ( ptca ) or coronary artery bypass graft ( cabg ) surgery less than three months prior to informed consent,Procedure,Procedure,C0010055,coronary artery bypass graft,FALSE,FALSE,NA,NA,NA
21,NCT00240474,Exclusion,unstable angina pectoris ; myocardial infarction ; percutaneous transluminal coronary angioplasty ( ptca ) or coronary artery bypass graft ( cabg ) surgery less than three months prior to informed consent,Procedure,Procedure,C0010055,cabg,FALSE,FALSE,NA,NA,NA
21,NCT00240474,Exclusion,unstable angina pectoris ; myocardial infarction ; percutaneous transluminal coronary angioplasty ( ptca ) or coronary artery bypass graft ( cabg ) surgery less than three months prior to informed consent,Procedure,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
21,NCT00240474,Exclusion,unstable angina pectoris ; myocardial infarction ; percutaneous transluminal coronary angioplasty ( ptca ) or coronary artery bypass graft ( cabg ) surgery less than three months prior to informed consent,Procedure,Other,C0543467;C1457907,surgery,FALSE,FALSE,NA,NA,NA
22,NCT00240474,Exclusion,stroke less than six months prior to informed consent,Other,NA,NA,NA,NA,NA,NA,NA,NA
23,NCT00240474,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0750197,sustained ventricular tachycardia,FALSE,FALSE,NA,NA,NA
23,NCT00240474,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0004239;C1963068,atrial flutter,FALSE,FALSE,NA,NA,NA
23,NCT00240474,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0003811,arrhythmias,FALSE,FALSE,NA,NA,NA
23,NCT00240474,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant arrhythmias as determined by the investigator,Condition Occurrence,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
24,NCT00240474,Exclusion,hypertrophic obstructive cardiomyopathy ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0007194,hypertrophic obstructive cardiomyopathy,FALSE,FALSE,NA,NA,NA
24,NCT00240474,Exclusion,hypertrophic obstructive cardiomyopathy ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0003501;C1269005,aortic valve,FALSE,FALSE,NA,NA,NA
24,NCT00240474,Exclusion,hypertrophic obstructive cardiomyopathy ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0026264;C1269004,mitral valve,FALSE,FALSE,NA,NA,NA
24,NCT00240474,Exclusion,hypertrophic obstructive cardiomyopathy ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Observation,C1261287;C0947637;C0009814,stenosis,FALSE,FALSE,NA,NA,NA
25,NCT00240474,Exclusion,insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for the previous three months,Condition Occurrence,Condition,C0011854,insulin-dependent diabetes mellitus,FALSE,FALSE,NA,NA,NA
25,NCT00240474,Exclusion,insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for the previous three months,Condition Occurrence,Condition,C0011849;C0011847,diabetes,FALSE,FALSE,NA,NA,NA
25,NCT00240474,Exclusion,insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for the previous three months,Condition Occurrence,Other,C1547311,stable,TRUE,FALSE,NA,NA,NA
26,NCT00240474,Exclusion,night-shift workers who routinely sleep during the daytime and whose working hours include midnight to 4 : 00 am,Observation,Person,C1527116,workers,FALSE,FALSE,NA,NA,NA
26,NCT00240474,Exclusion,night-shift workers who routinely sleep during the daytime and whose working hours include midnight to 4 : 00 am,Observation,Drug,C1654656,daytime,FALSE,FALSE,NA,equal 4 ; equal 00,NA
26,NCT00240474,Exclusion,night-shift workers who routinely sleep during the daytime and whose working hours include midnight to 4 : 00 am,Observation,Other,C0037313;C0723362,sleep,FALSE,FALSE,NA,NA,NA
27,NCT00240474,Exclusion,known allergic hypersensitivity to any component of the formulations under investigation,Observation,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
28,NCT00240474,Exclusion,concomitant therapy with lithium ; cholestyramine or colestipol resins,Drug Exposure,Drug,C0009279,colestipol,FALSE,FALSE,NA,NA,NA
28,NCT00240474,Exclusion,concomitant therapy with lithium ; cholestyramine or colestipol resins,Drug Exposure,Drug,C0008402,cholestyramine,FALSE,FALSE,NA,NA,NA
28,NCT00240474,Exclusion,concomitant therapy with lithium ; cholestyramine or colestipol resins,Drug Exposure,Procedure,C1707479,concomitant therapy,FALSE,FALSE,NA,NA,NA
28,NCT00240474,Exclusion,concomitant therapy with lithium ; cholestyramine or colestipol resins,Drug Exposure,Other,C0337452;C0023870;C3540800,lithium,FALSE,FALSE,NA,NA,NA
29,NCT00240474,Exclusion,non-compliance with study medication ( defined as less than 80 % or more than 120 % ) during the run-in period,Drug Exposure,Condition,C0376405,non-compliance,FALSE,FALSE,NA,NA,NA
29,NCT00240474,Exclusion,non-compliance with study medication ( defined as less than 80 % or more than 120 % ) during the run-in period,Drug Exposure,Other,C3539106,defined,FALSE,FALSE,NA,NA,lower 80 %; greater 120 %
30,NCT00240474,Exclusion,current treatment with any antihypertensive agent,Drug Exposure,Drug,C0003364,antihypertensive agent,FALSE,FALSE,NA,NA,NA
30,NCT00240474,Exclusion,current treatment with any antihypertensive agent,Drug Exposure,Procedure,C2827774,current treatment,FALSE,FALSE,NA,NA,NA
31,NCT00240474,Exclusion,any other clinical condition which ; in the opinion of the investigator ; would not allow safe completion of the protocol and safe administration of telmisartan ; amlodipine or hydrochlorothiazide,Drug Exposure,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,NA
31,NCT00240474,Exclusion,any other clinical condition which ; in the opinion of the investigator ; would not allow safe completion of the protocol and safe administration of telmisartan ; amlodipine or hydrochlorothiazide,Drug Exposure,Drug,C0020261,hydrochlorothiazide,FALSE,FALSE,NA,NA,NA
31,NCT00240474,Exclusion,any other clinical condition which ; in the opinion of the investigator ; would not allow safe completion of the protocol and safe administration of telmisartan ; amlodipine or hydrochlorothiazide,Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,NA
31,NCT00240474,Exclusion,any other clinical condition which ; in the opinion of the investigator ; would not allow safe completion of the protocol and safe administration of telmisartan ; amlodipine or hydrochlorothiazide,Drug Exposure,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
1,NCT00260923,Inclusion,male and female outpatients 18 years of age and older,Person,Person,C0025266,male,FALSE,FALSE,equal 18 years,NA,NA
1,NCT00260923,Inclusion,male and female outpatients 18 years of age and older,Person,Person,C0086287,female,FALSE,FALSE,equal 18 years,NA,NA
2,NCT00260923,Inclusion,patients who are eligible and able to participate in the study,Other,NA,NA,NA,NA,NA,NA,NA,NA
3,NCT00260923,Exclusion,severe hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00260923,Exclusion,severe hypertension,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
4,NCT00260923,Exclusion,history or evidence of a secondary form of hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
5,NCT00260923,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident .,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
5,NCT00260923,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident .,Condition Occurrence,Condition,C0000924;C2046386,accident,FALSE,FALSE,NA,NA,NA
5,NCT00260923,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident .,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
6,NCT00260923,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00262236,Inclusion,outpatients 18 years of age and older .,Person,Person,C0001779,age,FALSE,FALSE,equal 18 years,NA,NA
2,NCT00262236,Inclusion,patients with essential hypertension .,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00262236,Inclusion,outpatients 18 years of age and older .,Person,Person,C0001779,older,FALSE,FALSE,equal 18 years,NA,NA
3,NCT00262236,Exclusion,severe hypertension ; current diagnosis of heart failure ; history or evidence of a secondary form of hypertension ; participation in any investigational drug study within one month of planned participation ;,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
3,NCT00262236,Exclusion,severe hypertension ; current diagnosis of heart failure ; history or evidence of a secondary form of hypertension ; participation in any investigational drug study within one month of planned participation ;,Condition Occurrence,Drug,C0013230,investigational drug,FALSE,FALSE,NA,NA,NA
3,NCT00262236,Exclusion,severe hypertension ; current diagnosis of heart failure ; history or evidence of a secondary form of hypertension ; participation in any investigational drug study within one month of planned participation ;,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00262236,Exclusion,severe hypertension ; current diagnosis of heart failure ; history or evidence of a secondary form of hypertension ; participation in any investigational drug study within one month of planned participation ;,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00262236,Exclusion,severe hypertension ; current diagnosis of heart failure ; history or evidence of a secondary form of hypertension ; participation in any investigational drug study within one month of planned participation ;,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
4,NCT00262236,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00264212,Inclusion,main criteria are listed hereafter :,Other,NA,NA,NA,NA,NA,NA,NA,NA
2,NCT00264212,Inclusion,at screening,Other,NA,NA,NA,NA,NA,NA,NA,NA
3,NCT00264212,Inclusion,outpatients,Other,NA,NA,NA,NA,NA,NA,NA,NA
4,NCT00264212,Inclusion,with newly diagnosed and untreated or previously diagnosed ; treated and uncontrolled isolated systolic hypertension defined as :,Condition Occurrence,Condition,C0745133,isolated systolic hypertension,FALSE,FALSE,NA,NA,NA
4,NCT00264212,Inclusion,with newly diagnosed and untreated or previously diagnosed ; treated and uncontrolled isolated systolic hypertension defined as :,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
5,NCT00264212,Inclusion,seated systolic blood pressure ( sbp ) > = 160 mmhg and < 220 mmhg [ 160 - 220 [,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,NA,NA
5,NCT00264212,Inclusion,seated systolic blood pressure ( sbp ) > = 160 mmhg and < 220 mmhg [ 160 - 220 [,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 160 mmhg; lower 220 mmhg; greater_equal 160 ; lower_equal 220,NA
6,NCT00264212,Inclusion,and seated diastolic blood pressure ( dbp ) < 90 mmhg,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,NA,NA
6,NCT00264212,Inclusion,and seated diastolic blood pressure ( dbp ) < 90 mmhg,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,lower 90 mmhg,NA
7,NCT00264212,Inclusion,at randomization,Other,NA,NA,NA,NA,NA,NA,NA,NA
8,NCT00264212,Inclusion,having completed the 2 to 4 - week wash-out / placebo run-in phase,Drug Exposure,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,NA
8,NCT00264212,Inclusion,having completed the 2 to 4 - week wash-out / placebo run-in phase,Drug Exposure,Other,C1547959;C2699154;C1883550,wash,FALSE,FALSE,greater_equal 2 week; lower_equal 4 week,NA,NA
9,NCT00264212,Inclusion,still eligible for blood pressure,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
10,NCT00264212,Inclusion,seated sbp > = 160 mmhg and < 220 mmhg [ 160 - 220 [,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 160 mmhg; lower 220 mmhg; greater_equal 160 ; lower_equal 220,NA
11,NCT00264212,Inclusion,and seated dbp < 90 mmhg .,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,lower 90 mmhg,NA
12,NCT00264212,Exclusion,( at screening ) :,Other,NA,NA,NA,NA,NA,NA,NA,NA
13,NCT00264212,Exclusion,participation in a clinical trial within the previous 3 months,Other,Other,C1096775,clinical trial,FALSE,FALSE,lower 3 previous months,NA,NA
14,NCT00264212,Exclusion,patients with a history of irbesartan ; amlodipine ; or hydrochlorothiazide sensitivity defined as irbesartan ; amlodipine ; or hydrochlorothiazide discontinuation due to medically significant adverse effects,Drug Exposure,Condition,C0427965,sensitivity,FALSE,FALSE,NA,NA,NA
14,NCT00264212,Exclusion,patients with a history of irbesartan ; amlodipine ; or hydrochlorothiazide sensitivity defined as irbesartan ; amlodipine ; or hydrochlorothiazide discontinuation due to medically significant adverse effects,Drug Exposure,Condition,C0879626,adverse effects,FALSE,FALSE,NA,NA,NA
14,NCT00264212,Exclusion,patients with a history of irbesartan ; amlodipine ; or hydrochlorothiazide sensitivity defined as irbesartan ; amlodipine ; or hydrochlorothiazide discontinuation due to medically significant adverse effects,Drug Exposure,Drug,C0288171,irbesartan,FALSE,FALSE,NA,NA,NA
14,NCT00264212,Exclusion,patients with a history of irbesartan ; amlodipine ; or hydrochlorothiazide sensitivity defined as irbesartan ; amlodipine ; or hydrochlorothiazide discontinuation due to medically significant adverse effects,Drug Exposure,Drug,C0020261,hydrochlorothiazide,FALSE,FALSE,NA,NA,NA
14,NCT00264212,Exclusion,patients with a history of irbesartan ; amlodipine ; or hydrochlorothiazide sensitivity defined as irbesartan ; amlodipine ; or hydrochlorothiazide discontinuation due to medically significant adverse effects,Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,NA
14,NCT00264212,Exclusion,patients with a history of irbesartan ; amlodipine ; or hydrochlorothiazide sensitivity defined as irbesartan ; amlodipine ; or hydrochlorothiazide discontinuation due to medically significant adverse effects,Drug Exposure,Drug,C0288171,irbesartan,FALSE,FALSE,NA,NA,NA
14,NCT00264212,Exclusion,patients with a history of irbesartan ; amlodipine ; or hydrochlorothiazide sensitivity defined as irbesartan ; amlodipine ; or hydrochlorothiazide discontinuation due to medically significant adverse effects,Drug Exposure,Drug,C0020261,hydrochlorothiazide,FALSE,FALSE,NA,NA,NA
14,NCT00264212,Exclusion,patients with a history of irbesartan ; amlodipine ; or hydrochlorothiazide sensitivity defined as irbesartan ; amlodipine ; or hydrochlorothiazide discontinuation due to medically significant adverse effects,Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,NA
14,NCT00264212,Exclusion,patients with a history of irbesartan ; amlodipine ; or hydrochlorothiazide sensitivity defined as irbesartan ; amlodipine ; or hydrochlorothiazide discontinuation due to medically significant adverse effects,Drug Exposure,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
14,NCT00264212,Exclusion,patients with a history of irbesartan ; amlodipine ; or hydrochlorothiazide sensitivity defined as irbesartan ; amlodipine ; or hydrochlorothiazide discontinuation due to medically significant adverse effects,Drug Exposure,Other,C0457454;C1444662,discontinuation,FALSE,FALSE,NA,NA,NA
15,NCT00264212,Exclusion,patients currently or previously treated with angiotensin ii receptor blocker ( irbesartan ; losartan ; candesartan ; valsartan ; telmisartan ; etc . ) or dihydropiridine calcium channel blocker ( amlodipine ; nicardipine ; felodipine ; nifedipine ; etc ; ) and not responding despite maximum tolerated dose,Drug Exposure,Drug,C0521942;C3536793,angiotensin ii receptor blocker,FALSE,FALSE,NA,NA,NA
15,NCT00264212,Exclusion,patients currently or previously treated with angiotensin ii receptor blocker ( irbesartan ; losartan ; candesartan ; valsartan ; telmisartan ; etc . ) or dihydropiridine calcium channel blocker ( amlodipine ; nicardipine ; felodipine ; nifedipine ; etc ; ) and not responding despite maximum tolerated dose,Drug Exposure,Drug,C0288171,irbesartan,FALSE,FALSE,NA,NA,NA
15,NCT00264212,Exclusion,patients currently or previously treated with angiotensin ii receptor blocker ( irbesartan ; losartan ; candesartan ; valsartan ; telmisartan ; etc . ) or dihydropiridine calcium channel blocker ( amlodipine ; nicardipine ; felodipine ; nifedipine ; etc ; ) and not responding despite maximum tolerated dose,Drug Exposure,Drug,C0126174,losartan,FALSE,FALSE,NA,NA,NA
15,NCT00264212,Exclusion,patients currently or previously treated with angiotensin ii receptor blocker ( irbesartan ; losartan ; candesartan ; valsartan ; telmisartan ; etc . ) or dihydropiridine calcium channel blocker ( amlodipine ; nicardipine ; felodipine ; nifedipine ; etc ; ) and not responding despite maximum tolerated dose,Drug Exposure,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,NA
15,NCT00264212,Exclusion,patients currently or previously treated with angiotensin ii receptor blocker ( irbesartan ; losartan ; candesartan ; valsartan ; telmisartan ; etc . ) or dihydropiridine calcium channel blocker ( amlodipine ; nicardipine ; felodipine ; nifedipine ; etc ; ) and not responding despite maximum tolerated dose,Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,NA
15,NCT00264212,Exclusion,patients currently or previously treated with angiotensin ii receptor blocker ( irbesartan ; losartan ; candesartan ; valsartan ; telmisartan ; etc . ) or dihydropiridine calcium channel blocker ( amlodipine ; nicardipine ; felodipine ; nifedipine ; etc ; ) and not responding despite maximum tolerated dose,Drug Exposure,Drug,C0028066,nifedipine,FALSE,FALSE,NA,NA,NA
15,NCT00264212,Exclusion,patients currently or previously treated with angiotensin ii receptor blocker ( irbesartan ; losartan ; candesartan ; valsartan ; telmisartan ; etc . ) or dihydropiridine calcium channel blocker ( amlodipine ; nicardipine ; felodipine ; nifedipine ; etc ; ) and not responding despite maximum tolerated dose,Drug Exposure,Drug,C0015772,felodipine,FALSE,FALSE,NA,NA,NA
15,NCT00264212,Exclusion,patients currently or previously treated with angiotensin ii receptor blocker ( irbesartan ; losartan ; candesartan ; valsartan ; telmisartan ; etc . ) or dihydropiridine calcium channel blocker ( amlodipine ; nicardipine ; felodipine ; nifedipine ; etc ; ) and not responding despite maximum tolerated dose,Drug Exposure,Drug,C0028005,nicardipine,FALSE,FALSE,NA,NA,NA
15,NCT00264212,Exclusion,patients currently or previously treated with angiotensin ii receptor blocker ( irbesartan ; losartan ; candesartan ; valsartan ; telmisartan ; etc . ) or dihydropiridine calcium channel blocker ( amlodipine ; nicardipine ; felodipine ; nifedipine ; etc ; ) and not responding despite maximum tolerated dose,Drug Exposure,Other,C0006684;C3536851;C2757014,calcium channel blocker,FALSE,FALSE,NA,NA,NA
16,NCT00264212,Exclusion,known or suspected secondary hypertension ( eg ; coarctation of aorta ; renovascular stenosis ; etc ; ),Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
16,NCT00264212,Exclusion,known or suspected secondary hypertension ( eg ; coarctation of aorta ; renovascular stenosis ; etc ; ),Condition Occurrence,Condition,C0332886,coarctation,FALSE,FALSE,NA,NA,NA
16,NCT00264212,Exclusion,known or suspected secondary hypertension ( eg ; coarctation of aorta ; renovascular stenosis ; etc ; ),Condition Occurrence,Condition,C0748340,renovascular stenosis,FALSE,FALSE,NA,NA,NA
16,NCT00264212,Exclusion,known or suspected secondary hypertension ( eg ; coarctation of aorta ; renovascular stenosis ; etc ; ),Condition Occurrence,Other,C0869784;C0003483;C1278934,aorta,FALSE,FALSE,NA,NA,NA
17,NCT00264212,Exclusion,known single functional kidney,Condition Occurrence,Condition,C1504368,single functional kidney,FALSE,FALSE,NA,NA,NA
18,NCT00264212,Exclusion,history of recent myocardial infarction ; coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty ; or cerebrovascular accident ( transient ischaemic attack ; stroke ) within the last 6 months of study entry,Condition Occurrence,Condition,C1998297,recent myocardial infarction,FALSE,FALSE,NA,NA,NA
18,NCT00264212,Exclusion,history of recent myocardial infarction ; coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty ; or cerebrovascular accident ( transient ischaemic attack ; stroke ) within the last 6 months of study entry,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
18,NCT00264212,Exclusion,history of recent myocardial infarction ; coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty ; or cerebrovascular accident ( transient ischaemic attack ; stroke ) within the last 6 months of study entry,Condition Occurrence,Condition,C0007787,transient ischaemic attack,FALSE,FALSE,NA,NA,NA
18,NCT00264212,Exclusion,history of recent myocardial infarction ; coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty ; or cerebrovascular accident ( transient ischaemic attack ; stroke ) within the last 6 months of study entry,Condition Occurrence,Procedure,C2936173,percutaneous transluminal coronary angioplasty,FALSE,FALSE,NA,NA,NA
18,NCT00264212,Exclusion,history of recent myocardial infarction ; coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty ; or cerebrovascular accident ( transient ischaemic attack ; stroke ) within the last 6 months of study entry,Condition Occurrence,Procedure,C0010055,coronary artery bypass graft surgery,FALSE,FALSE,NA,NA,NA
18,NCT00264212,Exclusion,history of recent myocardial infarction ; coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty ; or cerebrovascular accident ( transient ischaemic attack ; stroke ) within the last 6 months of study entry,Condition Occurrence,Other,C1705654,entry,FALSE,FALSE,lower 6 last months,NA,NA
19,NCT00264212,Exclusion,patients with known gastrointestinal ; renal ; hepatic ; endocrine ; cardiovascular disease ; pulmonary disease ; immunological disease or hematological disease which in the opinion of the investigator is active or uncontrolled,Condition Occurrence,Condition,C1559265,gastrointestinal,FALSE,FALSE,NA,NA,NA
19,NCT00264212,Exclusion,patients with known gastrointestinal ; renal ; hepatic ; endocrine ; cardiovascular disease ; pulmonary disease ; immunological disease or hematological disease which in the opinion of the investigator is active or uncontrolled,Condition Occurrence,Condition,C0205054,hepatic,FALSE,FALSE,NA,NA,NA
19,NCT00264212,Exclusion,patients with known gastrointestinal ; renal ; hepatic ; endocrine ; cardiovascular disease ; pulmonary disease ; immunological disease or hematological disease which in the opinion of the investigator is active or uncontrolled,Condition Occurrence,Condition,C0007222,cardiovascular disease,FALSE,FALSE,NA,NA,NA
19,NCT00264212,Exclusion,patients with known gastrointestinal ; renal ; hepatic ; endocrine ; cardiovascular disease ; pulmonary disease ; immunological disease or hematological disease which in the opinion of the investigator is active or uncontrolled,Condition Occurrence,Condition,C0018939,hematological disease,FALSE,FALSE,NA,NA,NA
19,NCT00264212,Exclusion,patients with known gastrointestinal ; renal ; hepatic ; endocrine ; cardiovascular disease ; pulmonary disease ; immunological disease or hematological disease which in the opinion of the investigator is active or uncontrolled,Condition Occurrence,Condition,C0021053,immunological disease,FALSE,FALSE,NA,NA,NA
19,NCT00264212,Exclusion,patients with known gastrointestinal ; renal ; hepatic ; endocrine ; cardiovascular disease ; pulmonary disease ; immunological disease or hematological disease which in the opinion of the investigator is active or uncontrolled,Condition Occurrence,Condition,C0024115;C0455540,pulmonary disease,FALSE,FALSE,NA,NA,NA
19,NCT00264212,Exclusion,patients with known gastrointestinal ; renal ; hepatic ; endocrine ; cardiovascular disease ; pulmonary disease ; immunological disease or hematological disease which in the opinion of the investigator is active or uncontrolled,Condition Occurrence,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
20,NCT00264212,Exclusion,patients with significant renal ( clearance of creatinine < 30 ml / mn ) ; hepatic insufficiency or cardiac insufficiency ; or known valvular heart disease,Condition Occurrence,Condition,C1306571,hepatic insufficiency,FALSE,FALSE,NA,NA,NA
20,NCT00264212,Exclusion,patients with significant renal ( clearance of creatinine < 30 ml / mn ) ; hepatic insufficiency or cardiac insufficiency ; or known valvular heart disease,Condition Occurrence,Condition,C0018801,cardiac insufficiency,FALSE,FALSE,NA,NA,NA
20,NCT00264212,Exclusion,patients with significant renal ( clearance of creatinine < 30 ml / mn ) ; hepatic insufficiency or cardiac insufficiency ; or known valvular heart disease,Condition Occurrence,Condition,C0018824;C1963123,valvular heart disease,FALSE,FALSE,NA,NA,NA
20,NCT00264212,Exclusion,patients with significant renal ( clearance of creatinine < 30 ml / mn ) ; hepatic insufficiency or cardiac insufficiency ; or known valvular heart disease,Condition Occurrence,Drug,C2348271,mn,FALSE,FALSE,NA,NA,NA
20,NCT00264212,Exclusion,patients with significant renal ( clearance of creatinine < 30 ml / mn ) ; hepatic insufficiency or cardiac insufficiency ; or known valvular heart disease,Condition Occurrence,Observation,C0010294;C0201975;C1561535,creatinine,FALSE,FALSE,NA,NA,lower 30 ml
20,NCT00264212,Exclusion,patients with significant renal ( clearance of creatinine < 30 ml / mn ) ; hepatic insufficiency or cardiac insufficiency ; or known valvular heart disease,Condition Occurrence,Other,C0232813;C0699829,renal clearance,FALSE,FALSE,NA,NA,NA
21,NCT00264212,Exclusion,serum potassium < 3.5 mmol / l ( meq / l ) or > 5.55 mmol / l ( meq / l ),Observation,Observation,C0302353;C0543465,serum potassium,FALSE,FALSE,NA,lower 3.5 mmol/l; greater 5.55 mmol/l,NA
22,NCT00264212,Exclusion,presence of clinically significant ventricular arrhythmias or supraventricular arrhythmias ; or second degree or third degree atrioventricular block ; or qtc prolongation ( bazett > 450 msec ; ) on the ecg,Observation,Condition,C0085612,ventricular arrhythmias,FALSE,FALSE,NA,NA,NA
22,NCT00264212,Exclusion,presence of clinically significant ventricular arrhythmias or supraventricular arrhythmias ; or second degree or third degree atrioventricular block ; or qtc prolongation ( bazett > 450 msec ; ) on the ecg,Observation,Condition,C0428974,supraventricular arrhythmias,FALSE,FALSE,NA,NA,NA
22,NCT00264212,Exclusion,presence of clinically significant ventricular arrhythmias or supraventricular arrhythmias ; or second degree or third degree atrioventricular block ; or qtc prolongation ( bazett > 450 msec ; ) on the ecg,Observation,Condition,C0004245;C2108077,atrioventricular block,FALSE,FALSE,NA,greater 450 msec,NA
22,NCT00264212,Exclusion,presence of clinically significant ventricular arrhythmias or supraventricular arrhythmias ; or second degree or third degree atrioventricular block ; or qtc prolongation ( bazett > 450 msec ; ) on the ecg,Observation,Condition,C0855333,qtc prolongation,FALSE,FALSE,NA,greater 450 msec,NA
22,NCT00264212,Exclusion,presence of clinically significant ventricular arrhythmias or supraventricular arrhythmias ; or second degree or third degree atrioventricular block ; or qtc prolongation ( bazett > 450 msec ; ) on the ecg,Observation,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
22,NCT00264212,Exclusion,presence of clinically significant ventricular arrhythmias or supraventricular arrhythmias ; or second degree or third degree atrioventricular block ; or qtc prolongation ( bazett > 450 msec ; ) on the ecg,Observation,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
22,NCT00264212,Exclusion,presence of clinically significant ventricular arrhythmias or supraventricular arrhythmias ; or second degree or third degree atrioventricular block ; or qtc prolongation ( bazett > 450 msec ; ) on the ecg,Observation,Other,C1623258;C0018064,ecg,FALSE,FALSE,NA,NA,NA
23,NCT00264212,Exclusion,pregnancy or lactation,Condition Occurrence,Condition,C0022925,lactation,FALSE,FALSE,NA,NA,NA
23,NCT00264212,Exclusion,pregnancy or lactation,Condition Occurrence,Other,C0032961;C3484365,pregnancy,FALSE,FALSE,NA,NA,NA
24,NCT00264212,Exclusion,women of child bearing potential ( not post-menopausal ) should be using a reliable contraceptive method,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
24,NCT00264212,Exclusion,women of child bearing potential ( not post-menopausal ) should be using a reliable contraceptive method,Person,Procedure,C0700589,contraceptive method,FALSE,FALSE,NA,NA,NA
24,NCT00264212,Exclusion,women of child bearing potential ( not post-menopausal ) should be using a reliable contraceptive method,Person,Observation,C3831118,child bearing potential,FALSE,FALSE,NA,NA,NA
25,NCT00264212,Exclusion,the above information is not intended to contain all considerations relevant to a patient potential participation in a clinical trial,Other,Other,C1096775,clinical trial,FALSE,FALSE,NA,NA,NA
1,NCT00273299,Inclusion,diagnosed severe hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00273299,Inclusion,diagnosed severe hypertension,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
2,NCT00273299,Exclusion,inability to discontinue all prior antihypertensive medications,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
2,NCT00273299,Exclusion,inability to discontinue all prior antihypertensive medications,Drug Exposure,Other,C1706472,discontinue,FALSE,FALSE,NA,NA,NA
3,NCT00273299,Exclusion,heart failure of any kind,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
3,NCT00273299,Exclusion,heart failure of any kind,Condition Occurrence,Other,C1706124,kind,FALSE,FALSE,NA,NA,NA
4,NCT00273299,Exclusion,history of stroke ; transient ischemic attack ; myocardial infarction ; chest pain ; abnormal heart rhythm liver ; kidney ; or pancreas disease,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,NA,NA,NA
4,NCT00273299,Exclusion,history of stroke ; transient ischemic attack ; myocardial infarction ; chest pain ; abnormal heart rhythm liver ; kidney ; or pancreas disease,Condition Occurrence,Condition,C0232187,heart rhythm,FALSE,FALSE,NA,NA,NA
4,NCT00273299,Exclusion,history of stroke ; transient ischemic attack ; myocardial infarction ; chest pain ; abnormal heart rhythm liver ; kidney ; or pancreas disease,Condition Occurrence,Condition,C0545792,liver kidney,FALSE,FALSE,NA,NA,NA
4,NCT00273299,Exclusion,history of stroke ; transient ischemic attack ; myocardial infarction ; chest pain ; abnormal heart rhythm liver ; kidney ; or pancreas disease,Condition Occurrence,Condition,C0030286,pancreas disease,FALSE,FALSE,NA,NA,NA
4,NCT00273299,Exclusion,history of stroke ; transient ischemic attack ; myocardial infarction ; chest pain ; abnormal heart rhythm liver ; kidney ; or pancreas disease,Condition Occurrence,Other,C2699333,abnormal,FALSE,FALSE,NA,NA,NA
4,NCT00273299,Exclusion,history of stroke ; transient ischemic attack ; myocardial infarction ; chest pain ; abnormal heart rhythm liver ; kidney ; or pancreas disease,Condition Occurrence,Other,C0008031;C2926613,chest pain,FALSE,FALSE,NA,NA,NA
4,NCT00273299,Exclusion,history of stroke ; transient ischemic attack ; myocardial infarction ; chest pain ; abnormal heart rhythm liver ; kidney ; or pancreas disease,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
5,NCT00273299,Exclusion,diabetes with poor glucose control,Drug Exposure,Condition,C0011849;C0011847,diabetes,FALSE,FALSE,NA,NA,NA
5,NCT00273299,Exclusion,diabetes with poor glucose control,Drug Exposure,Drug,C0726398,glucose control,FALSE,FALSE,NA,NA,NA
6,NCT00273299,Exclusion,allergy to certain medications used to treat high blood pressure,Condition Occurrence,Other,C0489531;C0718579;C3542994;C3539909;C1314973;C1547315;C1611280,allergy,FALSE,FALSE,NA,NA,NA
6,NCT00273299,Exclusion,allergy to certain medications used to treat high blood pressure,Condition Occurrence,Other,C0020538;C2926615,high blood pressure,FALSE,FALSE,NA,NA,NA
7,NCT00273299,Exclusion,other protocol-defined may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00274612,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of greater than or equal to 95 mmhg and less than or equal to 109 mmhg ; measured by manual cuff sphygmomanometer at visit 2 .,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
1,NCT00274612,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of greater than or equal to 95 mmhg and less than or equal to 109 mmhg ; measured by manual cuff sphygmomanometer at visit 2 .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00274612,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of greater than or equal to 95 mmhg and less than or equal to 109 mmhg ; measured by manual cuff sphygmomanometer at visit 2 .,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater_equal 95 mmhg; lower_equal 109 mmhg,NA
1,NCT00274612,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of greater than or equal to 95 mmhg and less than or equal to 109 mmhg ; measured by manual cuff sphygmomanometer at visit 2 .,Observation,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
1,NCT00274612,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of greater than or equal to 95 mmhg and less than or equal to 109 mmhg ; measured by manual cuff sphygmomanometer at visit 2 .,Observation,Other,C1547225,mild,FALSE,FALSE,NA,NA,NA
1,NCT00274612,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of greater than or equal to 95 mmhg and less than or equal to 109 mmhg ; measured by manual cuff sphygmomanometer at visit 2 .,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00274612,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of greater than or equal to 95 mmhg and less than or equal to 109 mmhg ; measured by manual cuff sphygmomanometer at visit 2 .,Observation,Other,C0024763,manual,FALSE,FALSE,NA,NA,NA
2,NCT00274612,Inclusion,24 - hour mean dbp of greater than or equal to 85 mmhg at visit 3 as measured by abpm .,Observation,Observation,C1305849,dbp,FALSE,FALSE,equal 24 hour,greater_equal 85 mmhg,NA
2,NCT00274612,Inclusion,24 - hour mean dbp of greater than or equal to 85 mmhg at visit 3 as measured by abpm .,Observation,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
3,NCT00274612,Inclusion,age 18 years or older .,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 18 years,NA,NA
4,NCT00274612,Inclusion,ability to stop any current antihypertensive therapy without risk to the patient ( investigator discretion ) .,Drug Exposure,Drug,C0723457,stop,FALSE,FALSE,NA,NA,NA
4,NCT00274612,Inclusion,ability to stop any current antihypertensive therapy without risk to the patient ( investigator discretion ) .,Drug Exposure,Procedure,C0585941,antihypertensive therapy,FALSE,FALSE,NA,NA,NA
5,NCT00274612,Inclusion,ability to provide written informed consent in accordance with gcp and local legislation .,Other,Other,C2986419,gcp,FALSE,FALSE,NA,NA,NA
5,NCT00274612,Inclusion,ability to provide written informed consent in accordance with gcp and local legislation .,Other,Other,C0600657,legislation,FALSE,FALSE,NA,NA,NA
6,NCT00274612,Exclusion,pre-menopausal women ( last menstruation approximately less than or equal to 1 year prior to signing informed consent ) who :,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
6,NCT00274612,Exclusion,pre-menopausal women ( last menstruation approximately less than or equal to 1 year prior to signing informed consent ) who :,Condition Occurrence,Condition,C1096235,pre-menopausal,FALSE,FALSE,NA,NA,NA
6,NCT00274612,Exclusion,pre-menopausal women ( last menstruation approximately less than or equal to 1 year prior to signing informed consent ) who :,Condition Occurrence,Condition,C0025344;C2129647,menstruation,FALSE,FALSE,lower_equal 1 year,NA,NA
7,NCT00274612,Exclusion,are not surgically sterile,Other,NA,NA,NA,NA,NA,NA,NA,NA
8,NCT00274612,Exclusion,are nursing ;,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
9,NCT00274612,Exclusion,are of child-bearing potential and are not practicing acceptable methods of birth control ; or do not plan to continue practicing an acceptable method throughout the study,Observation,Observation,C3831118,child-bearing potential,FALSE,FALSE,NA,NA,NA
9,NCT00274612,Exclusion,are of child-bearing potential and are not practicing acceptable methods of birth control ; or do not plan to continue practicing an acceptable method throughout the study,Observation,Other,C0025663,methods,TRUE,FALSE,NA,NA,NA
9,NCT00274612,Exclusion,are of child-bearing potential and are not practicing acceptable methods of birth control ; or do not plan to continue practicing an acceptable method throughout the study,Observation,Other,C0700589;C2703065,birth control,TRUE,FALSE,NA,NA,NA
9,NCT00274612,Exclusion,are of child-bearing potential and are not practicing acceptable methods of birth control ; or do not plan to continue practicing an acceptable method throughout the study,Observation,Other,C2827714;C0871511;C2828387,method,FALSE,FALSE,NA,NA,NA
10,NCT00274612,Exclusion,acceptable methods of birth control include intra uterine device ; oral contraceptives ; implantable contraceptives or injectable contraceptives .,Drug Exposure,Drug,C0086466;C1272936,injectable,FALSE,FALSE,NA,NA,NA
10,NCT00274612,Exclusion,acceptable methods of birth control include intra uterine device ; oral contraceptives ; implantable contraceptives or injectable contraceptives .,Drug Exposure,Other,C0025663,methods,FALSE,FALSE,NA,NA,NA
10,NCT00274612,Exclusion,acceptable methods of birth control include intra uterine device ; oral contraceptives ; implantable contraceptives or injectable contraceptives .,Drug Exposure,Other,C0700589;C2703065,birth control,FALSE,FALSE,NA,NA,NA
10,NCT00274612,Exclusion,acceptable methods of birth control include intra uterine device ; oral contraceptives ; implantable contraceptives or injectable contraceptives .,Drug Exposure,Other,C0009905;C0274536;C0481121;C1548892,oral contraceptives,FALSE,FALSE,NA,NA,NA
11,NCT00274612,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 m .,Drug Exposure,Condition,C0555008,night shift workers,FALSE,FALSE,NA,NA,NA
11,NCT00274612,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 m .,Drug Exposure,Drug,C1654656,daytime,FALSE,FALSE,NA,equal 4,equal 00 m
11,NCT00274612,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 m .,Drug Exposure,Other,C0037313;C0723362,sleep,FALSE,FALSE,NA,NA,NA
12,NCT00274612,Exclusion,mean sitting sbp greater than or equal to180 mmhg or mean sitting dbp greater than or equal to 110 mmhg during any visit of the placebo run-in period .,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
12,NCT00274612,Exclusion,mean sitting sbp greater than or equal to180 mmhg or mean sitting dbp greater than or equal to 110 mmhg during any visit of the placebo run-in period .,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
12,NCT00274612,Exclusion,mean sitting sbp greater than or equal to180 mmhg or mean sitting dbp greater than or equal to 110 mmhg during any visit of the placebo run-in period .,Observation,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,NA
12,NCT00274612,Exclusion,mean sitting sbp greater than or equal to180 mmhg or mean sitting dbp greater than or equal to 110 mmhg during any visit of the placebo run-in period .,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,NA,NA
12,NCT00274612,Exclusion,mean sitting sbp greater than or equal to180 mmhg or mean sitting dbp greater than or equal to 110 mmhg during any visit of the placebo run-in period .,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 110 mmhg,NA
13,NCT00274612,Exclusion,known or suspected secondary hypertension ( ie ; pheochromocytoma ) .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
13,NCT00274612,Exclusion,known or suspected secondary hypertension ( ie ; pheochromocytoma ) .,Condition Occurrence,Condition,C0031511;C1706920,pheochromocytoma,FALSE,FALSE,NA,NA,NA
14,NCT00274612,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Condition,C0086565,hepatic dysfunction,FALSE,FALSE,NA,NA,NA
14,NCT00274612,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
14,NCT00274612,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
14,NCT00274612,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
15,NCT00274612,Exclusion,sgpt ( alt ) or sgot ( ast ) > 2 times the upper limit of normal range .,Observation,Observation,C0376147;C0036828,sgpt,FALSE,FALSE,NA,NA,NA
15,NCT00274612,Exclusion,sgpt ( alt ) or sgot ( ast ) > 2 times the upper limit of normal range .,Observation,Observation,C1140170;C2257651,alt,FALSE,FALSE,NA,NA,NA
15,NCT00274612,Exclusion,sgpt ( alt ) or sgot ( ast ) > 2 times the upper limit of normal range .,Observation,Observation,C0242192;C0201899,sgot,FALSE,FALSE,NA,NA,NA
15,NCT00274612,Exclusion,sgpt ( alt ) or sgot ( ast ) > 2 times the upper limit of normal range .,Observation,Observation,C0004002,ast,FALSE,FALSE,NA,NA,NA
15,NCT00274612,Exclusion,sgpt ( alt ) or sgot ( ast ) > 2 times the upper limit of normal range .,Observation,Observation,C3542016,range,FALSE,FALSE,NA,NA,greater 2 times the upper limit of normal
16,NCT00274612,Exclusion,serum creatinine > 2.3 mg / dl ( or > 203 micromol / l ) .,Observation,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,greater 203 micromol/l,greater 2.3 mg/dl
17,NCT00274612,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney .,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
17,NCT00274612,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney .,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
17,NCT00274612,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney .,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
17,NCT00274612,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney .,Condition Occurrence,Condition,C0478647,transplant,FALSE,FALSE,NA,NA,NA
17,NCT00274612,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney .,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
18,NCT00274612,Exclusion,clinically relevant sodium depletion ; hypokalaemia or hyperkalaemia .,Condition Occurrence,Condition,C0020625,sodium depletion,FALSE,FALSE,NA,NA,NA
19,NCT00274612,Exclusion,uncorrected volume depletion .,Condition Occurrence,Condition,C0546884,volume depletion,FALSE,FALSE,NA,NA,NA
20,NCT00274612,Exclusion,primary aldosteronism .,Condition Occurrence,Condition,C1384514,primary aldosteronism,FALSE,FALSE,NA,NA,NA
21,NCT00274612,Exclusion,hereditary fructose intolerance .,Condition Occurrence,Condition,C0016751,hereditary fructose intolerance,FALSE,FALSE,NA,NA,NA
22,NCT00274612,Exclusion,biliary obstructive disorders .,Other,NA,NA,NA,NA,NA,NA,NA,NA
23,NCT00274612,Exclusion,congestive heart failure ( nyha functional class chf iii- .,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
23,NCT00274612,Exclusion,congestive heart failure ( nyha functional class chf iii- .,Condition Occurrence,Condition,C0018802,chf,FALSE,FALSE,NA,NA,NA
23,NCT00274612,Exclusion,congestive heart failure ( nyha functional class chf iii- .,Condition Occurrence,Other,C0456387;C0489477,class,FALSE,FALSE,NA,NA,NA
23,NCT00274612,Exclusion,congestive heart failure ( nyha functional class chf iii- .,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii-,FALSE,FALSE,NA,NA,NA
24,NCT00274612,Exclusion,unstable angina within the past three months prior to start of run in period .,Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,NA,NA,NA
25,NCT00274612,Exclusion,stroke within the past six months prior to start of run in period .,Other,NA,NA,NA,NA,NA,NA,NA,NA
26,NCT00274612,Exclusion,myocardial infarction or cardiac surgery within the past three months prior to start of run in period . ;,Condition Occurrence,Procedure,C0018821,cardiac surgery,FALSE,FALSE,NA,NA,NA
26,NCT00274612,Exclusion,myocardial infarction or cardiac surgery within the past three months prior to start of run in period . ;,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
27,NCT00274612,Exclusion,ptca ( percutaneous transluminal coronary angioplasty ) within the past three months prior to start of run in period .,Procedure,Procedure,C2936173;C0002997,ptca,FALSE,FALSE,NA,NA,NA
27,NCT00274612,Exclusion,ptca ( percutaneous transluminal coronary angioplasty ) within the past three months prior to start of run in period .,Procedure,Procedure,C2936173,percutaneous transluminal coronary angioplasty,FALSE,FALSE,NA,NA,NA
28,NCT00274612,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator .,Condition Occurrence,Condition,C0750197,sustained ventricular tachycardia,FALSE,FALSE,NA,NA,NA
28,NCT00274612,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator .,Condition Occurrence,Condition,C0004239;C1963068,atrial flutter,FALSE,FALSE,NA,NA,NA
28,NCT00274612,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator .,Condition Occurrence,Condition,C0003811,cardiac arrhythmias,FALSE,FALSE,NA,NA,NA
28,NCT00274612,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator .,Condition Occurrence,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
29,NCT00274612,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; haemodynamically relevant stenosis of the aortic valve or mitral valve .,Condition Occurrence,Condition,C0007194,hypertrophic obstructive cardiomyopathy,FALSE,FALSE,NA,NA,NA
29,NCT00274612,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; haemodynamically relevant stenosis of the aortic valve or mitral valve .,Condition Occurrence,Condition,C0003507,aortic stenosis,FALSE,FALSE,NA,NA,NA
29,NCT00274612,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; haemodynamically relevant stenosis of the aortic valve or mitral valve .,Condition Occurrence,Condition,C0003501;C1269005,aortic valve,FALSE,FALSE,NA,NA,NA
29,NCT00274612,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; haemodynamically relevant stenosis of the aortic valve or mitral valve .,Condition Occurrence,Condition,C0026264;C1269004,mitral valve,FALSE,FALSE,NA,NA,NA
29,NCT00274612,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; haemodynamically relevant stenosis of the aortic valve or mitral valve .,Condition Occurrence,Observation,C1261287;C0947637;C0009814,stenosis,FALSE,FALSE,NA,NA,NA
30,NCT00274612,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c greater than or equal to 10 % .,Condition Occurrence,Condition,C0011854,insulin-dependent diabetes mellitus,FALSE,FALSE,NA,NA,NA
30,NCT00274612,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c greater than or equal to 10 % .,Condition Occurrence,Condition,C0011849;C0011847,diabetes,FALSE,FALSE,NA,NA,NA
30,NCT00274612,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c greater than or equal to 10 % .,Condition Occurrence,Observation,C0202054,hba1c,FALSE,FALSE,NA,NA,greater_equal 10 %
30,NCT00274612,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c greater than or equal to 10 % .,Condition Occurrence,Other,C1547311,stable,TRUE,FALSE,NA,NA,NA
30,NCT00274612,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c greater than or equal to 10 % .,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
31,NCT00274612,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or angiotensin ii receptor antagonists .,Condition Occurrence,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
31,NCT00274612,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or angiotensin ii receptor antagonists .,Condition Occurrence,Drug,C0003015,ace inhibitors,FALSE,FALSE,NA,NA,NA
31,NCT00274612,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or angiotensin ii receptor antagonists .,Condition Occurrence,Other,C0521942;C2757003,angiotensin ii receptor antagonists,FALSE,FALSE,NA,NA,NA
32,NCT00274612,Exclusion,history of drug or alcohol dependency within 6 months prior to start of run in period .,Condition Occurrence,Condition,C0001973,alcohol dependency,FALSE,FALSE,lower 6 months,NA,NA
32,NCT00274612,Exclusion,history of drug or alcohol dependency within 6 months prior to start of run in period .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,lower 6 months,NA,NA
33,NCT00274612,Exclusion,concomitant administration of any medications known to affect blood pressure ; except medication allowed by the protocol .,Observation,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
33,NCT00274612,Exclusion,concomitant administration of any medications known to affect blood pressure ; except medication allowed by the protocol .,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
34,NCT00274612,Exclusion,any investigational therapy within one month of start of run in period .,Procedure,Procedure,C0949266,investigational therapy,FALSE,FALSE,NA,NA,NA
35,NCT00274612,Exclusion,known hypersensitivity to any component of the formulations .,Observation,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
36,NCT00274612,Exclusion,any clinical condition which ; in the opinion of the investigator would not allow safe completion of the protocol and safe administration of trial medication .,Other,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
37,NCT00274612,Exclusion,inability to comply with the protocol,Other,NA,NA,NA,NA,NA,NA,NA,NA
1,NCT00277472,Inclusion,male or female 18 years of age and older,Person,Person,C0025266,male,FALSE,FALSE,equal 18 years,NA,NA
1,NCT00277472,Inclusion,male or female 18 years of age and older,Person,Person,C0086287,female,FALSE,FALSE,equal 18 years,NA,NA
2,NCT00277472,Inclusion,diagnosed as having hypertension ( mean seated systolic blood pressure > = 150 mm hg but < 180 mm hg and mean seated diastolic blood pressure > = 95 mm hg and < 110 mm hg,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00277472,Inclusion,diagnosed as having hypertension ( mean seated systolic blood pressure > = 150 mm hg but < 180 mm hg and mean seated diastolic blood pressure > = 95 mm hg and < 110 mm hg,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater_equal 150 mm hg; lower 180 mm hg,NA
2,NCT00277472,Inclusion,diagnosed as having hypertension ( mean seated systolic blood pressure > = 150 mm hg but < 180 mm hg and mean seated diastolic blood pressure > = 95 mm hg and < 110 mm hg,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater_equal 95 mm hg; lower 110 mm hg,NA
3,NCT00277472,Exclusion,patients with sever hypertension : systolic > = 180 mm hg or diastolic > = 110 mm hg,Observation,Condition,C0221155,hypertension systolic,FALSE,FALSE,NA,greater_equal 180 mm hg; greater_equal 110 mm hg,NA
4,NCT00277472,Exclusion,diabetes with fasting glucose > 126 mg / dl or on existing anti-diabetic medication,Drug Exposure,Condition,C0011849;C0011847,diabetes,FALSE,FALSE,NA,NA,NA
4,NCT00277472,Exclusion,diabetes with fasting glucose > 126 mg / dl or on existing anti-diabetic medication,Drug Exposure,Drug,C0935929,anti-diabetic,FALSE,FALSE,NA,NA,NA
4,NCT00277472,Exclusion,diabetes with fasting glucose > 126 mg / dl or on existing anti-diabetic medication,Drug Exposure,Observation,C0017725;C0337438,glucose,FALSE,FALSE,NA,NA,greater 126 mg/dl
4,NCT00277472,Exclusion,diabetes with fasting glucose > 126 mg / dl or on existing anti-diabetic medication,Drug Exposure,Other,C0015663;C1550565,fasting,FALSE,FALSE,NA,NA,NA
5,NCT00277472,Exclusion,history of stroke ; transient ischemic attack ; or myocardial infarction within the last 6 months ; or diagnosed with congestive heart failure .,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,lower 6 last months,NA,NA
5,NCT00277472,Exclusion,history of stroke ; transient ischemic attack ; or myocardial infarction within the last 6 months ; or diagnosed with congestive heart failure .,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
5,NCT00277472,Exclusion,history of stroke ; transient ischemic attack ; or myocardial infarction within the last 6 months ; or diagnosed with congestive heart failure .,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,lower 6 last months,NA,NA
6,NCT00277472,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00280540,Inclusion,male or female age 18 or older,Person,Person,C0025266,male,FALSE,FALSE,NA,NA,NA
1,NCT00280540,Inclusion,male or female age 18 or older,Person,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
2,NCT00280540,Inclusion,diagnosed as having hypertension ( mean seated systolic blood pressure > = 150 mm hg but < 180 mm hg and mean seated diastolic blood pressure > = 90 mm hg and < 110 mm hg ),Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00280540,Inclusion,diagnosed as having hypertension ( mean seated systolic blood pressure > = 150 mm hg but < 180 mm hg and mean seated diastolic blood pressure > = 90 mm hg and < 110 mm hg ),Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater_equal 150 mm hg; lower 180 mm hg,NA
2,NCT00280540,Inclusion,diagnosed as having hypertension ( mean seated systolic blood pressure > = 150 mm hg but < 180 mm hg and mean seated diastolic blood pressure > = 90 mm hg and < 110 mm hg ),Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater_equal 90 mm hg; lower 110 mm hg,NA
3,NCT00280540,Exclusion,patients with severe hypertension : systolic > = 180 mm hg or diastolic > = 110 mm hg,Observation,Condition,C0221155,hypertension systolic,FALSE,FALSE,NA,greater_equal 180 mm hg; greater_equal 110 mm hg,NA
3,NCT00280540,Exclusion,patients with severe hypertension : systolic > = 180 mm hg or diastolic > = 110 mm hg,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
4,NCT00280540,Exclusion,history of secondary hypertension ( including primary aldosteronism ; renovascular hypertension ; pheochromocytoma etc ; ),Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
4,NCT00280540,Exclusion,history of secondary hypertension ( including primary aldosteronism ; renovascular hypertension ; pheochromocytoma etc ; ),Condition Occurrence,Condition,C1384514,primary aldosteronism,FALSE,FALSE,NA,NA,NA
4,NCT00280540,Exclusion,history of secondary hypertension ( including primary aldosteronism ; renovascular hypertension ; pheochromocytoma etc ; ),Condition Occurrence,Condition,C0031511;C1706920,pheochromocytoma,FALSE,FALSE,NA,NA,NA
4,NCT00280540,Exclusion,history of secondary hypertension ( including primary aldosteronism ; renovascular hypertension ; pheochromocytoma etc ; ),Condition Occurrence,Condition,C0020545,renovascular hypertension,FALSE,FALSE,NA,NA,NA
5,NCT00280540,Exclusion,history of myocardial infarction ; stroke [ eg cerebrovascular accident ( cva ) ; thrombotic stroke ; transient ischemic attack ( tia ) ] ; or onset of heart failure within the last 6 months .,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
5,NCT00280540,Exclusion,history of myocardial infarction ; stroke [ eg cerebrovascular accident ( cva ) ; thrombotic stroke ; transient ischemic attack ( tia ) ] ; or onset of heart failure within the last 6 months .,Condition Occurrence,Condition,C0242129,thrombotic stroke,FALSE,FALSE,NA,NA,NA
5,NCT00280540,Exclusion,history of myocardial infarction ; stroke [ eg cerebrovascular accident ( cva ) ; thrombotic stroke ; transient ischemic attack ( tia ) ] ; or onset of heart failure within the last 6 months .,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,NA,NA,NA
5,NCT00280540,Exclusion,history of myocardial infarction ; stroke [ eg cerebrovascular accident ( cva ) ; thrombotic stroke ; transient ischemic attack ( tia ) ] ; or onset of heart failure within the last 6 months .,Condition Occurrence,Condition,C0917805,tia,FALSE,FALSE,NA,NA,NA
5,NCT00280540,Exclusion,history of myocardial infarction ; stroke [ eg cerebrovascular accident ( cva ) ; thrombotic stroke ; transient ischemic attack ( tia ) ] ; or onset of heart failure within the last 6 months .,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,lower 6 last months,NA,NA
5,NCT00280540,Exclusion,history of myocardial infarction ; stroke [ eg cerebrovascular accident ( cva ) ; thrombotic stroke ; transient ischemic attack ( tia ) ] ; or onset of heart failure within the last 6 months .,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
5,NCT00280540,Exclusion,history of myocardial infarction ; stroke [ eg cerebrovascular accident ( cva ) ; thrombotic stroke ; transient ischemic attack ( tia ) ] ; or onset of heart failure within the last 6 months .,Condition Occurrence,Other,C0038454;C0001365;C0054889,cva,FALSE,FALSE,NA,NA,NA
6,NCT00280540,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00281593,Inclusion,male and female patients > = 18 years of age with stage i or stage ii hypertension defined as :,Other,Person,C0025266,male,FALSE,FALSE,greater_equal 18 years,NA,NA
1,NCT00281593,Inclusion,male and female patients > = 18 years of age with stage i or stage ii hypertension defined as :,Other,Observation,C0150905,female patients,FALSE,FALSE,greater_equal 18 years,NA,NA
1,NCT00281593,Inclusion,male and female patients > = 18 years of age with stage i or stage ii hypertension defined as :,Other,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00281593,Inclusion,male and female patients > = 18 years of age with stage i or stage ii hypertension defined as :,Other,Other,C0441766,stage i,FALSE,FALSE,NA,NA,NA
1,NCT00281593,Inclusion,male and female patients > = 18 years of age with stage i or stage ii hypertension defined as :,Other,Other,C0441767,stage ii,FALSE,FALSE,NA,NA,NA
1,NCT00281593,Inclusion,male and female patients > = 18 years of age with stage i or stage ii hypertension defined as :,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
2,NCT00281593,Inclusion,a mean seated cuff diastolic blood pressure > = 95 and < = 119 mmhg main,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
2,NCT00281593,Inclusion,a mean seated cuff diastolic blood pressure > = 95 and < = 119 mmhg main,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater_equal 95 mmhg; lower_equal 119 mmhg,NA
3,NCT00281593,Exclusion,pregnant,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
4,NCT00281593,Exclusion,breast-feeding,Condition Occurrence,Condition,C0006147;C1623041;C1623040,breast-feeding,FALSE,FALSE,NA,NA,NA
5,NCT00281593,Exclusion,unwilling to use birth control during the study,Procedure,Other,C0700589;C2703065,birth control,FALSE,FALSE,NA,NA,NA
6,NCT00281593,Exclusion,secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
7,NCT00281593,Exclusion,sbp > = 180 mmhg,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 180 mmhg,NA
8,NCT00281593,Exclusion,dbp > = 120 mmhg,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 120 mmhg,NA
9,NCT00281593,Exclusion,severe renal dysfunction,Condition Occurrence,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
9,NCT00281593,Exclusion,severe renal dysfunction,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
11,NCT00281593,Exclusion,stroke within the last 6 months,Other,NA,NA,NA,NA,NA,NA,NA,NA
10,NCT00281593,Exclusion,hepatic insufficiency,Condition Occurrence,Condition,C1306571,hepatic insufficiency,FALSE,FALSE,NA,NA,NA
12,NCT00281593,Exclusion,myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past three months,Procedure,Condition,C0002965,unstable angina,FALSE,FALSE,NA,NA,NA
12,NCT00281593,Exclusion,myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past three months,Procedure,Procedure,C0010055,coronary artery bypass graft,FALSE,FALSE,NA,NA,NA
12,NCT00281593,Exclusion,myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past three months,Procedure,Procedure,C2936173,percutaneous transluminal coronary angioplasty,FALSE,FALSE,NA,NA,NA
12,NCT00281593,Exclusion,myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past three months,Procedure,Procedure,C0018821,cardiac surgery,FALSE,FALSE,NA,NA,NA
12,NCT00281593,Exclusion,myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past three months,Procedure,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
13,NCT00281593,Exclusion,unstable diabetes or uncontrolled diabetes,Condition Occurrence,Condition,C0342302,unstable diabetes,FALSE,FALSE,NA,NA,NA
13,NCT00281593,Exclusion,unstable diabetes or uncontrolled diabetes,Condition Occurrence,Condition,C0011849;C0011847,diabetes,FALSE,FALSE,NA,NA,NA
14,NCT00281593,Exclusion,history of angioedema of either of the study drugs ; and hypersensitivity to the study drugs,Procedure,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
14,NCT00281593,Exclusion,history of angioedema of either of the study drugs ; and hypersensitivity to the study drugs,Procedure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
14,NCT00281593,Exclusion,history of angioedema of either of the study drugs ; and hypersensitivity to the study drugs,Procedure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
14,NCT00281593,Exclusion,history of angioedema of either of the study drugs ; and hypersensitivity to the study drugs,Procedure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
1,NCT00294710,Inclusion,patients with essential hypertension,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00294710,Exclusion,severe hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00294710,Exclusion,severe hypertension,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
3,NCT00294710,Exclusion,history or evidence of a secondary form of hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
4,NCT00294710,Exclusion,history of myocardial infarction .,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
5,NCT00294710,Exclusion,other protocol-defined inclusion also apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00296218,Inclusion,the following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial,Other,Procedure,C0557061,discussion,FALSE,FALSE,NA,NA,NA
1,NCT00296218,Inclusion,the following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial,Other,Other,C1096775,clinical trials,FALSE,FALSE,NA,NA,NA
1,NCT00296218,Inclusion,the following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial,Other,Other,C1705684,initial,FALSE,FALSE,NA,NA,NA
2,NCT00296218,Inclusion,this information is not intended to be complete information about the trial ; to contain all considerations that may be relevant to potential participation in the trial ; or to replace the advice of a personal physician or health professional .,Drug Exposure,Drug,C1815293,complete,TRUE,FALSE,NA,NA,NA
2,NCT00296218,Inclusion,this information is not intended to be complete information about the trial ; to contain all considerations that may be relevant to potential participation in the trial ; or to replace the advice of a personal physician or health professional .,Drug Exposure,Procedure,C0150600,advice,FALSE,FALSE,NA,NA,NA
2,NCT00296218,Inclusion,this information is not intended to be complete information about the trial ; to contain all considerations that may be relevant to potential participation in the trial ; or to replace the advice of a personal physician or health professional .,Drug Exposure,Observation,C1519021,personal,FALSE,FALSE,NA,NA,NA
2,NCT00296218,Inclusion,this information is not intended to be complete information about the trial ; to contain all considerations that may be relevant to potential participation in the trial ; or to replace the advice of a personal physician or health professional .,Drug Exposure,Other,C1571886;C3273187;C1571885,professional,FALSE,FALSE,NA,NA,NA
3,NCT00296218,Inclusion,main criteria are listed hereafter :,Other,NA,NA,NA,NA,NA,NA,NA,NA
4,NCT00296218,Inclusion,patient hospitalised with ischemic symptoms ( last episode within the last 48 hours before randomization ) and at least one of the following characteristics of nsteacs ( non-st-segment-elevation acute coronary syndromes ) :,Condition Occurrence,Condition,C0948089,acute coronary syndromes,FALSE,FALSE,NA,NA,NA
4,NCT00296218,Inclusion,patient hospitalised with ischemic symptoms ( last episode within the last 48 hours before randomization ) and at least one of the following characteristics of nsteacs ( non-st-segment-elevation acute coronary syndromes ) :,Condition Occurrence,Other,C0038137;C3272372;C0175243,st,FALSE,FALSE,lower 48 last hours,NA,NA
5,NCT00296218,Inclusion,ecg st or t changes ( st depression or transient elevation of at least 1 mm or t wave changes in at least 2 leads ),Observation,Person,C0040704,transient,FALSE,FALSE,NA,NA,NA
5,NCT00296218,Inclusion,ecg st or t changes ( st depression or transient elevation of at least 1 mm or t wave changes in at least 2 leads ),Observation,Condition,C0520887,st depression,FALSE,FALSE,NA,NA,NA
5,NCT00296218,Inclusion,ecg st or t changes ( st depression or transient elevation of at least 1 mm or t wave changes in at least 2 leads ),Observation,Condition,C0429103,t wave,FALSE,FALSE,NA,greater_equal 2,NA
5,NCT00296218,Inclusion,ecg st or t changes ( st depression or transient elevation of at least 1 mm or t wave changes in at least 2 leads ),Observation,Procedure,C0439775,elevation,FALSE,FALSE,NA,greater_equal 1 mm,NA
5,NCT00296218,Inclusion,ecg st or t changes ( st depression or transient elevation of at least 1 mm or t wave changes in at least 2 leads ),Observation,Other,C1623258;C0018064,ecg,FALSE,FALSE,NA,NA,NA
5,NCT00296218,Inclusion,ecg st or t changes ( st depression or transient elevation of at least 1 mm or t wave changes in at least 2 leads ),Observation,Other,C0038137;C3272372;C0175243,st,FALSE,FALSE,NA,NA,NA
6,NCT00296218,Inclusion,positive troponin ( according to local threshold ),Observation,Observation,C1514241,positive,FALSE,FALSE,NA,NA,NA
6,NCT00296218,Inclusion,positive troponin ( according to local threshold ),Observation,Other,C0041199;C0523952,troponin,FALSE,FALSE,NA,NA,NA
7,NCT00296218,Exclusion,women of child bearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 4 weeks after the study wocbp using a prohibited contraceptive method ( not applicable ),Observation,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
7,NCT00296218,Exclusion,women of child bearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 4 weeks after the study wocbp using a prohibited contraceptive method ( not applicable ),Observation,Procedure,C0700589,contraceptive method,FALSE,FALSE,NA,NA,NA
7,NCT00296218,Exclusion,women of child bearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 4 weeks after the study wocbp using a prohibited contraceptive method ( not applicable ),Observation,Observation,C3831118,child bearing potential,FALSE,FALSE,NA,NA,NA
7,NCT00296218,Exclusion,women of child bearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 4 weeks after the study wocbp using a prohibited contraceptive method ( not applicable ),Observation,Other,C2827714;C0871511;C2828387,method,FALSE,FALSE,NA,NA,NA
7,NCT00296218,Exclusion,women of child bearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 4 weeks after the study wocbp using a prohibited contraceptive method ( not applicable ),Observation,Other,C0032961;C3484365,pregnancy,FALSE,FALSE,lower_equal 4 weeks,NA,NA
8,NCT00296218,Exclusion,women who are pregnant or breast feeding,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
8,NCT00296218,Exclusion,women who are pregnant or breast feeding,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
8,NCT00296218,Exclusion,women who are pregnant or breast feeding,Condition Occurrence,Condition,C0006147;C1623040;C1623041,breast feeding,FALSE,FALSE,NA,NA,NA
9,NCT00296218,Exclusion,women with a positive pregnancy test on enrolment or prior to study drug administration,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
9,NCT00296218,Exclusion,women with a positive pregnancy test on enrolment or prior to study drug administration,Person,Procedure,C3469597;C0150270,drug administration,FALSE,FALSE,NA,NA,NA
9,NCT00296218,Exclusion,women with a positive pregnancy test on enrolment or prior to study drug administration,Person,Observation,C0240802,positive pregnancy test,FALSE,FALSE,NA,NA,NA
10,NCT00296218,Exclusion,patient with dementia,Condition Occurrence,Condition,C0497327;C0011265,dementia,FALSE,FALSE,NA,NA,NA
11,NCT00296218,Exclusion,persistent st segment elevation at ecg,Drug Exposure,Condition,C0520886,st segment elevation,FALSE,FALSE,NA,NA,NA
11,NCT00296218,Exclusion,persistent st segment elevation at ecg,Drug Exposure,Other,C1623258;C0018064,ecg,FALSE,FALSE,NA,NA,NA
12,NCT00296218,Exclusion,systolic blood pressure < 100 mmhg,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,lower 100 mmhg,NA
13,NCT00296218,Exclusion,bilateral stenosis of renal artery,Observation,Condition,C0035065;C1278951,renal artery,FALSE,FALSE,NA,NA,NA
13,NCT00296218,Exclusion,bilateral stenosis of renal artery,Observation,Observation,C1261287;C0947637;C0009814,stenosis,FALSE,FALSE,NA,NA,NA
14,NCT00296218,Exclusion,creatinine clearance < or = 30 ml / mn,Drug Exposure,Drug,C2348271,mn,FALSE,FALSE,NA,NA,NA
14,NCT00296218,Exclusion,creatinine clearance < or = 30 ml / mn,Drug Exposure,Observation,C0373595;C0812399,creatinine clearance,FALSE,FALSE,NA,NA,lower_equal 30 ml
15,NCT00296218,Exclusion,congestive heart failure with symptoms consistent with new york heart association ( nyha ) class iii or class iv .,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
15,NCT00296218,Exclusion,congestive heart failure with symptoms consistent with new york heart association ( nyha ) class iii or class iv .,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
15,NCT00296218,Exclusion,congestive heart failure with symptoms consistent with new york heart association ( nyha ) class iii or class iv .,Condition Occurrence,Condition,C1882086,nyha class iii,FALSE,FALSE,NA,NA,NA
15,NCT00296218,Exclusion,congestive heart failure with symptoms consistent with new york heart association ( nyha ) class iii or class iv .,Condition Occurrence,Other,C0441888;C2698970,class iv,FALSE,FALSE,NA,NA,NA
16,NCT00296218,Exclusion,aortic valve stenosis or mitral valve stenosis,Condition Occurrence,Condition,C0003507;C3542024,aortic valve stenosis,FALSE,FALSE,NA,NA,NA
16,NCT00296218,Exclusion,aortic valve stenosis or mitral valve stenosis,Condition Occurrence,Condition,C0026269;C0264766,mitral valve stenosis,FALSE,FALSE,NA,NA,NA
17,NCT00296218,Exclusion,hypertrophic cardiomyopathy,Condition Occurrence,Condition,C0007194;C0340425,hypertrophic cardiomyopathy,FALSE,FALSE,NA,NA,NA
18,NCT00296218,Exclusion,connective tissue disease with vascular involvement,Condition Occurrence,Condition,C0009782,connective tissue disease,FALSE,FALSE,NA,NA,NA
18,NCT00296218,Exclusion,connective tissue disease with vascular involvement,Condition Occurrence,Condition,C1558950,vascular,FALSE,FALSE,NA,NA,NA
19,NCT00296218,Exclusion,angioplasty ; surgery or trauma within the last 3 months,Procedure,Procedure,C0162577;C1548817,angioplasty,FALSE,FALSE,lower 3 last months,NA,NA
19,NCT00296218,Exclusion,angioplasty ; surgery or trauma within the last 3 months,Procedure,Other,C0043251;C0548346,trauma,FALSE,FALSE,lower 3 last months,NA,NA
19,NCT00296218,Exclusion,angioplasty ; surgery or trauma within the last 3 months,Procedure,Other,C0543467;C1457907,surgery,FALSE,FALSE,lower 3 last months,NA,NA
20,NCT00296218,Exclusion,coronarography or angioplasty planned to be performed or performed before baseline sampling,Observation,Procedure,C0162577;C1548817,angioplasty,FALSE,FALSE,NA,NA,NA
20,NCT00296218,Exclusion,coronarography or angioplasty planned to be performed or performed before baseline sampling,Observation,Observation,C0441621,sampling,FALSE,FALSE,NA,NA,NA
21,NCT00296218,Exclusion,febrile ( > = 38 c ) disease ; known concomitant viral infection or bacterial infection ; chronic auto immune disease ; chronic inflammatory disease ; known cancer in evolution,Observation,Condition,C0042769,viral infection,FALSE,FALSE,NA,greater_equal 38 c,NA
21,NCT00296218,Exclusion,febrile ( > = 38 c ) disease ; known concomitant viral infection or bacterial infection ; chronic auto immune disease ; chronic inflammatory disease ; known cancer in evolution,Observation,Condition,C0004623,bacterial infection,FALSE,FALSE,NA,greater_equal 38 c,NA
21,NCT00296218,Exclusion,febrile ( > = 38 c ) disease ; known concomitant viral infection or bacterial infection ; chronic auto immune disease ; chronic inflammatory disease ; known cancer in evolution,Observation,Condition,C0021053,immune disease,FALSE,FALSE,NA,NA,NA
21,NCT00296218,Exclusion,febrile ( > = 38 c ) disease ; known concomitant viral infection or bacterial infection ; chronic auto immune disease ; chronic inflammatory disease ; known cancer in evolution,Observation,Condition,C1290886,chronic inflammatory disease,FALSE,FALSE,NA,NA,NA
21,NCT00296218,Exclusion,febrile ( > = 38 c ) disease ; known concomitant viral infection or bacterial infection ; chronic auto immune disease ; chronic inflammatory disease ; known cancer in evolution,Observation,Condition,C0015219,evolution,FALSE,FALSE,NA,NA,NA
21,NCT00296218,Exclusion,febrile ( > = 38 c ) disease ; known concomitant viral infection or bacterial infection ; chronic auto immune disease ; chronic inflammatory disease ; known cancer in evolution,Observation,Observation,C1441488,auto,FALSE,FALSE,NA,NA,NA
21,NCT00296218,Exclusion,febrile ( > = 38 c ) disease ; known concomitant viral infection or bacterial infection ; chronic auto immune disease ; chronic inflammatory disease ; known cancer in evolution,Observation,Other,C1547296;C1555457,chronic,FALSE,FALSE,NA,NA,NA
21,NCT00296218,Exclusion,febrile ( > = 38 c ) disease ; known concomitant viral infection or bacterial infection ; chronic auto immune disease ; chronic inflammatory disease ; known cancer in evolution,Observation,Other,C0260515;C2707253,cancer,FALSE,FALSE,NA,NA,NA
22,NCT00296218,Exclusion,hyperkalemia : serum potassium > 5.5 mmol / l,Observation,Condition,C0020461,hyperkalemia,FALSE,FALSE,NA,NA,NA
22,NCT00296218,Exclusion,hyperkalemia : serum potassium > 5.5 mmol / l,Observation,Observation,C0302353;C0543465,serum potassium,FALSE,FALSE,NA,greater 5.5 mmol/l,NA
23,NCT00296218,Exclusion,sensitivity or intolerance to angiotensin receptor blockers ( arbs ) : olmesartan ; candesartan ; irbesartan ; eprosartan ; losartan ; telmisartan ; valsartan or any other arb currently or previously in development .,Drug Exposure,Condition,C0427965,sensitivity,FALSE,FALSE,NA,NA,NA
23,NCT00296218,Exclusion,sensitivity or intolerance to angiotensin receptor blockers ( arbs ) : olmesartan ; candesartan ; irbesartan ; eprosartan ; losartan ; telmisartan ; valsartan or any other arb currently or previously in development .,Drug Exposure,Drug,C0521942;C0815017,angiotensin receptor blockers,FALSE,FALSE,NA,NA,NA
23,NCT00296218,Exclusion,sensitivity or intolerance to angiotensin receptor blockers ( arbs ) : olmesartan ; candesartan ; irbesartan ; eprosartan ; losartan ; telmisartan ; valsartan or any other arb currently or previously in development .,Drug Exposure,Drug,C1098320;C0386393,olmesartan,FALSE,FALSE,NA,NA,NA
23,NCT00296218,Exclusion,sensitivity or intolerance to angiotensin receptor blockers ( arbs ) : olmesartan ; candesartan ; irbesartan ; eprosartan ; losartan ; telmisartan ; valsartan or any other arb currently or previously in development .,Drug Exposure,Drug,C0288171,irbesartan,FALSE,FALSE,NA,NA,NA
23,NCT00296218,Exclusion,sensitivity or intolerance to angiotensin receptor blockers ( arbs ) : olmesartan ; candesartan ; irbesartan ; eprosartan ; losartan ; telmisartan ; valsartan or any other arb currently or previously in development .,Drug Exposure,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,NA
23,NCT00296218,Exclusion,sensitivity or intolerance to angiotensin receptor blockers ( arbs ) : olmesartan ; candesartan ; irbesartan ; eprosartan ; losartan ; telmisartan ; valsartan or any other arb currently or previously in development .,Drug Exposure,Drug,C0126174,losartan,FALSE,FALSE,NA,NA,NA
23,NCT00296218,Exclusion,sensitivity or intolerance to angiotensin receptor blockers ( arbs ) : olmesartan ; candesartan ; irbesartan ; eprosartan ; losartan ; telmisartan ; valsartan or any other arb currently or previously in development .,Drug Exposure,Drug,C0287041,eprosartan,FALSE,FALSE,NA,NA,NA
23,NCT00296218,Exclusion,sensitivity or intolerance to angiotensin receptor blockers ( arbs ) : olmesartan ; candesartan ; irbesartan ; eprosartan ; losartan ; telmisartan ; valsartan or any other arb currently or previously in development .,Drug Exposure,Other,C0231199;C1744706;C2355652;C1547317,intolerance,FALSE,FALSE,NA,NA,NA
23,NCT00296218,Exclusion,sensitivity or intolerance to angiotensin receptor blockers ( arbs ) : olmesartan ; candesartan ; irbesartan ; eprosartan ; losartan ; telmisartan ; valsartan or any other arb currently or previously in development .,Drug Exposure,Other,C0521942;C2678493,arb,FALSE,FALSE,NA,NA,NA
23,NCT00296218,Exclusion,sensitivity or intolerance to angiotensin receptor blockers ( arbs ) : olmesartan ; candesartan ; irbesartan ; eprosartan ; losartan ; telmisartan ; valsartan or any other arb currently or previously in development .,Drug Exposure,Other,C3272564;C0020119;C0243107,development,FALSE,FALSE,NA,NA,NA
24,NCT00296218,Exclusion,sensitivity or intolerance to angiotensin-converting enzyme inhibitors ( ace : benazepril ; captopril ; enalapril ; lisinopril ; trandolapril ; ramipril ; quinapril ; or any other ace-i currently or previously in development .,Drug Exposure,Condition,C0427965,sensitivity,FALSE,FALSE,NA,NA,NA
24,NCT00296218,Exclusion,sensitivity or intolerance to angiotensin-converting enzyme inhibitors ( ace : benazepril ; captopril ; enalapril ; lisinopril ; trandolapril ; ramipril ; quinapril ; or any other ace-i currently or previously in development .,Drug Exposure,Drug,C0053091,benazepril,FALSE,FALSE,NA,NA,NA
24,NCT00296218,Exclusion,sensitivity or intolerance to angiotensin-converting enzyme inhibitors ( ace : benazepril ; captopril ; enalapril ; lisinopril ; trandolapril ; ramipril ; quinapril ; or any other ace-i currently or previously in development .,Drug Exposure,Drug,C0072857,quinapril,FALSE,FALSE,NA,NA,NA
24,NCT00296218,Exclusion,sensitivity or intolerance to angiotensin-converting enzyme inhibitors ( ace : benazepril ; captopril ; enalapril ; lisinopril ; trandolapril ; ramipril ; quinapril ; or any other ace-i currently or previously in development .,Drug Exposure,Drug,C0072973,ramipril,FALSE,FALSE,NA,NA,NA
24,NCT00296218,Exclusion,sensitivity or intolerance to angiotensin-converting enzyme inhibitors ( ace : benazepril ; captopril ; enalapril ; lisinopril ; trandolapril ; ramipril ; quinapril ; or any other ace-i currently or previously in development .,Drug Exposure,Drug,C0076891,trandolapril,FALSE,FALSE,NA,NA,NA
24,NCT00296218,Exclusion,sensitivity or intolerance to angiotensin-converting enzyme inhibitors ( ace : benazepril ; captopril ; enalapril ; lisinopril ; trandolapril ; ramipril ; quinapril ; or any other ace-i currently or previously in development .,Drug Exposure,Drug,C0065374,lisinopril,FALSE,FALSE,NA,NA,NA
24,NCT00296218,Exclusion,sensitivity or intolerance to angiotensin-converting enzyme inhibitors ( ace : benazepril ; captopril ; enalapril ; lisinopril ; trandolapril ; ramipril ; quinapril ; or any other ace-i currently or previously in development .,Drug Exposure,Drug,C0014025,enalapril,FALSE,FALSE,NA,NA,NA
24,NCT00296218,Exclusion,sensitivity or intolerance to angiotensin-converting enzyme inhibitors ( ace : benazepril ; captopril ; enalapril ; lisinopril ; trandolapril ; ramipril ; quinapril ; or any other ace-i currently or previously in development .,Drug Exposure,Drug,C0006938,captopril,FALSE,FALSE,NA,NA,NA
24,NCT00296218,Exclusion,sensitivity or intolerance to angiotensin-converting enzyme inhibitors ( ace : benazepril ; captopril ; enalapril ; lisinopril ; trandolapril ; ramipril ; quinapril ; or any other ace-i currently or previously in development .,Drug Exposure,Other,C0231199;C1744706;C2355652;C1547317,intolerance,FALSE,FALSE,NA,NA,NA
24,NCT00296218,Exclusion,sensitivity or intolerance to angiotensin-converting enzyme inhibitors ( ace : benazepril ; captopril ; enalapril ; lisinopril ; trandolapril ; ramipril ; quinapril ; or any other ace-i currently or previously in development .,Drug Exposure,Other,C0003015;C2757044,angiotensin-converting enzyme inhibitors,FALSE,FALSE,NA,NA,NA
24,NCT00296218,Exclusion,sensitivity or intolerance to angiotensin-converting enzyme inhibitors ( ace : benazepril ; captopril ; enalapril ; lisinopril ; trandolapril ; ramipril ; quinapril ; or any other ace-i currently or previously in development .,Drug Exposure,Other,C0050385;C0201888,ace,FALSE,FALSE,NA,NA,NA
24,NCT00296218,Exclusion,sensitivity or intolerance to angiotensin-converting enzyme inhibitors ( ace : benazepril ; captopril ; enalapril ; lisinopril ; trandolapril ; ramipril ; quinapril ; or any other ace-i currently or previously in development .,Drug Exposure,Other,C0050385;C0201888,ace,FALSE,FALSE,NA,NA,NA
24,NCT00296218,Exclusion,sensitivity or intolerance to angiotensin-converting enzyme inhibitors ( ace : benazepril ; captopril ; enalapril ; lisinopril ; trandolapril ; ramipril ; quinapril ; or any other ace-i currently or previously in development .,Drug Exposure,Other,C3272564;C0020119;C0243107,development,FALSE,FALSE,NA,NA,NA
25,NCT00296218,Exclusion,chronic steroid or non-steroidal anti inflammatory drugs ( nsaids ) use,Drug Exposure,Drug,C2927350,non-steroidal,FALSE,FALSE,NA,NA,NA
25,NCT00296218,Exclusion,chronic steroid or non-steroidal anti inflammatory drugs ( nsaids ) use,Drug Exposure,Drug,C0003209,anti inflammatory drugs,FALSE,FALSE,NA,NA,NA
25,NCT00296218,Exclusion,chronic steroid or non-steroidal anti inflammatory drugs ( nsaids ) use,Drug Exposure,Drug,C0003211,nsaids,FALSE,FALSE,NA,NA,NA
25,NCT00296218,Exclusion,chronic steroid or non-steroidal anti inflammatory drugs ( nsaids ) use,Drug Exposure,Other,C1547296;C1555457,chronic,FALSE,FALSE,NA,NA,NA
26,NCT00296218,Exclusion,aspirin is permitted .,Drug Exposure,Drug,C0004057,aspirin,FALSE,FALSE,NA,NA,NA
27,NCT00296218,Exclusion,treatment with allopurinol or proca namide,Drug Exposure,Drug,C0002144,allopurinol,FALSE,FALSE,NA,NA,NA
28,NCT00296218,Exclusion,concomitant use of potassium sparing diuretics ( eg ; spironolactone ; triamterene or amiloride ) ; potassium preparations or salt substitutes containing potassium,Drug Exposure,Drug,C0304490,potassium sparing diuretics,FALSE,FALSE,NA,NA,NA
28,NCT00296218,Exclusion,concomitant use of potassium sparing diuretics ( eg ; spironolactone ; triamterene or amiloride ) ; potassium preparations or salt substitutes containing potassium,Drug Exposure,Drug,C0037982,spironolactone,FALSE,FALSE,NA,NA,NA
28,NCT00296218,Exclusion,concomitant use of potassium sparing diuretics ( eg ; spironolactone ; triamterene or amiloride ) ; potassium preparations or salt substitutes containing potassium,Drug Exposure,Drug,C0002502,amiloride,FALSE,FALSE,NA,NA,NA
28,NCT00296218,Exclusion,concomitant use of potassium sparing diuretics ( eg ; spironolactone ; triamterene or amiloride ) ; potassium preparations or salt substitutes containing potassium,Drug Exposure,Drug,C0040869,triamterene,FALSE,FALSE,NA,NA,NA
28,NCT00296218,Exclusion,concomitant use of potassium sparing diuretics ( eg ; spironolactone ; triamterene or amiloride ) ; potassium preparations or salt substitutes containing potassium,Drug Exposure,Drug,C0032821,potassium preparations,FALSE,FALSE,NA,NA,NA
28,NCT00296218,Exclusion,concomitant use of potassium sparing diuretics ( eg ; spironolactone ; triamterene or amiloride ) ; potassium preparations or salt substitutes containing potassium,Drug Exposure,Drug,C0784217,salt substitutes,FALSE,FALSE,NA,NA,NA
28,NCT00296218,Exclusion,concomitant use of potassium sparing diuretics ( eg ; spironolactone ; triamterene or amiloride ) ; potassium preparations or salt substitutes containing potassium,Drug Exposure,Other,C0032821;C0202194;C0304475,potassium,FALSE,FALSE,NA,NA,NA
29,NCT00296218,Exclusion,treatment with lithium,Observation,Other,C0337452;C0023870;C3540800,lithium,FALSE,FALSE,NA,NA,NA
30,NCT00296218,Exclusion,immunosupressive medication,Other,NA,NA,NA,NA,NA,NA,NA,NA
31,NCT00296218,Exclusion,administration of any other investigational drug in the last 30 days before enrolment and during the course of the study,Drug Exposure,Drug,C0013230,investigational drug,FALSE,FALSE,lower_equal 30 last days,NA,NA
32,NCT00296218,Exclusion,treatment with arb or ace inhibitor within the last 3 days,Drug Exposure,Other,C0521942;C2678493,arb,FALSE,FALSE,lower 3 last days,NA,NA
32,NCT00296218,Exclusion,treatment with arb or ace inhibitor within the last 3 days,Drug Exposure,Other,C0003015;C1152583,ace inhibitor,FALSE,FALSE,lower 3 last days,NA,NA
1,NCT00311740,Inclusion,essential hypertension measured by mercury sphygmomanometer,Drug Exposure,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00311740,Inclusion,essential hypertension measured by mercury sphygmomanometer,Drug Exposure,Drug,C0025424,mercury,FALSE,FALSE,NA,NA,NA
1,NCT00311740,Inclusion,essential hypertension measured by mercury sphygmomanometer,Drug Exposure,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
2,NCT00311740,Inclusion,outpatients,Other,NA,NA,NA,NA,NA,NA,NA,NA
3,NCT00311740,Exclusion,secondary hypertension or suspected of having secondary hypertension .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00311740,Exclusion,secondary hypertension or suspected of having secondary hypertension .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
4,NCT00311740,Exclusion,a history of malignant hypertension,Condition Occurrence,Condition,C0020540;C0024588,malignant hypertension,FALSE,FALSE,NA,NA,NA
5,NCT00311740,Exclusion,severe hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
5,NCT00311740,Exclusion,severe hypertension,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
6,NCT00311740,Exclusion,significant heart ; renal diseases ; hepatic diseases or significant cerebrovascular disorder,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
6,NCT00311740,Exclusion,significant heart ; renal diseases ; hepatic diseases or significant cerebrovascular disorder,Condition Occurrence,Condition,C0007820,cerebrovascular disorder,FALSE,FALSE,NA,NA,NA
6,NCT00311740,Exclusion,significant heart ; renal diseases ; hepatic diseases or significant cerebrovascular disorder,Condition Occurrence,Condition,C0023895,hepatic diseases,FALSE,FALSE,NA,NA,NA
6,NCT00311740,Exclusion,significant heart ; renal diseases ; hepatic diseases or significant cerebrovascular disorder,Condition Occurrence,Condition,C0022658,renal diseases,FALSE,FALSE,NA,NA,NA
7,NCT00311740,Exclusion,gout other protocol-defined inclusion / may apply,Condition Occurrence,Condition,C0018099,gout,FALSE,FALSE,NA,NA,NA
7,NCT00311740,Exclusion,gout other protocol-defined inclusion / may apply,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00316095,Inclusion,willing and able to provide written informed consent,Other,NA,NA,NA,NA,NA,NA,NA,NA
2,NCT00316095,Inclusion,age 18 years or older,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 18 years,NA,NA
3,NCT00316095,Inclusion,hypertension as defined by a mean seated cuff dbp of > = 95 - 109 mmhg,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
3,NCT00316095,Inclusion,hypertension as defined by a mean seated cuff dbp of > = 95 - 109 mmhg,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00316095,Inclusion,hypertension as defined by a mean seated cuff dbp of > = 95 - 109 mmhg,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 95 mmhg; greater_equal 109 mmhg,NA
3,NCT00316095,Inclusion,hypertension as defined by a mean seated cuff dbp of > = 95 - 109 mmhg,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
4,NCT00316095,Inclusion,hypercholesterolemia as defined by a fasting ldl-c level at visit 2 according to,Condition Occurrence,Condition,C0020443;C1522133,hypercholesterolemia,FALSE,FALSE,NA,NA,NA
4,NCT00316095,Inclusion,hypercholesterolemia as defined by a fasting ldl-c level at visit 2 according to,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
4,NCT00316095,Inclusion,hypercholesterolemia as defined by a fasting ldl-c level at visit 2 according to,Condition Occurrence,Other,C0015663;C1550565,fasting,FALSE,FALSE,NA,NA,NA
4,NCT00316095,Inclusion,hypercholesterolemia as defined by a fasting ldl-c level at visit 2 according to,Condition Occurrence,Other,C0202117;C1325353,ldl,FALSE,FALSE,NA,NA,NA
5,NCT00316095,Inclusion,cv risk shown in table below :,Procedure,Other,C0280551;C1880201,cv,FALSE,FALSE,NA,NA,NA
5,NCT00316095,Inclusion,cv risk shown in table below :,Procedure,Other,C1706074,table,FALSE,FALSE,NA,NA,NA
6,NCT00316095,Inclusion,cv risk group :,Procedure,Other,C0280551;C1880201,cv,FALSE,FALSE,NA,NA,NA
7,NCT00316095,Inclusion,group i hypertension and hypercholesterolemia only,Condition Occurrence,Condition,C0020443;C1522133,hypercholesterolemia,FALSE,FALSE,NA,NA,NA
7,NCT00316095,Inclusion,group i hypertension and hypercholesterolemia only,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
7,NCT00316095,Inclusion,group i hypertension and hypercholesterolemia only,Condition Occurrence,Other,C0441843,group i,FALSE,FALSE,NA,NA,NA
8,NCT00316095,Inclusion,group ii hypertension and hypercholesterolemia plus > 1 risk factors,Observation,Condition,C0020443;C1522133,hypercholesterolemia,FALSE,FALSE,NA,NA,NA
8,NCT00316095,Inclusion,group ii hypertension and hypercholesterolemia plus > 1 risk factors,Observation,Condition,C0455624,risk factors,FALSE,FALSE,NA,greater 1,NA
8,NCT00316095,Inclusion,group ii hypertension and hypercholesterolemia plus > 1 risk factors,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
9,NCT00316095,Inclusion,group iii hypertension and hypercholesterolemia plus chd or diabetes mellitus or other athero-sclerotic disease,Condition Occurrence,Condition,C0020443;C1522133,hypercholesterolemia,FALSE,FALSE,NA,NA,NA
9,NCT00316095,Inclusion,group iii hypertension and hypercholesterolemia plus chd or diabetes mellitus or other athero-sclerotic disease,Condition Occurrence,Condition,C0011849,diabetes mellitus,FALSE,FALSE,NA,NA,NA
9,NCT00316095,Inclusion,group iii hypertension and hypercholesterolemia plus chd or diabetes mellitus or other athero-sclerotic disease,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
9,NCT00316095,Inclusion,group iii hypertension and hypercholesterolemia plus chd or diabetes mellitus or other athero-sclerotic disease,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii,FALSE,FALSE,NA,NA,NA
10,NCT00316095,Inclusion,fasting ldl-c group i and ii : 100 - 250 mg / dl ( 2.6 - 6.55 mmol / l ),Observation,Other,C0015663;C1550565,fasting,FALSE,FALSE,NA,NA,NA
10,NCT00316095,Inclusion,fasting ldl-c group i and ii : 100 - 250 mg / dl ( 2.6 - 6.55 mmol / l ),Observation,Other,C0202117;C1325353,ldl,FALSE,FALSE,NA,NA,NA
10,NCT00316095,Inclusion,fasting ldl-c group i and ii : 100 - 250 mg / dl ( 2.6 - 6.55 mmol / l ),Observation,Other,C0441843,group i,FALSE,FALSE,NA,greater_equal 2.6 mmol/l; lower_equal 6.55 mmol/l,greater_equal 100 mg/dl; lower_equal 250 mg/dl
11,NCT00316095,Inclusion,fasting ldl-c group iii : 100 - 160 mg / dl ( 2.6 - 4.11 mmol / l ),Observation,Other,C0015663;C1550565,fasting,FALSE,FALSE,NA,NA,NA
11,NCT00316095,Inclusion,fasting ldl-c group iii : 100 - 160 mg / dl ( 2.6 - 4.11 mmol / l ),Observation,Other,C0202117;C1325353,ldl,FALSE,FALSE,NA,NA,NA
11,NCT00316095,Inclusion,fasting ldl-c group iii : 100 - 160 mg / dl ( 2.6 - 4.11 mmol / l ),Observation,Other,C0439070;C2337640;C3496532,iii,FALSE,FALSE,NA,greater_equal 2.6 mmol/l; lower_equal 4.11 mmol/l,greater_equal 100 mg/dl; lower_equal 160 mg/dl
12,NCT00316095,Inclusion,risk factors : > = 45 yrs if male ; > = 55 years if female ; family history of chd ; current smoker ; hdl-c < 40 mg / dl,Condition Occurrence,Person,C0025266,male,FALSE,FALSE,greater_equal 55 years,NA,NA
12,NCT00316095,Inclusion,risk factors : > = 45 yrs if male ; > = 55 years if female ; family history of chd ; current smoker ; hdl-c < 40 mg / dl,Condition Occurrence,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
12,NCT00316095,Inclusion,risk factors : > = 45 yrs if male ; > = 55 years if female ; family history of chd ; current smoker ; hdl-c < 40 mg / dl,Condition Occurrence,Condition,C0455624,risk factors,FALSE,FALSE,greater_equal 45 yrs,NA,NA
12,NCT00316095,Inclusion,risk factors : > = 45 yrs if male ; > = 55 years if female ; family history of chd ; current smoker ; hdl-c < 40 mg / dl,Condition Occurrence,Condition,C0241889,family history,FALSE,FALSE,NA,NA,NA
12,NCT00316095,Inclusion,risk factors : > = 45 yrs if male ; > = 55 years if female ; family history of chd ; current smoker ; hdl-c < 40 mg / dl,Condition Occurrence,Condition,C1704429,hdl-c,FALSE,FALSE,NA,NA,lower 40 mg/dl
12,NCT00316095,Inclusion,risk factors : > = 45 yrs if male ; > = 55 years if female ; family history of chd ; current smoker ; hdl-c < 40 mg / dl,Condition Occurrence,Other,C0337664;C3241966;C3173209,current smoker,FALSE,FALSE,NA,NA,lower 40 mg/dl
13,NCT00316095,Exclusion,pre-menopausal women who are not surgically sterile or are nursing or pregnant or are of child-bearing potential and are not practicing acceptable means of birth control,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
13,NCT00316095,Exclusion,pre-menopausal women who are not surgically sterile or are nursing or pregnant or are of child-bearing potential and are not practicing acceptable means of birth control,Condition Occurrence,Condition,C1096235,pre-menopausal,FALSE,FALSE,NA,NA,NA
13,NCT00316095,Exclusion,pre-menopausal women who are not surgically sterile or are nursing or pregnant or are of child-bearing potential and are not practicing acceptable means of birth control,Condition Occurrence,Condition,C0006147,nursing,TRUE,FALSE,NA,NA,NA
13,NCT00316095,Exclusion,pre-menopausal women who are not surgically sterile or are nursing or pregnant or are of child-bearing potential and are not practicing acceptable means of birth control,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
13,NCT00316095,Exclusion,pre-menopausal women who are not surgically sterile or are nursing or pregnant or are of child-bearing potential and are not practicing acceptable means of birth control,Condition Occurrence,Observation,C3831118,child-bearing potential,FALSE,FALSE,NA,NA,NA
13,NCT00316095,Exclusion,pre-menopausal women who are not surgically sterile or are nursing or pregnant or are of child-bearing potential and are not practicing acceptable means of birth control,Condition Occurrence,Other,C0700589;C2703065,birth control,FALSE,FALSE,NA,NA,NA
14,NCT00316095,Exclusion,inability to stop current antihypertensive or cholesterol-lowering therapies,Drug Exposure,Drug,C0723457,stop,FALSE,FALSE,NA,NA,NA
14,NCT00316095,Exclusion,inability to stop current antihypertensive or cholesterol-lowering therapies,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
14,NCT00316095,Exclusion,inability to stop current antihypertensive or cholesterol-lowering therapies,Drug Exposure,Observation,C0008377;C0201950,cholesterol,FALSE,FALSE,NA,NA,NA
15,NCT00316095,Exclusion,contraindication to a washout / placebo treatment,Drug Exposure,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,NA
15,NCT00316095,Exclusion,contraindication to a washout / placebo treatment,Drug Exposure,Other,C1301624;C1547316,contraindication,FALSE,FALSE,NA,NA,NA
16,NCT00316095,Exclusion,clinically relevant cardiac arrhythmias,Condition Occurrence,Condition,C0003811,cardiac arrhythmias,FALSE,FALSE,NA,NA,NA
17,NCT00316095,Exclusion,hypertrophic obstructive cardiomyopathy ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0007194,hypertrophic obstructive cardiomyopathy,FALSE,FALSE,NA,NA,NA
17,NCT00316095,Exclusion,hypertrophic obstructive cardiomyopathy ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0003501;C1269005,aortic valve,FALSE,FALSE,NA,NA,NA
17,NCT00316095,Exclusion,hypertrophic obstructive cardiomyopathy ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0026264;C1269004,mitral valve,FALSE,FALSE,NA,NA,NA
17,NCT00316095,Exclusion,hypertrophic obstructive cardiomyopathy ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Observation,C1261287;C0947637;C0009814,stenosis,FALSE,FALSE,NA,NA,NA
18,NCT00316095,Exclusion,mean sitting sbp > = 180 mmhg or mean sitting dbp > = 110 mmhg at two consecutive visits,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
18,NCT00316095,Exclusion,mean sitting sbp > = 180 mmhg or mean sitting dbp > = 110 mmhg at two consecutive visits,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
18,NCT00316095,Exclusion,mean sitting sbp > = 180 mmhg or mean sitting dbp > = 110 mmhg at two consecutive visits,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 180 mmhg,NA
18,NCT00316095,Exclusion,mean sitting sbp > = 180 mmhg or mean sitting dbp > = 110 mmhg at two consecutive visits,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 110 mmhg,NA
19,NCT00316095,Exclusion,known or suspected secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
20,NCT00316095,Exclusion,known or suspected secondary hyperlipidemia of any etiology,Condition Occurrence,Condition,C0853689,secondary hyperlipidemia,FALSE,FALSE,NA,NA,NA
21,NCT00316095,Exclusion,diabetes that has not been stable and controlled for the previous three months,Condition Occurrence,Condition,C0011849;C0011847,diabetes,FALSE,FALSE,NA,NA,NA
21,NCT00316095,Exclusion,diabetes that has not been stable and controlled for the previous three months,Condition Occurrence,Other,C1547311,stable,TRUE,FALSE,NA,NA,NA
22,NCT00316095,Exclusion,severe renal dysfunction,Condition Occurrence,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
22,NCT00316095,Exclusion,severe renal dysfunction,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
23,NCT00316095,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant or one kidney,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
23,NCT00316095,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant or one kidney,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
23,NCT00316095,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant or one kidney,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
23,NCT00316095,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant or one kidney,Condition Occurrence,Condition,C0478647,transplant,FALSE,FALSE,NA,NA,NA
23,NCT00316095,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant or one kidney,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
24,NCT00316095,Exclusion,biliary obstructive disorders ; hepatic insufficiency ; including past or current liver disease,Condition Occurrence,Condition,C1306571,hepatic insufficiency,FALSE,FALSE,NA,NA,NA
24,NCT00316095,Exclusion,biliary obstructive disorders ; hepatic insufficiency ; including past or current liver disease,Condition Occurrence,Condition,C0023895;C2186532,liver disease,FALSE,FALSE,NA,NA,NA
25,NCT00316095,Exclusion,clinically relevant hypokalaemia or hyperkalaemia,Other,NA,NA,NA,NA,NA,NA,NA,NA
26,NCT00316095,Exclusion,uncorrected volume depletion,Condition Occurrence,Condition,C0546884,volume depletion,FALSE,FALSE,NA,NA,NA
27,NCT00316095,Exclusion,uncorrected sodium depletion,Condition Occurrence,Condition,C0020625,sodium depletion,FALSE,FALSE,NA,NA,NA
28,NCT00316095,Exclusion,any history of myopathy or rhabdomyolysis during the past treatment with hmg co-a reductase inhibitors,Condition Occurrence,Condition,C0026848,myopathy,FALSE,FALSE,NA,NA,NA
28,NCT00316095,Exclusion,any history of myopathy or rhabdomyolysis during the past treatment with hmg co-a reductase inhibitors,Condition Occurrence,Condition,C0035410,rhabdomyolysis,FALSE,FALSE,NA,NA,NA
28,NCT00316095,Exclusion,any history of myopathy or rhabdomyolysis during the past treatment with hmg co-a reductase inhibitors,Condition Occurrence,Condition,C2945691,past treatment,FALSE,FALSE,NA,NA,NA
28,NCT00316095,Exclusion,any history of myopathy or rhabdomyolysis during the past treatment with hmg co-a reductase inhibitors,Condition Occurrence,Drug,C0178700,hmg,FALSE,FALSE,NA,NA,NA
28,NCT00316095,Exclusion,any history of myopathy or rhabdomyolysis during the past treatment with hmg co-a reductase inhibitors,Condition Occurrence,Other,C0687669;C0009226;C3495326,co-a,FALSE,FALSE,NA,NA,NA
29,NCT00316095,Exclusion,concurrent use of large quantities of grapefruit juice,Drug Exposure,Drug,C0440280;C2740624,grapefruit,FALSE,FALSE,NA,NA,NA
30,NCT00316095,Exclusion,known hypersensitivity or intolerance to hmg co-a reductase inhibitors or angiotensin receptor blockers ; hereditary fructose intolerance,Drug Exposure,Condition,C0016751,hereditary fructose intolerance,FALSE,FALSE,NA,NA,NA
30,NCT00316095,Exclusion,known hypersensitivity or intolerance to hmg co-a reductase inhibitors or angiotensin receptor blockers ; hereditary fructose intolerance,Drug Exposure,Drug,C0178700,hmg,FALSE,FALSE,NA,NA,NA
30,NCT00316095,Exclusion,known hypersensitivity or intolerance to hmg co-a reductase inhibitors or angiotensin receptor blockers ; hereditary fructose intolerance,Drug Exposure,Drug,C0521942;C0815017,angiotensin receptor blockers,FALSE,FALSE,NA,NA,NA
30,NCT00316095,Exclusion,known hypersensitivity or intolerance to hmg co-a reductase inhibitors or angiotensin receptor blockers ; hereditary fructose intolerance,Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
30,NCT00316095,Exclusion,known hypersensitivity or intolerance to hmg co-a reductase inhibitors or angiotensin receptor blockers ; hereditary fructose intolerance,Drug Exposure,Other,C0231199;C1744706;C2355652;C1547317,intolerance,FALSE,FALSE,NA,NA,NA
30,NCT00316095,Exclusion,known hypersensitivity or intolerance to hmg co-a reductase inhibitors or angiotensin receptor blockers ; hereditary fructose intolerance,Drug Exposure,Other,C0687669;C0009226;C3495326,co-a,FALSE,FALSE,NA,NA,NA
31,NCT00316095,Exclusion,planned significant diet or lifestyle ( including exercise ) changes during the treatment phase of the trial,Procedure,Procedure,C1522704,exercise,FALSE,FALSE,NA,NA,NA
31,NCT00316095,Exclusion,planned significant diet or lifestyle ( including exercise ) changes during the treatment phase of the trial,Procedure,Other,C0012159;C1519433;C1561465;C1550559;C1549512,diet,FALSE,FALSE,NA,NA,NA
32,NCT00316095,Exclusion,history of drug or alcohol dependency,Condition Occurrence,Condition,C0001973,alcohol dependency,FALSE,FALSE,NA,NA,NA
32,NCT00316095,Exclusion,history of drug or alcohol dependency,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
33,NCT00316095,Exclusion,any investigational drug therapy within one month of providing informed consent,Drug Exposure,Drug,C0013230,investigational drug,FALSE,FALSE,NA,NA,NA
34,NCT00316095,Exclusion,any other clinical condition which ; in the opinion of the investigator ; would not allow safe completion of the protocol and safe administration of the trial medications,Other,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
1,NCT00327145,Inclusion,male or female patients > = 18 years of age,Person,Person,C0025266,male,FALSE,FALSE,greater_equal 18 years,NA,NA
1,NCT00327145,Inclusion,male or female patients > = 18 years of age,Person,Observation,C0150905,female patients,FALSE,FALSE,greater_equal 18 years,NA,NA
2,NCT00327145,Inclusion,non-diabetic patients must have mssbp of > = 140 mmhg or msdbp > = 90 mmhg at visits 1 and,Observation,Condition,C0241863,diabetic,FALSE,FALSE,NA,greater_equal 140 mmhg; greater_equal 90 mmhg; equal 1,NA
3,NCT00327145,Inclusion,diabetic patients must have mssbp > = 130 mmhg or msdbp > = 80 mmhg at visits 1 and 2,Observation,Condition,C0241863,diabetic,FALSE,FALSE,NA,greater_equal 130 mmhg; greater_equal 80 mmhg; equal 1 ; equal 2,NA
4,NCT00327145,Inclusion,patients treated with monotherapy at a dose considered as adequate by the investigator for a minimum of two months prior to visit 1,Other,NA,NA,NA,NA,NA,NA,NA,NA
5,NCT00327145,Exclusion,known or suspected contraindications ; including history of allergy to arbs ; ccb ; thiazides or to drugs with similar chemical structure .,Drug Exposure,Condition,C0175556,ccb,FALSE,FALSE,NA,NA,NA
5,NCT00327145,Exclusion,known or suspected contraindications ; including history of allergy to arbs ; ccb ; thiazides or to drugs with similar chemical structure .,Drug Exposure,Drug,C0541746;C0012802,thiazides,FALSE,FALSE,NA,NA,NA
5,NCT00327145,Exclusion,known or suspected contraindications ; including history of allergy to arbs ; ccb ; thiazides or to drugs with similar chemical structure .,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
5,NCT00327145,Exclusion,known or suspected contraindications ; including history of allergy to arbs ; ccb ; thiazides or to drugs with similar chemical structure .,Drug Exposure,Other,C0489531;C0718579;C3542994;C3539909;C1314973;C1547315;C1611280,allergy,FALSE,FALSE,NA,NA,NA
5,NCT00327145,Exclusion,known or suspected contraindications ; including history of allergy to arbs ; ccb ; thiazides or to drugs with similar chemical structure .,Drug Exposure,Other,C0220807,chemical structure,FALSE,FALSE,NA,NA,NA
6,NCT00327145,Exclusion,mssbp > = 180 mmhg or msdbp > = 110 mmhg ( mssbp > = 160 mmhg or msdbp > = 100 mmhg for diabetic patients ) at any time between visit 1 and visit 2 .,Observation,Condition,C2024467,time,FALSE,FALSE,NA,NA,NA
6,NCT00327145,Exclusion,mssbp > = 180 mmhg or msdbp > = 110 mmhg ( mssbp > = 160 mmhg or msdbp > = 100 mmhg for diabetic patients ) at any time between visit 1 and visit 2 .,Observation,Condition,C0241863,diabetic,FALSE,FALSE,NA,greater_equal 100 mmhg; greater_equal 180 mmhg; greater_equal 110 mmhg; greater_equal 160 mmhg,NA
7,NCT00327145,Exclusion,evidence of a secondary form of hypertension ; to include coarctation of the aorta ; primary hyperaldosteronism ; renal artery stenosis ; or pheochromocytoma .,Condition Occurrence,Condition,C0332886,coarctation,FALSE,FALSE,NA,NA,NA
7,NCT00327145,Exclusion,evidence of a secondary form of hypertension ; to include coarctation of the aorta ; primary hyperaldosteronism ; renal artery stenosis ; or pheochromocytoma .,Condition Occurrence,Condition,C0031511;C1706920,pheochromocytoma,FALSE,FALSE,NA,NA,NA
7,NCT00327145,Exclusion,evidence of a secondary form of hypertension ; to include coarctation of the aorta ; primary hyperaldosteronism ; renal artery stenosis ; or pheochromocytoma .,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
7,NCT00327145,Exclusion,evidence of a secondary form of hypertension ; to include coarctation of the aorta ; primary hyperaldosteronism ; renal artery stenosis ; or pheochromocytoma .,Condition Occurrence,Condition,C1384514,primary hyperaldosteronism,FALSE,FALSE,NA,NA,NA
7,NCT00327145,Exclusion,evidence of a secondary form of hypertension ; to include coarctation of the aorta ; primary hyperaldosteronism ; renal artery stenosis ; or pheochromocytoma .,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
7,NCT00327145,Exclusion,evidence of a secondary form of hypertension ; to include coarctation of the aorta ; primary hyperaldosteronism ; renal artery stenosis ; or pheochromocytoma .,Condition Occurrence,Other,C0869784;C0003483;C1278934,aorta,FALSE,FALSE,NA,NA,NA
8,NCT00327145,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy .,Condition Occurrence,Condition,C0152132,hypertensive retinopathy,FALSE,FALSE,NA,NA,NA
8,NCT00327145,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy .,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii,FALSE,FALSE,NA,NA,NA
8,NCT00327145,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy .,Condition Occurrence,Other,C0677510;C0021440;C3496001,iv,FALSE,FALSE,NA,NA,NA
9,NCT00327145,Exclusion,other apply,Other,NA,NA,NA,NA,NA,NA,NA,NA
1,NCT00333489,Inclusion,incl patients with mild to moderate essential hypertension ( grade 1 and grade 2 of who classification ) .,Condition Occurrence,Condition,C0268281,incl,FALSE,FALSE,NA,NA,NA
1,NCT00333489,Inclusion,incl patients with mild to moderate essential hypertension ( grade 1 and grade 2 of who classification ) .,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00333489,Inclusion,incl patients with mild to moderate essential hypertension ( grade 1 and grade 2 of who classification ) .,Condition Occurrence,Other,C1547225,mild,FALSE,FALSE,NA,NA,NA
1,NCT00333489,Inclusion,incl patients with mild to moderate essential hypertension ( grade 1 and grade 2 of who classification ) .,Condition Occurrence,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
2,NCT00333489,Inclusion,patients with essential diastolic hypertension measured by a standard aneroid column or mercury column sphygmomanometer showing msdbp > 95 mmhg and < 110 mmhg and mssbp < 180 mmhg .,Observation,Condition,C3694763,essential diastolic hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00333489,Inclusion,patients with essential diastolic hypertension measured by a standard aneroid column or mercury column sphygmomanometer showing msdbp > 95 mmhg and < 110 mmhg and mssbp < 180 mmhg .,Observation,Condition,C1185738,column,FALSE,FALSE,NA,greater 95 mmhg; lower 110 mmhg; lower 180 mmhg,NA
2,NCT00333489,Inclusion,patients with essential diastolic hypertension measured by a standard aneroid column or mercury column sphygmomanometer showing msdbp > 95 mmhg and < 110 mmhg and mssbp < 180 mmhg .,Observation,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
2,NCT00333489,Inclusion,patients with essential diastolic hypertension measured by a standard aneroid column or mercury column sphygmomanometer showing msdbp > 95 mmhg and < 110 mmhg and mssbp < 180 mmhg .,Observation,Observation,C1441642,mercury column,FALSE,FALSE,NA,greater 95 mmhg; lower 110 mmhg; lower 180 mmhg,NA
2,NCT00333489,Inclusion,patients with essential diastolic hypertension measured by a standard aneroid column or mercury column sphygmomanometer showing msdbp > 95 mmhg and < 110 mmhg and mssbp < 180 mmhg .,Observation,Other,C2828392;C3272550,standard,FALSE,FALSE,NA,NA,NA
3,NCT00333489,Exclusion,severe hypertension ( grade 3 of who classification : dbp > = 110 mmhg or sbp > = 180 mmhg ) or malignant hypertension .,Observation,Condition,C0020540;C0024588,malignant hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00333489,Exclusion,severe hypertension ( grade 3 of who classification : dbp > = 110 mmhg or sbp > = 180 mmhg ) or malignant hypertension .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00333489,Exclusion,severe hypertension ( grade 3 of who classification : dbp > = 110 mmhg or sbp > = 180 mmhg ) or malignant hypertension .,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 110 mmhg; greater_equal 180 mmhg,NA
3,NCT00333489,Exclusion,severe hypertension ( grade 3 of who classification : dbp > = 110 mmhg or sbp > = 180 mmhg ) or malignant hypertension .,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 180 mmhg,NA
3,NCT00333489,Exclusion,severe hypertension ( grade 3 of who classification : dbp > = 110 mmhg or sbp > = 180 mmhg ) or malignant hypertension .,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
4,NCT00333489,Exclusion,inability to completely discontinue all antihypertensive medications safely for a period of at least 2 weeks as required by the protocol .,Other,Drug,C0003364,antihypertensive,FALSE,FALSE,greater_equal 2 weeks,NA,NA
4,NCT00333489,Exclusion,inability to completely discontinue all antihypertensive medications safely for a period of at least 2 weeks as required by the protocol .,Other,Other,C1706472,discontinue,FALSE,FALSE,NA,NA,NA
4,NCT00333489,Exclusion,inability to completely discontinue all antihypertensive medications safely for a period of at least 2 weeks as required by the protocol .,Other,Other,C3245502;C3245501;C1619636;C1546857,required,FALSE,FALSE,NA,NA,NA
5,NCT00333489,Exclusion,evidence of a secondary form of hypertension ; such as coarctation of aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; etc,Condition Occurrence,Condition,C0332886,coarctation,FALSE,FALSE,NA,NA,NA
5,NCT00333489,Exclusion,evidence of a secondary form of hypertension ; such as coarctation of aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; etc,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
5,NCT00333489,Exclusion,evidence of a secondary form of hypertension ; such as coarctation of aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; etc,Condition Occurrence,Condition,C0035065;C1278951,renal artery,FALSE,FALSE,NA,NA,NA
5,NCT00333489,Exclusion,evidence of a secondary form of hypertension ; such as coarctation of aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; etc,Condition Occurrence,Condition,C0020428,hyperaldosteronism,FALSE,FALSE,NA,NA,NA
5,NCT00333489,Exclusion,evidence of a secondary form of hypertension ; such as coarctation of aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; etc,Condition Occurrence,Condition,C0221406;C0010481,cushing disease,FALSE,FALSE,NA,NA,NA
5,NCT00333489,Exclusion,evidence of a secondary form of hypertension ; such as coarctation of aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; etc,Condition Occurrence,Condition,C0022680,polycystic kidney disease,FALSE,FALSE,NA,NA,NA
5,NCT00333489,Exclusion,evidence of a secondary form of hypertension ; such as coarctation of aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; etc,Condition Occurrence,Condition,C0031511;C1706920,pheochromocytoma,FALSE,FALSE,NA,NA,NA
5,NCT00333489,Exclusion,evidence of a secondary form of hypertension ; such as coarctation of aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; etc,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
5,NCT00333489,Exclusion,evidence of a secondary form of hypertension ; such as coarctation of aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; etc,Condition Occurrence,Other,C0869784;C0003483;C1278934,aorta,FALSE,FALSE,NA,NA,NA
1,NCT00343551,Inclusion,outpatients 18 years of age and older .,Person,Person,C0001779,age,FALSE,FALSE,equal 18 years,NA,NA
1,NCT00343551,Inclusion,outpatients 18 years of age and older .,Person,Person,C0001779,older,FALSE,FALSE,equal 18 years,NA,NA
3,NCT00343551,Inclusion,at visit 2 : office mean sitting diastolic blood pressure > = 90 mmhg and < 110 mmhg at visit 3 : office mean sitting diastolic blood pressure > = 95 mmhg and < 110 mmhg before application of ambulatory blood pressure measurement device at visit 3 : 24 - hr mean ambulatory diastolic blood pressure > = 85 mmhg,Observation,Condition,C1319894,sitting diastolic blood pressure,FALSE,FALSE,NA,greater_equal 90 mmhg; lower 110 mmhg,NA
3,NCT00343551,Inclusion,at visit 2 : office mean sitting diastolic blood pressure > = 90 mmhg and < 110 mmhg at visit 3 : office mean sitting diastolic blood pressure > = 95 mmhg and < 110 mmhg before application of ambulatory blood pressure measurement device at visit 3 : 24 - hr mean ambulatory diastolic blood pressure > = 85 mmhg,Observation,Condition,C1319894,sitting diastolic blood pressure,FALSE,FALSE,NA,greater_equal 95 mmhg; lower 110 mmhg,NA
3,NCT00343551,Inclusion,at visit 2 : office mean sitting diastolic blood pressure > = 90 mmhg and < 110 mmhg at visit 3 : office mean sitting diastolic blood pressure > = 95 mmhg and < 110 mmhg before application of ambulatory blood pressure measurement device at visit 3 : 24 - hr mean ambulatory diastolic blood pressure > = 85 mmhg,Observation,Condition,C0855316,ambulatory blood pressure,FALSE,FALSE,NA,equal 24,NA
3,NCT00343551,Inclusion,at visit 2 : office mean sitting diastolic blood pressure > = 90 mmhg and < 110 mmhg at visit 3 : office mean sitting diastolic blood pressure > = 95 mmhg and < 110 mmhg before application of ambulatory blood pressure measurement device at visit 3 : 24 - hr mean ambulatory diastolic blood pressure > = 85 mmhg,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater_equal 85 mmhg,NA
3,NCT00343551,Inclusion,at visit 2 : office mean sitting diastolic blood pressure > = 90 mmhg and < 110 mmhg at visit 3 : office mean sitting diastolic blood pressure > = 95 mmhg and < 110 mmhg before application of ambulatory blood pressure measurement device at visit 3 : 24 - hr mean ambulatory diastolic blood pressure > = 85 mmhg,Observation,Other,C0185125;C1947919;C2347934,application,FALSE,FALSE,NA,NA,NA
3,NCT00343551,Inclusion,at visit 2 : office mean sitting diastolic blood pressure > = 90 mmhg and < 110 mmhg at visit 3 : office mean sitting diastolic blood pressure > = 95 mmhg and < 110 mmhg before application of ambulatory blood pressure measurement device at visit 3 : 24 - hr mean ambulatory diastolic blood pressure > = 85 mmhg,Observation,Other,C1561560;C1547135,ambulatory,FALSE,FALSE,NA,NA,NA
4,NCT00343551,Inclusion,patient must have an absolute difference of < = 10 mmhg in their office mean sitting diastolic blood pressure between visit 2 and 3 .,Observation,Condition,C1319894,sitting diastolic blood pressure,FALSE,FALSE,NA,lower_equal 10 mmhg,NA
5,NCT00343551,Inclusion,male or female patients are eligible,Person,Person,C0025266,male,FALSE,FALSE,NA,NA,NA
5,NCT00343551,Inclusion,male or female patients are eligible,Person,Observation,C0150905,female patients,FALSE,FALSE,NA,NA,NA
6,NCT00343551,Inclusion,female patients must be either post-menopausal for at least one year ; surgically sterile or using effective contraceptive methods such as oral contraceptives ; barrier method with spermicide or an intrauterine device,Procedure,Drug,C0037862,spermicide,FALSE,FALSE,NA,NA,NA
6,NCT00343551,Inclusion,female patients must be either post-menopausal for at least one year ; surgically sterile or using effective contraceptive methods such as oral contraceptives ; barrier method with spermicide or an intrauterine device,Procedure,Procedure,C0700589,contraceptive methods,FALSE,FALSE,NA,NA,NA
6,NCT00343551,Inclusion,female patients must be either post-menopausal for at least one year ; surgically sterile or using effective contraceptive methods such as oral contraceptives ; barrier method with spermicide or an intrauterine device,Procedure,Procedure,C0004764,barrier method,FALSE,FALSE,NA,NA,NA
6,NCT00343551,Inclusion,female patients must be either post-menopausal for at least one year ; surgically sterile or using effective contraceptive methods such as oral contraceptives ; barrier method with spermicide or an intrauterine device,Procedure,Observation,C0150905,female patients,FALSE,FALSE,NA,NA,NA
6,NCT00343551,Inclusion,female patients must be either post-menopausal for at least one year ; surgically sterile or using effective contraceptive methods such as oral contraceptives ; barrier method with spermicide or an intrauterine device,Procedure,Other,C0009905;C0274536;C0481121;C1548892,oral contraceptives,FALSE,FALSE,NA,NA,NA
6,NCT00343551,Inclusion,female patients must be either post-menopausal for at least one year ; surgically sterile or using effective contraceptive methods such as oral contraceptives ; barrier method with spermicide or an intrauterine device,Procedure,Other,C1706306;C1548866;C1546682,intrauterine device,FALSE,FALSE,NA,NA,NA
7,NCT00343551,Inclusion,reliable contraception should be maintained throughout the study and for 7 days after study drug discontinuation .,Condition Occurrence,Procedure,C0700589,contraception,FALSE,FALSE,equal 7 days,NA,NA
7,NCT00343551,Inclusion,reliable contraception should be maintained throughout the study and for 7 days after study drug discontinuation .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
7,NCT00343551,Inclusion,reliable contraception should be maintained throughout the study and for 7 days after study drug discontinuation .,Condition Occurrence,Other,C0457454;C1444662,discontinuation,FALSE,FALSE,NA,NA,NA
8,NCT00343551,Inclusion,patients who are eligible and able to participate in the study ; and who consent to do so after the purpose and nature of the investigation has been clearly explained to them ( written informed consent ) .,Drug Exposure,Drug,C1995603,purpose,FALSE,FALSE,NA,NA,NA
9,NCT00343551,Exclusion,severe hypertension [ office mean sitting diastolic blood pressure > = 110 mmhg or office mean sitting systolic blood pressure ( mssbp ) > = 180 mmhg ] .,Observation,Condition,C1319894,sitting diastolic blood pressure,FALSE,FALSE,NA,greater_equal 110 mmhg; greater_equal 180 mmhg,NA
9,NCT00343551,Exclusion,severe hypertension [ office mean sitting diastolic blood pressure > = 110 mmhg or office mean sitting systolic blood pressure ( mssbp ) > = 180 mmhg ] .,Observation,Condition,C1319893,sitting systolic blood pressure,FALSE,FALSE,NA,greater_equal 180 mmhg,NA
9,NCT00343551,Exclusion,severe hypertension [ office mean sitting diastolic blood pressure > = 110 mmhg or office mean sitting systolic blood pressure ( mssbp ) > = 180 mmhg ] .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
9,NCT00343551,Exclusion,severe hypertension [ office mean sitting diastolic blood pressure > = 110 mmhg or office mean sitting systolic blood pressure ( mssbp ) > = 180 mmhg ] .,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
10,NCT00343551,Exclusion,current diagnosis of heart failure ( nyha class ii- .,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
10,NCT00343551,Exclusion,current diagnosis of heart failure ( nyha class ii- .,Condition Occurrence,Condition,C1882083,nyha class,FALSE,FALSE,NA,NA,NA
11,NCT00343551,Exclusion,history of myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention ( pci ) during the 12 months prior to visit 1 .,Procedure,Procedure,C1532338,percutaneous coronary intervention,FALSE,FALSE,NA,NA,NA
11,NCT00343551,Exclusion,history of myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention ( pci ) during the 12 months prior to visit 1 .,Procedure,Procedure,C0010055,coronary bypass surgery,FALSE,FALSE,NA,NA,NA
11,NCT00343551,Exclusion,history of myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention ( pci ) during the 12 months prior to visit 1 .,Procedure,Procedure,C1514496;C1532338,pci,FALSE,FALSE,lower_equal 12 months,NA,NA
11,NCT00343551,Exclusion,history of myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention ( pci ) during the 12 months prior to visit 1 .,Procedure,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
12,NCT00343551,Exclusion,known or suspected contraindications to the study medications ; including history of allergy to ace-inhibitors or arbs .,Drug Exposure,Drug,C0003015,ace-inhibitors,FALSE,FALSE,NA,NA,NA
12,NCT00343551,Exclusion,known or suspected contraindications to the study medications ; including history of allergy to ace-inhibitors or arbs .,Drug Exposure,Other,C0489531;C0718579;C3542994;C3539909;C1314973;C1547315;C1611280,allergy,FALSE,FALSE,NA,NA,NA
13,NCT00343551,Exclusion,upper arm circumference > 42 cm .,Observation,Condition,C0446516;C1269612,upper arm,FALSE,FALSE,NA,greater 42 cm,NA
14,NCT00343551,Exclusion,third shift or night workers .,Person,Person,C1527116,workers,FALSE,FALSE,NA,NA,NA
15,NCT00343551,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
2,NCT00343551,Inclusion,patients must meet following blood pressure criteria :,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
1,NCT00344110,Inclusion,age : 20 - 75 years old,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 20 years; lower_equal 75 years,NA,NA
2,NCT00344110,Inclusion,gender : male or female,Person,Person,C0025266,male,FALSE,FALSE,NA,NA,NA
2,NCT00344110,Inclusion,gender : male or female,Person,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
2,NCT00344110,Inclusion,gender : male or female,Person,Observation,C0079399;C0804628,gender,FALSE,FALSE,NA,NA,NA
3,NCT00344110,Inclusion,status : outpatients,Other,NA,NA,NA,NA,NA,NA,NA,NA
4,NCT00344110,Inclusion,mild to moderate essential hypertension,Other,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
4,NCT00344110,Inclusion,mild to moderate essential hypertension,Other,Other,C1547225,mild,FALSE,FALSE,NA,NA,NA
4,NCT00344110,Inclusion,mild to moderate essential hypertension,Other,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
5,NCT00344110,Exclusion,pregnant women ; lactating mothers ; women suspected of being pregnant ; or women who wish to be pregnant,Person,Person,C0033011,pregnant women,FALSE,FALSE,NA,NA,NA
5,NCT00344110,Exclusion,pregnant women ; lactating mothers ; women suspected of being pregnant ; or women who wish to be pregnant,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
5,NCT00344110,Exclusion,pregnant women ; lactating mothers ; women suspected of being pregnant ; or women who wish to be pregnant,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
5,NCT00344110,Exclusion,pregnant women ; lactating mothers ; women suspected of being pregnant ; or women who wish to be pregnant,Person,Condition,C2828358;C3668831,lactating,FALSE,FALSE,NA,NA,NA
5,NCT00344110,Exclusion,pregnant women ; lactating mothers ; women suspected of being pregnant ; or women who wish to be pregnant,Person,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
5,NCT00344110,Exclusion,pregnant women ; lactating mothers ; women suspected of being pregnant ; or women who wish to be pregnant,Person,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
6,NCT00344110,Exclusion,patients with mssbp > = = 180 mmhg or msdbp > = 110 mmhg at visit 1;2 or 3,Observation,NA,NA,NA,NA,NA,NA,NA,NA
7,NCT00344110,Exclusion,patients with or suspected of having secondary hypertension ( due to aortic coarctation ; primary aldosteronism ; etc ; ),Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
7,NCT00344110,Exclusion,patients with or suspected of having secondary hypertension ( due to aortic coarctation ; primary aldosteronism ; etc ; ),Condition Occurrence,Condition,C0003492,aortic coarctation,FALSE,FALSE,NA,NA,NA
7,NCT00344110,Exclusion,patients with or suspected of having secondary hypertension ( due to aortic coarctation ; primary aldosteronism ; etc ; ),Condition Occurrence,Condition,C1384514,primary aldosteronism,FALSE,FALSE,NA,NA,NA
8,NCT00344110,Exclusion,patients suspected of having malignant hypertension,Condition Occurrence,Condition,C0020540;C0024588,malignant hypertension,FALSE,FALSE,NA,NA,NA
9,NCT00344110,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00350168,Inclusion,18 years of age or older .,Person,NA,NA,NA,NA,NA,NA,NA,NA
2,NCT00350168,Inclusion,moderate to severe high blood pressure,Condition Occurrence,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
2,NCT00350168,Inclusion,moderate to severe high blood pressure,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
2,NCT00350168,Inclusion,moderate to severe high blood pressure,Condition Occurrence,Other,C0020538;C2926615,high blood pressure,FALSE,FALSE,NA,NA,NA
3,NCT00350168,Inclusion,this is defined as a systolic pressure ( the top number ) greater than or equal to 160 mmhg and less than 200 mmhg .,Observation,Procedure,C0392535,top,FALSE,FALSE,NA,greater_equal 160 mmhg; lower 200 mmhg,NA
3,NCT00350168,Inclusion,this is defined as a systolic pressure ( the top number ) greater than or equal to 160 mmhg and less than 200 mmhg .,Observation,Observation,C0871470,systolic pressure,FALSE,FALSE,NA,NA,NA
3,NCT00350168,Inclusion,this is defined as a systolic pressure ( the top number ) greater than or equal to 160 mmhg and less than 200 mmhg .,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
4,NCT00350168,Exclusion,history of allergy or hypersensitivity to arbs ; ccbs ; thiazide diuretics,Drug Exposure,Drug,C0012802,thiazide diuretics,FALSE,FALSE,NA,NA,NA
4,NCT00350168,Exclusion,history of allergy or hypersensitivity to arbs ; ccbs ; thiazide diuretics,Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
4,NCT00350168,Exclusion,history of allergy or hypersensitivity to arbs ; ccbs ; thiazide diuretics,Drug Exposure,Other,C0489531;C0718579;C3542994;C3539909;C1314973;C1547315;C1611280,allergy,FALSE,FALSE,NA,NA,NA
5,NCT00350168,Exclusion,inability to stop all prior blood pressure medications safely,Drug Exposure,Drug,C0723457,stop,FALSE,FALSE,NA,NA,NA
5,NCT00350168,Exclusion,inability to stop all prior blood pressure medications safely,Drug Exposure,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
6,NCT00350168,Exclusion,systolic bp > = 200 mmhg or diastolic bp > = 120 mmhg,Observation,Observation,C0871470,systolic bp,FALSE,FALSE,NA,greater_equal 200 mmhg; greater_equal 120 mmhg,NA
6,NCT00350168,Exclusion,systolic bp > = 200 mmhg or diastolic bp > = 120 mmhg,Observation,Observation,C0428883,diastolic bp,FALSE,FALSE,NA,greater_equal 120 mmhg,NA
7,NCT00350168,Exclusion,controlled blood pressure ( systolic bp < 140 mmhg ) taking more than 3 antihypertensive medications at screening,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,greater 3,NA
7,NCT00350168,Exclusion,controlled blood pressure ( systolic bp < 140 mmhg ) taking more than 3 antihypertensive medications at screening,Observation,Observation,C1306620,blood pressure systolic,FALSE,FALSE,NA,NA,NA
7,NCT00350168,Exclusion,controlled blood pressure ( systolic bp < 140 mmhg ) taking more than 3 antihypertensive medications at screening,Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,lower 140 mmhg,NA
8,NCT00350168,Exclusion,systolic bp > = 140 mmhg and < 180 mmhg taking more than two antihypertensive medications at screening,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
8,NCT00350168,Exclusion,systolic bp > = 140 mmhg and < 180 mmhg taking more than two antihypertensive medications at screening,Observation,Observation,C0871470,systolic bp,FALSE,FALSE,NA,greater_equal 140 mmhg; lower 180 mmhg,NA
9,NCT00350168,Exclusion,systolic bp > = 180 mmhg taking more than one antihypertensive medication at screening,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
9,NCT00350168,Exclusion,systolic bp > = 180 mmhg taking more than one antihypertensive medication at screening,Observation,Observation,C0871470,systolic bp,FALSE,FALSE,NA,greater_equal 180 mmhg,NA
10,NCT00350168,Exclusion,history of stroke ; angioplasty ; coronary artery bypass graft surgery ; heart attack or unstable angina,Procedure,Condition,C0002965,unstable angina,FALSE,FALSE,NA,NA,NA
10,NCT00350168,Exclusion,history of stroke ; angioplasty ; coronary artery bypass graft surgery ; heart attack or unstable angina,Procedure,Condition,C0027051,heart attack,FALSE,FALSE,NA,NA,NA
10,NCT00350168,Exclusion,history of stroke ; angioplasty ; coronary artery bypass graft surgery ; heart attack or unstable angina,Procedure,Procedure,C0190211,angioplasty coronary artery,FALSE,FALSE,NA,NA,NA
10,NCT00350168,Exclusion,history of stroke ; angioplasty ; coronary artery bypass graft surgery ; heart attack or unstable angina,Procedure,Procedure,C0185098,bypass graft,FALSE,FALSE,NA,NA,NA
10,NCT00350168,Exclusion,history of stroke ; angioplasty ; coronary artery bypass graft surgery ; heart attack or unstable angina,Procedure,Other,C0543467;C1457907,surgery,FALSE,FALSE,NA,NA,NA
11,NCT00350168,Exclusion,type 1 diabetes,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
12,NCT00350168,Exclusion,poorly controlled type 2 diabetes,Condition Occurrence,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
13,NCT00350168,Exclusion,history of heart failure,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
14,NCT00350168,Exclusion,arrhythmia,Condition Occurrence,Condition,C0003811,arrhythmia,FALSE,FALSE,NA,NA,NA
15,NCT00350168,Exclusion,significant valvular heart disease,Condition Occurrence,Condition,C0018824;C1963123,valvular heart disease,FALSE,FALSE,NA,NA,NA
16,NCT00350168,Exclusion,active gout,Drug Exposure,Condition,C0018099,gout,FALSE,FALSE,NA,NA,NA
16,NCT00350168,Exclusion,active gout,Drug Exposure,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
17,NCT00350168,Exclusion,history of autoimmune diseases,Condition Occurrence,Condition,C0004364,autoimmune diseases,FALSE,FALSE,NA,NA,NA
18,NCT00350168,Exclusion,history of multiple drug allergies,Condition Occurrence,Condition,C0013182,drug allergies,FALSE,FALSE,NA,NA,NA
19,NCT00350168,Exclusion,liver disease,Condition Occurrence,Condition,C0023895;C2186532,liver disease,FALSE,FALSE,NA,NA,NA
20,NCT00350168,Exclusion,pancreatic injury within 1 year of screening,Condition Occurrence,Condition,C0273163,pancreatic injury,FALSE,FALSE,lower 1 year,NA,NA
21,NCT00350168,Exclusion,evidence of kidney impairment or history of dialysis,Procedure,Procedure,C0011946;C0917873,dialysis,FALSE,FALSE,NA,NA,NA
21,NCT00350168,Exclusion,evidence of kidney impairment or history of dialysis,Procedure,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
22,NCT00350168,Exclusion,any surgical condition or medical condition which might alter the absorption ; distribution ; metabolism ; or excretion of any drug,Condition Occurrence,Condition,C1378698,distribution,FALSE,FALSE,NA,NA,NA
22,NCT00350168,Exclusion,any surgical condition or medical condition which might alter the absorption ; distribution ; metabolism ; or excretion of any drug,Condition Occurrence,Condition,C0504085,excretion,FALSE,FALSE,NA,NA,NA
22,NCT00350168,Exclusion,any surgical condition or medical condition which might alter the absorption ; distribution ; metabolism ; or excretion of any drug,Condition Occurrence,Condition,C0025519,metabolism,FALSE,FALSE,NA,NA,NA
22,NCT00350168,Exclusion,any surgical condition or medical condition which might alter the absorption ; distribution ; metabolism ; or excretion of any drug,Condition Occurrence,Other,C1561579;C1561578,medical,FALSE,FALSE,NA,NA,NA
22,NCT00350168,Exclusion,any surgical condition or medical condition which might alter the absorption ; distribution ; metabolism ; or excretion of any drug,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
23,NCT00350168,Exclusion,this could include currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction .,Condition Occurrence,Condition,C0017152,gastritis,FALSE,FALSE,NA,NA,NA
23,NCT00350168,Exclusion,this could include currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction .,Condition Occurrence,Condition,C1559265,gastrointestinal,FALSE,FALSE,NA,NA,NA
23,NCT00350168,Exclusion,this could include currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction .,Condition Occurrence,Condition,C0267596,rectal bleeding,FALSE,FALSE,NA,NA,NA
23,NCT00350168,Exclusion,this could include currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction .,Condition Occurrence,Condition,C0178879,urinary tract obstruction,FALSE,FALSE,NA,NA,NA
23,NCT00350168,Exclusion,this could include currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction .,Condition Occurrence,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
24,NCT00350168,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; would be excluded unless they are post-menopausal ; surgically sterile or are using acceptable methods of contraception,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
24,NCT00350168,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; would be excluded unless they are post-menopausal ; surgically sterile or are using acceptable methods of contraception,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
24,NCT00350168,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; would be excluded unless they are post-menopausal ; surgically sterile or are using acceptable methods of contraception,Person,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
24,NCT00350168,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; would be excluded unless they are post-menopausal ; surgically sterile or are using acceptable methods of contraception,Person,Procedure,C0700589,contraception,FALSE,FALSE,NA,NA,NA
24,NCT00350168,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; would be excluded unless they are post-menopausal ; surgically sterile or are using acceptable methods of contraception,Person,Observation,C3831118,child-bearing potential,FALSE,FALSE,NA,NA,NA
24,NCT00350168,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; would be excluded unless they are post-menopausal ; surgically sterile or are using acceptable methods of contraception,Person,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
24,NCT00350168,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; would be excluded unless they are post-menopausal ; surgically sterile or are using acceptable methods of contraception,Person,Other,C0025663,methods,FALSE,FALSE,NA,NA,NA
25,NCT00350168,Exclusion,the use of hormonal contraceptives is not allowed,Other,NA,NA,NA,NA,NA,NA,NA,NA
26,NCT00350168,Exclusion,pregnant or nursing ( lactating ) women,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
26,NCT00350168,Exclusion,pregnant or nursing ( lactating ) women,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
26,NCT00350168,Exclusion,pregnant or nursing ( lactating ) women,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
26,NCT00350168,Exclusion,pregnant or nursing ( lactating ) women,Condition Occurrence,Condition,C2828358;C3668831,lactating,FALSE,FALSE,NA,NA,NA
27,NCT00350168,Exclusion,history of malignancy of any organ system within the past five years,Condition Occurrence,Condition,C0006826;C1306459,malignancy,FALSE,FALSE,NA,NA,NA
28,NCT00350168,Exclusion,any severe disease ; life-threatening disease within the past five years,Condition Occurrence,Condition,C2826244;C3537125,life-threatening,FALSE,FALSE,NA,NA,NA
28,NCT00350168,Exclusion,any severe disease ; life-threatening disease within the past five years,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
29,NCT00350168,Exclusion,history of drug or alcohol abuse within the last 2 years .,Condition Occurrence,Condition,C0085762,alcohol abuse,FALSE,FALSE,lower 2 last years,NA,NA
29,NCT00350168,Exclusion,history of drug or alcohol abuse within the last 2 years .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,lower 2 last years,NA,NA
30,NCT00350168,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00353912,Inclusion,18 years of age or older .,Person,NA,NA,NA,NA,NA,NA,NA,NA
2,NCT00353912,Inclusion,moderate to severe high blood pressure,Condition Occurrence,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
2,NCT00353912,Inclusion,moderate to severe high blood pressure,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
2,NCT00353912,Inclusion,moderate to severe high blood pressure,Condition Occurrence,Other,C0020538;C2926615,high blood pressure,FALSE,FALSE,NA,NA,NA
3,NCT00353912,Inclusion,this is defined as a systolic pressure ( the top number ) greater than or equal to 160 mmhg and less than 200 mmhg .,Observation,Procedure,C0392535,top,FALSE,FALSE,NA,greater_equal 160 mmhg; lower 200 mmhg,NA
3,NCT00353912,Inclusion,this is defined as a systolic pressure ( the top number ) greater than or equal to 160 mmhg and less than 200 mmhg .,Observation,Observation,C0871470,systolic pressure,FALSE,FALSE,NA,NA,NA
3,NCT00353912,Inclusion,this is defined as a systolic pressure ( the top number ) greater than or equal to 160 mmhg and less than 200 mmhg .,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
4,NCT00353912,Exclusion,history of allergy or hypersensitivity to arbs ; ccbs ; thiazide diuretics,Drug Exposure,Drug,C0012802,thiazide diuretics,FALSE,FALSE,NA,NA,NA
4,NCT00353912,Exclusion,history of allergy or hypersensitivity to arbs ; ccbs ; thiazide diuretics,Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
4,NCT00353912,Exclusion,history of allergy or hypersensitivity to arbs ; ccbs ; thiazide diuretics,Drug Exposure,Other,C0489531;C0718579;C3542994;C3539909;C1314973;C1547315;C1611280,allergy,FALSE,FALSE,NA,NA,NA
5,NCT00353912,Exclusion,inability to stop all prior blood pressure medications safely,Drug Exposure,Drug,C0723457,stop,FALSE,FALSE,NA,NA,NA
5,NCT00353912,Exclusion,inability to stop all prior blood pressure medications safely,Drug Exposure,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
6,NCT00353912,Exclusion,systolic bp > = 200 mmhg or diastolic bp > = 120 mmhg,Observation,Observation,C0871470,systolic bp,FALSE,FALSE,NA,greater_equal 200 mmhg; greater_equal 120 mmhg,NA
6,NCT00353912,Exclusion,systolic bp > = 200 mmhg or diastolic bp > = 120 mmhg,Observation,Observation,C0428883,diastolic bp,FALSE,FALSE,NA,greater_equal 120 mmhg,NA
7,NCT00353912,Exclusion,controlled blood pressure ( systolic bp < 140 mmhg ) taking more than 3 antihypertensive medications at screening,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,greater 3,NA
7,NCT00353912,Exclusion,controlled blood pressure ( systolic bp < 140 mmhg ) taking more than 3 antihypertensive medications at screening,Observation,Observation,C1306620,blood pressure systolic,FALSE,FALSE,NA,NA,NA
7,NCT00353912,Exclusion,controlled blood pressure ( systolic bp < 140 mmhg ) taking more than 3 antihypertensive medications at screening,Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,lower 140 mmhg,NA
8,NCT00353912,Exclusion,systolic bp > = 140 mmhg and < 180 mmhg taking more than two antihypertensive medications at screening,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
8,NCT00353912,Exclusion,systolic bp > = 140 mmhg and < 180 mmhg taking more than two antihypertensive medications at screening,Observation,Observation,C0871470,systolic bp,FALSE,FALSE,NA,greater_equal 140 mmhg; lower 180 mmhg,NA
9,NCT00353912,Exclusion,systolic bp > = 180 mmhg taking more than one antihypertensive medication at screening,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
9,NCT00353912,Exclusion,systolic bp > = 180 mmhg taking more than one antihypertensive medication at screening,Observation,Observation,C0871470,systolic bp,FALSE,FALSE,NA,greater_equal 180 mmhg,NA
10,NCT00353912,Exclusion,history of autoimmune diseases,Condition Occurrence,Condition,C0004364,autoimmune diseases,FALSE,FALSE,NA,NA,NA
11,NCT00353912,Exclusion,history of multiple drug allergies,Condition Occurrence,Condition,C0013182,drug allergies,FALSE,FALSE,NA,NA,NA
12,NCT00353912,Exclusion,liver disease,Condition Occurrence,Condition,C0023895;C2186532,liver disease,FALSE,FALSE,NA,NA,NA
13,NCT00353912,Exclusion,pancreatic injury within 1 year of screening,Condition Occurrence,Condition,C0273163,pancreatic injury,FALSE,FALSE,lower 1 year,NA,NA
14,NCT00353912,Exclusion,evidence of kidney impairment or history of dialysis,Procedure,Procedure,C0011946;C0917873,dialysis,FALSE,FALSE,NA,NA,NA
14,NCT00353912,Exclusion,evidence of kidney impairment or history of dialysis,Procedure,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
15,NCT00353912,Exclusion,any surgical condition or medical condition which might alter the absorption ; distribution ; metabolism ; or excretion of any drug,Condition Occurrence,Condition,C1378698,distribution,FALSE,FALSE,NA,NA,NA
15,NCT00353912,Exclusion,any surgical condition or medical condition which might alter the absorption ; distribution ; metabolism ; or excretion of any drug,Condition Occurrence,Condition,C0504085,excretion,FALSE,FALSE,NA,NA,NA
15,NCT00353912,Exclusion,any surgical condition or medical condition which might alter the absorption ; distribution ; metabolism ; or excretion of any drug,Condition Occurrence,Condition,C0025519,metabolism,FALSE,FALSE,NA,NA,NA
15,NCT00353912,Exclusion,any surgical condition or medical condition which might alter the absorption ; distribution ; metabolism ; or excretion of any drug,Condition Occurrence,Other,C1561579;C1561578,medical,FALSE,FALSE,NA,NA,NA
15,NCT00353912,Exclusion,any surgical condition or medical condition which might alter the absorption ; distribution ; metabolism ; or excretion of any drug,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
16,NCT00353912,Exclusion,this could include currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction .,Condition Occurrence,Condition,C0017152,gastritis,FALSE,FALSE,NA,NA,NA
16,NCT00353912,Exclusion,this could include currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction .,Condition Occurrence,Condition,C1559265,gastrointestinal,FALSE,FALSE,NA,NA,NA
16,NCT00353912,Exclusion,this could include currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction .,Condition Occurrence,Condition,C0267596,rectal bleeding,FALSE,FALSE,NA,NA,NA
16,NCT00353912,Exclusion,this could include currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction .,Condition Occurrence,Condition,C0178879,urinary tract obstruction,FALSE,FALSE,NA,NA,NA
16,NCT00353912,Exclusion,this could include currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction .,Condition Occurrence,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
17,NCT00353912,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; would be excluded unless they are post-menopausal ; surgically sterile or are using acceptable methods of contraception,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
17,NCT00353912,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; would be excluded unless they are post-menopausal ; surgically sterile or are using acceptable methods of contraception,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
17,NCT00353912,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; would be excluded unless they are post-menopausal ; surgically sterile or are using acceptable methods of contraception,Person,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
17,NCT00353912,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; would be excluded unless they are post-menopausal ; surgically sterile or are using acceptable methods of contraception,Person,Procedure,C0700589,contraception,FALSE,FALSE,NA,NA,NA
17,NCT00353912,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; would be excluded unless they are post-menopausal ; surgically sterile or are using acceptable methods of contraception,Person,Observation,C3831118,child-bearing potential,FALSE,FALSE,NA,NA,NA
17,NCT00353912,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; would be excluded unless they are post-menopausal ; surgically sterile or are using acceptable methods of contraception,Person,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
17,NCT00353912,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; would be excluded unless they are post-menopausal ; surgically sterile or are using acceptable methods of contraception,Person,Other,C0025663,methods,FALSE,FALSE,NA,NA,NA
18,NCT00353912,Exclusion,the use of hormonal contraceptives is not allowed,Other,NA,NA,NA,NA,NA,NA,NA,NA
19,NCT00353912,Exclusion,pregnant or nursing ( lactating ) women,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
19,NCT00353912,Exclusion,pregnant or nursing ( lactating ) women,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
19,NCT00353912,Exclusion,pregnant or nursing ( lactating ) women,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
19,NCT00353912,Exclusion,pregnant or nursing ( lactating ) women,Condition Occurrence,Condition,C2828358;C3668831,lactating,FALSE,FALSE,NA,NA,NA
20,NCT00353912,Exclusion,history of malignancy of any organ system within the past five years,Condition Occurrence,Condition,C0006826;C1306459,malignancy,FALSE,FALSE,NA,NA,NA
21,NCT00353912,Exclusion,any severe disease ; life-threatening disease within the past five years,Condition Occurrence,Condition,C2826244;C3537125,life-threatening,FALSE,FALSE,NA,NA,NA
21,NCT00353912,Exclusion,any severe disease ; life-threatening disease within the past five years,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
22,NCT00353912,Exclusion,history of drug or alcohol abuse within the last 2 years .,Condition Occurrence,Condition,C0085762,alcohol abuse,FALSE,FALSE,lower 2 last years,NA,NA
22,NCT00353912,Exclusion,history of drug or alcohol abuse within the last 2 years .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,lower 2 last years,NA,NA
23,NCT00353912,Exclusion,history of stroke ; angioplasty ; coronary artery bypass graft surgery ; heart attack or unstable angina,Procedure,Condition,C0002965,unstable angina,FALSE,FALSE,NA,NA,NA
23,NCT00353912,Exclusion,history of stroke ; angioplasty ; coronary artery bypass graft surgery ; heart attack or unstable angina,Procedure,Condition,C0027051,heart attack,FALSE,FALSE,NA,NA,NA
23,NCT00353912,Exclusion,history of stroke ; angioplasty ; coronary artery bypass graft surgery ; heart attack or unstable angina,Procedure,Procedure,C0190211,angioplasty coronary artery,FALSE,FALSE,NA,NA,NA
23,NCT00353912,Exclusion,history of stroke ; angioplasty ; coronary artery bypass graft surgery ; heart attack or unstable angina,Procedure,Procedure,C0185098,bypass graft,FALSE,FALSE,NA,NA,NA
23,NCT00353912,Exclusion,history of stroke ; angioplasty ; coronary artery bypass graft surgery ; heart attack or unstable angina,Procedure,Other,C0543467;C1457907,surgery,FALSE,FALSE,NA,NA,NA
24,NCT00353912,Exclusion,type 1 diabetes,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
25,NCT00353912,Exclusion,poorly controlled type 2 diabetes,Condition Occurrence,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
26,NCT00353912,Exclusion,history of heart failure,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
27,NCT00353912,Exclusion,arrhythmia,Condition Occurrence,Condition,C0003811,arrhythmia,FALSE,FALSE,NA,NA,NA
28,NCT00353912,Exclusion,significant valvular heart disease,Condition Occurrence,Condition,C0018824;C1963123,valvular heart disease,FALSE,FALSE,NA,NA,NA
29,NCT00353912,Exclusion,active gout,Drug Exposure,Condition,C0018099,gout,FALSE,FALSE,NA,NA,NA
29,NCT00353912,Exclusion,active gout,Drug Exposure,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
30,NCT00353912,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00368277,Inclusion,male or female outpatients > = 65 years old .,Person,Person,C0025266,male,FALSE,FALSE,greater_equal 65 years,NA,NA
1,NCT00368277,Inclusion,male or female outpatients > = 65 years old .,Person,Person,C0086287,female,FALSE,FALSE,greater_equal 65 years,NA,NA
2,NCT00368277,Inclusion,patients with essential hypertension with an mssbp > = 140 mmhg and < 180 mmhg ; and msdbp < 110 mmhg at visits 2 and,Observation,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,greater_equal 140 mmhg; lower 180 mmhg; lower 110 mmhg; equal 2,NA
3,NCT00368277,Inclusion,( visit 201 was deleted by the administrative changes document ; ),Other,Other,C1547673,document,FALSE,FALSE,NA,NA,NA
4,NCT00368277,Inclusion,patients must have had a difference in mssbp of < = 20 mmhg between visit 3 and the visit immediately prior to visit 3 .,Observation,NA,NA,NA,NA,NA,NA,NA,NA
5,NCT00368277,Inclusion,patients who were eligible and able to participate in the study ; and who consented to do so after the purpose and nature of the investigation had been explained to them ( written informed consent ) .,Drug Exposure,Drug,C1995603,purpose,FALSE,FALSE,NA,NA,NA
6,NCT00368277,Exclusion,history of renal artery stenosis .,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
7,NCT00368277,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy .,Condition Occurrence,Condition,C0152132,hypertensive retinopathy,FALSE,FALSE,NA,NA,NA
7,NCT00368277,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy .,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii,FALSE,FALSE,NA,NA,NA
7,NCT00368277,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy .,Condition Occurrence,Other,C0677510;C0021440;C3496001,iv,FALSE,FALSE,NA,NA,NA
8,NCT00368277,Exclusion,history of hypertensive encephalopathy .,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
9,NCT00368277,Exclusion,current diagnosis of heart failure ( new york heart association class iii- .,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
9,NCT00368277,Exclusion,current diagnosis of heart failure ( new york heart association class iii- .,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
9,NCT00368277,Exclusion,current diagnosis of heart failure ( new york heart association class iii- .,Condition Occurrence,Other,C0456387;C0489477,class,FALSE,FALSE,NA,NA,NA
9,NCT00368277,Exclusion,current diagnosis of heart failure ( new york heart association class iii- .,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii-,FALSE,FALSE,NA,NA,NA
10,NCT00368277,Exclusion,history of transient ischemic cerebral attack or cerebrovascular accident within 6 months .,Person,Person,C0040704,transient,FALSE,FALSE,lower 6 months,NA,NA
10,NCT00368277,Exclusion,history of transient ischemic cerebral attack or cerebrovascular accident within 6 months .,Person,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,lower 6 months,NA,NA
11,NCT00368277,Exclusion,history of myocardial infarction ; bypass surgery ; or any percutaneous coronary intervention within 6 months .,Procedure,Procedure,C1532338,percutaneous coronary intervention,FALSE,FALSE,lower 6 months,NA,NA
11,NCT00368277,Exclusion,history of myocardial infarction ; bypass surgery ; or any percutaneous coronary intervention within 6 months .,Procedure,Procedure,C1536078,bypass surgery,FALSE,FALSE,lower 6 months,NA,NA
11,NCT00368277,Exclusion,history of myocardial infarction ; bypass surgery ; or any percutaneous coronary intervention within 6 months .,Procedure,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,lower 6 months,NA,NA
12,NCT00368277,Exclusion,current unstable angina pectoris,Condition Occurrence,Condition,C0002965,unstable angina pectoris,FALSE,FALSE,NA,NA,NA
13,NCT00368277,Exclusion,patients on a stable dose of oral nitrates or topical nitrates or beta blockers for angina were acceptable .,Drug Exposure,Drug,C1272919,oral,FALSE,FALSE,NA,NA,NA
13,NCT00368277,Exclusion,patients on a stable dose of oral nitrates or topical nitrates or beta blockers for angina were acceptable .,Drug Exposure,Drug,C0028125,nitrates,FALSE,FALSE,NA,NA,NA
13,NCT00368277,Exclusion,patients on a stable dose of oral nitrates or topical nitrates or beta blockers for angina were acceptable .,Drug Exposure,Drug,C1710439,topical,FALSE,FALSE,NA,NA,NA
13,NCT00368277,Exclusion,patients on a stable dose of oral nitrates or topical nitrates or beta blockers for angina were acceptable .,Drug Exposure,Drug,C0028125,nitrates,FALSE,FALSE,NA,NA,NA
13,NCT00368277,Exclusion,patients on a stable dose of oral nitrates or topical nitrates or beta blockers for angina were acceptable .,Drug Exposure,Drug,C0001645,beta blockers,FALSE,FALSE,NA,NA,NA
13,NCT00368277,Exclusion,patients on a stable dose of oral nitrates or topical nitrates or beta blockers for angina were acceptable .,Drug Exposure,Other,C1547311,stable,FALSE,FALSE,NA,NA,NA
13,NCT00368277,Exclusion,patients on a stable dose of oral nitrates or topical nitrates or beta blockers for angina were acceptable .,Drug Exposure,Other,C0002962;C2024883;C2926611,angina,FALSE,FALSE,NA,NA,NA
14,NCT00368277,Exclusion,concurrent potentially life threatening arrhythmia or symptomatic arrhythmia .,Condition Occurrence,Condition,C2826244;C3537125,life threatening,FALSE,FALSE,NA,NA,NA
14,NCT00368277,Exclusion,concurrent potentially life threatening arrhythmia or symptomatic arrhythmia .,Condition Occurrence,Condition,C0003811,arrhythmia,FALSE,FALSE,NA,NA,NA
14,NCT00368277,Exclusion,concurrent potentially life threatening arrhythmia or symptomatic arrhythmia .,Condition Occurrence,Condition,C0003811,arrhythmia,FALSE,FALSE,NA,NA,NA
15,NCT00368277,Exclusion,clinically significant valvular heart disease .,Condition Occurrence,Condition,C0018824;C1963123,valvular heart disease,FALSE,FALSE,NA,NA,NA
16,NCT00368277,Exclusion,concurrent use of any antihypersensitive medications except a stable dose 3 months prior to visit 1 of alpha adrenergic blockers for benign prostatic hypertrophy ( eg ; flomax for bph ) ; beta blockers for angina ; or beta blockers ophthalmic preparations,Drug Exposure,Condition,C0005001,benign prostatic hypertrophy,FALSE,FALSE,NA,NA,NA
16,NCT00368277,Exclusion,concurrent use of any antihypersensitive medications except a stable dose 3 months prior to visit 1 of alpha adrenergic blockers for benign prostatic hypertrophy ( eg ; flomax for bph ) ; beta blockers for angina ; or beta blockers ophthalmic preparations,Drug Exposure,Condition,C0005001;C1704272,bph,FALSE,FALSE,NA,NA,NA
16,NCT00368277,Exclusion,concurrent use of any antihypersensitive medications except a stable dose 3 months prior to visit 1 of alpha adrenergic blockers for benign prostatic hypertrophy ( eg ; flomax for bph ) ; beta blockers for angina ; or beta blockers ophthalmic preparations,Drug Exposure,Drug,C0001641,alpha adrenergic blockers,FALSE,FALSE,NA,NA,NA
16,NCT00368277,Exclusion,concurrent use of any antihypersensitive medications except a stable dose 3 months prior to visit 1 of alpha adrenergic blockers for benign prostatic hypertrophy ( eg ; flomax for bph ) ; beta blockers for angina ; or beta blockers ophthalmic preparations,Drug Exposure,Drug,C0662903,flomax,FALSE,FALSE,NA,NA,NA
16,NCT00368277,Exclusion,concurrent use of any antihypersensitive medications except a stable dose 3 months prior to visit 1 of alpha adrenergic blockers for benign prostatic hypertrophy ( eg ; flomax for bph ) ; beta blockers for angina ; or beta blockers ophthalmic preparations,Drug Exposure,Drug,C0001645,beta blockers,FALSE,FALSE,NA,NA,NA
16,NCT00368277,Exclusion,concurrent use of any antihypersensitive medications except a stable dose 3 months prior to visit 1 of alpha adrenergic blockers for benign prostatic hypertrophy ( eg ; flomax for bph ) ; beta blockers for angina ; or beta blockers ophthalmic preparations,Drug Exposure,Drug,C0001645,beta blockers,FALSE,FALSE,NA,NA,NA
16,NCT00368277,Exclusion,concurrent use of any antihypersensitive medications except a stable dose 3 months prior to visit 1 of alpha adrenergic blockers for benign prostatic hypertrophy ( eg ; flomax for bph ) ; beta blockers for angina ; or beta blockers ophthalmic preparations,Drug Exposure,Drug,C0304650,ophthalmic preparations,FALSE,FALSE,NA,NA,NA
16,NCT00368277,Exclusion,concurrent use of any antihypersensitive medications except a stable dose 3 months prior to visit 1 of alpha adrenergic blockers for benign prostatic hypertrophy ( eg ; flomax for bph ) ; beta blockers for angina ; or beta blockers ophthalmic preparations,Drug Exposure,Other,C1547311,stable,TRUE,FALSE,equal 3 months,NA,NA
16,NCT00368277,Exclusion,concurrent use of any antihypersensitive medications except a stable dose 3 months prior to visit 1 of alpha adrenergic blockers for benign prostatic hypertrophy ( eg ; flomax for bph ) ; beta blockers for angina ; or beta blockers ophthalmic preparations,Drug Exposure,Other,C0002962;C2024883;C2926611,angina,FALSE,FALSE,NA,NA,NA
1,NCT00385931,Inclusion,male or female patients at least 50 years of age,Person,Person,C0025266,male,FALSE,FALSE,greater_equal 50 years,NA,NA
1,NCT00385931,Inclusion,male or female patients at least 50 years of age,Person,Observation,C0150905,female patients,FALSE,FALSE,greater_equal 50 years,NA,NA
2,NCT00385931,Inclusion,mild to moderate essential systolic hypertension ( grades 1 and 2 who classification ) defined as mssbp > = 150 mmhg and < 180 mmhg,Observation,Condition,C0221155,systolic hypertension,FALSE,FALSE,NA,equal 1 ; equal 2,NA
2,NCT00385931,Inclusion,mild to moderate essential systolic hypertension ( grades 1 and 2 who classification ) defined as mssbp > = 150 mmhg and < 180 mmhg,Observation,Other,C1547225,mild,FALSE,FALSE,NA,NA,NA
2,NCT00385931,Inclusion,mild to moderate essential systolic hypertension ( grades 1 and 2 who classification ) defined as mssbp > = 150 mmhg and < 180 mmhg,Observation,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
2,NCT00385931,Inclusion,mild to moderate essential systolic hypertension ( grades 1 and 2 who classification ) defined as mssbp > = 150 mmhg and < 180 mmhg,Observation,Other,C3539106,defined,FALSE,FALSE,NA,greater_equal 150 mmhg; lower 180 mmhg,NA
3,NCT00385931,Inclusion,simultaneous primary hypercholesterolemia or mixed dislipidemia ( fredrickson types iia and iib ) defined by ldl-c level > = 130 mg / dl and < 190 mg / dl and triglyceride levels < = 400 mg / dl despite dietary therapy,Drug Exposure,Condition,C0342879,primary hypercholesterolemia,FALSE,FALSE,NA,NA,NA
3,NCT00385931,Inclusion,simultaneous primary hypercholesterolemia or mixed dislipidemia ( fredrickson types iia and iib ) defined by ldl-c level > = 130 mg / dl and < 190 mg / dl and triglyceride levels < = 400 mg / dl despite dietary therapy,Drug Exposure,Condition,C3160715,mixed,FALSE,FALSE,NA,NA,NA
3,NCT00385931,Inclusion,simultaneous primary hypercholesterolemia or mixed dislipidemia ( fredrickson types iia and iib ) defined by ldl-c level > = 130 mg / dl and < 190 mg / dl and triglyceride levels < = 400 mg / dl despite dietary therapy,Drug Exposure,Condition,C1578987,fredrickson types,FALSE,FALSE,NA,NA,NA
3,NCT00385931,Inclusion,simultaneous primary hypercholesterolemia or mixed dislipidemia ( fredrickson types iia and iib ) defined by ldl-c level > = 130 mg / dl and < 190 mg / dl and triglyceride levels < = 400 mg / dl despite dietary therapy,Drug Exposure,Drug,C0041004,triglyceride,FALSE,FALSE,NA,NA,lower_equal 400 mg/dl
3,NCT00385931,Inclusion,simultaneous primary hypercholesterolemia or mixed dislipidemia ( fredrickson types iia and iib ) defined by ldl-c level > = 130 mg / dl and < 190 mg / dl and triglyceride levels < = 400 mg / dl despite dietary therapy,Drug Exposure,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
3,NCT00385931,Inclusion,simultaneous primary hypercholesterolemia or mixed dislipidemia ( fredrickson types iia and iib ) defined by ldl-c level > = 130 mg / dl and < 190 mg / dl and triglyceride levels < = 400 mg / dl despite dietary therapy,Drug Exposure,Other,C0202117;C1325353,ldl,FALSE,FALSE,NA,NA,greater_equal 130 mg/dl; lower 190 mg/dl
4,NCT00385931,Inclusion,off medication at randomization,Other,NA,NA,NA,NA,NA,NA,NA,NA
5,NCT00385931,Exclusion,severe hypertension ( grade 3 who classification,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
5,NCT00385931,Exclusion,severe hypertension ( grade 3 who classification,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
6,NCT00385931,Exclusion,> = 180 mm hg systolic or > = 110 mm hg ( diastolic ),Observation,NA,NA,NA,NA,NA,NA,NA,NA
7,NCT00385931,Exclusion,secondary form of hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
8,NCT00385931,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy,Condition Occurrence,Condition,C0152132,hypertensive retinopathy,FALSE,FALSE,NA,NA,NA
8,NCT00385931,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii,FALSE,FALSE,NA,NA,NA
8,NCT00385931,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy,Condition Occurrence,Other,C0677510;C0021440;C3496001,iv,FALSE,FALSE,NA,NA,NA
9,NCT00385931,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident within the preceding 12 months,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
9,NCT00385931,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident within the preceding 12 months,Condition Occurrence,Condition,C0000924;C2046386,accident,FALSE,FALSE,lower 12 preceding months,NA,NA
9,NCT00385931,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident within the preceding 12 months,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,lower 12 preceding months,NA,NA
10,NCT00385931,Exclusion,transient ischemic cerebral attack during the preceding 6 months,Person,Person,C0040704,transient,FALSE,FALSE,lower_equal 6 preceding months,NA,NA
11,NCT00385931,Exclusion,dyslipidemia secondary to other causes,Condition Occurrence,Condition,C0242339,dyslipidemia,FALSE,FALSE,NA,NA,NA
12,NCT00385931,Exclusion,type 1 diabetes mellitus,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
13,NCT00385931,Exclusion,type 2 diabetes mellitus with poor glucose control,Drug Exposure,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
13,NCT00385931,Exclusion,type 2 diabetes mellitus with poor glucose control,Drug Exposure,Drug,C0726398,glucose control,FALSE,FALSE,NA,NA,NA
14,NCT00385931,Exclusion,history of systemic inflammatory diseases,Other,NA,NA,NA,NA,NA,NA,NA,NA
15,NCT00385931,Exclusion,serum ck more than twice uln,Condition Occurrence,Observation,C0201973,ck,FALSE,FALSE,NA,NA,NA
15,NCT00385931,Exclusion,serum ck more than twice uln,Condition Occurrence,Other,C0229671;C1546774;C1550100,serum,FALSE,FALSE,NA,NA,NA
16,NCT00385931,Exclusion,sodium depletion,Condition Occurrence,Condition,C0020625,sodium depletion,FALSE,FALSE,NA,NA,NA
17,NCT00385931,Exclusion,malignancy in preceding 5 years history of heart failure,Condition Occurrence,Condition,C0006826;C1306459,malignancy,FALSE,FALSE,lower_equal 5 preceding years,NA,NA
17,NCT00385931,Exclusion,malignancy in preceding 5 years history of heart failure,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
18,NCT00385931,Exclusion,myocardial infarction within the preceding 12 months,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,lower 12 preceding months,NA,NA
19,NCT00385931,Exclusion,second degree heart block or third degree heart block,Condition Occurrence,Condition,C0018794;C0542001;C0037188,heart block,FALSE,FALSE,NA,NA,NA
19,NCT00385931,Exclusion,second degree heart block or third degree heart block,Condition Occurrence,Condition,C0018794;C0542001;C0037188,heart block,FALSE,FALSE,NA,NA,NA
19,NCT00385931,Exclusion,second degree heart block or third degree heart block,Condition Occurrence,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
19,NCT00385931,Exclusion,second degree heart block or third degree heart block,Condition Occurrence,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
20,NCT00385931,Exclusion,concomitant refractory angina pectoris,Condition Occurrence,Condition,C1536180,refractory angina pectoris,FALSE,FALSE,NA,NA,NA
21,NCT00385931,Exclusion,symptomatic arrhythmia,Condition Occurrence,Condition,C0003811,arrhythmia,FALSE,FALSE,NA,NA,NA
22,NCT00385931,Exclusion,valvular heart disease,Condition Occurrence,Condition,C0018824;C1963123,valvular heart disease,FALSE,FALSE,NA,NA,NA
23,NCT00385931,Exclusion,any condition / surgery that may alter absorption ; distribution ; metabolism ; excretion of any drug ( eg history of major gastrointestinal tract surgery ; inflammatory bowel syndrome ; pancreatic dysfunction ; impaired renal function or liver function ),Condition Occurrence,Condition,C1378698,distribution,FALSE,FALSE,NA,NA,NA
23,NCT00385931,Exclusion,any condition / surgery that may alter absorption ; distribution ; metabolism ; excretion of any drug ( eg history of major gastrointestinal tract surgery ; inflammatory bowel syndrome ; pancreatic dysfunction ; impaired renal function or liver function ),Condition Occurrence,Condition,C0504085,excretion,FALSE,FALSE,NA,NA,NA
23,NCT00385931,Exclusion,any condition / surgery that may alter absorption ; distribution ; metabolism ; excretion of any drug ( eg history of major gastrointestinal tract surgery ; inflammatory bowel syndrome ; pancreatic dysfunction ; impaired renal function or liver function ),Condition Occurrence,Condition,C0025519,metabolism,FALSE,FALSE,NA,NA,NA
23,NCT00385931,Exclusion,any condition / surgery that may alter absorption ; distribution ; metabolism ; excretion of any drug ( eg history of major gastrointestinal tract surgery ; inflammatory bowel syndrome ; pancreatic dysfunction ; impaired renal function or liver function ),Condition Occurrence,Condition,C0021853,bowel,FALSE,FALSE,NA,NA,NA
23,NCT00385931,Exclusion,any condition / surgery that may alter absorption ; distribution ; metabolism ; excretion of any drug ( eg history of major gastrointestinal tract surgery ; inflammatory bowel syndrome ; pancreatic dysfunction ; impaired renal function or liver function ),Condition Occurrence,Condition,C1565489;C0035078,impaired renal function,FALSE,FALSE,NA,NA,NA
23,NCT00385931,Exclusion,any condition / surgery that may alter absorption ; distribution ; metabolism ; excretion of any drug ( eg history of major gastrointestinal tract surgery ; inflammatory bowel syndrome ; pancreatic dysfunction ; impaired renal function or liver function ),Condition Occurrence,Condition,C0232741,liver function,FALSE,FALSE,NA,NA,NA
23,NCT00385931,Exclusion,any condition / surgery that may alter absorption ; distribution ; metabolism ; excretion of any drug ( eg history of major gastrointestinal tract surgery ; inflammatory bowel syndrome ; pancreatic dysfunction ; impaired renal function or liver function ),Condition Occurrence,Procedure,C0399610,gastrointestinal tract surgery,FALSE,FALSE,NA,NA,NA
23,NCT00385931,Exclusion,any condition / surgery that may alter absorption ; distribution ; metabolism ; excretion of any drug ( eg history of major gastrointestinal tract surgery ; inflammatory bowel syndrome ; pancreatic dysfunction ; impaired renal function or liver function ),Condition Occurrence,Other,C0543467;C1457907,surgery,FALSE,FALSE,NA,NA,NA
23,NCT00385931,Exclusion,any condition / surgery that may alter absorption ; distribution ; metabolism ; excretion of any drug ( eg history of major gastrointestinal tract surgery ; inflammatory bowel syndrome ; pancreatic dysfunction ; impaired renal function or liver function ),Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
1,NCT00386139,Inclusion,male or female outpatients 18 years old or older .,Person,Person,C0025266,male,FALSE,FALSE,equal 18 years,NA,NA
1,NCT00386139,Inclusion,male or female outpatients 18 years old or older .,Person,Person,C0086287,female,FALSE,FALSE,equal 18 years,NA,NA
2,NCT00386139,Inclusion,patients with a diagnosis of hypertension .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00386139,Inclusion,patients who are eligible and consent to participate in the study,Other,NA,NA,NA,NA,NA,NA,NA,NA
4,NCT00386139,Exclusion,severe hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
4,NCT00386139,Exclusion,severe hypertension,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
5,NCT00386139,Exclusion,previous diagnosis or current diagnosis of heart failure .,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
6,NCT00386139,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; transient ischemic cerebral attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention ( pci ) .,Condition Occurrence,Person,C0040704,transient,FALSE,FALSE,NA,NA,NA
6,NCT00386139,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; transient ischemic cerebral attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention ( pci ) .,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
6,NCT00386139,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; transient ischemic cerebral attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention ( pci ) .,Condition Occurrence,Condition,C0000924;C2046386,accident,FALSE,FALSE,NA,NA,NA
6,NCT00386139,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; transient ischemic cerebral attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention ( pci ) .,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
6,NCT00386139,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; transient ischemic cerebral attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention ( pci ) .,Condition Occurrence,Condition,C0917805,tia,FALSE,FALSE,NA,NA,NA
6,NCT00386139,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; transient ischemic cerebral attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention ( pci ) .,Condition Occurrence,Procedure,C1532338,percutaneous coronary intervention,FALSE,FALSE,NA,NA,NA
6,NCT00386139,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; transient ischemic cerebral attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention ( pci ) .,Condition Occurrence,Procedure,C0010055,coronary bypass surgery,FALSE,FALSE,NA,NA,NA
6,NCT00386139,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; transient ischemic cerebral attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention ( pci ) .,Condition Occurrence,Procedure,C1514496;C1532338,pci,FALSE,FALSE,NA,NA,NA
6,NCT00386139,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; transient ischemic cerebral attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention ( pci ) .,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
7,NCT00386139,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00387517,Inclusion,male or female outpatients 18 years old or older .,Person,Person,C0025266,male,FALSE,FALSE,equal 18 years,NA,NA
1,NCT00387517,Inclusion,male or female outpatients 18 years old or older .,Person,Person,C0086287,female,FALSE,FALSE,equal 18 years,NA,NA
2,NCT00387517,Inclusion,patients with a diagnosis of hypertension defined as follows :,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00387517,Inclusion,patients with a diagnosis of hypertension defined as follows :,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
3,NCT00387517,Inclusion,newly diagnosed patients or patients who have not been treated for hypertension within the 4 weeks prior to visit 1 must have a msdbp > = mmhg and < 110 mmhg at visit 1 .,Observation,Observation,C0020538;C1963138,hypertension,TRUE,FALSE,lower 4 weeks,lower 110 mmhg,NA
4,NCT00387517,Inclusion,all patients who have been treated for hypertension within the 4 weeks prior to visit 1 must have a msdbp > = 85 mmhg and < 110 mmhg at visit 2 .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,lower 4 weeks,greater_equal 85 mmhg; lower 110 mmhg,NA
5,NCT00387517,Inclusion,all patients must have a msdbp > = 90 mmhg and < 110 mmhg at visit 5 .,Observation,NA,NA,NA,NA,NA,NA,NA,NA
6,NCT00387517,Inclusion,patients who are eligible and consent to participate in the study,Other,NA,NA,NA,NA,NA,NA,NA,NA
7,NCT00387517,Exclusion,severe hypertension ( msdbp > = 110 mmhg or mssbp > = 180 mmhg ) .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,greater_equal 110 mmhg; greater_equal 180 mmhg,NA
7,NCT00387517,Exclusion,severe hypertension ( msdbp > = 110 mmhg or mssbp > = 180 mmhg ) .,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
8,NCT00387517,Exclusion,previous diagnosis or current diagnosis of heart failure .,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
9,NCT00387517,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; transient ischemic cerebral attack ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention .,Condition Occurrence,Person,C0040704,transient,FALSE,FALSE,NA,NA,NA
9,NCT00387517,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; transient ischemic cerebral attack ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention .,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
9,NCT00387517,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; transient ischemic cerebral attack ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention .,Condition Occurrence,Condition,C0000924;C2046386,accident,FALSE,FALSE,NA,NA,NA
9,NCT00387517,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; transient ischemic cerebral attack ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention .,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
9,NCT00387517,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; transient ischemic cerebral attack ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention .,Condition Occurrence,Procedure,C1532338,percutaneous coronary intervention,FALSE,FALSE,NA,NA,NA
9,NCT00387517,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; transient ischemic cerebral attack ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention .,Condition Occurrence,Procedure,C0010055,coronary bypass surgery,FALSE,FALSE,NA,NA,NA
9,NCT00387517,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; transient ischemic cerebral attack ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention .,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
10,NCT00387517,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00400777,Inclusion,male or female patients > = 18 years of age,Person,Person,C0025266,male,FALSE,FALSE,greater_equal 18 years,NA,NA
1,NCT00400777,Inclusion,male or female patients > = 18 years of age,Person,Observation,C0150905,female patients,FALSE,FALSE,greater_equal 18 years,NA,NA
2,NCT00400777,Inclusion,patients treated with up to two high blood pressure medications in a stable dose considered adequate by the investigator ; for a minimum of two months ; with blood pressure not controlled according to the following criteria :,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
2,NCT00400777,Inclusion,patients treated with up to two high blood pressure medications in a stable dose considered adequate by the investigator ; for a minimum of two months ; with blood pressure not controlled according to the following criteria :,Observation,Other,C0020538;C2926615,high blood pressure,FALSE,FALSE,NA,NA,NA
2,NCT00400777,Inclusion,patients treated with up to two high blood pressure medications in a stable dose considered adequate by the investigator ; for a minimum of two months ; with blood pressure not controlled according to the following criteria :,Observation,Other,C1547311,stable,FALSE,FALSE,NA,NA,NA
3,NCT00400777,Inclusion,systolic blood pressure > = 140 mmhg blood pressure or diastolic blood pressure > = 90 mmhg for low risk patients ( no known target organ damage and without risk factor or presenting 1 except type 2 diabetes mellitus risk factor ) ;,Observation,Condition,C3272281,low risk,FALSE,FALSE,NA,NA,NA
3,NCT00400777,Inclusion,systolic blood pressure > = 140 mmhg blood pressure or diastolic blood pressure > = 90 mmhg for low risk patients ( no known target organ damage and without risk factor or presenting 1 except type 2 diabetes mellitus risk factor ) ;,Observation,Condition,C0010957,damage,TRUE,FALSE,NA,equal 1,NA
3,NCT00400777,Inclusion,systolic blood pressure > = 140 mmhg blood pressure or diastolic blood pressure > = 90 mmhg for low risk patients ( no known target organ damage and without risk factor or presenting 1 except type 2 diabetes mellitus risk factor ) ;,Observation,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
3,NCT00400777,Inclusion,systolic blood pressure > = 140 mmhg blood pressure or diastolic blood pressure > = 90 mmhg for low risk patients ( no known target organ damage and without risk factor or presenting 1 except type 2 diabetes mellitus risk factor ) ;,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater_equal 140 mmhg,NA
3,NCT00400777,Inclusion,systolic blood pressure > = 140 mmhg blood pressure or diastolic blood pressure > = 90 mmhg for low risk patients ( no known target organ damage and without risk factor or presenting 1 except type 2 diabetes mellitus risk factor ) ;,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,greater_equal 90 mmhg,NA
3,NCT00400777,Inclusion,systolic blood pressure > = 140 mmhg blood pressure or diastolic blood pressure > = 90 mmhg for low risk patients ( no known target organ damage and without risk factor or presenting 1 except type 2 diabetes mellitus risk factor ) ;,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater_equal 90 mmhg,NA
3,NCT00400777,Inclusion,systolic blood pressure > = 140 mmhg blood pressure or diastolic blood pressure > = 90 mmhg for low risk patients ( no known target organ damage and without risk factor or presenting 1 except type 2 diabetes mellitus risk factor ) ;,Observation,Observation,C2986546,target,TRUE,FALSE,NA,NA,NA
4,NCT00400777,Inclusion,systolic blood pressure > = 130 or diastolic blood pressure > = 85 mmhg for medium risk patients ( no known target organ damage and 2 or more risk factors except type 2 diabetes mellitus ) ;,Observation,Condition,C3272282,medium risk,FALSE,FALSE,NA,NA,NA
4,NCT00400777,Inclusion,systolic blood pressure > = 130 or diastolic blood pressure > = 85 mmhg for medium risk patients ( no known target organ damage and 2 or more risk factors except type 2 diabetes mellitus ) ;,Observation,Condition,C0010957,damage,TRUE,FALSE,NA,NA,NA
4,NCT00400777,Inclusion,systolic blood pressure > = 130 or diastolic blood pressure > = 85 mmhg for medium risk patients ( no known target organ damage and 2 or more risk factors except type 2 diabetes mellitus ) ;,Observation,Condition,C0455624,risk factors,FALSE,FALSE,NA,NA,NA
4,NCT00400777,Inclusion,systolic blood pressure > = 130 or diastolic blood pressure > = 85 mmhg for medium risk patients ( no known target organ damage and 2 or more risk factors except type 2 diabetes mellitus ) ;,Observation,Condition,C0011849,diabetes mellitus,FALSE,FALSE,NA,NA,NA
4,NCT00400777,Inclusion,systolic blood pressure > = 130 or diastolic blood pressure > = 85 mmhg for medium risk patients ( no known target organ damage and 2 or more risk factors except type 2 diabetes mellitus ) ;,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater_equal 130 ; greater_equal 85 mmhg,NA
4,NCT00400777,Inclusion,systolic blood pressure > = 130 or diastolic blood pressure > = 85 mmhg for medium risk patients ( no known target organ damage and 2 or more risk factors except type 2 diabetes mellitus ) ;,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater_equal 85 mmhg,NA
4,NCT00400777,Inclusion,systolic blood pressure > = 130 or diastolic blood pressure > = 85 mmhg for medium risk patients ( no known target organ damage and 2 or more risk factors except type 2 diabetes mellitus ) ;,Observation,Observation,C2986546,target,TRUE,FALSE,NA,NA,NA
4,NCT00400777,Inclusion,systolic blood pressure > = 130 or diastolic blood pressure > = 85 mmhg for medium risk patients ( no known target organ damage and 2 or more risk factors except type 2 diabetes mellitus ) ;,Observation,Other,C1552651,type,FALSE,FALSE,NA,greater_equal 2,NA
5,NCT00400777,Inclusion,systolic blood pressure > = 130 or diastolic blood pressure > = 80 mmhg for high risk patients ( known target organ damage ; or type 2 diabetic patients or any clinically identifiable cardiovascular disease ),Observation,Condition,C3272283,high risk,FALSE,FALSE,NA,NA,NA
5,NCT00400777,Inclusion,systolic blood pressure > = 130 or diastolic blood pressure > = 80 mmhg for high risk patients ( known target organ damage ; or type 2 diabetic patients or any clinically identifiable cardiovascular disease ),Observation,Condition,C0010957,damage,FALSE,FALSE,NA,NA,NA
5,NCT00400777,Inclusion,systolic blood pressure > = 130 or diastolic blood pressure > = 80 mmhg for high risk patients ( known target organ damage ; or type 2 diabetic patients or any clinically identifiable cardiovascular disease ),Observation,Condition,C0241863,diabetic,FALSE,FALSE,NA,NA,NA
5,NCT00400777,Inclusion,systolic blood pressure > = 130 or diastolic blood pressure > = 80 mmhg for high risk patients ( known target organ damage ; or type 2 diabetic patients or any clinically identifiable cardiovascular disease ),Observation,Condition,C0007222,cardiovascular disease,FALSE,FALSE,NA,NA,NA
5,NCT00400777,Inclusion,systolic blood pressure > = 130 or diastolic blood pressure > = 80 mmhg for high risk patients ( known target organ damage ; or type 2 diabetic patients or any clinically identifiable cardiovascular disease ),Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater_equal 130 ; greater_equal 80 mmhg,NA
5,NCT00400777,Inclusion,systolic blood pressure > = 130 or diastolic blood pressure > = 80 mmhg for high risk patients ( known target organ damage ; or type 2 diabetic patients or any clinically identifiable cardiovascular disease ),Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater_equal 80 mmhg,NA
5,NCT00400777,Inclusion,systolic blood pressure > = 130 or diastolic blood pressure > = 80 mmhg for high risk patients ( known target organ damage ; or type 2 diabetic patients or any clinically identifiable cardiovascular disease ),Observation,Observation,C2986546,target,FALSE,FALSE,NA,NA,NA
5,NCT00400777,Inclusion,systolic blood pressure > = 130 or diastolic blood pressure > = 80 mmhg for high risk patients ( known target organ damage ; or type 2 diabetic patients or any clinically identifiable cardiovascular disease ),Observation,Other,C1552651,type,FALSE,FALSE,NA,NA,NA
6,NCT00400777,Inclusion,systolic blood pressure > = 160 mmhg or diastolic blood pressure > = 100 mmhg at visits 1 and 2 for previously untreated patients,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater_equal 160 mmhg; greater_equal 100 mmhg; equal 1 ; equal 2,NA
6,NCT00400777,Inclusion,systolic blood pressure > = 160 mmhg or diastolic blood pressure > = 100 mmhg at visits 1 and 2 for previously untreated patients,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater_equal 100 mmhg; equal 1 ; equal 2,NA
7,NCT00400777,Inclusion,patients previously treated but who stopped their medications will be considered untreated after one month without treatment,Other,NA,NA,NA,NA,NA,NA,NA,NA
8,NCT00400777,Inclusion,obs : the target organ are : brain ; heart ; kidney ; retina .,Condition Occurrence,Condition,C0006111;C0006104;C1269537,brain,FALSE,FALSE,NA,NA,NA
8,NCT00400777,Inclusion,obs : the target organ are : brain ; heart ; kidney ; retina .,Condition Occurrence,Condition,C0024622;C0154027;C0035298;C1278894,retina,FALSE,FALSE,NA,NA,NA
8,NCT00400777,Inclusion,obs : the target organ are : brain ; heart ; kidney ; retina .,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
8,NCT00400777,Inclusion,obs : the target organ are : brain ; heart ; kidney ; retina .,Condition Occurrence,Observation,C2986546,target,FALSE,FALSE,NA,NA,NA
8,NCT00400777,Inclusion,obs : the target organ are : brain ; heart ; kidney ; retina .,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
9,NCT00400777,Inclusion,the risk factors are : smoking ; dyslipidemia ; age > 60 years old ; and family history of cardiovascular diseases ( women < 65 years old and men < 55 years old,Condition Occurrence,Person,C0001779,age,FALSE,FALSE,greater 60 years,NA,NA
9,NCT00400777,Inclusion,the risk factors are : smoking ; dyslipidemia ; age > 60 years old ; and family history of cardiovascular diseases ( women < 65 years old and men < 55 years old,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,lower 65 years,NA,NA
9,NCT00400777,Inclusion,the risk factors are : smoking ; dyslipidemia ; age > 60 years old ; and family history of cardiovascular diseases ( women < 65 years old and men < 55 years old,Condition Occurrence,Person,C0025266,men,FALSE,FALSE,lower 55 years,NA,NA
9,NCT00400777,Inclusion,the risk factors are : smoking ; dyslipidemia ; age > 60 years old ; and family history of cardiovascular diseases ( women < 65 years old and men < 55 years old,Condition Occurrence,Condition,C0455624,risk factors,FALSE,FALSE,NA,NA,NA
9,NCT00400777,Inclusion,the risk factors are : smoking ; dyslipidemia ; age > 60 years old ; and family history of cardiovascular diseases ( women < 65 years old and men < 55 years old,Condition Occurrence,Condition,C0242339,dyslipidemia,FALSE,FALSE,greater 60 years,NA,NA
9,NCT00400777,Inclusion,the risk factors are : smoking ; dyslipidemia ; age > 60 years old ; and family history of cardiovascular diseases ( women < 65 years old and men < 55 years old,Condition Occurrence,Condition,C0241889,family history,FALSE,FALSE,NA,NA,NA
9,NCT00400777,Inclusion,the risk factors are : smoking ; dyslipidemia ; age > 60 years old ; and family history of cardiovascular diseases ( women < 65 years old and men < 55 years old,Condition Occurrence,Condition,C0007222,cardiovascular diseases,FALSE,FALSE,NA,NA,NA
9,NCT00400777,Inclusion,the risk factors are : smoking ; dyslipidemia ; age > 60 years old ; and family history of cardiovascular diseases ( women < 65 years old and men < 55 years old,Condition Occurrence,Other,C0037369;C1519384;C0453996;C1548578,smoking,FALSE,FALSE,greater 60 years,NA,NA
10,NCT00400777,Exclusion,systolic blood pressure > = 180 mmhg or diastolic blood pressure > = 110 mmhg at visit 1 or visit 2,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater_equal 180 mmhg; greater_equal 110 mmhg,NA
10,NCT00400777,Exclusion,systolic blood pressure > = 180 mmhg or diastolic blood pressure > = 110 mmhg at visit 1 or visit 2,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater_equal 110 mmhg,NA
11,NCT00400777,Exclusion,evidence of a secondary form of hypertension ; to include coarctation of the aorta ; primary hyperaldosteronism ; renal artery stenosis ; or pheochromocytoma,Condition Occurrence,Condition,C0332886,coarctation,FALSE,FALSE,NA,NA,NA
11,NCT00400777,Exclusion,evidence of a secondary form of hypertension ; to include coarctation of the aorta ; primary hyperaldosteronism ; renal artery stenosis ; or pheochromocytoma,Condition Occurrence,Condition,C0031511;C1706920,pheochromocytoma,FALSE,FALSE,NA,NA,NA
11,NCT00400777,Exclusion,evidence of a secondary form of hypertension ; to include coarctation of the aorta ; primary hyperaldosteronism ; renal artery stenosis ; or pheochromocytoma,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
11,NCT00400777,Exclusion,evidence of a secondary form of hypertension ; to include coarctation of the aorta ; primary hyperaldosteronism ; renal artery stenosis ; or pheochromocytoma,Condition Occurrence,Condition,C1384514,primary hyperaldosteronism,FALSE,FALSE,NA,NA,NA
11,NCT00400777,Exclusion,evidence of a secondary form of hypertension ; to include coarctation of the aorta ; primary hyperaldosteronism ; renal artery stenosis ; or pheochromocytoma,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
11,NCT00400777,Exclusion,evidence of a secondary form of hypertension ; to include coarctation of the aorta ; primary hyperaldosteronism ; renal artery stenosis ; or pheochromocytoma,Condition Occurrence,Other,C0869784;C0003483;C1278934,aorta,FALSE,FALSE,NA,NA,NA
12,NCT00400777,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy,Condition Occurrence,Condition,C0152132,hypertensive retinopathy,FALSE,FALSE,NA,NA,NA
12,NCT00400777,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii,FALSE,FALSE,NA,NA,NA
12,NCT00400777,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy,Condition Occurrence,Other,C0677510;C0021440;C3496001,iv,FALSE,FALSE,NA,NA,NA
13,NCT00400777,Exclusion,history of hypertensive encephalopathy,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
14,NCT00400777,Exclusion,cerebrovascular accident or myocardial infarction 12 months prior to visit 1,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,equal 12 months,NA,NA
14,NCT00400777,Exclusion,cerebrovascular accident or myocardial infarction 12 months prior to visit 1,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,equal 12 months,NA,NA
15,NCT00400777,Exclusion,history of transient ischemic attack 12 months prior to visit 1,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,equal 12 months,NA,NA
16,NCT00400777,Exclusion,percutaneous coronary intervention or coronary artery bypass graft surgery 12 months prior to visit 1,Procedure,Procedure,C1532338,percutaneous coronary intervention,FALSE,FALSE,equal 12 months,NA,NA
16,NCT00400777,Exclusion,percutaneous coronary intervention or coronary artery bypass graft surgery 12 months prior to visit 1,Procedure,Procedure,C0010055,coronary artery bypass graft surgery,FALSE,FALSE,equal 12 months,NA,NA
17,NCT00400777,Exclusion,diabetes mellitus type 1,Condition Occurrence,Condition,C0011849,diabetes mellitus,FALSE,FALSE,NA,NA,NA
17,NCT00400777,Exclusion,diabetes mellitus type 1,Condition Occurrence,Other,C1552651,type,FALSE,FALSE,NA,NA,NA
18,NCT00400777,Exclusion,diabetes mellitus type 2 under insulin treatment,Condition Occurrence,Condition,C0011849,diabetes mellitus,FALSE,FALSE,NA,NA,NA
18,NCT00400777,Exclusion,diabetes mellitus type 2 under insulin treatment,Condition Occurrence,Procedure,C0745343,insulin treatment,FALSE,FALSE,NA,NA,NA
18,NCT00400777,Exclusion,diabetes mellitus type 2 under insulin treatment,Condition Occurrence,Other,C1552651,type,FALSE,FALSE,NA,NA,NA
19,NCT00400777,Exclusion,poorly controlled type 2 diabetes mellitus,Condition Occurrence,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
20,NCT00400777,Exclusion,history of heart failure grade ii iv according to the nyha classification,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
20,NCT00400777,Exclusion,history of heart failure grade ii iv according to the nyha classification,Condition Occurrence,Other,C0441802;C0475270,grade ii,FALSE,FALSE,NA,NA,NA
20,NCT00400777,Exclusion,history of heart failure grade ii iv according to the nyha classification,Condition Occurrence,Other,C0677510;C0021440;C3496001,iv,FALSE,FALSE,NA,NA,NA
20,NCT00400777,Exclusion,history of heart failure grade ii iv according to the nyha classification,Condition Occurrence,Other,C1275491,nyha classification,FALSE,FALSE,NA,NA,NA
21,NCT00400777,Exclusion,second degree heart block or third degree heart block without a pacemaker,Condition Occurrence,Condition,C0018794;C0542001;C0037188,heart block,FALSE,FALSE,NA,NA,NA
21,NCT00400777,Exclusion,second degree heart block or third degree heart block without a pacemaker,Condition Occurrence,Condition,C0018794;C0542001;C0037188,heart block,FALSE,FALSE,NA,NA,NA
21,NCT00400777,Exclusion,second degree heart block or third degree heart block without a pacemaker,Condition Occurrence,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
21,NCT00400777,Exclusion,second degree heart block or third degree heart block without a pacemaker,Condition Occurrence,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
21,NCT00400777,Exclusion,second degree heart block or third degree heart block without a pacemaker,Condition Occurrence,Other,C3275122;C1546728,pacemaker,TRUE,FALSE,NA,NA,NA
22,NCT00400777,Exclusion,concomitant unstable angina pectoris,Condition Occurrence,Condition,C0002965,unstable angina pectoris,FALSE,FALSE,NA,NA,NA
23,NCT00400777,Exclusion,concomitant potentially life threatening arrhythmia or symptomatic arrhythmia,Condition Occurrence,Condition,C2826244;C3537125,life threatening,FALSE,FALSE,NA,NA,NA
23,NCT00400777,Exclusion,concomitant potentially life threatening arrhythmia or symptomatic arrhythmia,Condition Occurrence,Condition,C0003811,arrhythmia,FALSE,FALSE,NA,NA,NA
23,NCT00400777,Exclusion,concomitant potentially life threatening arrhythmia or symptomatic arrhythmia,Condition Occurrence,Condition,C0003811,arrhythmia,FALSE,FALSE,NA,NA,NA
24,NCT00400777,Exclusion,clinically significant valvular heart disease,Condition Occurrence,Condition,C0018824;C1963123,valvular heart disease,FALSE,FALSE,NA,NA,NA
25,NCT00400777,Exclusion,women of child-bearing potential,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
25,NCT00400777,Exclusion,women of child-bearing potential,Person,Observation,C3831118,child-bearing potential,FALSE,FALSE,NA,NA,NA
26,NCT00400777,Exclusion,pregnant or nursing ( lactating ) women,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
26,NCT00400777,Exclusion,pregnant or nursing ( lactating ) women,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
26,NCT00400777,Exclusion,pregnant or nursing ( lactating ) women,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
26,NCT00400777,Exclusion,pregnant or nursing ( lactating ) women,Condition Occurrence,Condition,C2828358;C3668831,lactating,FALSE,FALSE,NA,NA,NA
27,NCT00400777,Exclusion,any surgical condition or medical condition which ; at the discretion of the investigator ; place the patient at higher risk from his / her participation in the study ; or are likely to prevent the patient from complying with the requirements of the study or completing the trial period,Drug Exposure,Drug,C0309872,prevent,FALSE,FALSE,NA,NA,NA
27,NCT00400777,Exclusion,any surgical condition or medical condition which ; at the discretion of the investigator ; place the patient at higher risk from his / her participation in the study ; or are likely to prevent the patient from complying with the requirements of the study or completing the trial period,Drug Exposure,Other,C1561579;C1561578,medical,FALSE,FALSE,NA,NA,NA
28,NCT00400777,Exclusion,additional protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00409643,Inclusion,outpatients 18 years and older .,Other,NA,NA,NA,NA,NA,NA,NA,NA
2,NCT00409643,Inclusion,male or female patients are eligible,Person,Person,C0025266,male,FALSE,FALSE,NA,NA,NA
2,NCT00409643,Inclusion,male or female patients are eligible,Person,Observation,C0150905,female patients,FALSE,FALSE,NA,NA,NA
3,NCT00409643,Inclusion,female patients must be either post-menopausal for one year or surgically sterile ; or using effective contraceptive methods such as barrier method with spermicide or an intra-uterine device,Procedure,Drug,C0037862,spermicide,FALSE,FALSE,NA,NA,NA
3,NCT00409643,Inclusion,female patients must be either post-menopausal for one year or surgically sterile ; or using effective contraceptive methods such as barrier method with spermicide or an intra-uterine device,Procedure,Procedure,C0700589,contraceptive methods,FALSE,FALSE,NA,NA,NA
3,NCT00409643,Inclusion,female patients must be either post-menopausal for one year or surgically sterile ; or using effective contraceptive methods such as barrier method with spermicide or an intra-uterine device,Procedure,Procedure,C0004764,barrier method,FALSE,FALSE,NA,NA,NA
3,NCT00409643,Inclusion,female patients must be either post-menopausal for one year or surgically sterile ; or using effective contraceptive methods such as barrier method with spermicide or an intra-uterine device,Procedure,Observation,C0150905,female patients,FALSE,FALSE,NA,NA,NA
4,NCT00409643,Inclusion,hormonal contraceptive use is disallowed .,Other,NA,NA,NA,NA,NA,NA,NA,NA
5,NCT00409643,Inclusion,patients with essential diastolic hypertension measured by calibrated standard aneroid or mercury ( preferable ) sphygmomanometer ; patients must have a msdbp > 90 mmhg and < 110 mmhg at visit 1 ( week 4 to 2 ) ; and a msdbp > 95 mmhg and < 110 mmhg at visit 2 ( week 0 ) .,Observation,Condition,C3694763,essential diastolic hypertension,FALSE,FALSE,NA,NA,NA
5,NCT00409643,Inclusion,patients with essential diastolic hypertension measured by calibrated standard aneroid or mercury ( preferable ) sphygmomanometer ; patients must have a msdbp > 90 mmhg and < 110 mmhg at visit 1 ( week 4 to 2 ) ; and a msdbp > 95 mmhg and < 110 mmhg at visit 2 ( week 0 ) .,Observation,Drug,C0025424,mercury,FALSE,FALSE,greater_equal 4 week; equal 0 week,greater 90 mmhg; lower 110 mmhg; greater 95 mmhg; lower 110 mmhg; lower_equal 2,NA
5,NCT00409643,Inclusion,patients with essential diastolic hypertension measured by calibrated standard aneroid or mercury ( preferable ) sphygmomanometer ; patients must have a msdbp > 90 mmhg and < 110 mmhg at visit 1 ( week 4 to 2 ) ; and a msdbp > 95 mmhg and < 110 mmhg at visit 2 ( week 0 ) .,Observation,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
5,NCT00409643,Inclusion,patients with essential diastolic hypertension measured by calibrated standard aneroid or mercury ( preferable ) sphygmomanometer ; patients must have a msdbp > 90 mmhg and < 110 mmhg at visit 1 ( week 4 to 2 ) ; and a msdbp > 95 mmhg and < 110 mmhg at visit 2 ( week 0 ) .,Observation,Other,C2828392;C3272550,standard,FALSE,FALSE,greater_equal 4 week; equal 0 week,greater 90 mmhg; lower 110 mmhg; greater 95 mmhg; lower 110 mmhg; lower_equal 2,NA
6,NCT00409643,Inclusion,patients must have an absolute difference of > 10 mmhg in their average sitting diastolic blood pressure between visits 1 and 2 .,Observation,Condition,C1319894,sitting diastolic blood pressure,FALSE,FALSE,NA,greater 10 mmhg; equal 1 ; equal 2,NA
7,NCT00409643,Inclusion,patients who are eligible and able to participate in the study ; and who consent to do so after the purpose and nature of the investigation has been clearly explained to them ( written informed consent ) .,Drug Exposure,Drug,C1995603,purpose,FALSE,FALSE,NA,NA,NA
8,NCT00409643,Exclusion,severe hypertension ( msdbp 110 mmhg or mssbp 180 mmhg ) at anytime .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,equal 110 mmhg; equal 180 mmhg,NA
8,NCT00409643,Exclusion,severe hypertension ( msdbp 110 mmhg or mssbp 180 mmhg ) at anytime .,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
9,NCT00409643,Exclusion,inability to discontinue all prior antihypertensive medications safely for a period of 14 weeks .,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,equal 14 weeks,NA,NA
9,NCT00409643,Exclusion,inability to discontinue all prior antihypertensive medications safely for a period of 14 weeks .,Drug Exposure,Other,C1706472,discontinue,FALSE,FALSE,NA,NA,NA
10,NCT00409643,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy .,Condition Occurrence,Condition,C0152132,hypertensive retinopathy,FALSE,FALSE,NA,NA,NA
10,NCT00409643,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy .,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii,FALSE,FALSE,NA,NA,NA
10,NCT00409643,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy .,Condition Occurrence,Other,C0677510;C0021440;C3496001,iv,FALSE,FALSE,NA,NA,NA
11,NCT00409643,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident at anytime prior to visit 0 ( week 6 to 4 ) .,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
11,NCT00409643,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident at anytime prior to visit 0 ( week 6 to 4 ) .,Condition Occurrence,Condition,C0000924;C2046386,accident,FALSE,FALSE,greater_equal 6 week; lower_equal 4,NA,NA
11,NCT00409643,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident at anytime prior to visit 0 ( week 6 to 4 ) .,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,greater_equal 6 week; lower_equal 4,NA,NA
12,NCT00409643,Exclusion,transient ischemic cerebral attack during the last 12 months prior to visit 0 ( week 6 to 4 ) .,Person,Person,C0040704,transient,FALSE,FALSE,lower_equal 12 last months; greater_equal 6 week; lower_equal 4,NA,NA
13,NCT00409643,Exclusion,evidence of a secondary form of hypertension ; such as coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma ; polycystic kidney disease etc .,Condition Occurrence,Condition,C0332886,coarctation,FALSE,FALSE,NA,NA,NA
13,NCT00409643,Exclusion,evidence of a secondary form of hypertension ; such as coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma ; polycystic kidney disease etc .,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
13,NCT00409643,Exclusion,evidence of a secondary form of hypertension ; such as coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma ; polycystic kidney disease etc .,Condition Occurrence,Condition,C0035065;C1278951,renal artery,FALSE,FALSE,NA,NA,NA
13,NCT00409643,Exclusion,evidence of a secondary form of hypertension ; such as coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma ; polycystic kidney disease etc .,Condition Occurrence,Condition,C0020428,hyperaldosteronism,FALSE,FALSE,NA,NA,NA
13,NCT00409643,Exclusion,evidence of a secondary form of hypertension ; such as coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma ; polycystic kidney disease etc .,Condition Occurrence,Condition,C0221406;C0010481,cushing disease,FALSE,FALSE,NA,NA,NA
13,NCT00409643,Exclusion,evidence of a secondary form of hypertension ; such as coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma ; polycystic kidney disease etc .,Condition Occurrence,Condition,C0022680,polycystic kidney disease,FALSE,FALSE,NA,NA,NA
13,NCT00409643,Exclusion,evidence of a secondary form of hypertension ; such as coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma ; polycystic kidney disease etc .,Condition Occurrence,Condition,C0031511;C1706920,pheochromocytoma,FALSE,FALSE,NA,NA,NA
13,NCT00409643,Exclusion,evidence of a secondary form of hypertension ; such as coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma ; polycystic kidney disease etc .,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
13,NCT00409643,Exclusion,evidence of a secondary form of hypertension ; such as coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma ; polycystic kidney disease etc .,Condition Occurrence,Other,C0869784;C0003483;C1278934,aorta,FALSE,FALSE,NA,NA,NA
14,NCT00409643,Exclusion,type 1 diabetes mellitus .,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
15,NCT00409643,Exclusion,type 2 diabetes mellitus with poor glucose control as defined by fasting glycosylated hemoglobin ( hba1c ) > 8 % at visit 1 ( week 4 to 2 ) .,Drug Exposure,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
15,NCT00409643,Exclusion,type 2 diabetes mellitus with poor glucose control as defined by fasting glycosylated hemoglobin ( hba1c ) > 8 % at visit 1 ( week 4 to 2 ) .,Drug Exposure,Drug,C0726398,glucose control,FALSE,FALSE,NA,NA,NA
15,NCT00409643,Exclusion,type 2 diabetes mellitus with poor glucose control as defined by fasting glycosylated hemoglobin ( hba1c ) > 8 % at visit 1 ( week 4 to 2 ) .,Drug Exposure,Observation,C0017853;C0373638;C0202054,glycosylated hemoglobin,FALSE,FALSE,NA,NA,NA
15,NCT00409643,Exclusion,type 2 diabetes mellitus with poor glucose control as defined by fasting glycosylated hemoglobin ( hba1c ) > 8 % at visit 1 ( week 4 to 2 ) .,Drug Exposure,Observation,C0202054,hba1c,FALSE,FALSE,greater_equal 4 week; lower_equal 2,NA,greater 8 %
15,NCT00409643,Exclusion,type 2 diabetes mellitus with poor glucose control as defined by fasting glycosylated hemoglobin ( hba1c ) > 8 % at visit 1 ( week 4 to 2 ) .,Drug Exposure,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
15,NCT00409643,Exclusion,type 2 diabetes mellitus with poor glucose control as defined by fasting glycosylated hemoglobin ( hba1c ) > 8 % at visit 1 ( week 4 to 2 ) .,Drug Exposure,Other,C0015663;C1550565,fasting,FALSE,FALSE,NA,NA,NA
16,NCT00409643,Exclusion,administration of any agent indicated for the treatment of hypertension within a minimum 4 weeks prior to randomization into the study ( visit 2 ; week 0 ) ; with the permitted exception of those anti-hypertensive medications requiring tapering down commencing at visit 0 ( week 6 to 4 ) .,Observation,Drug,C0003364,anti-hypertensive,TRUE,FALSE,NA,NA,NA
16,NCT00409643,Exclusion,administration of any agent indicated for the treatment of hypertension within a minimum 4 weeks prior to randomization into the study ( visit 2 ; week 0 ) ; with the permitted exception of those anti-hypertensive medications requiring tapering down commencing at visit 0 ( week 6 to 4 ) .,Observation,Procedure,C0441640,tapering,TRUE,FALSE,greater_equal 6 week; lower_equal 4,equal 0,NA
16,NCT00409643,Exclusion,administration of any agent indicated for the treatment of hypertension within a minimum 4 weeks prior to randomization into the study ( visit 2 ; week 0 ) ; with the permitted exception of those anti-hypertensive medications requiring tapering down commencing at visit 0 ( week 6 to 4 ) .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,greater_equal 4 weeks; equal 2 ; week,NA,NA
17,NCT00409643,Exclusion,known or suspected contraindications ; including history of allergy to angiotensin receptor blockers or calcium channel blockers .,Drug Exposure,Drug,C0521942;C0815017,angiotensin receptor blockers,FALSE,FALSE,NA,NA,NA
17,NCT00409643,Exclusion,known or suspected contraindications ; including history of allergy to angiotensin receptor blockers or calcium channel blockers .,Drug Exposure,Drug,C0006684,calcium channel blockers,FALSE,FALSE,NA,NA,NA
17,NCT00409643,Exclusion,known or suspected contraindications ; including history of allergy to angiotensin receptor blockers or calcium channel blockers .,Drug Exposure,Other,C0489531;C0718579;C3542994;C3539909;C1314973;C1547315;C1611280,allergy,FALSE,FALSE,NA,NA,NA
18,NCT00409643,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00409760,Inclusion,outpatients 18 years and older .,Other,NA,NA,NA,NA,NA,NA,NA,NA
2,NCT00409760,Inclusion,male or female patients are eligible .,Person,Person,C0025266,male,FALSE,FALSE,NA,NA,NA
2,NCT00409760,Inclusion,male or female patients are eligible .,Person,Observation,C0150905,female patients,FALSE,FALSE,NA,NA,NA
3,NCT00409760,Inclusion,female patients must be either post-menopausal for one year or surgically sterile ; or using effective contraceptive methods such as barrier method with spermicide or an intra-uterine device,Procedure,Drug,C0037862,spermicide,FALSE,FALSE,NA,NA,NA
3,NCT00409760,Inclusion,female patients must be either post-menopausal for one year or surgically sterile ; or using effective contraceptive methods such as barrier method with spermicide or an intra-uterine device,Procedure,Procedure,C0700589,contraceptive methods,FALSE,FALSE,NA,NA,NA
3,NCT00409760,Inclusion,female patients must be either post-menopausal for one year or surgically sterile ; or using effective contraceptive methods such as barrier method with spermicide or an intra-uterine device,Procedure,Procedure,C0004764,barrier method,FALSE,FALSE,NA,NA,NA
3,NCT00409760,Inclusion,female patients must be either post-menopausal for one year or surgically sterile ; or using effective contraceptive methods such as barrier method with spermicide or an intra-uterine device,Procedure,Observation,C0150905,female patients,FALSE,FALSE,NA,NA,NA
4,NCT00409760,Inclusion,hormonal contraceptive use is disallowed .,Other,NA,NA,NA,NA,NA,NA,NA,NA
5,NCT00409760,Inclusion,patients with mild to moderate essential diastolic hypertension ( grades 1 and 2 who classification ) measured by calibrated standard sphygmomanometer .,Observation,Condition,C3694763,essential diastolic hypertension,FALSE,FALSE,NA,equal 1 ; equal 2,NA
5,NCT00409760,Inclusion,patients with mild to moderate essential diastolic hypertension ( grades 1 and 2 who classification ) measured by calibrated standard sphygmomanometer .,Observation,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
5,NCT00409760,Inclusion,patients with mild to moderate essential diastolic hypertension ( grades 1 and 2 who classification ) measured by calibrated standard sphygmomanometer .,Observation,Other,C1547225,mild,FALSE,FALSE,NA,NA,NA
5,NCT00409760,Inclusion,patients with mild to moderate essential diastolic hypertension ( grades 1 and 2 who classification ) measured by calibrated standard sphygmomanometer .,Observation,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
5,NCT00409760,Inclusion,patients with mild to moderate essential diastolic hypertension ( grades 1 and 2 who classification ) measured by calibrated standard sphygmomanometer .,Observation,Other,C2828392;C3272550,standard,FALSE,FALSE,NA,NA,NA
6,NCT00409760,Inclusion,patients must have a msdbp > = 90 mmhg and < 110 mmhg at visit 1 ( week 2 to 4 );and a msdbp > = 95 mmhg and < 110 mmhg at visit 2 ( week 0 ) .,Observation,NA,NA,NA,NA,NA,NA,NA,NA
7,NCT00409760,Inclusion,patients must have an absolute difference of = < 10 mmhg in their average sitting diastolic blood pressure between visits 1 and 2 .,Observation,Condition,C1319894,sitting diastolic blood pressure,FALSE,FALSE,NA,lower_equal 10 mmhg; equal 1 ; equal 2,NA
8,NCT00409760,Inclusion,patients who are eligible and able to participate in the study ; and who consent to do so after the purpose and nature of the investigation has been clearly explained to them ( written informed consent ) .,Drug Exposure,Drug,C1995603,purpose,FALSE,FALSE,NA,NA,NA
9,NCT00409760,Exclusion,severe hypertension ( grade 3 who classification,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
9,NCT00409760,Exclusion,severe hypertension ( grade 3 who classification,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
10,NCT00409760,Exclusion,msdbp > = 110 mmhg diastolic or mssbp > = 180 mmhg systolic ) .,Observation,NA,NA,NA,NA,NA,NA,NA,NA
11,NCT00409760,Exclusion,inability to discontinue all prior anti-hypertensive medications safely for a period of 14 weeks ) .,Drug Exposure,Drug,C0003364,anti-hypertensive,FALSE,FALSE,equal 14 weeks,NA,NA
11,NCT00409760,Exclusion,inability to discontinue all prior anti-hypertensive medications safely for a period of 14 weeks ) .,Drug Exposure,Other,C1706472,discontinue,FALSE,FALSE,NA,NA,NA
12,NCT00409760,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy .,Condition Occurrence,Condition,C0152132,hypertensive retinopathy,FALSE,FALSE,NA,NA,NA
12,NCT00409760,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy .,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii,FALSE,FALSE,NA,NA,NA
12,NCT00409760,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy .,Condition Occurrence,Other,C0677510;C0021440;C3496001,iv,FALSE,FALSE,NA,NA,NA
13,NCT00409760,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident at anytime prior to visit 1 ( week 2 to 4 ) .,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
13,NCT00409760,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident at anytime prior to visit 1 ( week 2 to 4 ) .,Condition Occurrence,Condition,C0000924;C2046386,accident,FALSE,FALSE,greater_equal 2 week; lower_equal 4,NA,NA
13,NCT00409760,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident at anytime prior to visit 1 ( week 2 to 4 ) .,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,greater_equal 2 week; lower_equal 4,NA,NA
14,NCT00409760,Exclusion,transient ischemic cerebral attack during the last 12 months prior to visit 1 ( week 2 to 4 ) .,Person,Person,C0040704,transient,FALSE,FALSE,lower_equal 12 last months; greater_equal 2 week; lower_equal 4,NA,NA
15,NCT00409760,Exclusion,evidence of a secondary form of hypertension ; such as coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery stenosis ; or pheochromocytoma ; etc .,Condition Occurrence,Condition,C0332886,coarctation,FALSE,FALSE,NA,NA,NA
15,NCT00409760,Exclusion,evidence of a secondary form of hypertension ; such as coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery stenosis ; or pheochromocytoma ; etc .,Condition Occurrence,Condition,C0031511;C1706920,pheochromocytoma,FALSE,FALSE,NA,NA,NA
15,NCT00409760,Exclusion,evidence of a secondary form of hypertension ; such as coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery stenosis ; or pheochromocytoma ; etc .,Condition Occurrence,Condition,C0856759,unilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
15,NCT00409760,Exclusion,evidence of a secondary form of hypertension ; such as coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery stenosis ; or pheochromocytoma ; etc .,Condition Occurrence,Condition,C0020428,hyperaldosteronism,FALSE,FALSE,NA,NA,NA
15,NCT00409760,Exclusion,evidence of a secondary form of hypertension ; such as coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery stenosis ; or pheochromocytoma ; etc .,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
15,NCT00409760,Exclusion,evidence of a secondary form of hypertension ; such as coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery stenosis ; or pheochromocytoma ; etc .,Condition Occurrence,Other,C0869784;C0003483;C1278934,aorta,FALSE,FALSE,NA,NA,NA
16,NCT00409760,Exclusion,type 1 diabetes mellitus .,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
17,NCT00409760,Exclusion,type 2 diabetes mellitus with poor glucose control as defined by fasting glycosylated hemoglobin ( hba1c ) > 8 % at visit 1 ( week 2 to 4 ) .,Drug Exposure,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
17,NCT00409760,Exclusion,type 2 diabetes mellitus with poor glucose control as defined by fasting glycosylated hemoglobin ( hba1c ) > 8 % at visit 1 ( week 2 to 4 ) .,Drug Exposure,Drug,C0726398,glucose control,FALSE,FALSE,NA,NA,NA
17,NCT00409760,Exclusion,type 2 diabetes mellitus with poor glucose control as defined by fasting glycosylated hemoglobin ( hba1c ) > 8 % at visit 1 ( week 2 to 4 ) .,Drug Exposure,Observation,C0017853;C0373638;C0202054,glycosylated hemoglobin,FALSE,FALSE,NA,NA,NA
17,NCT00409760,Exclusion,type 2 diabetes mellitus with poor glucose control as defined by fasting glycosylated hemoglobin ( hba1c ) > 8 % at visit 1 ( week 2 to 4 ) .,Drug Exposure,Observation,C0202054,hba1c,FALSE,FALSE,greater_equal 2 week; lower_equal 4,NA,greater 8 %
17,NCT00409760,Exclusion,type 2 diabetes mellitus with poor glucose control as defined by fasting glycosylated hemoglobin ( hba1c ) > 8 % at visit 1 ( week 2 to 4 ) .,Drug Exposure,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
17,NCT00409760,Exclusion,type 2 diabetes mellitus with poor glucose control as defined by fasting glycosylated hemoglobin ( hba1c ) > 8 % at visit 1 ( week 2 to 4 ) .,Drug Exposure,Other,C0015663;C1550565,fasting,FALSE,FALSE,NA,NA,NA
18,NCT00409760,Exclusion,administration of any agent indicated for the treatment of hypertension within a minimum 4 weeks prior to randomization into the study ( visit 2 ; week 0 ) ; with the permitted exception of those anti-hypertensive medications requiring tapering down commencing at visit 0 ( week 4 to 6 ) .,Observation,Drug,C0003364,anti-hypertensive,TRUE,FALSE,NA,NA,NA
18,NCT00409760,Exclusion,administration of any agent indicated for the treatment of hypertension within a minimum 4 weeks prior to randomization into the study ( visit 2 ; week 0 ) ; with the permitted exception of those anti-hypertensive medications requiring tapering down commencing at visit 0 ( week 4 to 6 ) .,Observation,Procedure,C0441640,tapering,TRUE,FALSE,greater_equal 4 week; lower_equal 6,equal 0,NA
18,NCT00409760,Exclusion,administration of any agent indicated for the treatment of hypertension within a minimum 4 weeks prior to randomization into the study ( visit 2 ; week 0 ) ; with the permitted exception of those anti-hypertensive medications requiring tapering down commencing at visit 0 ( week 4 to 6 ) .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,greater_equal 4 weeks; equal 2 ; week,NA,NA
19,NCT00409760,Exclusion,known or suspected contraindications ; including history of allergy to angiotensin receptor blockers or calcium channel blockers .,Drug Exposure,Drug,C0521942;C0815017,angiotensin receptor blockers,FALSE,FALSE,NA,NA,NA
19,NCT00409760,Exclusion,known or suspected contraindications ; including history of allergy to angiotensin receptor blockers or calcium channel blockers .,Drug Exposure,Drug,C0006684,calcium channel blockers,FALSE,FALSE,NA,NA,NA
19,NCT00409760,Exclusion,known or suspected contraindications ; including history of allergy to angiotensin receptor blockers or calcium channel blockers .,Drug Exposure,Other,C0489531;C0718579;C3542994;C3539909;C1314973;C1547315;C1611280,allergy,FALSE,FALSE,NA,NA,NA
20,NCT00409760,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00409851,Inclusion,successful completion of vaa489a2201 core trial,Condition Occurrence,Condition,C3274653,core,FALSE,FALSE,NA,NA,NA
2,NCT00409851,Inclusion,visit 7 blood pressure must be msdbp < = 95 mmhg and mssbp < = 150 mmhg,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,lower_equal 95 mmhg; lower_equal 150 mmhg,NA
3,NCT00409851,Exclusion,patients who experienced any adverse events considered serious and drug related in vaa489a2201 core,Condition Occurrence,Condition,C0877248,adverse events,FALSE,FALSE,NA,NA,NA
3,NCT00409851,Exclusion,patients who experienced any adverse events considered serious and drug related in vaa489a2201 core,Condition Occurrence,Condition,C0445223,related,FALSE,FALSE,NA,NA,NA
3,NCT00409851,Exclusion,patients who experienced any adverse events considered serious and drug related in vaa489a2201 core,Condition Occurrence,Condition,C3274653,core,FALSE,FALSE,NA,NA,NA
3,NCT00409851,Exclusion,patients who experienced any adverse events considered serious and drug related in vaa489a2201 core,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
4,NCT00409851,Exclusion,other protocol-defined may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00413049,Inclusion,male or female outpatients > = 18 years and < 86 years,Person,Person,C0025266,male,FALSE,FALSE,greater_equal 18 years; lower 86 years,NA,NA
1,NCT00413049,Inclusion,male or female outpatients > = 18 years and < 86 years,Person,Person,C0086287,female,FALSE,FALSE,greater_equal 18 years; lower 86 years,NA,NA
2,NCT00413049,Inclusion,patients with essential hypertension measured by calibrated mercury sphygmomanometer ( preferred ) or an aneroid device if a mercury sphygmomanometer was not available .,Drug Exposure,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00413049,Inclusion,patients with essential hypertension measured by calibrated mercury sphygmomanometer ( preferred ) or an aneroid device if a mercury sphygmomanometer was not available .,Drug Exposure,Drug,C0025424,mercury,FALSE,FALSE,NA,NA,NA
2,NCT00413049,Inclusion,patients with essential hypertension measured by calibrated mercury sphygmomanometer ( preferred ) or an aneroid device if a mercury sphygmomanometer was not available .,Drug Exposure,Drug,C0025424,mercury,FALSE,FALSE,NA,NA,NA
2,NCT00413049,Inclusion,patients with essential hypertension measured by calibrated mercury sphygmomanometer ( preferred ) or an aneroid device if a mercury sphygmomanometer was not available .,Drug Exposure,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
3,NCT00413049,Inclusion,at visit 1 ; patients not treated with antihypertensive medications had to have a msdbp of > = 95 mmhg and < 110 mmhg,Observation,Drug,C0003364,antihypertensive,TRUE,FALSE,NA,greater_equal 95 mmhg; lower 110 mmhg,NA
4,NCT00413049,Inclusion,those patients treated with antihypertensive medication had to have a msdbp of < 110 mmhg .,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,lower 110 mmhg,NA
5,NCT00413049,Inclusion,at visit 2;patients must have a msdbp of > = 95 mmhg but < 110 mmhg .,Observation,NA,NA,NA,NA,NA,NA,NA,NA
6,NCT00413049,Inclusion,at visit 3;patients must have a msdbp of > = 90 mmhg and < 110 mmhg .,Observation,NA,NA,NA,NA,NA,NA,NA,NA
7,NCT00413049,Inclusion,patients who were eligible and able to participate in the study ; and who consented to do so after the purpose and nature of the investigation had been clearly explained to them ( written informed consent ) .,Drug Exposure,Drug,C1995603,purpose,FALSE,FALSE,NA,NA,NA
8,NCT00413049,Exclusion,severe hypertension ( msdbp > = 110 mmhg or mssbp > = 180 mmhg ) .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,greater_equal 110 mmhg; greater_equal 180 mmhg,NA
8,NCT00413049,Exclusion,severe hypertension ( msdbp > = 110 mmhg or mssbp > = 180 mmhg ) .,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
9,NCT00413049,Exclusion,in cases where the patient was on more than one antihypertensive drug whether in fixed or free combination ; the investigator considered the efficacy and strength of each active ingredient in order to determine if the patient could be safely removed from their antihypertensive treatment .,Drug Exposure,Condition,C2827483,fixed,FALSE,FALSE,NA,NA,NA
9,NCT00413049,Exclusion,in cases where the patient was on more than one antihypertensive drug whether in fixed or free combination ; the investigator considered the efficacy and strength of each active ingredient in order to determine if the patient could be safely removed from their antihypertensive treatment .,Drug Exposure,Drug,C0003364,antihypertensive drug,FALSE,FALSE,NA,NA,NA
9,NCT00413049,Exclusion,in cases where the patient was on more than one antihypertensive drug whether in fixed or free combination ; the investigator considered the efficacy and strength of each active ingredient in order to determine if the patient could be safely removed from their antihypertensive treatment .,Drug Exposure,Drug,C1372955,active ingredient,FALSE,FALSE,NA,NA,NA
9,NCT00413049,Exclusion,in cases where the patient was on more than one antihypertensive drug whether in fixed or free combination ; the investigator considered the efficacy and strength of each active ingredient in order to determine if the patient could be safely removed from their antihypertensive treatment .,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
9,NCT00413049,Exclusion,in cases where the patient was on more than one antihypertensive drug whether in fixed or free combination ; the investigator considered the efficacy and strength of each active ingredient in order to determine if the patient could be safely removed from their antihypertensive treatment .,Drug Exposure,Other,C1705175,order,FALSE,FALSE,NA,NA,NA
10,NCT00413049,Exclusion,known or suspected contraindications ; including history of allergy or hypersensitivity to angiotensin receptor blockers ( arb ) ; calcium channel blockers ( ccb ) ; or to drugs with similar chemical structures .,Drug Exposure,Condition,C0175556,ccb,FALSE,FALSE,NA,NA,NA
10,NCT00413049,Exclusion,known or suspected contraindications ; including history of allergy or hypersensitivity to angiotensin receptor blockers ( arb ) ; calcium channel blockers ( ccb ) ; or to drugs with similar chemical structures .,Drug Exposure,Drug,C0521942;C0815017,angiotensin receptor blockers,FALSE,FALSE,NA,NA,NA
10,NCT00413049,Exclusion,known or suspected contraindications ; including history of allergy or hypersensitivity to angiotensin receptor blockers ( arb ) ; calcium channel blockers ( ccb ) ; or to drugs with similar chemical structures .,Drug Exposure,Drug,C0006684,calcium channel blockers,FALSE,FALSE,NA,NA,NA
10,NCT00413049,Exclusion,known or suspected contraindications ; including history of allergy or hypersensitivity to angiotensin receptor blockers ( arb ) ; calcium channel blockers ( ccb ) ; or to drugs with similar chemical structures .,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
10,NCT00413049,Exclusion,known or suspected contraindications ; including history of allergy or hypersensitivity to angiotensin receptor blockers ( arb ) ; calcium channel blockers ( ccb ) ; or to drugs with similar chemical structures .,Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
10,NCT00413049,Exclusion,known or suspected contraindications ; including history of allergy or hypersensitivity to angiotensin receptor blockers ( arb ) ; calcium channel blockers ( ccb ) ; or to drugs with similar chemical structures .,Drug Exposure,Other,C0489531;C0718579;C3542994;C3539909;C1314973;C1547315;C1611280,allergy,FALSE,FALSE,NA,NA,NA
10,NCT00413049,Exclusion,known or suspected contraindications ; including history of allergy or hypersensitivity to angiotensin receptor blockers ( arb ) ; calcium channel blockers ( ccb ) ; or to drugs with similar chemical structures .,Drug Exposure,Other,C0521942;C2678493,arb,FALSE,FALSE,NA,NA,NA
10,NCT00413049,Exclusion,known or suspected contraindications ; including history of allergy or hypersensitivity to angiotensin receptor blockers ( arb ) ; calcium channel blockers ( ccb ) ; or to drugs with similar chemical structures .,Drug Exposure,Other,C0220806;C3272558,chemical,FALSE,FALSE,NA,NA,NA
11,NCT00413049,Exclusion,administration of any agent indicated for the treatment of hypertension after visit 1 with the exception of those agents that required tapering down .,Observation,Procedure,C0441640,tapering,TRUE,FALSE,NA,NA,NA
11,NCT00413049,Exclusion,administration of any agent indicated for the treatment of hypertension after visit 1 with the exception of those agents that required tapering down .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
11,NCT00413049,Exclusion,administration of any agent indicated for the treatment of hypertension after visit 1 with the exception of those agents that required tapering down .,Observation,Other,C3245502;C3245501;C1619636;C1546857,required,TRUE,FALSE,NA,NA,NA
12,NCT00413049,Exclusion,inability to discontinue all prior antihypertensive medications safely for a maximum period of up to 28 days prior to visit 2 ; as required by the protocol .,Other,Drug,C0003364,antihypertensive,FALSE,FALSE,lower_equal 28 days,NA,NA
12,NCT00413049,Exclusion,inability to discontinue all prior antihypertensive medications safely for a maximum period of up to 28 days prior to visit 2 ; as required by the protocol .,Other,Other,C1706472,discontinue,FALSE,FALSE,NA,NA,NA
12,NCT00413049,Exclusion,inability to discontinue all prior antihypertensive medications safely for a maximum period of up to 28 days prior to visit 2 ; as required by the protocol .,Other,Other,C3245502;C3245501;C1619636;C1546857,required,FALSE,FALSE,NA,NA,NA
13,NCT00413049,Exclusion,history of hypertensive encephalopathy ; cerebrovascular accident or transient ischemic attack ; myocardial infarction or all types of revascularization .,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
13,NCT00413049,Exclusion,history of hypertensive encephalopathy ; cerebrovascular accident or transient ischemic attack ; myocardial infarction or all types of revascularization .,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,NA,NA,NA
13,NCT00413049,Exclusion,history of hypertensive encephalopathy ; cerebrovascular accident or transient ischemic attack ; myocardial infarction or all types of revascularization .,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
13,NCT00413049,Exclusion,history of hypertensive encephalopathy ; cerebrovascular accident or transient ischemic attack ; myocardial infarction or all types of revascularization .,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
14,NCT00413049,Exclusion,malignant hypertension .,Condition Occurrence,Condition,C0020540;C0024588,malignant hypertension,FALSE,FALSE,NA,NA,NA
15,NCT00413049,Exclusion,all patients with type 1 diabetes mellitus and those patients with type 2 diabetes mellitus who were not well controlled based on the investigator clinical judgment,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
15,NCT00413049,Exclusion,all patients with type 1 diabetes mellitus and those patients with type 2 diabetes mellitus who were not well controlled based on the investigator clinical judgment,Condition Occurrence,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
15,NCT00413049,Exclusion,all patients with type 1 diabetes mellitus and those patients with type 2 diabetes mellitus who were not well controlled based on the investigator clinical judgment,Condition Occurrence,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
16,NCT00413049,Exclusion,patients being treated for diabetes mellitus had to have satisfactory metabolic control,Condition Occurrence,Condition,C0011849,diabetes mellitus,FALSE,FALSE,NA,NA,NA
16,NCT00413049,Exclusion,patients being treated for diabetes mellitus had to have satisfactory metabolic control,Condition Occurrence,Condition,C1513158,metabolic control,FALSE,FALSE,NA,NA,NA
16,NCT00413049,Exclusion,patients being treated for diabetes mellitus had to have satisfactory metabolic control,Condition Occurrence,Other,C1547307,satisfactory,FALSE,FALSE,NA,NA,NA
17,NCT00413049,Exclusion,type 2 diabetic patients taking oral anti-diabetic medication had to be on a stable dose for at least 4 weeks prior to visit 1 .,Other,Condition,C0241863,diabetic,FALSE,FALSE,NA,NA,NA
17,NCT00413049,Exclusion,type 2 diabetic patients taking oral anti-diabetic medication had to be on a stable dose for at least 4 weeks prior to visit 1 .,Other,Drug,C1272919,oral,FALSE,FALSE,NA,NA,NA
17,NCT00413049,Exclusion,type 2 diabetic patients taking oral anti-diabetic medication had to be on a stable dose for at least 4 weeks prior to visit 1 .,Other,Drug,C0935929,anti-diabetic,FALSE,FALSE,NA,NA,NA
17,NCT00413049,Exclusion,type 2 diabetic patients taking oral anti-diabetic medication had to be on a stable dose for at least 4 weeks prior to visit 1 .,Other,Other,C1552651,type,FALSE,FALSE,NA,NA,NA
17,NCT00413049,Exclusion,type 2 diabetic patients taking oral anti-diabetic medication had to be on a stable dose for at least 4 weeks prior to visit 1 .,Other,Other,C1547311,stable,FALSE,FALSE,greater_equal 4 weeks,NA,NA
18,NCT00413049,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy was defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive human chorionic gonadotropin ( hcg ) laboratory test ( > 5 miu / ml ) .,Observation,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
18,NCT00413049,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy was defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive human chorionic gonadotropin ( hcg ) laboratory test ( > 5 miu / ml ) .,Observation,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
18,NCT00413049,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy was defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive human chorionic gonadotropin ( hcg ) laboratory test ( > 5 miu / ml ) .,Observation,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
18,NCT00413049,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy was defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive human chorionic gonadotropin ( hcg ) laboratory test ( > 5 miu / ml ) .,Observation,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
18,NCT00413049,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy was defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive human chorionic gonadotropin ( hcg ) laboratory test ( > 5 miu / ml ) .,Observation,Condition,C2828358;C3668831,lactating,FALSE,FALSE,NA,NA,NA
18,NCT00413049,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy was defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive human chorionic gonadotropin ( hcg ) laboratory test ( > 5 miu / ml ) .,Observation,Condition,C0009637,conception,FALSE,FALSE,NA,NA,NA
18,NCT00413049,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy was defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive human chorionic gonadotropin ( hcg ) laboratory test ( > 5 miu / ml ) .,Observation,Condition,C0032961,gestation,FALSE,FALSE,NA,NA,NA
18,NCT00413049,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy was defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive human chorionic gonadotropin ( hcg ) laboratory test ( > 5 miu / ml ) .,Observation,Drug,C1141639;C0018062;C1527152,human chorionic gonadotropin,FALSE,FALSE,NA,NA,NA
18,NCT00413049,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy was defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive human chorionic gonadotropin ( hcg ) laboratory test ( > 5 miu / ml ) .,Observation,Observation,C1514241,positive,FALSE,FALSE,NA,NA,NA
18,NCT00413049,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy was defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive human chorionic gonadotropin ( hcg ) laboratory test ( > 5 miu / ml ) .,Observation,Observation,C0022885,laboratory test,FALSE,FALSE,NA,greater 5,NA
18,NCT00413049,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy was defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive human chorionic gonadotropin ( hcg ) laboratory test ( > 5 miu / ml ) .,Observation,Other,C0032961;C3484365,pregnancy,FALSE,FALSE,NA,NA,NA
18,NCT00413049,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy was defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive human chorionic gonadotropin ( hcg ) laboratory test ( > 5 miu / ml ) .,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
18,NCT00413049,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy was defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive human chorionic gonadotropin ( hcg ) laboratory test ( > 5 miu / ml ) .,Observation,Other,C1549081,termination,FALSE,FALSE,NA,NA,NA
18,NCT00413049,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy was defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive human chorionic gonadotropin ( hcg ) laboratory test ( > 5 miu / ml ) .,Observation,Other,C1141639;C1527152;C1880076,hcg,FALSE,FALSE,NA,NA,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Person,C0025266,male,FALSE,FALSE,NA,NA,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Person,C0025266,male,FALSE,FALSE,NA,NA,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Condition,C0002453;C2219717,amenorrhea,FALSE,FALSE,NA,NA,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Condition,C0002453;C2219717,amenorrhea,FALSE,FALSE,equal 6 months,NA,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Drug,C1706306,iud,FALSE,FALSE,NA,NA,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Drug,C0017243;C0972569,gel,FALSE,FALSE,NA,NA,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Drug,C1705741,sponge,FALSE,FALSE,NA,NA,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Procedure,C0042387,vasectomy,FALSE,FALSE,NA,NA,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Procedure,C0278321,bilateral oophorectomy,FALSE,FALSE,equal 6 weeks,NA,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Procedure,C0020699;C1548863,hysterectomy,FALSE,FALSE,NA,NA,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Procedure,C0700589,contraception,FALSE,FALSE,NA,NA,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Procedure,C0589114,bilateral tubal ligation,FALSE,FALSE,NA,NA,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Procedure,C0042387,vasectomy,FALSE,FALSE,NA,NA,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Observation,C3831118,child-bearing potential,FALSE,FALSE,NA,NA,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Observation,C0857927,serum follicle stimulating hormone,FALSE,FALSE,NA,NA,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Observation,C0428406,fsh levels,FALSE,FALSE,NA,greater 40,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Other,C3539923,orientation,FALSE,FALSE,NA,NA,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Other,C3539107,definition,FALSE,FALSE,equal 12 months,NA,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Other,C0025663,methods,FALSE,FALSE,NA,NA,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Other,C0038288;C0362065;C0038280,sterilization,FALSE,FALSE,NA,NA,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Other,C0025663,methods,FALSE,FALSE,NA,NA,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Other,C0152097;C0011980;C1705368;C1279038,diaphragm,FALSE,FALSE,NA,NA,NA
19,NCT00413049,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means ; unless they met the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone ( fsh ) levels > 40 miu / m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy or were using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ; vasectomy ) ; and double-barrier methods ( any double combination of : intra-uterine device [ iud ] ; male or female condom with spermicidal gel ; diaphragm ; sponge ; cervical cap ),Procedure,Other,C1855179;C0280547;C0278651,cap,FALSE,FALSE,NA,NA,NA
20,NCT00413049,Exclusion,acceptable methods of contraception included total abstinence at the discretion of the investigator in cases where the age ; career ; lifestyle ; or sexual orientation of the patient ensured compliance,Procedure,Procedure,C0700589,contraception,FALSE,FALSE,NA,NA,NA
20,NCT00413049,Exclusion,acceptable methods of contraception included total abstinence at the discretion of the investigator in cases where the age ; career ; lifestyle ; or sexual orientation of the patient ensured compliance,Procedure,Procedure,C0234008,total abstinence,FALSE,FALSE,NA,NA,NA
20,NCT00413049,Exclusion,acceptable methods of contraception included total abstinence at the discretion of the investigator in cases where the age ; career ; lifestyle ; or sexual orientation of the patient ensured compliance,Procedure,Other,C0025663,methods,FALSE,FALSE,NA,NA,NA
20,NCT00413049,Exclusion,acceptable methods of contraception included total abstinence at the discretion of the investigator in cases where the age ; career ; lifestyle ; or sexual orientation of the patient ensured compliance,Procedure,Other,C3539923,orientation,FALSE,FALSE,NA,NA,NA
21,NCT00413049,Exclusion,reliable contraception had to be maintained throughout the study and for 7 days after study drug discontinuation ; periodic abstinence ( eg ; calendar ; ovulation ; symptothermal methods ; post-ovulation methods ) and withdrawal were not acceptable methods of contraception,Condition Occurrence,Condition,C0029965,ovulation,FALSE,FALSE,NA,NA,NA
21,NCT00413049,Exclusion,reliable contraception had to be maintained throughout the study and for 7 days after study drug discontinuation ; periodic abstinence ( eg ; calendar ; ovulation ; symptothermal methods ; post-ovulation methods ) and withdrawal were not acceptable methods of contraception,Condition Occurrence,Condition,C0029965,ovulation,FALSE,FALSE,NA,NA,NA
21,NCT00413049,Exclusion,reliable contraception had to be maintained throughout the study and for 7 days after study drug discontinuation ; periodic abstinence ( eg ; calendar ; ovulation ; symptothermal methods ; post-ovulation methods ) and withdrawal were not acceptable methods of contraception,Condition Occurrence,Condition,C2825032,withdrawal,FALSE,FALSE,NA,NA,NA
21,NCT00413049,Exclusion,reliable contraception had to be maintained throughout the study and for 7 days after study drug discontinuation ; periodic abstinence ( eg ; calendar ; ovulation ; symptothermal methods ; post-ovulation methods ) and withdrawal were not acceptable methods of contraception,Condition Occurrence,Procedure,C0700589,contraception,FALSE,FALSE,equal 7 days,NA,NA
21,NCT00413049,Exclusion,reliable contraception had to be maintained throughout the study and for 7 days after study drug discontinuation ; periodic abstinence ( eg ; calendar ; ovulation ; symptothermal methods ; post-ovulation methods ) and withdrawal were not acceptable methods of contraception,Condition Occurrence,Procedure,C1256761,periodic abstinence,FALSE,FALSE,NA,NA,NA
21,NCT00413049,Exclusion,reliable contraception had to be maintained throughout the study and for 7 days after study drug discontinuation ; periodic abstinence ( eg ; calendar ; ovulation ; symptothermal methods ; post-ovulation methods ) and withdrawal were not acceptable methods of contraception,Condition Occurrence,Procedure,C0700589,contraception,TRUE,FALSE,NA,NA,NA
21,NCT00413049,Exclusion,reliable contraception had to be maintained throughout the study and for 7 days after study drug discontinuation ; periodic abstinence ( eg ; calendar ; ovulation ; symptothermal methods ; post-ovulation methods ) and withdrawal were not acceptable methods of contraception,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
21,NCT00413049,Exclusion,reliable contraception had to be maintained throughout the study and for 7 days after study drug discontinuation ; periodic abstinence ( eg ; calendar ; ovulation ; symptothermal methods ; post-ovulation methods ) and withdrawal were not acceptable methods of contraception,Condition Occurrence,Other,C0457454;C1444662,discontinuation,FALSE,FALSE,NA,NA,NA
21,NCT00413049,Exclusion,reliable contraception had to be maintained throughout the study and for 7 days after study drug discontinuation ; periodic abstinence ( eg ; calendar ; ovulation ; symptothermal methods ; post-ovulation methods ) and withdrawal were not acceptable methods of contraception,Condition Occurrence,Other,C1553746,calendar,FALSE,FALSE,NA,NA,NA
21,NCT00413049,Exclusion,reliable contraception had to be maintained throughout the study and for 7 days after study drug discontinuation ; periodic abstinence ( eg ; calendar ; ovulation ; symptothermal methods ; post-ovulation methods ) and withdrawal were not acceptable methods of contraception,Condition Occurrence,Other,C0025663,methods,FALSE,FALSE,NA,NA,NA
21,NCT00413049,Exclusion,reliable contraception had to be maintained throughout the study and for 7 days after study drug discontinuation ; periodic abstinence ( eg ; calendar ; ovulation ; symptothermal methods ; post-ovulation methods ) and withdrawal were not acceptable methods of contraception,Condition Occurrence,Other,C0025663,methods,TRUE,FALSE,NA,NA,NA
21,NCT00413049,Exclusion,reliable contraception had to be maintained throughout the study and for 7 days after study drug discontinuation ; periodic abstinence ( eg ; calendar ; ovulation ; symptothermal methods ; post-ovulation methods ) and withdrawal were not acceptable methods of contraception,Condition Occurrence,Other,C0025663,methods,FALSE,FALSE,NA,NA,NA
22,NCT00413049,Exclusion,hormonal contraceptive use was disallowed .,Other,NA,NA,NA,NA,NA,NA,NA,NA
23,NCT00413049,Exclusion,history of heart failure grade ii - grade iv according to the new york heart association ( nyha ) classification .,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
23,NCT00413049,Exclusion,history of heart failure grade ii - grade iv according to the new york heart association ( nyha ) classification .,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
23,NCT00413049,Exclusion,history of heart failure grade ii - grade iv according to the new york heart association ( nyha ) classification .,Condition Occurrence,Other,C0441802;C0475270,grade ii,FALSE,FALSE,NA,NA,NA
23,NCT00413049,Exclusion,history of heart failure grade ii - grade iv according to the new york heart association ( nyha ) classification .,Condition Occurrence,Other,C0677510;C0021440;C3496001,iv,FALSE,FALSE,NA,NA,NA
23,NCT00413049,Exclusion,history of heart failure grade ii - grade iv according to the new york heart association ( nyha ) classification .,Condition Occurrence,Other,C1275491,nyha classification,FALSE,FALSE,NA,NA,NA
24,NCT00413049,Exclusion,second degree heart block or third degree heart block with or without a pacemaker .,Condition Occurrence,Condition,C0018794;C0542001;C0037188,heart block,FALSE,FALSE,NA,NA,NA
24,NCT00413049,Exclusion,second degree heart block or third degree heart block with or without a pacemaker .,Condition Occurrence,Condition,C0018794;C0542001;C0037188,heart block,FALSE,FALSE,NA,NA,NA
24,NCT00413049,Exclusion,second degree heart block or third degree heart block with or without a pacemaker .,Condition Occurrence,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
24,NCT00413049,Exclusion,second degree heart block or third degree heart block with or without a pacemaker .,Condition Occurrence,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
24,NCT00413049,Exclusion,second degree heart block or third degree heart block with or without a pacemaker .,Condition Occurrence,Other,C3275122;C1546728,pacemaker,FALSE,FALSE,NA,NA,NA
25,NCT00413049,Exclusion,concomitant potentially life threatening arrhythmia or symptomatic arrhythmia .,Condition Occurrence,Condition,C2826244;C3537125,life threatening,FALSE,FALSE,NA,NA,NA
25,NCT00413049,Exclusion,concomitant potentially life threatening arrhythmia or symptomatic arrhythmia .,Condition Occurrence,Condition,C0003811,arrhythmia,FALSE,FALSE,NA,NA,NA
25,NCT00413049,Exclusion,concomitant potentially life threatening arrhythmia or symptomatic arrhythmia .,Condition Occurrence,Condition,C0003811,arrhythmia,FALSE,FALSE,NA,NA,NA
26,NCT00413049,Exclusion,angina pectoris of any type ; including unstable angina pectoris .,Condition Occurrence,Condition,C0002962;C0577698;C0235467;C0542052;C0010073;C0541777;C0235462,angina pectoris,FALSE,FALSE,NA,NA,NA
26,NCT00413049,Exclusion,angina pectoris of any type ; including unstable angina pectoris .,Condition Occurrence,Condition,C0002965,unstable angina pectoris,FALSE,FALSE,NA,NA,NA
26,NCT00413049,Exclusion,angina pectoris of any type ; including unstable angina pectoris .,Condition Occurrence,Other,C1552651,type,FALSE,FALSE,NA,NA,NA
27,NCT00413049,Exclusion,clinically significant valvular heart disease .,Condition Occurrence,Condition,C0018824;C1963123,valvular heart disease,FALSE,FALSE,NA,NA,NA
28,NCT00413049,Exclusion,evidence of a secondary form of hypertension ; including but not limited to any of the following : coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma ; polycystic kidney disease .,Condition Occurrence,Condition,C0332886,coarctation,FALSE,FALSE,NA,NA,NA
28,NCT00413049,Exclusion,evidence of a secondary form of hypertension ; including but not limited to any of the following : coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma ; polycystic kidney disease .,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
28,NCT00413049,Exclusion,evidence of a secondary form of hypertension ; including but not limited to any of the following : coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma ; polycystic kidney disease .,Condition Occurrence,Condition,C0035065;C1278951,renal artery,FALSE,FALSE,NA,NA,NA
28,NCT00413049,Exclusion,evidence of a secondary form of hypertension ; including but not limited to any of the following : coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma ; polycystic kidney disease .,Condition Occurrence,Condition,C0020428,hyperaldosteronism,FALSE,FALSE,NA,NA,NA
28,NCT00413049,Exclusion,evidence of a secondary form of hypertension ; including but not limited to any of the following : coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma ; polycystic kidney disease .,Condition Occurrence,Condition,C0221406;C0010481,cushing disease,FALSE,FALSE,NA,NA,NA
28,NCT00413049,Exclusion,evidence of a secondary form of hypertension ; including but not limited to any of the following : coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma ; polycystic kidney disease .,Condition Occurrence,Condition,C0022680,polycystic kidney disease,FALSE,FALSE,NA,NA,NA
28,NCT00413049,Exclusion,evidence of a secondary form of hypertension ; including but not limited to any of the following : coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma ; polycystic kidney disease .,Condition Occurrence,Condition,C0031511;C1706920,pheochromocytoma,FALSE,FALSE,NA,NA,NA
28,NCT00413049,Exclusion,evidence of a secondary form of hypertension ; including but not limited to any of the following : coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma ; polycystic kidney disease .,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
28,NCT00413049,Exclusion,evidence of a secondary form of hypertension ; including but not limited to any of the following : coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma ; polycystic kidney disease .,Condition Occurrence,Other,C3542948,limited,TRUE,FALSE,NA,NA,NA
28,NCT00413049,Exclusion,evidence of a secondary form of hypertension ; including but not limited to any of the following : coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma ; polycystic kidney disease .,Condition Occurrence,Other,C0869784;C0003483;C1278934,aorta,FALSE,FALSE,NA,NA,NA
29,NCT00413049,Exclusion,known moderate retinopathy or malignant retinopathy ; defined as : moderate ( retinal signs of hemorrhage ; microaneurysm ; cotton-wool spot ; hard exudates ; or a combination thereof ) or malignancy ( signs of moderate retinopathy plus swelling of the optic disk ) .,Condition Occurrence,Condition,C0035309;C1962966,retinopathy,FALSE,FALSE,NA,NA,NA
29,NCT00413049,Exclusion,known moderate retinopathy or malignant retinopathy ; defined as : moderate ( retinal signs of hemorrhage ; microaneurysm ; cotton-wool spot ; hard exudates ; or a combination thereof ) or malignancy ( signs of moderate retinopathy plus swelling of the optic disk ) .,Condition Occurrence,Condition,C0334590;C1533592,malignant,FALSE,FALSE,NA,NA,NA
29,NCT00413049,Exclusion,known moderate retinopathy or malignant retinopathy ; defined as : moderate ( retinal signs of hemorrhage ; microaneurysm ; cotton-wool spot ; hard exudates ; or a combination thereof ) or malignancy ( signs of moderate retinopathy plus swelling of the optic disk ) .,Condition Occurrence,Condition,C0035309;C1962966,retinopathy,FALSE,FALSE,NA,NA,NA
29,NCT00413049,Exclusion,known moderate retinopathy or malignant retinopathy ; defined as : moderate ( retinal signs of hemorrhage ; microaneurysm ; cotton-wool spot ; hard exudates ; or a combination thereof ) or malignancy ( signs of moderate retinopathy plus swelling of the optic disk ) .,Condition Occurrence,Condition,C0019080,hemorrhage,FALSE,FALSE,NA,NA,NA
29,NCT00413049,Exclusion,known moderate retinopathy or malignant retinopathy ; defined as : moderate ( retinal signs of hemorrhage ; microaneurysm ; cotton-wool spot ; hard exudates ; or a combination thereof ) or malignancy ( signs of moderate retinopathy plus swelling of the optic disk ) .,Condition Occurrence,Condition,C0423410,hard exudates,FALSE,FALSE,NA,NA,NA
29,NCT00413049,Exclusion,known moderate retinopathy or malignant retinopathy ; defined as : moderate ( retinal signs of hemorrhage ; microaneurysm ; cotton-wool spot ; hard exudates ; or a combination thereof ) or malignancy ( signs of moderate retinopathy plus swelling of the optic disk ) .,Condition Occurrence,Condition,C0333101,microaneurysm,FALSE,FALSE,NA,NA,NA
29,NCT00413049,Exclusion,known moderate retinopathy or malignant retinopathy ; defined as : moderate ( retinal signs of hemorrhage ; microaneurysm ; cotton-wool spot ; hard exudates ; or a combination thereof ) or malignancy ( signs of moderate retinopathy plus swelling of the optic disk ) .,Condition Occurrence,Condition,C0006826;C1306459,malignancy,FALSE,FALSE,NA,NA,NA
29,NCT00413049,Exclusion,known moderate retinopathy or malignant retinopathy ; defined as : moderate ( retinal signs of hemorrhage ; microaneurysm ; cotton-wool spot ; hard exudates ; or a combination thereof ) or malignancy ( signs of moderate retinopathy plus swelling of the optic disk ) .,Condition Occurrence,Condition,C0035309;C1962966,retinopathy,FALSE,FALSE,NA,NA,NA
29,NCT00413049,Exclusion,known moderate retinopathy or malignant retinopathy ; defined as : moderate ( retinal signs of hemorrhage ; microaneurysm ; cotton-wool spot ; hard exudates ; or a combination thereof ) or malignancy ( signs of moderate retinopathy plus swelling of the optic disk ) .,Condition Occurrence,Condition,C0038999,swelling,FALSE,FALSE,NA,NA,NA
29,NCT00413049,Exclusion,known moderate retinopathy or malignant retinopathy ; defined as : moderate ( retinal signs of hemorrhage ; microaneurysm ; cotton-wool spot ; hard exudates ; or a combination thereof ) or malignancy ( signs of moderate retinopathy plus swelling of the optic disk ) .,Condition Occurrence,Condition,C0029127,optic disk,FALSE,FALSE,NA,NA,NA
29,NCT00413049,Exclusion,known moderate retinopathy or malignant retinopathy ; defined as : moderate ( retinal signs of hemorrhage ; microaneurysm ; cotton-wool spot ; hard exudates ; or a combination thereof ) or malignancy ( signs of moderate retinopathy plus swelling of the optic disk ) .,Condition Occurrence,Drug,C0440207,cotton-wool,FALSE,FALSE,NA,NA,NA
29,NCT00413049,Exclusion,known moderate retinopathy or malignant retinopathy ; defined as : moderate ( retinal signs of hemorrhage ; microaneurysm ; cotton-wool spot ; hard exudates ; or a combination thereof ) or malignancy ( signs of moderate retinopathy plus swelling of the optic disk ) .,Condition Occurrence,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
29,NCT00413049,Exclusion,known moderate retinopathy or malignant retinopathy ; defined as : moderate ( retinal signs of hemorrhage ; microaneurysm ; cotton-wool spot ; hard exudates ; or a combination thereof ) or malignancy ( signs of moderate retinopathy plus swelling of the optic disk ) .,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
29,NCT00413049,Exclusion,known moderate retinopathy or malignant retinopathy ; defined as : moderate ( retinal signs of hemorrhage ; microaneurysm ; cotton-wool spot ; hard exudates ; or a combination thereof ) or malignancy ( signs of moderate retinopathy plus swelling of the optic disk ) .,Condition Occurrence,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
29,NCT00413049,Exclusion,known moderate retinopathy or malignant retinopathy ; defined as : moderate ( retinal signs of hemorrhage ; microaneurysm ; cotton-wool spot ; hard exudates ; or a combination thereof ) or malignancy ( signs of moderate retinopathy plus swelling of the optic disk ) .,Condition Occurrence,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
30,NCT00413049,Exclusion,evidence of hepatic disease as determined by any one of the following : aspartate aminotransferase ( ast ) or alanine aminotransferase ( alt ) values greater than two times the upper limit of normal at visit 1 ; a history of hepatic encephalopathy ; a history of esophageal varices ; or a history of a portocaval shunt .,Observation,Condition,C0023895,hepatic disease,FALSE,FALSE,NA,NA,NA
30,NCT00413049,Exclusion,evidence of hepatic disease as determined by any one of the following : aspartate aminotransferase ( ast ) or alanine aminotransferase ( alt ) values greater than two times the upper limit of normal at visit 1 ; a history of hepatic encephalopathy ; a history of esophageal varices ; or a history of a portocaval shunt .,Observation,Condition,C0019151,hepatic encephalopathy,FALSE,FALSE,NA,NA,NA
30,NCT00413049,Exclusion,evidence of hepatic disease as determined by any one of the following : aspartate aminotransferase ( ast ) or alanine aminotransferase ( alt ) values greater than two times the upper limit of normal at visit 1 ; a history of hepatic encephalopathy ; a history of esophageal varices ; or a history of a portocaval shunt .,Observation,Condition,C0014867,esophageal varices,FALSE,FALSE,NA,NA,NA
30,NCT00413049,Exclusion,evidence of hepatic disease as determined by any one of the following : aspartate aminotransferase ( ast ) or alanine aminotransferase ( alt ) values greater than two times the upper limit of normal at visit 1 ; a history of hepatic encephalopathy ; a history of esophageal varices ; or a history of a portocaval shunt .,Observation,Procedure,C0032716,portocaval shunt,FALSE,FALSE,NA,NA,NA
30,NCT00413049,Exclusion,evidence of hepatic disease as determined by any one of the following : aspartate aminotransferase ( ast ) or alanine aminotransferase ( alt ) values greater than two times the upper limit of normal at visit 1 ; a history of hepatic encephalopathy ; a history of esophageal varices ; or a history of a portocaval shunt .,Observation,Observation,C0004002;C0201899,aspartate aminotransferase,FALSE,FALSE,NA,NA,NA
30,NCT00413049,Exclusion,evidence of hepatic disease as determined by any one of the following : aspartate aminotransferase ( ast ) or alanine aminotransferase ( alt ) values greater than two times the upper limit of normal at visit 1 ; a history of hepatic encephalopathy ; a history of esophageal varices ; or a history of a portocaval shunt .,Observation,Observation,C0004002,ast,FALSE,FALSE,NA,NA,NA
30,NCT00413049,Exclusion,evidence of hepatic disease as determined by any one of the following : aspartate aminotransferase ( ast ) or alanine aminotransferase ( alt ) values greater than two times the upper limit of normal at visit 1 ; a history of hepatic encephalopathy ; a history of esophageal varices ; or a history of a portocaval shunt .,Observation,Observation,C0001899;C0201836,alanine aminotransferase,FALSE,FALSE,NA,NA,NA
30,NCT00413049,Exclusion,evidence of hepatic disease as determined by any one of the following : aspartate aminotransferase ( ast ) or alanine aminotransferase ( alt ) values greater than two times the upper limit of normal at visit 1 ; a history of hepatic encephalopathy ; a history of esophageal varices ; or a history of a portocaval shunt .,Observation,Observation,C1140170;C2257651,alt,FALSE,FALSE,NA,NA,NA
31,NCT00413049,Exclusion,evidence of renal impairment as determined by anyone of the following : serum creatinine > 1.5 times the upper limit of normal at visit 1 ; a history of dialysis ; or a history of nephrotic syndrome .,Condition Occurrence,Condition,C1565489;C0035078,renal impairment,FALSE,FALSE,NA,NA,NA
31,NCT00413049,Exclusion,evidence of renal impairment as determined by anyone of the following : serum creatinine > 1.5 times the upper limit of normal at visit 1 ; a history of dialysis ; or a history of nephrotic syndrome .,Condition Occurrence,Condition,C0027726,nephrotic syndrome,FALSE,FALSE,NA,NA,NA
31,NCT00413049,Exclusion,evidence of renal impairment as determined by anyone of the following : serum creatinine > 1.5 times the upper limit of normal at visit 1 ; a history of dialysis ; or a history of nephrotic syndrome .,Condition Occurrence,Procedure,C0011946;C0917873,dialysis,FALSE,FALSE,NA,NA,NA
31,NCT00413049,Exclusion,evidence of renal impairment as determined by anyone of the following : serum creatinine > 1.5 times the upper limit of normal at visit 1 ; a history of dialysis ; or a history of nephrotic syndrome .,Condition Occurrence,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,NA,greater 1.5 times the upper limit of normal
32,NCT00413049,Exclusion,history of clinically significant allergies including asthma ; or multiple drug allergies .,Condition Occurrence,Condition,C0020517,allergies,FALSE,FALSE,NA,NA,NA
32,NCT00413049,Exclusion,history of clinically significant allergies including asthma ; or multiple drug allergies .,Condition Occurrence,Condition,C0004096,asthma,FALSE,FALSE,NA,NA,NA
32,NCT00413049,Exclusion,history of clinically significant allergies including asthma ; or multiple drug allergies .,Condition Occurrence,Condition,C0013182,drug allergies,FALSE,FALSE,NA,NA,NA
33,NCT00413049,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel syndrome or active inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Condition,C1378698,distribution,FALSE,FALSE,NA,NA,NA
33,NCT00413049,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel syndrome or active inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Condition,C0504085,excretion,FALSE,FALSE,NA,NA,NA
33,NCT00413049,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel syndrome or active inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Condition,C0025519,metabolism,FALSE,FALSE,NA,NA,NA
33,NCT00413049,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel syndrome or active inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Condition,C0021853,bowel,FALSE,FALSE,NA,NA,NA
33,NCT00413049,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel syndrome or active inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Condition,C0021853,bowel,FALSE,FALSE,lower 12 months,NA,NA
33,NCT00413049,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel syndrome or active inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Condition,C0017152,gastritis,FALSE,FALSE,NA,NA,NA
33,NCT00413049,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel syndrome or active inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Condition,C1559265,gastrointestinal,FALSE,FALSE,NA,NA,NA
33,NCT00413049,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel syndrome or active inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Condition,C0267596,rectal bleeding,FALSE,FALSE,NA,NA,NA
33,NCT00413049,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel syndrome or active inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Condition,C0178879,urinary tract obstruction,FALSE,FALSE,NA,NA,NA
33,NCT00413049,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel syndrome or active inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
33,NCT00413049,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel syndrome or active inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
33,NCT00413049,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel syndrome or active inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
33,NCT00413049,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel syndrome or active inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Procedure,C0399610,gastrointestinal tract surgery,FALSE,FALSE,NA,NA,NA
33,NCT00413049,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel syndrome or active inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Procedure,C0017118,gastrectomy,FALSE,FALSE,NA,NA,NA
33,NCT00413049,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel syndrome or active inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Procedure,C1960832,gastric banding,FALSE,FALSE,NA,NA,NA
33,NCT00413049,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel syndrome or active inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Procedure,C0149701,gastric stapling,FALSE,FALSE,NA,NA,NA
33,NCT00413049,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel syndrome or active inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Procedure,C0017125,gastric bypass,FALSE,FALSE,NA,NA,NA
33,NCT00413049,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel syndrome or active inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Procedure,C0741614,bowel resection,FALSE,FALSE,NA,NA,NA
33,NCT00413049,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel syndrome or active inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Other,C1561579;C1561578,medical,FALSE,FALSE,NA,NA,NA
33,NCT00413049,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel syndrome or active inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
33,NCT00413049,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel syndrome or active inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Other,C3542948,limited,TRUE,FALSE,NA,NA,NA
33,NCT00413049,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel syndrome or active inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Other,C0017164;C2237939,gastroenterostomy,FALSE,FALSE,NA,NA,NA
34,NCT00413049,Exclusion,any surgical condition or medical condition ; which in the opinion of the investigator or the novartis monitor ; placed the patient at higher risk from his / her participation in the study ; or were likely to prevent the patient from complying with the requirement of the study or completing the trial period .,Drug Exposure,Drug,C1310652,novartis,FALSE,FALSE,NA,NA,NA
34,NCT00413049,Exclusion,any surgical condition or medical condition ; which in the opinion of the investigator or the novartis monitor ; placed the patient at higher risk from his / her participation in the study ; or were likely to prevent the patient from complying with the requirement of the study or completing the trial period .,Drug Exposure,Drug,C0309872,prevent,FALSE,FALSE,NA,NA,NA
34,NCT00413049,Exclusion,any surgical condition or medical condition ; which in the opinion of the investigator or the novartis monitor ; placed the patient at higher risk from his / her participation in the study ; or were likely to prevent the patient from complying with the requirement of the study or completing the trial period .,Drug Exposure,Other,C1561579;C1561578,medical,FALSE,FALSE,NA,NA,NA
34,NCT00413049,Exclusion,any surgical condition or medical condition ; which in the opinion of the investigator or the novartis monitor ; placed the patient at higher risk from his / her participation in the study ; or were likely to prevent the patient from complying with the requirement of the study or completing the trial period .,Drug Exposure,Other,C0728873;C0030695,monitor,FALSE,FALSE,NA,NA,NA
35,NCT00413049,Exclusion,volume depletion based on the investigator clinical judgment using vital signs ; skin turgor ; moistness of mucous membranes ; and laboratory values .,Condition Occurrence,Condition,C0546884,volume depletion,FALSE,FALSE,NA,NA,NA
35,NCT00413049,Exclusion,volume depletion based on the investigator clinical judgment using vital signs ; skin turgor ; moistness of mucous membranes ; and laboratory values .,Condition Occurrence,Condition,C0277937,skin turgor,FALSE,FALSE,NA,NA,NA
35,NCT00413049,Exclusion,volume depletion based on the investigator clinical judgment using vital signs ; skin turgor ; moistness of mucous membranes ; and laboratory values .,Condition Occurrence,Condition,C2230150,mucous membranes,FALSE,FALSE,NA,NA,NA
35,NCT00413049,Exclusion,volume depletion based on the investigator clinical judgment using vital signs ; skin turgor ; moistness of mucous membranes ; and laboratory values .,Condition Occurrence,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
35,NCT00413049,Exclusion,volume depletion based on the investigator clinical judgment using vital signs ; skin turgor ; moistness of mucous membranes ; and laboratory values .,Condition Occurrence,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
35,NCT00413049,Exclusion,volume depletion based on the investigator clinical judgment using vital signs ; skin turgor ; moistness of mucous membranes ; and laboratory values .,Condition Occurrence,Other,C0518766;C0150404;C1704752;C0488614,vital signs,FALSE,FALSE,NA,NA,NA
36,NCT00413049,Exclusion,any chronic inflammatory condition requiring chronic anti-inflammatory therapy .,Other,Other,C1547296;C1555457,chronic,FALSE,FALSE,NA,NA,NA
36,NCT00413049,Exclusion,any chronic inflammatory condition requiring chronic anti-inflammatory therapy .,Other,Other,C1547296;C1555457,chronic,FALSE,FALSE,NA,NA,NA
37,NCT00413049,Exclusion,history of malignancy of any organ system ; treated or untreated ; within the past 5 years whether or not there was evidence of local recurrence or metastases ; with the exception of localized basal cell carcinoma of the skin .,Condition Occurrence,Condition,C0006826;C1306459,malignancy,FALSE,FALSE,lower 5 past years,NA,NA
37,NCT00413049,Exclusion,history of malignancy of any organ system ; treated or untreated ; within the past 5 years whether or not there was evidence of local recurrence or metastases ; with the exception of localized basal cell carcinoma of the skin .,Condition Occurrence,Condition,C2825055;C1458156,recurrence,FALSE,FALSE,NA,NA,NA
37,NCT00413049,Exclusion,history of malignancy of any organ system ; treated or untreated ; within the past 5 years whether or not there was evidence of local recurrence or metastases ; with the exception of localized basal cell carcinoma of the skin .,Condition Occurrence,Condition,C0027627;C2939419,metastases,FALSE,FALSE,NA,NA,NA
37,NCT00413049,Exclusion,history of malignancy of any organ system ; treated or untreated ; within the past 5 years whether or not there was evidence of local recurrence or metastases ; with the exception of localized basal cell carcinoma of the skin .,Condition Occurrence,Condition,C0007117,basal cell carcinoma of the skin,TRUE,FALSE,NA,NA,NA
38,NCT00413049,Exclusion,history of drug of alcohol abuse within the last 2 years .,Condition Occurrence,Condition,C0085762,alcohol abuse,FALSE,FALSE,lower 2 last years,NA,NA
38,NCT00413049,Exclusion,history of drug of alcohol abuse within the last 2 years .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
39,NCT00413049,Exclusion,use of other investigational drugs at the time of enrollment ; or within 30 days or 5 half-lives of enrollment ; whichever was longer .,Condition Occurrence,Condition,C2024467,time,FALSE,FALSE,NA,NA,NA
39,NCT00413049,Exclusion,use of other investigational drugs at the time of enrollment ; or within 30 days or 5 half-lives of enrollment ; whichever was longer .,Condition Occurrence,Condition,C0595998,lives,FALSE,FALSE,lower 30 days; equal 5 days,NA,NA
39,NCT00413049,Exclusion,use of other investigational drugs at the time of enrollment ; or within 30 days or 5 half-lives of enrollment ; whichever was longer .,Condition Occurrence,Drug,C0013230,investigational drugs,FALSE,FALSE,NA,NA,NA
39,NCT00413049,Exclusion,use of other investigational drugs at the time of enrollment ; or within 30 days or 5 half-lives of enrollment ; whichever was longer .,Condition Occurrence,Other,C1696073;C1516879,enrollment,FALSE,FALSE,NA,NA,NA
39,NCT00413049,Exclusion,use of other investigational drugs at the time of enrollment ; or within 30 days or 5 half-lives of enrollment ; whichever was longer .,Condition Occurrence,Other,C1696073;C1516879,enrollment,FALSE,FALSE,NA,NA,NA
40,NCT00413049,Exclusion,inability to communicate and comply with all study requirements including the unwillingness or inability to provide informed consent .,Condition Occurrence,Condition,C1845266,inability to communicate,FALSE,FALSE,NA,NA,NA
41,NCT00413049,Exclusion,persons directly involved in the execution of this protocol .,Person,Person,C0027361,persons,FALSE,FALSE,NA,NA,NA
42,NCT00413049,Exclusion,history of non-compliance to medical regimens ; or unwillingness to comply with the study protocol .,Other,Condition,C0376405,non-compliance,FALSE,FALSE,NA,NA,NA
42,NCT00413049,Exclusion,history of non-compliance to medical regimens ; or unwillingness to comply with the study protocol .,Other,Other,C1561579;C1561578,medical,FALSE,FALSE,NA,NA,NA
42,NCT00413049,Exclusion,history of non-compliance to medical regimens ; or unwillingness to comply with the study protocol .,Other,Other,C2945654,regimens,FALSE,FALSE,NA,NA,NA
42,NCT00413049,Exclusion,history of non-compliance to medical regimens ; or unwillingness to comply with the study protocol .,Other,Other,C2348563;C1507394,study protocol,FALSE,FALSE,NA,NA,NA
43,NCT00413049,Exclusion,currently taking prohibited concomitant medications ( s ) listed and inability / unwillingness to discontinue them for the entire study period .,Other,Other,C1706472,discontinue,FALSE,FALSE,NA,NA,NA
44,NCT00413049,Exclusion,any severe disease ; life-threatening disease within the past five years .,Condition Occurrence,Condition,C2826244;C3537125,life-threatening,FALSE,FALSE,NA,NA,NA
44,NCT00413049,Exclusion,any severe disease ; life-threatening disease within the past five years .,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
45,NCT00413049,Exclusion,arm circumference > 42 cm for patients participating in ambulatory blood pressure monitoring ( abpm ),Observation,Condition,C2075184,arm circumference,FALSE,FALSE,NA,greater 42 cm,NA
45,NCT00413049,Exclusion,arm circumference > 42 cm for patients participating in ambulatory blood pressure monitoring ( abpm ),Observation,Observation,C0242876,ambulatory blood pressure monitoring,FALSE,FALSE,NA,NA,NA
1,NCT00413413,Inclusion,male or female outpatients > = 18 years and < 86 years,Person,Person,C0025266,male,FALSE,FALSE,greater_equal 18 years; lower 86 years,NA,NA
1,NCT00413413,Inclusion,male or female outpatients > = 18 years and < 86 years,Person,Person,C0086287,female,FALSE,FALSE,greater_equal 18 years; lower 86 years,NA,NA
2,NCT00413413,Inclusion,patients with essential diastolic hypertension,Condition Occurrence,Condition,C3694763,essential diastolic hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00413413,Inclusion,at visit 1 ; the patient must have mean sitting diastolic blood pressure > = 95 mmhg and < 10 mmhg,Observation,Condition,C1319894,sitting diastolic blood pressure,FALSE,FALSE,NA,greater_equal 95 mmhg; lower 10 mmhg,NA
4,NCT00413413,Inclusion,patients treated with antihypertensive medication must have a mean sitting diastolic blood pressure < 100 mmhg,Drug Exposure,Condition,C1319894,sitting diastolic blood pressure,FALSE,FALSE,NA,lower 100 mmhg,NA
4,NCT00413413,Inclusion,patients treated with antihypertensive medication must have a mean sitting diastolic blood pressure < 100 mmhg,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
5,NCT00413413,Inclusion,at visit 2 ; patients must have a mean sitting diastolic blood pressure of > = 95 mmhg and < 100 mmhg,Observation,Condition,C1319894,sitting diastolic blood pressure,FALSE,FALSE,NA,greater_equal 95 mmhg; lower 100 mmhg,NA
6,NCT00413413,Inclusion,at visit 3 ; patients must have a mean sitting diastolic blood pressure of > = 90 mmhg and < 110 mmhg,Observation,Condition,C1319894,sitting diastolic blood pressure,FALSE,FALSE,NA,greater_equal 90 mmhg; lower 110 mmhg,NA
7,NCT00413413,Exclusion,severe hypertension > = 180 / 110 mmhg,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,greater_equal 180 mmhg; greater_equal 110 mmhg,NA
7,NCT00413413,Exclusion,severe hypertension > = 180 / 110 mmhg,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
8,NCT00413413,Exclusion,known or suspected contraindications ; including a history of allergy or hypersensitivity to valsartan or amlodipine or to other drugs with similar chemical structures,Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,NA
8,NCT00413413,Exclusion,known or suspected contraindications ; including a history of allergy or hypersensitivity to valsartan or amlodipine or to other drugs with similar chemical structures,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
8,NCT00413413,Exclusion,known or suspected contraindications ; including a history of allergy or hypersensitivity to valsartan or amlodipine or to other drugs with similar chemical structures,Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
8,NCT00413413,Exclusion,known or suspected contraindications ; including a history of allergy or hypersensitivity to valsartan or amlodipine or to other drugs with similar chemical structures,Drug Exposure,Other,C0489531;C0718579;C3542994;C3539909;C1314973;C1547315;C1611280,allergy,FALSE,FALSE,NA,NA,NA
8,NCT00413413,Exclusion,known or suspected contraindications ; including a history of allergy or hypersensitivity to valsartan or amlodipine or to other drugs with similar chemical structures,Drug Exposure,Other,C0220806;C3272558,chemical,FALSE,FALSE,NA,NA,NA
9,NCT00413413,Exclusion,inability to discontinue all prior antihypertensive medications safely for a maximum period of up to 28 days prior to visit 2,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,lower_equal 28 days,NA,NA
9,NCT00413413,Exclusion,inability to discontinue all prior antihypertensive medications safely for a maximum period of up to 28 days prior to visit 2,Drug Exposure,Other,C1706472,discontinue,FALSE,FALSE,NA,NA,NA
10,NCT00413413,Exclusion,history of hypertensive encephalopathy ; cerebrovascular accident or transient ischemic attack ; myocardial infarction or other types of revascularization,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
10,NCT00413413,Exclusion,history of hypertensive encephalopathy ; cerebrovascular accident or transient ischemic attack ; myocardial infarction or other types of revascularization,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,NA,NA,NA
10,NCT00413413,Exclusion,history of hypertensive encephalopathy ; cerebrovascular accident or transient ischemic attack ; myocardial infarction or other types of revascularization,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
10,NCT00413413,Exclusion,history of hypertensive encephalopathy ; cerebrovascular accident or transient ischemic attack ; myocardial infarction or other types of revascularization,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
11,NCT00413413,Exclusion,malignant hypertension,Condition Occurrence,Condition,C0020540;C0024588,malignant hypertension,FALSE,FALSE,NA,NA,NA
12,NCT00413413,Exclusion,all patients with type i diabetes and those patients with type 2 diabetes who are not well controlled based on the investigator clinical judgment,Condition Occurrence,Condition,C0011854,type i diabetes,FALSE,FALSE,NA,NA,NA
12,NCT00413413,Exclusion,all patients with type i diabetes and those patients with type 2 diabetes who are not well controlled based on the investigator clinical judgment,Condition Occurrence,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
12,NCT00413413,Exclusion,all patients with type i diabetes and those patients with type 2 diabetes who are not well controlled based on the investigator clinical judgment,Condition Occurrence,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
13,NCT00413413,Exclusion,pregnant women or nursing women,Person,Person,C0033011,pregnant women,FALSE,FALSE,NA,NA,NA
13,NCT00413413,Exclusion,pregnant women or nursing women,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
13,NCT00413413,Exclusion,pregnant women or nursing women,Person,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
14,NCT00413413,Exclusion,history of heart failure,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
15,NCT00413413,Exclusion,angina pectoris,Condition Occurrence,Condition,C0002962;C0577698;C0235467;C0542052;C0010073;C0541777;C0235462,angina pectoris,FALSE,FALSE,NA,NA,NA
16,NCT00413413,Exclusion,second degree heart block or third degree heart block,Observation,Condition,C0018794;C0542001;C0037188,heart block,FALSE,FALSE,NA,NA,NA
16,NCT00413413,Exclusion,second degree heart block or third degree heart block,Observation,Condition,C0018794;C0542001;C0037188,heart block,FALSE,FALSE,NA,NA,NA
16,NCT00413413,Exclusion,second degree heart block or third degree heart block,Observation,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
16,NCT00413413,Exclusion,second degree heart block or third degree heart block,Observation,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
17,NCT00413413,Exclusion,life threatening or symptomatic arrhythmias,Condition Occurrence,Condition,C2826244;C3537125,life threatening,FALSE,FALSE,NA,NA,NA
17,NCT00413413,Exclusion,life threatening or symptomatic arrhythmias,Condition Occurrence,Condition,C0003811,arrhythmias,FALSE,FALSE,NA,NA,NA
18,NCT00413413,Exclusion,clinically significant valvular heart disease,Condition Occurrence,Condition,C0018824;C1963123,valvular heart disease,FALSE,FALSE,NA,NA,NA
19,NCT00413413,Exclusion,evidence of a secondary form of hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
20,NCT00413413,Exclusion,known or moderate malignant retinopathy,Condition Occurrence,Condition,C0334590;C1533592,malignant,FALSE,FALSE,NA,NA,NA
20,NCT00413413,Exclusion,known or moderate malignant retinopathy,Condition Occurrence,Condition,C0035309;C1962966,retinopathy,FALSE,FALSE,NA,NA,NA
20,NCT00413413,Exclusion,known or moderate malignant retinopathy,Condition Occurrence,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
21,NCT00413413,Exclusion,evidence of hepatic disease,Condition Occurrence,Condition,C0023895,hepatic disease,FALSE,FALSE,NA,NA,NA
22,NCT00413413,Exclusion,evidence of renal impairment,Condition Occurrence,Condition,C1565489;C0035078,renal impairment,FALSE,FALSE,NA,NA,NA
23,NCT00413413,Exclusion,other protocol-defined may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00425997,Inclusion,male or female patients 18 years of age or older,Person,Person,C0025266,male,FALSE,FALSE,equal 18 years,NA,NA
1,NCT00425997,Inclusion,male or female patients 18 years of age or older,Person,Observation,C0150905,female patients,FALSE,FALSE,equal 18 years,NA,NA
2,NCT00425997,Inclusion,diagnosed of having hypertension ; defined as a mean seated systolic bp > = 160 mmhg ( stage 2 hypertension ),Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00425997,Inclusion,diagnosed of having hypertension ; defined as a mean seated systolic bp > = 160 mmhg ( stage 2 hypertension ),Observation,Observation,C0871470,systolic bp,FALSE,FALSE,NA,greater_equal 160 mmhg,NA
2,NCT00425997,Inclusion,diagnosed of having hypertension ; defined as a mean seated systolic bp > = 160 mmhg ( stage 2 hypertension ),Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00425997,Inclusion,diagnosed of having hypertension ; defined as a mean seated systolic bp > = 160 mmhg ( stage 2 hypertension ),Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
3,NCT00425997,Exclusion,symptomatic hypertension or severe hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00425997,Exclusion,symptomatic hypertension or severe hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00425997,Exclusion,symptomatic hypertension or severe hypertension,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
4,NCT00425997,Exclusion,patients treated with more than 2 antihypertensive medications,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,greater 2,NA
5,NCT00425997,Exclusion,clinically known or suspected history of secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
6,NCT00425997,Exclusion,myocardial infarction ; stroke ; transient ischemic attack ; cardiovascular revascularizationgioplasty in last 6 months,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,lower_equal 6 last months,NA,NA
6,NCT00425997,Exclusion,myocardial infarction ; stroke ; transient ischemic attack ; cardiovascular revascularizationgioplasty in last 6 months,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
7,NCT00425997,Exclusion,diagnosis of heart failure ( nyha class ii-,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
7,NCT00425997,Exclusion,diagnosis of heart failure ( nyha class ii-,Condition Occurrence,Condition,C1882083,nyha class,FALSE,FALSE,NA,NA,NA
8,NCT00425997,Exclusion,chronic renal hepatic disease or severe hepatic disease,Condition Occurrence,Condition,C0023895,hepatic disease,FALSE,FALSE,NA,NA,NA
8,NCT00425997,Exclusion,chronic renal hepatic disease or severe hepatic disease,Condition Occurrence,Condition,C0023895,hepatic disease,FALSE,FALSE,NA,NA,NA
8,NCT00425997,Exclusion,chronic renal hepatic disease or severe hepatic disease,Condition Occurrence,Other,C1547296;C1555457,chronic,FALSE,FALSE,NA,NA,NA
8,NCT00425997,Exclusion,chronic renal hepatic disease or severe hepatic disease,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
1,NCT00439738,Inclusion,40 years of age or older,Person,NA,NA,NA,NA,NA,NA,NA,NA
2,NCT00439738,Inclusion,moderate high blood or severe high blood pressure defined as systolic blood pressure ( the top number ) greater than or equal to 150 mmhg and diastolic blood pressure ( the bottom number ) less then 110 mmhg,Observation,Procedure,C0392535,top,FALSE,FALSE,NA,greater_equal 150 mmhg,NA
2,NCT00439738,Inclusion,moderate high blood or severe high blood pressure defined as systolic blood pressure ( the top number ) greater than or equal to 150 mmhg and diastolic blood pressure ( the bottom number ) less then 110 mmhg,Observation,Observation,C2700149,high,FALSE,FALSE,NA,NA,NA
2,NCT00439738,Inclusion,moderate high blood or severe high blood pressure defined as systolic blood pressure ( the top number ) greater than or equal to 150 mmhg and diastolic blood pressure ( the bottom number ) less then 110 mmhg,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,NA,NA
2,NCT00439738,Inclusion,moderate high blood or severe high blood pressure defined as systolic blood pressure ( the top number ) greater than or equal to 150 mmhg and diastolic blood pressure ( the bottom number ) less then 110 mmhg,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,equal 110 mmhg,NA
2,NCT00439738,Inclusion,moderate high blood or severe high blood pressure defined as systolic blood pressure ( the top number ) greater than or equal to 150 mmhg and diastolic blood pressure ( the bottom number ) less then 110 mmhg,Observation,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
2,NCT00439738,Inclusion,moderate high blood or severe high blood pressure defined as systolic blood pressure ( the top number ) greater than or equal to 150 mmhg and diastolic blood pressure ( the bottom number ) less then 110 mmhg,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
2,NCT00439738,Inclusion,moderate high blood or severe high blood pressure defined as systolic blood pressure ( the top number ) greater than or equal to 150 mmhg and diastolic blood pressure ( the bottom number ) less then 110 mmhg,Observation,Other,C0020538;C2926615,high blood pressure,FALSE,FALSE,NA,NA,NA
2,NCT00439738,Inclusion,moderate high blood or severe high blood pressure defined as systolic blood pressure ( the top number ) greater than or equal to 150 mmhg and diastolic blood pressure ( the bottom number ) less then 110 mmhg,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
3,NCT00439738,Inclusion,central ( abdominal ) obesity,Drug Exposure,Condition,C0311277,abdominal obesity,FALSE,FALSE,NA,NA,NA
3,NCT00439738,Inclusion,central ( abdominal ) obesity,Drug Exposure,Drug,C0719205,central,FALSE,FALSE,NA,NA,NA
4,NCT00439738,Exclusion,systolic blood pressure ( the top number ) greater than or equal to 180 mmhg blood pressure and diastolic blood pressure ( the bottom number ) greater than or equal to 110 mmhg,Observation,Procedure,C0392535,top,FALSE,FALSE,NA,NA,NA
4,NCT00439738,Exclusion,systolic blood pressure ( the top number ) greater than or equal to 180 mmhg blood pressure and diastolic blood pressure ( the bottom number ) greater than or equal to 110 mmhg,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,NA,NA
4,NCT00439738,Exclusion,systolic blood pressure ( the top number ) greater than or equal to 180 mmhg blood pressure and diastolic blood pressure ( the bottom number ) greater than or equal to 110 mmhg,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,greater_equal 180 mmhg; greater_equal 110 mmhg,NA
4,NCT00439738,Exclusion,systolic blood pressure ( the top number ) greater than or equal to 180 mmhg blood pressure and diastolic blood pressure ( the bottom number ) greater than or equal to 110 mmhg,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater_equal 180 mmhg; greater_equal 110 mmhg,NA
5,NCT00439738,Exclusion,currently taking more then 3 medications to treat high blood pressure,Observation,Other,C0020538;C2926615,high blood pressure,FALSE,FALSE,NA,equal 3,NA
6,NCT00439738,Exclusion,inability to stop all current blood pressure medications if any up to 4 weeks,Drug Exposure,Drug,C0723457,stop,FALSE,FALSE,NA,NA,NA
6,NCT00439738,Exclusion,inability to stop all current blood pressure medications if any up to 4 weeks,Drug Exposure,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,lower_equal 4 weeks,NA,NA
7,NCT00439738,Exclusion,history of type 1 diabetes or type 2 diabetes,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
7,NCT00439738,Exclusion,history of type 1 diabetes or type 2 diabetes,Condition Occurrence,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
8,NCT00439738,Exclusion,history of stroke ; mini-stroke ( transient ischemic attack ) or heart attack within the last 6 months,Condition Occurrence,Condition,C1456577,mini-stroke,FALSE,FALSE,NA,NA,NA
8,NCT00439738,Exclusion,history of stroke ; mini-stroke ( transient ischemic attack ) or heart attack within the last 6 months,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,NA,NA,NA
8,NCT00439738,Exclusion,history of stroke ; mini-stroke ( transient ischemic attack ) or heart attack within the last 6 months,Condition Occurrence,Condition,C0027051,heart attack,FALSE,FALSE,lower 6 last months,NA,NA
9,NCT00439738,Exclusion,history of or current diagnosis of congestive heart failure,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
10,NCT00439738,Exclusion,history of cancer within the past 5 years with the exception of localized basal cell carcinoma or squamous cell carcinoma,Condition Occurrence,Condition,C0007137;C1302853,squamous cell carcinoma,TRUE,FALSE,NA,NA,NA
10,NCT00439738,Exclusion,history of cancer within the past 5 years with the exception of localized basal cell carcinoma or squamous cell carcinoma,Condition Occurrence,Other,C0260515;C2707253,cancer,FALSE,FALSE,lower 5 past years,NA,NA
10,NCT00439738,Exclusion,history of cancer within the past 5 years with the exception of localized basal cell carcinoma or squamous cell carcinoma,Condition Occurrence,Other,C0007117;C3540686;C1547219,basal cell carcinoma,TRUE,FALSE,NA,NA,NA
11,NCT00439738,Exclusion,women who are pregnant or nursing,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
11,NCT00439738,Exclusion,women who are pregnant or nursing,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
11,NCT00439738,Exclusion,women who are pregnant or nursing,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
12,NCT00439738,Exclusion,alcohol or drug abuse within the last 2 years,Drug Exposure,Condition,C0013146,drug abuse,FALSE,FALSE,lower 2 last years,NA,NA
12,NCT00439738,Exclusion,alcohol or drug abuse within the last 2 years,Drug Exposure,Other,C0001975;C0001962;C1547288,alcohol,FALSE,FALSE,lower 2 last years,NA,NA
13,NCT00439738,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00454662,Inclusion,outpatients aged 65 years or older ; and less than 85 years ( at the time of informed consent ) ; regardless of sex,Condition Occurrence,Person,C0001792,aged,FALSE,FALSE,greater_equal 65 years; lower 85 years,NA,NA
1,NCT00454662,Inclusion,outpatients aged 65 years or older ; and less than 85 years ( at the time of informed consent ) ; regardless of sex,Condition Occurrence,Condition,C2024467,time,FALSE,FALSE,NA,NA,NA
1,NCT00454662,Inclusion,outpatients aged 65 years or older ; and less than 85 years ( at the time of informed consent ) ; regardless of sex,Condition Occurrence,Other,C1522384;C1879943,sex,FALSE,FALSE,NA,NA,NA
2,NCT00454662,Inclusion,systolic blood pressure ( sbp ) > = 140 mmhg blood pressure or diastolic blood pressure ( dbp ) > = 90 mmhg in a sitting position on two consecutive measurements at clinic during use of 1 or more antihypertensive medications .,Observation,Condition,C0277814,sitting position,FALSE,FALSE,NA,NA,NA
2,NCT00454662,Inclusion,systolic blood pressure ( sbp ) > = 140 mmhg blood pressure or diastolic blood pressure ( dbp ) > = 90 mmhg in a sitting position on two consecutive measurements at clinic during use of 1 or more antihypertensive medications .,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,greater_equal 1,NA
2,NCT00454662,Inclusion,systolic blood pressure ( sbp ) > = 140 mmhg blood pressure or diastolic blood pressure ( dbp ) > = 90 mmhg in a sitting position on two consecutive measurements at clinic during use of 1 or more antihypertensive medications .,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,NA,NA
2,NCT00454662,Inclusion,systolic blood pressure ( sbp ) > = 140 mmhg blood pressure or diastolic blood pressure ( dbp ) > = 90 mmhg in a sitting position on two consecutive measurements at clinic during use of 1 or more antihypertensive medications .,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,NA,NA
2,NCT00454662,Inclusion,systolic blood pressure ( sbp ) > = 140 mmhg blood pressure or diastolic blood pressure ( dbp ) > = 90 mmhg in a sitting position on two consecutive measurements at clinic during use of 1 or more antihypertensive medications .,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,greater_equal 140 mmhg,NA
2,NCT00454662,Inclusion,systolic blood pressure ( sbp ) > = 140 mmhg blood pressure or diastolic blood pressure ( dbp ) > = 90 mmhg in a sitting position on two consecutive measurements at clinic during use of 1 or more antihypertensive medications .,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater_equal 140 mmhg,NA
2,NCT00454662,Inclusion,systolic blood pressure ( sbp ) > = 140 mmhg blood pressure or diastolic blood pressure ( dbp ) > = 90 mmhg in a sitting position on two consecutive measurements at clinic during use of 1 or more antihypertensive medications .,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 90 mmhg,NA
3,NCT00454662,Inclusion,systolic blood pressure ( sbp ) > = 160 mmhg or diastolic blood pressure ( dbp ) > = 100 mmhg in a sitting position on two consecutive measurements at clinic without antihypertensive medication .,Observation,Condition,C0277814,sitting position,FALSE,FALSE,NA,NA,NA
3,NCT00454662,Inclusion,systolic blood pressure ( sbp ) > = 160 mmhg or diastolic blood pressure ( dbp ) > = 100 mmhg in a sitting position on two consecutive measurements at clinic without antihypertensive medication .,Observation,Drug,C0003364,antihypertensive,TRUE,FALSE,NA,NA,NA
3,NCT00454662,Inclusion,systolic blood pressure ( sbp ) > = 160 mmhg or diastolic blood pressure ( dbp ) > = 100 mmhg in a sitting position on two consecutive measurements at clinic without antihypertensive medication .,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,NA,NA
3,NCT00454662,Inclusion,systolic blood pressure ( sbp ) > = 160 mmhg or diastolic blood pressure ( dbp ) > = 100 mmhg in a sitting position on two consecutive measurements at clinic without antihypertensive medication .,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 160 mmhg,NA
3,NCT00454662,Inclusion,systolic blood pressure ( sbp ) > = 160 mmhg or diastolic blood pressure ( dbp ) > = 100 mmhg in a sitting position on two consecutive measurements at clinic without antihypertensive medication .,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,NA,NA
3,NCT00454662,Inclusion,systolic blood pressure ( sbp ) > = 160 mmhg or diastolic blood pressure ( dbp ) > = 100 mmhg in a sitting position on two consecutive measurements at clinic without antihypertensive medication .,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 100 mmhg,NA
4,NCT00454662,Inclusion,require at least one of the following medical history or risk factors,Condition Occurrence,Condition,C0262926,medical history,FALSE,FALSE,NA,NA,NA
4,NCT00454662,Inclusion,require at least one of the following medical history or risk factors,Condition Occurrence,Condition,C0455624,risk factors,FALSE,FALSE,NA,NA,NA
5,NCT00454662,Inclusion,medical history,Condition Occurrence,Condition,C0262926,medical history,FALSE,FALSE,NA,NA,NA
6,NCT00454662,Inclusion,cerebrovascular accident : cerebral infarction ; brain hemorrhage ; subarachnoid hemorrhage ( 6 months or more prior to registration ),Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
6,NCT00454662,Inclusion,cerebrovascular accident : cerebral infarction ; brain hemorrhage ; subarachnoid hemorrhage ( 6 months or more prior to registration ),Condition Occurrence,Condition,C0007785;C0038454,cerebral infarction,FALSE,FALSE,greater_equal 6 months,NA,NA
6,NCT00454662,Inclusion,cerebrovascular accident : cerebral infarction ; brain hemorrhage ; subarachnoid hemorrhage ( 6 months or more prior to registration ),Condition Occurrence,Condition,C0038525,subarachnoid hemorrhage,FALSE,FALSE,greater_equal 6 months,NA,NA
6,NCT00454662,Inclusion,cerebrovascular accident : cerebral infarction ; brain hemorrhage ; subarachnoid hemorrhage ( 6 months or more prior to registration ),Condition Occurrence,Condition,C0553692;C2937358,brain hemorrhage,FALSE,FALSE,greater_equal 6 months,NA,NA
6,NCT00454662,Inclusion,cerebrovascular accident : cerebral infarction ; brain hemorrhage ; subarachnoid hemorrhage ( 6 months or more prior to registration ),Condition Occurrence,Procedure,C1514821,registration,FALSE,FALSE,NA,NA,NA
7,NCT00454662,Inclusion,myocardial infarction ; coronary revascularization ( pci or cabg ) ( 6 months or more prior to registration ),Procedure,Procedure,C0877341,coronary revascularization,FALSE,FALSE,NA,NA,NA
7,NCT00454662,Inclusion,myocardial infarction ; coronary revascularization ( pci or cabg ) ( 6 months or more prior to registration ),Procedure,Procedure,C1514496;C1532338,pci,FALSE,FALSE,greater_equal 6 months,NA,NA
7,NCT00454662,Inclusion,myocardial infarction ; coronary revascularization ( pci or cabg ) ( 6 months or more prior to registration ),Procedure,Procedure,C0010055,cabg,FALSE,FALSE,greater_equal 6 months,NA,NA
7,NCT00454662,Inclusion,myocardial infarction ; coronary revascularization ( pci or cabg ) ( 6 months or more prior to registration ),Procedure,Procedure,C1514821,registration,FALSE,FALSE,NA,NA,NA
7,NCT00454662,Inclusion,myocardial infarction ; coronary revascularization ( pci or cabg ) ( 6 months or more prior to registration ),Procedure,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
8,NCT00454662,Inclusion,angina pectoris ( except for the patients having history of hospitalization within 6 months prior to registration ),Procedure,Condition,C0002962;C0577698;C0235467;C0542052;C0010073;C0541777;C0235462,angina pectoris,FALSE,FALSE,NA,NA,NA
8,NCT00454662,Inclusion,angina pectoris ( except for the patients having history of hospitalization within 6 months prior to registration ),Procedure,Procedure,C0019993,hospitalization,FALSE,FALSE,lower 6 months,NA,NA
8,NCT00454662,Inclusion,angina pectoris ( except for the patients having history of hospitalization within 6 months prior to registration ),Procedure,Procedure,C1514821,registration,FALSE,FALSE,NA,NA,NA
9,NCT00454662,Inclusion,risk factors,Condition Occurrence,Condition,C0455624,risk factors,FALSE,FALSE,NA,NA,NA
10,NCT00454662,Inclusion,male,Person,Person,C0025266,male,FALSE,FALSE,NA,NA,NA
11,NCT00454662,Inclusion,current diabetes mellitus ; fasting glucose > = 110 mg / dl or postprandial glucose > = 140 mg / dl,Drug Exposure,Condition,C0011849,diabetes mellitus,FALSE,FALSE,NA,NA,NA
11,NCT00454662,Inclusion,current diabetes mellitus ; fasting glucose > = 110 mg / dl or postprandial glucose > = 140 mg / dl,Drug Exposure,Observation,C0017725;C0337438,glucose,FALSE,FALSE,NA,NA,greater_equal 110 mg/dl; greater_equal 140 mg/dl
11,NCT00454662,Inclusion,current diabetes mellitus ; fasting glucose > = 110 mg / dl or postprandial glucose > = 140 mg / dl,Drug Exposure,Observation,C0017725;C0337438,glucose,FALSE,FALSE,NA,NA,greater_equal 140 mg/dl
11,NCT00454662,Inclusion,current diabetes mellitus ; fasting glucose > = 110 mg / dl or postprandial glucose > = 140 mg / dl,Drug Exposure,Other,C0015663;C1550565,fasting,FALSE,FALSE,NA,NA,NA
12,NCT00454662,Inclusion,hypercholesterolemia ( total cholesterol > = 260 mg / dl ),Drug Exposure,Condition,C0020443;C1522133,hypercholesterolemia,FALSE,FALSE,NA,NA,NA
12,NCT00454662,Inclusion,hypercholesterolemia ( total cholesterol > = 260 mg / dl ),Drug Exposure,Other,C0543421;C1445957;C0201950,total cholesterol,FALSE,FALSE,NA,NA,greater_equal 260 mg/dl
13,NCT00454662,Inclusion,low hdl cholesterolemia ( hdl-c < 40 mg / dl ),Condition Occurrence,Condition,C0151691,low hdl,FALSE,FALSE,NA,NA,NA
13,NCT00454662,Inclusion,low hdl cholesterolemia ( hdl-c < 40 mg / dl ),Condition Occurrence,Condition,C1392499,cholesterolemia,FALSE,FALSE,NA,NA,NA
13,NCT00454662,Inclusion,low hdl cholesterolemia ( hdl-c < 40 mg / dl ),Condition Occurrence,Condition,C1704429,hdl-c,FALSE,FALSE,NA,NA,lower 40 mg/dl
14,NCT00454662,Inclusion,microalbuminuria ( albumin / cr > = 30 mg / gcr ) or proteinuria ( protein > = 1 + ),Drug Exposure,Condition,C0730345,microalbuminuria,FALSE,FALSE,NA,NA,NA
14,NCT00454662,Inclusion,microalbuminuria ( albumin / cr > = 30 mg / gcr ) or proteinuria ( protein > = 1 + ),Drug Exposure,Condition,C0033687;C1279888;C1962972,proteinuria,FALSE,FALSE,NA,greater_equal 1 protein,NA
14,NCT00454662,Inclusion,microalbuminuria ( albumin / cr > = 30 mg / gcr ) or proteinuria ( protein > = 1 + ),Drug Exposure,Other,C0001924;C0201838,albumin,FALSE,FALSE,NA,NA,NA
14,NCT00454662,Inclusion,microalbuminuria ( albumin / cr > = 30 mg / gcr ) or proteinuria ( protein > = 1 + ),Drug Exposure,Other,C2348261;C1707506;C0152369,cr,FALSE,FALSE,NA,NA,greater_equal 30 mg
15,NCT00454662,Inclusion,left ventricular hypertrophy ( st-t change in the ecg and sv1+rv5 > = 35 mm ; or left ventricular mass index : male > = 125 g / m2 ; female > = 110 g / m2 ),Observation,Person,C0025266,male,FALSE,FALSE,NA,NA,NA
15,NCT00454662,Inclusion,left ventricular hypertrophy ( st-t change in the ecg and sv1+rv5 > = 35 mm ; or left ventricular mass index : male > = 125 g / m2 ; female > = 110 g / m2 ),Observation,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
15,NCT00454662,Inclusion,left ventricular hypertrophy ( st-t change in the ecg and sv1+rv5 > = 35 mm ; or left ventricular mass index : male > = 125 g / m2 ; female > = 110 g / m2 ),Observation,Condition,C0228365,st-t,FALSE,FALSE,NA,NA,NA
15,NCT00454662,Inclusion,left ventricular hypertrophy ( st-t change in the ecg and sv1+rv5 > = 35 mm ; or left ventricular mass index : male > = 125 g / m2 ; female > = 110 g / m2 ),Observation,Condition,C0455825,left ventricular mass,FALSE,FALSE,NA,NA,NA
15,NCT00454662,Inclusion,left ventricular hypertrophy ( st-t change in the ecg and sv1+rv5 > = 35 mm ; or left ventricular mass index : male > = 125 g / m2 ; female > = 110 g / m2 ),Observation,Observation,C0918012,index,FALSE,FALSE,NA,NA,NA
15,NCT00454662,Inclusion,left ventricular hypertrophy ( st-t change in the ecg and sv1+rv5 > = 35 mm ; or left ventricular mass index : male > = 125 g / m2 ; female > = 110 g / m2 ),Observation,Other,C0149721;C0232306;C3484363,left ventricular hypertrophy,FALSE,FALSE,NA,NA,NA
15,NCT00454662,Inclusion,left ventricular hypertrophy ( st-t change in the ecg and sv1+rv5 > = 35 mm ; or left ventricular mass index : male > = 125 g / m2 ; female > = 110 g / m2 ),Observation,Other,C1623258;C0018064,ecg,FALSE,FALSE,NA,greater_equal 35 mm,NA
16,NCT00454662,Exclusion,secondary hypertension or malignant hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
16,NCT00454662,Exclusion,secondary hypertension or malignant hypertension,Condition Occurrence,Condition,C0020540;C0024588,malignant hypertension,FALSE,FALSE,NA,NA,NA
17,NCT00454662,Exclusion,history of cerebrovascular accident ( including tia ) or myocardial infarction within 6 months before registration,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
17,NCT00454662,Exclusion,history of cerebrovascular accident ( including tia ) or myocardial infarction within 6 months before registration,Condition Occurrence,Condition,C0917805,tia,FALSE,FALSE,NA,NA,NA
17,NCT00454662,Exclusion,history of cerebrovascular accident ( including tia ) or myocardial infarction within 6 months before registration,Condition Occurrence,Procedure,C1514821,registration,FALSE,FALSE,NA,NA,NA
17,NCT00454662,Exclusion,history of cerebrovascular accident ( including tia ) or myocardial infarction within 6 months before registration,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,lower 6 months,NA,NA
18,NCT00454662,Exclusion,percutaneous coronary intervention ( pci ) or coronary artery bypass grafting ( cabg ) done within 6 months before registration or scheduled,Procedure,Procedure,C1532338,percutaneous coronary intervention,FALSE,FALSE,NA,NA,NA
18,NCT00454662,Exclusion,percutaneous coronary intervention ( pci ) or coronary artery bypass grafting ( cabg ) done within 6 months before registration or scheduled,Procedure,Procedure,C1514496;C1532338,pci,FALSE,FALSE,NA,NA,NA
18,NCT00454662,Exclusion,percutaneous coronary intervention ( pci ) or coronary artery bypass grafting ( cabg ) done within 6 months before registration or scheduled,Procedure,Procedure,C0010055,coronary artery bypass grafting,FALSE,FALSE,NA,NA,NA
18,NCT00454662,Exclusion,percutaneous coronary intervention ( pci ) or coronary artery bypass grafting ( cabg ) done within 6 months before registration or scheduled,Procedure,Procedure,C0010055,cabg,FALSE,FALSE,lower 6 months,NA,NA
18,NCT00454662,Exclusion,percutaneous coronary intervention ( pci ) or coronary artery bypass grafting ( cabg ) done within 6 months before registration or scheduled,Procedure,Procedure,C1514821,registration,FALSE,FALSE,NA,NA,NA
19,NCT00454662,Exclusion,history of hospitalization for angina pectoris or heart failure within 6 months before registration,Procedure,Condition,C0002962;C0577698;C0235467;C0542052;C0010073;C0541777;C0235462,angina pectoris,FALSE,FALSE,lower 6 months,NA,NA
19,NCT00454662,Exclusion,history of hospitalization for angina pectoris or heart failure within 6 months before registration,Procedure,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,lower 6 months,NA,NA
19,NCT00454662,Exclusion,history of hospitalization for angina pectoris or heart failure within 6 months before registration,Procedure,Procedure,C0019993,hospitalization,FALSE,FALSE,NA,NA,NA
19,NCT00454662,Exclusion,history of hospitalization for angina pectoris or heart failure within 6 months before registration,Procedure,Procedure,C1514821,registration,FALSE,FALSE,NA,NA,NA
20,NCT00454662,Exclusion,severe heart failure ( new york heart association [ nyha ] functional class iii or more severe ),Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
20,NCT00454662,Exclusion,severe heart failure ( new york heart association [ nyha ] functional class iii or more severe ),Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
20,NCT00454662,Exclusion,severe heart failure ( new york heart association [ nyha ] functional class iii or more severe ),Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
20,NCT00454662,Exclusion,severe heart failure ( new york heart association [ nyha ] functional class iii or more severe ),Condition Occurrence,Other,C0441887;C2698969,class iii,FALSE,FALSE,NA,NA,NA
20,NCT00454662,Exclusion,severe heart failure ( new york heart association [ nyha ] functional class iii or more severe ),Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
21,NCT00454662,Exclusion,complications of atrial fibrillation ; atrial flutter or severe arrhythmia,Condition Occurrence,Condition,C0004239;C1963068,atrial flutter,FALSE,FALSE,NA,NA,NA
21,NCT00454662,Exclusion,complications of atrial fibrillation ; atrial flutter or severe arrhythmia,Condition Occurrence,Condition,C0003811,arrhythmia,FALSE,FALSE,NA,NA,NA
21,NCT00454662,Exclusion,complications of atrial fibrillation ; atrial flutter or severe arrhythmia,Condition Occurrence,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
21,NCT00454662,Exclusion,complications of atrial fibrillation ; atrial flutter or severe arrhythmia,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
22,NCT00454662,Exclusion,severe hepatic dysfunction or renal dysfunction ( including current treatment of dialysis or renal dysfunction with serum creatinine > = 2.00 mg / dl ),Condition Occurrence,Condition,C0086565,hepatic dysfunction,FALSE,FALSE,NA,NA,NA
22,NCT00454662,Exclusion,severe hepatic dysfunction or renal dysfunction ( including current treatment of dialysis or renal dysfunction with serum creatinine > = 2.00 mg / dl ),Condition Occurrence,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
22,NCT00454662,Exclusion,severe hepatic dysfunction or renal dysfunction ( including current treatment of dialysis or renal dysfunction with serum creatinine > = 2.00 mg / dl ),Condition Occurrence,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
22,NCT00454662,Exclusion,severe hepatic dysfunction or renal dysfunction ( including current treatment of dialysis or renal dysfunction with serum creatinine > = 2.00 mg / dl ),Condition Occurrence,Procedure,C2827774,current treatment,FALSE,FALSE,NA,NA,NA
22,NCT00454662,Exclusion,severe hepatic dysfunction or renal dysfunction ( including current treatment of dialysis or renal dysfunction with serum creatinine > = 2.00 mg / dl ),Condition Occurrence,Procedure,C0011946;C0917873,dialysis,FALSE,FALSE,NA,NA,NA
22,NCT00454662,Exclusion,severe hepatic dysfunction or renal dysfunction ( including current treatment of dialysis or renal dysfunction with serum creatinine > = 2.00 mg / dl ),Condition Occurrence,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,NA,greater_equal 2.00 mg/dl
22,NCT00454662,Exclusion,severe hepatic dysfunction or renal dysfunction ( including current treatment of dialysis or renal dysfunction with serum creatinine > = 2.00 mg / dl ),Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
23,NCT00454662,Exclusion,not appropriate for change to the study drugs from current therapy for concurrent disease including coronary diseases ( ie calcium channel blockers ; diuretics ; etc ),Drug Exposure,Condition,C0010068,coronary diseases,FALSE,FALSE,NA,NA,NA
23,NCT00454662,Exclusion,not appropriate for change to the study drugs from current therapy for concurrent disease including coronary diseases ( ie calcium channel blockers ; diuretics ; etc ),Drug Exposure,Drug,C0006684,calcium channel blockers,FALSE,FALSE,NA,NA,NA
23,NCT00454662,Exclusion,not appropriate for change to the study drugs from current therapy for concurrent disease including coronary diseases ( ie calcium channel blockers ; diuretics ; etc ),Drug Exposure,Drug,C0012798,diuretics,FALSE,FALSE,NA,NA,NA
23,NCT00454662,Exclusion,not appropriate for change to the study drugs from current therapy for concurrent disease including coronary diseases ( ie calcium channel blockers ; diuretics ; etc ),Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
23,NCT00454662,Exclusion,not appropriate for change to the study drugs from current therapy for concurrent disease including coronary diseases ( ie calcium channel blockers ; diuretics ; etc ),Drug Exposure,Procedure,C2827774,current therapy,FALSE,FALSE,NA,NA,NA
24,NCT00454662,Exclusion,history of serious side effect from study drugs ( at1 subtype angiotensin ii receptor antagonist ; calcium channel blocker ; diuretic ),Drug Exposure,Condition,C0879626,side effect,FALSE,FALSE,NA,NA,NA
24,NCT00454662,Exclusion,history of serious side effect from study drugs ( at1 subtype angiotensin ii receptor antagonist ; calcium channel blocker ; diuretic ),Drug Exposure,Drug,C0521942,angiotensin ii receptor antagonist,FALSE,FALSE,NA,NA,NA
24,NCT00454662,Exclusion,history of serious side effect from study drugs ( at1 subtype angiotensin ii receptor antagonist ; calcium channel blocker ; diuretic ),Drug Exposure,Drug,C0012798,diuretic,FALSE,FALSE,NA,NA,NA
24,NCT00454662,Exclusion,history of serious side effect from study drugs ( at1 subtype angiotensin ii receptor antagonist ; calcium channel blocker ; diuretic ),Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
24,NCT00454662,Exclusion,history of serious side effect from study drugs ( at1 subtype angiotensin ii receptor antagonist ; calcium channel blocker ; diuretic ),Drug Exposure,Other,C0006684;C3536851;C2757014,calcium channel blocker,FALSE,FALSE,NA,NA,NA
25,NCT00454662,Exclusion,life threatening condition ( malignant tumor ; etc ),Condition Occurrence,Condition,C2826244;C3537125,life threatening,FALSE,FALSE,NA,NA,NA
25,NCT00454662,Exclusion,life threatening condition ( malignant tumor ; etc ),Condition Occurrence,Condition,C0006826,malignant tumor,FALSE,FALSE,NA,NA,NA
26,NCT00454662,Exclusion,not suited to be study subject judged by a study physician,Other,NA,NA,NA,NA,NA,NA,NA,NA
1,NCT00500604,Inclusion,established essential hypertension ; untreated or treated but uncontrolled with treatment :,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00500604,Inclusion,office sbp > = 160 mmhg for untreated patients,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 160 mmhg,NA
3,NCT00500604,Inclusion,office sbp > = 140 mmhg for patients already treated with an antihypertensive drug .,Observation,Drug,C0003364,antihypertensive drug,FALSE,FALSE,NA,NA,NA
3,NCT00500604,Inclusion,office sbp > = 140 mmhg for patients already treated with an antihypertensive drug .,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 140 mmhg,NA
4,NCT00500604,Inclusion,previous antihypertensive therapy must have been implemented for a minimum of 4 weeks and must be either monotherapy or one of the following permitted combination drugs :,Drug Exposure,Drug,C0013162,combination drugs,FALSE,FALSE,NA,NA,NA
4,NCT00500604,Inclusion,previous antihypertensive therapy must have been implemented for a minimum of 4 weeks and must be either monotherapy or one of the following permitted combination drugs :,Drug Exposure,Procedure,C0585941,antihypertensive therapy,FALSE,FALSE,equal 4 weeks,NA,NA
5,NCT00500604,Inclusion,ace inhibitor / calcium channel blocker,Drug Exposure,Other,C0003015;C1152583,ace inhibitor,FALSE,FALSE,NA,NA,NA
5,NCT00500604,Inclusion,ace inhibitor / calcium channel blocker,Drug Exposure,Other,C0006684;C3536851;C2757014,calcium channel blocker,FALSE,FALSE,NA,NA,NA
6,NCT00500604,Inclusion,beta blocker / calcium channel blocker,Drug Exposure,Drug,C0001645,beta blocker,FALSE,FALSE,NA,NA,NA
6,NCT00500604,Inclusion,beta blocker / calcium channel blocker,Drug Exposure,Other,C0006684;C3536851;C2757014,calcium channel blocker,FALSE,FALSE,NA,NA,NA
7,NCT00500604,Inclusion,beta blocker / low dose diuretic,Drug Exposure,Drug,C0001645,beta blocker,FALSE,FALSE,NA,NA,NA
7,NCT00500604,Inclusion,beta blocker / low dose diuretic,Drug Exposure,Drug,C0012798,diuretic,FALSE,FALSE,NA,NA,NA
7,NCT00500604,Inclusion,beta blocker / low dose diuretic,Drug Exposure,Observation,C2700150,low,FALSE,FALSE,NA,NA,NA
8,NCT00500604,Inclusion,ace inhibitor / low dose diuretic,Drug Exposure,Drug,C0012798,diuretic,FALSE,FALSE,NA,NA,NA
8,NCT00500604,Inclusion,ace inhibitor / low dose diuretic,Drug Exposure,Observation,C2700150,low,FALSE,FALSE,NA,NA,NA
8,NCT00500604,Inclusion,ace inhibitor / low dose diuretic,Drug Exposure,Other,C0003015;C1152583,ace inhibitor,FALSE,FALSE,NA,NA,NA
9,NCT00500604,Exclusion,sbp > = 180 mmhg or dbp > = 110 mmhg evaluated at doctor office at visit 1,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 180 mmhg; greater_equal 110 mmhg,NA
9,NCT00500604,Exclusion,sbp > = 180 mmhg or dbp > = 110 mmhg evaluated at doctor office at visit 1,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 110 mmhg,NA
10,NCT00500604,Exclusion,known or suspected causes of secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
11,NCT00500604,Exclusion,patient with bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; a renal transplant or only has one functioning kidney,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
11,NCT00500604,Exclusion,patient with bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; a renal transplant or only has one functioning kidney,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
11,NCT00500604,Exclusion,patient with bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; a renal transplant or only has one functioning kidney,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
11,NCT00500604,Exclusion,patient with bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; a renal transplant or only has one functioning kidney,Condition Occurrence,Procedure,C0022671,renal transplant,FALSE,FALSE,NA,NA,NA
11,NCT00500604,Exclusion,patient with bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; a renal transplant or only has one functioning kidney,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
12,NCT00500604,Exclusion,type 1 diabetes mellitus,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
13,NCT00500604,Exclusion,significant cardiovascular ; neurological ; endocrine ; renal ; metabolic ; or gastrointestinal disease ; a malignancy or any other diseases considered by the investigator to make participation in the study not in the best interest of the subject,Condition Occurrence,Condition,C0017178,gastrointestinal disease,FALSE,FALSE,NA,NA,NA
13,NCT00500604,Exclusion,significant cardiovascular ; neurological ; endocrine ; renal ; metabolic ; or gastrointestinal disease ; a malignancy or any other diseases considered by the investigator to make participation in the study not in the best interest of the subject,Condition Occurrence,Condition,C0006826;C1306459,malignancy,FALSE,FALSE,NA,NA,NA
13,NCT00500604,Exclusion,significant cardiovascular ; neurological ; endocrine ; renal ; metabolic ; or gastrointestinal disease ; a malignancy or any other diseases considered by the investigator to make participation in the study not in the best interest of the subject,Condition Occurrence,Observation,C2707261,neurological,FALSE,FALSE,NA,NA,NA
13,NCT00500604,Exclusion,significant cardiovascular ; neurological ; endocrine ; renal ; metabolic ; or gastrointestinal disease ; a malignancy or any other diseases considered by the investigator to make participation in the study not in the best interest of the subject,Condition Occurrence,Other,C1524026;C2707259,metabolic,FALSE,FALSE,NA,NA,NA
14,NCT00500604,Exclusion,known hypersensitivity to diuretics or sulphonamides or history of angioedema or cough related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
14,NCT00500604,Exclusion,known hypersensitivity to diuretics or sulphonamides or history of angioedema or cough related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Condition,C0010200;C1961131,cough,FALSE,FALSE,NA,NA,NA
14,NCT00500604,Exclusion,known hypersensitivity to diuretics or sulphonamides or history of angioedema or cough related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Condition,C0445223,related,FALSE,FALSE,NA,NA,NA
14,NCT00500604,Exclusion,known hypersensitivity to diuretics or sulphonamides or history of angioedema or cough related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Drug,C0012798,diuretics,FALSE,FALSE,NA,NA,NA
14,NCT00500604,Exclusion,known hypersensitivity to diuretics or sulphonamides or history of angioedema or cough related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Drug,C0521942,angiotensin ii receptor antagonist,FALSE,FALSE,NA,NA,NA
14,NCT00500604,Exclusion,known hypersensitivity to diuretics or sulphonamides or history of angioedema or cough related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
14,NCT00500604,Exclusion,known hypersensitivity to diuretics or sulphonamides or history of angioedema or cough related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
15,NCT00500604,Exclusion,known contraindications to any of the study drugs,Procedure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
16,NCT00500604,Exclusion,concomitant use of any other antihypertensive treatment,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
17,NCT00500604,Exclusion,use of any of the investigational products for this study within the 3 months prior to the study,Other,Other,C3245491,investigational,FALSE,FALSE,lower 3 months,NA,NA
18,NCT00500604,Exclusion,inability to obtain a valid hbpm recording ie ; obesity ; arm circumference > 32 cm or arrhythmia,Condition Occurrence,Condition,C0028754;C1963185,obesity,FALSE,FALSE,NA,NA,NA
18,NCT00500604,Exclusion,inability to obtain a valid hbpm recording ie ; obesity ; arm circumference > 32 cm or arrhythmia,Condition Occurrence,Condition,C0003811,arrhythmia,FALSE,FALSE,NA,NA,NA
18,NCT00500604,Exclusion,inability to obtain a valid hbpm recording ie ; obesity ; arm circumference > 32 cm or arrhythmia,Condition Occurrence,Condition,C2075184,arm circumference,FALSE,FALSE,NA,greater 32 cm,NA
19,NCT00500604,Exclusion,administration of any other investigational drug in the last 30 days before enrolment and during the course of the study,Drug Exposure,Drug,C0013230,investigational drug,FALSE,FALSE,lower_equal 30 last days,NA,NA
20,NCT00500604,Exclusion,pregnant women or breast-feeding women,Person,Person,C0033011,pregnant women,FALSE,FALSE,NA,NA,NA
20,NCT00500604,Exclusion,pregnant women or breast-feeding women,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
20,NCT00500604,Exclusion,pregnant women or breast-feeding women,Person,Condition,C0006147;C1623041;C1623040,breast-feeding,FALSE,FALSE,NA,NA,NA
21,NCT00500604,Exclusion,women of childbearing potential not protected by effective contraceptive method of birth control or who are unwilling or unable to be tested for pregnancy,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
21,NCT00500604,Exclusion,women of childbearing potential not protected by effective contraceptive method of birth control or who are unwilling or unable to be tested for pregnancy,Condition Occurrence,Procedure,C0700589,contraceptive method,TRUE,FALSE,NA,NA,NA
21,NCT00500604,Exclusion,women of childbearing potential not protected by effective contraceptive method of birth control or who are unwilling or unable to be tested for pregnancy,Condition Occurrence,Observation,C3831118,childbearing potential,FALSE,FALSE,NA,NA,NA
21,NCT00500604,Exclusion,women of childbearing potential not protected by effective contraceptive method of birth control or who are unwilling or unable to be tested for pregnancy,Condition Occurrence,Other,C0700589;C2703065,birth control,FALSE,FALSE,NA,NA,NA
21,NCT00500604,Exclusion,women of childbearing potential not protected by effective contraceptive method of birth control or who are unwilling or unable to be tested for pregnancy,Condition Occurrence,Other,C0032961;C3484365,pregnancy,FALSE,FALSE,NA,NA,NA
22,NCT00500604,Exclusion,the above information is not intended to contain all considerations relevant to a patient potential participation in a clinical trial,Other,Other,C1096775,clinical trial,FALSE,FALSE,NA,NA,NA
2,NCT00529451,Inclusion,patients must have msdbp > or = 95 mmhg and < 110 mmhg at visit 3,Observation,NA,NA,NA,NA,NA,NA,NA,NA
1,NCT00529451,Inclusion,patients must have msdbp > = 90 mmhg and < 110 mmhg at the visit immediately prior to visit 3,Observation,NA,NA,NA,NA,NA,NA,NA,NA
3,NCT00529451,Inclusion,patients must have an absolute difference of < or = 10 mmhg in their mean sitting diastolic blood pressure ( msdbp ) from visit 2 to visit 3,Observation,Condition,C1319894,sitting diastolic blood pressure,FALSE,FALSE,NA,lower_equal 10 mmhg,NA
4,NCT00529451,Exclusion,severe hypertension ( grade 3 who classification,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
4,NCT00529451,Exclusion,severe hypertension ( grade 3 who classification,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
5,NCT00529451,Exclusion,msdbp > or = 110 mmhg or mssbp > or = 180 mmhg ) .,Observation,NA,NA,NA,NA,NA,NA,NA,NA
6,NCT00529451,Exclusion,history or evidence of a secondary form of hypertension .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
7,NCT00529451,Exclusion,history of transient ischemic cerebral attack within 12 months of visit 1 .,Person,Person,C0040704,transient,FALSE,FALSE,lower 12 months,NA,NA
8,NCT00529451,Exclusion,current angina pectoris requiring pharmacological therapy ( other than those patients on a stable dose of oral nitrates or topical nitrates ),Drug Exposure,Condition,C0002962;C0577698;C0235467;C0542052;C0010073;C0541777;C0235462,angina pectoris,FALSE,FALSE,NA,NA,NA
8,NCT00529451,Exclusion,current angina pectoris requiring pharmacological therapy ( other than those patients on a stable dose of oral nitrates or topical nitrates ),Drug Exposure,Drug,C1272919,oral,FALSE,FALSE,NA,NA,NA
8,NCT00529451,Exclusion,current angina pectoris requiring pharmacological therapy ( other than those patients on a stable dose of oral nitrates or topical nitrates ),Drug Exposure,Drug,C0028125,nitrates,FALSE,FALSE,NA,NA,NA
8,NCT00529451,Exclusion,current angina pectoris requiring pharmacological therapy ( other than those patients on a stable dose of oral nitrates or topical nitrates ),Drug Exposure,Drug,C1710439,topical,FALSE,FALSE,NA,NA,NA
8,NCT00529451,Exclusion,current angina pectoris requiring pharmacological therapy ( other than those patients on a stable dose of oral nitrates or topical nitrates ),Drug Exposure,Drug,C0028125,nitrates,FALSE,FALSE,NA,NA,NA
8,NCT00529451,Exclusion,current angina pectoris requiring pharmacological therapy ( other than those patients on a stable dose of oral nitrates or topical nitrates ),Drug Exposure,Other,C1547311,stable,TRUE,FALSE,NA,NA,NA
9,NCT00529451,Exclusion,type 1 diabetes or type 2 diabetesmellitus with glycosylated hemoglobin ( hba1c ) > 8 % at visit 1 .,Drug Exposure,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
9,NCT00529451,Exclusion,type 1 diabetes or type 2 diabetesmellitus with glycosylated hemoglobin ( hba1c ) > 8 % at visit 1 .,Drug Exposure,Observation,C0017853;C0373638;C0202054,glycosylated hemoglobin,FALSE,FALSE,NA,NA,NA
9,NCT00529451,Exclusion,type 1 diabetes or type 2 diabetesmellitus with glycosylated hemoglobin ( hba1c ) > 8 % at visit 1 .,Drug Exposure,Observation,C0202054,hba1c,FALSE,FALSE,NA,NA,greater 8 %
9,NCT00529451,Exclusion,type 1 diabetes or type 2 diabetesmellitus with glycosylated hemoglobin ( hba1c ) > 8 % at visit 1 .,Drug Exposure,Other,C1552651,type,FALSE,FALSE,NA,NA,NA
10,NCT00529451,Exclusion,known or suspected contraindications to the study medications ; including history of allergy to ramipril or other ace inhibitors .,Drug Exposure,Drug,C0072973,ramipril,FALSE,FALSE,NA,NA,NA
10,NCT00529451,Exclusion,known or suspected contraindications to the study medications ; including history of allergy to ramipril or other ace inhibitors .,Drug Exposure,Drug,C0003015,ace inhibitors,FALSE,FALSE,NA,NA,NA
10,NCT00529451,Exclusion,known or suspected contraindications to the study medications ; including history of allergy to ramipril or other ace inhibitors .,Drug Exposure,Other,C0489531;C0718579;C3542994;C3539909;C1314973;C1547315;C1611280,allergy,FALSE,FALSE,NA,NA,NA
11,NCT00529451,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00546754,Inclusion,an adult patient 18 to 75 years of age,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 18 years; lower_equal 75 years,NA,NA
2,NCT00546754,Inclusion,patient with essential hypertension receiving an antihypertensive agent in monotherapy for at least 4 weeks for whom the antihypertensive agent can ( and will ) be discontinued and whose blood pressure is not controlled :,Drug Exposure,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00546754,Inclusion,patient with essential hypertension receiving an antihypertensive agent in monotherapy for at least 4 weeks for whom the antihypertensive agent can ( and will ) be discontinued and whose blood pressure is not controlled :,Drug Exposure,Drug,C0003364,antihypertensive agent,FALSE,FALSE,greater_equal 4 weeks,NA,NA
2,NCT00546754,Inclusion,patient with essential hypertension receiving an antihypertensive agent in monotherapy for at least 4 weeks for whom the antihypertensive agent can ( and will ) be discontinued and whose blood pressure is not controlled :,Drug Exposure,Drug,C0003364,antihypertensive agent,FALSE,FALSE,NA,NA,NA
2,NCT00546754,Inclusion,patient with essential hypertension receiving an antihypertensive agent in monotherapy for at least 4 weeks for whom the antihypertensive agent can ( and will ) be discontinued and whose blood pressure is not controlled :,Drug Exposure,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
3,NCT00546754,Inclusion,either systolic blood pressure or diastolic blood pressure > 140 / 90 mm hg up to 180 / 110 mm hg ( inclusive ),Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater 140 mm hg; greater 90 mm hg; lower_equal 180 mm hg; lower_equal 110 mm hg,NA
3,NCT00546754,Inclusion,either systolic blood pressure or diastolic blood pressure > 140 / 90 mm hg up to 180 / 110 mm hg ( inclusive ),Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater 140 mm hg; greater 90 mm hg; lower_equal 180 mm hg; lower_equal 110 mm hg,NA
4,NCT00546754,Inclusion,either systolic blood pressure or diastolic blood pressure > 130 / 80 mm hg up to 160 / 100 mm hg ( inclusive ) for diabetic patients,Observation,Condition,C0241863,diabetic,FALSE,FALSE,NA,NA,NA
4,NCT00546754,Inclusion,either systolic blood pressure or diastolic blood pressure > 130 / 80 mm hg up to 160 / 100 mm hg ( inclusive ) for diabetic patients,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater 130 mm hg; greater 80 mm hg; lower_equal 160 mm hg; lower_equal 100 mm hg,NA
4,NCT00546754,Inclusion,either systolic blood pressure or diastolic blood pressure > 130 / 80 mm hg up to 160 / 100 mm hg ( inclusive ) for diabetic patients,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater 130 mm hg; greater 80 mm hg; lower_equal 160 mm hg; lower_equal 100 mm hg,NA
5,NCT00546754,Inclusion,patient is male or a female who is highly unlikely to conceive as she falls into one of the categories listed below :,Person,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
5,NCT00546754,Inclusion,patient is male or a female who is highly unlikely to conceive as she falls into one of the categories listed below :,Person,Condition,C0085639,falls,FALSE,FALSE,NA,NA,NA
5,NCT00546754,Inclusion,patient is male or a female who is highly unlikely to conceive as she falls into one of the categories listed below :,Person,Observation,C0150904,patient is male,FALSE,FALSE,NA,NA,NA
5,NCT00546754,Inclusion,patient is male or a female who is highly unlikely to conceive as she falls into one of the categories listed below :,Person,Other,C0683312,categories,FALSE,FALSE,NA,NA,NA
6,NCT00546754,Inclusion,surgically sterilized female,Person,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
7,NCT00546754,Inclusion,postmenopausal female > 45 years of age with > 2 years since her last menses,Person,Person,C0086287,female,FALSE,FALSE,greater 45 years,NA,NA
7,NCT00546754,Inclusion,postmenopausal female > 45 years of age with > 2 years since her last menses,Person,Person,C0001779,age,FALSE,FALSE,greater 2 years,NA,NA
7,NCT00546754,Inclusion,postmenopausal female > 45 years of age with > 2 years since her last menses,Person,Condition,C0559892,menses,FALSE,FALSE,NA,NA,NA
8,NCT00546754,Inclusion,non-sterilized pre-menopausal female who agrees to : 1 use 2 adequate methods of contraception to prevent pregnancy [ either 2 barrier methods or a barrier method plus a hormonal method ],Observation,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
8,NCT00546754,Inclusion,non-sterilized pre-menopausal female who agrees to : 1 use 2 adequate methods of contraception to prevent pregnancy [ either 2 barrier methods or a barrier method plus a hormonal method ],Observation,Condition,C1096235,pre-menopausal,FALSE,FALSE,NA,NA,NA
8,NCT00546754,Inclusion,non-sterilized pre-menopausal female who agrees to : 1 use 2 adequate methods of contraception to prevent pregnancy [ either 2 barrier methods or a barrier method plus a hormonal method ],Observation,Drug,C0309872,prevent,FALSE,FALSE,NA,NA,NA
8,NCT00546754,Inclusion,non-sterilized pre-menopausal female who agrees to : 1 use 2 adequate methods of contraception to prevent pregnancy [ either 2 barrier methods or a barrier method plus a hormonal method ],Observation,Procedure,C0700589,contraception,FALSE,FALSE,NA,equal 2 adequate methods; equal 1,NA
8,NCT00546754,Inclusion,non-sterilized pre-menopausal female who agrees to : 1 use 2 adequate methods of contraception to prevent pregnancy [ either 2 barrier methods or a barrier method plus a hormonal method ],Observation,Procedure,C2985296,hormonal method,FALSE,FALSE,NA,NA,NA
8,NCT00546754,Inclusion,non-sterilized pre-menopausal female who agrees to : 1 use 2 adequate methods of contraception to prevent pregnancy [ either 2 barrier methods or a barrier method plus a hormonal method ],Observation,Other,C0032961;C3484365,pregnancy,FALSE,FALSE,NA,equal 2 barrier methods,NA
8,NCT00546754,Inclusion,non-sterilized pre-menopausal female who agrees to : 1 use 2 adequate methods of contraception to prevent pregnancy [ either 2 barrier methods or a barrier method plus a hormonal method ],Observation,Other,C2827714;C0871511;C2828387,method,FALSE,FALSE,NA,NA,NA
9,NCT00546754,Inclusion,or 2 abstain from heterosexual activity throughout the study starting with visit 1 and for 14 days after the last dose of study medication,Observation,Observation,C0600075;C3668946,activity,FALSE,FALSE,equal 14 days,NA,NA
9,NCT00546754,Inclusion,or 2 abstain from heterosexual activity throughout the study starting with visit 1 and for 14 days after the last dose of study medication,Observation,Other,C1527360;C2129309,heterosexual,FALSE,FALSE,NA,equal 2,NA
10,NCT00546754,Inclusion,or 3 only engage in heterosexual activity with surgically sterilized male partner ( s ) throughout the study starting with visit 1 and for 14 days after the last dose of study medication,Observation,Person,C0025266,male,FALSE,FALSE,equal 14 days,NA,NA
10,NCT00546754,Inclusion,or 3 only engage in heterosexual activity with surgically sterilized male partner ( s ) throughout the study starting with visit 1 and for 14 days after the last dose of study medication,Observation,Observation,C0600075;C3668946,activity,FALSE,FALSE,NA,NA,NA
10,NCT00546754,Inclusion,or 3 only engage in heterosexual activity with surgically sterilized male partner ( s ) throughout the study starting with visit 1 and for 14 days after the last dose of study medication,Observation,Other,C1527360;C2129309,heterosexual,FALSE,FALSE,NA,equal 3,NA
11,NCT00546754,Inclusion,patient judged to be in otherwise good health ; stable health on the basis of medical history and physical examination,Condition Occurrence,Condition,C0031206,good health,FALSE,FALSE,NA,NA,NA
11,NCT00546754,Inclusion,patient judged to be in otherwise good health ; stable health on the basis of medical history and physical examination,Condition Occurrence,Condition,C0262926,medical history,FALSE,FALSE,NA,NA,NA
11,NCT00546754,Inclusion,patient judged to be in otherwise good health ; stable health on the basis of medical history and physical examination,Condition Occurrence,Procedure,C0031809,physical examination,FALSE,FALSE,NA,NA,NA
11,NCT00546754,Inclusion,patient judged to be in otherwise good health ; stable health on the basis of medical history and physical examination,Condition Occurrence,Other,C1547311,stable,FALSE,FALSE,NA,NA,NA
12,NCT00546754,Exclusion,known secondary hypertension of any aetiology ( eg ; uncorrected renal artery stenosis ; malignant hypertension ; or hypertensive encephalopathy ),Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
12,NCT00546754,Exclusion,known secondary hypertension of any aetiology ( eg ; uncorrected renal artery stenosis ; malignant hypertension ; or hypertensive encephalopathy ),Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
12,NCT00546754,Exclusion,known secondary hypertension of any aetiology ( eg ; uncorrected renal artery stenosis ; malignant hypertension ; or hypertensive encephalopathy ),Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
12,NCT00546754,Exclusion,known secondary hypertension of any aetiology ( eg ; uncorrected renal artery stenosis ; malignant hypertension ; or hypertensive encephalopathy ),Condition Occurrence,Condition,C0020540;C0024588,malignant hypertension,FALSE,FALSE,NA,NA,NA
13,NCT00546754,Exclusion,patient needing an initiation of a lipid lowering agent or a modification of his lipid therapy at visit 1 or during the study period ( 12 weeks ),Drug Exposure,Condition,C1158830,initiation,FALSE,FALSE,NA,NA,NA
13,NCT00546754,Exclusion,patient needing an initiation of a lipid lowering agent or a modification of his lipid therapy at visit 1 or during the study period ( 12 weeks ),Drug Exposure,Drug,C0003367,lipid lowering agent,FALSE,FALSE,NA,NA,NA
13,NCT00546754,Exclusion,patient needing an initiation of a lipid lowering agent or a modification of his lipid therapy at visit 1 or during the study period ( 12 weeks ),Drug Exposure,Drug,C0023779,lipid,FALSE,FALSE,equal 12 weeks,NA,NA
14,NCT00546754,Exclusion,patient taking allopurinol,Drug Exposure,Drug,C0002144,allopurinol,FALSE,FALSE,NA,NA,NA
15,NCT00546754,Exclusion,patient previously shown to be intolerant to any component of losartan valsartan ; or hctz or with a documented history of angioedema / anaphylaxis,Condition Occurrence,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
15,NCT00546754,Exclusion,patient previously shown to be intolerant to any component of losartan valsartan ; or hctz or with a documented history of angioedema / anaphylaxis,Condition Occurrence,Condition,C0002792;C0850803,anaphylaxis,FALSE,FALSE,NA,NA,NA
15,NCT00546754,Exclusion,patient previously shown to be intolerant to any component of losartan valsartan ; or hctz or with a documented history of angioedema / anaphylaxis,Condition Occurrence,Drug,C0126174,losartan,FALSE,FALSE,NA,NA,NA
15,NCT00546754,Exclusion,patient previously shown to be intolerant to any component of losartan valsartan ; or hctz or with a documented history of angioedema / anaphylaxis,Condition Occurrence,Procedure,C1301725,documented,FALSE,FALSE,NA,NA,NA
16,NCT00546754,Exclusion,patient with confirmed clinically significant renal dysfunction or hepatic dysfunction or electrolyte imbalance laboratory test within the last 3 months prior to visit 1 : serum creatinine > 130 umol / l clearance or creatinine clearance < 45 ml / min ; aspartate transaminase ( ast ) > 2 times above the normal range ; alanine transaminase ( alt ) > 2 times above the normal range ; serum potassium < 3.5 or > 5.5 meq / l,Observation,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
16,NCT00546754,Exclusion,patient with confirmed clinically significant renal dysfunction or hepatic dysfunction or electrolyte imbalance laboratory test within the last 3 months prior to visit 1 : serum creatinine > 130 umol / l clearance or creatinine clearance < 45 ml / min ; aspartate transaminase ( ast ) > 2 times above the normal range ; alanine transaminase ( alt ) > 2 times above the normal range ; serum potassium < 3.5 or > 5.5 meq / l,Observation,Condition,C0342579,electrolyte imbalance,FALSE,FALSE,NA,NA,NA
16,NCT00546754,Exclusion,patient with confirmed clinically significant renal dysfunction or hepatic dysfunction or electrolyte imbalance laboratory test within the last 3 months prior to visit 1 : serum creatinine > 130 umol / l clearance or creatinine clearance < 45 ml / min ; aspartate transaminase ( ast ) > 2 times above the normal range ; alanine transaminase ( alt ) > 2 times above the normal range ; serum potassium < 3.5 or > 5.5 meq / l,Observation,Condition,C0086565,hepatic dysfunction,FALSE,FALSE,NA,NA,NA
16,NCT00546754,Exclusion,patient with confirmed clinically significant renal dysfunction or hepatic dysfunction or electrolyte imbalance laboratory test within the last 3 months prior to visit 1 : serum creatinine > 130 umol / l clearance or creatinine clearance < 45 ml / min ; aspartate transaminase ( ast ) > 2 times above the normal range ; alanine transaminase ( alt ) > 2 times above the normal range ; serum potassium < 3.5 or > 5.5 meq / l,Observation,Drug,C0004002;C0242192,aspartate transaminase,FALSE,FALSE,NA,NA,NA
16,NCT00546754,Exclusion,patient with confirmed clinically significant renal dysfunction or hepatic dysfunction or electrolyte imbalance laboratory test within the last 3 months prior to visit 1 : serum creatinine > 130 umol / l clearance or creatinine clearance < 45 ml / min ; aspartate transaminase ( ast ) > 2 times above the normal range ; alanine transaminase ( alt ) > 2 times above the normal range ; serum potassium < 3.5 or > 5.5 meq / l,Observation,Drug,C0001899,alanine transaminase,FALSE,FALSE,NA,NA,NA
16,NCT00546754,Exclusion,patient with confirmed clinically significant renal dysfunction or hepatic dysfunction or electrolyte imbalance laboratory test within the last 3 months prior to visit 1 : serum creatinine > 130 umol / l clearance or creatinine clearance < 45 ml / min ; aspartate transaminase ( ast ) > 2 times above the normal range ; alanine transaminase ( alt ) > 2 times above the normal range ; serum potassium < 3.5 or > 5.5 meq / l,Observation,Observation,C0022885,laboratory test,FALSE,FALSE,lower 3 last months,NA,NA
16,NCT00546754,Exclusion,patient with confirmed clinically significant renal dysfunction or hepatic dysfunction or electrolyte imbalance laboratory test within the last 3 months prior to visit 1 : serum creatinine > 130 umol / l clearance or creatinine clearance < 45 ml / min ; aspartate transaminase ( ast ) > 2 times above the normal range ; alanine transaminase ( alt ) > 2 times above the normal range ; serum potassium < 3.5 or > 5.5 meq / l,Observation,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,greater 130 umol/l,NA
16,NCT00546754,Exclusion,patient with confirmed clinically significant renal dysfunction or hepatic dysfunction or electrolyte imbalance laboratory test within the last 3 months prior to visit 1 : serum creatinine > 130 umol / l clearance or creatinine clearance < 45 ml / min ; aspartate transaminase ( ast ) > 2 times above the normal range ; alanine transaminase ( alt ) > 2 times above the normal range ; serum potassium < 3.5 or > 5.5 meq / l,Observation,Observation,C0373595;C0812399,creatinine clearance,FALSE,FALSE,NA,lower 45 ml/min,NA
16,NCT00546754,Exclusion,patient with confirmed clinically significant renal dysfunction or hepatic dysfunction or electrolyte imbalance laboratory test within the last 3 months prior to visit 1 : serum creatinine > 130 umol / l clearance or creatinine clearance < 45 ml / min ; aspartate transaminase ( ast ) > 2 times above the normal range ; alanine transaminase ( alt ) > 2 times above the normal range ; serum potassium < 3.5 or > 5.5 meq / l,Observation,Observation,C0004002,ast,FALSE,FALSE,NA,NA,greater 2 times
16,NCT00546754,Exclusion,patient with confirmed clinically significant renal dysfunction or hepatic dysfunction or electrolyte imbalance laboratory test within the last 3 months prior to visit 1 : serum creatinine > 130 umol / l clearance or creatinine clearance < 45 ml / min ; aspartate transaminase ( ast ) > 2 times above the normal range ; alanine transaminase ( alt ) > 2 times above the normal range ; serum potassium < 3.5 or > 5.5 meq / l,Observation,Observation,C3542016,range,FALSE,FALSE,NA,NA,NA
16,NCT00546754,Exclusion,patient with confirmed clinically significant renal dysfunction or hepatic dysfunction or electrolyte imbalance laboratory test within the last 3 months prior to visit 1 : serum creatinine > 130 umol / l clearance or creatinine clearance < 45 ml / min ; aspartate transaminase ( ast ) > 2 times above the normal range ; alanine transaminase ( alt ) > 2 times above the normal range ; serum potassium < 3.5 or > 5.5 meq / l,Observation,Observation,C1140170;C2257651,alt,FALSE,FALSE,NA,NA,greater 2 times
16,NCT00546754,Exclusion,patient with confirmed clinically significant renal dysfunction or hepatic dysfunction or electrolyte imbalance laboratory test within the last 3 months prior to visit 1 : serum creatinine > 130 umol / l clearance or creatinine clearance < 45 ml / min ; aspartate transaminase ( ast ) > 2 times above the normal range ; alanine transaminase ( alt ) > 2 times above the normal range ; serum potassium < 3.5 or > 5.5 meq / l,Observation,Observation,C3542016,range,FALSE,FALSE,NA,greater 5.5,NA
16,NCT00546754,Exclusion,patient with confirmed clinically significant renal dysfunction or hepatic dysfunction or electrolyte imbalance laboratory test within the last 3 months prior to visit 1 : serum creatinine > 130 umol / l clearance or creatinine clearance < 45 ml / min ; aspartate transaminase ( ast ) > 2 times above the normal range ; alanine transaminase ( alt ) > 2 times above the normal range ; serum potassium < 3.5 or > 5.5 meq / l,Observation,Observation,C0302353;C0543465,serum potassium,FALSE,FALSE,NA,lower 3.5 ; greater 5.5,NA
17,NCT00546754,Exclusion,patient with osteoarthritis who has undergone hip or knee replacement within the last 4 months,Condition Occurrence,Drug,C1430701,hip,FALSE,FALSE,lower 4 last months,NA,NA
17,NCT00546754,Exclusion,patient with osteoarthritis who has undergone hip or knee replacement within the last 4 months,Condition Occurrence,Other,C0086511;C2186386,knee replacement,FALSE,FALSE,lower 4 last months,NA,NA
18,NCT00546754,Exclusion,patient with chronic inflammatory conditions such as rheumatoid arthritis ; lupus ; inflammatory bowel disease and those that need a chronic inflammatory therapy such as prednisone or other steroid agents,Condition Occurrence,Condition,C0003873,rheumatoid arthritis,FALSE,FALSE,NA,NA,NA
18,NCT00546754,Exclusion,patient with chronic inflammatory conditions such as rheumatoid arthritis ; lupus ; inflammatory bowel disease and those that need a chronic inflammatory therapy such as prednisone or other steroid agents,Condition Occurrence,Condition,C0021390,inflammatory bowel disease,FALSE,FALSE,NA,NA,NA
18,NCT00546754,Exclusion,patient with chronic inflammatory conditions such as rheumatoid arthritis ; lupus ; inflammatory bowel disease and those that need a chronic inflammatory therapy such as prednisone or other steroid agents,Condition Occurrence,Condition,C0024131;C0409974,lupus,FALSE,FALSE,NA,NA,NA
18,NCT00546754,Exclusion,patient with chronic inflammatory conditions such as rheumatoid arthritis ; lupus ; inflammatory bowel disease and those that need a chronic inflammatory therapy such as prednisone or other steroid agents,Condition Occurrence,Drug,C0032952,prednisone,FALSE,FALSE,NA,NA,NA
18,NCT00546754,Exclusion,patient with chronic inflammatory conditions such as rheumatoid arthritis ; lupus ; inflammatory bowel disease and those that need a chronic inflammatory therapy such as prednisone or other steroid agents,Condition Occurrence,Other,C1547296;C1555457,chronic,FALSE,FALSE,NA,NA,NA
18,NCT00546754,Exclusion,patient with chronic inflammatory conditions such as rheumatoid arthritis ; lupus ; inflammatory bowel disease and those that need a chronic inflammatory therapy such as prednisone or other steroid agents,Condition Occurrence,Other,C1547296;C1555457,chronic,FALSE,FALSE,NA,NA,NA
19,NCT00546754,Exclusion,patient with symptomatic heart failure ( classes 3 and 4 ),Observation,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,equal 3 ; equal 4,NA
20,NCT00546754,Exclusion,patient with a history of stroke within the last 6 months,Other,NA,NA,NA,NA,NA,NA,NA,NA
21,NCT00546754,Exclusion,patient with coronary heart disease : has undergone percutaneous coronary angioplasty ; has had coronary artery bypass ; has had past myocardial infarction ; all that occurred less than 6 months prior to visit 1 or has unstable angina,Condition Occurrence,Condition,C0010068;C0010054,coronary heart disease,FALSE,FALSE,NA,NA,NA
21,NCT00546754,Exclusion,patient with coronary heart disease : has undergone percutaneous coronary angioplasty ; has had coronary artery bypass ; has had past myocardial infarction ; all that occurred less than 6 months prior to visit 1 or has unstable angina,Condition Occurrence,Condition,C0155668,past myocardial infarction,FALSE,FALSE,lower 6 months,NA,NA
21,NCT00546754,Exclusion,patient with coronary heart disease : has undergone percutaneous coronary angioplasty ; has had coronary artery bypass ; has had past myocardial infarction ; all that occurred less than 6 months prior to visit 1 or has unstable angina,Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,NA,NA,NA
21,NCT00546754,Exclusion,patient with coronary heart disease : has undergone percutaneous coronary angioplasty ; has had coronary artery bypass ; has had past myocardial infarction ; all that occurred less than 6 months prior to visit 1 or has unstable angina,Condition Occurrence,Procedure,C0190211;C0002997,coronary angioplasty,FALSE,FALSE,NA,NA,NA
21,NCT00546754,Exclusion,patient with coronary heart disease : has undergone percutaneous coronary angioplasty ; has had coronary artery bypass ; has had past myocardial infarction ; all that occurred less than 6 months prior to visit 1 or has unstable angina,Condition Occurrence,Procedure,C0010055,coronary artery bypass,FALSE,FALSE,NA,NA,NA
22,NCT00546754,Exclusion,patient having participated in an investigational drug program in the last 30 days ( prior to visit 1 ),Drug Exposure,Drug,C0013230,investigational drug,FALSE,FALSE,lower_equal 30 last days,NA,NA
23,NCT00546754,Exclusion,unable or unwilling to comply with the protocol;therefore likely to leave the trial before its completion,Other,NA,NA,NA,NA,NA,NA,NA,NA
24,NCT00546754,Exclusion,patient intends to move or to vacation away from home during the course of the study which would interfere with the scheduled visits,Other,Other,C1548341,home,FALSE,FALSE,NA,NA,NA
1,NCT00550953,Inclusion,essential hypertensive patients who satisfying non-responder criteria,Condition Occurrence,Condition,C0857121,hypertensive,FALSE,FALSE,NA,NA,NA
4,NCT00550953,Inclusion,outpatient,Other,NA,NA,NA,NA,NA,NA,NA,NA
3,NCT00550953,Inclusion,age 20 years or older,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 20 years,NA,NA
5,NCT00550953,Exclusion,taking four or more anti-hypertensive medications,Drug Exposure,Drug,C0003364,anti-hypertensive,FALSE,FALSE,NA,NA,NA
6,NCT00550953,Exclusion,secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
7,NCT00550953,Exclusion,mean seated diastolic blood pressure ( dbp ) > 114 mmhg or mean seated systolic blood pressure ( sbp ) > 200 mmhg at visit 1 ; 2 ; 3 ; or 4 ; or mean seated dbp < 90 mmhg at visit 3 .,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,NA,NA
7,NCT00550953,Exclusion,mean seated diastolic blood pressure ( dbp ) > 114 mmhg or mean seated systolic blood pressure ( sbp ) > 200 mmhg at visit 1 ; 2 ; 3 ; or 4 ; or mean seated dbp < 90 mmhg at visit 3 .,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater 114 mmhg,NA
7,NCT00550953,Exclusion,mean seated diastolic blood pressure ( dbp ) > 114 mmhg or mean seated systolic blood pressure ( sbp ) > 200 mmhg at visit 1 ; 2 ; 3 ; or 4 ; or mean seated dbp < 90 mmhg at visit 3 .,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,NA,NA
7,NCT00550953,Exclusion,mean seated diastolic blood pressure ( dbp ) > 114 mmhg or mean seated systolic blood pressure ( sbp ) > 200 mmhg at visit 1 ; 2 ; 3 ; or 4 ; or mean seated dbp < 90 mmhg at visit 3 .,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater 200 mmhg; equal 2 ; equal 4,NA
7,NCT00550953,Exclusion,mean seated diastolic blood pressure ( dbp ) > 114 mmhg or mean seated systolic blood pressure ( sbp ) > 200 mmhg at visit 1 ; 2 ; 3 ; or 4 ; or mean seated dbp < 90 mmhg at visit 3 .,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,lower 90 mmhg; equal 3,NA
8,NCT00550953,Exclusion,sustained ventricular tachycardia or other clinically relevant cardiac arrhythmias,Condition Occurrence,Condition,C0750197,sustained ventricular tachycardia,FALSE,FALSE,NA,NA,NA
8,NCT00550953,Exclusion,sustained ventricular tachycardia or other clinically relevant cardiac arrhythmias,Condition Occurrence,Condition,C0003811,cardiac arrhythmias,FALSE,FALSE,NA,NA,NA
9,NCT00550953,Exclusion,congestive heart failure patients with the new york heart association ( nyha ) functional class iii - class iv,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
9,NCT00550953,Exclusion,congestive heart failure patients with the new york heart association ( nyha ) functional class iii - class iv,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
9,NCT00550953,Exclusion,congestive heart failure patients with the new york heart association ( nyha ) functional class iii - class iv,Condition Occurrence,Other,C0441887;C2698969,class iii,FALSE,FALSE,NA,NA,NA
9,NCT00550953,Exclusion,congestive heart failure patients with the new york heart association ( nyha ) functional class iii - class iv,Condition Occurrence,Other,C0441888;C2698970,class iv,FALSE,FALSE,NA,NA,NA
10,NCT00550953,Exclusion,history of myocardial infarction or cardiac surgery within last 6 months,Condition Occurrence,Procedure,C0018821,cardiac surgery,FALSE,FALSE,equal 6 months,NA,NA
10,NCT00550953,Exclusion,history of myocardial infarction or cardiac surgery within last 6 months,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,equal 6 months,NA,NA
11,NCT00550953,Exclusion,history of coronary artery bypass graft or percutaneous coronary intervention ( pci ) within last 3 months,Procedure,Procedure,C0010055,coronary artery bypass graft,FALSE,FALSE,NA,NA,NA
11,NCT00550953,Exclusion,history of coronary artery bypass graft or percutaneous coronary intervention ( pci ) within last 3 months,Procedure,Procedure,C1532338,percutaneous coronary intervention,FALSE,FALSE,NA,NA,NA
11,NCT00550953,Exclusion,history of coronary artery bypass graft or percutaneous coronary intervention ( pci ) within last 3 months,Procedure,Procedure,C1514496;C1532338,pci,FALSE,FALSE,equal 3 months,NA,NA
12,NCT00550953,Exclusion,history of unstable angina within last 3 months,Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,equal 3 months,NA,NA
13,NCT00550953,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of aortic valve or mitral valve,Condition Occurrence,Condition,C0007194,hypertrophic obstructive cardiomyopathy,FALSE,FALSE,NA,NA,NA
13,NCT00550953,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of aortic valve or mitral valve,Condition Occurrence,Condition,C0003507,aortic stenosis,FALSE,FALSE,NA,NA,NA
13,NCT00550953,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of aortic valve or mitral valve,Condition Occurrence,Condition,C0003501;C1269005,aortic valve,FALSE,FALSE,NA,NA,NA
13,NCT00550953,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of aortic valve or mitral valve,Condition Occurrence,Condition,C0026264;C1269004,mitral valve,FALSE,FALSE,NA,NA,NA
13,NCT00550953,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of aortic valve or mitral valve,Condition Occurrence,Observation,C1261287;C0947637;C0009814,stenosis,FALSE,FALSE,NA,NA,NA
14,NCT00550953,Exclusion,history of stroke or transient ischemic attack within last 6 months,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,equal 6 months,NA,NA
15,NCT00550953,Exclusion,history of sudden exacerbation of renal function with angiotensin ii receptor blockers ( arbs ) or angiotensin converting enzyme ( ace ) inhibitors ; or patients with post-renal transplant or post-nephrectomy,Condition Occurrence,Condition,C0478647,transplant,FALSE,FALSE,NA,NA,NA
15,NCT00550953,Exclusion,history of sudden exacerbation of renal function with angiotensin ii receptor blockers ( arbs ) or angiotensin converting enzyme ( ace ) inhibitors ; or patients with post-renal transplant or post-nephrectomy,Condition Occurrence,Drug,C0003015,ace inhibitors,FALSE,FALSE,NA,NA,NA
15,NCT00550953,Exclusion,history of sudden exacerbation of renal function with angiotensin ii receptor blockers ( arbs ) or angiotensin converting enzyme ( ace ) inhibitors ; or patients with post-renal transplant or post-nephrectomy,Condition Occurrence,Procedure,C0027695;C0176996,nephrectomy,FALSE,FALSE,NA,NA,NA
15,NCT00550953,Exclusion,history of sudden exacerbation of renal function with angiotensin ii receptor blockers ( arbs ) or angiotensin converting enzyme ( ace ) inhibitors ; or patients with post-renal transplant or post-nephrectomy,Condition Occurrence,Other,C0232804;C0022662,renal function,FALSE,FALSE,NA,NA,NA
15,NCT00550953,Exclusion,history of sudden exacerbation of renal function with angiotensin ii receptor blockers ( arbs ) or angiotensin converting enzyme ( ace ) inhibitors ; or patients with post-renal transplant or post-nephrectomy,Condition Occurrence,Other,C2757003;C0521942,angiotensin ii receptor blockers,FALSE,FALSE,NA,NA,NA
15,NCT00550953,Exclusion,history of sudden exacerbation of renal function with angiotensin ii receptor blockers ( arbs ) or angiotensin converting enzyme ( ace ) inhibitors ; or patients with post-renal transplant or post-nephrectomy,Condition Occurrence,Other,C0022709;C0201888;C2258685,angiotensin converting enzyme,FALSE,FALSE,NA,NA,NA
16,NCT00550953,Exclusion,experienced characteristic symptoms of angioedema during treatment with arbs or ace inhibitors,Condition Occurrence,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
16,NCT00550953,Exclusion,experienced characteristic symptoms of angioedema during treatment with arbs or ace inhibitors,Condition Occurrence,Drug,C0003015,ace inhibitors,FALSE,FALSE,NA,NA,NA
17,NCT00550953,Exclusion,known hypersensitivity to any component of the investigational drug ; or a known hypersensitivity to dihydropyridine derived drugs,Drug Exposure,Drug,C0013230,investigational drug,FALSE,FALSE,NA,NA,NA
17,NCT00550953,Exclusion,known hypersensitivity to any component of the investigational drug ; or a known hypersensitivity to dihydropyridine derived drugs,Drug Exposure,Drug,C0220821;C3537269,dihydropyridine,FALSE,FALSE,NA,NA,NA
17,NCT00550953,Exclusion,known hypersensitivity to any component of the investigational drug ; or a known hypersensitivity to dihydropyridine derived drugs,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
17,NCT00550953,Exclusion,known hypersensitivity to any component of the investigational drug ; or a known hypersensitivity to dihydropyridine derived drugs,Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
17,NCT00550953,Exclusion,known hypersensitivity to any component of the investigational drug ; or a known hypersensitivity to dihydropyridine derived drugs,Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
18,NCT00550953,Exclusion,hepatic dysfunction or renal dysfunction,Condition Occurrence,Condition,C0086565,hepatic dysfunction,FALSE,FALSE,NA,NA,NA
18,NCT00550953,Exclusion,hepatic dysfunction or renal dysfunction,Condition Occurrence,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
19,NCT00550953,Exclusion,diagnosed biliary atresia or cholestasis,Condition Occurrence,Condition,C0005411,biliary atresia,FALSE,FALSE,NA,NA,NA
19,NCT00550953,Exclusion,diagnosed biliary atresia or cholestasis,Condition Occurrence,Condition,C0008370,cholestasis,FALSE,FALSE,NA,NA,NA
20,NCT00550953,Exclusion,hyperkalemia,Condition Occurrence,Condition,C0020461,hyperkalemia,FALSE,FALSE,NA,NA,NA
21,NCT00550953,Exclusion,dehydration,Condition Occurrence,Condition,C0011175;C1963090,dehydration,FALSE,FALSE,NA,NA,NA
22,NCT00550953,Exclusion,sodium deficiency ; chronic administration of high doses of acidic nonsteroidal anti-inflammatory drugs ( nsaids ),Drug Exposure,Condition,C1971019;C0020625,sodium deficiency,FALSE,FALSE,NA,NA,NA
22,NCT00550953,Exclusion,sodium deficiency ; chronic administration of high doses of acidic nonsteroidal anti-inflammatory drugs ( nsaids ),Drug Exposure,Drug,C0003211,nonsteroidal anti-inflammatory drugs,FALSE,FALSE,NA,NA,NA
22,NCT00550953,Exclusion,sodium deficiency ; chronic administration of high doses of acidic nonsteroidal anti-inflammatory drugs ( nsaids ),Drug Exposure,Drug,C0003211,nsaids,FALSE,FALSE,NA,NA,NA
22,NCT00550953,Exclusion,sodium deficiency ; chronic administration of high doses of acidic nonsteroidal anti-inflammatory drugs ( nsaids ),Drug Exposure,Observation,C2700149,high,FALSE,FALSE,NA,NA,NA
22,NCT00550953,Exclusion,sodium deficiency ; chronic administration of high doses of acidic nonsteroidal anti-inflammatory drugs ( nsaids ),Drug Exposure,Other,C1547296;C1555457,chronic,FALSE,FALSE,NA,NA,NA
23,NCT00550953,Exclusion,patients who cannot change to the restricted administration and dosage during study period,Other,Other,C1549594,restricted,TRUE,FALSE,NA,NA,NA
24,NCT00550953,Exclusion,pre-menopausal women who meet any one of the following 1 - 3 :,Observation,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
24,NCT00550953,Exclusion,pre-menopausal women who meet any one of the following 1 - 3 :,Observation,Condition,C1096235,pre-menopausal,FALSE,FALSE,NA,NA,NA
25,NCT00550953,Exclusion,pregnant or possibly pregnant 1,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
25,NCT00550953,Exclusion,pregnant or possibly pregnant 1,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
26,NCT00550953,Exclusion,nursing 2,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
27,NCT00550953,Exclusion,desire to become pregnant during study period 3,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
28,NCT00550953,Exclusion,drug or alcohol dependency,Condition Occurrence,Condition,C0001973,alcohol dependency,FALSE,FALSE,NA,NA,NA
28,NCT00550953,Exclusion,drug or alcohol dependency,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
29,NCT00550953,Exclusion,complication of malignant tumour or a disease requiring immunosuppressants,Condition Occurrence,Condition,C0006826,malignant tumour,FALSE,FALSE,NA,NA,NA
30,NCT00550953,Exclusion,compliance of < 80 % or > 120 % during the run-in period,Drug Exposure,NA,NA,NA,NA,NA,NA,NA,NA
31,NCT00550953,Exclusion,receiving any investigational therapy within 3 months,Procedure,Procedure,C0949266,investigational therapy,FALSE,FALSE,lower 3 months,NA,NA
32,NCT00550953,Exclusion,judged to be inappropriate by the investigator or the sub-investigator,Other,NA,NA,NA,NA,NA,NA,NA,NA
2,NCT00550953,Inclusion,male or female,Person,Person,C0025266,male,FALSE,FALSE,NA,NA,NA
2,NCT00550953,Inclusion,male or female,Person,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
1,NCT00553267,Inclusion,diagnosis of essential hypertension and blood pressure not adequately controlled before informed consent ( inadequate control defined as seated diastolic blood pressure ( dbp ) > = 95 mmhg if on existing antihypertensive treatment or seated dbp > = 100 mmhg if treatment-na ve ) .,Observation,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00553267,Inclusion,diagnosis of essential hypertension and blood pressure not adequately controlled before informed consent ( inadequate control defined as seated diastolic blood pressure ( dbp ) > = 95 mmhg if on existing antihypertensive treatment or seated dbp > = 100 mmhg if treatment-na ve ) .,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
1,NCT00553267,Inclusion,diagnosis of essential hypertension and blood pressure not adequately controlled before informed consent ( inadequate control defined as seated diastolic blood pressure ( dbp ) > = 95 mmhg if on existing antihypertensive treatment or seated dbp > = 100 mmhg if treatment-na ve ) .,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
1,NCT00553267,Inclusion,diagnosis of essential hypertension and blood pressure not adequately controlled before informed consent ( inadequate control defined as seated diastolic blood pressure ( dbp ) > = 95 mmhg if on existing antihypertensive treatment or seated dbp > = 100 mmhg if treatment-na ve ) .,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,NA,NA
1,NCT00553267,Inclusion,diagnosis of essential hypertension and blood pressure not adequately controlled before informed consent ( inadequate control defined as seated diastolic blood pressure ( dbp ) > = 95 mmhg if on existing antihypertensive treatment or seated dbp > = 100 mmhg if treatment-na ve ) .,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 95 mmhg,NA
1,NCT00553267,Inclusion,diagnosis of essential hypertension and blood pressure not adequately controlled before informed consent ( inadequate control defined as seated diastolic blood pressure ( dbp ) > = 95 mmhg if on existing antihypertensive treatment or seated dbp > = 100 mmhg if treatment-na ve ) .,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 100 mmhg,NA
1,NCT00553267,Inclusion,diagnosis of essential hypertension and blood pressure not adequately controlled before informed consent ( inadequate control defined as seated diastolic blood pressure ( dbp ) > = 95 mmhg if on existing antihypertensive treatment or seated dbp > = 100 mmhg if treatment-na ve ) .,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
2,NCT00553267,Inclusion,failure to respond to six weeks treatment with amlodipine 10 mg,Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,equal 10 mg
3,NCT00553267,Inclusion,( failure to respond defined as seated dbp > = 90 mmhg ; ),Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 90 mmhg,NA
3,NCT00553267,Inclusion,( failure to respond defined as seated dbp > = 90 mmhg ; ),Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
4,NCT00553267,Inclusion,able to stop any current antihypertensive therapy without unacceptable risk to the patient .,Procedure,Drug,C0723457,stop,FALSE,FALSE,NA,NA,NA
4,NCT00553267,Inclusion,able to stop any current antihypertensive therapy without unacceptable risk to the patient .,Procedure,Procedure,C0585941,antihypertensive therapy,FALSE,FALSE,NA,NA,NA
5,NCT00553267,Inclusion,willing and able to provide written informed consent .,Other,NA,NA,NA,NA,NA,NA,NA,NA
6,NCT00553267,Exclusion,pregnancy ; breast-feeding ; unwilling to use effective contraception ( if female of child-bearing potential ) .,Condition Occurrence,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
6,NCT00553267,Exclusion,pregnancy ; breast-feeding ; unwilling to use effective contraception ( if female of child-bearing potential ) .,Condition Occurrence,Condition,C0006147;C1623041;C1623040,breast-feeding,FALSE,FALSE,NA,NA,NA
6,NCT00553267,Exclusion,pregnancy ; breast-feeding ; unwilling to use effective contraception ( if female of child-bearing potential ) .,Condition Occurrence,Procedure,C0700589,contraception,FALSE,FALSE,NA,NA,NA
6,NCT00553267,Exclusion,pregnancy ; breast-feeding ; unwilling to use effective contraception ( if female of child-bearing potential ) .,Condition Occurrence,Observation,C3831118,child-bearing potential,FALSE,FALSE,NA,NA,NA
6,NCT00553267,Exclusion,pregnancy ; breast-feeding ; unwilling to use effective contraception ( if female of child-bearing potential ) .,Condition Occurrence,Other,C0032961;C3484365,pregnancy,FALSE,FALSE,NA,NA,NA
7,NCT00553267,Exclusion,known or suspected secondary hypertension .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
8,NCT00553267,Exclusion,mean seated systolic blood pressure ( sbp ) > = 200 mmhg or mean seated dbp > = 120 mmhg during run-in treatment or mean seated sbp > = 180 mmhg or mean seated dbp > = 120 mmhg at the randomisation visit or at any time during randomised treatment .,Observation,Condition,C2024467,time,FALSE,FALSE,NA,NA,NA
8,NCT00553267,Exclusion,mean seated systolic blood pressure ( sbp ) > = 200 mmhg or mean seated dbp > = 120 mmhg during run-in treatment or mean seated sbp > = 180 mmhg or mean seated dbp > = 120 mmhg at the randomisation visit or at any time during randomised treatment .,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,NA,NA
8,NCT00553267,Exclusion,mean seated systolic blood pressure ( sbp ) > = 200 mmhg or mean seated dbp > = 120 mmhg during run-in treatment or mean seated sbp > = 180 mmhg or mean seated dbp > = 120 mmhg at the randomisation visit or at any time during randomised treatment .,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 200 mmhg,NA
8,NCT00553267,Exclusion,mean seated systolic blood pressure ( sbp ) > = 200 mmhg or mean seated dbp > = 120 mmhg during run-in treatment or mean seated sbp > = 180 mmhg or mean seated dbp > = 120 mmhg at the randomisation visit or at any time during randomised treatment .,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 120 mmhg,NA
8,NCT00553267,Exclusion,mean seated systolic blood pressure ( sbp ) > = 200 mmhg or mean seated dbp > = 120 mmhg during run-in treatment or mean seated sbp > = 180 mmhg or mean seated dbp > = 120 mmhg at the randomisation visit or at any time during randomised treatment .,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 180 mmhg,NA
8,NCT00553267,Exclusion,mean seated systolic blood pressure ( sbp ) > = 200 mmhg or mean seated dbp > = 120 mmhg during run-in treatment or mean seated sbp > = 180 mmhg or mean seated dbp > = 120 mmhg at the randomisation visit or at any time during randomised treatment .,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 120 mmhg,NA
9,NCT00553267,Exclusion,any clinically significant hepatic impairment or severe renal impairment bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post post-renal transplant .,Condition Occurrence,Condition,C0948807,hepatic impairment,FALSE,FALSE,NA,NA,NA
9,NCT00553267,Exclusion,any clinically significant hepatic impairment or severe renal impairment bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post post-renal transplant .,Condition Occurrence,Condition,C1565489;C0035078,renal impairment,FALSE,FALSE,NA,NA,NA
9,NCT00553267,Exclusion,any clinically significant hepatic impairment or severe renal impairment bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post post-renal transplant .,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
9,NCT00553267,Exclusion,any clinically significant hepatic impairment or severe renal impairment bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post post-renal transplant .,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
9,NCT00553267,Exclusion,any clinically significant hepatic impairment or severe renal impairment bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post post-renal transplant .,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
9,NCT00553267,Exclusion,any clinically significant hepatic impairment or severe renal impairment bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post post-renal transplant .,Condition Occurrence,Condition,C0478647,transplant,FALSE,FALSE,NA,NA,NA
9,NCT00553267,Exclusion,any clinically significant hepatic impairment or severe renal impairment bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post post-renal transplant .,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
10,NCT00553267,Exclusion,clinically relevant hyperkalaemia .,Other,NA,NA,NA,NA,NA,NA,NA,NA
11,NCT00553267,Exclusion,uncorrected volume or sodium depletion .,Condition Occurrence,Condition,C0020625,sodium depletion,FALSE,FALSE,NA,NA,NA
11,NCT00553267,Exclusion,uncorrected volume or sodium depletion .,Condition Occurrence,Observation,C1705102;C2700258,volume,FALSE,FALSE,NA,NA,NA
12,NCT00553267,Exclusion,primary aldosteronism .,Condition Occurrence,Condition,C1384514,primary aldosteronism,FALSE,FALSE,NA,NA,NA
13,NCT00553267,Exclusion,hereditary fructose or lactose intolerance .,Drug Exposure,Condition,C0022951,lactose intolerance,FALSE,FALSE,NA,NA,NA
13,NCT00553267,Exclusion,hereditary fructose or lactose intolerance .,Drug Exposure,Other,C0016745;C0391940,fructose,FALSE,FALSE,NA,NA,NA
14,NCT00553267,Exclusion,symptomatic congestive heart failure .,Condition Occurrence,Condition,C0742758,symptomatic congestive heart failure,FALSE,FALSE,NA,NA,NA
15,NCT00553267,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or arbs .,Condition Occurrence,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
15,NCT00553267,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or arbs .,Condition Occurrence,Drug,C0003015,ace inhibitors,FALSE,FALSE,NA,NA,NA
16,NCT00553267,Exclusion,history of drug or alcohol dependency within the six months prior to signing consent .,Condition Occurrence,Condition,C0001973,alcohol dependency,FALSE,FALSE,NA,NA,NA
16,NCT00553267,Exclusion,history of drug or alcohol dependency within the six months prior to signing consent .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
17,NCT00553267,Exclusion,concurrent participation in another clinical trial or any investigational therapy within thirty days prior to signing consent .,Procedure,Procedure,C0949266,investigational therapy,FALSE,FALSE,NA,NA,NA
17,NCT00553267,Exclusion,concurrent participation in another clinical trial or any investigational therapy within thirty days prior to signing consent .,Procedure,Other,C1096775,clinical trial,FALSE,FALSE,NA,NA,NA
18,NCT00553267,Exclusion,hypertrophic obstructive cardiomyopathy ; hemodynamically relevant stenosis of the aortic valve or mitral valve .,Condition Occurrence,Condition,C0007194,hypertrophic obstructive cardiomyopathy,FALSE,FALSE,NA,NA,NA
18,NCT00553267,Exclusion,hypertrophic obstructive cardiomyopathy ; hemodynamically relevant stenosis of the aortic valve or mitral valve .,Condition Occurrence,Condition,C0003501;C1269005,aortic valve,FALSE,FALSE,NA,NA,NA
18,NCT00553267,Exclusion,hypertrophic obstructive cardiomyopathy ; hemodynamically relevant stenosis of the aortic valve or mitral valve .,Condition Occurrence,Condition,C0026264;C1269004,mitral valve,FALSE,FALSE,NA,NA,NA
18,NCT00553267,Exclusion,hypertrophic obstructive cardiomyopathy ; hemodynamically relevant stenosis of the aortic valve or mitral valve .,Condition Occurrence,Observation,C1261287;C0947637;C0009814,stenosis,FALSE,FALSE,NA,NA,NA
19,NCT00553267,Exclusion,known allergic hypersensitivity to any component of the formulations under investigation,Observation,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
20,NCT00553267,Exclusion,( includes known hypersensitivity to telmisartan or other arbs or amlodipine or other dihydropyridine ccbs ; ),Drug Exposure,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,NA
20,NCT00553267,Exclusion,( includes known hypersensitivity to telmisartan or other arbs or amlodipine or other dihydropyridine ccbs ; ),Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,NA
20,NCT00553267,Exclusion,( includes known hypersensitivity to telmisartan or other arbs or amlodipine or other dihydropyridine ccbs ; ),Drug Exposure,Drug,C0220821;C3537269,dihydropyridine,FALSE,FALSE,NA,NA,NA
20,NCT00553267,Exclusion,( includes known hypersensitivity to telmisartan or other arbs or amlodipine or other dihydropyridine ccbs ; ),Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
21,NCT00553267,Exclusion,non-compliance with study medication ( defined as less than 80 % or more than 120 % ) during the open-label run-in treatment period .,Drug Exposure,Condition,C0376405,non-compliance,FALSE,FALSE,NA,NA,NA
21,NCT00553267,Exclusion,non-compliance with study medication ( defined as less than 80 % or more than 120 % ) during the open-label run-in treatment period .,Drug Exposure,Other,C3539106,defined,FALSE,FALSE,NA,NA,lower 80 %; greater 120 %
21,NCT00553267,Exclusion,non-compliance with study medication ( defined as less than 80 % or more than 120 % ) during the open-label run-in treatment period .,Drug Exposure,Other,C1705425,label,FALSE,FALSE,NA,NA,NA
22,NCT00553267,Exclusion,current treatment with any antihypertensive agents ; whether or not prescribed for this indication ; that cannot be safely stopped ( investigator s decision ) by the start of the run-in period .,Procedure,Drug,C0003364,antihypertensive agents,FALSE,FALSE,NA,NA,NA
22,NCT00553267,Exclusion,current treatment with any antihypertensive agents ; whether or not prescribed for this indication ; that cannot be safely stopped ( investigator s decision ) by the start of the run-in period .,Procedure,Procedure,C2827774,current treatment,FALSE,FALSE,NA,NA,NA
22,NCT00553267,Exclusion,current treatment with any antihypertensive agents ; whether or not prescribed for this indication ; that cannot be safely stopped ( investigator s decision ) by the start of the run-in period .,Procedure,Procedure,C0278329,prescribed,FALSE,FALSE,NA,NA,NA
23,NCT00553267,Exclusion,chronic administration of any medication known to affect blood pressure ; other than the trial medication .,Observation,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
23,NCT00553267,Exclusion,chronic administration of any medication known to affect blood pressure ; other than the trial medication .,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
23,NCT00553267,Exclusion,chronic administration of any medication known to affect blood pressure ; other than the trial medication .,Observation,Other,C1547296;C1555457,chronic,FALSE,FALSE,NA,NA,NA
24,NCT00553267,Exclusion,any other clinical condition which ; in the opinion of the investigator ; would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine,Drug Exposure,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,NA
24,NCT00553267,Exclusion,any other clinical condition which ; in the opinion of the investigator ; would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine,Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,NA
24,NCT00553267,Exclusion,any other clinical condition which ; in the opinion of the investigator ; would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine,Drug Exposure,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
1,NCT00558064,Inclusion,essential hypertensive patients satisfying all of the following criteria ;,Condition Occurrence,Condition,C0857121,hypertensive,FALSE,FALSE,NA,NA,NA
4,NCT00558064,Inclusion,outpatient,Other,NA,NA,NA,NA,NA,NA,NA,NA
5,NCT00558064,Inclusion,patients who are able to stop current anti-hypertensive therapy at visit 1 if taking any anti-hypertensive medications,Drug Exposure,Drug,C0723457,stop,FALSE,FALSE,NA,NA,NA
5,NCT00558064,Inclusion,patients who are able to stop current anti-hypertensive therapy at visit 1 if taking any anti-hypertensive medications,Drug Exposure,Drug,C0003364,anti-hypertensive,FALSE,FALSE,NA,NA,NA
5,NCT00558064,Inclusion,patients who are able to stop current anti-hypertensive therapy at visit 1 if taking any anti-hypertensive medications,Drug Exposure,Drug,C0003364,anti-hypertensive,FALSE,FALSE,NA,NA,NA
6,NCT00558064,Inclusion,patients with an ability to provide written informed consent in accordance with the related laws and guidelines such as good clinical practice ( gcp ) and the pharmaceutical affairs law .,Other,Condition,C0445223,related,FALSE,FALSE,NA,NA,NA
6,NCT00558064,Inclusion,patients with an ability to provide written informed consent in accordance with the related laws and guidelines such as good clinical practice ( gcp ) and the pharmaceutical affairs law .,Other,Other,C0162791;C0220845,guidelines,FALSE,FALSE,NA,NA,NA
6,NCT00558064,Inclusion,patients with an ability to provide written informed consent in accordance with the related laws and guidelines such as good clinical practice ( gcp ) and the pharmaceutical affairs law .,Other,Other,C2986419,good clinical practice,FALSE,FALSE,NA,NA,NA
6,NCT00558064,Inclusion,patients with an ability to provide written informed consent in accordance with the related laws and guidelines such as good clinical practice ( gcp ) and the pharmaceutical affairs law .,Other,Other,C2986419,gcp,FALSE,FALSE,NA,NA,NA
6,NCT00558064,Inclusion,patients with an ability to provide written informed consent in accordance with the related laws and guidelines such as good clinical practice ( gcp ) and the pharmaceutical affairs law .,Other,Other,C0013058;C1135440;C1553890,pharmaceutical,FALSE,FALSE,NA,NA,NA
6,NCT00558064,Inclusion,patients with an ability to provide written informed consent in accordance with the related laws and guidelines such as good clinical practice ( gcp ) and the pharmaceutical affairs law .,Other,Other,C1947938,law,FALSE,FALSE,NA,NA,NA
7,NCT00558064,Exclusion,taking four or more anti-hypertensive medications,Drug Exposure,Drug,C0003364,anti-hypertensive,FALSE,FALSE,NA,NA,NA
8,NCT00558064,Exclusion,secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
9,NCT00558064,Exclusion,mean seated diastolic blood pressure ( dbp ) > 114 mmhg or mean seated systolic blood pressure ( sbp ) > 200 mmhg at visit 1 ; 2 ; 3 ; or 4 ; or mean seated dbp < 90 mmhg at visit 3 .,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,NA,NA
9,NCT00558064,Exclusion,mean seated diastolic blood pressure ( dbp ) > 114 mmhg or mean seated systolic blood pressure ( sbp ) > 200 mmhg at visit 1 ; 2 ; 3 ; or 4 ; or mean seated dbp < 90 mmhg at visit 3 .,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater 114 mmhg,NA
9,NCT00558064,Exclusion,mean seated diastolic blood pressure ( dbp ) > 114 mmhg or mean seated systolic blood pressure ( sbp ) > 200 mmhg at visit 1 ; 2 ; 3 ; or 4 ; or mean seated dbp < 90 mmhg at visit 3 .,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,NA,NA
9,NCT00558064,Exclusion,mean seated diastolic blood pressure ( dbp ) > 114 mmhg or mean seated systolic blood pressure ( sbp ) > 200 mmhg at visit 1 ; 2 ; 3 ; or 4 ; or mean seated dbp < 90 mmhg at visit 3 .,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater 200 mmhg; equal 2 ; equal 4,NA
9,NCT00558064,Exclusion,mean seated diastolic blood pressure ( dbp ) > 114 mmhg or mean seated systolic blood pressure ( sbp ) > 200 mmhg at visit 1 ; 2 ; 3 ; or 4 ; or mean seated dbp < 90 mmhg at visit 3 .,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,lower 90 mmhg; equal 3,NA
10,NCT00558064,Exclusion,sustained ventricular tachycardia or other clinically relevant cardiac arrhythmias,Condition Occurrence,Condition,C0750197,sustained ventricular tachycardia,FALSE,FALSE,NA,NA,NA
10,NCT00558064,Exclusion,sustained ventricular tachycardia or other clinically relevant cardiac arrhythmias,Condition Occurrence,Condition,C0003811,cardiac arrhythmias,FALSE,FALSE,NA,NA,NA
11,NCT00558064,Exclusion,congestive heart failure patients with the new york heart association ( nyha ) functional class iii - class iv,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
11,NCT00558064,Exclusion,congestive heart failure patients with the new york heart association ( nyha ) functional class iii - class iv,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
11,NCT00558064,Exclusion,congestive heart failure patients with the new york heart association ( nyha ) functional class iii - class iv,Condition Occurrence,Other,C0441887;C2698969,class iii,FALSE,FALSE,NA,NA,NA
11,NCT00558064,Exclusion,congestive heart failure patients with the new york heart association ( nyha ) functional class iii - class iv,Condition Occurrence,Other,C0441888;C2698970,class iv,FALSE,FALSE,NA,NA,NA
12,NCT00558064,Exclusion,history of myocardial infarction or cardiac surgery within last 6 months,Condition Occurrence,Procedure,C0018821,cardiac surgery,FALSE,FALSE,equal 6 months,NA,NA
12,NCT00558064,Exclusion,history of myocardial infarction or cardiac surgery within last 6 months,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,equal 6 months,NA,NA
13,NCT00558064,Exclusion,history of coronary artery bypass graft or percutaneous coronary intervention ( pci ) within last 3 months,Procedure,Procedure,C0010055,coronary artery bypass graft,FALSE,FALSE,NA,NA,NA
13,NCT00558064,Exclusion,history of coronary artery bypass graft or percutaneous coronary intervention ( pci ) within last 3 months,Procedure,Procedure,C1532338,percutaneous coronary intervention,FALSE,FALSE,NA,NA,NA
13,NCT00558064,Exclusion,history of coronary artery bypass graft or percutaneous coronary intervention ( pci ) within last 3 months,Procedure,Procedure,C1514496;C1532338,pci,FALSE,FALSE,equal 3 months,NA,NA
14,NCT00558064,Exclusion,history of unstable angina within last 3 months,Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,equal 3 months,NA,NA
15,NCT00558064,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of aortic valve or mitral valve,Condition Occurrence,Condition,C0007194,hypertrophic obstructive cardiomyopathy,FALSE,FALSE,NA,NA,NA
15,NCT00558064,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of aortic valve or mitral valve,Condition Occurrence,Condition,C0003507,aortic stenosis,FALSE,FALSE,NA,NA,NA
15,NCT00558064,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of aortic valve or mitral valve,Condition Occurrence,Condition,C0003501;C1269005,aortic valve,FALSE,FALSE,NA,NA,NA
15,NCT00558064,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of aortic valve or mitral valve,Condition Occurrence,Condition,C0026264;C1269004,mitral valve,FALSE,FALSE,NA,NA,NA
15,NCT00558064,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of aortic valve or mitral valve,Condition Occurrence,Observation,C1261287;C0947637;C0009814,stenosis,FALSE,FALSE,NA,NA,NA
16,NCT00558064,Exclusion,history of stroke or transient ischemic attack within last 6 months,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,equal 6 months,NA,NA
17,NCT00558064,Exclusion,history of sudden exacerbation of renal function with angiotensin ii receptor blockers ( arbs ) or angiotensin converting enzyme ( ace ) inhibitors ; or patients with post-renal transplant or post-nephrectomy,Condition Occurrence,Condition,C0478647,transplant,FALSE,FALSE,NA,NA,NA
17,NCT00558064,Exclusion,history of sudden exacerbation of renal function with angiotensin ii receptor blockers ( arbs ) or angiotensin converting enzyme ( ace ) inhibitors ; or patients with post-renal transplant or post-nephrectomy,Condition Occurrence,Drug,C0003015,ace inhibitors,FALSE,FALSE,NA,NA,NA
17,NCT00558064,Exclusion,history of sudden exacerbation of renal function with angiotensin ii receptor blockers ( arbs ) or angiotensin converting enzyme ( ace ) inhibitors ; or patients with post-renal transplant or post-nephrectomy,Condition Occurrence,Procedure,C0027695;C0176996,nephrectomy,FALSE,FALSE,NA,NA,NA
17,NCT00558064,Exclusion,history of sudden exacerbation of renal function with angiotensin ii receptor blockers ( arbs ) or angiotensin converting enzyme ( ace ) inhibitors ; or patients with post-renal transplant or post-nephrectomy,Condition Occurrence,Other,C0232804;C0022662,renal function,FALSE,FALSE,NA,NA,NA
17,NCT00558064,Exclusion,history of sudden exacerbation of renal function with angiotensin ii receptor blockers ( arbs ) or angiotensin converting enzyme ( ace ) inhibitors ; or patients with post-renal transplant or post-nephrectomy,Condition Occurrence,Other,C2757003;C0521942,angiotensin ii receptor blockers,FALSE,FALSE,NA,NA,NA
17,NCT00558064,Exclusion,history of sudden exacerbation of renal function with angiotensin ii receptor blockers ( arbs ) or angiotensin converting enzyme ( ace ) inhibitors ; or patients with post-renal transplant or post-nephrectomy,Condition Occurrence,Other,C0022709;C0201888;C2258685,angiotensin converting enzyme,FALSE,FALSE,NA,NA,NA
18,NCT00558064,Exclusion,experienced characteristic symptoms of angioedema during treatment with arbs or ace inhibitors,Condition Occurrence,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
18,NCT00558064,Exclusion,experienced characteristic symptoms of angioedema during treatment with arbs or ace inhibitors,Condition Occurrence,Drug,C0003015,ace inhibitors,FALSE,FALSE,NA,NA,NA
19,NCT00558064,Exclusion,known hypersensitivity to any component of the investigational drug ; or a known hypersensitivity to dihydropyridine derived drugs,Drug Exposure,Drug,C0013230,investigational drug,FALSE,FALSE,NA,NA,NA
19,NCT00558064,Exclusion,known hypersensitivity to any component of the investigational drug ; or a known hypersensitivity to dihydropyridine derived drugs,Drug Exposure,Drug,C0220821;C3537269,dihydropyridine,FALSE,FALSE,NA,NA,NA
19,NCT00558064,Exclusion,known hypersensitivity to any component of the investigational drug ; or a known hypersensitivity to dihydropyridine derived drugs,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
19,NCT00558064,Exclusion,known hypersensitivity to any component of the investigational drug ; or a known hypersensitivity to dihydropyridine derived drugs,Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
19,NCT00558064,Exclusion,known hypersensitivity to any component of the investigational drug ; or a known hypersensitivity to dihydropyridine derived drugs,Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
20,NCT00558064,Exclusion,hepatic dysfunction or renal dysfunction,Condition Occurrence,Condition,C0086565,hepatic dysfunction,FALSE,FALSE,NA,NA,NA
20,NCT00558064,Exclusion,hepatic dysfunction or renal dysfunction,Condition Occurrence,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
21,NCT00558064,Exclusion,diagnosed biliary atresia or cholestasis,Condition Occurrence,Condition,C0005411,biliary atresia,FALSE,FALSE,NA,NA,NA
21,NCT00558064,Exclusion,diagnosed biliary atresia or cholestasis,Condition Occurrence,Condition,C0008370,cholestasis,FALSE,FALSE,NA,NA,NA
22,NCT00558064,Exclusion,hyperkalemia,Condition Occurrence,Condition,C0020461,hyperkalemia,FALSE,FALSE,NA,NA,NA
23,NCT00558064,Exclusion,dehydration,Condition Occurrence,Condition,C0011175;C1963090,dehydration,FALSE,FALSE,NA,NA,NA
24,NCT00558064,Exclusion,sodium deficiency ; chronic administration of high doses of acidic nonsteroidal anti-inflammatory drugs ( nsaids ),Drug Exposure,Condition,C1971019;C0020625,sodium deficiency,FALSE,FALSE,NA,NA,NA
24,NCT00558064,Exclusion,sodium deficiency ; chronic administration of high doses of acidic nonsteroidal anti-inflammatory drugs ( nsaids ),Drug Exposure,Drug,C0003211,nonsteroidal anti-inflammatory drugs,FALSE,FALSE,NA,NA,NA
24,NCT00558064,Exclusion,sodium deficiency ; chronic administration of high doses of acidic nonsteroidal anti-inflammatory drugs ( nsaids ),Drug Exposure,Drug,C0003211,nsaids,FALSE,FALSE,NA,NA,NA
24,NCT00558064,Exclusion,sodium deficiency ; chronic administration of high doses of acidic nonsteroidal anti-inflammatory drugs ( nsaids ),Drug Exposure,Observation,C2700149,high,FALSE,FALSE,NA,NA,NA
24,NCT00558064,Exclusion,sodium deficiency ; chronic administration of high doses of acidic nonsteroidal anti-inflammatory drugs ( nsaids ),Drug Exposure,Other,C1547296;C1555457,chronic,FALSE,FALSE,NA,NA,NA
25,NCT00558064,Exclusion,patients who cannot change to the restricted administration and dosage during study period,Other,Other,C1549594,restricted,TRUE,FALSE,NA,NA,NA
26,NCT00558064,Exclusion,pre-menopausal women who meet any one of the following 1 - 3 :,Observation,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
26,NCT00558064,Exclusion,pre-menopausal women who meet any one of the following 1 - 3 :,Observation,Condition,C1096235,pre-menopausal,FALSE,FALSE,NA,NA,NA
27,NCT00558064,Exclusion,pregnant or possibly pregnant 1,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
27,NCT00558064,Exclusion,pregnant or possibly pregnant 1,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
28,NCT00558064,Exclusion,nursing 2,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
29,NCT00558064,Exclusion,desire to become pregnant during study period 3,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
30,NCT00558064,Exclusion,drug or alcohol dependency,Condition Occurrence,Condition,C0001973,alcohol dependency,FALSE,FALSE,NA,NA,NA
30,NCT00558064,Exclusion,drug or alcohol dependency,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
31,NCT00558064,Exclusion,complication of malignant tumour or a disease requiring immunosuppressants,Condition Occurrence,Condition,C0006826,malignant tumour,FALSE,FALSE,NA,NA,NA
32,NCT00558064,Exclusion,compliance of < 80 % or > 120 % during the run-in period,Drug Exposure,NA,NA,NA,NA,NA,NA,NA,NA
33,NCT00558064,Exclusion,receiving any investigational therapy within 3 months,Procedure,Procedure,C0949266,investigational therapy,FALSE,FALSE,lower 3 months,NA,NA
34,NCT00558064,Exclusion,judged to be inappropriate by the investigator or the sub-investigator,Other,NA,NA,NA,NA,NA,NA,NA,NA
2,NCT00558064,Inclusion,male or female,Person,Person,C0025266,male,FALSE,FALSE,NA,NA,NA
2,NCT00558064,Inclusion,male or female,Person,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
3,NCT00558064,Inclusion,age > 20 years,Person,Person,C0001779,age,FALSE,FALSE,greater 20 years,NA,NA
1,NCT00558428,Inclusion,patients aged at least 18 years at the date of signing the consent form,Other,Person,C0001792,aged,FALSE,FALSE,greater_equal 18 years,NA,NA
1,NCT00558428,Inclusion,patients aged at least 18 years at the date of signing the consent form,Other,Other,C0009797,consent form,FALSE,FALSE,NA,NA,NA
2,NCT00558428,Inclusion,diagnosis of essential hypertension and blood pressure not adequately controlled before enrolment in the study,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00558428,Inclusion,diagnosis of essential hypertension and blood pressure not adequately controlled before enrolment in the study,Condition Occurrence,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
3,NCT00558428,Inclusion,failure to respond adequately to six weeks treatment with amlodipine 5 mg monotherapy,Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,equal 5 mg
4,NCT00558428,Inclusion,able to stop any current antihypertensive therapy without unacceptable risk to the patient ( investigator decision ) ; willing and able to provide written informed consent ( in accordance with good clinical practice and local legislation ) .,Other,Drug,C0723457,stop,FALSE,FALSE,NA,NA,NA
4,NCT00558428,Inclusion,able to stop any current antihypertensive therapy without unacceptable risk to the patient ( investigator decision ) ; willing and able to provide written informed consent ( in accordance with good clinical practice and local legislation ) .,Other,Procedure,C0585941,antihypertensive therapy,FALSE,FALSE,NA,NA,NA
4,NCT00558428,Inclusion,able to stop any current antihypertensive therapy without unacceptable risk to the patient ( investigator decision ) ; willing and able to provide written informed consent ( in accordance with good clinical practice and local legislation ) .,Other,Other,C2986419,good clinical practice,FALSE,FALSE,NA,NA,NA
4,NCT00558428,Inclusion,able to stop any current antihypertensive therapy without unacceptable risk to the patient ( investigator decision ) ; willing and able to provide written informed consent ( in accordance with good clinical practice and local legislation ) .,Other,Other,C0600657,legislation,FALSE,FALSE,NA,NA,NA
5,NCT00558428,Exclusion,are not practising acceptable means of birth control or do not plan to continue using acceptable means of birth control throughout the study and do not agree to submit to pregnancy testing during participation in the trial,Condition Occurrence,Observation,C0032976,pregnancy testing,FALSE,FALSE,NA,NA,NA
5,NCT00558428,Exclusion,are not practising acceptable means of birth control or do not plan to continue using acceptable means of birth control throughout the study and do not agree to submit to pregnancy testing during participation in the trial,Condition Occurrence,Other,C0700589;C2703065,birth control,TRUE,FALSE,NA,NA,NA
5,NCT00558428,Exclusion,are not practising acceptable means of birth control or do not plan to continue using acceptable means of birth control throughout the study and do not agree to submit to pregnancy testing during participation in the trial,Condition Occurrence,Other,C0700589;C2703065,birth control,FALSE,FALSE,NA,NA,NA
5,NCT00558428,Exclusion,are not practising acceptable means of birth control or do not plan to continue using acceptable means of birth control throughout the study and do not agree to submit to pregnancy testing during participation in the trial,Condition Occurrence,Other,C3641827,agree,FALSE,FALSE,NA,NA,NA
6,NCT00558428,Exclusion,acceptable methods of birth control include the transdermal patch ; oral contraceptives ; implantable contraceptives or injectable contraceptives ; sexual abstinence and vasectomised partner .,Drug Exposure,Drug,C0445403;C1707974;C1533128,patch,FALSE,FALSE,NA,NA,NA
6,NCT00558428,Exclusion,acceptable methods of birth control include the transdermal patch ; oral contraceptives ; implantable contraceptives or injectable contraceptives ; sexual abstinence and vasectomised partner .,Drug Exposure,Drug,C0086466;C1272936,injectable,FALSE,FALSE,NA,NA,NA
6,NCT00558428,Exclusion,acceptable methods of birth control include the transdermal patch ; oral contraceptives ; implantable contraceptives or injectable contraceptives ; sexual abstinence and vasectomised partner .,Drug Exposure,Other,C0025663,methods,FALSE,FALSE,NA,NA,NA
6,NCT00558428,Exclusion,acceptable methods of birth control include the transdermal patch ; oral contraceptives ; implantable contraceptives or injectable contraceptives ; sexual abstinence and vasectomised partner .,Drug Exposure,Other,C0700589;C2703065,birth control,FALSE,FALSE,NA,NA,NA
6,NCT00558428,Exclusion,acceptable methods of birth control include the transdermal patch ; oral contraceptives ; implantable contraceptives or injectable contraceptives ; sexual abstinence and vasectomised partner .,Drug Exposure,Other,C0009905;C0274536;C0481121;C1548892,oral contraceptives,FALSE,FALSE,NA,NA,NA
6,NCT00558428,Exclusion,acceptable methods of birth control include the transdermal patch ; oral contraceptives ; implantable contraceptives or injectable contraceptives ; sexual abstinence and vasectomised partner .,Drug Exposure,Other,C0036899,sexual abstinence,FALSE,FALSE,NA,NA,NA
7,NCT00558428,Exclusion,known or suspected secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
8,NCT00558428,Exclusion,mean seated systolic blood pressure ( sbp ) over 200 mmhg or mean seated diastolic blood pressure ( dbp ) over 120 mmhg at visit 1 or 2 or mean seated sbp over 180 mmhg or mean seated dbp over 120 mmhg at the end of the run-in period ( visit 3 ),Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,NA,NA
8,NCT00558428,Exclusion,mean seated systolic blood pressure ( sbp ) over 200 mmhg or mean seated diastolic blood pressure ( dbp ) over 120 mmhg at visit 1 or 2 or mean seated sbp over 180 mmhg or mean seated dbp over 120 mmhg at the end of the run-in period ( visit 3 ),Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater 200 mmhg,NA
8,NCT00558428,Exclusion,mean seated systolic blood pressure ( sbp ) over 200 mmhg or mean seated diastolic blood pressure ( dbp ) over 120 mmhg at visit 1 or 2 or mean seated sbp over 180 mmhg or mean seated dbp over 120 mmhg at the end of the run-in period ( visit 3 ),Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,NA,NA
8,NCT00558428,Exclusion,mean seated systolic blood pressure ( sbp ) over 200 mmhg or mean seated diastolic blood pressure ( dbp ) over 120 mmhg at visit 1 or 2 or mean seated sbp over 180 mmhg or mean seated dbp over 120 mmhg at the end of the run-in period ( visit 3 ),Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater 120 mmhg,NA
8,NCT00558428,Exclusion,mean seated systolic blood pressure ( sbp ) over 200 mmhg or mean seated diastolic blood pressure ( dbp ) over 120 mmhg at visit 1 or 2 or mean seated sbp over 180 mmhg or mean seated dbp over 120 mmhg at the end of the run-in period ( visit 3 ),Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater 180 mmhg,NA
8,NCT00558428,Exclusion,mean seated systolic blood pressure ( sbp ) over 200 mmhg or mean seated diastolic blood pressure ( dbp ) over 120 mmhg at visit 1 or 2 or mean seated sbp over 180 mmhg or mean seated dbp over 120 mmhg at the end of the run-in period ( visit 3 ),Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater 120 mmhg,NA
9,NCT00558428,Exclusion,any clinically significant hepatic impairment ( eg clinically significant cholestasis ; biliary obstructive disorder or hepatic insufficiency ),Condition Occurrence,Condition,C0948807,hepatic impairment,FALSE,FALSE,NA,NA,NA
9,NCT00558428,Exclusion,any clinically significant hepatic impairment ( eg clinically significant cholestasis ; biliary obstructive disorder or hepatic insufficiency ),Condition Occurrence,Condition,C0008370,cholestasis,FALSE,FALSE,NA,NA,NA
9,NCT00558428,Exclusion,any clinically significant hepatic impairment ( eg clinically significant cholestasis ; biliary obstructive disorder or hepatic insufficiency ),Condition Occurrence,Condition,C1306571,hepatic insufficiency,FALSE,FALSE,NA,NA,NA
10,NCT00558428,Exclusion,severe renal impairment ( eg serum creatinine > 3.00 mg / dl or > 265 mcmol / l ; known creatinine clearance < 30 ml / min or clinical markers of severe renal impairment ),Condition Occurrence,Condition,C1565489;C0035078,renal impairment,FALSE,FALSE,NA,NA,NA
10,NCT00558428,Exclusion,severe renal impairment ( eg serum creatinine > 3.00 mg / dl or > 265 mcmol / l ; known creatinine clearance < 30 ml / min or clinical markers of severe renal impairment ),Condition Occurrence,Condition,C1565489;C0035078,renal impairment,FALSE,FALSE,NA,NA,NA
10,NCT00558428,Exclusion,severe renal impairment ( eg serum creatinine > 3.00 mg / dl or > 265 mcmol / l ; known creatinine clearance < 30 ml / min or clinical markers of severe renal impairment ),Condition Occurrence,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,NA,greater 3.00 mg/dl; greater 265 mg/dl
10,NCT00558428,Exclusion,severe renal impairment ( eg serum creatinine > 3.00 mg / dl or > 265 mcmol / l ; known creatinine clearance < 30 ml / min or clinical markers of severe renal impairment ),Condition Occurrence,Observation,C0373595;C0812399,creatinine clearance,FALSE,FALSE,NA,lower 30 ml/min,NA
10,NCT00558428,Exclusion,severe renal impairment ( eg serum creatinine > 3.00 mg / dl or > 265 mcmol / l ; known creatinine clearance < 30 ml / min or clinical markers of severe renal impairment ),Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
10,NCT00558428,Exclusion,severe renal impairment ( eg serum creatinine > 3.00 mg / dl or > 265 mcmol / l ; known creatinine clearance < 30 ml / min or clinical markers of severe renal impairment ),Condition Occurrence,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
10,NCT00558428,Exclusion,severe renal impairment ( eg serum creatinine > 3.00 mg / dl or > 265 mcmol / l ; known creatinine clearance < 30 ml / min or clinical markers of severe renal impairment ),Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
11,NCT00558428,Exclusion,bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post-renal transplant,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
11,NCT00558428,Exclusion,bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post-renal transplant,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
11,NCT00558428,Exclusion,bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post-renal transplant,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
11,NCT00558428,Exclusion,bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post-renal transplant,Condition Occurrence,Condition,C0478647,transplant,FALSE,FALSE,NA,NA,NA
12,NCT00558428,Exclusion,clinically relevant hyperkalaemia,Other,NA,NA,NA,NA,NA,NA,NA,NA
13,NCT00558428,Exclusion,uncorrected volume or sodium depletion .,Condition Occurrence,Condition,C0020625,sodium depletion,FALSE,FALSE,NA,NA,NA
13,NCT00558428,Exclusion,uncorrected volume or sodium depletion .,Condition Occurrence,Observation,C1705102;C2700258,volume,FALSE,FALSE,NA,NA,NA
14,NCT00558428,Exclusion,primary aldosteronism .,Condition Occurrence,Condition,C1384514,primary aldosteronism,FALSE,FALSE,NA,NA,NA
15,NCT00558428,Exclusion,hereditary fructose or lactose intolerance,Drug Exposure,Condition,C0022951,lactose intolerance,FALSE,FALSE,NA,NA,NA
15,NCT00558428,Exclusion,hereditary fructose or lactose intolerance,Drug Exposure,Other,C0016745;C0391940,fructose,FALSE,FALSE,NA,NA,NA
1,NCT00591578,Inclusion,essential hypertension ( defined as sitting trough clinic systolic blood pressure between 150 and 180 mm hg inclusive at day minus 1 and 24 - hour mean systolic blood pressure between 130 and 170 mm hg inclusive at day 1 ) .,Observation,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00591578,Inclusion,essential hypertension ( defined as sitting trough clinic systolic blood pressure between 150 and 180 mm hg inclusive at day minus 1 and 24 - hour mean systolic blood pressure between 130 and 170 mm hg inclusive at day 1 ) .,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
1,NCT00591578,Inclusion,essential hypertension ( defined as sitting trough clinic systolic blood pressure between 150 and 180 mm hg inclusive at day minus 1 and 24 - hour mean systolic blood pressure between 130 and 170 mm hg inclusive at day 1 ) .,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,equal 1 hour; equal 24 hour,greater_equal 150 mm hg; lower_equal 180 mm hg,NA
1,NCT00591578,Inclusion,essential hypertension ( defined as sitting trough clinic systolic blood pressure between 150 and 180 mm hg inclusive at day minus 1 and 24 - hour mean systolic blood pressure between 130 and 170 mm hg inclusive at day 1 ) .,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,equal 1 day,greater_equal 130 mm hg; lower_equal 170 mm hg,NA
1,NCT00591578,Inclusion,essential hypertension ( defined as sitting trough clinic systolic blood pressure between 150 and 180 mm hg inclusive at day minus 1 and 24 - hour mean systolic blood pressure between 130 and 170 mm hg inclusive at day 1 ) .,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
2,NCT00591578,Inclusion,females of childbearing potential who are sexually active must agree to use adequate contraception ; and can neither be pregnant nor lactating from screening throughout the duration of the study . ;,Condition Occurrence,Person,C0086287,females,FALSE,FALSE,NA,NA,NA
2,NCT00591578,Inclusion,females of childbearing potential who are sexually active must agree to use adequate contraception ; and can neither be pregnant nor lactating from screening throughout the duration of the study . ;,Condition Occurrence,Condition,C0241028,sexually active,FALSE,FALSE,NA,NA,NA
2,NCT00591578,Inclusion,females of childbearing potential who are sexually active must agree to use adequate contraception ; and can neither be pregnant nor lactating from screening throughout the duration of the study . ;,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
2,NCT00591578,Inclusion,females of childbearing potential who are sexually active must agree to use adequate contraception ; and can neither be pregnant nor lactating from screening throughout the duration of the study . ;,Condition Occurrence,Condition,C2828358;C3668831,lactating,FALSE,FALSE,NA,NA,NA
2,NCT00591578,Inclusion,females of childbearing potential who are sexually active must agree to use adequate contraception ; and can neither be pregnant nor lactating from screening throughout the duration of the study . ;,Condition Occurrence,Procedure,C0700589,contraception,FALSE,FALSE,NA,NA,NA
2,NCT00591578,Inclusion,females of childbearing potential who are sexually active must agree to use adequate contraception ; and can neither be pregnant nor lactating from screening throughout the duration of the study . ;,Condition Occurrence,Observation,C3831118,childbearing potential,FALSE,FALSE,NA,NA,NA
2,NCT00591578,Inclusion,females of childbearing potential who are sexually active must agree to use adequate contraception ; and can neither be pregnant nor lactating from screening throughout the duration of the study . ;,Condition Occurrence,Other,C3641827,agree,FALSE,FALSE,NA,NA,NA
3,NCT00591578,Inclusion,clinical laboratory evaluations ( including clinical chemistry ; hematology ; and complete urinalysis ) within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator .,Observation,Drug,C1815293,complete,FALSE,FALSE,NA,NA,NA
3,NCT00591578,Inclusion,clinical laboratory evaluations ( including clinical chemistry ; hematology ; and complete urinalysis ) within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator .,Observation,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
3,NCT00591578,Inclusion,clinical laboratory evaluations ( including clinical chemistry ; hematology ; and complete urinalysis ) within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator .,Observation,Observation,C0042014;C0373521,urinalysis,FALSE,FALSE,NA,NA,NA
3,NCT00591578,Inclusion,clinical laboratory evaluations ( including clinical chemistry ; hematology ; and complete urinalysis ) within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator .,Observation,Observation,C3542016,range,FALSE,FALSE,NA,NA,NA
3,NCT00591578,Inclusion,clinical laboratory evaluations ( including clinical chemistry ; hematology ; and complete urinalysis ) within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator .,Observation,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
3,NCT00591578,Inclusion,clinical laboratory evaluations ( including clinical chemistry ; hematology ; and complete urinalysis ) within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator .,Observation,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
3,NCT00591578,Inclusion,clinical laboratory evaluations ( including clinical chemistry ; hematology ; and complete urinalysis ) within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator .,Observation,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
3,NCT00591578,Inclusion,clinical laboratory evaluations ( including clinical chemistry ; hematology ; and complete urinalysis ) within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator .,Observation,Other,C2183231;C1547978,chemistry,FALSE,FALSE,NA,NA,NA
3,NCT00591578,Inclusion,clinical laboratory evaluations ( including clinical chemistry ; hematology ; and complete urinalysis ) within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator .,Observation,Other,C0200627;C0018941;C2183233;C1547985,hematology,FALSE,FALSE,NA,NA,NA
4,NCT00591578,Inclusion,willing to discontinue current antihypertensive medications at the screening day minus 21 visit,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,equal 21,NA
4,NCT00591578,Inclusion,willing to discontinue current antihypertensive medications at the screening day minus 21 visit,Observation,Other,C1706472,discontinue,FALSE,FALSE,NA,NA,NA
5,NCT00591578,Inclusion,if the subject is on amlodipine prior to screening ; the subject is willing to discontinue this medication at screening day minus 28 .,Observation,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,NA
5,NCT00591578,Inclusion,if the subject is on amlodipine prior to screening ; the subject is willing to discontinue this medication at screening day minus 28 .,Observation,Other,C1706472,discontinue,FALSE,FALSE,NA,equal 28,NA
6,NCT00591578,Exclusion,sitting trough clinic diastolic blood pressure greater than 114 mm hg at day minus 1 .,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
6,NCT00591578,Exclusion,sitting trough clinic diastolic blood pressure greater than 114 mm hg at day minus 1 .,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater 114 mm hg; equal 1,NA
7,NCT00591578,Exclusion,the subject has a baseline 24 - hour ambulatory blood pressure monitor reading of insufficient quality .,Condition Occurrence,Condition,C0855316,ambulatory blood pressure,FALSE,FALSE,equal 24 hour,NA,NA
7,NCT00591578,Exclusion,the subject has a baseline 24 - hour ambulatory blood pressure monitor reading of insufficient quality .,Condition Occurrence,Condition,C1705179,reading,FALSE,FALSE,NA,NA,NA
7,NCT00591578,Exclusion,the subject has a baseline 24 - hour ambulatory blood pressure monitor reading of insufficient quality .,Condition Occurrence,Other,C0728873;C0030695,monitor,FALSE,FALSE,NA,NA,NA
8,NCT00591578,Exclusion,is required to take or continues taking any disallowed medication ; prescription medication ; herbal treatment or over-the counter medication that may interfere with evaluation of the study medication .,Other,Drug,C0702263,counter,FALSE,FALSE,NA,NA,NA
8,NCT00591578,Exclusion,is required to take or continues taking any disallowed medication ; prescription medication ; herbal treatment or over-the counter medication that may interfere with evaluation of the study medication .,Other,Other,C3245502;C3245501;C1619636;C1546857,required,FALSE,FALSE,NA,NA,NA
8,NCT00591578,Exclusion,is required to take or continues taking any disallowed medication ; prescription medication ; herbal treatment or over-the counter medication that may interfere with evaluation of the study medication .,Other,Other,C0033081;C2239117,medication prescription,FALSE,FALSE,NA,NA,NA
9,NCT00591578,Exclusion,hypersensitive to angiotensin ii receptor blockers .,Condition Occurrence,Other,C2757003;C0521942,angiotensin ii receptor blockers,FALSE,FALSE,NA,NA,NA
10,NCT00591578,Exclusion,recent history ( within the last 6 months ) of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,lower 6 last months,NA,NA
10,NCT00591578,Exclusion,recent history ( within the last 6 months ) of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,lower 6 last months,NA,NA
10,NCT00591578,Exclusion,recent history ( within the last 6 months ) of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,lower 6 last months,NA,NA
10,NCT00591578,Exclusion,recent history ( within the last 6 months ) of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,lower 6 last months,NA,NA
10,NCT00591578,Exclusion,recent history ( within the last 6 months ) of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,lower 6 last months,NA,NA
10,NCT00591578,Exclusion,recent history ( within the last 6 months ) of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Procedure,C1532338,percutaneous coronary intervention,FALSE,FALSE,lower 6 last months,NA,NA
10,NCT00591578,Exclusion,recent history ( within the last 6 months ) of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Procedure,C0010055,coronary artery bypass graft,FALSE,FALSE,lower 6 last months,NA,NA
10,NCT00591578,Exclusion,recent history ( within the last 6 months ) of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,lower 6 last months,NA,NA
11,NCT00591578,Exclusion,clinically significant cardiac conduction defects ( eg ; 3 rd degree atrioventricular block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation or flutter ) .,Condition Occurrence,Condition,C0264886,cardiac conduction defects,FALSE,FALSE,NA,NA,NA
11,NCT00591578,Exclusion,clinically significant cardiac conduction defects ( eg ; 3 rd degree atrioventricular block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation or flutter ) .,Condition Occurrence,Condition,C0004245;C2108077,atrioventricular block,FALSE,FALSE,NA,NA,NA
11,NCT00591578,Exclusion,clinically significant cardiac conduction defects ( eg ; 3 rd degree atrioventricular block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation or flutter ) .,Condition Occurrence,Condition,C0016385,flutter,FALSE,FALSE,NA,NA,NA
11,NCT00591578,Exclusion,clinically significant cardiac conduction defects ( eg ; 3 rd degree atrioventricular block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation or flutter ) .,Condition Occurrence,Condition,C0037052;C1963235,sick sinus syndrome,FALSE,FALSE,NA,NA,NA
11,NCT00591578,Exclusion,clinically significant cardiac conduction defects ( eg ; 3 rd degree atrioventricular block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation or flutter ) .,Condition Occurrence,Condition,C0023211,left bundle branch block,FALSE,FALSE,NA,NA,NA
11,NCT00591578,Exclusion,clinically significant cardiac conduction defects ( eg ; 3 rd degree atrioventricular block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation or flutter ) .,Condition Occurrence,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
11,NCT00591578,Exclusion,clinically significant cardiac conduction defects ( eg ; 3 rd degree atrioventricular block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation or flutter ) .,Condition Occurrence,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
12,NCT00591578,Exclusion,hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease .,Condition Occurrence,Condition,C0023213,left ventricular outflow obstruction,FALSE,FALSE,NA,NA,NA
12,NCT00591578,Exclusion,hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease .,Condition Occurrence,Condition,C1260873,aortic valvular disease,FALSE,FALSE,NA,NA,NA
13,NCT00591578,Exclusion,secondary hypertension of any etiology .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
14,NCT00591578,Exclusion,non-compliant ( less than 70 % or greater than 130 % ) with study medication during placebo run-in period .,Drug Exposure,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,lower 70 %; greater 130 %
15,NCT00591578,Exclusion,severe renal dysfunction or disease ( based on calculated creatinine clearance less than 30 ml per min / 1.73 m2 ),Observation,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
15,NCT00591578,Exclusion,severe renal dysfunction or disease ( based on calculated creatinine clearance less than 30 ml per min / 1.73 m2 ),Observation,Observation,C0373595;C0812399,creatinine clearance,FALSE,FALSE,NA,lower 30 ml/min; equal 1.73 m2,NA
15,NCT00591578,Exclusion,severe renal dysfunction or disease ( based on calculated creatinine clearance less than 30 ml per min / 1.73 m2 ),Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
16,NCT00591578,Exclusion,at screening .,Other,NA,NA,NA,NA,NA,NA,NA,NA
17,NCT00591578,Exclusion,known or suspected unilateral renal artery or bilateral renal artery stenosis .,Condition Occurrence,Condition,C0035065;C1278951,renal artery,FALSE,FALSE,NA,NA,NA
17,NCT00591578,Exclusion,known or suspected unilateral renal artery or bilateral renal artery stenosis .,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
18,NCT00591578,Exclusion,history of drug or alcohol abuse within the past 2 years .,Condition Occurrence,Condition,C0085762,alcohol abuse,FALSE,FALSE,lower 2 past years,NA,NA
18,NCT00591578,Exclusion,history of drug or alcohol abuse within the past 2 years .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,lower 2 past years,NA,NA
19,NCT00591578,Exclusion,previous history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug,Condition Occurrence,Condition,C0544452,remission,TRUE,FALSE,greater_equal 5 years,NA,NA
19,NCT00591578,Exclusion,previous history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug,Condition Occurrence,Other,C0260515;C2707253,cancer,FALSE,FALSE,NA,NA,NA
19,NCT00591578,Exclusion,previous history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
20,NCT00591578,Exclusion,( this criterion does not apply to those subjects with basal cell or stage 1 squamous cell carcinoma of the skin ) .,Condition Occurrence,Condition,C0007137;C1302853,squamous cell carcinoma,FALSE,FALSE,NA,NA,NA
20,NCT00591578,Exclusion,( this criterion does not apply to those subjects with basal cell or stage 1 squamous cell carcinoma of the skin ) .,Condition Occurrence,Other,C0243161,criterion,FALSE,FALSE,NA,NA,NA
21,NCT00591578,Exclusion,type 1 or poorly controlled type 2 diabetes mellitus ( glycosylated hemoglobin greater than 8.0 % ) at screening .,Condition Occurrence,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
21,NCT00591578,Exclusion,type 1 or poorly controlled type 2 diabetes mellitus ( glycosylated hemoglobin greater than 8.0 % ) at screening .,Condition Occurrence,Observation,C0017853;C0373638;C0202054,glycosylated hemoglobin,FALSE,FALSE,NA,NA,greater 8.0 %
21,NCT00591578,Exclusion,type 1 or poorly controlled type 2 diabetes mellitus ( glycosylated hemoglobin greater than 8.0 % ) at screening .,Condition Occurrence,Other,C1552651,type,FALSE,FALSE,NA,NA,NA
22,NCT00591578,Exclusion,hyperkalemia as defined by the central laboratory normal reference range at screening .,Condition Occurrence,Condition,C0020461,hyperkalemia,FALSE,FALSE,NA,NA,NA
22,NCT00591578,Exclusion,hyperkalemia as defined by the central laboratory normal reference range at screening .,Condition Occurrence,Condition,C0028378,laboratory normal,FALSE,FALSE,NA,NA,NA
22,NCT00591578,Exclusion,hyperkalemia as defined by the central laboratory normal reference range at screening .,Condition Occurrence,Drug,C0719205,central,FALSE,FALSE,NA,NA,NA
22,NCT00591578,Exclusion,hyperkalemia as defined by the central laboratory normal reference range at screening .,Condition Occurrence,Observation,C3542016,range,FALSE,FALSE,NA,NA,NA
22,NCT00591578,Exclusion,hyperkalemia as defined by the central laboratory normal reference range at screening .,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
23,NCT00591578,Exclusion,upper arm circumference less than 24 cm or greater than 42 cm .,Observation,Condition,C0446516;C1269612,upper arm,FALSE,FALSE,NA,lower 24 cm; greater 42 cm,NA
24,NCT00591578,Exclusion,works night ( 3 rd ) shift ( defined as 11 pm to 7 am ) .,Observation,Drug,C1867051,pm,FALSE,FALSE,NA,equal 11 ; equal 7,NA
24,NCT00591578,Exclusion,works night ( 3 rd ) shift ( defined as 11 pm to 7 am ) .,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
25,NCT00591578,Exclusion,alanine aminotransferase level of greater than 2.5 times the upper limit of normal liver disease ; active liver disease ; or jaundice at screening .,Condition Occurrence,Condition,C0023895;C2186532,liver disease,FALSE,FALSE,NA,NA,NA
25,NCT00591578,Exclusion,alanine aminotransferase level of greater than 2.5 times the upper limit of normal liver disease ; active liver disease ; or jaundice at screening .,Condition Occurrence,Condition,C0023895;C2186532,liver disease,FALSE,FALSE,NA,NA,NA
25,NCT00591578,Exclusion,alanine aminotransferase level of greater than 2.5 times the upper limit of normal liver disease ; active liver disease ; or jaundice at screening .,Condition Occurrence,Condition,C2203646,jaundice,FALSE,FALSE,NA,NA,NA
25,NCT00591578,Exclusion,alanine aminotransferase level of greater than 2.5 times the upper limit of normal liver disease ; active liver disease ; or jaundice at screening .,Condition Occurrence,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
25,NCT00591578,Exclusion,alanine aminotransferase level of greater than 2.5 times the upper limit of normal liver disease ; active liver disease ; or jaundice at screening .,Condition Occurrence,Observation,C0001899;C0201836,alanine aminotransferase,FALSE,FALSE,NA,NA,greater 2.5 times the upper limit of normal
26,NCT00591578,Exclusion,currently is participating in another investigational study or has participated in an investigational study within 30 days prior to randomization . ; any other serious disease or condition at screening ( or randomization ) that would compromise subject safety ; might affect life expectancy ; or make it difficult to successfully manage and follow the subject according to the protocol .,Other,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
26,NCT00591578,Exclusion,currently is participating in another investigational study or has participated in an investigational study within 30 days prior to randomization . ; any other serious disease or condition at screening ( or randomization ) that would compromise subject safety ; might affect life expectancy ; or make it difficult to successfully manage and follow the subject according to the protocol .,Other,Other,C3245491,investigational,FALSE,FALSE,NA,NA,NA
26,NCT00591578,Exclusion,currently is participating in another investigational study or has participated in an investigational study within 30 days prior to randomization . ; any other serious disease or condition at screening ( or randomization ) that would compromise subject safety ; might affect life expectancy ; or make it difficult to successfully manage and follow the subject according to the protocol .,Other,Other,C3245491,investigational,FALSE,FALSE,lower 30 days,NA,NA
26,NCT00591578,Exclusion,currently is participating in another investigational study or has participated in an investigational study within 30 days prior to randomization . ; any other serious disease or condition at screening ( or randomization ) that would compromise subject safety ; might affect life expectancy ; or make it difficult to successfully manage and follow the subject according to the protocol .,Other,Other,C0023671,life expectancy,FALSE,FALSE,NA,NA,NA
26,NCT00591578,Exclusion,currently is participating in another investigational study or has participated in an investigational study within 30 days prior to randomization . ; any other serious disease or condition at screening ( or randomization ) that would compromise subject safety ; might affect life expectancy ; or make it difficult to successfully manage and follow the subject according to the protocol .,Other,Other,C1719822,follow,FALSE,FALSE,NA,NA,NA
27,NCT00591578,Exclusion,randomized in a previous azilsartan medoxomil study,Drug Exposure,Drug,C2698291,azilsartan medoxomil,FALSE,FALSE,NA,NA,NA
1,NCT00614380,Inclusion,patients aged at least 18 years,Other,Person,C0001792,aged,FALSE,FALSE,greater_equal 18 years,NA,NA
2,NCT00614380,Inclusion,diagnosis of essential hypertension and blood pressure not adequately controlled before enrolment in the preceding trial .,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00614380,Inclusion,diagnosis of essential hypertension and blood pressure not adequately controlled before enrolment in the preceding trial .,Condition Occurrence,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
3,NCT00614380,Inclusion,failure to respond to six weeks treatment with amlodipine 5 mg in the run-in period of the preceding trial .,Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,equal 5 mg
4,NCT00614380,Exclusion,pre-menopausal women who are not surgically sterile,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
4,NCT00614380,Exclusion,pre-menopausal women who are not surgically sterile,Person,Condition,C1096235,pre-menopausal,FALSE,FALSE,NA,NA,NA
5,NCT00614380,Exclusion,or are nursing or pregnant,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
5,NCT00614380,Exclusion,or are nursing or pregnant,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
6,NCT00614380,Exclusion,or are not practising acceptable means of birth control or do not plan to continue using acceptable means of birth control throughout the study,Condition Occurrence,Other,C0700589;C2703065,birth control,TRUE,FALSE,NA,NA,NA
6,NCT00614380,Exclusion,or are not practising acceptable means of birth control or do not plan to continue using acceptable means of birth control throughout the study,Condition Occurrence,Other,C0700589;C2703065,birth control,FALSE,FALSE,NA,NA,NA
7,NCT00614380,Exclusion,development of any medical condition in the preceding trial that in the investigator opinion could be worsened by treatment with either telmisartan 40 mg / amlodipine 5 mg or telmisartan 80 mg / amlodipine 5 mg,Drug Exposure,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,equal 40 mg
7,NCT00614380,Exclusion,development of any medical condition in the preceding trial that in the investigator opinion could be worsened by treatment with either telmisartan 40 mg / amlodipine 5 mg or telmisartan 80 mg / amlodipine 5 mg,Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,equal 5 mg; equal 80 mg
7,NCT00614380,Exclusion,development of any medical condition in the preceding trial that in the investigator opinion could be worsened by treatment with either telmisartan 40 mg / amlodipine 5 mg or telmisartan 80 mg / amlodipine 5 mg,Drug Exposure,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,equal 80 mg
7,NCT00614380,Exclusion,development of any medical condition in the preceding trial that in the investigator opinion could be worsened by treatment with either telmisartan 40 mg / amlodipine 5 mg or telmisartan 80 mg / amlodipine 5 mg,Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,equal 5 mg
7,NCT00614380,Exclusion,development of any medical condition in the preceding trial that in the investigator opinion could be worsened by treatment with either telmisartan 40 mg / amlodipine 5 mg or telmisartan 80 mg / amlodipine 5 mg,Drug Exposure,Other,C3272564;C0020119;C0243107,development,FALSE,FALSE,NA,NA,NA
7,NCT00614380,Exclusion,development of any medical condition in the preceding trial that in the investigator opinion could be worsened by treatment with either telmisartan 40 mg / amlodipine 5 mg or telmisartan 80 mg / amlodipine 5 mg,Drug Exposure,Other,C1561579;C1561578,medical,FALSE,FALSE,NA,NA,NA
8,NCT00614380,Exclusion,discontinuation from the preceding trial because of any adverse event or any other reason,Condition Occurrence,Condition,C0877248,adverse event,FALSE,FALSE,NA,NA,NA
8,NCT00614380,Exclusion,discontinuation from the preceding trial because of any adverse event or any other reason,Condition Occurrence,Other,C0457454;C1444662,discontinuation,FALSE,FALSE,NA,NA,NA
9,NCT00614380,Exclusion,known or suspected secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
10,NCT00614380,Exclusion,mean seated systolic blood pressure = > 180 mmhg or mean seated diastolic blood pressure = > 120 mmhg at any visit,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater_equal 180 mmhg,NA
10,NCT00614380,Exclusion,mean seated systolic blood pressure = > 180 mmhg or mean seated diastolic blood pressure = > 120 mmhg at any visit,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater_equal 120 mmhg,NA
1,NCT00624052,Inclusion,diagnosis of essential hypertension,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00624052,Exclusion,pregnancy ; breast-feeding ; unwilling to use effective contraception ( if female of child-bearing potential ) .,Condition Occurrence,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
2,NCT00624052,Exclusion,pregnancy ; breast-feeding ; unwilling to use effective contraception ( if female of child-bearing potential ) .,Condition Occurrence,Condition,C0006147;C1623041;C1623040,breast-feeding,FALSE,FALSE,NA,NA,NA
2,NCT00624052,Exclusion,pregnancy ; breast-feeding ; unwilling to use effective contraception ( if female of child-bearing potential ) .,Condition Occurrence,Procedure,C0700589,contraception,FALSE,FALSE,NA,NA,NA
2,NCT00624052,Exclusion,pregnancy ; breast-feeding ; unwilling to use effective contraception ( if female of child-bearing potential ) .,Condition Occurrence,Observation,C3831118,child-bearing potential,FALSE,FALSE,NA,NA,NA
2,NCT00624052,Exclusion,pregnancy ; breast-feeding ; unwilling to use effective contraception ( if female of child-bearing potential ) .,Condition Occurrence,Other,C0032961;C3484365,pregnancy,FALSE,FALSE,NA,NA,NA
3,NCT00624052,Exclusion,development of any condition in the preceding trial that could be worsened by telmisartan 40 mg / amlodipine 10 mg ( t40 / a10 ) or telmisartan 80 mg / amlodipine 10 mg ( t80 / a10 ) .,Drug Exposure,Condition,C0933649,a10,FALSE,FALSE,NA,NA,NA
3,NCT00624052,Exclusion,development of any condition in the preceding trial that could be worsened by telmisartan 40 mg / amlodipine 10 mg ( t40 / a10 ) or telmisartan 80 mg / amlodipine 10 mg ( t80 / a10 ) .,Drug Exposure,Condition,C0933649,a10,FALSE,FALSE,NA,NA,NA
3,NCT00624052,Exclusion,development of any condition in the preceding trial that could be worsened by telmisartan 40 mg / amlodipine 10 mg ( t40 / a10 ) or telmisartan 80 mg / amlodipine 10 mg ( t80 / a10 ) .,Drug Exposure,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,equal 40 mg
3,NCT00624052,Exclusion,development of any condition in the preceding trial that could be worsened by telmisartan 40 mg / amlodipine 10 mg ( t40 / a10 ) or telmisartan 80 mg / amlodipine 10 mg ( t80 / a10 ) .,Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,equal 10 mg
3,NCT00624052,Exclusion,development of any condition in the preceding trial that could be worsened by telmisartan 40 mg / amlodipine 10 mg ( t40 / a10 ) or telmisartan 80 mg / amlodipine 10 mg ( t80 / a10 ) .,Drug Exposure,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,equal 80 mg
3,NCT00624052,Exclusion,development of any condition in the preceding trial that could be worsened by telmisartan 40 mg / amlodipine 10 mg ( t40 / a10 ) or telmisartan 80 mg / amlodipine 10 mg ( t80 / a10 ) .,Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,equal 10 mg
3,NCT00624052,Exclusion,development of any condition in the preceding trial that could be worsened by telmisartan 40 mg / amlodipine 10 mg ( t40 / a10 ) or telmisartan 80 mg / amlodipine 10 mg ( t80 / a10 ) .,Drug Exposure,Other,C3272564;C0020119;C0243107,development,FALSE,FALSE,NA,NA,NA
4,NCT00624052,Exclusion,discontinuation from the preceding trial .,Condition Occurrence,Other,C0457454;C1444662,discontinuation,FALSE,FALSE,NA,NA,NA
5,NCT00624052,Exclusion,known or suspected secondary hypertension .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
6,NCT00624052,Exclusion,mean seated systolic blood pressure ( sbp ) > = 180 mmhg or mean seated diastolic blood pressure ( dbp ) > = 120 mmhg at any visit .,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,NA,NA
6,NCT00624052,Exclusion,mean seated systolic blood pressure ( sbp ) > = 180 mmhg or mean seated diastolic blood pressure ( dbp ) > = 120 mmhg at any visit .,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 180 mmhg,NA
6,NCT00624052,Exclusion,mean seated systolic blood pressure ( sbp ) > = 180 mmhg or mean seated diastolic blood pressure ( dbp ) > = 120 mmhg at any visit .,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,NA,NA
6,NCT00624052,Exclusion,mean seated systolic blood pressure ( sbp ) > = 180 mmhg or mean seated diastolic blood pressure ( dbp ) > = 120 mmhg at any visit .,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 120 mmhg,NA
7,NCT00624052,Exclusion,any clinically significant hepatic impairment or severe renal impairment bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post post-renal transplant .,Condition Occurrence,Condition,C0948807,hepatic impairment,FALSE,FALSE,NA,NA,NA
7,NCT00624052,Exclusion,any clinically significant hepatic impairment or severe renal impairment bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post post-renal transplant .,Condition Occurrence,Condition,C1565489;C0035078,renal impairment,FALSE,FALSE,NA,NA,NA
7,NCT00624052,Exclusion,any clinically significant hepatic impairment or severe renal impairment bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post post-renal transplant .,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
7,NCT00624052,Exclusion,any clinically significant hepatic impairment or severe renal impairment bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post post-renal transplant .,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
7,NCT00624052,Exclusion,any clinically significant hepatic impairment or severe renal impairment bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post post-renal transplant .,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
7,NCT00624052,Exclusion,any clinically significant hepatic impairment or severe renal impairment bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post post-renal transplant .,Condition Occurrence,Condition,C0478647,transplant,FALSE,FALSE,NA,NA,NA
7,NCT00624052,Exclusion,any clinically significant hepatic impairment or severe renal impairment bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post post-renal transplant .,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
8,NCT00624052,Exclusion,clinically relevant hyperkalaemia .,Other,NA,NA,NA,NA,NA,NA,NA,NA
9,NCT00624052,Exclusion,uncorrected volume or sodium depletion .,Condition Occurrence,Condition,C0020625,sodium depletion,FALSE,FALSE,NA,NA,NA
9,NCT00624052,Exclusion,uncorrected volume or sodium depletion .,Condition Occurrence,Observation,C1705102;C2700258,volume,FALSE,FALSE,NA,NA,NA
10,NCT00624052,Exclusion,primary aldosteronism .,Condition Occurrence,Condition,C1384514,primary aldosteronism,FALSE,FALSE,NA,NA,NA
11,NCT00624052,Exclusion,hereditary fructose or lactose intolerance .,Drug Exposure,Condition,C0022951,lactose intolerance,FALSE,FALSE,NA,NA,NA
11,NCT00624052,Exclusion,hereditary fructose or lactose intolerance .,Drug Exposure,Other,C0016745;C0391940,fructose,FALSE,FALSE,NA,NA,NA
12,NCT00624052,Exclusion,symptomatic congestive heart failure .,Condition Occurrence,Condition,C0742758,symptomatic congestive heart failure,FALSE,FALSE,NA,NA,NA
13,NCT00624052,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with angiotensin converting enzyme ( ace ) inhibitors or angiotensin receptor blockers ( arbs ) .,Drug Exposure,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
13,NCT00624052,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with angiotensin converting enzyme ( ace ) inhibitors or angiotensin receptor blockers ( arbs ) .,Drug Exposure,Drug,C0003015,ace inhibitors,FALSE,FALSE,NA,NA,NA
13,NCT00624052,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with angiotensin converting enzyme ( ace ) inhibitors or angiotensin receptor blockers ( arbs ) .,Drug Exposure,Drug,C0521942;C0815017,angiotensin receptor blockers,FALSE,FALSE,NA,NA,NA
13,NCT00624052,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with angiotensin converting enzyme ( ace ) inhibitors or angiotensin receptor blockers ( arbs ) .,Drug Exposure,Other,C0022709;C0201888;C2258685,angiotensin converting enzyme,FALSE,FALSE,NA,NA,NA
14,NCT00624052,Exclusion,any new drug or alcohol dependency since signing consent of the preceding trial .,Condition Occurrence,Condition,C0001973,alcohol dependency,FALSE,FALSE,NA,NA,NA
14,NCT00624052,Exclusion,any new drug or alcohol dependency since signing consent of the preceding trial .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
15,NCT00624052,Exclusion,concurrent participation in another clinical trial or any investigational therapy since completing the preceding trial .,Procedure,Procedure,C0949266,investigational therapy,FALSE,FALSE,NA,NA,NA
15,NCT00624052,Exclusion,concurrent participation in another clinical trial or any investigational therapy since completing the preceding trial .,Procedure,Other,C1096775,clinical trial,FALSE,FALSE,NA,NA,NA
16,NCT00624052,Exclusion,hypertrophic obstructive cardiomyopathy ; hemodynamically relevant stenosis of the aortic valve or mitral valve .,Condition Occurrence,Condition,C0007194,hypertrophic obstructive cardiomyopathy,FALSE,FALSE,NA,NA,NA
16,NCT00624052,Exclusion,hypertrophic obstructive cardiomyopathy ; hemodynamically relevant stenosis of the aortic valve or mitral valve .,Condition Occurrence,Condition,C0003501;C1269005,aortic valve,FALSE,FALSE,NA,NA,NA
16,NCT00624052,Exclusion,hypertrophic obstructive cardiomyopathy ; hemodynamically relevant stenosis of the aortic valve or mitral valve .,Condition Occurrence,Condition,C0026264;C1269004,mitral valve,FALSE,FALSE,NA,NA,NA
16,NCT00624052,Exclusion,hypertrophic obstructive cardiomyopathy ; hemodynamically relevant stenosis of the aortic valve or mitral valve .,Condition Occurrence,Observation,C1261287;C0947637;C0009814,stenosis,FALSE,FALSE,NA,NA,NA
17,NCT00624052,Exclusion,known allergic hypersensitivity to any component of the formulations under investigation,Observation,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
18,NCT00624052,Exclusion,[ includes known hypersensitivity to telmisartan or other arbs or amlodipine or other dihydropyridine calcium channel blockers ( ccbs ) ; ] non-compliance with study medication ( defined as < 80 % or > 120 % ) during the preceding trial .,Drug Exposure,Condition,C0376405,non-compliance,FALSE,FALSE,NA,NA,NA
18,NCT00624052,Exclusion,[ includes known hypersensitivity to telmisartan or other arbs or amlodipine or other dihydropyridine calcium channel blockers ( ccbs ) ; ] non-compliance with study medication ( defined as < 80 % or > 120 % ) during the preceding trial .,Drug Exposure,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,NA
18,NCT00624052,Exclusion,[ includes known hypersensitivity to telmisartan or other arbs or amlodipine or other dihydropyridine calcium channel blockers ( ccbs ) ; ] non-compliance with study medication ( defined as < 80 % or > 120 % ) during the preceding trial .,Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,NA
18,NCT00624052,Exclusion,[ includes known hypersensitivity to telmisartan or other arbs or amlodipine or other dihydropyridine calcium channel blockers ( ccbs ) ; ] non-compliance with study medication ( defined as < 80 % or > 120 % ) during the preceding trial .,Drug Exposure,Drug,C0220821;C3537269,dihydropyridine,FALSE,FALSE,NA,NA,NA
18,NCT00624052,Exclusion,[ includes known hypersensitivity to telmisartan or other arbs or amlodipine or other dihydropyridine calcium channel blockers ( ccbs ) ; ] non-compliance with study medication ( defined as < 80 % or > 120 % ) during the preceding trial .,Drug Exposure,Drug,C0006684,calcium channel blockers,FALSE,FALSE,NA,NA,NA
18,NCT00624052,Exclusion,[ includes known hypersensitivity to telmisartan or other arbs or amlodipine or other dihydropyridine calcium channel blockers ( ccbs ) ; ] non-compliance with study medication ( defined as < 80 % or > 120 % ) during the preceding trial .,Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
18,NCT00624052,Exclusion,[ includes known hypersensitivity to telmisartan or other arbs or amlodipine or other dihydropyridine calcium channel blockers ( ccbs ) ; ] non-compliance with study medication ( defined as < 80 % or > 120 % ) during the preceding trial .,Drug Exposure,Other,C3539106,defined,FALSE,FALSE,NA,NA,lower 80 %; greater 120 %
19,NCT00624052,Exclusion,administration of arbs or dihydropyridine ccbs ( apart from trial medication ),Drug Exposure,Drug,C0220821;C3537269,dihydropyridine,FALSE,FALSE,NA,NA,NA
20,NCT00624052,Exclusion,any other clinical condition which ; in the opinion of the investigator ; would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine,Drug Exposure,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,NA
20,NCT00624052,Exclusion,any other clinical condition which ; in the opinion of the investigator ; would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine,Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,NA
20,NCT00624052,Exclusion,any other clinical condition which ; in the opinion of the investigator ; would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine,Drug Exposure,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
1,NCT00631917,Inclusion,male or female outpatients ; 50 years of age and older with a diagnosis of essential hypertension,Person,Person,C0025266,male,FALSE,FALSE,NA,NA,NA
1,NCT00631917,Inclusion,male or female outpatients ; 50 years of age and older with a diagnosis of essential hypertension,Person,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
1,NCT00631917,Inclusion,male or female outpatients ; 50 years of age and older with a diagnosis of essential hypertension,Person,Person,C0001779,age,FALSE,FALSE,equal 50 years,NA,NA
1,NCT00631917,Inclusion,male or female outpatients ; 50 years of age and older with a diagnosis of essential hypertension,Person,Person,C0001779,older,FALSE,FALSE,equal 50 years,NA,NA
1,NCT00631917,Inclusion,male or female outpatients ; 50 years of age and older with a diagnosis of essential hypertension,Person,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00631917,Inclusion,successful high quality colonoscopy at baseline including visualization of the entire colon and the cecum as confirmed by a photograph and collection of the rectal and cecal mucosal biopsy samples,Observation,Condition,C1281569,entire colon,FALSE,FALSE,NA,NA,NA
2,NCT00631917,Inclusion,successful high quality colonoscopy at baseline including visualization of the entire colon and the cecum as confirmed by a photograph and collection of the rectal and cecal mucosal biopsy samples,Observation,Condition,C0153437;C0496859;C0007531;C1278925,cecum,FALSE,FALSE,NA,NA,NA
2,NCT00631917,Inclusion,successful high quality colonoscopy at baseline including visualization of the entire colon and the cecum as confirmed by a photograph and collection of the rectal and cecal mucosal biopsy samples,Observation,Drug,C1272938,rectal,FALSE,FALSE,NA,NA,NA
2,NCT00631917,Inclusion,successful high quality colonoscopy at baseline including visualization of the entire colon and the cecum as confirmed by a photograph and collection of the rectal and cecal mucosal biopsy samples,Observation,Observation,C2700149,high,FALSE,FALSE,NA,NA,NA
2,NCT00631917,Inclusion,successful high quality colonoscopy at baseline including visualization of the entire colon and the cecum as confirmed by a photograph and collection of the rectal and cecal mucosal biopsy samples,Observation,Observation,C0852695,mucosal biopsy,FALSE,FALSE,NA,NA,NA
2,NCT00631917,Inclusion,successful high quality colonoscopy at baseline including visualization of the entire colon and the cecum as confirmed by a photograph and collection of the rectal and cecal mucosal biopsy samples,Observation,Other,C0009378;C0372087;C1548837,colonoscopy,FALSE,FALSE,NA,NA,NA
3,NCT00631917,Inclusion,all rectal ; colon or cecal polyps found at baseline colonoscopy must be completely resected endoscopically at the time of the procedure .,Condition Occurrence,Condition,C1112566,cecal polyps,FALSE,FALSE,NA,NA,NA
3,NCT00631917,Inclusion,all rectal ; colon or cecal polyps found at baseline colonoscopy must be completely resected endoscopically at the time of the procedure .,Condition Occurrence,Condition,C0009373;C0154061;C0496907;C0009368;C0750873;C1281569,colon,FALSE,FALSE,NA,NA,NA
3,NCT00631917,Inclusion,all rectal ; colon or cecal polyps found at baseline colonoscopy must be completely resected endoscopically at the time of the procedure .,Condition Occurrence,Condition,C2024467,time,FALSE,FALSE,NA,NA,NA
3,NCT00631917,Inclusion,all rectal ; colon or cecal polyps found at baseline colonoscopy must be completely resected endoscopically at the time of the procedure .,Condition Occurrence,Drug,C1272938,rectal,FALSE,FALSE,NA,NA,NA
3,NCT00631917,Inclusion,all rectal ; colon or cecal polyps found at baseline colonoscopy must be completely resected endoscopically at the time of the procedure .,Condition Occurrence,Procedure,C3274817,baseline colonoscopy,FALSE,FALSE,NA,NA,NA
4,NCT00631917,Inclusion,patients who are eligible and able to participate in the study ; and who consent to do so after the purpose and nature of the investigation have been clearly explained to them ( written informed consent ) .,Drug Exposure,Drug,C1995603,purpose,FALSE,FALSE,NA,NA,NA
5,NCT00631917,Exclusion,previously treated in an aliskiren study .,Drug Exposure,Drug,C1120110,aliskiren,FALSE,FALSE,NA,NA,NA
6,NCT00631917,Exclusion,current evidence of inflammatory bowel disease ; the presence of colonic ulcerations ( or other indices of colitis of any type ) or colorectal carcinoma including carcinoma in situ found at baseline colonoscopy .,Condition Occurrence,Condition,C0021390,inflammatory bowel disease,FALSE,FALSE,NA,NA,NA
6,NCT00631917,Exclusion,current evidence of inflammatory bowel disease ; the presence of colonic ulcerations ( or other indices of colitis of any type ) or colorectal carcinoma including carcinoma in situ found at baseline colonoscopy .,Condition Occurrence,Condition,C0009319;C1963084,colitis,FALSE,FALSE,NA,NA,NA
6,NCT00631917,Exclusion,current evidence of inflammatory bowel disease ; the presence of colonic ulcerations ( or other indices of colitis of any type ) or colorectal carcinoma including carcinoma in situ found at baseline colonoscopy .,Condition Occurrence,Condition,C0009402,colorectal carcinoma,FALSE,FALSE,NA,NA,NA
6,NCT00631917,Exclusion,current evidence of inflammatory bowel disease ; the presence of colonic ulcerations ( or other indices of colitis of any type ) or colorectal carcinoma including carcinoma in situ found at baseline colonoscopy .,Condition Occurrence,Condition,C0007099,carcinoma in situ,FALSE,FALSE,NA,NA,NA
6,NCT00631917,Exclusion,current evidence of inflammatory bowel disease ; the presence of colonic ulcerations ( or other indices of colitis of any type ) or colorectal carcinoma including carcinoma in situ found at baseline colonoscopy .,Condition Occurrence,Procedure,C3274817,baseline colonoscopy,FALSE,FALSE,NA,NA,NA
6,NCT00631917,Exclusion,current evidence of inflammatory bowel disease ; the presence of colonic ulcerations ( or other indices of colitis of any type ) or colorectal carcinoma including carcinoma in situ found at baseline colonoscopy .,Condition Occurrence,Other,C1552651,type,FALSE,FALSE,NA,NA,NA
7,NCT00631917,Exclusion,history of gastrointestinal carcinoma ; crohn disease ; ulcerative colitis ; microscopic colitis .,Condition Occurrence,Condition,C0151544,gastrointestinal carcinoma,FALSE,FALSE,NA,NA,NA
7,NCT00631917,Exclusion,history of gastrointestinal carcinoma ; crohn disease ; ulcerative colitis ; microscopic colitis .,Condition Occurrence,Condition,C0400821,microscopic colitis,FALSE,FALSE,NA,NA,NA
7,NCT00631917,Exclusion,history of gastrointestinal carcinoma ; crohn disease ; ulcerative colitis ; microscopic colitis .,Condition Occurrence,Condition,C0009324,ulcerative colitis,FALSE,FALSE,NA,NA,NA
7,NCT00631917,Exclusion,history of gastrointestinal carcinoma ; crohn disease ; ulcerative colitis ; microscopic colitis .,Condition Occurrence,Condition,C0010346,crohn disease,FALSE,FALSE,NA,NA,NA
8,NCT00631917,Exclusion,history of familial polyposis or hereditary nonpolyposis colorectal cancer .,Condition Occurrence,Condition,C0032580,familial polyposis,FALSE,FALSE,NA,NA,NA
8,NCT00631917,Exclusion,history of familial polyposis or hereditary nonpolyposis colorectal cancer .,Condition Occurrence,Condition,C1333990,hereditary nonpolyposis colorectal cancer,FALSE,FALSE,NA,NA,NA
9,NCT00631917,Exclusion,history of confirmed diverticulitis within 12 months of visit 1 .,Condition Occurrence,Condition,C0012813,diverticulitis,FALSE,FALSE,lower 12 months,NA,NA
10,NCT00631917,Exclusion,history of celiac disease ( gluten intolerance ) .,Condition Occurrence,Condition,C0007570,celiac disease,FALSE,FALSE,NA,NA,NA
10,NCT00631917,Exclusion,history of celiac disease ( gluten intolerance ) .,Condition Occurrence,Condition,C0007570,gluten intolerance,FALSE,FALSE,NA,NA,NA
11,NCT00631917,Exclusion,history of or current evidence on the baseline colonoscopy of melanosis coli,Condition Occurrence,Condition,C0221391,melanosis coli,FALSE,FALSE,NA,NA,NA
11,NCT00631917,Exclusion,history of or current evidence on the baseline colonoscopy of melanosis coli,Condition Occurrence,Procedure,C3274817,baseline colonoscopy,FALSE,FALSE,NA,NA,NA
1,NCT00649389,Inclusion,demonstrable hypertension defined as mean sitting trough cuff blood pressure > = 140 / 100 mmhg ( sesbp > = 140 mmhg and sedbp > = 100 mmhg ) or mean sitting trough cuff bp > = 160 / 90 mmhg ( sesbp > = 160 mmhg and sedbp > = 90 mmhg ) .,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
1,NCT00649389,Inclusion,demonstrable hypertension defined as mean sitting trough cuff blood pressure > = 140 / 100 mmhg ( sesbp > = 140 mmhg and sedbp > = 100 mmhg ) or mean sitting trough cuff bp > = 160 / 90 mmhg ( sesbp > = 160 mmhg and sedbp > = 90 mmhg ) .,Observation,Condition,C0428889,cuff blood pressure,FALSE,FALSE,NA,greater_equal 140 mmhg; greater_equal 100 mmhg; greater_equal 140 mmhg; greater_equal 100 mmhg,NA
1,NCT00649389,Inclusion,demonstrable hypertension defined as mean sitting trough cuff blood pressure > = 140 / 100 mmhg ( sesbp > = 140 mmhg and sedbp > = 100 mmhg ) or mean sitting trough cuff bp > = 160 / 90 mmhg ( sesbp > = 160 mmhg and sedbp > = 90 mmhg ) .,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
1,NCT00649389,Inclusion,demonstrable hypertension defined as mean sitting trough cuff blood pressure > = 140 / 100 mmhg ( sesbp > = 140 mmhg and sedbp > = 100 mmhg ) or mean sitting trough cuff bp > = 160 / 90 mmhg ( sesbp > = 160 mmhg and sedbp > = 90 mmhg ) .,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
1,NCT00649389,Inclusion,demonstrable hypertension defined as mean sitting trough cuff blood pressure > = 140 / 100 mmhg ( sesbp > = 140 mmhg and sedbp > = 100 mmhg ) or mean sitting trough cuff bp > = 160 / 90 mmhg ( sesbp > = 160 mmhg and sedbp > = 90 mmhg ) .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00649389,Inclusion,demonstrable hypertension defined as mean sitting trough cuff blood pressure > = 140 / 100 mmhg ( sesbp > = 140 mmhg and sedbp > = 100 mmhg ) or mean sitting trough cuff bp > = 160 / 90 mmhg ( sesbp > = 160 mmhg and sedbp > = 90 mmhg ) .,Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,greater_equal 160 mmhg; greater_equal 90 mmhg; greater_equal 160 mmhg; greater_equal 90 mmhg,NA
1,NCT00649389,Inclusion,demonstrable hypertension defined as mean sitting trough cuff blood pressure > = 140 / 100 mmhg ( sesbp > = 140 mmhg and sedbp > = 100 mmhg ) or mean sitting trough cuff bp > = 160 / 90 mmhg ( sesbp > = 160 mmhg and sedbp > = 90 mmhg ) .,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
2,NCT00649389,Inclusion,male or female newly diagnosed hypertensive subjects or currently on hypertension medication .,Person,Person,C0025266,male,FALSE,FALSE,NA,NA,NA
2,NCT00649389,Inclusion,male or female newly diagnosed hypertensive subjects or currently on hypertension medication .,Person,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
2,NCT00649389,Inclusion,male or female newly diagnosed hypertensive subjects or currently on hypertension medication .,Person,Condition,C0857121,hypertensive,FALSE,FALSE,NA,NA,NA
2,NCT00649389,Inclusion,male or female newly diagnosed hypertensive subjects or currently on hypertension medication .,Person,Drug,C0684167,hypertension medication,FALSE,FALSE,NA,NA,NA
3,NCT00649389,Inclusion,negative urine pregnancy test at screening,Observation,Observation,C1513916,negative,FALSE,FALSE,NA,NA,NA
3,NCT00649389,Inclusion,negative urine pregnancy test at screening,Observation,Observation,C0430056;C0373524,urine pregnancy test,FALSE,FALSE,NA,NA,NA
4,NCT00649389,Inclusion,not lactating,Condition Occurrence,Condition,C2828358;C3668831,lactating,FALSE,FALSE,NA,NA,NA
5,NCT00649389,Inclusion,do not plan to become pregnant during the study,Condition Occurrence,Condition,C0549206,pregnant,TRUE,FALSE,NA,NA,NA
6,NCT00649389,Inclusion,will practice birth control throughout the study by the following : oral contraceptive or patch contraceptive ; injectable contraceptive medication or implantable contraceptive medication ; intrauterine device ; diaphragm or female condom plus spermicide,Drug Exposure,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
6,NCT00649389,Inclusion,will practice birth control throughout the study by the following : oral contraceptive or patch contraceptive ; injectable contraceptive medication or implantable contraceptive medication ; intrauterine device ; diaphragm or female condom plus spermicide,Drug Exposure,Drug,C0445403;C1707974;C1533128,patch,FALSE,FALSE,NA,NA,NA
6,NCT00649389,Inclusion,will practice birth control throughout the study by the following : oral contraceptive or patch contraceptive ; injectable contraceptive medication or implantable contraceptive medication ; intrauterine device ; diaphragm or female condom plus spermicide,Drug Exposure,Drug,C0086466;C1272936,injectable,FALSE,FALSE,NA,NA,NA
6,NCT00649389,Inclusion,will practice birth control throughout the study by the following : oral contraceptive or patch contraceptive ; injectable contraceptive medication or implantable contraceptive medication ; intrauterine device ; diaphragm or female condom plus spermicide,Drug Exposure,Drug,C0037862,spermicide,FALSE,FALSE,NA,NA,NA
6,NCT00649389,Inclusion,will practice birth control throughout the study by the following : oral contraceptive or patch contraceptive ; injectable contraceptive medication or implantable contraceptive medication ; intrauterine device ; diaphragm or female condom plus spermicide,Drug Exposure,Other,C3245512,practice,FALSE,FALSE,NA,NA,NA
6,NCT00649389,Inclusion,will practice birth control throughout the study by the following : oral contraceptive or patch contraceptive ; injectable contraceptive medication or implantable contraceptive medication ; intrauterine device ; diaphragm or female condom plus spermicide,Drug Exposure,Other,C0700589;C2703065,birth control,FALSE,FALSE,NA,NA,NA
6,NCT00649389,Inclusion,will practice birth control throughout the study by the following : oral contraceptive or patch contraceptive ; injectable contraceptive medication or implantable contraceptive medication ; intrauterine device ; diaphragm or female condom plus spermicide,Drug Exposure,Other,C0029151;C0009905,oral contraceptive,FALSE,FALSE,NA,NA,NA
6,NCT00649389,Inclusion,will practice birth control throughout the study by the following : oral contraceptive or patch contraceptive ; injectable contraceptive medication or implantable contraceptive medication ; intrauterine device ; diaphragm or female condom plus spermicide,Drug Exposure,Other,C1706306;C1548866;C1546682,intrauterine device,FALSE,FALSE,NA,NA,NA
6,NCT00649389,Inclusion,will practice birth control throughout the study by the following : oral contraceptive or patch contraceptive ; injectable contraceptive medication or implantable contraceptive medication ; intrauterine device ; diaphragm or female condom plus spermicide,Drug Exposure,Other,C0152097;C0011980;C1705368;C1279038,diaphragm,FALSE,FALSE,NA,NA,NA
7,NCT00649389,Inclusion,non childbearing potential must be classified by one of the following criteria,Observation,Observation,C3831118,childbearing potential,FALSE,FALSE,NA,NA,NA
8,NCT00649389,Inclusion,had a hysterectomy or tubal ligation at least 6 months prior to consent,Procedure,Procedure,C0020699;C1548863,hysterectomy,FALSE,FALSE,greater_equal 6 months,NA,NA
8,NCT00649389,Inclusion,had a hysterectomy or tubal ligation at least 6 months prior to consent,Procedure,Procedure,C0520483,tubal ligation,FALSE,FALSE,greater_equal 6 months,NA,NA
9,NCT00649389,Inclusion,has been postmenopausal for a least 1 year,Other,NA,NA,NA,NA,NA,NA,NA,NA
10,NCT00649389,Exclusion,mean sitting trough cuff dbp < 90 mmhg or mean sitting trough cuff sbp < 140 mmhg ( off antihypertensive medication ) .,Condition Occurrence,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
10,NCT00649389,Exclusion,mean sitting trough cuff dbp < 90 mmhg or mean sitting trough cuff sbp < 140 mmhg ( off antihypertensive medication ) .,Condition Occurrence,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
10,NCT00649389,Exclusion,mean sitting trough cuff dbp < 90 mmhg or mean sitting trough cuff sbp < 140 mmhg ( off antihypertensive medication ) .,Condition Occurrence,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
10,NCT00649389,Exclusion,mean sitting trough cuff dbp < 90 mmhg or mean sitting trough cuff sbp < 140 mmhg ( off antihypertensive medication ) .,Condition Occurrence,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
10,NCT00649389,Exclusion,mean sitting trough cuff dbp < 90 mmhg or mean sitting trough cuff sbp < 140 mmhg ( off antihypertensive medication ) .,Condition Occurrence,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
10,NCT00649389,Exclusion,mean sitting trough cuff dbp < 90 mmhg or mean sitting trough cuff sbp < 140 mmhg ( off antihypertensive medication ) .,Condition Occurrence,Observation,C1305849,dbp,FALSE,FALSE,NA,lower 90 mmhg,NA
10,NCT00649389,Exclusion,mean sitting trough cuff dbp < 90 mmhg or mean sitting trough cuff sbp < 140 mmhg ( off antihypertensive medication ) .,Condition Occurrence,Observation,C1306620,sbp,FALSE,FALSE,NA,lower 140 mmhg,NA
11,NCT00649389,Exclusion,subjects with uncontrolled hypertension taking multiple antihypertensive therapies ( at the discretion of the investigator ) .,Condition Occurrence,Condition,C1868885,uncontrolled hypertension,FALSE,FALSE,NA,NA,NA
11,NCT00649389,Exclusion,subjects with uncontrolled hypertension taking multiple antihypertensive therapies ( at the discretion of the investigator ) .,Condition Occurrence,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
12,NCT00649389,Exclusion,signs or symptoms which could exacerbate the occurrence of hypotension such as volume and salt depletion .,Condition Occurrence,Condition,C0020649;C3163620,hypotension,FALSE,FALSE,NA,NA,NA
12,NCT00649389,Exclusion,signs or symptoms which could exacerbate the occurrence of hypotension such as volume and salt depletion .,Condition Occurrence,Condition,C0235425,salt depletion,FALSE,FALSE,NA,NA,NA
12,NCT00649389,Exclusion,signs or symptoms which could exacerbate the occurrence of hypotension such as volume and salt depletion .,Condition Occurrence,Observation,C1705102;C2700258,volume,FALSE,FALSE,NA,NA,NA
13,NCT00649389,Exclusion,history of hypertensive encephalopathy ; stroke or transient ischemic attack ( tia ) .,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
13,NCT00649389,Exclusion,history of hypertensive encephalopathy ; stroke or transient ischemic attack ( tia ) .,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,NA,NA,NA
13,NCT00649389,Exclusion,history of hypertensive encephalopathy ; stroke or transient ischemic attack ( tia ) .,Condition Occurrence,Condition,C0917805,tia,FALSE,FALSE,NA,NA,NA
14,NCT00649389,Exclusion,participation in another clinical trial involving an investigational drug within one month prior to screening .,Drug Exposure,Drug,C0013230,investigational drug,FALSE,FALSE,NA,NA,NA
14,NCT00649389,Exclusion,participation in another clinical trial involving an investigational drug within one month prior to screening .,Drug Exposure,Other,C1096775,clinical trial,FALSE,FALSE,NA,NA,NA
15,NCT00649389,Exclusion,history of myocardial infarction ; percutaneous transluminal coronary revascularization ; coronary artery bypass graft ; or unstable angina within the past 6 months .,Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,lower 6 past months,NA,NA
15,NCT00649389,Exclusion,history of myocardial infarction ; percutaneous transluminal coronary revascularization ; coronary artery bypass graft ; or unstable angina within the past 6 months .,Condition Occurrence,Procedure,C0010055,coronary artery bypass graft,FALSE,FALSE,lower 6 past months,NA,NA
15,NCT00649389,Exclusion,history of myocardial infarction ; percutaneous transluminal coronary revascularization ; coronary artery bypass graft ; or unstable angina within the past 6 months .,Condition Occurrence,Procedure,C0877341,coronary revascularization,FALSE,FALSE,lower 6 past months,NA,NA
15,NCT00649389,Exclusion,history of myocardial infarction ; percutaneous transluminal coronary revascularization ; coronary artery bypass graft ; or unstable angina within the past 6 months .,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,lower 6 past months,NA,NA
16,NCT00649389,Exclusion,any history of new york heart association class iii or class iv congestive heart failure ( chf ),Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
16,NCT00649389,Exclusion,any history of new york heart association class iii or class iv congestive heart failure ( chf ),Condition Occurrence,Condition,C0018802,congestive heart failure chf,FALSE,FALSE,NA,NA,NA
16,NCT00649389,Exclusion,any history of new york heart association class iii or class iv congestive heart failure ( chf ),Condition Occurrence,Other,C0441887;C2698969,class iii,FALSE,FALSE,NA,NA,NA
16,NCT00649389,Exclusion,any history of new york heart association class iii or class iv congestive heart failure ( chf ),Condition Occurrence,Other,C0441888;C2698970,class iv,FALSE,FALSE,NA,NA,NA
17,NCT00649389,Exclusion,a history of new york heart association class i or class ii chf may be exclusionary at the discretion of the investigator .,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
17,NCT00649389,Exclusion,a history of new york heart association class i or class ii chf may be exclusionary at the discretion of the investigator .,Condition Occurrence,Condition,C2698967,class i,FALSE,FALSE,NA,NA,NA
17,NCT00649389,Exclusion,a history of new york heart association class i or class ii chf may be exclusionary at the discretion of the investigator .,Condition Occurrence,Condition,C0018802,chf,FALSE,FALSE,NA,NA,NA
17,NCT00649389,Exclusion,a history of new york heart association class i or class ii chf may be exclusionary at the discretion of the investigator .,Condition Occurrence,Other,C0441886;C2698968,class ii,FALSE,FALSE,NA,NA,NA
18,NCT00649389,Exclusion,history of secondary hypertension including renal disease ; pheochromocytoma ; or cushing syndrome .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
18,NCT00649389,Exclusion,history of secondary hypertension including renal disease ; pheochromocytoma ; or cushing syndrome .,Condition Occurrence,Condition,C0022658,renal disease,FALSE,FALSE,NA,NA,NA
18,NCT00649389,Exclusion,history of secondary hypertension including renal disease ; pheochromocytoma ; or cushing syndrome .,Condition Occurrence,Condition,C0010481,cushing syndrome,FALSE,FALSE,NA,NA,NA
18,NCT00649389,Exclusion,history of secondary hypertension including renal disease ; pheochromocytoma ; or cushing syndrome .,Condition Occurrence,Condition,C0031511;C1706920,pheochromocytoma,FALSE,FALSE,NA,NA,NA
19,NCT00649389,Exclusion,uncorrected coarctation of the aorta ; bilateral renal artery stenosis ; or unilateral renal artery stenosis in a solitary kidney .,Condition Occurrence,Condition,C0332886,coarctation,FALSE,FALSE,NA,NA,NA
19,NCT00649389,Exclusion,uncorrected coarctation of the aorta ; bilateral renal artery stenosis ; or unilateral renal artery stenosis in a solitary kidney .,Condition Occurrence,Condition,C0856759,unilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
19,NCT00649389,Exclusion,uncorrected coarctation of the aorta ; bilateral renal artery stenosis ; or unilateral renal artery stenosis in a solitary kidney .,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
19,NCT00649389,Exclusion,uncorrected coarctation of the aorta ; bilateral renal artery stenosis ; or unilateral renal artery stenosis in a solitary kidney .,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
19,NCT00649389,Exclusion,uncorrected coarctation of the aorta ; bilateral renal artery stenosis ; or unilateral renal artery stenosis in a solitary kidney .,Condition Occurrence,Other,C0869784;C0003483;C1278934,aorta,FALSE,FALSE,NA,NA,NA
20,NCT00649389,Exclusion,evidence of symptomatic resting bradycardia .,Observation,Observation,C0428977,bradycardia,FALSE,FALSE,NA,NA,NA
21,NCT00649389,Exclusion,evidence of hemodynamically significant cardiac valvular disease .,Condition Occurrence,Condition,C0018824,cardiac valvular disease,FALSE,FALSE,NA,NA,NA
22,NCT00649389,Exclusion,presence of heart block greater than first degree atrioventricular block ; chronic atrial fibrillation or flutter .,Condition Occurrence,Condition,C0018794;C0542001;C0037188,heart block,FALSE,FALSE,NA,NA,NA
22,NCT00649389,Exclusion,presence of heart block greater than first degree atrioventricular block ; chronic atrial fibrillation or flutter .,Condition Occurrence,Condition,C0004245;C2108077,atrioventricular block,FALSE,FALSE,NA,NA,NA
22,NCT00649389,Exclusion,presence of heart block greater than first degree atrioventricular block ; chronic atrial fibrillation or flutter .,Condition Occurrence,Condition,C0016385,flutter,FALSE,FALSE,NA,NA,NA
22,NCT00649389,Exclusion,presence of heart block greater than first degree atrioventricular block ; chronic atrial fibrillation or flutter .,Condition Occurrence,Condition,C0694539,chronic atrial fibrillation,FALSE,FALSE,NA,NA,NA
22,NCT00649389,Exclusion,presence of heart block greater than first degree atrioventricular block ; chronic atrial fibrillation or flutter .,Condition Occurrence,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
23,NCT00649389,Exclusion,uncontrolled type i diabetes or type ii diabetesdefined as hba1c > 9.0 %,Drug Exposure,Condition,C0011854,type i diabetes,FALSE,FALSE,NA,NA,NA
23,NCT00649389,Exclusion,uncontrolled type i diabetes or type ii diabetesdefined as hba1c > 9.0 %,Drug Exposure,Observation,C0202054,hba1c,FALSE,FALSE,NA,NA,greater 9.0 %
23,NCT00649389,Exclusion,uncontrolled type i diabetes or type ii diabetesdefined as hba1c > 9.0 %,Drug Exposure,Other,C1552651,type,FALSE,FALSE,NA,NA,NA
24,NCT00649389,Exclusion,diabetics must have documentation of hba1c within 6 months of the screening visit,Observation,Observation,C0202054,hba1c,FALSE,FALSE,lower 6 months,NA,NA
25,NCT00649389,Exclusion,undocumented subjects must have their hba1c assessed prior to randomization,Observation,Observation,C0202054,hba1c,FALSE,FALSE,NA,NA,NA
26,NCT00649389,Exclusion,note : subjects with type i diabetes or type ii diabetescontrolled with insulin ; diet or oral hypoglycemic agents on a stable dose for at least 30 days may be included .,Other,Condition,C0011854,type i diabetes,FALSE,TRUE,NA,NA,NA
26,NCT00649389,Exclusion,note : subjects with type i diabetes or type ii diabetescontrolled with insulin ; diet or oral hypoglycemic agents on a stable dose for at least 30 days may be included .,Other,Drug,C0359086,oral hypoglycemic agents,FALSE,TRUE,NA,NA,NA
26,NCT00649389,Exclusion,note : subjects with type i diabetes or type ii diabetescontrolled with insulin ; diet or oral hypoglycemic agents on a stable dose for at least 30 days may be included .,Other,Observation,C0021641;C0202098;C1533581;C1145751;C1579433;C2739803,insulin,FALSE,TRUE,NA,NA,NA
26,NCT00649389,Exclusion,note : subjects with type i diabetes or type ii diabetescontrolled with insulin ; diet or oral hypoglycemic agents on a stable dose for at least 30 days may be included .,Other,Other,C1317574;C1316572,note,FALSE,TRUE,NA,NA,NA
26,NCT00649389,Exclusion,note : subjects with type i diabetes or type ii diabetescontrolled with insulin ; diet or oral hypoglycemic agents on a stable dose for at least 30 days may be included .,Other,Other,C1552651,type,FALSE,TRUE,NA,NA,NA
26,NCT00649389,Exclusion,note : subjects with type i diabetes or type ii diabetescontrolled with insulin ; diet or oral hypoglycemic agents on a stable dose for at least 30 days may be included .,Other,Other,C0012159;C1519433;C1561465;C1550559;C1549512,diet,FALSE,TRUE,NA,NA,NA
26,NCT00649389,Exclusion,note : subjects with type i diabetes or type ii diabetescontrolled with insulin ; diet or oral hypoglycemic agents on a stable dose for at least 30 days may be included .,Other,Other,C1547311,stable,FALSE,TRUE,greater_equal 30 days,NA,NA
27,NCT00649389,Exclusion,evidence of liver disease as indicated by alt and ast bilirubin or total bilirubin > 3 times the upper limit of normal .,Observation,Condition,C0023895;C2186532,liver disease,FALSE,FALSE,NA,NA,NA
27,NCT00649389,Exclusion,evidence of liver disease as indicated by alt and ast bilirubin or total bilirubin > 3 times the upper limit of normal .,Observation,Observation,C1140170;C2257651,alt,FALSE,FALSE,NA,NA,NA
27,NCT00649389,Exclusion,evidence of liver disease as indicated by alt and ast bilirubin or total bilirubin > 3 times the upper limit of normal .,Observation,Observation,C0004002,ast,FALSE,FALSE,NA,NA,NA
27,NCT00649389,Exclusion,evidence of liver disease as indicated by alt and ast bilirubin or total bilirubin > 3 times the upper limit of normal .,Observation,Observation,C0005437;C0863174;C0201913;C0428441,bilirubin,FALSE,FALSE,NA,NA,greater 3 times the upper limit of normal
27,NCT00649389,Exclusion,evidence of liver disease as indicated by alt and ast bilirubin or total bilirubin > 3 times the upper limit of normal .,Observation,Other,C0368753;C0005437;C0201913,total bilirubin,FALSE,FALSE,NA,NA,greater 3 times the upper limit of normal
28,NCT00649389,Exclusion,severe renal insufficiency defined as a creatinine clearance ( based on the cockcroft-gault formula ) of < 30 ml / min .,Observation,Condition,C1565489;C0035078,renal insufficiency,FALSE,FALSE,NA,NA,NA
28,NCT00649389,Exclusion,severe renal insufficiency defined as a creatinine clearance ( based on the cockcroft-gault formula ) of < 30 ml / min .,Observation,Observation,C0373595;C0812399,creatinine clearance,FALSE,FALSE,NA,NA,NA
28,NCT00649389,Exclusion,severe renal insufficiency defined as a creatinine clearance ( based on the cockcroft-gault formula ) of < 30 ml / min .,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
28,NCT00649389,Exclusion,severe renal insufficiency defined as a creatinine clearance ( based on the cockcroft-gault formula ) of < 30 ml / min .,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
28,NCT00649389,Exclusion,severe renal insufficiency defined as a creatinine clearance ( based on the cockcroft-gault formula ) of < 30 ml / min .,Observation,Other,C1705501;C0489829,formula,FALSE,FALSE,NA,lower 30 ml/min,NA
29,NCT00649389,Exclusion,clinically significant laboratory elevations at visit 1 that compromise subject safety ; based on the investigator judgment,Observation,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
30,NCT00649389,Exclusion,consideration should take into account the potential laboratory effects of the component blinded therapies .,Observation,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
31,NCT00649389,Exclusion,positive for any one of the following tests : hepatitis b surface antigen ; hepatitis c antibody ( confirmed by radio immunobinding assay ; riba ) or hiv antibody ( confirmed by western blot assay ) .,Observation,Observation,C1514241,positive,FALSE,FALSE,NA,NA,NA
31,NCT00649389,Exclusion,positive for any one of the following tests : hepatitis b surface antigen ; hepatitis c antibody ( confirmed by radio immunobinding assay ; riba ) or hiv antibody ( confirmed by western blot assay ) .,Observation,Observation,C0392366;C2239224,tests,FALSE,FALSE,NA,NA,NA
31,NCT00649389,Exclusion,positive for any one of the following tests : hepatitis b surface antigen ; hepatitis c antibody ( confirmed by radio immunobinding assay ; riba ) or hiv antibody ( confirmed by western blot assay ) .,Observation,Observation,C1510438,assay,FALSE,FALSE,NA,NA,NA
31,NCT00649389,Exclusion,positive for any one of the following tests : hepatitis b surface antigen ; hepatitis c antibody ( confirmed by radio immunobinding assay ; riba ) or hiv antibody ( confirmed by western blot assay ) .,Observation,Observation,C0949466,western blot assay,FALSE,FALSE,NA,NA,NA
31,NCT00649389,Exclusion,positive for any one of the following tests : hepatitis b surface antigen ; hepatitis c antibody ( confirmed by radio immunobinding assay ; riba ) or hiv antibody ( confirmed by western blot assay ) .,Observation,Other,C0019168;C0201477,hepatitis b surface antigen,FALSE,FALSE,NA,NA,NA
31,NCT00649389,Exclusion,positive for any one of the following tests : hepatitis b surface antigen ; hepatitis c antibody ( confirmed by radio immunobinding assay ; riba ) or hiv antibody ( confirmed by western blot assay ) .,Observation,Other,C0201487;C0166049,hepatitis c antibody,FALSE,FALSE,NA,NA,NA
31,NCT00649389,Exclusion,positive for any one of the following tests : hepatitis b surface antigen ; hepatitis c antibody ( confirmed by radio immunobinding assay ; riba ) or hiv antibody ( confirmed by western blot assay ) .,Observation,Other,C0034546,radio,FALSE,FALSE,NA,NA,NA
31,NCT00649389,Exclusion,positive for any one of the following tests : hepatitis b surface antigen ; hepatitis c antibody ( confirmed by radio immunobinding assay ; riba ) or hiv antibody ( confirmed by western blot assay ) .,Observation,Other,C0019683;C1321876,hiv antibody,FALSE,FALSE,NA,NA,NA
32,NCT00649389,Exclusion,subjects with malignancy during the past 2 years excluding squamous cell carcinoma or basal cell carcinoma of the skin .,Condition Occurrence,Condition,C0006826;C1306459,malignancy,FALSE,FALSE,lower_equal 2 past years,NA,NA
32,NCT00649389,Exclusion,subjects with malignancy during the past 2 years excluding squamous cell carcinoma or basal cell carcinoma of the skin .,Condition Occurrence,Condition,C0007137;C1302853,squamous cell carcinoma,TRUE,FALSE,NA,NA,NA
32,NCT00649389,Exclusion,subjects with malignancy during the past 2 years excluding squamous cell carcinoma or basal cell carcinoma of the skin .,Condition Occurrence,Condition,C0007117,basal cell carcinoma of the skin,TRUE,FALSE,NA,NA,NA
33,NCT00649389,Exclusion,known allergy to any of the medications used in the study .,Drug Exposure,Other,C0489531;C0718579;C3542994;C3539909;C1314973;C1547315;C1611280,allergy,FALSE,FALSE,NA,NA,NA
34,NCT00649389,Exclusion,subjects who require or are taking any concomitant medication ; which may interfere with the objectives of the study ( refer to section 5.22 for a listing of excluded medications ) .,Procedure,Procedure,C0420168;C0420170;C0420167;C0420169,section,FALSE,FALSE,NA,NA,NA
35,NCT00649389,Exclusion,pregnant or lactating females .,Condition Occurrence,Person,C0086287,females,FALSE,FALSE,NA,NA,NA
35,NCT00649389,Exclusion,pregnant or lactating females .,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
35,NCT00649389,Exclusion,pregnant or lactating females .,Condition Occurrence,Condition,C2828358;C3668831,lactating,FALSE,FALSE,NA,NA,NA
36,NCT00649389,Exclusion,current history of drug or alcohol abuse .,Condition Occurrence,Condition,C0085762,alcohol abuse,FALSE,FALSE,NA,NA,NA
36,NCT00649389,Exclusion,current history of drug or alcohol abuse .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
37,NCT00649389,Exclusion,a subject with any medical condition ; which in the judgment of the investigator would jeopardize the evaluation of efficacy or safety or constitute a significant safety risk to the subject,Other,Other,C1561579;C1561578,medical,FALSE,FALSE,NA,NA,NA
1,NCT00687973,Inclusion,male or female patients 18 years of age or older,Person,Person,C0025266,male,FALSE,FALSE,equal 18 years,NA,NA
2,NCT00687973,Inclusion,hypertension defined by msdbp > 90 and or mssbp > 140 mmhg ; msdbp > 80 mmhg ; or mssbp > 130 mmhg if diabetes or chronic renal impairment uncontrolled under their previous therapy ; or untreated ; or experiencing unacceptable side effects,Observation,Condition,C0011849;C0011847,diabetes,FALSE,FALSE,NA,NA,NA
1,NCT00687973,Inclusion,male or female patients 18 years of age or older,Person,Observation,C0150905,female patients,FALSE,FALSE,equal 18 years,NA,NA
2,NCT00687973,Inclusion,hypertension defined by msdbp > 90 and or mssbp > 140 mmhg ; msdbp > 80 mmhg ; or mssbp > 130 mmhg if diabetes or chronic renal impairment uncontrolled under their previous therapy ; or untreated ; or experiencing unacceptable side effects,Observation,Condition,C0403447,chronic renal impairment,FALSE,FALSE,NA,NA,NA
2,NCT00687973,Inclusion,hypertension defined by msdbp > 90 and or mssbp > 140 mmhg ; msdbp > 80 mmhg ; or mssbp > 130 mmhg if diabetes or chronic renal impairment uncontrolled under their previous therapy ; or untreated ; or experiencing unacceptable side effects,Observation,Condition,C2114510,previous therapy,FALSE,FALSE,NA,NA,NA
2,NCT00687973,Inclusion,hypertension defined by msdbp > 90 and or mssbp > 140 mmhg ; msdbp > 80 mmhg ; or mssbp > 130 mmhg if diabetes or chronic renal impairment uncontrolled under their previous therapy ; or untreated ; or experiencing unacceptable side effects,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00687973,Inclusion,hypertension defined by msdbp > 90 and or mssbp > 140 mmhg ; msdbp > 80 mmhg ; or mssbp > 130 mmhg if diabetes or chronic renal impairment uncontrolled under their previous therapy ; or untreated ; or experiencing unacceptable side effects,Observation,Other,C3539106,defined,FALSE,FALSE,NA,greater 90 ; greater 140 mmhg; greater 80 mmhg; greater 130 mmhg,NA
3,NCT00687973,Inclusion,written informed consent to participate in the study prior to any study procedures,Other,NA,NA,NA,NA,NA,NA,NA,NA
4,NCT00687973,Exclusion,severe hypertension ( grade 3 who classification msdbp > 110 mmhg or mssbp > 180 mmhg ),Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,greater 110 mmhg; greater 180 mmhg,NA
4,NCT00687973,Exclusion,severe hypertension ( grade 3 who classification msdbp > 110 mmhg or mssbp > 180 mmhg ),Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
5,NCT00687973,Exclusion,evidence of a secondary form of hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
6,NCT00687973,Exclusion,type 1 diabetes mellitus,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
7,NCT00687973,Exclusion,history of congestive heart failure ; unstable coronary insufficiency ; life threatening arrhythmia ; significant valvular disease ; second degree heart block or third degree heart block etc,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
7,NCT00687973,Exclusion,history of congestive heart failure ; unstable coronary insufficiency ; life threatening arrhythmia ; significant valvular disease ; second degree heart block or third degree heart block etc,Condition Occurrence,Condition,C0443343,unstable,FALSE,FALSE,NA,NA,NA
7,NCT00687973,Exclusion,history of congestive heart failure ; unstable coronary insufficiency ; life threatening arrhythmia ; significant valvular disease ; second degree heart block or third degree heart block etc,Condition Occurrence,Condition,C0542052,coronary insufficiency,FALSE,FALSE,NA,NA,NA
7,NCT00687973,Exclusion,history of congestive heart failure ; unstable coronary insufficiency ; life threatening arrhythmia ; significant valvular disease ; second degree heart block or third degree heart block etc,Condition Occurrence,Condition,C2826244;C3537125,life threatening,FALSE,FALSE,NA,NA,NA
7,NCT00687973,Exclusion,history of congestive heart failure ; unstable coronary insufficiency ; life threatening arrhythmia ; significant valvular disease ; second degree heart block or third degree heart block etc,Condition Occurrence,Condition,C0003811,arrhythmia,FALSE,FALSE,NA,NA,NA
7,NCT00687973,Exclusion,history of congestive heart failure ; unstable coronary insufficiency ; life threatening arrhythmia ; significant valvular disease ; second degree heart block or third degree heart block etc,Condition Occurrence,Condition,C3258293,valvular disease,FALSE,FALSE,NA,NA,NA
7,NCT00687973,Exclusion,history of congestive heart failure ; unstable coronary insufficiency ; life threatening arrhythmia ; significant valvular disease ; second degree heart block or third degree heart block etc,Condition Occurrence,Condition,C0018794;C0542001;C0037188,heart block,FALSE,FALSE,NA,NA,NA
7,NCT00687973,Exclusion,history of congestive heart failure ; unstable coronary insufficiency ; life threatening arrhythmia ; significant valvular disease ; second degree heart block or third degree heart block etc,Condition Occurrence,Condition,C0018794;C0542001;C0037188,heart block,FALSE,FALSE,NA,NA,NA
7,NCT00687973,Exclusion,history of congestive heart failure ; unstable coronary insufficiency ; life threatening arrhythmia ; significant valvular disease ; second degree heart block or third degree heart block etc,Condition Occurrence,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
7,NCT00687973,Exclusion,history of congestive heart failure ; unstable coronary insufficiency ; life threatening arrhythmia ; significant valvular disease ; second degree heart block or third degree heart block etc,Condition Occurrence,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
1,NCT00696241,Inclusion,has essential hypertension ( defined as sitting trough clinic systolic blood pressure between 150 and 180 mm hg ; inclusive at day minus 1 ) and 24 - hour mean systolic blood pressure greater than or equal to 130 mm hg and less than or equal to 170 mm hg at day 1 ) .,Observation,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00696241,Inclusion,has essential hypertension ( defined as sitting trough clinic systolic blood pressure between 150 and 180 mm hg ; inclusive at day minus 1 ) and 24 - hour mean systolic blood pressure greater than or equal to 130 mm hg and less than or equal to 170 mm hg at day 1 ) .,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
1,NCT00696241,Inclusion,has essential hypertension ( defined as sitting trough clinic systolic blood pressure between 150 and 180 mm hg ; inclusive at day minus 1 ) and 24 - hour mean systolic blood pressure greater than or equal to 130 mm hg and less than or equal to 170 mm hg at day 1 ) .,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,equal 24 hour,greater_equal 150 mm hg; lower_equal 180 mm hg; equal 1,NA
1,NCT00696241,Inclusion,has essential hypertension ( defined as sitting trough clinic systolic blood pressure between 150 and 180 mm hg ; inclusive at day minus 1 ) and 24 - hour mean systolic blood pressure greater than or equal to 130 mm hg and less than or equal to 170 mm hg at day 1 ) .,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,equal 1 day,greater_equal 130 mm hg; lower_equal 170 mm hg,NA
1,NCT00696241,Inclusion,has essential hypertension ( defined as sitting trough clinic systolic blood pressure between 150 and 180 mm hg ; inclusive at day minus 1 ) and 24 - hour mean systolic blood pressure greater than or equal to 130 mm hg and less than or equal to 170 mm hg at day 1 ) .,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
2,NCT00696241,Inclusion,females of childbearing potential who are sexually active must agree to use adequate contraception ; and can neither be pregnant nor lactating from screening throughout the duration of the study . ;,Condition Occurrence,Person,C0086287,females,FALSE,FALSE,NA,NA,NA
2,NCT00696241,Inclusion,females of childbearing potential who are sexually active must agree to use adequate contraception ; and can neither be pregnant nor lactating from screening throughout the duration of the study . ;,Condition Occurrence,Condition,C0241028,sexually active,FALSE,FALSE,NA,NA,NA
2,NCT00696241,Inclusion,females of childbearing potential who are sexually active must agree to use adequate contraception ; and can neither be pregnant nor lactating from screening throughout the duration of the study . ;,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
2,NCT00696241,Inclusion,females of childbearing potential who are sexually active must agree to use adequate contraception ; and can neither be pregnant nor lactating from screening throughout the duration of the study . ;,Condition Occurrence,Condition,C2828358;C3668831,lactating,FALSE,FALSE,NA,NA,NA
2,NCT00696241,Inclusion,females of childbearing potential who are sexually active must agree to use adequate contraception ; and can neither be pregnant nor lactating from screening throughout the duration of the study . ;,Condition Occurrence,Procedure,C0700589,contraception,FALSE,FALSE,NA,NA,NA
2,NCT00696241,Inclusion,females of childbearing potential who are sexually active must agree to use adequate contraception ; and can neither be pregnant nor lactating from screening throughout the duration of the study . ;,Condition Occurrence,Observation,C3831118,childbearing potential,FALSE,FALSE,NA,NA,NA
2,NCT00696241,Inclusion,females of childbearing potential who are sexually active must agree to use adequate contraception ; and can neither be pregnant nor lactating from screening throughout the duration of the study . ;,Condition Occurrence,Other,C3641827,agree,FALSE,FALSE,NA,NA,NA
3,NCT00696241,Inclusion,clinical laboratory evaluations ( including clinical chemistry ; hematology ; and complete urinalysis ) within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator .,Observation,Drug,C1815293,complete,FALSE,FALSE,NA,NA,NA
3,NCT00696241,Inclusion,clinical laboratory evaluations ( including clinical chemistry ; hematology ; and complete urinalysis ) within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator .,Observation,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
3,NCT00696241,Inclusion,clinical laboratory evaluations ( including clinical chemistry ; hematology ; and complete urinalysis ) within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator .,Observation,Observation,C0042014;C0373521,urinalysis,FALSE,FALSE,NA,NA,NA
3,NCT00696241,Inclusion,clinical laboratory evaluations ( including clinical chemistry ; hematology ; and complete urinalysis ) within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator .,Observation,Observation,C3542016,range,FALSE,FALSE,NA,NA,NA
3,NCT00696241,Inclusion,clinical laboratory evaluations ( including clinical chemistry ; hematology ; and complete urinalysis ) within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator .,Observation,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
3,NCT00696241,Inclusion,clinical laboratory evaluations ( including clinical chemistry ; hematology ; and complete urinalysis ) within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator .,Observation,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
3,NCT00696241,Inclusion,clinical laboratory evaluations ( including clinical chemistry ; hematology ; and complete urinalysis ) within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator .,Observation,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
3,NCT00696241,Inclusion,clinical laboratory evaluations ( including clinical chemistry ; hematology ; and complete urinalysis ) within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator .,Observation,Other,C2183231;C1547978,chemistry,FALSE,FALSE,NA,NA,NA
3,NCT00696241,Inclusion,clinical laboratory evaluations ( including clinical chemistry ; hematology ; and complete urinalysis ) within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator .,Observation,Other,C0200627;C0018941;C2183233;C1547985,hematology,FALSE,FALSE,NA,NA,NA
4,NCT00696241,Inclusion,the subject is willing to discontinue current antihypertensive medications at the screening day minus 21 visit,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,equal 21,NA
4,NCT00696241,Inclusion,the subject is willing to discontinue current antihypertensive medications at the screening day minus 21 visit,Observation,Other,C1706472,discontinue,FALSE,FALSE,NA,NA,NA
5,NCT00696241,Inclusion,if the subject is on amlodipine prior to screening ; the subject is willing to discontinue this medication at screening day minus 28 .,Observation,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,NA
5,NCT00696241,Inclusion,if the subject is on amlodipine prior to screening ; the subject is willing to discontinue this medication at screening day minus 28 .,Observation,Other,C1706472,discontinue,FALSE,FALSE,NA,equal 28,NA
6,NCT00696241,Exclusion,sitting trough clinic diastolic blood pressure greater than 114 mm hg at day minus 1 .,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
6,NCT00696241,Exclusion,sitting trough clinic diastolic blood pressure greater than 114 mm hg at day minus 1 .,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater 114 mm hg; equal 1,NA
7,NCT00696241,Exclusion,baseline 24 - hour ambulatory blood pressure monitor reading of insufficient quality .,Condition Occurrence,Condition,C0855316,ambulatory blood pressure,FALSE,FALSE,equal 24 hour,NA,NA
7,NCT00696241,Exclusion,baseline 24 - hour ambulatory blood pressure monitor reading of insufficient quality .,Condition Occurrence,Condition,C1705179,reading,FALSE,FALSE,NA,NA,NA
7,NCT00696241,Exclusion,baseline 24 - hour ambulatory blood pressure monitor reading of insufficient quality .,Condition Occurrence,Other,C0728873;C0030695,monitor,FALSE,FALSE,NA,NA,NA
8,NCT00696241,Exclusion,history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,NA,NA,NA
8,NCT00696241,Exclusion,history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
8,NCT00696241,Exclusion,history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
8,NCT00696241,Exclusion,history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,NA,NA,NA
8,NCT00696241,Exclusion,history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
8,NCT00696241,Exclusion,history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Procedure,C1532338,percutaneous coronary intervention,FALSE,FALSE,NA,NA,NA
8,NCT00696241,Exclusion,history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Procedure,C0010055,coronary artery bypass graft,FALSE,FALSE,NA,NA,NA
8,NCT00696241,Exclusion,history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
9,NCT00696241,Exclusion,clinically significant cardiac conduction defects ( eg ; third degree atrioventricular block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation or atrial flutter ) .,Condition Occurrence,Condition,C0264886,cardiac conduction defects,FALSE,FALSE,NA,NA,NA
9,NCT00696241,Exclusion,clinically significant cardiac conduction defects ( eg ; third degree atrioventricular block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation or atrial flutter ) .,Condition Occurrence,Condition,C0004245;C2108077,atrioventricular block,FALSE,FALSE,NA,NA,NA
9,NCT00696241,Exclusion,clinically significant cardiac conduction defects ( eg ; third degree atrioventricular block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation or atrial flutter ) .,Condition Occurrence,Condition,C0004239;C1963068,atrial flutter,FALSE,FALSE,NA,NA,NA
9,NCT00696241,Exclusion,clinically significant cardiac conduction defects ( eg ; third degree atrioventricular block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation or atrial flutter ) .,Condition Occurrence,Condition,C0037052;C1963235,sick sinus syndrome,FALSE,FALSE,NA,NA,NA
9,NCT00696241,Exclusion,clinically significant cardiac conduction defects ( eg ; third degree atrioventricular block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation or atrial flutter ) .,Condition Occurrence,Condition,C0023211,left bundle branch block,FALSE,FALSE,NA,NA,NA
9,NCT00696241,Exclusion,clinically significant cardiac conduction defects ( eg ; third degree atrioventricular block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation or atrial flutter ) .,Condition Occurrence,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
9,NCT00696241,Exclusion,clinically significant cardiac conduction defects ( eg ; third degree atrioventricular block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation or atrial flutter ) .,Condition Occurrence,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
10,NCT00696241,Exclusion,hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease .,Condition Occurrence,Condition,C0023213,left ventricular outflow obstruction,FALSE,FALSE,NA,NA,NA
10,NCT00696241,Exclusion,hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease .,Condition Occurrence,Condition,C1260873,aortic valvular disease,FALSE,FALSE,NA,NA,NA
11,NCT00696241,Exclusion,secondary hypertension of any etiology .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
12,NCT00696241,Exclusion,is noncompliant ( less than 70 % or greater than 130 % ) with study medication during placebo run-in period .,Drug Exposure,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,lower 70 %; greater 130 %
13,NCT00696241,Exclusion,severe renal dysfunction or disease ( based on calculated creatinine clearance less than 30 ml / min / 1.73 m2 ) at screening .,Observation,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
13,NCT00696241,Exclusion,severe renal dysfunction or disease ( based on calculated creatinine clearance less than 30 ml / min / 1.73 m2 ) at screening .,Observation,Observation,C0373595;C0812399,creatinine clearance,FALSE,FALSE,NA,lower 30 ml/min; equal 1.73 m2,NA
13,NCT00696241,Exclusion,severe renal dysfunction or disease ( based on calculated creatinine clearance less than 30 ml / min / 1.73 m2 ) at screening .,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
14,NCT00696241,Exclusion,known or suspected unilateral renal artery or bilateral renal artery stenosis .,Condition Occurrence,Condition,C0035065;C1278951,renal artery,FALSE,FALSE,NA,NA,NA
14,NCT00696241,Exclusion,known or suspected unilateral renal artery or bilateral renal artery stenosis .,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
15,NCT00696241,Exclusion,history of drug abuse ( defined as illicit drug use ) or a history of alcohol abuse ( defined as regular consumption or daily consumption of more than 2 alcoholic drinks per day ) within the past 2 years .,Condition Occurrence,Condition,C0013146,drug abuse,FALSE,FALSE,NA,NA,NA
15,NCT00696241,Exclusion,history of drug abuse ( defined as illicit drug use ) or a history of alcohol abuse ( defined as regular consumption or daily consumption of more than 2 alcoholic drinks per day ) within the past 2 years .,Condition Occurrence,Condition,C0085762,alcohol abuse,FALSE,FALSE,NA,NA,NA
15,NCT00696241,Exclusion,history of drug abuse ( defined as illicit drug use ) or a history of alcohol abuse ( defined as regular consumption or daily consumption of more than 2 alcoholic drinks per day ) within the past 2 years .,Condition Occurrence,Condition,C0220811;C1947907,consumption,FALSE,FALSE,lower 2 past years,greater 2 alcoholic drinks/day,NA
15,NCT00696241,Exclusion,history of drug abuse ( defined as illicit drug use ) or a history of alcohol abuse ( defined as regular consumption or daily consumption of more than 2 alcoholic drinks per day ) within the past 2 years .,Condition Occurrence,Condition,C0220811;C1947907,consumption,FALSE,FALSE,lower 2 past years,greater 2 alcoholic drinks/day,NA
15,NCT00696241,Exclusion,history of drug abuse ( defined as illicit drug use ) or a history of alcohol abuse ( defined as regular consumption or daily consumption of more than 2 alcoholic drinks per day ) within the past 2 years .,Condition Occurrence,Drug,C0086190,illicit drug,FALSE,FALSE,NA,NA,NA
15,NCT00696241,Exclusion,history of drug abuse ( defined as illicit drug use ) or a history of alcohol abuse ( defined as regular consumption or daily consumption of more than 2 alcoholic drinks per day ) within the past 2 years .,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
15,NCT00696241,Exclusion,history of drug abuse ( defined as illicit drug use ) or a history of alcohol abuse ( defined as regular consumption or daily consumption of more than 2 alcoholic drinks per day ) within the past 2 years .,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
16,NCT00696241,Exclusion,history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug,Condition Occurrence,Condition,C0544452,remission,TRUE,FALSE,greater_equal 5 years,NA,NA
16,NCT00696241,Exclusion,history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug,Condition Occurrence,Other,C0260515;C2707253,cancer,FALSE,FALSE,NA,NA,NA
16,NCT00696241,Exclusion,history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
17,NCT00696241,Exclusion,( this criterion does not apply to those subjects with basal cell or stage i squamous cell carcinoma of the skin ) .,Other,Condition,C0007137;C1302853,squamous cell carcinoma,FALSE,FALSE,NA,NA,NA
17,NCT00696241,Exclusion,( this criterion does not apply to those subjects with basal cell or stage i squamous cell carcinoma of the skin ) .,Other,Other,C0243161,criterion,FALSE,FALSE,NA,NA,NA
17,NCT00696241,Exclusion,( this criterion does not apply to those subjects with basal cell or stage i squamous cell carcinoma of the skin ) .,Other,Other,C0441766,stage i,FALSE,FALSE,NA,NA,NA
18,NCT00696241,Exclusion,type 1 or poorly controlled type 2 diabetes mellitus ( glycosylated hemoglobin greater than 8.0 % ) at screening .,Observation,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
18,NCT00696241,Exclusion,type 1 or poorly controlled type 2 diabetes mellitus ( glycosylated hemoglobin greater than 8.0 % ) at screening .,Observation,Observation,C0017853;C0373638;C0202054,glycosylated hemoglobin,FALSE,FALSE,NA,NA,greater 8.0 %
18,NCT00696241,Exclusion,type 1 or poorly controlled type 2 diabetes mellitus ( glycosylated hemoglobin greater than 8.0 % ) at screening .,Observation,Other,C1552651,type,FALSE,FALSE,NA,NA,NA
19,NCT00696241,Exclusion,alanine aminotransferase level greater than 2.5 times the upper limit of normal liver disease ; active liver disease ; or jaundice at screening .,Condition Occurrence,Condition,C0023895;C2186532,liver disease,FALSE,FALSE,NA,NA,NA
19,NCT00696241,Exclusion,alanine aminotransferase level greater than 2.5 times the upper limit of normal liver disease ; active liver disease ; or jaundice at screening .,Condition Occurrence,Condition,C0023895;C2186532,liver disease,FALSE,FALSE,NA,NA,NA
19,NCT00696241,Exclusion,alanine aminotransferase level greater than 2.5 times the upper limit of normal liver disease ; active liver disease ; or jaundice at screening .,Condition Occurrence,Condition,C2203646,jaundice,FALSE,FALSE,NA,NA,NA
19,NCT00696241,Exclusion,alanine aminotransferase level greater than 2.5 times the upper limit of normal liver disease ; active liver disease ; or jaundice at screening .,Condition Occurrence,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
19,NCT00696241,Exclusion,alanine aminotransferase level greater than 2.5 times the upper limit of normal liver disease ; active liver disease ; or jaundice at screening .,Condition Occurrence,Observation,C0001899;C0201836,alanine aminotransferase,FALSE,FALSE,NA,NA,greater 2.5 times the upper limit of normal
20,NCT00696241,Exclusion,hyperkalemia ( defined as serum potassium greater than the upper limit of normal per the central laboratory ) at screening .,Observation,Condition,C0020461,hyperkalemia,FALSE,FALSE,NA,NA,NA
20,NCT00696241,Exclusion,hyperkalemia ( defined as serum potassium greater than the upper limit of normal per the central laboratory ) at screening .,Observation,Drug,C0719205,central,FALSE,FALSE,NA,NA,NA
20,NCT00696241,Exclusion,hyperkalemia ( defined as serum potassium greater than the upper limit of normal per the central laboratory ) at screening .,Observation,Observation,C0302353;C0543465,serum potassium,FALSE,FALSE,NA,NA,NA
20,NCT00696241,Exclusion,hyperkalemia ( defined as serum potassium greater than the upper limit of normal per the central laboratory ) at screening .,Observation,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
20,NCT00696241,Exclusion,hyperkalemia ( defined as serum potassium greater than the upper limit of normal per the central laboratory ) at screening .,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
21,NCT00696241,Exclusion,upper arm circumference less than 24 cm or greater than 42 cm .,Observation,Condition,C0446516;C1269612,upper arm,FALSE,FALSE,NA,lower 24 cm; greater 42 cm,NA
22,NCT00696241,Exclusion,works night ( 3 rd ) shift ( defined as 11 pm to 7 am ) .,Observation,Drug,C1867051,pm,FALSE,FALSE,NA,equal 11 ; equal 7,NA
22,NCT00696241,Exclusion,works night ( 3 rd ) shift ( defined as 11 pm to 7 am ) .,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
23,NCT00696241,Exclusion,currently participating in another investigational study or has participated in an investigational study within 30 days prior to screening . ; any other serious disease or condition at screening ( or randomization ) that would compromise subject safety ; might affect life expectancy ; or make it difficult to successfully manage and follow the subject according to the protocol .,Other,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
23,NCT00696241,Exclusion,currently participating in another investigational study or has participated in an investigational study within 30 days prior to screening . ; any other serious disease or condition at screening ( or randomization ) that would compromise subject safety ; might affect life expectancy ; or make it difficult to successfully manage and follow the subject according to the protocol .,Other,Other,C3245491,investigational,FALSE,FALSE,NA,NA,NA
23,NCT00696241,Exclusion,currently participating in another investigational study or has participated in an investigational study within 30 days prior to screening . ; any other serious disease or condition at screening ( or randomization ) that would compromise subject safety ; might affect life expectancy ; or make it difficult to successfully manage and follow the subject according to the protocol .,Other,Other,C3245491,investigational,FALSE,FALSE,lower 30 days,NA,NA
23,NCT00696241,Exclusion,currently participating in another investigational study or has participated in an investigational study within 30 days prior to screening . ; any other serious disease or condition at screening ( or randomization ) that would compromise subject safety ; might affect life expectancy ; or make it difficult to successfully manage and follow the subject according to the protocol .,Other,Other,C0023671,life expectancy,FALSE,FALSE,NA,NA,NA
23,NCT00696241,Exclusion,currently participating in another investigational study or has participated in an investigational study within 30 days prior to screening . ; any other serious disease or condition at screening ( or randomization ) that would compromise subject safety ; might affect life expectancy ; or make it difficult to successfully manage and follow the subject according to the protocol .,Other,Other,C1719822,follow,FALSE,FALSE,NA,NA,NA
24,NCT00696241,Exclusion,randomized in a previous azilsartan medoxomil study,Drug Exposure,Drug,C2698291,azilsartan medoxomil,FALSE,FALSE,NA,NA,NA
1,NCT00696436,Inclusion,essential hypertension ( sitting systolic blood pressure between 150 and 180 mm hg ; inclusive ; at day 1 and 24 - hour mean systolic blood pressure between 130 and 170 mm hg ; inclusive ; at day 1 ) .,Observation,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00696436,Inclusion,essential hypertension ( sitting systolic blood pressure between 150 and 180 mm hg ; inclusive ; at day 1 and 24 - hour mean systolic blood pressure between 130 and 170 mm hg ; inclusive ; at day 1 ) .,Observation,Condition,C1319893,sitting systolic blood pressure,FALSE,FALSE,greater_equal 1 hour; lower_equal 24 hour,greater_equal 150 mm hg; lower_equal 180 mm hg,NA
2,NCT00696436,Inclusion,capable of understanding and complying with protocol requirements .,Other,NA,NA,NA,NA,NA,NA,NA,NA
1,NCT00696436,Inclusion,essential hypertension ( sitting systolic blood pressure between 150 and 180 mm hg ; inclusive ; at day 1 and 24 - hour mean systolic blood pressure between 130 and 170 mm hg ; inclusive ; at day 1 ) .,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,equal 1 day,greater_equal 130 mm hg; lower_equal 170 mm hg,NA
3,NCT00696436,Inclusion,females of childbearing potential who are sexually active must agree to use adequate contraception ; and can neither be pregnant nor lactating from screening throughout the duration of the study,Condition Occurrence,Person,C0086287,females,FALSE,FALSE,NA,NA,NA
3,NCT00696436,Inclusion,females of childbearing potential who are sexually active must agree to use adequate contraception ; and can neither be pregnant nor lactating from screening throughout the duration of the study,Condition Occurrence,Condition,C0241028,sexually active,FALSE,FALSE,NA,NA,NA
3,NCT00696436,Inclusion,females of childbearing potential who are sexually active must agree to use adequate contraception ; and can neither be pregnant nor lactating from screening throughout the duration of the study,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
3,NCT00696436,Inclusion,females of childbearing potential who are sexually active must agree to use adequate contraception ; and can neither be pregnant nor lactating from screening throughout the duration of the study,Condition Occurrence,Condition,C2828358;C3668831,lactating,FALSE,FALSE,NA,NA,NA
3,NCT00696436,Inclusion,females of childbearing potential who are sexually active must agree to use adequate contraception ; and can neither be pregnant nor lactating from screening throughout the duration of the study,Condition Occurrence,Procedure,C0700589,contraception,FALSE,FALSE,NA,NA,NA
3,NCT00696436,Inclusion,females of childbearing potential who are sexually active must agree to use adequate contraception ; and can neither be pregnant nor lactating from screening throughout the duration of the study,Condition Occurrence,Observation,C3831118,childbearing potential,FALSE,FALSE,NA,NA,NA
3,NCT00696436,Inclusion,females of childbearing potential who are sexually active must agree to use adequate contraception ; and can neither be pregnant nor lactating from screening throughout the duration of the study,Condition Occurrence,Other,C3641827,agree,FALSE,FALSE,NA,NA,NA
4,NCT00696436,Inclusion,clinical laboratory evaluations within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator .,Observation,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
4,NCT00696436,Inclusion,clinical laboratory evaluations within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator .,Observation,Observation,C3542016,range,FALSE,FALSE,NA,NA,NA
4,NCT00696436,Inclusion,clinical laboratory evaluations within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator .,Observation,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
4,NCT00696436,Inclusion,clinical laboratory evaluations within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator .,Observation,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
5,NCT00696436,Inclusion,willing to discontinue current antihypertensive medications at screening day 21 visit,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,equal 21 day,NA,NA
6,NCT00696436,Inclusion,if the participant is on amlodipine prior to screening ; the participant is willing to discontinue this medication at screening day 28 .,Person,Person,C0679646,participant,FALSE,FALSE,NA,NA,NA
5,NCT00696436,Inclusion,willing to discontinue current antihypertensive medications at screening day 21 visit,Drug Exposure,Other,C1706472,discontinue,FALSE,FALSE,NA,NA,NA
6,NCT00696436,Inclusion,if the participant is on amlodipine prior to screening ; the participant is willing to discontinue this medication at screening day 28 .,Person,Person,C0679646,participant,FALSE,FALSE,NA,NA,NA
6,NCT00696436,Inclusion,if the participant is on amlodipine prior to screening ; the participant is willing to discontinue this medication at screening day 28 .,Person,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,NA
6,NCT00696436,Inclusion,if the participant is on amlodipine prior to screening ; the participant is willing to discontinue this medication at screening day 28 .,Person,Other,C1706472,discontinue,FALSE,FALSE,equal 28 day,NA,NA
7,NCT00696436,Exclusion,sitting diastolic blood pressure greater than 114 mm hg at day 1 ( day prior to randomization ) .,Observation,Condition,C1319894,sitting diastolic blood pressure,FALSE,FALSE,equal 1 day,greater 114 mm hg,NA
8,NCT00696436,Exclusion,baseline 24 - hour ambulatory blood pressure monitor reading of insufficient quality .,Condition Occurrence,Condition,C0855316,ambulatory blood pressure,FALSE,FALSE,equal 24 hour,NA,NA
8,NCT00696436,Exclusion,baseline 24 - hour ambulatory blood pressure monitor reading of insufficient quality .,Condition Occurrence,Condition,C1705179,reading,FALSE,FALSE,NA,NA,NA
8,NCT00696436,Exclusion,baseline 24 - hour ambulatory blood pressure monitor reading of insufficient quality .,Condition Occurrence,Other,C0728873;C0030695,monitor,FALSE,FALSE,NA,NA,NA
9,NCT00696436,Exclusion,taking or expected to take an excluded medication as described in the excluded medications .,Other,NA,NA,NA,NA,NA,NA,NA,NA
10,NCT00696436,Exclusion,hypersensitive to angiotensin ii receptor blockers .,Condition Occurrence,Other,C2757003;C0521942,angiotensin ii receptor blockers,FALSE,FALSE,NA,NA,NA
11,NCT00696436,Exclusion,history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,NA,NA,NA
11,NCT00696436,Exclusion,history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
11,NCT00696436,Exclusion,history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
11,NCT00696436,Exclusion,history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,NA,NA,NA
11,NCT00696436,Exclusion,history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
11,NCT00696436,Exclusion,history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Procedure,C1532338,percutaneous coronary intervention,FALSE,FALSE,NA,NA,NA
11,NCT00696436,Exclusion,history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Procedure,C0010055,coronary artery bypass graft,FALSE,FALSE,NA,NA,NA
11,NCT00696436,Exclusion,history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
12,NCT00696436,Exclusion,clinically significant cardiac conduction defects .,Condition Occurrence,Condition,C0264886,cardiac conduction defects,FALSE,FALSE,NA,NA,NA
13,NCT00696436,Exclusion,hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease .,Condition Occurrence,Condition,C0023213,left ventricular outflow obstruction,FALSE,FALSE,NA,NA,NA
13,NCT00696436,Exclusion,hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease .,Condition Occurrence,Condition,C1260873,aortic valvular disease,FALSE,FALSE,NA,NA,NA
14,NCT00696436,Exclusion,secondary hypertension of any etiology .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
15,NCT00696436,Exclusion,noncompliant ( less than 70 % or greater than 130 % ) with study medication during run-in period .,Drug Exposure,NA,NA,NA,NA,NA,NA,NA,NA
16,NCT00696436,Exclusion,moderate to severe renal dysfunction or disease .,Other,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
16,NCT00696436,Exclusion,moderate to severe renal dysfunction or disease .,Other,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
16,NCT00696436,Exclusion,moderate to severe renal dysfunction or disease .,Other,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
17,NCT00696436,Exclusion,known or suspected unilateral renal artery or bilateral renal artery stenosis .,Condition Occurrence,Condition,C0035065;C1278951,renal artery,FALSE,FALSE,NA,NA,NA
17,NCT00696436,Exclusion,known or suspected unilateral renal artery or bilateral renal artery stenosis .,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
18,NCT00696436,Exclusion,history of drug or alcohol abuse within the past 2 years .,Condition Occurrence,Condition,C0085762,alcohol abuse,FALSE,FALSE,lower 2 past years,NA,NA
18,NCT00696436,Exclusion,history of drug or alcohol abuse within the past 2 years .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,lower 2 past years,NA,NA
19,NCT00696436,Exclusion,previous history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug,Condition Occurrence,Condition,C0544452,remission,TRUE,FALSE,greater_equal 5 years,NA,NA
19,NCT00696436,Exclusion,previous history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug,Condition Occurrence,Other,C0260515;C2707253,cancer,FALSE,FALSE,NA,NA,NA
19,NCT00696436,Exclusion,previous history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
20,NCT00696436,Exclusion,( this criterion does not apply to those participants with basal cell or stage i squamous cell carcinoma of the skin ) .,Other,Condition,C0007137;C1302853,squamous cell carcinoma,FALSE,FALSE,NA,NA,NA
20,NCT00696436,Exclusion,( this criterion does not apply to those participants with basal cell or stage i squamous cell carcinoma of the skin ) .,Other,Other,C0243161,criterion,FALSE,FALSE,NA,NA,NA
20,NCT00696436,Exclusion,( this criterion does not apply to those participants with basal cell or stage i squamous cell carcinoma of the skin ) .,Other,Other,C0441766,stage i,FALSE,FALSE,NA,NA,NA
21,NCT00696436,Exclusion,type 1 or poorly-controlled type 2 diabetes mellitus ( glycosylate hemoglobin greater than 8.0 % ) at screening .,Drug Exposure,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
21,NCT00696436,Exclusion,type 1 or poorly-controlled type 2 diabetes mellitus ( glycosylate hemoglobin greater than 8.0 % ) at screening .,Drug Exposure,Drug,C0017853,glycosylate hemoglobin,FALSE,FALSE,NA,NA,greater 8.0 %
21,NCT00696436,Exclusion,type 1 or poorly-controlled type 2 diabetes mellitus ( glycosylate hemoglobin greater than 8.0 % ) at screening .,Drug Exposure,Other,C1552651,type,FALSE,FALSE,NA,NA,NA
22,NCT00696436,Exclusion,hyperkalemia as defined by the central laboratory normal reference range at screening .,Condition Occurrence,Condition,C0020461,hyperkalemia,FALSE,FALSE,NA,NA,NA
22,NCT00696436,Exclusion,hyperkalemia as defined by the central laboratory normal reference range at screening .,Condition Occurrence,Condition,C0028378,laboratory normal,FALSE,FALSE,NA,NA,NA
22,NCT00696436,Exclusion,hyperkalemia as defined by the central laboratory normal reference range at screening .,Condition Occurrence,Drug,C0719205,central,FALSE,FALSE,NA,NA,NA
22,NCT00696436,Exclusion,hyperkalemia as defined by the central laboratory normal reference range at screening .,Condition Occurrence,Observation,C3542016,range,FALSE,FALSE,NA,NA,NA
22,NCT00696436,Exclusion,hyperkalemia as defined by the central laboratory normal reference range at screening .,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
23,NCT00696436,Exclusion,alanine aminotransferase level of greater than 2.5 times the upper limit of normal liver disease ; active liver disease ; or jaundice at screening .,Condition Occurrence,Condition,C0023895;C2186532,liver disease,FALSE,FALSE,NA,NA,NA
23,NCT00696436,Exclusion,alanine aminotransferase level of greater than 2.5 times the upper limit of normal liver disease ; active liver disease ; or jaundice at screening .,Condition Occurrence,Condition,C0023895;C2186532,liver disease,FALSE,FALSE,NA,NA,NA
23,NCT00696436,Exclusion,alanine aminotransferase level of greater than 2.5 times the upper limit of normal liver disease ; active liver disease ; or jaundice at screening .,Condition Occurrence,Condition,C2203646,jaundice,FALSE,FALSE,NA,NA,NA
23,NCT00696436,Exclusion,alanine aminotransferase level of greater than 2.5 times the upper limit of normal liver disease ; active liver disease ; or jaundice at screening .,Condition Occurrence,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
23,NCT00696436,Exclusion,alanine aminotransferase level of greater than 2.5 times the upper limit of normal liver disease ; active liver disease ; or jaundice at screening .,Condition Occurrence,Observation,C0001899;C0201836,alanine aminotransferase,FALSE,FALSE,NA,NA,greater 2.5 times the upper limit of normal
24,NCT00696436,Exclusion,upper arm circumference less than 24 cm or greater than 42 cm . ; works night ( 3 rd ) shift ( defined as 11 pm [ 2300 ] to 7 am [ 0700 ] ) .,Observation,Condition,C0446516;C1269612,upper arm,FALSE,FALSE,NA,lower 24 cm; greater 42 cm,NA
24,NCT00696436,Exclusion,upper arm circumference less than 24 cm or greater than 42 cm . ; works night ( 3 rd ) shift ( defined as 11 pm [ 2300 ] to 7 am [ 0700 ] ) .,Observation,Drug,C1867051,pm,FALSE,FALSE,NA,equal 11 ; equal 7,NA
24,NCT00696436,Exclusion,upper arm circumference less than 24 cm or greater than 42 cm . ; works night ( 3 rd ) shift ( defined as 11 pm [ 2300 ] to 7 am [ 0700 ] ) .,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
25,NCT00696436,Exclusion,unwilling or unable to comply with the protocol or scheduled appointments .,Other,NA,NA,NA,NA,NA,NA,NA,NA
26,NCT00696436,Exclusion,currently is participating in another investigational study or has participated in an investigational study within 30 days prior to randomization .,Other,Other,C3245491,investigational,FALSE,FALSE,NA,NA,NA
26,NCT00696436,Exclusion,currently is participating in another investigational study or has participated in an investigational study within 30 days prior to randomization .,Other,Other,C3245491,investigational,FALSE,FALSE,lower 30 days,NA,NA
27,NCT00696436,Exclusion,any other serious disease or condition at screening or randomization that would compromise participant safety ; might affect life expectancy ; or make it difficult to successfully manage and follow the subject according to the protocol .,Other,Person,C0679646,participant,FALSE,FALSE,NA,NA,NA
27,NCT00696436,Exclusion,any other serious disease or condition at screening or randomization that would compromise participant safety ; might affect life expectancy ; or make it difficult to successfully manage and follow the subject according to the protocol .,Other,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
27,NCT00696436,Exclusion,any other serious disease or condition at screening or randomization that would compromise participant safety ; might affect life expectancy ; or make it difficult to successfully manage and follow the subject according to the protocol .,Other,Other,C0023671,life expectancy,FALSE,FALSE,NA,NA,NA
27,NCT00696436,Exclusion,any other serious disease or condition at screening or randomization that would compromise participant safety ; might affect life expectancy ; or make it difficult to successfully manage and follow the subject according to the protocol .,Other,Other,C1719822,follow,FALSE,FALSE,NA,NA,NA
28,NCT00696436,Exclusion,has been randomized in a previous azilsartan medoxomil study .,Drug Exposure,Drug,C2698291,azilsartan medoxomil,FALSE,FALSE,NA,NA,NA
29,NCT00696436,Exclusion,is required to take or continues taking any disallowed medication ; prescription medication ; herbal treatment or over-the counter medication that may interfere with evaluation of the study medication,Other,Drug,C0702263,counter,FALSE,FALSE,NA,NA,NA
29,NCT00696436,Exclusion,is required to take or continues taking any disallowed medication ; prescription medication ; herbal treatment or over-the counter medication that may interfere with evaluation of the study medication,Other,Other,C3245502;C3245501;C1619636;C1546857,required,FALSE,FALSE,NA,NA,NA
29,NCT00696436,Exclusion,is required to take or continues taking any disallowed medication ; prescription medication ; herbal treatment or over-the counter medication that may interfere with evaluation of the study medication,Other,Other,C0033081;C2239117,medication prescription,FALSE,FALSE,NA,NA,NA
1,NCT00698646,Inclusion,age 70 years or older .,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 70 years,NA,NA
2,NCT00698646,Inclusion,patients with hypertension prior to being randomized into study .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00698646,Inclusion,patients must have an office cuff mssbp > = 140 and < = 200 mmhg systolic .,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,greater_equal 140 mmhg; lower_equal 200 mmhg,NA
4,NCT00698646,Inclusion,have the ability to communicate and comply with all study requirements .,Condition Occurrence,Condition,C0565998,ability to communicate,FALSE,FALSE,NA,NA,NA
5,NCT00698646,Inclusion,provide written informed consent to participate in the study prior to any screening or study procedures .,Other,NA,NA,NA,NA,NA,NA,NA,NA
6,NCT00698646,Exclusion,use of other investigational drugs within 30 days of enrollment .,Drug Exposure,Drug,C0013230,investigational drugs,FALSE,FALSE,lower 30 days,NA,NA
6,NCT00698646,Exclusion,use of other investigational drugs within 30 days of enrollment .,Drug Exposure,Other,C1696073;C1516879,enrollment,FALSE,FALSE,NA,NA,NA
7,NCT00698646,Exclusion,history of hypersensitivity to any of the study drugs or to drugs of similar chemical classes .,Procedure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
7,NCT00698646,Exclusion,history of hypersensitivity to any of the study drugs or to drugs of similar chemical classes .,Procedure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
7,NCT00698646,Exclusion,history of hypersensitivity to any of the study drugs or to drugs of similar chemical classes .,Procedure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
7,NCT00698646,Exclusion,history of hypersensitivity to any of the study drugs or to drugs of similar chemical classes .,Procedure,Other,C0220806;C3272558,chemical,FALSE,FALSE,NA,NA,NA
8,NCT00698646,Exclusion,office blood pressure measured by office machine cuff with a mean of 3 msdbp > = 120 mmhg at anytime during the screening / washout period .,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,equal 3 ; greater_equal 120 mmhg,NA
8,NCT00698646,Exclusion,office blood pressure measured by office machine cuff with a mean of 3 msdbp > = 120 mmhg at anytime during the screening / washout period .,Observation,Procedure,C2224281;C1314130,blood pressure measured,FALSE,FALSE,NA,NA,NA
9,NCT00698646,Exclusion,patients taking 3 or more antihypertensive drugs and mssbp > = 160 mmhg at the time of visit 1 .,Observation,Condition,C2024467,time,FALSE,FALSE,NA,NA,NA
9,NCT00698646,Exclusion,patients taking 3 or more antihypertensive drugs and mssbp > = 160 mmhg at the time of visit 1 .,Observation,Drug,C0003364,antihypertensive drugs,FALSE,FALSE,NA,greater_equal 3 ; greater_equal 160 mmhg,NA
10,NCT00698646,Exclusion,other protocol-defined may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00699192,Inclusion,provide written informed consent before any assessment was performed .,Observation,Other,C0542573;C0549068;C0870300;C0549070;C0549071;C0549072;C0549073;C0549074;C0028708;C0549075;C0549076;C0549077;C0549078;C0549079;C0549080;C0679207,assessment,FALSE,FALSE,NA,NA,NA
2,NCT00699192,Inclusion,male or female at least 65 years of age .,Person,Person,C0025266,male,FALSE,FALSE,greater_equal 65 years,NA,NA
4,NCT00699192,Inclusion,at visit 1 / screening ; treatment na ve patients had to have a mean seated sbp > = 155 mmhg and < 180 mmhg,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 155 mmhg; lower 180 mmhg,NA
5,NCT00699192,Inclusion,patients undergoing washout from their previous antihypertension medication had to have a mean seated sbp < 180 mmhg .,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,lower 180 mmhg,NA
6,NCT00699192,Inclusion,at visit 2 / single-blind run-in entry ; all patients had to have a mean seated sbp > = 155 mmhg and < 180 mmhg .,Observation,Condition,C1549113,single,FALSE,FALSE,NA,NA,NA
6,NCT00699192,Inclusion,at visit 2 / single-blind run-in entry ; all patients had to have a mean seated sbp > = 155 mmhg and < 180 mmhg .,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 155 mmhg; lower 180 mmhg,NA
6,NCT00699192,Inclusion,at visit 2 / single-blind run-in entry ; all patients had to have a mean seated sbp > = 155 mmhg and < 180 mmhg .,Observation,Other,C1705654,entry,FALSE,FALSE,NA,NA,NA
7,NCT00699192,Inclusion,at visit 3 / core double-blind treatment period entry ; all patients had to have a mean seated sbp > = 145 mmhg and < 180 mmhg .,Observation,Condition,C3274653,core,FALSE,FALSE,NA,NA,NA
7,NCT00699192,Inclusion,at visit 3 / core double-blind treatment period entry ; all patients had to have a mean seated sbp > = 145 mmhg and < 180 mmhg .,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 145 mmhg; lower 180 mmhg,NA
7,NCT00699192,Inclusion,at visit 3 / core double-blind treatment period entry ; all patients had to have a mean seated sbp > = 145 mmhg and < 180 mmhg .,Observation,Other,C1561606;C1561605,blind,FALSE,FALSE,NA,NA,NA
7,NCT00699192,Inclusion,at visit 3 / core double-blind treatment period entry ; all patients had to have a mean seated sbp > = 145 mmhg and < 180 mmhg .,Observation,Other,C1705654,entry,FALSE,FALSE,NA,NA,NA
8,NCT00699192,Inclusion,ability to communicate and comply with all study requirements including measuring their blood pressure at home ; daily as instructed ; using the home blood pressure monitor provided by the sponsor .,Observation,Condition,C0565998,ability to communicate,FALSE,FALSE,NA,NA,NA
8,NCT00699192,Inclusion,ability to communicate and comply with all study requirements including measuring their blood pressure at home ; daily as instructed ; using the home blood pressure monitor provided by the sponsor .,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
8,NCT00699192,Inclusion,ability to communicate and comply with all study requirements including measuring their blood pressure at home ; daily as instructed ; using the home blood pressure monitor provided by the sponsor .,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
8,NCT00699192,Inclusion,ability to communicate and comply with all study requirements including measuring their blood pressure at home ; daily as instructed ; using the home blood pressure monitor provided by the sponsor .,Observation,Other,C1548341,home,FALSE,FALSE,NA,NA,NA
8,NCT00699192,Inclusion,ability to communicate and comply with all study requirements including measuring their blood pressure at home ; daily as instructed ; using the home blood pressure monitor provided by the sponsor .,Observation,Other,C1548341,home,FALSE,FALSE,NA,NA,NA
8,NCT00699192,Inclusion,ability to communicate and comply with all study requirements including measuring their blood pressure at home ; daily as instructed ; using the home blood pressure monitor provided by the sponsor .,Observation,Other,C0728873;C0030695,monitor,FALSE,FALSE,NA,NA,NA
9,NCT00699192,Inclusion,female patients had to be post-menopausal for at least one year .,Observation,Observation,C0150905,female patients,FALSE,FALSE,NA,NA,NA
10,NCT00699192,Exclusion,severe hypertension ( mean seated sbp > = 180 mmhg or a mean seated dbp > = 110 mmhg ) .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
10,NCT00699192,Exclusion,severe hypertension ( mean seated sbp > = 180 mmhg or a mean seated dbp > = 110 mmhg ) .,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 180 mmhg,NA
10,NCT00699192,Exclusion,severe hypertension ( mean seated sbp > = 180 mmhg or a mean seated dbp > = 110 mmhg ) .,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 110 mmhg,NA
10,NCT00699192,Exclusion,severe hypertension ( mean seated sbp > = 180 mmhg or a mean seated dbp > = 110 mmhg ) .,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
11,NCT00699192,Exclusion,history of secondary hypertension ( including primary aldosteronism ; renovascular hypertension ; pheochromocytoma ; etc ; ) .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
11,NCT00699192,Exclusion,history of secondary hypertension ( including primary aldosteronism ; renovascular hypertension ; pheochromocytoma ; etc ; ) .,Condition Occurrence,Condition,C1384514,primary aldosteronism,FALSE,FALSE,NA,NA,NA
11,NCT00699192,Exclusion,history of secondary hypertension ( including primary aldosteronism ; renovascular hypertension ; pheochromocytoma ; etc ; ) .,Condition Occurrence,Condition,C0031511;C1706920,pheochromocytoma,FALSE,FALSE,NA,NA,NA
11,NCT00699192,Exclusion,history of secondary hypertension ( including primary aldosteronism ; renovascular hypertension ; pheochromocytoma ; etc ; ) .,Condition Occurrence,Condition,C0020545,renovascular hypertension,FALSE,FALSE,NA,NA,NA
12,NCT00699192,Exclusion,use of three or more antihypertensive drugs,Drug Exposure,Drug,C0003364,antihypertensive drugs,FALSE,FALSE,NA,NA,NA
13,NCT00699192,Exclusion,dual fixed dose combination therapy was considered as two antihypertensive drugs .,Drug Exposure,Condition,C2827483,fixed,FALSE,FALSE,NA,NA,NA
13,NCT00699192,Exclusion,dual fixed dose combination therapy was considered as two antihypertensive drugs .,Drug Exposure,Drug,C0003364,antihypertensive drugs,FALSE,FALSE,NA,NA,NA
13,NCT00699192,Exclusion,dual fixed dose combination therapy was considered as two antihypertensive drugs .,Drug Exposure,Procedure,C0009429;C0556895,combination therapy,FALSE,FALSE,NA,NA,NA
13,NCT00699192,Exclusion,dual fixed dose combination therapy was considered as two antihypertensive drugs .,Drug Exposure,Other,C1554184,dual,FALSE,FALSE,NA,NA,NA
14,NCT00699192,Exclusion,administration of any agent indicated for the treatment of hypertension after visit 1 ; with the permitted exception of those antihypertensive medications requiring tapering down ( eg beta-blocker or clonidine ) commencing with visit 1 .,Drug Exposure,Drug,C0003364,antihypertensive,TRUE,FALSE,NA,NA,NA
14,NCT00699192,Exclusion,administration of any agent indicated for the treatment of hypertension after visit 1 ; with the permitted exception of those antihypertensive medications requiring tapering down ( eg beta-blocker or clonidine ) commencing with visit 1 .,Drug Exposure,Drug,C0001645,beta-blocker,FALSE,FALSE,NA,NA,NA
14,NCT00699192,Exclusion,administration of any agent indicated for the treatment of hypertension after visit 1 ; with the permitted exception of those antihypertensive medications requiring tapering down ( eg beta-blocker or clonidine ) commencing with visit 1 .,Drug Exposure,Drug,C0009014,clonidine,FALSE,FALSE,NA,NA,NA
14,NCT00699192,Exclusion,administration of any agent indicated for the treatment of hypertension after visit 1 ; with the permitted exception of those antihypertensive medications requiring tapering down ( eg beta-blocker or clonidine ) commencing with visit 1 .,Drug Exposure,Procedure,C0441640,tapering,TRUE,FALSE,NA,NA,NA
14,NCT00699192,Exclusion,administration of any agent indicated for the treatment of hypertension after visit 1 ; with the permitted exception of those antihypertensive medications requiring tapering down ( eg beta-blocker or clonidine ) commencing with visit 1 .,Drug Exposure,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
15,NCT00699192,Exclusion,known moderate retinopathy or malignant retinopathy,Condition Occurrence,Condition,C0035309;C1962966,retinopathy,FALSE,FALSE,NA,NA,NA
15,NCT00699192,Exclusion,known moderate retinopathy or malignant retinopathy,Condition Occurrence,Condition,C0334590;C1533592,malignant,FALSE,FALSE,NA,NA,NA
15,NCT00699192,Exclusion,known moderate retinopathy or malignant retinopathy,Condition Occurrence,Condition,C0035309;C1962966,retinopathy,FALSE,FALSE,NA,NA,NA
15,NCT00699192,Exclusion,known moderate retinopathy or malignant retinopathy,Condition Occurrence,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
16,NCT00699192,Exclusion,moderate was defined as retinal signs of hemorrhage ; microaneurysm ; cotton-wool spot ; hard exudates ; or a combination thereof,Condition Occurrence,Condition,C0019080,hemorrhage,FALSE,FALSE,NA,NA,NA
16,NCT00699192,Exclusion,moderate was defined as retinal signs of hemorrhage ; microaneurysm ; cotton-wool spot ; hard exudates ; or a combination thereof,Condition Occurrence,Condition,C0423410,hard exudates,FALSE,FALSE,NA,NA,NA
16,NCT00699192,Exclusion,moderate was defined as retinal signs of hemorrhage ; microaneurysm ; cotton-wool spot ; hard exudates ; or a combination thereof,Condition Occurrence,Condition,C0333101,microaneurysm,FALSE,FALSE,NA,NA,NA
16,NCT00699192,Exclusion,moderate was defined as retinal signs of hemorrhage ; microaneurysm ; cotton-wool spot ; hard exudates ; or a combination thereof,Condition Occurrence,Drug,C0440207,cotton-wool,FALSE,FALSE,NA,NA,NA
16,NCT00699192,Exclusion,moderate was defined as retinal signs of hemorrhage ; microaneurysm ; cotton-wool spot ; hard exudates ; or a combination thereof,Condition Occurrence,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
16,NCT00699192,Exclusion,moderate was defined as retinal signs of hemorrhage ; microaneurysm ; cotton-wool spot ; hard exudates ; or a combination thereof,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
17,NCT00699192,Exclusion,malignant defined as signs of moderate retinopathy plus swelling of the optic disk .,Condition Occurrence,Condition,C0334590;C1533592,malignant,FALSE,FALSE,NA,NA,NA
17,NCT00699192,Exclusion,malignant defined as signs of moderate retinopathy plus swelling of the optic disk .,Condition Occurrence,Condition,C0035309;C1962966,retinopathy,FALSE,FALSE,NA,NA,NA
17,NCT00699192,Exclusion,malignant defined as signs of moderate retinopathy plus swelling of the optic disk .,Condition Occurrence,Condition,C0038999,swelling,FALSE,FALSE,NA,NA,NA
17,NCT00699192,Exclusion,malignant defined as signs of moderate retinopathy plus swelling of the optic disk .,Condition Occurrence,Condition,C0029127,optic disk,FALSE,FALSE,NA,NA,NA
17,NCT00699192,Exclusion,malignant defined as signs of moderate retinopathy plus swelling of the optic disk .,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
17,NCT00699192,Exclusion,malignant defined as signs of moderate retinopathy plus swelling of the optic disk .,Condition Occurrence,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
18,NCT00699192,Exclusion,known or suspected contraindications ; including history of allergy or hypersensitivity to angiotensin receptor blockers ( arb ) ; calcium channel blockers ( ccb ) ; or to drugs with similar chemical structures .,Drug Exposure,Condition,C0175556,ccb,FALSE,FALSE,NA,NA,NA
18,NCT00699192,Exclusion,known or suspected contraindications ; including history of allergy or hypersensitivity to angiotensin receptor blockers ( arb ) ; calcium channel blockers ( ccb ) ; or to drugs with similar chemical structures .,Drug Exposure,Drug,C0521942;C0815017,angiotensin receptor blockers,FALSE,FALSE,NA,NA,NA
18,NCT00699192,Exclusion,known or suspected contraindications ; including history of allergy or hypersensitivity to angiotensin receptor blockers ( arb ) ; calcium channel blockers ( ccb ) ; or to drugs with similar chemical structures .,Drug Exposure,Drug,C0006684,calcium channel blockers,FALSE,FALSE,NA,NA,NA
18,NCT00699192,Exclusion,known or suspected contraindications ; including history of allergy or hypersensitivity to angiotensin receptor blockers ( arb ) ; calcium channel blockers ( ccb ) ; or to drugs with similar chemical structures .,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
18,NCT00699192,Exclusion,known or suspected contraindications ; including history of allergy or hypersensitivity to angiotensin receptor blockers ( arb ) ; calcium channel blockers ( ccb ) ; or to drugs with similar chemical structures .,Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
18,NCT00699192,Exclusion,known or suspected contraindications ; including history of allergy or hypersensitivity to angiotensin receptor blockers ( arb ) ; calcium channel blockers ( ccb ) ; or to drugs with similar chemical structures .,Drug Exposure,Other,C0489531;C0718579;C3542994;C3539909;C1314973;C1547315;C1611280,allergy,FALSE,FALSE,NA,NA,NA
18,NCT00699192,Exclusion,known or suspected contraindications ; including history of allergy or hypersensitivity to angiotensin receptor blockers ( arb ) ; calcium channel blockers ( ccb ) ; or to drugs with similar chemical structures .,Drug Exposure,Other,C0521942;C2678493,arb,FALSE,FALSE,NA,NA,NA
18,NCT00699192,Exclusion,known or suspected contraindications ; including history of allergy or hypersensitivity to angiotensin receptor blockers ( arb ) ; calcium channel blockers ( ccb ) ; or to drugs with similar chemical structures .,Drug Exposure,Other,C0220806;C3272558,chemical,FALSE,FALSE,NA,NA,NA
19,NCT00699192,Exclusion,history of cerebrovascular accident ; thrombotic stroke ; or transient ischemic attack .,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
19,NCT00699192,Exclusion,history of cerebrovascular accident ; thrombotic stroke ; or transient ischemic attack .,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,NA,NA,NA
19,NCT00699192,Exclusion,history of cerebrovascular accident ; thrombotic stroke ; or transient ischemic attack .,Condition Occurrence,Condition,C0242129,thrombotic stroke,FALSE,FALSE,NA,NA,NA
20,NCT00699192,Exclusion,significant history of coronary artery disease ( cad ) such as any history of myocardial infarction ( mi ) ; angina pectoris ; and all types of revascularization procedures .,Condition Occurrence,Condition,C1956346;C0010068;C0010054,coronary artery disease,FALSE,FALSE,NA,NA,NA
20,NCT00699192,Exclusion,significant history of coronary artery disease ( cad ) such as any history of myocardial infarction ( mi ) ; angina pectoris ; and all types of revascularization procedures .,Condition Occurrence,Condition,C0002962;C0577698;C0235467;C0542052;C0010073;C0541777;C0235462,angina pectoris,FALSE,FALSE,NA,NA,NA
20,NCT00699192,Exclusion,significant history of coronary artery disease ( cad ) such as any history of myocardial infarction ( mi ) ; angina pectoris ; and all types of revascularization procedures .,Condition Occurrence,Other,C1956346;C0011905;C0010068;C0170509,cad,FALSE,FALSE,NA,NA,NA
20,NCT00699192,Exclusion,significant history of coronary artery disease ( cad ) such as any history of myocardial infarction ( mi ) ; angina pectoris ; and all types of revascularization procedures .,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
20,NCT00699192,Exclusion,significant history of coronary artery disease ( cad ) such as any history of myocardial infarction ( mi ) ; angina pectoris ; and all types of revascularization procedures .,Condition Occurrence,Other,C0027051;C0025953;C3496280;C0278960,mi,FALSE,FALSE,NA,NA,NA
21,NCT00699192,Exclusion,history of or diagnosis of congestive heart failure grade ii - grade iv according to the new york heart association ( nyha ) classification .,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
21,NCT00699192,Exclusion,history of or diagnosis of congestive heart failure grade ii - grade iv according to the new york heart association ( nyha ) classification .,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
21,NCT00699192,Exclusion,history of or diagnosis of congestive heart failure grade ii - grade iv according to the new york heart association ( nyha ) classification .,Condition Occurrence,Other,C0441802;C0475270,grade ii,FALSE,FALSE,NA,NA,NA
21,NCT00699192,Exclusion,history of or diagnosis of congestive heart failure grade ii - grade iv according to the new york heart association ( nyha ) classification .,Condition Occurrence,Other,C0677510;C0021440;C3496001,iv,FALSE,FALSE,NA,NA,NA
21,NCT00699192,Exclusion,history of or diagnosis of congestive heart failure grade ii - grade iv according to the new york heart association ( nyha ) classification .,Condition Occurrence,Other,C1275491,nyha classification,FALSE,FALSE,NA,NA,NA
22,NCT00699192,Exclusion,clinically significant valvular heart disease .,Condition Occurrence,Condition,C0018824;C1963123,valvular heart disease,FALSE,FALSE,NA,NA,NA
23,NCT00699192,Exclusion,all patients with type 1 diabetes mellitus and those patients with type 2 diabetes mellitus who ; in the opinion of the investigator ; were not well controlled,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
23,NCT00699192,Exclusion,all patients with type 1 diabetes mellitus and those patients with type 2 diabetes mellitus who ; in the opinion of the investigator ; were not well controlled,Condition Occurrence,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
24,NCT00699192,Exclusion,patients who needed oral anti-diabetic medication to adequately control their type 2 diabetes had to be on a stable dose of oral anti-diabetic medication for at least 4 weeks prior to visit 1 .,Drug Exposure,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
24,NCT00699192,Exclusion,patients who needed oral anti-diabetic medication to adequately control their type 2 diabetes had to be on a stable dose of oral anti-diabetic medication for at least 4 weeks prior to visit 1 .,Drug Exposure,Drug,C1272919,oral,FALSE,FALSE,NA,NA,NA
24,NCT00699192,Exclusion,patients who needed oral anti-diabetic medication to adequately control their type 2 diabetes had to be on a stable dose of oral anti-diabetic medication for at least 4 weeks prior to visit 1 .,Drug Exposure,Drug,C0935929,anti-diabetic,FALSE,FALSE,NA,NA,NA
24,NCT00699192,Exclusion,patients who needed oral anti-diabetic medication to adequately control their type 2 diabetes had to be on a stable dose of oral anti-diabetic medication for at least 4 weeks prior to visit 1 .,Drug Exposure,Drug,C1272919,oral,FALSE,FALSE,NA,NA,NA
24,NCT00699192,Exclusion,patients who needed oral anti-diabetic medication to adequately control their type 2 diabetes had to be on a stable dose of oral anti-diabetic medication for at least 4 weeks prior to visit 1 .,Drug Exposure,Drug,C0935929,anti-diabetic,FALSE,FALSE,greater_equal 4 weeks,NA,NA
24,NCT00699192,Exclusion,patients who needed oral anti-diabetic medication to adequately control their type 2 diabetes had to be on a stable dose of oral anti-diabetic medication for at least 4 weeks prior to visit 1 .,Drug Exposure,Other,C1547311,stable,FALSE,FALSE,NA,NA,NA
25,NCT00699192,Exclusion,concomitant potentially life threatening arrhythmia or symptomatic arrhythmia .,Condition Occurrence,Condition,C2826244;C3537125,life threatening,FALSE,FALSE,NA,NA,NA
25,NCT00699192,Exclusion,concomitant potentially life threatening arrhythmia or symptomatic arrhythmia .,Condition Occurrence,Condition,C0003811,arrhythmia,FALSE,FALSE,NA,NA,NA
25,NCT00699192,Exclusion,concomitant potentially life threatening arrhythmia or symptomatic arrhythmia .,Condition Occurrence,Condition,C0003811,arrhythmia,FALSE,FALSE,NA,NA,NA
26,NCT00699192,Exclusion,second degree heart block or third degree heart block with or without a pacemaker .,Observation,Condition,C0018794;C0542001;C0037188,heart block,FALSE,FALSE,NA,NA,NA
26,NCT00699192,Exclusion,second degree heart block or third degree heart block with or without a pacemaker .,Observation,Condition,C0018794;C0542001;C0037188,heart block,FALSE,FALSE,NA,NA,NA
26,NCT00699192,Exclusion,second degree heart block or third degree heart block with or without a pacemaker .,Observation,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
26,NCT00699192,Exclusion,second degree heart block or third degree heart block with or without a pacemaker .,Observation,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
26,NCT00699192,Exclusion,second degree heart block or third degree heart block with or without a pacemaker .,Observation,Other,C3275122;C1546728,pacemaker,FALSE,FALSE,NA,NA,NA
27,NCT00699192,Exclusion,significant hepatic disease ; as demonstrated by any one of the following : aspartate aminotransferase ( ast ) or alanine aminotransferase ( alt ) values greater than two times the upper limit of normal at visit 1 ; a history of hepatic encephalopathy ; a history of esophageal varices ; or a history of a portocaval shunt .,Observation,Condition,C0023895,hepatic disease,FALSE,FALSE,NA,NA,NA
27,NCT00699192,Exclusion,significant hepatic disease ; as demonstrated by any one of the following : aspartate aminotransferase ( ast ) or alanine aminotransferase ( alt ) values greater than two times the upper limit of normal at visit 1 ; a history of hepatic encephalopathy ; a history of esophageal varices ; or a history of a portocaval shunt .,Observation,Condition,C0019151,hepatic encephalopathy,FALSE,FALSE,NA,NA,NA
27,NCT00699192,Exclusion,significant hepatic disease ; as demonstrated by any one of the following : aspartate aminotransferase ( ast ) or alanine aminotransferase ( alt ) values greater than two times the upper limit of normal at visit 1 ; a history of hepatic encephalopathy ; a history of esophageal varices ; or a history of a portocaval shunt .,Observation,Condition,C0014867,esophageal varices,FALSE,FALSE,NA,NA,NA
27,NCT00699192,Exclusion,significant hepatic disease ; as demonstrated by any one of the following : aspartate aminotransferase ( ast ) or alanine aminotransferase ( alt ) values greater than two times the upper limit of normal at visit 1 ; a history of hepatic encephalopathy ; a history of esophageal varices ; or a history of a portocaval shunt .,Observation,Procedure,C0032716,portocaval shunt,FALSE,FALSE,NA,NA,NA
27,NCT00699192,Exclusion,significant hepatic disease ; as demonstrated by any one of the following : aspartate aminotransferase ( ast ) or alanine aminotransferase ( alt ) values greater than two times the upper limit of normal at visit 1 ; a history of hepatic encephalopathy ; a history of esophageal varices ; or a history of a portocaval shunt .,Observation,Observation,C0004002;C0201899,aspartate aminotransferase,FALSE,FALSE,NA,NA,NA
27,NCT00699192,Exclusion,significant hepatic disease ; as demonstrated by any one of the following : aspartate aminotransferase ( ast ) or alanine aminotransferase ( alt ) values greater than two times the upper limit of normal at visit 1 ; a history of hepatic encephalopathy ; a history of esophageal varices ; or a history of a portocaval shunt .,Observation,Observation,C0004002,ast,FALSE,FALSE,NA,NA,NA
27,NCT00699192,Exclusion,significant hepatic disease ; as demonstrated by any one of the following : aspartate aminotransferase ( ast ) or alanine aminotransferase ( alt ) values greater than two times the upper limit of normal at visit 1 ; a history of hepatic encephalopathy ; a history of esophageal varices ; or a history of a portocaval shunt .,Observation,Observation,C0001899;C0201836,alanine aminotransferase,FALSE,FALSE,NA,NA,NA
27,NCT00699192,Exclusion,significant hepatic disease ; as demonstrated by any one of the following : aspartate aminotransferase ( ast ) or alanine aminotransferase ( alt ) values greater than two times the upper limit of normal at visit 1 ; a history of hepatic encephalopathy ; a history of esophageal varices ; or a history of a portocaval shunt .,Observation,Observation,C1140170;C2257651,alt,FALSE,FALSE,NA,NA,NA
28,NCT00699192,Exclusion,evidence of renal impairment as determined by any one of the following : glomerular filtration rate ( gfr ) < 50 ml / min / 1.773 m2 as measured by the modification of diet in renal disease ( mdrd ) formula at visit 1 ; a history of dialysis ; or a history of nephrotic syndrome .,Observation,Condition,C1565489;C0035078,renal impairment,FALSE,FALSE,NA,NA,NA
28,NCT00699192,Exclusion,evidence of renal impairment as determined by any one of the following : glomerular filtration rate ( gfr ) < 50 ml / min / 1.773 m2 as measured by the modification of diet in renal disease ( mdrd ) formula at visit 1 ; a history of dialysis ; or a history of nephrotic syndrome .,Observation,Condition,C0022658,renal disease,FALSE,FALSE,NA,NA,NA
28,NCT00699192,Exclusion,evidence of renal impairment as determined by any one of the following : glomerular filtration rate ( gfr ) < 50 ml / min / 1.773 m2 as measured by the modification of diet in renal disease ( mdrd ) formula at visit 1 ; a history of dialysis ; or a history of nephrotic syndrome .,Observation,Condition,C0027726,nephrotic syndrome,FALSE,FALSE,NA,NA,NA
28,NCT00699192,Exclusion,evidence of renal impairment as determined by any one of the following : glomerular filtration rate ( gfr ) < 50 ml / min / 1.773 m2 as measured by the modification of diet in renal disease ( mdrd ) formula at visit 1 ; a history of dialysis ; or a history of nephrotic syndrome .,Observation,Procedure,C0011946;C0917873,dialysis,FALSE,FALSE,NA,NA,NA
28,NCT00699192,Exclusion,evidence of renal impairment as determined by any one of the following : glomerular filtration rate ( gfr ) < 50 ml / min / 1.773 m2 as measured by the modification of diet in renal disease ( mdrd ) formula at visit 1 ; a history of dialysis ; or a history of nephrotic syndrome .,Observation,Observation,C0017654,gfr,FALSE,FALSE,NA,lower 50 ml/min; equal 1.773 m2,NA
28,NCT00699192,Exclusion,evidence of renal impairment as determined by any one of the following : glomerular filtration rate ( gfr ) < 50 ml / min / 1.773 m2 as measured by the modification of diet in renal disease ( mdrd ) formula at visit 1 ; a history of dialysis ; or a history of nephrotic syndrome .,Observation,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
28,NCT00699192,Exclusion,evidence of renal impairment as determined by any one of the following : glomerular filtration rate ( gfr ) < 50 ml / min / 1.773 m2 as measured by the modification of diet in renal disease ( mdrd ) formula at visit 1 ; a history of dialysis ; or a history of nephrotic syndrome .,Observation,Other,C0017654;C1561549,glomerular filtration rate,FALSE,FALSE,NA,NA,NA
28,NCT00699192,Exclusion,evidence of renal impairment as determined by any one of the following : glomerular filtration rate ( gfr ) < 50 ml / min / 1.773 m2 as measured by the modification of diet in renal disease ( mdrd ) formula at visit 1 ; a history of dialysis ; or a history of nephrotic syndrome .,Observation,Other,C0012159;C1519433;C1561465;C1550559;C1549512,diet,FALSE,FALSE,NA,NA,NA
28,NCT00699192,Exclusion,evidence of renal impairment as determined by any one of the following : glomerular filtration rate ( gfr ) < 50 ml / min / 1.773 m2 as measured by the modification of diet in renal disease ( mdrd ) formula at visit 1 ; a history of dialysis ; or a history of nephrotic syndrome .,Observation,Other,C1705501;C0489829,formula,FALSE,FALSE,NA,NA,NA
29,NCT00699192,Exclusion,history of clinically significant allergies including asthma or multiple drug allergies .,Condition Occurrence,Condition,C0020517,allergies,FALSE,FALSE,NA,NA,NA
29,NCT00699192,Exclusion,history of clinically significant allergies including asthma or multiple drug allergies .,Condition Occurrence,Condition,C0004096,asthma,FALSE,FALSE,NA,NA,NA
29,NCT00699192,Exclusion,history of clinically significant allergies including asthma or multiple drug allergies .,Condition Occurrence,Condition,C0013182,drug allergies,FALSE,FALSE,NA,NA,NA
30,NCT00699192,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel or inactive inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Condition,C1378698,distribution,FALSE,FALSE,NA,NA,NA
30,NCT00699192,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel or inactive inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Condition,C0504085,excretion,FALSE,FALSE,NA,NA,NA
30,NCT00699192,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel or inactive inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Condition,C0025519,metabolism,FALSE,FALSE,NA,NA,NA
30,NCT00699192,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel or inactive inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Condition,C0021853,bowel,FALSE,FALSE,NA,NA,NA
30,NCT00699192,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel or inactive inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Condition,C3244313,inactive,FALSE,FALSE,NA,NA,NA
30,NCT00699192,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel or inactive inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Condition,C0021853,bowel,FALSE,FALSE,lower 12 months,NA,NA
30,NCT00699192,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel or inactive inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Condition,C0017152,gastritis,FALSE,FALSE,NA,NA,NA
30,NCT00699192,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel or inactive inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Condition,C1559265,gastrointestinal,FALSE,FALSE,NA,NA,NA
30,NCT00699192,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel or inactive inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Condition,C0267596,rectal bleeding,FALSE,FALSE,NA,NA,NA
30,NCT00699192,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel or inactive inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Condition,C0178879,urinary tract obstruction,FALSE,FALSE,NA,NA,NA
30,NCT00699192,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel or inactive inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
30,NCT00699192,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel or inactive inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
30,NCT00699192,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel or inactive inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Procedure,C0399610,gastrointestinal tract surgery,FALSE,FALSE,NA,NA,NA
30,NCT00699192,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel or inactive inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Procedure,C0017118,gastrectomy,FALSE,FALSE,NA,NA,NA
30,NCT00699192,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel or inactive inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Procedure,C1960832,gastric banding,FALSE,FALSE,NA,NA,NA
30,NCT00699192,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel or inactive inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Procedure,C0149701,gastric stapling,FALSE,FALSE,NA,NA,NA
30,NCT00699192,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel or inactive inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Procedure,C0017125,gastric bypass,FALSE,FALSE,NA,NA,NA
30,NCT00699192,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel or inactive inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Procedure,C0741614,bowel resection,FALSE,FALSE,NA,NA,NA
30,NCT00699192,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel or inactive inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Other,C1561579;C1561578,medical,FALSE,FALSE,NA,NA,NA
30,NCT00699192,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel or inactive inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
30,NCT00699192,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel or inactive inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Other,C3542948,limited,TRUE,FALSE,NA,NA,NA
30,NCT00699192,Exclusion,any surgical condition or medical condition with the potential to significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug including but not limited to any of the following : history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; bowel resection ; gastric bypass ; gastric stapling ; or gastric banding ; currently active inflammatory bowel or inactive inflammatory bowel syndrome within 12 months prior to visit 1 ; currently active gastritis ; ulcers ; or gastrointestinal / rectal bleeding ; or urinary tract obstruction regarded as clinically meaningful by the investigator .,Condition Occurrence,Other,C0017164;C2237939,gastroenterostomy,FALSE,FALSE,NA,NA,NA
31,NCT00699192,Exclusion,any condition ; not identified in the protocol ; that ; in the opinion of the investigator or the novartis monitor ; placed the patient at higher risk from his / her participation in the study ; or was likely to prevent the patient from complying with the requirement of the study or completing the trial period .,Drug Exposure,Condition,C1550043,identified,TRUE,FALSE,NA,NA,NA
31,NCT00699192,Exclusion,any condition ; not identified in the protocol ; that ; in the opinion of the investigator or the novartis monitor ; placed the patient at higher risk from his / her participation in the study ; or was likely to prevent the patient from complying with the requirement of the study or completing the trial period .,Drug Exposure,Drug,C1310652,novartis,FALSE,FALSE,NA,NA,NA
31,NCT00699192,Exclusion,any condition ; not identified in the protocol ; that ; in the opinion of the investigator or the novartis monitor ; placed the patient at higher risk from his / her participation in the study ; or was likely to prevent the patient from complying with the requirement of the study or completing the trial period .,Drug Exposure,Drug,C0309872,prevent,FALSE,FALSE,NA,NA,NA
31,NCT00699192,Exclusion,any condition ; not identified in the protocol ; that ; in the opinion of the investigator or the novartis monitor ; placed the patient at higher risk from his / her participation in the study ; or was likely to prevent the patient from complying with the requirement of the study or completing the trial period .,Drug Exposure,Other,C0728873;C0030695,monitor,FALSE,FALSE,NA,NA,NA
32,NCT00699192,Exclusion,history of malignancy of any organ system ; treated or untreated ; within the past 5 years whether or not there was evidence of local recurrence or metastases ; with the exception of localized basal cell carcinoma of the skin .,Condition Occurrence,Condition,C0006826;C1306459,malignancy,FALSE,FALSE,lower 5 past years,NA,NA
32,NCT00699192,Exclusion,history of malignancy of any organ system ; treated or untreated ; within the past 5 years whether or not there was evidence of local recurrence or metastases ; with the exception of localized basal cell carcinoma of the skin .,Condition Occurrence,Condition,C2825055;C1458156,recurrence,FALSE,FALSE,NA,NA,NA
32,NCT00699192,Exclusion,history of malignancy of any organ system ; treated or untreated ; within the past 5 years whether or not there was evidence of local recurrence or metastases ; with the exception of localized basal cell carcinoma of the skin .,Condition Occurrence,Condition,C0027627;C2939419,metastases,FALSE,FALSE,NA,NA,NA
32,NCT00699192,Exclusion,history of malignancy of any organ system ; treated or untreated ; within the past 5 years whether or not there was evidence of local recurrence or metastases ; with the exception of localized basal cell carcinoma of the skin .,Condition Occurrence,Condition,C0007117,basal cell carcinoma of the skin,TRUE,FALSE,NA,NA,NA
33,NCT00699192,Exclusion,any chronic inflammatory condition needing chronic anti-inflammatory therapy .,Other,Other,C1547296;C1555457,chronic,FALSE,FALSE,NA,NA,NA
33,NCT00699192,Exclusion,any chronic inflammatory condition needing chronic anti-inflammatory therapy .,Other,Other,C1547296;C1555457,chronic,FALSE,FALSE,NA,NA,NA
34,NCT00699192,Exclusion,history of drug or alcohol abuse within the last 2 years .,Condition Occurrence,Condition,C0085762,alcohol abuse,FALSE,FALSE,lower 2 last years,NA,NA
34,NCT00699192,Exclusion,history of drug or alcohol abuse within the last 2 years .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,lower 2 last years,NA,NA
35,NCT00699192,Exclusion,use of investigational drugs at the time of enrollment ; or within 30 days prior to visit 1 ( week 8 ) .,Drug Exposure,Condition,C2024467,time,FALSE,FALSE,NA,NA,NA
35,NCT00699192,Exclusion,use of investigational drugs at the time of enrollment ; or within 30 days prior to visit 1 ( week 8 ) .,Drug Exposure,Drug,C0013230,investigational drugs,FALSE,FALSE,NA,NA,NA
35,NCT00699192,Exclusion,use of investigational drugs at the time of enrollment ; or within 30 days prior to visit 1 ( week 8 ) .,Drug Exposure,Other,C1696073;C1516879,enrollment,FALSE,FALSE,lower 30 days; equal 8 week,NA,NA
36,NCT00699192,Exclusion,inability to communicate and comply with all study requirements including the unwillingness or inability to provide informed consent .,Condition Occurrence,Condition,C1845266,inability to communicate,FALSE,FALSE,NA,NA,NA
37,NCT00699192,Exclusion,persons directly involved in the execution of this protocol .,Person,Person,C0027361,persons,FALSE,FALSE,NA,NA,NA
38,NCT00699192,Exclusion,history of non-compliance to medical regimens ; or patients unwilling to comply with the study protocol .,Other,Condition,C0376405,non-compliance,FALSE,FALSE,NA,NA,NA
38,NCT00699192,Exclusion,history of non-compliance to medical regimens ; or patients unwilling to comply with the study protocol .,Other,Other,C1561579;C1561578,medical,FALSE,FALSE,NA,NA,NA
38,NCT00699192,Exclusion,history of non-compliance to medical regimens ; or patients unwilling to comply with the study protocol .,Other,Other,C2945654,regimens,FALSE,FALSE,NA,NA,NA
38,NCT00699192,Exclusion,history of non-compliance to medical regimens ; or patients unwilling to comply with the study protocol .,Other,Other,C2348563;C1507394,study protocol,FALSE,FALSE,NA,NA,NA
39,NCT00699192,Exclusion,any severe disease ; life-threatening disease within the past five years,Condition Occurrence,Condition,C2826244;C3537125,life-threatening,FALSE,FALSE,NA,NA,NA
39,NCT00699192,Exclusion,any severe disease ; life-threatening disease within the past five years,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
2,NCT00699192,Inclusion,male or female at least 65 years of age .,Person,Person,C0086287,female,FALSE,FALSE,greater_equal 65 years,NA,NA
3,NCT00699192,Inclusion,diagnosed as having hypertension :,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00705575,Inclusion,outpatients > = 18 years of age .,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 18 years,NA,NA
2,NCT00705575,Inclusion,patients with a diagnosis of stage ii hypertension ; defined as mean sitting systolic blood pressure ( mssbp ) > = 160 mmhg and < 180 mmhg at visit 2 .,Observation,Condition,C1319893,sitting systolic blood pressure,FALSE,FALSE,NA,greater_equal 160 mmhg; lower 180 mmhg,NA
2,NCT00705575,Inclusion,patients with a diagnosis of stage ii hypertension ; defined as mean sitting systolic blood pressure ( mssbp ) > = 160 mmhg and < 180 mmhg at visit 2 .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00705575,Inclusion,patients with a diagnosis of stage ii hypertension ; defined as mean sitting systolic blood pressure ( mssbp ) > = 160 mmhg and < 180 mmhg at visit 2 .,Observation,Other,C0441767,stage ii,FALSE,FALSE,NA,NA,NA
2,NCT00705575,Inclusion,patients with a diagnosis of stage ii hypertension ; defined as mean sitting systolic blood pressure ( mssbp ) > = 160 mmhg and < 180 mmhg at visit 2 .,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
3,NCT00705575,Exclusion,severe hypertension defined as mssbp > = 180 mmhg or mean sitting diastolic blood pressure ( msdbp ) > = 110 mmhg .,Observation,Condition,C1319894,sitting diastolic blood pressure,FALSE,FALSE,NA,greater_equal 110 mmhg,NA
3,NCT00705575,Exclusion,severe hypertension defined as mssbp > = 180 mmhg or mean sitting diastolic blood pressure ( msdbp ) > = 110 mmhg .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00705575,Exclusion,severe hypertension defined as mssbp > = 180 mmhg or mean sitting diastolic blood pressure ( msdbp ) > = 110 mmhg .,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
3,NCT00705575,Exclusion,severe hypertension defined as mssbp > = 180 mmhg or mean sitting diastolic blood pressure ( msdbp ) > = 110 mmhg .,Observation,Other,C3539106,defined,FALSE,FALSE,NA,greater_equal 180 mmhg,NA
4,NCT00705575,Exclusion,secondary form of hypertension .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
5,NCT00705575,Exclusion,current diagnosis of heart failure ( new york heart association [ nyha ] class ii- .,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
5,NCT00705575,Exclusion,current diagnosis of heart failure ( new york heart association [ nyha ] class ii- .,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
5,NCT00705575,Exclusion,current diagnosis of heart failure ( new york heart association [ nyha ] class ii- .,Condition Occurrence,Condition,C1882083,nyha class,FALSE,FALSE,NA,NA,NA
6,NCT00705575,Exclusion,current angina pectoris requiring pharmacological therapy ( other than stable doses of oral nitrates or topical nitrates ) .,Drug Exposure,Condition,C0002962;C0577698;C0235467;C0542052;C0010073;C0541777;C0235462,angina pectoris,FALSE,FALSE,NA,NA,NA
6,NCT00705575,Exclusion,current angina pectoris requiring pharmacological therapy ( other than stable doses of oral nitrates or topical nitrates ) .,Drug Exposure,Drug,C1272919,oral,TRUE,FALSE,NA,NA,NA
6,NCT00705575,Exclusion,current angina pectoris requiring pharmacological therapy ( other than stable doses of oral nitrates or topical nitrates ) .,Drug Exposure,Drug,C0028125,nitrates,TRUE,FALSE,NA,NA,NA
6,NCT00705575,Exclusion,current angina pectoris requiring pharmacological therapy ( other than stable doses of oral nitrates or topical nitrates ) .,Drug Exposure,Drug,C1710439,topical,FALSE,FALSE,NA,NA,NA
6,NCT00705575,Exclusion,current angina pectoris requiring pharmacological therapy ( other than stable doses of oral nitrates or topical nitrates ) .,Drug Exposure,Drug,C0028125,nitrates,FALSE,FALSE,NA,NA,NA
6,NCT00705575,Exclusion,current angina pectoris requiring pharmacological therapy ( other than stable doses of oral nitrates or topical nitrates ) .,Drug Exposure,Other,C1547311,stable,TRUE,FALSE,NA,NA,NA
7,NCT00705575,Exclusion,second degree heart block or third degree heart block without a pacemaker .,Condition Occurrence,Condition,C0018794;C0542001;C0037188,heart block,FALSE,FALSE,NA,NA,NA
7,NCT00705575,Exclusion,second degree heart block or third degree heart block without a pacemaker .,Condition Occurrence,Condition,C0018794;C0542001;C0037188,heart block,FALSE,FALSE,NA,NA,NA
7,NCT00705575,Exclusion,second degree heart block or third degree heart block without a pacemaker .,Condition Occurrence,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
7,NCT00705575,Exclusion,second degree heart block or third degree heart block without a pacemaker .,Condition Occurrence,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
7,NCT00705575,Exclusion,second degree heart block or third degree heart block without a pacemaker .,Condition Occurrence,Other,C3275122;C1546728,pacemaker,TRUE,FALSE,NA,NA,NA
8,NCT00705575,Exclusion,concurrent potentially life threatening arrhythmia or symptomatic arrhythmia ; atrial fibrillation or atrial flutter ; during the 12 months prior to visit 1 .,Condition Occurrence,Condition,C2826244;C3537125,life threatening,FALSE,FALSE,NA,NA,NA
8,NCT00705575,Exclusion,concurrent potentially life threatening arrhythmia or symptomatic arrhythmia ; atrial fibrillation or atrial flutter ; during the 12 months prior to visit 1 .,Condition Occurrence,Condition,C0003811,arrhythmia,FALSE,FALSE,NA,NA,NA
8,NCT00705575,Exclusion,concurrent potentially life threatening arrhythmia or symptomatic arrhythmia ; atrial fibrillation or atrial flutter ; during the 12 months prior to visit 1 .,Condition Occurrence,Condition,C0085611,arrhythmia atrial,FALSE,FALSE,NA,NA,NA
8,NCT00705575,Exclusion,concurrent potentially life threatening arrhythmia or symptomatic arrhythmia ; atrial fibrillation or atrial flutter ; during the 12 months prior to visit 1 .,Condition Occurrence,Condition,C0232197,fibrillation,FALSE,FALSE,lower_equal 12 months,NA,NA
8,NCT00705575,Exclusion,concurrent potentially life threatening arrhythmia or symptomatic arrhythmia ; atrial fibrillation or atrial flutter ; during the 12 months prior to visit 1 .,Condition Occurrence,Condition,C0004239;C1963068,atrial flutter,FALSE,FALSE,lower_equal 12 months,NA,NA
9,NCT00705575,Exclusion,clinically significant valvular heart disease .,Condition Occurrence,Condition,C0018824;C1963123,valvular heart disease,FALSE,FALSE,NA,NA,NA
10,NCT00705575,Exclusion,previous history of hypertensive encephalopathy or stroke ; transcient ischemic attack ( tia ) ; heart attack ; coronary bypass surgery or any pci .,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
10,NCT00705575,Exclusion,previous history of hypertensive encephalopathy or stroke ; transcient ischemic attack ( tia ) ; heart attack ; coronary bypass surgery or any pci .,Condition Occurrence,Condition,C0745413,ischemic attack,FALSE,FALSE,NA,NA,NA
10,NCT00705575,Exclusion,previous history of hypertensive encephalopathy or stroke ; transcient ischemic attack ( tia ) ; heart attack ; coronary bypass surgery or any pci .,Condition Occurrence,Condition,C0917805,tia,FALSE,FALSE,NA,NA,NA
10,NCT00705575,Exclusion,previous history of hypertensive encephalopathy or stroke ; transcient ischemic attack ( tia ) ; heart attack ; coronary bypass surgery or any pci .,Condition Occurrence,Condition,C0027051,heart attack,FALSE,FALSE,NA,NA,NA
10,NCT00705575,Exclusion,previous history of hypertensive encephalopathy or stroke ; transcient ischemic attack ( tia ) ; heart attack ; coronary bypass surgery or any pci .,Condition Occurrence,Procedure,C1514496;C1532338,pci,FALSE,FALSE,NA,NA,NA
10,NCT00705575,Exclusion,previous history of hypertensive encephalopathy or stroke ; transcient ischemic attack ( tia ) ; heart attack ; coronary bypass surgery or any pci .,Condition Occurrence,Procedure,C0010055,coronary bypass surgery,FALSE,FALSE,NA,NA,NA
11,NCT00705575,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy .,Condition Occurrence,Condition,C0152132,hypertensive retinopathy,FALSE,FALSE,NA,NA,NA
11,NCT00705575,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy .,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii,FALSE,FALSE,NA,NA,NA
11,NCT00705575,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy .,Condition Occurrence,Other,C0677510;C0021440;C3496001,iv,FALSE,FALSE,NA,NA,NA
12,NCT00705575,Exclusion,in the month prior to visit 1 ; patients on combination antihypertensive therapy that includes more than 2 classes of antihypertensive medications .,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
12,NCT00705575,Exclusion,in the month prior to visit 1 ; patients on combination antihypertensive therapy that includes more than 2 classes of antihypertensive medications .,Drug Exposure,Procedure,C0585941,antihypertensive therapy,FALSE,FALSE,NA,greater 2,NA
13,NCT00705575,Exclusion,patients on combined antihypertensive medication that contain two classes of antihypertensive medications are considered to take two antihypertensive medications .,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
13,NCT00705575,Exclusion,patients on combined antihypertensive medication that contain two classes of antihypertensive medications are considered to take two antihypertensive medications .,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
13,NCT00705575,Exclusion,patients on combined antihypertensive medication that contain two classes of antihypertensive medications are considered to take two antihypertensive medications .,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
14,NCT00705575,Exclusion,inability to discontinue prior antihypertensive or other cv medications as required by the protocol .,Other,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
14,NCT00705575,Exclusion,inability to discontinue prior antihypertensive or other cv medications as required by the protocol .,Other,Other,C1706472,discontinue,FALSE,FALSE,NA,NA,NA
14,NCT00705575,Exclusion,inability to discontinue prior antihypertensive or other cv medications as required by the protocol .,Other,Other,C0280551;C1880201,cv,FALSE,FALSE,NA,NA,NA
14,NCT00705575,Exclusion,inability to discontinue prior antihypertensive or other cv medications as required by the protocol .,Other,Other,C3245502;C3245501;C1619636;C1546857,required,FALSE,FALSE,NA,NA,NA
15,NCT00705575,Exclusion,patients with type 1 diabetes mellitus .,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
16,NCT00705575,Exclusion,patients with type 2 diabetes mellitus not well controlled .,Condition Occurrence,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
17,NCT00705575,Exclusion,elevated serum potassium ( over 5.33 meq / l ( mmol / l ) .,Observation,Condition,C0553704,elevated serum potassium,FALSE,FALSE,NA,greater 5.33,NA
18,NCT00705575,Exclusion,any surgical condition or medical condition or the use of any medication which might significantly alter the absorption ; distribution ; metabolism ; or excretion of study drugs .,Condition Occurrence,Condition,C1378698,distribution,FALSE,FALSE,NA,NA,NA
18,NCT00705575,Exclusion,any surgical condition or medical condition or the use of any medication which might significantly alter the absorption ; distribution ; metabolism ; or excretion of study drugs .,Condition Occurrence,Condition,C0504085,excretion,FALSE,FALSE,NA,NA,NA
18,NCT00705575,Exclusion,any surgical condition or medical condition or the use of any medication which might significantly alter the absorption ; distribution ; metabolism ; or excretion of study drugs .,Condition Occurrence,Condition,C0025519,metabolism,FALSE,FALSE,NA,NA,NA
18,NCT00705575,Exclusion,any surgical condition or medical condition or the use of any medication which might significantly alter the absorption ; distribution ; metabolism ; or excretion of study drugs .,Condition Occurrence,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
18,NCT00705575,Exclusion,any surgical condition or medical condition or the use of any medication which might significantly alter the absorption ; distribution ; metabolism ; or excretion of study drugs .,Condition Occurrence,Other,C1561579;C1561578,medical,FALSE,FALSE,NA,NA,NA
19,NCT00705575,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00706134,Inclusion,male and female outpatients 65 years of age and older .,Person,Person,C0025266,male,FALSE,FALSE,equal 65 years,NA,NA
1,NCT00706134,Inclusion,male and female outpatients 65 years of age and older .,Person,Person,C0086287,female,FALSE,FALSE,equal 65 years,NA,NA
2,NCT00706134,Inclusion,patients who are eligible and able to participate in the study ; and who consent to do so after the purpose and nature of the investigation has been clearly explained to them ( written informed consent ) .,Drug Exposure,Drug,C1995603,purpose,FALSE,FALSE,NA,NA,NA
3,NCT00706134,Inclusion,at the randomization visit patients must have an office mssbp greater than or equal to 150 mmhg and < 180 mmhg ( msdbp < 110 mmhg ) with a less than or equal to 15 mmhg difference during the last two visits of the single blind run-in period .,Observation,Condition,C1549113,single,FALSE,FALSE,NA,greater_equal 150 mmhg; lower 180 mmhg; lower 110 mmhg; lower_equal 15 mmhg,NA
3,NCT00706134,Inclusion,at the randomization visit patients must have an office mssbp greater than or equal to 150 mmhg and < 180 mmhg ( msdbp < 110 mmhg ) with a less than or equal to 15 mmhg difference during the last two visits of the single blind run-in period .,Observation,Other,C1561606;C1561605,blind,FALSE,FALSE,NA,NA,NA
4,NCT00706134,Exclusion,severe hypertension [ office msdbp > = 110 mmhg or mean sitting systolic blood pressure ( mssbp ) > = 180 mmhg ] .,Observation,Condition,C1319893,sitting systolic blood pressure,FALSE,FALSE,NA,greater_equal 180 mmhg,NA
4,NCT00706134,Exclusion,severe hypertension [ office msdbp > = 110 mmhg or mean sitting systolic blood pressure ( mssbp ) > = 180 mmhg ] .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,greater_equal 110 mmhg,NA
4,NCT00706134,Exclusion,severe hypertension [ office msdbp > = 110 mmhg or mean sitting systolic blood pressure ( mssbp ) > = 180 mmhg ] .,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
5,NCT00706134,Exclusion,history or evidence of a secondary form of hypertension .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
6,NCT00706134,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy .,Condition Occurrence,Condition,C0152132,hypertensive retinopathy,FALSE,FALSE,NA,NA,NA
6,NCT00706134,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy .,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii,FALSE,FALSE,NA,NA,NA
6,NCT00706134,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy .,Condition Occurrence,Other,C0677510;C0021440;C3496001,iv,FALSE,FALSE,NA,NA,NA
7,NCT00706134,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; including a history of transient ischemic cerebral attack ( tia ) .,Condition Occurrence,Person,C0040704,transient,FALSE,FALSE,NA,NA,NA
7,NCT00706134,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; including a history of transient ischemic cerebral attack ( tia ) .,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
7,NCT00706134,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; including a history of transient ischemic cerebral attack ( tia ) .,Condition Occurrence,Condition,C0000924;C2046386,accident,FALSE,FALSE,NA,NA,NA
7,NCT00706134,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; including a history of transient ischemic cerebral attack ( tia ) .,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
7,NCT00706134,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; including a history of transient ischemic cerebral attack ( tia ) .,Condition Occurrence,Condition,C0917805,tia,FALSE,FALSE,NA,NA,NA
8,NCT00706134,Exclusion,current diagnosis of heart failure ( nyha class ii- .,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
8,NCT00706134,Exclusion,current diagnosis of heart failure ( nyha class ii- .,Condition Occurrence,Condition,C1882083,nyha class,FALSE,FALSE,NA,NA,NA
9,NCT00706134,Exclusion,history of myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention ( pci ) .,Procedure,Procedure,C1532338,percutaneous coronary intervention,FALSE,FALSE,NA,NA,NA
9,NCT00706134,Exclusion,history of myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention ( pci ) .,Procedure,Procedure,C0010055,coronary bypass surgery,FALSE,FALSE,NA,NA,NA
9,NCT00706134,Exclusion,history of myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention ( pci ) .,Procedure,Procedure,C1514496;C1532338,pci,FALSE,FALSE,NA,NA,NA
9,NCT00706134,Exclusion,history of myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention ( pci ) .,Procedure,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
10,NCT00706134,Exclusion,current angina pectoris requiring pharmacological therapy other than nitrates .,Drug Exposure,Condition,C0002962;C0577698;C0235467;C0542052;C0010073;C0541777;C0235462,angina pectoris,FALSE,FALSE,NA,NA,NA
10,NCT00706134,Exclusion,current angina pectoris requiring pharmacological therapy other than nitrates .,Drug Exposure,Drug,C0028125,nitrates,TRUE,FALSE,NA,NA,NA
11,NCT00706134,Exclusion,other protocol-defined inclusiopplied to the study,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00750113,Inclusion,hypertension ( office systolic blood pressure > 135 mmhg ) ; untreated or poorly controlled but stable antihypertensive regimen for > / = 4 weeks,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
1,NCT00750113,Inclusion,hypertension ( office systolic blood pressure > 135 mmhg ) ; untreated or poorly controlled but stable antihypertensive regimen for > / = 4 weeks,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00750113,Inclusion,hypertension ( office systolic blood pressure > 135 mmhg ) ; untreated or poorly controlled but stable antihypertensive regimen for > / = 4 weeks,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater 135 mmhg,NA
1,NCT00750113,Inclusion,hypertension ( office systolic blood pressure > 135 mmhg ) ; untreated or poorly controlled but stable antihypertensive regimen for > / = 4 weeks,Observation,Other,C1547311,stable,FALSE,FALSE,NA,NA,NA
2,NCT00750113,Inclusion,presence of type 2 diabetes mellitus or target organ damage ( echocardiographic left ventricular hypertrophy or electrocardiographic left ventricular hypertrophy or microalbuminuria ),Condition Occurrence,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
2,NCT00750113,Inclusion,presence of type 2 diabetes mellitus or target organ damage ( echocardiographic left ventricular hypertrophy or electrocardiographic left ventricular hypertrophy or microalbuminuria ),Condition Occurrence,Condition,C0010957,damage,FALSE,FALSE,NA,NA,NA
2,NCT00750113,Inclusion,presence of type 2 diabetes mellitus or target organ damage ( echocardiographic left ventricular hypertrophy or electrocardiographic left ventricular hypertrophy or microalbuminuria ),Condition Occurrence,Condition,C0730345,microalbuminuria,FALSE,FALSE,NA,NA,NA
2,NCT00750113,Inclusion,presence of type 2 diabetes mellitus or target organ damage ( echocardiographic left ventricular hypertrophy or electrocardiographic left ventricular hypertrophy or microalbuminuria ),Condition Occurrence,Observation,C2986546,target,FALSE,FALSE,NA,NA,NA
2,NCT00750113,Inclusion,presence of type 2 diabetes mellitus or target organ damage ( echocardiographic left ventricular hypertrophy or electrocardiographic left ventricular hypertrophy or microalbuminuria ),Condition Occurrence,Other,C0149721;C0232306;C3484363,left ventricular hypertrophy,FALSE,FALSE,NA,NA,NA
3,NCT00750113,Inclusion,presence of a metabolic syndrome ; e at least two of the following [ ( from letter ( a ) to letter ( d ) ] in patients with organ damage or at least one of the following [ from letter ( b ) to letter ( d ) ] in patients with diabetes mellitus : ( a ) impaired glucose tolerance ( fasting plasma glucose 110 - 125 mg / dl ) ( b ) raised serum triglycerides ( > / = 150 mg / dl ) or comitant use of statins for this indication ( c ) low hdl cholesterol ( males : < 40 mg / dl ; females : < 50 mg / dl ) ( d ) waist circumference > 102 cm in men and > 88 cm in women,Drug Exposure,Person,C0025266,males,FALSE,FALSE,NA,NA,NA
3,NCT00750113,Inclusion,presence of a metabolic syndrome ; e at least two of the following [ ( from letter ( a ) to letter ( d ) ] in patients with organ damage or at least one of the following [ from letter ( b ) to letter ( d ) ] in patients with diabetes mellitus : ( a ) impaired glucose tolerance ( fasting plasma glucose 110 - 125 mg / dl ) ( b ) raised serum triglycerides ( > / = 150 mg / dl ) or comitant use of statins for this indication ( c ) low hdl cholesterol ( males : < 40 mg / dl ; females : < 50 mg / dl ) ( d ) waist circumference > 102 cm in men and > 88 cm in women,Drug Exposure,Person,C0086287,females,FALSE,FALSE,NA,NA,NA
3,NCT00750113,Inclusion,presence of a metabolic syndrome ; e at least two of the following [ ( from letter ( a ) to letter ( d ) ] in patients with organ damage or at least one of the following [ from letter ( b ) to letter ( d ) ] in patients with diabetes mellitus : ( a ) impaired glucose tolerance ( fasting plasma glucose 110 - 125 mg / dl ) ( b ) raised serum triglycerides ( > / = 150 mg / dl ) or comitant use of statins for this indication ( c ) low hdl cholesterol ( males : < 40 mg / dl ; females : < 50 mg / dl ) ( d ) waist circumference > 102 cm in men and > 88 cm in women,Drug Exposure,Person,C0025266,men,FALSE,FALSE,NA,NA,NA
3,NCT00750113,Inclusion,presence of a metabolic syndrome ; e at least two of the following [ ( from letter ( a ) to letter ( d ) ] in patients with organ damage or at least one of the following [ from letter ( b ) to letter ( d ) ] in patients with diabetes mellitus : ( a ) impaired glucose tolerance ( fasting plasma glucose 110 - 125 mg / dl ) ( b ) raised serum triglycerides ( > / = 150 mg / dl ) or comitant use of statins for this indication ( c ) low hdl cholesterol ( males : < 40 mg / dl ; females : < 50 mg / dl ) ( d ) waist circumference > 102 cm in men and > 88 cm in women,Drug Exposure,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
3,NCT00750113,Inclusion,presence of a metabolic syndrome ; e at least two of the following [ ( from letter ( a ) to letter ( d ) ] in patients with organ damage or at least one of the following [ from letter ( b ) to letter ( d ) ] in patients with diabetes mellitus : ( a ) impaired glucose tolerance ( fasting plasma glucose 110 - 125 mg / dl ) ( b ) raised serum triglycerides ( > / = 150 mg / dl ) or comitant use of statins for this indication ( c ) low hdl cholesterol ( males : < 40 mg / dl ; females : < 50 mg / dl ) ( d ) waist circumference > 102 cm in men and > 88 cm in women,Drug Exposure,Condition,C0524620,metabolic syndrome,FALSE,FALSE,NA,NA,NA
1,NCT00750113,Inclusion,hypertension ( office systolic blood pressure > 135 mmhg ) ; untreated or poorly controlled but stable antihypertensive regimen for > / = 4 weeks,Observation,Procedure,C0040808,regimen,FALSE,FALSE,greater_equal 4 weeks,NA,NA
2,NCT00750113,Inclusion,presence of type 2 diabetes mellitus or target organ damage ( echocardiographic left ventricular hypertrophy or electrocardiographic left ventricular hypertrophy or microalbuminuria ),Condition Occurrence,Other,C0149721;C0232306;C3484363,left ventricular hypertrophy,FALSE,FALSE,NA,NA,NA
3,NCT00750113,Inclusion,presence of a metabolic syndrome ; e at least two of the following [ ( from letter ( a ) to letter ( d ) ] in patients with organ damage or at least one of the following [ from letter ( b ) to letter ( d ) ] in patients with diabetes mellitus : ( a ) impaired glucose tolerance ( fasting plasma glucose 110 - 125 mg / dl ) ( b ) raised serum triglycerides ( > / = 150 mg / dl ) or comitant use of statins for this indication ( c ) low hdl cholesterol ( males : < 40 mg / dl ; females : < 50 mg / dl ) ( d ) waist circumference > 102 cm in men and > 88 cm in women,Drug Exposure,Condition,C0010957,damage,FALSE,FALSE,NA,NA,NA
3,NCT00750113,Inclusion,presence of a metabolic syndrome ; e at least two of the following [ ( from letter ( a ) to letter ( d ) ] in patients with organ damage or at least one of the following [ from letter ( b ) to letter ( d ) ] in patients with diabetes mellitus : ( a ) impaired glucose tolerance ( fasting plasma glucose 110 - 125 mg / dl ) ( b ) raised serum triglycerides ( > / = 150 mg / dl ) or comitant use of statins for this indication ( c ) low hdl cholesterol ( males : < 40 mg / dl ; females : < 50 mg / dl ) ( d ) waist circumference > 102 cm in men and > 88 cm in women,Drug Exposure,Condition,C0011849,diabetes mellitus,FALSE,FALSE,NA,NA,NA
3,NCT00750113,Inclusion,presence of a metabolic syndrome ; e at least two of the following [ ( from letter ( a ) to letter ( d ) ] in patients with organ damage or at least one of the following [ from letter ( b ) to letter ( d ) ] in patients with diabetes mellitus : ( a ) impaired glucose tolerance ( fasting plasma glucose 110 - 125 mg / dl ) ( b ) raised serum triglycerides ( > / = 150 mg / dl ) or comitant use of statins for this indication ( c ) low hdl cholesterol ( males : < 40 mg / dl ; females : < 50 mg / dl ) ( d ) waist circumference > 102 cm in men and > 88 cm in women,Drug Exposure,Condition,C0271650;C0159069,impaired glucose tolerance,FALSE,FALSE,NA,NA,NA
3,NCT00750113,Inclusion,presence of a metabolic syndrome ; e at least two of the following [ ( from letter ( a ) to letter ( d ) ] in patients with organ damage or at least one of the following [ from letter ( b ) to letter ( d ) ] in patients with diabetes mellitus : ( a ) impaired glucose tolerance ( fasting plasma glucose 110 - 125 mg / dl ) ( b ) raised serum triglycerides ( > / = 150 mg / dl ) or comitant use of statins for this indication ( c ) low hdl cholesterol ( males : < 40 mg / dl ; females : < 50 mg / dl ) ( d ) waist circumference > 102 cm in men and > 88 cm in women,Drug Exposure,Condition,C0151691,low hdl cholesterol,FALSE,FALSE,NA,NA,NA
3,NCT00750113,Inclusion,presence of a metabolic syndrome ; e at least two of the following [ ( from letter ( a ) to letter ( d ) ] in patients with organ damage or at least one of the following [ from letter ( b ) to letter ( d ) ] in patients with diabetes mellitus : ( a ) impaired glucose tolerance ( fasting plasma glucose 110 - 125 mg / dl ) ( b ) raised serum triglycerides ( > / = 150 mg / dl ) or comitant use of statins for this indication ( c ) low hdl cholesterol ( males : < 40 mg / dl ; females : < 50 mg / dl ) ( d ) waist circumference > 102 cm in men and > 88 cm in women,Drug Exposure,Observation,C0583513,fasting plasma glucose,FALSE,FALSE,NA,NA,greater_equal 110 mg/dl; lower_equal 125 mg/dl
3,NCT00750113,Inclusion,presence of a metabolic syndrome ; e at least two of the following [ ( from letter ( a ) to letter ( d ) ] in patients with organ damage or at least one of the following [ from letter ( b ) to letter ( d ) ] in patients with diabetes mellitus : ( a ) impaired glucose tolerance ( fasting plasma glucose 110 - 125 mg / dl ) ( b ) raised serum triglycerides ( > / = 150 mg / dl ) or comitant use of statins for this indication ( c ) low hdl cholesterol ( males : < 40 mg / dl ; females : < 50 mg / dl ) ( d ) waist circumference > 102 cm in men and > 88 cm in women,Drug Exposure,Observation,C0542495,serum triglycerides,FALSE,FALSE,NA,NA,greater_equal 150 mg/dl
3,NCT00750113,Inclusion,presence of a metabolic syndrome ; e at least two of the following [ ( from letter ( a ) to letter ( d ) ] in patients with organ damage or at least one of the following [ from letter ( b ) to letter ( d ) ] in patients with diabetes mellitus : ( a ) impaired glucose tolerance ( fasting plasma glucose 110 - 125 mg / dl ) ( b ) raised serum triglycerides ( > / = 150 mg / dl ) or comitant use of statins for this indication ( c ) low hdl cholesterol ( males : < 40 mg / dl ; females : < 50 mg / dl ) ( d ) waist circumference > 102 cm in men and > 88 cm in women,Drug Exposure,Other,C1096774,letter,FALSE,FALSE,NA,NA,NA
3,NCT00750113,Inclusion,presence of a metabolic syndrome ; e at least two of the following [ ( from letter ( a ) to letter ( d ) ] in patients with organ damage or at least one of the following [ from letter ( b ) to letter ( d ) ] in patients with diabetes mellitus : ( a ) impaired glucose tolerance ( fasting plasma glucose 110 - 125 mg / dl ) ( b ) raised serum triglycerides ( > / = 150 mg / dl ) or comitant use of statins for this indication ( c ) low hdl cholesterol ( males : < 40 mg / dl ; females : < 50 mg / dl ) ( d ) waist circumference > 102 cm in men and > 88 cm in women,Drug Exposure,Other,C1096774,letter,FALSE,FALSE,NA,NA,NA
3,NCT00750113,Inclusion,presence of a metabolic syndrome ; e at least two of the following [ ( from letter ( a ) to letter ( d ) ] in patients with organ damage or at least one of the following [ from letter ( b ) to letter ( d ) ] in patients with diabetes mellitus : ( a ) impaired glucose tolerance ( fasting plasma glucose 110 - 125 mg / dl ) ( b ) raised serum triglycerides ( > / = 150 mg / dl ) or comitant use of statins for this indication ( c ) low hdl cholesterol ( males : < 40 mg / dl ; females : < 50 mg / dl ) ( d ) waist circumference > 102 cm in men and > 88 cm in women,Drug Exposure,Other,C1096774,letter,FALSE,FALSE,NA,NA,NA
3,NCT00750113,Inclusion,presence of a metabolic syndrome ; e at least two of the following [ ( from letter ( a ) to letter ( d ) ] in patients with organ damage or at least one of the following [ from letter ( b ) to letter ( d ) ] in patients with diabetes mellitus : ( a ) impaired glucose tolerance ( fasting plasma glucose 110 - 125 mg / dl ) ( b ) raised serum triglycerides ( > / = 150 mg / dl ) or comitant use of statins for this indication ( c ) low hdl cholesterol ( males : < 40 mg / dl ; females : < 50 mg / dl ) ( d ) waist circumference > 102 cm in men and > 88 cm in women,Drug Exposure,Other,C1096774,letter,FALSE,FALSE,NA,NA,NA
3,NCT00750113,Inclusion,presence of a metabolic syndrome ; e at least two of the following [ ( from letter ( a ) to letter ( d ) ] in patients with organ damage or at least one of the following [ from letter ( b ) to letter ( d ) ] in patients with diabetes mellitus : ( a ) impaired glucose tolerance ( fasting plasma glucose 110 - 125 mg / dl ) ( b ) raised serum triglycerides ( > / = 150 mg / dl ) or comitant use of statins for this indication ( c ) low hdl cholesterol ( males : < 40 mg / dl ; females : < 50 mg / dl ) ( d ) waist circumference > 102 cm in men and > 88 cm in women,Drug Exposure,Other,C0455829;C2366869,waist circumference,FALSE,FALSE,NA,greater 102 cm,NA
4,NCT00750113,Inclusion,age : 18 - 75 years,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 18 years; lower_equal 75 years,NA,NA
5,NCT00750113,Inclusion,negative pregnancy test in females,Person,Person,C0086287,females,FALSE,FALSE,NA,NA,NA
5,NCT00750113,Inclusion,negative pregnancy test in females,Person,Observation,C0427780,negative pregnancy test,FALSE,FALSE,NA,NA,NA
6,NCT00750113,Inclusion,written informed consent,Other,NA,NA,NA,NA,NA,NA,NA,NA
7,NCT00750113,Exclusion,concomitant treatment with at1-antagonists eg losartan ; eprosartan ; telmisartan ) or calcium-antagonists ( eg amlodipine ; felodipine ; isradipine ; nifedipine ; nimodipine ) .,Drug Exposure,Drug,C0126174,losartan,FALSE,FALSE,NA,NA,NA
7,NCT00750113,Exclusion,concomitant treatment with at1-antagonists eg losartan ; eprosartan ; telmisartan ) or calcium-antagonists ( eg amlodipine ; felodipine ; isradipine ; nifedipine ; nimodipine ) .,Drug Exposure,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,NA
7,NCT00750113,Exclusion,concomitant treatment with at1-antagonists eg losartan ; eprosartan ; telmisartan ) or calcium-antagonists ( eg amlodipine ; felodipine ; isradipine ; nifedipine ; nimodipine ) .,Drug Exposure,Drug,C0287041,eprosartan,FALSE,FALSE,NA,NA,NA
7,NCT00750113,Exclusion,concomitant treatment with at1-antagonists eg losartan ; eprosartan ; telmisartan ) or calcium-antagonists ( eg amlodipine ; felodipine ; isradipine ; nifedipine ; nimodipine ) .,Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,NA
7,NCT00750113,Exclusion,concomitant treatment with at1-antagonists eg losartan ; eprosartan ; telmisartan ) or calcium-antagonists ( eg amlodipine ; felodipine ; isradipine ; nifedipine ; nimodipine ) .,Drug Exposure,Drug,C0028094,nimodipine,FALSE,FALSE,NA,NA,NA
7,NCT00750113,Exclusion,concomitant treatment with at1-antagonists eg losartan ; eprosartan ; telmisartan ) or calcium-antagonists ( eg amlodipine ; felodipine ; isradipine ; nifedipine ; nimodipine ) .,Drug Exposure,Drug,C0028066,nifedipine,FALSE,FALSE,NA,NA,NA
7,NCT00750113,Exclusion,concomitant treatment with at1-antagonists eg losartan ; eprosartan ; telmisartan ) or calcium-antagonists ( eg amlodipine ; felodipine ; isradipine ; nifedipine ; nimodipine ) .,Drug Exposure,Drug,C0071304,isradipine,FALSE,FALSE,NA,NA,NA
7,NCT00750113,Exclusion,concomitant treatment with at1-antagonists eg losartan ; eprosartan ; telmisartan ) or calcium-antagonists ( eg amlodipine ; felodipine ; isradipine ; nifedipine ; nimodipine ) .,Drug Exposure,Drug,C0015772,felodipine,FALSE,FALSE,NA,NA,NA
7,NCT00750113,Exclusion,concomitant treatment with at1-antagonists eg losartan ; eprosartan ; telmisartan ) or calcium-antagonists ( eg amlodipine ; felodipine ; isradipine ; nifedipine ; nimodipine ) .,Drug Exposure,Other,C0006675;C0201925;C0006726;C2936886;C3540037,calcium,FALSE,FALSE,NA,NA,NA
8,NCT00750113,Exclusion,concomitant treatment with any other antihypertensive medication that cannot be safely withdrawn at entry ( i ; e taken on a stable regimen for > / = 4 week ) and that won ' t possibly be kept stable over the whole duration of the study .,Other,Condition,C0424092,withdrawn,TRUE,FALSE,NA,NA,NA
8,NCT00750113,Exclusion,concomitant treatment with any other antihypertensive medication that cannot be safely withdrawn at entry ( i ; e taken on a stable regimen for > / = 4 week ) and that won ' t possibly be kept stable over the whole duration of the study .,Other,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
8,NCT00750113,Exclusion,concomitant treatment with any other antihypertensive medication that cannot be safely withdrawn at entry ( i ; e taken on a stable regimen for > / = 4 week ) and that won ' t possibly be kept stable over the whole duration of the study .,Other,Procedure,C0040808,regimen,FALSE,FALSE,greater_equal 4 week,NA,NA
8,NCT00750113,Exclusion,concomitant treatment with any other antihypertensive medication that cannot be safely withdrawn at entry ( i ; e taken on a stable regimen for > / = 4 week ) and that won ' t possibly be kept stable over the whole duration of the study .,Other,Other,C1705654,entry,TRUE,FALSE,NA,NA,NA
8,NCT00750113,Exclusion,concomitant treatment with any other antihypertensive medication that cannot be safely withdrawn at entry ( i ; e taken on a stable regimen for > / = 4 week ) and that won ' t possibly be kept stable over the whole duration of the study .,Other,Other,C0683454,i e,FALSE,FALSE,NA,NA,NA
8,NCT00750113,Exclusion,concomitant treatment with any other antihypertensive medication that cannot be safely withdrawn at entry ( i ; e taken on a stable regimen for > / = 4 week ) and that won ' t possibly be kept stable over the whole duration of the study .,Other,Other,C1547311,stable,FALSE,FALSE,NA,NA,NA
8,NCT00750113,Exclusion,concomitant treatment with any other antihypertensive medication that cannot be safely withdrawn at entry ( i ; e taken on a stable regimen for > / = 4 week ) and that won ' t possibly be kept stable over the whole duration of the study .,Other,Other,C1547311,stable,FALSE,FALSE,NA,NA,NA
9,NCT00750113,Exclusion,concomitant treatment with known cytochrome p450-3a4 inhibitors ( e . g cimetidine ; anti-hiv protease inhibitors eg ritonavir ; azole anti-mycotics eg,Drug Exposure,Drug,C1142644,p450-3a4,FALSE,FALSE,NA,NA,NA
9,NCT00750113,Exclusion,concomitant treatment with known cytochrome p450-3a4 inhibitors ( e . g cimetidine ; anti-hiv protease inhibitors eg ritonavir ; azole anti-mycotics eg,Drug Exposure,Drug,C0008783,cimetidine,FALSE,FALSE,NA,NA,NA
9,NCT00750113,Exclusion,concomitant treatment with known cytochrome p450-3a4 inhibitors ( e . g cimetidine ; anti-hiv protease inhibitors eg ritonavir ; azole anti-mycotics eg,Drug Exposure,Drug,C0292818,ritonavir,FALSE,FALSE,NA,NA,NA
9,NCT00750113,Exclusion,concomitant treatment with known cytochrome p450-3a4 inhibitors ( e . g cimetidine ; anti-hiv protease inhibitors eg ritonavir ; azole anti-mycotics eg,Drug Exposure,Other,C0010798;C1325304,cytochrome,FALSE,FALSE,NA,NA,NA
9,NCT00750113,Exclusion,concomitant treatment with known cytochrome p450-3a4 inhibitors ( e . g cimetidine ; anti-hiv protease inhibitors eg ritonavir ; azole anti-mycotics eg,Drug Exposure,Other,C0019682;C0086413,hiv,FALSE,FALSE,NA,NA,NA
9,NCT00750113,Exclusion,concomitant treatment with known cytochrome p450-3a4 inhibitors ( e . g cimetidine ; anti-hiv protease inhibitors eg ritonavir ; azole anti-mycotics eg,Drug Exposure,Other,C0033607;C2756997;C3540755,protease inhibitors,FALSE,FALSE,NA,NA,NA
10,NCT00750113,Exclusion,ketoconazole ; digoxin ; quinidine ; tacrolimus ) or inducers such as anti-epileptic drugs ( eg ; phenytoin ; carbamazepine and phenobarbitone ) or rifampicin,Drug Exposure,Drug,C0022625,ketoconazole,FALSE,FALSE,NA,NA,NA
10,NCT00750113,Exclusion,ketoconazole ; digoxin ; quinidine ; tacrolimus ) or inducers such as anti-epileptic drugs ( eg ; phenytoin ; carbamazepine and phenobarbitone ) or rifampicin,Drug Exposure,Drug,C3537002,anti-epileptic,FALSE,FALSE,NA,NA,NA
10,NCT00750113,Exclusion,ketoconazole ; digoxin ; quinidine ; tacrolimus ) or inducers such as anti-epileptic drugs ( eg ; phenytoin ; carbamazepine and phenobarbitone ) or rifampicin,Drug Exposure,Drug,C0031507,phenytoin,FALSE,FALSE,NA,NA,NA
10,NCT00750113,Exclusion,ketoconazole ; digoxin ; quinidine ; tacrolimus ) or inducers such as anti-epileptic drugs ( eg ; phenytoin ; carbamazepine and phenobarbitone ) or rifampicin,Drug Exposure,Drug,C0006949,carbamazepine,FALSE,FALSE,NA,NA,NA
10,NCT00750113,Exclusion,ketoconazole ; digoxin ; quinidine ; tacrolimus ) or inducers such as anti-epileptic drugs ( eg ; phenytoin ; carbamazepine and phenobarbitone ) or rifampicin,Drug Exposure,Drug,C0035608,rifampicin,FALSE,FALSE,NA,NA,NA
10,NCT00750113,Exclusion,ketoconazole ; digoxin ; quinidine ; tacrolimus ) or inducers such as anti-epileptic drugs ( eg ; phenytoin ; carbamazepine and phenobarbitone ) or rifampicin,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
10,NCT00750113,Exclusion,ketoconazole ; digoxin ; quinidine ; tacrolimus ) or inducers such as anti-epileptic drugs ( eg ; phenytoin ; carbamazepine and phenobarbitone ) or rifampicin,Drug Exposure,Other,C0519826;C0085149,tacrolimus,FALSE,FALSE,NA,NA,NA
10,NCT00750113,Exclusion,ketoconazole ; digoxin ; quinidine ; tacrolimus ) or inducers such as anti-epileptic drugs ( eg ; phenytoin ; carbamazepine and phenobarbitone ) or rifampicin,Drug Exposure,Other,C0034414;C0337453,quinidine,FALSE,FALSE,NA,NA,NA
10,NCT00750113,Exclusion,ketoconazole ; digoxin ; quinidine ; tacrolimus ) or inducers such as anti-epileptic drugs ( eg ; phenytoin ; carbamazepine and phenobarbitone ) or rifampicin,Drug Exposure,Other,C0337449;C0012265,digoxin,FALSE,FALSE,NA,NA,NA
11,NCT00750113,Exclusion,concomitant treatment with potassium sparingdiuretics .,Drug Exposure,Other,C0032821;C0202194;C0304475,potassium,FALSE,FALSE,NA,NA,NA
12,NCT00750113,Exclusion,malignant ; severe or labile essential hypertension ; orthostatic hypotension,Condition Occurrence,Condition,C0334590;C1533592,malignant,FALSE,FALSE,NA,NA,NA
12,NCT00750113,Exclusion,malignant ; severe or labile essential hypertension ; orthostatic hypotension,Condition Occurrence,Condition,C1299569,labile essential hypertension,FALSE,FALSE,NA,NA,NA
12,NCT00750113,Exclusion,malignant ; severe or labile essential hypertension ; orthostatic hypotension,Condition Occurrence,Condition,C0020651,orthostatic hypotension,FALSE,FALSE,NA,NA,NA
12,NCT00750113,Exclusion,malignant ; severe or labile essential hypertension ; orthostatic hypotension,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
13,NCT00750113,Exclusion,cardiovascular shock,Other,NA,NA,NA,NA,NA,NA,NA,NA
14,NCT00750113,Exclusion,evidence of secondary form of hypertension ; including coarctation of the aorta ; hyperaldosteronism ; renal artery stenosis or pheochromocytoma,Condition Occurrence,Condition,C0332886,coarctation,FALSE,FALSE,NA,NA,NA
14,NCT00750113,Exclusion,evidence of secondary form of hypertension ; including coarctation of the aorta ; hyperaldosteronism ; renal artery stenosis or pheochromocytoma,Condition Occurrence,Condition,C0031511;C1706920,pheochromocytoma,FALSE,FALSE,NA,NA,NA
14,NCT00750113,Exclusion,evidence of secondary form of hypertension ; including coarctation of the aorta ; hyperaldosteronism ; renal artery stenosis or pheochromocytoma,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
14,NCT00750113,Exclusion,evidence of secondary form of hypertension ; including coarctation of the aorta ; hyperaldosteronism ; renal artery stenosis or pheochromocytoma,Condition Occurrence,Condition,C0020428,hyperaldosteronism,FALSE,FALSE,NA,NA,NA
14,NCT00750113,Exclusion,evidence of secondary form of hypertension ; including coarctation of the aorta ; hyperaldosteronism ; renal artery stenosis or pheochromocytoma,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
14,NCT00750113,Exclusion,evidence of secondary form of hypertension ; including coarctation of the aorta ; hyperaldosteronism ; renal artery stenosis or pheochromocytoma,Condition Occurrence,Other,C0869784;C0003483;C1278934,aorta,FALSE,FALSE,NA,NA,NA
15,NCT00750113,Exclusion,myocardial infarction or unstable angina within the previous 12 months,Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,lower 12 previous months,NA,NA
15,NCT00750113,Exclusion,myocardial infarction or unstable angina within the previous 12 months,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,lower 12 previous months,NA,NA
16,NCT00750113,Exclusion,severe cardiac valve disease,Condition Occurrence,Condition,C0018824,cardiac valve disease,FALSE,FALSE,NA,NA,NA
16,NCT00750113,Exclusion,severe cardiac valve disease,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
17,NCT00750113,Exclusion,severe rhythm or conduction disorder :,Condition Occurrence,Condition,C1523018;C0871269,rhythm,FALSE,FALSE,NA,NA,NA
17,NCT00750113,Exclusion,severe rhythm or conduction disorder :,Condition Occurrence,Condition,C0264886,conduction disorder,FALSE,FALSE,NA,NA,NA
17,NCT00750113,Exclusion,severe rhythm or conduction disorder :,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
18,NCT00750113,Exclusion,cerebrovascular ischaemic event ( stroke ; transient ischaemic attack ) within the previous 12 months,Condition Occurrence,Condition,C0007787,transient ischaemic attack,FALSE,FALSE,lower 12 previous months,NA,NA
19,NCT00750113,Exclusion,history of intra-cerebral haemorrhage or sub-arachnoid haemorrhage within the previous 12 months,Condition Occurrence,Condition,C2937358,intra-cerebral haemorrhage,FALSE,FALSE,lower 12 previous months,NA,NA
19,NCT00750113,Exclusion,history of intra-cerebral haemorrhage or sub-arachnoid haemorrhage within the previous 12 months,Condition Occurrence,Condition,C0003707,arachnoid,FALSE,FALSE,lower 12 previous months,NA,NA
20,NCT00750113,Exclusion,type 1 diabetes mellitus,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
21,NCT00750113,Exclusion,proteinuria ( determined by uristix ),Condition Occurrence,Condition,C0033687;C1279888;C1962972,proteinuria,FALSE,FALSE,NA,NA,NA
22,NCT00750113,Exclusion,bmi > 34,Observation,Observation,C1305855;C1542867;C0005893,bmi,FALSE,FALSE,NA,NA,NA
23,NCT00750113,Exclusion,uncorrected hypokalemia or hyperkalemia ; potassium outside the range 3.0 to 5.5 mmol / l,Observation,Condition,C0020621,hypokalemia,FALSE,FALSE,NA,NA,NA
23,NCT00750113,Exclusion,uncorrected hypokalemia or hyperkalemia ; potassium outside the range 3.0 to 5.5 mmol / l,Observation,Condition,C0020461,hyperkalemia,FALSE,FALSE,NA,NA,NA
23,NCT00750113,Exclusion,uncorrected hypokalemia or hyperkalemia ; potassium outside the range 3.0 to 5.5 mmol / l,Observation,Other,C0032821;C0202194;C0304475,potassium,FALSE,FALSE,NA,greater_equal 3.0 mmol/l; lower_equal 5.5 mmol/l,NA
24,NCT00750113,Exclusion,sodium depletion or hypovolemia,Condition Occurrence,Condition,C0020625,sodium depletion,FALSE,FALSE,NA,NA,NA
24,NCT00750113,Exclusion,sodium depletion or hypovolemia,Condition Occurrence,Condition,C0546884,hypovolemia,FALSE,FALSE,NA,NA,NA
25,NCT00750113,Exclusion,gastrointestinal disease resulting in the potential for malabsorption ),Condition Occurrence,Condition,C0017178,gastrointestinal disease,FALSE,FALSE,NA,NA,NA
26,NCT00750113,Exclusion,liver disease or transaminase ( ast ; alt ) levels > 3 x the upper limit of normal range .,Observation,Condition,C0023895;C2186532,liver disease,FALSE,FALSE,NA,NA,NA
26,NCT00750113,Exclusion,liver disease or transaminase ( ast ; alt ) levels > 3 x the upper limit of normal range .,Observation,Drug,C0002594,transaminase,FALSE,FALSE,NA,NA,NA
26,NCT00750113,Exclusion,liver disease or transaminase ( ast ; alt ) levels > 3 x the upper limit of normal range .,Observation,Observation,C0004002,ast,FALSE,FALSE,NA,NA,NA
26,NCT00750113,Exclusion,liver disease or transaminase ( ast ; alt ) levels > 3 x the upper limit of normal range .,Observation,Observation,C1140170;C2257651,alt,FALSE,FALSE,NA,NA,NA
26,NCT00750113,Exclusion,liver disease or transaminase ( ast ; alt ) levels > 3 x the upper limit of normal range .,Observation,Observation,C3542016,range,FALSE,FALSE,NA,greater 3 x the upper limit of normal,NA
27,NCT00750113,Exclusion,renal failure ; creatinine > 2.0 mg / dl,Drug Exposure,Condition,C0035078;C1963154,renal failure,FALSE,FALSE,NA,NA,greater 2.0 mg/dl
27,NCT00750113,Exclusion,renal failure ; creatinine > 2.0 mg / dl,Drug Exposure,Observation,C0010294;C0201975;C1561535,creatinine,FALSE,FALSE,NA,NA,greater 2.0 mg/dl
28,NCT00750113,Exclusion,general any malignant disease that has required treatment within the last five years ; dementia or psychosis ; history of non-compliance ; alcoholism or drug abuse ; treatment with any other investigational drug in the 30 days prior to entering the study ; pregnancy and lactation ; known state of allergy or hypersensitivity to nifedipine or any other dihydropyridine or to telmisartan ; any surgical condition or medical condition which at the discretion of the investigator place the subject at higher risk from his / her participation in the study or are likely to prevent the subject from complying with the requirements of the study or completing the trial period ; history of non compliance to medical regimens or subjects unwilling to comply with the study protocol,Condition Occurrence,Condition,C0442867,malignant disease,FALSE,FALSE,NA,NA,NA
28,NCT00750113,Exclusion,general any malignant disease that has required treatment within the last five years ; dementia or psychosis ; history of non-compliance ; alcoholism or drug abuse ; treatment with any other investigational drug in the 30 days prior to entering the study ; pregnancy and lactation ; known state of allergy or hypersensitivity to nifedipine or any other dihydropyridine or to telmisartan ; any surgical condition or medical condition which at the discretion of the investigator place the subject at higher risk from his / her participation in the study or are likely to prevent the subject from complying with the requirements of the study or completing the trial period ; history of non compliance to medical regimens or subjects unwilling to comply with the study protocol,Condition Occurrence,Condition,C0497327;C0011265,dementia,FALSE,FALSE,NA,NA,NA
28,NCT00750113,Exclusion,general any malignant disease that has required treatment within the last five years ; dementia or psychosis ; history of non-compliance ; alcoholism or drug abuse ; treatment with any other investigational drug in the 30 days prior to entering the study ; pregnancy and lactation ; known state of allergy or hypersensitivity to nifedipine or any other dihydropyridine or to telmisartan ; any surgical condition or medical condition which at the discretion of the investigator place the subject at higher risk from his / her participation in the study or are likely to prevent the subject from complying with the requirements of the study or completing the trial period ; history of non compliance to medical regimens or subjects unwilling to comply with the study protocol,Condition Occurrence,Condition,C0033975;C0349204,psychosis,FALSE,FALSE,NA,NA,NA
28,NCT00750113,Exclusion,general any malignant disease that has required treatment within the last five years ; dementia or psychosis ; history of non-compliance ; alcoholism or drug abuse ; treatment with any other investigational drug in the 30 days prior to entering the study ; pregnancy and lactation ; known state of allergy or hypersensitivity to nifedipine or any other dihydropyridine or to telmisartan ; any surgical condition or medical condition which at the discretion of the investigator place the subject at higher risk from his / her participation in the study or are likely to prevent the subject from complying with the requirements of the study or completing the trial period ; history of non compliance to medical regimens or subjects unwilling to comply with the study protocol,Condition Occurrence,Condition,C0376405,non-compliance,FALSE,FALSE,NA,NA,NA
28,NCT00750113,Exclusion,general any malignant disease that has required treatment within the last five years ; dementia or psychosis ; history of non-compliance ; alcoholism or drug abuse ; treatment with any other investigational drug in the 30 days prior to entering the study ; pregnancy and lactation ; known state of allergy or hypersensitivity to nifedipine or any other dihydropyridine or to telmisartan ; any surgical condition or medical condition which at the discretion of the investigator place the subject at higher risk from his / her participation in the study or are likely to prevent the subject from complying with the requirements of the study or completing the trial period ; history of non compliance to medical regimens or subjects unwilling to comply with the study protocol,Condition Occurrence,Condition,C0013146,drug abuse,FALSE,FALSE,NA,NA,NA
28,NCT00750113,Exclusion,general any malignant disease that has required treatment within the last five years ; dementia or psychosis ; history of non-compliance ; alcoholism or drug abuse ; treatment with any other investigational drug in the 30 days prior to entering the study ; pregnancy and lactation ; known state of allergy or hypersensitivity to nifedipine or any other dihydropyridine or to telmisartan ; any surgical condition or medical condition which at the discretion of the investigator place the subject at higher risk from his / her participation in the study or are likely to prevent the subject from complying with the requirements of the study or completing the trial period ; history of non compliance to medical regimens or subjects unwilling to comply with the study protocol,Condition Occurrence,Condition,C0001973,alcoholism,FALSE,FALSE,NA,NA,NA
28,NCT00750113,Exclusion,general any malignant disease that has required treatment within the last five years ; dementia or psychosis ; history of non-compliance ; alcoholism or drug abuse ; treatment with any other investigational drug in the 30 days prior to entering the study ; pregnancy and lactation ; known state of allergy or hypersensitivity to nifedipine or any other dihydropyridine or to telmisartan ; any surgical condition or medical condition which at the discretion of the investigator place the subject at higher risk from his / her participation in the study or are likely to prevent the subject from complying with the requirements of the study or completing the trial period ; history of non compliance to medical regimens or subjects unwilling to comply with the study protocol,Condition Occurrence,Condition,C0022925,lactation,FALSE,FALSE,NA,NA,NA
28,NCT00750113,Exclusion,general any malignant disease that has required treatment within the last five years ; dementia or psychosis ; history of non-compliance ; alcoholism or drug abuse ; treatment with any other investigational drug in the 30 days prior to entering the study ; pregnancy and lactation ; known state of allergy or hypersensitivity to nifedipine or any other dihydropyridine or to telmisartan ; any surgical condition or medical condition which at the discretion of the investigator place the subject at higher risk from his / her participation in the study or are likely to prevent the subject from complying with the requirements of the study or completing the trial period ; history of non compliance to medical regimens or subjects unwilling to comply with the study protocol,Condition Occurrence,Drug,C0013230,investigational drug,FALSE,FALSE,lower_equal 30 days,NA,NA
28,NCT00750113,Exclusion,general any malignant disease that has required treatment within the last five years ; dementia or psychosis ; history of non-compliance ; alcoholism or drug abuse ; treatment with any other investigational drug in the 30 days prior to entering the study ; pregnancy and lactation ; known state of allergy or hypersensitivity to nifedipine or any other dihydropyridine or to telmisartan ; any surgical condition or medical condition which at the discretion of the investigator place the subject at higher risk from his / her participation in the study or are likely to prevent the subject from complying with the requirements of the study or completing the trial period ; history of non compliance to medical regimens or subjects unwilling to comply with the study protocol,Condition Occurrence,Drug,C0028066,nifedipine,FALSE,FALSE,NA,NA,NA
28,NCT00750113,Exclusion,general any malignant disease that has required treatment within the last five years ; dementia or psychosis ; history of non-compliance ; alcoholism or drug abuse ; treatment with any other investigational drug in the 30 days prior to entering the study ; pregnancy and lactation ; known state of allergy or hypersensitivity to nifedipine or any other dihydropyridine or to telmisartan ; any surgical condition or medical condition which at the discretion of the investigator place the subject at higher risk from his / her participation in the study or are likely to prevent the subject from complying with the requirements of the study or completing the trial period ; history of non compliance to medical regimens or subjects unwilling to comply with the study protocol,Condition Occurrence,Drug,C0220821;C3537269,dihydropyridine,FALSE,FALSE,NA,NA,NA
28,NCT00750113,Exclusion,general any malignant disease that has required treatment within the last five years ; dementia or psychosis ; history of non-compliance ; alcoholism or drug abuse ; treatment with any other investigational drug in the 30 days prior to entering the study ; pregnancy and lactation ; known state of allergy or hypersensitivity to nifedipine or any other dihydropyridine or to telmisartan ; any surgical condition or medical condition which at the discretion of the investigator place the subject at higher risk from his / her participation in the study or are likely to prevent the subject from complying with the requirements of the study or completing the trial period ; history of non compliance to medical regimens or subjects unwilling to comply with the study protocol,Condition Occurrence,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,NA
28,NCT00750113,Exclusion,general any malignant disease that has required treatment within the last five years ; dementia or psychosis ; history of non-compliance ; alcoholism or drug abuse ; treatment with any other investigational drug in the 30 days prior to entering the study ; pregnancy and lactation ; known state of allergy or hypersensitivity to nifedipine or any other dihydropyridine or to telmisartan ; any surgical condition or medical condition which at the discretion of the investigator place the subject at higher risk from his / her participation in the study or are likely to prevent the subject from complying with the requirements of the study or completing the trial period ; history of non compliance to medical regimens or subjects unwilling to comply with the study protocol,Condition Occurrence,Drug,C0309872,prevent,FALSE,FALSE,NA,NA,NA
28,NCT00750113,Exclusion,general any malignant disease that has required treatment within the last five years ; dementia or psychosis ; history of non-compliance ; alcoholism or drug abuse ; treatment with any other investigational drug in the 30 days prior to entering the study ; pregnancy and lactation ; known state of allergy or hypersensitivity to nifedipine or any other dihydropyridine or to telmisartan ; any surgical condition or medical condition which at the discretion of the investigator place the subject at higher risk from his / her participation in the study or are likely to prevent the subject from complying with the requirements of the study or completing the trial period ; history of non compliance to medical regimens or subjects unwilling to comply with the study protocol,Condition Occurrence,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
28,NCT00750113,Exclusion,general any malignant disease that has required treatment within the last five years ; dementia or psychosis ; history of non-compliance ; alcoholism or drug abuse ; treatment with any other investigational drug in the 30 days prior to entering the study ; pregnancy and lactation ; known state of allergy or hypersensitivity to nifedipine or any other dihydropyridine or to telmisartan ; any surgical condition or medical condition which at the discretion of the investigator place the subject at higher risk from his / her participation in the study or are likely to prevent the subject from complying with the requirements of the study or completing the trial period ; history of non compliance to medical regimens or subjects unwilling to comply with the study protocol,Condition Occurrence,Other,C3245502;C3245501;C1619636;C1546857,required,FALSE,FALSE,NA,NA,NA
28,NCT00750113,Exclusion,general any malignant disease that has required treatment within the last five years ; dementia or psychosis ; history of non-compliance ; alcoholism or drug abuse ; treatment with any other investigational drug in the 30 days prior to entering the study ; pregnancy and lactation ; known state of allergy or hypersensitivity to nifedipine or any other dihydropyridine or to telmisartan ; any surgical condition or medical condition which at the discretion of the investigator place the subject at higher risk from his / her participation in the study or are likely to prevent the subject from complying with the requirements of the study or completing the trial period ; history of non compliance to medical regimens or subjects unwilling to comply with the study protocol,Condition Occurrence,Other,C0032961;C3484365,pregnancy,FALSE,FALSE,NA,NA,NA
28,NCT00750113,Exclusion,general any malignant disease that has required treatment within the last five years ; dementia or psychosis ; history of non-compliance ; alcoholism or drug abuse ; treatment with any other investigational drug in the 30 days prior to entering the study ; pregnancy and lactation ; known state of allergy or hypersensitivity to nifedipine or any other dihydropyridine or to telmisartan ; any surgical condition or medical condition which at the discretion of the investigator place the subject at higher risk from his / her participation in the study or are likely to prevent the subject from complying with the requirements of the study or completing the trial period ; history of non compliance to medical regimens or subjects unwilling to comply with the study protocol,Condition Occurrence,Other,C0489531;C0718579;C3542994;C3539909;C1314973;C1547315;C1611280,allergy,FALSE,FALSE,NA,NA,NA
28,NCT00750113,Exclusion,general any malignant disease that has required treatment within the last five years ; dementia or psychosis ; history of non-compliance ; alcoholism or drug abuse ; treatment with any other investigational drug in the 30 days prior to entering the study ; pregnancy and lactation ; known state of allergy or hypersensitivity to nifedipine or any other dihydropyridine or to telmisartan ; any surgical condition or medical condition which at the discretion of the investigator place the subject at higher risk from his / her participation in the study or are likely to prevent the subject from complying with the requirements of the study or completing the trial period ; history of non compliance to medical regimens or subjects unwilling to comply with the study protocol,Condition Occurrence,Other,C1561579;C1561578,medical,FALSE,FALSE,NA,NA,NA
28,NCT00750113,Exclusion,general any malignant disease that has required treatment within the last five years ; dementia or psychosis ; history of non-compliance ; alcoholism or drug abuse ; treatment with any other investigational drug in the 30 days prior to entering the study ; pregnancy and lactation ; known state of allergy or hypersensitivity to nifedipine or any other dihydropyridine or to telmisartan ; any surgical condition or medical condition which at the discretion of the investigator place the subject at higher risk from his / her participation in the study or are likely to prevent the subject from complying with the requirements of the study or completing the trial period ; history of non compliance to medical regimens or subjects unwilling to comply with the study protocol,Condition Occurrence,Other,C1561579;C1561578,medical,FALSE,FALSE,NA,NA,NA
28,NCT00750113,Exclusion,general any malignant disease that has required treatment within the last five years ; dementia or psychosis ; history of non-compliance ; alcoholism or drug abuse ; treatment with any other investigational drug in the 30 days prior to entering the study ; pregnancy and lactation ; known state of allergy or hypersensitivity to nifedipine or any other dihydropyridine or to telmisartan ; any surgical condition or medical condition which at the discretion of the investigator place the subject at higher risk from his / her participation in the study or are likely to prevent the subject from complying with the requirements of the study or completing the trial period ; history of non compliance to medical regimens or subjects unwilling to comply with the study protocol,Condition Occurrence,Other,C2945654,regimens,FALSE,FALSE,NA,NA,NA
28,NCT00750113,Exclusion,general any malignant disease that has required treatment within the last five years ; dementia or psychosis ; history of non-compliance ; alcoholism or drug abuse ; treatment with any other investigational drug in the 30 days prior to entering the study ; pregnancy and lactation ; known state of allergy or hypersensitivity to nifedipine or any other dihydropyridine or to telmisartan ; any surgical condition or medical condition which at the discretion of the investigator place the subject at higher risk from his / her participation in the study or are likely to prevent the subject from complying with the requirements of the study or completing the trial period ; history of non compliance to medical regimens or subjects unwilling to comply with the study protocol,Condition Occurrence,Other,C2348563;C1507394,study protocol,FALSE,FALSE,NA,NA,NA
1,NCT00751751,Inclusion,age 65 years or older,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 65 years,NA,NA
2,NCT00751751,Inclusion,mean sitting diastolic bp = 100 - 114 mmhg and mean sitting systolic bp > = 150 mm hg,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
2,NCT00751751,Inclusion,mean sitting diastolic bp = 100 - 114 mmhg and mean sitting systolic bp > = 150 mm hg,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
2,NCT00751751,Inclusion,mean sitting diastolic bp = 100 - 114 mmhg and mean sitting systolic bp > = 150 mm hg,Observation,Observation,C0871470,systolic bp,FALSE,FALSE,NA,greater_equal 150 mm hg,NA
3,NCT00751751,Exclusion,secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
4,NCT00751751,Exclusion,malignant hypertension,Condition Occurrence,Condition,C0020540;C0024588,malignant hypertension,FALSE,FALSE,NA,NA,NA
5,NCT00751751,Exclusion,severe heart failure ( nyha iii-,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
5,NCT00751751,Exclusion,severe heart failure ( nyha iii-,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
5,NCT00751751,Exclusion,severe heart failure ( nyha iii-,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii-,FALSE,FALSE,NA,NA,NA
6,NCT00751751,Exclusion,history or evidence of renal disease,Condition Occurrence,Condition,C0022658,renal disease,FALSE,FALSE,NA,NA,NA
7,NCT00751751,Exclusion,recent history of myocardial infarction,Observation,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
8,NCT00751751,Exclusion,hypersensitivity to study drugs,Observation,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
8,NCT00751751,Exclusion,hypersensitivity to study drugs,Observation,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
2,NCT00751751,Inclusion,mean sitting diastolic bp = 100 - 114 mmhg and mean sitting systolic bp > = 150 mm hg,Observation,Observation,C0428883,diastolic bp,FALSE,FALSE,NA,greater_equal 100 mmhg; lower_equal 114 mmhg,NA
9,NCT00751751,Exclusion,history of drug or alcohol abuse,Condition Occurrence,Condition,C0085762,alcohol abuse,FALSE,FALSE,NA,NA,NA
9,NCT00751751,Exclusion,history of drug or alcohol abuse,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
1,NCT00751829,Inclusion,age 65 or older,Person,NA,NA,NA,NA,NA,NA,NA,NA
2,NCT00751829,Inclusion,mean sitting bp > 160 mmhg and mean sitting dbp < 90 mmhg,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
2,NCT00751829,Inclusion,mean sitting bp > 160 mmhg and mean sitting dbp < 90 mmhg,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
2,NCT00751829,Inclusion,mean sitting bp > 160 mmhg and mean sitting dbp < 90 mmhg,Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,greater 160 mmhg,NA
2,NCT00751829,Inclusion,mean sitting bp > 160 mmhg and mean sitting dbp < 90 mmhg,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,lower 90 mmhg,NA
3,NCT00751829,Exclusion,secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
4,NCT00751829,Exclusion,malignant hypertension,Condition Occurrence,Condition,C0020540;C0024588,malignant hypertension,FALSE,FALSE,NA,NA,NA
5,NCT00751829,Exclusion,severe heart failure ( nyha iii-,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
5,NCT00751829,Exclusion,severe heart failure ( nyha iii-,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
5,NCT00751829,Exclusion,severe heart failure ( nyha iii-,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii-,FALSE,FALSE,NA,NA,NA
6,NCT00751829,Exclusion,recent history of myocardial infarction,Observation,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
7,NCT00751829,Exclusion,hypersensitivity to study medications,Observation,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
8,NCT00751829,Exclusion,history of drug or alcohol abuse,Condition Occurrence,Condition,C0085762,alcohol abuse,FALSE,FALSE,NA,NA,NA
8,NCT00751829,Exclusion,history of drug or alcohol abuse,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
9,NCT00751829,Exclusion,history or evidence of renal disease,Condition Occurrence,Condition,C0022658,renal disease,FALSE,FALSE,NA,NA,NA
1,NCT00760266,Inclusion,male or female outpatients ; > = 55 years old,Person,Person,C0025266,male,FALSE,FALSE,greater_equal 55 years,NA,NA
3,NCT00760266,Inclusion,prior to randomization : patients must have an office cuff mean sitting systolic blood pressure > = 160 mm hg and < 200 mm hg,Observation,Condition,C1319893,sitting systolic blood pressure,FALSE,FALSE,NA,greater_equal 160 mm hg; lower 200 mm hg,NA
4,NCT00760266,Inclusion,patients who are eligible and able to participate in the study ; and who are willing to give informed consent before any assessment is performed,Observation,Other,C0542573;C0549068;C0870300;C0549070;C0549071;C0549072;C0549073;C0549074;C0028708;C0549075;C0549076;C0549077;C0549078;C0549079;C0549080;C0679207,assessment,FALSE,FALSE,NA,NA,NA
5,NCT00760266,Exclusion,office blood pressure measured by cuff ( mssbp > = 200 mm hg or msdbp > = 110 mm hg ) at visits 1 - 5,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,greater_equal 200 mm hg; greater_equal 110 mm hg; greater_equal 1 ; lower_equal 5,NA
5,NCT00760266,Exclusion,office blood pressure measured by cuff ( mssbp > = 200 mm hg or msdbp > = 110 mm hg ) at visits 1 - 5,Observation,Procedure,C2224281;C1314130,blood pressure measured,FALSE,FALSE,NA,NA,NA
6,NCT00760266,Exclusion,history or evidence of a secondary hypertension of any etiology ( eg ; uncorrected renal artery stenosis ; pheochromocytoma ) .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
6,NCT00760266,Exclusion,history or evidence of a secondary hypertension of any etiology ( eg ; uncorrected renal artery stenosis ; pheochromocytoma ) .,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
6,NCT00760266,Exclusion,history or evidence of a secondary hypertension of any etiology ( eg ; uncorrected renal artery stenosis ; pheochromocytoma ) .,Condition Occurrence,Condition,C0031511;C1706920,pheochromocytoma,FALSE,FALSE,NA,NA,NA
7,NCT00760266,Exclusion,history of hypertensive encephalopathy or heart failure ( new york heart association [ nyha ] class ii-,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
7,NCT00760266,Exclusion,history of hypertensive encephalopathy or heart failure ( new york heart association [ nyha ] class ii-,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
7,NCT00760266,Exclusion,history of hypertensive encephalopathy or heart failure ( new york heart association [ nyha ] class ii-,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
7,NCT00760266,Exclusion,history of hypertensive encephalopathy or heart failure ( new york heart association [ nyha ] class ii-,Condition Occurrence,Condition,C1882083,nyha class,FALSE,FALSE,NA,NA,NA
8,NCT00760266,Exclusion,cerebrovascular accident ; transient ischemic cerebral attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention ( pci ) within 1 year prior to visit 1,Condition Occurrence,Person,C0040704,transient,FALSE,FALSE,NA,NA,NA
1,NCT00760266,Inclusion,male or female outpatients ; > = 55 years old,Person,Person,C0086287,female,FALSE,FALSE,greater_equal 55 years,NA,NA
8,NCT00760266,Exclusion,cerebrovascular accident ; transient ischemic cerebral attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention ( pci ) within 1 year prior to visit 1,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
8,NCT00760266,Exclusion,cerebrovascular accident ; transient ischemic cerebral attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention ( pci ) within 1 year prior to visit 1,Condition Occurrence,Condition,C0917805,tia,FALSE,FALSE,NA,NA,NA
8,NCT00760266,Exclusion,cerebrovascular accident ; transient ischemic cerebral attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention ( pci ) within 1 year prior to visit 1,Condition Occurrence,Procedure,C1532338,percutaneous coronary intervention,FALSE,FALSE,NA,NA,NA
8,NCT00760266,Exclusion,cerebrovascular accident ; transient ischemic cerebral attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention ( pci ) within 1 year prior to visit 1,Condition Occurrence,Procedure,C0010055,coronary bypass surgery,FALSE,FALSE,NA,NA,NA
8,NCT00760266,Exclusion,cerebrovascular accident ; transient ischemic cerebral attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention ( pci ) within 1 year prior to visit 1,Condition Occurrence,Procedure,C1514496;C1532338,pci,FALSE,FALSE,lower 1 year,NA,NA
8,NCT00760266,Exclusion,cerebrovascular accident ; transient ischemic cerebral attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention ( pci ) within 1 year prior to visit 1,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
9,NCT00760266,Exclusion,serum sodium less than the lower limit of normal potassium ; serum potassium < 3.5 meq / l ( corresponding to 3.5 mmol / l ) or > = 5.3 meq / l ( corresponding to 5.3 mmol / l ) ; or dehydration at visit 1 . ; pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ),Observation,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
9,NCT00760266,Exclusion,serum sodium less than the lower limit of normal potassium ; serum potassium < 3.5 meq / l ( corresponding to 3.5 mmol / l ) or > = 5.3 meq / l ( corresponding to 5.3 mmol / l ) ; or dehydration at visit 1 . ; pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ),Observation,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
9,NCT00760266,Exclusion,serum sodium less than the lower limit of normal potassium ; serum potassium < 3.5 meq / l ( corresponding to 3.5 mmol / l ) or > = 5.3 meq / l ( corresponding to 5.3 mmol / l ) ; or dehydration at visit 1 . ; pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ),Observation,Condition,C0860869,normal potassium,FALSE,FALSE,NA,lower 3.5 ; equal 3.5 mmol/l; greater_equal 5.3 ; equal 5.3 mmol/l,NA
9,NCT00760266,Exclusion,serum sodium less than the lower limit of normal potassium ; serum potassium < 3.5 meq / l ( corresponding to 3.5 mmol / l ) or > = 5.3 meq / l ( corresponding to 5.3 mmol / l ) ; or dehydration at visit 1 . ; pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ),Observation,Condition,C0011175;C1963090,dehydration,FALSE,FALSE,NA,NA,NA
9,NCT00760266,Exclusion,serum sodium less than the lower limit of normal potassium ; serum potassium < 3.5 meq / l ( corresponding to 3.5 mmol / l ) or > = 5.3 meq / l ( corresponding to 5.3 mmol / l ) ; or dehydration at visit 1 . ; pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ),Observation,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
9,NCT00760266,Exclusion,serum sodium less than the lower limit of normal potassium ; serum potassium < 3.5 meq / l ( corresponding to 3.5 mmol / l ) or > = 5.3 meq / l ( corresponding to 5.3 mmol / l ) ; or dehydration at visit 1 . ; pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ),Observation,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
9,NCT00760266,Exclusion,serum sodium less than the lower limit of normal potassium ; serum potassium < 3.5 meq / l ( corresponding to 3.5 mmol / l ) or > = 5.3 meq / l ( corresponding to 5.3 mmol / l ) ; or dehydration at visit 1 . ; pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ),Observation,Condition,C2828358;C3668831,lactating,FALSE,FALSE,NA,NA,NA
9,NCT00760266,Exclusion,serum sodium less than the lower limit of normal potassium ; serum potassium < 3.5 meq / l ( corresponding to 3.5 mmol / l ) or > = 5.3 meq / l ( corresponding to 5.3 mmol / l ) ; or dehydration at visit 1 . ; pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ),Observation,Condition,C0009637,conception,FALSE,FALSE,NA,NA,NA
9,NCT00760266,Exclusion,serum sodium less than the lower limit of normal potassium ; serum potassium < 3.5 meq / l ( corresponding to 3.5 mmol / l ) or > = 5.3 meq / l ( corresponding to 5.3 mmol / l ) ; or dehydration at visit 1 . ; pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ),Observation,Condition,C0032961,gestation,FALSE,FALSE,NA,NA,NA
9,NCT00760266,Exclusion,serum sodium less than the lower limit of normal potassium ; serum potassium < 3.5 meq / l ( corresponding to 3.5 mmol / l ) or > = 5.3 meq / l ( corresponding to 5.3 mmol / l ) ; or dehydration at visit 1 . ; pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ),Observation,Observation,C0523891;C0587356,serum sodium,FALSE,FALSE,NA,NA,NA
9,NCT00760266,Exclusion,serum sodium less than the lower limit of normal potassium ; serum potassium < 3.5 meq / l ( corresponding to 3.5 mmol / l ) or > = 5.3 meq / l ( corresponding to 5.3 mmol / l ) ; or dehydration at visit 1 . ; pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ),Observation,Observation,C1548802,lower,FALSE,FALSE,NA,NA,NA
9,NCT00760266,Exclusion,serum sodium less than the lower limit of normal potassium ; serum potassium < 3.5 meq / l ( corresponding to 3.5 mmol / l ) or > = 5.3 meq / l ( corresponding to 5.3 mmol / l ) ; or dehydration at visit 1 . ; pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ),Observation,Observation,C0302353;C0543465,serum potassium,FALSE,FALSE,NA,lower 3.5 ; equal 3.5 mmol/l; greater_equal 5.3 ; equal 5.3 mmol/l,NA
9,NCT00760266,Exclusion,serum sodium less than the lower limit of normal potassium ; serum potassium < 3.5 meq / l ( corresponding to 3.5 mmol / l ) or > = 5.3 meq / l ( corresponding to 5.3 mmol / l ) ; or dehydration at visit 1 . ; pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ),Observation,Observation,C0241904,positive hcg,FALSE,FALSE,NA,NA,NA
9,NCT00760266,Exclusion,serum sodium less than the lower limit of normal potassium ; serum potassium < 3.5 meq / l ( corresponding to 3.5 mmol / l ) or > = 5.3 meq / l ( corresponding to 5.3 mmol / l ) ; or dehydration at visit 1 . ; pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ),Observation,Observation,C0022885,laboratory test,FALSE,FALSE,NA,greater 5,NA
9,NCT00760266,Exclusion,serum sodium less than the lower limit of normal potassium ; serum potassium < 3.5 meq / l ( corresponding to 3.5 mmol / l ) or > = 5.3 meq / l ( corresponding to 5.3 mmol / l ) ; or dehydration at visit 1 . ; pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ),Observation,Other,C0032961;C3484365,pregnancy,FALSE,FALSE,NA,NA,NA
9,NCT00760266,Exclusion,serum sodium less than the lower limit of normal potassium ; serum potassium < 3.5 meq / l ( corresponding to 3.5 mmol / l ) or > = 5.3 meq / l ( corresponding to 5.3 mmol / l ) ; or dehydration at visit 1 . ; pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ),Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
9,NCT00760266,Exclusion,serum sodium less than the lower limit of normal potassium ; serum potassium < 3.5 meq / l ( corresponding to 3.5 mmol / l ) or > = 5.3 meq / l ( corresponding to 5.3 mmol / l ) ; or dehydration at visit 1 . ; pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ),Observation,Other,C1549081,termination,FALSE,FALSE,NA,NA,NA
10,NCT00760266,Exclusion,use of other investigational drugs within 30 days of enrollment .,Drug Exposure,Drug,C0013230,investigational drugs,FALSE,FALSE,lower 30 days,NA,NA
10,NCT00760266,Exclusion,use of other investigational drugs within 30 days of enrollment .,Drug Exposure,Other,C1696073;C1516879,enrollment,FALSE,FALSE,NA,NA,NA
11,NCT00760266,Exclusion,other exclusions may apply,Other,NA,NA,NA,NA,NA,NA,NA,NA
2,NCT00760266,Inclusion,patients with essential hypertension,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00760266,Inclusion,prior to randomization : patients must have an office cuff mean sitting systolic blood pressure > = 160 mm hg and < 200 mm hg,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
1,NCT00765674,Inclusion,male or female,Person,Person,C0025266,male,FALSE,FALSE,NA,NA,NA
1,NCT00765674,Inclusion,male or female,Person,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
2,NCT00765674,Inclusion,18 years of age or older,Person,NA,NA,NA,NA,NA,NA,NA,NA
3,NCT00765674,Inclusion,msdbp and mssbp requirements :,Other,NA,NA,NA,NA,NA,NA,NA,NA
4,NCT00765674,Inclusion,0.125,Other,NA,NA,NA,NA,NA,NA,NA,NA
5,NCT00765674,Inclusion,diagnosis of moderate to severe hypertension ( mssbp > = 160 mmhg and < 200 mmhg ; or msdbp > = 100 mmhg and < 120 mmhg ) at visits 4 ; 5 or 6 ( qualifying bp visit ),Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,greater_equal 160 mmhg; lower 200 mmhg; greater_equal 100 mmhg; lower 120 mmhg; equal 4 ; equal 5 ; equal 6,NA
5,NCT00765674,Inclusion,diagnosis of moderate to severe hypertension ( mssbp > = 160 mmhg and < 200 mmhg ; or msdbp > = 100 mmhg and < 120 mmhg ) at visits 4 ; 5 or 6 ( qualifying bp visit ),Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,NA,NA
5,NCT00765674,Inclusion,diagnosis of moderate to severe hypertension ( mssbp > = 160 mmhg and < 200 mmhg ; or msdbp > = 100 mmhg and < 120 mmhg ) at visits 4 ; 5 or 6 ( qualifying bp visit ),Observation,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
5,NCT00765674,Inclusion,diagnosis of moderate to severe hypertension ( mssbp > = 160 mmhg and < 200 mmhg ; or msdbp > = 100 mmhg and < 120 mmhg ) at visits 4 ; 5 or 6 ( qualifying bp visit ),Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
6,NCT00765674,Inclusion,in addition;at the visit immediately prior to the above qualifying visit;patients were also to have mssbp > = 145 mmhg and < 200 mmhg and msdbp > = 95 mmhg and < 120 mmhg ) at visits 3;5 or 5 .,Observation,NA,NA,NA,NA,NA,NA,NA,NA
7,NCT00765674,Inclusion,patients had to meet the above two sets of requirements at subsequent adjacent visits;ie either visits 3 and 4;visits 4 and 5;or visits 5 and 6 .,Observation,NA,NA,NA,NA,NA,NA,NA,NA
8,NCT00765674,Inclusion,3 b :,Other,NA,NA,NA,NA,NA,NA,NA,NA
9,NCT00765674,Inclusion,mssbp > = 180 mmhg and < 200 mmhg with msdbp > = 95 mmhg and < 120 mmhg ; or msdbp > = 110 mmhg and < 120 mmhg with mssbp > = 150 mmhg and < 200 mmhg after at least one week of treatment with placebo ( visit 3 and on ) .,Observation,Drug,C1696465,placebo,FALSE,FALSE,NA,greater_equal 180 mmhg; lower 200 mmhg; greater_equal 95 mmhg; lower 120 mmhg; greater_equal 110 mmhg; lower 120 mmhg; greater_equal 150 mmhg; lower 200 mmhg,NA
10,NCT00765674,Exclusion,continued use of anti-hypertensive medicines or use of 4 or more hypertensive medicines at study start,Drug Exposure,Condition,C0857121,hypertensive,FALSE,FALSE,NA,greater_equal 4,NA
10,NCT00765674,Exclusion,continued use of anti-hypertensive medicines or use of 4 or more hypertensive medicines at study start,Drug Exposure,Drug,C0003364,anti-hypertensive,FALSE,FALSE,NA,NA,NA
11,NCT00765674,Exclusion,patients with an mssbp > = 200 mmhg or msdbp > = 120 mmhg at any time during the placebo run-in period were to be discontinued from the study .,Observation,Condition,C2024467,time,FALSE,FALSE,NA,greater_equal 200 mmhg; greater_equal 120 mmhg,NA
11,NCT00765674,Exclusion,patients with an mssbp > = 200 mmhg or msdbp > = 120 mmhg at any time during the placebo run-in period were to be discontinued from the study .,Observation,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,NA
12,NCT00765674,Exclusion,extremely elevated ( defined ) blood pressure at any point during the study,Other,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
12,NCT00765674,Exclusion,extremely elevated ( defined ) blood pressure at any point during the study,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
12,NCT00765674,Exclusion,extremely elevated ( defined ) blood pressure at any point during the study,Other,Other,C1553441,point,FALSE,FALSE,NA,NA,NA
13,NCT00765674,Exclusion,pregnant or lactating women,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
13,NCT00765674,Exclusion,pregnant or lactating women,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
13,NCT00765674,Exclusion,pregnant or lactating women,Condition Occurrence,Condition,C2828358;C3668831,lactating,FALSE,FALSE,NA,NA,NA
14,NCT00765674,Exclusion,pre-menopausal women not taking accepted form of birth control,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
14,NCT00765674,Exclusion,pre-menopausal women not taking accepted form of birth control,Condition Occurrence,Condition,C1096235,pre-menopausal,FALSE,FALSE,NA,NA,NA
14,NCT00765674,Exclusion,pre-menopausal women not taking accepted form of birth control,Condition Occurrence,Other,C0700589;C2703065,birth control,TRUE,FALSE,NA,NA,NA
15,NCT00765674,Exclusion,history or evidence of secondary form of hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
16,NCT00765674,Exclusion,history of cardiovascular conditions,Other,NA,NA,NA,NA,NA,NA,NA,NA
17,NCT00765674,Exclusion,other protocol-defined inclusiopplied to the study,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00778921,Inclusion,newly diagnosed patients or patients who have not been treated for hypertension within the 4 weeks prior to visit 1 must have a msdbp > = 95 mmhg and < 110 mmhg at visits 1 and 2,Observation,Observation,C0020538;C1963138,hypertension,TRUE,FALSE,lower 4 weeks,greater_equal 95 mmhg; lower 110 mmhg; equal 1 ; equal 2,NA
2,NCT00778921,Inclusion,patients who have been treated for hypertension within the 4 weeks prior to visit 1 must have a msdbp > = 90 mmhg and < 110 mmhg at visit 2,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,lower 4 weeks,greater_equal 90 mmhg; lower 110 mmhg,NA
3,NCT00778921,Inclusion,all patients must have a msdbp > = 90 mmhg and < 110 mmhg at visit 5 ( randomization ),Observation,NA,NA,NA,NA,NA,NA,NA,NA
4,NCT00778921,Exclusion,severe hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
4,NCT00778921,Exclusion,severe hypertension,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
5,NCT00778921,Exclusion,pregnant or nursing ( lactating ) women,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
5,NCT00778921,Exclusion,pregnant or nursing ( lactating ) women,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
5,NCT00778921,Exclusion,pregnant or nursing ( lactating ) women,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
5,NCT00778921,Exclusion,pregnant or nursing ( lactating ) women,Condition Occurrence,Condition,C2828358;C3668831,lactating,FALSE,FALSE,NA,NA,NA
6,NCT00778921,Exclusion,pre-menopausal women not taking accepted form of birth control,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
6,NCT00778921,Exclusion,pre-menopausal women not taking accepted form of birth control,Condition Occurrence,Condition,C1096235,pre-menopausal,FALSE,FALSE,NA,NA,NA
6,NCT00778921,Exclusion,pre-menopausal women not taking accepted form of birth control,Condition Occurrence,Other,C0700589;C2703065,birth control,TRUE,FALSE,NA,NA,NA
7,NCT00778921,Exclusion,serum potassium > = 5.3 meq / l ( mmol / l ) at visit 1,Observation,Observation,C0302353;C0543465,serum potassium,FALSE,FALSE,NA,greater_equal 5.3,NA
8,NCT00778921,Exclusion,history of cardiovascular conditions,Other,NA,NA,NA,NA,NA,NA,NA,NA
9,NCT00778921,Exclusion,uncontrolled type 1 diabetes or type 2 diabetesmellitus,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
9,NCT00778921,Exclusion,uncontrolled type 1 diabetes or type 2 diabetesmellitus,Condition Occurrence,Other,C1552651,type,FALSE,FALSE,NA,NA,NA
10,NCT00778921,Exclusion,hypersensitivity to renin inhibitors ; calcium channel blockers ; or to drugs with similar chemical structures,Drug Exposure,Condition,C2917241,renin inhibitors,FALSE,FALSE,NA,NA,NA
10,NCT00778921,Exclusion,hypersensitivity to renin inhibitors ; calcium channel blockers ; or to drugs with similar chemical structures,Drug Exposure,Drug,C0006684,calcium channel blockers,FALSE,FALSE,NA,NA,NA
10,NCT00778921,Exclusion,hypersensitivity to renin inhibitors ; calcium channel blockers ; or to drugs with similar chemical structures,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
10,NCT00778921,Exclusion,hypersensitivity to renin inhibitors ; calcium channel blockers ; or to drugs with similar chemical structures,Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
10,NCT00778921,Exclusion,hypersensitivity to renin inhibitors ; calcium channel blockers ; or to drugs with similar chemical structures,Drug Exposure,Other,C0220806;C3272558,chemical,FALSE,FALSE,NA,NA,NA
11,NCT00778921,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00787605,Inclusion,male or female outpatients > = 18 years old .,Person,Person,C0025266,male,FALSE,FALSE,greater_equal 18 years,NA,NA
2,NCT00787605,Inclusion,patients with a diagnosis of stage 2 hypertension ( defined as an office cuff mssbp > = 160 mmhg and < 200 mmhg ) at visit 5 ( randomization ) . ;,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00787605,Inclusion,patients with a diagnosis of stage 2 hypertension ( defined as an office cuff mssbp > = 160 mmhg and < 200 mmhg ) at visit 5 ( randomization ) . ;,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
3,NCT00787605,Inclusion,patients with diabetes mellitus ( type 2 ) with an hba1c at visit 1 < = 9.0 % and currently on stable anti-diabetic regimen diet or stable diet and exercise for at least 4 weeks prior to visit 1 .,Other,Condition,C0011849,diabetes mellitus,FALSE,FALSE,NA,NA,NA
3,NCT00787605,Inclusion,patients with diabetes mellitus ( type 2 ) with an hba1c at visit 1 < = 9.0 % and currently on stable anti-diabetic regimen diet or stable diet and exercise for at least 4 weeks prior to visit 1 .,Other,Drug,C0935929,anti-diabetic,FALSE,FALSE,NA,NA,NA
3,NCT00787605,Inclusion,patients with diabetes mellitus ( type 2 ) with an hba1c at visit 1 < = 9.0 % and currently on stable anti-diabetic regimen diet or stable diet and exercise for at least 4 weeks prior to visit 1 .,Other,Procedure,C0040808,regimen,FALSE,FALSE,NA,NA,NA
3,NCT00787605,Inclusion,patients with diabetes mellitus ( type 2 ) with an hba1c at visit 1 < = 9.0 % and currently on stable anti-diabetic regimen diet or stable diet and exercise for at least 4 weeks prior to visit 1 .,Other,Procedure,C1522704,exercise,FALSE,FALSE,greater_equal 4 weeks,NA,NA
3,NCT00787605,Inclusion,patients with diabetes mellitus ( type 2 ) with an hba1c at visit 1 < = 9.0 % and currently on stable anti-diabetic regimen diet or stable diet and exercise for at least 4 weeks prior to visit 1 .,Other,Observation,C0202054,hba1c,FALSE,FALSE,NA,NA,lower_equal 9.0 %
3,NCT00787605,Inclusion,patients with diabetes mellitus ( type 2 ) with an hba1c at visit 1 < = 9.0 % and currently on stable anti-diabetic regimen diet or stable diet and exercise for at least 4 weeks prior to visit 1 .,Other,Other,C1552651,type,FALSE,FALSE,NA,NA,NA
3,NCT00787605,Inclusion,patients with diabetes mellitus ( type 2 ) with an hba1c at visit 1 < = 9.0 % and currently on stable anti-diabetic regimen diet or stable diet and exercise for at least 4 weeks prior to visit 1 .,Other,Other,C1547311,stable,FALSE,FALSE,NA,NA,NA
3,NCT00787605,Inclusion,patients with diabetes mellitus ( type 2 ) with an hba1c at visit 1 < = 9.0 % and currently on stable anti-diabetic regimen diet or stable diet and exercise for at least 4 weeks prior to visit 1 .,Other,Other,C0012159;C1519433;C1561465;C1550559;C1549512,diet,FALSE,FALSE,NA,NA,NA
3,NCT00787605,Inclusion,patients with diabetes mellitus ( type 2 ) with an hba1c at visit 1 < = 9.0 % and currently on stable anti-diabetic regimen diet or stable diet and exercise for at least 4 weeks prior to visit 1 .,Other,Other,C1547311,stable,FALSE,FALSE,NA,NA,NA
3,NCT00787605,Inclusion,patients with diabetes mellitus ( type 2 ) with an hba1c at visit 1 < = 9.0 % and currently on stable anti-diabetic regimen diet or stable diet and exercise for at least 4 weeks prior to visit 1 .,Other,Other,C0012159;C1519433;C1561465;C1550559;C1549512,diet,FALSE,FALSE,greater_equal 4 weeks,NA,NA
4,NCT00787605,Inclusion,patients who are eligible and able to participate in the study ; and who are willing to give written informed consent before any assessment is performed .,Observation,Other,C0542573;C0549068;C0870300;C0549070;C0549071;C0549072;C0549073;C0549074;C0028708;C0549075;C0549076;C0549077;C0549078;C0549079;C0549080;C0679207,assessment,FALSE,FALSE,NA,NA,NA
5,NCT00787605,Exclusion,office blood pressure measured by cuff ( mssbp > = 200 mmhg or msdbp > = 110 mmhg ) at visits 1 - 5 .,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,greater_equal 200 mmhg; greater_equal 110 mmhg; greater_equal 1 ; lower_equal 5,NA
5,NCT00787605,Exclusion,office blood pressure measured by cuff ( mssbp > = 200 mmhg or msdbp > = 110 mmhg ) at visits 1 - 5 .,Observation,Procedure,C2224281;C1314130,blood pressure measured,FALSE,FALSE,NA,NA,NA
6,NCT00787605,Exclusion,history or evidence of secondary hypertension of any etiology ( eg ; uncorrected renal artery stenosis ; pheochromocytoma ) .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
6,NCT00787605,Exclusion,history or evidence of secondary hypertension of any etiology ( eg ; uncorrected renal artery stenosis ; pheochromocytoma ) .,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
6,NCT00787605,Exclusion,history or evidence of secondary hypertension of any etiology ( eg ; uncorrected renal artery stenosis ; pheochromocytoma ) .,Condition Occurrence,Condition,C0031511;C1706920,pheochromocytoma,FALSE,FALSE,NA,NA,NA
7,NCT00787605,Exclusion,history of hypertensive encephalopathy or heart failure ( nyha class ii- .,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
7,NCT00787605,Exclusion,history of hypertensive encephalopathy or heart failure ( nyha class ii- .,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
7,NCT00787605,Exclusion,history of hypertensive encephalopathy or heart failure ( nyha class ii- .,Condition Occurrence,Condition,C1882083,nyha class,FALSE,FALSE,NA,NA,NA
8,NCT00787605,Exclusion,cerebrovascular accident ; transient ischemic cerebral attack ( tia ) ; coronary bypass surgery ; myocardial infarction or any percutaneous coronary intervention ( pci ) within 1 year prior to visit 1 .,Condition Occurrence,Person,C0040704,transient,FALSE,FALSE,NA,NA,NA
8,NCT00787605,Exclusion,cerebrovascular accident ; transient ischemic cerebral attack ( tia ) ; coronary bypass surgery ; myocardial infarction or any percutaneous coronary intervention ( pci ) within 1 year prior to visit 1 .,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
8,NCT00787605,Exclusion,cerebrovascular accident ; transient ischemic cerebral attack ( tia ) ; coronary bypass surgery ; myocardial infarction or any percutaneous coronary intervention ( pci ) within 1 year prior to visit 1 .,Condition Occurrence,Condition,C0917805,tia,FALSE,FALSE,NA,NA,NA
8,NCT00787605,Exclusion,cerebrovascular accident ; transient ischemic cerebral attack ( tia ) ; coronary bypass surgery ; myocardial infarction or any percutaneous coronary intervention ( pci ) within 1 year prior to visit 1 .,Condition Occurrence,Procedure,C0010055,coronary bypass surgery,FALSE,FALSE,NA,NA,NA
8,NCT00787605,Exclusion,cerebrovascular accident ; transient ischemic cerebral attack ( tia ) ; coronary bypass surgery ; myocardial infarction or any percutaneous coronary intervention ( pci ) within 1 year prior to visit 1 .,Condition Occurrence,Procedure,C1532338,percutaneous coronary intervention,FALSE,FALSE,NA,NA,NA
8,NCT00787605,Exclusion,cerebrovascular accident ; transient ischemic cerebral attack ( tia ) ; coronary bypass surgery ; myocardial infarction or any percutaneous coronary intervention ( pci ) within 1 year prior to visit 1 .,Condition Occurrence,Procedure,C1514496;C1532338,pci,FALSE,FALSE,lower 1 year,NA,NA
8,NCT00787605,Exclusion,cerebrovascular accident ; transient ischemic cerebral attack ( tia ) ; coronary bypass surgery ; myocardial infarction or any percutaneous coronary intervention ( pci ) within 1 year prior to visit 1 .,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
9,NCT00787605,Exclusion,serum sodium less than the lower limit of normal potassium ; serum potassium < 3.5 meq / l ( corresponding to 3.5 mmol / l ) or > = 5.3 meq / l ( corresponding to 5.3 mmol / l ) ; or dehydration at visit 1 .,Observation,Condition,C0860869,normal potassium,FALSE,FALSE,NA,lower 3.5 ; equal 3.5 mmol/l; greater_equal 5.3 ; equal 5.3 mmol/l,NA
9,NCT00787605,Exclusion,serum sodium less than the lower limit of normal potassium ; serum potassium < 3.5 meq / l ( corresponding to 3.5 mmol / l ) or > = 5.3 meq / l ( corresponding to 5.3 mmol / l ) ; or dehydration at visit 1 .,Observation,Condition,C0011175;C1963090,dehydration,FALSE,FALSE,NA,NA,NA
9,NCT00787605,Exclusion,serum sodium less than the lower limit of normal potassium ; serum potassium < 3.5 meq / l ( corresponding to 3.5 mmol / l ) or > = 5.3 meq / l ( corresponding to 5.3 mmol / l ) ; or dehydration at visit 1 .,Observation,Observation,C0523891;C0587356,serum sodium,FALSE,FALSE,NA,NA,NA
9,NCT00787605,Exclusion,serum sodium less than the lower limit of normal potassium ; serum potassium < 3.5 meq / l ( corresponding to 3.5 mmol / l ) or > = 5.3 meq / l ( corresponding to 5.3 mmol / l ) ; or dehydration at visit 1 .,Observation,Observation,C1548802,lower,FALSE,FALSE,NA,NA,NA
9,NCT00787605,Exclusion,serum sodium less than the lower limit of normal potassium ; serum potassium < 3.5 meq / l ( corresponding to 3.5 mmol / l ) or > = 5.3 meq / l ( corresponding to 5.3 mmol / l ) ; or dehydration at visit 1 .,Observation,Observation,C0302353;C0543465,serum potassium,FALSE,FALSE,NA,lower 3.5 ; equal 3.5 mmol/l; greater_equal 5.3 ; equal 5.3 mmol/l,NA
10,NCT00787605,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ) .,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
10,NCT00787605,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ) .,Condition Occurrence,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
10,NCT00787605,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ) .,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
10,NCT00787605,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ) .,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
10,NCT00787605,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ) .,Condition Occurrence,Condition,C2828358;C3668831,lactating,FALSE,FALSE,NA,NA,NA
10,NCT00787605,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ) .,Condition Occurrence,Condition,C0009637,conception,FALSE,FALSE,NA,NA,NA
10,NCT00787605,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ) .,Condition Occurrence,Condition,C0032961,gestation,FALSE,FALSE,NA,NA,NA
10,NCT00787605,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ) .,Condition Occurrence,Observation,C0241904,positive hcg,FALSE,FALSE,NA,NA,NA
10,NCT00787605,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ) .,Condition Occurrence,Observation,C0022885,laboratory test,FALSE,FALSE,NA,greater 5,NA
10,NCT00787605,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ) .,Condition Occurrence,Other,C0032961;C3484365,pregnancy,FALSE,FALSE,NA,NA,NA
10,NCT00787605,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ) .,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
10,NCT00787605,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ) .,Condition Occurrence,Other,C1549081,termination,FALSE,FALSE,NA,NA,NA
11,NCT00787605,Exclusion,use of other investigational drugs within 30 days of enrollment .,Other,Drug,C0013230,investigational drugs,FALSE,FALSE,lower 30 days,NA,NA
11,NCT00787605,Exclusion,use of other investigational drugs within 30 days of enrollment .,Other,Other,C1696073;C1516879,enrollment,FALSE,FALSE,NA,NA,NA
12,NCT00787605,Exclusion,history of hypersensitivity to any of the study drugs or to drugs belonging to the same therapeutic class ( thiazide diuretics ; renin inhibitors ; calcium channel blockers ; or dihydropyridine like calcium channel blockers ) as the study drugs .,Drug Exposure,Condition,C2917241,renin inhibitors,FALSE,FALSE,NA,NA,NA
12,NCT00787605,Exclusion,history of hypersensitivity to any of the study drugs or to drugs belonging to the same therapeutic class ( thiazide diuretics ; renin inhibitors ; calcium channel blockers ; or dihydropyridine like calcium channel blockers ) as the study drugs .,Drug Exposure,Drug,C0012802,thiazide diuretics,FALSE,FALSE,NA,NA,NA
12,NCT00787605,Exclusion,history of hypersensitivity to any of the study drugs or to drugs belonging to the same therapeutic class ( thiazide diuretics ; renin inhibitors ; calcium channel blockers ; or dihydropyridine like calcium channel blockers ) as the study drugs .,Drug Exposure,Drug,C0220821;C3537269,dihydropyridine,FALSE,FALSE,NA,NA,NA
12,NCT00787605,Exclusion,history of hypersensitivity to any of the study drugs or to drugs belonging to the same therapeutic class ( thiazide diuretics ; renin inhibitors ; calcium channel blockers ; or dihydropyridine like calcium channel blockers ) as the study drugs .,Drug Exposure,Drug,C0006684,calcium channel blockers,FALSE,FALSE,NA,NA,NA
12,NCT00787605,Exclusion,history of hypersensitivity to any of the study drugs or to drugs belonging to the same therapeutic class ( thiazide diuretics ; renin inhibitors ; calcium channel blockers ; or dihydropyridine like calcium channel blockers ) as the study drugs .,Drug Exposure,Drug,C0006684,calcium channel blockers,FALSE,FALSE,NA,NA,NA
12,NCT00787605,Exclusion,history of hypersensitivity to any of the study drugs or to drugs belonging to the same therapeutic class ( thiazide diuretics ; renin inhibitors ; calcium channel blockers ; or dihydropyridine like calcium channel blockers ) as the study drugs .,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
12,NCT00787605,Exclusion,history of hypersensitivity to any of the study drugs or to drugs belonging to the same therapeutic class ( thiazide diuretics ; renin inhibitors ; calcium channel blockers ; or dihydropyridine like calcium channel blockers ) as the study drugs .,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
12,NCT00787605,Exclusion,history of hypersensitivity to any of the study drugs or to drugs belonging to the same therapeutic class ( thiazide diuretics ; renin inhibitors ; calcium channel blockers ; or dihydropyridine like calcium channel blockers ) as the study drugs .,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
12,NCT00787605,Exclusion,history of hypersensitivity to any of the study drugs or to drugs belonging to the same therapeutic class ( thiazide diuretics ; renin inhibitors ; calcium channel blockers ; or dihydropyridine like calcium channel blockers ) as the study drugs .,Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
12,NCT00787605,Exclusion,history of hypersensitivity to any of the study drugs or to drugs belonging to the same therapeutic class ( thiazide diuretics ; renin inhibitors ; calcium channel blockers ; or dihydropyridine like calcium channel blockers ) as the study drugs .,Drug Exposure,Other,C0723712;C0039796;C1547427,therapeutic,FALSE,FALSE,NA,NA,NA
12,NCT00787605,Exclusion,history of hypersensitivity to any of the study drugs or to drugs belonging to the same therapeutic class ( thiazide diuretics ; renin inhibitors ; calcium channel blockers ; or dihydropyridine like calcium channel blockers ) as the study drugs .,Drug Exposure,Other,C0456387;C0489477,class,FALSE,FALSE,NA,NA,NA
13,NCT00787605,Exclusion,history of gouty arthritis .,Condition Occurrence,Condition,C0003868,gouty arthritis,FALSE,FALSE,NA,NA,NA
14,NCT00787605,Exclusion,long qt syndrome or qtc > 450 msec for males and > 470 msec for females at screening . ; history of malignancy of any organ system ( other than localized basal cell carcinoma of the skin ) ; treated or untreated ; within the past 5 years ; regardless of whether there is evidence of local recurrence or metastases .,Condition Occurrence,Person,C0025266,males,FALSE,FALSE,NA,NA,NA
14,NCT00787605,Exclusion,long qt syndrome or qtc > 450 msec for males and > 470 msec for females at screening . ; history of malignancy of any organ system ( other than localized basal cell carcinoma of the skin ) ; treated or untreated ; within the past 5 years ; regardless of whether there is evidence of local recurrence or metastases .,Condition Occurrence,Person,C0086287,females,FALSE,FALSE,NA,NA,NA
14,NCT00787605,Exclusion,long qt syndrome or qtc > 450 msec for males and > 470 msec for females at screening . ; history of malignancy of any organ system ( other than localized basal cell carcinoma of the skin ) ; treated or untreated ; within the past 5 years ; regardless of whether there is evidence of local recurrence or metastases .,Condition Occurrence,Condition,C0023976,long qt syndrome,FALSE,FALSE,NA,NA,NA
14,NCT00787605,Exclusion,long qt syndrome or qtc > 450 msec for males and > 470 msec for females at screening . ; history of malignancy of any organ system ( other than localized basal cell carcinoma of the skin ) ; treated or untreated ; within the past 5 years ; regardless of whether there is evidence of local recurrence or metastases .,Condition Occurrence,Condition,C0006826;C1306459,malignancy,FALSE,FALSE,NA,NA,NA
14,NCT00787605,Exclusion,long qt syndrome or qtc > 450 msec for males and > 470 msec for females at screening . ; history of malignancy of any organ system ( other than localized basal cell carcinoma of the skin ) ; treated or untreated ; within the past 5 years ; regardless of whether there is evidence of local recurrence or metastases .,Condition Occurrence,Condition,C0007117,basal cell carcinoma of the skin,TRUE,FALSE,lower 5 past years,NA,NA
14,NCT00787605,Exclusion,long qt syndrome or qtc > 450 msec for males and > 470 msec for females at screening . ; history of malignancy of any organ system ( other than localized basal cell carcinoma of the skin ) ; treated or untreated ; within the past 5 years ; regardless of whether there is evidence of local recurrence or metastases .,Condition Occurrence,Condition,C2825055;C1458156,recurrence,FALSE,FALSE,NA,NA,NA
14,NCT00787605,Exclusion,long qt syndrome or qtc > 450 msec for males and > 470 msec for females at screening . ; history of malignancy of any organ system ( other than localized basal cell carcinoma of the skin ) ; treated or untreated ; within the past 5 years ; regardless of whether there is evidence of local recurrence or metastases .,Condition Occurrence,Condition,C0027627;C2939419,metastases,FALSE,FALSE,NA,NA,NA
15,NCT00787605,Exclusion,women of child-bearing potential ; defined as all women physiologically capable of becoming pregnant including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they are using two birth control methods,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
15,NCT00787605,Exclusion,women of child-bearing potential ; defined as all women physiologically capable of becoming pregnant including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they are using two birth control methods,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
15,NCT00787605,Exclusion,women of child-bearing potential ; defined as all women physiologically capable of becoming pregnant including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they are using two birth control methods,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
15,NCT00787605,Exclusion,women of child-bearing potential ; defined as all women physiologically capable of becoming pregnant including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they are using two birth control methods,Person,Person,C0025266,male,FALSE,FALSE,NA,NA,NA
15,NCT00787605,Exclusion,women of child-bearing potential ; defined as all women physiologically capable of becoming pregnant including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they are using two birth control methods,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
15,NCT00787605,Exclusion,women of child-bearing potential ; defined as all women physiologically capable of becoming pregnant including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they are using two birth control methods,Person,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
15,NCT00787605,Exclusion,women of child-bearing potential ; defined as all women physiologically capable of becoming pregnant including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they are using two birth control methods,Person,Procedure,C0042387,vasectomy,FALSE,FALSE,NA,NA,NA
15,NCT00787605,Exclusion,women of child-bearing potential ; defined as all women physiologically capable of becoming pregnant including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they are using two birth control methods,Person,Procedure,C0700589,birth control methods,FALSE,FALSE,NA,NA,NA
15,NCT00787605,Exclusion,women of child-bearing potential ; defined as all women physiologically capable of becoming pregnant including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they are using two birth control methods,Person,Observation,C3831118,child-bearing potential,FALSE,FALSE,NA,NA,NA
15,NCT00787605,Exclusion,women of child-bearing potential ; defined as all women physiologically capable of becoming pregnant including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they are using two birth control methods,Person,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
15,NCT00787605,Exclusion,women of child-bearing potential ; defined as all women physiologically capable of becoming pregnant including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they are using two birth control methods,Person,Other,C3539923,orientation,FALSE,FALSE,NA,NA,NA
16,NCT00787605,Exclusion,the two methods can be a double barrier method or a barrier method plus a hormonal method .,Procedure,Procedure,C0004764,barrier method,FALSE,FALSE,NA,NA,NA
16,NCT00787605,Exclusion,the two methods can be a double barrier method or a barrier method plus a hormonal method .,Procedure,Procedure,C2985296,hormonal method,FALSE,FALSE,NA,NA,NA
16,NCT00787605,Exclusion,the two methods can be a double barrier method or a barrier method plus a hormonal method .,Procedure,Procedure,C0004764,barrier method,FALSE,FALSE,NA,NA,NA
16,NCT00787605,Exclusion,the two methods can be a double barrier method or a barrier method plus a hormonal method .,Procedure,Other,C0025663,methods,FALSE,FALSE,NA,NA,NA
17,NCT00787605,Exclusion,adequate barrier methods of contraception include : diaphragm ; condom ( by the partner ) ; intrauterine device ( copper or hormonal ) ; sponge or spermicide,Drug Exposure,Drug,C1705741,sponge,FALSE,FALSE,NA,NA,NA
17,NCT00787605,Exclusion,adequate barrier methods of contraception include : diaphragm ; condom ( by the partner ) ; intrauterine device ( copper or hormonal ) ; sponge or spermicide,Drug Exposure,Drug,C0037862,spermicide,FALSE,FALSE,NA,NA,NA
17,NCT00787605,Exclusion,adequate barrier methods of contraception include : diaphragm ; condom ( by the partner ) ; intrauterine device ( copper or hormonal ) ; sponge or spermicide,Drug Exposure,Procedure,C0004764,barrier methods,FALSE,FALSE,NA,NA,NA
17,NCT00787605,Exclusion,adequate barrier methods of contraception include : diaphragm ; condom ( by the partner ) ; intrauterine device ( copper or hormonal ) ; sponge or spermicide,Drug Exposure,Procedure,C0700589,contraception,FALSE,FALSE,NA,NA,NA
17,NCT00787605,Exclusion,adequate barrier methods of contraception include : diaphragm ; condom ( by the partner ) ; intrauterine device ( copper or hormonal ) ; sponge or spermicide,Drug Exposure,Other,C0152097;C0011980;C1705368;C1279038,diaphragm,FALSE,FALSE,NA,NA,NA
17,NCT00787605,Exclusion,adequate barrier methods of contraception include : diaphragm ; condom ( by the partner ) ; intrauterine device ( copper or hormonal ) ; sponge or spermicide,Drug Exposure,Other,C1706306;C1548866;C1546682,intrauterine device,FALSE,FALSE,NA,NA,NA
17,NCT00787605,Exclusion,adequate barrier methods of contraception include : diaphragm ; condom ( by the partner ) ; intrauterine device ( copper or hormonal ) ; sponge or spermicide,Drug Exposure,Other,C0373587;C0009968;C2348263,copper,FALSE,FALSE,NA,NA,NA
18,NCT00787605,Exclusion,hormonal contraceptives include any marketed contraceptive agent that includes an estrogen or a progestational agent,Drug Exposure,Drug,C0009871,contraceptive agent,FALSE,FALSE,NA,NA,NA
18,NCT00787605,Exclusion,hormonal contraceptives include any marketed contraceptive agent that includes an estrogen or a progestational agent,Drug Exposure,Other,C0014939;C0202006;C2936882,estrogen,FALSE,FALSE,NA,NA,NA
19,NCT00787605,Exclusion,reliable contraception should be maintained throughout the study and for 7 days after study drug discontinuation .,Condition Occurrence,Procedure,C0700589,contraception,FALSE,FALSE,equal 7 days,NA,NA
19,NCT00787605,Exclusion,reliable contraception should be maintained throughout the study and for 7 days after study drug discontinuation .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
19,NCT00787605,Exclusion,reliable contraception should be maintained throughout the study and for 7 days after study drug discontinuation .,Condition Occurrence,Other,C0457454;C1444662,discontinuation,FALSE,FALSE,NA,NA,NA
20,NCT00787605,Exclusion,women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural ( spontaneous ) amenorrhea with an appropriate clinical profile ( eg age appropriate ; history of vasomotor symptoms ) or six months of spontaneous amenorrhea with serum fsh levels > 40 miu / ml ( and estradiol < 20 pg / ml ) or have had surgical bilateral oophorectomy ( with or without hysterectomy ) at least six weeks ago,Observation,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
20,NCT00787605,Exclusion,women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural ( spontaneous ) amenorrhea with an appropriate clinical profile ( eg age appropriate ; history of vasomotor symptoms ) or six months of spontaneous amenorrhea with serum fsh levels > 40 miu / ml ( and estradiol < 20 pg / ml ) or have had surgical bilateral oophorectomy ( with or without hysterectomy ) at least six weeks ago,Observation,Condition,C0002453;C2219717,amenorrhea,FALSE,FALSE,NA,NA,NA
20,NCT00787605,Exclusion,women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural ( spontaneous ) amenorrhea with an appropriate clinical profile ( eg age appropriate ; history of vasomotor symptoms ) or six months of spontaneous amenorrhea with serum fsh levels > 40 miu / ml ( and estradiol < 20 pg / ml ) or have had surgical bilateral oophorectomy ( with or without hysterectomy ) at least six weeks ago,Observation,Condition,C0002453;C2219717,amenorrhea,FALSE,FALSE,NA,NA,NA
20,NCT00787605,Exclusion,women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural ( spontaneous ) amenorrhea with an appropriate clinical profile ( eg age appropriate ; history of vasomotor symptoms ) or six months of spontaneous amenorrhea with serum fsh levels > 40 miu / ml ( and estradiol < 20 pg / ml ) or have had surgical bilateral oophorectomy ( with or without hysterectomy ) at least six weeks ago,Observation,Procedure,C0278321,bilateral oophorectomy,FALSE,FALSE,NA,NA,NA
20,NCT00787605,Exclusion,women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural ( spontaneous ) amenorrhea with an appropriate clinical profile ( eg age appropriate ; history of vasomotor symptoms ) or six months of spontaneous amenorrhea with serum fsh levels > 40 miu / ml ( and estradiol < 20 pg / ml ) or have had surgical bilateral oophorectomy ( with or without hysterectomy ) at least six weeks ago,Observation,Procedure,C0020699;C1548863,hysterectomy,FALSE,FALSE,NA,NA,NA
20,NCT00787605,Exclusion,women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural ( spontaneous ) amenorrhea with an appropriate clinical profile ( eg age appropriate ; history of vasomotor symptoms ) or six months of spontaneous amenorrhea with serum fsh levels > 40 miu / ml ( and estradiol < 20 pg / ml ) or have had surgical bilateral oophorectomy ( with or without hysterectomy ) at least six weeks ago,Observation,Observation,C3831118,child bearing potential,TRUE,FALSE,equal 12 months,NA,NA
20,NCT00787605,Exclusion,women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural ( spontaneous ) amenorrhea with an appropriate clinical profile ( eg age appropriate ; history of vasomotor symptoms ) or six months of spontaneous amenorrhea with serum fsh levels > 40 miu / ml ( and estradiol < 20 pg / ml ) or have had surgical bilateral oophorectomy ( with or without hysterectomy ) at least six weeks ago,Observation,Observation,C1979963,profile,FALSE,FALSE,NA,NA,NA
20,NCT00787605,Exclusion,women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural ( spontaneous ) amenorrhea with an appropriate clinical profile ( eg age appropriate ; history of vasomotor symptoms ) or six months of spontaneous amenorrhea with serum fsh levels > 40 miu / ml ( and estradiol < 20 pg / ml ) or have had surgical bilateral oophorectomy ( with or without hysterectomy ) at least six weeks ago,Observation,Observation,C0455276,serum fsh,FALSE,FALSE,NA,greater 40,NA
20,NCT00787605,Exclusion,women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural ( spontaneous ) amenorrhea with an appropriate clinical profile ( eg age appropriate ; history of vasomotor symptoms ) or six months of spontaneous amenorrhea with serum fsh levels > 40 miu / ml ( and estradiol < 20 pg / ml ) or have had surgical bilateral oophorectomy ( with or without hysterectomy ) at least six weeks ago,Observation,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
20,NCT00787605,Exclusion,women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural ( spontaneous ) amenorrhea with an appropriate clinical profile ( eg age appropriate ; history of vasomotor symptoms ) or six months of spontaneous amenorrhea with serum fsh levels > 40 miu / ml ( and estradiol < 20 pg / ml ) or have had surgical bilateral oophorectomy ( with or without hysterectomy ) at least six weeks ago,Observation,Other,C0014912;C0337434,estradiol,FALSE,FALSE,NA,lower 20 pg/ml,NA
21,NCT00787605,Exclusion,in the case of oophorectomy alone ; only when the reproductive status of the woman has been confirmed by follow up hormone level assessment .,Observation,Person,C0086287,woman,FALSE,FALSE,NA,NA,NA
21,NCT00787605,Exclusion,in the case of oophorectomy alone ; only when the reproductive status of the woman has been confirmed by follow up hormone level assessment .,Observation,Observation,C1287355,hormone level,FALSE,FALSE,NA,NA,NA
21,NCT00787605,Exclusion,in the case of oophorectomy alone ; only when the reproductive status of the woman has been confirmed by follow up hormone level assessment .,Observation,Other,C1719822,follow,FALSE,FALSE,NA,NA,NA
21,NCT00787605,Exclusion,in the case of oophorectomy alone ; only when the reproductive status of the woman has been confirmed by follow up hormone level assessment .,Observation,Other,C0542573;C0549068;C0870300;C0549070;C0549071;C0549072;C0549073;C0549074;C0028708;C0549075;C0549076;C0549077;C0549078;C0549079;C0549080;C0679207,assessment,FALSE,FALSE,NA,NA,NA
22,NCT00787605,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy . ;,Condition Occurrence,Condition,C0152132,hypertensive retinopathy,FALSE,FALSE,NA,NA,NA
22,NCT00787605,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy . ;,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii,FALSE,FALSE,NA,NA,NA
22,NCT00787605,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy . ;,Condition Occurrence,Other,C0677510;C0021440;C3496001,iv,FALSE,FALSE,NA,NA,NA
23,NCT00787605,Exclusion,current angina pectoris requiring pharmacological therapy ( except sublingual nitroglycerin ) .,Condition Occurrence,Condition,C0002962;C0577698;C0235467;C0542052;C0010073;C0541777;C0235462,angina pectoris,FALSE,FALSE,NA,NA,NA
23,NCT00787605,Exclusion,current angina pectoris requiring pharmacological therapy ( except sublingual nitroglycerin ) .,Condition Occurrence,Condition,C0558302,sublingual,TRUE,FALSE,NA,NA,NA
23,NCT00787605,Exclusion,current angina pectoris requiring pharmacological therapy ( except sublingual nitroglycerin ) .,Condition Occurrence,Drug,C0017887,nitroglycerin,TRUE,FALSE,NA,NA,NA
24,NCT00787605,Exclusion,second degree heart block or third degree heart block without a pacemaker .,Condition Occurrence,Condition,C0018794;C0542001;C0037188,heart block,FALSE,FALSE,NA,NA,NA
24,NCT00787605,Exclusion,second degree heart block or third degree heart block without a pacemaker .,Condition Occurrence,Condition,C0018794;C0542001;C0037188,heart block,FALSE,FALSE,NA,NA,NA
24,NCT00787605,Exclusion,second degree heart block or third degree heart block without a pacemaker .,Condition Occurrence,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
24,NCT00787605,Exclusion,second degree heart block or third degree heart block without a pacemaker .,Condition Occurrence,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
24,NCT00787605,Exclusion,second degree heart block or third degree heart block without a pacemaker .,Condition Occurrence,Other,C3275122;C1546728,pacemaker,TRUE,FALSE,NA,NA,NA
25,NCT00787605,Exclusion,atrial fibrillation or atrial flutter at visit 1 ; or potentially life-threatening or any symptomatic arrhythmia during the 12 months prior to visit 1 .,Condition Occurrence,Condition,C0004239;C1963068,atrial flutter,FALSE,FALSE,NA,NA,NA
25,NCT00787605,Exclusion,atrial fibrillation or atrial flutter at visit 1 ; or potentially life-threatening or any symptomatic arrhythmia during the 12 months prior to visit 1 .,Condition Occurrence,Condition,C2826244;C3537125,life-threatening,FALSE,FALSE,lower_equal 12 months,NA,NA
25,NCT00787605,Exclusion,atrial fibrillation or atrial flutter at visit 1 ; or potentially life-threatening or any symptomatic arrhythmia during the 12 months prior to visit 1 .,Condition Occurrence,Condition,C0003811,arrhythmia,FALSE,FALSE,lower_equal 12 months,NA,NA
25,NCT00787605,Exclusion,atrial fibrillation or atrial flutter at visit 1 ; or potentially life-threatening or any symptomatic arrhythmia during the 12 months prior to visit 1 .,Condition Occurrence,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
26,NCT00787605,Exclusion,clinically significant valvular heart disease .,Condition Occurrence,Condition,C0018824;C1963123,valvular heart disease,FALSE,FALSE,NA,NA,NA
27,NCT00787605,Exclusion,history of angioedema during use of an ace inhibitor .,Condition Occurrence,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
27,NCT00787605,Exclusion,history of angioedema during use of an ace inhibitor .,Condition Occurrence,Other,C0003015;C1152583,ace inhibitor,FALSE,FALSE,NA,NA,NA
28,NCT00787605,Exclusion,history or evidence of drug or alcohol abuse within the last 12 months .,Condition Occurrence,Condition,C0085762,alcohol abuse,FALSE,FALSE,lower 12 last months,NA,NA
28,NCT00787605,Exclusion,history or evidence of drug or alcohol abuse within the last 12 months .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,lower 12 last months,NA,NA
29,NCT00787605,Exclusion,any surgical condition or medical condition ; which in the opinion of the investigator ; may place the patient at higher risk from his / her participation in the study ; or is likely to prevent the patient from complying with the requirements of the study or completing the study .,Drug Exposure,Drug,C0309872,prevent,FALSE,FALSE,NA,NA,NA
29,NCT00787605,Exclusion,any surgical condition or medical condition ; which in the opinion of the investigator ; may place the patient at higher risk from his / her participation in the study ; or is likely to prevent the patient from complying with the requirements of the study or completing the study .,Drug Exposure,Other,C1561579;C1561578,medical,FALSE,FALSE,NA,NA,NA
1,NCT00787605,Inclusion,male or female outpatients > = 18 years old .,Person,Person,C0086287,female,FALSE,FALSE,greater_equal 18 years,NA,NA
2,NCT00787605,Inclusion,patients with a diagnosis of stage 2 hypertension ( defined as an office cuff mssbp > = 160 mmhg and < 200 mmhg ) at visit 5 ( randomization ) . ;,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,greater_equal 160 mmhg; lower 200 mmhg,NA
30,NCT00787605,Exclusion,any surgical condition or medical condition which might significantly alter the absorption ; distribution ; metabolism ; or excretion of study drugs including ; but not limited to ; any of the following :,Condition Occurrence,Condition,C1378698,distribution,FALSE,FALSE,NA,NA,NA
30,NCT00787605,Exclusion,any surgical condition or medical condition which might significantly alter the absorption ; distribution ; metabolism ; or excretion of study drugs including ; but not limited to ; any of the following :,Condition Occurrence,Condition,C0504085,excretion,FALSE,FALSE,NA,NA,NA
30,NCT00787605,Exclusion,any surgical condition or medical condition which might significantly alter the absorption ; distribution ; metabolism ; or excretion of study drugs including ; but not limited to ; any of the following :,Condition Occurrence,Condition,C0025519,metabolism,FALSE,FALSE,NA,NA,NA
30,NCT00787605,Exclusion,any surgical condition or medical condition which might significantly alter the absorption ; distribution ; metabolism ; or excretion of study drugs including ; but not limited to ; any of the following :,Condition Occurrence,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
30,NCT00787605,Exclusion,any surgical condition or medical condition which might significantly alter the absorption ; distribution ; metabolism ; or excretion of study drugs including ; but not limited to ; any of the following :,Condition Occurrence,Other,C1561579;C1561578,medical,FALSE,FALSE,NA,NA,NA
30,NCT00787605,Exclusion,any surgical condition or medical condition which might significantly alter the absorption ; distribution ; metabolism ; or excretion of study drugs including ; but not limited to ; any of the following :,Condition Occurrence,Other,C3542948,limited,TRUE,FALSE,NA,NA,NA
31,NCT00787605,Exclusion,history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; or bowel resection .,Procedure,Procedure,C0399610,gastrointestinal tract surgery,FALSE,FALSE,NA,NA,NA
31,NCT00787605,Exclusion,history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; or bowel resection .,Procedure,Procedure,C0017118,gastrectomy,FALSE,FALSE,NA,NA,NA
31,NCT00787605,Exclusion,history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; or bowel resection .,Procedure,Procedure,C0741614,bowel resection,FALSE,FALSE,NA,NA,NA
31,NCT00787605,Exclusion,history of major gastrointestinal tract surgery such as gastrectomy ; gastroenterostomy ; or bowel resection .,Procedure,Other,C0017164;C2237939,gastroenterostomy,FALSE,FALSE,NA,NA,NA
32,NCT00787605,Exclusion,history of active inflammatory bowel disease during the 12 months prior to visit 1 .,Drug Exposure,Condition,C0021390,inflammatory bowel disease,FALSE,FALSE,lower_equal 12 months,NA,NA
32,NCT00787605,Exclusion,history of active inflammatory bowel disease during the 12 months prior to visit 1 .,Drug Exposure,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
33,NCT00787605,Exclusion,currently active gastritis ; duodenal ulcers or gastric ulcers ; or gastrointestinal bleeding during the 3 months prior to visit 1 .,Condition Occurrence,Condition,C0038358,gastric ulcers,FALSE,FALSE,NA,NA,NA
33,NCT00787605,Exclusion,currently active gastritis ; duodenal ulcers or gastric ulcers ; or gastrointestinal bleeding during the 3 months prior to visit 1 .,Condition Occurrence,Condition,C0017152,gastritis,FALSE,FALSE,NA,NA,NA
33,NCT00787605,Exclusion,currently active gastritis ; duodenal ulcers or gastric ulcers ; or gastrointestinal bleeding during the 3 months prior to visit 1 .,Condition Occurrence,Condition,C0013295,duodenal ulcers,FALSE,FALSE,NA,NA,NA
33,NCT00787605,Exclusion,currently active gastritis ; duodenal ulcers or gastric ulcers ; or gastrointestinal bleeding during the 3 months prior to visit 1 .,Condition Occurrence,Condition,C0017181,gastrointestinal bleeding,FALSE,FALSE,lower_equal 3 months,NA,NA
33,NCT00787605,Exclusion,currently active gastritis ; duodenal ulcers or gastric ulcers ; or gastrointestinal bleeding during the 3 months prior to visit 1 .,Condition Occurrence,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
34,NCT00787605,Exclusion,any history of pancreatic injury ; pancreatitis ; or evidence of impaired pancreatic function / injury as indicated by abnormal lipase or amylase during the 12 months prior to visit 1 .,Condition Occurrence,Condition,C0273163,pancreatic injury,FALSE,FALSE,NA,NA,NA
34,NCT00787605,Exclusion,any history of pancreatic injury ; pancreatitis ; or evidence of impaired pancreatic function / injury as indicated by abnormal lipase or amylase during the 12 months prior to visit 1 .,Condition Occurrence,Condition,C0030305;C1963198,pancreatitis,FALSE,FALSE,NA,NA,NA
34,NCT00787605,Exclusion,any history of pancreatic injury ; pancreatitis ; or evidence of impaired pancreatic function / injury as indicated by abnormal lipase or amylase during the 12 months prior to visit 1 .,Condition Occurrence,Condition,C0232786,pancreatic function,FALSE,FALSE,NA,NA,NA
34,NCT00787605,Exclusion,any history of pancreatic injury ; pancreatitis ; or evidence of impaired pancreatic function / injury as indicated by abnormal lipase or amylase during the 12 months prior to visit 1 .,Condition Occurrence,Other,C2699333,abnormal,FALSE,FALSE,NA,NA,NA
34,NCT00787605,Exclusion,any history of pancreatic injury ; pancreatitis ; or evidence of impaired pancreatic function / injury as indicated by abnormal lipase or amylase during the 12 months prior to visit 1 .,Condition Occurrence,Other,C0373670;C0023764;C1561534;C0523940,lipase,FALSE,FALSE,lower_equal 12 months,NA,NA
34,NCT00787605,Exclusion,any history of pancreatic injury ; pancreatitis ; or evidence of impaired pancreatic function / injury as indicated by abnormal lipase or amylase during the 12 months prior to visit 1 .,Condition Occurrence,Other,C0201883;C0002712;C1561551,amylase,FALSE,FALSE,lower_equal 12 months,NA,NA
35,NCT00787605,Exclusion,evidence of hepatic disease as determined by any one of the following : alt or ast values exceeding 3 x uln at visit 1 ; a history of hepatic encephalopathy ; a history of esophageal varices ; or a history of portocaval shunt .,Condition Occurrence,Condition,C0023895,hepatic disease,FALSE,FALSE,NA,NA,NA
35,NCT00787605,Exclusion,evidence of hepatic disease as determined by any one of the following : alt or ast values exceeding 3 x uln at visit 1 ; a history of hepatic encephalopathy ; a history of esophageal varices ; or a history of portocaval shunt .,Condition Occurrence,Condition,C0019151,hepatic encephalopathy,FALSE,FALSE,NA,NA,NA
35,NCT00787605,Exclusion,evidence of hepatic disease as determined by any one of the following : alt or ast values exceeding 3 x uln at visit 1 ; a history of hepatic encephalopathy ; a history of esophageal varices ; or a history of portocaval shunt .,Condition Occurrence,Condition,C0014867,esophageal varices,FALSE,FALSE,NA,NA,NA
35,NCT00787605,Exclusion,evidence of hepatic disease as determined by any one of the following : alt or ast values exceeding 3 x uln at visit 1 ; a history of hepatic encephalopathy ; a history of esophageal varices ; or a history of portocaval shunt .,Condition Occurrence,Procedure,C0032716,portocaval shunt,FALSE,FALSE,NA,NA,NA
35,NCT00787605,Exclusion,evidence of hepatic disease as determined by any one of the following : alt or ast values exceeding 3 x uln at visit 1 ; a history of hepatic encephalopathy ; a history of esophageal varices ; or a history of portocaval shunt .,Condition Occurrence,Observation,C1140170;C2257651,alt,FALSE,FALSE,NA,NA,greater 3 x uln
35,NCT00787605,Exclusion,evidence of hepatic disease as determined by any one of the following : alt or ast values exceeding 3 x uln at visit 1 ; a history of hepatic encephalopathy ; a history of esophageal varices ; or a history of portocaval shunt .,Condition Occurrence,Observation,C0004002,ast,FALSE,FALSE,NA,NA,greater 3 x uln
36,NCT00787605,Exclusion,evidence of renal impairment as determined by any one of the following : serum creatinine > 1.5 x uln at visit 1 ; a history of dialysis ; or a history of nephrotic syndrome .,Condition Occurrence,Condition,C1565489;C0035078,renal impairment,FALSE,FALSE,NA,NA,NA
36,NCT00787605,Exclusion,evidence of renal impairment as determined by any one of the following : serum creatinine > 1.5 x uln at visit 1 ; a history of dialysis ; or a history of nephrotic syndrome .,Condition Occurrence,Condition,C0027726,nephrotic syndrome,FALSE,FALSE,NA,NA,NA
36,NCT00787605,Exclusion,evidence of renal impairment as determined by any one of the following : serum creatinine > 1.5 x uln at visit 1 ; a history of dialysis ; or a history of nephrotic syndrome .,Condition Occurrence,Procedure,C0011946;C0917873,dialysis,FALSE,FALSE,NA,NA,NA
36,NCT00787605,Exclusion,evidence of renal impairment as determined by any one of the following : serum creatinine > 1.5 x uln at visit 1 ; a history of dialysis ; or a history of nephrotic syndrome .,Condition Occurrence,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,NA,greater 1.5 x uln
37,NCT00787605,Exclusion,current treatment with cholestyramine or colestipol resins,Drug Exposure,Drug,C0008402,cholestyramine,FALSE,FALSE,NA,NA,NA
37,NCT00787605,Exclusion,current treatment with cholestyramine or colestipol resins,Drug Exposure,Drug,C0009279,colestipol,FALSE,FALSE,NA,NA,NA
37,NCT00787605,Exclusion,current treatment with cholestyramine or colestipol resins,Drug Exposure,Procedure,C2827774,current treatment,FALSE,FALSE,NA,NA,NA
38,NCT00787605,Exclusion,history of noncompliance to medical regimes or unwillingness to comply with the study protocol .,Other,Condition,C0376405,noncompliance,FALSE,FALSE,NA,NA,NA
38,NCT00787605,Exclusion,history of noncompliance to medical regimes or unwillingness to comply with the study protocol .,Other,Other,C1561579;C1561578,medical,FALSE,FALSE,NA,NA,NA
38,NCT00787605,Exclusion,history of noncompliance to medical regimes or unwillingness to comply with the study protocol .,Other,Other,C2348563;C1507394,study protocol,FALSE,FALSE,NA,NA,NA
40,NCT00787605,Exclusion,persons directly involved in the execution of this protocol .,Person,Person,C0027361,persons,FALSE,FALSE,NA,NA,NA
41,NCT00787605,Exclusion,known contraindications to the study drugs,Procedure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
39,NCT00787605,Exclusion,any condition that in the opinion of the investigator would confound the evaluation and interpretation of efficacy or safety data .,Other,Other,C0459471,interpretation,FALSE,FALSE,NA,NA,NA
1,NCT00797316,Inclusion,patients who are eligible and able to participate in the study ; and who give written informed consent before any assessment is performed .,Observation,Other,C0542573;C0549068;C0870300;C0549070;C0549071;C0549072;C0549073;C0549074;C0028708;C0549075;C0549076;C0549077;C0549078;C0549079;C0549080;C0679207,assessment,FALSE,FALSE,NA,NA,NA
2,NCT00797316,Inclusion,male or female outpatients > = 18 years old .,Person,Person,C0025266,male,FALSE,FALSE,greater_equal 18 years,NA,NA
2,NCT00797316,Inclusion,male or female outpatients > = 18 years old .,Person,Person,C0086287,female,FALSE,FALSE,greater_equal 18 years,NA,NA
3,NCT00797316,Inclusion,patients with stage 2 systolic hypertension,Condition Occurrence,Condition,C0221155,systolic hypertension,FALSE,FALSE,NA,NA,NA
4,NCT00797316,Inclusion,patients must have a mssbp > = 160 mmhg and < 200 mmhg at study visit 5 ( randomization ) .,Observation,NA,NA,NA,NA,NA,NA,NA,NA
5,NCT00797316,Inclusion,patients who have stage 2 systolic hypertension that meet at least 2 additional components of the metabolic syndrome as defined by the national cholesterol education program ( ncep ) criteria :,Observation,Condition,C0221155,systolic hypertension,FALSE,FALSE,NA,greater_equal 2,NA
5,NCT00797316,Inclusion,patients who have stage 2 systolic hypertension that meet at least 2 additional components of the metabolic syndrome as defined by the national cholesterol education program ( ncep ) criteria :,Observation,Condition,C0524620,metabolic syndrome,FALSE,FALSE,NA,NA,NA
5,NCT00797316,Inclusion,patients who have stage 2 systolic hypertension that meet at least 2 additional components of the metabolic syndrome as defined by the national cholesterol education program ( ncep ) criteria :,Observation,Observation,C0008377;C0201950,cholesterol,FALSE,FALSE,NA,NA,NA
5,NCT00797316,Inclusion,patients who have stage 2 systolic hypertension that meet at least 2 additional components of the metabolic syndrome as defined by the national cholesterol education program ( ncep ) criteria :,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
5,NCT00797316,Inclusion,patients who have stage 2 systolic hypertension that meet at least 2 additional components of the metabolic syndrome as defined by the national cholesterol education program ( ncep ) criteria :,Observation,Other,C3245503,national,FALSE,FALSE,NA,NA,NA
6,NCT00797316,Inclusion,abdominal obesity ( waist circumference > than 102 cm for men and > 88 cm for women ),Observation,Person,C0025266,men,FALSE,FALSE,NA,NA,NA
6,NCT00797316,Inclusion,abdominal obesity ( waist circumference > than 102 cm for men and > 88 cm for women ),Observation,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
6,NCT00797316,Inclusion,abdominal obesity ( waist circumference > than 102 cm for men and > 88 cm for women ),Observation,Condition,C0311277,abdominal obesity,FALSE,FALSE,NA,NA,NA
6,NCT00797316,Inclusion,abdominal obesity ( waist circumference > than 102 cm for men and > 88 cm for women ),Observation,Other,C0455829;C2366869,waist circumference,FALSE,FALSE,NA,NA,NA
7,NCT00797316,Inclusion,current triglycerides > = 150 mg / dl or medical treatment for this condition .,Drug Exposure,Other,C0041004;C0202236,triglycerides,FALSE,FALSE,NA,NA,greater_equal 150 mg/dl
7,NCT00797316,Inclusion,current triglycerides > = 150 mg / dl or medical treatment for this condition .,Drug Exposure,Other,C1561579;C1561578,medical,FALSE,FALSE,NA,NA,NA
8,NCT00797316,Inclusion,current hdl cholesterol < 40 mg / dl in men and < 50 mg / dl in women or medical treatment for this condition .,Drug Exposure,Person,C0025266,men,FALSE,FALSE,NA,NA,NA
8,NCT00797316,Inclusion,current hdl cholesterol < 40 mg / dl in men and < 50 mg / dl in women or medical treatment for this condition .,Drug Exposure,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
8,NCT00797316,Inclusion,current hdl cholesterol < 40 mg / dl in men and < 50 mg / dl in women or medical treatment for this condition .,Drug Exposure,Other,C0023822;C0428472;C0392885,hdl cholesterol,FALSE,FALSE,NA,NA,lower 40 mg/dl
8,NCT00797316,Inclusion,current hdl cholesterol < 40 mg / dl in men and < 50 mg / dl in women or medical treatment for this condition .,Drug Exposure,Other,C1561579;C1561578,medical,FALSE,FALSE,NA,NA,NA
9,NCT00797316,Inclusion,fasting glucose > 100 mg / dl and < 126 mg / dl,Drug Exposure,Observation,C0017725;C0337438,glucose,FALSE,FALSE,NA,NA,greater 100 mg/dl; lower 126 mg/dl
9,NCT00797316,Inclusion,fasting glucose > 100 mg / dl and < 126 mg / dl,Drug Exposure,Other,C0015663;C1550565,fasting,FALSE,FALSE,NA,NA,NA
10,NCT00797316,Exclusion,office blood pressure measured by cuff ( msdbp > = 110 mmhg and or mssbp > = 200 mmhg ) at any visit .,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,greater_equal 110 mmhg; greater_equal 200 mmhg,NA
10,NCT00797316,Exclusion,office blood pressure measured by cuff ( msdbp > = 110 mmhg and or mssbp > = 200 mmhg ) at any visit .,Observation,Procedure,C2224281;C1314130,blood pressure measured,FALSE,FALSE,NA,NA,NA
11,NCT00797316,Exclusion,use of other investigational drugs at the time of enrollment ; or within 30 days or 5 half-lives of enrollment ; whichever is longer .,Condition Occurrence,Condition,C2024467,time,FALSE,FALSE,NA,NA,NA
11,NCT00797316,Exclusion,use of other investigational drugs at the time of enrollment ; or within 30 days or 5 half-lives of enrollment ; whichever is longer .,Condition Occurrence,Condition,C0595998,lives,FALSE,FALSE,lower 30 days; equal 5 days,NA,NA
11,NCT00797316,Exclusion,use of other investigational drugs at the time of enrollment ; or within 30 days or 5 half-lives of enrollment ; whichever is longer .,Condition Occurrence,Drug,C0013230,investigational drugs,FALSE,FALSE,NA,NA,NA
11,NCT00797316,Exclusion,use of other investigational drugs at the time of enrollment ; or within 30 days or 5 half-lives of enrollment ; whichever is longer .,Condition Occurrence,Other,C1696073;C1516879,enrollment,FALSE,FALSE,NA,NA,NA
11,NCT00797316,Exclusion,use of other investigational drugs at the time of enrollment ; or within 30 days or 5 half-lives of enrollment ; whichever is longer .,Condition Occurrence,Other,C1696073;C1516879,enrollment,FALSE,FALSE,NA,NA,NA
12,NCT00797316,Exclusion,use of aliskiren or a fixed dose combination of aliskiren hctz or participation in a clinical trial that had aliskiren or aliskiren hctz as treatment within 30 days of visit 1 .,Drug Exposure,Condition,C2827483,fixed,FALSE,FALSE,NA,NA,NA
12,NCT00797316,Exclusion,use of aliskiren or a fixed dose combination of aliskiren hctz or participation in a clinical trial that had aliskiren or aliskiren hctz as treatment within 30 days of visit 1 .,Drug Exposure,Drug,C1120110,aliskiren,FALSE,FALSE,NA,NA,NA
12,NCT00797316,Exclusion,use of aliskiren or a fixed dose combination of aliskiren hctz or participation in a clinical trial that had aliskiren or aliskiren hctz as treatment within 30 days of visit 1 .,Drug Exposure,Drug,C1120110,aliskiren,FALSE,FALSE,NA,NA,NA
12,NCT00797316,Exclusion,use of aliskiren or a fixed dose combination of aliskiren hctz or participation in a clinical trial that had aliskiren or aliskiren hctz as treatment within 30 days of visit 1 .,Drug Exposure,Drug,C1120110,aliskiren,FALSE,FALSE,lower 30 days,NA,NA
12,NCT00797316,Exclusion,use of aliskiren or a fixed dose combination of aliskiren hctz or participation in a clinical trial that had aliskiren or aliskiren hctz as treatment within 30 days of visit 1 .,Drug Exposure,Drug,C1120110,aliskiren,FALSE,FALSE,lower 30 days,NA,NA
12,NCT00797316,Exclusion,use of aliskiren or a fixed dose combination of aliskiren hctz or participation in a clinical trial that had aliskiren or aliskiren hctz as treatment within 30 days of visit 1 .,Drug Exposure,Other,C1096775,clinical trial,FALSE,FALSE,NA,NA,NA
13,NCT00797316,Exclusion,history of hypersensitivity to any of the medications or to drugs belonging to a similar therapeutic class ( diuretics or renin inhibitors ) as the study drugs .,Procedure,Condition,C2917241,renin inhibitors,FALSE,FALSE,NA,NA,NA
13,NCT00797316,Exclusion,history of hypersensitivity to any of the medications or to drugs belonging to a similar therapeutic class ( diuretics or renin inhibitors ) as the study drugs .,Procedure,Drug,C0012798,diuretics,FALSE,FALSE,NA,NA,NA
13,NCT00797316,Exclusion,history of hypersensitivity to any of the medications or to drugs belonging to a similar therapeutic class ( diuretics or renin inhibitors ) as the study drugs .,Procedure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
13,NCT00797316,Exclusion,history of hypersensitivity to any of the medications or to drugs belonging to a similar therapeutic class ( diuretics or renin inhibitors ) as the study drugs .,Procedure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
13,NCT00797316,Exclusion,history of hypersensitivity to any of the medications or to drugs belonging to a similar therapeutic class ( diuretics or renin inhibitors ) as the study drugs .,Procedure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
13,NCT00797316,Exclusion,history of hypersensitivity to any of the medications or to drugs belonging to a similar therapeutic class ( diuretics or renin inhibitors ) as the study drugs .,Procedure,Other,C0723712;C0039796;C1547427,therapeutic,FALSE,FALSE,NA,NA,NA
13,NCT00797316,Exclusion,history of hypersensitivity to any of the medications or to drugs belonging to a similar therapeutic class ( diuretics or renin inhibitors ) as the study drugs .,Procedure,Other,C0456387;C0489477,class,FALSE,FALSE,NA,NA,NA
14,NCT00797316,Exclusion,history or evidence of secondary form of hypertension .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
15,NCT00797316,Exclusion,refractory hypertension ; defined as unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ),Observation,Condition,C0860493,refractory hypertension,FALSE,FALSE,NA,NA,NA
15,NCT00797316,Exclusion,refractory hypertension ; defined as unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ),Observation,Drug,C0012798,diuretic,FALSE,FALSE,NA,NA,NA
15,NCT00797316,Exclusion,refractory hypertension ; defined as unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ),Observation,Procedure,C0013216;C0013217,drug therapy,FALSE,FALSE,NA,NA,NA
15,NCT00797316,Exclusion,refractory hypertension ; defined as unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ),Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,TRUE,FALSE,NA,NA,NA
15,NCT00797316,Exclusion,refractory hypertension ; defined as unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ),Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
15,NCT00797316,Exclusion,refractory hypertension ; defined as unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ),Observation,Other,C0237284;C0205269,unresponsive,FALSE,FALSE,NA,NA,NA
15,NCT00797316,Exclusion,refractory hypertension ; defined as unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ),Observation,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
15,NCT00797316,Exclusion,refractory hypertension ; defined as unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ),Observation,Other,C0018017,goal,TRUE,FALSE,NA,greater_equal 140 mmhg; lower_equal 90 mmhg,NA
16,NCT00797316,Exclusion,therapy with a fixed dose combination of two active substances represent two drugs .,Drug Exposure,Condition,C2827483,fixed,FALSE,FALSE,NA,NA,NA
16,NCT00797316,Exclusion,therapy with a fixed dose combination of two active substances represent two drugs .,Drug Exposure,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
16,NCT00797316,Exclusion,therapy with a fixed dose combination of two active substances represent two drugs .,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
17,NCT00797316,Exclusion,patients on 4 or more antihypertensive medications,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,greater_equal 4,NA
1,NCT00809926,Inclusion,patients who are eligible and able to participate in the study ; and who give written informed consent before any assessment is performed .,Observation,Other,C0542573;C0549068;C0870300;C0549070;C0549071;C0549072;C0549073;C0549074;C0028708;C0549075;C0549076;C0549077;C0549078;C0549079;C0549080;C0679207,assessment,FALSE,FALSE,NA,NA,NA
2,NCT00809926,Inclusion,men or women 18 years and older .,Person,Person,C0025266,men,FALSE,FALSE,greater_equal 18 years,NA,NA
2,NCT00809926,Inclusion,men or women 18 years and older .,Person,Person,C0086287,women,FALSE,FALSE,greater_equal 18 years,NA,NA
3,NCT00809926,Inclusion,patients with stage 2 systolic hypertension,Condition Occurrence,Condition,C0221155,systolic hypertension,FALSE,FALSE,NA,NA,NA
4,NCT00809926,Inclusion,defined as having a mssbp > = 160 mmhg and < 180 mmhg at visit 5 ( randomization ) .,Observation,Other,C3539106,defined,FALSE,FALSE,NA,greater_equal 160 mmhg; lower 180 mmhg,NA
5,NCT00809926,Exclusion,use of aliskiren or participation in a clinical trial that had aliskiren as treatment within 30 days of visit 1 .,Drug Exposure,Drug,C1120110,aliskiren,FALSE,FALSE,NA,NA,NA
5,NCT00809926,Exclusion,use of aliskiren or participation in a clinical trial that had aliskiren as treatment within 30 days of visit 1 .,Drug Exposure,Drug,C1120110,aliskiren,FALSE,FALSE,lower 30 days,NA,NA
5,NCT00809926,Exclusion,use of aliskiren or participation in a clinical trial that had aliskiren as treatment within 30 days of visit 1 .,Drug Exposure,Other,C1096775,clinical trial,FALSE,FALSE,NA,NA,NA
6,NCT00809926,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ) .,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
6,NCT00809926,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ) .,Condition Occurrence,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
6,NCT00809926,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ) .,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
6,NCT00809926,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ) .,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
6,NCT00809926,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ) .,Condition Occurrence,Condition,C2828358;C3668831,lactating,FALSE,FALSE,NA,NA,NA
6,NCT00809926,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ) .,Condition Occurrence,Condition,C0009637,conception,FALSE,FALSE,NA,NA,NA
6,NCT00809926,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ) .,Condition Occurrence,Condition,C0032961,gestation,FALSE,FALSE,NA,NA,NA
6,NCT00809926,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ) .,Condition Occurrence,Observation,C0241904,positive hcg,FALSE,FALSE,NA,NA,NA
6,NCT00809926,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ) .,Condition Occurrence,Observation,C0022885,laboratory test,FALSE,FALSE,NA,greater 5,NA
6,NCT00809926,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ) .,Condition Occurrence,Other,C0032961;C3484365,pregnancy,FALSE,FALSE,NA,NA,NA
6,NCT00809926,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ) .,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
6,NCT00809926,Exclusion,pregnant or nursing ( lactating ) women ; where pregnancy is defined as the state of a female after conception and until the termination of gestation ; confirmed by a positive hcg laboratory test ( > 5 miu / ml ) .,Condition Occurrence,Other,C1549081,termination,FALSE,FALSE,NA,NA,NA
7,NCT00809926,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they meet the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum fsh levels > 40 miu / m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or are using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ) ; hormonal contraception ( implantable ; patch ; oral ) ; and double-barrier methods,Procedure,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
7,NCT00809926,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they meet the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum fsh levels > 40 miu / m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or are using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ) ; hormonal contraception ( implantable ; patch ; oral ) ; and double-barrier methods,Procedure,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
7,NCT00809926,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they meet the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum fsh levels > 40 miu / m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or are using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ) ; hormonal contraception ( implantable ; patch ; oral ) ; and double-barrier methods,Procedure,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
7,NCT00809926,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they meet the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum fsh levels > 40 miu / m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or are using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ) ; hormonal contraception ( implantable ; patch ; oral ) ; and double-barrier methods,Procedure,Person,C0025266,male,FALSE,FALSE,NA,NA,NA
7,NCT00809926,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they meet the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum fsh levels > 40 miu / m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or are using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ) ; hormonal contraception ( implantable ; patch ; oral ) ; and double-barrier methods,Procedure,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
7,NCT00809926,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they meet the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum fsh levels > 40 miu / m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or are using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ) ; hormonal contraception ( implantable ; patch ; oral ) ; and double-barrier methods,Procedure,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
7,NCT00809926,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they meet the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum fsh levels > 40 miu / m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or are using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ) ; hormonal contraception ( implantable ; patch ; oral ) ; and double-barrier methods,Procedure,Condition,C0002453;C2219717,amenorrhea,FALSE,FALSE,NA,NA,NA
7,NCT00809926,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they meet the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum fsh levels > 40 miu / m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or are using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ) ; hormonal contraception ( implantable ; patch ; oral ) ; and double-barrier methods,Procedure,Condition,C0002453;C2219717,amenorrhea,FALSE,FALSE,equal 6 months,NA,NA
7,NCT00809926,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they meet the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum fsh levels > 40 miu / m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or are using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ) ; hormonal contraception ( implantable ; patch ; oral ) ; and double-barrier methods,Procedure,Drug,C1272919,oral,FALSE,FALSE,NA,NA,NA
7,NCT00809926,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they meet the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum fsh levels > 40 miu / m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or are using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ) ; hormonal contraception ( implantable ; patch ; oral ) ; and double-barrier methods,Procedure,Procedure,C0042387,vasectomy,FALSE,FALSE,NA,NA,NA
7,NCT00809926,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they meet the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum fsh levels > 40 miu / m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or are using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ) ; hormonal contraception ( implantable ; patch ; oral ) ; and double-barrier methods,Procedure,Drug,C0445403;C1707974;C1533128,patch,FALSE,FALSE,NA,NA,NA
7,NCT00809926,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they meet the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum fsh levels > 40 miu / m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or are using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ) ; hormonal contraception ( implantable ; patch ; oral ) ; and double-barrier methods,Procedure,Procedure,C0278321,bilateral oophorectomy,FALSE,FALSE,NA,NA,NA
7,NCT00809926,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they meet the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum fsh levels > 40 miu / m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or are using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ) ; hormonal contraception ( implantable ; patch ; oral ) ; and double-barrier methods,Procedure,Procedure,C0020699;C1548863,hysterectomy,FALSE,FALSE,NA,NA,NA
7,NCT00809926,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they meet the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum fsh levels > 40 miu / m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or are using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ) ; hormonal contraception ( implantable ; patch ; oral ) ; and double-barrier methods,Procedure,Procedure,C0700589,contraception,FALSE,FALSE,NA,NA,NA
7,NCT00809926,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they meet the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum fsh levels > 40 miu / m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or are using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ) ; hormonal contraception ( implantable ; patch ; oral ) ; and double-barrier methods,Procedure,Procedure,C0589114,bilateral tubal ligation,FALSE,FALSE,NA,NA,NA
7,NCT00809926,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they meet the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum fsh levels > 40 miu / m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or are using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ) ; hormonal contraception ( implantable ; patch ; oral ) ; and double-barrier methods,Procedure,Procedure,C2985296,hormonal contraception,FALSE,FALSE,NA,NA,NA
7,NCT00809926,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they meet the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum fsh levels > 40 miu / m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or are using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ) ; hormonal contraception ( implantable ; patch ; oral ) ; and double-barrier methods,Procedure,Observation,C3831118,child-bearing potential,FALSE,FALSE,NA,NA,NA
7,NCT00809926,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they meet the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum fsh levels > 40 miu / m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or are using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ) ; hormonal contraception ( implantable ; patch ; oral ) ; and double-barrier methods,Procedure,Observation,C0455276,serum fsh,FALSE,FALSE,equal 6 weeks,greater 40,NA
7,NCT00809926,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they meet the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum fsh levels > 40 miu / m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or are using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ) ; hormonal contraception ( implantable ; patch ; oral ) ; and double-barrier methods,Procedure,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
7,NCT00809926,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they meet the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum fsh levels > 40 miu / m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or are using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ) ; hormonal contraception ( implantable ; patch ; oral ) ; and double-barrier methods,Procedure,Other,C3539923,orientation,FALSE,FALSE,NA,NA,NA
7,NCT00809926,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they meet the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum fsh levels > 40 miu / m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or are using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ) ; hormonal contraception ( implantable ; patch ; oral ) ; and double-barrier methods,Procedure,Other,C3539107,definition,FALSE,FALSE,equal 12 months,NA,NA
7,NCT00809926,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they meet the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum fsh levels > 40 miu / m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or are using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ) ; hormonal contraception ( implantable ; patch ; oral ) ; and double-barrier methods,Procedure,Other,C0025663,methods,FALSE,FALSE,NA,NA,NA
7,NCT00809926,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they meet the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum fsh levels > 40 miu / m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or are using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ) ; hormonal contraception ( implantable ; patch ; oral ) ; and double-barrier methods,Procedure,Other,C0038288;C0362065;C0038280,sterilization,FALSE,FALSE,NA,NA,NA
7,NCT00809926,Exclusion,women of child-bearing potential ( wocbp ) ; defined as all women physiologically capable of becoming pregnant ; including women whose career ; lifestyle ; or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means ; unless they meet the following definition of post-menopausal : 12 months of natural ( spontaneous ) amenorrhea or 6 months of spontaneous amenorrhea with serum fsh levels > 40 miu / m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or are using one or more of the following acceptable methods of contraception : surgical sterilization ( eg ; bilateral tubal ligation ) ; hormonal contraception ( implantable ; patch ; oral ) ; and double-barrier methods,Procedure,Other,C0025663,methods,FALSE,FALSE,NA,NA,NA
8,NCT00809926,Exclusion,reliable contraception should be maintained throughout the study and for 7 days after study drug discontinuation .,Condition Occurrence,Procedure,C0700589,contraception,FALSE,FALSE,equal 7 days,NA,NA
8,NCT00809926,Exclusion,reliable contraception should be maintained throughout the study and for 7 days after study drug discontinuation .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
8,NCT00809926,Exclusion,reliable contraception should be maintained throughout the study and for 7 days after study drug discontinuation .,Condition Occurrence,Other,C0457454;C1444662,discontinuation,FALSE,FALSE,NA,NA,NA
9,NCT00809926,Exclusion,severe hypertension ( an office cuff msdbp > = 110 mmhg or mssbp > = 180 mmhg ) .,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,greater_equal 110 mmhg; greater_equal 180 mmhg,NA
9,NCT00809926,Exclusion,severe hypertension ( an office cuff msdbp > = 110 mmhg or mssbp > = 180 mmhg ) .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
9,NCT00809926,Exclusion,severe hypertension ( an office cuff msdbp > = 110 mmhg or mssbp > = 180 mmhg ) .,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
10,NCT00809926,Exclusion,refractory hypertension ; defined as unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ) .,Observation,Condition,C0860493,refractory hypertension,FALSE,FALSE,NA,NA,NA
10,NCT00809926,Exclusion,refractory hypertension ; defined as unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ) .,Observation,Drug,C0012798,diuretic,FALSE,FALSE,NA,NA,NA
10,NCT00809926,Exclusion,refractory hypertension ; defined as unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ) .,Observation,Procedure,C0013216;C0013217,drug therapy,FALSE,FALSE,NA,NA,NA
10,NCT00809926,Exclusion,refractory hypertension ; defined as unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ) .,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,TRUE,FALSE,NA,NA,NA
10,NCT00809926,Exclusion,refractory hypertension ; defined as unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ) .,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
10,NCT00809926,Exclusion,refractory hypertension ; defined as unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ) .,Observation,Other,C0237284;C0205269,unresponsive,FALSE,FALSE,NA,NA,NA
10,NCT00809926,Exclusion,refractory hypertension ; defined as unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ) .,Observation,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
10,NCT00809926,Exclusion,refractory hypertension ; defined as unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ) .,Observation,Other,C0018017,goal,TRUE,FALSE,NA,greater_equal 140 mmhg; lower_equal 90 mmhg,NA
11,NCT00809926,Exclusion,patients treated with more than 3 antihypertensive medications ( each component of a combination drug counts individually ) .,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,greater 3,NA
11,NCT00809926,Exclusion,patients treated with more than 3 antihypertensive medications ( each component of a combination drug counts individually ) .,Drug Exposure,Drug,C0013162,combination drug,FALSE,FALSE,NA,NA,NA
12,NCT00809926,Exclusion,history or evidence of a secondary form of hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00841672,Inclusion,outpatients > = 18 years of age,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 18 years,NA,NA
2,NCT00841672,Inclusion,patients with a diagnosis of moderate to severe hypertension ; defined as mssbp > = 160 mmhg and < 200 mmhg at visit 2,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,greater_equal 160 mmhg; lower 200 mmhg,NA
2,NCT00841672,Inclusion,patients with a diagnosis of moderate to severe hypertension ; defined as mssbp > = 160 mmhg and < 200 mmhg at visit 2,Observation,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
2,NCT00841672,Inclusion,patients with a diagnosis of moderate to severe hypertension ; defined as mssbp > = 160 mmhg and < 200 mmhg at visit 2,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
2,NCT00841672,Inclusion,patients with a diagnosis of moderate to severe hypertension ; defined as mssbp > = 160 mmhg and < 200 mmhg at visit 2,Observation,Other,C3539106,defined,FALSE,FALSE,NA,greater_equal 160 mmhg; lower 200 mmhg,NA
3,NCT00841672,Exclusion,mild to moderate hypertension,Other,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00841672,Exclusion,mild to moderate hypertension,Other,Other,C1547225,mild,FALSE,FALSE,NA,NA,NA
3,NCT00841672,Exclusion,mild to moderate hypertension,Other,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
4,NCT00841672,Exclusion,pregnant or nursing ( lactating ) women,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
4,NCT00841672,Exclusion,pregnant or nursing ( lactating ) women,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
4,NCT00841672,Exclusion,pregnant or nursing ( lactating ) women,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
4,NCT00841672,Exclusion,pregnant or nursing ( lactating ) women,Condition Occurrence,Condition,C2828358;C3668831,lactating,FALSE,FALSE,NA,NA,NA
5,NCT00841672,Exclusion,women of child-bearing potential,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
5,NCT00841672,Exclusion,women of child-bearing potential,Person,Observation,C3831118,child-bearing potential,FALSE,FALSE,NA,NA,NA
6,NCT00841672,Exclusion,previous diagnosis or current diagnosis of heart failure new york heart association ( nyha ) class ii - class iv .,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
6,NCT00841672,Exclusion,previous diagnosis or current diagnosis of heart failure new york heart association ( nyha ) class ii - class iv .,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
6,NCT00841672,Exclusion,previous diagnosis or current diagnosis of heart failure new york heart association ( nyha ) class ii - class iv .,Condition Occurrence,Condition,C1882085,nyha class ii,FALSE,FALSE,NA,NA,NA
6,NCT00841672,Exclusion,previous diagnosis or current diagnosis of heart failure new york heart association ( nyha ) class ii - class iv .,Condition Occurrence,Other,C0441888;C2698970,class iv,FALSE,FALSE,NA,NA,NA
7,NCT00841672,Exclusion,serum potassium > = 5.3 meq / l ( mmol / l ) at visit 1 .,Observation,Observation,C0302353;C0543465,serum potassium,FALSE,FALSE,NA,greater_equal 5.3,NA
8,NCT00841672,Exclusion,uncontrolled type 1 diabetes or type 2 diabetesmellitus,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
8,NCT00841672,Exclusion,uncontrolled type 1 diabetes or type 2 diabetesmellitus,Condition Occurrence,Other,C1552651,type,FALSE,FALSE,NA,NA,NA
9,NCT00841672,Exclusion,hypersensitivity to renin inhibitors ; calcium channel blockers ; or to drugs with similar chemical structures,Drug Exposure,Condition,C2917241,renin inhibitors,FALSE,FALSE,NA,NA,NA
9,NCT00841672,Exclusion,hypersensitivity to renin inhibitors ; calcium channel blockers ; or to drugs with similar chemical structures,Drug Exposure,Drug,C0006684,calcium channel blockers,FALSE,FALSE,NA,NA,NA
9,NCT00841672,Exclusion,hypersensitivity to renin inhibitors ; calcium channel blockers ; or to drugs with similar chemical structures,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
9,NCT00841672,Exclusion,hypersensitivity to renin inhibitors ; calcium channel blockers ; or to drugs with similar chemical structures,Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
9,NCT00841672,Exclusion,hypersensitivity to renin inhibitors ; calcium channel blockers ; or to drugs with similar chemical structures,Drug Exposure,Other,C0220806;C3272558,chemical,FALSE,FALSE,NA,NA,NA
10,NCT00841672,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; or history of transient ischemic attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
10,NCT00841672,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; or history of transient ischemic attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention,Condition Occurrence,Condition,C0000924;C2046386,accident,FALSE,FALSE,NA,NA,NA
10,NCT00841672,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; or history of transient ischemic attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
10,NCT00841672,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; or history of transient ischemic attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,NA,NA,NA
10,NCT00841672,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; or history of transient ischemic attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention,Condition Occurrence,Condition,C0917805,tia,FALSE,FALSE,NA,NA,NA
10,NCT00841672,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; or history of transient ischemic attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention,Condition Occurrence,Procedure,C1532338,percutaneous coronary intervention,FALSE,FALSE,NA,NA,NA
10,NCT00841672,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; or history of transient ischemic attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention,Condition Occurrence,Procedure,C0010055,coronary bypass surgery,FALSE,FALSE,NA,NA,NA
10,NCT00841672,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; or history of transient ischemic attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
11,NCT00841672,Exclusion,patients on a combination of 3 or more antihypertensive medications,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,greater_equal 3,NA
12,NCT00841672,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00846365,Inclusion,190 mm hg on day 1 or if the participant has not received antihypertensive treatment within 28 days before screening and has a mean sitting clinic systolic blood pressure greater than or equal to 160 and less than or equal to 190 mm hg at the screening visit and on day 1 .,Observation,Person,C0679646,participant,FALSE,FALSE,equal 1 day,NA,NA
1,NCT00846365,Inclusion,190 mm hg on day 1 or if the participant has not received antihypertensive treatment within 28 days before screening and has a mean sitting clinic systolic blood pressure greater than or equal to 160 and less than or equal to 190 mm hg at the screening visit and on day 1 .,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
1,NCT00846365,Inclusion,190 mm hg on day 1 or if the participant has not received antihypertensive treatment within 28 days before screening and has a mean sitting clinic systolic blood pressure greater than or equal to 160 and less than or equal to 190 mm hg at the screening visit and on day 1 .,Observation,Drug,C0003364,antihypertensive,TRUE,FALSE,lower 28 days,NA,NA
1,NCT00846365,Inclusion,190 mm hg on day 1 or if the participant has not received antihypertensive treatment within 28 days before screening and has a mean sitting clinic systolic blood pressure greater than or equal to 160 and less than or equal to 190 mm hg at the screening visit and on day 1 .,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,equal 1 day,greater_equal 160 mm hg; lower_equal 190 mm hg,NA
2,NCT00846365,Inclusion,females of childbearing potential who are sexually active must agree to use adequate contraception ; and can neither be pregnant nor lactating from screening throughout the duration of the study .,Condition Occurrence,Person,C0086287,females,FALSE,FALSE,NA,NA,NA
2,NCT00846365,Inclusion,females of childbearing potential who are sexually active must agree to use adequate contraception ; and can neither be pregnant nor lactating from screening throughout the duration of the study .,Condition Occurrence,Condition,C0241028,sexually active,FALSE,FALSE,NA,NA,NA
2,NCT00846365,Inclusion,females of childbearing potential who are sexually active must agree to use adequate contraception ; and can neither be pregnant nor lactating from screening throughout the duration of the study .,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
2,NCT00846365,Inclusion,females of childbearing potential who are sexually active must agree to use adequate contraception ; and can neither be pregnant nor lactating from screening throughout the duration of the study .,Condition Occurrence,Condition,C2828358;C3668831,lactating,FALSE,FALSE,NA,NA,NA
2,NCT00846365,Inclusion,females of childbearing potential who are sexually active must agree to use adequate contraception ; and can neither be pregnant nor lactating from screening throughout the duration of the study .,Condition Occurrence,Procedure,C0700589,contraception,FALSE,FALSE,NA,NA,NA
2,NCT00846365,Inclusion,females of childbearing potential who are sexually active must agree to use adequate contraception ; and can neither be pregnant nor lactating from screening throughout the duration of the study .,Condition Occurrence,Observation,C3831118,childbearing potential,FALSE,FALSE,NA,NA,NA
2,NCT00846365,Inclusion,females of childbearing potential who are sexually active must agree to use adequate contraception ; and can neither be pregnant nor lactating from screening throughout the duration of the study .,Condition Occurrence,Other,C3641827,agree,FALSE,FALSE,NA,NA,NA
3,NCT00846365,Inclusion,has clinical laboratory test results within the reference range for the testing laboratory or the investigator does not consider the results to be clinically significant .,Observation,Observation,C0022885,laboratory test,FALSE,FALSE,NA,NA,NA
3,NCT00846365,Inclusion,has clinical laboratory test results within the reference range for the testing laboratory or the investigator does not consider the results to be clinically significant .,Observation,Observation,C3542016,range,FALSE,FALSE,NA,NA,NA
3,NCT00846365,Inclusion,has clinical laboratory test results within the reference range for the testing laboratory or the investigator does not consider the results to be clinically significant .,Observation,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
3,NCT00846365,Inclusion,has clinical laboratory test results within the reference range for the testing laboratory or the investigator does not consider the results to be clinically significant .,Observation,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
4,NCT00846365,Inclusion,is willing to discontinue current antihypertensive medications on day 21 or on day 28 if is on amlodipine or chlorthalidone .,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,equal 21 day; equal 28 day,NA,NA
4,NCT00846365,Inclusion,is willing to discontinue current antihypertensive medications on day 21 or on day 28 if is on amlodipine or chlorthalidone .,Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,NA
4,NCT00846365,Inclusion,is willing to discontinue current antihypertensive medications on day 21 or on day 28 if is on amlodipine or chlorthalidone .,Drug Exposure,Drug,C0008294,chlorthalidone,FALSE,FALSE,NA,NA,NA
4,NCT00846365,Inclusion,is willing to discontinue current antihypertensive medications on day 21 or on day 28 if is on amlodipine or chlorthalidone .,Drug Exposure,Other,C1706472,discontinue,FALSE,FALSE,NA,NA,NA
5,NCT00846365,Exclusion,has a mean sitting clinic diastolic blood pressure greater than 119 mm hg .,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
5,NCT00846365,Exclusion,has a mean sitting clinic diastolic blood pressure greater than 119 mm hg .,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater 119 mm hg,NA
6,NCT00846365,Exclusion,has a baseline 24 - hour ambulatory blood pressure monitoring reading of insufficient quality .,Observation,Condition,C1705179,reading,FALSE,FALSE,NA,NA,NA
6,NCT00846365,Exclusion,has a baseline 24 - hour ambulatory blood pressure monitoring reading of insufficient quality .,Observation,Observation,C0242876,ambulatory blood pressure monitoring,FALSE,FALSE,equal 24 hour,NA,NA
7,NCT00846365,Exclusion,works a night ( third ) shift ( from 11 pm [ 2300 ] to 7 am [ 0700 ] ) .,Observation,Drug,C1867051,pm,FALSE,FALSE,NA,equal 11 ; equal 7,NA
8,NCT00846365,Exclusion,has an upper arm circumference less than 24 cm or greater than 42 cm .,Observation,Condition,C0446516;C1269612,upper arm,FALSE,FALSE,NA,lower 24 cm; greater 42 cm,NA
9,NCT00846365,Exclusion,is noncompliant with study medication during the placebo run-in period .,Drug Exposure,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,NA
10,NCT00846365,Exclusion,has secondary hypertension of any etiology .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
11,NCT00846365,Exclusion,has a recent history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident or transient ischemic attack .,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,NA,NA,NA
11,NCT00846365,Exclusion,has a recent history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident or transient ischemic attack .,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
11,NCT00846365,Exclusion,has a recent history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident or transient ischemic attack .,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
11,NCT00846365,Exclusion,has a recent history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident or transient ischemic attack .,Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,NA,NA,NA
11,NCT00846365,Exclusion,has a recent history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident or transient ischemic attack .,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
11,NCT00846365,Exclusion,has a recent history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident or transient ischemic attack .,Condition Occurrence,Procedure,C1532338,percutaneous coronary intervention,FALSE,FALSE,NA,NA,NA
11,NCT00846365,Exclusion,has a recent history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident or transient ischemic attack .,Condition Occurrence,Procedure,C0010055,coronary artery bypass graft,FALSE,FALSE,NA,NA,NA
11,NCT00846365,Exclusion,has a recent history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident or transient ischemic attack .,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
12,NCT00846365,Exclusion,has a clinically significant cardiac conduction .,Condition Occurrence,Condition,C0232217,cardiac conduction,FALSE,FALSE,NA,NA,NA
13,NCT00846365,Exclusion,has hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease .,Condition Occurrence,Condition,C0023213,left ventricular outflow obstruction,FALSE,FALSE,NA,NA,NA
13,NCT00846365,Exclusion,has hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease .,Condition Occurrence,Condition,C1260873,aortic valvular disease,FALSE,FALSE,NA,NA,NA
14,NCT00846365,Exclusion,has severe renal dysfunction or disease .,Condition Occurrence,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
14,NCT00846365,Exclusion,has severe renal dysfunction or disease .,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
15,NCT00846365,Exclusion,has a known or suspected unilateral renal artery or bilateral renal artery stenosis .,Condition Occurrence,Condition,C0035065;C1278951,renal artery,FALSE,FALSE,NA,NA,NA
15,NCT00846365,Exclusion,has a known or suspected unilateral renal artery or bilateral renal artery stenosis .,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
16,NCT00846365,Exclusion,has a history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug .,Condition Occurrence,Condition,C0544452,remission,TRUE,FALSE,greater_equal 5 years,NA,NA
16,NCT00846365,Exclusion,has a history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug .,Condition Occurrence,Other,C0260515;C2707253,cancer,FALSE,FALSE,NA,NA,NA
16,NCT00846365,Exclusion,has a history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
17,NCT00846365,Exclusion,has poorly controlled type 1 diabetes or type 2 diabetesmellitus .,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
17,NCT00846365,Exclusion,has poorly controlled type 1 diabetes or type 2 diabetesmellitus .,Condition Occurrence,Other,C1552651,type,FALSE,FALSE,NA,NA,NA
18,NCT00846365,Exclusion,has hypokalemia or hyperkalemia .,Condition Occurrence,Condition,C0020621,hypokalemia,FALSE,FALSE,NA,NA,NA
18,NCT00846365,Exclusion,has hypokalemia or hyperkalemia .,Condition Occurrence,Condition,C0020461,hyperkalemia,FALSE,FALSE,NA,NA,NA
19,NCT00846365,Exclusion,has an alanine aminotransferase or aspartate aminotransferase level of greater than 2.5 times the upper limit of normal liver disease ; active liver disease or jaundice .,Drug Exposure,Condition,C0023895;C2186532,liver disease,FALSE,FALSE,NA,NA,NA
19,NCT00846365,Exclusion,has an alanine aminotransferase or aspartate aminotransferase level of greater than 2.5 times the upper limit of normal liver disease ; active liver disease or jaundice .,Drug Exposure,Condition,C0023895;C2186532,liver disease,FALSE,FALSE,NA,NA,NA
19,NCT00846365,Exclusion,has an alanine aminotransferase or aspartate aminotransferase level of greater than 2.5 times the upper limit of normal liver disease ; active liver disease or jaundice .,Drug Exposure,Condition,C2203646,jaundice,FALSE,FALSE,NA,NA,NA
19,NCT00846365,Exclusion,has an alanine aminotransferase or aspartate aminotransferase level of greater than 2.5 times the upper limit of normal liver disease ; active liver disease or jaundice .,Drug Exposure,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
19,NCT00846365,Exclusion,has an alanine aminotransferase or aspartate aminotransferase level of greater than 2.5 times the upper limit of normal liver disease ; active liver disease or jaundice .,Drug Exposure,Observation,C0001899;C0201836,alanine aminotransferase,FALSE,FALSE,NA,NA,greater 2.5 times the upper limit of normal
19,NCT00846365,Exclusion,has an alanine aminotransferase or aspartate aminotransferase level of greater than 2.5 times the upper limit of normal liver disease ; active liver disease or jaundice .,Drug Exposure,Observation,C0428339,aspartate aminotransferase level,FALSE,FALSE,NA,NA,greater 2.5 times the upper limit of normal
20,NCT00846365,Exclusion,has any other known serious disease or condition that would compromise safety ; might affect life expectancy or make it difficult to successfully manage and follow the participant according to the protocol .,Other,Person,C0679646,participant,FALSE,FALSE,NA,NA,NA
20,NCT00846365,Exclusion,has any other known serious disease or condition that would compromise safety ; might affect life expectancy or make it difficult to successfully manage and follow the participant according to the protocol .,Other,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
20,NCT00846365,Exclusion,has any other known serious disease or condition that would compromise safety ; might affect life expectancy or make it difficult to successfully manage and follow the participant according to the protocol .,Other,Other,C0023671,life expectancy,FALSE,FALSE,NA,NA,NA
20,NCT00846365,Exclusion,has any other known serious disease or condition that would compromise safety ; might affect life expectancy or make it difficult to successfully manage and follow the participant according to the protocol .,Other,Other,C1719822,follow,FALSE,FALSE,NA,NA,NA
21,NCT00846365,Exclusion,has a known hypersensitivity to angiotensin ii receptor blockers or thiazide-type diuretics or other sulfonamide-derived compounds .,Drug Exposure,Drug,C0541746,thiazide,FALSE,FALSE,NA,NA,NA
21,NCT00846365,Exclusion,has a known hypersensitivity to angiotensin ii receptor blockers or thiazide-type diuretics or other sulfonamide-derived compounds .,Drug Exposure,Drug,C0012798,diuretics,FALSE,FALSE,NA,NA,NA
21,NCT00846365,Exclusion,has a known hypersensitivity to angiotensin ii receptor blockers or thiazide-type diuretics or other sulfonamide-derived compounds .,Drug Exposure,Drug,C0599503;C3536763,sulfonamide,FALSE,FALSE,NA,NA,NA
21,NCT00846365,Exclusion,has a known hypersensitivity to angiotensin ii receptor blockers or thiazide-type diuretics or other sulfonamide-derived compounds .,Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
21,NCT00846365,Exclusion,has a known hypersensitivity to angiotensin ii receptor blockers or thiazide-type diuretics or other sulfonamide-derived compounds .,Drug Exposure,Other,C2757003;C0521942,angiotensin ii receptor blockers,FALSE,FALSE,NA,NA,NA
22,NCT00846365,Exclusion,has been randomized in a previous azilsartan medoxomil study .,Drug Exposure,Drug,C2698291,azilsartan medoxomil,FALSE,FALSE,NA,NA,NA
23,NCT00846365,Exclusion,is currently participating in another investigational study or has participated in an investigational study or is receiving or has received any investigational compound within 30 days prior to randomization .,Other,Drug,C1706082,compound,FALSE,FALSE,lower 30 days,NA,NA
23,NCT00846365,Exclusion,is currently participating in another investigational study or has participated in an investigational study or is receiving or has received any investigational compound within 30 days prior to randomization .,Other,Other,C3245491,investigational,FALSE,FALSE,NA,NA,NA
23,NCT00846365,Exclusion,is currently participating in another investigational study or has participated in an investigational study or is receiving or has received any investigational compound within 30 days prior to randomization .,Other,Other,C3245491,investigational,FALSE,FALSE,NA,NA,NA
23,NCT00846365,Exclusion,is currently participating in another investigational study or has participated in an investigational study or is receiving or has received any investigational compound within 30 days prior to randomization .,Other,Other,C3245491,investigational,FALSE,FALSE,NA,NA,NA
24,NCT00846365,Exclusion,has a history of drug abuse or a history of alcohol abuse within the past 2 years,Condition Occurrence,Condition,C0013146,drug abuse,FALSE,FALSE,NA,NA,NA
24,NCT00846365,Exclusion,has a history of drug abuse or a history of alcohol abuse within the past 2 years,Condition Occurrence,Condition,C0085762,alcohol abuse,FALSE,FALSE,lower 2 past years,NA,NA
1,NCT00853957,Inclusion,men or women of african american background,Person,Person,C0025266,men,FALSE,FALSE,NA,NA,NA
1,NCT00853957,Inclusion,men or women of african american background,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
1,NCT00853957,Inclusion,men or women of african american background,Person,Person,C0085756,african american,FALSE,FALSE,NA,NA,NA
2,NCT00853957,Inclusion,self identified,Condition Occurrence,Condition,C1550043,identified,FALSE,FALSE,NA,NA,NA
3,NCT00853957,Inclusion,patients with stage 2 hypertension defined as mssbp > = 160 mmhg and < 200 mmhg at visit 5 ( randomization,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00853957,Inclusion,patients with stage 2 hypertension defined as mssbp > = 160 mmhg and < 200 mmhg at visit 5 ( randomization,Observation,Other,C3539106,defined,FALSE,FALSE,NA,greater_equal 160 mmhg; lower 200 mmhg,NA
4,NCT00853957,Exclusion,office blood pressure measured by cuff ( msdbp > = 110 mmhg or mssbp > = 200 mmhg ),Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,greater_equal 110 mmhg; greater_equal 200 mmhg,NA
4,NCT00853957,Exclusion,office blood pressure measured by cuff ( msdbp > = 110 mmhg or mssbp > = 200 mmhg ),Observation,Procedure,C2224281;C1314130,blood pressure measured,FALSE,FALSE,NA,NA,NA
5,NCT00853957,Exclusion,patients on 4 or more antihypertensive medications .,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,greater_equal 4,NA
6,NCT00853957,Exclusion,patients with uncontrolled hypertension ( mssbp > 180 mmhg ) taking more than 1 antihypertensive medication at visit 1,Observation,Condition,C1868885,uncontrolled hypertension,FALSE,FALSE,NA,greater 180 mmhg,NA
6,NCT00853957,Exclusion,patients with uncontrolled hypertension ( mssbp > 180 mmhg ) taking more than 1 antihypertensive medication at visit 1,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,greater 1,NA
7,NCT00853957,Exclusion,refractory hypertension ; defined as ; unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ),Observation,Condition,C0860493,refractory hypertension,FALSE,FALSE,NA,NA,NA
7,NCT00853957,Exclusion,refractory hypertension ; defined as ; unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ),Observation,Drug,C0012798,diuretic,FALSE,FALSE,NA,NA,NA
7,NCT00853957,Exclusion,refractory hypertension ; defined as ; unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ),Observation,Procedure,C0013216;C0013217,drug therapy,FALSE,FALSE,NA,NA,NA
7,NCT00853957,Exclusion,refractory hypertension ; defined as ; unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ),Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,TRUE,FALSE,NA,NA,NA
7,NCT00853957,Exclusion,refractory hypertension ; defined as ; unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ),Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
7,NCT00853957,Exclusion,refractory hypertension ; defined as ; unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ),Observation,Other,C0237284;C0205269,unresponsive,FALSE,FALSE,NA,NA,NA
7,NCT00853957,Exclusion,refractory hypertension ; defined as ; unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ),Observation,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
7,NCT00853957,Exclusion,refractory hypertension ; defined as ; unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ),Observation,Other,C0018017,goal,TRUE,FALSE,NA,greater_equal 140 mmhg; lower_equal 90 mmhg,NA
8,NCT00853957,Exclusion,therapy with a fixed dose combination of two active substances represent two drugs .,Drug Exposure,Condition,C2827483,fixed,FALSE,FALSE,NA,NA,NA
8,NCT00853957,Exclusion,therapy with a fixed dose combination of two active substances represent two drugs .,Drug Exposure,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
8,NCT00853957,Exclusion,therapy with a fixed dose combination of two active substances represent two drugs .,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
9,NCT00853957,Exclusion,history of malignancy of any organ system ( other than localized basal cell carcinoma of the skin ) ; treated or untreated ; within the past 5 years ; regardless of whether there is evidence of local recurrence or metastases .,Condition Occurrence,Condition,C0006826;C1306459,malignancy,FALSE,FALSE,NA,NA,NA
9,NCT00853957,Exclusion,history of malignancy of any organ system ( other than localized basal cell carcinoma of the skin ) ; treated or untreated ; within the past 5 years ; regardless of whether there is evidence of local recurrence or metastases .,Condition Occurrence,Condition,C0007117,basal cell carcinoma of the skin,TRUE,FALSE,lower 5 past years,NA,NA
9,NCT00853957,Exclusion,history of malignancy of any organ system ( other than localized basal cell carcinoma of the skin ) ; treated or untreated ; within the past 5 years ; regardless of whether there is evidence of local recurrence or metastases .,Condition Occurrence,Condition,C2825055;C1458156,recurrence,FALSE,FALSE,NA,NA,NA
9,NCT00853957,Exclusion,history of malignancy of any organ system ( other than localized basal cell carcinoma of the skin ) ; treated or untreated ; within the past 5 years ; regardless of whether there is evidence of local recurrence or metastases .,Condition Occurrence,Condition,C0027627;C2939419,metastases,FALSE,FALSE,NA,NA,NA
10,NCT00853957,Exclusion,evidence of a secondary form of hypertension ; including but not limited to any of the following :,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
10,NCT00853957,Exclusion,evidence of a secondary form of hypertension ; including but not limited to any of the following :,Observation,Other,C3542948,limited,TRUE,FALSE,NA,NA,NA
11,NCT00853957,Exclusion,coarctation of the aorta,Condition Occurrence,Condition,C0332886,coarctation,FALSE,FALSE,NA,NA,NA
11,NCT00853957,Exclusion,coarctation of the aorta,Condition Occurrence,Other,C0869784;C0003483;C1278934,aorta,FALSE,FALSE,NA,NA,NA
12,NCT00853957,Exclusion,hyperaldosteronism,Condition Occurrence,Condition,C0020428,hyperaldosteronism,FALSE,FALSE,NA,NA,NA
13,NCT00853957,Exclusion,unilateral renal artery or bilateral renal artery stenosis,Condition Occurrence,Condition,C0035065;C1278951,renal artery,FALSE,FALSE,NA,NA,NA
13,NCT00853957,Exclusion,unilateral renal artery or bilateral renal artery stenosis,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
14,NCT00853957,Exclusion,cushing disease,Condition Occurrence,Condition,C0221406;C0010481,cushing disease,FALSE,FALSE,NA,NA,NA
15,NCT00853957,Exclusion,polycystic kidney disease,Condition Occurrence,Condition,C0022680,polycystic kidney disease,FALSE,FALSE,NA,NA,NA
16,NCT00853957,Exclusion,pheochromocytoma,Condition Occurrence,Condition,C0031511;C1706920,pheochromocytoma,FALSE,FALSE,NA,NA,NA
17,NCT00853957,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy .,Condition Occurrence,Condition,C0152132,hypertensive retinopathy,FALSE,FALSE,NA,NA,NA
17,NCT00853957,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy .,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii,FALSE,FALSE,NA,NA,NA
17,NCT00853957,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy .,Condition Occurrence,Other,C0677510;C0021440;C3496001,iv,FALSE,FALSE,NA,NA,NA
18,NCT00853957,Exclusion,history of angioedema due to usage of an arb or ace inhibitor .,Condition Occurrence,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
18,NCT00853957,Exclusion,history of angioedema due to usage of an arb or ace inhibitor .,Condition Occurrence,Other,C0521942;C2678493,arb,FALSE,FALSE,NA,NA,NA
18,NCT00853957,Exclusion,history of angioedema due to usage of an arb or ace inhibitor .,Condition Occurrence,Other,C0003015;C1152583,ace inhibitor,FALSE,FALSE,NA,NA,NA
19,NCT00853957,Exclusion,history of hypertensive encephalopathy ; cerebrovascular accident ; transient ischemic attack ; heart failure ( nyha class ii- ; coronary bypass graft surgery ( cabg ) ; percutaneous coronary intervention ( pci ) ; unstable angina pectoris ; or myocardial infarction in the last 12 months,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
19,NCT00853957,Exclusion,history of hypertensive encephalopathy ; cerebrovascular accident ; transient ischemic attack ; heart failure ( nyha class ii- ; coronary bypass graft surgery ( cabg ) ; percutaneous coronary intervention ( pci ) ; unstable angina pectoris ; or myocardial infarction in the last 12 months,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
19,NCT00853957,Exclusion,history of hypertensive encephalopathy ; cerebrovascular accident ; transient ischemic attack ; heart failure ( nyha class ii- ; coronary bypass graft surgery ( cabg ) ; percutaneous coronary intervention ( pci ) ; unstable angina pectoris ; or myocardial infarction in the last 12 months,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,NA,NA,NA
19,NCT00853957,Exclusion,history of hypertensive encephalopathy ; cerebrovascular accident ; transient ischemic attack ; heart failure ( nyha class ii- ; coronary bypass graft surgery ( cabg ) ; percutaneous coronary intervention ( pci ) ; unstable angina pectoris ; or myocardial infarction in the last 12 months,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
19,NCT00853957,Exclusion,history of hypertensive encephalopathy ; cerebrovascular accident ; transient ischemic attack ; heart failure ( nyha class ii- ; coronary bypass graft surgery ( cabg ) ; percutaneous coronary intervention ( pci ) ; unstable angina pectoris ; or myocardial infarction in the last 12 months,Condition Occurrence,Condition,C1882083,nyha class,FALSE,FALSE,NA,NA,NA
19,NCT00853957,Exclusion,history of hypertensive encephalopathy ; cerebrovascular accident ; transient ischemic attack ; heart failure ( nyha class ii- ; coronary bypass graft surgery ( cabg ) ; percutaneous coronary intervention ( pci ) ; unstable angina pectoris ; or myocardial infarction in the last 12 months,Condition Occurrence,Condition,C0002965,unstable angina pectoris,FALSE,FALSE,lower_equal 12 last months,NA,NA
19,NCT00853957,Exclusion,history of hypertensive encephalopathy ; cerebrovascular accident ; transient ischemic attack ; heart failure ( nyha class ii- ; coronary bypass graft surgery ( cabg ) ; percutaneous coronary intervention ( pci ) ; unstable angina pectoris ; or myocardial infarction in the last 12 months,Condition Occurrence,Procedure,C0010055,coronary bypass,FALSE,FALSE,NA,NA,NA
19,NCT00853957,Exclusion,history of hypertensive encephalopathy ; cerebrovascular accident ; transient ischemic attack ; heart failure ( nyha class ii- ; coronary bypass graft surgery ( cabg ) ; percutaneous coronary intervention ( pci ) ; unstable angina pectoris ; or myocardial infarction in the last 12 months,Condition Occurrence,Procedure,C0010055,cabg,FALSE,FALSE,NA,NA,NA
19,NCT00853957,Exclusion,history of hypertensive encephalopathy ; cerebrovascular accident ; transient ischemic attack ; heart failure ( nyha class ii- ; coronary bypass graft surgery ( cabg ) ; percutaneous coronary intervention ( pci ) ; unstable angina pectoris ; or myocardial infarction in the last 12 months,Condition Occurrence,Procedure,C1532338,percutaneous coronary intervention,FALSE,FALSE,NA,NA,NA
19,NCT00853957,Exclusion,history of hypertensive encephalopathy ; cerebrovascular accident ; transient ischemic attack ; heart failure ( nyha class ii- ; coronary bypass graft surgery ( cabg ) ; percutaneous coronary intervention ( pci ) ; unstable angina pectoris ; or myocardial infarction in the last 12 months,Condition Occurrence,Procedure,C1514496;C1532338,pci,FALSE,FALSE,NA,NA,NA
19,NCT00853957,Exclusion,history of hypertensive encephalopathy ; cerebrovascular accident ; transient ischemic attack ; heart failure ( nyha class ii- ; coronary bypass graft surgery ( cabg ) ; percutaneous coronary intervention ( pci ) ; unstable angina pectoris ; or myocardial infarction in the last 12 months,Condition Occurrence,Other,C0181074;C1705210;C3683798;C1546653,graft,FALSE,FALSE,NA,NA,NA
19,NCT00853957,Exclusion,history of hypertensive encephalopathy ; cerebrovascular accident ; transient ischemic attack ; heart failure ( nyha class ii- ; coronary bypass graft surgery ( cabg ) ; percutaneous coronary intervention ( pci ) ; unstable angina pectoris ; or myocardial infarction in the last 12 months,Condition Occurrence,Other,C0543467;C1457907,surgery,FALSE,FALSE,NA,NA,NA
19,NCT00853957,Exclusion,history of hypertensive encephalopathy ; cerebrovascular accident ; transient ischemic attack ; heart failure ( nyha class ii- ; coronary bypass graft surgery ( cabg ) ; percutaneous coronary intervention ( pci ) ; unstable angina pectoris ; or myocardial infarction in the last 12 months,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,lower_equal 12 last months,NA,NA
20,NCT00853957,Exclusion,other protocol defined inclusiopplied,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00860262,Inclusion,ability to provide written informed consent in accordance with good clinical practice and local legislation,Other,Other,C2986419,good clinical practice,FALSE,FALSE,NA,NA,NA
1,NCT00860262,Inclusion,ability to provide written informed consent in accordance with good clinical practice and local legislation,Other,Other,C0600657,legislation,FALSE,FALSE,NA,NA,NA
2,NCT00860262,Inclusion,age 18 years or older,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 18 years,NA,NA
3,NCT00860262,Inclusion,patients with severe hypertension as defined sbp greater than 180 mmhg and dbp greater than 95 mmhg at randomisation,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00860262,Inclusion,patients with severe hypertension as defined sbp greater than 180 mmhg and dbp greater than 95 mmhg at randomisation,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater 180 mmhg; greater 95 mmhg,NA
3,NCT00860262,Inclusion,patients with severe hypertension as defined sbp greater than 180 mmhg and dbp greater than 95 mmhg at randomisation,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater 95 mmhg,NA
3,NCT00860262,Inclusion,patients with severe hypertension as defined sbp greater than 180 mmhg and dbp greater than 95 mmhg at randomisation,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
3,NCT00860262,Inclusion,patients with severe hypertension as defined sbp greater than 180 mmhg and dbp greater than 95 mmhg at randomisation,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
4,NCT00860262,Inclusion,ability to stop any current antihypertensive therapy without unacceptable risk to the patient ( investigators discretion ),Drug Exposure,Drug,C0723457,stop,FALSE,FALSE,NA,NA,NA
4,NCT00860262,Inclusion,ability to stop any current antihypertensive therapy without unacceptable risk to the patient ( investigators discretion ),Drug Exposure,Procedure,C0585941,antihypertensive therapy,FALSE,FALSE,NA,NA,NA
5,NCT00860262,Exclusion,mean in-clinic seated cuff sbp > / = 200 mmhg or diastolic blood pressure [ dbp ] > / = 95 mmhg,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
5,NCT00860262,Exclusion,mean in-clinic seated cuff sbp > / = 200 mmhg or diastolic blood pressure [ dbp ] > / = 95 mmhg,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 200 mmhg,NA
5,NCT00860262,Exclusion,mean in-clinic seated cuff sbp > / = 200 mmhg or diastolic blood pressure [ dbp ] > / = 95 mmhg,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,NA,NA
5,NCT00860262,Exclusion,mean in-clinic seated cuff sbp > / = 200 mmhg or diastolic blood pressure [ dbp ] > / = 95 mmhg,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 95 mmhg,NA
1,NCT00865020,Inclusion,mean sitting systolic blood pressure > = 140 mmhg and < 180 mmhg,Observation,Condition,C1319893,sitting systolic blood pressure,FALSE,FALSE,NA,greater_equal 140 mmhg; lower 180 mmhg,NA
2,NCT00865020,Inclusion,24 - hr mean ambulatory systolic blood pressure > = 135 mmhg,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater_equal 135 mmhg,NA
2,NCT00865020,Inclusion,24 - hr mean ambulatory systolic blood pressure > = 135 mmhg,Observation,Other,C1561560;C1547135,ambulatory,FALSE,FALSE,NA,equal 24,NA
3,NCT00865020,Exclusion,severe hypertension defined as mean sitting systolic blood pressure > = 180 mmhg or mean sitting diastolic blood pressure > = 110 mmhg,Condition Occurrence,Condition,C1319893,sitting systolic blood pressure,FALSE,FALSE,NA,greater_equal 180 mmhg,NA
3,NCT00865020,Exclusion,severe hypertension defined as mean sitting systolic blood pressure > = 180 mmhg or mean sitting diastolic blood pressure > = 110 mmhg,Condition Occurrence,Condition,C1319894,sitting diastolic blood pressure,FALSE,FALSE,NA,greater_equal 110 mmhg,NA
3,NCT00865020,Exclusion,severe hypertension defined as mean sitting systolic blood pressure > = 180 mmhg or mean sitting diastolic blood pressure > = 110 mmhg,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00865020,Exclusion,severe hypertension defined as mean sitting systolic blood pressure > = 180 mmhg or mean sitting diastolic blood pressure > = 110 mmhg,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
3,NCT00865020,Exclusion,severe hypertension defined as mean sitting systolic blood pressure > = 180 mmhg or mean sitting diastolic blood pressure > = 110 mmhg,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
4,NCT00865020,Exclusion,patients with type 1 diabetes mellitus,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
5,NCT00865020,Exclusion,secondary hypertension of any etiology,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
6,NCT00865020,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00872586,Inclusion,at visit 3 ; mean seated diastolic blood pressure ( sedbp ) > = 95 mmhg and < 110 mmhg ; and mean seated systolic blood pressure ( sesbp ) > = 140 mmhg and < 180 mmhg,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater_equal 95 mmhg; lower 110 mmhg,NA
1,NCT00872586,Inclusion,at visit 3 ; mean seated diastolic blood pressure ( sedbp ) > = 95 mmhg and < 110 mmhg ; and mean seated systolic blood pressure ( sesbp ) > = 140 mmhg and < 180 mmhg,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater_equal 140 mmhg; lower 180 mmhg,NA
2,NCT00872586,Inclusion,at visit 4;mean sedbp > = 90 mmh,Observation,NA,NA,NA,NA,NA,NA,NA,NA
3,NCT00872586,Inclusion,no significant disorder in blood ; kidney ; liver ; cardiovascular system or endocrinology system,Condition Occurrence,Condition,C0545792,kidney liver,FALSE,FALSE,NA,NA,NA
3,NCT00872586,Inclusion,no significant disorder in blood ; kidney ; liver ; cardiovascular system or endocrinology system,Condition Occurrence,Other,C0425560;C3540015;C3540036,cardiovascular system,FALSE,FALSE,NA,NA,NA
4,NCT00872586,Exclusion,patients with known or suspect secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
5,NCT00872586,Exclusion,unstable angina,Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,NA,NA,NA
6,NCT00872586,Exclusion,history of acute myocardial infarct ; or ptca or surgical cardiac procedures 3 months before entry into this study,Procedure,Condition,C0027051,myocardial infarct,FALSE,FALSE,equal 3 months,NA,NA
6,NCT00872586,Exclusion,history of acute myocardial infarct ; or ptca or surgical cardiac procedures 3 months before entry into this study,Procedure,Procedure,C1279986,cardiac procedures,FALSE,FALSE,equal 3 months,NA,NA
6,NCT00872586,Exclusion,history of acute myocardial infarct ; or ptca or surgical cardiac procedures 3 months before entry into this study,Procedure,Procedure,C2936173;C0002997,ptca,FALSE,FALSE,equal 3 months,NA,NA
6,NCT00872586,Exclusion,history of acute myocardial infarct ; or ptca or surgical cardiac procedures 3 months before entry into this study,Procedure,Other,C1547229;C1547295,acute,FALSE,FALSE,NA,NA,NA
6,NCT00872586,Exclusion,history of acute myocardial infarct ; or ptca or surgical cardiac procedures 3 months before entry into this study,Procedure,Other,C1705654,entry,FALSE,FALSE,NA,NA,NA
7,NCT00872586,Exclusion,prior or current congestive heart failure ( nyha grade iii or ; hypertrophic obstructive cardiomyopathy ; valvular disease or rheumatic heart disease,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
7,NCT00872586,Exclusion,prior or current congestive heart failure ( nyha grade iii or ; hypertrophic obstructive cardiomyopathy ; valvular disease or rheumatic heart disease,Condition Occurrence,Condition,C0007194,hypertrophic obstructive cardiomyopathy,FALSE,FALSE,NA,NA,NA
7,NCT00872586,Exclusion,prior or current congestive heart failure ( nyha grade iii or ; hypertrophic obstructive cardiomyopathy ; valvular disease or rheumatic heart disease,Condition Occurrence,Condition,C0035439,rheumatic heart disease,FALSE,FALSE,NA,NA,NA
7,NCT00872586,Exclusion,prior or current congestive heart failure ( nyha grade iii or ; hypertrophic obstructive cardiomyopathy ; valvular disease or rheumatic heart disease,Condition Occurrence,Condition,C3258293,valvular disease,FALSE,FALSE,NA,NA,NA
7,NCT00872586,Exclusion,prior or current congestive heart failure ( nyha grade iii or ; hypertrophic obstructive cardiomyopathy ; valvular disease or rheumatic heart disease,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii,FALSE,FALSE,NA,NA,NA
8,NCT00872586,Exclusion,arrhythmia of clinical significance,Condition Occurrence,Condition,C0003811,arrhythmia,FALSE,FALSE,NA,NA,NA
8,NCT00872586,Exclusion,arrhythmia of clinical significance,Condition Occurrence,Condition,C2826293,clinical significance,FALSE,FALSE,NA,NA,NA
9,NCT00872586,Exclusion,bilateral renal artery stenosis ; isolated renal artery stenosis ; post kidney transplantation,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
9,NCT00872586,Exclusion,bilateral renal artery stenosis ; isolated renal artery stenosis ; post kidney transplantation,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
9,NCT00872586,Exclusion,bilateral renal artery stenosis ; isolated renal artery stenosis ; post kidney transplantation,Condition Occurrence,Procedure,C0022671,kidney transplantation,FALSE,FALSE,NA,NA,NA
10,NCT00872586,Exclusion,acute glomerular nephritis,Condition Occurrence,Condition,C0268731,glomerular,FALSE,FALSE,NA,NA,NA
10,NCT00872586,Exclusion,acute glomerular nephritis,Condition Occurrence,Other,C1547229;C1547295,acute,FALSE,FALSE,NA,NA,NA
10,NCT00872586,Exclusion,acute glomerular nephritis,Condition Occurrence,Condition,C0027697,nephritis,FALSE,FALSE,NA,NA,NA
11,NCT00872586,Exclusion,gout sufferers ; even with the normal serum uric acid at entry,Condition Occurrence,Condition,C0018099,gout,FALSE,FALSE,NA,NA,NA
11,NCT00872586,Exclusion,gout sufferers ; even with the normal serum uric acid at entry,Condition Occurrence,Other,C0455272;C0700634,serum uric acid,FALSE,FALSE,NA,NA,NA
11,NCT00872586,Exclusion,gout sufferers ; even with the normal serum uric acid at entry,Condition Occurrence,Other,C1705654,entry,FALSE,FALSE,NA,NA,NA
12,NCT00872586,Exclusion,retinal hemorrhage / exudate,Condition Occurrence,Condition,C0035317,retinal hemorrhage,FALSE,FALSE,NA,NA,NA
12,NCT00872586,Exclusion,retinal hemorrhage / exudate,Condition Occurrence,Other,C0015388;C1546629,exudate,FALSE,FALSE,NA,NA,NA
13,NCT00872586,Exclusion,type 1 diabetes mellitus,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
14,NCT00872586,Exclusion,uncontrolled type 2 diabetes mellitus,Condition Occurrence,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
15,NCT00872586,Exclusion,hypovolemia,Condition Occurrence,Condition,C0546884,hypovolemia,FALSE,FALSE,NA,NA,NA
16,NCT00872586,Exclusion,patients with autoimmune disease,Condition Occurrence,Condition,C0004364,autoimmune disease,FALSE,FALSE,NA,NA,NA
1,NCT00877929,Inclusion,hypertension defined as a mean in-clinic seated cuff systolic blood pressure > 150 mmhg at visit 3 ( randomisation visit ),Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
1,NCT00877929,Inclusion,hypertension defined as a mean in-clinic seated cuff systolic blood pressure > 150 mmhg at visit 3 ( randomisation visit ),Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00877929,Inclusion,hypertension defined as a mean in-clinic seated cuff systolic blood pressure > 150 mmhg at visit 3 ( randomisation visit ),Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater 150 mmhg,NA
1,NCT00877929,Inclusion,hypertension defined as a mean in-clinic seated cuff systolic blood pressure > 150 mmhg at visit 3 ( randomisation visit ),Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
2,NCT00877929,Inclusion,diagnosis of type 2 diabetes mellitus,Condition Occurrence,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
3,NCT00877929,Inclusion,Err:509,Person,Person,C0001779,age,FALSE,FALSE,equal 18 years,NA,NA
3,NCT00877929,Inclusion,Err:509,Person,Drug,C0723457,stop,FALSE,FALSE,NA,NA,NA
3,NCT00877929,Inclusion,Err:509,Person,Procedure,C0585941,antihypertensive therapy,FALSE,FALSE,NA,NA,NA
4,NCT00877929,Inclusion,ability to provide written informed consent,Other,NA,NA,NA,NA,NA,NA,NA,NA
5,NCT00877929,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to start of run-in period ) who :,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
5,NCT00877929,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to start of run-in period ) who :,Condition Occurrence,Condition,C1096235,pre-menopausal,FALSE,FALSE,NA,NA,NA
5,NCT00877929,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to start of run-in period ) who :,Condition Occurrence,Condition,C0025344;C2129647,menstruation,FALSE,FALSE,lower_equal 1 year,NA,NA
6,NCT00877929,Exclusion,are not surgically sterile,Other,NA,NA,NA,NA,NA,NA,NA,NA
7,NCT00877929,Exclusion,are nursing or pregnant ; or,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
7,NCT00877929,Exclusion,are nursing or pregnant ; or,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
8,NCT00877929,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control or do not plan to continue practising an acceptable method throughout the study .,Observation,Observation,C3831118,child-bearing potential,FALSE,FALSE,NA,NA,NA
8,NCT00877929,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control or do not plan to continue practising an acceptable method throughout the study .,Observation,Other,C0700589;C2703065,birth control,TRUE,FALSE,NA,NA,NA
8,NCT00877929,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control or do not plan to continue practising an acceptable method throughout the study .,Observation,Other,C2827714;C0871511;C2828387,method,FALSE,FALSE,NA,NA,NA
9,NCT00877929,Exclusion,the only acceptable methods of birth control are :,Condition Occurrence,Other,C0025663,methods,FALSE,FALSE,NA,NA,NA
9,NCT00877929,Exclusion,the only acceptable methods of birth control are :,Condition Occurrence,Other,C0700589;C2703065,birth control,FALSE,FALSE,NA,NA,NA
10,NCT00877929,Exclusion,intrauterine device ( iud ) ;,Drug Exposure,Drug,C1706306,iud,FALSE,FALSE,NA,NA,NA
10,NCT00877929,Exclusion,intrauterine device ( iud ) ;,Drug Exposure,Other,C1706306;C1548866;C1546682,intrauterine device,FALSE,FALSE,NA,NA,NA
11,NCT00877929,Exclusion,oral contraceptives ( started at least three months prior to start of run-in period ),Drug Exposure,Other,C0009905;C0274536;C0481121;C1548892,oral contraceptives,FALSE,FALSE,NA,NA,NA
12,NCT00877929,Exclusion,implantable contraceptives or injectable contraceptives and,Drug Exposure,Drug,C0086466;C1272936,injectable,FALSE,FALSE,NA,NA,NA
13,NCT00877929,Exclusion,estrogen patch,Drug Exposure,Drug,C0445403;C1707974;C1533128,patch,FALSE,FALSE,NA,NA,NA
13,NCT00877929,Exclusion,estrogen patch,Drug Exposure,Other,C0014939;C0202006;C2936882,estrogen,FALSE,FALSE,NA,NA,NA
14,NCT00877929,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 m .,Drug Exposure,Condition,C0555008,night shift workers,FALSE,FALSE,NA,NA,NA
14,NCT00877929,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 m .,Drug Exposure,Drug,C1654656,daytime,FALSE,FALSE,NA,equal 4,equal 00 m
14,NCT00877929,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 m .,Drug Exposure,Other,C0037313;C0723362,sleep,FALSE,FALSE,NA,NA,NA
15,NCT00877929,Exclusion,known or suspected secondary hypertension ( eg ; renal artery stenosis ; phaeochromocytoma ),Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
15,NCT00877929,Exclusion,known or suspected secondary hypertension ( eg ; renal artery stenosis ; phaeochromocytoma ),Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
16,NCT00877929,Exclusion,mean seated systolic blood pressure ( sbp ) = 180 mm hg or mean seated diastolic blood pressure ( dbp ) = 110 mm hg during any visit of the screening and placebo run-in periods,Observation,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,NA
16,NCT00877929,Exclusion,mean seated systolic blood pressure ( sbp ) = 180 mm hg or mean seated diastolic blood pressure ( dbp ) = 110 mm hg during any visit of the screening and placebo run-in periods,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,NA,NA
16,NCT00877929,Exclusion,mean seated systolic blood pressure ( sbp ) = 180 mm hg or mean seated diastolic blood pressure ( dbp ) = 110 mm hg during any visit of the screening and placebo run-in periods,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,equal 180 mm hg,NA
16,NCT00877929,Exclusion,mean seated systolic blood pressure ( sbp ) = 180 mm hg or mean seated diastolic blood pressure ( dbp ) = 110 mm hg during any visit of the screening and placebo run-in periods,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,NA,NA
16,NCT00877929,Exclusion,mean seated systolic blood pressure ( sbp ) = 180 mm hg or mean seated diastolic blood pressure ( dbp ) = 110 mm hg during any visit of the screening and placebo run-in periods,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,equal 110 mm hg,NA
17,NCT00877929,Exclusion,patients with type 1 diabetes mellitus,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
18,NCT00877929,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance < 30 ml / min or clinical markers of severe renal impairment,Observation,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
18,NCT00877929,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance < 30 ml / min or clinical markers of severe renal impairment,Observation,Condition,C1565489;C0035078,renal impairment,FALSE,FALSE,NA,NA,NA
18,NCT00877929,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance < 30 ml / min or clinical markers of severe renal impairment,Observation,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
18,NCT00877929,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance < 30 ml / min or clinical markers of severe renal impairment,Observation,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,greater 265 umol/l,greater 3.0 mg/dl
18,NCT00877929,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance < 30 ml / min or clinical markers of severe renal impairment,Observation,Observation,C0373595;C0812399,creatinine clearance,FALSE,FALSE,NA,lower 30 ml/min,NA
18,NCT00877929,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance < 30 ml / min or clinical markers of severe renal impairment,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
18,NCT00877929,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance < 30 ml / min or clinical markers of severe renal impairment,Observation,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
18,NCT00877929,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance < 30 ml / min or clinical markers of severe renal impairment,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
19,NCT00877929,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
19,NCT00877929,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
19,NCT00877929,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
19,NCT00877929,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney,Condition Occurrence,Condition,C0478647,transplant,FALSE,FALSE,NA,NA,NA
19,NCT00877929,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
20,NCT00877929,Exclusion,clinically relevant hypokalaemia or hyperkalaemia,Other,NA,NA,NA,NA,NA,NA,NA,NA
21,NCT00877929,Exclusion,uncorrected sodium or volume depletion,Drug Exposure,Condition,C0546884,volume depletion,FALSE,FALSE,NA,NA,NA
21,NCT00877929,Exclusion,uncorrected sodium or volume depletion,Drug Exposure,Other,C0037473;C0337443;C0037570;C3541959,sodium,FALSE,FALSE,NA,NA,NA
22,NCT00877929,Exclusion,primary aldosteronism,Condition Occurrence,Condition,C1384514,primary aldosteronism,FALSE,FALSE,NA,NA,NA
23,NCT00877929,Exclusion,hereditary fructose intolerance,Condition Occurrence,Condition,C0016751,hereditary fructose intolerance,FALSE,FALSE,NA,NA,NA
24,NCT00877929,Exclusion,biliary obstructive disorders ( eg ; cholestatis ) or hepatic insufficiency,Condition Occurrence,Condition,C1306571,hepatic insufficiency,FALSE,FALSE,NA,NA,NA
25,NCT00877929,Exclusion,congestive heart failure new york heart academy ( nyha ) functional class chf iii-iv ( refer to appendix 10,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
25,NCT00877929,Exclusion,congestive heart failure new york heart academy ( nyha ) functional class chf iii-iv ( refer to appendix 10,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
25,NCT00877929,Exclusion,congestive heart failure new york heart academy ( nyha ) functional class chf iii-iv ( refer to appendix 10,Condition Occurrence,Condition,C0018802,chf,FALSE,FALSE,NA,NA,NA
25,NCT00877929,Exclusion,congestive heart failure new york heart academy ( nyha ) functional class chf iii-iv ( refer to appendix 10,Condition Occurrence,Other,C0456387;C0489477,class,FALSE,FALSE,NA,NA,NA
25,NCT00877929,Exclusion,congestive heart failure new york heart academy ( nyha ) functional class chf iii-iv ( refer to appendix 10,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii,FALSE,FALSE,NA,NA,NA
26,NCT00877929,Exclusion,contraindication to a placebo run-in period ( eg ; stroke with-in the past six months ; myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past three months prior to start of run-in period ),Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,NA,NA,NA
26,NCT00877929,Exclusion,contraindication to a placebo run-in period ( eg ; stroke with-in the past six months ; myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past three months prior to start of run-in period ),Condition Occurrence,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,NA
26,NCT00877929,Exclusion,contraindication to a placebo run-in period ( eg ; stroke with-in the past six months ; myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past three months prior to start of run-in period ),Condition Occurrence,Procedure,C0010055,coronary artery bypass graft,FALSE,FALSE,NA,NA,NA
26,NCT00877929,Exclusion,contraindication to a placebo run-in period ( eg ; stroke with-in the past six months ; myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past three months prior to start of run-in period ),Condition Occurrence,Procedure,C2936173,percutaneous transluminal coronary angioplasty,FALSE,FALSE,NA,NA,NA
26,NCT00877929,Exclusion,contraindication to a placebo run-in period ( eg ; stroke with-in the past six months ; myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past three months prior to start of run-in period ),Condition Occurrence,Procedure,C0018821,cardiac surgery,FALSE,FALSE,NA,NA,NA
26,NCT00877929,Exclusion,contraindication to a placebo run-in period ( eg ; stroke with-in the past six months ; myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past three months prior to start of run-in period ),Condition Occurrence,Other,C1301624;C1547316,contraindication,FALSE,FALSE,NA,NA,NA
26,NCT00877929,Exclusion,contraindication to a placebo run-in period ( eg ; stroke with-in the past six months ; myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past three months prior to start of run-in period ),Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
27,NCT00877929,Exclusion,clinically significant ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0042514;C1963247;C2108113,ventricular tachycardia,FALSE,FALSE,NA,NA,NA
27,NCT00877929,Exclusion,clinically significant ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0004239;C1963068,atrial flutter,FALSE,FALSE,NA,NA,NA
27,NCT00877929,Exclusion,clinically significant ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0003811,cardiac arrhythmias,FALSE,FALSE,NA,NA,NA
27,NCT00877929,Exclusion,clinically significant ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
28,NCT00877929,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0007194,hypertrophic obstructive cardiomyopathy,FALSE,FALSE,NA,NA,NA
28,NCT00877929,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C1956346;C0010068;C0010054,coronary artery disease,FALSE,FALSE,NA,NA,NA
28,NCT00877929,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0003507,aortic stenosis,FALSE,FALSE,NA,NA,NA
28,NCT00877929,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0003501;C1269005,aortic valve,FALSE,FALSE,NA,NA,NA
28,NCT00877929,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0026264;C1269004,mitral valve,FALSE,FALSE,NA,NA,NA
28,NCT00877929,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Observation,C1261287;C0947637;C0009814,stenosis,FALSE,FALSE,NA,NA,NA
28,NCT00877929,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
29,NCT00877929,Exclusion,patients whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > 10 %,Other,Condition,C0011849;C0011847,diabetes,FALSE,FALSE,NA,NA,NA
29,NCT00877929,Exclusion,patients whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > 10 %,Other,Observation,C0202054,hba1c,FALSE,FALSE,NA,NA,greater 10 %
29,NCT00877929,Exclusion,patients whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > 10 %,Other,Other,C1547311,stable,TRUE,FALSE,NA,NA,NA
29,NCT00877929,Exclusion,patients whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > 10 %,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
30,NCT00877929,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with angiotensin converting enzyme ( ace ) inhibitors or angiotensin-ii receptor antagonists,Drug Exposure,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
30,NCT00877929,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with angiotensin converting enzyme ( ace ) inhibitors or angiotensin-ii receptor antagonists,Drug Exposure,Drug,C0003015,ace inhibitors,FALSE,FALSE,NA,NA,NA
30,NCT00877929,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with angiotensin converting enzyme ( ace ) inhibitors or angiotensin-ii receptor antagonists,Drug Exposure,Other,C0022709;C0201888;C2258685,angiotensin converting enzyme,FALSE,FALSE,NA,NA,NA
30,NCT00877929,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with angiotensin converting enzyme ( ace ) inhibitors or angiotensin-ii receptor antagonists,Drug Exposure,Other,C0373546;C0003009,angiotensin-ii,FALSE,FALSE,NA,NA,NA
31,NCT00877929,Exclusion,history of drug or alcohol dependency within six months prior to signing the informed consent form,Condition Occurrence,Condition,C0001973,alcohol dependency,FALSE,FALSE,NA,NA,NA
31,NCT00877929,Exclusion,history of drug or alcohol dependency within six months prior to signing the informed consent form,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
31,NCT00877929,Exclusion,history of drug or alcohol dependency within six months prior to signing the informed consent form,Condition Occurrence,Other,C0009797,informed consent form,FALSE,FALSE,NA,NA,NA
32,NCT00877929,Exclusion,concomitant administration of any medications known to affect blood pressure ; except medications allowed by the protocol,Observation,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
32,NCT00877929,Exclusion,concomitant administration of any medications known to affect blood pressure ; except medications allowed by the protocol,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
33,NCT00877929,Exclusion,any investigational drug therapy within one month of signing the informed consent ; known hypersensitivity to any component of the study drugs ( telmisartan ; amlodipine ; or placebo ),Drug Exposure,Drug,C0013230,investigational drug,FALSE,FALSE,NA,NA,NA
33,NCT00877929,Exclusion,any investigational drug therapy within one month of signing the informed consent ; known hypersensitivity to any component of the study drugs ( telmisartan ; amlodipine ; or placebo ),Drug Exposure,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,NA
33,NCT00877929,Exclusion,any investigational drug therapy within one month of signing the informed consent ; known hypersensitivity to any component of the study drugs ( telmisartan ; amlodipine ; or placebo ),Drug Exposure,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,NA
33,NCT00877929,Exclusion,any investigational drug therapy within one month of signing the informed consent ; known hypersensitivity to any component of the study drugs ( telmisartan ; amlodipine ; or placebo ),Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,NA
33,NCT00877929,Exclusion,any investigational drug therapy within one month of signing the informed consent ; known hypersensitivity to any component of the study drugs ( telmisartan ; amlodipine ; or placebo ),Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
33,NCT00877929,Exclusion,any investigational drug therapy within one month of signing the informed consent ; known hypersensitivity to any component of the study drugs ( telmisartan ; amlodipine ; or placebo ),Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
34,NCT00877929,Exclusion,history of non-compliance or inability to comply with prescribed medications or protocol procedures,Condition Occurrence,Condition,C0376405,non-compliance,FALSE,FALSE,NA,NA,NA
34,NCT00877929,Exclusion,history of non-compliance or inability to comply with prescribed medications or protocol procedures,Condition Occurrence,Observation,C3202967;C3166216,prescribed medications,FALSE,FALSE,NA,NA,NA
35,NCT00877929,Exclusion,any other clinical condition which ; in the opinion of the investigator ; would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine,Drug Exposure,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,NA
35,NCT00877929,Exclusion,any other clinical condition which ; in the opinion of the investigator ; would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine,Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,NA
35,NCT00877929,Exclusion,any other clinical condition which ; in the opinion of the investigator ; would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine,Drug Exposure,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
1,NCT00902304,Inclusion,newly diagnosed or currently treated hypertensive patients who have not attained their blood pressure target and require active pharmacological treatment as recommended by the local guidelines as judged by the general practitioner,Observation,Condition,C0857121,hypertensive,FALSE,FALSE,NA,NA,NA
1,NCT00902304,Inclusion,newly diagnosed or currently treated hypertensive patients who have not attained their blood pressure target and require active pharmacological treatment as recommended by the local guidelines as judged by the general practitioner,Observation,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
1,NCT00902304,Inclusion,newly diagnosed or currently treated hypertensive patients who have not attained their blood pressure target and require active pharmacological treatment as recommended by the local guidelines as judged by the general practitioner,Observation,Procedure,C0013216,pharmacological treatment,FALSE,FALSE,NA,NA,NA
1,NCT00902304,Inclusion,newly diagnosed or currently treated hypertensive patients who have not attained their blood pressure target and require active pharmacological treatment as recommended by the local guidelines as judged by the general practitioner,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,TRUE,FALSE,NA,NA,NA
1,NCT00902304,Inclusion,newly diagnosed or currently treated hypertensive patients who have not attained their blood pressure target and require active pharmacological treatment as recommended by the local guidelines as judged by the general practitioner,Observation,Observation,C2986546,target,TRUE,FALSE,NA,NA,NA
1,NCT00902304,Inclusion,newly diagnosed or currently treated hypertensive patients who have not attained their blood pressure target and require active pharmacological treatment as recommended by the local guidelines as judged by the general practitioner,Observation,Other,C0162791;C0220845,guidelines,FALSE,FALSE,NA,NA,NA
2,NCT00902304,Exclusion,significantly elevated blood pressure ( severe hypertension ),Condition Occurrence,Condition,C0497247,elevated blood pressure,FALSE,FALSE,NA,NA,NA
2,NCT00902304,Exclusion,significantly elevated blood pressure ( severe hypertension ),Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00902304,Exclusion,significantly elevated blood pressure ( severe hypertension ),Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
3,NCT00902304,Exclusion,requiring 3 or more antihypertensive drugs,Drug Exposure,Drug,C0003364,antihypertensive drugs,FALSE,FALSE,NA,greater_equal 3,NA
4,NCT00902304,Exclusion,severe kidney disease or dialyses,Condition Occurrence,Condition,C0022658,kidney disease,FALSE,FALSE,NA,NA,NA
4,NCT00902304,Exclusion,severe kidney disease or dialyses,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
5,NCT00902304,Exclusion,clinical diagnosis requiring concomitant therapy with antihypertensive treatment that would be outside the therapies allowed under study protocol,Other,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
5,NCT00902304,Exclusion,clinical diagnosis requiring concomitant therapy with antihypertensive treatment that would be outside the therapies allowed under study protocol,Other,Procedure,C1707479,concomitant therapy,FALSE,FALSE,NA,NA,NA
5,NCT00902304,Exclusion,clinical diagnosis requiring concomitant therapy with antihypertensive treatment that would be outside the therapies allowed under study protocol,Other,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
5,NCT00902304,Exclusion,clinical diagnosis requiring concomitant therapy with antihypertensive treatment that would be outside the therapies allowed under study protocol,Other,Other,C2348563;C1507394,study protocol,FALSE,FALSE,NA,NA,NA
6,NCT00902304,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00926289,Inclusion,ability to provide written informed consent in accordance with good clinical practice and local legislation ;,Other,Other,C2986419,good clinical practice,FALSE,FALSE,NA,NA,NA
1,NCT00926289,Inclusion,ability to provide written informed consent in accordance with good clinical practice and local legislation ;,Other,Other,C0600657,legislation,FALSE,FALSE,NA,NA,NA
2,NCT00926289,Inclusion,age 18 years or older ;,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 18 years,NA,NA
3,NCT00926289,Inclusion,patients with grade 2 or grade 3 hypertension as defined sbp > = 160 mmhg and dbp > = 100 mmhg at randomization,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00926289,Inclusion,patients with grade 2 or grade 3 hypertension as defined sbp > = 160 mmhg and dbp > = 100 mmhg at randomization,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 160 mmhg; greater_equal 100 mmhg,NA
3,NCT00926289,Inclusion,patients with grade 2 or grade 3 hypertension as defined sbp > = 160 mmhg and dbp > = 100 mmhg at randomization,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 100 mmhg,NA
3,NCT00926289,Inclusion,patients with grade 2 or grade 3 hypertension as defined sbp > = 160 mmhg and dbp > = 100 mmhg at randomization,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
4,NCT00926289,Inclusion,ability to stop any current antihypertensive therapy without unacceptable risk to the patient ( investigator discretion ),Drug Exposure,Drug,C0723457,stop,FALSE,FALSE,NA,NA,NA
4,NCT00926289,Inclusion,ability to stop any current antihypertensive therapy without unacceptable risk to the patient ( investigator discretion ),Drug Exposure,Procedure,C0585941,antihypertensive therapy,FALSE,FALSE,NA,NA,NA
5,NCT00926289,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to signing informed consent ) who,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
5,NCT00926289,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to signing informed consent ) who,Condition Occurrence,Condition,C1096235,pre-menopausal,FALSE,FALSE,NA,NA,NA
5,NCT00926289,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to signing informed consent ) who,Condition Occurrence,Condition,C0025344;C2129647,menstruation,FALSE,FALSE,lower_equal 1 year,NA,NA
6,NCT00926289,Exclusion,are not surgically sterile,Other,NA,NA,NA,NA,NA,NA,NA,NA
7,NCT00926289,Exclusion,or b ) are nursing ; or c ) are pregnant ; or d ) are of childbearing potential and are not practicing acceptable methods of birth control ; or do not plan to continue practicing an acceptable method throughout the trial,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
7,NCT00926289,Exclusion,or b ) are nursing ; or c ) are pregnant ; or d ) are of childbearing potential and are not practicing acceptable methods of birth control ; or do not plan to continue practicing an acceptable method throughout the trial,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
7,NCT00926289,Exclusion,or b ) are nursing ; or c ) are pregnant ; or d ) are of childbearing potential and are not practicing acceptable methods of birth control ; or do not plan to continue practicing an acceptable method throughout the trial,Condition Occurrence,Observation,C3831118,childbearing potential,FALSE,FALSE,NA,NA,NA
7,NCT00926289,Exclusion,or b ) are nursing ; or c ) are pregnant ; or d ) are of childbearing potential and are not practicing acceptable methods of birth control ; or do not plan to continue practicing an acceptable method throughout the trial,Condition Occurrence,Other,C0025663,methods,TRUE,FALSE,NA,NA,NA
7,NCT00926289,Exclusion,or b ) are nursing ; or c ) are pregnant ; or d ) are of childbearing potential and are not practicing acceptable methods of birth control ; or do not plan to continue practicing an acceptable method throughout the trial,Condition Occurrence,Other,C0700589;C2703065,birth control,TRUE,FALSE,NA,NA,NA
7,NCT00926289,Exclusion,or b ) are nursing ; or c ) are pregnant ; or d ) are of childbearing potential and are not practicing acceptable methods of birth control ; or do not plan to continue practicing an acceptable method throughout the trial,Condition Occurrence,Other,C2827714;C0871511;C2828387,method,FALSE,FALSE,NA,NA,NA
8,NCT00926289,Exclusion,the only acceptable methods of birth control are : intra-uterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives ; estrogen patch hormonal birth control should have been in use for at least three months before the study and continue at least until the next menstrual period after completing the study .,Drug Exposure,Condition,C2129647;C0025344,menstrual period,FALSE,FALSE,NA,NA,NA
8,NCT00926289,Exclusion,the only acceptable methods of birth control are : intra-uterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives ; estrogen patch hormonal birth control should have been in use for at least three months before the study and continue at least until the next menstrual period after completing the study .,Drug Exposure,Drug,C1706306,iud,FALSE,FALSE,NA,NA,NA
8,NCT00926289,Exclusion,the only acceptable methods of birth control are : intra-uterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives ; estrogen patch hormonal birth control should have been in use for at least three months before the study and continue at least until the next menstrual period after completing the study .,Drug Exposure,Drug,C0086466;C1272936,injectable,FALSE,FALSE,NA,NA,NA
8,NCT00926289,Exclusion,the only acceptable methods of birth control are : intra-uterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives ; estrogen patch hormonal birth control should have been in use for at least three months before the study and continue at least until the next menstrual period after completing the study .,Drug Exposure,Drug,C0445403;C1707974;C1533128,patch,FALSE,FALSE,NA,NA,NA
8,NCT00926289,Exclusion,the only acceptable methods of birth control are : intra-uterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives ; estrogen patch hormonal birth control should have been in use for at least three months before the study and continue at least until the next menstrual period after completing the study .,Drug Exposure,Other,C0025663,methods,FALSE,FALSE,NA,NA,NA
8,NCT00926289,Exclusion,the only acceptable methods of birth control are : intra-uterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives ; estrogen patch hormonal birth control should have been in use for at least three months before the study and continue at least until the next menstrual period after completing the study .,Drug Exposure,Other,C0700589;C2703065,birth control,FALSE,FALSE,NA,NA,NA
8,NCT00926289,Exclusion,the only acceptable methods of birth control are : intra-uterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives ; estrogen patch hormonal birth control should have been in use for at least three months before the study and continue at least until the next menstrual period after completing the study .,Drug Exposure,Other,C0009905;C0274536;C0481121;C1548892,oral contraceptives,FALSE,FALSE,NA,NA,NA
8,NCT00926289,Exclusion,the only acceptable methods of birth control are : intra-uterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives ; estrogen patch hormonal birth control should have been in use for at least three months before the study and continue at least until the next menstrual period after completing the study .,Drug Exposure,Other,C0014939;C0202006;C2936882,estrogen,FALSE,FALSE,NA,NA,NA
8,NCT00926289,Exclusion,the only acceptable methods of birth control are : intra-uterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives ; estrogen patch hormonal birth control should have been in use for at least three months before the study and continue at least until the next menstrual period after completing the study .,Drug Exposure,Other,C0700589;C2703065,birth control,FALSE,FALSE,NA,NA,NA
9,NCT00926289,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 m .,Drug Exposure,Condition,C0555008,night shift workers,FALSE,FALSE,NA,NA,NA
9,NCT00926289,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 m .,Drug Exposure,Drug,C1654656,daytime,FALSE,FALSE,NA,equal 4,equal 00 m
9,NCT00926289,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 m .,Drug Exposure,Other,C0037313;C0723362,sleep,FALSE,FALSE,NA,NA,NA
10,NCT00926289,Exclusion,known or suspected secondary hypertension ( eg ; renal artery stenosis orphaeochromocytoma ),Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
10,NCT00926289,Exclusion,known or suspected secondary hypertension ( eg ; renal artery stenosis orphaeochromocytoma ),Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
11,NCT00926289,Exclusion,mean in-clinic seated cuff sbp > = 200 mmhg or dbp > = 120 mmhg,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
11,NCT00926289,Exclusion,mean in-clinic seated cuff sbp > = 200 mmhg or dbp > = 120 mmhg,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 200 mmhg; greater_equal 120 mmhg,NA
11,NCT00926289,Exclusion,mean in-clinic seated cuff sbp > = 200 mmhg or dbp > = 120 mmhg,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 120 mmhg,NA
12,NCT00926289,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance of < 30 ml / min or clinical markers of severe renal impairment .,Observation,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
12,NCT00926289,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance of < 30 ml / min or clinical markers of severe renal impairment .,Observation,Condition,C1565489;C0035078,renal impairment,FALSE,FALSE,NA,NA,NA
12,NCT00926289,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance of < 30 ml / min or clinical markers of severe renal impairment .,Observation,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
12,NCT00926289,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance of < 30 ml / min or clinical markers of severe renal impairment .,Observation,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,greater 265 umol/l,greater 3.0 mg/dl
12,NCT00926289,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance of < 30 ml / min or clinical markers of severe renal impairment .,Observation,Observation,C0373595;C0812399,creatinine clearance,FALSE,FALSE,NA,lower 30 ml/min,NA
12,NCT00926289,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance of < 30 ml / min or clinical markers of severe renal impairment .,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
12,NCT00926289,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance of < 30 ml / min or clinical markers of severe renal impairment .,Observation,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
12,NCT00926289,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance of < 30 ml / min or clinical markers of severe renal impairment .,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
13,NCT00926289,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
13,NCT00926289,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
13,NCT00926289,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
13,NCT00926289,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney,Condition Occurrence,Condition,C0478647,transplant,FALSE,FALSE,NA,NA,NA
13,NCT00926289,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
14,NCT00926289,Exclusion,clinically relevant hypokalemia or hyperkalemia ( ie ; < 3.5 mmol / l or > 5.5 mmol / l ; may be rechecked for suspected error in result ),Observation,Condition,C0020621,hypokalemia,FALSE,FALSE,NA,lower 3.5 mmol/l; greater 5.5 mmol/l,NA
14,NCT00926289,Exclusion,clinically relevant hypokalemia or hyperkalemia ( ie ; < 3.5 mmol / l or > 5.5 mmol / l ; may be rechecked for suspected error in result ),Observation,Condition,C0020461,hyperkalemia,FALSE,FALSE,NA,lower 3.5 mmol/l; greater 5.5 mmol/l,NA
15,NCT00926289,Exclusion,uncorrected sodium or volume depletion,Drug Exposure,Condition,C0546884,volume depletion,FALSE,FALSE,NA,NA,NA
17,NCT00926289,Exclusion,hereditary fructose intolerance,Condition Occurrence,Condition,C0016751,hereditary fructose intolerance,FALSE,FALSE,NA,NA,NA
18,NCT00926289,Exclusion,biliary obstructive disorders ( eg ; cholestasis ) or hepatic insufficiency,Condition Occurrence,Condition,C0008370,cholestasis,FALSE,FALSE,NA,NA,NA
18,NCT00926289,Exclusion,biliary obstructive disorders ( eg ; cholestasis ) or hepatic insufficiency,Condition Occurrence,Condition,C1306571,hepatic insufficiency,FALSE,FALSE,NA,NA,NA
19,NCT00926289,Exclusion,congestive heart failure new york heart association functional class congestive heart failure iii-iv ( refer to appendix 10,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
19,NCT00926289,Exclusion,congestive heart failure new york heart association functional class congestive heart failure iii-iv ( refer to appendix 10,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
19,NCT00926289,Exclusion,congestive heart failure new york heart association functional class congestive heart failure iii-iv ( refer to appendix 10,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
19,NCT00926289,Exclusion,congestive heart failure new york heart association functional class congestive heart failure iii-iv ( refer to appendix 10,Condition Occurrence,Other,C0456387;C0489477,class,FALSE,FALSE,NA,NA,NA
19,NCT00926289,Exclusion,congestive heart failure new york heart association functional class congestive heart failure iii-iv ( refer to appendix 10,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii,FALSE,FALSE,NA,NA,NA
20,NCT00926289,Exclusion,contra-indication to a placebo run-in period ( eg ; stroke with-in the past 6 months ; myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past 3 months prior to start of run in period ),Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,lower 3 past months,NA,NA
20,NCT00926289,Exclusion,contra-indication to a placebo run-in period ( eg ; stroke with-in the past 6 months ; myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past 3 months prior to start of run in period ),Condition Occurrence,Drug,C1696465,placebo,FALSE,FALSE,equal 6 past months,NA,NA
20,NCT00926289,Exclusion,contra-indication to a placebo run-in period ( eg ; stroke with-in the past 6 months ; myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past 3 months prior to start of run in period ),Condition Occurrence,Procedure,C0010055,coronary artery bypass graft,FALSE,FALSE,lower 3 past months,NA,NA
20,NCT00926289,Exclusion,contra-indication to a placebo run-in period ( eg ; stroke with-in the past 6 months ; myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past 3 months prior to start of run in period ),Condition Occurrence,Procedure,C2936173,percutaneous transluminal coronary angioplasty,FALSE,FALSE,lower 3 past months,NA,NA
20,NCT00926289,Exclusion,contra-indication to a placebo run-in period ( eg ; stroke with-in the past 6 months ; myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past 3 months prior to start of run in period ),Condition Occurrence,Procedure,C0018821,cardiac surgery,FALSE,FALSE,lower 3 past months,NA,NA
20,NCT00926289,Exclusion,contra-indication to a placebo run-in period ( eg ; stroke with-in the past 6 months ; myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past 3 months prior to start of run in period ),Condition Occurrence,Other,C1301624;C1547316,contra-indication,FALSE,FALSE,NA,NA,NA
20,NCT00926289,Exclusion,contra-indication to a placebo run-in period ( eg ; stroke with-in the past 6 months ; myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past 3 months prior to start of run in period ),Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,lower 3 past months,NA,NA
21,NCT00926289,Exclusion,clinically significant ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0042514;C1963247;C2108113,ventricular tachycardia,FALSE,FALSE,NA,NA,NA
21,NCT00926289,Exclusion,clinically significant ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0004239;C1963068,atrial flutter,FALSE,FALSE,NA,NA,NA
21,NCT00926289,Exclusion,clinically significant ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0003811,cardiac arrhythmias,FALSE,FALSE,NA,NA,NA
21,NCT00926289,Exclusion,clinically significant ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
22,NCT00926289,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0007194,hypertrophic obstructive cardiomyopathy,FALSE,FALSE,NA,NA,NA
22,NCT00926289,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C1956346;C0010068;C0010054,coronary artery disease,FALSE,FALSE,NA,NA,NA
22,NCT00926289,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0003507,aortic stenosis,FALSE,FALSE,NA,NA,NA
22,NCT00926289,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0003501;C1269005,aortic valve,FALSE,FALSE,NA,NA,NA
22,NCT00926289,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0026264;C1269004,mitral valve,FALSE,FALSE,NA,NA,NA
22,NCT00926289,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Observation,C1261287;C0947637;C0009814,stenosis,FALSE,FALSE,NA,NA,NA
22,NCT00926289,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
23,NCT00926289,Exclusion,patients whose diabetes has not been stable and controlled for at least the past 3 months as defined by an glycosylated hemoglobin > = 10 %,Other,Condition,C0011849;C0011847,diabetes,FALSE,FALSE,NA,NA,NA
23,NCT00926289,Exclusion,patients whose diabetes has not been stable and controlled for at least the past 3 months as defined by an glycosylated hemoglobin > = 10 %,Other,Observation,C0017853;C0373638;C0202054,glycosylated hemoglobin,FALSE,FALSE,NA,NA,greater_equal 10 %
23,NCT00926289,Exclusion,patients whose diabetes has not been stable and controlled for at least the past 3 months as defined by an glycosylated hemoglobin > = 10 %,Other,Other,C1547311,stable,TRUE,FALSE,greater_equal 3 past months,NA,NA
23,NCT00926289,Exclusion,patients whose diabetes has not been stable and controlled for at least the past 3 months as defined by an glycosylated hemoglobin > = 10 %,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
24,NCT00926289,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or angiotensin-ii receptor antagonists,Drug Exposure,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
24,NCT00926289,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or angiotensin-ii receptor antagonists,Drug Exposure,Drug,C0003015,ace inhibitors,FALSE,FALSE,NA,NA,NA
24,NCT00926289,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or angiotensin-ii receptor antagonists,Drug Exposure,Other,C0373546;C0003009,angiotensin-ii,FALSE,FALSE,NA,NA,NA
25,NCT00926289,Exclusion,history of drug or alcohol dependency within 6 months prior to signing the informed consent form,Condition Occurrence,Condition,C0001973,alcohol dependency,FALSE,FALSE,lower 6 months,NA,NA
25,NCT00926289,Exclusion,history of drug or alcohol dependency within 6 months prior to signing the informed consent form,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,lower 6 months,NA,NA
25,NCT00926289,Exclusion,history of drug or alcohol dependency within 6 months prior to signing the informed consent form,Condition Occurrence,Other,C0009797,informed consent form,FALSE,FALSE,NA,NA,NA
26,NCT00926289,Exclusion,concomitant administration of any medications known to affect blood pressure ; except medications allowed by the protocol,Observation,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
26,NCT00926289,Exclusion,concomitant administration of any medications known to affect blood pressure ; except medications allowed by the protocol,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
27,NCT00926289,Exclusion,any investigational drug therapy within 1 month of signing the informed consent,Drug Exposure,Drug,C0013230,investigational drug,FALSE,FALSE,lower 1 month,NA,NA
28,NCT00926289,Exclusion,known hypersensitivity to any component of the trial drugs ( telmisartan ; hydrochlorothiazide ; or placebo ) ; history of non-compliance or inability to comply with prescribed medications or protocol procedures ( less than 80 % or more than 120 % ; especially during run-in ),Drug Exposure,Condition,C0376405,non-compliance,FALSE,FALSE,NA,NA,NA
28,NCT00926289,Exclusion,known hypersensitivity to any component of the trial drugs ( telmisartan ; hydrochlorothiazide ; or placebo ) ; history of non-compliance or inability to comply with prescribed medications or protocol procedures ( less than 80 % or more than 120 % ; especially during run-in ),Drug Exposure,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,NA
28,NCT00926289,Exclusion,known hypersensitivity to any component of the trial drugs ( telmisartan ; hydrochlorothiazide ; or placebo ) ; history of non-compliance or inability to comply with prescribed medications or protocol procedures ( less than 80 % or more than 120 % ; especially during run-in ),Drug Exposure,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,NA
28,NCT00926289,Exclusion,known hypersensitivity to any component of the trial drugs ( telmisartan ; hydrochlorothiazide ; or placebo ) ; history of non-compliance or inability to comply with prescribed medications or protocol procedures ( less than 80 % or more than 120 % ; especially during run-in ),Drug Exposure,Drug,C0020261,hydrochlorothiazide,FALSE,FALSE,NA,NA,NA
28,NCT00926289,Exclusion,known hypersensitivity to any component of the trial drugs ( telmisartan ; hydrochlorothiazide ; or placebo ) ; history of non-compliance or inability to comply with prescribed medications or protocol procedures ( less than 80 % or more than 120 % ; especially during run-in ),Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
28,NCT00926289,Exclusion,known hypersensitivity to any component of the trial drugs ( telmisartan ; hydrochlorothiazide ; or placebo ) ; history of non-compliance or inability to comply with prescribed medications or protocol procedures ( less than 80 % or more than 120 % ; especially during run-in ),Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
28,NCT00926289,Exclusion,known hypersensitivity to any component of the trial drugs ( telmisartan ; hydrochlorothiazide ; or placebo ) ; history of non-compliance or inability to comply with prescribed medications or protocol procedures ( less than 80 % or more than 120 % ; especially during run-in ),Drug Exposure,Observation,C3202967;C3166216,prescribed medications,FALSE,FALSE,NA,NA,lower 80 %; greater 120 %
29,NCT00926289,Exclusion,any other clinical condition which ; in the opinion of the investigator ; would not allow safe completion of the protocol and safe administration of the trial medication,Other,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
15,NCT00926289,Exclusion,uncorrected sodium or volume depletion,Drug Exposure,Other,C0037473;C0337443;C0037570;C3541959,sodium,FALSE,FALSE,NA,NA,NA
16,NCT00926289,Exclusion,primary aldosteronism .,Condition Occurrence,Condition,C1384514,primary aldosteronism,FALSE,FALSE,NA,NA,NA
1,NCT00927394,Inclusion,patients who are eligible and able to participate in the study ; and who give written informed consent before any assessment is performed .,Procedure,Other,C0542573;C0549068;C0870300;C0549070;C0549071;C0549072;C0549073;C0549074;C0028708;C0549075;C0549076;C0549077;C0549078;C0549079;C0549080;C0679207,assessment,FALSE,FALSE,NA,NA,NA
2,NCT00927394,Inclusion,men or women 18 years and older .,Person,Person,C0025266,men,FALSE,FALSE,greater_equal 18 years,NA,NA
2,NCT00927394,Inclusion,men or women 18 years and older .,Person,Person,C0086287,women,FALSE,FALSE,greater_equal 18 years,NA,NA
3,NCT00927394,Inclusion,patients with type 2 diabetes mellitus with an hba1c < = 9 % at visit 1 and on a stable anti-diabetic regimen not including insulin or stable diet and exercise for at least 4 weeks prior to visit 1 .,Procedure,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
3,NCT00927394,Inclusion,patients with type 2 diabetes mellitus with an hba1c < = 9 % at visit 1 and on a stable anti-diabetic regimen not including insulin or stable diet and exercise for at least 4 weeks prior to visit 1 .,Procedure,Drug,C0935929,anti-diabetic,FALSE,FALSE,NA,NA,NA
3,NCT00927394,Inclusion,patients with type 2 diabetes mellitus with an hba1c < = 9 % at visit 1 and on a stable anti-diabetic regimen not including insulin or stable diet and exercise for at least 4 weeks prior to visit 1 .,Procedure,Procedure,C0040808,regimen,FALSE,FALSE,NA,NA,NA
3,NCT00927394,Inclusion,patients with type 2 diabetes mellitus with an hba1c < = 9 % at visit 1 and on a stable anti-diabetic regimen not including insulin or stable diet and exercise for at least 4 weeks prior to visit 1 .,Procedure,Procedure,C1522704,exercise,FALSE,FALSE,greater_equal 4 weeks,NA,NA
3,NCT00927394,Inclusion,patients with type 2 diabetes mellitus with an hba1c < = 9 % at visit 1 and on a stable anti-diabetic regimen not including insulin or stable diet and exercise for at least 4 weeks prior to visit 1 .,Procedure,Observation,C0202054,hba1c,FALSE,FALSE,NA,NA,lower_equal 9 %
3,NCT00927394,Inclusion,patients with type 2 diabetes mellitus with an hba1c < = 9 % at visit 1 and on a stable anti-diabetic regimen not including insulin or stable diet and exercise for at least 4 weeks prior to visit 1 .,Procedure,Observation,C0021641;C0202098;C1533581;C1145751;C1579433;C2739803,insulin,TRUE,FALSE,NA,NA,NA
3,NCT00927394,Inclusion,patients with type 2 diabetes mellitus with an hba1c < = 9 % at visit 1 and on a stable anti-diabetic regimen not including insulin or stable diet and exercise for at least 4 weeks prior to visit 1 .,Procedure,Other,C1547311,stable,FALSE,FALSE,NA,NA,NA
3,NCT00927394,Inclusion,patients with type 2 diabetes mellitus with an hba1c < = 9 % at visit 1 and on a stable anti-diabetic regimen not including insulin or stable diet and exercise for at least 4 weeks prior to visit 1 .,Procedure,Other,C1547311,stable,TRUE,FALSE,NA,NA,NA
3,NCT00927394,Inclusion,patients with type 2 diabetes mellitus with an hba1c < = 9 % at visit 1 and on a stable anti-diabetic regimen not including insulin or stable diet and exercise for at least 4 weeks prior to visit 1 .,Procedure,Other,C0012159;C1519433;C1561465;C1550559;C1549512,diet,TRUE,FALSE,greater_equal 4 weeks,NA,NA
4,NCT00927394,Inclusion,cohort 1 :,Person,Person,C0599755,cohort,FALSE,FALSE,NA,NA,NA
5,NCT00927394,Inclusion,patients with stage 2 systolic hypertension ; defined as having a mssbp > = 160 mmhg and < 200 mmhg at visit 5 ( randomization ) .,Observation,Condition,C0221155,systolic hypertension,FALSE,FALSE,NA,greater_equal 160 mmhg; lower 200 mmhg,NA
5,NCT00927394,Inclusion,patients with stage 2 systolic hypertension ; defined as having a mssbp > = 160 mmhg and < 200 mmhg at visit 5 ( randomization ) .,Observation,Other,C3539106,defined,FALSE,FALSE,NA,greater_equal 160 mmhg; lower 200 mmhg,NA
6,NCT00927394,Inclusion,patients who have been newly diagnosed with hypertension or who have not received antihypertensive medication for at least 4 weeks ( 28 days ) prior to visit 1 must have mssbp > = 160 mmhg and < 200 mmhg at visit 1 ; otherwise ; they will be considered screen failures .,Observation,Drug,C0003364,antihypertensive,TRUE,FALSE,greater_equal 4 weeks,greater_equal 160 mmhg; lower 200 mmhg,NA
6,NCT00927394,Inclusion,patients who have been newly diagnosed with hypertension or who have not received antihypertensive medication for at least 4 weeks ( 28 days ) prior to visit 1 must have mssbp > = 160 mmhg and < 200 mmhg at visit 1 ; otherwise ; they will be considered screen failures .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
6,NCT00927394,Inclusion,patients who have been newly diagnosed with hypertension or who have not received antihypertensive medication for at least 4 weeks ( 28 days ) prior to visit 1 must have mssbp > = 160 mmhg and < 200 mmhg at visit 1 ; otherwise ; they will be considered screen failures .,Observation,Observation,C0430054;C0199230,screen,FALSE,FALSE,NA,NA,NA
7,NCT00927394,Inclusion,patients receiving antihypertensive medication must have a mssbp of > = 150 mmhg and < 200 mmhg at study visit 1 ; otherwise they will be considered screen failures .,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,greater_equal 150 mmhg; lower 200 mmhg,NA
7,NCT00927394,Inclusion,patients receiving antihypertensive medication must have a mssbp of > = 150 mmhg and < 200 mmhg at study visit 1 ; otherwise they will be considered screen failures .,Observation,Observation,C0430054;C0199230,screen,FALSE,FALSE,NA,NA,NA
8,NCT00927394,Inclusion,cohort 2 :,Person,Person,C0599755,cohort,FALSE,FALSE,NA,NA,NA
9,NCT00927394,Inclusion,patients must also have had a mean 8 - hour daytime ambulatory systolic blood pressure ( asbp ) > = 140 mmhg and mean 8 - hour daytime ambulatory diastolic blood pressure ( adbp ) > = 90 mmhg at visit 5 ( randomization ) .,Observation,Drug,C1654656,daytime,FALSE,FALSE,equal 8 hour,NA,NA
9,NCT00927394,Inclusion,patients must also have had a mean 8 - hour daytime ambulatory systolic blood pressure ( asbp ) > = 140 mmhg and mean 8 - hour daytime ambulatory diastolic blood pressure ( adbp ) > = 90 mmhg at visit 5 ( randomization ) .,Observation,Drug,C1654656,daytime,FALSE,FALSE,equal 8 hour,NA,NA
9,NCT00927394,Inclusion,patients must also have had a mean 8 - hour daytime ambulatory systolic blood pressure ( asbp ) > = 140 mmhg and mean 8 - hour daytime ambulatory diastolic blood pressure ( adbp ) > = 90 mmhg at visit 5 ( randomization ) .,Observation,Drug,C0168370,adbp,FALSE,FALSE,NA,greater_equal 90 mmhg,NA
9,NCT00927394,Inclusion,patients must also have had a mean 8 - hour daytime ambulatory systolic blood pressure ( asbp ) > = 140 mmhg and mean 8 - hour daytime ambulatory diastolic blood pressure ( adbp ) > = 90 mmhg at visit 5 ( randomization ) .,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater_equal 140 mmhg,NA
9,NCT00927394,Inclusion,patients must also have had a mean 8 - hour daytime ambulatory systolic blood pressure ( asbp ) > = 140 mmhg and mean 8 - hour daytime ambulatory diastolic blood pressure ( adbp ) > = 90 mmhg at visit 5 ( randomization ) .,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,NA,NA
9,NCT00927394,Inclusion,patients must also have had a mean 8 - hour daytime ambulatory systolic blood pressure ( asbp ) > = 140 mmhg and mean 8 - hour daytime ambulatory diastolic blood pressure ( adbp ) > = 90 mmhg at visit 5 ( randomization ) .,Observation,Other,C1561560;C1547135,ambulatory,FALSE,FALSE,NA,NA,NA
9,NCT00927394,Inclusion,patients must also have had a mean 8 - hour daytime ambulatory systolic blood pressure ( asbp ) > = 140 mmhg and mean 8 - hour daytime ambulatory diastolic blood pressure ( adbp ) > = 90 mmhg at visit 5 ( randomization ) .,Observation,Other,C1561560;C1547135,ambulatory,FALSE,FALSE,NA,NA,NA
10,NCT00927394,Inclusion,hypertensive patients with mssbp > = 150 mmhg and but < 200 mmhg and msdbp > = 95 but < 120 mmhg at visit 5 ( randomization ) .,Observation,Condition,C0857121,hypertensive,FALSE,FALSE,NA,greater_equal 150 mmhg; lower 200 mmhg; greater_equal 95 ; lower 120 mmhg,NA
11,NCT00927394,Inclusion,patients who had been newly diagnosed with hypertension or who had not received antihypertensive medication for at least 4 weeks ( 28 days ) prior to visit 1 must have had mssbp > = 150 mmhg but < 200 mmhg and msdbp > = 95 but < 120 mmhg at visit 1 ; otherwise ; they were considered screen failures .,Observation,Drug,C0003364,antihypertensive,TRUE,FALSE,greater_equal 4 weeks,greater_equal 150 mmhg; lower 200 mmhg; greater_equal 95 ; lower 120 mmhg,NA
11,NCT00927394,Inclusion,patients who had been newly diagnosed with hypertension or who had not received antihypertensive medication for at least 4 weeks ( 28 days ) prior to visit 1 must have had mssbp > = 150 mmhg but < 200 mmhg and msdbp > = 95 but < 120 mmhg at visit 1 ; otherwise ; they were considered screen failures .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
11,NCT00927394,Inclusion,patients who had been newly diagnosed with hypertension or who had not received antihypertensive medication for at least 4 weeks ( 28 days ) prior to visit 1 must have had mssbp > = 150 mmhg but < 200 mmhg and msdbp > = 95 but < 120 mmhg at visit 1 ; otherwise ; they were considered screen failures .,Observation,Observation,C0430054;C0199230,screen,FALSE,FALSE,NA,NA,NA
12,NCT00927394,Exclusion,office blood pressure measured by cuff ( mssbp > = 200 mmhg or msdbp > = 120 mmhg ) .,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,greater_equal 200 mmhg; greater_equal 120 mmhg,NA
12,NCT00927394,Exclusion,office blood pressure measured by cuff ( mssbp > = 200 mmhg or msdbp > = 120 mmhg ) .,Observation,Procedure,C2224281;C1314130,blood pressure measured,FALSE,FALSE,NA,NA,NA
13,NCT00927394,Exclusion,history or evidence of secondary hypertension of any etiology .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
14,NCT00927394,Exclusion,refractory hypertension ; defined as having uncontrolled bp ( > = 140 / 90 mmhg ) while receiving 3 antihypertensive medications at the maximum approved dose of each drug ; one of which must be a diuretic .,Observation,Condition,C0860493,refractory hypertension,FALSE,FALSE,NA,NA,NA
14,NCT00927394,Exclusion,refractory hypertension ; defined as having uncontrolled bp ( > = 140 / 90 mmhg ) while receiving 3 antihypertensive medications at the maximum approved dose of each drug ; one of which must be a diuretic .,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,equal 3,NA
14,NCT00927394,Exclusion,refractory hypertension ; defined as having uncontrolled bp ( > = 140 / 90 mmhg ) while receiving 3 antihypertensive medications at the maximum approved dose of each drug ; one of which must be a diuretic .,Observation,Drug,C0012798,diuretic,FALSE,FALSE,NA,NA,NA
14,NCT00927394,Exclusion,refractory hypertension ; defined as having uncontrolled bp ( > = 140 / 90 mmhg ) while receiving 3 antihypertensive medications at the maximum approved dose of each drug ; one of which must be a diuretic .,Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,greater_equal 140 mmhg; greater_equal 90 mmhg,NA
14,NCT00927394,Exclusion,refractory hypertension ; defined as having uncontrolled bp ( > = 140 / 90 mmhg ) while receiving 3 antihypertensive medications at the maximum approved dose of each drug ; one of which must be a diuretic .,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
14,NCT00927394,Exclusion,refractory hypertension ; defined as having uncontrolled bp ( > = 140 / 90 mmhg ) while receiving 3 antihypertensive medications at the maximum approved dose of each drug ; one of which must be a diuretic .,Observation,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
15,NCT00927394,Exclusion,patients treated with more than 3 antihypertensive medications ( each component of a combination drug counts individually ) .,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,greater 3,NA
15,NCT00927394,Exclusion,patients treated with more than 3 antihypertensive medications ( each component of a combination drug counts individually ) .,Drug Exposure,Drug,C0013162,combination drug,FALSE,FALSE,NA,NA,NA
16,NCT00927394,Exclusion,type 2 diabetes mellitus currently requiring insulin treatment .,Condition Occurrence,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
16,NCT00927394,Exclusion,type 2 diabetes mellitus currently requiring insulin treatment .,Condition Occurrence,Procedure,C0745343,insulin treatment,FALSE,FALSE,NA,NA,NA
17,NCT00927394,Exclusion,modification of diet in renal disease ( mdrd ) estimated glomerular filtration rate ( egfr ) < 60 ml / min / 1.73 m2,Observation,Condition,C0022658,renal disease,FALSE,FALSE,NA,NA,NA
17,NCT00927394,Exclusion,modification of diet in renal disease ( mdrd ) estimated glomerular filtration rate ( egfr ) < 60 ml / min / 1.73 m2,Observation,Observation,C0034802;C1150617,egfr,FALSE,FALSE,NA,lower 60 ml/min; equal 1.73 m2,NA
17,NCT00927394,Exclusion,modification of diet in renal disease ( mdrd ) estimated glomerular filtration rate ( egfr ) < 60 ml / min / 1.73 m2,Observation,Other,C0012159;C1519433;C1561465;C1550559;C1549512,diet,FALSE,FALSE,NA,NA,NA
17,NCT00927394,Exclusion,modification of diet in renal disease ( mdrd ) estimated glomerular filtration rate ( egfr ) < 60 ml / min / 1.73 m2,Observation,Other,C0017654;C1561549,glomerular filtration rate,FALSE,FALSE,NA,NA,NA
18,NCT00927394,Exclusion,serum sodium less than lower limit of normal potassium ; serum potassium < 3.5 meq / l or > = 5.3 meq / l at visit 1 .,Observation,Condition,C0860869,normal potassium,FALSE,FALSE,NA,lower 3.5 ; greater_equal 5.3,NA
18,NCT00927394,Exclusion,serum sodium less than lower limit of normal potassium ; serum potassium < 3.5 meq / l or > = 5.3 meq / l at visit 1 .,Observation,Observation,C0523891;C0587356,serum sodium,FALSE,FALSE,NA,NA,NA
18,NCT00927394,Exclusion,serum sodium less than lower limit of normal potassium ; serum potassium < 3.5 meq / l or > = 5.3 meq / l at visit 1 .,Observation,Observation,C1548802,lower,FALSE,FALSE,NA,NA,NA
18,NCT00927394,Exclusion,serum sodium less than lower limit of normal potassium ; serum potassium < 3.5 meq / l or > = 5.3 meq / l at visit 1 .,Observation,Observation,C0302353;C0543465,serum potassium,FALSE,FALSE,NA,lower 3.5 ; greater_equal 5.3,NA
19,NCT00927394,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy .,Condition Occurrence,Condition,C0152132,hypertensive retinopathy,FALSE,FALSE,NA,NA,NA
19,NCT00927394,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy .,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii,FALSE,FALSE,NA,NA,NA
19,NCT00927394,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy .,Condition Occurrence,Other,C0677510;C0021440;C3496001,iv,FALSE,FALSE,NA,NA,NA
20,NCT00927394,Exclusion,cohort 1 :,Person,Person,C0599755,cohort,FALSE,FALSE,NA,NA,NA
21,NCT00927394,Exclusion,patients with known diabetic retinopathy ( eg ; having a history of laser therapy for diabetic retinopathy ) or diabetic neuropathy ( eg ; receiving medication for diabetic neuropathy ) .,Condition Occurrence,Condition,C0011884,diabetic retinopathy,FALSE,FALSE,NA,NA,NA
21,NCT00927394,Exclusion,patients with known diabetic retinopathy ( eg ; having a history of laser therapy for diabetic retinopathy ) or diabetic neuropathy ( eg ; receiving medication for diabetic neuropathy ) .,Condition Occurrence,Condition,C0011884,diabetic retinopathy,FALSE,FALSE,NA,NA,NA
21,NCT00927394,Exclusion,patients with known diabetic retinopathy ( eg ; having a history of laser therapy for diabetic retinopathy ) or diabetic neuropathy ( eg ; receiving medication for diabetic neuropathy ) .,Condition Occurrence,Condition,C0011882,diabetic neuropathy,FALSE,FALSE,NA,NA,NA
21,NCT00927394,Exclusion,patients with known diabetic retinopathy ( eg ; having a history of laser therapy for diabetic retinopathy ) or diabetic neuropathy ( eg ; receiving medication for diabetic neuropathy ) .,Condition Occurrence,Condition,C0011882,diabetic neuropathy,FALSE,FALSE,NA,NA,NA
21,NCT00927394,Exclusion,patients with known diabetic retinopathy ( eg ; having a history of laser therapy for diabetic retinopathy ) or diabetic neuropathy ( eg ; receiving medication for diabetic neuropathy ) .,Condition Occurrence,Procedure,C1955835;C0279027,laser therapy,FALSE,FALSE,NA,NA,NA
22,NCT00927394,Exclusion,cohort 2 :,Person,Person,C0599755,cohort,FALSE,FALSE,NA,NA,NA
23,NCT00927394,Exclusion,patients with known diabetic retinopathy or diabetic neuropathy or having a history of treatment for either .,Condition Occurrence,Condition,C0011884,diabetic retinopathy,FALSE,FALSE,NA,NA,NA
23,NCT00927394,Exclusion,patients with known diabetic retinopathy or diabetic neuropathy or having a history of treatment for either .,Condition Occurrence,Condition,C0011882,diabetic neuropathy,FALSE,FALSE,NA,NA,NA
24,NCT00927394,Exclusion,other protocol-defined inclusiopplied,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00931710,Inclusion,male or female outpatient of 18 years of age or greater,Person,Person,C0025266,male,FALSE,FALSE,equal 18 years,NA,NA
1,NCT00931710,Inclusion,male or female outpatient of 18 years of age or greater,Person,Person,C0086287,female,FALSE,FALSE,equal 18 years,NA,NA
2,NCT00931710,Inclusion,stage 2 systolic hypertension defined as office mean sitting systolic blood pressure ( mssbp ) greater than or equal to 160 and < 200 mmhg at randomization,Observation,Condition,C0221155,systolic hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00931710,Inclusion,stage 2 systolic hypertension defined as office mean sitting systolic blood pressure ( mssbp ) greater than or equal to 160 and < 200 mmhg at randomization,Observation,Condition,C1319893,sitting systolic blood pressure,FALSE,FALSE,NA,greater_equal 160 mmhg; lower 200 mmhg,NA
2,NCT00931710,Inclusion,stage 2 systolic hypertension defined as office mean sitting systolic blood pressure ( mssbp ) greater than or equal to 160 and < 200 mmhg at randomization,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
3,NCT00931710,Inclusion,patients who were able to participate in the study ; and who gave written informed consent before any study assessment was performed .,Observation,Other,C0542573;C0549068;C0870300;C0549070;C0549071;C0549072;C0549073;C0549074;C0028708;C0549075;C0549076;C0549077;C0549078;C0549079;C0549080;C0679207,assessment,FALSE,FALSE,NA,NA,NA
4,NCT00931710,Exclusion,office systolic blood pressure > 200 or mean sitting diastolic blood pressure ( msdbp ) greater than or equal to 110 mmhg at visit 1 .,Observation,Condition,C1319894,sitting diastolic blood pressure,FALSE,FALSE,NA,greater_equal 110 mmhg,NA
4,NCT00931710,Exclusion,office systolic blood pressure > 200 or mean sitting diastolic blood pressure ( msdbp ) greater than or equal to 110 mmhg at visit 1 .,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater 200,NA
5,NCT00931710,Exclusion,use of four 4 or more antihypertensive medications within 30 days of visit 1 .,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,lower 30 days,greater_equal 4,NA
6,NCT00931710,Exclusion,refractory hypertension ; defined as blood pressure > 140 / 90 mmhg while taking three 3 drugs at the maximum dose of each drug ; one of which must be a diuretic,Observation,Condition,C0860493,refractory hypertension,FALSE,FALSE,NA,NA,NA
6,NCT00931710,Exclusion,refractory hypertension ; defined as blood pressure > 140 / 90 mmhg while taking three 3 drugs at the maximum dose of each drug ; one of which must be a diuretic,Observation,Drug,C0012798,diuretic,FALSE,FALSE,NA,NA,NA
6,NCT00931710,Exclusion,refractory hypertension ; defined as blood pressure > 140 / 90 mmhg while taking three 3 drugs at the maximum dose of each drug ; one of which must be a diuretic,Observation,Procedure,C3687832,drugs,FALSE,FALSE,NA,equal 3,NA
6,NCT00931710,Exclusion,refractory hypertension ; defined as blood pressure > 140 / 90 mmhg while taking three 3 drugs at the maximum dose of each drug ; one of which must be a diuretic,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,greater 140 mmhg; greater 90 mmhg,NA
6,NCT00931710,Exclusion,refractory hypertension ; defined as blood pressure > 140 / 90 mmhg while taking three 3 drugs at the maximum dose of each drug ; one of which must be a diuretic,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
6,NCT00931710,Exclusion,refractory hypertension ; defined as blood pressure > 140 / 90 mmhg while taking three 3 drugs at the maximum dose of each drug ; one of which must be a diuretic,Observation,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
7,NCT00931710,Exclusion,( therapy with a fixed-dose combination of two active medications represents two drugs ) .,Drug Exposure,Condition,C2827483,fixed,FALSE,FALSE,NA,NA,NA
7,NCT00931710,Exclusion,( therapy with a fixed-dose combination of two active medications represents two drugs ) .,Drug Exposure,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
7,NCT00931710,Exclusion,( therapy with a fixed-dose combination of two active medications represents two drugs ) .,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
8,NCT00931710,Exclusion,inability to safely discontinue all antihypertensive medications for 1 - 2 weeks prior to randomization .,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,greater_equal 1 weeks; lower_equal 2 weeks,NA,NA
8,NCT00931710,Exclusion,inability to safely discontinue all antihypertensive medications for 1 - 2 weeks prior to randomization .,Drug Exposure,Other,C1706472,discontinue,FALSE,FALSE,NA,NA,NA
9,NCT00931710,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00942994,Inclusion,patients who are newly diagnosed or have a history of hypertension ; who are eligible and able to participate in the study ; and who give written informed consent before any assessment is performed .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00942994,Inclusion,patients who are newly diagnosed or have a history of hypertension ; who are eligible and able to participate in the study ; and who give written informed consent before any assessment is performed .,Observation,Other,C0542573;C0549068;C0870300;C0549070;C0549071;C0549072;C0549073;C0549074;C0028708;C0549075;C0549076;C0549077;C0549078;C0549079;C0549080;C0679207,assessment,FALSE,FALSE,NA,NA,NA
2,NCT00942994,Inclusion,men or women 18 years and older of minority background,Person,Person,C0025266,men,FALSE,FALSE,greater_equal 18 years,NA,NA
2,NCT00942994,Inclusion,men or women 18 years and older of minority background,Person,Person,C0086287,women,FALSE,FALSE,greater_equal 18 years,NA,NA
2,NCT00942994,Inclusion,men or women 18 years and older of minority background,Person,Person,C0026192,minority,FALSE,FALSE,NA,NA,NA
3,NCT00942994,Inclusion,self-identified .,Condition Occurrence,Condition,C1550043,identified,FALSE,FALSE,NA,NA,NA
4,NCT00942994,Inclusion,patients with stage 2 hypertension defined as mssbp > = 160 mmhg and < 200 mmhg at visit 5 ( randomization ) .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
4,NCT00942994,Inclusion,patients with stage 2 hypertension defined as mssbp > = 160 mmhg and < 200 mmhg at visit 5 ( randomization ) .,Observation,Other,C3539106,defined,FALSE,FALSE,NA,greater_equal 160 mmhg; lower 200 mmhg,NA
5,NCT00942994,Exclusion,patients with msdbp > = 110 mmhg or mssbp > = 200 mmhg as measured by office cuff at any visit .,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
5,NCT00942994,Exclusion,patients with msdbp > = 110 mmhg or mssbp > = 200 mmhg as measured by office cuff at any visit .,Observation,Observation,C3541902,measured,FALSE,FALSE,NA,greater_equal 110 mmhg; greater_equal 200 mmhg,NA
6,NCT00942994,Exclusion,patients on 4 or more antihypertensive medications .,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,greater_equal 4,NA
7,NCT00942994,Exclusion,patients with uncontrolled hypertension ( mssbp > 180 mmhg ) taking more than 1 antihypertensive medication at visit,Observation,Condition,C1868885,uncontrolled hypertension,FALSE,FALSE,NA,greater 180 mmhg,NA
7,NCT00942994,Exclusion,patients with uncontrolled hypertension ( mssbp > 180 mmhg ) taking more than 1 antihypertensive medication at visit,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,greater 1,NA
1,NCT00949884,Inclusion,males or females aged > 18 years who are not institutionalized and have signed informed consent .,Person,Person,C0025266,males,FALSE,FALSE,NA,NA,NA
1,NCT00949884,Inclusion,males or females aged > 18 years who are not institutionalized and have signed informed consent .,Person,Person,C0086287,females,FALSE,FALSE,NA,NA,NA
1,NCT00949884,Inclusion,males or females aged > 18 years who are not institutionalized and have signed informed consent .,Person,Person,C0001792,aged,FALSE,FALSE,greater 18 years,NA,NA
1,NCT00949884,Inclusion,males or females aged > 18 years who are not institutionalized and have signed informed consent .,Person,Condition,C0562359,institutionalized,TRUE,FALSE,NA,NA,NA
1,NCT00949884,Inclusion,males or females aged > 18 years who are not institutionalized and have signed informed consent .,Person,Other,C1519316,signed,TRUE,FALSE,NA,NA,NA
2,NCT00949884,Inclusion,mean cuff seated diastolic blood pressure ( bp ) must be > 95 mmhg and < 115 mmhg and a mean cuff seated systolic bp must be < 180 mmhg when measured at two consecutive qualification study visits during the placebo run-in phase .,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
2,NCT00949884,Inclusion,mean cuff seated diastolic blood pressure ( bp ) must be > 95 mmhg and < 115 mmhg and a mean cuff seated systolic bp must be < 180 mmhg when measured at two consecutive qualification study visits during the placebo run-in phase .,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
2,NCT00949884,Inclusion,mean cuff seated diastolic blood pressure ( bp ) must be > 95 mmhg and < 115 mmhg and a mean cuff seated systolic bp must be < 180 mmhg when measured at two consecutive qualification study visits during the placebo run-in phase .,Observation,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,NA
2,NCT00949884,Inclusion,mean cuff seated diastolic blood pressure ( bp ) must be > 95 mmhg and < 115 mmhg and a mean cuff seated systolic bp must be < 180 mmhg when measured at two consecutive qualification study visits during the placebo run-in phase .,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,NA,NA
2,NCT00949884,Inclusion,mean cuff seated diastolic blood pressure ( bp ) must be > 95 mmhg and < 115 mmhg and a mean cuff seated systolic bp must be < 180 mmhg when measured at two consecutive qualification study visits during the placebo run-in phase .,Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,greater 95 mmhg; lower 115 mmhg,NA
2,NCT00949884,Inclusion,mean cuff seated diastolic blood pressure ( bp ) must be > 95 mmhg and < 115 mmhg and a mean cuff seated systolic bp must be < 180 mmhg when measured at two consecutive qualification study visits during the placebo run-in phase .,Observation,Observation,C0871470,systolic bp,FALSE,FALSE,NA,lower 180 mmhg,NA
2,NCT00949884,Inclusion,mean cuff seated diastolic blood pressure ( bp ) must be > 95 mmhg and < 115 mmhg and a mean cuff seated systolic bp must be < 180 mmhg when measured at two consecutive qualification study visits during the placebo run-in phase .,Observation,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
3,NCT00949884,Inclusion,the difference in mean cuff seated diastolic bp must be < 7 mmhg between two consecutive qualification study visits during the placebo run-in phase .,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
3,NCT00949884,Inclusion,the difference in mean cuff seated diastolic bp must be < 7 mmhg between two consecutive qualification study visits during the placebo run-in phase .,Observation,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,NA
3,NCT00949884,Inclusion,the difference in mean cuff seated diastolic bp must be < 7 mmhg between two consecutive qualification study visits during the placebo run-in phase .,Observation,Observation,C0428883,diastolic bp,FALSE,FALSE,NA,lower 7 mmhg,NA
4,NCT00949884,Exclusion,subjects with type 2 diabetes mellitus with an hba1c > = 9.5 % at screening .,Condition Occurrence,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
4,NCT00949884,Exclusion,subjects with type 2 diabetes mellitus with an hba1c > = 9.5 % at screening .,Condition Occurrence,Observation,C0202054,hba1c,FALSE,FALSE,NA,NA,greater_equal 9.5 %
5,NCT00949884,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of olmesartan medoxomil and losartan potassium ; including cardiovascular ; renal ( including the absence of one kidney ) ; pulmonary ; hepatic ; gastrointestinal ( including clinically significant malabsorption ) ; endocrine / metabolic ( with the exception of non-insulin ; dependent type 2 diabetes mellitus with hba1c < 9.55 % at screening ) ; hematologic / oncologic ( including an active malignancy other than basal cell carcinoma ) ; neurologic and psychiatric diseases .,Condition Occurrence,Condition,C0205054,hepatic,FALSE,FALSE,NA,NA,NA
5,NCT00949884,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of olmesartan medoxomil and losartan potassium ; including cardiovascular ; renal ( including the absence of one kidney ) ; pulmonary ; hepatic ; gastrointestinal ( including clinically significant malabsorption ) ; endocrine / metabolic ( with the exception of non-insulin ; dependent type 2 diabetes mellitus with hba1c < 9.55 % at screening ) ; hematologic / oncologic ( including an active malignancy other than basal cell carcinoma ) ; neurologic and psychiatric diseases .,Condition Occurrence,Condition,C1559265,gastrointestinal,FALSE,FALSE,NA,NA,NA
5,NCT00949884,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of olmesartan medoxomil and losartan potassium ; including cardiovascular ; renal ( including the absence of one kidney ) ; pulmonary ; hepatic ; gastrointestinal ( including clinically significant malabsorption ) ; endocrine / metabolic ( with the exception of non-insulin ; dependent type 2 diabetes mellitus with hba1c < 9.55 % at screening ) ; hematologic / oncologic ( including an active malignancy other than basal cell carcinoma ) ; neurologic and psychiatric diseases .,Condition Occurrence,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
5,NCT00949884,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of olmesartan medoxomil and losartan potassium ; including cardiovascular ; renal ( including the absence of one kidney ) ; pulmonary ; hepatic ; gastrointestinal ( including clinically significant malabsorption ) ; endocrine / metabolic ( with the exception of non-insulin ; dependent type 2 diabetes mellitus with hba1c < 9.55 % at screening ) ; hematologic / oncologic ( including an active malignancy other than basal cell carcinoma ) ; neurologic and psychiatric diseases .,Condition Occurrence,Condition,C0006826;C1306459,malignancy,FALSE,FALSE,NA,NA,NA
5,NCT00949884,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of olmesartan medoxomil and losartan potassium ; including cardiovascular ; renal ( including the absence of one kidney ) ; pulmonary ; hepatic ; gastrointestinal ( including clinically significant malabsorption ) ; endocrine / metabolic ( with the exception of non-insulin ; dependent type 2 diabetes mellitus with hba1c < 9.55 % at screening ) ; hematologic / oncologic ( including an active malignancy other than basal cell carcinoma ) ; neurologic and psychiatric diseases .,Condition Occurrence,Drug,C0386393,olmesartan medoxomil,FALSE,FALSE,NA,NA,NA
5,NCT00949884,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of olmesartan medoxomil and losartan potassium ; including cardiovascular ; renal ( including the absence of one kidney ) ; pulmonary ; hepatic ; gastrointestinal ( including clinically significant malabsorption ) ; endocrine / metabolic ( with the exception of non-insulin ; dependent type 2 diabetes mellitus with hba1c < 9.55 % at screening ) ; hematologic / oncologic ( including an active malignancy other than basal cell carcinoma ) ; neurologic and psychiatric diseases .,Condition Occurrence,Drug,C0700492,losartan potassium,FALSE,FALSE,NA,NA,NA
5,NCT00949884,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of olmesartan medoxomil and losartan potassium ; including cardiovascular ; renal ( including the absence of one kidney ) ; pulmonary ; hepatic ; gastrointestinal ( including clinically significant malabsorption ) ; endocrine / metabolic ( with the exception of non-insulin ; dependent type 2 diabetes mellitus with hba1c < 9.55 % at screening ) ; hematologic / oncologic ( including an active malignancy other than basal cell carcinoma ) ; neurologic and psychiatric diseases .,Condition Occurrence,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
5,NCT00949884,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of olmesartan medoxomil and losartan potassium ; including cardiovascular ; renal ( including the absence of one kidney ) ; pulmonary ; hepatic ; gastrointestinal ( including clinically significant malabsorption ) ; endocrine / metabolic ( with the exception of non-insulin ; dependent type 2 diabetes mellitus with hba1c < 9.55 % at screening ) ; hematologic / oncologic ( including an active malignancy other than basal cell carcinoma ) ; neurologic and psychiatric diseases .,Condition Occurrence,Observation,C0021641;C0202098;C1533581;C1145751;C1579433;C2739803,insulin,FALSE,FALSE,NA,NA,NA
5,NCT00949884,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of olmesartan medoxomil and losartan potassium ; including cardiovascular ; renal ( including the absence of one kidney ) ; pulmonary ; hepatic ; gastrointestinal ( including clinically significant malabsorption ) ; endocrine / metabolic ( with the exception of non-insulin ; dependent type 2 diabetes mellitus with hba1c < 9.55 % at screening ) ; hematologic / oncologic ( including an active malignancy other than basal cell carcinoma ) ; neurologic and psychiatric diseases .,Condition Occurrence,Observation,C0202054,hba1c,FALSE,FALSE,NA,NA,lower 9.55 %
5,NCT00949884,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of olmesartan medoxomil and losartan potassium ; including cardiovascular ; renal ( including the absence of one kidney ) ; pulmonary ; hepatic ; gastrointestinal ( including clinically significant malabsorption ) ; endocrine / metabolic ( with the exception of non-insulin ; dependent type 2 diabetes mellitus with hba1c < 9.55 % at screening ) ; hematologic / oncologic ( including an active malignancy other than basal cell carcinoma ) ; neurologic and psychiatric diseases .,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,TRUE,FALSE,NA,NA,NA
5,NCT00949884,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of olmesartan medoxomil and losartan potassium ; including cardiovascular ; renal ( including the absence of one kidney ) ; pulmonary ; hepatic ; gastrointestinal ( including clinically significant malabsorption ) ; endocrine / metabolic ( with the exception of non-insulin ; dependent type 2 diabetes mellitus with hba1c < 9.55 % at screening ) ; hematologic / oncologic ( including an active malignancy other than basal cell carcinoma ) ; neurologic and psychiatric diseases .,Condition Occurrence,Other,C1524026;C2707259,metabolic,FALSE,FALSE,NA,NA,NA
5,NCT00949884,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of olmesartan medoxomil and losartan potassium ; including cardiovascular ; renal ( including the absence of one kidney ) ; pulmonary ; hepatic ; gastrointestinal ( including clinically significant malabsorption ) ; endocrine / metabolic ( with the exception of non-insulin ; dependent type 2 diabetes mellitus with hba1c < 9.55 % at screening ) ; hematologic / oncologic ( including an active malignancy other than basal cell carcinoma ) ; neurologic and psychiatric diseases .,Condition Occurrence,Other,C0007117;C3540686;C1547219,basal cell carcinoma,TRUE,FALSE,NA,NA,NA
5,NCT00949884,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of olmesartan medoxomil and losartan potassium ; including cardiovascular ; renal ( including the absence of one kidney ) ; pulmonary ; hepatic ; gastrointestinal ( including clinically significant malabsorption ) ; endocrine / metabolic ( with the exception of non-insulin ; dependent type 2 diabetes mellitus with hba1c < 9.55 % at screening ) ; hematologic / oncologic ( including an active malignancy other than basal cell carcinoma ) ; neurologic and psychiatric diseases .,Condition Occurrence,Other,C1548428;C1561580,psychiatric,TRUE,FALSE,NA,NA,NA
6,NCT00949884,Exclusion,subjects with a history of myocardial infarction ; angina ; coronary angioplasty ; bypass surgery or heart failure within the last 12 months .,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,lower 12 last months,NA,NA
6,NCT00949884,Exclusion,subjects with a history of myocardial infarction ; angina ; coronary angioplasty ; bypass surgery or heart failure within the last 12 months .,Condition Occurrence,Procedure,C1536078,bypass surgery,FALSE,FALSE,lower 12 last months,NA,NA
6,NCT00949884,Exclusion,subjects with a history of myocardial infarction ; angina ; coronary angioplasty ; bypass surgery or heart failure within the last 12 months .,Condition Occurrence,Procedure,C0190211;C0002997,coronary angioplasty,FALSE,FALSE,lower 12 last months,NA,NA
6,NCT00949884,Exclusion,subjects with a history of myocardial infarction ; angina ; coronary angioplasty ; bypass surgery or heart failure within the last 12 months .,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,lower 12 last months,NA,NA
6,NCT00949884,Exclusion,subjects with a history of myocardial infarction ; angina ; coronary angioplasty ; bypass surgery or heart failure within the last 12 months .,Condition Occurrence,Other,C0002962;C2024883;C2926611,angina,FALSE,FALSE,lower 12 last months,NA,NA
7,NCT00949884,Exclusion,subjects with any history of new york heart association class iii or class iv congestive heart failure ( chf ),Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
7,NCT00949884,Exclusion,subjects with any history of new york heart association class iii or class iv congestive heart failure ( chf ),Condition Occurrence,Condition,C0018802,congestive heart failure chf,FALSE,FALSE,NA,NA,NA
7,NCT00949884,Exclusion,subjects with any history of new york heart association class iii or class iv congestive heart failure ( chf ),Condition Occurrence,Other,C0441887;C2698969,class iii,FALSE,FALSE,NA,NA,NA
7,NCT00949884,Exclusion,subjects with any history of new york heart association class iii or class iv congestive heart failure ( chf ),Condition Occurrence,Other,C0441888;C2698970,class iv,FALSE,FALSE,NA,NA,NA
8,NCT00949884,Exclusion,a history of new york heart association class i or class ii chf may be exclusionary at the discretion of the investigator .,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
8,NCT00949884,Exclusion,a history of new york heart association class i or class ii chf may be exclusionary at the discretion of the investigator .,Condition Occurrence,Condition,C2698967,class i,FALSE,FALSE,NA,NA,NA
8,NCT00949884,Exclusion,a history of new york heart association class i or class ii chf may be exclusionary at the discretion of the investigator .,Condition Occurrence,Condition,C0018802,chf,FALSE,FALSE,NA,NA,NA
8,NCT00949884,Exclusion,a history of new york heart association class i or class ii chf may be exclusionary at the discretion of the investigator .,Condition Occurrence,Other,C0441886;C2698968,class ii,FALSE,FALSE,NA,NA,NA
9,NCT00949884,Exclusion,subjects with a history of cerebrovascular accident or transient ischemic attack within the last 1 year .,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,lower 1 last year,NA,NA
9,NCT00949884,Exclusion,subjects with a history of cerebrovascular accident or transient ischemic attack within the last 1 year .,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,lower 1 last year,NA,NA
10,NCT00949884,Exclusion,subjects with clinically significant cardiac conduction defects ; including second degree or third degree atrioventricular ( av ) block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation ; atrial flutter ; an accessory bypass tract ; or any arrhythmia requiring medication,Condition Occurrence,Condition,C0264886,cardiac conduction defects,FALSE,FALSE,NA,NA,NA
10,NCT00949884,Exclusion,subjects with clinically significant cardiac conduction defects ; including second degree or third degree atrioventricular ( av ) block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation ; atrial flutter ; an accessory bypass tract ; or any arrhythmia requiring medication,Condition Occurrence,Condition,C0004245,av block,FALSE,FALSE,NA,NA,NA
10,NCT00949884,Exclusion,subjects with clinically significant cardiac conduction defects ; including second degree or third degree atrioventricular ( av ) block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation ; atrial flutter ; an accessory bypass tract ; or any arrhythmia requiring medication,Condition Occurrence,Condition,C0004239;C1963068,atrial flutter,FALSE,FALSE,NA,NA,NA
10,NCT00949884,Exclusion,subjects with clinically significant cardiac conduction defects ; including second degree or third degree atrioventricular ( av ) block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation ; atrial flutter ; an accessory bypass tract ; or any arrhythmia requiring medication,Condition Occurrence,Condition,C0037052;C1963235,sick sinus syndrome,FALSE,FALSE,NA,NA,NA
10,NCT00949884,Exclusion,subjects with clinically significant cardiac conduction defects ; including second degree or third degree atrioventricular ( av ) block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation ; atrial flutter ; an accessory bypass tract ; or any arrhythmia requiring medication,Condition Occurrence,Condition,C0023211,left bundle branch block,FALSE,FALSE,NA,NA,NA
10,NCT00949884,Exclusion,subjects with clinically significant cardiac conduction defects ; including second degree or third degree atrioventricular ( av ) block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation ; atrial flutter ; an accessory bypass tract ; or any arrhythmia requiring medication,Condition Occurrence,Condition,C1185740,tract,FALSE,FALSE,NA,NA,NA
10,NCT00949884,Exclusion,subjects with clinically significant cardiac conduction defects ; including second degree or third degree atrioventricular ( av ) block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation ; atrial flutter ; an accessory bypass tract ; or any arrhythmia requiring medication,Condition Occurrence,Condition,C0003811,arrhythmia,FALSE,FALSE,NA,NA,NA
10,NCT00949884,Exclusion,subjects with clinically significant cardiac conduction defects ; including second degree or third degree atrioventricular ( av ) block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation ; atrial flutter ; an accessory bypass tract ; or any arrhythmia requiring medication,Condition Occurrence,Procedure,C0741847,bypass,FALSE,FALSE,NA,NA,NA
10,NCT00949884,Exclusion,subjects with clinically significant cardiac conduction defects ; including second degree or third degree atrioventricular ( av ) block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation ; atrial flutter ; an accessory bypass tract ; or any arrhythmia requiring medication,Condition Occurrence,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
10,NCT00949884,Exclusion,subjects with clinically significant cardiac conduction defects ; including second degree or third degree atrioventricular ( av ) block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation ; atrial flutter ; an accessory bypass tract ; or any arrhythmia requiring medication,Condition Occurrence,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
10,NCT00949884,Exclusion,subjects with clinically significant cardiac conduction defects ; including second degree or third degree atrioventricular ( av ) block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation ; atrial flutter ; an accessory bypass tract ; or any arrhythmia requiring medication,Condition Occurrence,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
1,NCT00956644,Inclusion,established essential hypertension,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00956644,Inclusion,treated with amlodipine 5 mg monotherapy for at least 4 weeks,Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,greater_equal 4 weeks,NA,equal 5 mg
3,NCT00956644,Inclusion,with uncontrolled bp defined as mean sbp = or > 145 mmhg assessed by obpm,Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,NA,NA
3,NCT00956644,Inclusion,with uncontrolled bp defined as mean sbp = or > 145 mmhg assessed by obpm,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 145 mmhg,NA
3,NCT00956644,Inclusion,with uncontrolled bp defined as mean sbp = or > 145 mmhg assessed by obpm,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
4,NCT00956644,Inclusion,signed written inform consent obtained prior to inclusion in the study,Other,Other,C1519316,signed,FALSE,FALSE,NA,NA,NA
5,NCT00956644,Inclusion,randomisation criteria :,Other,NA,NA,NA,NA,NA,NA,NA,NA
6,NCT00956644,Inclusion,mean sbp = or > 135 mmhg assessed by hbpm,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 135 mmhg,NA
7,NCT00956644,Inclusion,good compliance with the hbpm protocol defined as at least 12 correct measurements performed over the last 6 days of the first period of measurements,Observation,Other,C3539106,defined,FALSE,FALSE,greater 6 last days,greater_equal 12 correct measurements,NA
8,NCT00956644,Inclusion,creatinine clearance = or > 30 ml / min ; determined by cockroft formula,Observation,Observation,C0373595;C0812399,creatinine clearance,FALSE,FALSE,NA,greater_equal 30 ml/min,NA
8,NCT00956644,Inclusion,creatinine clearance = or > 30 ml / min ; determined by cockroft formula,Observation,Other,C1705501;C0489829,formula,FALSE,FALSE,NA,NA,NA
9,NCT00956644,Exclusion,mean sbp = or > 180 mm hg or mean dbp = or > 110 mm hg measured at doctor office at visit 1,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 180 mm hg,NA
9,NCT00956644,Exclusion,mean sbp = or > 180 mm hg or mean dbp = or > 110 mm hg measured at doctor office at visit 1,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 110 mm hg,NA
9,NCT00956644,Exclusion,mean sbp = or > 180 mm hg or mean dbp = or > 110 mm hg measured at doctor office at visit 1,Observation,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
10,NCT00956644,Exclusion,known or suspected causes of secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
11,NCT00956644,Exclusion,patients with bilateral artery stenosis ; renal artery stenosis in a solitary kidney ; renal transplant or only one functioning kidney,Condition Occurrence,Condition,C0038449,artery stenosis,FALSE,FALSE,NA,NA,NA
11,NCT00956644,Exclusion,patients with bilateral artery stenosis ; renal artery stenosis in a solitary kidney ; renal transplant or only one functioning kidney,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
11,NCT00956644,Exclusion,patients with bilateral artery stenosis ; renal artery stenosis in a solitary kidney ; renal transplant or only one functioning kidney,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
11,NCT00956644,Exclusion,patients with bilateral artery stenosis ; renal artery stenosis in a solitary kidney ; renal transplant or only one functioning kidney,Condition Occurrence,Procedure,C0022671,renal transplant,FALSE,FALSE,NA,NA,NA
11,NCT00956644,Exclusion,patients with bilateral artery stenosis ; renal artery stenosis in a solitary kidney ; renal transplant or only one functioning kidney,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
12,NCT00956644,Exclusion,know contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination or history of angioedema related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
12,NCT00956644,Exclusion,know contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination or history of angioedema related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Condition,C0445223,related,FALSE,FALSE,NA,NA,NA
12,NCT00956644,Exclusion,know contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination or history of angioedema related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,NA
12,NCT00956644,Exclusion,know contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination or history of angioedema related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Drug,C0288171,irbesartan,FALSE,FALSE,NA,NA,NA
12,NCT00956644,Exclusion,know contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination or history of angioedema related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Drug,C0521942,angiotensin ii receptor antagonist,FALSE,FALSE,NA,NA,NA
12,NCT00956644,Exclusion,know contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination or history of angioedema related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
12,NCT00956644,Exclusion,know contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination or history of angioedema related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
13,NCT00956644,Exclusion,known type 1 diabetes,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
14,NCT00956644,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history or hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Condition,C0948807,hepatic impairment,FALSE,FALSE,NA,NA,NA
14,NCT00956644,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history or hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Condition,C0019151,hepatic encephalopathy,FALSE,FALSE,NA,NA,NA
14,NCT00956644,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history or hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Condition,C0014867,esophageal varices,FALSE,FALSE,NA,NA,NA
14,NCT00956644,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history or hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Procedure,C0032716,portocaval shunt,FALSE,FALSE,NA,NA,NA
14,NCT00956644,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history or hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Observation,C0001899;C0201836,alanine aminotransferase,FALSE,FALSE,NA,NA,NA
14,NCT00956644,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history or hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Observation,C1140170;C2257651,alt,FALSE,FALSE,NA,NA,NA
14,NCT00956644,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history or hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Observation,C0004002;C0201899,aspartate aminotransferase,FALSE,FALSE,NA,NA,NA
14,NCT00956644,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history or hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Observation,C0004002,ast,FALSE,FALSE,NA,NA,greater 5 times the upper limit of normal
14,NCT00956644,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history or hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
15,NCT00956644,Exclusion,known severe renal impairment ( creatinine clearance < 30 ml / mn ),Drug Exposure,Condition,C1565489;C0035078,renal impairment,FALSE,FALSE,NA,NA,NA
15,NCT00956644,Exclusion,known severe renal impairment ( creatinine clearance < 30 ml / mn ),Drug Exposure,Drug,C2348271,mn,FALSE,FALSE,NA,NA,NA
15,NCT00956644,Exclusion,known severe renal impairment ( creatinine clearance < 30 ml / mn ),Drug Exposure,Observation,C0373595;C0812399,creatinine clearance,FALSE,FALSE,NA,NA,lower 30 ml
15,NCT00956644,Exclusion,known severe renal impairment ( creatinine clearance < 30 ml / mn ),Drug Exposure,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
16,NCT00956644,Exclusion,concomitant use of any other antihypertensive treatment,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
17,NCT00956644,Exclusion,administration of any other investigational drug within 30 days before inclusion,Drug Exposure,Drug,C0013230,investigational drug,FALSE,FALSE,lower 30 days,NA,NA
18,NCT00956644,Exclusion,inability to obtain a valid automatic bp measurement recording,Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,NA,NA
19,NCT00956644,Exclusion,presence of any severe medical condition or psychological condition that ; in the opinion of the investigator ; indicate that participation in the study is not in the best interest of the patient,Condition Occurrence,Condition,C1306597,psychological,FALSE,FALSE,NA,NA,NA
19,NCT00956644,Exclusion,presence of any severe medical condition or psychological condition that ; in the opinion of the investigator ; indicate that participation in the study is not in the best interest of the patient,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
19,NCT00956644,Exclusion,presence of any severe medical condition or psychological condition that ; in the opinion of the investigator ; indicate that participation in the study is not in the best interest of the patient,Condition Occurrence,Other,C1561579;C1561578,medical,FALSE,FALSE,NA,NA,NA
20,NCT00956644,Exclusion,presence of any other conditions ( eg : geographical ; social ; etc ) that would restrict or limit the patient participation for the duration of the study,Procedure,Procedure,C0030699,patient participation,FALSE,FALSE,NA,NA,NA
21,NCT00956644,Exclusion,pregnant or breast feeding women,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
21,NCT00956644,Exclusion,pregnant or breast feeding women,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
21,NCT00956644,Exclusion,pregnant or breast feeding women,Condition Occurrence,Condition,C0006147;C1623040;C1623041,breast feeding,FALSE,FALSE,NA,NA,NA
22,NCT00956644,Exclusion,women of childbearing potential unable or unwilling to use an acceptable method to avoid pregnancy for the entire study period,Observation,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
22,NCT00956644,Exclusion,women of childbearing potential unable or unwilling to use an acceptable method to avoid pregnancy for the entire study period,Observation,Observation,C3831118,childbearing potential,FALSE,FALSE,NA,NA,NA
22,NCT00956644,Exclusion,women of childbearing potential unable or unwilling to use an acceptable method to avoid pregnancy for the entire study period,Observation,Other,C2827714;C0871511;C2828387,method,FALSE,FALSE,NA,NA,NA
22,NCT00956644,Exclusion,women of childbearing potential unable or unwilling to use an acceptable method to avoid pregnancy for the entire study period,Observation,Other,C0032961;C3484365,pregnancy,FALSE,FALSE,NA,NA,NA
23,NCT00956644,Exclusion,the above information is not intended to contain all considerations relevant to a patient potential participation in a clinical trial,Other,Other,C1096775,clinical trial,FALSE,FALSE,NA,NA,NA
1,NCT00957554,Inclusion,established essential hypertension,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00957554,Inclusion,treated with irbesartan 150 mg monotherapy for at least 4 weeks,Drug Exposure,Drug,C0288171,irbesartan,FALSE,FALSE,greater_equal 4 weeks,NA,equal 150 mg
3,NCT00957554,Inclusion,with uncontrolled bp defined as mean sbp = or > 145 mmhg assessed by obpm,Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,NA,NA
3,NCT00957554,Inclusion,with uncontrolled bp defined as mean sbp = or > 145 mmhg assessed by obpm,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 145 mmhg,NA
3,NCT00957554,Inclusion,with uncontrolled bp defined as mean sbp = or > 145 mmhg assessed by obpm,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
4,NCT00957554,Inclusion,signed written inform consent obtained prior to inclusion in the study,Other,Other,C1519316,signed,FALSE,FALSE,NA,NA,NA
5,NCT00957554,Inclusion,randomisation criteria :,Other,NA,NA,NA,NA,NA,NA,NA,NA
6,NCT00957554,Inclusion,mean sbp = or > 135 mmhg assessed by hbpm,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 135 mmhg,NA
7,NCT00957554,Inclusion,good compliance with the hbpm protocol defined as at least 12 correct measurements performed over the last 6 days of the first period of measurements,Observation,Other,C3539106,defined,FALSE,FALSE,greater 6 last days,greater_equal 12 correct measurements,NA
8,NCT00957554,Inclusion,creatinine clearance = or > 30 ml / min determined ny cockroft formula,Observation,Observation,C0373595;C0812399,creatinine clearance,FALSE,FALSE,NA,greater_equal 30 ml/min,NA
8,NCT00957554,Inclusion,creatinine clearance = or > 30 ml / min determined ny cockroft formula,Observation,Other,C1879958,ny,FALSE,FALSE,NA,NA,NA
8,NCT00957554,Inclusion,creatinine clearance = or > 30 ml / min determined ny cockroft formula,Observation,Other,C1705501;C0489829,formula,FALSE,FALSE,NA,NA,NA
9,NCT00957554,Exclusion,mean sbp = or > 180 mmhg or mean dbp = or > 110 mmhg measured at doctor office at visit 1,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 180 mmhg,NA
9,NCT00957554,Exclusion,mean sbp = or > 180 mmhg or mean dbp = or > 110 mmhg measured at doctor office at visit 1,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 110 mmhg,NA
9,NCT00957554,Exclusion,mean sbp = or > 180 mmhg or mean dbp = or > 110 mmhg measured at doctor office at visit 1,Observation,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
10,NCT00957554,Exclusion,known or suspected causes of secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
11,NCT00957554,Exclusion,patients with bilateral artery stenosis ; renal artery stenosis in a solitary kidney ; renal transplant or only has one functioning kidney,Condition Occurrence,Condition,C0038449,artery stenosis,FALSE,FALSE,NA,NA,NA
11,NCT00957554,Exclusion,patients with bilateral artery stenosis ; renal artery stenosis in a solitary kidney ; renal transplant or only has one functioning kidney,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
11,NCT00957554,Exclusion,patients with bilateral artery stenosis ; renal artery stenosis in a solitary kidney ; renal transplant or only has one functioning kidney,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
11,NCT00957554,Exclusion,patients with bilateral artery stenosis ; renal artery stenosis in a solitary kidney ; renal transplant or only has one functioning kidney,Condition Occurrence,Procedure,C0022671,renal transplant,FALSE,FALSE,NA,NA,NA
11,NCT00957554,Exclusion,patients with bilateral artery stenosis ; renal artery stenosis in a solitary kidney ; renal transplant or only has one functioning kidney,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
12,NCT00957554,Exclusion,know contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination or history of angioedema related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
12,NCT00957554,Exclusion,know contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination or history of angioedema related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Condition,C0445223,related,FALSE,FALSE,NA,NA,NA
12,NCT00957554,Exclusion,know contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination or history of angioedema related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,NA
12,NCT00957554,Exclusion,know contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination or history of angioedema related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Drug,C0288171,irbesartan,FALSE,FALSE,NA,NA,NA
12,NCT00957554,Exclusion,know contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination or history of angioedema related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Drug,C0521942,angiotensin ii receptor antagonist,FALSE,FALSE,NA,NA,NA
12,NCT00957554,Exclusion,know contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination or history of angioedema related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
12,NCT00957554,Exclusion,know contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination or history of angioedema related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
13,NCT00957554,Exclusion,know type 1 diabetes,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
14,NCT00957554,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history of hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Condition,C0948807,hepatic impairment,FALSE,FALSE,NA,NA,NA
14,NCT00957554,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history of hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Condition,C0019151,hepatic encephalopathy,FALSE,FALSE,NA,NA,NA
14,NCT00957554,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history of hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Condition,C0014867,esophageal varices,FALSE,FALSE,NA,NA,NA
14,NCT00957554,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history of hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Procedure,C0032716,portocaval shunt,FALSE,FALSE,NA,NA,NA
14,NCT00957554,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history of hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Observation,C0001899;C0201836,alanine aminotransferase,FALSE,FALSE,NA,NA,NA
14,NCT00957554,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history of hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Observation,C1140170;C2257651,alt,FALSE,FALSE,NA,NA,NA
14,NCT00957554,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history of hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Observation,C0004002;C0201899,aspartate aminotransferase,FALSE,FALSE,NA,NA,NA
14,NCT00957554,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history of hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Observation,C0004002,ast,FALSE,FALSE,NA,NA,greater 5 times the upper limit of normal
14,NCT00957554,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history of hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
15,NCT00957554,Exclusion,know severe renal impairment ( creatinine clearance < 30 ml / mn ),Drug Exposure,Condition,C1565489;C0035078,renal impairment,FALSE,FALSE,NA,NA,NA
15,NCT00957554,Exclusion,know severe renal impairment ( creatinine clearance < 30 ml / mn ),Drug Exposure,Drug,C2348271,mn,FALSE,FALSE,NA,NA,NA
15,NCT00957554,Exclusion,know severe renal impairment ( creatinine clearance < 30 ml / mn ),Drug Exposure,Observation,C0373595;C0812399,creatinine clearance,FALSE,FALSE,NA,NA,lower 30 ml
15,NCT00957554,Exclusion,know severe renal impairment ( creatinine clearance < 30 ml / mn ),Drug Exposure,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
16,NCT00957554,Exclusion,concomitant use of any other antihypertensive treatment,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
17,NCT00957554,Exclusion,administration of any other investigational drug within 30 days before inclusion,Drug Exposure,Drug,C0013230,investigational drug,FALSE,FALSE,lower 30 days,NA,NA
18,NCT00957554,Exclusion,inability to obtain a valid automatic bp measurement recording,Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,NA,NA
19,NCT00957554,Exclusion,presence of any severe medical condition or psychological condition that ; in the opinion of the investigator ; indicate that participation in the study is not in the best interest of of the patient,Condition Occurrence,Condition,C1306597,psychological,FALSE,FALSE,NA,NA,NA
19,NCT00957554,Exclusion,presence of any severe medical condition or psychological condition that ; in the opinion of the investigator ; indicate that participation in the study is not in the best interest of of the patient,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
19,NCT00957554,Exclusion,presence of any severe medical condition or psychological condition that ; in the opinion of the investigator ; indicate that participation in the study is not in the best interest of of the patient,Condition Occurrence,Other,C1561579;C1561578,medical,FALSE,FALSE,NA,NA,NA
20,NCT00957554,Exclusion,presence of any other conditions ( eg : geographical ; social ; etc ) that would restrict or limit the patient participation for the duration of the study,Procedure,Procedure,C0030699,patient participation,FALSE,FALSE,NA,NA,NA
21,NCT00957554,Exclusion,pregnant or breast feeding women,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
21,NCT00957554,Exclusion,pregnant or breast feeding women,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
21,NCT00957554,Exclusion,pregnant or breast feeding women,Condition Occurrence,Condition,C0006147;C1623040;C1623041,breast feeding,FALSE,FALSE,NA,NA,NA
22,NCT00957554,Exclusion,women of childbearing potential unable or unwilling to use an acceptable method to avoid pregnancy for the entire study period,Observation,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
22,NCT00957554,Exclusion,women of childbearing potential unable or unwilling to use an acceptable method to avoid pregnancy for the entire study period,Observation,Observation,C3831118,childbearing potential,FALSE,FALSE,NA,NA,NA
22,NCT00957554,Exclusion,women of childbearing potential unable or unwilling to use an acceptable method to avoid pregnancy for the entire study period,Observation,Other,C2827714;C0871511;C2828387,method,FALSE,FALSE,NA,NA,NA
22,NCT00957554,Exclusion,women of childbearing potential unable or unwilling to use an acceptable method to avoid pregnancy for the entire study period,Observation,Other,C0032961;C3484365,pregnancy,FALSE,FALSE,NA,NA,NA
23,NCT00957554,Exclusion,the above information is not intended to contain all considerations relevant to a patient potential participation in a clinical trial,Other,Other,C1096775,clinical trial,FALSE,FALSE,NA,NA,NA
1,NCT00993109,Inclusion,men and women aged 18 - 75 years,Person,Person,C0025266,men,FALSE,FALSE,NA,NA,NA
1,NCT00993109,Inclusion,men and women aged 18 - 75 years,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
1,NCT00993109,Inclusion,men and women aged 18 - 75 years,Person,Person,C0001792,aged,FALSE,FALSE,greater_equal 18 years; lower_equal 75 years,NA,NA
2,NCT00993109,Inclusion,essential hypertension not well controlled by current low dose ( 80 mg ) valsartan monotherapy for at least 4 weeks,Drug Exposure,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00993109,Inclusion,essential hypertension not well controlled by current low dose ( 80 mg ) valsartan monotherapy for at least 4 weeks,Drug Exposure,Observation,C2700150,low,TRUE,FALSE,greater_equal 4 weeks,NA,equal 80 mg
3,NCT00993109,Inclusion,patients on prior treatment with monotherapy diuretic blocker ; ace-i blocker or beta blocker or an arb other than valsartan and switched to the current low dose valsartan 80 mg monotherapy for at least 4 weeks are also eligible ; provided the hypertension is still not well controlled .,Drug Exposure,Drug,C0012798,diuretic,FALSE,FALSE,NA,NA,NA
3,NCT00993109,Inclusion,patients on prior treatment with monotherapy diuretic blocker ; ace-i blocker or beta blocker or an arb other than valsartan and switched to the current low dose valsartan 80 mg monotherapy for at least 4 weeks are also eligible ; provided the hypertension is still not well controlled .,Drug Exposure,Drug,C0001645,beta blocker,FALSE,FALSE,NA,NA,NA
3,NCT00993109,Inclusion,patients on prior treatment with monotherapy diuretic blocker ; ace-i blocker or beta blocker or an arb other than valsartan and switched to the current low dose valsartan 80 mg monotherapy for at least 4 weeks are also eligible ; provided the hypertension is still not well controlled .,Drug Exposure,Observation,C1514463,prior treatment,FALSE,FALSE,NA,NA,NA
3,NCT00993109,Inclusion,patients on prior treatment with monotherapy diuretic blocker ; ace-i blocker or beta blocker or an arb other than valsartan and switched to the current low dose valsartan 80 mg monotherapy for at least 4 weeks are also eligible ; provided the hypertension is still not well controlled .,Drug Exposure,Observation,C2700150,low,FALSE,FALSE,greater_equal 4 weeks,NA,equal 80 mg
3,NCT00993109,Inclusion,patients on prior treatment with monotherapy diuretic blocker ; ace-i blocker or beta blocker or an arb other than valsartan and switched to the current low dose valsartan 80 mg monotherapy for at least 4 weeks are also eligible ; provided the hypertension is still not well controlled .,Drug Exposure,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00993109,Inclusion,patients on prior treatment with monotherapy diuretic blocker ; ace-i blocker or beta blocker or an arb other than valsartan and switched to the current low dose valsartan 80 mg monotherapy for at least 4 weeks are also eligible ; provided the hypertension is still not well controlled .,Drug Exposure,Other,C0050385;C0201888,ace,FALSE,FALSE,NA,NA,NA
3,NCT00993109,Inclusion,patients on prior treatment with monotherapy diuretic blocker ; ace-i blocker or beta blocker or an arb other than valsartan and switched to the current low dose valsartan 80 mg monotherapy for at least 4 weeks are also eligible ; provided the hypertension is still not well controlled .,Drug Exposure,Other,C0521942;C2678493,arb,FALSE,FALSE,NA,NA,NA
4,NCT00993109,Inclusion,office systolic blood pressure ( sitting ) > 140 mmhg ( sitting for > / = 5 min . ;,Condition Occurrence,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,greater 140 mmhg,NA
4,NCT00993109,Inclusion,office systolic blood pressure ( sitting ) > 140 mmhg ( sitting for > / = 5 min . ;,Condition Occurrence,Condition,C0277814;C2584297,sitting,FALSE,FALSE,greater_equal 5 min,NA,NA
4,NCT00993109,Inclusion,office systolic blood pressure ( sitting ) > 140 mmhg ( sitting for > / = 5 min . ;,Condition Occurrence,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,NA,NA
5,NCT00993109,Inclusion,no cigarettes or coffee / tea for > / = 30 min ; before bp measurement ) .,Condition Occurrence,Condition,C3496018,tea,TRUE,FALSE,greater_equal 30 min,NA,NA
5,NCT00993109,Inclusion,no cigarettes or coffee / tea for > / = 30 min ; before bp measurement ) .,Condition Occurrence,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,NA,NA
6,NCT00993109,Inclusion,bmi < 33 kg / m2,Observation,Observation,C1305855;C1542867;C0005893,bmi,FALSE,FALSE,NA,lower 33 kg/m2,NA
7,NCT00993109,Exclusion,participation in any clinical investigational drug study within the previous 12 weeks,Drug Exposure,Drug,C0013230,investigational drug,FALSE,FALSE,lower 12 previous weeks,NA,NA
7,NCT00993109,Exclusion,participation in any clinical investigational drug study within the previous 12 weeks,Drug Exposure,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
8,NCT00993109,Exclusion,concomitant treatments with :,Other,NA,NA,NA,NA,NA,NA,NA,NA
9,NCT00993109,Exclusion,any anti-hypertensive treatment other than valsartan 80 mg,Drug Exposure,Drug,C0003364,anti-hypertensive,FALSE,FALSE,NA,NA,equal 80 mg
10,NCT00993109,Exclusion,cytochrome p450-3a4 inhibitors or inducers,Drug Exposure,Drug,C1142644,p450-3a4,FALSE,FALSE,NA,NA,NA
10,NCT00993109,Exclusion,cytochrome p450-3a4 inhibitors or inducers,Drug Exposure,Other,C0010798;C1325304,cytochrome,FALSE,FALSE,NA,NA,NA
11,NCT00993109,Exclusion,potassium-sparing diuretics,Drug Exposure,Drug,C0304490,potassium-sparing diuretics,FALSE,FALSE,NA,NA,NA
12,NCT00993109,Exclusion,severe hypertension ( dbp > / = 110 mm hg or sbp > / = 180 mm hg ) or evidence of secondary forms of hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
12,NCT00993109,Exclusion,severe hypertension ( dbp > / = 110 mm hg or sbp > / = 180 mm hg ) or evidence of secondary forms of hypertension,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 110 mm hg; greater_equal 180 mm hg,NA
12,NCT00993109,Exclusion,severe hypertension ( dbp > / = 110 mm hg or sbp > / = 180 mm hg ) or evidence of secondary forms of hypertension,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 180 mm hg,NA
12,NCT00993109,Exclusion,severe hypertension ( dbp > / = 110 mm hg or sbp > / = 180 mm hg ) or evidence of secondary forms of hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
12,NCT00993109,Exclusion,severe hypertension ( dbp > / = 110 mm hg or sbp > / = 180 mm hg ) or evidence of secondary forms of hypertension,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
13,NCT00993109,Exclusion,any of the following cardiovascular diseases :,Condition Occurrence,Condition,C0007222,cardiovascular diseases,FALSE,FALSE,NA,NA,NA
14,NCT00993109,Exclusion,history of cardiovascular shock,Other,NA,NA,NA,NA,NA,NA,NA,NA
15,NCT00993109,Exclusion,myocardial infarction or unstable angina within the previous 6 months,Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,lower 6 previous months,NA,NA
15,NCT00993109,Exclusion,myocardial infarction or unstable angina within the previous 6 months,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,lower 6 previous months,NA,NA
16,NCT00993109,Exclusion,severe cardiac valve disease,Condition Occurrence,Condition,C0018824,cardiac valve disease,FALSE,FALSE,NA,NA,NA
16,NCT00993109,Exclusion,severe cardiac valve disease,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
17,NCT00993109,Exclusion,past or present severe rhythm or conduction disorder .,Condition Occurrence,Condition,C1523018;C0871269,rhythm,FALSE,FALSE,NA,NA,NA
17,NCT00993109,Exclusion,past or present severe rhythm or conduction disorder .,Condition Occurrence,Condition,C0264886,conduction disorder,FALSE,FALSE,NA,NA,NA
17,NCT00993109,Exclusion,past or present severe rhythm or conduction disorder .,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
18,NCT00993109,Exclusion,cerebrovascular ischemic event or history of intracerebral hemorrhage or subarachnoid hemorrhage ( sah ) within the previous 12 months,Condition Occurrence,Condition,C2937358,intracerebral hemorrhage,FALSE,FALSE,lower 12 previous months,NA,NA
18,NCT00993109,Exclusion,cerebrovascular ischemic event or history of intracerebral hemorrhage or subarachnoid hemorrhage ( sah ) within the previous 12 months,Condition Occurrence,Condition,C0038525,subarachnoid hemorrhage,FALSE,FALSE,lower 12 previous months,NA,NA
19,NCT00993109,Exclusion,type 1 diabetes or type 2 diabetesmellitus,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
19,NCT00993109,Exclusion,type 1 diabetes or type 2 diabetesmellitus,Condition Occurrence,Other,C1552651,type,FALSE,FALSE,NA,NA,NA
20,NCT00993109,Exclusion,proteinuria,Condition Occurrence,Condition,C0033687;C1279888;C1962972,proteinuria,FALSE,FALSE,NA,NA,NA
21,NCT00993109,Exclusion,uncorrected hypokalemia or hyperkalemia ; sodium depletion or hypovolemia,Condition Occurrence,Condition,C0020621,hypokalemia,FALSE,FALSE,NA,NA,NA
21,NCT00993109,Exclusion,uncorrected hypokalemia or hyperkalemia ; sodium depletion or hypovolemia,Condition Occurrence,Condition,C0020461,hyperkalemia,FALSE,FALSE,NA,NA,NA
21,NCT00993109,Exclusion,uncorrected hypokalemia or hyperkalemia ; sodium depletion or hypovolemia,Condition Occurrence,Condition,C0020625,sodium depletion,FALSE,FALSE,NA,NA,NA
21,NCT00993109,Exclusion,uncorrected hypokalemia or hyperkalemia ; sodium depletion or hypovolemia,Condition Occurrence,Condition,C0546884,hypovolemia,FALSE,FALSE,NA,NA,NA
22,NCT00993109,Exclusion,gastrointestinal disease resulting in the potential for malabsorption or severe gastro-intestinal tract narrowing,Condition Occurrence,Condition,C0017178,gastrointestinal disease,FALSE,FALSE,NA,NA,NA
22,NCT00993109,Exclusion,gastrointestinal disease resulting in the potential for malabsorption or severe gastro-intestinal tract narrowing,Condition Occurrence,Condition,C1559265,gastro-intestinal,FALSE,FALSE,NA,NA,NA
22,NCT00993109,Exclusion,gastrointestinal disease resulting in the potential for malabsorption or severe gastro-intestinal tract narrowing,Condition Occurrence,Condition,C1185740,tract,FALSE,FALSE,NA,NA,NA
22,NCT00993109,Exclusion,gastrointestinal disease resulting in the potential for malabsorption or severe gastro-intestinal tract narrowing,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
23,NCT00993109,Exclusion,kock pouch ( ileostomy after proctocolectomy ),Condition Occurrence,Condition,C0086512,kock pouch,FALSE,FALSE,NA,NA,NA
23,NCT00993109,Exclusion,kock pouch ( ileostomy after proctocolectomy ),Condition Occurrence,Condition,C1550267,ileostomy,FALSE,FALSE,NA,NA,NA
23,NCT00993109,Exclusion,kock pouch ( ileostomy after proctocolectomy ),Condition Occurrence,Procedure,C0400076,proctocolectomy,FALSE,FALSE,NA,NA,NA
24,NCT00993109,Exclusion,cholestasis or biliary obstruction,Condition Occurrence,Condition,C0008370,cholestasis,FALSE,FALSE,NA,NA,NA
24,NCT00993109,Exclusion,cholestasis or biliary obstruction,Condition Occurrence,Condition,C0400979,biliary obstruction,FALSE,FALSE,NA,NA,NA
25,NCT00993109,Exclusion,liver disease or aspartate aminotransferase ( ast ) / alanine aminotransferase ( alt ) levels > 3 x upper limits of normal ( uln ),Observation,Condition,C0023895;C2186532,liver disease,FALSE,FALSE,NA,NA,NA
25,NCT00993109,Exclusion,liver disease or aspartate aminotransferase ( ast ) / alanine aminotransferase ( alt ) levels > 3 x upper limits of normal ( uln ),Observation,Observation,C0004002;C0201899,aspartate aminotransferase,FALSE,FALSE,NA,NA,NA
25,NCT00993109,Exclusion,liver disease or aspartate aminotransferase ( ast ) / alanine aminotransferase ( alt ) levels > 3 x upper limits of normal ( uln ),Observation,Observation,C0004002,ast,FALSE,FALSE,NA,NA,NA
25,NCT00993109,Exclusion,liver disease or aspartate aminotransferase ( ast ) / alanine aminotransferase ( alt ) levels > 3 x upper limits of normal ( uln ),Observation,Observation,C0001899;C0201836,alanine aminotransferase,FALSE,FALSE,NA,NA,NA
25,NCT00993109,Exclusion,liver disease or aspartate aminotransferase ( ast ) / alanine aminotransferase ( alt ) levels > 3 x upper limits of normal ( uln ),Observation,Observation,C1140170;C2257651,alt,FALSE,FALSE,NA,greater 3 x upper limits of normal,NA
26,NCT00993109,Exclusion,renal failure ; creatinine level > 2.0 mg / dl,Drug Exposure,Condition,C0035078;C1963154,renal failure,FALSE,FALSE,NA,NA,greater 2.0 mg/dl
26,NCT00993109,Exclusion,renal failure ; creatinine level > 2.0 mg / dl,Drug Exposure,Observation,C0428279;C1318439,creatinine level,FALSE,FALSE,NA,NA,greater 2.0 mg/dl
1,NCT00996281,Inclusion,is treated with antihypertensive therapy and has a post-washout mean sitting clinic systolic blood pressure greater than or equal to 160 and less than or equal to 190 mm hg on day ; or has not received antihypertensive treatment within 14 days prior to screening and has a mean sitting clinic systolic blood pressure greater than or equal to 160 and less than or equal to 190 mm hg at the screening visit and on day 1 .,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
1,NCT00996281,Inclusion,is treated with antihypertensive therapy and has a post-washout mean sitting clinic systolic blood pressure greater than or equal to 160 and less than or equal to 190 mm hg on day ; or has not received antihypertensive treatment within 14 days prior to screening and has a mean sitting clinic systolic blood pressure greater than or equal to 160 and less than or equal to 190 mm hg at the screening visit and on day 1 .,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
1,NCT00996281,Inclusion,is treated with antihypertensive therapy and has a post-washout mean sitting clinic systolic blood pressure greater than or equal to 160 and less than or equal to 190 mm hg on day ; or has not received antihypertensive treatment within 14 days prior to screening and has a mean sitting clinic systolic blood pressure greater than or equal to 160 and less than or equal to 190 mm hg at the screening visit and on day 1 .,Observation,Drug,C0003364,antihypertensive,TRUE,FALSE,lower 14 days,NA,NA
1,NCT00996281,Inclusion,is treated with antihypertensive therapy and has a post-washout mean sitting clinic systolic blood pressure greater than or equal to 160 and less than or equal to 190 mm hg on day ; or has not received antihypertensive treatment within 14 days prior to screening and has a mean sitting clinic systolic blood pressure greater than or equal to 160 and less than or equal to 190 mm hg at the screening visit and on day 1 .,Observation,Procedure,C0585941,antihypertensive therapy,FALSE,FALSE,NA,NA,NA
1,NCT00996281,Inclusion,is treated with antihypertensive therapy and has a post-washout mean sitting clinic systolic blood pressure greater than or equal to 160 and less than or equal to 190 mm hg on day ; or has not received antihypertensive treatment within 14 days prior to screening and has a mean sitting clinic systolic blood pressure greater than or equal to 160 and less than or equal to 190 mm hg at the screening visit and on day 1 .,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater_equal 160 mm hg; lower_equal 190 mm hg,NA
1,NCT00996281,Inclusion,is treated with antihypertensive therapy and has a post-washout mean sitting clinic systolic blood pressure greater than or equal to 160 and less than or equal to 190 mm hg on day ; or has not received antihypertensive treatment within 14 days prior to screening and has a mean sitting clinic systolic blood pressure greater than or equal to 160 and less than or equal to 190 mm hg at the screening visit and on day 1 .,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,equal 1 day,greater_equal 160 mm hg; lower_equal 190 mm hg,NA
2,NCT00996281,Inclusion,females of childbearing potential who are sexually active agree to routinely use adequate contraception ; and can neither be pregnant nor lactating from before study participation to screening to 30 days after the last study drug dose .,Condition Occurrence,Person,C0086287,females,FALSE,FALSE,NA,NA,NA
2,NCT00996281,Inclusion,females of childbearing potential who are sexually active agree to routinely use adequate contraception ; and can neither be pregnant nor lactating from before study participation to screening to 30 days after the last study drug dose .,Condition Occurrence,Condition,C0241028,sexually active,FALSE,FALSE,NA,NA,NA
2,NCT00996281,Inclusion,females of childbearing potential who are sexually active agree to routinely use adequate contraception ; and can neither be pregnant nor lactating from before study participation to screening to 30 days after the last study drug dose .,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,equal 30 days,NA,NA
2,NCT00996281,Inclusion,females of childbearing potential who are sexually active agree to routinely use adequate contraception ; and can neither be pregnant nor lactating from before study participation to screening to 30 days after the last study drug dose .,Condition Occurrence,Condition,C2828358;C3668831,lactating,FALSE,FALSE,equal 30 days,NA,NA
2,NCT00996281,Inclusion,females of childbearing potential who are sexually active agree to routinely use adequate contraception ; and can neither be pregnant nor lactating from before study participation to screening to 30 days after the last study drug dose .,Condition Occurrence,Procedure,C0700589,contraception,FALSE,FALSE,NA,NA,NA
2,NCT00996281,Inclusion,females of childbearing potential who are sexually active agree to routinely use adequate contraception ; and can neither be pregnant nor lactating from before study participation to screening to 30 days after the last study drug dose .,Condition Occurrence,Observation,C3831118,childbearing potential,FALSE,FALSE,NA,NA,NA
2,NCT00996281,Inclusion,females of childbearing potential who are sexually active agree to routinely use adequate contraception ; and can neither be pregnant nor lactating from before study participation to screening to 30 days after the last study drug dose .,Condition Occurrence,Other,C3641827,agree,FALSE,FALSE,NA,NA,NA
2,NCT00996281,Inclusion,females of childbearing potential who are sexually active agree to routinely use adequate contraception ; and can neither be pregnant nor lactating from before study participation to screening to 30 days after the last study drug dose .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
3,NCT00996281,Inclusion,has clinical laboratory test results within the reference range for the testing laboratory or the investigator does not consider the results to be clinically significant .,Observation,Observation,C0022885,laboratory test,FALSE,FALSE,NA,NA,NA
3,NCT00996281,Inclusion,has clinical laboratory test results within the reference range for the testing laboratory or the investigator does not consider the results to be clinically significant .,Observation,Observation,C3542016,range,FALSE,FALSE,NA,NA,NA
3,NCT00996281,Inclusion,has clinical laboratory test results within the reference range for the testing laboratory or the investigator does not consider the results to be clinically significant .,Observation,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
3,NCT00996281,Inclusion,has clinical laboratory test results within the reference range for the testing laboratory or the investigator does not consider the results to be clinically significant .,Observation,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
4,NCT00996281,Inclusion,is willing to discontinue current antihypertensive medications up to 3 weeks before enrollment .,Other,Drug,C0003364,antihypertensive,FALSE,FALSE,lower_equal 3 weeks,NA,NA
4,NCT00996281,Inclusion,is willing to discontinue current antihypertensive medications up to 3 weeks before enrollment .,Other,Other,C1706472,discontinue,FALSE,FALSE,NA,NA,NA
4,NCT00996281,Inclusion,is willing to discontinue current antihypertensive medications up to 3 weeks before enrollment .,Other,Other,C1696073;C1516879,enrollment,FALSE,FALSE,NA,NA,NA
5,NCT00996281,Exclusion,has a mean clinic diastolic blood pressure ( sitting ; trough ) greater than 119 mm hg on day 1 .,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,equal 1 day,greater 119 mm hg,NA
5,NCT00996281,Exclusion,has a mean clinic diastolic blood pressure ( sitting ; trough ) greater than 119 mm hg on day 1 .,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,NA,NA
6,NCT00996281,Exclusion,has secondary hypertension of any etiology ( eg ; renovascular disease ; pheochromocytoma ; cushing syndrome ) .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
6,NCT00996281,Exclusion,has secondary hypertension of any etiology ( eg ; renovascular disease ; pheochromocytoma ; cushing syndrome ) .,Condition Occurrence,Condition,C0268790,renovascular,FALSE,FALSE,NA,NA,NA
6,NCT00996281,Exclusion,has secondary hypertension of any etiology ( eg ; renovascular disease ; pheochromocytoma ; cushing syndrome ) .,Condition Occurrence,Condition,C0010481,cushing syndrome,FALSE,FALSE,NA,NA,NA
6,NCT00996281,Exclusion,has secondary hypertension of any etiology ( eg ; renovascular disease ; pheochromocytoma ; cushing syndrome ) .,Condition Occurrence,Condition,C0031511;C1706920,pheochromocytoma,FALSE,FALSE,NA,NA,NA
7,NCT00996281,Exclusion,has a recent history ( within the last 6 months ) of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident or transient ischemic attack .,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,lower 6 last months,NA,NA
7,NCT00996281,Exclusion,has a recent history ( within the last 6 months ) of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident or transient ischemic attack .,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,lower 6 last months,NA,NA
7,NCT00996281,Exclusion,has a recent history ( within the last 6 months ) of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident or transient ischemic attack .,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,lower 6 last months,NA,NA
7,NCT00996281,Exclusion,has a recent history ( within the last 6 months ) of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident or transient ischemic attack .,Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,lower 6 last months,NA,NA
7,NCT00996281,Exclusion,has a recent history ( within the last 6 months ) of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident or transient ischemic attack .,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,lower 6 last months,NA,NA
7,NCT00996281,Exclusion,has a recent history ( within the last 6 months ) of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident or transient ischemic attack .,Condition Occurrence,Procedure,C1532338,percutaneous coronary intervention,FALSE,FALSE,lower 6 last months,NA,NA
7,NCT00996281,Exclusion,has a recent history ( within the last 6 months ) of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident or transient ischemic attack .,Condition Occurrence,Procedure,C0010055,coronary artery bypass graft,FALSE,FALSE,lower 6 last months,NA,NA
7,NCT00996281,Exclusion,has a recent history ( within the last 6 months ) of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident or transient ischemic attack .,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,lower 6 last months,NA,NA
8,NCT00996281,Exclusion,has clinically significant cardiac conduction defects ( ie ; third-degree atrioventricular block ; sick sinus syndrome ) .,Condition Occurrence,Condition,C0264886,cardiac conduction defects,FALSE,FALSE,NA,NA,NA
8,NCT00996281,Exclusion,has clinically significant cardiac conduction defects ( ie ; third-degree atrioventricular block ; sick sinus syndrome ) .,Condition Occurrence,Condition,C0004245;C2108077,atrioventricular block,FALSE,FALSE,NA,NA,NA
8,NCT00996281,Exclusion,has clinically significant cardiac conduction defects ( ie ; third-degree atrioventricular block ; sick sinus syndrome ) .,Condition Occurrence,Condition,C0037052;C1963235,sick sinus syndrome,FALSE,FALSE,NA,NA,NA
8,NCT00996281,Exclusion,has clinically significant cardiac conduction defects ( ie ; third-degree atrioventricular block ; sick sinus syndrome ) .,Condition Occurrence,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
9,NCT00996281,Exclusion,has hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease .,Condition Occurrence,Condition,C0023213,left ventricular outflow obstruction,FALSE,FALSE,NA,NA,NA
9,NCT00996281,Exclusion,has hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease .,Condition Occurrence,Condition,C1260873,aortic valvular disease,FALSE,FALSE,NA,NA,NA
10,NCT00996281,Exclusion,has severe renal dysfunction or disease .,Condition Occurrence,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
10,NCT00996281,Exclusion,has severe renal dysfunction or disease .,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
11,NCT00996281,Exclusion,has known or suspected unilateral renal artery or bilateral renal artery stenosis .,Condition Occurrence,Condition,C0035065;C1278951,renal artery,FALSE,FALSE,NA,NA,NA
11,NCT00996281,Exclusion,has known or suspected unilateral renal artery or bilateral renal artery stenosis .,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
12,NCT00996281,Exclusion,has a history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug .,Condition Occurrence,Condition,C0544452,remission,TRUE,FALSE,greater_equal 5 years,NA,NA
12,NCT00996281,Exclusion,has a history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug .,Condition Occurrence,Other,C0260515;C2707253,cancer,FALSE,FALSE,NA,NA,NA
12,NCT00996281,Exclusion,has a history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
13,NCT00996281,Exclusion,has poorly-controlled type 1 diabetes or type 2 diabetesmellitus at screening .,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
13,NCT00996281,Exclusion,has poorly-controlled type 1 diabetes or type 2 diabetesmellitus at screening .,Condition Occurrence,Other,C1552651,type,FALSE,FALSE,NA,NA,NA
14,NCT00996281,Exclusion,has hypokalemia or hyperkalemia at screening .,Condition Occurrence,Condition,C0020621,hypokalemia,FALSE,FALSE,NA,NA,NA
14,NCT00996281,Exclusion,has hypokalemia or hyperkalemia at screening .,Condition Occurrence,Condition,C0020461,hyperkalemia,FALSE,FALSE,NA,NA,NA
15,NCT00996281,Exclusion,has an alanine aminotransferase or aspartate aminotransferase level of greater than 2.5 times the upper limit of normal liver disease ; active liver disease ; or jaundice at screening .,Drug Exposure,Condition,C0023895;C2186532,liver disease,FALSE,FALSE,NA,NA,NA
15,NCT00996281,Exclusion,has an alanine aminotransferase or aspartate aminotransferase level of greater than 2.5 times the upper limit of normal liver disease ; active liver disease ; or jaundice at screening .,Drug Exposure,Condition,C0023895;C2186532,liver disease,FALSE,FALSE,NA,NA,NA
15,NCT00996281,Exclusion,has an alanine aminotransferase or aspartate aminotransferase level of greater than 2.5 times the upper limit of normal liver disease ; active liver disease ; or jaundice at screening .,Drug Exposure,Condition,C2203646,jaundice,FALSE,FALSE,NA,NA,NA
15,NCT00996281,Exclusion,has an alanine aminotransferase or aspartate aminotransferase level of greater than 2.5 times the upper limit of normal liver disease ; active liver disease ; or jaundice at screening .,Drug Exposure,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
15,NCT00996281,Exclusion,has an alanine aminotransferase or aspartate aminotransferase level of greater than 2.5 times the upper limit of normal liver disease ; active liver disease ; or jaundice at screening .,Drug Exposure,Observation,C0001899;C0201836,alanine aminotransferase,FALSE,FALSE,NA,NA,greater 2.5 times the upper limit of normal
15,NCT00996281,Exclusion,has an alanine aminotransferase or aspartate aminotransferase level of greater than 2.5 times the upper limit of normal liver disease ; active liver disease ; or jaundice at screening .,Drug Exposure,Observation,C0428339,aspartate aminotransferase level,FALSE,FALSE,NA,NA,greater 2.5 times the upper limit of normal
16,NCT00996281,Exclusion,has any other known serious disease or condition that would compromise safety ; might affect life expectancy ; or make it difficult to successfully manage and follow according to the protocol .,Other,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
16,NCT00996281,Exclusion,has any other known serious disease or condition that would compromise safety ; might affect life expectancy ; or make it difficult to successfully manage and follow according to the protocol .,Other,Other,C0023671,life expectancy,FALSE,FALSE,NA,NA,NA
16,NCT00996281,Exclusion,has any other known serious disease or condition that would compromise safety ; might affect life expectancy ; or make it difficult to successfully manage and follow according to the protocol .,Other,Other,C1719822,follow,FALSE,FALSE,NA,NA,NA
17,NCT00996281,Exclusion,has known hypersensitivity to angiotensin ii receptor blockers or thiazide-type diuretics or other sulfonamide-derived compounds .,Drug Exposure,Drug,C0541746,thiazide,FALSE,FALSE,NA,NA,NA
17,NCT00996281,Exclusion,has known hypersensitivity to angiotensin ii receptor blockers or thiazide-type diuretics or other sulfonamide-derived compounds .,Drug Exposure,Drug,C0012798,diuretics,FALSE,FALSE,NA,NA,NA
17,NCT00996281,Exclusion,has known hypersensitivity to angiotensin ii receptor blockers or thiazide-type diuretics or other sulfonamide-derived compounds .,Drug Exposure,Drug,C0599503;C3536763,sulfonamide,FALSE,FALSE,NA,NA,NA
17,NCT00996281,Exclusion,has known hypersensitivity to angiotensin ii receptor blockers or thiazide-type diuretics or other sulfonamide-derived compounds .,Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
17,NCT00996281,Exclusion,has known hypersensitivity to angiotensin ii receptor blockers or thiazide-type diuretics or other sulfonamide-derived compounds .,Drug Exposure,Other,C2757003;C0521942,angiotensin ii receptor blockers,FALSE,FALSE,NA,NA,NA
18,NCT00996281,Exclusion,has been randomized / enrolled in a previous azilsartan or azilsartan medoxomil plus chlorthalidone study .,Drug Exposure,Drug,C1958569,azilsartan,FALSE,FALSE,NA,NA,NA
18,NCT00996281,Exclusion,has been randomized / enrolled in a previous azilsartan or azilsartan medoxomil plus chlorthalidone study .,Drug Exposure,Drug,C0008294,chlorthalidone,FALSE,FALSE,NA,NA,NA
18,NCT00996281,Exclusion,has been randomized / enrolled in a previous azilsartan or azilsartan medoxomil plus chlorthalidone study .,Drug Exposure,Drug,C2698291,azilsartan medoxomil,FALSE,FALSE,NA,NA,NA
19,NCT00996281,Exclusion,currently is participating in another investigational study or has received any investigational compound within 30 days prior to screening .,Other,Drug,C1706082,compound,FALSE,FALSE,lower 30 days,NA,NA
19,NCT00996281,Exclusion,currently is participating in another investigational study or has received any investigational compound within 30 days prior to screening .,Other,Other,C3245491,investigational,FALSE,FALSE,NA,NA,NA
19,NCT00996281,Exclusion,currently is participating in another investigational study or has received any investigational compound within 30 days prior to screening .,Other,Other,C3245491,investigational,FALSE,FALSE,NA,NA,NA
20,NCT00996281,Exclusion,has a history of drug abuse or a history of alcohol abuse within the past 2 years .,Condition Occurrence,Condition,C0013146,drug abuse,FALSE,FALSE,NA,NA,NA
20,NCT00996281,Exclusion,has a history of drug abuse or a history of alcohol abuse within the past 2 years .,Condition Occurrence,Condition,C0085762,alcohol abuse,FALSE,FALSE,lower 2 past years,NA,NA
21,NCT00996281,Exclusion,is taking or expected to take any excluded medication;including :,Other,NA,NA,NA,NA,NA,NA,NA,NA
22,NCT00996281,Exclusion,antihypertensive medications must be discontinued completely by day 14 ; except antihypertensive medications used in the open-label treatment period in accordance with the titration-to-target blood pressure titration .,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,equal 14 day,NA,NA
22,NCT00996281,Exclusion,antihypertensive medications must be discontinued completely by day 14 ; except antihypertensive medications used in the open-label treatment period in accordance with the titration-to-target blood pressure titration .,Observation,Drug,C0003364,antihypertensive,TRUE,FALSE,NA,NA,NA
22,NCT00996281,Exclusion,antihypertensive medications must be discontinued completely by day 14 ; except antihypertensive medications used in the open-label treatment period in accordance with the titration-to-target blood pressure titration .,Observation,Observation,C0162621,titration,FALSE,FALSE,NA,NA,NA
22,NCT00996281,Exclusion,antihypertensive medications must be discontinued completely by day 14 ; except antihypertensive medications used in the open-label treatment period in accordance with the titration-to-target blood pressure titration .,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
22,NCT00996281,Exclusion,antihypertensive medications must be discontinued completely by day 14 ; except antihypertensive medications used in the open-label treatment period in accordance with the titration-to-target blood pressure titration .,Observation,Observation,C0162621,titration,FALSE,FALSE,NA,NA,NA
22,NCT00996281,Exclusion,antihypertensive medications must be discontinued completely by day 14 ; except antihypertensive medications used in the open-label treatment period in accordance with the titration-to-target blood pressure titration .,Observation,Other,C1705425,label,FALSE,FALSE,NA,NA,NA
23,NCT00996281,Exclusion,angiotensin ii receptor blockers or thiazide-type diuretics other than study medication .,Drug Exposure,Drug,C0541746,thiazide,FALSE,FALSE,NA,NA,NA
23,NCT00996281,Exclusion,angiotensin ii receptor blockers or thiazide-type diuretics other than study medication .,Drug Exposure,Drug,C0012798,diuretics,FALSE,FALSE,NA,NA,NA
23,NCT00996281,Exclusion,angiotensin ii receptor blockers or thiazide-type diuretics other than study medication .,Drug Exposure,Other,C2757003;C0521942,angiotensin ii receptor blockers,FALSE,FALSE,NA,NA,NA
24,NCT00996281,Exclusion,over-the-counter products not permitted by investigator,Drug Exposure,Drug,C0013231,over-the-counter,FALSE,FALSE,NA,NA,NA
1,NCT01001572,Inclusion,patients must give written informed consent,Other,NA,NA,NA,NA,NA,NA,NA,NA
2,NCT01001572,Inclusion,male or female ages 18 or older and less than 86 years,Person,Person,C0025266,male,FALSE,FALSE,NA,NA,NA
2,NCT01001572,Inclusion,male or female ages 18 or older and less than 86 years,Person,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
2,NCT01001572,Inclusion,male or female ages 18 or older and less than 86 years,Person,Person,C0001779,ages,FALSE,FALSE,greater_equal 18 years; lower 86 years,NA,NA
3,NCT01001572,Inclusion,diagnosed as having essential diastolic hypertension ; as follows :,Condition Occurrence,Condition,C3694763,essential diastolic hypertension,FALSE,FALSE,NA,NA,NA
4,NCT01001572,Inclusion,visit 2 / single-blind run-in entry ; all participants must have a msdbp > = 95 mmhg and < 100 mmhg,Observation,Condition,C1549113,single,FALSE,FALSE,NA,NA,NA
4,NCT01001572,Inclusion,visit 2 / single-blind run-in entry ; all participants must have a msdbp > = 95 mmhg and < 100 mmhg,Observation,Other,C1705654,entry,FALSE,FALSE,NA,greater_equal 95 mmhg; lower 100 mmhg,NA
5,NCT01001572,Inclusion,at visit 3 / core double-blind treatment period entry ; all patients must have a msdbp > = 90 mmhg and < 110 mmhg,Observation,Condition,C3274653,core,FALSE,FALSE,NA,NA,NA
5,NCT01001572,Inclusion,at visit 3 / core double-blind treatment period entry ; all patients must have a msdbp > = 90 mmhg and < 110 mmhg,Observation,Other,C1561606;C1561605,blind,FALSE,FALSE,NA,NA,NA
5,NCT01001572,Inclusion,at visit 3 / core double-blind treatment period entry ; all patients must have a msdbp > = 90 mmhg and < 110 mmhg,Observation,Other,C1705654,entry,FALSE,FALSE,NA,greater_equal 90 mmhg; lower 110 mmhg,NA
6,NCT01001572,Exclusion,severe hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
6,NCT01001572,Exclusion,severe hypertension,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
7,NCT01001572,Exclusion,evidence of secondary form of hypertension ( coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma or polycystic kidney disease ),Condition Occurrence,Condition,C0332886,coarctation,FALSE,FALSE,NA,NA,NA
7,NCT01001572,Exclusion,evidence of secondary form of hypertension ( coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma or polycystic kidney disease ),Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
7,NCT01001572,Exclusion,evidence of secondary form of hypertension ( coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma or polycystic kidney disease ),Condition Occurrence,Condition,C0035065;C1278951,renal artery,FALSE,FALSE,NA,NA,NA
7,NCT01001572,Exclusion,evidence of secondary form of hypertension ( coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma or polycystic kidney disease ),Condition Occurrence,Condition,C0020428,hyperaldosteronism,FALSE,FALSE,NA,NA,NA
7,NCT01001572,Exclusion,evidence of secondary form of hypertension ( coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma or polycystic kidney disease ),Condition Occurrence,Condition,C0221406;C0010481,cushing disease,FALSE,FALSE,NA,NA,NA
7,NCT01001572,Exclusion,evidence of secondary form of hypertension ( coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma or polycystic kidney disease ),Condition Occurrence,Condition,C0022680,polycystic kidney disease,FALSE,FALSE,NA,NA,NA
7,NCT01001572,Exclusion,evidence of secondary form of hypertension ( coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma or polycystic kidney disease ),Condition Occurrence,Condition,C0031511;C1706920,pheochromocytoma,FALSE,FALSE,NA,NA,NA
7,NCT01001572,Exclusion,evidence of secondary form of hypertension ( coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma or polycystic kidney disease ),Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
7,NCT01001572,Exclusion,evidence of secondary form of hypertension ( coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing disease ; pheochromocytoma or polycystic kidney disease ),Condition Occurrence,Other,C0869784;C0003483;C1278934,aorta,FALSE,FALSE,NA,NA,NA
8,NCT01001572,Exclusion,malignant hypertension,Condition Occurrence,Condition,C0020540;C0024588,malignant hypertension,FALSE,FALSE,NA,NA,NA
9,NCT01001572,Exclusion,administration of any agent indicated for the treatment of hypertension after visit 1,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
10,NCT01001572,Exclusion,known moderate retinopathy or malignant retinopathy .,Condition Occurrence,Condition,C0035309;C1962966,retinopathy,FALSE,FALSE,NA,NA,NA
10,NCT01001572,Exclusion,known moderate retinopathy or malignant retinopathy .,Condition Occurrence,Condition,C0334590;C1533592,malignant,FALSE,FALSE,NA,NA,NA
10,NCT01001572,Exclusion,known moderate retinopathy or malignant retinopathy .,Condition Occurrence,Condition,C0035309;C1962966,retinopathy,FALSE,FALSE,NA,NA,NA
10,NCT01001572,Exclusion,known moderate retinopathy or malignant retinopathy .,Condition Occurrence,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
11,NCT01001572,Exclusion,known or suspected contraindications ; including history of allergy or hypersensitivity to angiotensin ii receptor blockers ( arbs ) ; calcium channel blockers ( ccbs ) ; or to drugs with similar chemical structures,Drug Exposure,Drug,C0006684,calcium channel blockers,FALSE,FALSE,NA,NA,NA
11,NCT01001572,Exclusion,known or suspected contraindications ; including history of allergy or hypersensitivity to angiotensin ii receptor blockers ( arbs ) ; calcium channel blockers ( ccbs ) ; or to drugs with similar chemical structures,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
11,NCT01001572,Exclusion,known or suspected contraindications ; including history of allergy or hypersensitivity to angiotensin ii receptor blockers ( arbs ) ; calcium channel blockers ( ccbs ) ; or to drugs with similar chemical structures,Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
11,NCT01001572,Exclusion,known or suspected contraindications ; including history of allergy or hypersensitivity to angiotensin ii receptor blockers ( arbs ) ; calcium channel blockers ( ccbs ) ; or to drugs with similar chemical structures,Drug Exposure,Other,C0489531;C0718579;C3542994;C3539909;C1314973;C1547315;C1611280,allergy,FALSE,FALSE,NA,NA,NA
11,NCT01001572,Exclusion,known or suspected contraindications ; including history of allergy or hypersensitivity to angiotensin ii receptor blockers ( arbs ) ; calcium channel blockers ( ccbs ) ; or to drugs with similar chemical structures,Drug Exposure,Other,C2757003;C0521942,angiotensin ii receptor blockers,FALSE,FALSE,NA,NA,NA
11,NCT01001572,Exclusion,known or suspected contraindications ; including history of allergy or hypersensitivity to angiotensin ii receptor blockers ( arbs ) ; calcium channel blockers ( ccbs ) ; or to drugs with similar chemical structures,Drug Exposure,Other,C0220806;C3272558,chemical,FALSE,FALSE,NA,NA,NA
12,NCT01001572,Exclusion,history of hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack ; myocardial infarction or all types of revascularization ; angina pectoris of any type ; including unstable angina,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
12,NCT01001572,Exclusion,history of hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack ; myocardial infarction or all types of revascularization ; angina pectoris of any type ; including unstable angina,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,NA,NA,NA
12,NCT01001572,Exclusion,history of hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack ; myocardial infarction or all types of revascularization ; angina pectoris of any type ; including unstable angina,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
12,NCT01001572,Exclusion,history of hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack ; myocardial infarction or all types of revascularization ; angina pectoris of any type ; including unstable angina,Condition Occurrence,Condition,C0002962;C0577698;C0235467;C0542052;C0010073;C0541777;C0235462,angina pectoris,FALSE,FALSE,NA,NA,NA
12,NCT01001572,Exclusion,history of hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack ; myocardial infarction or all types of revascularization ; angina pectoris of any type ; including unstable angina,Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,NA,NA,NA
12,NCT01001572,Exclusion,history of hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack ; myocardial infarction or all types of revascularization ; angina pectoris of any type ; including unstable angina,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
12,NCT01001572,Exclusion,history of hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack ; myocardial infarction or all types of revascularization ; angina pectoris of any type ; including unstable angina,Condition Occurrence,Other,C1552651,type,FALSE,FALSE,NA,NA,NA
13,NCT01001572,Exclusion,history of heart failure grade ii - grade iv according to new york heart association ( nyha ) classification,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
13,NCT01001572,Exclusion,history of heart failure grade ii - grade iv according to new york heart association ( nyha ) classification,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
13,NCT01001572,Exclusion,history of heart failure grade ii - grade iv according to new york heart association ( nyha ) classification,Condition Occurrence,Other,C0441802;C0475270,grade ii,FALSE,FALSE,NA,NA,NA
13,NCT01001572,Exclusion,history of heart failure grade ii - grade iv according to new york heart association ( nyha ) classification,Condition Occurrence,Other,C0677510;C0021440;C3496001,iv,FALSE,FALSE,NA,NA,NA
13,NCT01001572,Exclusion,history of heart failure grade ii - grade iv according to new york heart association ( nyha ) classification,Condition Occurrence,Other,C1275491,nyha classification,FALSE,FALSE,NA,NA,NA
14,NCT01001572,Exclusion,second of third degree heart block regardless of the use of a pacemaker ; concomitant potentially life-threatening arrhythmia or symptomatic arrhythmia,Condition Occurrence,Condition,C0018794;C0542001;C0037188,heart block,FALSE,FALSE,NA,NA,NA
14,NCT01001572,Exclusion,second of third degree heart block regardless of the use of a pacemaker ; concomitant potentially life-threatening arrhythmia or symptomatic arrhythmia,Condition Occurrence,Condition,C2826244;C3537125,life-threatening,FALSE,FALSE,NA,NA,NA
14,NCT01001572,Exclusion,second of third degree heart block regardless of the use of a pacemaker ; concomitant potentially life-threatening arrhythmia or symptomatic arrhythmia,Condition Occurrence,Condition,C0003811,arrhythmia,FALSE,FALSE,NA,NA,NA
14,NCT01001572,Exclusion,second of third degree heart block regardless of the use of a pacemaker ; concomitant potentially life-threatening arrhythmia or symptomatic arrhythmia,Condition Occurrence,Condition,C0003811,arrhythmia,FALSE,FALSE,NA,NA,NA
14,NCT01001572,Exclusion,second of third degree heart block regardless of the use of a pacemaker ; concomitant potentially life-threatening arrhythmia or symptomatic arrhythmia,Condition Occurrence,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
14,NCT01001572,Exclusion,second of third degree heart block regardless of the use of a pacemaker ; concomitant potentially life-threatening arrhythmia or symptomatic arrhythmia,Condition Occurrence,Other,C3275122;C1546728,pacemaker,FALSE,FALSE,NA,NA,NA
15,NCT01001572,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT01033071,Inclusion,has a mean sitting clinic systolic blood pressure greater than or equal to 160 and less than or equal to 190 mm hg .,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
1,NCT01033071,Inclusion,has a mean sitting clinic systolic blood pressure greater than or equal to 160 and less than or equal to 190 mm hg .,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater_equal 160 mm hg; lower_equal 190 mm hg,NA
2,NCT01033071,Inclusion,females of childbearing potential who are sexually active agree to routinely use adequate contraception from screening through 30 days after the last administered study drug dose .,Condition Occurrence,Person,C0086287,females,FALSE,FALSE,NA,NA,NA
2,NCT01033071,Inclusion,females of childbearing potential who are sexually active agree to routinely use adequate contraception from screening through 30 days after the last administered study drug dose .,Condition Occurrence,Condition,C0241028,sexually active,FALSE,FALSE,NA,NA,NA
2,NCT01033071,Inclusion,females of childbearing potential who are sexually active agree to routinely use adequate contraception from screening through 30 days after the last administered study drug dose .,Condition Occurrence,Procedure,C0700589,contraception,FALSE,FALSE,equal 30 days,NA,NA
2,NCT01033071,Inclusion,females of childbearing potential who are sexually active agree to routinely use adequate contraception from screening through 30 days after the last administered study drug dose .,Condition Occurrence,Observation,C3831118,childbearing potential,FALSE,FALSE,NA,NA,NA
2,NCT01033071,Inclusion,females of childbearing potential who are sexually active agree to routinely use adequate contraception from screening through 30 days after the last administered study drug dose .,Condition Occurrence,Other,C3641827,agree,FALSE,FALSE,NA,NA,NA
2,NCT01033071,Inclusion,females of childbearing potential who are sexually active agree to routinely use adequate contraception from screening through 30 days after the last administered study drug dose .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
3,NCT01033071,Inclusion,has clinical laboratory test results within the reference range for the testing laboratory or the investigator does not consider the results to be clinically significant .,Observation,Observation,C0022885,laboratory test,FALSE,FALSE,NA,NA,NA
3,NCT01033071,Inclusion,has clinical laboratory test results within the reference range for the testing laboratory or the investigator does not consider the results to be clinically significant .,Observation,Observation,C3542016,range,FALSE,FALSE,NA,NA,NA
3,NCT01033071,Inclusion,has clinical laboratory test results within the reference range for the testing laboratory or the investigator does not consider the results to be clinically significant .,Observation,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
3,NCT01033071,Inclusion,has clinical laboratory test results within the reference range for the testing laboratory or the investigator does not consider the results to be clinically significant .,Observation,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
4,NCT01033071,Inclusion,is willing to discontinue current antihypertensive medications on day 21 or day 28 if the participant is on amlodipine or chlorthalidone .,Drug Exposure,Person,C0679646,participant,FALSE,FALSE,NA,NA,NA
4,NCT01033071,Inclusion,is willing to discontinue current antihypertensive medications on day 21 or day 28 if the participant is on amlodipine or chlorthalidone .,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,equal 21 or day,equal 28,NA
4,NCT01033071,Inclusion,is willing to discontinue current antihypertensive medications on day 21 or day 28 if the participant is on amlodipine or chlorthalidone .,Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,NA
4,NCT01033071,Inclusion,is willing to discontinue current antihypertensive medications on day 21 or day 28 if the participant is on amlodipine or chlorthalidone .,Drug Exposure,Drug,C0008294,chlorthalidone,FALSE,FALSE,NA,NA,NA
4,NCT01033071,Inclusion,is willing to discontinue current antihypertensive medications on day 21 or day 28 if the participant is on amlodipine or chlorthalidone .,Drug Exposure,Other,C1706472,discontinue,FALSE,FALSE,NA,NA,NA
5,NCT01033071,Exclusion,has a mean sitting clinic diastolic blood pressure greater than 119 mm hg on day 1 .,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
5,NCT01033071,Exclusion,has a mean sitting clinic diastolic blood pressure greater than 119 mm hg on day 1 .,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,equal 1 day,greater 119 mm hg,NA
6,NCT01033071,Exclusion,has a baseline 24 - hour ambulatory blood pressure monitoring reading of insufficient quality .,Observation,Condition,C1705179,reading,FALSE,FALSE,NA,NA,NA
6,NCT01033071,Exclusion,has a baseline 24 - hour ambulatory blood pressure monitoring reading of insufficient quality .,Observation,Observation,C0242876,ambulatory blood pressure monitoring,FALSE,FALSE,equal 24 hour,NA,NA
7,NCT01033071,Exclusion,works a night ( third ) shift .,Other,NA,NA,NA,NA,NA,NA,NA,NA
8,NCT01033071,Exclusion,has an upper arm circumference less than 24 cm or greater than 42 cm .,Observation,Condition,C0446516;C1269612,upper arm,FALSE,FALSE,NA,lower 24 cm; greater 42 cm,NA
9,NCT01033071,Exclusion,has secondary hypertension of any etiology .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
10,NCT01033071,Exclusion,has a recent history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,NA,NA,NA
10,NCT01033071,Exclusion,has a recent history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
10,NCT01033071,Exclusion,has a recent history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
10,NCT01033071,Exclusion,has a recent history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,NA,NA,NA
10,NCT01033071,Exclusion,has a recent history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
10,NCT01033071,Exclusion,has a recent history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Procedure,C1532338,percutaneous coronary intervention,FALSE,FALSE,NA,NA,NA
10,NCT01033071,Exclusion,has a recent history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Procedure,C0010055,coronary artery bypass graft,FALSE,FALSE,NA,NA,NA
10,NCT01033071,Exclusion,has a recent history of myocardial infarction ; heart failure ; unstable angina ; coronary artery bypass graft ; percutaneous coronary intervention ; hypertensive encephalopathy ; cerebrovascular accident ; or transient ischemic attack .,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
11,NCT01033071,Exclusion,has clinically significant cardiac conduction defects .,Condition Occurrence,Condition,C0264886,cardiac conduction defects,FALSE,FALSE,NA,NA,NA
12,NCT01033071,Exclusion,has hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease .,Condition Occurrence,Condition,C0023213,left ventricular outflow obstruction,FALSE,FALSE,NA,NA,NA
12,NCT01033071,Exclusion,has hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease .,Condition Occurrence,Condition,C1260873,aortic valvular disease,FALSE,FALSE,NA,NA,NA
13,NCT01033071,Exclusion,has severe renal dysfunction or disease .,Condition Occurrence,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
13,NCT01033071,Exclusion,has severe renal dysfunction or disease .,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
14,NCT01033071,Exclusion,has known or suspected unilateral renal artery or bilateral renal artery stenosis .,Condition Occurrence,Condition,C0035065;C1278951,renal artery,FALSE,FALSE,NA,NA,NA
14,NCT01033071,Exclusion,has known or suspected unilateral renal artery or bilateral renal artery stenosis .,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
15,NCT01033071,Exclusion,has a history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug .,Condition Occurrence,Condition,C0544452,remission,TRUE,FALSE,greater_equal 5 years,NA,NA
15,NCT01033071,Exclusion,has a history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug .,Condition Occurrence,Other,C0260515;C2707253,cancer,FALSE,FALSE,NA,NA,NA
15,NCT01033071,Exclusion,has a history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
16,NCT01033071,Exclusion,has poorly-controlled diabetes mellitus at screening .,Condition Occurrence,Condition,C0011849,diabetes mellitus,FALSE,FALSE,NA,NA,NA
17,NCT01033071,Exclusion,has hypokalemia or hyperkalemia .,Condition Occurrence,Condition,C0020621,hypokalemia,FALSE,FALSE,NA,NA,NA
17,NCT01033071,Exclusion,has hypokalemia or hyperkalemia .,Condition Occurrence,Condition,C0020461,hyperkalemia,FALSE,FALSE,NA,NA,NA
18,NCT01033071,Exclusion,has an alanine aminotransferase or aspartate aminotransferase level of greater than 2.5 times the upper limit of normal liver disease ; active liver disease ; or jaundice .,Drug Exposure,Condition,C0023895;C2186532,liver disease,FALSE,FALSE,NA,NA,NA
18,NCT01033071,Exclusion,has an alanine aminotransferase or aspartate aminotransferase level of greater than 2.5 times the upper limit of normal liver disease ; active liver disease ; or jaundice .,Drug Exposure,Condition,C0023895;C2186532,liver disease,FALSE,FALSE,NA,NA,NA
18,NCT01033071,Exclusion,has an alanine aminotransferase or aspartate aminotransferase level of greater than 2.5 times the upper limit of normal liver disease ; active liver disease ; or jaundice .,Drug Exposure,Condition,C2203646,jaundice,FALSE,FALSE,NA,NA,NA
18,NCT01033071,Exclusion,has an alanine aminotransferase or aspartate aminotransferase level of greater than 2.5 times the upper limit of normal liver disease ; active liver disease ; or jaundice .,Drug Exposure,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
18,NCT01033071,Exclusion,has an alanine aminotransferase or aspartate aminotransferase level of greater than 2.5 times the upper limit of normal liver disease ; active liver disease ; or jaundice .,Drug Exposure,Observation,C0001899;C0201836,alanine aminotransferase,FALSE,FALSE,NA,NA,greater 2.5 times the upper limit of normal
18,NCT01033071,Exclusion,has an alanine aminotransferase or aspartate aminotransferase level of greater than 2.5 times the upper limit of normal liver disease ; active liver disease ; or jaundice .,Drug Exposure,Observation,C0428339,aspartate aminotransferase level,FALSE,FALSE,NA,NA,greater 2.5 times the upper limit of normal
19,NCT01033071,Exclusion,has any other known serious disease or condition that would compromise safety ; might affect life expectancy ; or make it difficult to successfully manage and follow the participant according to the protocol .,Other,Person,C0679646,participant,FALSE,FALSE,NA,NA,NA
19,NCT01033071,Exclusion,has any other known serious disease or condition that would compromise safety ; might affect life expectancy ; or make it difficult to successfully manage and follow the participant according to the protocol .,Other,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
19,NCT01033071,Exclusion,has any other known serious disease or condition that would compromise safety ; might affect life expectancy ; or make it difficult to successfully manage and follow the participant according to the protocol .,Other,Other,C0023671,life expectancy,FALSE,FALSE,NA,NA,NA
19,NCT01033071,Exclusion,has any other known serious disease or condition that would compromise safety ; might affect life expectancy ; or make it difficult to successfully manage and follow the participant according to the protocol .,Other,Other,C1719822,follow,FALSE,FALSE,NA,NA,NA
20,NCT01033071,Exclusion,has known hypersensitivity to angiotensin ii receptor blockers or thiazide-type diuretics or other sulfonamide-derived compounds .,Drug Exposure,Drug,C0541746,thiazide,FALSE,FALSE,NA,NA,NA
20,NCT01033071,Exclusion,has known hypersensitivity to angiotensin ii receptor blockers or thiazide-type diuretics or other sulfonamide-derived compounds .,Drug Exposure,Drug,C0012798,diuretics,FALSE,FALSE,NA,NA,NA
20,NCT01033071,Exclusion,has known hypersensitivity to angiotensin ii receptor blockers or thiazide-type diuretics or other sulfonamide-derived compounds .,Drug Exposure,Drug,C0599503;C3536763,sulfonamide,FALSE,FALSE,NA,NA,NA
20,NCT01033071,Exclusion,has known hypersensitivity to angiotensin ii receptor blockers or thiazide-type diuretics or other sulfonamide-derived compounds .,Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
20,NCT01033071,Exclusion,has known hypersensitivity to angiotensin ii receptor blockers or thiazide-type diuretics or other sulfonamide-derived compounds .,Drug Exposure,Other,C2757003;C0521942,angiotensin ii receptor blockers,FALSE,FALSE,NA,NA,NA
21,NCT01033071,Exclusion,has a history of drug abuse or a history of alcohol abuse within the past 2 years,Condition Occurrence,Condition,C0013146,drug abuse,FALSE,FALSE,NA,NA,NA
21,NCT01033071,Exclusion,has a history of drug abuse or a history of alcohol abuse within the past 2 years,Condition Occurrence,Condition,C0085762,alcohol abuse,FALSE,FALSE,lower 2 past years,NA,NA
1,NCT01042392,Inclusion,outpatients > 18 years,Other,NA,NA,NA,NA,NA,NA,NA,NA
2,NCT01042392,Inclusion,male or female patients,Person,Person,C0025266,male,FALSE,FALSE,NA,NA,NA
2,NCT01042392,Inclusion,male or female patients,Person,Observation,C0150905,female patients,FALSE,FALSE,NA,NA,NA
3,NCT01042392,Inclusion,female patients must have been either post-menopausal for one year ; surgically sterile ; or using effective contraceptive methods,Observation,Procedure,C0700589,contraceptive methods,FALSE,FALSE,NA,NA,NA
3,NCT01042392,Inclusion,female patients must have been either post-menopausal for one year ; surgically sterile ; or using effective contraceptive methods,Observation,Observation,C0150905,female patients,FALSE,FALSE,NA,NA,NA
4,NCT01042392,Inclusion,patients with essential hypertension ; previously treated with an antihypertensive single-drug therapy ; either uncontrolled or intolerant .,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
4,NCT01042392,Inclusion,patients with essential hypertension ; previously treated with an antihypertensive single-drug therapy ; either uncontrolled or intolerant .,Condition Occurrence,Condition,C1549113,single,FALSE,FALSE,NA,NA,NA
4,NCT01042392,Inclusion,patients with essential hypertension ; previously treated with an antihypertensive single-drug therapy ; either uncontrolled or intolerant .,Condition Occurrence,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
5,NCT01042392,Inclusion,bp thresholds at visit 1 :,Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,NA,NA
6,NCT01042392,Inclusion,for patients previously treated and uncontrolled : 140 < = office sbp < 180 mmhg,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,lower 180 mmhg; greater_equal 140 mmhg,NA
7,NCT01042392,Inclusion,for patients previously treated ; controlled but intolerant : office sbp > = 130 mmhg,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 130 mmhg,NA
8,NCT01042392,Inclusion,bp thresholds at visit 2 ( for all patients ) :,Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,NA,NA
9,NCT01042392,Inclusion,160 < = office sbp < 180 mmhg and,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,lower 180 mmhg; greater_equal 160 mmhg,NA
10,NCT01042392,Inclusion,155 < = home sbp < 175 mmhg ( 3 - day period of home blood pressure monitoring just before randomization ),Observation,Procedure,C0026426,blood pressure monitoring,FALSE,FALSE,NA,NA,NA
10,NCT01042392,Inclusion,155 < = home sbp < 175 mmhg ( 3 - day period of home blood pressure monitoring just before randomization ),Observation,Observation,C1306620,sbp,FALSE,FALSE,equal 3 day,lower 175 mmhg,NA
10,NCT01042392,Inclusion,155 < = home sbp < 175 mmhg ( 3 - day period of home blood pressure monitoring just before randomization ),Observation,Other,C1548341,home,FALSE,FALSE,NA,greater_equal 155 mmhg,NA
11,NCT01042392,Exclusion,women of child-bearing potential not using any effective methods of contraception,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
11,NCT01042392,Exclusion,women of child-bearing potential not using any effective methods of contraception,Person,Procedure,C0700589,contraception,FALSE,FALSE,NA,NA,NA
11,NCT01042392,Exclusion,women of child-bearing potential not using any effective methods of contraception,Person,Observation,C3831118,child-bearing potential,FALSE,FALSE,NA,NA,NA
11,NCT01042392,Exclusion,women of child-bearing potential not using any effective methods of contraception,Person,Other,C0025663,methods,TRUE,FALSE,NA,NA,NA
12,NCT01042392,Exclusion,severe hypertension ( office bp > = 180 / 110 mmhg ),Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
12,NCT01042392,Exclusion,severe hypertension ( office bp > = 180 / 110 mmhg ),Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,greater_equal 180 mmhg; greater_equal 110 mmhg,NA
12,NCT01042392,Exclusion,severe hypertension ( office bp > = 180 / 110 mmhg ),Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
13,NCT01042392,Exclusion,impossibility to stop abruptly previous antihypertensive treatments at visit 1,Drug Exposure,Drug,C0723457,stop,FALSE,FALSE,NA,NA,NA
13,NCT01042392,Exclusion,impossibility to stop abruptly previous antihypertensive treatments at visit 1,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
14,NCT01042392,Exclusion,patients previously untreated or patients treated with two or three antihypertensive medications,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
15,NCT01042392,Exclusion,history or evidence of a secondary form of hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
16,NCT01042392,Exclusion,history of hypersensitivity to acei or renin inhibitors,Condition Occurrence,Condition,C2917241,renin inhibitors,FALSE,FALSE,NA,NA,NA
16,NCT01042392,Exclusion,history of hypersensitivity to acei or renin inhibitors,Condition Occurrence,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
17,NCT01042392,Exclusion,history of heart failure ; stroke or coronary heart disease,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
17,NCT01042392,Exclusion,history of heart failure ; stroke or coronary heart disease,Condition Occurrence,Condition,C0010068;C0010054,coronary heart disease,FALSE,FALSE,NA,NA,NA
18,NCT01042392,Exclusion,serum potassium > = 5.2 mmol / l,Observation,Observation,C0302353;C0543465,serum potassium,FALSE,FALSE,NA,greater_equal 5.2 mmol/l,NA
19,NCT01042392,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT01071122,Inclusion,untreated grade 2 or grade 3 hypertension defined by mean diastolic blood pressure ( bp ) > / = 100 or mean systolic bp > / = 160 mmhg without anti-hypertensive treatment or treated grade 2 hypertension defined by mean diastolic bp > / = 100 or mean systolic bp > / = 160 mmhg with current diuretics or beta-blockers use for > / = 4 weeks,Observation,Drug,C0003364,anti-hypertensive,TRUE,FALSE,NA,NA,NA
1,NCT01071122,Inclusion,untreated grade 2 or grade 3 hypertension defined by mean diastolic blood pressure ( bp ) > / = 100 or mean systolic bp > / = 160 mmhg without anti-hypertensive treatment or treated grade 2 hypertension defined by mean diastolic bp > / = 100 or mean systolic bp > / = 160 mmhg with current diuretics or beta-blockers use for > / = 4 weeks,Observation,Drug,C0012798,diuretics,FALSE,FALSE,greater_equal 4 weeks,NA,NA
1,NCT01071122,Inclusion,untreated grade 2 or grade 3 hypertension defined by mean diastolic blood pressure ( bp ) > / = 100 or mean systolic bp > / = 160 mmhg without anti-hypertensive treatment or treated grade 2 hypertension defined by mean diastolic bp > / = 100 or mean systolic bp > / = 160 mmhg with current diuretics or beta-blockers use for > / = 4 weeks,Observation,Drug,C0001645,beta-blockers,FALSE,FALSE,greater_equal 4 weeks,NA,NA
1,NCT01071122,Inclusion,untreated grade 2 or grade 3 hypertension defined by mean diastolic blood pressure ( bp ) > / = 100 or mean systolic bp > / = 160 mmhg without anti-hypertensive treatment or treated grade 2 hypertension defined by mean diastolic bp > / = 100 or mean systolic bp > / = 160 mmhg with current diuretics or beta-blockers use for > / = 4 weeks,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT01071122,Inclusion,untreated grade 2 or grade 3 hypertension defined by mean diastolic blood pressure ( bp ) > / = 100 or mean systolic bp > / = 160 mmhg without anti-hypertensive treatment or treated grade 2 hypertension defined by mean diastolic bp > / = 100 or mean systolic bp > / = 160 mmhg with current diuretics or beta-blockers use for > / = 4 weeks,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,NA,NA
1,NCT01071122,Inclusion,untreated grade 2 or grade 3 hypertension defined by mean diastolic blood pressure ( bp ) > / = 100 or mean systolic bp > / = 160 mmhg without anti-hypertensive treatment or treated grade 2 hypertension defined by mean diastolic bp > / = 100 or mean systolic bp > / = 160 mmhg with current diuretics or beta-blockers use for > / = 4 weeks,Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,greater_equal 100,NA
1,NCT01071122,Inclusion,untreated grade 2 or grade 3 hypertension defined by mean diastolic blood pressure ( bp ) > / = 100 or mean systolic bp > / = 160 mmhg without anti-hypertensive treatment or treated grade 2 hypertension defined by mean diastolic bp > / = 100 or mean systolic bp > / = 160 mmhg with current diuretics or beta-blockers use for > / = 4 weeks,Observation,Observation,C0871470,systolic bp,FALSE,FALSE,NA,greater_equal 160 mmhg,NA
1,NCT01071122,Inclusion,untreated grade 2 or grade 3 hypertension defined by mean diastolic blood pressure ( bp ) > / = 100 or mean systolic bp > / = 160 mmhg without anti-hypertensive treatment or treated grade 2 hypertension defined by mean diastolic bp > / = 100 or mean systolic bp > / = 160 mmhg with current diuretics or beta-blockers use for > / = 4 weeks,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT01071122,Inclusion,untreated grade 2 or grade 3 hypertension defined by mean diastolic blood pressure ( bp ) > / = 100 or mean systolic bp > / = 160 mmhg without anti-hypertensive treatment or treated grade 2 hypertension defined by mean diastolic bp > / = 100 or mean systolic bp > / = 160 mmhg with current diuretics or beta-blockers use for > / = 4 weeks,Observation,Observation,C0428883,diastolic bp,FALSE,FALSE,NA,greater_equal 100,NA
1,NCT01071122,Inclusion,untreated grade 2 or grade 3 hypertension defined by mean diastolic blood pressure ( bp ) > / = 100 or mean systolic bp > / = 160 mmhg without anti-hypertensive treatment or treated grade 2 hypertension defined by mean diastolic bp > / = 100 or mean systolic bp > / = 160 mmhg with current diuretics or beta-blockers use for > / = 4 weeks,Observation,Observation,C0871470,systolic bp,FALSE,FALSE,NA,greater_equal 160 mmhg,NA
1,NCT01071122,Inclusion,untreated grade 2 or grade 3 hypertension defined by mean diastolic blood pressure ( bp ) > / = 100 or mean systolic bp > / = 160 mmhg without anti-hypertensive treatment or treated grade 2 hypertension defined by mean diastolic bp > / = 100 or mean systolic bp > / = 160 mmhg with current diuretics or beta-blockers use for > / = 4 weeks,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT01071122,Inclusion,untreated grade 2 or grade 3 hypertension defined by mean diastolic blood pressure ( bp ) > / = 100 or mean systolic bp > / = 160 mmhg without anti-hypertensive treatment or treated grade 2 hypertension defined by mean diastolic bp > / = 100 or mean systolic bp > / = 160 mmhg with current diuretics or beta-blockers use for > / = 4 weeks,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
2,NCT01071122,Exclusion,secondary form of hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT01071122,Exclusion,mean systolic bp > / = 200 mmhg and or mean diastolic bp > / = 120 mmhg,Observation,Observation,C0871470,systolic bp,FALSE,FALSE,NA,greater_equal 200 mmhg,NA
3,NCT01071122,Exclusion,mean systolic bp > / = 200 mmhg and or mean diastolic bp > / = 120 mmhg,Observation,Observation,C0428883,diastolic bp,FALSE,FALSE,NA,greater_equal 120 mmhg,NA
4,NCT01071122,Exclusion,treated with other antihypertensive medication except diuretics or beta-blockers,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
4,NCT01071122,Exclusion,treated with other antihypertensive medication except diuretics or beta-blockers,Drug Exposure,Drug,C0012798,diuretics,TRUE,FALSE,NA,NA,NA
4,NCT01071122,Exclusion,treated with other antihypertensive medication except diuretics or beta-blockers,Drug Exposure,Drug,C0001645,beta-blockers,TRUE,FALSE,NA,NA,NA
5,NCT01071122,Exclusion,type 1 diabetes mellitus,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
6,NCT01071122,Exclusion,known cardiovascular disease including history of angina pectoris ; heart failure ; history of myocardial infarction or revascularization procedure ; or cerebrovascular disease ( including stroke and transient ischaemic attack ) within the previous 12 months,Condition Occurrence,Condition,C0007222,cardiovascular disease,FALSE,FALSE,NA,NA,NA
6,NCT01071122,Exclusion,known cardiovascular disease including history of angina pectoris ; heart failure ; history of myocardial infarction or revascularization procedure ; or cerebrovascular disease ( including stroke and transient ischaemic attack ) within the previous 12 months,Condition Occurrence,Condition,C0002962;C0577698;C0235467;C0542052;C0010073;C0541777;C0235462,angina pectoris,FALSE,FALSE,NA,NA,NA
6,NCT01071122,Exclusion,known cardiovascular disease including history of angina pectoris ; heart failure ; history of myocardial infarction or revascularization procedure ; or cerebrovascular disease ( including stroke and transient ischaemic attack ) within the previous 12 months,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
6,NCT01071122,Exclusion,known cardiovascular disease including history of angina pectoris ; heart failure ; history of myocardial infarction or revascularization procedure ; or cerebrovascular disease ( including stroke and transient ischaemic attack ) within the previous 12 months,Condition Occurrence,Condition,C0007820,cerebrovascular disease,FALSE,FALSE,NA,NA,NA
6,NCT01071122,Exclusion,known cardiovascular disease including history of angina pectoris ; heart failure ; history of myocardial infarction or revascularization procedure ; or cerebrovascular disease ( including stroke and transient ischaemic attack ) within the previous 12 months,Condition Occurrence,Condition,C0007787,transient ischaemic attack,FALSE,FALSE,lower 12 previous months,NA,NA
6,NCT01071122,Exclusion,known cardiovascular disease including history of angina pectoris ; heart failure ; history of myocardial infarction or revascularization procedure ; or cerebrovascular disease ( including stroke and transient ischaemic attack ) within the previous 12 months,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
7,NCT01071122,Exclusion,renal insufficiency defined as a serum creatinine : > / = 1.7 mg / dl,Drug Exposure,Condition,C1565489;C0035078,renal insufficiency,FALSE,FALSE,NA,NA,NA
7,NCT01071122,Exclusion,renal insufficiency defined as a serum creatinine : > / = 1.7 mg / dl,Drug Exposure,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,NA,greater_equal 1.7 mg/dl
7,NCT01071122,Exclusion,renal insufficiency defined as a serum creatinine : > / = 1.7 mg / dl,Drug Exposure,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
8,NCT01071122,Exclusion,pregnancy or not using contraceptive in childbearing aged women,Person,Person,C0001792,aged,TRUE,FALSE,NA,NA,NA
8,NCT01071122,Exclusion,pregnancy or not using contraceptive in childbearing aged women,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
8,NCT01071122,Exclusion,pregnancy or not using contraceptive in childbearing aged women,Person,Other,C0032961;C3484365,pregnancy,FALSE,FALSE,NA,NA,NA
9,NCT01071122,Exclusion,breast feeding women,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
9,NCT01071122,Exclusion,breast feeding women,Person,Condition,C0006147;C1623040;C1623041,breast feeding,FALSE,FALSE,NA,NA,NA
10,NCT01071122,Exclusion,any disease or condition that in the opinion of the investigator may interfere with completion of the study,Other,NA,NA,NA,NA,NA,NA,NA,NA
1,NCT01075698,Inclusion,patients who meet all of the criteria listed in [ 1 ] to [ 4 ] below and who have at least one cardiovascular risk listed in [ 1 ] to [ 5 ] below will be included in the study .,Other,NA,NA,NA,NA,NA,NA,NA,NA
3,NCT01075698,Inclusion,age : > = 40 to < 80,Observation,NA,NA,NA,NA,NA,NA,NA,NA
4,NCT01075698,Inclusion,hypertension : systolic blood pressure of > = 140 mmhg blood pressure or diastolic blood pressure of > = 90 mmhg in the two latest measurements of casual blood pressure ( in the sitting position ) regardless of treated or untreated condition ; or systolic blood pressure of < 140 mmhg blood pressure and diastolic blood pressure of < 90 mmhg that require antihypertensive treatment .,Observation,Condition,C0221155,hypertension systolic,FALSE,FALSE,NA,NA,NA
4,NCT01075698,Inclusion,hypertension : systolic blood pressure of > = 140 mmhg blood pressure or diastolic blood pressure of > = 90 mmhg in the two latest measurements of casual blood pressure ( in the sitting position ) regardless of treated or untreated condition ; or systolic blood pressure of < 140 mmhg blood pressure and diastolic blood pressure of < 90 mmhg that require antihypertensive treatment .,Observation,Condition,C0277814,sitting position,FALSE,FALSE,NA,NA,NA
4,NCT01075698,Inclusion,hypertension : systolic blood pressure of > = 140 mmhg blood pressure or diastolic blood pressure of > = 90 mmhg in the two latest measurements of casual blood pressure ( in the sitting position ) regardless of treated or untreated condition ; or systolic blood pressure of < 140 mmhg blood pressure and diastolic blood pressure of < 90 mmhg that require antihypertensive treatment .,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
4,NCT01075698,Inclusion,hypertension : systolic blood pressure of > = 140 mmhg blood pressure or diastolic blood pressure of > = 90 mmhg in the two latest measurements of casual blood pressure ( in the sitting position ) regardless of treated or untreated condition ; or systolic blood pressure of < 140 mmhg blood pressure and diastolic blood pressure of < 90 mmhg that require antihypertensive treatment .,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,greater_equal 140 mmhg,NA
4,NCT01075698,Inclusion,hypertension : systolic blood pressure of > = 140 mmhg blood pressure or diastolic blood pressure of > = 90 mmhg in the two latest measurements of casual blood pressure ( in the sitting position ) regardless of treated or untreated condition ; or systolic blood pressure of < 140 mmhg blood pressure and diastolic blood pressure of < 90 mmhg that require antihypertensive treatment .,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,greater_equal 90 mmhg,NA
4,NCT01075698,Inclusion,hypertension : systolic blood pressure of > = 140 mmhg blood pressure or diastolic blood pressure of > = 90 mmhg in the two latest measurements of casual blood pressure ( in the sitting position ) regardless of treated or untreated condition ; or systolic blood pressure of < 140 mmhg blood pressure and diastolic blood pressure of < 90 mmhg that require antihypertensive treatment .,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater_equal 90 mmhg,NA
4,NCT01075698,Inclusion,hypertension : systolic blood pressure of > = 140 mmhg blood pressure or diastolic blood pressure of > = 90 mmhg in the two latest measurements of casual blood pressure ( in the sitting position ) regardless of treated or untreated condition ; or systolic blood pressure of < 140 mmhg blood pressure and diastolic blood pressure of < 90 mmhg that require antihypertensive treatment .,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
4,NCT01075698,Inclusion,hypertension : systolic blood pressure of > = 140 mmhg blood pressure or diastolic blood pressure of > = 90 mmhg in the two latest measurements of casual blood pressure ( in the sitting position ) regardless of treated or untreated condition ; or systolic blood pressure of < 140 mmhg blood pressure and diastolic blood pressure of < 90 mmhg that require antihypertensive treatment .,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,lower 140 mmhg,NA
4,NCT01075698,Inclusion,hypertension : systolic blood pressure of > = 140 mmhg blood pressure or diastolic blood pressure of > = 90 mmhg in the two latest measurements of casual blood pressure ( in the sitting position ) regardless of treated or untreated condition ; or systolic blood pressure of < 140 mmhg blood pressure and diastolic blood pressure of < 90 mmhg that require antihypertensive treatment .,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,lower 90 mmhg,NA
4,NCT01075698,Inclusion,hypertension : systolic blood pressure of > = 140 mmhg blood pressure or diastolic blood pressure of > = 90 mmhg in the two latest measurements of casual blood pressure ( in the sitting position ) regardless of treated or untreated condition ; or systolic blood pressure of < 140 mmhg blood pressure and diastolic blood pressure of < 90 mmhg that require antihypertensive treatment .,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,lower 90 mmhg,NA
5,NCT01075698,Inclusion,assessment of hypertension : blood pressure will be measured at least twice at an interval of 1 to 2 minutes,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
5,NCT01075698,Inclusion,assessment of hypertension : blood pressure will be measured at least twice at an interval of 1 to 2 minutes,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
5,NCT01075698,Inclusion,assessment of hypertension : blood pressure will be measured at least twice at an interval of 1 to 2 minutes,Observation,Observation,C3541902,measured,FALSE,FALSE,greater_equal 1 minutes; lower_equal 2 minutes,NA,NA
2,NCT01075698,Inclusion,outpatients,Other,NA,NA,NA,NA,NA,NA,NA,NA
5,NCT01075698,Inclusion,assessment of hypertension : blood pressure will be measured at least twice at an interval of 1 to 2 minutes,Observation,Other,C0542573;C0549068;C0870300;C0549070;C0549071;C0549072;C0549073;C0549074;C0028708;C0549075;C0549076;C0549077;C0549078;C0549079;C0549080;C0679207,assessment,FALSE,FALSE,NA,NA,NA
6,NCT01075698,Inclusion,if the measured values obtained are substantially different measurements ; additional measurements will be performed and the average of two stable measurements will be used for assessment .,Observation,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
6,NCT01075698,Inclusion,if the measured values obtained are substantially different measurements ; additional measurements will be performed and the average of two stable measurements will be used for assessment .,Observation,Other,C1547311,stable,FALSE,FALSE,NA,NA,NA
6,NCT01075698,Inclusion,if the measured values obtained are substantially different measurements ; additional measurements will be performed and the average of two stable measurements will be used for assessment .,Observation,Other,C0542573;C0549068;C0870300;C0549070;C0549071;C0549072;C0549073;C0549074;C0028708;C0549075;C0549076;C0549077;C0549078;C0549079;C0549080;C0679207,assessment,FALSE,FALSE,NA,NA,NA
7,NCT01075698,Inclusion,patients who have given consent to participate in the present study .,Other,NA,NA,NA,NA,NA,NA,NA,NA
8,NCT01075698,Inclusion,cardiovascular risks :,Other,NA,NA,NA,NA,NA,NA,NA,NA
9,NCT01075698,Inclusion,diabetes mellitus,Condition Occurrence,Condition,C0011849,diabetes mellitus,FALSE,FALSE,NA,NA,NA
10,NCT01075698,Inclusion,type 2 diabetes mellitus,Condition Occurrence,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
11,NCT01075698,Inclusion,kidney,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
12,NCT01075698,Inclusion,serum creatinine2 mg / dl < 2.0 mg / dl for males0 mg / dl < 2.0 mg / dl for females proteinuria : qualitative value of > = + 1 ( quantitative value : proteinuria with the value of > = 0.3 g / g cr in casual urine when adjusted with urine creatinine ) ckd stage 3 or higher ( gfr < 60 ml / min / 1.773 m2 ),Observation,Person,C0086287,females,FALSE,FALSE,NA,NA,NA
12,NCT01075698,Inclusion,serum creatinine2 mg / dl < 2.0 mg / dl for males0 mg / dl < 2.0 mg / dl for females proteinuria : qualitative value of > = + 1 ( quantitative value : proteinuria with the value of > = 0.3 g / g cr in casual urine when adjusted with urine creatinine ) ckd stage 3 or higher ( gfr < 60 ml / min / 1.773 m2 ),Observation,Condition,C0033687;C1279888;C1962972,proteinuria,FALSE,FALSE,NA,greater_equal 1,NA
12,NCT01075698,Inclusion,serum creatinine2 mg / dl < 2.0 mg / dl for males0 mg / dl < 2.0 mg / dl for females proteinuria : qualitative value of > = + 1 ( quantitative value : proteinuria with the value of > = 0.3 g / g cr in casual urine when adjusted with urine creatinine ) ckd stage 3 or higher ( gfr < 60 ml / min / 1.773 m2 ),Observation,Condition,C0033687;C1279888;C1962972,proteinuria,FALSE,FALSE,NA,NA,NA
12,NCT01075698,Inclusion,serum creatinine2 mg / dl < 2.0 mg / dl for males0 mg / dl < 2.0 mg / dl for females proteinuria : qualitative value of > = + 1 ( quantitative value : proteinuria with the value of > = 0.3 g / g cr in casual urine when adjusted with urine creatinine ) ckd stage 3 or higher ( gfr < 60 ml / min / 1.773 m2 ),Observation,Condition,C1561643,ckd,FALSE,FALSE,NA,greater_equal 3,NA
12,NCT01075698,Inclusion,serum creatinine2 mg / dl < 2.0 mg / dl for males0 mg / dl < 2.0 mg / dl for females proteinuria : qualitative value of > = + 1 ( quantitative value : proteinuria with the value of > = 0.3 g / g cr in casual urine when adjusted with urine creatinine ) ckd stage 3 or higher ( gfr < 60 ml / min / 1.773 m2 ),Observation,Observation,C0428283;C1318439,urine creatinine,FALSE,FALSE,NA,NA,NA
12,NCT01075698,Inclusion,serum creatinine2 mg / dl < 2.0 mg / dl for males0 mg / dl < 2.0 mg / dl for females proteinuria : qualitative value of > = + 1 ( quantitative value : proteinuria with the value of > = 0.3 g / g cr in casual urine when adjusted with urine creatinine ) ckd stage 3 or higher ( gfr < 60 ml / min / 1.773 m2 ),Observation,Observation,C0017654,gfr,FALSE,FALSE,NA,lower 60 ml/min; equal 1.773 m2,NA
12,NCT01075698,Inclusion,serum creatinine2 mg / dl < 2.0 mg / dl for males0 mg / dl < 2.0 mg / dl for females proteinuria : qualitative value of > = + 1 ( quantitative value : proteinuria with the value of > = 0.3 g / g cr in casual urine when adjusted with urine creatinine ) ckd stage 3 or higher ( gfr < 60 ml / min / 1.773 m2 ),Observation,Other,C0229671;C1546774;C1550100,serum,FALSE,FALSE,NA,NA,lower 2.0 mg/dl
12,NCT01075698,Inclusion,serum creatinine2 mg / dl < 2.0 mg / dl for males0 mg / dl < 2.0 mg / dl for females proteinuria : qualitative value of > = + 1 ( quantitative value : proteinuria with the value of > = 0.3 g / g cr in casual urine when adjusted with urine creatinine ) ckd stage 3 or higher ( gfr < 60 ml / min / 1.773 m2 ),Observation,Other,C2348261;C1707506;C0152369,cr,FALSE,FALSE,NA,greater_equal 0.3 g/g,NA
13,NCT01075698,Inclusion,heart,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
14,NCT01075698,Inclusion,previous myocardial infarction noted more than 6 months before obtaining the informed consent diagnosis of angina pectoris diagnosis of heart failure ( nyha i or ii class ) diagnosis of left ventricular hypertrophy ( left ventricular posterior wall of > = 12 mm evidenced by echocardiography performed prior to obtaining the informed consent ; or sv1+rv5 of > = 35 mm noted as ecg finding ) diagnosis of transient or persisting atrial fibrillation,Observation,Person,C0040704,transient,FALSE,FALSE,NA,NA,NA
14,NCT01075698,Inclusion,previous myocardial infarction noted more than 6 months before obtaining the informed consent diagnosis of angina pectoris diagnosis of heart failure ( nyha i or ii class ) diagnosis of left ventricular hypertrophy ( left ventricular posterior wall of > = 12 mm evidenced by echocardiography performed prior to obtaining the informed consent ; or sv1+rv5 of > = 35 mm noted as ecg finding ) diagnosis of transient or persisting atrial fibrillation,Observation,Condition,C0155668,previous myocardial infarction,FALSE,FALSE,greater 6 months,NA,NA
14,NCT01075698,Inclusion,previous myocardial infarction noted more than 6 months before obtaining the informed consent diagnosis of angina pectoris diagnosis of heart failure ( nyha i or ii class ) diagnosis of left ventricular hypertrophy ( left ventricular posterior wall of > = 12 mm evidenced by echocardiography performed prior to obtaining the informed consent ; or sv1+rv5 of > = 35 mm noted as ecg finding ) diagnosis of transient or persisting atrial fibrillation,Observation,Condition,C0002962;C0577698;C0235467;C0542052;C0010073;C0541777;C0235462,angina pectoris,FALSE,FALSE,NA,NA,NA
14,NCT01075698,Inclusion,previous myocardial infarction noted more than 6 months before obtaining the informed consent diagnosis of angina pectoris diagnosis of heart failure ( nyha i or ii class ) diagnosis of left ventricular hypertrophy ( left ventricular posterior wall of > = 12 mm evidenced by echocardiography performed prior to obtaining the informed consent ; or sv1+rv5 of > = 35 mm noted as ecg finding ) diagnosis of transient or persisting atrial fibrillation,Observation,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
14,NCT01075698,Inclusion,previous myocardial infarction noted more than 6 months before obtaining the informed consent diagnosis of angina pectoris diagnosis of heart failure ( nyha i or ii class ) diagnosis of left ventricular hypertrophy ( left ventricular posterior wall of > = 12 mm evidenced by echocardiography performed prior to obtaining the informed consent ; or sv1+rv5 of > = 35 mm noted as ecg finding ) diagnosis of transient or persisting atrial fibrillation,Observation,Condition,C0438154,ecg finding,FALSE,FALSE,NA,NA,NA
14,NCT01075698,Inclusion,previous myocardial infarction noted more than 6 months before obtaining the informed consent diagnosis of angina pectoris diagnosis of heart failure ( nyha i or ii class ) diagnosis of left ventricular hypertrophy ( left ventricular posterior wall of > = 12 mm evidenced by echocardiography performed prior to obtaining the informed consent ; or sv1+rv5 of > = 35 mm noted as ecg finding ) diagnosis of transient or persisting atrial fibrillation,Observation,Observation,C0013516,echocardiography,FALSE,FALSE,NA,greater_equal 35 mm,NA
14,NCT01075698,Inclusion,previous myocardial infarction noted more than 6 months before obtaining the informed consent diagnosis of angina pectoris diagnosis of heart failure ( nyha i or ii class ) diagnosis of left ventricular hypertrophy ( left ventricular posterior wall of > = 12 mm evidenced by echocardiography performed prior to obtaining the informed consent ; or sv1+rv5 of > = 35 mm noted as ecg finding ) diagnosis of transient or persisting atrial fibrillation,Observation,Other,C0441886,ii class,FALSE,FALSE,NA,NA,NA
14,NCT01075698,Inclusion,previous myocardial infarction noted more than 6 months before obtaining the informed consent diagnosis of angina pectoris diagnosis of heart failure ( nyha i or ii class ) diagnosis of left ventricular hypertrophy ( left ventricular posterior wall of > = 12 mm evidenced by echocardiography performed prior to obtaining the informed consent ; or sv1+rv5 of > = 35 mm noted as ecg finding ) diagnosis of transient or persisting atrial fibrillation,Observation,Other,C0149721;C0232306;C3484363,left ventricular hypertrophy,FALSE,FALSE,NA,greater_equal 12 mm,NA
14,NCT01075698,Inclusion,previous myocardial infarction noted more than 6 months before obtaining the informed consent diagnosis of angina pectoris diagnosis of heart failure ( nyha i or ii class ) diagnosis of left ventricular hypertrophy ( left ventricular posterior wall of > = 12 mm evidenced by echocardiography performed prior to obtaining the informed consent ; or sv1+rv5 of > = 35 mm noted as ecg finding ) diagnosis of transient or persisting atrial fibrillation,Observation,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
15,NCT01075698,Inclusion,brain,Condition Occurrence,Condition,C0006111;C0006104;C1269537,brain,FALSE,FALSE,NA,NA,NA
16,NCT01075698,Inclusion,previous cerebral infarction ; cerebral hemorrhage ; subarachnoid hemorrhage or transient cerebral ischemic attack noted more than 6 months before obtaining the informed consent,Condition Occurrence,Condition,C0007785;C0038454,cerebral infarction,FALSE,FALSE,greater 6 months,NA,NA
16,NCT01075698,Inclusion,previous cerebral infarction ; cerebral hemorrhage ; subarachnoid hemorrhage or transient cerebral ischemic attack noted more than 6 months before obtaining the informed consent,Condition Occurrence,Condition,C0007787,transient cerebral ischemic attack,FALSE,FALSE,greater 6 months,NA,NA
16,NCT01075698,Inclusion,previous cerebral infarction ; cerebral hemorrhage ; subarachnoid hemorrhage or transient cerebral ischemic attack noted more than 6 months before obtaining the informed consent,Condition Occurrence,Condition,C0038525,subarachnoid hemorrhage,FALSE,FALSE,greater 6 months,NA,NA
16,NCT01075698,Inclusion,previous cerebral infarction ; cerebral hemorrhage ; subarachnoid hemorrhage or transient cerebral ischemic attack noted more than 6 months before obtaining the informed consent,Condition Occurrence,Condition,C2937358;C0007784,cerebral hemorrhage,FALSE,FALSE,greater 6 months,NA,NA
17,NCT01075698,Inclusion,peripheral arterial diseases,Condition Occurrence,Condition,C1704436,peripheral arterial diseases,FALSE,FALSE,NA,NA,NA
18,NCT01075698,Inclusion,previous lower-limb bypass surgery or angioplasty performed more than 6 months before obtaining the informed consent ankle-brachial pressure index of < 0.9 or intermittent claudication,Condition Occurrence,Condition,C0153665;C0023216;C1269079,lower-limb,FALSE,FALSE,NA,NA,NA
18,NCT01075698,Inclusion,previous lower-limb bypass surgery or angioplasty performed more than 6 months before obtaining the informed consent ankle-brachial pressure index of < 0.9 or intermittent claudication,Condition Occurrence,Condition,C0021775,intermittent claudication,FALSE,FALSE,NA,NA,NA
18,NCT01075698,Inclusion,previous lower-limb bypass surgery or angioplasty performed more than 6 months before obtaining the informed consent ankle-brachial pressure index of < 0.9 or intermittent claudication,Condition Occurrence,Procedure,C1536078,bypass surgery,FALSE,FALSE,greater 6 months,NA,NA
18,NCT01075698,Inclusion,previous lower-limb bypass surgery or angioplasty performed more than 6 months before obtaining the informed consent ankle-brachial pressure index of < 0.9 or intermittent claudication,Condition Occurrence,Procedure,C0162577;C1548817,angioplasty,FALSE,FALSE,greater 6 months,NA,NA
18,NCT01075698,Inclusion,previous lower-limb bypass surgery or angioplasty performed more than 6 months before obtaining the informed consent ankle-brachial pressure index of < 0.9 or intermittent claudication,Condition Occurrence,Observation,C1328319,ankle-brachial pressure index,FALSE,FALSE,NA,lower 0.9,NA
19,NCT01075698,Exclusion,patients who meet any of the following criteria will be excluded from the study .,Other,NA,NA,NA,NA,NA,NA,NA,NA
20,NCT01075698,Exclusion,type 1 diabetes mellitus,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
21,NCT01075698,Exclusion,severe renal disorders ( serum creatinine of > = 2.0 mg / dl ),Condition Occurrence,Condition,C0022658,renal disorders,FALSE,FALSE,NA,NA,NA
21,NCT01075698,Exclusion,severe renal disorders ( serum creatinine of > = 2.0 mg / dl ),Condition Occurrence,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,NA,greater_equal 2.0 mg/dl
21,NCT01075698,Exclusion,severe renal disorders ( serum creatinine of > = 2.0 mg / dl ),Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
22,NCT01075698,Exclusion,myocardial infarction ; percutaneous transluminal angioplasty and bypass surgery of coronary artery / lower-limb blood vessel ; cerebral infarction ; cerebral hemorrhage ; subarachnoid hemorrhage and transient cerebral ischemic attack noted within 6 months before initiation of the observation ; diagnosis of heart failure ( nyha iii or iv class ),Condition Occurrence,Condition,C0205042;C1269008,coronary artery,FALSE,FALSE,NA,NA,NA
22,NCT01075698,Exclusion,myocardial infarction ; percutaneous transluminal angioplasty and bypass surgery of coronary artery / lower-limb blood vessel ; cerebral infarction ; cerebral hemorrhage ; subarachnoid hemorrhage and transient cerebral ischemic attack noted within 6 months before initiation of the observation ; diagnosis of heart failure ( nyha iii or iv class ),Condition Occurrence,Condition,C0153665;C0023216;C1269079,lower-limb,FALSE,FALSE,NA,NA,NA
22,NCT01075698,Exclusion,myocardial infarction ; percutaneous transluminal angioplasty and bypass surgery of coronary artery / lower-limb blood vessel ; cerebral infarction ; cerebral hemorrhage ; subarachnoid hemorrhage and transient cerebral ischemic attack noted within 6 months before initiation of the observation ; diagnosis of heart failure ( nyha iii or iv class ),Condition Occurrence,Condition,C0005847;C1283786,blood vessel,FALSE,FALSE,lower 6 months,NA,NA
22,NCT01075698,Exclusion,myocardial infarction ; percutaneous transluminal angioplasty and bypass surgery of coronary artery / lower-limb blood vessel ; cerebral infarction ; cerebral hemorrhage ; subarachnoid hemorrhage and transient cerebral ischemic attack noted within 6 months before initiation of the observation ; diagnosis of heart failure ( nyha iii or iv class ),Condition Occurrence,Condition,C0007787,transient cerebral ischemic attack,FALSE,FALSE,lower 6 months,NA,NA
22,NCT01075698,Exclusion,myocardial infarction ; percutaneous transluminal angioplasty and bypass surgery of coronary artery / lower-limb blood vessel ; cerebral infarction ; cerebral hemorrhage ; subarachnoid hemorrhage and transient cerebral ischemic attack noted within 6 months before initiation of the observation ; diagnosis of heart failure ( nyha iii or iv class ),Condition Occurrence,Condition,C0038525,subarachnoid hemorrhage,FALSE,FALSE,lower 6 months,NA,NA
22,NCT01075698,Exclusion,myocardial infarction ; percutaneous transluminal angioplasty and bypass surgery of coronary artery / lower-limb blood vessel ; cerebral infarction ; cerebral hemorrhage ; subarachnoid hemorrhage and transient cerebral ischemic attack noted within 6 months before initiation of the observation ; diagnosis of heart failure ( nyha iii or iv class ),Condition Occurrence,Condition,C2937358;C0007784,cerebral hemorrhage,FALSE,FALSE,lower 6 months,NA,NA
22,NCT01075698,Exclusion,myocardial infarction ; percutaneous transluminal angioplasty and bypass surgery of coronary artery / lower-limb blood vessel ; cerebral infarction ; cerebral hemorrhage ; subarachnoid hemorrhage and transient cerebral ischemic attack noted within 6 months before initiation of the observation ; diagnosis of heart failure ( nyha iii or iv class ),Condition Occurrence,Condition,C0007785;C0038454,cerebral infarction,FALSE,FALSE,lower 6 months,NA,NA
22,NCT01075698,Exclusion,myocardial infarction ; percutaneous transluminal angioplasty and bypass surgery of coronary artery / lower-limb blood vessel ; cerebral infarction ; cerebral hemorrhage ; subarachnoid hemorrhage and transient cerebral ischemic attack noted within 6 months before initiation of the observation ; diagnosis of heart failure ( nyha iii or iv class ),Condition Occurrence,Condition,C1158830,initiation,FALSE,FALSE,NA,NA,NA
22,NCT01075698,Exclusion,myocardial infarction ; percutaneous transluminal angioplasty and bypass surgery of coronary artery / lower-limb blood vessel ; cerebral infarction ; cerebral hemorrhage ; subarachnoid hemorrhage and transient cerebral ischemic attack noted within 6 months before initiation of the observation ; diagnosis of heart failure ( nyha iii or iv class ),Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
22,NCT01075698,Exclusion,myocardial infarction ; percutaneous transluminal angioplasty and bypass surgery of coronary artery / lower-limb blood vessel ; cerebral infarction ; cerebral hemorrhage ; subarachnoid hemorrhage and transient cerebral ischemic attack noted within 6 months before initiation of the observation ; diagnosis of heart failure ( nyha iii or iv class ),Condition Occurrence,Procedure,C1536078,bypass surgery,FALSE,FALSE,NA,NA,NA
22,NCT01075698,Exclusion,myocardial infarction ; percutaneous transluminal angioplasty and bypass surgery of coronary artery / lower-limb blood vessel ; cerebral infarction ; cerebral hemorrhage ; subarachnoid hemorrhage and transient cerebral ischemic attack noted within 6 months before initiation of the observation ; diagnosis of heart failure ( nyha iii or iv class ),Condition Occurrence,Procedure,C2936666,percutaneous transluminal angioplasty,FALSE,FALSE,NA,NA,NA
22,NCT01075698,Exclusion,myocardial infarction ; percutaneous transluminal angioplasty and bypass surgery of coronary artery / lower-limb blood vessel ; cerebral infarction ; cerebral hemorrhage ; subarachnoid hemorrhage and transient cerebral ischemic attack noted within 6 months before initiation of the observation ; diagnosis of heart failure ( nyha iii or iv class ),Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
22,NCT01075698,Exclusion,myocardial infarction ; percutaneous transluminal angioplasty and bypass surgery of coronary artery / lower-limb blood vessel ; cerebral infarction ; cerebral hemorrhage ; subarachnoid hemorrhage and transient cerebral ischemic attack noted within 6 months before initiation of the observation ; diagnosis of heart failure ( nyha iii or iv class ),Condition Occurrence,Other,C0700325;C0557985;C0478530,observation,FALSE,FALSE,NA,NA,NA
22,NCT01075698,Exclusion,myocardial infarction ; percutaneous transluminal angioplasty and bypass surgery of coronary artery / lower-limb blood vessel ; cerebral infarction ; cerebral hemorrhage ; subarachnoid hemorrhage and transient cerebral ischemic attack noted within 6 months before initiation of the observation ; diagnosis of heart failure ( nyha iii or iv class ),Condition Occurrence,Other,C0439070;C2337640;C3496532,iii,FALSE,FALSE,NA,NA,NA
22,NCT01075698,Exclusion,myocardial infarction ; percutaneous transluminal angioplasty and bypass surgery of coronary artery / lower-limb blood vessel ; cerebral infarction ; cerebral hemorrhage ; subarachnoid hemorrhage and transient cerebral ischemic attack noted within 6 months before initiation of the observation ; diagnosis of heart failure ( nyha iii or iv class ),Condition Occurrence,Other,C0677510;C0021440;C3496001,iv,FALSE,FALSE,NA,NA,NA
22,NCT01075698,Exclusion,myocardial infarction ; percutaneous transluminal angioplasty and bypass surgery of coronary artery / lower-limb blood vessel ; cerebral infarction ; cerebral hemorrhage ; subarachnoid hemorrhage and transient cerebral ischemic attack noted within 6 months before initiation of the observation ; diagnosis of heart failure ( nyha iii or iv class ),Condition Occurrence,Other,C0456387;C0489477,class,FALSE,FALSE,NA,NA,NA
23,NCT01075698,Exclusion,virulent hypertension and secondary hypertension,Observation,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
23,NCT01075698,Exclusion,virulent hypertension and secondary hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
24,NCT01075698,Exclusion,pregnant women,Person,Person,C0033011,pregnant women,FALSE,FALSE,NA,NA,NA
25,NCT01075698,Exclusion,clinically relevant allergic symptoms or past history of hypersensitivity to drugs / significant adverse drug reactions,Condition Occurrence,Condition,C0740903,allergic symptoms,FALSE,FALSE,NA,NA,NA
25,NCT01075698,Exclusion,clinically relevant allergic symptoms or past history of hypersensitivity to drugs / significant adverse drug reactions,Condition Occurrence,Condition,C0041755,adverse drug reactions,FALSE,FALSE,NA,NA,NA
25,NCT01075698,Exclusion,clinically relevant allergic symptoms or past history of hypersensitivity to drugs / significant adverse drug reactions,Condition Occurrence,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
25,NCT01075698,Exclusion,clinically relevant allergic symptoms or past history of hypersensitivity to drugs / significant adverse drug reactions,Condition Occurrence,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
26,NCT01075698,Exclusion,extremely poor bile secretion or serious liver disorders,Condition Occurrence,Condition,C0232754,bile secretion,FALSE,FALSE,NA,NA,NA
26,NCT01075698,Exclusion,extremely poor bile secretion or serious liver disorders,Condition Occurrence,Condition,C0023895,liver disorders,FALSE,FALSE,NA,NA,NA
27,NCT01075698,Exclusion,treatment-required malignant tumors,Condition Occurrence,Condition,C0006826,malignant tumors,FALSE,FALSE,NA,NA,NA
27,NCT01075698,Exclusion,treatment-required malignant tumors,Condition Occurrence,Other,C3245502;C3245501;C1619636;C1546857,required,FALSE,FALSE,NA,NA,NA
28,NCT01075698,Exclusion,patients who are judged by the physician in charge to be ineligible for the study for any other reasons,Observation,Observation,C1706211,charge,FALSE,FALSE,NA,NA,NA
1,NCT01101009,Inclusion,moderate to severe hypertension,Other,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT01101009,Inclusion,moderate to severe hypertension,Other,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
1,NCT01101009,Inclusion,moderate to severe hypertension,Other,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
2,NCT01101009,Inclusion,3 additional risk factors such as age > 55 ( male ) ; > 65 female ; smoker ; type 2 diabetes ; obesity ; cardiovascular disease ; congestive heart failure ; chronic kidney disease ;,Observation,Person,C0025266,male,FALSE,FALSE,NA,NA,NA
2,NCT01101009,Inclusion,3 additional risk factors such as age > 55 ( male ) ; > 65 female ; smoker ; type 2 diabetes ; obesity ; cardiovascular disease ; congestive heart failure ; chronic kidney disease ;,Observation,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
2,NCT01101009,Inclusion,3 additional risk factors such as age > 55 ( male ) ; > 65 female ; smoker ; type 2 diabetes ; obesity ; cardiovascular disease ; congestive heart failure ; chronic kidney disease ;,Observation,Condition,C0455624,risk factors,FALSE,FALSE,NA,equal 3,NA
2,NCT01101009,Inclusion,3 additional risk factors such as age > 55 ( male ) ; > 65 female ; smoker ; type 2 diabetes ; obesity ; cardiovascular disease ; congestive heart failure ; chronic kidney disease ;,Observation,Condition,C0264722,congestive heart failure chronic,FALSE,FALSE,NA,greater 65,NA
2,NCT01101009,Inclusion,3 additional risk factors such as age > 55 ( male ) ; > 65 female ; smoker ; type 2 diabetes ; obesity ; cardiovascular disease ; congestive heart failure ; chronic kidney disease ;,Observation,Condition,C0007222,cardiovascular disease,FALSE,FALSE,NA,greater 65,NA
2,NCT01101009,Inclusion,3 additional risk factors such as age > 55 ( male ) ; > 65 female ; smoker ; type 2 diabetes ; obesity ; cardiovascular disease ; congestive heart failure ; chronic kidney disease ;,Observation,Condition,C0028754;C1963185,obesity,FALSE,FALSE,NA,greater 65,NA
2,NCT01101009,Inclusion,3 additional risk factors such as age > 55 ( male ) ; > 65 female ; smoker ; type 2 diabetes ; obesity ; cardiovascular disease ; congestive heart failure ; chronic kidney disease ;,Observation,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,greater 65,NA
2,NCT01101009,Inclusion,3 additional risk factors such as age > 55 ( male ) ; > 65 female ; smoker ; type 2 diabetes ; obesity ; cardiovascular disease ; congestive heart failure ; chronic kidney disease ;,Observation,Condition,C0337664,smoker,FALSE,FALSE,NA,greater 65,NA
2,NCT01101009,Inclusion,3 additional risk factors such as age > 55 ( male ) ; > 65 female ; smoker ; type 2 diabetes ; obesity ; cardiovascular disease ; congestive heart failure ; chronic kidney disease ;,Observation,Condition,C0022658,kidney disease,FALSE,FALSE,NA,NA,NA
3,NCT01101009,Inclusion,ability to give informed consent,Other,NA,NA,NA,NA,NA,NA,NA,NA
4,NCT01101009,Exclusion,secondary hypertension or malignant hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
4,NCT01101009,Exclusion,secondary hypertension or malignant hypertension,Condition Occurrence,Condition,C0020540;C0024588,malignant hypertension,FALSE,FALSE,NA,NA,NA
5,NCT01101009,Exclusion,contraindication to any of the study drugs,Condition Occurrence,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
5,NCT01101009,Exclusion,contraindication to any of the study drugs,Condition Occurrence,Other,C1301624;C1547316,contraindication,FALSE,FALSE,NA,NA,NA
6,NCT01101009,Exclusion,creatinine clearance level < 40 ml / min,Observation,Observation,C0373595;C0812399,creatinine clearance,FALSE,FALSE,NA,lower 40 ml/min,NA
7,NCT01101009,Exclusion,treatment with more than 3 antihypertensive drugs,Drug Exposure,Drug,C0003364,antihypertensive drugs,FALSE,FALSE,NA,greater 3,NA
8,NCT01101009,Exclusion,myocardial infarction ; percutaneous transluminal coronary angioplasty ; cardiac bypass surgery < 6 month prior to start of the study ;,Procedure,Procedure,C1536078,bypass surgery,FALSE,FALSE,lower 6 month,NA,NA
8,NCT01101009,Exclusion,myocardial infarction ; percutaneous transluminal coronary angioplasty ; cardiac bypass surgery < 6 month prior to start of the study ;,Procedure,Procedure,C2936173,percutaneous transluminal coronary angioplasty,FALSE,FALSE,lower 6 month,NA,NA
8,NCT01101009,Exclusion,myocardial infarction ; percutaneous transluminal coronary angioplasty ; cardiac bypass surgery < 6 month prior to start of the study ;,Procedure,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,lower 6 month,NA,NA
9,NCT01101009,Exclusion,unstable angina pectoris ;,Condition Occurrence,Condition,C0002965,unstable angina pectoris,FALSE,FALSE,NA,NA,NA
10,NCT01101009,Exclusion,stroke ; transient ischemic attack < 3 months prior to start ;,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,lower 3 months,NA,NA
11,NCT01101009,Exclusion,congestive heart failure nyha ii-iv ;,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
11,NCT01101009,Exclusion,congestive heart failure nyha ii-iv ;,Condition Occurrence,Other,C0677510;C0021440;C3496001,iv,FALSE,FALSE,NA,NA,NA
12,NCT01101009,Exclusion,clinically relevant concomitant diseases,NA,Other,NA,NA,NA,NA,NA,NA,NA
13,NCT01101009,Exclusion,alcohol or drug abuse ;,Drug Exposure,Condition,C0013146,drug abuse,FALSE,FALSE,NA,NA,NA
13,NCT01101009,Exclusion,alcohol or drug abuse ;,Drug Exposure,Other,C0001975;C0001962;C1547288,alcohol,FALSE,FALSE,NA,NA,NA
14,NCT01101009,Exclusion,pregnancy or women of childbearing potential without contraceptive precaution ;,Observation,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
14,NCT01101009,Exclusion,pregnancy or women of childbearing potential without contraceptive precaution ;,Observation,Observation,C3831118,childbearing potential,FALSE,FALSE,NA,NA,NA
14,NCT01101009,Exclusion,pregnancy or women of childbearing potential without contraceptive precaution ;,Observation,Other,C0032961;C3484365,pregnancy,FALSE,FALSE,NA,NA,NA
1,NCT01167153,Inclusion,male and female adult outpatients had uncontrolled hypertension at both screening and randomization despite current antihypertensive monotherapy ( initial dose of angiotensin receptor blockers ( arb ) ; angiotensin converting enzyme inhibitors ( acei ) ; calcium channel blockers ( ccb ) ; diuretics or beta receptor blocker ),Drug Exposure,Person,C0025266,male,FALSE,FALSE,NA,NA,NA
1,NCT01167153,Inclusion,male and female adult outpatients had uncontrolled hypertension at both screening and randomization despite current antihypertensive monotherapy ( initial dose of angiotensin receptor blockers ( arb ) ; angiotensin converting enzyme inhibitors ( acei ) ; calcium channel blockers ( ccb ) ; diuretics or beta receptor blocker ),Drug Exposure,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
1,NCT01167153,Inclusion,male and female adult outpatients had uncontrolled hypertension at both screening and randomization despite current antihypertensive monotherapy ( initial dose of angiotensin receptor blockers ( arb ) ; angiotensin converting enzyme inhibitors ( acei ) ; calcium channel blockers ( ccb ) ; diuretics or beta receptor blocker ),Drug Exposure,Condition,C1868885,uncontrolled hypertension,FALSE,FALSE,NA,NA,NA
1,NCT01167153,Inclusion,male and female adult outpatients had uncontrolled hypertension at both screening and randomization despite current antihypertensive monotherapy ( initial dose of angiotensin receptor blockers ( arb ) ; angiotensin converting enzyme inhibitors ( acei ) ; calcium channel blockers ( ccb ) ; diuretics or beta receptor blocker ),Drug Exposure,Condition,C0175556,ccb,FALSE,FALSE,NA,NA,NA
1,NCT01167153,Inclusion,male and female adult outpatients had uncontrolled hypertension at both screening and randomization despite current antihypertensive monotherapy ( initial dose of angiotensin receptor blockers ( arb ) ; angiotensin converting enzyme inhibitors ( acei ) ; calcium channel blockers ( ccb ) ; diuretics or beta receptor blocker ),Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
1,NCT01167153,Inclusion,male and female adult outpatients had uncontrolled hypertension at both screening and randomization despite current antihypertensive monotherapy ( initial dose of angiotensin receptor blockers ( arb ) ; angiotensin converting enzyme inhibitors ( acei ) ; calcium channel blockers ( ccb ) ; diuretics or beta receptor blocker ),Drug Exposure,Drug,C0521942;C0815017,angiotensin receptor blockers,FALSE,FALSE,NA,NA,NA
1,NCT01167153,Inclusion,male and female adult outpatients had uncontrolled hypertension at both screening and randomization despite current antihypertensive monotherapy ( initial dose of angiotensin receptor blockers ( arb ) ; angiotensin converting enzyme inhibitors ( acei ) ; calcium channel blockers ( ccb ) ; diuretics or beta receptor blocker ),Drug Exposure,Drug,C0003015,angiotensin converting enzyme inhibitors,FALSE,FALSE,NA,NA,NA
1,NCT01167153,Inclusion,male and female adult outpatients had uncontrolled hypertension at both screening and randomization despite current antihypertensive monotherapy ( initial dose of angiotensin receptor blockers ( arb ) ; angiotensin converting enzyme inhibitors ( acei ) ; calcium channel blockers ( ccb ) ; diuretics or beta receptor blocker ),Drug Exposure,Drug,C0006684,calcium channel blockers,FALSE,FALSE,NA,NA,NA
1,NCT01167153,Inclusion,male and female adult outpatients had uncontrolled hypertension at both screening and randomization despite current antihypertensive monotherapy ( initial dose of angiotensin receptor blockers ( arb ) ; angiotensin converting enzyme inhibitors ( acei ) ; calcium channel blockers ( ccb ) ; diuretics or beta receptor blocker ),Drug Exposure,Drug,C0012798,diuretics,FALSE,FALSE,NA,NA,NA
1,NCT01167153,Inclusion,male and female adult outpatients had uncontrolled hypertension at both screening and randomization despite current antihypertensive monotherapy ( initial dose of angiotensin receptor blockers ( arb ) ; angiotensin converting enzyme inhibitors ( acei ) ; calcium channel blockers ( ccb ) ; diuretics or beta receptor blocker ),Drug Exposure,Other,C0521942;C2678493,arb,FALSE,FALSE,NA,NA,NA
1,NCT01167153,Inclusion,male and female adult outpatients had uncontrolled hypertension at both screening and randomization despite current antihypertensive monotherapy ( initial dose of angiotensin receptor blockers ( arb ) ; angiotensin converting enzyme inhibitors ( acei ) ; calcium channel blockers ( ccb ) ; diuretics or beta receptor blocker ),Drug Exposure,Other,C1705684,initial,FALSE,FALSE,NA,NA,NA
1,NCT01167153,Inclusion,male and female adult outpatients had uncontrolled hypertension at both screening and randomization despite current antihypertensive monotherapy ( initial dose of angiotensin receptor blockers ( arb ) ; angiotensin converting enzyme inhibitors ( acei ) ; calcium channel blockers ( ccb ) ; diuretics or beta receptor blocker ),Drug Exposure,Other,C0439096,beta,FALSE,FALSE,NA,NA,NA
2,NCT01167153,Exclusion,systolic bp ( sbp ) level > = 160 mm hg ( > = 160 mm hg in diabetics ) or a diastolic bp ( dbp ) level > = 110 mm hg ( > = 100 mm hg in diabetics ) at any time between screening and randomization .,Observation,Condition,C2024467,time,FALSE,FALSE,NA,NA,NA
2,NCT01167153,Exclusion,systolic bp ( sbp ) level > = 160 mm hg ( > = 160 mm hg in diabetics ) or a diastolic bp ( dbp ) level > = 110 mm hg ( > = 100 mm hg in diabetics ) at any time between screening and randomization .,Observation,Observation,C0871470,systolic bp,FALSE,FALSE,NA,NA,NA
2,NCT01167153,Exclusion,systolic bp ( sbp ) level > = 160 mm hg ( > = 160 mm hg in diabetics ) or a diastolic bp ( dbp ) level > = 110 mm hg ( > = 100 mm hg in diabetics ) at any time between screening and randomization .,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 160 mm hg; greater_equal 160 mm hg,NA
2,NCT01167153,Exclusion,systolic bp ( sbp ) level > = 160 mm hg ( > = 160 mm hg in diabetics ) or a diastolic bp ( dbp ) level > = 110 mm hg ( > = 100 mm hg in diabetics ) at any time between screening and randomization .,Observation,Observation,C0428883,diastolic bp,FALSE,FALSE,NA,NA,NA
2,NCT01167153,Exclusion,systolic bp ( sbp ) level > = 160 mm hg ( > = 160 mm hg in diabetics ) or a diastolic bp ( dbp ) level > = 110 mm hg ( > = 100 mm hg in diabetics ) at any time between screening and randomization .,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 110 mm hg; greater_equal 100 mm hg,NA
3,NCT01167153,Exclusion,patients with type 1 diabetes or poorly controlled type 2 diabetes ( glycosylated hemoglobin > 8.00 % ),Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
3,NCT01167153,Exclusion,patients with type 1 diabetes or poorly controlled type 2 diabetes ( glycosylated hemoglobin > 8.00 % ),Condition Occurrence,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
3,NCT01167153,Exclusion,patients with type 1 diabetes or poorly controlled type 2 diabetes ( glycosylated hemoglobin > 8.00 % ),Condition Occurrence,Observation,C0017853;C0373638;C0202054,glycosylated hemoglobin,FALSE,FALSE,NA,NA,greater 8.00 %
4,NCT01167153,Exclusion,patients had evidence of hepatic disease or renal impairment,Condition Occurrence,Condition,C0023895,hepatic disease,FALSE,FALSE,NA,NA,NA
4,NCT01167153,Exclusion,patients had evidence of hepatic disease or renal impairment,Condition Occurrence,Condition,C1565489;C0035078,renal impairment,FALSE,FALSE,NA,NA,NA
5,NCT01167153,Exclusion,other included evidence of secondary hypertension or history of cardio-vascular disease .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
5,NCT01167153,Exclusion,other included evidence of secondary hypertension or history of cardio-vascular disease .,Condition Occurrence,Condition,C1558950,vascular,FALSE,FALSE,NA,NA,NA
6,NCT01167153,Exclusion,women who were pregnant ; nursing ; or of childbearing potential and not using acceptable contraception .,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
6,NCT01167153,Exclusion,women who were pregnant ; nursing ; or of childbearing potential and not using acceptable contraception .,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
6,NCT01167153,Exclusion,women who were pregnant ; nursing ; or of childbearing potential and not using acceptable contraception .,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
6,NCT01167153,Exclusion,women who were pregnant ; nursing ; or of childbearing potential and not using acceptable contraception .,Condition Occurrence,Procedure,C0700589,contraception,TRUE,FALSE,NA,NA,NA
6,NCT01167153,Exclusion,women who were pregnant ; nursing ; or of childbearing potential and not using acceptable contraception .,Condition Occurrence,Observation,C3831118,childbearing potential,FALSE,FALSE,NA,NA,NA
7,NCT01167153,Exclusion,other protocol-defined inclusiopplied,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT01368536,Inclusion,patients with stage 2 hypertension within protocol limits at randomization,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
2,NCT01368536,Inclusion,patients with type 2 diabetes mellitus with hga1c less than or equal to 9 %,Drug Exposure,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,lower_equal 9 %
3,NCT01368536,Inclusion,patients with newly diagnosed hypertension or patients who have not received antihypertensive therapy for at least 4 weeks prior to screening,Observation,Procedure,C0585941,antihypertensive therapy,TRUE,FALSE,greater_equal 4 weeks,NA,NA
3,NCT01368536,Inclusion,patients with newly diagnosed hypertension or patients who have not received antihypertensive therapy for at least 4 weeks prior to screening,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
4,NCT01368536,Exclusion,patients taking 4 or more antihypertensive medications at screening visit,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,greater_equal 4,NA
5,NCT01368536,Exclusion,patients with uncontrolled bp ( > 140 / 90 mmhg ) while taking 3 or more antihypertensives at their maximum approved doses,Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,greater 140 mmhg; greater 90 mmhg; greater_equal 3,NA
6,NCT01368536,Exclusion,type 2 diabetes mellitus requiring insulin treatment,Condition Occurrence,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
6,NCT01368536,Exclusion,type 2 diabetes mellitus requiring insulin treatment,Condition Occurrence,Procedure,C0745343,insulin treatment,FALSE,FALSE,NA,NA,NA
7,NCT01368536,Exclusion,patients with hga1c > 9 %,Drug Exposure,NA,NA,NA,NA,NA,NA,NA,NA
8,NCT01368536,Exclusion,patients with known gout,Condition Occurrence,Condition,C0018099,gout,FALSE,FALSE,NA,NA,NA
9,NCT01368536,Exclusion,known history of cancer within the past 5 years,Condition Occurrence,Other,C0260515;C2707253,cancer,FALSE,FALSE,lower 5 past years,NA,NA
10,NCT01368536,Exclusion,patients who are pregnant mothers or nursing mothers,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
10,NCT01368536,Exclusion,patients who are pregnant mothers or nursing mothers,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
11,NCT01368536,Exclusion,patients who have participated in an investigational clinical trial within the 30 days prior to screening .,Other,Other,C3245491,investigational,FALSE,FALSE,NA,NA,NA
11,NCT01368536,Exclusion,patients who have participated in an investigational clinical trial within the 30 days prior to screening .,Other,Other,C1096775,clinical trial,FALSE,FALSE,lower 30 days,NA,NA
12,NCT01368536,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT01518855,Inclusion,untreated patients or patients with previous treatment by antihypertensive agents whose blood pressure at sitting position at the time of the entry ( visit 1 ) is :,Condition Occurrence,Condition,C0277814,sitting position,FALSE,FALSE,NA,NA,NA
1,NCT01518855,Inclusion,untreated patients or patients with previous treatment by antihypertensive agents whose blood pressure at sitting position at the time of the entry ( visit 1 ) is :,Condition Occurrence,Condition,C2024467,time,FALSE,FALSE,NA,NA,NA
1,NCT01518855,Inclusion,untreated patients or patients with previous treatment by antihypertensive agents whose blood pressure at sitting position at the time of the entry ( visit 1 ) is :,Condition Occurrence,Drug,C0003364,antihypertensive agents,FALSE,FALSE,NA,NA,NA
1,NCT01518855,Inclusion,untreated patients or patients with previous treatment by antihypertensive agents whose blood pressure at sitting position at the time of the entry ( visit 1 ) is :,Condition Occurrence,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
1,NCT01518855,Inclusion,untreated patients or patients with previous treatment by antihypertensive agents whose blood pressure at sitting position at the time of the entry ( visit 1 ) is :,Condition Occurrence,Other,C1705654,entry,FALSE,FALSE,NA,NA,NA
2,NCT01518855,Inclusion,sbp > / = 160 mmhg or dbp > / = 100 mmhg for untreated patients ( sbp systolic blood pressure ; dbp diastolic blood pressure ),Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 160 mmhg; greater_equal 100 mmhg,NA
2,NCT01518855,Inclusion,sbp > / = 160 mmhg or dbp > / = 100 mmhg for untreated patients ( sbp systolic blood pressure ; dbp diastolic blood pressure ),Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 100 mmhg,NA
2,NCT01518855,Inclusion,sbp > / = 160 mmhg or dbp > / = 100 mmhg for untreated patients ( sbp systolic blood pressure ; dbp diastolic blood pressure ),Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,NA,NA
2,NCT01518855,Inclusion,sbp > / = 160 mmhg or dbp > / = 100 mmhg for untreated patients ( sbp systolic blood pressure ; dbp diastolic blood pressure ),Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,NA,NA
3,NCT01518855,Inclusion,sbp > / = 150 mmhg or dbp > / = 95 mmhg for patients with previous treatment by antihypertensive agents,Observation,Drug,C0003364,antihypertensive agents,FALSE,FALSE,NA,NA,NA
3,NCT01518855,Inclusion,sbp > / = 150 mmhg or dbp > / = 95 mmhg for patients with previous treatment by antihypertensive agents,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 150 mmhg; greater_equal 95 mmhg,NA
3,NCT01518855,Inclusion,sbp > / = 150 mmhg or dbp > / = 95 mmhg for patients with previous treatment by antihypertensive agents,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 95 mmhg,NA
4,NCT01518855,Exclusion,patients whose blood pressure on either day of visit 1 or 2 is : sbp > 200 mmhg or dbp > 120 mmhg .,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
4,NCT01518855,Exclusion,patients whose blood pressure on either day of visit 1 or 2 is : sbp > 200 mmhg or dbp > 120 mmhg .,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater 200 mmhg; greater 120 mmhg,NA
4,NCT01518855,Exclusion,patients whose blood pressure on either day of visit 1 or 2 is : sbp > 200 mmhg or dbp > 120 mmhg .,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater 120 mmhg,NA
5,NCT01518855,Exclusion,patients with secondary hypertension or hypertensive emergency such as malignant hypertension .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
5,NCT01518855,Exclusion,patients with secondary hypertension or hypertensive emergency such as malignant hypertension .,Condition Occurrence,Condition,C0745136,hypertensive emergency,FALSE,FALSE,NA,NA,NA
5,NCT01518855,Exclusion,patients with secondary hypertension or hypertensive emergency such as malignant hypertension .,Condition Occurrence,Condition,C0020540;C0024588,malignant hypertension,FALSE,FALSE,NA,NA,NA
6,NCT01518855,Exclusion,patients with a history of cardiovascular ischemic event or cerebrovascular ischemic event ( stroke ; transient ischemic attack ; myocardial infarction or unstable angina ) within six months prior to the study .,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,NA,NA,NA
6,NCT01518855,Exclusion,patients with a history of cardiovascular ischemic event or cerebrovascular ischemic event ( stroke ; transient ischemic attack ; myocardial infarction or unstable angina ) within six months prior to the study .,Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,NA,NA,NA
6,NCT01518855,Exclusion,patients with a history of cardiovascular ischemic event or cerebrovascular ischemic event ( stroke ; transient ischemic attack ; myocardial infarction or unstable angina ) within six months prior to the study .,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
7,NCT01518855,Exclusion,patients with a history of intracranial hemorrhage or subarachnoid hemorrhage within six months prior to the study .,Condition Occurrence,Condition,C0151699,intracranial hemorrhage,FALSE,FALSE,NA,NA,NA
7,NCT01518855,Exclusion,patients with a history of intracranial hemorrhage or subarachnoid hemorrhage within six months prior to the study .,Condition Occurrence,Condition,C0038525,subarachnoid hemorrhage,FALSE,FALSE,NA,NA,NA
8,NCT01518855,Exclusion,patients with uncontrolled diabetes ( hba1c > / = 8 % ),Condition Occurrence,Condition,C0011849;C0011847,diabetes,FALSE,FALSE,NA,NA,NA
8,NCT01518855,Exclusion,patients with uncontrolled diabetes ( hba1c > / = 8 % ),Condition Occurrence,Observation,C0202054,hba1c,FALSE,FALSE,NA,NA,greater_equal 8 %
9,NCT01518855,Exclusion,patients with bradycardia or tachycardia ( < 50 bpm ; > / = 100 bpm ) ; arrhythmia such as atrioventricular block ( second degree and third degree ) ; sinoatrial block or atrial fibrillation,Condition Occurrence,Condition,C0039231;C2029900,tachycardia,FALSE,FALSE,NA,NA,NA
9,NCT01518855,Exclusion,patients with bradycardia or tachycardia ( < 50 bpm ; > / = 100 bpm ) ; arrhythmia such as atrioventricular block ( second degree and third degree ) ; sinoatrial block or atrial fibrillation,Condition Occurrence,Condition,C0003811,arrhythmia,FALSE,FALSE,NA,NA,NA
9,NCT01518855,Exclusion,patients with bradycardia or tachycardia ( < 50 bpm ; > / = 100 bpm ) ; arrhythmia such as atrioventricular block ( second degree and third degree ) ; sinoatrial block or atrial fibrillation,Condition Occurrence,Condition,C0264906,atrioventricular block second degree,FALSE,FALSE,NA,NA,NA
9,NCT01518855,Exclusion,patients with bradycardia or tachycardia ( < 50 bpm ; > / = 100 bpm ) ; arrhythmia such as atrioventricular block ( second degree and third degree ) ; sinoatrial block or atrial fibrillation,Condition Occurrence,Condition,C0037188,sinoatrial block,FALSE,FALSE,NA,NA,NA
9,NCT01518855,Exclusion,patients with bradycardia or tachycardia ( < 50 bpm ; > / = 100 bpm ) ; arrhythmia such as atrioventricular block ( second degree and third degree ) ; sinoatrial block or atrial fibrillation,Condition Occurrence,Observation,C0428977,bradycardia,FALSE,FALSE,NA,NA,NA
9,NCT01518855,Exclusion,patients with bradycardia or tachycardia ( < 50 bpm ; > / = 100 bpm ) ; arrhythmia such as atrioventricular block ( second degree and third degree ) ; sinoatrial block or atrial fibrillation,Condition Occurrence,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
9,NCT01518855,Exclusion,patients with bradycardia or tachycardia ( < 50 bpm ; > / = 100 bpm ) ; arrhythmia such as atrioventricular block ( second degree and third degree ) ; sinoatrial block or atrial fibrillation,Condition Occurrence,Other,C0053672;C1706504,bpm,FALSE,FALSE,NA,lower 50,NA
9,NCT01518855,Exclusion,patients with bradycardia or tachycardia ( < 50 bpm ; > / = 100 bpm ) ; arrhythmia such as atrioventricular block ( second degree and third degree ) ; sinoatrial block or atrial fibrillation,Condition Occurrence,Other,C0053672;C1706504,bpm,FALSE,FALSE,NA,greater_equal 100,NA
9,NCT01518855,Exclusion,patients with bradycardia or tachycardia ( < 50 bpm ; > / = 100 bpm ) ; arrhythmia such as atrioventricular block ( second degree and third degree ) ; sinoatrial block or atrial fibrillation,Condition Occurrence,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
1,NCT01599104,Inclusion,patients with mild-to-moderate hypertension ; untreated or currently taking antihypertensive therapy .,Condition Occurrence,Condition,C0745134,hypertension untreated,FALSE,FALSE,NA,NA,NA
1,NCT01599104,Inclusion,patients with mild-to-moderate hypertension ; untreated or currently taking antihypertensive therapy .,Condition Occurrence,Condition,C2054151,taking antihypertensive,FALSE,FALSE,NA,NA,NA
1,NCT01599104,Inclusion,patients with mild-to-moderate hypertension ; untreated or currently taking antihypertensive therapy .,Condition Occurrence,Other,C1547225,mild,FALSE,FALSE,NA,NA,NA
2,NCT01599104,Inclusion,treated patients ( using antihypertensive treatments within 4 weeks prior to visit 1 ) must have an mssbp > = 150 mmhg and < 180 mmhg at the randomization visit ( visit 201 ) and mssbp > = 140 mmhg < 180 mmhg at the visit immediately proceeding visit 201 ( visit 102 or 103 ) .,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,lower 4 weeks,greater_equal 150 mmhg; lower 180 mmhg; greater_equal 140 mmhg; lower 180 mmhg,NA
3,NCT01599104,Inclusion,untreated patients ( newly diagnosed with essential hypertension or having a history of hypertension but have not been taking any antihypertensive drugs for at least 4 weeks prior to visit 1 ) must have an mssbp > = 150 mmhg and < 180 mmhg at both visit 1 and visit 201 .,Observation,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
3,NCT01599104,Inclusion,untreated patients ( newly diagnosed with essential hypertension or having a history of hypertension but have not been taking any antihypertensive drugs for at least 4 weeks prior to visit 1 ) must have an mssbp > = 150 mmhg and < 180 mmhg at both visit 1 and visit 201 .,Observation,Drug,C0003364,antihypertensive drugs,TRUE,FALSE,greater_equal 4 weeks,greater_equal 150 mmhg; lower 180 mmhg,NA
3,NCT01599104,Inclusion,untreated patients ( newly diagnosed with essential hypertension or having a history of hypertension but have not been taking any antihypertensive drugs for at least 4 weeks prior to visit 1 ) must have an mssbp > = 150 mmhg and < 180 mmhg at both visit 1 and visit 201 .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
4,NCT01599104,Inclusion,patients must have an absolute difference of < = 15 mmhg in mssbp between visit 201 and the immediately preceding visit ;,Observation,NA,NA,NA,NA,NA,NA,NA,NA
5,NCT01599104,Exclusion,severe hypertension ( msdbp > = 110 mmhg or mssbp > = 180 mmhg ) .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,greater_equal 110 mmhg; greater_equal 180 mmhg,NA
5,NCT01599104,Exclusion,severe hypertension ( msdbp > = 110 mmhg or mssbp > = 180 mmhg ) .,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
6,NCT01599104,Exclusion,history of angioedema ; drug-related or otherwise ; as reported by the patient .,Condition Occurrence,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
6,NCT01599104,Exclusion,history of angioedema ; drug-related or otherwise ; as reported by the patient .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
7,NCT01599104,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; and drug-induced hypertension .,Condition Occurrence,Condition,C0264649,renal parenchymal hypertension,FALSE,FALSE,NA,NA,NA
7,NCT01599104,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; and drug-induced hypertension .,Condition Occurrence,Condition,C0020545,renovascular hypertension,FALSE,FALSE,NA,NA,NA
7,NCT01599104,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; and drug-induced hypertension .,Condition Occurrence,Condition,C0035065;C1278951,renal artery,FALSE,FALSE,NA,NA,NA
7,NCT01599104,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; and drug-induced hypertension .,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
7,NCT01599104,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; and drug-induced hypertension .,Condition Occurrence,Condition,C0332886,coarctation,FALSE,FALSE,NA,NA,NA
7,NCT01599104,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; and drug-induced hypertension .,Condition Occurrence,Condition,C0022680,polycystic kidney disease,FALSE,FALSE,NA,NA,NA
7,NCT01599104,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; and drug-induced hypertension .,Condition Occurrence,Condition,C0031511;C1706920,pheochromocytoma,FALSE,FALSE,NA,NA,NA
7,NCT01599104,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; and drug-induced hypertension .,Condition Occurrence,Condition,C0221406;C0010481,cushing disease,FALSE,FALSE,NA,NA,NA
7,NCT01599104,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; and drug-induced hypertension .,Condition Occurrence,Condition,C1384514,primary hyperaldosteronism,FALSE,FALSE,NA,NA,NA
7,NCT01599104,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; and drug-induced hypertension .,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
7,NCT01599104,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; and drug-induced hypertension .,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
7,NCT01599104,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; and drug-induced hypertension .,Condition Occurrence,Other,C3542948,limited,TRUE,FALSE,NA,NA,NA
7,NCT01599104,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; and drug-induced hypertension .,Condition Occurrence,Other,C0869784;C0003483;C1278934,aorta,FALSE,FALSE,NA,NA,NA
7,NCT01599104,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; and drug-induced hypertension .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
8,NCT01599104,Exclusion,patients who previously entered a lcz696 study and had been randomized or enrolled into the active drug treatment epoch .,Drug Exposure,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
8,NCT01599104,Exclusion,patients who previously entered a lcz696 study and had been randomized or enrolled into the active drug treatment epoch .,Drug Exposure,Drug,C2946699,epoch,FALSE,FALSE,NA,NA,NA
8,NCT01599104,Exclusion,patients who previously entered a lcz696 study and had been randomized or enrolled into the active drug treatment epoch .,Drug Exposure,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
9,NCT01599104,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT01615198,Inclusion,patients must give written informed consent before any assessment is performed,Observation,Other,C0542573;C0549068;C0870300;C0549070;C0549071;C0549072;C0549073;C0549074;C0028708;C0549075;C0549076;C0549077;C0549078;C0549079;C0549080;C0679207,assessment,FALSE,FALSE,NA,NA,NA
2,NCT01615198,Inclusion,patients with essential hypertension ; untreated or currently taking antihypertensive therapy must have a mean sitting systolic blood pressure > = 150 mmhg and < 180 mmhg,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT01615198,Inclusion,patients with essential hypertension ; untreated or currently taking antihypertensive therapy must have a mean sitting systolic blood pressure > = 150 mmhg and < 180 mmhg,Condition Occurrence,Condition,C2054151,taking antihypertensive,FALSE,FALSE,NA,NA,NA
2,NCT01615198,Inclusion,patients with essential hypertension ; untreated or currently taking antihypertensive therapy must have a mean sitting systolic blood pressure > = 150 mmhg and < 180 mmhg,Condition Occurrence,Condition,C1319893,sitting systolic blood pressure,FALSE,FALSE,NA,greater_equal 150 mmhg; lower 180 mmhg,NA
3,NCT01615198,Inclusion,patients must be able to communicate and comply with all study requirements and demonstrate good medication compliance,Other,Other,C3489773;C2364172,medication compliance,FALSE,FALSE,NA,NA,NA
4,NCT01615198,Exclusion,patients with severe hypertension ( msdbp > = 110 mmhg or mssbp > = 180 mmhg ),Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,greater_equal 110 mmhg; greater_equal 180 mmhg,NA
4,NCT01615198,Exclusion,patients with severe hypertension ( msdbp > = 110 mmhg or mssbp > = 180 mmhg ),Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
5,NCT01615198,Exclusion,patients with history of angioedema ; drug-related or otherwise,Condition Occurrence,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
5,NCT01615198,Exclusion,patients with history of angioedema ; drug-related or otherwise,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
6,NCT01615198,Exclusion,patients with history or evidence of a secondary form of hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
7,NCT01615198,Exclusion,transient ischemic cerebral attack ( tia ) during the 12 months prior to visit 1 or any history of stroke,Person,Person,C0040704,transient,FALSE,FALSE,NA,NA,NA
7,NCT01615198,Exclusion,transient ischemic cerebral attack ( tia ) during the 12 months prior to visit 1 or any history of stroke,Person,Condition,C0917805,tia,FALSE,FALSE,lower_equal 12 months,NA,NA
8,NCT01615198,Exclusion,history of myocardial infarction ; coronary bypass surgery or any percutaneous coronary intervention ( pci ) during the 12 months prior to visit 1 .,Procedure,Procedure,C1532338,percutaneous coronary intervention,FALSE,FALSE,NA,NA,NA
8,NCT01615198,Exclusion,history of myocardial infarction ; coronary bypass surgery or any percutaneous coronary intervention ( pci ) during the 12 months prior to visit 1 .,Procedure,Procedure,C0010055,coronary bypass surgery,FALSE,FALSE,NA,NA,NA
8,NCT01615198,Exclusion,history of myocardial infarction ; coronary bypass surgery or any percutaneous coronary intervention ( pci ) during the 12 months prior to visit 1 .,Procedure,Procedure,C1514496;C1532338,pci,FALSE,FALSE,lower_equal 12 months,NA,NA
8,NCT01615198,Exclusion,history of myocardial infarction ; coronary bypass surgery or any percutaneous coronary intervention ( pci ) during the 12 months prior to visit 1 .,Procedure,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
9,NCT01615198,Exclusion,current angina pectoris requiring medication ( other than patients on a stable dose of oral nitrates or topical nitrates ) .,Drug Exposure,Condition,C0002962;C0577698;C0235467;C0542052;C0010073;C0541777;C0235462,angina pectoris,FALSE,FALSE,NA,NA,NA
9,NCT01615198,Exclusion,current angina pectoris requiring medication ( other than patients on a stable dose of oral nitrates or topical nitrates ) .,Drug Exposure,Drug,C1272919,oral,FALSE,FALSE,NA,NA,NA
9,NCT01615198,Exclusion,current angina pectoris requiring medication ( other than patients on a stable dose of oral nitrates or topical nitrates ) .,Drug Exposure,Drug,C0028125,nitrates,FALSE,FALSE,NA,NA,NA
9,NCT01615198,Exclusion,current angina pectoris requiring medication ( other than patients on a stable dose of oral nitrates or topical nitrates ) .,Drug Exposure,Drug,C1710439,topical,FALSE,FALSE,NA,NA,NA
9,NCT01615198,Exclusion,current angina pectoris requiring medication ( other than patients on a stable dose of oral nitrates or topical nitrates ) .,Drug Exposure,Drug,C0028125,nitrates,FALSE,FALSE,NA,NA,NA
9,NCT01615198,Exclusion,current angina pectoris requiring medication ( other than patients on a stable dose of oral nitrates or topical nitrates ) .,Drug Exposure,Other,C1547311,stable,TRUE,FALSE,NA,NA,NA
10,NCT01615198,Exclusion,patients with type 1 diabetes or type 2 diabetesmellitus who are not well controlled and are not on a stable dose of antidiabetic medication,Other,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
10,NCT01615198,Exclusion,patients with type 1 diabetes or type 2 diabetesmellitus who are not well controlled and are not on a stable dose of antidiabetic medication,Other,Drug,C0935929,antidiabetic,FALSE,FALSE,NA,NA,NA
10,NCT01615198,Exclusion,patients with type 1 diabetes or type 2 diabetesmellitus who are not well controlled and are not on a stable dose of antidiabetic medication,Other,Other,C1552651,type,FALSE,FALSE,NA,NA,NA
10,NCT01615198,Exclusion,patients with type 1 diabetes or type 2 diabetesmellitus who are not well controlled and are not on a stable dose of antidiabetic medication,Other,Other,C1547311,stable,FALSE,FALSE,NA,NA,NA
11,NCT01615198,Exclusion,patients with previous diagnosis or current diagnosis of heart failure ( nyha class ii- .,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
11,NCT01615198,Exclusion,patients with previous diagnosis or current diagnosis of heart failure ( nyha class ii- .,Condition Occurrence,Condition,C1882083,nyha class,FALSE,FALSE,NA,NA,NA
12,NCT01615198,Exclusion,patients with a clinically significant valvular heart disease at the time of screening,Condition Occurrence,Condition,C0018824;C1963123,valvular heart disease,FALSE,FALSE,NA,NA,NA
12,NCT01615198,Exclusion,patients with a clinically significant valvular heart disease at the time of screening,Condition Occurrence,Condition,C2024467,time,FALSE,FALSE,NA,NA,NA
13,NCT01615198,Exclusion,women of child-bearing potential ; who do not use adequate birth control methods other protocol-defined inclusion / may apply,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
13,NCT01615198,Exclusion,women of child-bearing potential ; who do not use adequate birth control methods other protocol-defined inclusion / may apply,Person,Procedure,C0700589,birth control methods,TRUE,FALSE,NA,NA,NA
13,NCT01615198,Exclusion,women of child-bearing potential ; who do not use adequate birth control methods other protocol-defined inclusion / may apply,Person,Observation,C3831118,child-bearing potential,FALSE,FALSE,NA,NA,NA
13,NCT01615198,Exclusion,women of child-bearing potential ; who do not use adequate birth control methods other protocol-defined inclusion / may apply,Person,Other,C3539106,defined,TRUE,FALSE,NA,NA,NA
1,NCT01785472,Inclusion,patients with mild-to-moderate hypertension ; untreated or currently taking antihypertensive therapy .,Condition Occurrence,Condition,C0745134,hypertension untreated,FALSE,FALSE,NA,NA,NA
1,NCT01785472,Inclusion,patients with mild-to-moderate hypertension ; untreated or currently taking antihypertensive therapy .,Condition Occurrence,Condition,C2054151,taking antihypertensive,FALSE,FALSE,NA,NA,NA
1,NCT01785472,Inclusion,patients with mild-to-moderate hypertension ; untreated or currently taking antihypertensive therapy .,Condition Occurrence,Other,C1547225,mild,FALSE,FALSE,NA,NA,NA
2,NCT01785472,Inclusion,treated patients ( using antihypertensive treatments within 4 weeks prior to visit 1 ) must have an mssbp > = 150 mmhg and < 180 mmhg at the randomization visit ( visit 201 ) and mssbp > = 140 mmhg < 180 mmhg at the visit immediately preceding visit 201 ( visit 102 or 103 ) .,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,lower 4 weeks,greater_equal 150 mmhg; lower 180 mmhg; greater_equal 140 mmhg; lower 180 mmhg,NA
3,NCT01785472,Inclusion,untreated patients ( newly diagnosed with essential hypertension or having a history of hypertension but have not been taking any antihypertensive drugs for at least 4 weeks prior to visit 1 ) must have an mssbp > = 150 mmhg and < 180 mmhg at both visit 1 and visit 201 .,Observation,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
3,NCT01785472,Inclusion,untreated patients ( newly diagnosed with essential hypertension or having a history of hypertension but have not been taking any antihypertensive drugs for at least 4 weeks prior to visit 1 ) must have an mssbp > = 150 mmhg and < 180 mmhg at both visit 1 and visit 201 .,Observation,Drug,C0003364,antihypertensive drugs,TRUE,FALSE,greater_equal 4 weeks,greater_equal 150 mmhg; lower 180 mmhg,NA
3,NCT01785472,Inclusion,untreated patients ( newly diagnosed with essential hypertension or having a history of hypertension but have not been taking any antihypertensive drugs for at least 4 weeks prior to visit 1 ) must have an mssbp > = 150 mmhg and < 180 mmhg at both visit 1 and visit 201 .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
4,NCT01785472,Inclusion,patients must have an absolute difference of < = 15 mmhg in mssbp between visit 201 and the immediately preceding visit .,Observation,NA,NA,NA,NA,NA,NA,NA,NA
5,NCT01785472,Exclusion,patients with severe hypertension ( msdbp > = 110 mmhg and or mssbp > = 180 mmhg ) .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,greater_equal 110 mmhg; greater_equal 180 mmhg,NA
5,NCT01785472,Exclusion,patients with severe hypertension ( msdbp > = 110 mmhg and or mssbp > = 180 mmhg ) .,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
6,NCT01785472,Exclusion,history of angioedema ; drug-related or otherwise ; as reported by the patient .,Condition Occurrence,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
6,NCT01785472,Exclusion,history of angioedema ; drug-related or otherwise ; as reported by the patient .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
7,NCT01785472,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; and drug-induced hypertension .,Condition Occurrence,Condition,C0264649,renal parenchymal hypertension,FALSE,FALSE,NA,NA,NA
7,NCT01785472,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; and drug-induced hypertension .,Condition Occurrence,Condition,C0020545,renovascular hypertension,FALSE,FALSE,NA,NA,NA
7,NCT01785472,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; and drug-induced hypertension .,Condition Occurrence,Condition,C0035065;C1278951,renal artery,FALSE,FALSE,NA,NA,NA
7,NCT01785472,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; and drug-induced hypertension .,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
7,NCT01785472,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; and drug-induced hypertension .,Condition Occurrence,Condition,C0332886,coarctation,FALSE,FALSE,NA,NA,NA
7,NCT01785472,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; and drug-induced hypertension .,Condition Occurrence,Condition,C0022680,polycystic kidney disease,FALSE,FALSE,NA,NA,NA
7,NCT01785472,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; and drug-induced hypertension .,Condition Occurrence,Condition,C0031511;C1706920,pheochromocytoma,FALSE,FALSE,NA,NA,NA
7,NCT01785472,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; and drug-induced hypertension .,Condition Occurrence,Condition,C0221406;C0010481,cushing disease,FALSE,FALSE,NA,NA,NA
7,NCT01785472,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; and drug-induced hypertension .,Condition Occurrence,Condition,C1384514,primary hyperaldosteronism,FALSE,FALSE,NA,NA,NA
7,NCT01785472,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; and drug-induced hypertension .,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
7,NCT01785472,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; and drug-induced hypertension .,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
7,NCT01785472,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; and drug-induced hypertension .,Condition Occurrence,Other,C3542948,limited,TRUE,FALSE,NA,NA,NA
7,NCT01785472,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; and drug-induced hypertension .,Condition Occurrence,Other,C0869784;C0003483;C1278934,aorta,FALSE,FALSE,NA,NA,NA
7,NCT01785472,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ; and drug-induced hypertension .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
8,NCT01785472,Exclusion,patients who previously entered a lcz696 study and had been randomized or enrolled into the active drug treatment epoch .,Drug Exposure,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
8,NCT01785472,Exclusion,patients who previously entered a lcz696 study and had been randomized or enrolled into the active drug treatment epoch .,Drug Exposure,Drug,C2946699,epoch,FALSE,FALSE,NA,NA,NA
8,NCT01785472,Exclusion,patients who previously entered a lcz696 study and had been randomized or enrolled into the active drug treatment epoch .,Drug Exposure,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
9,NCT01785472,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT01838850,Inclusion,for screening,Other,NA,NA,NA,NA,NA,NA,NA,NA
2,NCT01838850,Inclusion,male or female at the age of 20 to 75 years,Person,Person,C0025266,male,FALSE,FALSE,NA,NA,NA
2,NCT01838850,Inclusion,male or female at the age of 20 to 75 years,Person,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
2,NCT01838850,Inclusion,male or female at the age of 20 to 75 years,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 20 years; lower_equal 75 years,NA,NA
3,NCT01838850,Inclusion,voluntary written informed consent to participation in this study,Other,Other,C0439656;C3543419,voluntary,FALSE,FALSE,NA,NA,NA
4,NCT01838850,Inclusion,patients with hypertension either newly diagnosed or without treatment of antihypertensive drugs within 4 weeks of screening ; who have mean seated diastolic blood pressure ( msdbp ) > = 100 mmhg at screening ; or,Observation,Drug,C0003364,antihypertensive drugs,TRUE,FALSE,lower 4 weeks,NA,NA
4,NCT01838850,Inclusion,patients with hypertension either newly diagnosed or without treatment of antihypertensive drugs within 4 weeks of screening ; who have mean seated diastolic blood pressure ( msdbp ) > = 100 mmhg at screening ; or,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
4,NCT01838850,Inclusion,patients with hypertension either newly diagnosed or without treatment of antihypertensive drugs within 4 weeks of screening ; who have mean seated diastolic blood pressure ( msdbp ) > = 100 mmhg at screening ; or,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater_equal 100 mmhg,NA
5,NCT01838850,Inclusion,patients who have been on a stable dose of antihypertensive drugs for at least 4 weeks before run-in period and meet the following blood pressure criteria at screening : monotherapy : msdbp > = 95 mmhg ; or dual combination therapy : msdbp > = 90 mmhg ; or triple combination therapy : 70 mmhg < = msdbp < 90 mmhg,Observation,Drug,C0003364,antihypertensive drugs,FALSE,FALSE,greater_equal 4 weeks,NA,NA
5,NCT01838850,Inclusion,patients who have been on a stable dose of antihypertensive drugs for at least 4 weeks before run-in period and meet the following blood pressure criteria at screening : monotherapy : msdbp > = 95 mmhg ; or dual combination therapy : msdbp > = 90 mmhg ; or triple combination therapy : 70 mmhg < = msdbp < 90 mmhg,Observation,Procedure,C0009429;C0556895,combination therapy,FALSE,FALSE,NA,greater_equal 90 mmhg,NA
5,NCT01838850,Inclusion,patients who have been on a stable dose of antihypertensive drugs for at least 4 weeks before run-in period and meet the following blood pressure criteria at screening : monotherapy : msdbp > = 95 mmhg ; or dual combination therapy : msdbp > = 90 mmhg ; or triple combination therapy : 70 mmhg < = msdbp < 90 mmhg,Observation,Procedure,C0009429;C0556895,combination therapy,FALSE,FALSE,NA,greater_equal 70 mmhg; lower 90 mmhg,NA
5,NCT01838850,Inclusion,patients who have been on a stable dose of antihypertensive drugs for at least 4 weeks before run-in period and meet the following blood pressure criteria at screening : monotherapy : msdbp > = 95 mmhg ; or dual combination therapy : msdbp > = 90 mmhg ; or triple combination therapy : 70 mmhg < = msdbp < 90 mmhg,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,greater_equal 95 mmhg,NA
5,NCT01838850,Inclusion,patients who have been on a stable dose of antihypertensive drugs for at least 4 weeks before run-in period and meet the following blood pressure criteria at screening : monotherapy : msdbp > = 95 mmhg ; or dual combination therapy : msdbp > = 90 mmhg ; or triple combination therapy : 70 mmhg < = msdbp < 90 mmhg,Observation,Other,C1547311,stable,FALSE,FALSE,NA,NA,NA
5,NCT01838850,Inclusion,patients who have been on a stable dose of antihypertensive drugs for at least 4 weeks before run-in period and meet the following blood pressure criteria at screening : monotherapy : msdbp > = 95 mmhg ; or dual combination therapy : msdbp > = 90 mmhg ; or triple combination therapy : 70 mmhg < = msdbp < 90 mmhg,Observation,Other,C1554184,dual,FALSE,FALSE,NA,NA,NA
6,NCT01838850,Inclusion,for randomization,Other,NA,NA,NA,NA,NA,NA,NA,NA
7,NCT01838850,Inclusion,mssbp / dbp at randomization : mssbp > = 140 mmhg ( mssbp > = 130 mmhg in subjects with diabetes or chronic renal disease ) ; and msdbp > = 90 mmhg ( msdbp > = 80 mmhg in subjects with diabetes or chronic renal disease ),Observation,Condition,C0011849;C0011847,diabetes,FALSE,FALSE,NA,greater_equal 90 mmhg; greater_equal 80 mmhg,NA
7,NCT01838850,Inclusion,mssbp / dbp at randomization : mssbp > = 140 mmhg ( mssbp > = 130 mmhg in subjects with diabetes or chronic renal disease ) ; and msdbp > = 90 mmhg ( msdbp > = 80 mmhg in subjects with diabetes or chronic renal disease ),Observation,Condition,C0403447;C1561643;C0022661,chronic renal disease,FALSE,FALSE,NA,greater_equal 90 mmhg; greater_equal 80 mmhg,NA
7,NCT01838850,Inclusion,mssbp / dbp at randomization : mssbp > = 140 mmhg ( mssbp > = 130 mmhg in subjects with diabetes or chronic renal disease ) ; and msdbp > = 90 mmhg ( msdbp > = 80 mmhg in subjects with diabetes or chronic renal disease ),Observation,Condition,C0011849;C0011847,diabetes,FALSE,FALSE,NA,NA,NA
7,NCT01838850,Inclusion,mssbp / dbp at randomization : mssbp > = 140 mmhg ( mssbp > = 130 mmhg in subjects with diabetes or chronic renal disease ) ; and msdbp > = 90 mmhg ( msdbp > = 80 mmhg in subjects with diabetes or chronic renal disease ),Observation,Condition,C0403447;C1561643;C0022661,chronic renal disease,FALSE,FALSE,NA,NA,NA
7,NCT01838850,Inclusion,mssbp / dbp at randomization : mssbp > = 140 mmhg ( mssbp > = 130 mmhg in subjects with diabetes or chronic renal disease ) ; and msdbp > = 90 mmhg ( msdbp > = 80 mmhg in subjects with diabetes or chronic renal disease ),Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 140 mmhg; greater_equal 130 mmhg,NA
8,NCT01838850,Exclusion,msdbp > = 115 mmhg or mssbp > = 200 mmhg measured at screening and randomization,Observation,Observation,C3541902,measured,FALSE,FALSE,NA,greater_equal 200 mmhg; greater_equal 115 mmhg,NA
9,NCT01838850,Exclusion,patients with mini-max blood pressure difference of sesbp > = 20 mmhg or sedbp > = 10 mmhg in the chosen arm at screening,Observation,Condition,C0446516;C1140618;C1269078;C1269612,arm,FALSE,FALSE,NA,NA,NA
9,NCT01838850,Exclusion,patients with mini-max blood pressure difference of sesbp > = 20 mmhg or sedbp > = 10 mmhg in the chosen arm at screening,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,greater_equal 20 mmhg; greater_equal 10 mmhg,NA
10,NCT01838850,Exclusion,patients with blood pressure difference of sesbp > = 20 mmhg and sedbp > = 10 mmhg in both arms at screening,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,greater_equal 20 mmhg; greater_equal 10 mmhg,NA
11,NCT01838850,Exclusion,patients with hypersensitivity to the investigational product or any of its components,Observation,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
11,NCT01838850,Exclusion,patients with hypersensitivity to the investigational product or any of its components,Observation,Other,C3245491,investigational,FALSE,FALSE,NA,NA,NA
12,NCT01838850,Exclusion,patients with medical history or hypersensitivity to sulfonamide ; dihydropyridine ; or thiazide diuretics,Drug Exposure,Condition,C0262926,medical history,FALSE,FALSE,NA,NA,NA
12,NCT01838850,Exclusion,patients with medical history or hypersensitivity to sulfonamide ; dihydropyridine ; or thiazide diuretics,Drug Exposure,Drug,C0599503;C3536763,sulfonamide,FALSE,FALSE,NA,NA,NA
12,NCT01838850,Exclusion,patients with medical history or hypersensitivity to sulfonamide ; dihydropyridine ; or thiazide diuretics,Drug Exposure,Drug,C0012802,thiazide diuretics,FALSE,FALSE,NA,NA,NA
12,NCT01838850,Exclusion,patients with medical history or hypersensitivity to sulfonamide ; dihydropyridine ; or thiazide diuretics,Drug Exposure,Drug,C0220821;C3537269,dihydropyridine,FALSE,FALSE,NA,NA,NA
12,NCT01838850,Exclusion,patients with medical history or hypersensitivity to sulfonamide ; dihydropyridine ; or thiazide diuretics,Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
13,NCT01838850,Exclusion,history of secondary hypertension or history of any of the diseases suspected of secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
13,NCT01838850,Exclusion,history of secondary hypertension or history of any of the diseases suspected of secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
14,NCT01838850,Exclusion,symptomatic orthostatic hypotension,Condition Occurrence,Condition,C0020651,orthostatic hypotension,FALSE,FALSE,NA,NA,NA
15,NCT01838850,Exclusion,uncontrolled diabetes mellitus,Condition Occurrence,Condition,C0011849,diabetes mellitus,FALSE,FALSE,NA,NA,NA
16,NCT01838850,Exclusion,severe heart disease ; or ischemic heart disease ; peripheral vascular disease,Condition Occurrence,Condition,C0018799,heart disease,FALSE,FALSE,NA,NA,NA
16,NCT01838850,Exclusion,severe heart disease ; or ischemic heart disease ; peripheral vascular disease,Condition Occurrence,Condition,C0151744;C1313980,ischemic heart disease,FALSE,FALSE,NA,NA,NA
16,NCT01838850,Exclusion,severe heart disease ; or ischemic heart disease ; peripheral vascular disease,Condition Occurrence,Condition,C0085096,peripheral vascular disease,FALSE,FALSE,NA,NA,NA
16,NCT01838850,Exclusion,severe heart disease ; or ischemic heart disease ; peripheral vascular disease,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
17,NCT01838850,Exclusion,clinically significant ventricular tachycardia ; atrial fibrillation ; atrial flutter ; or other arrhythmia considered clinically significant,Condition Occurrence,Condition,C0042514;C1963247;C2108113,ventricular tachycardia,FALSE,FALSE,NA,NA,NA
17,NCT01838850,Exclusion,clinically significant ventricular tachycardia ; atrial fibrillation ; atrial flutter ; or other arrhythmia considered clinically significant,Condition Occurrence,Condition,C0004239;C1963068,atrial flutter,FALSE,FALSE,NA,NA,NA
17,NCT01838850,Exclusion,clinically significant ventricular tachycardia ; atrial fibrillation ; atrial flutter ; or other arrhythmia considered clinically significant,Condition Occurrence,Condition,C0003811,arrhythmia,FALSE,FALSE,NA,NA,NA
17,NCT01838850,Exclusion,clinically significant ventricular tachycardia ; atrial fibrillation ; atrial flutter ; or other arrhythmia considered clinically significant,Condition Occurrence,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
18,NCT01838850,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; or hemodynamically significant stenosis on aortic valve or mitral valve .,Condition Occurrence,Condition,C0007194,hypertrophic obstructive cardiomyopathy,FALSE,FALSE,NA,NA,NA
18,NCT01838850,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; or hemodynamically significant stenosis on aortic valve or mitral valve .,Condition Occurrence,Condition,C1956346;C0010068;C0010054,coronary artery disease,FALSE,FALSE,NA,NA,NA
18,NCT01838850,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; or hemodynamically significant stenosis on aortic valve or mitral valve .,Condition Occurrence,Condition,C0003507,aortic stenosis,FALSE,FALSE,NA,NA,NA
18,NCT01838850,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; or hemodynamically significant stenosis on aortic valve or mitral valve .,Condition Occurrence,Condition,C0003501;C1269005,aortic valve,FALSE,FALSE,NA,NA,NA
18,NCT01838850,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; or hemodynamically significant stenosis on aortic valve or mitral valve .,Condition Occurrence,Condition,C0026264;C1269004,mitral valve,FALSE,FALSE,NA,NA,NA
18,NCT01838850,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; or hemodynamically significant stenosis on aortic valve or mitral valve .,Condition Occurrence,Observation,C1261287;C0947637;C0009814,stenosis,FALSE,FALSE,NA,NA,NA
18,NCT01838850,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; or hemodynamically significant stenosis on aortic valve or mitral valve .,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
19,NCT01838850,Exclusion,severe cerebrovascular disorder,Condition Occurrence,Condition,C0007820,cerebrovascular disorder,FALSE,FALSE,NA,NA,NA
19,NCT01838850,Exclusion,severe cerebrovascular disorder,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
20,NCT01838850,Exclusion,known moderate retinopathy or malignant retinopathy,Condition Occurrence,Condition,C0035309;C1962966,retinopathy,FALSE,FALSE,NA,NA,NA
20,NCT01838850,Exclusion,known moderate retinopathy or malignant retinopathy,Condition Occurrence,Condition,C0334590;C1533592,malignant,FALSE,FALSE,NA,NA,NA
20,NCT01838850,Exclusion,known moderate retinopathy or malignant retinopathy,Condition Occurrence,Condition,C0035309;C1962966,retinopathy,FALSE,FALSE,NA,NA,NA
20,NCT01838850,Exclusion,known moderate retinopathy or malignant retinopathy,Condition Occurrence,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
21,NCT01838850,Exclusion,consumption disease ; autoimmune disease ; or connective tissue disease,Condition Occurrence,Condition,C0220811;C1947907,consumption,FALSE,FALSE,NA,NA,NA
21,NCT01838850,Exclusion,consumption disease ; autoimmune disease ; or connective tissue disease,Condition Occurrence,Condition,C0009782,connective tissue disease,FALSE,FALSE,NA,NA,NA
21,NCT01838850,Exclusion,consumption disease ; autoimmune disease ; or connective tissue disease,Condition Occurrence,Condition,C0004364,autoimmune disease,FALSE,FALSE,NA,NA,NA
22,NCT01838850,Exclusion,patients requiring chronic anti-inflammatory treatment,Other,Other,C1547296;C1555457,chronic,FALSE,FALSE,NA,NA,NA
23,NCT01838850,Exclusion,anuria or severe renal failure,Condition Occurrence,Condition,C0003460;C2188545,anuria,FALSE,FALSE,NA,NA,NA
23,NCT01838850,Exclusion,anuria or severe renal failure,Condition Occurrence,Condition,C0035078;C1963154,renal failure,FALSE,FALSE,NA,NA,NA
23,NCT01838850,Exclusion,anuria or severe renal failure,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
24,NCT01838850,Exclusion,severe hepatic failure ; ast or alt > 3 times the upper limit of normal obstruction ; biliary obstruction ; biliary cirrhosis ; or cholestasis,Condition Occurrence,Condition,C0085605,hepatic failure,FALSE,FALSE,NA,NA,greater 3 times the upper limit of normal
24,NCT01838850,Exclusion,severe hepatic failure ; ast or alt > 3 times the upper limit of normal obstruction ; biliary obstruction ; biliary cirrhosis ; or cholestasis,Condition Occurrence,Condition,C0400979,biliary obstruction,FALSE,FALSE,NA,NA,NA
24,NCT01838850,Exclusion,severe hepatic failure ; ast or alt > 3 times the upper limit of normal obstruction ; biliary obstruction ; biliary cirrhosis ; or cholestasis,Condition Occurrence,Condition,C0008370,cholestasis,FALSE,FALSE,NA,NA,NA
24,NCT01838850,Exclusion,severe hepatic failure ; ast or alt > 3 times the upper limit of normal obstruction ; biliary obstruction ; biliary cirrhosis ; or cholestasis,Condition Occurrence,Condition,C0023892;C0008312,biliary cirrhosis,FALSE,FALSE,NA,NA,NA
24,NCT01838850,Exclusion,severe hepatic failure ; ast or alt > 3 times the upper limit of normal obstruction ; biliary obstruction ; biliary cirrhosis ; or cholestasis,Condition Occurrence,Observation,C1140170;C2257651,alt,FALSE,FALSE,NA,NA,greater 3 times the upper limit of normal
24,NCT01838850,Exclusion,severe hepatic failure ; ast or alt > 3 times the upper limit of normal obstruction ; biliary obstruction ; biliary cirrhosis ; or cholestasis,Condition Occurrence,Observation,C0004002,ast,FALSE,FALSE,NA,NA,greater 3 times the upper limit of normal
24,NCT01838850,Exclusion,severe hepatic failure ; ast or alt > 3 times the upper limit of normal obstruction ; biliary obstruction ; biliary cirrhosis ; or cholestasis,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
25,NCT01838850,Exclusion,patients who have been treated for hyponatremia ; hypokalemia ; hyperkalemia ; hypercalcemia ; or symptomatic hyperuricemia,Condition Occurrence,Condition,C0020625,hyponatremia,FALSE,FALSE,NA,NA,NA
25,NCT01838850,Exclusion,patients who have been treated for hyponatremia ; hypokalemia ; hyperkalemia ; hypercalcemia ; or symptomatic hyperuricemia,Condition Occurrence,Condition,C0740394,hyperuricemia,FALSE,FALSE,NA,NA,NA
25,NCT01838850,Exclusion,patients who have been treated for hyponatremia ; hypokalemia ; hyperkalemia ; hypercalcemia ; or symptomatic hyperuricemia,Condition Occurrence,Condition,C0020437,hypercalcemia,FALSE,FALSE,NA,NA,NA
25,NCT01838850,Exclusion,patients who have been treated for hyponatremia ; hypokalemia ; hyperkalemia ; hypercalcemia ; or symptomatic hyperuricemia,Condition Occurrence,Condition,C0020461,hyperkalemia,FALSE,FALSE,NA,NA,NA
25,NCT01838850,Exclusion,patients who have been treated for hyponatremia ; hypokalemia ; hyperkalemia ; hypercalcemia ; or symptomatic hyperuricemia,Condition Occurrence,Condition,C0020621,hypokalemia,FALSE,FALSE,NA,NA,NA
26,NCT01838850,Exclusion,addison disease,Condition Occurrence,Condition,C0001403;C0266273,addison disease,FALSE,FALSE,NA,NA,NA
27,NCT01838850,Exclusion,glucose-galactose malabsorption ; galactose intolerance ; or lapp lactase deficiency,Condition Occurrence,Condition,C0268186,glucose-galactose malabsorption,FALSE,FALSE,NA,NA,NA
27,NCT01838850,Exclusion,glucose-galactose malabsorption ; galactose intolerance ; or lapp lactase deficiency,Condition Occurrence,Condition,C0302813,lactase deficiency,FALSE,FALSE,NA,NA,NA
27,NCT01838850,Exclusion,glucose-galactose malabsorption ; galactose intolerance ; or lapp lactase deficiency,Condition Occurrence,Condition,C0016952,galactose intolerance,FALSE,FALSE,NA,NA,NA
28,NCT01838850,Exclusion,gastrointestinal tract disease or surgical operation that may affect absorption ; distribution ; metabolism ; and excretion of drugs ; presence of active gastritis or gastrointestinal / rectal bleeding considered clinical significant by the investigator ; active inflammatory bowel syndrome within the last 12 months ; etc,Condition Occurrence,Condition,C1559265,gastrointestinal,FALSE,FALSE,NA,NA,NA
28,NCT01838850,Exclusion,gastrointestinal tract disease or surgical operation that may affect absorption ; distribution ; metabolism ; and excretion of drugs ; presence of active gastritis or gastrointestinal / rectal bleeding considered clinical significant by the investigator ; active inflammatory bowel syndrome within the last 12 months ; etc,Condition Occurrence,Condition,C1185740,tract,FALSE,FALSE,NA,NA,NA
28,NCT01838850,Exclusion,gastrointestinal tract disease or surgical operation that may affect absorption ; distribution ; metabolism ; and excretion of drugs ; presence of active gastritis or gastrointestinal / rectal bleeding considered clinical significant by the investigator ; active inflammatory bowel syndrome within the last 12 months ; etc,Condition Occurrence,Condition,C0504085,excretion,FALSE,FALSE,NA,NA,NA
28,NCT01838850,Exclusion,gastrointestinal tract disease or surgical operation that may affect absorption ; distribution ; metabolism ; and excretion of drugs ; presence of active gastritis or gastrointestinal / rectal bleeding considered clinical significant by the investigator ; active inflammatory bowel syndrome within the last 12 months ; etc,Condition Occurrence,Condition,C0025519,metabolism,FALSE,FALSE,NA,NA,NA
28,NCT01838850,Exclusion,gastrointestinal tract disease or surgical operation that may affect absorption ; distribution ; metabolism ; and excretion of drugs ; presence of active gastritis or gastrointestinal / rectal bleeding considered clinical significant by the investigator ; active inflammatory bowel syndrome within the last 12 months ; etc,Condition Occurrence,Condition,C1378698,distribution,FALSE,FALSE,NA,NA,NA
28,NCT01838850,Exclusion,gastrointestinal tract disease or surgical operation that may affect absorption ; distribution ; metabolism ; and excretion of drugs ; presence of active gastritis or gastrointestinal / rectal bleeding considered clinical significant by the investigator ; active inflammatory bowel syndrome within the last 12 months ; etc,Condition Occurrence,Condition,C0017152,gastritis,FALSE,FALSE,NA,NA,NA
28,NCT01838850,Exclusion,gastrointestinal tract disease or surgical operation that may affect absorption ; distribution ; metabolism ; and excretion of drugs ; presence of active gastritis or gastrointestinal / rectal bleeding considered clinical significant by the investigator ; active inflammatory bowel syndrome within the last 12 months ; etc,Condition Occurrence,Condition,C1559265,gastrointestinal,FALSE,FALSE,NA,NA,NA
28,NCT01838850,Exclusion,gastrointestinal tract disease or surgical operation that may affect absorption ; distribution ; metabolism ; and excretion of drugs ; presence of active gastritis or gastrointestinal / rectal bleeding considered clinical significant by the investigator ; active inflammatory bowel syndrome within the last 12 months ; etc,Condition Occurrence,Condition,C0267596,rectal bleeding,FALSE,FALSE,NA,NA,NA
28,NCT01838850,Exclusion,gastrointestinal tract disease or surgical operation that may affect absorption ; distribution ; metabolism ; and excretion of drugs ; presence of active gastritis or gastrointestinal / rectal bleeding considered clinical significant by the investigator ; active inflammatory bowel syndrome within the last 12 months ; etc,Condition Occurrence,Condition,C0021853,bowel,FALSE,FALSE,lower 12 last months,NA,NA
28,NCT01838850,Exclusion,gastrointestinal tract disease or surgical operation that may affect absorption ; distribution ; metabolism ; and excretion of drugs ; presence of active gastritis or gastrointestinal / rectal bleeding considered clinical significant by the investigator ; active inflammatory bowel syndrome within the last 12 months ; etc,Condition Occurrence,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
28,NCT01838850,Exclusion,gastrointestinal tract disease or surgical operation that may affect absorption ; distribution ; metabolism ; and excretion of drugs ; presence of active gastritis or gastrointestinal / rectal bleeding considered clinical significant by the investigator ; active inflammatory bowel syndrome within the last 12 months ; etc,Condition Occurrence,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
28,NCT01838850,Exclusion,gastrointestinal tract disease or surgical operation that may affect absorption ; distribution ; metabolism ; and excretion of drugs ; presence of active gastritis or gastrointestinal / rectal bleeding considered clinical significant by the investigator ; active inflammatory bowel syndrome within the last 12 months ; etc,Condition Occurrence,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
28,NCT01838850,Exclusion,gastrointestinal tract disease or surgical operation that may affect absorption ; distribution ; metabolism ; and excretion of drugs ; presence of active gastritis or gastrointestinal / rectal bleeding considered clinical significant by the investigator ; active inflammatory bowel syndrome within the last 12 months ; etc,Condition Occurrence,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
28,NCT01838850,Exclusion,gastrointestinal tract disease or surgical operation that may affect absorption ; distribution ; metabolism ; and excretion of drugs ; presence of active gastritis or gastrointestinal / rectal bleeding considered clinical significant by the investigator ; active inflammatory bowel syndrome within the last 12 months ; etc,Condition Occurrence,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
29,NCT01838850,Exclusion,patients with history of or suspected of drug or alcohol abuse,Condition Occurrence,Condition,C0085762,alcohol abuse,FALSE,FALSE,NA,NA,NA
29,NCT01838850,Exclusion,patients with history of or suspected of drug or alcohol abuse,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
30,NCT01838850,Exclusion,pregnant or lactating women ; or women of childbearing potential who do not agree to use appropriate contraceptive methods such as progestin hormone therapy ( oral ; implant ) ; intrauterine device ; barrier methods of contraception ( condom or occlusive cap ( diaphragm or cervical / vault caps ) with spermicide ) ; male sterilisation or true abstinence,Procedure,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
30,NCT01838850,Exclusion,pregnant or lactating women ; or women of childbearing potential who do not agree to use appropriate contraceptive methods such as progestin hormone therapy ( oral ; implant ) ; intrauterine device ; barrier methods of contraception ( condom or occlusive cap ( diaphragm or cervical / vault caps ) with spermicide ) ; male sterilisation or true abstinence,Procedure,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
30,NCT01838850,Exclusion,pregnant or lactating women ; or women of childbearing potential who do not agree to use appropriate contraceptive methods such as progestin hormone therapy ( oral ; implant ) ; intrauterine device ; barrier methods of contraception ( condom or occlusive cap ( diaphragm or cervical / vault caps ) with spermicide ) ; male sterilisation or true abstinence,Procedure,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
30,NCT01838850,Exclusion,pregnant or lactating women ; or women of childbearing potential who do not agree to use appropriate contraceptive methods such as progestin hormone therapy ( oral ; implant ) ; intrauterine device ; barrier methods of contraception ( condom or occlusive cap ( diaphragm or cervical / vault caps ) with spermicide ) ; male sterilisation or true abstinence,Procedure,Condition,C2828358;C3668831,lactating,FALSE,FALSE,NA,NA,NA
30,NCT01838850,Exclusion,pregnant or lactating women ; or women of childbearing potential who do not agree to use appropriate contraceptive methods such as progestin hormone therapy ( oral ; implant ) ; intrauterine device ; barrier methods of contraception ( condom or occlusive cap ( diaphragm or cervical / vault caps ) with spermicide ) ; male sterilisation or true abstinence,Procedure,Condition,C1550319,vault,FALSE,FALSE,NA,NA,NA
30,NCT01838850,Exclusion,pregnant or lactating women ; or women of childbearing potential who do not agree to use appropriate contraceptive methods such as progestin hormone therapy ( oral ; implant ) ; intrauterine device ; barrier methods of contraception ( condom or occlusive cap ( diaphragm or cervical / vault caps ) with spermicide ) ; male sterilisation or true abstinence,Procedure,Drug,C3536710,progestin,FALSE,FALSE,NA,NA,NA
30,NCT01838850,Exclusion,pregnant or lactating women ; or women of childbearing potential who do not agree to use appropriate contraceptive methods such as progestin hormone therapy ( oral ; implant ) ; intrauterine device ; barrier methods of contraception ( condom or occlusive cap ( diaphragm or cervical / vault caps ) with spermicide ) ; male sterilisation or true abstinence,Procedure,Drug,C1272919,oral,FALSE,FALSE,NA,NA,NA
30,NCT01838850,Exclusion,pregnant or lactating women ; or women of childbearing potential who do not agree to use appropriate contraceptive methods such as progestin hormone therapy ( oral ; implant ) ; intrauterine device ; barrier methods of contraception ( condom or occlusive cap ( diaphragm or cervical / vault caps ) with spermicide ) ; male sterilisation or true abstinence,Procedure,Drug,C0037862,spermicide,FALSE,FALSE,NA,NA,NA
30,NCT01838850,Exclusion,pregnant or lactating women ; or women of childbearing potential who do not agree to use appropriate contraceptive methods such as progestin hormone therapy ( oral ; implant ) ; intrauterine device ; barrier methods of contraception ( condom or occlusive cap ( diaphragm or cervical / vault caps ) with spermicide ) ; male sterilisation or true abstinence,Procedure,Procedure,C0700589,contraceptive methods,TRUE,FALSE,NA,NA,NA
30,NCT01838850,Exclusion,pregnant or lactating women ; or women of childbearing potential who do not agree to use appropriate contraceptive methods such as progestin hormone therapy ( oral ; implant ) ; intrauterine device ; barrier methods of contraception ( condom or occlusive cap ( diaphragm or cervical / vault caps ) with spermicide ) ; male sterilisation or true abstinence,Procedure,Procedure,C0279025,hormone therapy,FALSE,FALSE,NA,NA,NA
30,NCT01838850,Exclusion,pregnant or lactating women ; or women of childbearing potential who do not agree to use appropriate contraceptive methods such as progestin hormone therapy ( oral ; implant ) ; intrauterine device ; barrier methods of contraception ( condom or occlusive cap ( diaphragm or cervical / vault caps ) with spermicide ) ; male sterilisation or true abstinence,Procedure,Procedure,C0004764,barrier methods,FALSE,FALSE,NA,NA,NA
30,NCT01838850,Exclusion,pregnant or lactating women ; or women of childbearing potential who do not agree to use appropriate contraceptive methods such as progestin hormone therapy ( oral ; implant ) ; intrauterine device ; barrier methods of contraception ( condom or occlusive cap ( diaphragm or cervical / vault caps ) with spermicide ) ; male sterilisation or true abstinence,Procedure,Procedure,C0700589,contraception,FALSE,FALSE,NA,NA,NA
30,NCT01838850,Exclusion,pregnant or lactating women ; or women of childbearing potential who do not agree to use appropriate contraceptive methods such as progestin hormone therapy ( oral ; implant ) ; intrauterine device ; barrier methods of contraception ( condom or occlusive cap ( diaphragm or cervical / vault caps ) with spermicide ) ; male sterilisation or true abstinence,Procedure,Procedure,C0024559,male sterilisation,FALSE,FALSE,NA,NA,NA
30,NCT01838850,Exclusion,pregnant or lactating women ; or women of childbearing potential who do not agree to use appropriate contraceptive methods such as progestin hormone therapy ( oral ; implant ) ; intrauterine device ; barrier methods of contraception ( condom or occlusive cap ( diaphragm or cervical / vault caps ) with spermicide ) ; male sterilisation or true abstinence,Procedure,Observation,C3831118,childbearing potential,FALSE,FALSE,NA,NA,NA
30,NCT01838850,Exclusion,pregnant or lactating women ; or women of childbearing potential who do not agree to use appropriate contraceptive methods such as progestin hormone therapy ( oral ; implant ) ; intrauterine device ; barrier methods of contraception ( condom or occlusive cap ( diaphragm or cervical / vault caps ) with spermicide ) ; male sterilisation or true abstinence,Procedure,Other,C3641827,agree,TRUE,FALSE,NA,NA,NA
30,NCT01838850,Exclusion,pregnant or lactating women ; or women of childbearing potential who do not agree to use appropriate contraceptive methods such as progestin hormone therapy ( oral ; implant ) ; intrauterine device ; barrier methods of contraception ( condom or occlusive cap ( diaphragm or cervical / vault caps ) with spermicide ) ; male sterilisation or true abstinence,Procedure,Other,C0332837;C1546675,implant,FALSE,FALSE,NA,NA,NA
30,NCT01838850,Exclusion,pregnant or lactating women ; or women of childbearing potential who do not agree to use appropriate contraceptive methods such as progestin hormone therapy ( oral ; implant ) ; intrauterine device ; barrier methods of contraception ( condom or occlusive cap ( diaphragm or cervical / vault caps ) with spermicide ) ; male sterilisation or true abstinence,Procedure,Other,C1706306;C1548866;C1546682,intrauterine device,FALSE,FALSE,NA,NA,NA
30,NCT01838850,Exclusion,pregnant or lactating women ; or women of childbearing potential who do not agree to use appropriate contraceptive methods such as progestin hormone therapy ( oral ; implant ) ; intrauterine device ; barrier methods of contraception ( condom or occlusive cap ( diaphragm or cervical / vault caps ) with spermicide ) ; male sterilisation or true abstinence,Procedure,Other,C1855179;C0280547;C0278651,cap,FALSE,FALSE,NA,NA,NA
30,NCT01838850,Exclusion,pregnant or lactating women ; or women of childbearing potential who do not agree to use appropriate contraceptive methods such as progestin hormone therapy ( oral ; implant ) ; intrauterine device ; barrier methods of contraception ( condom or occlusive cap ( diaphragm or cervical / vault caps ) with spermicide ) ; male sterilisation or true abstinence,Procedure,Other,C0152097;C0011980;C1705368;C1279038,diaphragm,FALSE,FALSE,NA,NA,NA
31,NCT01838850,Exclusion,patients who participated in other clinical study within 1 month prior to screening,Other,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,lower 1 month,NA,NA
32,NCT01838850,Exclusion,patients considered to be incapable of complying with the protocol,Other,NA,NA,NA,NA,NA,NA,NA,NA
1,NCT01876368,Inclusion,patients with mild to moderate hypertension ; untreated or currently taking antihypertensive therapy,Condition Occurrence,Condition,C0745134,hypertension untreated,FALSE,FALSE,NA,NA,NA
1,NCT01876368,Inclusion,patients with mild to moderate hypertension ; untreated or currently taking antihypertensive therapy,Condition Occurrence,Condition,C2054151,taking antihypertensive,FALSE,FALSE,NA,NA,NA
1,NCT01876368,Inclusion,patients with mild to moderate hypertension ; untreated or currently taking antihypertensive therapy,Condition Occurrence,Other,C1547225,mild,FALSE,FALSE,NA,NA,NA
1,NCT01876368,Inclusion,patients with mild to moderate hypertension ; untreated or currently taking antihypertensive therapy,Condition Occurrence,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
2,NCT01876368,Inclusion,treated patients ( using antihypertensive drugs within 4 weeks prior to first visit ) must have an office mssbp > = 145 mmhg and < 180 mmhg after washout epoch and after 4 weeks run-in epoch,Observation,Drug,C0003364,antihypertensive drugs,FALSE,FALSE,lower 4 weeks,greater_equal 145 mmhg; lower 180 mmhg,NA
2,NCT01876368,Inclusion,treated patients ( using antihypertensive drugs within 4 weeks prior to first visit ) must have an office mssbp > = 145 mmhg and < 180 mmhg after washout epoch and after 4 weeks run-in epoch,Observation,Drug,C2946699,epoch,FALSE,FALSE,NA,NA,NA
2,NCT01876368,Inclusion,treated patients ( using antihypertensive drugs within 4 weeks prior to first visit ) must have an office mssbp > = 145 mmhg and < 180 mmhg after washout epoch and after 4 weeks run-in epoch,Observation,Drug,C2946699,epoch,FALSE,FALSE,equal 4 weeks,NA,NA
3,NCT01876368,Inclusion,untreated patients ( either newly diagnosed or those patients with a history of hypertension but have not been taking any antihypertensive drugs for at least 4 weeks prior to first visit ) must have an offcie mssbp > = 150 mmhg and < 180 mmhg at screening and 1 week after screening and must have an office mssbp > = 145 mmhg and < 180 mmhg after 4 weeks run-in epoch,Observation,Drug,C0003364,antihypertensive drugs,TRUE,FALSE,greater_equal 4 weeks; equal 1 week,greater_equal 150 mmhg; lower 180 mmhg; greater_equal 145 mmhg; lower 180 mmhg,NA
3,NCT01876368,Inclusion,untreated patients ( either newly diagnosed or those patients with a history of hypertension but have not been taking any antihypertensive drugs for at least 4 weeks prior to first visit ) must have an offcie mssbp > = 150 mmhg and < 180 mmhg at screening and 1 week after screening and must have an office mssbp > = 145 mmhg and < 180 mmhg after 4 weeks run-in epoch,Observation,Drug,C2946699,epoch,FALSE,FALSE,equal 4 weeks,NA,NA
3,NCT01876368,Inclusion,untreated patients ( either newly diagnosed or those patients with a history of hypertension but have not been taking any antihypertensive drugs for at least 4 weeks prior to first visit ) must have an offcie mssbp > = 150 mmhg and < 180 mmhg at screening and 1 week after screening and must have an office mssbp > = 145 mmhg and < 180 mmhg after 4 weeks run-in epoch,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
4,NCT01876368,Inclusion,patients must successfully complete abpm and pass technical requirements to be qualified for randomization,Drug Exposure,Condition,C2828386,pass,FALSE,FALSE,NA,NA,NA
4,NCT01876368,Inclusion,patients must successfully complete abpm and pass technical requirements to be qualified for randomization,Drug Exposure,Drug,C1815293,complete,FALSE,FALSE,NA,NA,NA
5,NCT01876368,Exclusion,malignant hypertension or severe hypertension ( grade 3 of who classification,Condition Occurrence,Condition,C0020540;C0024588,malignant hypertension,FALSE,FALSE,NA,NA,NA
5,NCT01876368,Exclusion,malignant hypertension or severe hypertension ( grade 3 of who classification,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
5,NCT01876368,Exclusion,malignant hypertension or severe hypertension ( grade 3 of who classification,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
6,NCT01876368,Exclusion,msdbp > = 110 mmhg or mssbp > = 180 mmhg ),Observation,NA,NA,NA,NA,NA,NA,NA,NA
7,NCT01876368,Exclusion,history of angioedema ; drug-related or otherwise,Drug Exposure,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
7,NCT01876368,Exclusion,history of angioedema ; drug-related or otherwise,Drug Exposure,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
8,NCT01876368,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ( pkd ) ; drug-induced hypertension,Condition Occurrence,Condition,C0264649,renal parenchymal hypertension,FALSE,FALSE,NA,NA,NA
8,NCT01876368,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ( pkd ) ; drug-induced hypertension,Condition Occurrence,Condition,C0020545,renovascular hypertension,FALSE,FALSE,NA,NA,NA
8,NCT01876368,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ( pkd ) ; drug-induced hypertension,Condition Occurrence,Condition,C0035065;C1278951,renal artery,FALSE,FALSE,NA,NA,NA
8,NCT01876368,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ( pkd ) ; drug-induced hypertension,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
8,NCT01876368,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ( pkd ) ; drug-induced hypertension,Condition Occurrence,Condition,C0332886,coarctation,FALSE,FALSE,NA,NA,NA
8,NCT01876368,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ( pkd ) ; drug-induced hypertension,Condition Occurrence,Condition,C0022680,polycystic kidney disease,FALSE,FALSE,NA,NA,NA
8,NCT01876368,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ( pkd ) ; drug-induced hypertension,Condition Occurrence,Condition,C0031511;C1706920,pheochromocytoma,FALSE,FALSE,NA,NA,NA
8,NCT01876368,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ( pkd ) ; drug-induced hypertension,Condition Occurrence,Condition,C0221406;C0010481,cushing disease,FALSE,FALSE,NA,NA,NA
8,NCT01876368,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ( pkd ) ; drug-induced hypertension,Condition Occurrence,Condition,C1384514,primary hyperaldosteronism,FALSE,FALSE,NA,NA,NA
8,NCT01876368,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ( pkd ) ; drug-induced hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
8,NCT01876368,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ( pkd ) ; drug-induced hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
8,NCT01876368,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ( pkd ) ; drug-induced hypertension,Condition Occurrence,Other,C3542948,limited,TRUE,FALSE,NA,NA,NA
8,NCT01876368,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ( pkd ) ; drug-induced hypertension,Condition Occurrence,Other,C0869784;C0003483;C1278934,aorta,FALSE,FALSE,NA,NA,NA
8,NCT01876368,Exclusion,history or evidence of a secondary form of hypertension ; including but not limited to any of the following : renal parenchymal hypertension ; renovascular hypertension ( unilateral renal artery or bilateral renal artery stenosis ) ; coarctation of the aorta ; primary hyperaldosteronism ; cushing disease ; pheochromocytoma ; polycystic kidney disease ( pkd ) ; drug-induced hypertension,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
9,NCT01876368,Exclusion,patients who previously entered a lcz696 study and had been randomized or enrolled to receive active drug treatment,Drug Exposure,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
9,NCT01876368,Exclusion,patients who previously entered a lcz696 study and had been randomized or enrolled to receive active drug treatment,Drug Exposure,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
1,NCT01928628,Inclusion,patients aged > = 20 to < = 75 years old,Other,Person,C0001792,aged,FALSE,FALSE,greater_equal 20 years; lower_equal 75 years,NA,NA
2,NCT01928628,Inclusion,patient with essential hypertension,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
3,NCT01928628,Exclusion,when the bp level measured at screening was sitdbp > 120 mmhg or sitsbp > 180 mmhg,Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,NA,NA
3,NCT01928628,Exclusion,when the bp level measured at screening was sitdbp > 120 mmhg or sitsbp > 180 mmhg,Observation,Observation,C3541902,measured,FALSE,FALSE,NA,greater 120 mmhg; greater 180 mmhg,NA
4,NCT01928628,Exclusion,patient with difference in repeatedly measured blood pressures from the selected arm at screening was sitsbp > = 20 mmhg or sitdbp > = 10 mmhg,Observation,Condition,C1272641,blood pressures,FALSE,FALSE,NA,NA,NA
4,NCT01928628,Exclusion,patient with difference in repeatedly measured blood pressures from the selected arm at screening was sitsbp > = 20 mmhg or sitdbp > = 10 mmhg,Observation,Condition,C0446516;C1140618;C1269078;C1269612,arm,FALSE,FALSE,NA,greater_equal 20 mmhg; greater_equal 10 mmhg,NA
4,NCT01928628,Exclusion,patient with difference in repeatedly measured blood pressures from the selected arm at screening was sitsbp > = 20 mmhg or sitdbp > = 10 mmhg,Observation,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
1,NCT01975246,Inclusion,essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs and mean seated diastolic blood pressure ( dbp ) must be > = 90 and < = 114 mmhg and mean seated systolic blood pressure ( sbp ) must be = < 200 mmhg,Observation,Condition,C0857121,hypertensive,FALSE,FALSE,NA,equal 2,NA
1,NCT01975246,Inclusion,essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs and mean seated diastolic blood pressure ( dbp ) must be > = 90 and < = 114 mmhg and mean seated systolic blood pressure ( sbp ) must be = < 200 mmhg,Observation,Drug,C0003364,antihypertensive drugs,FALSE,FALSE,NA,equal 3,NA
1,NCT01975246,Inclusion,essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs and mean seated diastolic blood pressure ( dbp ) must be > = 90 and < = 114 mmhg and mean seated systolic blood pressure ( sbp ) must be = < 200 mmhg,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,NA,NA
1,NCT01975246,Inclusion,essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs and mean seated diastolic blood pressure ( dbp ) must be > = 90 and < = 114 mmhg and mean seated systolic blood pressure ( sbp ) must be = < 200 mmhg,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 90 mmhg; lower_equal 114 mmhg,NA
1,NCT01975246,Inclusion,essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs and mean seated diastolic blood pressure ( dbp ) must be > = 90 and < = 114 mmhg and mean seated systolic blood pressure ( sbp ) must be = < 200 mmhg,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,NA,NA
1,NCT01975246,Inclusion,essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs and mean seated diastolic blood pressure ( dbp ) must be > = 90 and < = 114 mmhg and mean seated systolic blood pressure ( sbp ) must be = < 200 mmhg,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,lower_equal 200 mmhg,NA
2,NCT01975246,Inclusion,able to stop all current antihypertensive drugs ( other than study medication ) from visit 1 b through the end of the trial without risk to the patient based on the investigator opinion,Drug Exposure,Drug,C0723457,stop,FALSE,FALSE,NA,NA,NA
2,NCT01975246,Inclusion,able to stop all current antihypertensive drugs ( other than study medication ) from visit 1 b through the end of the trial without risk to the patient based on the investigator opinion,Drug Exposure,Drug,C0003364,antihypertensive drugs,FALSE,FALSE,NA,NA,NA
3,NCT01975246,Inclusion,age 20 years or older,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 20 years,NA,NA
4,NCT01975246,Exclusion,patients with known or suspected secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
5,NCT01975246,Exclusion,patients with clinically relevant cardiac arrhythmia,Condition Occurrence,Condition,C0003811;C1560249,cardiac arrhythmia,FALSE,FALSE,NA,NA,NA
6,NCT01975246,Exclusion,congestive heart failure with new york heart association ( nyha ) functional class iii - class iv,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
6,NCT01975246,Exclusion,congestive heart failure with new york heart association ( nyha ) functional class iii - class iv,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
6,NCT01975246,Exclusion,congestive heart failure with new york heart association ( nyha ) functional class iii - class iv,Condition Occurrence,Other,C0441887;C2698969,class iii,FALSE,FALSE,NA,NA,NA
6,NCT01975246,Exclusion,congestive heart failure with new york heart association ( nyha ) functional class iii - class iv,Condition Occurrence,Other,C0441888;C2698970,class iv,FALSE,FALSE,NA,NA,NA
7,NCT01975246,Exclusion,patients with recent cardiovascular events,Condition Occurrence,Condition,C1320716,cardiovascular events,FALSE,FALSE,NA,NA,NA
8,NCT01975246,Exclusion,patients with recent stroke events,Other,NA,NA,NA,NA,NA,NA,NA,NA
9,NCT01975246,Exclusion,patients with a history of sudden deterioration of renal function with angiotensin ii receptor blockers or angiotensin converting enzyme inhibitors,Drug Exposure,Drug,C0003015,angiotensin converting enzyme inhibitors,FALSE,FALSE,NA,NA,NA
9,NCT01975246,Exclusion,patients with a history of sudden deterioration of renal function with angiotensin ii receptor blockers or angiotensin converting enzyme inhibitors,Drug Exposure,Other,C0232804;C0022662,renal function,FALSE,FALSE,NA,NA,NA
9,NCT01975246,Exclusion,patients with a history of sudden deterioration of renal function with angiotensin ii receptor blockers or angiotensin converting enzyme inhibitors,Drug Exposure,Other,C2757003;C0521942,angiotensin ii receptor blockers,FALSE,FALSE,NA,NA,NA
10,NCT01975246,Exclusion,or patients with post-renal transplant or post-nephrectomy,Condition Occurrence,Condition,C0478647,transplant,FALSE,FALSE,NA,NA,NA
10,NCT01975246,Exclusion,or patients with post-renal transplant or post-nephrectomy,Condition Occurrence,Procedure,C0027695;C0176996,nephrectomy,FALSE,FALSE,NA,NA,NA
11,NCT01975246,Exclusion,patients with hepatic dysfunction or renal dysfunction,Condition Occurrence,Condition,C0086565,hepatic dysfunction,FALSE,FALSE,NA,NA,NA
11,NCT01975246,Exclusion,patients with hepatic dysfunction or renal dysfunction,Condition Occurrence,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
12,NCT01975246,Exclusion,pre-menopausal women who are nursing or pregnant,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
12,NCT01975246,Exclusion,pre-menopausal women who are nursing or pregnant,Condition Occurrence,Condition,C1096235,pre-menopausal,FALSE,FALSE,NA,NA,NA
12,NCT01975246,Exclusion,pre-menopausal women who are nursing or pregnant,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
12,NCT01975246,Exclusion,pre-menopausal women who are nursing or pregnant,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
1,NCT02172586,Inclusion,age > = 18 years,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 18 years,NA,NA
2,NCT02172586,Inclusion,mild-to-moderate essential hypertension defined as a mean diastolic blood pressure ( dbp ) > = 95 mmhg and < 110 mmhg and systolic blood pressure ( sbp ) < 180 mmhg measured by manual cuff sphygmomanometer at the end of the wash-out period,Observation,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT02172586,Inclusion,mild-to-moderate essential hypertension defined as a mean diastolic blood pressure ( dbp ) > = 95 mmhg and < 110 mmhg and systolic blood pressure ( sbp ) < 180 mmhg measured by manual cuff sphygmomanometer at the end of the wash-out period,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
2,NCT02172586,Inclusion,mild-to-moderate essential hypertension defined as a mean diastolic blood pressure ( dbp ) > = 95 mmhg and < 110 mmhg and systolic blood pressure ( sbp ) < 180 mmhg measured by manual cuff sphygmomanometer at the end of the wash-out period,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,NA,NA
2,NCT02172586,Inclusion,mild-to-moderate essential hypertension defined as a mean diastolic blood pressure ( dbp ) > = 95 mmhg and < 110 mmhg and systolic blood pressure ( sbp ) < 180 mmhg measured by manual cuff sphygmomanometer at the end of the wash-out period,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 95 mmhg; lower 110 mmhg,NA
2,NCT02172586,Inclusion,mild-to-moderate essential hypertension defined as a mean diastolic blood pressure ( dbp ) > = 95 mmhg and < 110 mmhg and systolic blood pressure ( sbp ) < 180 mmhg measured by manual cuff sphygmomanometer at the end of the wash-out period,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,NA,NA
2,NCT02172586,Inclusion,mild-to-moderate essential hypertension defined as a mean diastolic blood pressure ( dbp ) > = 95 mmhg and < 110 mmhg and systolic blood pressure ( sbp ) < 180 mmhg measured by manual cuff sphygmomanometer at the end of the wash-out period,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,NA,NA
2,NCT02172586,Inclusion,mild-to-moderate essential hypertension defined as a mean diastolic blood pressure ( dbp ) > = 95 mmhg and < 110 mmhg and systolic blood pressure ( sbp ) < 180 mmhg measured by manual cuff sphygmomanometer at the end of the wash-out period,Observation,Observation,C3541902,measured,FALSE,FALSE,NA,lower 180 mmhg,NA
2,NCT02172586,Inclusion,mild-to-moderate essential hypertension defined as a mean diastolic blood pressure ( dbp ) > = 95 mmhg and < 110 mmhg and systolic blood pressure ( sbp ) < 180 mmhg measured by manual cuff sphygmomanometer at the end of the wash-out period,Observation,Other,C1547225,mild,FALSE,FALSE,NA,NA,NA
2,NCT02172586,Inclusion,mild-to-moderate essential hypertension defined as a mean diastolic blood pressure ( dbp ) > = 95 mmhg and < 110 mmhg and systolic blood pressure ( sbp ) < 180 mmhg measured by manual cuff sphygmomanometer at the end of the wash-out period,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
2,NCT02172586,Inclusion,mild-to-moderate essential hypertension defined as a mean diastolic blood pressure ( dbp ) > = 95 mmhg and < 110 mmhg and systolic blood pressure ( sbp ) < 180 mmhg measured by manual cuff sphygmomanometer at the end of the wash-out period,Observation,Other,C0024763,manual,FALSE,FALSE,NA,NA,NA
2,NCT02172586,Inclusion,mild-to-moderate essential hypertension defined as a mean diastolic blood pressure ( dbp ) > = 95 mmhg and < 110 mmhg and systolic blood pressure ( sbp ) < 180 mmhg measured by manual cuff sphygmomanometer at the end of the wash-out period,Observation,Other,C1547959;C2699154;C1883550,wash,FALSE,FALSE,NA,NA,NA
3,NCT02172586,Inclusion,written informed consent,Other,NA,NA,NA,NA,NA,NA,NA,NA
4,NCT02172586,Exclusion,nursing ; pregnancy or childbearing potential women ; post-menopausal women will be enrolled with last menstruation > 1 year prior to start wash-out phase or surgically sterile,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
4,NCT02172586,Exclusion,nursing ; pregnancy or childbearing potential women ; post-menopausal women will be enrolled with last menstruation > 1 year prior to start wash-out phase or surgically sterile,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
4,NCT02172586,Exclusion,nursing ; pregnancy or childbearing potential women ; post-menopausal women will be enrolled with last menstruation > 1 year prior to start wash-out phase or surgically sterile,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
4,NCT02172586,Exclusion,nursing ; pregnancy or childbearing potential women ; post-menopausal women will be enrolled with last menstruation > 1 year prior to start wash-out phase or surgically sterile,Condition Occurrence,Condition,C0025344;C2129647,menstruation,FALSE,FALSE,greater 1 year,NA,NA
4,NCT02172586,Exclusion,nursing ; pregnancy or childbearing potential women ; post-menopausal women will be enrolled with last menstruation > 1 year prior to start wash-out phase or surgically sterile,Condition Occurrence,Observation,C3831118,childbearing potential,FALSE,FALSE,NA,NA,NA
4,NCT02172586,Exclusion,nursing ; pregnancy or childbearing potential women ; post-menopausal women will be enrolled with last menstruation > 1 year prior to start wash-out phase or surgically sterile,Condition Occurrence,Other,C0032961;C3484365,pregnancy,FALSE,FALSE,NA,NA,NA
4,NCT02172586,Exclusion,nursing ; pregnancy or childbearing potential women ; post-menopausal women will be enrolled with last menstruation > 1 year prior to start wash-out phase or surgically sterile,Condition Occurrence,Other,C1547959;C2699154;C1883550,wash,FALSE,FALSE,NA,NA,NA
5,NCT02172586,Exclusion,secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
6,NCT02172586,Exclusion,malignant hypertension ( retinal haemorrhage ; exudates or papillary oedema ),Condition Occurrence,Condition,C0020540;C0024588,malignant hypertension,FALSE,FALSE,NA,NA,NA
6,NCT02172586,Exclusion,malignant hypertension ( retinal haemorrhage ; exudates or papillary oedema ),Condition Occurrence,Condition,C0035317,retinal haemorrhage,FALSE,FALSE,NA,NA,NA
7,NCT02172586,Exclusion,clinically significant sodium depletion as defined by serum sodium level < 130 meq / l hyperkaliemia or clinically significant hyperkaliemia as defined by serum potassium level > 5.5 meq / l or clinically significant hypokaliemia as defined by serum potassium level < 3.0 meq / l,Observation,Condition,C0020625,sodium depletion,FALSE,FALSE,NA,NA,NA
7,NCT02172586,Exclusion,clinically significant sodium depletion as defined by serum sodium level < 130 meq / l hyperkaliemia or clinically significant hyperkaliemia as defined by serum potassium level > 5.5 meq / l or clinically significant hypokaliemia as defined by serum potassium level < 3.0 meq / l,Observation,Observation,C0587356;C0523891,serum sodium level,FALSE,FALSE,NA,lower 130,NA
7,NCT02172586,Exclusion,clinically significant sodium depletion as defined by serum sodium level < 130 meq / l hyperkaliemia or clinically significant hyperkaliemia as defined by serum potassium level > 5.5 meq / l or clinically significant hypokaliemia as defined by serum potassium level < 3.0 meq / l,Observation,Observation,C0543465;C0302353,serum potassium level,FALSE,FALSE,NA,greater 5.5,NA
7,NCT02172586,Exclusion,clinically significant sodium depletion as defined by serum sodium level < 130 meq / l hyperkaliemia or clinically significant hyperkaliemia as defined by serum potassium level > 5.5 meq / l or clinically significant hypokaliemia as defined by serum potassium level < 3.0 meq / l,Observation,Observation,C0543465;C0302353,serum potassium level,FALSE,FALSE,NA,lower 3.0,NA
7,NCT02172586,Exclusion,clinically significant sodium depletion as defined by serum sodium level < 130 meq / l hyperkaliemia or clinically significant hyperkaliemia as defined by serum potassium level > 5.5 meq / l or clinically significant hypokaliemia as defined by serum potassium level < 3.0 meq / l,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
7,NCT02172586,Exclusion,clinically significant sodium depletion as defined by serum sodium level < 130 meq / l hyperkaliemia or clinically significant hyperkaliemia as defined by serum potassium level > 5.5 meq / l or clinically significant hypokaliemia as defined by serum potassium level < 3.0 meq / l,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
7,NCT02172586,Exclusion,clinically significant sodium depletion as defined by serum sodium level < 130 meq / l hyperkaliemia or clinically significant hyperkaliemia as defined by serum potassium level > 5.5 meq / l or clinically significant hypokaliemia as defined by serum potassium level < 3.0 meq / l,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
8,NCT02172586,Exclusion,atrial fibrillation or frequent ventricular ectopic beats or other arrhythmias which ; in the investigator opinion could compromise patient participation to the trial,Condition Occurrence,Condition,C0151636,ventricular ectopic beats,FALSE,FALSE,NA,NA,NA
8,NCT02172586,Exclusion,atrial fibrillation or frequent ventricular ectopic beats or other arrhythmias which ; in the investigator opinion could compromise patient participation to the trial,Condition Occurrence,Condition,C0003811,arrhythmias,FALSE,FALSE,NA,NA,NA
8,NCT02172586,Exclusion,atrial fibrillation or frequent ventricular ectopic beats or other arrhythmias which ; in the investigator opinion could compromise patient participation to the trial,Condition Occurrence,Procedure,C0030699,patient participation,FALSE,FALSE,NA,NA,NA
8,NCT02172586,Exclusion,atrial fibrillation or frequent ventricular ectopic beats or other arrhythmias which ; in the investigator opinion could compromise patient participation to the trial,Condition Occurrence,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
9,NCT02172586,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) functional class chf iii-,Condition Occurrence,Condition,C0018802,congestive heart failure chf,FALSE,FALSE,NA,NA,NA
9,NCT02172586,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) functional class chf iii-,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
9,NCT02172586,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) functional class chf iii-,Condition Occurrence,Condition,C0018802,chf,FALSE,FALSE,NA,NA,NA
9,NCT02172586,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) functional class chf iii-,Condition Occurrence,Other,C0456387;C0489477,class,FALSE,FALSE,NA,NA,NA
9,NCT02172586,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) functional class chf iii-,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii-,FALSE,FALSE,NA,NA,NA
10,NCT02172586,Exclusion,angina pectoris or myocardial infarction,Condition Occurrence,Condition,C0002962;C0577698;C0235467;C0542052;C0010073;C0541777;C0235462,angina pectoris,FALSE,FALSE,NA,NA,NA
10,NCT02172586,Exclusion,angina pectoris or myocardial infarction,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
11,NCT02172586,Exclusion,cardiac surgery within the past 3 months prior to start the wash-out period,Drug Exposure,Procedure,C0018821,cardiac surgery,FALSE,FALSE,lower 3 past months,NA,NA
11,NCT02172586,Exclusion,cardiac surgery within the past 3 months prior to start the wash-out period,Drug Exposure,Other,C1547959;C2699154;C1883550,wash,FALSE,FALSE,NA,NA,NA
12,NCT02172586,Exclusion,stroke within the past 6 months prior to start the wash-out period,Drug Exposure,Other,C1547959;C2699154;C1883550,wash,FALSE,FALSE,lower 6 past months,NA,NA
13,NCT02172586,Exclusion,renal insufficiency defined as creatininaemia > 2 mg / dl,Drug Exposure,Condition,C1565489;C0035078,renal insufficiency,FALSE,FALSE,NA,NA,NA
13,NCT02172586,Exclusion,renal insufficiency defined as creatininaemia > 2 mg / dl,Drug Exposure,Other,C3539106,defined,FALSE,FALSE,NA,NA,greater 2 mg/dl
14,NCT02172586,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post renal transplant ; presence of only one functioning kidney,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
14,NCT02172586,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post renal transplant ; presence of only one functioning kidney,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
14,NCT02172586,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post renal transplant ; presence of only one functioning kidney,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
14,NCT02172586,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post renal transplant ; presence of only one functioning kidney,Condition Occurrence,Procedure,C0022671,renal transplant,FALSE,FALSE,NA,NA,NA
14,NCT02172586,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post renal transplant ; presence of only one functioning kidney,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
15,NCT02172586,Exclusion,liver insufficiency ; defined as bilirubinaemia > 2 mg / dl and ast ( aspartate aminotransferase ) or alt ( alanine-aminotransferase ) > twice the upper normal range,Observation,Condition,C1306571,liver insufficiency,FALSE,FALSE,NA,NA,greater 2 mg/dl
15,NCT02172586,Exclusion,liver insufficiency ; defined as bilirubinaemia > 2 mg / dl and ast ( aspartate aminotransferase ) or alt ( alanine-aminotransferase ) > twice the upper normal range,Observation,Observation,C0004002,ast,FALSE,FALSE,NA,NA,NA
15,NCT02172586,Exclusion,liver insufficiency ; defined as bilirubinaemia > 2 mg / dl and ast ( aspartate aminotransferase ) or alt ( alanine-aminotransferase ) > twice the upper normal range,Observation,Observation,C0004002;C0201899,aspartate aminotransferase,FALSE,FALSE,NA,NA,NA
15,NCT02172586,Exclusion,liver insufficiency ; defined as bilirubinaemia > 2 mg / dl and ast ( aspartate aminotransferase ) or alt ( alanine-aminotransferase ) > twice the upper normal range,Observation,Observation,C1140170;C2257651,alt,FALSE,FALSE,NA,NA,NA
15,NCT02172586,Exclusion,liver insufficiency ; defined as bilirubinaemia > 2 mg / dl and ast ( aspartate aminotransferase ) or alt ( alanine-aminotransferase ) > twice the upper normal range,Observation,Observation,C3542016,range,FALSE,FALSE,NA,NA,NA
15,NCT02172586,Exclusion,liver insufficiency ; defined as bilirubinaemia > 2 mg / dl and ast ( aspartate aminotransferase ) or alt ( alanine-aminotransferase ) > twice the upper normal range,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,greater 2 mg/dl
15,NCT02172586,Exclusion,liver insufficiency ; defined as bilirubinaemia > 2 mg / dl and ast ( aspartate aminotransferase ) or alt ( alanine-aminotransferase ) > twice the upper normal range,Observation,Other,C0001899;C0201836,alanine-aminotransferase,FALSE,FALSE,NA,NA,NA
16,NCT02172586,Exclusion,clinically significant metabolic disease and endocrine disease,Condition Occurrence,Condition,C0025517,metabolic disease,FALSE,FALSE,NA,NA,NA
16,NCT02172586,Exclusion,clinically significant metabolic disease and endocrine disease,Condition Occurrence,Condition,C0014130,endocrine disease,FALSE,FALSE,NA,NA,NA
17,NCT02172586,Exclusion,autoimmune disease,Condition Occurrence,Condition,C0004364,autoimmune disease,FALSE,FALSE,NA,NA,NA
18,NCT02172586,Exclusion,previous history of angioedema,Condition Occurrence,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
19,NCT02172586,Exclusion,body mass index > 30 kg / m2,Observation,Observation,C0005893;C1305855;C2240399,body mass index,FALSE,FALSE,NA,greater 30 kg/m2,NA
20,NCT02172586,Exclusion,arm circumference > 32 cm,Condition Occurrence,Condition,C2075184,arm circumference,FALSE,FALSE,NA,greater 32 cm,NA
21,NCT02172586,Exclusion,any condition that may be likely to compromise patients participation to the trial ( alcohol or drug abuse ; disability illness ; etc ; ),Condition Occurrence,Condition,C0013146,drug abuse,FALSE,FALSE,NA,NA,NA
21,NCT02172586,Exclusion,any condition that may be likely to compromise patients participation to the trial ( alcohol or drug abuse ; disability illness ; etc ; ),Condition Occurrence,Condition,C0231170,disability,FALSE,FALSE,NA,NA,NA
21,NCT02172586,Exclusion,any condition that may be likely to compromise patients participation to the trial ( alcohol or drug abuse ; disability illness ; etc ; ),Condition Occurrence,Other,C0001975;C0001962;C1547288,alcohol,FALSE,FALSE,NA,NA,NA
22,NCT02172586,Exclusion,concomitant therapy with antihypertensive drugs non permitted by protocol ; corticosteroids or drugs known to affect blood pressure,Procedure,Drug,C0003364,antihypertensive drugs,FALSE,FALSE,NA,NA,NA
22,NCT02172586,Exclusion,concomitant therapy with antihypertensive drugs non permitted by protocol ; corticosteroids or drugs known to affect blood pressure,Procedure,Drug,C3540726;C3540725;C3539185;C3540727,corticosteroids,FALSE,FALSE,NA,NA,NA
22,NCT02172586,Exclusion,concomitant therapy with antihypertensive drugs non permitted by protocol ; corticosteroids or drugs known to affect blood pressure,Procedure,Procedure,C1707479,concomitant therapy,FALSE,FALSE,NA,NA,NA
22,NCT02172586,Exclusion,concomitant therapy with antihypertensive drugs non permitted by protocol ; corticosteroids or drugs known to affect blood pressure,Procedure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
22,NCT02172586,Exclusion,concomitant therapy with antihypertensive drugs non permitted by protocol ; corticosteroids or drugs known to affect blood pressure,Procedure,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
22,NCT02172586,Exclusion,concomitant therapy with antihypertensive drugs non permitted by protocol ; corticosteroids or drugs known to affect blood pressure,Procedure,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
23,NCT02172586,Exclusion,concomitant use of lithium or cholestyramine or colestipol resins ( potential drug interactions with hctz ),Drug Exposure,Condition,C0687133,drug interactions,FALSE,FALSE,NA,NA,NA
23,NCT02172586,Exclusion,concomitant use of lithium or cholestyramine or colestipol resins ( potential drug interactions with hctz ),Drug Exposure,Drug,C0009279,colestipol,FALSE,FALSE,NA,NA,NA
23,NCT02172586,Exclusion,concomitant use of lithium or cholestyramine or colestipol resins ( potential drug interactions with hctz ),Drug Exposure,Drug,C0008402,cholestyramine,FALSE,FALSE,NA,NA,NA
23,NCT02172586,Exclusion,concomitant use of lithium or cholestyramine or colestipol resins ( potential drug interactions with hctz ),Drug Exposure,Other,C0337452;C0023870;C3540800,lithium,FALSE,FALSE,NA,NA,NA
24,NCT02172586,Exclusion,investigational drug treatment within the past 30 days before the enrolment or concurrent participation to any other trial,Drug Exposure,Drug,C0013230,investigational drug,FALSE,FALSE,lower 30 past days,NA,NA
25,NCT02172586,Exclusion,sensitivity ; significant adverse reaction or contraindications to the study drugs ( telmisartan ; losartan ; hctz ),Drug Exposure,Condition,C0427965,sensitivity,FALSE,FALSE,NA,NA,NA
25,NCT02172586,Exclusion,sensitivity ; significant adverse reaction or contraindications to the study drugs ( telmisartan ; losartan ; hctz ),Drug Exposure,Condition,C0559546,adverse reaction,FALSE,FALSE,NA,NA,NA
25,NCT02172586,Exclusion,sensitivity ; significant adverse reaction or contraindications to the study drugs ( telmisartan ; losartan ; hctz ),Drug Exposure,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,NA
25,NCT02172586,Exclusion,sensitivity ; significant adverse reaction or contraindications to the study drugs ( telmisartan ; losartan ; hctz ),Drug Exposure,Drug,C0126174,losartan,FALSE,FALSE,NA,NA,NA
25,NCT02172586,Exclusion,sensitivity ; significant adverse reaction or contraindications to the study drugs ( telmisartan ; losartan ; hctz ),Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
26,NCT02172586,Exclusion,predictable lack of patient co-operation,Other,NA,NA,NA,NA,NA,NA,NA,NA
1,NCT02175355,Inclusion,at least 35 years ; but less than 85 years of age,Person,Person,C0001779,age,FALSE,FALSE,lower 85 years; greater_equal 35 years,NA,NA
2,NCT02175355,Inclusion,mean sbp > = 150 mm hg and mean dbp < 90 mm hg at the randomisation visit ( visit 2 ) ; according to who definitions of ish ( excluding the subgroup of borderline ish ),Observation,Condition,C1079230,subgroup,TRUE,FALSE,NA,NA,NA
2,NCT02175355,Inclusion,mean sbp > = 150 mm hg and mean dbp < 90 mm hg at the randomisation visit ( visit 2 ) ; according to who definitions of ish ( excluding the subgroup of borderline ish ),Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 150 mm hg,NA
2,NCT02175355,Inclusion,mean sbp > = 150 mm hg and mean dbp < 90 mm hg at the randomisation visit ( visit 2 ) ; according to who definitions of ish ( excluding the subgroup of borderline ish ),Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,lower 90 mm hg,NA
3,NCT02175355,Inclusion,hypertensive patients not on current antihypertensive therapy or able to stop current treatment for a period of up to 8 - 10 weeks without endangering the health of the patient ( investigator discretion ),Procedure,Condition,C0857121,hypertensive,FALSE,FALSE,NA,NA,NA
3,NCT02175355,Inclusion,hypertensive patients not on current antihypertensive therapy or able to stop current treatment for a period of up to 8 - 10 weeks without endangering the health of the patient ( investigator discretion ),Procedure,Drug,C0723457,stop,FALSE,FALSE,NA,NA,NA
3,NCT02175355,Inclusion,hypertensive patients not on current antihypertensive therapy or able to stop current treatment for a period of up to 8 - 10 weeks without endangering the health of the patient ( investigator discretion ),Procedure,Procedure,C0585941,antihypertensive therapy,TRUE,FALSE,NA,NA,NA
3,NCT02175355,Inclusion,hypertensive patients not on current antihypertensive therapy or able to stop current treatment for a period of up to 8 - 10 weeks without endangering the health of the patient ( investigator discretion ),Procedure,Procedure,C2827774,current treatment,FALSE,FALSE,lower_equal 8 weeks; lower_equal 10 weeks,NA,NA
4,NCT02175355,Inclusion,ability to provide written informed consent,Other,NA,NA,NA,NA,NA,NA,NA,NA
5,NCT02175355,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to start of run-in period ) who :,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
5,NCT02175355,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to start of run-in period ) who :,Condition Occurrence,Condition,C1096235,pre-menopausal,FALSE,FALSE,NA,NA,NA
5,NCT02175355,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to start of run-in period ) who :,Condition Occurrence,Condition,C0025344;C2129647,menstruation,FALSE,FALSE,lower_equal 1 year,NA,NA
6,NCT02175355,Exclusion,are not surgically sterile,Other,NA,NA,NA,NA,NA,NA,NA,NA
7,NCT02175355,Exclusion,are nursing,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
8,NCT02175355,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control or do not plan to continue using this method throughout the study,Observation,Observation,C3831118,child-bearing potential,FALSE,FALSE,NA,NA,NA
8,NCT02175355,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control or do not plan to continue using this method throughout the study,Observation,Other,C0700589;C2703065,birth control,TRUE,FALSE,NA,NA,NA
8,NCT02175355,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control or do not plan to continue using this method throughout the study,Observation,Other,C2827714;C0871511;C2828387,method,FALSE,FALSE,NA,NA,NA
9,NCT02175355,Exclusion,acceptable methods of birth control include oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Drug,C0086466;C1272936,injectable,FALSE,FALSE,NA,NA,NA
9,NCT02175355,Exclusion,acceptable methods of birth control include oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Other,C0025663,methods,FALSE,FALSE,NA,NA,NA
9,NCT02175355,Exclusion,acceptable methods of birth control include oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Other,C0700589;C2703065,birth control,FALSE,FALSE,NA,NA,NA
9,NCT02175355,Exclusion,acceptable methods of birth control include oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Other,C0009905;C0274536;C0481121;C1548892,oral contraceptives,FALSE,FALSE,NA,NA,NA
10,NCT02175355,Exclusion,mean systolic blood pressure > = 180 mmhg at the randomization visit 2,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater_equal 180 mmhg,NA
11,NCT02175355,Exclusion,known or suspected secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
12,NCT02175355,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Condition,C0086565,hepatic dysfunction,FALSE,FALSE,NA,NA,NA
12,NCT02175355,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
12,NCT02175355,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
12,NCT02175355,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
13,NCT02175355,Exclusion,serum glutamic pyruvate transaminase ( alt ) or serum glutamic oxaloacetic transaminase ( ast ) > than 2 times the upper limit of normal range,Observation,Drug,C0002594,transaminase,FALSE,FALSE,NA,NA,NA
13,NCT02175355,Exclusion,serum glutamic pyruvate transaminase ( alt ) or serum glutamic oxaloacetic transaminase ( ast ) > than 2 times the upper limit of normal range,Observation,Drug,C0242192,serum glutamic oxaloacetic transaminase,FALSE,FALSE,NA,NA,NA
13,NCT02175355,Exclusion,serum glutamic pyruvate transaminase ( alt ) or serum glutamic oxaloacetic transaminase ( ast ) > than 2 times the upper limit of normal range,Observation,Observation,C1140170;C2257651,alt,FALSE,FALSE,NA,NA,NA
13,NCT02175355,Exclusion,serum glutamic pyruvate transaminase ( alt ) or serum glutamic oxaloacetic transaminase ( ast ) > than 2 times the upper limit of normal range,Observation,Observation,C0004002,ast,FALSE,FALSE,NA,NA,NA
13,NCT02175355,Exclusion,serum glutamic pyruvate transaminase ( alt ) or serum glutamic oxaloacetic transaminase ( ast ) > than 2 times the upper limit of normal range,Observation,Observation,C3542016,range,FALSE,FALSE,NA,NA,equal 2 times the upper limit of normal
13,NCT02175355,Exclusion,serum glutamic pyruvate transaminase ( alt ) or serum glutamic oxaloacetic transaminase ( ast ) > than 2 times the upper limit of normal range,Observation,Other,C0229671;C1546774;C1550100,serum,FALSE,FALSE,NA,NA,NA
13,NCT02175355,Exclusion,serum glutamic pyruvate transaminase ( alt ) or serum glutamic oxaloacetic transaminase ( ast ) > than 2 times the upper limit of normal range,Observation,Other,C0302278;C0244104,pyruvate,FALSE,FALSE,NA,NA,NA
14,NCT02175355,Exclusion,serum creatinine > or 1.88 mg / dl ( or 159 umol / l ),Observation,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,equal 159 umol/l,equal 1.88 mg/dl
15,NCT02175355,Exclusion,bilateral renal artery stenosis,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
16,NCT02175355,Exclusion,renal artery stenosis in a solitary kidney ; patients post-renal transplant or with only one functioning kidney,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
16,NCT02175355,Exclusion,renal artery stenosis in a solitary kidney ; patients post-renal transplant or with only one functioning kidney,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
16,NCT02175355,Exclusion,renal artery stenosis in a solitary kidney ; patients post-renal transplant or with only one functioning kidney,Condition Occurrence,Condition,C0478647,transplant,FALSE,FALSE,NA,NA,NA
16,NCT02175355,Exclusion,renal artery stenosis in a solitary kidney ; patients post-renal transplant or with only one functioning kidney,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
17,NCT02175355,Exclusion,clinically relevant hypokalemia or hyperkalemia,Condition Occurrence,Condition,C0020621,hypokalemia,FALSE,FALSE,NA,NA,NA
17,NCT02175355,Exclusion,clinically relevant hypokalemia or hyperkalemia,Condition Occurrence,Condition,C0020461,hyperkalemia,FALSE,FALSE,NA,NA,NA
18,NCT02175355,Exclusion,uncorrected volume or sodium depletion,Condition Occurrence,Condition,C0020625,sodium depletion,FALSE,FALSE,NA,NA,NA
18,NCT02175355,Exclusion,uncorrected volume or sodium depletion,Condition Occurrence,Observation,C1705102;C2700258,volume,FALSE,FALSE,NA,NA,NA
19,NCT02175355,Exclusion,primary aldosteronism,Condition Occurrence,Condition,C1384514,primary aldosteronism,FALSE,FALSE,NA,NA,NA
20,NCT02175355,Exclusion,hereditary fructose intolerance,Condition Occurrence,Condition,C0016751,hereditary fructose intolerance,FALSE,FALSE,NA,NA,NA
21,NCT02175355,Exclusion,biliary obstructive disorders,Other,NA,NA,NA,NA,NA,NA,NA,NA
22,NCT02175355,Exclusion,symptomatic congestive heart failure,Condition Occurrence,Condition,C0742758,symptomatic congestive heart failure,FALSE,FALSE,NA,NA,NA
23,NCT02175355,Exclusion,angina pectoris or previous myocardial infarction,Condition Occurrence,Condition,C0002962;C0577698;C0235467;C0542052;C0010073;C0541777;C0235462,angina pectoris,FALSE,FALSE,NA,NA,NA
23,NCT02175355,Exclusion,angina pectoris or previous myocardial infarction,Condition Occurrence,Condition,C0155668,previous myocardial infarction,FALSE,FALSE,NA,NA,NA
24,NCT02175355,Exclusion,previous percutaneous transluminal coronary angioplasty or coronary artery bypass craft,Procedure,Procedure,C2936173,percutaneous transluminal coronary angioplasty,FALSE,FALSE,NA,NA,NA
24,NCT02175355,Exclusion,previous percutaneous transluminal coronary angioplasty or coronary artery bypass craft,Procedure,Procedure,C0010055,coronary artery bypass,FALSE,FALSE,NA,NA,NA
25,NCT02175355,Exclusion,previous cerebrovascular accident or hypertensive encephalopathy ischemic attack or transient ischemic attack ( s ),Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
25,NCT02175355,Exclusion,previous cerebrovascular accident or hypertensive encephalopathy ischemic attack or transient ischemic attack ( s ),Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
25,NCT02175355,Exclusion,previous cerebrovascular accident or hypertensive encephalopathy ischemic attack or transient ischemic attack ( s ),Condition Occurrence,Condition,C0745413,ischemic attack,FALSE,FALSE,NA,NA,NA
25,NCT02175355,Exclusion,previous cerebrovascular accident or hypertensive encephalopathy ischemic attack or transient ischemic attack ( s ),Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,NA,NA,NA
26,NCT02175355,Exclusion,current treatment with any antihypertensive agents ; whether or not prescribed for this indication ; that cannot be safely stopped ( investigators decision ) by the start of the run-in period,Procedure,Drug,C0003364,antihypertensive agents,FALSE,FALSE,NA,NA,NA
26,NCT02175355,Exclusion,current treatment with any antihypertensive agents ; whether or not prescribed for this indication ; that cannot be safely stopped ( investigators decision ) by the start of the run-in period,Procedure,Procedure,C2827774,current treatment,FALSE,FALSE,NA,NA,NA
26,NCT02175355,Exclusion,current treatment with any antihypertensive agents ; whether or not prescribed for this indication ; that cannot be safely stopped ( investigators decision ) by the start of the run-in period,Procedure,Procedure,C0278329,prescribed,FALSE,FALSE,NA,NA,NA
27,NCT02175355,Exclusion,any pre-treatment with diuretics ; ace inhibitors or angiotensin ii receptor antagonists requires an extension of the run-in period from 2 to 4 weeks for adequate wash-out,Drug Exposure,Condition,C2257086,pre,FALSE,FALSE,NA,NA,NA
27,NCT02175355,Exclusion,any pre-treatment with diuretics ; ace inhibitors or angiotensin ii receptor antagonists requires an extension of the run-in period from 2 to 4 weeks for adequate wash-out,Drug Exposure,Drug,C0012798,diuretics,FALSE,FALSE,NA,NA,NA
27,NCT02175355,Exclusion,any pre-treatment with diuretics ; ace inhibitors or angiotensin ii receptor antagonists requires an extension of the run-in period from 2 to 4 weeks for adequate wash-out,Drug Exposure,Drug,C0003015,ace inhibitors,FALSE,FALSE,NA,NA,NA
27,NCT02175355,Exclusion,any pre-treatment with diuretics ; ace inhibitors or angiotensin ii receptor antagonists requires an extension of the run-in period from 2 to 4 weeks for adequate wash-out,Drug Exposure,Other,C0521942;C2757003,angiotensin ii receptor antagonists,FALSE,FALSE,NA,NA,NA
27,NCT02175355,Exclusion,any pre-treatment with diuretics ; ace inhibitors or angiotensin ii receptor antagonists requires an extension of the run-in period from 2 to 4 weeks for adequate wash-out,Drug Exposure,Other,C1547959;C2699154;C1883550,wash,FALSE,FALSE,greater_equal 2 weeks; lower_equal 4 weeks,NA,NA
28,NCT02175355,Exclusion,atrial fibrillation ( controlled or otherwise ) or any other clinically relevant cardiac arrhythmias as determined by the clinical investigator,Condition Occurrence,Condition,C0577699,atrial fibrillation controlled,FALSE,FALSE,NA,NA,NA
28,NCT02175355,Exclusion,atrial fibrillation ( controlled or otherwise ) or any other clinically relevant cardiac arrhythmias as determined by the clinical investigator,Condition Occurrence,Condition,C0003811,cardiac arrhythmias,FALSE,FALSE,NA,NA,NA
28,NCT02175355,Exclusion,atrial fibrillation ( controlled or otherwise ) or any other clinically relevant cardiac arrhythmias as determined by the clinical investigator,Condition Occurrence,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
29,NCT02175355,Exclusion,hemodynamically relevant aortic or mitral valve stenosis ; obstructive hypertrophic cardiomyopathy or other outflow obstruction of the left ventricle,Condition Occurrence,Condition,C0026269;C0264766,mitral valve stenosis,FALSE,FALSE,NA,NA,NA
29,NCT02175355,Exclusion,hemodynamically relevant aortic or mitral valve stenosis ; obstructive hypertrophic cardiomyopathy or other outflow obstruction of the left ventricle,Condition Occurrence,Condition,C0007194,obstructive hypertrophic cardiomyopathy,FALSE,FALSE,NA,NA,NA
29,NCT02175355,Exclusion,hemodynamically relevant aortic or mitral valve stenosis ; obstructive hypertrophic cardiomyopathy or other outflow obstruction of the left ventricle,Condition Occurrence,Condition,C0225897;C1269892,left ventricle,FALSE,FALSE,NA,NA,NA
30,NCT02175355,Exclusion,patients with non-insulin-dependent diabetes mellitus requiring treatment with oral hypoglycemics who fail to meet the following criteria by history :,Condition Occurrence,Condition,C0011860,non-insulin-dependent diabetes mellitus,FALSE,FALSE,NA,NA,NA
30,NCT02175355,Exclusion,patients with non-insulin-dependent diabetes mellitus requiring treatment with oral hypoglycemics who fail to meet the following criteria by history :,Condition Occurrence,Drug,C0359086,oral hypoglycemics,FALSE,FALSE,NA,NA,NA
31,NCT02175355,Exclusion,fasting blood glucose less than 200 mg / dl ( 11.11 mmol / l ),Observation,Observation,C0428568;C1261430,fasting blood glucose,FALSE,FALSE,NA,NA,lower 200 mg/dl
32,NCT02175355,Exclusion,therapy stabilized for at least one month prior to start of placebo run-period,Drug Exposure,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,NA
33,NCT02175355,Exclusion,patients with diabetes mellitus requiring treatment with insulin,Condition Occurrence,Condition,C0011849,diabetes mellitus,FALSE,FALSE,NA,NA,NA
33,NCT02175355,Exclusion,patients with diabetes mellitus requiring treatment with insulin,Condition Occurrence,Observation,C0021641;C0202098;C1533581;C1145751;C1579433;C2739803,insulin,FALSE,FALSE,NA,NA,NA
34,NCT02175355,Exclusion,patients who have previously experienced symptoms characteristics of angioedema during treatment with ace inhibitors or angiotensin ii receptor antagonists,Condition Occurrence,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
34,NCT02175355,Exclusion,patients who have previously experienced symptoms characteristics of angioedema during treatment with ace inhibitors or angiotensin ii receptor antagonists,Condition Occurrence,Drug,C0003015,ace inhibitors,FALSE,FALSE,NA,NA,NA
34,NCT02175355,Exclusion,patients who have previously experienced symptoms characteristics of angioedema during treatment with ace inhibitors or angiotensin ii receptor antagonists,Condition Occurrence,Other,C0521942;C2757003,angiotensin ii receptor antagonists,FALSE,FALSE,NA,NA,NA
35,NCT02175355,Exclusion,known drug or alcohol dependency,Condition Occurrence,Condition,C0001973,alcohol dependency,FALSE,FALSE,NA,NA,NA
35,NCT02175355,Exclusion,known drug or alcohol dependency,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
36,NCT02175355,Exclusion,any investigational therapy within one month of signing the informed consent form and during the trial,Procedure,Procedure,C0949266,investigational therapy,FALSE,FALSE,NA,NA,NA
36,NCT02175355,Exclusion,any investigational therapy within one month of signing the informed consent form and during the trial,Procedure,Other,C0009797,informed consent form,FALSE,FALSE,NA,NA,NA
37,NCT02175355,Exclusion,known hypersensitivity to any component of the formulation of telmisartan or hydrochlorothiazide including allergy to sulfonamides,Drug Exposure,Condition,C0038757,allergy to sulfonamides,FALSE,FALSE,NA,NA,NA
37,NCT02175355,Exclusion,known hypersensitivity to any component of the formulation of telmisartan or hydrochlorothiazide including allergy to sulfonamides,Drug Exposure,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,NA
37,NCT02175355,Exclusion,known hypersensitivity to any component of the formulation of telmisartan or hydrochlorothiazide including allergy to sulfonamides,Drug Exposure,Drug,C0020261,hydrochlorothiazide,FALSE,FALSE,NA,NA,NA
37,NCT02175355,Exclusion,known hypersensitivity to any component of the formulation of telmisartan or hydrochlorothiazide including allergy to sulfonamides,Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
38,NCT02175355,Exclusion,concomitant use of lithium or cholestyramine or colestipol resins ( potential drug interactions with hctz ),Drug Exposure,Condition,C0687133,drug interactions,FALSE,FALSE,NA,NA,NA
38,NCT02175355,Exclusion,concomitant use of lithium or cholestyramine or colestipol resins ( potential drug interactions with hctz ),Drug Exposure,Drug,C0009279,colestipol,FALSE,FALSE,NA,NA,NA
38,NCT02175355,Exclusion,concomitant use of lithium or cholestyramine or colestipol resins ( potential drug interactions with hctz ),Drug Exposure,Drug,C0008402,cholestyramine,FALSE,FALSE,NA,NA,NA
38,NCT02175355,Exclusion,concomitant use of lithium or cholestyramine or colestipol resins ( potential drug interactions with hctz ),Drug Exposure,Other,C0337452;C0023870;C3540800,lithium,FALSE,FALSE,NA,NA,NA
39,NCT02175355,Exclusion,gout ( contraindication for treatment with hctz ),Condition Occurrence,Condition,C0018099,gout,FALSE,FALSE,NA,NA,NA
39,NCT02175355,Exclusion,gout ( contraindication for treatment with hctz ),Condition Occurrence,Other,C1301624;C1547316,contraindication,FALSE,FALSE,NA,NA,NA
40,NCT02175355,Exclusion,any other clinical condition which ; in the opinion of the principal investigator ; would not allow safe completion of the protocol and safe administration of telmisartan or hydrochlorothiazide,Drug Exposure,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,NA
40,NCT02175355,Exclusion,any other clinical condition which ; in the opinion of the principal investigator ; would not allow safe completion of the protocol and safe administration of telmisartan or hydrochlorothiazide,Drug Exposure,Drug,C0020261,hydrochlorothiazide,FALSE,FALSE,NA,NA,NA
40,NCT02175355,Exclusion,any other clinical condition which ; in the opinion of the principal investigator ; would not allow safe completion of the protocol and safe administration of telmisartan or hydrochlorothiazide,Drug Exposure,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
1,NCT02177396,Inclusion,mild to moderate hypertension defined as mean seated diastolic blood pressure measurement of > = 95 mm hg and < = 114 mm hg ; measured by manual cuff sphygmomanometer ; on the last visit ( visit 6 ) of the four-week placebo run-in period ( baseline bp ),Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
1,NCT02177396,Inclusion,mild to moderate hypertension defined as mean seated diastolic blood pressure measurement of > = 95 mm hg and < = 114 mm hg ; measured by manual cuff sphygmomanometer ; on the last visit ( visit 6 ) of the four-week placebo run-in period ( baseline bp ),Observation,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,NA
1,NCT02177396,Inclusion,mild to moderate hypertension defined as mean seated diastolic blood pressure measurement of > = 95 mm hg and < = 114 mm hg ; measured by manual cuff sphygmomanometer ; on the last visit ( visit 6 ) of the four-week placebo run-in period ( baseline bp ),Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT02177396,Inclusion,mild to moderate hypertension defined as mean seated diastolic blood pressure measurement of > = 95 mm hg and < = 114 mm hg ; measured by manual cuff sphygmomanometer ; on the last visit ( visit 6 ) of the four-week placebo run-in period ( baseline bp ),Observation,Observation,C1305849,diastolic blood pressure measurement,FALSE,FALSE,NA,greater_equal 95 mm hg; lower_equal 114 mm hg,NA
1,NCT02177396,Inclusion,mild to moderate hypertension defined as mean seated diastolic blood pressure measurement of > = 95 mm hg and < = 114 mm hg ; measured by manual cuff sphygmomanometer ; on the last visit ( visit 6 ) of the four-week placebo run-in period ( baseline bp ),Observation,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
1,NCT02177396,Inclusion,mild to moderate hypertension defined as mean seated diastolic blood pressure measurement of > = 95 mm hg and < = 114 mm hg ; measured by manual cuff sphygmomanometer ; on the last visit ( visit 6 ) of the four-week placebo run-in period ( baseline bp ),Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,NA,NA
1,NCT02177396,Inclusion,mild to moderate hypertension defined as mean seated diastolic blood pressure measurement of > = 95 mm hg and < = 114 mm hg ; measured by manual cuff sphygmomanometer ; on the last visit ( visit 6 ) of the four-week placebo run-in period ( baseline bp ),Observation,Other,C1547225,mild,FALSE,FALSE,NA,NA,NA
1,NCT02177396,Inclusion,mild to moderate hypertension defined as mean seated diastolic blood pressure measurement of > = 95 mm hg and < = 114 mm hg ; measured by manual cuff sphygmomanometer ; on the last visit ( visit 6 ) of the four-week placebo run-in period ( baseline bp ),Observation,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
1,NCT02177396,Inclusion,mild to moderate hypertension defined as mean seated diastolic blood pressure measurement of > = 95 mm hg and < = 114 mm hg ; measured by manual cuff sphygmomanometer ; on the last visit ( visit 6 ) of the four-week placebo run-in period ( baseline bp ),Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT02177396,Inclusion,mild to moderate hypertension defined as mean seated diastolic blood pressure measurement of > = 95 mm hg and < = 114 mm hg ; measured by manual cuff sphygmomanometer ; on the last visit ( visit 6 ) of the four-week placebo run-in period ( baseline bp ),Observation,Other,C0024763,manual,FALSE,FALSE,NA,NA,NA
2,NCT02177396,Inclusion,mean seated systolic blood pressure > = 140 mm hg and < = 200 mm hg ; measured by manual cuff at visit 6 ( baseline bp ),Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
2,NCT02177396,Inclusion,mean seated systolic blood pressure > = 140 mm hg and < = 200 mm hg ; measured by manual cuff at visit 6 ( baseline bp ),Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater_equal 140 mm hg; lower_equal 200 mm hg,NA
2,NCT02177396,Inclusion,mean seated systolic blood pressure > = 140 mm hg and < = 200 mm hg ; measured by manual cuff at visit 6 ( baseline bp ),Observation,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
2,NCT02177396,Inclusion,mean seated systolic blood pressure > = 140 mm hg and < = 200 mm hg ; measured by manual cuff at visit 6 ( baseline bp ),Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,NA,NA
2,NCT02177396,Inclusion,mean seated systolic blood pressure > = 140 mm hg and < = 200 mm hg ; measured by manual cuff at visit 6 ( baseline bp ),Observation,Other,C0024763,manual,FALSE,FALSE,NA,NA,NA
3,NCT02177396,Inclusion,a 24 - hour mean abpm measurement of > = 130 / 85 mm hg evaluated at visit 7 ( baseline abpm ),Observation,NA,NA,NA,NA,NA,NA,NA,NA
4,NCT02177396,Inclusion,age 18 or older,Person,NA,NA,NA,NA,NA,NA,NA,NA
5,NCT02177396,Inclusion,ability to provide written informed consent,Other,NA,NA,NA,NA,NA,NA,NA,NA
6,NCT02177396,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to start of screening ) :,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
6,NCT02177396,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to start of screening ) :,Condition Occurrence,Condition,C1096235,pre-menopausal,FALSE,FALSE,NA,NA,NA
6,NCT02177396,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to start of screening ) :,Condition Occurrence,Condition,C0025344;C2129647,menstruation,FALSE,FALSE,lower_equal 1 year,NA,NA
7,NCT02177396,Exclusion,who are not surgically sterile ( hysterectomy ; tubal ligation ),Procedure,Procedure,C0020699;C1548863,hysterectomy,TRUE,FALSE,NA,NA,NA
7,NCT02177396,Exclusion,who are not surgically sterile ( hysterectomy ; tubal ligation ),Procedure,Procedure,C0520483,tubal ligation,FALSE,FALSE,NA,NA,NA
8,NCT02177396,Exclusion,who are not practicing acceptable means of birth control or who do not plan to continue using an acceptable method throughout the study,Condition Occurrence,Other,C0700589;C2703065,birth control,TRUE,FALSE,NA,NA,NA
8,NCT02177396,Exclusion,who are not practicing acceptable means of birth control or who do not plan to continue using an acceptable method throughout the study,Condition Occurrence,Other,C2827714;C0871511;C2828387,method,FALSE,FALSE,NA,NA,NA
9,NCT02177396,Exclusion,acceptable methods of birth control include iud ( intrauterine device ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Drug,C1706306,iud,FALSE,FALSE,NA,NA,NA
9,NCT02177396,Exclusion,acceptable methods of birth control include iud ( intrauterine device ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Drug,C0086466;C1272936,injectable,FALSE,FALSE,NA,NA,NA
9,NCT02177396,Exclusion,acceptable methods of birth control include iud ( intrauterine device ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Other,C0025663,methods,FALSE,FALSE,NA,NA,NA
9,NCT02177396,Exclusion,acceptable methods of birth control include iud ( intrauterine device ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Other,C0700589;C2703065,birth control,FALSE,FALSE,NA,NA,NA
9,NCT02177396,Exclusion,acceptable methods of birth control include iud ( intrauterine device ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Other,C1706306;C1548866;C1546682,intrauterine device,FALSE,FALSE,NA,NA,NA
9,NCT02177396,Exclusion,acceptable methods of birth control include iud ( intrauterine device ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Other,C0009905;C0274536;C0481121;C1548892,oral contraceptives,FALSE,FALSE,NA,NA,NA
10,NCT02177396,Exclusion,any woman :,Person,Person,C0086287,woman,FALSE,FALSE,NA,NA,NA
11,NCT02177396,Exclusion,who has a positive serum pregnancy test at screening ( visit 1 ) or baseline ( visit 7 ),Observation,Observation,C1514241,positive,FALSE,FALSE,NA,NA,NA
11,NCT02177396,Exclusion,who has a positive serum pregnancy test at screening ( visit 1 ) or baseline ( visit 7 ),Observation,Observation,C0430064,serum pregnancy test,FALSE,FALSE,NA,NA,NA
12,NCT02177396,Exclusion,who is nursing,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
13,NCT02177396,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters,Condition Occurrence,Condition,C0086565,hepatic dysfunction,FALSE,FALSE,NA,NA,NA
13,NCT02177396,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters,Condition Occurrence,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
13,NCT02177396,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters,Condition Occurrence,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
13,NCT02177396,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
14,NCT02177396,Exclusion,sgpt ( alt ) ( serum glutamate pyruvate transaminase ) or sgot ( ast ) ( serum glutamate oxaloacetate transaminase ) greater than two times the upper limit of normal,Observation,Drug,C0376147,serum glutamate pyruvate transaminase,FALSE,FALSE,NA,NA,NA
14,NCT02177396,Exclusion,sgpt ( alt ) ( serum glutamate pyruvate transaminase ) or sgot ( ast ) ( serum glutamate oxaloacetate transaminase ) greater than two times the upper limit of normal,Observation,Drug,C0004002,glutamate oxaloacetate transaminase,FALSE,FALSE,NA,NA,NA
14,NCT02177396,Exclusion,sgpt ( alt ) ( serum glutamate pyruvate transaminase ) or sgot ( ast ) ( serum glutamate oxaloacetate transaminase ) greater than two times the upper limit of normal,Observation,Observation,C0376147;C0036828,sgpt,FALSE,FALSE,NA,NA,NA
14,NCT02177396,Exclusion,sgpt ( alt ) ( serum glutamate pyruvate transaminase ) or sgot ( ast ) ( serum glutamate oxaloacetate transaminase ) greater than two times the upper limit of normal,Observation,Observation,C1140170;C2257651,alt,FALSE,FALSE,NA,NA,NA
14,NCT02177396,Exclusion,sgpt ( alt ) ( serum glutamate pyruvate transaminase ) or sgot ( ast ) ( serum glutamate oxaloacetate transaminase ) greater than two times the upper limit of normal,Observation,Observation,C0242192;C0201899,sgot,FALSE,FALSE,NA,NA,NA
14,NCT02177396,Exclusion,sgpt ( alt ) ( serum glutamate pyruvate transaminase ) or sgot ( ast ) ( serum glutamate oxaloacetate transaminase ) greater than two times the upper limit of normal,Observation,Observation,C0004002,ast,FALSE,FALSE,NA,NA,NA
14,NCT02177396,Exclusion,sgpt ( alt ) ( serum glutamate pyruvate transaminase ) or sgot ( ast ) ( serum glutamate oxaloacetate transaminase ) greater than two times the upper limit of normal,Observation,Other,C0229671;C1546774;C1550100,serum,FALSE,FALSE,NA,NA,NA
15,NCT02177396,Exclusion,serum creatinine > 2.3 mg / dl,Drug Exposure,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,NA,greater 2.3 mg/dl
16,NCT02177396,Exclusion,at screening ( visit 1 ) : clinically relevant sodium depletion ; hyperkalemia ; or hypokalemia,Condition Occurrence,Condition,C0020625,sodium depletion,FALSE,FALSE,NA,NA,NA
16,NCT02177396,Exclusion,at screening ( visit 1 ) : clinically relevant sodium depletion ; hyperkalemia ; or hypokalemia,Condition Occurrence,Condition,C0020621,hypokalemia,FALSE,FALSE,NA,NA,NA
16,NCT02177396,Exclusion,at screening ( visit 1 ) : clinically relevant sodium depletion ; hyperkalemia ; or hypokalemia,Condition Occurrence,Condition,C0020461,hyperkalemia,FALSE,FALSE,NA,NA,NA
17,NCT02177396,Exclusion,known or suspected secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
18,NCT02177396,Exclusion,bilateral renal artery stenosis,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
19,NCT02177396,Exclusion,renal artery stenosis in a solitary kidney,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
19,NCT02177396,Exclusion,renal artery stenosis in a solitary kidney,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
20,NCT02177396,Exclusion,post-renal transplant patients ; presence of only one functioning kidney,Condition Occurrence,Condition,C0478647,transplant,FALSE,FALSE,NA,NA,NA
20,NCT02177396,Exclusion,post-renal transplant patients ; presence of only one functioning kidney,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
21,NCT02177396,Exclusion,congestive heart failure ( nyha ( new york heart association ) functional class chf ( congestive heart failure ) iii-iv,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
21,NCT02177396,Exclusion,congestive heart failure ( nyha ( new york heart association ) functional class chf ( congestive heart failure ) iii-iv,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
21,NCT02177396,Exclusion,congestive heart failure ( nyha ( new york heart association ) functional class chf ( congestive heart failure ) iii-iv,Condition Occurrence,Condition,C0018802,chf,FALSE,FALSE,NA,NA,NA
21,NCT02177396,Exclusion,congestive heart failure ( nyha ( new york heart association ) functional class chf ( congestive heart failure ) iii-iv,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
21,NCT02177396,Exclusion,congestive heart failure ( nyha ( new york heart association ) functional class chf ( congestive heart failure ) iii-iv,Condition Occurrence,Other,C0456387;C0489477,class,FALSE,FALSE,NA,NA,NA
21,NCT02177396,Exclusion,congestive heart failure ( nyha ( new york heart association ) functional class chf ( congestive heart failure ) iii-iv,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii,FALSE,FALSE,NA,NA,NA
22,NCT02177396,Exclusion,unstable angina within the past three months,Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,NA,NA,NA
23,NCT02177396,Exclusion,stroke within the past six months,Other,NA,NA,NA,NA,NA,NA,NA,NA
24,NCT02177396,Exclusion,myocardial infarction or cardiac surgery within the past three months,Condition Occurrence,Procedure,C0018821,cardiac surgery,FALSE,FALSE,NA,NA,NA
24,NCT02177396,Exclusion,myocardial infarction or cardiac surgery within the past three months,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
25,NCT02177396,Exclusion,ptca ( percutaneous transluminal coronary angioplasty ) within the past three months,Procedure,Procedure,C2936173;C0002997,ptca,FALSE,FALSE,NA,NA,NA
25,NCT02177396,Exclusion,ptca ( percutaneous transluminal coronary angioplasty ) within the past three months,Procedure,Procedure,C2936173,percutaneous transluminal coronary angioplasty,FALSE,FALSE,NA,NA,NA
26,NCT02177396,Exclusion,history of angioedema,Condition Occurrence,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
27,NCT02177396,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0750197,sustained ventricular tachycardia,FALSE,FALSE,NA,NA,NA
27,NCT02177396,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0004239;C1963068,atrial flutter,FALSE,FALSE,NA,NA,NA
27,NCT02177396,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0003811,cardiac arrhythmias,FALSE,FALSE,NA,NA,NA
27,NCT02177396,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
28,NCT02177396,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0007194,hypertrophic obstructive cardiomyopathy,FALSE,FALSE,NA,NA,NA
28,NCT02177396,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0003507,aortic stenosis,FALSE,FALSE,NA,NA,NA
28,NCT02177396,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0003501;C1269005,aortic valve,FALSE,FALSE,NA,NA,NA
28,NCT02177396,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0026264;C1269004,mitral valve,FALSE,FALSE,NA,NA,NA
28,NCT02177396,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Observation,C1261287;C0947637;C0009814,stenosis,FALSE,FALSE,NA,NA,NA
29,NCT02177396,Exclusion,administration of digoxin or other digitalis-type drugs,Drug Exposure,Drug,C0304520,digitalis,FALSE,FALSE,NA,NA,NA
29,NCT02177396,Exclusion,administration of digoxin or other digitalis-type drugs,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
29,NCT02177396,Exclusion,administration of digoxin or other digitalis-type drugs,Drug Exposure,Other,C0337449;C0012265,digoxin,FALSE,FALSE,NA,NA,NA
30,NCT02177396,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by hba1c > = 10 %,Condition Occurrence,Condition,C0011854,insulin-dependent diabetes mellitus,FALSE,FALSE,NA,NA,NA
30,NCT02177396,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by hba1c > = 10 %,Condition Occurrence,Condition,C0011849;C0011847,diabetes,FALSE,FALSE,NA,NA,NA
30,NCT02177396,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by hba1c > = 10 %,Condition Occurrence,Observation,C0202054,hba1c,FALSE,FALSE,NA,NA,greater_equal 10 %
30,NCT02177396,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by hba1c > = 10 %,Condition Occurrence,Other,C1547311,stable,TRUE,FALSE,NA,NA,NA
30,NCT02177396,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by hba1c > = 10 %,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
31,NCT02177396,Exclusion,known drug or alcohol dependency within the past one year period,Condition Occurrence,Condition,C0001973,alcohol dependency,FALSE,FALSE,NA,NA,NA
31,NCT02177396,Exclusion,known drug or alcohol dependency within the past one year period,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
32,NCT02177396,Exclusion,concomitant administration of medications known to affect blood pressure ; except medications allowed by the protocol,Observation,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
32,NCT02177396,Exclusion,concomitant administration of medications known to affect blood pressure ; except medications allowed by the protocol,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
33,NCT02177396,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 am,Observation,Condition,C0555008,night shift workers,FALSE,FALSE,NA,NA,NA
33,NCT02177396,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 am,Observation,Drug,C1654656,daytime,FALSE,FALSE,NA,equal 4 ; equal 00,NA
33,NCT02177396,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 am,Observation,Other,C0037313;C0723362,sleep,FALSE,FALSE,NA,NA,NA
34,NCT02177396,Exclusion,patients receiving any investigational therapy within one month of signing the informed consent form,Procedure,Procedure,C0949266,investigational therapy,FALSE,FALSE,NA,NA,NA
34,NCT02177396,Exclusion,patients receiving any investigational therapy within one month of signing the informed consent form,Procedure,Other,C0009797,informed consent form,FALSE,FALSE,NA,NA,NA
35,NCT02177396,Exclusion,note that patients who have participated in previous micardis ( telmisartan ) studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study,Drug Exposure,Drug,C0721704,micardis,FALSE,FALSE,NA,NA,NA
35,NCT02177396,Exclusion,note that patients who have participated in previous micardis ( telmisartan ) studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study,Drug Exposure,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,NA
35,NCT02177396,Exclusion,note that patients who have participated in previous micardis ( telmisartan ) studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study,Drug Exposure,Observation,C0947630,studies,FALSE,FALSE,NA,NA,NA
35,NCT02177396,Exclusion,note that patients who have participated in previous micardis ( telmisartan ) studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study,Drug Exposure,Other,C1317574;C1316572,note,FALSE,FALSE,NA,NA,NA
36,NCT02177396,Exclusion,known hypersensitivity to any component of the formulations,Observation,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
37,NCT02177396,Exclusion,any clinical condition which ; in the opinion of the investigator ; would not allow safe completion of the protocol and safe administration of trial medication,Other,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
1,NCT02177409,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure ( bp ) of > = 95 mm hg and < = 114 mm hg ; measured by manual cuff sphygmomanometer ; on the last visit ( visit 6 ) of the four-week placebo run-in period ( baseline bp ),Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
1,NCT02177409,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure ( bp ) of > = 95 mm hg and < = 114 mm hg ; measured by manual cuff sphygmomanometer ; on the last visit ( visit 6 ) of the four-week placebo run-in period ( baseline bp ),Observation,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,NA
1,NCT02177409,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure ( bp ) of > = 95 mm hg and < = 114 mm hg ; measured by manual cuff sphygmomanometer ; on the last visit ( visit 6 ) of the four-week placebo run-in period ( baseline bp ),Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT02177409,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure ( bp ) of > = 95 mm hg and < = 114 mm hg ; measured by manual cuff sphygmomanometer ; on the last visit ( visit 6 ) of the four-week placebo run-in period ( baseline bp ),Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,NA,NA
1,NCT02177409,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure ( bp ) of > = 95 mm hg and < = 114 mm hg ; measured by manual cuff sphygmomanometer ; on the last visit ( visit 6 ) of the four-week placebo run-in period ( baseline bp ),Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,greater_equal 95 mm hg; lower_equal 114 mm hg,NA
1,NCT02177409,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure ( bp ) of > = 95 mm hg and < = 114 mm hg ; measured by manual cuff sphygmomanometer ; on the last visit ( visit 6 ) of the four-week placebo run-in period ( baseline bp ),Observation,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
1,NCT02177409,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure ( bp ) of > = 95 mm hg and < = 114 mm hg ; measured by manual cuff sphygmomanometer ; on the last visit ( visit 6 ) of the four-week placebo run-in period ( baseline bp ),Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,NA,NA
1,NCT02177409,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure ( bp ) of > = 95 mm hg and < = 114 mm hg ; measured by manual cuff sphygmomanometer ; on the last visit ( visit 6 ) of the four-week placebo run-in period ( baseline bp ),Observation,Other,C1547225,mild,FALSE,FALSE,NA,NA,NA
1,NCT02177409,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure ( bp ) of > = 95 mm hg and < = 114 mm hg ; measured by manual cuff sphygmomanometer ; on the last visit ( visit 6 ) of the four-week placebo run-in period ( baseline bp ),Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT02177409,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure ( bp ) of > = 95 mm hg and < = 114 mm hg ; measured by manual cuff sphygmomanometer ; on the last visit ( visit 6 ) of the four-week placebo run-in period ( baseline bp ),Observation,Other,C0024763,manual,FALSE,FALSE,NA,NA,NA
2,NCT02177409,Inclusion,mean seated systolic blood pressure > = 140 mm hg and < = 200 mm hg ; measured by manual cuff at visit 6 ( baseline bp ),Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
2,NCT02177409,Inclusion,mean seated systolic blood pressure > = 140 mm hg and < = 200 mm hg ; measured by manual cuff at visit 6 ( baseline bp ),Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater_equal 140 mm hg; lower_equal 200 mm hg,NA
2,NCT02177409,Inclusion,mean seated systolic blood pressure > = 140 mm hg and < = 200 mm hg ; measured by manual cuff at visit 6 ( baseline bp ),Observation,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
2,NCT02177409,Inclusion,mean seated systolic blood pressure > = 140 mm hg and < = 200 mm hg ; measured by manual cuff at visit 6 ( baseline bp ),Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,NA,NA
2,NCT02177409,Inclusion,mean seated systolic blood pressure > = 140 mm hg and < = 200 mm hg ; measured by manual cuff at visit 6 ( baseline bp ),Observation,Other,C0024763,manual,FALSE,FALSE,NA,NA,NA
3,NCT02177409,Inclusion,a 24 - hour mean abpm measurement of > = 130 / 85 mm hg evaluated at visit 7 ( baseline abpm ),Observation,NA,NA,NA,NA,NA,NA,NA,NA
4,NCT02177409,Inclusion,age 18 or older,Person,NA,NA,NA,NA,NA,NA,NA,NA
5,NCT02177409,Inclusion,ability to provide written informed consent,Other,NA,NA,NA,NA,NA,NA,NA,NA
6,NCT02177409,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to start of screening ) :,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
6,NCT02177409,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to start of screening ) :,Condition Occurrence,Condition,C1096235,pre-menopausal,FALSE,FALSE,NA,NA,NA
6,NCT02177409,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to start of screening ) :,Condition Occurrence,Condition,C0025344;C2129647,menstruation,FALSE,FALSE,lower_equal 1 year,NA,NA
7,NCT02177409,Exclusion,who are not surgically sterile ( hysterectomy ; tubal ligation ),Procedure,Procedure,C0020699;C1548863,hysterectomy,TRUE,FALSE,NA,NA,NA
7,NCT02177409,Exclusion,who are not surgically sterile ( hysterectomy ; tubal ligation ),Procedure,Procedure,C0520483,tubal ligation,FALSE,FALSE,NA,NA,NA
8,NCT02177409,Exclusion,who are not practicing acceptable means of birth control or who do not plan to continue using an acceptable method throughout the study,Condition Occurrence,Other,C0700589;C2703065,birth control,TRUE,FALSE,NA,NA,NA
8,NCT02177409,Exclusion,who are not practicing acceptable means of birth control or who do not plan to continue using an acceptable method throughout the study,Condition Occurrence,Other,C2827714;C0871511;C2828387,method,FALSE,FALSE,NA,NA,NA
9,NCT02177409,Exclusion,any women :,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
10,NCT02177409,Exclusion,who has a positive serum pregnancy test at screening ( visit 1 ) or baseline ( visit 7 ),Observation,Observation,C1514241,positive,FALSE,FALSE,NA,NA,NA
10,NCT02177409,Exclusion,who has a positive serum pregnancy test at screening ( visit 1 ) or baseline ( visit 7 ),Observation,Observation,C0430064,serum pregnancy test,FALSE,FALSE,NA,NA,NA
11,NCT02177409,Exclusion,who is nursing,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
12,NCT02177409,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters,Condition Occurrence,Condition,C0086565,hepatic dysfunction,FALSE,FALSE,NA,NA,NA
12,NCT02177409,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters,Condition Occurrence,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
12,NCT02177409,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters,Condition Occurrence,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
12,NCT02177409,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
13,NCT02177409,Exclusion,sgpt ( alt ) ( serum glutamate pyruvate transaminase ) or sgot ( ast ) ( serum glutamate oxaloacetate transaminase ) greater than two times the upper limit of normal,Observation,Drug,C0376147,serum glutamate pyruvate transaminase,FALSE,FALSE,NA,NA,NA
13,NCT02177409,Exclusion,sgpt ( alt ) ( serum glutamate pyruvate transaminase ) or sgot ( ast ) ( serum glutamate oxaloacetate transaminase ) greater than two times the upper limit of normal,Observation,Drug,C0004002,glutamate oxaloacetate transaminase,FALSE,FALSE,NA,NA,NA
13,NCT02177409,Exclusion,sgpt ( alt ) ( serum glutamate pyruvate transaminase ) or sgot ( ast ) ( serum glutamate oxaloacetate transaminase ) greater than two times the upper limit of normal,Observation,Observation,C0376147;C0036828,sgpt,FALSE,FALSE,NA,NA,NA
13,NCT02177409,Exclusion,sgpt ( alt ) ( serum glutamate pyruvate transaminase ) or sgot ( ast ) ( serum glutamate oxaloacetate transaminase ) greater than two times the upper limit of normal,Observation,Observation,C1140170;C2257651,alt,FALSE,FALSE,NA,NA,NA
13,NCT02177409,Exclusion,sgpt ( alt ) ( serum glutamate pyruvate transaminase ) or sgot ( ast ) ( serum glutamate oxaloacetate transaminase ) greater than two times the upper limit of normal,Observation,Observation,C0242192;C0201899,sgot,FALSE,FALSE,NA,NA,NA
13,NCT02177409,Exclusion,sgpt ( alt ) ( serum glutamate pyruvate transaminase ) or sgot ( ast ) ( serum glutamate oxaloacetate transaminase ) greater than two times the upper limit of normal,Observation,Observation,C0004002,ast,FALSE,FALSE,NA,NA,NA
13,NCT02177409,Exclusion,sgpt ( alt ) ( serum glutamate pyruvate transaminase ) or sgot ( ast ) ( serum glutamate oxaloacetate transaminase ) greater than two times the upper limit of normal,Observation,Other,C0229671;C1546774;C1550100,serum,FALSE,FALSE,NA,NA,NA
14,NCT02177409,Exclusion,serum creatinine > 2.3 mg / dl,Drug Exposure,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,NA,greater 2.3 mg/dl
15,NCT02177409,Exclusion,at screening ( visit 1 ) : clinically relevant sodium depletion ; hyperkalemia ; or hypokalemia,Condition Occurrence,Condition,C0020625,sodium depletion,FALSE,FALSE,NA,NA,NA
15,NCT02177409,Exclusion,at screening ( visit 1 ) : clinically relevant sodium depletion ; hyperkalemia ; or hypokalemia,Condition Occurrence,Condition,C0020621,hypokalemia,FALSE,FALSE,NA,NA,NA
15,NCT02177409,Exclusion,at screening ( visit 1 ) : clinically relevant sodium depletion ; hyperkalemia ; or hypokalemia,Condition Occurrence,Condition,C0020461,hyperkalemia,FALSE,FALSE,NA,NA,NA
16,NCT02177409,Exclusion,known or suspected secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
17,NCT02177409,Exclusion,bilateral renal artery stenosis,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
18,NCT02177409,Exclusion,renal artery stenosis in a solitary kidney,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
18,NCT02177409,Exclusion,renal artery stenosis in a solitary kidney,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
19,NCT02177409,Exclusion,post-renal transplant patients ; presence of only one functioning kidney,Condition Occurrence,Condition,C0478647,transplant,FALSE,FALSE,NA,NA,NA
19,NCT02177409,Exclusion,post-renal transplant patients ; presence of only one functioning kidney,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
20,NCT02177409,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) class chf iii-,Condition Occurrence,Condition,C0018802,congestive heart failure chf,FALSE,FALSE,NA,NA,NA
20,NCT02177409,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) class chf iii-,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
20,NCT02177409,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) class chf iii-,Condition Occurrence,Condition,C0018802,chf,FALSE,FALSE,NA,NA,NA
20,NCT02177409,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) class chf iii-,Condition Occurrence,Other,C0456387;C0489477,class,FALSE,FALSE,NA,NA,NA
20,NCT02177409,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) class chf iii-,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii-,FALSE,FALSE,NA,NA,NA
21,NCT02177409,Exclusion,unstable angina within the past three months,Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,NA,NA,NA
22,NCT02177409,Exclusion,stroke within the past six months,Other,NA,NA,NA,NA,NA,NA,NA,NA
23,NCT02177409,Exclusion,myocardial infarction or cardiac surgery within the past three months,Condition Occurrence,Procedure,C0018821,cardiac surgery,FALSE,FALSE,NA,NA,NA
23,NCT02177409,Exclusion,myocardial infarction or cardiac surgery within the past three months,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
24,NCT02177409,Exclusion,ptca ( percutaneous transluminal coronary angioplasty ) within the past three months,Procedure,Procedure,C2936173;C0002997,ptca,FALSE,FALSE,NA,NA,NA
24,NCT02177409,Exclusion,ptca ( percutaneous transluminal coronary angioplasty ) within the past three months,Procedure,Procedure,C2936173,percutaneous transluminal coronary angioplasty,FALSE,FALSE,NA,NA,NA
25,NCT02177409,Exclusion,history of angioedema,Condition Occurrence,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
26,NCT02177409,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0750197,sustained ventricular tachycardia,FALSE,FALSE,NA,NA,NA
26,NCT02177409,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0004239;C1963068,atrial flutter,FALSE,FALSE,NA,NA,NA
26,NCT02177409,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0003811,cardiac arrhythmias,FALSE,FALSE,NA,NA,NA
26,NCT02177409,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
27,NCT02177409,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0007194,hypertrophic obstructive cardiomyopathy,FALSE,FALSE,NA,NA,NA
27,NCT02177409,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0003507,aortic stenosis,FALSE,FALSE,NA,NA,NA
27,NCT02177409,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0003501;C1269005,aortic valve,FALSE,FALSE,NA,NA,NA
27,NCT02177409,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0026264;C1269004,mitral valve,FALSE,FALSE,NA,NA,NA
27,NCT02177409,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Observation,C1261287;C0947637;C0009814,stenosis,FALSE,FALSE,NA,NA,NA
28,NCT02177409,Exclusion,administration of digoxin or other digitalis-type drugs,Drug Exposure,Drug,C0304520,digitalis,FALSE,FALSE,NA,NA,NA
28,NCT02177409,Exclusion,administration of digoxin or other digitalis-type drugs,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
28,NCT02177409,Exclusion,administration of digoxin or other digitalis-type drugs,Drug Exposure,Other,C0337449;C0012265,digoxin,FALSE,FALSE,NA,NA,NA
29,NCT02177409,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > = 10 %,Condition Occurrence,Condition,C0011854,insulin-dependent diabetes mellitus,FALSE,FALSE,NA,NA,NA
29,NCT02177409,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > = 10 %,Condition Occurrence,Condition,C0011849;C0011847,diabetes,FALSE,FALSE,NA,NA,NA
29,NCT02177409,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > = 10 %,Condition Occurrence,Observation,C0202054,hba1c,FALSE,FALSE,NA,NA,greater_equal 10 %
29,NCT02177409,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > = 10 %,Condition Occurrence,Other,C1547311,stable,TRUE,FALSE,NA,NA,NA
29,NCT02177409,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > = 10 %,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
30,NCT02177409,Exclusion,known drug or alcohol dependency within the past one year period,Condition Occurrence,Condition,C0001973,alcohol dependency,FALSE,FALSE,NA,NA,NA
30,NCT02177409,Exclusion,known drug or alcohol dependency within the past one year period,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
31,NCT02177409,Exclusion,concomitant administration of medications known to affect blood pressure ; except medications allowed by the protocol,Observation,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
31,NCT02177409,Exclusion,concomitant administration of medications known to affect blood pressure ; except medications allowed by the protocol,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
32,NCT02177409,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 am ( ante meridian ),Observation,Condition,C0555008,night shift workers,FALSE,FALSE,NA,NA,NA
32,NCT02177409,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 am ( ante meridian ),Observation,Drug,C1654656,daytime,FALSE,FALSE,NA,equal 4 ; equal 00,NA
32,NCT02177409,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 am ( ante meridian ),Observation,Other,C0037313;C0723362,sleep,FALSE,FALSE,NA,NA,NA
33,NCT02177409,Exclusion,patients receiving any investigational therapy within one month of signing the informed consent form,Procedure,Procedure,C0949266,investigational therapy,FALSE,FALSE,NA,NA,NA
33,NCT02177409,Exclusion,patients receiving any investigational therapy within one month of signing the informed consent form,Procedure,Other,C0009797,informed consent form,FALSE,FALSE,NA,NA,NA
34,NCT02177409,Exclusion,note that patients who have participated in previous micardis ( telmisartan ) studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study,Drug Exposure,Drug,C0721704,micardis,FALSE,FALSE,NA,NA,NA
34,NCT02177409,Exclusion,note that patients who have participated in previous micardis ( telmisartan ) studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study,Drug Exposure,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,NA
34,NCT02177409,Exclusion,note that patients who have participated in previous micardis ( telmisartan ) studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study,Drug Exposure,Observation,C0947630,studies,FALSE,FALSE,NA,NA,NA
34,NCT02177409,Exclusion,note that patients who have participated in previous micardis ( telmisartan ) studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study,Drug Exposure,Other,C1317574;C1316572,note,FALSE,FALSE,NA,NA,NA
35,NCT02177409,Exclusion,known hypersensitivity to any component of the formulations,Observation,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
36,NCT02177409,Exclusion,any clinical condition which ; in the opinion of the investigator would not allow safe completion of the protocol and safe administration of trial medication,Other,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
1,NCT02177435,Inclusion,history of mild-to-moderate hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT02177435,Inclusion,history of mild-to-moderate hypertension,Observation,Other,C1547225,mild,FALSE,FALSE,NA,NA,NA
2,NCT02177435,Inclusion,patients who fail to respond adequately to telmisartan monotherapy,Drug Exposure,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,NA
3,NCT02177435,Inclusion,participants between 18 and 80 years of age,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 18 years; lower_equal 80 years,NA,NA
4,NCT02177435,Inclusion,ability to provide written informed consent,Other,NA,NA,NA,NA,NA,NA,NA,NA
5,NCT02177435,Exclusion,patients taking more than three anti-hypertensive medications at the screening visit,Drug Exposure,Drug,C0003364,anti-hypertensive,FALSE,FALSE,NA,NA,NA
6,NCT02177435,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to start of screening ),Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
6,NCT02177435,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to start of screening ),Condition Occurrence,Condition,C1096235,pre-menopausal,FALSE,FALSE,NA,NA,NA
6,NCT02177435,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to start of screening ),Condition Occurrence,Condition,C0025344;C2129647,menstruation,FALSE,FALSE,lower_equal 1 year,NA,NA
7,NCT02177435,Exclusion,who are not surgically sterile ( hysterectomy ; tubal ligation ),Procedure,Procedure,C0020699;C1548863,hysterectomy,TRUE,FALSE,NA,NA,NA
7,NCT02177435,Exclusion,who are not surgically sterile ( hysterectomy ; tubal ligation ),Procedure,Procedure,C0520483,tubal ligation,FALSE,FALSE,NA,NA,NA
8,NCT02177435,Exclusion,who are not practicing acceptable means of birth control or who do not plan to continue using an acceptable method throughout the study,Condition Occurrence,Other,C0700589;C2703065,birth control,TRUE,FALSE,NA,NA,NA
8,NCT02177435,Exclusion,who are not practicing acceptable means of birth control or who do not plan to continue using an acceptable method throughout the study,Condition Occurrence,Other,C2827714;C0871511;C2828387,method,FALSE,FALSE,NA,NA,NA
9,NCT02177435,Exclusion,any women :,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
10,NCT02177435,Exclusion,who has a positive serum pregnancy test at screening ( visit 1 ) or baseline ( visit 4 ),Observation,Observation,C1514241,positive,FALSE,FALSE,NA,NA,NA
11,NCT02177435,Exclusion,who is nursing,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
12,NCT02177435,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Condition,C0086565,hepatic dysfunction,FALSE,FALSE,NA,NA,NA
12,NCT02177435,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
12,NCT02177435,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
12,NCT02177435,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
13,NCT02177435,Exclusion,sgpt ( alt ) ( serum glutamate pyruvate transaminase ) or sgot ( ast ) ( serum glutamate oxaloacetate transaminase ) greater than two times the upper limit of normal,Observation,Drug,C0376147,serum glutamate pyruvate transaminase,FALSE,FALSE,NA,NA,NA
13,NCT02177435,Exclusion,sgpt ( alt ) ( serum glutamate pyruvate transaminase ) or sgot ( ast ) ( serum glutamate oxaloacetate transaminase ) greater than two times the upper limit of normal,Observation,Drug,C0004002,glutamate oxaloacetate transaminase,FALSE,FALSE,NA,NA,NA
13,NCT02177435,Exclusion,sgpt ( alt ) ( serum glutamate pyruvate transaminase ) or sgot ( ast ) ( serum glutamate oxaloacetate transaminase ) greater than two times the upper limit of normal,Observation,Observation,C0376147;C0036828,sgpt,FALSE,FALSE,NA,NA,NA
13,NCT02177435,Exclusion,sgpt ( alt ) ( serum glutamate pyruvate transaminase ) or sgot ( ast ) ( serum glutamate oxaloacetate transaminase ) greater than two times the upper limit of normal,Observation,Observation,C1140170;C2257651,alt,FALSE,FALSE,NA,NA,NA
13,NCT02177435,Exclusion,sgpt ( alt ) ( serum glutamate pyruvate transaminase ) or sgot ( ast ) ( serum glutamate oxaloacetate transaminase ) greater than two times the upper limit of normal,Observation,Observation,C0242192;C0201899,sgot,FALSE,FALSE,NA,NA,NA
13,NCT02177435,Exclusion,sgpt ( alt ) ( serum glutamate pyruvate transaminase ) or sgot ( ast ) ( serum glutamate oxaloacetate transaminase ) greater than two times the upper limit of normal,Observation,Observation,C0004002,ast,FALSE,FALSE,NA,NA,NA
13,NCT02177435,Exclusion,sgpt ( alt ) ( serum glutamate pyruvate transaminase ) or sgot ( ast ) ( serum glutamate oxaloacetate transaminase ) greater than two times the upper limit of normal,Observation,Other,C0229671;C1546774;C1550100,serum,FALSE,FALSE,NA,NA,NA
14,NCT02177435,Exclusion,serum creatinine > 2.3 mg / dl,Observation,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,NA,greater 2.3 mg/dl
15,NCT02177435,Exclusion,clinically relevant sodium depletion ; hyperkalemia ; or hypokalemia at baseline,Condition Occurrence,Condition,C0020625,sodium depletion,FALSE,FALSE,NA,NA,NA
15,NCT02177435,Exclusion,clinically relevant sodium depletion ; hyperkalemia ; or hypokalemia at baseline,Condition Occurrence,Condition,C0020621,hypokalemia,FALSE,FALSE,NA,NA,NA
15,NCT02177435,Exclusion,clinically relevant sodium depletion ; hyperkalemia ; or hypokalemia at baseline,Condition Occurrence,Condition,C0020461,hyperkalemia,FALSE,FALSE,NA,NA,NA
16,NCT02177435,Exclusion,known or suspected secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
17,NCT02177435,Exclusion,bilateral renal artery stenosis,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
18,NCT02177435,Exclusion,renal artery stenosis in a solitary kidney,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
18,NCT02177435,Exclusion,renal artery stenosis in a solitary kidney,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
19,NCT02177435,Exclusion,post-renal transplant patients ; presence of only one functioning kidney,Condition Occurrence,Condition,C0478647,transplant,FALSE,FALSE,NA,NA,NA
10,NCT02177435,Exclusion,who has a positive serum pregnancy test at screening ( visit 1 ) or baseline ( visit 4 ),Observation,Observation,C0430064,serum pregnancy test,FALSE,FALSE,NA,NA,NA
19,NCT02177435,Exclusion,post-renal transplant patients ; presence of only one functioning kidney,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
20,NCT02177435,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) class chf iii-,Condition Occurrence,Condition,C0018802,congestive heart failure chf,FALSE,FALSE,NA,NA,NA
20,NCT02177435,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) class chf iii-,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
20,NCT02177435,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) class chf iii-,Condition Occurrence,Condition,C0018802,chf,FALSE,FALSE,NA,NA,NA
20,NCT02177435,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) class chf iii-,Condition Occurrence,Other,C0456387;C0489477,class,FALSE,FALSE,NA,NA,NA
20,NCT02177435,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) class chf iii-,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii-,FALSE,FALSE,NA,NA,NA
21,NCT02177435,Exclusion,unstable angina within the past three months,Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,NA,NA,NA
22,NCT02177435,Exclusion,stroke within the past six months,Other,NA,NA,NA,NA,NA,NA,NA,NA
23,NCT02177435,Exclusion,myocardial infarction or cardiac surgery within the past three months,Condition Occurrence,Procedure,C0018821,cardiac surgery,FALSE,FALSE,NA,NA,NA
23,NCT02177435,Exclusion,myocardial infarction or cardiac surgery within the past three months,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
24,NCT02177435,Exclusion,ptca ( percutaneous transluminal coronary angioplasty ) within the past three months,Procedure,Procedure,C2936173;C0002997,ptca,FALSE,FALSE,NA,NA,NA
24,NCT02177435,Exclusion,ptca ( percutaneous transluminal coronary angioplasty ) within the past three months,Procedure,Procedure,C2936173,percutaneous transluminal coronary angioplasty,FALSE,FALSE,NA,NA,NA
25,NCT02177435,Exclusion,history of angioedema,Condition Occurrence,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
26,NCT02177435,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0750197,sustained ventricular tachycardia,FALSE,FALSE,NA,NA,NA
26,NCT02177435,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0004239;C1963068,atrial flutter,FALSE,FALSE,NA,NA,NA
26,NCT02177435,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0003811,cardiac arrhythmias,FALSE,FALSE,NA,NA,NA
26,NCT02177435,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
27,NCT02177435,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0007194,hypertrophic obstructive cardiomyopathy,FALSE,FALSE,NA,NA,NA
27,NCT02177435,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0003507,aortic stenosis,FALSE,FALSE,NA,NA,NA
27,NCT02177435,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0003501;C1269005,aortic valve,FALSE,FALSE,NA,NA,NA
27,NCT02177435,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0026264;C1269004,mitral valve,FALSE,FALSE,NA,NA,NA
27,NCT02177435,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Observation,C1261287;C0947637;C0009814,stenosis,FALSE,FALSE,NA,NA,NA
28,NCT02177435,Exclusion,administration of digoxin or other digitalis-type drugs,Drug Exposure,Drug,C0304520,digitalis,FALSE,FALSE,NA,NA,NA
28,NCT02177435,Exclusion,administration of digoxin or other digitalis-type drugs,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
28,NCT02177435,Exclusion,administration of digoxin or other digitalis-type drugs,Drug Exposure,Other,C0337449;C0012265,digoxin,FALSE,FALSE,NA,NA,NA
29,NCT02177435,Exclusion,patients with insulin treated type ii diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > = 10 %,Condition Occurrence,Condition,C0342266,insulin treated type ii diabetes mellitus,FALSE,FALSE,NA,NA,NA
29,NCT02177435,Exclusion,patients with insulin treated type ii diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > = 10 %,Condition Occurrence,Condition,C0011849;C0011847,diabetes,FALSE,FALSE,NA,NA,NA
29,NCT02177435,Exclusion,patients with insulin treated type ii diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > = 10 %,Condition Occurrence,Observation,C0202054,hba1c,FALSE,FALSE,NA,NA,greater_equal 10 %
29,NCT02177435,Exclusion,patients with insulin treated type ii diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > = 10 %,Condition Occurrence,Other,C1547311,stable,TRUE,FALSE,NA,NA,NA
29,NCT02177435,Exclusion,patients with insulin treated type ii diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > = 10 %,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
30,NCT02177435,Exclusion,known drug or alcohol dependency within the past one year period,Condition Occurrence,Condition,C0001973,alcohol dependency,FALSE,FALSE,NA,NA,NA
30,NCT02177435,Exclusion,known drug or alcohol dependency within the past one year period,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
31,NCT02177435,Exclusion,concomitant administration of medications known to affect blood pressure ; except medications allowed by the protocol,Observation,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
31,NCT02177435,Exclusion,concomitant administration of medications known to affect blood pressure ; except medications allowed by the protocol,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
32,NCT02177435,Exclusion,patients receiving any investigational therapy within one month of signing the informed consent form,Procedure,Procedure,C0949266,investigational therapy,FALSE,FALSE,NA,NA,NA
32,NCT02177435,Exclusion,patients receiving any investigational therapy within one month of signing the informed consent form,Procedure,Other,C0009797,informed consent form,FALSE,FALSE,NA,NA,NA
33,NCT02177435,Exclusion,patients who have participated in previous telmisartan studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study,Observation,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,NA
33,NCT02177435,Exclusion,patients who have participated in previous telmisartan studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study,Observation,Observation,C0947630,studies,FALSE,FALSE,NA,NA,NA
34,NCT02177435,Exclusion,known hypersensitivity to any component of the formulations,Observation,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
35,NCT02177435,Exclusion,any clinical condition which ; in the opinion of the investigator ; would not allow safe completion of the protocol and safe administration of trial medication,Other,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
1,NCT02177461,Inclusion,age > = 65 years,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 65 years,NA,NA
2,NCT02177461,Inclusion,sitting systolic blood pressure ( sbp ) > = 160 mmhg and any diastolic blood pressure ( dbp ) ( safety maximum of sitting dbp 110 mmhg ) ; measured by manual cuff sphygmomanometer at the end of the wash-out period,Observation,Condition,C1319893,sitting systolic blood pressure,FALSE,FALSE,NA,NA,NA
2,NCT02177461,Inclusion,sitting systolic blood pressure ( sbp ) > = 160 mmhg and any diastolic blood pressure ( dbp ) ( safety maximum of sitting dbp 110 mmhg ) ; measured by manual cuff sphygmomanometer at the end of the wash-out period,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
2,NCT02177461,Inclusion,sitting systolic blood pressure ( sbp ) > = 160 mmhg and any diastolic blood pressure ( dbp ) ( safety maximum of sitting dbp 110 mmhg ) ; measured by manual cuff sphygmomanometer at the end of the wash-out period,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
2,NCT02177461,Inclusion,sitting systolic blood pressure ( sbp ) > = 160 mmhg and any diastolic blood pressure ( dbp ) ( safety maximum of sitting dbp 110 mmhg ) ; measured by manual cuff sphygmomanometer at the end of the wash-out period,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 160 mmhg,NA
2,NCT02177461,Inclusion,sitting systolic blood pressure ( sbp ) > = 160 mmhg and any diastolic blood pressure ( dbp ) ( safety maximum of sitting dbp 110 mmhg ) ; measured by manual cuff sphygmomanometer at the end of the wash-out period,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,NA,NA
2,NCT02177461,Inclusion,sitting systolic blood pressure ( sbp ) > = 160 mmhg and any diastolic blood pressure ( dbp ) ( safety maximum of sitting dbp 110 mmhg ) ; measured by manual cuff sphygmomanometer at the end of the wash-out period,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,NA,NA
2,NCT02177461,Inclusion,sitting systolic blood pressure ( sbp ) > = 160 mmhg and any diastolic blood pressure ( dbp ) ( safety maximum of sitting dbp 110 mmhg ) ; measured by manual cuff sphygmomanometer at the end of the wash-out period,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,equal 110 mmhg,NA
2,NCT02177461,Inclusion,sitting systolic blood pressure ( sbp ) > = 160 mmhg and any diastolic blood pressure ( dbp ) ( safety maximum of sitting dbp 110 mmhg ) ; measured by manual cuff sphygmomanometer at the end of the wash-out period,Observation,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
2,NCT02177461,Inclusion,sitting systolic blood pressure ( sbp ) > = 160 mmhg and any diastolic blood pressure ( dbp ) ( safety maximum of sitting dbp 110 mmhg ) ; measured by manual cuff sphygmomanometer at the end of the wash-out period,Observation,Other,C0024763,manual,FALSE,FALSE,NA,NA,NA
2,NCT02177461,Inclusion,sitting systolic blood pressure ( sbp ) > = 160 mmhg and any diastolic blood pressure ( dbp ) ( safety maximum of sitting dbp 110 mmhg ) ; measured by manual cuff sphygmomanometer at the end of the wash-out period,Observation,Other,C1547959;C2699154;C1883550,wash,FALSE,FALSE,NA,NA,NA
3,NCT02177461,Inclusion,written informed consent,Other,NA,NA,NA,NA,NA,NA,NA,NA
4,NCT02177461,Exclusion,secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
5,NCT02177461,Exclusion,malignant hypertension ( retinal haemorrhage ; exudates or papillary oedema ),Condition Occurrence,Condition,C0020540;C0024588,malignant hypertension,FALSE,FALSE,NA,NA,NA
5,NCT02177461,Exclusion,malignant hypertension ( retinal haemorrhage ; exudates or papillary oedema ),Condition Occurrence,Condition,C0035317,retinal haemorrhage,FALSE,FALSE,NA,NA,NA
6,NCT02177461,Exclusion,clinically significant sodium depletion as defined by serum sodium level < 130 meq / l hyperkaliemia ; clinically significant hyperkaliemia as defined by serum potassium level > 5.5 meq / l ; clinically significant hypokaliemia as defined by serum potassium level < 3.0 meq / l,Observation,Condition,C0020625,sodium depletion,FALSE,FALSE,NA,NA,NA
6,NCT02177461,Exclusion,clinically significant sodium depletion as defined by serum sodium level < 130 meq / l hyperkaliemia ; clinically significant hyperkaliemia as defined by serum potassium level > 5.5 meq / l ; clinically significant hypokaliemia as defined by serum potassium level < 3.0 meq / l,Observation,Observation,C0587356;C0523891,serum sodium level,FALSE,FALSE,NA,lower 130,NA
6,NCT02177461,Exclusion,clinically significant sodium depletion as defined by serum sodium level < 130 meq / l hyperkaliemia ; clinically significant hyperkaliemia as defined by serum potassium level > 5.5 meq / l ; clinically significant hypokaliemia as defined by serum potassium level < 3.0 meq / l,Observation,Observation,C0543465;C0302353,serum potassium level,FALSE,FALSE,NA,greater 5.5,NA
6,NCT02177461,Exclusion,clinically significant sodium depletion as defined by serum sodium level < 130 meq / l hyperkaliemia ; clinically significant hyperkaliemia as defined by serum potassium level > 5.5 meq / l ; clinically significant hypokaliemia as defined by serum potassium level < 3.0 meq / l,Observation,Observation,C0543465;C0302353,serum potassium level,FALSE,FALSE,NA,lower 3.0,NA
6,NCT02177461,Exclusion,clinically significant sodium depletion as defined by serum sodium level < 130 meq / l hyperkaliemia ; clinically significant hyperkaliemia as defined by serum potassium level > 5.5 meq / l ; clinically significant hypokaliemia as defined by serum potassium level < 3.0 meq / l,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
6,NCT02177461,Exclusion,clinically significant sodium depletion as defined by serum sodium level < 130 meq / l hyperkaliemia ; clinically significant hyperkaliemia as defined by serum potassium level > 5.5 meq / l ; clinically significant hypokaliemia as defined by serum potassium level < 3.0 meq / l,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
6,NCT02177461,Exclusion,clinically significant sodium depletion as defined by serum sodium level < 130 meq / l hyperkaliemia ; clinically significant hyperkaliemia as defined by serum potassium level > 5.5 meq / l ; clinically significant hypokaliemia as defined by serum potassium level < 3.0 meq / l,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
7,NCT02177461,Exclusion,atrial fibrillation or frequent ventricular ectopic beats or other arrhythmias which could interfere with the cardiac rhythm,Condition Occurrence,Condition,C0151636,ventricular ectopic beats,FALSE,FALSE,NA,NA,NA
7,NCT02177461,Exclusion,atrial fibrillation or frequent ventricular ectopic beats or other arrhythmias which could interfere with the cardiac rhythm,Condition Occurrence,Condition,C0003811,arrhythmias,FALSE,FALSE,NA,NA,NA
7,NCT02177461,Exclusion,atrial fibrillation or frequent ventricular ectopic beats or other arrhythmias which could interfere with the cardiac rhythm,Condition Occurrence,Condition,C0232187,cardiac rhythm,FALSE,FALSE,NA,NA,NA
7,NCT02177461,Exclusion,atrial fibrillation or frequent ventricular ectopic beats or other arrhythmias which could interfere with the cardiac rhythm,Condition Occurrence,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
8,NCT02177461,Exclusion,heart rate < 50 bpm,Observation,Observation,C0018810;C2197023;C2041121;C0488794,heart rate,FALSE,FALSE,NA,lower 50,NA
8,NCT02177461,Exclusion,heart rate < 50 bpm,Observation,Other,C0053672;C1706504,bpm,FALSE,FALSE,NA,NA,NA
9,NCT02177461,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) functional class chf iii-,Condition Occurrence,Condition,C0018802,congestive heart failure chf,FALSE,FALSE,NA,NA,NA
9,NCT02177461,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) functional class chf iii-,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
9,NCT02177461,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) functional class chf iii-,Condition Occurrence,Condition,C0018802,chf,FALSE,FALSE,NA,NA,NA
9,NCT02177461,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) functional class chf iii-,Condition Occurrence,Other,C0456387;C0489477,class,FALSE,FALSE,NA,NA,NA
9,NCT02177461,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) functional class chf iii-,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii-,FALSE,FALSE,NA,NA,NA
10,NCT02177461,Exclusion,angina pectoris or myocardial infarction,Condition Occurrence,Condition,C0002962;C0577698;C0235467;C0542052;C0010073;C0541777;C0235462,angina pectoris,FALSE,FALSE,NA,NA,NA
10,NCT02177461,Exclusion,angina pectoris or myocardial infarction,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
11,NCT02177461,Exclusion,cardiac surgery within the past 3 months prior to start the wash-out period,Drug Exposure,Procedure,C0018821,cardiac surgery,FALSE,FALSE,lower 3 past months,NA,NA
11,NCT02177461,Exclusion,cardiac surgery within the past 3 months prior to start the wash-out period,Drug Exposure,Other,C1547959;C2699154;C1883550,wash,FALSE,FALSE,NA,NA,NA
12,NCT02177461,Exclusion,stroke within the past 6 months prior to start the wash-out period,Drug Exposure,Other,C1547959;C2699154;C1883550,wash,FALSE,FALSE,lower 6 past months,NA,NA
13,NCT02177461,Exclusion,renal insufficiency defined as creatininaemia > 2 mg / dl,Drug Exposure,Condition,C1565489;C0035078,renal insufficiency,FALSE,FALSE,NA,NA,NA
13,NCT02177461,Exclusion,renal insufficiency defined as creatininaemia > 2 mg / dl,Drug Exposure,Other,C3539106,defined,FALSE,FALSE,NA,NA,greater 2 mg/dl
14,NCT02177461,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post renal transplant,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
14,NCT02177461,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post renal transplant,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
14,NCT02177461,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post renal transplant,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
14,NCT02177461,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post renal transplant,Condition Occurrence,Procedure,C0022671,renal transplant,FALSE,FALSE,NA,NA,NA
15,NCT02177461,Exclusion,liver insufficiency ; defined as bilirubinaemia > 2 mg / dl and ast ( aspartate aminotransferase ) or alt ( alanine-aminotransferase ) > twice the upper normal range,Observation,Condition,C1306571,liver insufficiency,FALSE,FALSE,NA,NA,greater 2 mg/dl
15,NCT02177461,Exclusion,liver insufficiency ; defined as bilirubinaemia > 2 mg / dl and ast ( aspartate aminotransferase ) or alt ( alanine-aminotransferase ) > twice the upper normal range,Observation,Observation,C0004002,ast,FALSE,FALSE,NA,NA,NA
15,NCT02177461,Exclusion,liver insufficiency ; defined as bilirubinaemia > 2 mg / dl and ast ( aspartate aminotransferase ) or alt ( alanine-aminotransferase ) > twice the upper normal range,Observation,Observation,C0004002;C0201899,aspartate aminotransferase,FALSE,FALSE,NA,NA,NA
15,NCT02177461,Exclusion,liver insufficiency ; defined as bilirubinaemia > 2 mg / dl and ast ( aspartate aminotransferase ) or alt ( alanine-aminotransferase ) > twice the upper normal range,Observation,Observation,C1140170;C2257651,alt,FALSE,FALSE,NA,NA,NA
15,NCT02177461,Exclusion,liver insufficiency ; defined as bilirubinaemia > 2 mg / dl and ast ( aspartate aminotransferase ) or alt ( alanine-aminotransferase ) > twice the upper normal range,Observation,Observation,C3542016,range,FALSE,FALSE,NA,NA,NA
15,NCT02177461,Exclusion,liver insufficiency ; defined as bilirubinaemia > 2 mg / dl and ast ( aspartate aminotransferase ) or alt ( alanine-aminotransferase ) > twice the upper normal range,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,greater 2 mg/dl
15,NCT02177461,Exclusion,liver insufficiency ; defined as bilirubinaemia > 2 mg / dl and ast ( aspartate aminotransferase ) or alt ( alanine-aminotransferase ) > twice the upper normal range,Observation,Other,C0001899;C0201836,alanine-aminotransferase,FALSE,FALSE,NA,NA,NA
16,NCT02177461,Exclusion,clinically significant metabolic disease and endocrine disease,Condition Occurrence,Condition,C0025517,metabolic disease,FALSE,FALSE,NA,NA,NA
16,NCT02177461,Exclusion,clinically significant metabolic disease and endocrine disease,Condition Occurrence,Condition,C0014130,endocrine disease,FALSE,FALSE,NA,NA,NA
17,NCT02177461,Exclusion,autoimmune disease,Condition Occurrence,Condition,C0004364,autoimmune disease,FALSE,FALSE,NA,NA,NA
18,NCT02177461,Exclusion,previous history of angioedema,Condition Occurrence,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
19,NCT02177461,Exclusion,body mass index > 30 kg / m2,Observation,Observation,C0005893;C1305855;C2240399,body mass index,FALSE,FALSE,NA,greater 30 kg/m2,NA
20,NCT02177461,Exclusion,arm circumference > 32 cm,Condition Occurrence,Condition,C2075184,arm circumference,FALSE,FALSE,NA,greater 32 cm,NA
21,NCT02177461,Exclusion,any condition that may be likely to compromise the trial ( alcohol or drug abuse ; disability illness ; etc ; ),Condition Occurrence,Condition,C0013146,drug abuse,FALSE,FALSE,NA,NA,NA
21,NCT02177461,Exclusion,any condition that may be likely to compromise the trial ( alcohol or drug abuse ; disability illness ; etc ; ),Condition Occurrence,Condition,C0231170,disability,FALSE,FALSE,NA,NA,NA
21,NCT02177461,Exclusion,any condition that may be likely to compromise the trial ( alcohol or drug abuse ; disability illness ; etc ; ),Condition Occurrence,Other,C0001975;C0001962;C1547288,alcohol,FALSE,FALSE,NA,NA,NA
22,NCT02177461,Exclusion,concomitant therapy with antihypertensive drugs non-permitted by protocol ; or present use of tricyclic antidepressant ; corticosteroids or drugs known to affect blood pressure,Drug Exposure,Drug,C0003364,antihypertensive drugs,FALSE,FALSE,NA,NA,NA
22,NCT02177461,Exclusion,concomitant therapy with antihypertensive drugs non-permitted by protocol ; or present use of tricyclic antidepressant ; corticosteroids or drugs known to affect blood pressure,Drug Exposure,Drug,C0003290;C3536819,tricyclic antidepressant,FALSE,FALSE,NA,NA,NA
22,NCT02177461,Exclusion,concomitant therapy with antihypertensive drugs non-permitted by protocol ; or present use of tricyclic antidepressant ; corticosteroids or drugs known to affect blood pressure,Drug Exposure,Drug,C3540726;C3540725;C3539185;C3540727,corticosteroids,FALSE,FALSE,NA,NA,NA
22,NCT02177461,Exclusion,concomitant therapy with antihypertensive drugs non-permitted by protocol ; or present use of tricyclic antidepressant ; corticosteroids or drugs known to affect blood pressure,Drug Exposure,Procedure,C1707479,concomitant therapy,FALSE,FALSE,NA,NA,NA
22,NCT02177461,Exclusion,concomitant therapy with antihypertensive drugs non-permitted by protocol ; or present use of tricyclic antidepressant ; corticosteroids or drugs known to affect blood pressure,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
22,NCT02177461,Exclusion,concomitant therapy with antihypertensive drugs non-permitted by protocol ; or present use of tricyclic antidepressant ; corticosteroids or drugs known to affect blood pressure,Drug Exposure,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
22,NCT02177461,Exclusion,concomitant therapy with antihypertensive drugs non-permitted by protocol ; or present use of tricyclic antidepressant ; corticosteroids or drugs known to affect blood pressure,Drug Exposure,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
23,NCT02177461,Exclusion,investigational drug treatment within the past 30 days before the enrolment or concurrent participation to any other trial,Drug Exposure,Drug,C0013230,investigational drug,FALSE,FALSE,lower 30 past days,NA,NA
24,NCT02177461,Exclusion,sensitivity ; significant adverse reaction or contraindications to the study drugs ( telmisartan ; enalapril ; clonidine tts ),Drug Exposure,Condition,C0427965,sensitivity,FALSE,FALSE,NA,NA,NA
24,NCT02177461,Exclusion,sensitivity ; significant adverse reaction or contraindications to the study drugs ( telmisartan ; enalapril ; clonidine tts ),Drug Exposure,Condition,C0559546,adverse reaction,FALSE,FALSE,NA,NA,NA
24,NCT02177461,Exclusion,sensitivity ; significant adverse reaction or contraindications to the study drugs ( telmisartan ; enalapril ; clonidine tts ),Drug Exposure,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,NA
24,NCT02177461,Exclusion,sensitivity ; significant adverse reaction or contraindications to the study drugs ( telmisartan ; enalapril ; clonidine tts ),Drug Exposure,Drug,C0009014,clonidine,FALSE,FALSE,NA,NA,NA
24,NCT02177461,Exclusion,sensitivity ; significant adverse reaction or contraindications to the study drugs ( telmisartan ; enalapril ; clonidine tts ),Drug Exposure,Drug,C0014025,enalapril,FALSE,FALSE,NA,NA,NA
24,NCT02177461,Exclusion,sensitivity ; significant adverse reaction or contraindications to the study drugs ( telmisartan ; enalapril ; clonidine tts ),Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
25,NCT02177461,Exclusion,predictable lack of patient co-operation,Other,NA,NA,NA,NA,NA,NA,NA,NA
1,NCT02177500,Inclusion,history of mild-to-moderate hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT02177500,Inclusion,history of mild-to-moderate hypertension,Observation,Other,C1547225,mild,FALSE,FALSE,NA,NA,NA
2,NCT02177500,Inclusion,patients who fail to respond adequately to telmisartan monotherapy,Drug Exposure,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,NA
3,NCT02177500,Inclusion,participants between 18 and 80 years of age,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 18 years; lower_equal 80 years,NA,NA
4,NCT02177500,Inclusion,willingness and ability to provide written informed consent,Other,NA,NA,NA,NA,NA,NA,NA,NA
5,NCT02177500,Exclusion,patients taking more than three anti-hypertensive medications at the screening visit,Drug Exposure,Drug,C0003364,anti-hypertensive,FALSE,FALSE,NA,NA,NA
6,NCT02177500,Exclusion,pre-menopausal women,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
6,NCT02177500,Exclusion,pre-menopausal women,Person,Condition,C1096235,pre-menopausal,FALSE,FALSE,NA,NA,NA
7,NCT02177500,Exclusion,who are not surgically sterile,Other,NA,NA,NA,NA,NA,NA,NA,NA
8,NCT02177500,Exclusion,who are not practicing acceptable means of birth control or who do not plan to continue using an acceptable method throughout the study,Condition Occurrence,Other,C0700589;C2703065,birth control,TRUE,FALSE,NA,NA,NA
8,NCT02177500,Exclusion,who are not practicing acceptable means of birth control or who do not plan to continue using an acceptable method throughout the study,Condition Occurrence,Other,C2827714;C0871511;C2828387,method,FALSE,FALSE,NA,NA,NA
9,NCT02177500,Exclusion,acceptable methods of birth control include intrauterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Drug,C1706306,iud,FALSE,FALSE,NA,NA,NA
9,NCT02177500,Exclusion,acceptable methods of birth control include intrauterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Drug,C0086466;C1272936,injectable,FALSE,FALSE,NA,NA,NA
9,NCT02177500,Exclusion,acceptable methods of birth control include intrauterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Other,C0025663,methods,FALSE,FALSE,NA,NA,NA
9,NCT02177500,Exclusion,acceptable methods of birth control include intrauterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Other,C0700589;C2703065,birth control,FALSE,FALSE,NA,NA,NA
9,NCT02177500,Exclusion,acceptable methods of birth control include intrauterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Other,C1706306;C1548866;C1546682,intrauterine device,FALSE,FALSE,NA,NA,NA
9,NCT02177500,Exclusion,acceptable methods of birth control include intrauterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Other,C0009905;C0274536;C0481121;C1548892,oral contraceptives,FALSE,FALSE,NA,NA,NA
10,NCT02177500,Exclusion,any women :,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
11,NCT02177500,Exclusion,who has a positive serum pregnancy test at screening ( visit 1 ) or baseline ( visit 3 ),Observation,Observation,C1514241,positive,FALSE,FALSE,NA,NA,NA
11,NCT02177500,Exclusion,who has a positive serum pregnancy test at screening ( visit 1 ) or baseline ( visit 3 ),Observation,Observation,C0430064,serum pregnancy test,FALSE,FALSE,NA,NA,NA
12,NCT02177500,Exclusion,who is nursing,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
13,NCT02177500,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters,Condition Occurrence,Condition,C0086565,hepatic dysfunction,FALSE,FALSE,NA,NA,NA
13,NCT02177500,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters,Condition Occurrence,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
13,NCT02177500,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters,Condition Occurrence,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
13,NCT02177500,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
14,NCT02177500,Exclusion,sgpt ( serum glutamate pyruvate transaminase ) or sgot ( serum glutamate oxaloacetate transaminase ) greater than two times the upper limit of normal,Drug Exposure,Drug,C0376147,serum glutamate pyruvate transaminase,FALSE,FALSE,NA,NA,NA
14,NCT02177500,Exclusion,sgpt ( serum glutamate pyruvate transaminase ) or sgot ( serum glutamate oxaloacetate transaminase ) greater than two times the upper limit of normal,Drug Exposure,Drug,C0004002,glutamate oxaloacetate transaminase,FALSE,FALSE,NA,NA,NA
14,NCT02177500,Exclusion,sgpt ( serum glutamate pyruvate transaminase ) or sgot ( serum glutamate oxaloacetate transaminase ) greater than two times the upper limit of normal,Drug Exposure,Observation,C0376147;C0036828,sgpt,FALSE,FALSE,NA,NA,NA
14,NCT02177500,Exclusion,sgpt ( serum glutamate pyruvate transaminase ) or sgot ( serum glutamate oxaloacetate transaminase ) greater than two times the upper limit of normal,Drug Exposure,Observation,C0242192;C0201899,sgot,FALSE,FALSE,NA,NA,NA
14,NCT02177500,Exclusion,sgpt ( serum glutamate pyruvate transaminase ) or sgot ( serum glutamate oxaloacetate transaminase ) greater than two times the upper limit of normal,Drug Exposure,Other,C0229671;C1546774;C1550100,serum,FALSE,FALSE,NA,NA,NA
15,NCT02177500,Exclusion,serum creatinine > 2.3 mg / dl,Drug Exposure,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,NA,greater 2.3 mg/dl
16,NCT02177500,Exclusion,clinically relevant sodium depletion ; hyperkalemia ; or hypokalemia at baseline,Condition Occurrence,Condition,C0020625,sodium depletion,FALSE,FALSE,NA,NA,NA
16,NCT02177500,Exclusion,clinically relevant sodium depletion ; hyperkalemia ; or hypokalemia at baseline,Condition Occurrence,Condition,C0020621,hypokalemia,FALSE,FALSE,NA,NA,NA
16,NCT02177500,Exclusion,clinically relevant sodium depletion ; hyperkalemia ; or hypokalemia at baseline,Condition Occurrence,Condition,C0020461,hyperkalemia,FALSE,FALSE,NA,NA,NA
17,NCT02177500,Exclusion,known or suspected secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
18,NCT02177500,Exclusion,bilateral renal artery stenosis,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
19,NCT02177500,Exclusion,renal artery stenosis in a solitary kidney,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
19,NCT02177500,Exclusion,renal artery stenosis in a solitary kidney,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
20,NCT02177500,Exclusion,post-renal transplant patients ; presence of only one functioning kidney,Condition Occurrence,Condition,C0478647,transplant,FALSE,FALSE,NA,NA,NA
20,NCT02177500,Exclusion,post-renal transplant patients ; presence of only one functioning kidney,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
21,NCT02177500,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) functional class chf iii-,Condition Occurrence,Condition,C0018802,congestive heart failure chf,FALSE,FALSE,NA,NA,NA
21,NCT02177500,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) functional class chf iii-,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
21,NCT02177500,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) functional class chf iii-,Condition Occurrence,Condition,C0018802,chf,FALSE,FALSE,NA,NA,NA
21,NCT02177500,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) functional class chf iii-,Condition Occurrence,Other,C0456387;C0489477,class,FALSE,FALSE,NA,NA,NA
21,NCT02177500,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) functional class chf iii-,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii-,FALSE,FALSE,NA,NA,NA
22,NCT02177500,Exclusion,unstable angina within the past three months,Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,NA,NA,NA
23,NCT02177500,Exclusion,stroke within the past six months,Other,NA,NA,NA,NA,NA,NA,NA,NA
24,NCT02177500,Exclusion,myocardial infarction or cardiac surgery within the past three months,Condition Occurrence,Procedure,C0018821,cardiac surgery,FALSE,FALSE,NA,NA,NA
24,NCT02177500,Exclusion,myocardial infarction or cardiac surgery within the past three months,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
25,NCT02177500,Exclusion,ptca ( percutaneous transluminal coronary angioplasty ) within the past three months,Procedure,Procedure,C2936173;C0002997,ptca,FALSE,FALSE,NA,NA,NA
25,NCT02177500,Exclusion,ptca ( percutaneous transluminal coronary angioplasty ) within the past three months,Procedure,Procedure,C2936173,percutaneous transluminal coronary angioplasty,FALSE,FALSE,NA,NA,NA
26,NCT02177500,Exclusion,history of symptoms characteristic of angioedema during treatment with ace inhibitors ; angiotension ii antagonists ; thiazide diuretics ; beta-blockers or calcium channel blockers,Drug Exposure,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
26,NCT02177500,Exclusion,history of symptoms characteristic of angioedema during treatment with ace inhibitors ; angiotension ii antagonists ; thiazide diuretics ; beta-blockers or calcium channel blockers,Drug Exposure,Drug,C0003015,ace inhibitors,FALSE,FALSE,NA,NA,NA
26,NCT02177500,Exclusion,history of symptoms characteristic of angioedema during treatment with ace inhibitors ; angiotension ii antagonists ; thiazide diuretics ; beta-blockers or calcium channel blockers,Drug Exposure,Drug,C0012802,thiazide diuretics,FALSE,FALSE,NA,NA,NA
26,NCT02177500,Exclusion,history of symptoms characteristic of angioedema during treatment with ace inhibitors ; angiotension ii antagonists ; thiazide diuretics ; beta-blockers or calcium channel blockers,Drug Exposure,Drug,C0006684,calcium channel blockers,FALSE,FALSE,NA,NA,NA
26,NCT02177500,Exclusion,history of symptoms characteristic of angioedema during treatment with ace inhibitors ; angiotension ii antagonists ; thiazide diuretics ; beta-blockers or calcium channel blockers,Drug Exposure,Drug,C0001645,beta-blockers,FALSE,FALSE,NA,NA,NA
27,NCT02177500,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0750197,sustained ventricular tachycardia,FALSE,FALSE,NA,NA,NA
27,NCT02177500,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0004239;C1963068,atrial flutter,FALSE,FALSE,NA,NA,NA
27,NCT02177500,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0003811,cardiac arrhythmias,FALSE,FALSE,NA,NA,NA
27,NCT02177500,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
28,NCT02177500,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0007194,hypertrophic obstructive cardiomyopathy,FALSE,FALSE,NA,NA,NA
28,NCT02177500,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0003507,aortic stenosis,FALSE,FALSE,NA,NA,NA
28,NCT02177500,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0003501;C1269005,aortic valve,FALSE,FALSE,NA,NA,NA
28,NCT02177500,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0026264;C1269004,mitral valve,FALSE,FALSE,NA,NA,NA
28,NCT02177500,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Observation,C1261287;C0947637;C0009814,stenosis,FALSE,FALSE,NA,NA,NA
29,NCT02177500,Exclusion,administration of digoxin or other digitalis-type drugs,Drug Exposure,Drug,C0304520,digitalis,FALSE,FALSE,NA,NA,NA
29,NCT02177500,Exclusion,administration of digoxin or other digitalis-type drugs,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
29,NCT02177500,Exclusion,administration of digoxin or other digitalis-type drugs,Drug Exposure,Other,C0337449;C0012265,digoxin,FALSE,FALSE,NA,NA,NA
30,NCT02177500,Exclusion,patients with type i diabetes or type ii diabetesmellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > = 10 %,Other,Condition,C0011854,type i diabetes,FALSE,FALSE,NA,NA,NA
30,NCT02177500,Exclusion,patients with type i diabetes or type ii diabetesmellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > = 10 %,Other,Condition,C0011849;C0011847,diabetes,FALSE,FALSE,NA,NA,NA
30,NCT02177500,Exclusion,patients with type i diabetes or type ii diabetesmellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > = 10 %,Other,Observation,C0202054,hba1c,FALSE,FALSE,NA,NA,greater_equal 10 %
30,NCT02177500,Exclusion,patients with type i diabetes or type ii diabetesmellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > = 10 %,Other,Other,C1552651,type,FALSE,FALSE,NA,NA,NA
30,NCT02177500,Exclusion,patients with type i diabetes or type ii diabetesmellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > = 10 %,Other,Other,C1547311,stable,TRUE,FALSE,NA,NA,NA
30,NCT02177500,Exclusion,patients with type i diabetes or type ii diabetesmellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > = 10 %,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
31,NCT02177500,Exclusion,known drug or alcohol dependency within the past one year period,Condition Occurrence,Condition,C0001973,alcohol dependency,FALSE,FALSE,NA,NA,NA
31,NCT02177500,Exclusion,known drug or alcohol dependency within the past one year period,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
32,NCT02177500,Exclusion,concomitant administration of medications known to affect blood pressure ; except medications allowed by the protocol,Observation,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
32,NCT02177500,Exclusion,concomitant administration of medications known to affect blood pressure ; except medications allowed by the protocol,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
33,NCT02177500,Exclusion,patients receiving any investigational therapy within one month of signing the informed consent form,Procedure,Procedure,C0949266,investigational therapy,FALSE,FALSE,NA,NA,NA
33,NCT02177500,Exclusion,patients receiving any investigational therapy within one month of signing the informed consent form,Procedure,Other,C0009797,informed consent form,FALSE,FALSE,NA,NA,NA
34,NCT02177500,Exclusion,patients who have participated in previous telmisartan ( except if they were on the fixed dose combination in the 502.261 study or enrolled in the 502.3321 open-label extension study ) studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study,Observation,Condition,C2827483,fixed,FALSE,FALSE,NA,lower_equal 502.261,NA
34,NCT02177500,Exclusion,patients who have participated in previous telmisartan ( except if they were on the fixed dose combination in the 502.261 study or enrolled in the 502.3321 open-label extension study ) studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study,Observation,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,NA
34,NCT02177500,Exclusion,patients who have participated in previous telmisartan ( except if they were on the fixed dose combination in the 502.261 study or enrolled in the 502.3321 open-label extension study ) studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study,Observation,Observation,C0947630,studies,FALSE,FALSE,NA,NA,NA
34,NCT02177500,Exclusion,patients who have participated in previous telmisartan ( except if they were on the fixed dose combination in the 502.261 study or enrolled in the 502.3321 open-label extension study ) studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study,Observation,Other,C1705425,label,FALSE,FALSE,NA,lower_equal 502.3321,NA
35,NCT02177500,Exclusion,known hypersensitivity to any component of the formulations,Observation,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
36,NCT02177500,Exclusion,any clinical condition which ; in the opinion of the investigator ; would not allow safe completion of the protocol and safe administration of trial medication,Other,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
1,NCT02183701,Inclusion,mild-to-moderate essential hypertension defined as a mean seated diastolic blood pressure measurement of > = 95 mmhg measured by manual cuff sphygmomanometer ; on visit 2 of the four-week placebo run-in period ( baseline ),Observation,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
1,NCT02183701,Inclusion,mild-to-moderate essential hypertension defined as a mean seated diastolic blood pressure measurement of > = 95 mmhg measured by manual cuff sphygmomanometer ; on visit 2 of the four-week placebo run-in period ( baseline ),Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
1,NCT02183701,Inclusion,mild-to-moderate essential hypertension defined as a mean seated diastolic blood pressure measurement of > = 95 mmhg measured by manual cuff sphygmomanometer ; on visit 2 of the four-week placebo run-in period ( baseline ),Observation,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,NA
1,NCT02183701,Inclusion,mild-to-moderate essential hypertension defined as a mean seated diastolic blood pressure measurement of > = 95 mmhg measured by manual cuff sphygmomanometer ; on visit 2 of the four-week placebo run-in period ( baseline ),Observation,Observation,C1305849,diastolic blood pressure measurement,FALSE,FALSE,NA,greater_equal 95 mmhg,NA
1,NCT02183701,Inclusion,mild-to-moderate essential hypertension defined as a mean seated diastolic blood pressure measurement of > = 95 mmhg measured by manual cuff sphygmomanometer ; on visit 2 of the four-week placebo run-in period ( baseline ),Observation,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
1,NCT02183701,Inclusion,mild-to-moderate essential hypertension defined as a mean seated diastolic blood pressure measurement of > = 95 mmhg measured by manual cuff sphygmomanometer ; on visit 2 of the four-week placebo run-in period ( baseline ),Observation,Other,C1547225,mild,FALSE,FALSE,NA,NA,NA
1,NCT02183701,Inclusion,mild-to-moderate essential hypertension defined as a mean seated diastolic blood pressure measurement of > = 95 mmhg measured by manual cuff sphygmomanometer ; on visit 2 of the four-week placebo run-in period ( baseline ),Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT02183701,Inclusion,mild-to-moderate essential hypertension defined as a mean seated diastolic blood pressure measurement of > = 95 mmhg measured by manual cuff sphygmomanometer ; on visit 2 of the four-week placebo run-in period ( baseline ),Observation,Other,C0024763,manual,FALSE,FALSE,NA,NA,NA
2,NCT02183701,Inclusion,mean seated systolic blood pressure > = 140 mmhg ; measured by manual cuff at baseline ( visit 2 ),Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
2,NCT02183701,Inclusion,mean seated systolic blood pressure > = 140 mmhg ; measured by manual cuff at baseline ( visit 2 ),Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater_equal 140 mmhg,NA
2,NCT02183701,Inclusion,mean seated systolic blood pressure > = 140 mmhg ; measured by manual cuff at baseline ( visit 2 ),Observation,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
2,NCT02183701,Inclusion,mean seated systolic blood pressure > = 140 mmhg ; measured by manual cuff at baseline ( visit 2 ),Observation,Other,C0024763,manual,FALSE,FALSE,NA,NA,NA
3,NCT02183701,Inclusion,a 24 - hour mean diastolic blood pressure ; measured by abpm ; of > = 85 mmhg evaluated at baseline ( visit 3 ),Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,equal 24 hour,greater_equal 85 mmhg,NA
3,NCT02183701,Inclusion,a 24 - hour mean diastolic blood pressure ; measured by abpm ; of > = 85 mmhg evaluated at baseline ( visit 3 ),Observation,Observation,C3541902,measured,FALSE,FALSE,equal 24 hour,greater_equal 85 mmhg,NA
4,NCT02183701,Inclusion,age 18 or older,Person,NA,NA,NA,NA,NA,NA,NA,NA
5,NCT02183701,Inclusion,patient written informed consent in accordance with gcp ( good clinical practice ) and local legislation,Other,Other,C2986419,gcp,FALSE,FALSE,NA,NA,NA
5,NCT02183701,Inclusion,patient written informed consent in accordance with gcp ( good clinical practice ) and local legislation,Other,Other,C2986419,good clinical practice,FALSE,FALSE,NA,NA,NA
5,NCT02183701,Inclusion,patient written informed consent in accordance with gcp ( good clinical practice ) and local legislation,Other,Other,C0600657,legislation,FALSE,FALSE,NA,NA,NA
6,NCT02183701,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to date of consent ) :,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
6,NCT02183701,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to date of consent ) :,Condition Occurrence,Condition,C1096235,pre-menopausal,FALSE,FALSE,NA,NA,NA
6,NCT02183701,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to date of consent ) :,Condition Occurrence,Condition,C0025344;C2129647,menstruation,FALSE,FALSE,lower_equal 1 year,NA,NA
7,NCT02183701,Exclusion,who are not surgically sterile ( hysterectomy ; tubal ligation ),Procedure,Procedure,C0020699;C1548863,hysterectomy,TRUE,FALSE,NA,NA,NA
7,NCT02183701,Exclusion,who are not surgically sterile ( hysterectomy ; tubal ligation ),Procedure,Procedure,C0520483,tubal ligation,FALSE,FALSE,NA,NA,NA
8,NCT02183701,Exclusion,who are not practising acceptable means of birth control or who do not plan to continue using an acceptable method throughout the trial,Condition Occurrence,Other,C0700589;C2703065,birth control,TRUE,FALSE,NA,NA,NA
8,NCT02183701,Exclusion,who are not practising acceptable means of birth control or who do not plan to continue using an acceptable method throughout the trial,Condition Occurrence,Other,C2827714;C0871511;C2828387,method,FALSE,FALSE,NA,NA,NA
9,NCT02183701,Exclusion,acceptable methods of birth control include iud ( intrauterine device ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Drug,C1706306,iud,FALSE,FALSE,NA,NA,NA
9,NCT02183701,Exclusion,acceptable methods of birth control include iud ( intrauterine device ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Drug,C0086466;C1272936,injectable,FALSE,FALSE,NA,NA,NA
9,NCT02183701,Exclusion,acceptable methods of birth control include iud ( intrauterine device ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Other,C0025663,methods,FALSE,FALSE,NA,NA,NA
9,NCT02183701,Exclusion,acceptable methods of birth control include iud ( intrauterine device ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Other,C0700589;C2703065,birth control,FALSE,FALSE,NA,NA,NA
9,NCT02183701,Exclusion,acceptable methods of birth control include iud ( intrauterine device ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Other,C1706306;C1548866;C1546682,intrauterine device,FALSE,FALSE,NA,NA,NA
9,NCT02183701,Exclusion,acceptable methods of birth control include iud ( intrauterine device ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Other,C0009905;C0274536;C0481121;C1548892,oral contraceptives,FALSE,FALSE,NA,NA,NA
10,NCT02183701,Exclusion,who have a positive urine pregnancy test,Observation,Observation,C1514241,positive,FALSE,FALSE,NA,NA,NA
10,NCT02183701,Exclusion,who have a positive urine pregnancy test,Observation,Observation,C0430056;C0373524,urine pregnancy test,FALSE,FALSE,NA,NA,NA
11,NCT02183701,Exclusion,who are nursing,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
12,NCT02183701,Exclusion,mean seated diastolic blood pressure ( dbp ) > 114 mmhg or mean seated systolic bp > 200 mmhg ; by manual cuff,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
12,NCT02183701,Exclusion,mean seated diastolic blood pressure ( dbp ) > 114 mmhg or mean seated systolic bp > 200 mmhg ; by manual cuff,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,NA,NA
12,NCT02183701,Exclusion,mean seated diastolic blood pressure ( dbp ) > 114 mmhg or mean seated systolic bp > 200 mmhg ; by manual cuff,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater 114 mmhg,NA
12,NCT02183701,Exclusion,mean seated diastolic blood pressure ( dbp ) > 114 mmhg or mean seated systolic bp > 200 mmhg ; by manual cuff,Observation,Observation,C0871470,systolic bp,FALSE,FALSE,NA,greater 200 mmhg,NA
12,NCT02183701,Exclusion,mean seated diastolic blood pressure ( dbp ) > 114 mmhg or mean seated systolic bp > 200 mmhg ; by manual cuff,Observation,Other,C0024763,manual,FALSE,FALSE,NA,NA,NA
13,NCT02183701,Exclusion,any known hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Condition,C0086565,hepatic dysfunction,FALSE,FALSE,NA,NA,NA
13,NCT02183701,Exclusion,any known hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
13,NCT02183701,Exclusion,any known hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
13,NCT02183701,Exclusion,any known hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
14,NCT02183701,Exclusion,sgpt ( serum glutamate pyruvate transaminase ) ( alt ) or sgot ( serum glutamate oxaloacetate transaminase ) ( ast ) greater than two times the upper limit of normal,Observation,Drug,C0376147,serum glutamate pyruvate transaminase,FALSE,FALSE,NA,NA,NA
14,NCT02183701,Exclusion,sgpt ( serum glutamate pyruvate transaminase ) ( alt ) or sgot ( serum glutamate oxaloacetate transaminase ) ( ast ) greater than two times the upper limit of normal,Observation,Drug,C0004002,glutamate oxaloacetate transaminase,FALSE,FALSE,NA,NA,NA
14,NCT02183701,Exclusion,sgpt ( serum glutamate pyruvate transaminase ) ( alt ) or sgot ( serum glutamate oxaloacetate transaminase ) ( ast ) greater than two times the upper limit of normal,Observation,Observation,C0376147;C0036828,sgpt,FALSE,FALSE,NA,NA,NA
14,NCT02183701,Exclusion,sgpt ( serum glutamate pyruvate transaminase ) ( alt ) or sgot ( serum glutamate oxaloacetate transaminase ) ( ast ) greater than two times the upper limit of normal,Observation,Observation,C1140170;C2257651,alt,FALSE,FALSE,NA,NA,NA
14,NCT02183701,Exclusion,sgpt ( serum glutamate pyruvate transaminase ) ( alt ) or sgot ( serum glutamate oxaloacetate transaminase ) ( ast ) greater than two times the upper limit of normal,Observation,Observation,C0242192;C0201899,sgot,FALSE,FALSE,NA,NA,NA
14,NCT02183701,Exclusion,sgpt ( serum glutamate pyruvate transaminase ) ( alt ) or sgot ( serum glutamate oxaloacetate transaminase ) ( ast ) greater than two times the upper limit of normal,Observation,Observation,C0004002,ast,FALSE,FALSE,NA,NA,NA
14,NCT02183701,Exclusion,sgpt ( serum glutamate pyruvate transaminase ) ( alt ) or sgot ( serum glutamate oxaloacetate transaminase ) ( ast ) greater than two times the upper limit of normal,Observation,Other,C0229671;C1546774;C1550100,serum,FALSE,FALSE,NA,NA,NA
15,NCT02183701,Exclusion,serum creatinine > 1.8 mg / dl ( or 159 umol / l ),Observation,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,equal 159 umol/l,greater 1.8 mg/dl
16,NCT02183701,Exclusion,clinically relevant hypokalemia,Condition Occurrence,Condition,C0020621,hypokalemia,FALSE,FALSE,NA,NA,NA
17,NCT02183701,Exclusion,known or suspected secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
18,NCT02183701,Exclusion,known bilateral renal artery stenosis,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
19,NCT02183701,Exclusion,renal artery stenosis in a solitary kidney,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
19,NCT02183701,Exclusion,renal artery stenosis in a solitary kidney,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
20,NCT02183701,Exclusion,post-renal transplant patients ; presence of only one functioning kidney .,Condition Occurrence,Condition,C0478647,transplant,FALSE,FALSE,NA,NA,NA
20,NCT02183701,Exclusion,post-renal transplant patients ; presence of only one functioning kidney .,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
21,NCT02183701,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) class chf iii-,Condition Occurrence,Condition,C0018802,congestive heart failure chf,FALSE,FALSE,NA,NA,NA
21,NCT02183701,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) class chf iii-,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
21,NCT02183701,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) class chf iii-,Condition Occurrence,Condition,C0018802,chf,FALSE,FALSE,NA,NA,NA
21,NCT02183701,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) class chf iii-,Condition Occurrence,Other,C0456387;C0489477,class,FALSE,FALSE,NA,NA,NA
21,NCT02183701,Exclusion,congestive heart failure ( chf ) ( nyha ( new york heart association ) class chf iii-,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii-,FALSE,FALSE,NA,NA,NA
22,NCT02183701,Exclusion,unstable angina within the past 3 months,Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,lower 3 past months,NA,NA
23,NCT02183701,Exclusion,stable angina where a change in nitrate therapy ( dose or frequency ) during the run-in period was required,Drug Exposure,Condition,C0340288,stable angina,FALSE,FALSE,NA,NA,NA
23,NCT02183701,Exclusion,stable angina where a change in nitrate therapy ( dose or frequency ) during the run-in period was required,Drug Exposure,Drug,C0028125;C0699857,nitrate,FALSE,FALSE,NA,NA,NA
23,NCT02183701,Exclusion,stable angina where a change in nitrate therapy ( dose or frequency ) during the run-in period was required,Drug Exposure,Other,C3245502;C3245501;C1619636;C1546857,required,FALSE,FALSE,NA,NA,NA
24,NCT02183701,Exclusion,stroke within the past 6 months prior to start of run-in period,Other,NA,NA,NA,NA,NA,NA,NA,NA
25,NCT02183701,Exclusion,myocardial infarction or cardiac surgery within the past 3 months prior to start of run-in period,Condition Occurrence,Procedure,C0018821,cardiac surgery,FALSE,FALSE,lower 3 past months,NA,NA
25,NCT02183701,Exclusion,myocardial infarction or cardiac surgery within the past 3 months prior to start of run-in period,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,lower 3 past months,NA,NA
26,NCT02183701,Exclusion,ptca ( percutaneous transluminal coronary angioplasty ) within the past 3 months prior to start of run-in period,Procedure,Procedure,C2936173;C0002997,ptca,FALSE,FALSE,NA,NA,NA
26,NCT02183701,Exclusion,ptca ( percutaneous transluminal coronary angioplasty ) within the past 3 months prior to start of run-in period,Procedure,Procedure,C2936173,percutaneous transluminal coronary angioplasty,FALSE,FALSE,lower 3 past months,NA,NA
27,NCT02183701,Exclusion,previous history of angioedema,Condition Occurrence,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
28,NCT02183701,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0750197,sustained ventricular tachycardia,FALSE,FALSE,NA,NA,NA
28,NCT02183701,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0004239;C1963068,atrial flutter,FALSE,FALSE,NA,NA,NA
28,NCT02183701,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0003811,cardiac arrhythmias,FALSE,FALSE,NA,NA,NA
28,NCT02183701,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
29,NCT02183701,Exclusion,hypertrophic obstructive cardiomyopathy ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0007194,hypertrophic obstructive cardiomyopathy,FALSE,FALSE,NA,NA,NA
29,NCT02183701,Exclusion,hypertrophic obstructive cardiomyopathy ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0003501;C1269005,aortic valve,FALSE,FALSE,NA,NA,NA
29,NCT02183701,Exclusion,hypertrophic obstructive cardiomyopathy ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0026264;C1269004,mitral valve,FALSE,FALSE,NA,NA,NA
29,NCT02183701,Exclusion,hypertrophic obstructive cardiomyopathy ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Observation,C1261287;C0947637;C0009814,stenosis,FALSE,FALSE,NA,NA,NA
30,NCT02183701,Exclusion,patients with unstable insulin-dependent diabetes mellitus ( risk of hypoglycemia or hba1c > = 10 % in history within 6 months prior to start of run-in period ),Condition Occurrence,Condition,C0567407,unstable insulin-dependent diabetes mellitus,FALSE,FALSE,NA,NA,NA
30,NCT02183701,Exclusion,patients with unstable insulin-dependent diabetes mellitus ( risk of hypoglycemia or hba1c > = 10 % in history within 6 months prior to start of run-in period ),Condition Occurrence,Condition,C0020615;C0595883,hypoglycemia,FALSE,FALSE,lower 6 months,NA,greater_equal 10 %
30,NCT02183701,Exclusion,patients with unstable insulin-dependent diabetes mellitus ( risk of hypoglycemia or hba1c > = 10 % in history within 6 months prior to start of run-in period ),Condition Occurrence,Observation,C0202054,hba1c,FALSE,FALSE,lower 6 months,NA,greater_equal 10 %
31,NCT02183701,Exclusion,known drug or alcohol dependency within the past 6 months period prior to start of run-in period,Condition Occurrence,Condition,C0001973,alcohol dependency,FALSE,FALSE,lower 6 past months,NA,NA
31,NCT02183701,Exclusion,known drug or alcohol dependency within the past 6 months period prior to start of run-in period,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,lower 6 past months,NA,NA
32,NCT02183701,Exclusion,concomitant administration of medications known to affect blood pressure ; except medications allowed by the protocol,Observation,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
32,NCT02183701,Exclusion,concomitant administration of medications known to affect blood pressure ; except medications allowed by the protocol,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
33,NCT02183701,Exclusion,patients receiving any investigational therapy within one month of signing the informed consent form,Procedure,Procedure,C0949266,investigational therapy,FALSE,FALSE,NA,NA,NA
33,NCT02183701,Exclusion,patients receiving any investigational therapy within one month of signing the informed consent form,Procedure,Other,C0009797,informed consent form,FALSE,FALSE,NA,NA,NA
34,NCT02183701,Exclusion,known hypersensitivity to any component of the formulations,Observation,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
35,NCT02183701,Exclusion,any clinical condition which ; in the opinion of the investigator ; would not allow safe completion of the protocol and safe administration of trial medication,Other,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
36,NCT02183701,Exclusion,concomitant use of lithium or cholestyramine or colestipol resins ( potential drug interactions with hctz ),Drug Exposure,Condition,C0687133,drug interactions,FALSE,FALSE,NA,NA,NA
36,NCT02183701,Exclusion,concomitant use of lithium or cholestyramine or colestipol resins ( potential drug interactions with hctz ),Drug Exposure,Drug,C0009279,colestipol,FALSE,FALSE,NA,NA,NA
36,NCT02183701,Exclusion,concomitant use of lithium or cholestyramine or colestipol resins ( potential drug interactions with hctz ),Drug Exposure,Drug,C0008402,cholestyramine,FALSE,FALSE,NA,NA,NA
36,NCT02183701,Exclusion,concomitant use of lithium or cholestyramine or colestipol resins ( potential drug interactions with hctz ),Drug Exposure,Other,C0337452;C0023870;C3540800,lithium,FALSE,FALSE,NA,NA,NA
1,NCT02200640,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of > = 95 mmhg and < = 109 mmhg ; measured by manual cuff sphygmomanometer ; on the last visit ( visit 6 ) of the four-week placebo run-in period ( baseline bp ),Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
1,NCT02200640,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of > = 95 mmhg and < = 109 mmhg ; measured by manual cuff sphygmomanometer ; on the last visit ( visit 6 ) of the four-week placebo run-in period ( baseline bp ),Observation,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,NA
1,NCT02200640,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of > = 95 mmhg and < = 109 mmhg ; measured by manual cuff sphygmomanometer ; on the last visit ( visit 6 ) of the four-week placebo run-in period ( baseline bp ),Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT02200640,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of > = 95 mmhg and < = 109 mmhg ; measured by manual cuff sphygmomanometer ; on the last visit ( visit 6 ) of the four-week placebo run-in period ( baseline bp ),Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater_equal 95 mmhg; lower_equal 109 mmhg,NA
1,NCT02200640,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of > = 95 mmhg and < = 109 mmhg ; measured by manual cuff sphygmomanometer ; on the last visit ( visit 6 ) of the four-week placebo run-in period ( baseline bp ),Observation,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
1,NCT02200640,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of > = 95 mmhg and < = 109 mmhg ; measured by manual cuff sphygmomanometer ; on the last visit ( visit 6 ) of the four-week placebo run-in period ( baseline bp ),Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,NA,NA
1,NCT02200640,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of > = 95 mmhg and < = 109 mmhg ; measured by manual cuff sphygmomanometer ; on the last visit ( visit 6 ) of the four-week placebo run-in period ( baseline bp ),Observation,Other,C1547225,mild,FALSE,FALSE,NA,NA,NA
1,NCT02200640,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of > = 95 mmhg and < = 109 mmhg ; measured by manual cuff sphygmomanometer ; on the last visit ( visit 6 ) of the four-week placebo run-in period ( baseline bp ),Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT02200640,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of > = 95 mmhg and < = 109 mmhg ; measured by manual cuff sphygmomanometer ; on the last visit ( visit 6 ) of the four-week placebo run-in period ( baseline bp ),Observation,Other,C0024763,manual,FALSE,FALSE,NA,NA,NA
2,NCT02200640,Inclusion,the manual cuff value is calculated as the mean of three seated measurements taken two minutes apart ; after the patient has been seated quietly for 5 minutes,Condition Occurrence,Condition,C3668885;C1550244,cuff,FALSE,FALSE,equal 5 minutes,NA,NA
2,NCT02200640,Inclusion,the manual cuff value is calculated as the mean of three seated measurements taken two minutes apart ; after the patient has been seated quietly for 5 minutes,Condition Occurrence,Other,C0024763,manual,FALSE,FALSE,NA,NA,NA
3,NCT02200640,Inclusion,a 24 - mean dbp of > = 85 mmhg at visit 7 as measured by abpm,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 85 mmhg; equal 24,NA
3,NCT02200640,Inclusion,a 24 - mean dbp of > = 85 mmhg at visit 7 as measured by abpm,Observation,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
4,NCT02200640,Inclusion,age 18 years or older,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 18 years,NA,NA
5,NCT02200640,Inclusion,ability to stop current antihypertensive therapy without risk to the patient ( investigator discretion ),Drug Exposure,Drug,C0723457,stop,FALSE,FALSE,NA,NA,NA
5,NCT02200640,Inclusion,ability to stop current antihypertensive therapy without risk to the patient ( investigator discretion ),Drug Exposure,Procedure,C0585941,antihypertensive therapy,FALSE,FALSE,NA,NA,NA
6,NCT02200640,Inclusion,ability to provide written informed consent,Other,NA,NA,NA,NA,NA,NA,NA,NA
7,NCT02200640,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to start of run-in period ) who :,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
7,NCT02200640,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to start of run-in period ) who :,Condition Occurrence,Condition,C1096235,pre-menopausal,FALSE,FALSE,NA,NA,NA
7,NCT02200640,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to start of run-in period ) who :,Condition Occurrence,Condition,C0025344;C2129647,menstruation,FALSE,FALSE,lower_equal 1 year,NA,NA
8,NCT02200640,Exclusion,are not surgically sterile,Other,NA,NA,NA,NA,NA,NA,NA,NA
9,NCT02200640,Exclusion,are nursing,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
10,NCT02200640,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control ; do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in studies of > = 3 - months duration,Observation,Observation,C3831118,child-bearing potential,FALSE,FALSE,NA,NA,NA
10,NCT02200640,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control ; do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in studies of > = 3 - months duration,Observation,Observation,C0032976,pregnancy testing,FALSE,FALSE,NA,NA,NA
10,NCT02200640,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control ; do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in studies of > = 3 - months duration,Observation,Observation,C0947630,studies,FALSE,FALSE,greater_equal 3 months,NA,NA
10,NCT02200640,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control ; do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in studies of > = 3 - months duration,Observation,Other,C0700589;C2703065,birth control,TRUE,FALSE,NA,NA,NA
10,NCT02200640,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control ; do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in studies of > = 3 - months duration,Observation,Other,C2827714;C0871511;C2828387,method,FALSE,FALSE,NA,NA,NA
10,NCT02200640,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control ; do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in studies of > = 3 - months duration,Observation,Other,C3641827,agree,FALSE,FALSE,NA,NA,NA
10,NCT02200640,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control ; do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in studies of > = 3 - months duration,Observation,Other,C1706381,periodic,FALSE,FALSE,NA,NA,NA
11,NCT02200640,Exclusion,acceptable methods of birth control include intrauterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Drug,C1706306,iud,FALSE,FALSE,NA,NA,NA
11,NCT02200640,Exclusion,acceptable methods of birth control include intrauterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Drug,C0086466;C1272936,injectable,FALSE,FALSE,NA,NA,NA
11,NCT02200640,Exclusion,acceptable methods of birth control include intrauterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Other,C0025663,methods,FALSE,FALSE,NA,NA,NA
11,NCT02200640,Exclusion,acceptable methods of birth control include intrauterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Other,C0700589;C2703065,birth control,FALSE,FALSE,NA,NA,NA
11,NCT02200640,Exclusion,acceptable methods of birth control include intrauterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Other,C1706306;C1548866;C1546682,intrauterine device,FALSE,FALSE,NA,NA,NA
11,NCT02200640,Exclusion,acceptable methods of birth control include intrauterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Other,C0009905;C0274536;C0481121;C1548892,oral contraceptives,FALSE,FALSE,NA,NA,NA
12,NCT02200640,Exclusion,mean sitting sbp > = 180 mmhg or mean sitting dbp > = 110 mmhg during any visit of the placebo run-in period,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
12,NCT02200640,Exclusion,mean sitting sbp > = 180 mmhg or mean sitting dbp > = 110 mmhg during any visit of the placebo run-in period,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
12,NCT02200640,Exclusion,mean sitting sbp > = 180 mmhg or mean sitting dbp > = 110 mmhg during any visit of the placebo run-in period,Observation,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,NA
12,NCT02200640,Exclusion,mean sitting sbp > = 180 mmhg or mean sitting dbp > = 110 mmhg during any visit of the placebo run-in period,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 180 mmhg,NA
12,NCT02200640,Exclusion,mean sitting sbp > = 180 mmhg or mean sitting dbp > = 110 mmhg during any visit of the placebo run-in period,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 110 mmhg,NA
13,NCT02200640,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Condition,C0086565,hepatic dysfunction,FALSE,FALSE,NA,NA,NA
13,NCT02200640,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
13,NCT02200640,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
13,NCT02200640,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
14,NCT02200640,Exclusion,serum glutamate-pyruvate-transaminase ( alanine aminotransferase ) or serum glutamate-oxaloacetate-transaminase ( aspartate aminotransferase ) greater than two times the upper limit of normal,Condition Occurrence,Drug,C0001899,glutamate-pyruvate-transaminase,FALSE,FALSE,NA,NA,NA
14,NCT02200640,Exclusion,serum glutamate-pyruvate-transaminase ( alanine aminotransferase ) or serum glutamate-oxaloacetate-transaminase ( aspartate aminotransferase ) greater than two times the upper limit of normal,Condition Occurrence,Drug,C0004002,glutamate-oxaloacetate-transaminase,FALSE,FALSE,NA,NA,NA
14,NCT02200640,Exclusion,serum glutamate-pyruvate-transaminase ( alanine aminotransferase ) or serum glutamate-oxaloacetate-transaminase ( aspartate aminotransferase ) greater than two times the upper limit of normal,Condition Occurrence,Observation,C0001899;C0201836,alanine aminotransferase,FALSE,FALSE,NA,NA,NA
14,NCT02200640,Exclusion,serum glutamate-pyruvate-transaminase ( alanine aminotransferase ) or serum glutamate-oxaloacetate-transaminase ( aspartate aminotransferase ) greater than two times the upper limit of normal,Condition Occurrence,Observation,C0004002;C0201899,aspartate aminotransferase,FALSE,FALSE,NA,NA,NA
14,NCT02200640,Exclusion,serum glutamate-pyruvate-transaminase ( alanine aminotransferase ) or serum glutamate-oxaloacetate-transaminase ( aspartate aminotransferase ) greater than two times the upper limit of normal,Condition Occurrence,Other,C0229671;C1546774;C1550100,serum,FALSE,FALSE,NA,NA,NA
14,NCT02200640,Exclusion,serum glutamate-pyruvate-transaminase ( alanine aminotransferase ) or serum glutamate-oxaloacetate-transaminase ( aspartate aminotransferase ) greater than two times the upper limit of normal,Condition Occurrence,Other,C0229671;C1546774;C1550100,serum,FALSE,FALSE,NA,NA,NA
15,NCT02200640,Exclusion,serum creatinine > 2.3 mg / dl,Drug Exposure,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,NA,greater 2.3 mg/dl
16,NCT02200640,Exclusion,clinically relevant sodium depletion ; hyperkalemia ; or hypokalemia,Condition Occurrence,Condition,C0020625,sodium depletion,FALSE,FALSE,NA,NA,NA
16,NCT02200640,Exclusion,clinically relevant sodium depletion ; hyperkalemia ; or hypokalemia,Condition Occurrence,Condition,C0020621,hypokalemia,FALSE,FALSE,NA,NA,NA
16,NCT02200640,Exclusion,clinically relevant sodium depletion ; hyperkalemia ; or hypokalemia,Condition Occurrence,Condition,C0020461,hyperkalemia,FALSE,FALSE,NA,NA,NA
17,NCT02200640,Exclusion,uncorrected volume depletion,Condition Occurrence,Condition,C0546884,volume depletion,FALSE,FALSE,NA,NA,NA
18,NCT02200640,Exclusion,primary aldosteronism,Condition Occurrence,Condition,C1384514,primary aldosteronism,FALSE,FALSE,NA,NA,NA
19,NCT02200640,Exclusion,biliary obstructive disorders,Other,NA,NA,NA,NA,NA,NA,NA,NA
20,NCT02200640,Exclusion,known or suspected secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
21,NCT02200640,Exclusion,hereditary fructose intolerance,Condition Occurrence,Condition,C0016751,hereditary fructose intolerance,FALSE,FALSE,NA,NA,NA
22,NCT02200640,Exclusion,bilateral renal artery stenosis,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
23,NCT02200640,Exclusion,renal artery stenosis in a solitary kidney,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
23,NCT02200640,Exclusion,renal artery stenosis in a solitary kidney,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
24,NCT02200640,Exclusion,post-renal transplant patients ; presence of only one functioning kidney,Condition Occurrence,Condition,C0478647,transplant,FALSE,FALSE,NA,NA,NA
24,NCT02200640,Exclusion,post-renal transplant patients ; presence of only one functioning kidney,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
25,NCT02200640,Exclusion,congestive heart failure ( nyha functional class congestive heart failure ( chf ) class iii-,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
25,NCT02200640,Exclusion,congestive heart failure ( nyha functional class congestive heart failure ( chf ) class iii-,Condition Occurrence,Condition,C0018802,congestive heart failure chf,FALSE,FALSE,NA,NA,NA
25,NCT02200640,Exclusion,congestive heart failure ( nyha functional class congestive heart failure ( chf ) class iii-,Condition Occurrence,Other,C0456387;C0489477,class,FALSE,FALSE,NA,NA,NA
25,NCT02200640,Exclusion,congestive heart failure ( nyha functional class congestive heart failure ( chf ) class iii-,Condition Occurrence,Other,C0456387;C0489477,class,FALSE,FALSE,NA,NA,NA
25,NCT02200640,Exclusion,congestive heart failure ( nyha functional class congestive heart failure ( chf ) class iii-,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii-,FALSE,FALSE,NA,NA,NA
26,NCT02200640,Exclusion,unstable angina within the past three months,Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,NA,NA,NA
27,NCT02200640,Exclusion,stroke within the past six months,Other,NA,NA,NA,NA,NA,NA,NA,NA
28,NCT02200640,Exclusion,myocardial infarction or cardiac surgery within the past three months,Condition Occurrence,Procedure,C0018821,cardiac surgery,FALSE,FALSE,NA,NA,NA
28,NCT02200640,Exclusion,myocardial infarction or cardiac surgery within the past three months,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
29,NCT02200640,Exclusion,percutaneous transluminal coronary angioplasty ( ptca ) within the past three months,Procedure,Procedure,C2936173,percutaneous transluminal coronary angioplasty,FALSE,FALSE,NA,NA,NA
29,NCT02200640,Exclusion,percutaneous transluminal coronary angioplasty ( ptca ) within the past three months,Procedure,Procedure,C2936173;C0002997,ptca,FALSE,FALSE,NA,NA,NA
30,NCT02200640,Exclusion,history of angioedema,Condition Occurrence,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
31,NCT02200640,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0750197,sustained ventricular tachycardia,FALSE,FALSE,NA,NA,NA
31,NCT02200640,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0004239;C1963068,atrial flutter,FALSE,FALSE,NA,NA,NA
31,NCT02200640,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0003811,cardiac arrhythmias,FALSE,FALSE,NA,NA,NA
31,NCT02200640,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
32,NCT02200640,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0007194,hypertrophic obstructive cardiomyopathy,FALSE,FALSE,NA,NA,NA
32,NCT02200640,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0003507,aortic stenosis,FALSE,FALSE,NA,NA,NA
32,NCT02200640,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0003501;C1269005,aortic valve,FALSE,FALSE,NA,NA,NA
32,NCT02200640,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0026264;C1269004,mitral valve,FALSE,FALSE,NA,NA,NA
32,NCT02200640,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Observation,C1261287;C0947637;C0009814,stenosis,FALSE,FALSE,NA,NA,NA
33,NCT02200640,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes hast not been stable and controlled for at least the past three months as defined by an hba1c > = 10 %,Condition Occurrence,Condition,C0011854,insulin-dependent diabetes mellitus,FALSE,FALSE,NA,NA,NA
33,NCT02200640,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes hast not been stable and controlled for at least the past three months as defined by an hba1c > = 10 %,Condition Occurrence,Condition,C0011849;C0011847,diabetes,FALSE,FALSE,NA,NA,NA
33,NCT02200640,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes hast not been stable and controlled for at least the past three months as defined by an hba1c > = 10 %,Condition Occurrence,Observation,C0202054,hba1c,FALSE,FALSE,NA,NA,greater_equal 10 %
33,NCT02200640,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes hast not been stable and controlled for at least the past three months as defined by an hba1c > = 10 %,Condition Occurrence,Other,C1547311,stable,TRUE,FALSE,NA,NA,NA
33,NCT02200640,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes hast not been stable and controlled for at least the past three months as defined by an hba1c > = 10 %,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
34,NCT02200640,Exclusion,known drug or alcohol dependency within the past 6 months,Condition Occurrence,Condition,C0001973,alcohol dependency,FALSE,FALSE,lower 6 past months,NA,NA
34,NCT02200640,Exclusion,known drug or alcohol dependency within the past 6 months,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,lower 6 past months,NA,NA
35,NCT02200640,Exclusion,concomitant administration of medications known to affect blood pressure ; except medications allowed by the protocol,Observation,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
35,NCT02200640,Exclusion,concomitant administration of medications known to affect blood pressure ; except medications allowed by the protocol,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
36,NCT02200640,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 ante meridien ( am ),Observation,Condition,C0555008,night shift workers,FALSE,FALSE,NA,NA,NA
36,NCT02200640,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 ante meridien ( am ),Observation,Drug,C1654656,daytime,FALSE,FALSE,NA,equal 4 ; equal 00,NA
36,NCT02200640,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 ante meridien ( am ),Observation,Other,C0037313;C0723362,sleep,FALSE,FALSE,NA,NA,NA
37,NCT02200640,Exclusion,patients receiving any investigational therapy within one month of signing the informed consent form,Procedure,Procedure,C0949266,investigational therapy,FALSE,FALSE,NA,NA,NA
37,NCT02200640,Exclusion,patients receiving any investigational therapy within one month of signing the informed consent form,Procedure,Other,C0009797,informed consent form,FALSE,FALSE,NA,NA,NA
38,NCT02200640,Exclusion,known hypersensitivity to any component of the formulations,Observation,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
39,NCT02200640,Exclusion,any clinical condition which ; in the opinion of the investigator would not allow safe completion of the protocol and safe administration of trial medication,Other,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
1,NCT02200653,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of > = 95 mmhg and < = 109 mmhg ; measured by manual cuff sphygmomanometer ; at visit 3 ( baseline cuff bp ),Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
1,NCT02200653,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of > = 95 mmhg and < = 109 mmhg ; measured by manual cuff sphygmomanometer ; at visit 3 ( baseline cuff bp ),Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
1,NCT02200653,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of > = 95 mmhg and < = 109 mmhg ; measured by manual cuff sphygmomanometer ; at visit 3 ( baseline cuff bp ),Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT02200653,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of > = 95 mmhg and < = 109 mmhg ; measured by manual cuff sphygmomanometer ; at visit 3 ( baseline cuff bp ),Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater_equal 95 mmhg; lower_equal 109 mmhg,NA
1,NCT02200653,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of > = 95 mmhg and < = 109 mmhg ; measured by manual cuff sphygmomanometer ; at visit 3 ( baseline cuff bp ),Observation,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
1,NCT02200653,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of > = 95 mmhg and < = 109 mmhg ; measured by manual cuff sphygmomanometer ; at visit 3 ( baseline cuff bp ),Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,NA,NA
1,NCT02200653,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of > = 95 mmhg and < = 109 mmhg ; measured by manual cuff sphygmomanometer ; at visit 3 ( baseline cuff bp ),Observation,Other,C1547225,mild,FALSE,FALSE,NA,NA,NA
1,NCT02200653,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of > = 95 mmhg and < = 109 mmhg ; measured by manual cuff sphygmomanometer ; at visit 3 ( baseline cuff bp ),Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT02200653,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of > = 95 mmhg and < = 109 mmhg ; measured by manual cuff sphygmomanometer ; at visit 3 ( baseline cuff bp ),Observation,Other,C0024763,manual,FALSE,FALSE,NA,NA,NA
2,NCT02200653,Inclusion,a 24 - mean dbp of > = 85 mmhg at visit 4 as measured by abpm,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 85 mmhg; equal 24,NA
2,NCT02200653,Inclusion,a 24 - mean dbp of > = 85 mmhg at visit 4 as measured by abpm,Observation,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
3,NCT02200653,Inclusion,age 18 years or older,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 18 years,NA,NA
4,NCT02200653,Inclusion,ability to stop current antihypertensive therapy without risk to the patient ( investigator discretion ),Drug Exposure,Drug,C0723457,stop,FALSE,FALSE,NA,NA,NA
4,NCT02200653,Inclusion,ability to stop current antihypertensive therapy without risk to the patient ( investigator discretion ),Drug Exposure,Procedure,C0585941,antihypertensive therapy,FALSE,FALSE,NA,NA,NA
5,NCT02200653,Inclusion,patient written informed consent in accordance with good clinical practice ( gcp ) and local legislation,Other,Other,C2986419,good clinical practice,FALSE,FALSE,NA,NA,NA
5,NCT02200653,Inclusion,patient written informed consent in accordance with good clinical practice ( gcp ) and local legislation,Other,Other,C2986419,gcp,FALSE,FALSE,NA,NA,NA
5,NCT02200653,Inclusion,patient written informed consent in accordance with good clinical practice ( gcp ) and local legislation,Other,Other,C0600657,legislation,FALSE,FALSE,NA,NA,NA
6,NCT02200653,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to start of run-in period ) who :,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
6,NCT02200653,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to start of run-in period ) who :,Condition Occurrence,Condition,C1096235,pre-menopausal,FALSE,FALSE,NA,NA,NA
6,NCT02200653,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to start of run-in period ) who :,Condition Occurrence,Condition,C0025344;C2129647,menstruation,FALSE,FALSE,lower_equal 1 year,NA,NA
7,NCT02200653,Exclusion,are not surgically sterile,Other,NA,NA,NA,NA,NA,NA,NA,NA
8,NCT02200653,Exclusion,are nursing,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
9,NCT02200653,Exclusion,are of child-bearing potential and are not practising acceptable means of birth control ; do not plan to continue using this method throughout the study,Observation,Observation,C3831118,child-bearing potential,FALSE,FALSE,NA,NA,NA
9,NCT02200653,Exclusion,are of child-bearing potential and are not practising acceptable means of birth control ; do not plan to continue using this method throughout the study,Observation,Other,C0700589;C2703065,birth control,TRUE,FALSE,NA,NA,NA
9,NCT02200653,Exclusion,are of child-bearing potential and are not practising acceptable means of birth control ; do not plan to continue using this method throughout the study,Observation,Other,C2827714;C0871511;C2828387,method,FALSE,FALSE,NA,NA,NA
10,NCT02200653,Exclusion,acceptable methods of birth control include oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Drug,C0086466;C1272936,injectable,FALSE,FALSE,NA,NA,NA
10,NCT02200653,Exclusion,acceptable methods of birth control include oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Other,C0025663,methods,FALSE,FALSE,NA,NA,NA
10,NCT02200653,Exclusion,acceptable methods of birth control include oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Other,C0700589;C2703065,birth control,FALSE,FALSE,NA,NA,NA
10,NCT02200653,Exclusion,acceptable methods of birth control include oral contraceptives ; implantable contraceptives or injectable contraceptives,Drug Exposure,Other,C0009905;C0274536;C0481121;C1548892,oral contraceptives,FALSE,FALSE,NA,NA,NA
11,NCT02200653,Exclusion,known or suspected secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
12,NCT02200653,Exclusion,mean sitting sbp > = 180 mmhg or mean sitting dbp > = 110 mmhg during any visit of the placebo run-in period,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
12,NCT02200653,Exclusion,mean sitting sbp > = 180 mmhg or mean sitting dbp > = 110 mmhg during any visit of the placebo run-in period,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
12,NCT02200653,Exclusion,mean sitting sbp > = 180 mmhg or mean sitting dbp > = 110 mmhg during any visit of the placebo run-in period,Observation,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,NA
12,NCT02200653,Exclusion,mean sitting sbp > = 180 mmhg or mean sitting dbp > = 110 mmhg during any visit of the placebo run-in period,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 180 mmhg,NA
12,NCT02200653,Exclusion,mean sitting sbp > = 180 mmhg or mean sitting dbp > = 110 mmhg during any visit of the placebo run-in period,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 110 mmhg,NA
13,NCT02200653,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Condition,C0086565,hepatic dysfunction,FALSE,FALSE,NA,NA,NA
13,NCT02200653,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
13,NCT02200653,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
13,NCT02200653,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
14,NCT02200653,Exclusion,serum glutamate-pyruvate-transaminase ( alanine aminotransferase ) or serum glutamate-oxaloacetate-transaminase ( aspartate aminotransferase ) > than 2 times the upper limit of normal range,Drug Exposure,Drug,C0001899,glutamate-pyruvate-transaminase,FALSE,FALSE,NA,NA,NA
14,NCT02200653,Exclusion,serum glutamate-pyruvate-transaminase ( alanine aminotransferase ) or serum glutamate-oxaloacetate-transaminase ( aspartate aminotransferase ) > than 2 times the upper limit of normal range,Drug Exposure,Drug,C0004002,glutamate-oxaloacetate-transaminase,FALSE,FALSE,NA,NA,NA
14,NCT02200653,Exclusion,serum glutamate-pyruvate-transaminase ( alanine aminotransferase ) or serum glutamate-oxaloacetate-transaminase ( aspartate aminotransferase ) > than 2 times the upper limit of normal range,Drug Exposure,Observation,C0001899;C0201836,alanine aminotransferase,FALSE,FALSE,NA,NA,NA
14,NCT02200653,Exclusion,serum glutamate-pyruvate-transaminase ( alanine aminotransferase ) or serum glutamate-oxaloacetate-transaminase ( aspartate aminotransferase ) > than 2 times the upper limit of normal range,Drug Exposure,Observation,C0004002;C0201899,aspartate aminotransferase,FALSE,FALSE,NA,NA,NA
14,NCT02200653,Exclusion,serum glutamate-pyruvate-transaminase ( alanine aminotransferase ) or serum glutamate-oxaloacetate-transaminase ( aspartate aminotransferase ) > than 2 times the upper limit of normal range,Drug Exposure,Observation,C3542016,range,FALSE,FALSE,NA,NA,equal 2 times the upper limit of normal
14,NCT02200653,Exclusion,serum glutamate-pyruvate-transaminase ( alanine aminotransferase ) or serum glutamate-oxaloacetate-transaminase ( aspartate aminotransferase ) > than 2 times the upper limit of normal range,Drug Exposure,Other,C0229671;C1546774;C1550100,serum,FALSE,FALSE,NA,NA,NA
14,NCT02200653,Exclusion,serum glutamate-pyruvate-transaminase ( alanine aminotransferase ) or serum glutamate-oxaloacetate-transaminase ( aspartate aminotransferase ) > than 2 times the upper limit of normal range,Drug Exposure,Other,C0229671;C1546774;C1550100,serum,FALSE,FALSE,NA,NA,NA
15,NCT02200653,Exclusion,serum creatinine > 2.3 mg / dl ( or > 203 umol / l ),Observation,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,greater 203 umol/l,greater 2.3 mg/dl
16,NCT02200653,Exclusion,bilateral renal artery stenosis,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
17,NCT02200653,Exclusion,renal artery stenosis in a solitary kidney,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
17,NCT02200653,Exclusion,renal artery stenosis in a solitary kidney,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
18,NCT02200653,Exclusion,patients post-renal transplant or with only one kidney,Condition Occurrence,Condition,C0478647,transplant,FALSE,FALSE,NA,NA,NA
18,NCT02200653,Exclusion,patients post-renal transplant or with only one kidney,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
19,NCT02200653,Exclusion,clinically relevant sodium depletion ; hypokalaemia ; or hyperkalaemia,Condition Occurrence,Condition,C0020625,sodium depletion,FALSE,FALSE,NA,NA,NA
20,NCT02200653,Exclusion,uncorrected volume depletion,Condition Occurrence,Condition,C0546884,volume depletion,FALSE,FALSE,NA,NA,NA
21,NCT02200653,Exclusion,primary aldosteronism,Condition Occurrence,Condition,C1384514,primary aldosteronism,FALSE,FALSE,NA,NA,NA
22,NCT02200653,Exclusion,hereditary fructose intolerance,Condition Occurrence,Condition,C0016751,hereditary fructose intolerance,FALSE,FALSE,NA,NA,NA
23,NCT02200653,Exclusion,biliary obstructive disorders,Other,NA,NA,NA,NA,NA,NA,NA,NA
24,NCT02200653,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or angiotensin ii receptor antagonists,Condition Occurrence,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
24,NCT02200653,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or angiotensin ii receptor antagonists,Condition Occurrence,Drug,C0003015,ace inhibitors,FALSE,FALSE,NA,NA,NA
24,NCT02200653,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or angiotensin ii receptor antagonists,Condition Occurrence,Other,C0521942;C2757003,angiotensin ii receptor antagonists,FALSE,FALSE,NA,NA,NA
25,NCT02200653,Exclusion,history of drug or alcohol dependency within 6 months,Condition Occurrence,Condition,C0001973,alcohol dependency,FALSE,FALSE,lower 6 months,NA,NA
25,NCT02200653,Exclusion,history of drug or alcohol dependency within 6 months,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,lower 6 months,NA,NA
26,NCT02200653,Exclusion,chronic administration of any medications known to affect blood pressure ; except medications allowed by the protocol,Observation,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
26,NCT02200653,Exclusion,chronic administration of any medications known to affect blood pressure ; except medications allowed by the protocol,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
26,NCT02200653,Exclusion,chronic administration of any medications known to affect blood pressure ; except medications allowed by the protocol,Observation,Other,C1547296;C1555457,chronic,FALSE,FALSE,NA,NA,NA
27,NCT02200653,Exclusion,any investigational therapy within one month of signing the informed consent form,Procedure,Procedure,C0949266,investigational therapy,FALSE,FALSE,NA,NA,NA
27,NCT02200653,Exclusion,any investigational therapy within one month of signing the informed consent form,Procedure,Other,C0009797,informed consent form,FALSE,FALSE,NA,NA,NA
28,NCT02200653,Exclusion,congestive heart failure ( nyha functional class congestive heart failure ( chf ) class iii-,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
28,NCT02200653,Exclusion,congestive heart failure ( nyha functional class congestive heart failure ( chf ) class iii-,Condition Occurrence,Condition,C0018802,congestive heart failure chf,FALSE,FALSE,NA,NA,NA
28,NCT02200653,Exclusion,congestive heart failure ( nyha functional class congestive heart failure ( chf ) class iii-,Condition Occurrence,Other,C0456387;C0489477,class,FALSE,FALSE,NA,NA,NA
28,NCT02200653,Exclusion,congestive heart failure ( nyha functional class congestive heart failure ( chf ) class iii-,Condition Occurrence,Other,C0456387;C0489477,class,FALSE,FALSE,NA,NA,NA
28,NCT02200653,Exclusion,congestive heart failure ( nyha functional class congestive heart failure ( chf ) class iii-,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii-,FALSE,FALSE,NA,NA,NA
29,NCT02200653,Exclusion,unstable angina within the past six months,Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,NA,NA,NA
30,NCT02200653,Exclusion,stroke within the past six months,Other,NA,NA,NA,NA,NA,NA,NA,NA
31,NCT02200653,Exclusion,myocardial infarction or cardiac surgery within the past six months,Condition Occurrence,Procedure,C0018821,cardiac surgery,FALSE,FALSE,NA,NA,NA
31,NCT02200653,Exclusion,myocardial infarction or cardiac surgery within the past six months,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
32,NCT02200653,Exclusion,percutaneous transluminal coronary angioplasty ( ptca ) within the past six months,Procedure,Procedure,C2936173,percutaneous transluminal coronary angioplasty,FALSE,FALSE,NA,NA,NA
32,NCT02200653,Exclusion,percutaneous transluminal coronary angioplasty ( ptca ) within the past six months,Procedure,Procedure,C2936173;C0002997,ptca,FALSE,FALSE,NA,NA,NA
33,NCT02200653,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0750197,sustained ventricular tachycardia,FALSE,FALSE,NA,NA,NA
33,NCT02200653,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0004239;C1963068,atrial flutter,FALSE,FALSE,NA,NA,NA
33,NCT02200653,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0003811,cardiac arrhythmias,FALSE,FALSE,NA,NA,NA
33,NCT02200653,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
34,NCT02200653,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0007194,hypertrophic obstructive cardiomyopathy,FALSE,FALSE,NA,NA,NA
34,NCT02200653,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0003507,aortic stenosis,FALSE,FALSE,NA,NA,NA
34,NCT02200653,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0003501;C1269005,aortic valve,FALSE,FALSE,NA,NA,NA
34,NCT02200653,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0026264;C1269004,mitral valve,FALSE,FALSE,NA,NA,NA
34,NCT02200653,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Observation,C1261287;C0947637;C0009814,stenosis,FALSE,FALSE,NA,NA,NA
35,NCT02200653,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes hast not been stable and controlled for at least the past three months as defined by an hba1c > = 10 %,Condition Occurrence,Condition,C0011854,insulin-dependent diabetes mellitus,FALSE,FALSE,NA,NA,NA
35,NCT02200653,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes hast not been stable and controlled for at least the past three months as defined by an hba1c > = 10 %,Condition Occurrence,Condition,C0011849;C0011847,diabetes,FALSE,FALSE,NA,NA,NA
35,NCT02200653,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes hast not been stable and controlled for at least the past three months as defined by an hba1c > = 10 %,Condition Occurrence,Observation,C0202054,hba1c,FALSE,FALSE,NA,NA,greater_equal 10 %
35,NCT02200653,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes hast not been stable and controlled for at least the past three months as defined by an hba1c > = 10 %,Condition Occurrence,Other,C1547311,stable,TRUE,FALSE,NA,NA,NA
35,NCT02200653,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes hast not been stable and controlled for at least the past three months as defined by an hba1c > = 10 %,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
36,NCT02200653,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 ante meridiem ( am ),Observation,Condition,C0555008,night shift workers,FALSE,FALSE,NA,NA,NA
36,NCT02200653,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 ante meridiem ( am ),Observation,Drug,C1654656,daytime,FALSE,FALSE,NA,equal 4 ; equal 00,NA
36,NCT02200653,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 ante meridiem ( am ),Observation,Other,C0037313;C0723362,sleep,FALSE,FALSE,NA,NA,NA
37,NCT02200653,Exclusion,known hypersensitivity to any component of the formulations,Observation,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
38,NCT02200653,Exclusion,any clinical condition which ; in the opinion of the investigator would not allow safe completion of the protocol and safe administration of trial medication,Other,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
1,NCT02242318,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of > = 95 mmhg and < = 109 mmhg ; measured by manual cuff sphygmomanometer ; at visit 2,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
1,NCT02242318,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of > = 95 mmhg and < = 109 mmhg ; measured by manual cuff sphygmomanometer ; at visit 2,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT02242318,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of > = 95 mmhg and < = 109 mmhg ; measured by manual cuff sphygmomanometer ; at visit 2,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater_equal 95 mmhg; lower_equal 109 mmhg,NA
1,NCT02242318,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of > = 95 mmhg and < = 109 mmhg ; measured by manual cuff sphygmomanometer ; at visit 2,Observation,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
1,NCT02242318,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of > = 95 mmhg and < = 109 mmhg ; measured by manual cuff sphygmomanometer ; at visit 2,Observation,Other,C1547225,mild,FALSE,FALSE,NA,NA,NA
1,NCT02242318,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of > = 95 mmhg and < = 109 mmhg ; measured by manual cuff sphygmomanometer ; at visit 2,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT02242318,Inclusion,mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of > = 95 mmhg and < = 109 mmhg ; measured by manual cuff sphygmomanometer ; at visit 2,Observation,Other,C0024763,manual,FALSE,FALSE,NA,NA,NA
2,NCT02242318,Inclusion,24 - hour mean dbp of > = 85 mmhg at visit 3 as measured by abpm,Observation,Observation,C1305849,dbp,FALSE,FALSE,equal 24 hour,greater_equal 85 mmhg,NA
2,NCT02242318,Inclusion,24 - hour mean dbp of > = 85 mmhg at visit 3 as measured by abpm,Observation,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
3,NCT02242318,Inclusion,age 18 years or older,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 18 years,NA,NA
4,NCT02242318,Inclusion,ability to stop any current antihypertensive therapy without risk to the patient ( investigator discretion ) ; patient written informed consent in accordance with good clinical practice ( gcp ) and local legislation,Other,Drug,C0723457,stop,FALSE,FALSE,NA,NA,NA
4,NCT02242318,Inclusion,ability to stop any current antihypertensive therapy without risk to the patient ( investigator discretion ) ; patient written informed consent in accordance with good clinical practice ( gcp ) and local legislation,Other,Procedure,C0585941,antihypertensive therapy,FALSE,FALSE,NA,NA,NA
4,NCT02242318,Inclusion,ability to stop any current antihypertensive therapy without risk to the patient ( investigator discretion ) ; patient written informed consent in accordance with good clinical practice ( gcp ) and local legislation,Other,Other,C2986419,good clinical practice,FALSE,FALSE,NA,NA,NA
4,NCT02242318,Inclusion,ability to stop any current antihypertensive therapy without risk to the patient ( investigator discretion ) ; patient written informed consent in accordance with good clinical practice ( gcp ) and local legislation,Other,Other,C2986419,gcp,FALSE,FALSE,NA,NA,NA
4,NCT02242318,Inclusion,ability to stop any current antihypertensive therapy without risk to the patient ( investigator discretion ) ; patient written informed consent in accordance with good clinical practice ( gcp ) and local legislation,Other,Other,C0600657,legislation,FALSE,FALSE,NA,NA,NA
5,NCT02242318,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to start of run-in period ) who,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
5,NCT02242318,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to start of run-in period ) who,Condition Occurrence,Condition,C1096235,pre-menopausal,FALSE,FALSE,NA,NA,NA
5,NCT02242318,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to start of run-in period ) who,Condition Occurrence,Condition,C0025344;C2129647,menstruation,FALSE,FALSE,lower_equal 1 year,NA,NA
6,NCT02242318,Exclusion,are not surgically sterile,NA,Other,NA,NA,NA,NA,NA,NA,NA
7,NCT02242318,Exclusion,are nursing ;,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
8,NCT02242318,Exclusion,are of child-bearing potential and are not practising acceptable methods of birth control ; or do not plan to continue practising an acceptable method throughout the study,Observation,Observation,C3831118,child-bearing potential,FALSE,FALSE,NA,NA,NA
8,NCT02242318,Exclusion,are of child-bearing potential and are not practising acceptable methods of birth control ; or do not plan to continue practising an acceptable method throughout the study,Observation,Other,C0025663,methods,TRUE,FALSE,NA,NA,NA
8,NCT02242318,Exclusion,are of child-bearing potential and are not practising acceptable methods of birth control ; or do not plan to continue practising an acceptable method throughout the study,Observation,Other,C0700589;C2703065,birth control,TRUE,FALSE,NA,NA,NA
8,NCT02242318,Exclusion,are of child-bearing potential and are not practising acceptable methods of birth control ; or do not plan to continue practising an acceptable method throughout the study,Observation,Other,C2827714;C0871511;C2828387,method,FALSE,FALSE,NA,NA,NA
9,NCT02242318,Exclusion,acceptable methods of birth control include oral contraceptives ; implantable contraceptives or injectable contraceptives and intra uterine devices ( iud ),Drug Exposure,Drug,C0086466;C1272936,injectable,FALSE,FALSE,NA,NA,NA
9,NCT02242318,Exclusion,acceptable methods of birth control include oral contraceptives ; implantable contraceptives or injectable contraceptives and intra uterine devices ( iud ),Drug Exposure,Drug,C1706306,iud,FALSE,FALSE,NA,NA,NA
9,NCT02242318,Exclusion,acceptable methods of birth control include oral contraceptives ; implantable contraceptives or injectable contraceptives and intra uterine devices ( iud ),Drug Exposure,Other,C0025663,methods,FALSE,FALSE,NA,NA,NA
9,NCT02242318,Exclusion,acceptable methods of birth control include oral contraceptives ; implantable contraceptives or injectable contraceptives and intra uterine devices ( iud ),Drug Exposure,Other,C0700589;C2703065,birth control,FALSE,FALSE,NA,NA,NA
9,NCT02242318,Exclusion,acceptable methods of birth control include oral contraceptives ; implantable contraceptives or injectable contraceptives and intra uterine devices ( iud ),Drug Exposure,Other,C0009905;C0274536;C0481121;C1548892,oral contraceptives,FALSE,FALSE,NA,NA,NA
10,NCT02242318,Exclusion,known or suspected secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
11,NCT02242318,Exclusion,mean sitting sbp > = 180 mmhg or mean sitting dbp > = 110 mmhg during any visit of the placebo run-in period,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
11,NCT02242318,Exclusion,mean sitting sbp > = 180 mmhg or mean sitting dbp > = 110 mmhg during any visit of the placebo run-in period,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
11,NCT02242318,Exclusion,mean sitting sbp > = 180 mmhg or mean sitting dbp > = 110 mmhg during any visit of the placebo run-in period,Observation,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,NA
11,NCT02242318,Exclusion,mean sitting sbp > = 180 mmhg or mean sitting dbp > = 110 mmhg during any visit of the placebo run-in period,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 180 mmhg,NA
11,NCT02242318,Exclusion,mean sitting sbp > = 180 mmhg or mean sitting dbp > = 110 mmhg during any visit of the placebo run-in period,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 110 mmhg,NA
12,NCT02242318,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Condition,C0086565,hepatic dysfunction,FALSE,FALSE,NA,NA,NA
12,NCT02242318,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
12,NCT02242318,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
12,NCT02242318,Exclusion,hepatic dysfunction or renal dysfunction as defined by the following laboratory parameters :,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
13,NCT02242318,Exclusion,serum glutamate-pyruvate-transaminase ( alanine aminotransferase ) ( sgpt ( alt ) ) or serum glutamate-oxaloacetate-transaminase ( aspartate aminotransferase ) ( sgot ( ast ) ) > than 2 times the upper limit of normal range ;,Observation,Drug,C0001899,glutamate-pyruvate-transaminase,FALSE,FALSE,NA,NA,NA
13,NCT02242318,Exclusion,serum glutamate-pyruvate-transaminase ( alanine aminotransferase ) ( sgpt ( alt ) ) or serum glutamate-oxaloacetate-transaminase ( aspartate aminotransferase ) ( sgot ( ast ) ) > than 2 times the upper limit of normal range ;,Observation,Drug,C0004002,glutamate-oxaloacetate-transaminase,FALSE,FALSE,NA,NA,NA
13,NCT02242318,Exclusion,serum glutamate-pyruvate-transaminase ( alanine aminotransferase ) ( sgpt ( alt ) ) or serum glutamate-oxaloacetate-transaminase ( aspartate aminotransferase ) ( sgot ( ast ) ) > than 2 times the upper limit of normal range ;,Observation,Observation,C0001899;C0201836,alanine aminotransferase,FALSE,FALSE,NA,NA,NA
13,NCT02242318,Exclusion,serum glutamate-pyruvate-transaminase ( alanine aminotransferase ) ( sgpt ( alt ) ) or serum glutamate-oxaloacetate-transaminase ( aspartate aminotransferase ) ( sgot ( ast ) ) > than 2 times the upper limit of normal range ;,Observation,Observation,C0376147;C0036828,sgpt,FALSE,FALSE,NA,NA,NA
13,NCT02242318,Exclusion,serum glutamate-pyruvate-transaminase ( alanine aminotransferase ) ( sgpt ( alt ) ) or serum glutamate-oxaloacetate-transaminase ( aspartate aminotransferase ) ( sgot ( ast ) ) > than 2 times the upper limit of normal range ;,Observation,Observation,C1140170;C2257651,alt,FALSE,FALSE,NA,NA,NA
13,NCT02242318,Exclusion,serum glutamate-pyruvate-transaminase ( alanine aminotransferase ) ( sgpt ( alt ) ) or serum glutamate-oxaloacetate-transaminase ( aspartate aminotransferase ) ( sgot ( ast ) ) > than 2 times the upper limit of normal range ;,Observation,Observation,C0004002;C0201899,aspartate aminotransferase,FALSE,FALSE,NA,NA,NA
13,NCT02242318,Exclusion,serum glutamate-pyruvate-transaminase ( alanine aminotransferase ) ( sgpt ( alt ) ) or serum glutamate-oxaloacetate-transaminase ( aspartate aminotransferase ) ( sgot ( ast ) ) > than 2 times the upper limit of normal range ;,Observation,Observation,C0242192;C0201899,sgot,FALSE,FALSE,NA,NA,NA
13,NCT02242318,Exclusion,serum glutamate-pyruvate-transaminase ( alanine aminotransferase ) ( sgpt ( alt ) ) or serum glutamate-oxaloacetate-transaminase ( aspartate aminotransferase ) ( sgot ( ast ) ) > than 2 times the upper limit of normal range ;,Observation,Observation,C0004002,ast,FALSE,FALSE,NA,NA,NA
13,NCT02242318,Exclusion,serum glutamate-pyruvate-transaminase ( alanine aminotransferase ) ( sgpt ( alt ) ) or serum glutamate-oxaloacetate-transaminase ( aspartate aminotransferase ) ( sgot ( ast ) ) > than 2 times the upper limit of normal range ;,Observation,Observation,C3542016,range,FALSE,FALSE,NA,NA,equal 2 times the upper limit of normal
13,NCT02242318,Exclusion,serum glutamate-pyruvate-transaminase ( alanine aminotransferase ) ( sgpt ( alt ) ) or serum glutamate-oxaloacetate-transaminase ( aspartate aminotransferase ) ( sgot ( ast ) ) > than 2 times the upper limit of normal range ;,Observation,Other,C0229671;C1546774;C1550100,serum,FALSE,FALSE,NA,NA,NA
13,NCT02242318,Exclusion,serum glutamate-pyruvate-transaminase ( alanine aminotransferase ) ( sgpt ( alt ) ) or serum glutamate-oxaloacetate-transaminase ( aspartate aminotransferase ) ( sgot ( ast ) ) > than 2 times the upper limit of normal range ;,Observation,Other,C0229671;C1546774;C1550100,serum,FALSE,FALSE,NA,NA,NA
14,NCT02242318,Exclusion,serum creatinine > 2.3 mg / dl ( or > 203 umol / l ),Observation,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,greater 203 umol/l,greater 2.3 mg/dl
15,NCT02242318,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; patients postrenal transplant or with only one kidney,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
15,NCT02242318,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; patients postrenal transplant or with only one kidney,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
15,NCT02242318,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; patients postrenal transplant or with only one kidney,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
15,NCT02242318,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; patients postrenal transplant or with only one kidney,Condition Occurrence,Condition,C0478647,transplant,FALSE,FALSE,NA,NA,NA
15,NCT02242318,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; patients postrenal transplant or with only one kidney,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
16,NCT02242318,Exclusion,clinically relevant sodium depletion ; hypokalaemia or hyperkalaemia,Condition Occurrence,Condition,C0020625,sodium depletion,FALSE,FALSE,NA,NA,NA
17,NCT02242318,Exclusion,uncorrected volume depletion,Condition Occurrence,Condition,C0546884,volume depletion,FALSE,FALSE,NA,NA,NA
18,NCT02242318,Exclusion,primary aldosteronism,Condition Occurrence,Condition,C1384514,primary aldosteronism,FALSE,FALSE,NA,NA,NA
19,NCT02242318,Exclusion,hereditary fructose intolerance,Condition Occurrence,Condition,C0016751,hereditary fructose intolerance,FALSE,FALSE,NA,NA,NA
20,NCT02242318,Exclusion,biliary obstructive disorders,Other,NA,NA,NA,NA,NA,NA,NA,NA
21,NCT02242318,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or angiotensin ii receptor antagonists,Condition Occurrence,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
21,NCT02242318,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or angiotensin ii receptor antagonists,Condition Occurrence,Drug,C0003015,ace inhibitors,FALSE,FALSE,NA,NA,NA
21,NCT02242318,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or angiotensin ii receptor antagonists,Condition Occurrence,Other,C0521942;C2757003,angiotensin ii receptor antagonists,FALSE,FALSE,NA,NA,NA
22,NCT02242318,Exclusion,history of drug or alcohol dependency within six months prior to start of run-in period,Condition Occurrence,Condition,C0001973,alcohol dependency,FALSE,FALSE,NA,NA,NA
22,NCT02242318,Exclusion,history of drug or alcohol dependency within six months prior to start of run-in period,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
23,NCT02242318,Exclusion,concomitant administration of any medications known to affect blood pressure ; except medication allowed by the protocol,Observation,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
23,NCT02242318,Exclusion,concomitant administration of any medications known to affect blood pressure ; except medication allowed by the protocol,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
24,NCT02242318,Exclusion,any investigational therapy within one month of signing the informed consent form,Procedure,Procedure,C0949266,investigational therapy,FALSE,FALSE,NA,NA,NA
24,NCT02242318,Exclusion,any investigational therapy within one month of signing the informed consent form,Procedure,Other,C0009797,informed consent form,FALSE,FALSE,NA,NA,NA
25,NCT02242318,Exclusion,congestive heart failure ( new york heart association ( nyha ) functional class congestive heart failure ( chf iii- ),Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
25,NCT02242318,Exclusion,congestive heart failure ( new york heart association ( nyha ) functional class congestive heart failure ( chf iii- ),Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
25,NCT02242318,Exclusion,congestive heart failure ( new york heart association ( nyha ) functional class congestive heart failure ( chf iii- ),Condition Occurrence,Condition,C0018802,congestive heart failure chf,FALSE,FALSE,NA,NA,NA
25,NCT02242318,Exclusion,congestive heart failure ( new york heart association ( nyha ) functional class congestive heart failure ( chf iii- ),Condition Occurrence,Other,C0456387;C0489477,class,FALSE,FALSE,NA,NA,NA
25,NCT02242318,Exclusion,congestive heart failure ( new york heart association ( nyha ) functional class congestive heart failure ( chf iii- ),Condition Occurrence,Other,C0439070;C2337640;C3496532,iii-,FALSE,FALSE,NA,NA,NA
26,NCT02242318,Exclusion,unstable angina within the past three months prior to start of run-in period,Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,NA,NA,NA
27,NCT02242318,Exclusion,stroke within the past six months prior to start of run-in period,Other,NA,NA,NA,NA,NA,NA,NA,NA
28,NCT02242318,Exclusion,myocardial infarction or cardiac surgery within the past three months prior to start of run-in period,Condition Occurrence,Procedure,C0018821,cardiac surgery,FALSE,FALSE,NA,NA,NA
28,NCT02242318,Exclusion,myocardial infarction or cardiac surgery within the past three months prior to start of run-in period,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
29,NCT02242318,Exclusion,percutaneous transluminal coronary angioplasty ( ptca ) within the past three months prior to start of run-in period,Procedure,Procedure,C2936173,percutaneous transluminal coronary angioplasty,FALSE,FALSE,NA,NA,NA
29,NCT02242318,Exclusion,percutaneous transluminal coronary angioplasty ( ptca ) within the past three months prior to start of run-in period,Procedure,Procedure,C2936173;C0002997,ptca,FALSE,FALSE,NA,NA,NA
30,NCT02242318,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0750197,sustained ventricular tachycardia,FALSE,FALSE,NA,NA,NA
30,NCT02242318,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0004239;C1963068,atrial flutter,FALSE,FALSE,NA,NA,NA
30,NCT02242318,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0003811,cardiac arrhythmias,FALSE,FALSE,NA,NA,NA
30,NCT02242318,Exclusion,sustained ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
31,NCT02242318,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0007194,hypertrophic obstructive cardiomyopathy,FALSE,FALSE,NA,NA,NA
31,NCT02242318,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0003507,aortic stenosis,FALSE,FALSE,NA,NA,NA
31,NCT02242318,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0003501;C1269005,aortic valve,FALSE,FALSE,NA,NA,NA
31,NCT02242318,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0026264;C1269004,mitral valve,FALSE,FALSE,NA,NA,NA
31,NCT02242318,Exclusion,hypertrophic obstructive cardiomyopathy ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Observation,C1261287;C0947637;C0009814,stenosis,FALSE,FALSE,NA,NA,NA
32,NCT02242318,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > = 10 % ; night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 ante meridiem ( am ),Observation,Condition,C0011854,insulin-dependent diabetes mellitus,FALSE,FALSE,NA,NA,NA
32,NCT02242318,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > = 10 % ; night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 ante meridiem ( am ),Observation,Condition,C0011849;C0011847,diabetes,FALSE,FALSE,NA,NA,NA
32,NCT02242318,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > = 10 % ; night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 ante meridiem ( am ),Observation,Condition,C0555008,night shift workers,FALSE,FALSE,NA,NA,NA
32,NCT02242318,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > = 10 % ; night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 ante meridiem ( am ),Observation,Drug,C1654656,daytime,FALSE,FALSE,NA,equal 4 ; equal 00,NA
32,NCT02242318,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > = 10 % ; night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 ante meridiem ( am ),Observation,Observation,C0202054,hba1c,FALSE,FALSE,NA,NA,greater_equal 10 %
32,NCT02242318,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > = 10 % ; night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 ante meridiem ( am ),Observation,Other,C1547311,stable,TRUE,FALSE,NA,NA,NA
32,NCT02242318,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > = 10 % ; night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 ante meridiem ( am ),Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
32,NCT02242318,Exclusion,patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > = 10 % ; night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 ante meridiem ( am ),Observation,Other,C0037313;C0723362,sleep,FALSE,FALSE,NA,NA,NA
33,NCT02242318,Exclusion,known hypersensitivity to any component of the formulations,Observation,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
34,NCT02242318,Exclusion,any clinical condition which ; in the opinion of the investigator would not allow safe completion of the protocol and safe administration of trial medication,Other,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
35,NCT02242318,Exclusion,inability to comply with the protocol,Other,NA,NA,NA,NA,NA,NA,NA,NA
1,NCT02269176,Inclusion,mild to moderate primary hypertension ; the mean sitting valley value of diastolic blood pressure ( dbp ) > = 95 and < 110 mmhg ; and the mean sitting valley value of systolic blood pressure ( sbp ) < 180 mmhg,Observation,Condition,C0085580,primary hypertension,FALSE,FALSE,NA,NA,NA
1,NCT02269176,Inclusion,mild to moderate primary hypertension ; the mean sitting valley value of diastolic blood pressure ( dbp ) > = 95 and < 110 mmhg ; and the mean sitting valley value of systolic blood pressure ( sbp ) < 180 mmhg,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
1,NCT02269176,Inclusion,mild to moderate primary hypertension ; the mean sitting valley value of diastolic blood pressure ( dbp ) > = 95 and < 110 mmhg ; and the mean sitting valley value of systolic blood pressure ( sbp ) < 180 mmhg,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
1,NCT02269176,Inclusion,mild to moderate primary hypertension ; the mean sitting valley value of diastolic blood pressure ( dbp ) > = 95 and < 110 mmhg ; and the mean sitting valley value of systolic blood pressure ( sbp ) < 180 mmhg,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,NA,NA
1,NCT02269176,Inclusion,mild to moderate primary hypertension ; the mean sitting valley value of diastolic blood pressure ( dbp ) > = 95 and < 110 mmhg ; and the mean sitting valley value of systolic blood pressure ( sbp ) < 180 mmhg,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 95 mmhg; lower 110 mmhg,NA
1,NCT02269176,Inclusion,mild to moderate primary hypertension ; the mean sitting valley value of diastolic blood pressure ( dbp ) > = 95 and < 110 mmhg ; and the mean sitting valley value of systolic blood pressure ( sbp ) < 180 mmhg,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,NA,NA
1,NCT02269176,Inclusion,mild to moderate primary hypertension ; the mean sitting valley value of diastolic blood pressure ( dbp ) > = 95 and < 110 mmhg ; and the mean sitting valley value of systolic blood pressure ( sbp ) < 180 mmhg,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,lower 180 mmhg,NA
1,NCT02269176,Inclusion,mild to moderate primary hypertension ; the mean sitting valley value of diastolic blood pressure ( dbp ) > = 95 and < 110 mmhg ; and the mean sitting valley value of systolic blood pressure ( sbp ) < 180 mmhg,Observation,Other,C1547225,mild,FALSE,FALSE,NA,NA,NA
1,NCT02269176,Inclusion,mild to moderate primary hypertension ; the mean sitting valley value of diastolic blood pressure ( dbp ) > = 95 and < 110 mmhg ; and the mean sitting valley value of systolic blood pressure ( sbp ) < 180 mmhg,Observation,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
1,NCT02495324,Inclusion,subjects who voluntarily signed informed consent for participating in this clinical trial,Other,Other,C1519316,signed,FALSE,FALSE,NA,NA,NA
1,NCT02495324,Inclusion,subjects who voluntarily signed informed consent for participating in this clinical trial,Other,Other,C1096775,clinical trial,FALSE,FALSE,NA,NA,NA
2,NCT02495324,Inclusion,male and female between 19 and 70 years old,Person,Person,C0025266,male,FALSE,FALSE,greater_equal 19 years; lower_equal 70 years,NA,NA
2,NCT02495324,Inclusion,male and female between 19 and 70 years old,Person,Person,C0086287,female,FALSE,FALSE,greater_equal 19 years; lower_equal 70 years,NA,NA
3,NCT02495324,Inclusion,subjects whose mean sitting sbp ( sisbp ) of 3 measurements is above 140 mmhg at visit 2 with mild to moderate essential hypertension ( subjects who have not taken anti-hypertensive drugs within 3 months should have mean sisbp above 140 mmhg at visit 1 ),Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
3,NCT02495324,Inclusion,subjects whose mean sitting sbp ( sisbp ) of 3 measurements is above 140 mmhg at visit 2 with mild to moderate essential hypertension ( subjects who have not taken anti-hypertensive drugs within 3 months should have mean sisbp above 140 mmhg at visit 1 ),Observation,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
3,NCT02495324,Inclusion,subjects whose mean sitting sbp ( sisbp ) of 3 measurements is above 140 mmhg at visit 2 with mild to moderate essential hypertension ( subjects who have not taken anti-hypertensive drugs within 3 months should have mean sisbp above 140 mmhg at visit 1 ),Observation,Drug,C0003364,anti-hypertensive drugs,TRUE,FALSE,lower 3 months,greater 140 mmhg,NA
3,NCT02495324,Inclusion,subjects whose mean sitting sbp ( sisbp ) of 3 measurements is above 140 mmhg at visit 2 with mild to moderate essential hypertension ( subjects who have not taken anti-hypertensive drugs within 3 months should have mean sisbp above 140 mmhg at visit 1 ),Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,equal 3 measurements; greater 140 mmhg,NA
3,NCT02495324,Inclusion,subjects whose mean sitting sbp ( sisbp ) of 3 measurements is above 140 mmhg at visit 2 with mild to moderate essential hypertension ( subjects who have not taken anti-hypertensive drugs within 3 months should have mean sisbp above 140 mmhg at visit 1 ),Observation,Other,C1547225,mild,FALSE,FALSE,NA,NA,NA
3,NCT02495324,Inclusion,subjects whose mean sitting sbp ( sisbp ) of 3 measurements is above 140 mmhg at visit 2 with mild to moderate essential hypertension ( subjects who have not taken anti-hypertensive drugs within 3 months should have mean sisbp above 140 mmhg at visit 1 ),Observation,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
4,NCT02495324,Inclusion,subject who can understand the trial procedures and be willing to cooperate the trial,Other,NA,NA,NA,NA,NA,NA,NA,NA
5,NCT02495324,Exclusion,severe hypertension patients with mean sisbp > = 180 mmhg or sidbp > = 110 mmhg at the assessment of screening visit ( visit1 ) and baseline visit ( visit2 ) .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,greater_equal 180 mmhg; greater_equal 110 mmhg,NA
5,NCT02495324,Exclusion,severe hypertension patients with mean sisbp > = 180 mmhg or sidbp > = 110 mmhg at the assessment of screening visit ( visit1 ) and baseline visit ( visit2 ) .,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
5,NCT02495324,Exclusion,severe hypertension patients with mean sisbp > = 180 mmhg or sidbp > = 110 mmhg at the assessment of screening visit ( visit1 ) and baseline visit ( visit2 ) .,Observation,Other,C0542573;C0549068;C0870300;C0549070;C0549071;C0549072;C0549073;C0549074;C0028708;C0549075;C0549076;C0549077;C0549078;C0549079;C0549080;C0679207,assessment,FALSE,FALSE,NA,NA,NA
6,NCT02495324,Exclusion,patients whose difference between maximum and minimum among 3 times of blood pressure measurement is over 20 mmhg ( sisbp ) or 10 mmhg ( sidbp ) at visit1 and visit2 .,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,greater 20 mmhg; equal 10 mmhg,equal 3 times
7,NCT02495324,Exclusion,patients whose medication compliance is under 70 % at visit 2 .,Drug Exposure,Other,C3489773;C2364172,medication compliance,FALSE,FALSE,NA,NA,lower 70 %
8,NCT02495324,Exclusion,secondary hypertension patients ; but not limited to the following diseases ( example : renovascular disease ; adrenal medullary and cortical hyperfunctions ; coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing syndrome ; pheochromocytoma ; polycystic kidney disease ; etc ) .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
8,NCT02495324,Exclusion,secondary hypertension patients ; but not limited to the following diseases ( example : renovascular disease ; adrenal medullary and cortical hyperfunctions ; coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing syndrome ; pheochromocytoma ; polycystic kidney disease ; etc ) .,Condition Occurrence,Condition,C0268790,renovascular,FALSE,FALSE,NA,NA,NA
8,NCT02495324,Exclusion,secondary hypertension patients ; but not limited to the following diseases ( example : renovascular disease ; adrenal medullary and cortical hyperfunctions ; coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing syndrome ; pheochromocytoma ; polycystic kidney disease ; etc ) .,Condition Occurrence,Condition,C0001629;C1550278,medullary,FALSE,FALSE,NA,NA,NA
8,NCT02495324,Exclusion,secondary hypertension patients ; but not limited to the following diseases ( example : renovascular disease ; adrenal medullary and cortical hyperfunctions ; coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing syndrome ; pheochromocytoma ; polycystic kidney disease ; etc ) .,Condition Occurrence,Condition,C0001613;C0007776;C0022655,cortical,FALSE,FALSE,NA,NA,NA
8,NCT02495324,Exclusion,secondary hypertension patients ; but not limited to the following diseases ( example : renovascular disease ; adrenal medullary and cortical hyperfunctions ; coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing syndrome ; pheochromocytoma ; polycystic kidney disease ; etc ) .,Condition Occurrence,Condition,C0332886,coarctation,FALSE,FALSE,NA,NA,NA
8,NCT02495324,Exclusion,secondary hypertension patients ; but not limited to the following diseases ( example : renovascular disease ; adrenal medullary and cortical hyperfunctions ; coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing syndrome ; pheochromocytoma ; polycystic kidney disease ; etc ) .,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
8,NCT02495324,Exclusion,secondary hypertension patients ; but not limited to the following diseases ( example : renovascular disease ; adrenal medullary and cortical hyperfunctions ; coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing syndrome ; pheochromocytoma ; polycystic kidney disease ; etc ) .,Condition Occurrence,Condition,C0035065;C1278951,renal artery,FALSE,FALSE,NA,NA,NA
8,NCT02495324,Exclusion,secondary hypertension patients ; but not limited to the following diseases ( example : renovascular disease ; adrenal medullary and cortical hyperfunctions ; coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing syndrome ; pheochromocytoma ; polycystic kidney disease ; etc ) .,Condition Occurrence,Condition,C0020428,hyperaldosteronism,FALSE,FALSE,NA,NA,NA
8,NCT02495324,Exclusion,secondary hypertension patients ; but not limited to the following diseases ( example : renovascular disease ; adrenal medullary and cortical hyperfunctions ; coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing syndrome ; pheochromocytoma ; polycystic kidney disease ; etc ) .,Condition Occurrence,Condition,C0010481,cushing syndrome,FALSE,FALSE,NA,NA,NA
8,NCT02495324,Exclusion,secondary hypertension patients ; but not limited to the following diseases ( example : renovascular disease ; adrenal medullary and cortical hyperfunctions ; coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing syndrome ; pheochromocytoma ; polycystic kidney disease ; etc ) .,Condition Occurrence,Condition,C0022680,polycystic kidney disease,FALSE,FALSE,NA,NA,NA
8,NCT02495324,Exclusion,secondary hypertension patients ; but not limited to the following diseases ( example : renovascular disease ; adrenal medullary and cortical hyperfunctions ; coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing syndrome ; pheochromocytoma ; polycystic kidney disease ; etc ) .,Condition Occurrence,Condition,C0031511;C1706920,pheochromocytoma,FALSE,FALSE,NA,NA,NA
8,NCT02495324,Exclusion,secondary hypertension patients ; but not limited to the following diseases ( example : renovascular disease ; adrenal medullary and cortical hyperfunctions ; coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing syndrome ; pheochromocytoma ; polycystic kidney disease ; etc ) .,Condition Occurrence,Other,C3542948,limited,TRUE,FALSE,NA,NA,NA
8,NCT02495324,Exclusion,secondary hypertension patients ; but not limited to the following diseases ( example : renovascular disease ; adrenal medullary and cortical hyperfunctions ; coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing syndrome ; pheochromocytoma ; polycystic kidney disease ; etc ) .,Condition Occurrence,Other,C0521428;C1445654,adrenal,FALSE,FALSE,NA,NA,NA
8,NCT02495324,Exclusion,secondary hypertension patients ; but not limited to the following diseases ( example : renovascular disease ; adrenal medullary and cortical hyperfunctions ; coarctation of the aorta ; hyperaldosteronism ; unilateral renal artery or bilateral renal artery stenosis ; cushing syndrome ; pheochromocytoma ; polycystic kidney disease ; etc ) .,Condition Occurrence,Other,C0869784;C0003483;C1278934,aorta,FALSE,FALSE,NA,NA,NA
9,NCT02495324,Exclusion,patients who have postural hypotension with manifestation .,Condition Occurrence,Condition,C0020651,postural hypotension,FALSE,FALSE,NA,NA,NA
10,NCT02495324,Exclusion,subjects with severe insulin-dependent diabetes mellitus ( dm ) or uncontrolled dm ( hba1c > 9 % at screening visit ; modified dosage of an oral hypoglycemic agent within 12 weeks prior to screening visit ; or currently use of active insulin treatment ) .,Condition Occurrence,Condition,C0011854,insulin-dependent diabetes mellitus,FALSE,FALSE,NA,NA,NA
10,NCT02495324,Exclusion,subjects with severe insulin-dependent diabetes mellitus ( dm ) or uncontrolled dm ( hba1c > 9 % at screening visit ; modified dosage of an oral hypoglycemic agent within 12 weeks prior to screening visit ; or currently use of active insulin treatment ) .,Condition Occurrence,Condition,C0027126;C1512047,dm,FALSE,FALSE,NA,NA,NA
10,NCT02495324,Exclusion,subjects with severe insulin-dependent diabetes mellitus ( dm ) or uncontrolled dm ( hba1c > 9 % at screening visit ; modified dosage of an oral hypoglycemic agent within 12 weeks prior to screening visit ; or currently use of active insulin treatment ) .,Condition Occurrence,Condition,C0027126;C1512047,dm,FALSE,FALSE,NA,NA,NA
10,NCT02495324,Exclusion,subjects with severe insulin-dependent diabetes mellitus ( dm ) or uncontrolled dm ( hba1c > 9 % at screening visit ; modified dosage of an oral hypoglycemic agent within 12 weeks prior to screening visit ; or currently use of active insulin treatment ) .,Condition Occurrence,Drug,C0359086,oral hypoglycemic agent,FALSE,FALSE,lower 12 weeks,NA,NA
10,NCT02495324,Exclusion,subjects with severe insulin-dependent diabetes mellitus ( dm ) or uncontrolled dm ( hba1c > 9 % at screening visit ; modified dosage of an oral hypoglycemic agent within 12 weeks prior to screening visit ; or currently use of active insulin treatment ) .,Condition Occurrence,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
10,NCT02495324,Exclusion,subjects with severe insulin-dependent diabetes mellitus ( dm ) or uncontrolled dm ( hba1c > 9 % at screening visit ; modified dosage of an oral hypoglycemic agent within 12 weeks prior to screening visit ; or currently use of active insulin treatment ) .,Condition Occurrence,Procedure,C0745343,insulin treatment,FALSE,FALSE,NA,NA,NA
10,NCT02495324,Exclusion,subjects with severe insulin-dependent diabetes mellitus ( dm ) or uncontrolled dm ( hba1c > 9 % at screening visit ; modified dosage of an oral hypoglycemic agent within 12 weeks prior to screening visit ; or currently use of active insulin treatment ) .,Condition Occurrence,Observation,C0202054,hba1c,FALSE,FALSE,NA,NA,greater 9 %
10,NCT02495324,Exclusion,subjects with severe insulin-dependent diabetes mellitus ( dm ) or uncontrolled dm ( hba1c > 9 % at screening visit ; modified dosage of an oral hypoglycemic agent within 12 weeks prior to screening visit ; or currently use of active insulin treatment ) .,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
11,NCT02495324,Exclusion,history of malignant tumor including leukemia and lymphoma in the past 5 years . ;,Condition Occurrence,Condition,C0006826,malignant tumor,FALSE,FALSE,NA,NA,NA
11,NCT02495324,Exclusion,history of malignant tumor including leukemia and lymphoma in the past 5 years . ;,Condition Occurrence,Condition,C0023418,leukemia,FALSE,FALSE,lower_equal 5 past years,NA,NA
11,NCT02495324,Exclusion,history of malignant tumor including leukemia and lymphoma in the past 5 years . ;,Condition Occurrence,Condition,C0024299,lymphoma,FALSE,FALSE,lower_equal 5 past years,NA,NA
12,NCT02495324,Exclusion,subjects with chronic inflammatory disease requiring an chronic anti-inflammatory therapy ; past or current medical history with wasting disease ; autoimmune diseases ( eg rheumatoid arthritis ; systemic lupus erythematosus ) or connective tissue disease .,Condition Occurrence,Condition,C1290886,chronic inflammatory disease,FALSE,FALSE,NA,NA,NA
12,NCT02495324,Exclusion,subjects with chronic inflammatory disease requiring an chronic anti-inflammatory therapy ; past or current medical history with wasting disease ; autoimmune diseases ( eg rheumatoid arthritis ; systemic lupus erythematosus ) or connective tissue disease .,Condition Occurrence,Condition,C0262926,medical history,FALSE,FALSE,NA,NA,NA
12,NCT02495324,Exclusion,subjects with chronic inflammatory disease requiring an chronic anti-inflammatory therapy ; past or current medical history with wasting disease ; autoimmune diseases ( eg rheumatoid arthritis ; systemic lupus erythematosus ) or connective tissue disease .,Condition Occurrence,Condition,C0043046,wasting disease,FALSE,FALSE,NA,NA,NA
12,NCT02495324,Exclusion,subjects with chronic inflammatory disease requiring an chronic anti-inflammatory therapy ; past or current medical history with wasting disease ; autoimmune diseases ( eg rheumatoid arthritis ; systemic lupus erythematosus ) or connective tissue disease .,Condition Occurrence,Condition,C0004364,autoimmune diseases,FALSE,FALSE,NA,NA,NA
12,NCT02495324,Exclusion,subjects with chronic inflammatory disease requiring an chronic anti-inflammatory therapy ; past or current medical history with wasting disease ; autoimmune diseases ( eg rheumatoid arthritis ; systemic lupus erythematosus ) or connective tissue disease .,Condition Occurrence,Condition,C0003873,rheumatoid arthritis systemic,FALSE,FALSE,NA,NA,NA
12,NCT02495324,Exclusion,subjects with chronic inflammatory disease requiring an chronic anti-inflammatory therapy ; past or current medical history with wasting disease ; autoimmune diseases ( eg rheumatoid arthritis ; systemic lupus erythematosus ) or connective tissue disease .,Condition Occurrence,Condition,C0409974,lupus erythematosus,FALSE,FALSE,NA,NA,NA
12,NCT02495324,Exclusion,subjects with chronic inflammatory disease requiring an chronic anti-inflammatory therapy ; past or current medical history with wasting disease ; autoimmune diseases ( eg rheumatoid arthritis ; systemic lupus erythematosus ) or connective tissue disease .,Condition Occurrence,Condition,C0009782,connective tissue disease,FALSE,FALSE,NA,NA,NA
12,NCT02495324,Exclusion,subjects with chronic inflammatory disease requiring an chronic anti-inflammatory therapy ; past or current medical history with wasting disease ; autoimmune diseases ( eg rheumatoid arthritis ; systemic lupus erythematosus ) or connective tissue disease .,Condition Occurrence,Other,C1547296;C1555457,chronic,FALSE,FALSE,NA,NA,NA
13,NCT02495324,Exclusion,medical history with hypersensitivity to angiotensin ii antagonist .,Observation,Condition,C0262926,medical history,FALSE,FALSE,NA,NA,NA
13,NCT02495324,Exclusion,medical history with hypersensitivity to angiotensin ii antagonist .,Observation,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
13,NCT02495324,Exclusion,medical history with hypersensitivity to angiotensin ii antagonist .,Observation,Other,C0373546;C0003009,angiotensin ii,FALSE,FALSE,NA,NA,NA
14,NCT02495324,Exclusion,clinically significant renal disorders and liver disorders such as dialysis ; cirrhosis ; biliary obstruction ; cholestasis and liver failure,Condition Occurrence,Condition,C0022658,renal disorders,FALSE,FALSE,NA,NA,NA
14,NCT02495324,Exclusion,clinically significant renal disorders and liver disorders such as dialysis ; cirrhosis ; biliary obstruction ; cholestasis and liver failure,Condition Occurrence,Condition,C0023895,liver disorders,FALSE,FALSE,NA,NA,NA
14,NCT02495324,Exclusion,clinically significant renal disorders and liver disorders such as dialysis ; cirrhosis ; biliary obstruction ; cholestasis and liver failure,Condition Occurrence,Condition,C0085605,liver failure,FALSE,FALSE,NA,NA,NA
14,NCT02495324,Exclusion,clinically significant renal disorders and liver disorders such as dialysis ; cirrhosis ; biliary obstruction ; cholestasis and liver failure,Condition Occurrence,Condition,C0008370,cholestasis,FALSE,FALSE,NA,NA,NA
14,NCT02495324,Exclusion,clinically significant renal disorders and liver disorders such as dialysis ; cirrhosis ; biliary obstruction ; cholestasis and liver failure,Condition Occurrence,Condition,C0023892,cirrhosis biliary,FALSE,FALSE,NA,NA,NA
14,NCT02495324,Exclusion,clinically significant renal disorders and liver disorders such as dialysis ; cirrhosis ; biliary obstruction ; cholestasis and liver failure,Condition Occurrence,Procedure,C0011946;C0917873,dialysis,FALSE,FALSE,NA,NA,NA
15,NCT02495324,Exclusion,patients who have below abnormality in the laboratory results at screening visit .,Observation,Observation,C1254595,laboratory results,FALSE,FALSE,NA,NA,NA
16,NCT02495324,Exclusion,creatinine clearance ( cockroft-gault ) < 30 ml / min,Observation,Observation,C0373595;C0812399,creatinine clearance,FALSE,FALSE,NA,lower 30 ml/min,NA
17,NCT02495324,Exclusion,alt ; ast > = 2 times upper normal limit,Observation,Condition,C1265570,normal limit,FALSE,FALSE,NA,NA,NA
17,NCT02495324,Exclusion,alt ; ast > = 2 times upper normal limit,Observation,Observation,C1140170;C2257651,alt,FALSE,FALSE,NA,NA,greater_equal 2 times
17,NCT02495324,Exclusion,alt ; ast > = 2 times upper normal limit,Observation,Observation,C0004002,ast,FALSE,FALSE,NA,NA,greater_equal 2 times
18,NCT02495324,Exclusion,clinically significant hypokalemia ( k < 3.5 mmol / l ) or hyperkalemia ( k > 5.55 mmol / l ),Observation,Condition,C0020621,hypokalemia,FALSE,FALSE,NA,lower 3.5 mmol/l,NA
18,NCT02495324,Exclusion,clinically significant hypokalemia ( k < 3.5 mmol / l ) or hyperkalemia ( k > 5.55 mmol / l ),Observation,Condition,C0020461,hyperkalemia,FALSE,FALSE,NA,greater 5.55 mmol/l,NA
19,NCT02495324,Exclusion,subjects have history of any of the followings within the past 6 months or determined clinically significant by investigators .,Other,NA,NA,NA,NA,NA,NA,NA,NA
20,NCT02495324,Exclusion,severe heart disease ( heart failure new york heart association ( nyha ) class 3 and class 4 ) ; ischemic heart disease ( angina pectoris ; myocardial infarction ) ; peripheral vascular disease ; percutaneous transluminal coronary angioplasty or coronary artery bypass graft .,Condition Occurrence,Condition,C0018799,heart disease,FALSE,FALSE,NA,NA,NA
20,NCT02495324,Exclusion,severe heart disease ( heart failure new york heart association ( nyha ) class 3 and class 4 ) ; ischemic heart disease ( angina pectoris ; myocardial infarction ) ; peripheral vascular disease ; percutaneous transluminal coronary angioplasty or coronary artery bypass graft .,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
20,NCT02495324,Exclusion,severe heart disease ( heart failure new york heart association ( nyha ) class 3 and class 4 ) ; ischemic heart disease ( angina pectoris ; myocardial infarction ) ; peripheral vascular disease ; percutaneous transluminal coronary angioplasty or coronary artery bypass graft .,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
20,NCT02495324,Exclusion,severe heart disease ( heart failure new york heart association ( nyha ) class 3 and class 4 ) ; ischemic heart disease ( angina pectoris ; myocardial infarction ) ; peripheral vascular disease ; percutaneous transluminal coronary angioplasty or coronary artery bypass graft .,Condition Occurrence,Condition,C1882083,nyha class,FALSE,FALSE,NA,NA,NA
20,NCT02495324,Exclusion,severe heart disease ( heart failure new york heart association ( nyha ) class 3 and class 4 ) ; ischemic heart disease ( angina pectoris ; myocardial infarction ) ; peripheral vascular disease ; percutaneous transluminal coronary angioplasty or coronary artery bypass graft .,Condition Occurrence,Condition,C0151744;C1313980,ischemic heart disease,FALSE,FALSE,NA,NA,NA
20,NCT02495324,Exclusion,severe heart disease ( heart failure new york heart association ( nyha ) class 3 and class 4 ) ; ischemic heart disease ( angina pectoris ; myocardial infarction ) ; peripheral vascular disease ; percutaneous transluminal coronary angioplasty or coronary artery bypass graft .,Condition Occurrence,Condition,C0002962;C0577698;C0235467;C0542052;C0010073;C0541777;C0235462,angina pectoris,FALSE,FALSE,NA,NA,NA
20,NCT02495324,Exclusion,severe heart disease ( heart failure new york heart association ( nyha ) class 3 and class 4 ) ; ischemic heart disease ( angina pectoris ; myocardial infarction ) ; peripheral vascular disease ; percutaneous transluminal coronary angioplasty or coronary artery bypass graft .,Condition Occurrence,Condition,C0085096,peripheral vascular disease,FALSE,FALSE,NA,NA,NA
20,NCT02495324,Exclusion,severe heart disease ( heart failure new york heart association ( nyha ) class 3 and class 4 ) ; ischemic heart disease ( angina pectoris ; myocardial infarction ) ; peripheral vascular disease ; percutaneous transluminal coronary angioplasty or coronary artery bypass graft .,Condition Occurrence,Procedure,C0010055,coronary artery bypass graft,FALSE,FALSE,NA,NA,NA
20,NCT02495324,Exclusion,severe heart disease ( heart failure new york heart association ( nyha ) class 3 and class 4 ) ; ischemic heart disease ( angina pectoris ; myocardial infarction ) ; peripheral vascular disease ; percutaneous transluminal coronary angioplasty or coronary artery bypass graft .,Condition Occurrence,Procedure,C2936173,percutaneous transluminal coronary angioplasty,FALSE,FALSE,NA,NA,NA
20,NCT02495324,Exclusion,severe heart disease ( heart failure new york heart association ( nyha ) class 3 and class 4 ) ; ischemic heart disease ( angina pectoris ; myocardial infarction ) ; peripheral vascular disease ; percutaneous transluminal coronary angioplasty or coronary artery bypass graft .,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
20,NCT02495324,Exclusion,severe heart disease ( heart failure new york heart association ( nyha ) class 3 and class 4 ) ; ischemic heart disease ( angina pectoris ; myocardial infarction ) ; peripheral vascular disease ; percutaneous transluminal coronary angioplasty or coronary artery bypass graft .,Condition Occurrence,Other,C0456387;C0489477,class,FALSE,FALSE,NA,NA,NA
20,NCT02495324,Exclusion,severe heart disease ( heart failure new york heart association ( nyha ) class 3 and class 4 ) ; ischemic heart disease ( angina pectoris ; myocardial infarction ) ; peripheral vascular disease ; percutaneous transluminal coronary angioplasty or coronary artery bypass graft .,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
21,NCT02495324,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically significant aortic valve stenosis ; or mitral valve stenosis .,Condition Occurrence,Condition,C0007194,hypertrophic obstructive cardiomyopathy,FALSE,FALSE,NA,NA,NA
21,NCT02495324,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically significant aortic valve stenosis ; or mitral valve stenosis .,Condition Occurrence,Condition,C1956346;C0010068;C0010054,coronary artery disease,FALSE,FALSE,NA,NA,NA
21,NCT02495324,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically significant aortic valve stenosis ; or mitral valve stenosis .,Condition Occurrence,Condition,C0003507,aortic stenosis,FALSE,FALSE,NA,NA,NA
21,NCT02495324,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically significant aortic valve stenosis ; or mitral valve stenosis .,Condition Occurrence,Condition,C0003507;C3542024,aortic valve stenosis,FALSE,FALSE,NA,NA,NA
21,NCT02495324,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically significant aortic valve stenosis ; or mitral valve stenosis .,Condition Occurrence,Condition,C0026269;C0264766,mitral valve stenosis,FALSE,FALSE,NA,NA,NA
21,NCT02495324,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically significant aortic valve stenosis ; or mitral valve stenosis .,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
22,NCT02495324,Exclusion,clinically significant ventricular tachycardia ; atrial fibrillation ; atrial flutter or any other clinical significant arrhythmia .,Condition Occurrence,Condition,C0042514;C1963247;C2108113,ventricular tachycardia,FALSE,FALSE,NA,NA,NA
22,NCT02495324,Exclusion,clinically significant ventricular tachycardia ; atrial fibrillation ; atrial flutter or any other clinical significant arrhythmia .,Condition Occurrence,Condition,C0004239;C1963068,atrial flutter,FALSE,FALSE,NA,NA,NA
22,NCT02495324,Exclusion,clinically significant ventricular tachycardia ; atrial fibrillation ; atrial flutter or any other clinical significant arrhythmia .,Condition Occurrence,Condition,C0003811,arrhythmia,FALSE,FALSE,NA,NA,NA
22,NCT02495324,Exclusion,clinically significant ventricular tachycardia ; atrial fibrillation ; atrial flutter or any other clinical significant arrhythmia .,Condition Occurrence,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
22,NCT02495324,Exclusion,clinically significant ventricular tachycardia ; atrial fibrillation ; atrial flutter or any other clinical significant arrhythmia .,Condition Occurrence,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
23,NCT02495324,Exclusion,severe cerebrovascular disorder ( egstroke ; cerebral infarction or cerebral hemorrhage ),Condition Occurrence,Condition,C0007820,cerebrovascular disorder,FALSE,FALSE,NA,NA,NA
23,NCT02495324,Exclusion,severe cerebrovascular disorder ( egstroke ; cerebral infarction or cerebral hemorrhage ),Condition Occurrence,Condition,C0007785;C0038454,cerebral infarction,FALSE,FALSE,NA,NA,NA
23,NCT02495324,Exclusion,severe cerebrovascular disorder ( egstroke ; cerebral infarction or cerebral hemorrhage ),Condition Occurrence,Condition,C2937358;C0007784,cerebral hemorrhage,FALSE,FALSE,NA,NA,NA
23,NCT02495324,Exclusion,severe cerebrovascular disorder ( egstroke ; cerebral infarction or cerebral hemorrhage ),Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
24,NCT02495324,Exclusion,subjects with known moderate retinosis or malignant retinosis in the past 6 months ( eg retinal hemorrhage ; visual disturbance or retinal microaneurysm ),Condition Occurrence,Condition,C0334590;C1533592,malignant,FALSE,FALSE,lower_equal 6 past months,NA,NA
24,NCT02495324,Exclusion,subjects with known moderate retinosis or malignant retinosis in the past 6 months ( eg retinal hemorrhage ; visual disturbance or retinal microaneurysm ),Condition Occurrence,Condition,C0035317,retinal hemorrhage,FALSE,FALSE,NA,NA,NA
24,NCT02495324,Exclusion,subjects with known moderate retinosis or malignant retinosis in the past 6 months ( eg retinal hemorrhage ; visual disturbance or retinal microaneurysm ),Condition Occurrence,Condition,C0154834,retinal microaneurysm,FALSE,FALSE,NA,NA,NA
24,NCT02495324,Exclusion,subjects with known moderate retinosis or malignant retinosis in the past 6 months ( eg retinal hemorrhage ; visual disturbance or retinal microaneurysm ),Condition Occurrence,Condition,C0547030,visual disturbance,FALSE,FALSE,NA,NA,NA
24,NCT02495324,Exclusion,subjects with known moderate retinosis or malignant retinosis in the past 6 months ( eg retinal hemorrhage ; visual disturbance or retinal microaneurysm ),Condition Occurrence,Other,C1547226,moderate,FALSE,FALSE,lower_equal 6 past months,NA,NA
25,NCT02495324,Exclusion,subjects with history of abusing drugs or alcohol within the past 2 years .,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,lower 2 past years,NA,NA
25,NCT02495324,Exclusion,subjects with history of abusing drugs or alcohol within the past 2 years .,Drug Exposure,Other,C0001975;C0001962;C1547288,alcohol,FALSE,FALSE,lower 2 past years,NA,NA
26,NCT02495324,Exclusion,pregnant women or lactating female . ;,Person,Person,C0033011,pregnant women,FALSE,FALSE,NA,NA,NA
26,NCT02495324,Exclusion,pregnant women or lactating female . ;,Person,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
26,NCT02495324,Exclusion,pregnant women or lactating female . ;,Person,Condition,C2828358;C3668831,lactating,FALSE,FALSE,NA,NA,NA
27,NCT02495324,Exclusion,subjects with following surgical disease and internal disease that may affect absorption ; distribution ; metabolism or excretion of drugs and have conditions which include the following ( but are not limited to ) : history of major gastrointestinal surgeries including gastrectomy ; gastro-enterostomy or bowel resection ; gastrointestinal bypass graft and stabling,Procedure,Condition,C0504085,excretion,FALSE,FALSE,NA,NA,NA
27,NCT02495324,Exclusion,subjects with following surgical disease and internal disease that may affect absorption ; distribution ; metabolism or excretion of drugs and have conditions which include the following ( but are not limited to ) : history of major gastrointestinal surgeries including gastrectomy ; gastro-enterostomy or bowel resection ; gastrointestinal bypass graft and stabling,Procedure,Condition,C0025519,metabolism,FALSE,FALSE,NA,NA,NA
27,NCT02495324,Exclusion,subjects with following surgical disease and internal disease that may affect absorption ; distribution ; metabolism or excretion of drugs and have conditions which include the following ( but are not limited to ) : history of major gastrointestinal surgeries including gastrectomy ; gastro-enterostomy or bowel resection ; gastrointestinal bypass graft and stabling,Procedure,Condition,C1378698,distribution,FALSE,FALSE,NA,NA,NA
27,NCT02495324,Exclusion,subjects with following surgical disease and internal disease that may affect absorption ; distribution ; metabolism or excretion of drugs and have conditions which include the following ( but are not limited to ) : history of major gastrointestinal surgeries including gastrectomy ; gastro-enterostomy or bowel resection ; gastrointestinal bypass graft and stabling,Procedure,Condition,C1559265,gastrointestinal,FALSE,FALSE,NA,NA,NA
27,NCT02495324,Exclusion,subjects with following surgical disease and internal disease that may affect absorption ; distribution ; metabolism or excretion of drugs and have conditions which include the following ( but are not limited to ) : history of major gastrointestinal surgeries including gastrectomy ; gastro-enterostomy or bowel resection ; gastrointestinal bypass graft and stabling,Procedure,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
27,NCT02495324,Exclusion,subjects with following surgical disease and internal disease that may affect absorption ; distribution ; metabolism or excretion of drugs and have conditions which include the following ( but are not limited to ) : history of major gastrointestinal surgeries including gastrectomy ; gastro-enterostomy or bowel resection ; gastrointestinal bypass graft and stabling,Procedure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
27,NCT02495324,Exclusion,subjects with following surgical disease and internal disease that may affect absorption ; distribution ; metabolism or excretion of drugs and have conditions which include the following ( but are not limited to ) : history of major gastrointestinal surgeries including gastrectomy ; gastro-enterostomy or bowel resection ; gastrointestinal bypass graft and stabling,Procedure,Procedure,C0524722,gastrointestinal surgeries,FALSE,FALSE,NA,NA,NA
27,NCT02495324,Exclusion,subjects with following surgical disease and internal disease that may affect absorption ; distribution ; metabolism or excretion of drugs and have conditions which include the following ( but are not limited to ) : history of major gastrointestinal surgeries including gastrectomy ; gastro-enterostomy or bowel resection ; gastrointestinal bypass graft and stabling,Procedure,Procedure,C0741614,bowel resection,FALSE,FALSE,NA,NA,NA
27,NCT02495324,Exclusion,subjects with following surgical disease and internal disease that may affect absorption ; distribution ; metabolism or excretion of drugs and have conditions which include the following ( but are not limited to ) : history of major gastrointestinal surgeries including gastrectomy ; gastro-enterostomy or bowel resection ; gastrointestinal bypass graft and stabling,Procedure,Procedure,C0185098,bypass graft,FALSE,FALSE,NA,NA,NA
27,NCT02495324,Exclusion,subjects with following surgical disease and internal disease that may affect absorption ; distribution ; metabolism or excretion of drugs and have conditions which include the following ( but are not limited to ) : history of major gastrointestinal surgeries including gastrectomy ; gastro-enterostomy or bowel resection ; gastrointestinal bypass graft and stabling,Procedure,Other,C1619620;C1553872,internal,FALSE,FALSE,NA,NA,NA
27,NCT02495324,Exclusion,subjects with following surgical disease and internal disease that may affect absorption ; distribution ; metabolism or excretion of drugs and have conditions which include the following ( but are not limited to ) : history of major gastrointestinal surgeries including gastrectomy ; gastro-enterostomy or bowel resection ; gastrointestinal bypass graft and stabling,Procedure,Other,C3542948,limited,TRUE,FALSE,NA,NA,NA
27,NCT02495324,Exclusion,subjects with following surgical disease and internal disease that may affect absorption ; distribution ; metabolism or excretion of drugs and have conditions which include the following ( but are not limited to ) : history of major gastrointestinal surgeries including gastrectomy ; gastro-enterostomy or bowel resection ; gastrointestinal bypass graft and stabling,Procedure,Other,C0017164;C2237939,gastro-enterostomy,FALSE,FALSE,NA,NA,NA
28,NCT02495324,Exclusion,current active gastritis ; gastrointestinal bleeding and rectal bleeding ; presence of active inflammatory bowel syndrome within the past 12 months .,Condition Occurrence,Condition,C0017152,gastritis,FALSE,FALSE,NA,NA,NA
28,NCT02495324,Exclusion,current active gastritis ; gastrointestinal bleeding and rectal bleeding ; presence of active inflammatory bowel syndrome within the past 12 months .,Condition Occurrence,Condition,C0267596,rectal bleeding,FALSE,FALSE,NA,NA,NA
28,NCT02495324,Exclusion,current active gastritis ; gastrointestinal bleeding and rectal bleeding ; presence of active inflammatory bowel syndrome within the past 12 months .,Condition Occurrence,Condition,C0017181,gastrointestinal bleeding,FALSE,FALSE,NA,NA,NA
28,NCT02495324,Exclusion,current active gastritis ; gastrointestinal bleeding and rectal bleeding ; presence of active inflammatory bowel syndrome within the past 12 months .,Condition Occurrence,Condition,C0021853,bowel,FALSE,FALSE,lower 12 past months,NA,NA
28,NCT02495324,Exclusion,current active gastritis ; gastrointestinal bleeding and rectal bleeding ; presence of active inflammatory bowel syndrome within the past 12 months .,Condition Occurrence,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
28,NCT02495324,Exclusion,current active gastritis ; gastrointestinal bleeding and rectal bleeding ; presence of active inflammatory bowel syndrome within the past 12 months .,Condition Occurrence,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
29,NCT02495324,Exclusion,subjects with shock ; depletion of body fluid or sodium ion not able to correct .,Drug Exposure,Condition,C0005889,body fluid,FALSE,FALSE,NA,NA,NA
29,NCT02495324,Exclusion,subjects with shock ; depletion of body fluid or sodium ion not able to correct .,Drug Exposure,Drug,C0597484,sodium ion,FALSE,FALSE,NA,NA,NA
29,NCT02495324,Exclusion,subjects with shock ; depletion of body fluid or sodium ion not able to correct .,Drug Exposure,Other,C0719517;C1548444,correct,TRUE,FALSE,NA,NA,NA
30,NCT02495324,Exclusion,subjects with hereditary disorders of galactose intolerance ; lapp lactase deficiency or glucose-galactose malabsorption .,Condition Occurrence,Condition,C0019247,hereditary disorders,FALSE,FALSE,NA,NA,NA
30,NCT02495324,Exclusion,subjects with hereditary disorders of galactose intolerance ; lapp lactase deficiency or glucose-galactose malabsorption .,Condition Occurrence,Condition,C0016952,galactose intolerance,FALSE,FALSE,NA,NA,NA
30,NCT02495324,Exclusion,subjects with hereditary disorders of galactose intolerance ; lapp lactase deficiency or glucose-galactose malabsorption .,Condition Occurrence,Condition,C0268186,glucose-galactose malabsorption,FALSE,FALSE,NA,NA,NA
30,NCT02495324,Exclusion,subjects with hereditary disorders of galactose intolerance ; lapp lactase deficiency or glucose-galactose malabsorption .,Condition Occurrence,Condition,C0302813,lactase deficiency,FALSE,FALSE,NA,NA,NA
31,NCT02495324,Exclusion,medical history with clinically significant hypersensitivity to any components or other drugs on the investigational product or additives ( yellow4 and yellow 5 ) .,Observation,Condition,C0262926,medical history,FALSE,FALSE,NA,NA,NA
31,NCT02495324,Exclusion,medical history with clinically significant hypersensitivity to any components or other drugs on the investigational product or additives ( yellow4 and yellow 5 ) .,Observation,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
31,NCT02495324,Exclusion,medical history with clinically significant hypersensitivity to any components or other drugs on the investigational product or additives ( yellow4 and yellow 5 ) .,Observation,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
31,NCT02495324,Exclusion,medical history with clinically significant hypersensitivity to any components or other drugs on the investigational product or additives ( yellow4 and yellow 5 ) .,Observation,Other,C3245491,investigational,FALSE,FALSE,NA,equal 5,NA
32,NCT02495324,Exclusion,subjects planning pregnancy or childbearing potential who are not using effective contraceptive methods .,Condition Occurrence,Condition,C0032992,planning pregnancy,FALSE,FALSE,NA,NA,NA
32,NCT02495324,Exclusion,subjects planning pregnancy or childbearing potential who are not using effective contraceptive methods .,Condition Occurrence,Procedure,C0700589,contraceptive methods,TRUE,FALSE,NA,NA,NA
32,NCT02495324,Exclusion,subjects planning pregnancy or childbearing potential who are not using effective contraceptive methods .,Condition Occurrence,Observation,C3831118,childbearing potential,FALSE,FALSE,NA,NA,NA
33,NCT02495324,Exclusion,subjects who are participating in another trial or took other investigational product within 12 weeks prior to screening visit .,Other,Other,C3245491,investigational,FALSE,FALSE,lower 12 weeks,NA,NA
34,NCT02495324,Exclusion,subjects with other reasons not specified above and ineligible to participate in this clinical trial at discretion of study investigators,Other,Other,C1096775,clinical trial,FALSE,FALSE,NA,NA,NA
27,NCT02495324,Exclusion,subjects with following surgical disease and internal disease that may affect absorption ; distribution ; metabolism or excretion of drugs and have conditions which include the following ( but are not limited to ) : history of major gastrointestinal surgeries including gastrectomy ; gastro-enterostomy or bowel resection ; gastrointestinal bypass graft and stabling,Procedure,Procedure,C0017118,gastrectomy,FALSE,FALSE,NA,NA,NA
1,NCT02738632,Inclusion,19 years old or above koreans living in korea,Other,NA,NA,NA,NA,NA,NA,NA,NA
2,NCT02738632,Inclusion,patients with uncontrolled essential hypertension at screening time ( visit 1 ),Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT02738632,Inclusion,patients with uncontrolled essential hypertension at screening time ( visit 1 ),Condition Occurrence,Condition,C2024467,time,FALSE,FALSE,NA,NA,NA
3,NCT02738632,Inclusion,na ve : 160 mmhg < = sitsbp < 200 mmhg,Observation,NA,NA,NA,NA,NA,NA,NA,NA
4,NCT02738632,Inclusion,use antihypertensive drugs : 140 mmhg < = sitsbp < 200 mmhg,Observation,Drug,C0003364,antihypertensive drugs,FALSE,FALSE,NA,greater_equal 140 mmhg; lower 200 mmhg,NA
5,NCT02738632,Inclusion,patients with uncontrolled hypertension after telmisartamlodipine 40 / 5 mg treatment for 6 weeks at randomization ( visit 2 ),Drug Exposure,Condition,C1868885,uncontrolled hypertension,FALSE,FALSE,equal 6 weeks,NA,greater_equal 40 mg; lower_equal 5 mg
6,NCT02738632,Inclusion,140 mmhg < = sitsbp < 200 mmhg,Observation,NA,NA,NA,NA,NA,NA,NA,NA
7,NCT02738632,Inclusion,patients who agreed to participate in the trial,Other,NA,NA,NA,NA,NA,NA,NA,NA
8,NCT02738632,Exclusion,test results showing the following values at screening time ( visit 1 ),Condition Occurrence,Condition,C0456984,test results,FALSE,FALSE,NA,NA,NA
8,NCT02738632,Exclusion,test results showing the following values at screening time ( visit 1 ),Condition Occurrence,Condition,C2024467,time,FALSE,FALSE,NA,NA,NA
9,NCT02738632,Exclusion,the change of mean sitsbp > = 20 mmhg or sitdbp > = 10 mmhg on target arm between 1 st and 2 nd measurement,Observation,Condition,C0446516;C1140618;C1269078;C1269612,arm,FALSE,FALSE,NA,NA,NA
9,NCT02738632,Exclusion,the change of mean sitsbp > = 20 mmhg or sitdbp > = 10 mmhg on target arm between 1 st and 2 nd measurement,Observation,Observation,C2986546,target,FALSE,FALSE,NA,greater_equal 20 mmhg; greater_equal 10 mmhg,NA
10,NCT02738632,Exclusion,screening time ( visit 1 ) ; time of randomization ( visit 2 ) : sitdbp > = 120 mmhg ; patients with secondary blood pressure or suspected of secondary blood pressure ( for example ; aortic coarctation ; primary aldosteronism ; renal artery stenosis ; pheochromocytoma ),Condition Occurrence,Condition,C2024467,time,FALSE,FALSE,NA,NA,NA
10,NCT02738632,Exclusion,screening time ( visit 1 ) ; time of randomization ( visit 2 ) : sitdbp > = 120 mmhg ; patients with secondary blood pressure or suspected of secondary blood pressure ( for example ; aortic coarctation ; primary aldosteronism ; renal artery stenosis ; pheochromocytoma ),Condition Occurrence,Condition,C2024467,time,FALSE,FALSE,NA,greater_equal 120 mmhg,NA
10,NCT02738632,Exclusion,screening time ( visit 1 ) ; time of randomization ( visit 2 ) : sitdbp > = 120 mmhg ; patients with secondary blood pressure or suspected of secondary blood pressure ( for example ; aortic coarctation ; primary aldosteronism ; renal artery stenosis ; pheochromocytoma ),Condition Occurrence,Condition,C0003492,aortic coarctation,FALSE,FALSE,NA,NA,NA
10,NCT02738632,Exclusion,screening time ( visit 1 ) ; time of randomization ( visit 2 ) : sitdbp > = 120 mmhg ; patients with secondary blood pressure or suspected of secondary blood pressure ( for example ; aortic coarctation ; primary aldosteronism ; renal artery stenosis ; pheochromocytoma ),Condition Occurrence,Condition,C0031511;C1706920,pheochromocytoma,FALSE,FALSE,NA,NA,NA
10,NCT02738632,Exclusion,screening time ( visit 1 ) ; time of randomization ( visit 2 ) : sitdbp > = 120 mmhg ; patients with secondary blood pressure or suspected of secondary blood pressure ( for example ; aortic coarctation ; primary aldosteronism ; renal artery stenosis ; pheochromocytoma ),Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
10,NCT02738632,Exclusion,screening time ( visit 1 ) ; time of randomization ( visit 2 ) : sitdbp > = 120 mmhg ; patients with secondary blood pressure or suspected of secondary blood pressure ( for example ; aortic coarctation ; primary aldosteronism ; renal artery stenosis ; pheochromocytoma ),Condition Occurrence,Condition,C1384514,primary aldosteronism,FALSE,FALSE,NA,NA,NA
10,NCT02738632,Exclusion,screening time ( visit 1 ) ; time of randomization ( visit 2 ) : sitdbp > = 120 mmhg ; patients with secondary blood pressure or suspected of secondary blood pressure ( for example ; aortic coarctation ; primary aldosteronism ; renal artery stenosis ; pheochromocytoma ),Condition Occurrence,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
10,NCT02738632,Exclusion,screening time ( visit 1 ) ; time of randomization ( visit 2 ) : sitdbp > = 120 mmhg ; patients with secondary blood pressure or suspected of secondary blood pressure ( for example ; aortic coarctation ; primary aldosteronism ; renal artery stenosis ; pheochromocytoma ),Condition Occurrence,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
11,NCT02738632,Exclusion,patients with congestive heart failure ( nyha class iii ~,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
11,NCT02738632,Exclusion,patients with congestive heart failure ( nyha class iii ~,Condition Occurrence,Condition,C1882086,nyha class iii,FALSE,FALSE,NA,NA,NA
12,NCT02738632,Exclusion,patients with unstable angina or myocardial infarction or valvular heart disease within 6 months prior to study entry,Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,lower 6 months,NA,NA
12,NCT02738632,Exclusion,patients with unstable angina or myocardial infarction or valvular heart disease within 6 months prior to study entry,Condition Occurrence,Condition,C0018824;C1963123,valvular heart disease,FALSE,FALSE,lower 6 months,NA,NA
12,NCT02738632,Exclusion,patients with unstable angina or myocardial infarction or valvular heart disease within 6 months prior to study entry,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,lower 6 months,NA,NA
12,NCT02738632,Exclusion,patients with unstable angina or myocardial infarction or valvular heart disease within 6 months prior to study entry,Condition Occurrence,Other,C1705654,entry,FALSE,FALSE,NA,NA,NA
13,NCT02738632,Exclusion,patients who have severe ventricular tachycardia ; atrial fibrillation ; atrial flutter or clinically significant arrhythmia,Condition Occurrence,Condition,C0042514;C1963247;C2108113,ventricular tachycardia,FALSE,FALSE,NA,NA,NA
13,NCT02738632,Exclusion,patients who have severe ventricular tachycardia ; atrial fibrillation ; atrial flutter or clinically significant arrhythmia,Condition Occurrence,Condition,C0004239;C1963068,atrial flutter,FALSE,FALSE,NA,NA,NA
13,NCT02738632,Exclusion,patients who have severe ventricular tachycardia ; atrial fibrillation ; atrial flutter or clinically significant arrhythmia,Condition Occurrence,Condition,C0003811,arrhythmia,FALSE,FALSE,NA,NA,NA
13,NCT02738632,Exclusion,patients who have severe ventricular tachycardia ; atrial fibrillation ; atrial flutter or clinically significant arrhythmia,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
13,NCT02738632,Exclusion,patients who have severe ventricular tachycardia ; atrial fibrillation ; atrial flutter or clinically significant arrhythmia,Condition Occurrence,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
14,NCT02738632,Exclusion,patients who have history of cerebrovascular disease as cerebral infarction ; cerebral hemorrhage within 6 months prior to study entry,Condition Occurrence,Condition,C0007820,cerebrovascular disease,FALSE,FALSE,NA,NA,NA
14,NCT02738632,Exclusion,patients who have history of cerebrovascular disease as cerebral infarction ; cerebral hemorrhage within 6 months prior to study entry,Condition Occurrence,Condition,C0007785;C0038454,cerebral infarction,FALSE,FALSE,lower 6 months,NA,NA
14,NCT02738632,Exclusion,patients who have history of cerebrovascular disease as cerebral infarction ; cerebral hemorrhage within 6 months prior to study entry,Condition Occurrence,Condition,C2937358;C0007784,cerebral hemorrhage,FALSE,FALSE,lower 6 months,NA,NA
14,NCT02738632,Exclusion,patients who have history of cerebrovascular disease as cerebral infarction ; cerebral hemorrhage within 6 months prior to study entry,Condition Occurrence,Other,C1705654,entry,FALSE,FALSE,NA,NA,NA
15,NCT02738632,Exclusion,type i diabets mellitus or type ii diabetes mellitus with hba1c > 9 %,Drug Exposure,Condition,C0011860,type ii diabetes mellitus,FALSE,FALSE,NA,NA,NA
15,NCT02738632,Exclusion,type i diabets mellitus or type ii diabetes mellitus with hba1c > 9 %,Drug Exposure,Observation,C0202054,hba1c,FALSE,FALSE,NA,NA,greater 9 %
15,NCT02738632,Exclusion,type i diabets mellitus or type ii diabetes mellitus with hba1c > 9 %,Drug Exposure,Other,C1552651,type,FALSE,FALSE,NA,NA,NA
16,NCT02738632,Exclusion,patients who have history of severe retinopathy or malignant retinopathy within 6 months prior to study entry,Condition Occurrence,Condition,C0035309;C1962966,retinopathy,FALSE,FALSE,NA,NA,NA
16,NCT02738632,Exclusion,patients who have history of severe retinopathy or malignant retinopathy within 6 months prior to study entry,Condition Occurrence,Condition,C0334590;C1533592,malignant,FALSE,FALSE,NA,NA,NA
16,NCT02738632,Exclusion,patients who have history of severe retinopathy or malignant retinopathy within 6 months prior to study entry,Condition Occurrence,Condition,C0035309;C1962966,retinopathy,FALSE,FALSE,lower 6 months,NA,NA
16,NCT02738632,Exclusion,patients who have history of severe retinopathy or malignant retinopathy within 6 months prior to study entry,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
16,NCT02738632,Exclusion,patients who have history of severe retinopathy or malignant retinopathy within 6 months prior to study entry,Condition Occurrence,Other,C1705654,entry,FALSE,FALSE,NA,NA,NA
17,NCT02738632,Exclusion,patients who suspected of renal dysfunction that may affect the absorption ; distribution ; metabolism or excretion ( serum creatinine : > 2 mg / dl ) ; gastrointestinal ; haematological disease ; liver disease ( ast or alt > 2.5 times of upper limit of normal range ) ; patients who should be administered antihypertensive drugs other than clinical trial medication ( diuretics ; beta-blockers ; ace inhibitors ; angiotensin ii receptor blocker ; calcium channel blockers ; alfa-blockers ; renin inhibitors ; vasodilators ),Drug Exposure,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
17,NCT02738632,Exclusion,patients who suspected of renal dysfunction that may affect the absorption ; distribution ; metabolism or excretion ( serum creatinine : > 2 mg / dl ) ; gastrointestinal ; haematological disease ; liver disease ( ast or alt > 2.5 times of upper limit of normal range ) ; patients who should be administered antihypertensive drugs other than clinical trial medication ( diuretics ; beta-blockers ; ace inhibitors ; angiotensin ii receptor blocker ; calcium channel blockers ; alfa-blockers ; renin inhibitors ; vasodilators ),Drug Exposure,Condition,C0504085,excretion,FALSE,FALSE,NA,NA,NA
17,NCT02738632,Exclusion,patients who suspected of renal dysfunction that may affect the absorption ; distribution ; metabolism or excretion ( serum creatinine : > 2 mg / dl ) ; gastrointestinal ; haematological disease ; liver disease ( ast or alt > 2.5 times of upper limit of normal range ) ; patients who should be administered antihypertensive drugs other than clinical trial medication ( diuretics ; beta-blockers ; ace inhibitors ; angiotensin ii receptor blocker ; calcium channel blockers ; alfa-blockers ; renin inhibitors ; vasodilators ),Drug Exposure,Condition,C0025519,metabolism,FALSE,FALSE,NA,NA,NA
17,NCT02738632,Exclusion,patients who suspected of renal dysfunction that may affect the absorption ; distribution ; metabolism or excretion ( serum creatinine : > 2 mg / dl ) ; gastrointestinal ; haematological disease ; liver disease ( ast or alt > 2.5 times of upper limit of normal range ) ; patients who should be administered antihypertensive drugs other than clinical trial medication ( diuretics ; beta-blockers ; ace inhibitors ; angiotensin ii receptor blocker ; calcium channel blockers ; alfa-blockers ; renin inhibitors ; vasodilators ),Drug Exposure,Condition,C1378698,distribution,FALSE,FALSE,NA,NA,NA
17,NCT02738632,Exclusion,patients who suspected of renal dysfunction that may affect the absorption ; distribution ; metabolism or excretion ( serum creatinine : > 2 mg / dl ) ; gastrointestinal ; haematological disease ; liver disease ( ast or alt > 2.5 times of upper limit of normal range ) ; patients who should be administered antihypertensive drugs other than clinical trial medication ( diuretics ; beta-blockers ; ace inhibitors ; angiotensin ii receptor blocker ; calcium channel blockers ; alfa-blockers ; renin inhibitors ; vasodilators ),Drug Exposure,Condition,C1559265,gastrointestinal,FALSE,FALSE,NA,NA,NA
17,NCT02738632,Exclusion,patients who suspected of renal dysfunction that may affect the absorption ; distribution ; metabolism or excretion ( serum creatinine : > 2 mg / dl ) ; gastrointestinal ; haematological disease ; liver disease ( ast or alt > 2.5 times of upper limit of normal range ) ; patients who should be administered antihypertensive drugs other than clinical trial medication ( diuretics ; beta-blockers ; ace inhibitors ; angiotensin ii receptor blocker ; calcium channel blockers ; alfa-blockers ; renin inhibitors ; vasodilators ),Drug Exposure,Condition,C0023895;C2186532,liver disease,FALSE,FALSE,NA,NA,NA
17,NCT02738632,Exclusion,patients who suspected of renal dysfunction that may affect the absorption ; distribution ; metabolism or excretion ( serum creatinine : > 2 mg / dl ) ; gastrointestinal ; haematological disease ; liver disease ( ast or alt > 2.5 times of upper limit of normal range ) ; patients who should be administered antihypertensive drugs other than clinical trial medication ( diuretics ; beta-blockers ; ace inhibitors ; angiotensin ii receptor blocker ; calcium channel blockers ; alfa-blockers ; renin inhibitors ; vasodilators ),Drug Exposure,Condition,C2917241,renin inhibitors,FALSE,FALSE,NA,NA,NA
17,NCT02738632,Exclusion,patients who suspected of renal dysfunction that may affect the absorption ; distribution ; metabolism or excretion ( serum creatinine : > 2 mg / dl ) ; gastrointestinal ; haematological disease ; liver disease ( ast or alt > 2.5 times of upper limit of normal range ) ; patients who should be administered antihypertensive drugs other than clinical trial medication ( diuretics ; beta-blockers ; ace inhibitors ; angiotensin ii receptor blocker ; calcium channel blockers ; alfa-blockers ; renin inhibitors ; vasodilators ),Drug Exposure,Drug,C0003364,antihypertensive drugs,FALSE,FALSE,NA,NA,NA
17,NCT02738632,Exclusion,patients who suspected of renal dysfunction that may affect the absorption ; distribution ; metabolism or excretion ( serum creatinine : > 2 mg / dl ) ; gastrointestinal ; haematological disease ; liver disease ( ast or alt > 2.5 times of upper limit of normal range ) ; patients who should be administered antihypertensive drugs other than clinical trial medication ( diuretics ; beta-blockers ; ace inhibitors ; angiotensin ii receptor blocker ; calcium channel blockers ; alfa-blockers ; renin inhibitors ; vasodilators ),Drug Exposure,Drug,C0012798,diuretics,TRUE,FALSE,NA,NA,NA
17,NCT02738632,Exclusion,patients who suspected of renal dysfunction that may affect the absorption ; distribution ; metabolism or excretion ( serum creatinine : > 2 mg / dl ) ; gastrointestinal ; haematological disease ; liver disease ( ast or alt > 2.5 times of upper limit of normal range ) ; patients who should be administered antihypertensive drugs other than clinical trial medication ( diuretics ; beta-blockers ; ace inhibitors ; angiotensin ii receptor blocker ; calcium channel blockers ; alfa-blockers ; renin inhibitors ; vasodilators ),Drug Exposure,Drug,C0006684,calcium channel blockers,FALSE,FALSE,NA,NA,NA
17,NCT02738632,Exclusion,patients who suspected of renal dysfunction that may affect the absorption ; distribution ; metabolism or excretion ( serum creatinine : > 2 mg / dl ) ; gastrointestinal ; haematological disease ; liver disease ( ast or alt > 2.5 times of upper limit of normal range ) ; patients who should be administered antihypertensive drugs other than clinical trial medication ( diuretics ; beta-blockers ; ace inhibitors ; angiotensin ii receptor blocker ; calcium channel blockers ; alfa-blockers ; renin inhibitors ; vasodilators ),Drug Exposure,Drug,C0521942;C3536793,angiotensin ii receptor blocker,FALSE,FALSE,NA,NA,NA
17,NCT02738632,Exclusion,patients who suspected of renal dysfunction that may affect the absorption ; distribution ; metabolism or excretion ( serum creatinine : > 2 mg / dl ) ; gastrointestinal ; haematological disease ; liver disease ( ast or alt > 2.5 times of upper limit of normal range ) ; patients who should be administered antihypertensive drugs other than clinical trial medication ( diuretics ; beta-blockers ; ace inhibitors ; angiotensin ii receptor blocker ; calcium channel blockers ; alfa-blockers ; renin inhibitors ; vasodilators ),Drug Exposure,Drug,C0003015,ace inhibitors,FALSE,FALSE,NA,NA,NA
17,NCT02738632,Exclusion,patients who suspected of renal dysfunction that may affect the absorption ; distribution ; metabolism or excretion ( serum creatinine : > 2 mg / dl ) ; gastrointestinal ; haematological disease ; liver disease ( ast or alt > 2.5 times of upper limit of normal range ) ; patients who should be administered antihypertensive drugs other than clinical trial medication ( diuretics ; beta-blockers ; ace inhibitors ; angiotensin ii receptor blocker ; calcium channel blockers ; alfa-blockers ; renin inhibitors ; vasodilators ),Drug Exposure,Drug,C0001645,beta-blockers,TRUE,FALSE,NA,NA,NA
17,NCT02738632,Exclusion,patients who suspected of renal dysfunction that may affect the absorption ; distribution ; metabolism or excretion ( serum creatinine : > 2 mg / dl ) ; gastrointestinal ; haematological disease ; liver disease ( ast or alt > 2.5 times of upper limit of normal range ) ; patients who should be administered antihypertensive drugs other than clinical trial medication ( diuretics ; beta-blockers ; ace inhibitors ; angiotensin ii receptor blocker ; calcium channel blockers ; alfa-blockers ; renin inhibitors ; vasodilators ),Drug Exposure,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
17,NCT02738632,Exclusion,patients who suspected of renal dysfunction that may affect the absorption ; distribution ; metabolism or excretion ( serum creatinine : > 2 mg / dl ) ; gastrointestinal ; haematological disease ; liver disease ( ast or alt > 2.5 times of upper limit of normal range ) ; patients who should be administered antihypertensive drugs other than clinical trial medication ( diuretics ; beta-blockers ; ace inhibitors ; angiotensin ii receptor blocker ; calcium channel blockers ; alfa-blockers ; renin inhibitors ; vasodilators ),Drug Exposure,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,NA,greater 2 mg/dl
17,NCT02738632,Exclusion,patients who suspected of renal dysfunction that may affect the absorption ; distribution ; metabolism or excretion ( serum creatinine : > 2 mg / dl ) ; gastrointestinal ; haematological disease ; liver disease ( ast or alt > 2.5 times of upper limit of normal range ) ; patients who should be administered antihypertensive drugs other than clinical trial medication ( diuretics ; beta-blockers ; ace inhibitors ; angiotensin ii receptor blocker ; calcium channel blockers ; alfa-blockers ; renin inhibitors ; vasodilators ),Drug Exposure,Observation,C0004002,ast,FALSE,FALSE,NA,NA,greater 2.5 times
17,NCT02738632,Exclusion,patients who suspected of renal dysfunction that may affect the absorption ; distribution ; metabolism or excretion ( serum creatinine : > 2 mg / dl ) ; gastrointestinal ; haematological disease ; liver disease ( ast or alt > 2.5 times of upper limit of normal range ) ; patients who should be administered antihypertensive drugs other than clinical trial medication ( diuretics ; beta-blockers ; ace inhibitors ; angiotensin ii receptor blocker ; calcium channel blockers ; alfa-blockers ; renin inhibitors ; vasodilators ),Drug Exposure,Observation,C1140170;C2257651,alt,FALSE,FALSE,NA,NA,greater 2.5 times
17,NCT02738632,Exclusion,patients who suspected of renal dysfunction that may affect the absorption ; distribution ; metabolism or excretion ( serum creatinine : > 2 mg / dl ) ; gastrointestinal ; haematological disease ; liver disease ( ast or alt > 2.5 times of upper limit of normal range ) ; patients who should be administered antihypertensive drugs other than clinical trial medication ( diuretics ; beta-blockers ; ace inhibitors ; angiotensin ii receptor blocker ; calcium channel blockers ; alfa-blockers ; renin inhibitors ; vasodilators ),Drug Exposure,Observation,C3542016,range,FALSE,FALSE,NA,NA,NA
17,NCT02738632,Exclusion,patients who suspected of renal dysfunction that may affect the absorption ; distribution ; metabolism or excretion ( serum creatinine : > 2 mg / dl ) ; gastrointestinal ; haematological disease ; liver disease ( ast or alt > 2.5 times of upper limit of normal range ) ; patients who should be administered antihypertensive drugs other than clinical trial medication ( diuretics ; beta-blockers ; ace inhibitors ; angiotensin ii receptor blocker ; calcium channel blockers ; alfa-blockers ; renin inhibitors ; vasodilators ),Drug Exposure,Other,C1096775,clinical trial,TRUE,FALSE,NA,NA,NA
18,NCT02738632,Exclusion,patients who should be administered medications prohibited for concomitant use during study period,Other,NA,NA,NA,NA,NA,NA,NA,NA
19,NCT02738632,Exclusion,patients who are dependent on drugs or alcohol,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
19,NCT02738632,Exclusion,patients who are dependent on drugs or alcohol,Drug Exposure,Other,C0001975;C0001962;C1547288,alcohol,FALSE,FALSE,NA,NA,NA
20,NCT02738632,Exclusion,patients with surgical disease and medical disease that may affect the absorption ; distribution ; metabolism or excretion,Condition Occurrence,Condition,C0504085,excretion,FALSE,FALSE,NA,NA,NA
20,NCT02738632,Exclusion,patients with surgical disease and medical disease that may affect the absorption ; distribution ; metabolism or excretion,Condition Occurrence,Condition,C0025519,metabolism,FALSE,FALSE,NA,NA,NA
20,NCT02738632,Exclusion,patients with surgical disease and medical disease that may affect the absorption ; distribution ; metabolism or excretion,Condition Occurrence,Condition,C1378698,distribution,FALSE,FALSE,NA,NA,NA
20,NCT02738632,Exclusion,patients with surgical disease and medical disease that may affect the absorption ; distribution ; metabolism or excretion,Condition Occurrence,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
20,NCT02738632,Exclusion,patients with surgical disease and medical disease that may affect the absorption ; distribution ; metabolism or excretion,Condition Occurrence,Other,C1561579;C1561578,medical,FALSE,FALSE,NA,NA,NA
21,NCT02738632,Exclusion,patients with hypersensitivity to the components of investigational drug .,Observation,Drug,C0013230,investigational drug,FALSE,FALSE,NA,NA,NA
21,NCT02738632,Exclusion,patients with hypersensitivity to the components of investigational drug .,Observation,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
22,NCT02738632,Exclusion,patients with hypersensitivity to sulfonamide,Observation,Drug,C0599503;C3536763,sulfonamide,FALSE,FALSE,NA,NA,NA
22,NCT02738632,Exclusion,patients with hypersensitivity to sulfonamide,Observation,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
23,NCT02738632,Exclusion,patients with anuria,Condition Occurrence,Condition,C0003460;C2188545,anuria,FALSE,FALSE,NA,NA,NA
24,NCT02738632,Exclusion,patients with hypercalcemia ; hyponatremia / hypokalemia,Condition Occurrence,Condition,C0020437,hypercalcemia,FALSE,FALSE,NA,NA,NA
24,NCT02738632,Exclusion,patients with hypercalcemia ; hyponatremia / hypokalemia,Condition Occurrence,Condition,C0020625,hyponatremia,FALSE,FALSE,NA,NA,NA
24,NCT02738632,Exclusion,patients with hypercalcemia ; hyponatremia / hypokalemia,Condition Occurrence,Condition,C0020621,hypokalemia,FALSE,FALSE,NA,NA,NA
25,NCT02738632,Exclusion,patients with addison disease,Condition Occurrence,Condition,C0001403;C0266273,addison disease,FALSE,FALSE,NA,NA,NA
26,NCT02738632,Exclusion,patients who have hereditary problems such as galactose intolerance ; lapp lactase deficiency ; or glucose-galactose malabsorption,Condition Occurrence,Condition,C0016952,galactose intolerance,FALSE,FALSE,NA,NA,NA
26,NCT02738632,Exclusion,patients who have hereditary problems such as galactose intolerance ; lapp lactase deficiency ; or glucose-galactose malabsorption,Condition Occurrence,Condition,C0268186,glucose-galactose malabsorption,FALSE,FALSE,NA,NA,NA
26,NCT02738632,Exclusion,patients who have hereditary problems such as galactose intolerance ; lapp lactase deficiency ; or glucose-galactose malabsorption,Condition Occurrence,Condition,C0302813,lactase deficiency,FALSE,FALSE,NA,NA,NA
27,NCT02738632,Exclusion,patients with any chronic inflammation disease or accute inflammation disease needed to chronic inflammation therapy,Condition Occurrence,Condition,C0021376,chronic inflammation,FALSE,FALSE,NA,NA,NA
27,NCT02738632,Exclusion,patients with any chronic inflammation disease or accute inflammation disease needed to chronic inflammation therapy,Condition Occurrence,Condition,C0021368,inflammation,FALSE,FALSE,NA,NA,NA
27,NCT02738632,Exclusion,patients with any chronic inflammation disease or accute inflammation disease needed to chronic inflammation therapy,Condition Occurrence,Condition,C0021376,chronic inflammation,FALSE,FALSE,NA,NA,NA
28,NCT02738632,Exclusion,history of malignant tumor including leukemia ; lymphoma within 5 years,Condition Occurrence,Condition,C0006826,malignant tumor,FALSE,FALSE,NA,NA,NA
28,NCT02738632,Exclusion,history of malignant tumor including leukemia ; lymphoma within 5 years,Condition Occurrence,Condition,C0023418,leukemia,FALSE,FALSE,lower 5 years,NA,NA
28,NCT02738632,Exclusion,history of malignant tumor including leukemia ; lymphoma within 5 years,Condition Occurrence,Condition,C0024299,lymphoma,FALSE,FALSE,lower 5 years,NA,NA
29,NCT02738632,Exclusion,patients taking other clinical trial drugs within 30 days from the time of visit for screening,Condition Occurrence,Condition,C2024467,time,FALSE,FALSE,NA,NA,NA
29,NCT02738632,Exclusion,patients taking other clinical trial drugs within 30 days from the time of visit for screening,Condition Occurrence,Procedure,C3687832,drugs,FALSE,FALSE,lower 30 days,NA,NA
29,NCT02738632,Exclusion,patients taking other clinical trial drugs within 30 days from the time of visit for screening,Condition Occurrence,Other,C1096775,clinical trial,FALSE,FALSE,NA,NA,NA
30,NCT02738632,Exclusion,pregnancy ; breast-feeding ; or child-bearing potential patients,Condition Occurrence,Condition,C0006147;C1623041;C1623040,breast-feeding,FALSE,FALSE,NA,NA,NA
30,NCT02738632,Exclusion,pregnancy ; breast-feeding ; or child-bearing potential patients,Condition Occurrence,Observation,C3831118,child-bearing potential,FALSE,FALSE,NA,NA,NA
30,NCT02738632,Exclusion,pregnancy ; breast-feeding ; or child-bearing potential patients,Condition Occurrence,Other,C0032961;C3484365,pregnancy,FALSE,FALSE,NA,NA,NA
31,NCT02738632,Exclusion,patients who are judged unsuitable to participate in this study by investigator,Other,NA,NA,NA,NA,NA,NA,NA,NA
1,NCT00219154,Inclusion,NA,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00219154,Exclusion,severe hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00219154,Exclusion,severe hypertension,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
3,NCT00219154,Exclusion,history or evidence of a secondary form of hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
4,NCT00219154,Exclusion,history of myocardial infarction,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
5,NCT00219154,Exclusion,other protocol-defined inclusion also apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00219193,Inclusion,patients with essential hypertension,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00219193,Inclusion,patients who are eligible and able to participate in the study,Other,NA,NA,NA,NA,NA,NA,NA,NA
3,NCT00219193,Exclusion,severe hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00219193,Exclusion,severe hypertension,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
4,NCT00219193,Exclusion,history or evidence of a secondary form of hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
5,NCT00219193,Exclusion,other protocol-defined may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00294710,Inclusion,patients with essential hypertension,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00294710,Exclusion,severe hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00294710,Exclusion,severe hypertension,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
3,NCT00294710,Exclusion,history or evidence of a secondary form of hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
4,NCT00294710,Exclusion,history of myocardial infarction .,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
5,NCT00294710,Exclusion,other protocol-defined inclusion also apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00153023,Inclusion,type 2 diabetes mellitus,Condition Occurrence,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
2,NCT00153023,Inclusion,aged 30 - 70 years of age,Person,Person,C0001792,aged,FALSE,FALSE,greater_equal 30 years; lower_equal 70 years,NA,NA
3,NCT00153023,Inclusion,hypertension at screening defined as :,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00153023,Inclusion,hypertension at screening defined as :,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
4,NCT00153023,Inclusion,an average cuff systolic blood pressure > 130 mmhg or diastolic blood pressure > 80 mmhg in untreated patients or,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
4,NCT00153023,Inclusion,an average cuff systolic blood pressure > 130 mmhg or diastolic blood pressure > 80 mmhg in untreated patients or,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater 130 mmhg; greater 80 mmhg,NA
4,NCT00153023,Inclusion,an average cuff systolic blood pressure > 130 mmhg or diastolic blood pressure > 80 mmhg in untreated patients or,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater 80 mmhg,NA
5,NCT00153023,Inclusion,patients receiving antihypertensive therapy ( ie ; medications specifically prescribed to treat hypertension ),Procedure,Procedure,C0585941,antihypertensive therapy,FALSE,FALSE,NA,NA,NA
5,NCT00153023,Inclusion,patients receiving antihypertensive therapy ( ie ; medications specifically prescribed to treat hypertension ),Procedure,Procedure,C0278329,prescribed,FALSE,FALSE,NA,NA,NA
5,NCT00153023,Inclusion,patients receiving antihypertensive therapy ( ie ; medications specifically prescribed to treat hypertension ),Procedure,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
6,NCT00153023,Inclusion,overt nephropathy defined by 24 hour proteinuria > = 900 mg and by serum creatinine below 265 mol / l ( 3.00 mg / dl ),Condition Occurrence,Condition,C0022658,nephropathy,FALSE,FALSE,NA,NA,NA
6,NCT00153023,Inclusion,overt nephropathy defined by 24 hour proteinuria > = 900 mg and by serum creatinine below 265 mol / l ( 3.00 mg / dl ),Condition Occurrence,Condition,C0033687;C1279888;C1962972,proteinuria,FALSE,FALSE,equal 24 hour,NA,greater_equal 900 mg
6,NCT00153023,Inclusion,overt nephropathy defined by 24 hour proteinuria > = 900 mg and by serum creatinine below 265 mol / l ( 3.00 mg / dl ),Condition Occurrence,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,lower 265 mol/l,NA
6,NCT00153023,Inclusion,overt nephropathy defined by 24 hour proteinuria > = 900 mg and by serum creatinine below 265 mol / l ( 3.00 mg / dl ),Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00154271,Inclusion,stage 2 hypertension as defined by the mean of three 3 repeated seated bp measurements of : sbp of 160 to 185 mmhg ; inclusive or dbp of 100 to 109 mmhg ; inclusive .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00154271,Inclusion,stage 2 hypertension as defined by the mean of three 3 repeated seated bp measurements of : sbp of 160 to 185 mmhg ; inclusive or dbp of 100 to 109 mmhg ; inclusive .,Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,NA,NA
1,NCT00154271,Inclusion,stage 2 hypertension as defined by the mean of three 3 repeated seated bp measurements of : sbp of 160 to 185 mmhg ; inclusive or dbp of 100 to 109 mmhg ; inclusive .,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 160 mmhg; lower_equal 185 mmhg,NA
1,NCT00154271,Inclusion,stage 2 hypertension as defined by the mean of three 3 repeated seated bp measurements of : sbp of 160 to 185 mmhg ; inclusive or dbp of 100 to 109 mmhg ; inclusive .,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 100 mmhg; lower_equal 109 mmhg,NA
1,NCT00154271,Inclusion,stage 2 hypertension as defined by the mean of three 3 repeated seated bp measurements of : sbp of 160 to 185 mmhg ; inclusive or dbp of 100 to 109 mmhg ; inclusive .,Observation,Other,C3539106,defined,FALSE,FALSE,NA,equal 3,NA
2,NCT00154271,Inclusion,patients must have documentation of serum creatinine equal or < 2.0 mg / dl ; serum potassium equal or > 3.5 and equal or < 5.5 mmol / l ; and serum ast or alt < 2 xuln obtained within 3 months prior to visit 1 .,Observation,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,NA,lower 2.0 mg/dl
2,NCT00154271,Inclusion,patients must have documentation of serum creatinine equal or < 2.0 mg / dl ; serum potassium equal or > 3.5 and equal or < 5.5 mmol / l ; and serum ast or alt < 2 xuln obtained within 3 months prior to visit 1 .,Observation,Observation,C0302353;C0543465,serum potassium,FALSE,FALSE,NA,greater 3.5 ; lower 5.5 mmol/l,NA
2,NCT00154271,Inclusion,patients must have documentation of serum creatinine equal or < 2.0 mg / dl ; serum potassium equal or > 3.5 and equal or < 5.5 mmol / l ; and serum ast or alt < 2 xuln obtained within 3 months prior to visit 1 .,Observation,Observation,C0201899,serum ast,FALSE,FALSE,lower 3 months,lower 2,NA
2,NCT00154271,Inclusion,patients must have documentation of serum creatinine equal or < 2.0 mg / dl ; serum potassium equal or > 3.5 and equal or < 5.5 mmol / l ; and serum ast or alt < 2 xuln obtained within 3 months prior to visit 1 .,Observation,Observation,C1140170;C2257651,alt,FALSE,FALSE,lower 3 months,lower 2,NA
3,NCT00154271,Inclusion,patients must have documentation of hba1c equal or < 11.0 % obtained within 1 month prior to visit 1 .,Drug Exposure,Observation,C0202054,hba1c,FALSE,FALSE,lower 1 month,NA,lower 11.0 %
4,NCT00154271,Exclusion,history of secondary hypertension .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
5,NCT00154271,Exclusion,pharmacologic antihypertensive therapy with ace inhibitors ; angiotensin receptor blockers ; or aldosterone blockers within 3 months prior to visit 1 ; or with thiazide diuretics within 1 month prior to visit,Drug Exposure,Drug,C0003015,ace inhibitors,FALSE,FALSE,lower 3 months,NA,NA
5,NCT00154271,Exclusion,pharmacologic antihypertensive therapy with ace inhibitors ; angiotensin receptor blockers ; or aldosterone blockers within 3 months prior to visit 1 ; or with thiazide diuretics within 1 month prior to visit,Drug Exposure,Drug,C0521942;C0815017,angiotensin receptor blockers,FALSE,FALSE,lower 3 months,NA,NA
5,NCT00154271,Exclusion,pharmacologic antihypertensive therapy with ace inhibitors ; angiotensin receptor blockers ; or aldosterone blockers within 3 months prior to visit 1 ; or with thiazide diuretics within 1 month prior to visit,Drug Exposure,Drug,C0012802,thiazide diuretics,FALSE,FALSE,lower 1 month,NA,NA
5,NCT00154271,Exclusion,pharmacologic antihypertensive therapy with ace inhibitors ; angiotensin receptor blockers ; or aldosterone blockers within 3 months prior to visit 1 ; or with thiazide diuretics within 1 month prior to visit,Drug Exposure,Procedure,C0585941,antihypertensive therapy,FALSE,FALSE,NA,NA,NA
5,NCT00154271,Exclusion,pharmacologic antihypertensive therapy with ace inhibitors ; angiotensin receptor blockers ; or aldosterone blockers within 3 months prior to visit 1 ; or with thiazide diuretics within 1 month prior to visit,Drug Exposure,Other,C0373535;C0002006,aldosterone,FALSE,FALSE,lower 3 months,NA,NA
6,NCT00154271,Exclusion,the use of other classes of agents which lower bp but are being used for other therapy or for htn ; are allowed as long as these agents are started at least 3 months prior to randomization ; are not initiated after enrollment and doses remain unchanged during the study .,Observation,Condition,C0442739,unchanged,FALSE,FALSE,NA,NA,NA
6,NCT00154271,Exclusion,the use of other classes of agents which lower bp but are being used for other therapy or for htn ; are allowed as long as these agents are started at least 3 months prior to randomization ; are not initiated after enrollment and doses remain unchanged during the study .,Observation,Observation,C1548802,lower,FALSE,FALSE,NA,NA,NA
6,NCT00154271,Exclusion,the use of other classes of agents which lower bp but are being used for other therapy or for htn ; are allowed as long as these agents are started at least 3 months prior to randomization ; are not initiated after enrollment and doses remain unchanged during the study .,Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,greater_equal 3 months,NA,NA
6,NCT00154271,Exclusion,the use of other classes of agents which lower bp but are being used for other therapy or for htn ; are allowed as long as these agents are started at least 3 months prior to randomization ; are not initiated after enrollment and doses remain unchanged during the study .,Observation,Other,C1696073;C1516879,enrollment,TRUE,FALSE,NA,NA,NA
7,NCT00154271,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00220233,Inclusion,without antihypertensive pre-treatment mean seated bp greater than 160 / 100 mmhg,Observation,Condition,C2257086,pre,TRUE,FALSE,NA,NA,NA
1,NCT00220233,Inclusion,without antihypertensive pre-treatment mean seated bp greater than 160 / 100 mmhg,Observation,Drug,C0003364,antihypertensive,TRUE,FALSE,NA,NA,NA
1,NCT00220233,Inclusion,without antihypertensive pre-treatment mean seated bp greater than 160 / 100 mmhg,Observation,Observation,C0005824;C0005823,bp,TRUE,FALSE,NA,greater 160 mmhg; greater 100 mmhg,NA
2,NCT00220233,Inclusion,pre-treatment with amlodipine 5 or 10 mg : mean seated bp greater than or equal to 140 / 90 mmhg,Observation,Condition,C2257086,pre,FALSE,FALSE,NA,NA,NA
2,NCT00220233,Inclusion,pre-treatment with amlodipine 5 or 10 mg : mean seated bp greater than or equal to 140 / 90 mmhg,Observation,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,equal 5 mg; equal 10 mg
2,NCT00220233,Inclusion,pre-treatment with amlodipine 5 or 10 mg : mean seated bp greater than or equal to 140 / 90 mmhg,Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,greater_equal 140 mmhg; greater_equal 90 mmhg,NA
3,NCT00220233,Exclusion,secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
4,NCT00220233,Exclusion,any serious disorder which may limit the ability to evaluate the efficacy or safety of the test drugs,Observation,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
4,NCT00220233,Exclusion,any serious disorder which may limit the ability to evaluate the efficacy or safety of the test drugs,Observation,Observation,C0022885;C2826273,test,FALSE,FALSE,NA,NA,NA
1,NCT00409851,Inclusion,successful completion of vaa489a2201 core trial,Condition Occurrence,Condition,C3274653,core,FALSE,FALSE,NA,NA,NA
2,NCT00409851,Inclusion,visit 7 blood pressure must be msdbp < = 95 mmhg and mssbp < = 150 mmhg,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,lower_equal 95 mmhg; lower_equal 150 mmhg,NA
3,NCT00409851,Exclusion,patients who experienced any adverse events considered serious and drug related in vaa489a2201 core,Condition Occurrence,Condition,C0877248,adverse events,FALSE,FALSE,NA,NA,NA
3,NCT00409851,Exclusion,patients who experienced any adverse events considered serious and drug related in vaa489a2201 core,Condition Occurrence,Condition,C0445223,related,FALSE,FALSE,NA,NA,NA
3,NCT00409851,Exclusion,patients who experienced any adverse events considered serious and drug related in vaa489a2201 core,Condition Occurrence,Condition,C3274653,core,FALSE,FALSE,NA,NA,NA
3,NCT00409851,Exclusion,patients who experienced any adverse events considered serious and drug related in vaa489a2201 core,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
4,NCT00409851,Exclusion,other protocol-defined may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00281580,Inclusion,main male and female patients > = 18 years of age with stage i or stage ii hypertension defined as : a mean seated cuff diastolic blood pressure > = 95 and < = 119 mmhg main,Observation,Person,C0025266;C1706429,male,FALSE,FALSE,greater_equal 18 years,NA,NA
1,NCT00281580,Inclusion,main male and female patients > = 18 years of age with stage i or stage ii hypertension defined as : a mean seated cuff diastolic blood pressure > = 95 and < = 119 mmhg main,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
1,NCT00281580,Inclusion,main male and female patients > = 18 years of age with stage i or stage ii hypertension defined as : a mean seated cuff diastolic blood pressure > = 95 and < = 119 mmhg main,Observation,Observation,C0150905,female patients,FALSE,FALSE,greater_equal 18 years,NA,NA
1,NCT00281580,Inclusion,main male and female patients > = 18 years of age with stage i or stage ii hypertension defined as : a mean seated cuff diastolic blood pressure > = 95 and < = 119 mmhg main,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00281580,Inclusion,main male and female patients > = 18 years of age with stage i or stage ii hypertension defined as : a mean seated cuff diastolic blood pressure > = 95 and < = 119 mmhg main,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater_equal 95 mmhg; lower_equal 119 mmhg,NA
1,NCT00281580,Inclusion,main male and female patients > = 18 years of age with stage i or stage ii hypertension defined as : a mean seated cuff diastolic blood pressure > = 95 and < = 119 mmhg main,Observation,Other,C0441766,stage i,FALSE,FALSE,NA,NA,NA
1,NCT00281580,Inclusion,main male and female patients > = 18 years of age with stage i or stage ii hypertension defined as : a mean seated cuff diastolic blood pressure > = 95 and < = 119 mmhg main,Observation,Other,C0441767,stage ii,FALSE,FALSE,NA,NA,NA
1,NCT00281580,Inclusion,main male and female patients > = 18 years of age with stage i or stage ii hypertension defined as : a mean seated cuff diastolic blood pressure > = 95 and < = 119 mmhg main,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
2,NCT00281580,Exclusion,patient is pregnant,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
3,NCT00281580,Exclusion,breast-feeding,Condition Occurrence,Condition,C0006147;C1623041;C1623040,breast-feeding,FALSE,FALSE,NA,NA,NA
4,NCT00281580,Exclusion,unwilling to use birth control during the study,Procedure,Other,C0700589;C2703065,birth control,FALSE,FALSE,NA,NA,NA
5,NCT00281580,Exclusion,has secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
6,NCT00281580,Exclusion,severe renal dysfunction,Condition Occurrence,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
6,NCT00281580,Exclusion,severe renal dysfunction,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
7,NCT00281580,Exclusion,hepatic insufficiency,Condition Occurrence,Condition,C1306571,hepatic insufficiency,FALSE,FALSE,NA,NA,NA
8,NCT00281580,Exclusion,stroke within the last six months,Other,NA,NA,NA,NA,NA,NA,NA,NA
9,NCT00281580,Exclusion,myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past three months,Procedure,Condition,C0002965,unstable angina,FALSE,FALSE,NA,NA,NA
9,NCT00281580,Exclusion,myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past three months,Procedure,Procedure,C0010055,coronary artery bypass graft,FALSE,FALSE,NA,NA,NA
9,NCT00281580,Exclusion,myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past three months,Procedure,Procedure,C2936173,percutaneous transluminal coronary angioplasty,FALSE,FALSE,NA,NA,NA
9,NCT00281580,Exclusion,myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past three months,Procedure,Procedure,C0018821,cardiac surgery,FALSE,FALSE,NA,NA,NA
9,NCT00281580,Exclusion,myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past three months,Procedure,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
10,NCT00281580,Exclusion,unstable diabetes or uncontrolled diabetes for the past three months defined as a glucosylates hemoglobin ( hba1c ) greater than ten percent,Condition Occurrence,Condition,C0342302,unstable diabetes,FALSE,FALSE,NA,NA,NA
10,NCT00281580,Exclusion,unstable diabetes or uncontrolled diabetes for the past three months defined as a glucosylates hemoglobin ( hba1c ) greater than ten percent,Condition Occurrence,Condition,C0011849;C0011847,diabetes,FALSE,FALSE,NA,NA,NA
10,NCT00281580,Exclusion,unstable diabetes or uncontrolled diabetes for the past three months defined as a glucosylates hemoglobin ( hba1c ) greater than ten percent,Condition Occurrence,Observation,C0019046;C0518015;C1561562;C2239101,hemoglobin,FALSE,FALSE,NA,NA,NA
10,NCT00281580,Exclusion,unstable diabetes or uncontrolled diabetes for the past three months defined as a glucosylates hemoglobin ( hba1c ) greater than ten percent,Condition Occurrence,Observation,C0202054,hba1c,FALSE,FALSE,NA,NA,NA
10,NCT00281580,Exclusion,unstable diabetes or uncontrolled diabetes for the past three months defined as a glucosylates hemoglobin ( hba1c ) greater than ten percent,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
11,NCT00281580,Exclusion,history of angioedema or hypersensitivity related to either study drug .,Condition Occurrence,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
11,NCT00281580,Exclusion,history of angioedema or hypersensitivity related to either study drug .,Condition Occurrence,Condition,C0445223,related,FALSE,FALSE,NA,NA,NA
11,NCT00281580,Exclusion,history of angioedema or hypersensitivity related to either study drug .,Condition Occurrence,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
11,NCT00281580,Exclusion,history of angioedema or hypersensitivity related to either study drug .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
12,NCT00281580,Exclusion,systolic blood pressure ( sbp ) is greater than or equal to 180 millimeters of mercury ( mmhg ) ; diastolic blood pressure ( dbp ) is greater than or equal to 110 mmhg,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,NA,NA
12,NCT00281580,Exclusion,systolic blood pressure ( sbp ) is greater than or equal to 180 millimeters of mercury ( mmhg ) ; diastolic blood pressure ( dbp ) is greater than or equal to 110 mmhg,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 180 millimeters of mercury,NA
12,NCT00281580,Exclusion,systolic blood pressure ( sbp ) is greater than or equal to 180 millimeters of mercury ( mmhg ) ; diastolic blood pressure ( dbp ) is greater than or equal to 110 mmhg,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,NA,NA
12,NCT00281580,Exclusion,systolic blood pressure ( sbp ) is greater than or equal to 180 millimeters of mercury ( mmhg ) ; diastolic blood pressure ( dbp ) is greater than or equal to 110 mmhg,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 110 mmhg,NA
1,NCT00425373,Inclusion,patients with essential hypertension measured by electronic hemodynamometer,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00425373,Inclusion,patients with essential hypertension measured by electronic hemodynamometer,Condition Occurrence,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
2,NCT00425373,Inclusion,patients must satisfy the following criteria .,Other,NA,NA,NA,NA,NA,NA,NA,NA
3,NCT00425373,Inclusion,msdbp < 110 mmhg and mssbp < 180 mmhg at visit 1,Observation,NA,NA,NA,NA,NA,NA,NA,NA
4,NCT00425373,Inclusion,msdbp > = 90 mmhg and < 110 mmhg and mssbp < 180 mmhg at visit 2,Observation,NA,NA,NA,NA,NA,NA,NA,NA
5,NCT00425373,Inclusion,msdbp > = 95 mmhg and < 110 mmhg and mssbp < 180 mmhg at visit 3,Observation,NA,NA,NA,NA,NA,NA,NA,NA
6,NCT00425373,Inclusion,the absolute difference in msdbp between visit 2 and 3 is < = 10 mmhg,Observation,NA,NA,NA,NA,NA,NA,NA,NA
7,NCT00425373,Inclusion,male or female outpatients .,Person,Person,C0025266;C1706429,male,FALSE,FALSE,NA,NA,NA
7,NCT00425373,Inclusion,male or female outpatients .,Person,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
8,NCT00425373,Inclusion,aged = > 20 and = < 80 years ( at the time of signing informed consent ) .,Condition Occurrence,Person,C0001792,aged,FALSE,FALSE,greater_equal 20 years; lower_equal 80 years,NA,NA
8,NCT00425373,Inclusion,aged = > 20 and = < 80 years ( at the time of signing informed consent ) .,Condition Occurrence,Condition,C2024467,time,FALSE,FALSE,NA,NA,NA
9,NCT00425373,Inclusion,patients who have written informed consent to participate in this study .,Other,NA,NA,NA,NA,NA,NA,NA,NA
10,NCT00425373,Exclusion,pregnant women ; nursing ( lactating ) mothers ; women suspected of being pregnant ; or women who wish to be pregnant during the study ; women of child-bearing potential .,Person,Person,C0033011,pregnant women,FALSE,FALSE,NA,NA,NA
10,NCT00425373,Exclusion,pregnant women ; nursing ( lactating ) mothers ; women suspected of being pregnant ; or women who wish to be pregnant during the study ; women of child-bearing potential .,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
10,NCT00425373,Exclusion,pregnant women ; nursing ( lactating ) mothers ; women suspected of being pregnant ; or women who wish to be pregnant during the study ; women of child-bearing potential .,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
10,NCT00425373,Exclusion,pregnant women ; nursing ( lactating ) mothers ; women suspected of being pregnant ; or women who wish to be pregnant during the study ; women of child-bearing potential .,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
10,NCT00425373,Exclusion,pregnant women ; nursing ( lactating ) mothers ; women suspected of being pregnant ; or women who wish to be pregnant during the study ; women of child-bearing potential .,Person,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
10,NCT00425373,Exclusion,pregnant women ; nursing ( lactating ) mothers ; women suspected of being pregnant ; or women who wish to be pregnant during the study ; women of child-bearing potential .,Person,Condition,C2828358;C3668831,lactating,FALSE,FALSE,NA,NA,NA
10,NCT00425373,Exclusion,pregnant women ; nursing ( lactating ) mothers ; women suspected of being pregnant ; or women who wish to be pregnant during the study ; women of child-bearing potential .,Person,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
10,NCT00425373,Exclusion,pregnant women ; nursing ( lactating ) mothers ; women suspected of being pregnant ; or women who wish to be pregnant during the study ; women of child-bearing potential .,Person,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
10,NCT00425373,Exclusion,pregnant women ; nursing ( lactating ) mothers ; women suspected of being pregnant ; or women who wish to be pregnant during the study ; women of child-bearing potential .,Person,Observation,C3831118,child-bearing potential,FALSE,FALSE,NA,NA,NA
11,NCT00425373,Exclusion,patients with secondary hypertension or suspected of having secondary hypertension .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
11,NCT00425373,Exclusion,patients with secondary hypertension or suspected of having secondary hypertension .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
12,NCT00425373,Exclusion,patients with a history of malignant hypertension .,Condition Occurrence,Condition,C0020540;C0024588,malignant hypertension,FALSE,FALSE,NA,NA,NA
13,NCT00425373,Exclusion,patients with an inability to completely discontinue all prior antihypertensive medications safely for a period of 12 weeks as required by the protocol .,Other,Drug,C0003364,antihypertensive,FALSE,FALSE,equal 12 weeks,NA,NA
13,NCT00425373,Exclusion,patients with an inability to completely discontinue all prior antihypertensive medications safely for a period of 12 weeks as required by the protocol .,Other,Other,C1706472,discontinue,FALSE,FALSE,NA,NA,NA
13,NCT00425373,Exclusion,patients with an inability to completely discontinue all prior antihypertensive medications safely for a period of 12 weeks as required by the protocol .,Other,Other,C3245502;C3245501;C1619636;C1546857,required,FALSE,FALSE,NA,NA,NA
14,NCT00425373,Exclusion,patients with or with a history of any of the following diseases or signs : cardiac disease ; renal disease ; cerebrovascular disorder,Condition Occurrence,Condition,C0018799,cardiac disease,FALSE,FALSE,NA,NA,NA
14,NCT00425373,Exclusion,patients with or with a history of any of the following diseases or signs : cardiac disease ; renal disease ; cerebrovascular disorder,Condition Occurrence,Condition,C0007820,cerebrovascular disorder,FALSE,FALSE,NA,NA,NA
14,NCT00425373,Exclusion,patients with or with a history of any of the following diseases or signs : cardiac disease ; renal disease ; cerebrovascular disorder,Condition Occurrence,Condition,C0022658,renal disease,FALSE,FALSE,NA,NA,NA
15,NCT00425373,Exclusion,patients with a clinically significant allergy ( asthma on pharmacotherapy ; multi-drug allergy ; or drug-induced anaphylactic reactions or food-induced anaphylactic reactions ) .,Condition Occurrence,Condition,C0004096,asthma,FALSE,FALSE,NA,NA,NA
15,NCT00425373,Exclusion,patients with a clinically significant allergy ( asthma on pharmacotherapy ; multi-drug allergy ; or drug-induced anaphylactic reactions or food-induced anaphylactic reactions ) .,Condition Occurrence,Condition,C0002792,anaphylactic reactions,FALSE,FALSE,NA,NA,NA
15,NCT00425373,Exclusion,patients with a clinically significant allergy ( asthma on pharmacotherapy ; multi-drug allergy ; or drug-induced anaphylactic reactions or food-induced anaphylactic reactions ) .,Condition Occurrence,Condition,C0002792,anaphylactic reactions,FALSE,FALSE,NA,NA,NA
15,NCT00425373,Exclusion,patients with a clinically significant allergy ( asthma on pharmacotherapy ; multi-drug allergy ; or drug-induced anaphylactic reactions or food-induced anaphylactic reactions ) .,Condition Occurrence,Drug,C3540798,food,FALSE,FALSE,NA,NA,NA
15,NCT00425373,Exclusion,patients with a clinically significant allergy ( asthma on pharmacotherapy ; multi-drug allergy ; or drug-induced anaphylactic reactions or food-induced anaphylactic reactions ) .,Condition Occurrence,Other,C0489531;C0718579;C3542994;C3539909;C1314973;C1547315;C1611280,allergy,FALSE,FALSE,NA,NA,NA
15,NCT00425373,Exclusion,patients with a clinically significant allergy ( asthma on pharmacotherapy ; multi-drug allergy ; or drug-induced anaphylactic reactions or food-induced anaphylactic reactions ) .,Condition Occurrence,Other,C0013216;C1552222,pharmacotherapy,FALSE,FALSE,NA,NA,NA
15,NCT00425373,Exclusion,patients with a clinically significant allergy ( asthma on pharmacotherapy ; multi-drug allergy ; or drug-induced anaphylactic reactions or food-induced anaphylactic reactions ) .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
15,NCT00425373,Exclusion,patients with a clinically significant allergy ( asthma on pharmacotherapy ; multi-drug allergy ; or drug-induced anaphylactic reactions or food-induced anaphylactic reactions ) .,Condition Occurrence,Other,C0489531;C0718579;C3542994;C3539909;C1314973;C1547315;C1611280,allergy,FALSE,FALSE,NA,NA,NA
15,NCT00425373,Exclusion,patients with a clinically significant allergy ( asthma on pharmacotherapy ; multi-drug allergy ; or drug-induced anaphylactic reactions or food-induced anaphylactic reactions ) .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
16,NCT00425373,Exclusion,patients hypersensitive to aii receptor antagonists ; calcium channel blockers or dihydropyridine derivatives .,Drug Exposure,Drug,C0006684,calcium channel blockers,FALSE,FALSE,NA,NA,NA
16,NCT00425373,Exclusion,patients hypersensitive to aii receptor antagonists ; calcium channel blockers or dihydropyridine derivatives .,Drug Exposure,Drug,C3653438,dihydropyridine derivatives,FALSE,FALSE,NA,NA,NA
17,NCT00425373,Exclusion,known moderate retinopathy or malignant retinopathy .,Condition Occurrence,Condition,C0035309;C1962966,retinopathy,FALSE,FALSE,NA,NA,NA
17,NCT00425373,Exclusion,known moderate retinopathy or malignant retinopathy .,Condition Occurrence,Condition,C0334590;C1533592,malignant,FALSE,FALSE,NA,NA,NA
17,NCT00425373,Exclusion,known moderate retinopathy or malignant retinopathy .,Condition Occurrence,Condition,C0035309;C1962966,retinopathy,FALSE,FALSE,NA,NA,NA
17,NCT00425373,Exclusion,known moderate retinopathy or malignant retinopathy .,Condition Occurrence,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
18,NCT00425373,Exclusion,patients with or with a history of pancreatitis,Condition Occurrence,Condition,C0030305;C1963198,pancreatitis,FALSE,FALSE,NA,NA,NA
19,NCT00425373,Exclusion,patients with pancreatic injury ; or evidence of impaired pancreatic function / injury within 12 months of visit 1 .,Condition Occurrence,Condition,C0273163,pancreatic injury,FALSE,FALSE,NA,NA,NA
19,NCT00425373,Exclusion,patients with pancreatic injury ; or evidence of impaired pancreatic function / injury within 12 months of visit 1 .,Condition Occurrence,Condition,C0232786,pancreatic function,FALSE,FALSE,lower 12 months,NA,NA
20,NCT00425373,Exclusion,patients with any surgical condition or medical condition which might significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug .,Condition Occurrence,Condition,C1378698,distribution,FALSE,FALSE,NA,NA,NA
20,NCT00425373,Exclusion,patients with any surgical condition or medical condition which might significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug .,Condition Occurrence,Condition,C0504085,excretion,FALSE,FALSE,NA,NA,NA
20,NCT00425373,Exclusion,patients with any surgical condition or medical condition which might significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug .,Condition Occurrence,Condition,C0025519,metabolism,FALSE,FALSE,NA,NA,NA
20,NCT00425373,Exclusion,patients with any surgical condition or medical condition which might significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug .,Condition Occurrence,Other,C1561579;C1561578,medical,FALSE,FALSE,NA,NA,NA
20,NCT00425373,Exclusion,patients with any surgical condition or medical condition which might significantly alter the absorption ; distribution ; metabolism ; or excretion of any drug .,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
21,NCT00425373,Exclusion,patients with volume depletion based on the investigator or subinvestigator clinical judgment using vital signs ; skin turgor ; moistness of mucous membrane and laboratory values .,Condition Occurrence,Condition,C0546884,volume depletion,FALSE,FALSE,NA,NA,NA
21,NCT00425373,Exclusion,patients with volume depletion based on the investigator or subinvestigator clinical judgment using vital signs ; skin turgor ; moistness of mucous membrane and laboratory values .,Condition Occurrence,Condition,C0277937,skin turgor,FALSE,FALSE,NA,NA,NA
21,NCT00425373,Exclusion,patients with volume depletion based on the investigator or subinvestigator clinical judgment using vital signs ; skin turgor ; moistness of mucous membrane and laboratory values .,Condition Occurrence,Condition,C0151785,mucous membrane,FALSE,FALSE,NA,NA,NA
21,NCT00425373,Exclusion,patients with volume depletion based on the investigator or subinvestigator clinical judgment using vital signs ; skin turgor ; moistness of mucous membrane and laboratory values .,Condition Occurrence,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
21,NCT00425373,Exclusion,patients with volume depletion based on the investigator or subinvestigator clinical judgment using vital signs ; skin turgor ; moistness of mucous membrane and laboratory values .,Condition Occurrence,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
21,NCT00425373,Exclusion,patients with volume depletion based on the investigator or subinvestigator clinical judgment using vital signs ; skin turgor ; moistness of mucous membrane and laboratory values .,Condition Occurrence,Other,C0518766;C0150404;C1704752;C0488614,vital signs,FALSE,FALSE,NA,NA,NA
22,NCT00425373,Exclusion,patients who are found to have low na and k ( na < 130 meq / l ; k < 3.3 meq / l ) or high in these parameters ( na > = 152 meq / l ; k > = 5.22 meq / l ) by laboratory tests at visit 1 .,Observation,Observation,C2700150,low,FALSE,FALSE,NA,lower 130 ; lower 3.3,NA
22,NCT00425373,Exclusion,patients who are found to have low na and k ( na < 130 meq / l ; k < 3.3 meq / l ) or high in these parameters ( na > = 152 meq / l ; k > = 5.22 meq / l ) by laboratory tests at visit 1 .,Observation,Observation,C2700149,high,FALSE,FALSE,NA,greater_equal 152 ; greater_equal 5.22,NA
22,NCT00425373,Exclusion,patients who are found to have low na and k ( na < 130 meq / l ; k < 3.3 meq / l ) or high in these parameters ( na > = 152 meq / l ; k > = 5.22 meq / l ) by laboratory tests at visit 1 .,Observation,Observation,C0022885,laboratory tests,FALSE,FALSE,NA,NA,NA
23,NCT00425373,Exclusion,patients with type i diabetes mellitus on treatment with insulin ; or patients with type ii diabetes with poor glucose control defined as a glycosylated hemoglobin ( hba1c ) > 8.0 % at visit 1 .,Drug Exposure,Condition,C0011854,type i diabetes mellitus,FALSE,FALSE,NA,NA,NA
23,NCT00425373,Exclusion,patients with type i diabetes mellitus on treatment with insulin ; or patients with type ii diabetes with poor glucose control defined as a glycosylated hemoglobin ( hba1c ) > 8.0 % at visit 1 .,Drug Exposure,Condition,C0011860,type ii diabetes,FALSE,FALSE,NA,NA,NA
23,NCT00425373,Exclusion,patients with type i diabetes mellitus on treatment with insulin ; or patients with type ii diabetes with poor glucose control defined as a glycosylated hemoglobin ( hba1c ) > 8.0 % at visit 1 .,Drug Exposure,Drug,C0726398,glucose control,FALSE,FALSE,NA,NA,NA
23,NCT00425373,Exclusion,patients with type i diabetes mellitus on treatment with insulin ; or patients with type ii diabetes with poor glucose control defined as a glycosylated hemoglobin ( hba1c ) > 8.0 % at visit 1 .,Drug Exposure,Observation,C0021641;C0202098;C1533581;C1145751;C1579433;C2739803,insulin,FALSE,FALSE,NA,NA,NA
23,NCT00425373,Exclusion,patients with type i diabetes mellitus on treatment with insulin ; or patients with type ii diabetes with poor glucose control defined as a glycosylated hemoglobin ( hba1c ) > 8.0 % at visit 1 .,Drug Exposure,Observation,C0017853;C0373638;C0202054,glycosylated hemoglobin,FALSE,FALSE,NA,NA,NA
23,NCT00425373,Exclusion,patients with type i diabetes mellitus on treatment with insulin ; or patients with type ii diabetes with poor glucose control defined as a glycosylated hemoglobin ( hba1c ) > 8.0 % at visit 1 .,Drug Exposure,Observation,C0202054,hba1c,FALSE,FALSE,NA,NA,greater 8.0 %
23,NCT00425373,Exclusion,patients with type i diabetes mellitus on treatment with insulin ; or patients with type ii diabetes with poor glucose control defined as a glycosylated hemoglobin ( hba1c ) > 8.0 % at visit 1 .,Drug Exposure,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
24,NCT00425373,Exclusion,patients with or with a history of malignant tumors including leukemia and lymphoma ; treated or untreated ; within the past 5 years of visit 1 whether or not there is evidence of local recurrence or metastases ( except for localized basal cell carcinoma of the skin ) .,Condition Occurrence,Condition,C0006826,malignant tumors,FALSE,FALSE,NA,NA,NA
24,NCT00425373,Exclusion,patients with or with a history of malignant tumors including leukemia and lymphoma ; treated or untreated ; within the past 5 years of visit 1 whether or not there is evidence of local recurrence or metastases ( except for localized basal cell carcinoma of the skin ) .,Condition Occurrence,Condition,C0023418,leukemia,FALSE,FALSE,lower 5 past years,NA,NA
24,NCT00425373,Exclusion,patients with or with a history of malignant tumors including leukemia and lymphoma ; treated or untreated ; within the past 5 years of visit 1 whether or not there is evidence of local recurrence or metastases ( except for localized basal cell carcinoma of the skin ) .,Condition Occurrence,Condition,C0024299,lymphoma,FALSE,FALSE,lower 5 past years,NA,NA
24,NCT00425373,Exclusion,patients with or with a history of malignant tumors including leukemia and lymphoma ; treated or untreated ; within the past 5 years of visit 1 whether or not there is evidence of local recurrence or metastases ( except for localized basal cell carcinoma of the skin ) .,Condition Occurrence,Condition,C2825055;C1458156,recurrence,FALSE,FALSE,NA,NA,NA
24,NCT00425373,Exclusion,patients with or with a history of malignant tumors including leukemia and lymphoma ; treated or untreated ; within the past 5 years of visit 1 whether or not there is evidence of local recurrence or metastases ( except for localized basal cell carcinoma of the skin ) .,Condition Occurrence,Condition,C0027627;C2939419,metastases,FALSE,FALSE,NA,NA,NA
24,NCT00425373,Exclusion,patients with or with a history of malignant tumors including leukemia and lymphoma ; treated or untreated ; within the past 5 years of visit 1 whether or not there is evidence of local recurrence or metastases ( except for localized basal cell carcinoma of the skin ) .,Condition Occurrence,Condition,C0007117,basal cell carcinoma of the skin,TRUE,FALSE,NA,NA,NA
25,NCT00425373,Exclusion,patients with any severe disease ; life-threatening disease within the past 5 years,Condition Occurrence,Condition,C2826244;C3537125,life-threatening,FALSE,FALSE,lower 5 past years,NA,NA
25,NCT00425373,Exclusion,patients with any severe disease ; life-threatening disease within the past 5 years,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,lower 5 past years,NA,NA
26,NCT00425373,Exclusion,patients with a history of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus .,Condition Occurrence,Condition,C0004364,autoimmune diseases,FALSE,FALSE,NA,NA,NA
26,NCT00425373,Exclusion,patients with a history of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus .,Condition Occurrence,Condition,C0003873,rheumatoid arthritis,FALSE,FALSE,NA,NA,NA
26,NCT00425373,Exclusion,patients with a history of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus .,Condition Occurrence,Condition,C0024141,systemic lupus erythematosus,FALSE,FALSE,NA,NA,NA
27,NCT00425373,Exclusion,any surgical condition or medical condition ; which in the opinion of the investigator or subinvestigator ; place the patient at higher risk from his / her participation in the study ; or are likely to prevent the patient from complying with the requirement of the study or completing the trial period .,Other,Drug,C0309872,prevent,FALSE,FALSE,NA,NA,NA
27,NCT00425373,Exclusion,any surgical condition or medical condition ; which in the opinion of the investigator or subinvestigator ; place the patient at higher risk from his / her participation in the study ; or are likely to prevent the patient from complying with the requirement of the study or completing the trial period .,Other,Other,C1561579;C1561578,medical,FALSE,FALSE,NA,NA,NA
28,NCT00425373,Exclusion,patients who have with or with a history of drug or alcohol abuse within the last 2 years of visit,Condition Occurrence,Condition,C0085762,alcohol abuse,FALSE,FALSE,lower 2 last years,NA,NA
28,NCT00425373,Exclusion,patients who have with or with a history of drug or alcohol abuse within the last 2 years of visit,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,lower 2 last years,NA,NA
29,NCT00425373,Exclusion,patients who have received other investigational product within 12 weeks of visit 1 .,Other,Other,C3245491,investigational,FALSE,FALSE,lower 12 weeks,NA,NA
30,NCT00425373,Exclusion,any chronic inflammatory condition needing chronic anti-inflammatory drug therapy .,Other,Procedure,C0013216;C0013217,drug therapy,FALSE,FALSE,NA,NA,NA
30,NCT00425373,Exclusion,any chronic inflammatory condition needing chronic anti-inflammatory drug therapy .,Other,Other,C1547296;C1555457,chronic,FALSE,FALSE,NA,NA,NA
30,NCT00425373,Exclusion,any chronic inflammatory condition needing chronic anti-inflammatory drug therapy .,Other,Other,C1547296;C1555457,chronic,FALSE,FALSE,NA,NA,NA
31,NCT00425373,Exclusion,persons directly involved in the execution of this study .,Person,Person,C0027361,persons,FALSE,FALSE,NA,NA,NA
32,NCT00425373,Exclusion,patients who are considered unlikely to comply with the requirements specified in the protocol by the investigator or subinvestigator,Other,NA,NA,NA,NA,NA,NA,NA,NA
1,NCT00538486,Inclusion,grade 1 or grade 2 hypertension : 140 mmhg < = sbp < 180 mmhg ; or 90 mmhg < = dbp < 110 mmhg,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,greater_equal 140 mmhg; lower 180 mmhg; greater_equal 90 mmhg; lower 110 mmhg,NA
2,NCT00538486,Inclusion,waist circumference higher than 90 cm in men ; 80 cm in women,Observation,Person,C0025266,men,FALSE,FALSE,NA,NA,NA
2,NCT00538486,Inclusion,waist circumference higher than 90 cm in men ; 80 cm in women,Observation,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
2,NCT00538486,Inclusion,waist circumference higher than 90 cm in men ; 80 cm in women,Observation,Other,C0455829;C2366869,waist circumference,FALSE,FALSE,NA,greater 90 cm,NA
3,NCT00538486,Exclusion,diabetes,Condition Occurrence,Condition,C0011849;C0011847,diabetes,FALSE,FALSE,NA,NA,NA
4,NCT00538486,Exclusion,grade 3 hypertension : sbp > = 180 mmhg ; or dbp > = 110 mmhg,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
4,NCT00538486,Exclusion,grade 3 hypertension : sbp > = 180 mmhg ; or dbp > = 110 mmhg,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 180 mmhg; greater_equal 110 mmhg,NA
4,NCT00538486,Exclusion,grade 3 hypertension : sbp > = 180 mmhg ; or dbp > = 110 mmhg,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 110 mmhg,NA
5,NCT00538486,Exclusion,known allergy or hypersensitivity to trial drugs,Observation,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
5,NCT00538486,Exclusion,known allergy or hypersensitivity to trial drugs,Observation,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
5,NCT00538486,Exclusion,known allergy or hypersensitivity to trial drugs,Observation,Other,C0489531;C0718579;C3542994;C3539909;C1314973;C1547315;C1611280,allergy,FALSE,FALSE,NA,NA,NA
6,NCT00538486,Exclusion,myocardial infarction or cerebrovascular accident in the year preceding the trial,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
6,NCT00538486,Exclusion,myocardial infarction or cerebrovascular accident in the year preceding the trial,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
7,NCT00538486,Exclusion,clinical congestive heart failure,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
7,NCT00538486,Exclusion,clinical congestive heart failure,Condition Occurrence,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
8,NCT00538486,Exclusion,history of hepatitis or cirrhosis,Condition Occurrence,Condition,C1623038;C0023890,cirrhosis,FALSE,FALSE,NA,NA,NA
8,NCT00538486,Exclusion,history of hepatitis or cirrhosis,Condition Occurrence,Other,C0019158;C0019159;C0795623,hepatitis,FALSE,FALSE,NA,NA,NA
9,NCT00538486,Exclusion,history of kidney disease,Condition Occurrence,Condition,C0022658,kidney disease,FALSE,FALSE,NA,NA,NA
1,NCT00698646,Inclusion,age 70 years or older .,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 70 years,NA,NA
2,NCT00698646,Inclusion,patients with hypertension prior to being randomized into study .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00698646,Inclusion,patients must have an office cuff mssbp > = 140 and < = 200 mmhg systolic .,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,greater_equal 140 mmhg; lower_equal 200 mmhg,NA
4,NCT00698646,Inclusion,have the ability to communicate and comply with all study requirements .,Condition Occurrence,Condition,C0565998,ability to communicate,FALSE,FALSE,NA,NA,NA
5,NCT00698646,Inclusion,provide written informed consent to participate in the study prior to any screening or study procedures .,Other,NA,NA,NA,NA,NA,NA,NA,NA
6,NCT00698646,Exclusion,use of other investigational drugs within 30 days of enrollment .,Drug Exposure,Drug,C0013230,investigational drugs,FALSE,FALSE,lower 30 days,NA,NA
6,NCT00698646,Exclusion,use of other investigational drugs within 30 days of enrollment .,Drug Exposure,Other,C1696073;C1516879,enrollment,FALSE,FALSE,NA,NA,NA
7,NCT00698646,Exclusion,history of hypersensitivity to any of the study drugs or to drugs of similar chemical classes .,Procedure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
7,NCT00698646,Exclusion,history of hypersensitivity to any of the study drugs or to drugs of similar chemical classes .,Procedure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
7,NCT00698646,Exclusion,history of hypersensitivity to any of the study drugs or to drugs of similar chemical classes .,Procedure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
7,NCT00698646,Exclusion,history of hypersensitivity to any of the study drugs or to drugs of similar chemical classes .,Procedure,Other,C0220806;C3272558,chemical,FALSE,FALSE,NA,NA,NA
8,NCT00698646,Exclusion,office blood pressure measured by office machine cuff with a mean of 3 msdbp > = 120 mmhg at anytime during the screening / washout period .,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,equal 3 ; greater_equal 120 mmhg,NA
8,NCT00698646,Exclusion,office blood pressure measured by office machine cuff with a mean of 3 msdbp > = 120 mmhg at anytime during the screening / washout period .,Observation,Procedure,C2224281;C1314130,blood pressure measured,FALSE,FALSE,NA,NA,NA
9,NCT00698646,Exclusion,patients taking 3 or more antihypertensive drugs and mssbp > = 160 mmhg at the time of visit 1 .,Observation,Condition,C2024467,time,FALSE,FALSE,NA,NA,NA
9,NCT00698646,Exclusion,patients taking 3 or more antihypertensive drugs and mssbp > = 160 mmhg at the time of visit 1 .,Observation,Drug,C0003364,antihypertensive drugs,FALSE,FALSE,NA,greater_equal 3 ; greater_equal 160 mmhg,NA
10,NCT00698646,Exclusion,other protocol-defined may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00739973,Inclusion,msdbp > = 90 mmhg and < 110 mmhg at the visit prior to visit 3 ( visit 2 or optional visit 201 ),Observation,NA,NA,NA,NA,NA,NA,NA,NA
2,NCT00739973,Inclusion,msdbp > = 95 mmhg and < 110 mmhg at visit 3 ( day 1 / randomization ) .,Observation,NA,NA,NA,NA,NA,NA,NA,NA
3,NCT00739973,Inclusion,all patients must have an absolute difference of < = 10 mmhg in their msdbp during the last 2 visits of the single-blind run-in period ( visit 2 and 3 or visits 201 and 3 ) .,Observation,Condition,C1549113,single,FALSE,FALSE,NA,lower_equal 10 mmhg; lower_equal 2 last; equal 201 ; equal 3,NA
4,NCT00739973,Exclusion,severe hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
4,NCT00739973,Exclusion,severe hypertension,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
5,NCT00739973,Exclusion,pregnant or nursing ( lactating ) women,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
5,NCT00739973,Exclusion,pregnant or nursing ( lactating ) women,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
5,NCT00739973,Exclusion,pregnant or nursing ( lactating ) women,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
5,NCT00739973,Exclusion,pregnant or nursing ( lactating ) women,Condition Occurrence,Condition,C2828358;C3668831,lactating,FALSE,FALSE,NA,NA,NA
6,NCT00739973,Exclusion,women of child-bearing potential,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
6,NCT00739973,Exclusion,women of child-bearing potential,Person,Observation,C3831118,child-bearing potential,FALSE,FALSE,NA,NA,NA
7,NCT00739973,Exclusion,previous diagnosis or current diagnosis of heart failure ( nyha class ii- .,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
7,NCT00739973,Exclusion,previous diagnosis or current diagnosis of heart failure ( nyha class ii- .,Condition Occurrence,Condition,C1882083,nyha class,FALSE,FALSE,NA,NA,NA
8,NCT00739973,Exclusion,serum potassium > = 5.3 meq / l ( mmol / l ) at visit 1 .,Observation,Observation,C0302353;C0543465,serum potassium,FALSE,FALSE,NA,greater_equal 5.3,NA
9,NCT00739973,Exclusion,uncontrolled type 1 diabetes or type 2 diabetesmellitus,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
9,NCT00739973,Exclusion,uncontrolled type 1 diabetes or type 2 diabetesmellitus,Condition Occurrence,Other,C1552651,type,FALSE,FALSE,NA,NA,NA
10,NCT00739973,Exclusion,hypersensitivity to renin inhibitors ; calcium channel blockers ; or to drugs with similar chemical structures,Drug Exposure,Condition,C2917241,renin inhibitors,FALSE,FALSE,NA,NA,NA
10,NCT00739973,Exclusion,hypersensitivity to renin inhibitors ; calcium channel blockers ; or to drugs with similar chemical structures,Drug Exposure,Drug,C0006684,calcium channel blockers,FALSE,FALSE,NA,NA,NA
10,NCT00739973,Exclusion,hypersensitivity to renin inhibitors ; calcium channel blockers ; or to drugs with similar chemical structures,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
10,NCT00739973,Exclusion,hypersensitivity to renin inhibitors ; calcium channel blockers ; or to drugs with similar chemical structures,Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
10,NCT00739973,Exclusion,hypersensitivity to renin inhibitors ; calcium channel blockers ; or to drugs with similar chemical structures,Drug Exposure,Other,C0220806;C3272558,chemical,FALSE,FALSE,NA,NA,NA
11,NCT00739973,Exclusion,history of malignancy within 5 years,Condition Occurrence,Condition,C0006826;C1306459,malignancy,FALSE,FALSE,lower 5 years,NA,NA
12,NCT00739973,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; or history of transient ischemic attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
12,NCT00739973,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; or history of transient ischemic attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention,Condition Occurrence,Condition,C0000924;C2046386,accident,FALSE,FALSE,NA,NA,NA
12,NCT00739973,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; or history of transient ischemic attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
12,NCT00739973,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; or history of transient ischemic attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,NA,NA,NA
12,NCT00739973,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; or history of transient ischemic attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention,Condition Occurrence,Condition,C0917805,tia,FALSE,FALSE,NA,NA,NA
12,NCT00739973,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; or history of transient ischemic attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention,Condition Occurrence,Procedure,C1532338,percutaneous coronary intervention,FALSE,FALSE,NA,NA,NA
12,NCT00739973,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; or history of transient ischemic attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention,Condition Occurrence,Procedure,C0010055,coronary bypass surgery,FALSE,FALSE,NA,NA,NA
12,NCT00739973,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; or history of transient ischemic attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
1,NCT00765674,Inclusion,male or female,Person,Person,C0025266;C1706429,male,FALSE,FALSE,NA,NA,NA
1,NCT00765674,Inclusion,male or female,Person,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
2,NCT00765674,Inclusion,18 years of age or older,Person,NA,NA,NA,NA,NA,NA,NA,NA
3,NCT00765674,Inclusion,msdbp and mssbp requirements :,Other,NA,NA,NA,NA,NA,NA,NA,NA
4,NCT00765674,Inclusion,0.125,Other,NA,NA,NA,NA,NA,NA,NA,NA
5,NCT00765674,Inclusion,diagnosis of moderate to severe hypertension ( mssbp > = 160 mmhg and < 200 mmhg ; or msdbp > = 100 mmhg and < 120 mmhg ) at visits 4 ; 5 or 6 ( qualifying bp visit ),Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,greater_equal 160 mmhg; lower 200 mmhg; greater_equal 100 mmhg; lower 120 mmhg; equal 4 ; equal 5 ; equal 6,NA
5,NCT00765674,Inclusion,diagnosis of moderate to severe hypertension ( mssbp > = 160 mmhg and < 200 mmhg ; or msdbp > = 100 mmhg and < 120 mmhg ) at visits 4 ; 5 or 6 ( qualifying bp visit ),Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,NA,NA
5,NCT00765674,Inclusion,diagnosis of moderate to severe hypertension ( mssbp > = 160 mmhg and < 200 mmhg ; or msdbp > = 100 mmhg and < 120 mmhg ) at visits 4 ; 5 or 6 ( qualifying bp visit ),Observation,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
5,NCT00765674,Inclusion,diagnosis of moderate to severe hypertension ( mssbp > = 160 mmhg and < 200 mmhg ; or msdbp > = 100 mmhg and < 120 mmhg ) at visits 4 ; 5 or 6 ( qualifying bp visit ),Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
6,NCT00765674,Inclusion,in addition;at the visit immediately prior to the above qualifying visit;patients were also to have mssbp > = 145 mmhg and < 200 mmhg and msdbp > = 95 mmhg and < 120 mmhg ) at visits 3;5 or 5 .,Observation,NA,NA,NA,NA,NA,NA,NA,NA
7,NCT00765674,Inclusion,patients had to meet the above two sets of requirements at subsequent adjacent visits;ie either visits 3 and 4;visits 4 and 5;or visits 5 and 6 .,Observation,NA,NA,NA,NA,NA,NA,NA,NA
8,NCT00765674,Inclusion,3 b :,Other,NA,NA,NA,NA,NA,NA,NA,NA
9,NCT00765674,Inclusion,mssbp > = 180 mmhg and < 200 mmhg with msdbp > = 95 mmhg and < 120 mmhg ; or msdbp > = 110 mmhg and < 120 mmhg with mssbp > = 150 mmhg and < 200 mmhg after at least one week of treatment with placebo ( visit 3 and on ) .,Observation,Drug,C1696465,placebo,FALSE,FALSE,NA,greater_equal 180 mmhg; lower 200 mmhg; greater_equal 95 mmhg; lower 120 mmhg; greater_equal 110 mmhg; lower 120 mmhg; greater_equal 150 mmhg; lower 200 mmhg,NA
10,NCT00765674,Exclusion,continued use of anti-hypertensive medicines or use of 4 or more hypertensive medicines at study start,Drug Exposure,Condition,C0857121,hypertensive,FALSE,FALSE,NA,greater_equal 4,NA
10,NCT00765674,Exclusion,continued use of anti-hypertensive medicines or use of 4 or more hypertensive medicines at study start,Drug Exposure,Drug,C0003364,anti-hypertensive,FALSE,FALSE,NA,NA,NA
11,NCT00765674,Exclusion,patients with an mssbp > = 200 mmhg or msdbp > = 120 mmhg at any time during the placebo run-in period were to be discontinued from the study .,Observation,Condition,C2024467,time,FALSE,FALSE,NA,greater_equal 200 mmhg; greater_equal 120 mmhg,NA
11,NCT00765674,Exclusion,patients with an mssbp > = 200 mmhg or msdbp > = 120 mmhg at any time during the placebo run-in period were to be discontinued from the study .,Observation,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,NA
12,NCT00765674,Exclusion,extremely elevated ( defined ) blood pressure at any point during the study,Other,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
12,NCT00765674,Exclusion,extremely elevated ( defined ) blood pressure at any point during the study,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
12,NCT00765674,Exclusion,extremely elevated ( defined ) blood pressure at any point during the study,Other,Other,C1553441,point,FALSE,FALSE,NA,NA,NA
13,NCT00765674,Exclusion,pregnant or lactating women,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
13,NCT00765674,Exclusion,pregnant or lactating women,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
13,NCT00765674,Exclusion,pregnant or lactating women,Condition Occurrence,Condition,C2828358;C3668831,lactating,FALSE,FALSE,NA,NA,NA
14,NCT00765674,Exclusion,pre-menopausal women not taking accepted form of birth control,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
14,NCT00765674,Exclusion,pre-menopausal women not taking accepted form of birth control,Condition Occurrence,Condition,C1096235,pre-menopausal,FALSE,FALSE,NA,NA,NA
14,NCT00765674,Exclusion,pre-menopausal women not taking accepted form of birth control,Condition Occurrence,Other,C0700589;C2703065,birth control,TRUE,FALSE,NA,NA,NA
15,NCT00765674,Exclusion,history or evidence of secondary form of hypertension,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
16,NCT00765674,Exclusion,history of cardiovascular conditions,Other,NA,NA,NA,NA,NA,NA,NA,NA
17,NCT00765674,Exclusion,other protocol-defined inclusiopplied to the study,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00777946,Inclusion,newly diagnosed patients or patients who have not been treated for hypertension within the 4 weeks prior to visit 1 must have a mean sitting diastolic blood pressure ( msdbp ) > = 95 mmhg and < 110 mmhg at visits 1 and 2,Observation,Condition,C1319894,sitting diastolic blood pressure,FALSE,FALSE,NA,greater_equal 95 mmhg; lower 110 mmhg; equal 1 ; equal 2,NA
1,NCT00777946,Inclusion,newly diagnosed patients or patients who have not been treated for hypertension within the 4 weeks prior to visit 1 must have a mean sitting diastolic blood pressure ( msdbp ) > = 95 mmhg and < 110 mmhg at visits 1 and 2,Observation,Observation,C0020538;C1963138,hypertension,TRUE,FALSE,lower 4 weeks,NA,NA
2,NCT00777946,Inclusion,patients who have been treated for hypertension within the 4 weeks prior to visit 1 must have a msdbp > = 90 mmhg and < 110 mmhg at visit 2,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,lower 4 weeks,greater_equal 90 mmhg; lower 110 mmhg,NA
3,NCT00777946,Inclusion,all patients must have a msdbp > = 90 mmhg and < 110 mmhg at visit 4,Observation,NA,NA,NA,NA,NA,NA,NA,NA
4,NCT00777946,Exclusion,severe hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
4,NCT00777946,Exclusion,severe hypertension,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
5,NCT00777946,Exclusion,pregnant or nursing ( lactating ) women,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
5,NCT00777946,Exclusion,pregnant or nursing ( lactating ) women,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
5,NCT00777946,Exclusion,pregnant or nursing ( lactating ) women,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
5,NCT00777946,Exclusion,pregnant or nursing ( lactating ) women,Condition Occurrence,Condition,C2828358;C3668831,lactating,FALSE,FALSE,NA,NA,NA
6,NCT00777946,Exclusion,women of child-bearing potential,Person,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
6,NCT00777946,Exclusion,women of child-bearing potential,Person,Observation,C3831118,child-bearing potential,FALSE,FALSE,NA,NA,NA
7,NCT00777946,Exclusion,previous diagnosis or current diagnosis of heart failure new york heart association ( nyha class ii-,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
7,NCT00777946,Exclusion,previous diagnosis or current diagnosis of heart failure new york heart association ( nyha class ii-,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
7,NCT00777946,Exclusion,previous diagnosis or current diagnosis of heart failure new york heart association ( nyha class ii-,Condition Occurrence,Condition,C1882083,nyha class,FALSE,FALSE,NA,NA,NA
8,NCT00777946,Exclusion,serum potassium > = 5.3 meq / l ( mmol / l ) at visit 1,Observation,Observation,C0302353;C0543465,serum potassium,FALSE,FALSE,NA,greater_equal 5.3,NA
9,NCT00777946,Exclusion,uncontrolled type 1 diabetes or type 2 diabetesmellitus,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
9,NCT00777946,Exclusion,uncontrolled type 1 diabetes or type 2 diabetesmellitus,Condition Occurrence,Other,C1552651,type,FALSE,FALSE,NA,NA,NA
10,NCT00777946,Exclusion,hypersensitivity to renin inhibitors ; calcium channel blockers ; or to drugs with similar chemical structures,Drug Exposure,Condition,C2917241,renin inhibitors,FALSE,FALSE,NA,NA,NA
10,NCT00777946,Exclusion,hypersensitivity to renin inhibitors ; calcium channel blockers ; or to drugs with similar chemical structures,Drug Exposure,Drug,C0006684,calcium channel blockers,FALSE,FALSE,NA,NA,NA
10,NCT00777946,Exclusion,hypersensitivity to renin inhibitors ; calcium channel blockers ; or to drugs with similar chemical structures,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
10,NCT00777946,Exclusion,hypersensitivity to renin inhibitors ; calcium channel blockers ; or to drugs with similar chemical structures,Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
10,NCT00777946,Exclusion,hypersensitivity to renin inhibitors ; calcium channel blockers ; or to drugs with similar chemical structures,Drug Exposure,Other,C0220806;C3272558,chemical,FALSE,FALSE,NA,NA,NA
11,NCT00777946,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; or history of transient ischemic attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
11,NCT00777946,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; or history of transient ischemic attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention,Condition Occurrence,Condition,C0000924;C2046386,accident,FALSE,FALSE,NA,NA,NA
11,NCT00777946,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; or history of transient ischemic attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
11,NCT00777946,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; or history of transient ischemic attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,NA,NA,NA
11,NCT00777946,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; or history of transient ischemic attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention,Condition Occurrence,Condition,C0917805,tia,FALSE,FALSE,NA,NA,NA
11,NCT00777946,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; or history of transient ischemic attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention,Condition Occurrence,Procedure,C1532338,percutaneous coronary intervention,FALSE,FALSE,NA,NA,NA
11,NCT00777946,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; or history of transient ischemic attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention,Condition Occurrence,Procedure,C0010055,coronary bypass surgery,FALSE,FALSE,NA,NA,NA
11,NCT00777946,Exclusion,history of hypertensive encephalopathy accident or cerebrovascular accident ; or history of transient ischemic attack ( tia ) ; myocardial infarction ; coronary bypass surgery ; or any percutaneous coronary intervention,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
12,NCT00777946,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00797316,Inclusion,patients who are eligible and able to participate in the study ; and who give written informed consent before any assessment is performed .,Observation,Other,C0542573;C0549068;C0870300;C0549070;C0549071;C0549072;C0549073;C0549074;C0028708;C0549075;C0549076;C0549077;C0549078;C0549079;C0549080;C0679207,assessment,FALSE,FALSE,NA,NA,NA
2,NCT00797316,Inclusion,male or female outpatients > = 18 years old .,Person,Person,C0025266;C1706429,male,FALSE,FALSE,greater_equal 18 years,NA,NA
4,NCT00797316,Inclusion,patients must have a mssbp > = 160 mmhg and < 200 mmhg at study visit 5 ( randomization ) .,Observation,NA,NA,NA,NA,NA,NA,NA,NA
5,NCT00797316,Inclusion,patients who have stage 2 systolic hypertension that meet at least 2 additional components of the metabolic syndrome as defined by the national cholesterol education program ( ncep ) criteria :,Observation,Condition,C0221155,systolic hypertension,FALSE,FALSE,NA,greater_equal 2,NA
5,NCT00797316,Inclusion,patients who have stage 2 systolic hypertension that meet at least 2 additional components of the metabolic syndrome as defined by the national cholesterol education program ( ncep ) criteria :,Observation,Condition,C0524620,metabolic syndrome,FALSE,FALSE,NA,NA,NA
5,NCT00797316,Inclusion,patients who have stage 2 systolic hypertension that meet at least 2 additional components of the metabolic syndrome as defined by the national cholesterol education program ( ncep ) criteria :,Observation,Observation,C0008377;C0201950,cholesterol,FALSE,FALSE,NA,NA,NA
5,NCT00797316,Inclusion,patients who have stage 2 systolic hypertension that meet at least 2 additional components of the metabolic syndrome as defined by the national cholesterol education program ( ncep ) criteria :,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
5,NCT00797316,Inclusion,patients who have stage 2 systolic hypertension that meet at least 2 additional components of the metabolic syndrome as defined by the national cholesterol education program ( ncep ) criteria :,Observation,Other,C3245503,national,FALSE,FALSE,NA,NA,NA
6,NCT00797316,Inclusion,abdominal obesity ( waist circumference > than 102 cm for men and > 88 cm for women ),Observation,Person,C0025266,men,FALSE,FALSE,NA,NA,NA
6,NCT00797316,Inclusion,abdominal obesity ( waist circumference > than 102 cm for men and > 88 cm for women ),Observation,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
6,NCT00797316,Inclusion,abdominal obesity ( waist circumference > than 102 cm for men and > 88 cm for women ),Observation,Condition,C0311277,abdominal obesity,FALSE,FALSE,NA,NA,NA
6,NCT00797316,Inclusion,abdominal obesity ( waist circumference > than 102 cm for men and > 88 cm for women ),Observation,Other,C0455829;C2366869,waist circumference,FALSE,FALSE,NA,NA,NA
7,NCT00797316,Inclusion,current triglycerides > = 150 mg / dl or medical treatment for this condition .,Drug Exposure,Other,C0041004;C0202236,triglycerides,FALSE,FALSE,NA,NA,greater_equal 150 mg/dl
7,NCT00797316,Inclusion,current triglycerides > = 150 mg / dl or medical treatment for this condition .,Drug Exposure,Other,C1561579;C1561578,medical,FALSE,FALSE,NA,NA,NA
8,NCT00797316,Inclusion,current hdl cholesterol < 40 mg / dl in men and < 50 mg / dl in women or medical treatment for this condition .,Drug Exposure,Person,C0025266,men,FALSE,FALSE,NA,NA,NA
8,NCT00797316,Inclusion,current hdl cholesterol < 40 mg / dl in men and < 50 mg / dl in women or medical treatment for this condition .,Drug Exposure,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
8,NCT00797316,Inclusion,current hdl cholesterol < 40 mg / dl in men and < 50 mg / dl in women or medical treatment for this condition .,Drug Exposure,Other,C0023822;C0428472;C0392885,hdl cholesterol,FALSE,FALSE,NA,NA,lower 40 mg/dl
8,NCT00797316,Inclusion,current hdl cholesterol < 40 mg / dl in men and < 50 mg / dl in women or medical treatment for this condition .,Drug Exposure,Other,C1561579;C1561578,medical,FALSE,FALSE,NA,NA,NA
9,NCT00797316,Inclusion,fasting glucose > 100 mg / dl and < 126 mg / dl,Drug Exposure,Observation,C0017725;C0337438,glucose,FALSE,FALSE,NA,NA,greater 100 mg/dl; lower 126 mg/dl
9,NCT00797316,Inclusion,fasting glucose > 100 mg / dl and < 126 mg / dl,Drug Exposure,Other,C0015663;C1550565,fasting,FALSE,FALSE,NA,NA,NA
10,NCT00797316,Exclusion,office blood pressure measured by cuff ( msdbp > = 110 mmhg and or mssbp > = 200 mmhg ) at any visit .,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,greater_equal 110 mmhg; greater_equal 200 mmhg,NA
10,NCT00797316,Exclusion,office blood pressure measured by cuff ( msdbp > = 110 mmhg and or mssbp > = 200 mmhg ) at any visit .,Observation,Procedure,C2224281;C1314130,blood pressure measured,FALSE,FALSE,NA,NA,NA
11,NCT00797316,Exclusion,use of other investigational drugs at the time of enrollment ; or within 30 days or 5 half-lives of enrollment ; whichever is longer .,Condition Occurrence,Condition,C2024467,time,FALSE,FALSE,NA,NA,NA
11,NCT00797316,Exclusion,use of other investigational drugs at the time of enrollment ; or within 30 days or 5 half-lives of enrollment ; whichever is longer .,Condition Occurrence,Condition,C0595998,lives,FALSE,FALSE,lower 30 days; equal 5 days,NA,NA
11,NCT00797316,Exclusion,use of other investigational drugs at the time of enrollment ; or within 30 days or 5 half-lives of enrollment ; whichever is longer .,Condition Occurrence,Drug,C0013230,investigational drugs,FALSE,FALSE,NA,NA,NA
11,NCT00797316,Exclusion,use of other investigational drugs at the time of enrollment ; or within 30 days or 5 half-lives of enrollment ; whichever is longer .,Condition Occurrence,Other,C1696073;C1516879,enrollment,FALSE,FALSE,NA,NA,NA
11,NCT00797316,Exclusion,use of other investigational drugs at the time of enrollment ; or within 30 days or 5 half-lives of enrollment ; whichever is longer .,Condition Occurrence,Other,C1696073;C1516879,enrollment,FALSE,FALSE,NA,NA,NA
12,NCT00797316,Exclusion,use of aliskiren or a fixed dose combination of aliskiren hctz or participation in a clinical trial that had aliskiren or aliskiren hctz as treatment within 30 days of visit 1 .,Drug Exposure,Condition,C2827483,fixed,FALSE,FALSE,NA,NA,NA
12,NCT00797316,Exclusion,use of aliskiren or a fixed dose combination of aliskiren hctz or participation in a clinical trial that had aliskiren or aliskiren hctz as treatment within 30 days of visit 1 .,Drug Exposure,Drug,C1120110,aliskiren,FALSE,FALSE,NA,NA,NA
12,NCT00797316,Exclusion,use of aliskiren or a fixed dose combination of aliskiren hctz or participation in a clinical trial that had aliskiren or aliskiren hctz as treatment within 30 days of visit 1 .,Drug Exposure,Drug,C1120110,aliskiren,FALSE,FALSE,NA,NA,NA
12,NCT00797316,Exclusion,use of aliskiren or a fixed dose combination of aliskiren hctz or participation in a clinical trial that had aliskiren or aliskiren hctz as treatment within 30 days of visit 1 .,Drug Exposure,Drug,C1120110,aliskiren,FALSE,FALSE,lower 30 days,NA,NA
12,NCT00797316,Exclusion,use of aliskiren or a fixed dose combination of aliskiren hctz or participation in a clinical trial that had aliskiren or aliskiren hctz as treatment within 30 days of visit 1 .,Drug Exposure,Drug,C1120110,aliskiren,FALSE,FALSE,lower 30 days,NA,NA
12,NCT00797316,Exclusion,use of aliskiren or a fixed dose combination of aliskiren hctz or participation in a clinical trial that had aliskiren or aliskiren hctz as treatment within 30 days of visit 1 .,Drug Exposure,Other,C1096775,clinical trial,FALSE,FALSE,NA,NA,NA
13,NCT00797316,Exclusion,history of hypersensitivity to any of the medications or to drugs belonging to a similar therapeutic class ( diuretics or renin inhibitors ) as the study drugs .,Procedure,Condition,C2917241,renin inhibitors,FALSE,FALSE,NA,NA,NA
13,NCT00797316,Exclusion,history of hypersensitivity to any of the medications or to drugs belonging to a similar therapeutic class ( diuretics or renin inhibitors ) as the study drugs .,Procedure,Drug,C0012798,diuretics,FALSE,FALSE,NA,NA,NA
13,NCT00797316,Exclusion,history of hypersensitivity to any of the medications or to drugs belonging to a similar therapeutic class ( diuretics or renin inhibitors ) as the study drugs .,Procedure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
13,NCT00797316,Exclusion,history of hypersensitivity to any of the medications or to drugs belonging to a similar therapeutic class ( diuretics or renin inhibitors ) as the study drugs .,Procedure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
13,NCT00797316,Exclusion,history of hypersensitivity to any of the medications or to drugs belonging to a similar therapeutic class ( diuretics or renin inhibitors ) as the study drugs .,Procedure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
13,NCT00797316,Exclusion,history of hypersensitivity to any of the medications or to drugs belonging to a similar therapeutic class ( diuretics or renin inhibitors ) as the study drugs .,Procedure,Other,C0723712;C0039796;C1547427,therapeutic,FALSE,FALSE,NA,NA,NA
13,NCT00797316,Exclusion,history of hypersensitivity to any of the medications or to drugs belonging to a similar therapeutic class ( diuretics or renin inhibitors ) as the study drugs .,Procedure,Other,C0456387;C0489477,class,FALSE,FALSE,NA,NA,NA
14,NCT00797316,Exclusion,history or evidence of secondary form of hypertension .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
15,NCT00797316,Exclusion,refractory hypertension ; defined as unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ),Observation,Condition,C0860493,refractory hypertension,FALSE,FALSE,NA,NA,NA
15,NCT00797316,Exclusion,refractory hypertension ; defined as unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ),Observation,Drug,C0012798,diuretic,FALSE,FALSE,NA,NA,NA
15,NCT00797316,Exclusion,refractory hypertension ; defined as unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ),Observation,Procedure,C0013216;C0013217,drug therapy,FALSE,FALSE,NA,NA,NA
15,NCT00797316,Exclusion,refractory hypertension ; defined as unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ),Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,TRUE,FALSE,NA,NA,NA
15,NCT00797316,Exclusion,refractory hypertension ; defined as unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ),Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
15,NCT00797316,Exclusion,refractory hypertension ; defined as unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ),Observation,Other,C0237284;C0205269,unresponsive,FALSE,FALSE,NA,NA,NA
15,NCT00797316,Exclusion,refractory hypertension ; defined as unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ),Observation,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
15,NCT00797316,Exclusion,refractory hypertension ; defined as unresponsive to triple drug therapy at the maximum dose of each drug ; one of which must be a diuretic ; and not at blood pressure goal ( 140 / 90 mmhg ),Observation,Other,C0018017,goal,TRUE,FALSE,NA,greater_equal 140 mmhg; lower_equal 90 mmhg,NA
16,NCT00797316,Exclusion,therapy with a fixed dose combination of two active substances represent two drugs .,Drug Exposure,Condition,C2827483,fixed,FALSE,FALSE,NA,NA,NA
16,NCT00797316,Exclusion,therapy with a fixed dose combination of two active substances represent two drugs .,Drug Exposure,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
16,NCT00797316,Exclusion,therapy with a fixed dose combination of two active substances represent two drugs .,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
17,NCT00797316,Exclusion,patients on 4 or more antihypertensive medications,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,greater_equal 4,NA
2,NCT00797316,Inclusion,male or female outpatients > = 18 years old .,Person,Person,C0086287,female,FALSE,FALSE,greater_equal 18 years,NA,NA
3,NCT00797316,Inclusion,patients with stage 2 systolic hypertension,Condition Occurrence,Condition,C0221155,systolic hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00860262,Inclusion,ability to provide written informed consent in accordance with good clinical practice and local legislation,Other,Other,C2986419,good clinical practice,FALSE,FALSE,NA,NA,NA
1,NCT00860262,Inclusion,ability to provide written informed consent in accordance with good clinical practice and local legislation,Other,Other,C0600657,legislation,FALSE,FALSE,NA,NA,NA
2,NCT00860262,Inclusion,age 18 years or older,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 18 years,NA,NA
3,NCT00860262,Inclusion,patients with severe hypertension as defined sbp greater than 180 mmhg and dbp greater than 95 mmhg at randomisation,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00860262,Inclusion,patients with severe hypertension as defined sbp greater than 180 mmhg and dbp greater than 95 mmhg at randomisation,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater 180 mmhg; greater 95 mmhg,NA
3,NCT00860262,Inclusion,patients with severe hypertension as defined sbp greater than 180 mmhg and dbp greater than 95 mmhg at randomisation,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
3,NCT00860262,Inclusion,patients with severe hypertension as defined sbp greater than 180 mmhg and dbp greater than 95 mmhg at randomisation,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater 95 mmhg,NA
3,NCT00860262,Inclusion,patients with severe hypertension as defined sbp greater than 180 mmhg and dbp greater than 95 mmhg at randomisation,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
4,NCT00860262,Inclusion,ability to stop any current antihypertensive therapy without unacceptable risk to the patient ( investigators discretion ),Drug Exposure,Drug,C0723457,stop,FALSE,FALSE,NA,NA,NA
4,NCT00860262,Inclusion,ability to stop any current antihypertensive therapy without unacceptable risk to the patient ( investigators discretion ),Drug Exposure,Procedure,C0585941,antihypertensive therapy,FALSE,FALSE,NA,NA,NA
5,NCT00860262,Exclusion,mean in-clinic seated cuff sbp > / = 200 mmhg or diastolic blood pressure [ dbp ] > / = 95 mmhg,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
5,NCT00860262,Exclusion,mean in-clinic seated cuff sbp > / = 200 mmhg or diastolic blood pressure [ dbp ] > / = 95 mmhg,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 200 mmhg,NA
5,NCT00860262,Exclusion,mean in-clinic seated cuff sbp > / = 200 mmhg or diastolic blood pressure [ dbp ] > / = 95 mmhg,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,NA,NA
5,NCT00860262,Exclusion,mean in-clinic seated cuff sbp > / = 200 mmhg or diastolic blood pressure [ dbp ] > / = 95 mmhg,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 95 mmhg,NA
1,NCT00865020,Inclusion,mean sitting systolic blood pressure > = 140 mmhg and < 180 mmhg,Observation,Condition,C1319893,sitting systolic blood pressure,FALSE,FALSE,NA,greater_equal 140 mmhg; lower 180 mmhg,NA
2,NCT00865020,Inclusion,24 - hr mean ambulatory systolic blood pressure > = 135 mmhg,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater_equal 135 mmhg,NA
2,NCT00865020,Inclusion,24 - hr mean ambulatory systolic blood pressure > = 135 mmhg,Observation,Other,C1561560;C1547135,ambulatory,FALSE,FALSE,NA,equal 24,NA
3,NCT00865020,Exclusion,severe hypertension defined as mean sitting systolic blood pressure > = 180 mmhg or mean sitting diastolic blood pressure > = 110 mmhg,Condition Occurrence,Condition,C1319893,sitting systolic blood pressure,FALSE,FALSE,NA,greater_equal 180 mmhg,NA
3,NCT00865020,Exclusion,severe hypertension defined as mean sitting systolic blood pressure > = 180 mmhg or mean sitting diastolic blood pressure > = 110 mmhg,Condition Occurrence,Condition,C1319894,sitting diastolic blood pressure,FALSE,FALSE,NA,greater_equal 110 mmhg,NA
3,NCT00865020,Exclusion,severe hypertension defined as mean sitting systolic blood pressure > = 180 mmhg or mean sitting diastolic blood pressure > = 110 mmhg,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00865020,Exclusion,severe hypertension defined as mean sitting systolic blood pressure > = 180 mmhg or mean sitting diastolic blood pressure > = 110 mmhg,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
3,NCT00865020,Exclusion,severe hypertension defined as mean sitting systolic blood pressure > = 180 mmhg or mean sitting diastolic blood pressure > = 110 mmhg,Condition Occurrence,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
4,NCT00865020,Exclusion,patients with type 1 diabetes mellitus,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
5,NCT00865020,Exclusion,secondary hypertension of any etiology,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
6,NCT00865020,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00872586,Inclusion,at visit 3 ; mean seated diastolic blood pressure ( sedbp ) > = 95 mmhg and < 110 mmhg ; and mean seated systolic blood pressure ( sesbp ) > = 140 mmhg and < 180 mmhg,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater_equal 95 mmhg; lower 110 mmhg,NA
1,NCT00872586,Inclusion,at visit 3 ; mean seated diastolic blood pressure ( sedbp ) > = 95 mmhg and < 110 mmhg ; and mean seated systolic blood pressure ( sesbp ) > = 140 mmhg and < 180 mmhg,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater_equal 140 mmhg; lower 180 mmhg,NA
2,NCT00872586,Inclusion,at visit 4;mean sedbp > = 90 mmh,Observation,NA,NA,NA,NA,NA,NA,NA,NA
3,NCT00872586,Inclusion,no significant disorder in blood ; kidney ; liver ; cardiovascular system or endocrinology system,Condition Occurrence,Condition,C0545792,kidney liver,FALSE,FALSE,NA,NA,NA
3,NCT00872586,Inclusion,no significant disorder in blood ; kidney ; liver ; cardiovascular system or endocrinology system,Condition Occurrence,Other,C0425560;C3540015;C3540036,cardiovascular system,FALSE,FALSE,NA,NA,NA
4,NCT00872586,Exclusion,patients with known or suspect secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
5,NCT00872586,Exclusion,unstable angina,Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,NA,NA,NA
6,NCT00872586,Exclusion,history of acute myocardial infarct ; or ptca or surgical cardiac procedures 3 months before entry into this study,Procedure,Condition,C0027051,myocardial infarct,FALSE,FALSE,equal 3 months,NA,NA
6,NCT00872586,Exclusion,history of acute myocardial infarct ; or ptca or surgical cardiac procedures 3 months before entry into this study,Procedure,Procedure,C1279986,cardiac procedures,FALSE,FALSE,equal 3 months,NA,NA
6,NCT00872586,Exclusion,history of acute myocardial infarct ; or ptca or surgical cardiac procedures 3 months before entry into this study,Procedure,Procedure,C2936173;C0002997,ptca,FALSE,FALSE,equal 3 months,NA,NA
6,NCT00872586,Exclusion,history of acute myocardial infarct ; or ptca or surgical cardiac procedures 3 months before entry into this study,Procedure,Other,C1547229;C1547295,acute,FALSE,FALSE,NA,NA,NA
6,NCT00872586,Exclusion,history of acute myocardial infarct ; or ptca or surgical cardiac procedures 3 months before entry into this study,Procedure,Other,C1705654,entry,FALSE,FALSE,NA,NA,NA
7,NCT00872586,Exclusion,prior or current congestive heart failure ( nyha grade iii or ; hypertrophic obstructive cardiomyopathy ; valvular disease or rheumatic heart disease,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
7,NCT00872586,Exclusion,prior or current congestive heart failure ( nyha grade iii or ; hypertrophic obstructive cardiomyopathy ; valvular disease or rheumatic heart disease,Condition Occurrence,Condition,C0007194,hypertrophic obstructive cardiomyopathy,FALSE,FALSE,NA,NA,NA
7,NCT00872586,Exclusion,prior or current congestive heart failure ( nyha grade iii or ; hypertrophic obstructive cardiomyopathy ; valvular disease or rheumatic heart disease,Condition Occurrence,Condition,C0035439,rheumatic heart disease,FALSE,FALSE,NA,NA,NA
7,NCT00872586,Exclusion,prior or current congestive heart failure ( nyha grade iii or ; hypertrophic obstructive cardiomyopathy ; valvular disease or rheumatic heart disease,Condition Occurrence,Condition,C3258293,valvular disease,FALSE,FALSE,NA,NA,NA
7,NCT00872586,Exclusion,prior or current congestive heart failure ( nyha grade iii or ; hypertrophic obstructive cardiomyopathy ; valvular disease or rheumatic heart disease,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii,FALSE,FALSE,NA,NA,NA
8,NCT00872586,Exclusion,arrhythmia of clinical significance,Condition Occurrence,Condition,C0003811,arrhythmia,FALSE,FALSE,NA,NA,NA
8,NCT00872586,Exclusion,arrhythmia of clinical significance,Condition Occurrence,Condition,C2826293,clinical significance,FALSE,FALSE,NA,NA,NA
9,NCT00872586,Exclusion,bilateral renal artery stenosis ; isolated renal artery stenosis ; post kidney transplantation,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
9,NCT00872586,Exclusion,bilateral renal artery stenosis ; isolated renal artery stenosis ; post kidney transplantation,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
9,NCT00872586,Exclusion,bilateral renal artery stenosis ; isolated renal artery stenosis ; post kidney transplantation,Condition Occurrence,Procedure,C0022671,kidney transplantation,FALSE,FALSE,NA,NA,NA
10,NCT00872586,Exclusion,acute glomerular nephritis,Condition Occurrence,Condition,C0268731,glomerular,FALSE,FALSE,NA,NA,NA
10,NCT00872586,Exclusion,acute glomerular nephritis,Condition Occurrence,Condition,C0027697,nephritis,FALSE,FALSE,NA,NA,NA
10,NCT00872586,Exclusion,acute glomerular nephritis,Condition Occurrence,Other,C1547229;C1547295,acute,FALSE,FALSE,NA,NA,NA
11,NCT00872586,Exclusion,gout sufferers ; even with the normal serum uric acid at entry,Condition Occurrence,Condition,C0018099,gout,FALSE,FALSE,NA,NA,NA
11,NCT00872586,Exclusion,gout sufferers ; even with the normal serum uric acid at entry,Condition Occurrence,Other,C0455272;C0700634,serum uric acid,FALSE,FALSE,NA,NA,NA
11,NCT00872586,Exclusion,gout sufferers ; even with the normal serum uric acid at entry,Condition Occurrence,Other,C1705654,entry,FALSE,FALSE,NA,NA,NA
12,NCT00872586,Exclusion,retinal hemorrhage / exudate,Condition Occurrence,Condition,C0035317,retinal hemorrhage,FALSE,FALSE,NA,NA,NA
12,NCT00872586,Exclusion,retinal hemorrhage / exudate,Condition Occurrence,Other,C0015388;C1546629,exudate,FALSE,FALSE,NA,NA,NA
13,NCT00872586,Exclusion,type 1 diabetes mellitus,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
14,NCT00872586,Exclusion,uncontrolled type 2 diabetes mellitus,Condition Occurrence,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
15,NCT00872586,Exclusion,hypovolemia,Condition Occurrence,Condition,C0546884,hypovolemia,FALSE,FALSE,NA,NA,NA
16,NCT00872586,Exclusion,patients with autoimmune disease,Condition Occurrence,Condition,C0004364,autoimmune disease,FALSE,FALSE,NA,NA,NA
1,NCT00877929,Inclusion,hypertension defined as a mean in-clinic seated cuff systolic blood pressure > 150 mmhg at visit 3 ( randomisation visit ),Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
1,NCT00877929,Inclusion,hypertension defined as a mean in-clinic seated cuff systolic blood pressure > 150 mmhg at visit 3 ( randomisation visit ),Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00877929,Inclusion,hypertension defined as a mean in-clinic seated cuff systolic blood pressure > 150 mmhg at visit 3 ( randomisation visit ),Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater 150 mmhg,NA
1,NCT00877929,Inclusion,hypertension defined as a mean in-clinic seated cuff systolic blood pressure > 150 mmhg at visit 3 ( randomisation visit ),Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
2,NCT00877929,Inclusion,diagnosis of type 2 diabetes mellitus,Condition Occurrence,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
3,NCT00877929,Inclusion,Err:509,Person,Person,C0001779,age,FALSE,FALSE,equal 18 years,NA,NA
3,NCT00877929,Inclusion,Err:509,Person,Drug,C0723457,stop,FALSE,FALSE,NA,NA,NA
3,NCT00877929,Inclusion,Err:509,Person,Procedure,C0585941,antihypertensive therapy,FALSE,FALSE,NA,NA,NA
4,NCT00877929,Inclusion,ability to provide written informed consent,Other,NA,NA,NA,NA,NA,NA,NA,NA
5,NCT00877929,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to start of run-in period ) who :,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
5,NCT00877929,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to start of run-in period ) who :,Condition Occurrence,Condition,C1096235,pre-menopausal,FALSE,FALSE,NA,NA,NA
5,NCT00877929,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to start of run-in period ) who :,Condition Occurrence,Condition,C0025344;C2129647,menstruation,FALSE,FALSE,lower_equal 1 year,NA,NA
6,NCT00877929,Exclusion,are not surgically sterile,Other,NA,NA,NA,NA,NA,NA,NA,NA
7,NCT00877929,Exclusion,are nursing or pregnant ; or,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
7,NCT00877929,Exclusion,are nursing or pregnant ; or,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
8,NCT00877929,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control or do not plan to continue practising an acceptable method throughout the study .,Observation,Observation,C3831118,child-bearing potential,FALSE,FALSE,NA,NA,NA
8,NCT00877929,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control or do not plan to continue practising an acceptable method throughout the study .,Observation,Other,C0700589;C2703065,birth control,TRUE,FALSE,NA,NA,NA
8,NCT00877929,Exclusion,are of child-bearing potential and are not practicing acceptable means of birth control or do not plan to continue practising an acceptable method throughout the study .,Observation,Other,C2827714;C0871511;C2828387,method,FALSE,FALSE,NA,NA,NA
9,NCT00877929,Exclusion,the only acceptable methods of birth control are :,Condition Occurrence,Other,C0025663,methods,FALSE,FALSE,NA,NA,NA
9,NCT00877929,Exclusion,the only acceptable methods of birth control are :,Condition Occurrence,Other,C0700589;C2703065,birth control,FALSE,FALSE,NA,NA,NA
10,NCT00877929,Exclusion,intrauterine device ( iud ) ;,Drug Exposure,Drug,C1706306,iud,FALSE,FALSE,NA,NA,NA
10,NCT00877929,Exclusion,intrauterine device ( iud ) ;,Drug Exposure,Other,C1706306;C1548866;C1546682,intrauterine device,FALSE,FALSE,NA,NA,NA
11,NCT00877929,Exclusion,oral contraceptives ( started at least three months prior to start of run-in period ),Drug Exposure,Other,C0009905;C0274536;C0481121;C1548892,oral contraceptives,FALSE,FALSE,NA,NA,NA
12,NCT00877929,Exclusion,implantable contraceptives or injectable contraceptives and,Drug Exposure,Drug,C0086466;C1272936,injectable,FALSE,FALSE,NA,NA,NA
13,NCT00877929,Exclusion,estrogen patch,Drug Exposure,Drug,C0445403;C1707974;C1533128,patch,FALSE,FALSE,NA,NA,NA
13,NCT00877929,Exclusion,estrogen patch,Drug Exposure,Other,C0014939;C0202006;C2936882,estrogen,FALSE,FALSE,NA,NA,NA
14,NCT00877929,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 m .,Drug Exposure,Condition,C0555008,night shift workers,FALSE,FALSE,NA,NA,NA
14,NCT00877929,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 m .,Drug Exposure,Drug,C1654656,daytime,FALSE,FALSE,NA,equal 4,equal 00 m
14,NCT00877929,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 m .,Drug Exposure,Other,C0037313;C0723362,sleep,FALSE,FALSE,NA,NA,NA
15,NCT00877929,Exclusion,known or suspected secondary hypertension ( eg ; renal artery stenosis ; phaeochromocytoma ),Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
15,NCT00877929,Exclusion,known or suspected secondary hypertension ( eg ; renal artery stenosis ; phaeochromocytoma ),Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
16,NCT00877929,Exclusion,mean seated systolic blood pressure ( sbp ) = 180 mm hg or mean seated diastolic blood pressure ( dbp ) = 110 mm hg during any visit of the screening and placebo run-in periods,Observation,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,NA
16,NCT00877929,Exclusion,mean seated systolic blood pressure ( sbp ) = 180 mm hg or mean seated diastolic blood pressure ( dbp ) = 110 mm hg during any visit of the screening and placebo run-in periods,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,NA,NA
16,NCT00877929,Exclusion,mean seated systolic blood pressure ( sbp ) = 180 mm hg or mean seated diastolic blood pressure ( dbp ) = 110 mm hg during any visit of the screening and placebo run-in periods,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,equal 180 mm hg,NA
16,NCT00877929,Exclusion,mean seated systolic blood pressure ( sbp ) = 180 mm hg or mean seated diastolic blood pressure ( dbp ) = 110 mm hg during any visit of the screening and placebo run-in periods,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,equal 110 mm hg,NA
16,NCT00877929,Exclusion,mean seated systolic blood pressure ( sbp ) = 180 mm hg or mean seated diastolic blood pressure ( dbp ) = 110 mm hg during any visit of the screening and placebo run-in periods,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,NA,NA
17,NCT00877929,Exclusion,patients with type 1 diabetes mellitus,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
18,NCT00877929,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance < 30 ml / min or clinical markers of severe renal impairment,Observation,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
18,NCT00877929,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance < 30 ml / min or clinical markers of severe renal impairment,Observation,Condition,C1565489;C0035078,renal impairment,FALSE,FALSE,NA,NA,NA
18,NCT00877929,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance < 30 ml / min or clinical markers of severe renal impairment,Observation,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
18,NCT00877929,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance < 30 ml / min or clinical markers of severe renal impairment,Observation,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,greater 265 umol/l,greater 3.0 mg/dl
18,NCT00877929,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance < 30 ml / min or clinical markers of severe renal impairment,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
18,NCT00877929,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance < 30 ml / min or clinical markers of severe renal impairment,Observation,Observation,C0373595;C0812399,creatinine clearance,FALSE,FALSE,NA,lower 30 ml/min,NA
18,NCT00877929,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance < 30 ml / min or clinical markers of severe renal impairment,Observation,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
19,NCT00877929,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
18,NCT00877929,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance < 30 ml / min or clinical markers of severe renal impairment,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
19,NCT00877929,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
19,NCT00877929,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney,Condition Occurrence,Condition,C0478647,transplant,FALSE,FALSE,NA,NA,NA
19,NCT00877929,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
19,NCT00877929,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
20,NCT00877929,Exclusion,clinically relevant hypokalaemia or hyperkalaemia,Other,NA,NA,NA,NA,NA,NA,NA,NA
21,NCT00877929,Exclusion,uncorrected sodium or volume depletion,Drug Exposure,Condition,C0546884,volume depletion,FALSE,FALSE,NA,NA,NA
21,NCT00877929,Exclusion,uncorrected sodium or volume depletion,Drug Exposure,Other,C0037473;C0337443;C0037570;C3541959,sodium,FALSE,FALSE,NA,NA,NA
22,NCT00877929,Exclusion,primary aldosteronism,Condition Occurrence,Condition,C1384514,primary aldosteronism,FALSE,FALSE,NA,NA,NA
23,NCT00877929,Exclusion,hereditary fructose intolerance,Condition Occurrence,Condition,C0016751,hereditary fructose intolerance,FALSE,FALSE,NA,NA,NA
24,NCT00877929,Exclusion,biliary obstructive disorders ( eg ; cholestatis ) or hepatic insufficiency,Condition Occurrence,Condition,C1306571,hepatic insufficiency,FALSE,FALSE,NA,NA,NA
25,NCT00877929,Exclusion,congestive heart failure new york heart academy ( nyha ) functional class chf iii-iv ( refer to appendix 10,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
25,NCT00877929,Exclusion,congestive heart failure new york heart academy ( nyha ) functional class chf iii-iv ( refer to appendix 10,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
25,NCT00877929,Exclusion,congestive heart failure new york heart academy ( nyha ) functional class chf iii-iv ( refer to appendix 10,Condition Occurrence,Condition,C0018802,chf,FALSE,FALSE,NA,NA,NA
25,NCT00877929,Exclusion,congestive heart failure new york heart academy ( nyha ) functional class chf iii-iv ( refer to appendix 10,Condition Occurrence,Other,C0456387;C0489477,class,FALSE,FALSE,NA,NA,NA
25,NCT00877929,Exclusion,congestive heart failure new york heart academy ( nyha ) functional class chf iii-iv ( refer to appendix 10,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii,FALSE,FALSE,NA,NA,NA
26,NCT00877929,Exclusion,contraindication to a placebo run-in period ( eg ; stroke with-in the past six months ; myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past three months prior to start of run-in period ),Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,NA,NA,NA
26,NCT00877929,Exclusion,contraindication to a placebo run-in period ( eg ; stroke with-in the past six months ; myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past three months prior to start of run-in period ),Condition Occurrence,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,NA
26,NCT00877929,Exclusion,contraindication to a placebo run-in period ( eg ; stroke with-in the past six months ; myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past three months prior to start of run-in period ),Condition Occurrence,Procedure,C0010055,coronary artery bypass graft,FALSE,FALSE,NA,NA,NA
26,NCT00877929,Exclusion,contraindication to a placebo run-in period ( eg ; stroke with-in the past six months ; myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past three months prior to start of run-in period ),Condition Occurrence,Procedure,C2936173,percutaneous transluminal coronary angioplasty,FALSE,FALSE,NA,NA,NA
26,NCT00877929,Exclusion,contraindication to a placebo run-in period ( eg ; stroke with-in the past six months ; myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past three months prior to start of run-in period ),Condition Occurrence,Procedure,C0018821,cardiac surgery,FALSE,FALSE,NA,NA,NA
26,NCT00877929,Exclusion,contraindication to a placebo run-in period ( eg ; stroke with-in the past six months ; myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past three months prior to start of run-in period ),Condition Occurrence,Other,C1301624;C1547316,contraindication,FALSE,FALSE,NA,NA,NA
26,NCT00877929,Exclusion,contraindication to a placebo run-in period ( eg ; stroke with-in the past six months ; myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past three months prior to start of run-in period ),Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
27,NCT00877929,Exclusion,clinically significant ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0042514;C1963247;C2108113,ventricular tachycardia,FALSE,FALSE,NA,NA,NA
27,NCT00877929,Exclusion,clinically significant ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0004239;C1963068,atrial flutter,FALSE,FALSE,NA,NA,NA
27,NCT00877929,Exclusion,clinically significant ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0003811,cardiac arrhythmias,FALSE,FALSE,NA,NA,NA
27,NCT00877929,Exclusion,clinically significant ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
28,NCT00877929,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0007194,hypertrophic obstructive cardiomyopathy,FALSE,FALSE,NA,NA,NA
28,NCT00877929,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C1956346;C0010068;C0010054,coronary artery disease,FALSE,FALSE,NA,NA,NA
28,NCT00877929,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0003507,aortic stenosis,FALSE,FALSE,NA,NA,NA
28,NCT00877929,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0003501;C1269005,aortic valve,FALSE,FALSE,NA,NA,NA
28,NCT00877929,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0026264;C1269004,mitral valve,FALSE,FALSE,NA,NA,NA
28,NCT00877929,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Observation,C1261287;C0947637;C0009814,stenosis,FALSE,FALSE,NA,NA,NA
28,NCT00877929,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
29,NCT00877929,Exclusion,patients whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > 10 %,Other,Condition,C0011849;C0011847,diabetes,FALSE,FALSE,NA,NA,NA
29,NCT00877929,Exclusion,patients whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > 10 %,Other,Observation,C0202054,hba1c,FALSE,FALSE,NA,NA,greater 10 %
29,NCT00877929,Exclusion,patients whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > 10 %,Other,Other,C1547311,stable,TRUE,FALSE,NA,NA,NA
29,NCT00877929,Exclusion,patients whose diabetes has not been stable and controlled for at least the past three months as defined by an hba1c > 10 %,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
30,NCT00877929,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with angiotensin converting enzyme ( ace ) inhibitors or angiotensin-ii receptor antagonists,Drug Exposure,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
30,NCT00877929,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with angiotensin converting enzyme ( ace ) inhibitors or angiotensin-ii receptor antagonists,Drug Exposure,Drug,C0003015,ace inhibitors,FALSE,FALSE,NA,NA,NA
30,NCT00877929,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with angiotensin converting enzyme ( ace ) inhibitors or angiotensin-ii receptor antagonists,Drug Exposure,Other,C0022709;C0201888;C2258685,angiotensin converting enzyme,FALSE,FALSE,NA,NA,NA
30,NCT00877929,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with angiotensin converting enzyme ( ace ) inhibitors or angiotensin-ii receptor antagonists,Drug Exposure,Other,C0373546;C0003009,angiotensin-ii,FALSE,FALSE,NA,NA,NA
31,NCT00877929,Exclusion,history of drug or alcohol dependency within six months prior to signing the informed consent form,Condition Occurrence,Condition,C0001973,alcohol dependency,FALSE,FALSE,NA,NA,NA
31,NCT00877929,Exclusion,history of drug or alcohol dependency within six months prior to signing the informed consent form,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
31,NCT00877929,Exclusion,history of drug or alcohol dependency within six months prior to signing the informed consent form,Condition Occurrence,Other,C0009797,informed consent form,FALSE,FALSE,NA,NA,NA
32,NCT00877929,Exclusion,concomitant administration of any medications known to affect blood pressure ; except medications allowed by the protocol,Observation,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
32,NCT00877929,Exclusion,concomitant administration of any medications known to affect blood pressure ; except medications allowed by the protocol,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
33,NCT00877929,Exclusion,any investigational drug therapy within one month of signing the informed consent ; known hypersensitivity to any component of the study drugs ( telmisartan ; amlodipine ; or placebo ),Drug Exposure,Drug,C0013230,investigational drug,FALSE,FALSE,NA,NA,NA
33,NCT00877929,Exclusion,any investigational drug therapy within one month of signing the informed consent ; known hypersensitivity to any component of the study drugs ( telmisartan ; amlodipine ; or placebo ),Drug Exposure,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,NA
33,NCT00877929,Exclusion,any investigational drug therapy within one month of signing the informed consent ; known hypersensitivity to any component of the study drugs ( telmisartan ; amlodipine ; or placebo ),Drug Exposure,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,NA
33,NCT00877929,Exclusion,any investigational drug therapy within one month of signing the informed consent ; known hypersensitivity to any component of the study drugs ( telmisartan ; amlodipine ; or placebo ),Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,NA
33,NCT00877929,Exclusion,any investigational drug therapy within one month of signing the informed consent ; known hypersensitivity to any component of the study drugs ( telmisartan ; amlodipine ; or placebo ),Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
33,NCT00877929,Exclusion,any investigational drug therapy within one month of signing the informed consent ; known hypersensitivity to any component of the study drugs ( telmisartan ; amlodipine ; or placebo ),Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
34,NCT00877929,Exclusion,history of non-compliance or inability to comply with prescribed medications or protocol procedures,Condition Occurrence,Condition,C0376405,non-compliance,FALSE,FALSE,NA,NA,NA
34,NCT00877929,Exclusion,history of non-compliance or inability to comply with prescribed medications or protocol procedures,Condition Occurrence,Observation,C3202967;C3166216,prescribed medications,FALSE,FALSE,NA,NA,NA
35,NCT00877929,Exclusion,any other clinical condition which ; in the opinion of the investigator ; would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine,Drug Exposure,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,NA
35,NCT00877929,Exclusion,any other clinical condition which ; in the opinion of the investigator ; would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine,Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,NA
35,NCT00877929,Exclusion,any other clinical condition which ; in the opinion of the investigator ; would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine,Drug Exposure,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
1,NCT00902304,Inclusion,newly diagnosed or currently treated hypertensive patients who have not attained their blood pressure target and require active pharmacological treatment as recommended by the local guidelines as judged by the general practitioner,Observation,Condition,C0857121,hypertensive,FALSE,FALSE,NA,NA,NA
1,NCT00902304,Inclusion,newly diagnosed or currently treated hypertensive patients who have not attained their blood pressure target and require active pharmacological treatment as recommended by the local guidelines as judged by the general practitioner,Observation,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
1,NCT00902304,Inclusion,newly diagnosed or currently treated hypertensive patients who have not attained their blood pressure target and require active pharmacological treatment as recommended by the local guidelines as judged by the general practitioner,Observation,Procedure,C0013216,pharmacological treatment,FALSE,FALSE,NA,NA,NA
1,NCT00902304,Inclusion,newly diagnosed or currently treated hypertensive patients who have not attained their blood pressure target and require active pharmacological treatment as recommended by the local guidelines as judged by the general practitioner,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,TRUE,FALSE,NA,NA,NA
1,NCT00902304,Inclusion,newly diagnosed or currently treated hypertensive patients who have not attained their blood pressure target and require active pharmacological treatment as recommended by the local guidelines as judged by the general practitioner,Observation,Observation,C2986546,target,TRUE,FALSE,NA,NA,NA
1,NCT00902304,Inclusion,newly diagnosed or currently treated hypertensive patients who have not attained their blood pressure target and require active pharmacological treatment as recommended by the local guidelines as judged by the general practitioner,Observation,Other,C0162791;C0220845,guidelines,FALSE,FALSE,NA,NA,NA
2,NCT00902304,Exclusion,significantly elevated blood pressure ( severe hypertension ),Condition Occurrence,Condition,C0497247,elevated blood pressure,FALSE,FALSE,NA,NA,NA
2,NCT00902304,Exclusion,significantly elevated blood pressure ( severe hypertension ),Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00902304,Exclusion,significantly elevated blood pressure ( severe hypertension ),Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
3,NCT00902304,Exclusion,requiring 3 or more antihypertensive drugs,Drug Exposure,Drug,C0003364,antihypertensive drugs,FALSE,FALSE,NA,greater_equal 3,NA
4,NCT00902304,Exclusion,severe kidney disease or dialyses,Condition Occurrence,Condition,C0022658,kidney disease,FALSE,FALSE,NA,NA,NA
4,NCT00902304,Exclusion,severe kidney disease or dialyses,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
5,NCT00902304,Exclusion,clinical diagnosis requiring concomitant therapy with antihypertensive treatment that would be outside the therapies allowed under study protocol,Other,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
5,NCT00902304,Exclusion,clinical diagnosis requiring concomitant therapy with antihypertensive treatment that would be outside the therapies allowed under study protocol,Other,Procedure,C1707479,concomitant therapy,FALSE,FALSE,NA,NA,NA
5,NCT00902304,Exclusion,clinical diagnosis requiring concomitant therapy with antihypertensive treatment that would be outside the therapies allowed under study protocol,Other,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
5,NCT00902304,Exclusion,clinical diagnosis requiring concomitant therapy with antihypertensive treatment that would be outside the therapies allowed under study protocol,Other,Other,C2348563;C1507394,study protocol,FALSE,FALSE,NA,NA,NA
6,NCT00902304,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00902538,Inclusion,male or female aged 18 years or older .,Person,Person,C0025266;C1706429,male,FALSE,FALSE,NA,NA,NA
1,NCT00902538,Inclusion,male or female aged 18 years or older .,Person,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
1,NCT00902538,Inclusion,male or female aged 18 years or older .,Person,Person,C0001792,aged,FALSE,FALSE,greater_equal 18 years,NA,NA
2,NCT00902538,Inclusion,mean trough seated systolic blood pressure ( sesbp ) of > = 160 / 100 mmhg ( sesbp of > = 160 mmhg and seated diastolic blood pressure ( sedbp ) > = 100 mmhg ) at screening if not currently on antihypertensive medication ( eg newly diagnosed subjects ),Observation,Drug,C0003364,antihypertensive,TRUE,FALSE,NA,NA,NA
2,NCT00902538,Inclusion,mean trough seated systolic blood pressure ( sesbp ) of > = 160 / 100 mmhg ( sesbp of > = 160 mmhg and seated diastolic blood pressure ( sedbp ) > = 100 mmhg ) at screening if not currently on antihypertensive medication ( eg newly diagnosed subjects ),Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater_equal 160 mmhg; greater_equal 100 mmhg; greater_equal 160 mmhg,NA
2,NCT00902538,Inclusion,mean trough seated systolic blood pressure ( sesbp ) of > = 160 / 100 mmhg ( sesbp of > = 160 mmhg and seated diastolic blood pressure ( sedbp ) > = 100 mmhg ) at screening if not currently on antihypertensive medication ( eg newly diagnosed subjects ),Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater_equal 100 mmhg,NA
3,NCT00902538,Inclusion,or :,Other,NA,NA,NA,NA,NA,NA,NA,NA
4,NCT00902538,Inclusion,for subjects on monotherapy : mean trough sesbp of > = 150 / 95 mmhg ( sesbp of > = 150 mmhg and sedbp > = 95 mmhg ) at screening,Observation,NA,NA,NA,NA,NA,NA,NA,NA
5,NCT00902538,Inclusion,or :,Other,NA,NA,NA,NA,NA,NA,NA,NA
6,NCT00902538,Inclusion,for subjects on any combination of antihypertensive medications that includes either hydrochlorothiazide or amlodipine or olmesartan for a duration of at least four weeks : mean trough sesbp of > = 140 / 90 mmhg ( sesbp of > = 140 mmhg and sedbp > = 90 mmhg ) at screening,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
6,NCT00902538,Inclusion,for subjects on any combination of antihypertensive medications that includes either hydrochlorothiazide or amlodipine or olmesartan for a duration of at least four weeks : mean trough sesbp of > = 140 / 90 mmhg ( sesbp of > = 140 mmhg and sedbp > = 90 mmhg ) at screening,Observation,Drug,C0020261,hydrochlorothiazide,FALSE,FALSE,NA,greater_equal 140 mmhg; greater_equal 90 mmhg; greater_equal 140 mmhg; greater_equal 90 mmhg,NA
6,NCT00902538,Inclusion,for subjects on any combination of antihypertensive medications that includes either hydrochlorothiazide or amlodipine or olmesartan for a duration of at least four weeks : mean trough sesbp of > = 140 / 90 mmhg ( sesbp of > = 140 mmhg and sedbp > = 90 mmhg ) at screening,Observation,Drug,C1098320;C0386393,olmesartan,FALSE,FALSE,NA,greater_equal 140 mmhg; greater_equal 90 mmhg; greater_equal 140 mmhg; greater_equal 90 mmhg,NA
6,NCT00902538,Inclusion,for subjects on any combination of antihypertensive medications that includes either hydrochlorothiazide or amlodipine or olmesartan for a duration of at least four weeks : mean trough sesbp of > = 140 / 90 mmhg ( sesbp of > = 140 mmhg and sedbp > = 90 mmhg ) at screening,Observation,Drug,C0051696,amlodipine,FALSE,FALSE,NA,greater_equal 140 mmhg; greater_equal 90 mmhg; greater_equal 140 mmhg; greater_equal 90 mmhg,NA
7,NCT00902538,Inclusion,or :,Other,NA,NA,NA,NA,NA,NA,NA,NA
8,NCT00902538,Inclusion,for subjects on any other combination of antihypertensive medications that includes neither hydrochlorothiazide ; amlodipine nor olmesartan : mean trough sesbp > = 160 mmhg ; mean trough sedbp > = 100 mmhg ; at the end of the taper-off period,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
8,NCT00902538,Inclusion,for subjects on any other combination of antihypertensive medications that includes neither hydrochlorothiazide ; amlodipine nor olmesartan : mean trough sesbp > = 160 mmhg ; mean trough sedbp > = 100 mmhg ; at the end of the taper-off period,Observation,Drug,C0020261,hydrochlorothiazide,FALSE,FALSE,NA,greater_equal 160 mmhg; greater_equal 100 mmhg,NA
8,NCT00902538,Inclusion,for subjects on any other combination of antihypertensive medications that includes neither hydrochlorothiazide ; amlodipine nor olmesartan : mean trough sesbp > = 160 mmhg ; mean trough sedbp > = 100 mmhg ; at the end of the taper-off period,Observation,Drug,C1098320;C0386393,olmesartan,FALSE,FALSE,NA,greater_equal 160 mmhg; greater_equal 100 mmhg,NA
8,NCT00902538,Inclusion,for subjects on any other combination of antihypertensive medications that includes neither hydrochlorothiazide ; amlodipine nor olmesartan : mean trough sesbp > = 160 mmhg ; mean trough sedbp > = 100 mmhg ; at the end of the taper-off period,Observation,Drug,C0051696,amlodipine,FALSE,FALSE,NA,greater_equal 160 mmhg; greater_equal 100 mmhg,NA
8,NCT00902538,Inclusion,for subjects on any other combination of antihypertensive medications that includes neither hydrochlorothiazide ; amlodipine nor olmesartan : mean trough sesbp > = 160 mmhg ; mean trough sedbp > = 100 mmhg ; at the end of the taper-off period,Observation,Procedure,C0441640,taper-off,FALSE,FALSE,NA,NA,NA
9,NCT00902538,Inclusion,subject freely signs the informed consent form ( icf ) after the nature of the study and the disclosure of his / her data has been explained .,Other,Other,C0009797,informed consent form,FALSE,FALSE,NA,NA,NA
9,NCT00902538,Inclusion,subject freely signs the informed consent form ( icf ) after the nature of the study and the disclosure of his / her data has been explained .,Other,Other,C0444966;C0009797;C2370861,icf,FALSE,FALSE,NA,NA,NA
9,NCT00902538,Inclusion,subject freely signs the informed consent form ( icf ) after the nature of the study and the disclosure of his / her data has been explained .,Other,Other,C0012625,disclosure,FALSE,FALSE,NA,NA,NA
10,NCT00902538,Inclusion,female subjects of childbearing potential must be using adequate contraception ( female of childbearing potential is defined as one who has not been postmenopausal for at least one year ; or has not been surgically sterilised ; or has not had a hysterectomy at least three months prior to the start of this study [ visit 1 ] ),Person,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
10,NCT00902538,Inclusion,female subjects of childbearing potential must be using adequate contraception ( female of childbearing potential is defined as one who has not been postmenopausal for at least one year ; or has not been surgically sterilised ; or has not had a hysterectomy at least three months prior to the start of this study [ visit 1 ] ),Person,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
10,NCT00902538,Inclusion,female subjects of childbearing potential must be using adequate contraception ( female of childbearing potential is defined as one who has not been postmenopausal for at least one year ; or has not been surgically sterilised ; or has not had a hysterectomy at least three months prior to the start of this study [ visit 1 ] ),Person,Procedure,C0700589,contraception,FALSE,FALSE,NA,NA,NA
10,NCT00902538,Inclusion,female subjects of childbearing potential must be using adequate contraception ( female of childbearing potential is defined as one who has not been postmenopausal for at least one year ; or has not been surgically sterilised ; or has not had a hysterectomy at least three months prior to the start of this study [ visit 1 ] ),Person,Procedure,C0020699;C1548863,hysterectomy,FALSE,FALSE,NA,NA,NA
10,NCT00902538,Inclusion,female subjects of childbearing potential must be using adequate contraception ( female of childbearing potential is defined as one who has not been postmenopausal for at least one year ; or has not been surgically sterilised ; or has not had a hysterectomy at least three months prior to the start of this study [ visit 1 ] ),Person,Observation,C3831118,childbearing potential,FALSE,FALSE,NA,NA,NA
10,NCT00902538,Inclusion,female subjects of childbearing potential must be using adequate contraception ( female of childbearing potential is defined as one who has not been postmenopausal for at least one year ; or has not been surgically sterilised ; or has not had a hysterectomy at least three months prior to the start of this study [ visit 1 ] ),Person,Observation,C3831118,childbearing potential,FALSE,FALSE,NA,NA,NA
10,NCT00902538,Inclusion,female subjects of childbearing potential must be using adequate contraception ( female of childbearing potential is defined as one who has not been postmenopausal for at least one year ; or has not been surgically sterilised ; or has not had a hysterectomy at least three months prior to the start of this study [ visit 1 ] ),Person,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
11,NCT00902538,Inclusion,females taking oral contraceptives should have been on therapy for at least three months ; adequate contraceptives include hormonal intra-uterine devices ; hormonal contraceptives ( oral ; depot ; patch or injectable ) ; and double barrier methods such as condoms or diaphragms with spermicidal gel or foam,Drug Exposure,Person,C0086287,females,FALSE,FALSE,NA,NA,NA
11,NCT00902538,Inclusion,females taking oral contraceptives should have been on therapy for at least three months ; adequate contraceptives include hormonal intra-uterine devices ; hormonal contraceptives ( oral ; depot ; patch or injectable ) ; and double barrier methods such as condoms or diaphragms with spermicidal gel or foam,Drug Exposure,Condition,C2013447,taking oral contraceptives,FALSE,FALSE,NA,NA,NA
11,NCT00902538,Inclusion,females taking oral contraceptives should have been on therapy for at least three months ; adequate contraceptives include hormonal intra-uterine devices ; hormonal contraceptives ( oral ; depot ; patch or injectable ) ; and double barrier methods such as condoms or diaphragms with spermicidal gel or foam,Drug Exposure,Drug,C1272919,oral,FALSE,FALSE,NA,NA,NA
11,NCT00902538,Inclusion,females taking oral contraceptives should have been on therapy for at least three months ; adequate contraceptives include hormonal intra-uterine devices ; hormonal contraceptives ( oral ; depot ; patch or injectable ) ; and double barrier methods such as condoms or diaphragms with spermicidal gel or foam,Drug Exposure,Drug,C0445403;C1707974;C1533128,patch,FALSE,FALSE,NA,NA,NA
11,NCT00902538,Inclusion,females taking oral contraceptives should have been on therapy for at least three months ; adequate contraceptives include hormonal intra-uterine devices ; hormonal contraceptives ( oral ; depot ; patch or injectable ) ; and double barrier methods such as condoms or diaphragms with spermicidal gel or foam,Drug Exposure,Drug,C0086466;C1272936,injectable,FALSE,FALSE,NA,NA,NA
11,NCT00902538,Inclusion,females taking oral contraceptives should have been on therapy for at least three months ; adequate contraceptives include hormonal intra-uterine devices ; hormonal contraceptives ( oral ; depot ; patch or injectable ) ; and double barrier methods such as condoms or diaphragms with spermicidal gel or foam,Drug Exposure,Drug,C0017243;C0972569,gel,FALSE,FALSE,NA,NA,NA
11,NCT00902538,Inclusion,females taking oral contraceptives should have been on therapy for at least three months ; adequate contraceptives include hormonal intra-uterine devices ; hormonal contraceptives ( oral ; depot ; patch or injectable ) ; and double barrier methods such as condoms or diaphragms with spermicidal gel or foam,Drug Exposure,Drug,C0991510,foam,FALSE,FALSE,NA,NA,NA
11,NCT00902538,Inclusion,females taking oral contraceptives should have been on therapy for at least three months ; adequate contraceptives include hormonal intra-uterine devices ; hormonal contraceptives ( oral ; depot ; patch or injectable ) ; and double barrier methods such as condoms or diaphragms with spermicidal gel or foam,Drug Exposure,Procedure,C0004764,barrier methods,FALSE,FALSE,NA,NA,NA
12,NCT00902538,Inclusion,if a female becomes pregnant during the study ; she has to be withdrawn immediately .,Condition Occurrence,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
12,NCT00902538,Inclusion,if a female becomes pregnant during the study ; she has to be withdrawn immediately .,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
12,NCT00902538,Inclusion,if a female becomes pregnant during the study ; she has to be withdrawn immediately .,Condition Occurrence,Condition,C0424092,withdrawn,FALSE,FALSE,NA,NA,NA
13,NCT00902538,Exclusion,female subjects of childbearing potential who are pregnant or lactating .,Condition Occurrence,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
13,NCT00902538,Exclusion,female subjects of childbearing potential who are pregnant or lactating .,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
13,NCT00902538,Exclusion,female subjects of childbearing potential who are pregnant or lactating .,Condition Occurrence,Condition,C2828358;C3668831,lactating,FALSE,FALSE,NA,NA,NA
13,NCT00902538,Exclusion,female subjects of childbearing potential who are pregnant or lactating .,Condition Occurrence,Observation,C3831118,childbearing potential,FALSE,FALSE,NA,NA,NA
14,NCT00902538,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of the investigational products ; including cerebrovascular ; cardiovascular ; renal ; respiratory ; hepatic ; gastrointestinal ; endocrine or metabolic ; haematological or oncological ; neurological ; and psychiatric diseases,Condition Occurrence,Condition,C1559265,gastrointestinal,FALSE,FALSE,NA,NA,NA
14,NCT00902538,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of the investigational products ; including cerebrovascular ; cardiovascular ; renal ; respiratory ; hepatic ; gastrointestinal ; endocrine or metabolic ; haematological or oncological ; neurological ; and psychiatric diseases,Condition Occurrence,Condition,C0205054,hepatic,FALSE,FALSE,NA,NA,NA
14,NCT00902538,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of the investigational products ; including cerebrovascular ; cardiovascular ; renal ; respiratory ; hepatic ; gastrointestinal ; endocrine or metabolic ; haematological or oncological ; neurological ; and psychiatric diseases,Condition Occurrence,Observation,C2707261,neurological,FALSE,FALSE,NA,NA,NA
14,NCT00902538,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of the investigational products ; including cerebrovascular ; cardiovascular ; renal ; respiratory ; hepatic ; gastrointestinal ; endocrine or metabolic ; haematological or oncological ; neurological ; and psychiatric diseases,Condition Occurrence,Other,C3245491,investigational,FALSE,FALSE,NA,NA,NA
14,NCT00902538,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of the investigational products ; including cerebrovascular ; cardiovascular ; renal ; respiratory ; hepatic ; gastrointestinal ; endocrine or metabolic ; haematological or oncological ; neurological ; and psychiatric diseases,Condition Occurrence,Other,C1546767,respiratory,FALSE,FALSE,NA,NA,NA
14,NCT00902538,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of the investigational products ; including cerebrovascular ; cardiovascular ; renal ; respiratory ; hepatic ; gastrointestinal ; endocrine or metabolic ; haematological or oncological ; neurological ; and psychiatric diseases,Condition Occurrence,Other,C1524026;C2707259,metabolic,FALSE,FALSE,NA,NA,NA
14,NCT00902538,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of the investigational products ; including cerebrovascular ; cardiovascular ; renal ; respiratory ; hepatic ; gastrointestinal ; endocrine or metabolic ; haematological or oncological ; neurological ; and psychiatric diseases,Condition Occurrence,Other,C1548428;C1561580,psychiatric,FALSE,FALSE,NA,NA,NA
15,NCT00902538,Exclusion,the same applies for immunocompromised subjects or neutropenic subjects .,Condition Occurrence,Condition,C0085393,immunocompromised,FALSE,FALSE,NA,NA,NA
16,NCT00902538,Exclusion,subjects having a history of the following within the last six months : myocardial infarction ( mi ) ; unstable angina pectoris ; percutaneous coronary intervention ; heart failure ; hypertensive encephalopathy ; cerebrovascular accident ( stroke ) ; or transient ischaemic attack .,Condition Occurrence,Condition,C0002965,unstable angina pectoris,FALSE,FALSE,NA,NA,NA
16,NCT00902538,Exclusion,subjects having a history of the following within the last six months : myocardial infarction ( mi ) ; unstable angina pectoris ; percutaneous coronary intervention ; heart failure ; hypertensive encephalopathy ; cerebrovascular accident ( stroke ) ; or transient ischaemic attack .,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
16,NCT00902538,Exclusion,subjects having a history of the following within the last six months : myocardial infarction ( mi ) ; unstable angina pectoris ; percutaneous coronary intervention ; heart failure ; hypertensive encephalopathy ; cerebrovascular accident ( stroke ) ; or transient ischaemic attack .,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
16,NCT00902538,Exclusion,subjects having a history of the following within the last six months : myocardial infarction ( mi ) ; unstable angina pectoris ; percutaneous coronary intervention ; heart failure ; hypertensive encephalopathy ; cerebrovascular accident ( stroke ) ; or transient ischaemic attack .,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
16,NCT00902538,Exclusion,subjects having a history of the following within the last six months : myocardial infarction ( mi ) ; unstable angina pectoris ; percutaneous coronary intervention ; heart failure ; hypertensive encephalopathy ; cerebrovascular accident ( stroke ) ; or transient ischaemic attack .,Condition Occurrence,Condition,C0007787,transient ischaemic attack,FALSE,FALSE,NA,NA,NA
16,NCT00902538,Exclusion,subjects having a history of the following within the last six months : myocardial infarction ( mi ) ; unstable angina pectoris ; percutaneous coronary intervention ; heart failure ; hypertensive encephalopathy ; cerebrovascular accident ( stroke ) ; or transient ischaemic attack .,Condition Occurrence,Procedure,C1532338,percutaneous coronary intervention,FALSE,FALSE,NA,NA,NA
16,NCT00902538,Exclusion,subjects having a history of the following within the last six months : myocardial infarction ( mi ) ; unstable angina pectoris ; percutaneous coronary intervention ; heart failure ; hypertensive encephalopathy ; cerebrovascular accident ( stroke ) ; or transient ischaemic attack .,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
16,NCT00902538,Exclusion,subjects having a history of the following within the last six months : myocardial infarction ( mi ) ; unstable angina pectoris ; percutaneous coronary intervention ; heart failure ; hypertensive encephalopathy ; cerebrovascular accident ( stroke ) ; or transient ischaemic attack .,Condition Occurrence,Other,C0027051;C0025953;C3496280;C0278960,mi,FALSE,FALSE,NA,NA,NA
17,NCT00902538,Exclusion,subjects with clinically significant abnormal laboratory values at screening ; including subjects with one or more of the following :,Observation,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
17,NCT00902538,Exclusion,subjects with clinically significant abnormal laboratory values at screening ; including subjects with one or more of the following :,Observation,Other,C2699333,abnormal,FALSE,FALSE,NA,NA,NA
18,NCT00902538,Exclusion,aspartate aminotransferase ( ast ) > 3 times upper limit of normal ( uln ),Drug Exposure,Observation,C0004002;C0201899,aspartate aminotransferase,FALSE,FALSE,NA,NA,NA
18,NCT00902538,Exclusion,aspartate aminotransferase ( ast ) > 3 times upper limit of normal ( uln ),Drug Exposure,Observation,C0004002,ast,FALSE,FALSE,NA,NA,greater 3 times upper limit of normal
19,NCT00902538,Exclusion,alanine aminotransferase ( alt ) > 3 times uln,Drug Exposure,Observation,C0001899;C0201836,alanine aminotransferase,FALSE,FALSE,NA,NA,NA
19,NCT00902538,Exclusion,alanine aminotransferase ( alt ) > 3 times uln,Drug Exposure,Observation,C1140170;C2257651,alt,FALSE,FALSE,NA,NA,greater 3 times uln
20,NCT00902538,Exclusion,gamma-glutamyltransferase ( ggt ) > 3 times uln,Drug Exposure,Drug,C0017040,gamma-glutamyltransferase,FALSE,FALSE,NA,NA,greater 3 times uln
21,NCT00902538,Exclusion,potassium above uln ( unless high value is due to haemolytic blood sample ),Observation,Observation,C2700149,high,FALSE,FALSE,NA,NA,NA
21,NCT00902538,Exclusion,potassium above uln ( unless high value is due to haemolytic blood sample ),Observation,Condition,C0178913,blood sample,FALSE,FALSE,NA,NA,NA
21,NCT00902538,Exclusion,potassium above uln ( unless high value is due to haemolytic blood sample ),Observation,Other,C0032821;C0202194;C0304475,potassium,FALSE,FALSE,NA,NA,NA
22,NCT00902538,Exclusion,subjects with secondary hypertension of any aetiology such as renal disease ; phaeochromocytoma ; or cushing syndrome .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
22,NCT00902538,Exclusion,subjects with secondary hypertension of any aetiology such as renal disease ; phaeochromocytoma ; or cushing syndrome .,Condition Occurrence,Condition,C0022658,renal disease,FALSE,FALSE,NA,NA,NA
22,NCT00902538,Exclusion,subjects with secondary hypertension of any aetiology such as renal disease ; phaeochromocytoma ; or cushing syndrome .,Condition Occurrence,Condition,C0010481,cushing syndrome,FALSE,FALSE,NA,NA,NA
23,NCT00902538,Exclusion,subjects with contraindication to olmesartan ; amlodipine ; hydrochlorothiazide ; or any of the excipients .,Drug Exposure,Drug,C1098320;C0386393,olmesartan,FALSE,FALSE,NA,NA,NA
23,NCT00902538,Exclusion,subjects with contraindication to olmesartan ; amlodipine ; hydrochlorothiazide ; or any of the excipients .,Drug Exposure,Drug,C0020261,hydrochlorothiazide,FALSE,FALSE,NA,NA,NA
23,NCT00902538,Exclusion,subjects with contraindication to olmesartan ; amlodipine ; hydrochlorothiazide ; or any of the excipients .,Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,NA
23,NCT00902538,Exclusion,subjects with contraindication to olmesartan ; amlodipine ; hydrochlorothiazide ; or any of the excipients .,Drug Exposure,Drug,C0015237,excipients,FALSE,FALSE,NA,NA,NA
23,NCT00902538,Exclusion,subjects with contraindication to olmesartan ; amlodipine ; hydrochlorothiazide ; or any of the excipients .,Drug Exposure,Other,C1301624;C1547316,contraindication,FALSE,FALSE,NA,NA,NA
24,NCT00902538,Exclusion,subjects with a mean sesbp > 200 mmhg or mean sedbp > 115 mmhg or bradycardia ( heart rate < 50 beats / min at rest documented by mean radial pulse rate [ pr ] or electrocardiogram [ ecg ] ) at screening ( visit 1 ) or immediately before taking period i study medication ( visit 2 ),Observation,Condition,C0518831,radial pulse rate,FALSE,FALSE,NA,NA,NA
24,NCT00902538,Exclusion,subjects with a mean sesbp > 200 mmhg or mean sedbp > 115 mmhg or bradycardia ( heart rate < 50 beats / min at rest documented by mean radial pulse rate [ pr ] or electrocardiogram [ ecg ] ) at screening ( visit 1 ) or immediately before taking period i study medication ( visit 2 ),Observation,Condition,C0013798,electrocardiogram,FALSE,FALSE,NA,NA,NA
24,NCT00902538,Exclusion,subjects with a mean sesbp > 200 mmhg or mean sedbp > 115 mmhg or bradycardia ( heart rate < 50 beats / min at rest documented by mean radial pulse rate [ pr ] or electrocardiogram [ ecg ] ) at screening ( visit 1 ) or immediately before taking period i study medication ( visit 2 ),Observation,Procedure,C1301725,documented,FALSE,FALSE,NA,NA,NA
24,NCT00902538,Exclusion,subjects with a mean sesbp > 200 mmhg or mean sedbp > 115 mmhg or bradycardia ( heart rate < 50 beats / min at rest documented by mean radial pulse rate [ pr ] or electrocardiogram [ ecg ] ) at screening ( visit 1 ) or immediately before taking period i study medication ( visit 2 ),Observation,Observation,C0428977,bradycardia,FALSE,FALSE,NA,greater 200 mmhg; greater 115 mmhg,NA
24,NCT00902538,Exclusion,subjects with a mean sesbp > 200 mmhg or mean sedbp > 115 mmhg or bradycardia ( heart rate < 50 beats / min at rest documented by mean radial pulse rate [ pr ] or electrocardiogram [ ecg ] ) at screening ( visit 1 ) or immediately before taking period i study medication ( visit 2 ),Observation,Observation,C0018810;C2197023;C2041121;C0488794,heart rate,FALSE,FALSE,NA,lower 50 beats/min,NA
24,NCT00902538,Exclusion,subjects with a mean sesbp > 200 mmhg or mean sedbp > 115 mmhg or bradycardia ( heart rate < 50 beats / min at rest documented by mean radial pulse rate [ pr ] or electrocardiogram [ ecg ] ) at screening ( visit 1 ) or immediately before taking period i study medication ( visit 2 ),Observation,Other,C1521726;C2365506;C0034833;C3484362,pr,FALSE,FALSE,NA,NA,NA
24,NCT00902538,Exclusion,subjects with a mean sesbp > 200 mmhg or mean sedbp > 115 mmhg or bradycardia ( heart rate < 50 beats / min at rest documented by mean radial pulse rate [ pr ] or electrocardiogram [ ecg ] ) at screening ( visit 1 ) or immediately before taking period i study medication ( visit 2 ),Observation,Other,C1623258;C0018064,ecg,FALSE,FALSE,NA,NA,NA
1,NCT00923091,Inclusion,male or female subjects aged 18 years or older .,Person,Person,C0025266;C1706429,male,FALSE,FALSE,NA,NA,NA
1,NCT00923091,Inclusion,male or female subjects aged 18 years or older .,Person,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
1,NCT00923091,Inclusion,male or female subjects aged 18 years or older .,Person,Person,C0001792,aged,FALSE,FALSE,greater_equal 18 years,NA,NA
2,NCT00923091,Inclusion,subjects with mean trough seated blood pressure ( sebp ) > = 160 / 100 mmhg ; ( seated systolic blood pressure ( sesbp ) > = 160 mmhg and seated diastolic blood pressure ( sedbp ) > = 100 mmhg ) at screening if not currently on antihypertensive medication ( newly diagnosed subjects or subjects who are not taking any antihypertensive medication for at least 3 weeks ),Observation,Drug,C0003364,antihypertensive,TRUE,FALSE,NA,NA,NA
2,NCT00923091,Inclusion,subjects with mean trough seated blood pressure ( sebp ) > = 160 / 100 mmhg ; ( seated systolic blood pressure ( sesbp ) > = 160 mmhg and seated diastolic blood pressure ( sedbp ) > = 100 mmhg ) at screening if not currently on antihypertensive medication ( newly diagnosed subjects or subjects who are not taking any antihypertensive medication for at least 3 weeks ),Observation,Drug,C0003364,antihypertensive,TRUE,FALSE,greater_equal 3 weeks,NA,NA
2,NCT00923091,Inclusion,subjects with mean trough seated blood pressure ( sebp ) > = 160 / 100 mmhg ; ( seated systolic blood pressure ( sesbp ) > = 160 mmhg and seated diastolic blood pressure ( sedbp ) > = 100 mmhg ) at screening if not currently on antihypertensive medication ( newly diagnosed subjects or subjects who are not taking any antihypertensive medication for at least 3 weeks ),Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,greater_equal 160 mmhg; greater_equal 100 mmhg,NA
2,NCT00923091,Inclusion,subjects with mean trough seated blood pressure ( sebp ) > = 160 / 100 mmhg ; ( seated systolic blood pressure ( sesbp ) > = 160 mmhg and seated diastolic blood pressure ( sedbp ) > = 100 mmhg ) at screening if not currently on antihypertensive medication ( newly diagnosed subjects or subjects who are not taking any antihypertensive medication for at least 3 weeks ),Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater_equal 160 mmhg,NA
2,NCT00923091,Inclusion,subjects with mean trough seated blood pressure ( sebp ) > = 160 / 100 mmhg ; ( seated systolic blood pressure ( sesbp ) > = 160 mmhg and seated diastolic blood pressure ( sedbp ) > = 100 mmhg ) at screening if not currently on antihypertensive medication ( newly diagnosed subjects or subjects who are not taking any antihypertensive medication for at least 3 weeks ),Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,greater_equal 100 mmhg,NA
3,NCT00923091,Inclusion,or subjects with mean trough sebp > = 160 / 100 mmhg ; sesbp > = 160 mmhg and sedbp > = 100 mmhg ) after washout of prior antihypertensive medication in subjects who discontinued their previous antihypertensive medication .,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,greater_equal 160 mmhg; greater_equal 100 mmhg; greater_equal 160 mmhg; greater_equal 100 mmhg,NA
3,NCT00923091,Inclusion,or subjects with mean trough sebp > = 160 / 100 mmhg ; sesbp > = 160 mmhg and sedbp > = 100 mmhg ) after washout of prior antihypertensive medication in subjects who discontinued their previous antihypertensive medication .,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
4,NCT00923091,Inclusion,the difference in mean sesbp / sedbp between the visit prior to randomisation and the randomisation visit must be < = 20 / 10 mmhg,Observation,NA,NA,NA,NA,NA,NA,NA,NA
5,NCT00923091,Inclusion,subjects not currently on antihypertensive ( htn ) medication may meet this requirement at the screening visit ( visit 1 ) and the randomization visit ( visit 3 ),Drug Exposure,Drug,C0003364,antihypertensive,TRUE,FALSE,NA,NA,NA
6,NCT00923091,Inclusion,subjects washing out of htn medication must meet this requirement at least by visit 2 ( or visit 2.11;if needed ) and visit,Other,NA,NA,NA,NA,NA,NA,NA,NA
7,NCT00923091,Inclusion,all subjects undergoing washout of their prior antihypertensive medication will have the opportunity to re-visit the study sites for additional visits during washout ( visits 2 and 2,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,equal 2 ; equal 2,NA
8,NCT00923091,Inclusion,to assess eligibility for randomisation .,Procedure,Procedure,C0013893,eligibility,FALSE,FALSE,NA,NA,NA
9,NCT00923091,Inclusion,subjects freely sign the informed consent form ( icf ) after the nature of the study and the disclosure of his / her data has been explained .,Other,Other,C0009797,informed consent form,FALSE,FALSE,NA,NA,NA
9,NCT00923091,Inclusion,subjects freely sign the informed consent form ( icf ) after the nature of the study and the disclosure of his / her data has been explained .,Other,Other,C0444966;C0009797;C2370861,icf,FALSE,FALSE,NA,NA,NA
9,NCT00923091,Inclusion,subjects freely sign the informed consent form ( icf ) after the nature of the study and the disclosure of his / her data has been explained .,Other,Other,C0012625,disclosure,FALSE,FALSE,NA,NA,NA
10,NCT00923091,Inclusion,female subjects of childbearing potential must be using adequate contraception ( female of childbearing potential is defined as one who has not been postmenopausal for at least one year ; or has not been surgically sterilised ; or has not had a hysterectomy at least three months prior to the start of this study [ visit 1 ] ) ; adequate contraceptives include hormonal intra-uterine devices ; hormonal contraceptives ( oral ; depot ; patch or injectable ) ; and double barrier methods such as condoms or diaphragms with spermicidal gel or foam .,Drug Exposure,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
10,NCT00923091,Inclusion,female subjects of childbearing potential must be using adequate contraception ( female of childbearing potential is defined as one who has not been postmenopausal for at least one year ; or has not been surgically sterilised ; or has not had a hysterectomy at least three months prior to the start of this study [ visit 1 ] ) ; adequate contraceptives include hormonal intra-uterine devices ; hormonal contraceptives ( oral ; depot ; patch or injectable ) ; and double barrier methods such as condoms or diaphragms with spermicidal gel or foam .,Drug Exposure,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
10,NCT00923091,Inclusion,female subjects of childbearing potential must be using adequate contraception ( female of childbearing potential is defined as one who has not been postmenopausal for at least one year ; or has not been surgically sterilised ; or has not had a hysterectomy at least three months prior to the start of this study [ visit 1 ] ) ; adequate contraceptives include hormonal intra-uterine devices ; hormonal contraceptives ( oral ; depot ; patch or injectable ) ; and double barrier methods such as condoms or diaphragms with spermicidal gel or foam .,Drug Exposure,Drug,C1272919,oral,FALSE,FALSE,NA,NA,NA
10,NCT00923091,Inclusion,female subjects of childbearing potential must be using adequate contraception ( female of childbearing potential is defined as one who has not been postmenopausal for at least one year ; or has not been surgically sterilised ; or has not had a hysterectomy at least three months prior to the start of this study [ visit 1 ] ) ; adequate contraceptives include hormonal intra-uterine devices ; hormonal contraceptives ( oral ; depot ; patch or injectable ) ; and double barrier methods such as condoms or diaphragms with spermicidal gel or foam .,Drug Exposure,Drug,C0445403;C1707974;C1533128,patch,FALSE,FALSE,NA,NA,NA
10,NCT00923091,Inclusion,female subjects of childbearing potential must be using adequate contraception ( female of childbearing potential is defined as one who has not been postmenopausal for at least one year ; or has not been surgically sterilised ; or has not had a hysterectomy at least three months prior to the start of this study [ visit 1 ] ) ; adequate contraceptives include hormonal intra-uterine devices ; hormonal contraceptives ( oral ; depot ; patch or injectable ) ; and double barrier methods such as condoms or diaphragms with spermicidal gel or foam .,Drug Exposure,Drug,C0086466;C1272936,injectable,FALSE,FALSE,NA,NA,NA
10,NCT00923091,Inclusion,female subjects of childbearing potential must be using adequate contraception ( female of childbearing potential is defined as one who has not been postmenopausal for at least one year ; or has not been surgically sterilised ; or has not had a hysterectomy at least three months prior to the start of this study [ visit 1 ] ) ; adequate contraceptives include hormonal intra-uterine devices ; hormonal contraceptives ( oral ; depot ; patch or injectable ) ; and double barrier methods such as condoms or diaphragms with spermicidal gel or foam .,Drug Exposure,Drug,C0017243;C0972569,gel,FALSE,FALSE,NA,NA,NA
10,NCT00923091,Inclusion,female subjects of childbearing potential must be using adequate contraception ( female of childbearing potential is defined as one who has not been postmenopausal for at least one year ; or has not been surgically sterilised ; or has not had a hysterectomy at least three months prior to the start of this study [ visit 1 ] ) ; adequate contraceptives include hormonal intra-uterine devices ; hormonal contraceptives ( oral ; depot ; patch or injectable ) ; and double barrier methods such as condoms or diaphragms with spermicidal gel or foam .,Drug Exposure,Drug,C0991510,foam,FALSE,FALSE,NA,NA,NA
10,NCT00923091,Inclusion,female subjects of childbearing potential must be using adequate contraception ( female of childbearing potential is defined as one who has not been postmenopausal for at least one year ; or has not been surgically sterilised ; or has not had a hysterectomy at least three months prior to the start of this study [ visit 1 ] ) ; adequate contraceptives include hormonal intra-uterine devices ; hormonal contraceptives ( oral ; depot ; patch or injectable ) ; and double barrier methods such as condoms or diaphragms with spermicidal gel or foam .,Drug Exposure,Procedure,C0700589,contraception,FALSE,FALSE,NA,NA,NA
10,NCT00923091,Inclusion,female subjects of childbearing potential must be using adequate contraception ( female of childbearing potential is defined as one who has not been postmenopausal for at least one year ; or has not been surgically sterilised ; or has not had a hysterectomy at least three months prior to the start of this study [ visit 1 ] ) ; adequate contraceptives include hormonal intra-uterine devices ; hormonal contraceptives ( oral ; depot ; patch or injectable ) ; and double barrier methods such as condoms or diaphragms with spermicidal gel or foam .,Drug Exposure,Procedure,C0020699;C1548863,hysterectomy,FALSE,FALSE,NA,NA,NA
10,NCT00923091,Inclusion,female subjects of childbearing potential must be using adequate contraception ( female of childbearing potential is defined as one who has not been postmenopausal for at least one year ; or has not been surgically sterilised ; or has not had a hysterectomy at least three months prior to the start of this study [ visit 1 ] ) ; adequate contraceptives include hormonal intra-uterine devices ; hormonal contraceptives ( oral ; depot ; patch or injectable ) ; and double barrier methods such as condoms or diaphragms with spermicidal gel or foam .,Drug Exposure,Procedure,C0004764,barrier methods,FALSE,FALSE,NA,NA,NA
10,NCT00923091,Inclusion,female subjects of childbearing potential must be using adequate contraception ( female of childbearing potential is defined as one who has not been postmenopausal for at least one year ; or has not been surgically sterilised ; or has not had a hysterectomy at least three months prior to the start of this study [ visit 1 ] ) ; adequate contraceptives include hormonal intra-uterine devices ; hormonal contraceptives ( oral ; depot ; patch or injectable ) ; and double barrier methods such as condoms or diaphragms with spermicidal gel or foam .,Drug Exposure,Observation,C3831118,childbearing potential,FALSE,FALSE,NA,NA,NA
10,NCT00923091,Inclusion,female subjects of childbearing potential must be using adequate contraception ( female of childbearing potential is defined as one who has not been postmenopausal for at least one year ; or has not been surgically sterilised ; or has not had a hysterectomy at least three months prior to the start of this study [ visit 1 ] ) ; adequate contraceptives include hormonal intra-uterine devices ; hormonal contraceptives ( oral ; depot ; patch or injectable ) ; and double barrier methods such as condoms or diaphragms with spermicidal gel or foam .,Drug Exposure,Observation,C3831118,childbearing potential,FALSE,FALSE,NA,NA,NA
10,NCT00923091,Inclusion,female subjects of childbearing potential must be using adequate contraception ( female of childbearing potential is defined as one who has not been postmenopausal for at least one year ; or has not been surgically sterilised ; or has not had a hysterectomy at least three months prior to the start of this study [ visit 1 ] ) ; adequate contraceptives include hormonal intra-uterine devices ; hormonal contraceptives ( oral ; depot ; patch or injectable ) ; and double barrier methods such as condoms or diaphragms with spermicidal gel or foam .,Drug Exposure,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
11,NCT00923091,Exclusion,female subjects of childbearing potential who are pregnant or lactating .,Condition Occurrence,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
11,NCT00923091,Exclusion,female subjects of childbearing potential who are pregnant or lactating .,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
11,NCT00923091,Exclusion,female subjects of childbearing potential who are pregnant or lactating .,Condition Occurrence,Condition,C2828358;C3668831,lactating,FALSE,FALSE,NA,NA,NA
11,NCT00923091,Exclusion,female subjects of childbearing potential who are pregnant or lactating .,Condition Occurrence,Observation,C3831118,childbearing potential,FALSE,FALSE,NA,NA,NA
12,NCT00923091,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of the investigational products ; including cerebrovascular ; cardiovascular ; renal ; respiratory ; hepatic ; gastrointestinal ; endocrine or metabolic ; haematologic or ; neurologic ; and psychiatric diseases,Condition Occurrence,Condition,C1559265,gastrointestinal,FALSE,FALSE,NA,NA,NA
12,NCT00923091,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of the investigational products ; including cerebrovascular ; cardiovascular ; renal ; respiratory ; hepatic ; gastrointestinal ; endocrine or metabolic ; haematologic or ; neurologic ; and psychiatric diseases,Condition Occurrence,Condition,C0205054,hepatic,FALSE,FALSE,NA,NA,NA
12,NCT00923091,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of the investigational products ; including cerebrovascular ; cardiovascular ; renal ; respiratory ; hepatic ; gastrointestinal ; endocrine or metabolic ; haematologic or ; neurologic ; and psychiatric diseases,Condition Occurrence,Other,C3245491,investigational,FALSE,FALSE,NA,NA,NA
12,NCT00923091,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of the investigational products ; including cerebrovascular ; cardiovascular ; renal ; respiratory ; hepatic ; gastrointestinal ; endocrine or metabolic ; haematologic or ; neurologic ; and psychiatric diseases,Condition Occurrence,Other,C1546767,respiratory,FALSE,FALSE,NA,NA,NA
12,NCT00923091,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of the investigational products ; including cerebrovascular ; cardiovascular ; renal ; respiratory ; hepatic ; gastrointestinal ; endocrine or metabolic ; haematologic or ; neurologic ; and psychiatric diseases,Condition Occurrence,Other,C1524026;C2707259,metabolic,FALSE,FALSE,NA,NA,NA
12,NCT00923091,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of the investigational products ; including cerebrovascular ; cardiovascular ; renal ; respiratory ; hepatic ; gastrointestinal ; endocrine or metabolic ; haematologic or ; neurologic ; and psychiatric diseases,Condition Occurrence,Other,C1548428;C1561580,psychiatric,FALSE,FALSE,NA,NA,NA
13,NCT00923091,Exclusion,the same applies for immunocompromised subjects or neutropenic subjects .,Condition Occurrence,Condition,C0085393,immunocompromised,FALSE,FALSE,NA,NA,NA
14,NCT00923091,Exclusion,subjects having a history of the following within the last six months : myocardial infarction ( mi ) ; unstable angina pectoris ; percutaneous coronary intervention ; heart failure ; hypertensive encephalopathy ; cerebrovascular accident ( stroke ) ; or transient ischaemic attack .,Condition Occurrence,Condition,C0002965,unstable angina pectoris,FALSE,FALSE,NA,NA,NA
14,NCT00923091,Exclusion,subjects having a history of the following within the last six months : myocardial infarction ( mi ) ; unstable angina pectoris ; percutaneous coronary intervention ; heart failure ; hypertensive encephalopathy ; cerebrovascular accident ( stroke ) ; or transient ischaemic attack .,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,NA,NA,NA
14,NCT00923091,Exclusion,subjects having a history of the following within the last six months : myocardial infarction ( mi ) ; unstable angina pectoris ; percutaneous coronary intervention ; heart failure ; hypertensive encephalopathy ; cerebrovascular accident ( stroke ) ; or transient ischaemic attack .,Condition Occurrence,Condition,C0151620,hypertensive encephalopathy,FALSE,FALSE,NA,NA,NA
14,NCT00923091,Exclusion,subjects having a history of the following within the last six months : myocardial infarction ( mi ) ; unstable angina pectoris ; percutaneous coronary intervention ; heart failure ; hypertensive encephalopathy ; cerebrovascular accident ( stroke ) ; or transient ischaemic attack .,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
14,NCT00923091,Exclusion,subjects having a history of the following within the last six months : myocardial infarction ( mi ) ; unstable angina pectoris ; percutaneous coronary intervention ; heart failure ; hypertensive encephalopathy ; cerebrovascular accident ( stroke ) ; or transient ischaemic attack .,Condition Occurrence,Condition,C0007787,transient ischaemic attack,FALSE,FALSE,NA,NA,NA
14,NCT00923091,Exclusion,subjects having a history of the following within the last six months : myocardial infarction ( mi ) ; unstable angina pectoris ; percutaneous coronary intervention ; heart failure ; hypertensive encephalopathy ; cerebrovascular accident ( stroke ) ; or transient ischaemic attack .,Condition Occurrence,Procedure,C1532338,percutaneous coronary intervention,FALSE,FALSE,NA,NA,NA
14,NCT00923091,Exclusion,subjects having a history of the following within the last six months : myocardial infarction ( mi ) ; unstable angina pectoris ; percutaneous coronary intervention ; heart failure ; hypertensive encephalopathy ; cerebrovascular accident ( stroke ) ; or transient ischaemic attack .,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,NA,NA,NA
14,NCT00923091,Exclusion,subjects having a history of the following within the last six months : myocardial infarction ( mi ) ; unstable angina pectoris ; percutaneous coronary intervention ; heart failure ; hypertensive encephalopathy ; cerebrovascular accident ( stroke ) ; or transient ischaemic attack .,Condition Occurrence,Other,C0027051;C0025953;C3496280;C0278960,mi,FALSE,FALSE,NA,NA,NA
15,NCT00923091,Exclusion,subjects with clinically significant abnormal laboratory values at screening ; including subjects with one or more of the following :,Observation,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
15,NCT00923091,Exclusion,subjects with clinically significant abnormal laboratory values at screening ; including subjects with one or more of the following :,Observation,Other,C2699333,abnormal,FALSE,FALSE,NA,NA,NA
16,NCT00923091,Exclusion,aspartate aminotransferase ( ast ) > 3 times upper limit of normal ( uln ) .,Drug Exposure,Observation,C0004002;C0201899,aspartate aminotransferase,FALSE,FALSE,NA,NA,NA
16,NCT00923091,Exclusion,aspartate aminotransferase ( ast ) > 3 times upper limit of normal ( uln ) .,Drug Exposure,Observation,C0004002,ast,FALSE,FALSE,NA,NA,greater 3 times upper limit of normal
17,NCT00923091,Exclusion,alanine aminotransferase ( alt ) > 3 times uln .,Drug Exposure,Observation,C0001899;C0201836,alanine aminotransferase,FALSE,FALSE,NA,NA,NA
17,NCT00923091,Exclusion,alanine aminotransferase ( alt ) > 3 times uln .,Drug Exposure,Observation,C1140170;C2257651,alt,FALSE,FALSE,NA,NA,greater 3 times uln
18,NCT00923091,Exclusion,gamma-glutamyl transferase ( ggt ) > 3 times uln .,Drug Exposure,Drug,C0017040,gamma-glutamyl transferase,FALSE,FALSE,NA,NA,greater 3 times uln
19,NCT00923091,Exclusion,potassium above uln ( unless high value is due to haemolytic blood sample ) .,Observation,Condition,C0178913,blood sample,FALSE,FALSE,NA,NA,NA
19,NCT00923091,Exclusion,potassium above uln ( unless high value is due to haemolytic blood sample ) .,Observation,Observation,C2700149,high,FALSE,FALSE,NA,NA,NA
19,NCT00923091,Exclusion,potassium above uln ( unless high value is due to haemolytic blood sample ) .,Observation,Other,C0032821;C0202194;C0304475,potassium,FALSE,FALSE,NA,NA,NA
20,NCT00923091,Exclusion,subjects with secondary hypertension of any aetiology such as renal disease ; phaeochromocytoma ; or cushing syndrome .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
20,NCT00923091,Exclusion,subjects with secondary hypertension of any aetiology such as renal disease ; phaeochromocytoma ; or cushing syndrome .,Condition Occurrence,Condition,C0022658,renal disease,FALSE,FALSE,NA,NA,NA
20,NCT00923091,Exclusion,subjects with secondary hypertension of any aetiology such as renal disease ; phaeochromocytoma ; or cushing syndrome .,Condition Occurrence,Condition,C0010481,cushing syndrome,FALSE,FALSE,NA,NA,NA
21,NCT00923091,Exclusion,subjects with contraindication to olmesartan ; amlodipine ; hydrochlorothiazide ; or any of the tablet excipients .,Drug Exposure,Drug,C1098320;C0386393,olmesartan,FALSE,FALSE,NA,NA,NA
21,NCT00923091,Exclusion,subjects with contraindication to olmesartan ; amlodipine ; hydrochlorothiazide ; or any of the tablet excipients .,Drug Exposure,Drug,C0020261,hydrochlorothiazide,FALSE,FALSE,NA,NA,NA
21,NCT00923091,Exclusion,subjects with contraindication to olmesartan ; amlodipine ; hydrochlorothiazide ; or any of the tablet excipients .,Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,NA
21,NCT00923091,Exclusion,subjects with contraindication to olmesartan ; amlodipine ; hydrochlorothiazide ; or any of the tablet excipients .,Drug Exposure,Drug,C0015237,excipients,FALSE,FALSE,NA,NA,NA
21,NCT00923091,Exclusion,subjects with contraindication to olmesartan ; amlodipine ; hydrochlorothiazide ; or any of the tablet excipients .,Drug Exposure,Other,C1301624;C1547316,contraindication,FALSE,FALSE,NA,NA,NA
22,NCT00923091,Exclusion,newly diagnosed subjects with a mean trough sesbp > 200 mmhg or mean trough sedbp > 115 mmhg or any subjects with bradycardia ( heart rate < 50 beats / min at rest documented by mean radial pulse rate [ pr ] or electrocardiogram [ ecg ] ) at screening ( visit 1 ) or immediately before taking period i study medication ( visit 3 ) .,Observation,Condition,C0518831,radial pulse rate,FALSE,FALSE,NA,NA,NA
22,NCT00923091,Exclusion,newly diagnosed subjects with a mean trough sesbp > 200 mmhg or mean trough sedbp > 115 mmhg or any subjects with bradycardia ( heart rate < 50 beats / min at rest documented by mean radial pulse rate [ pr ] or electrocardiogram [ ecg ] ) at screening ( visit 1 ) or immediately before taking period i study medication ( visit 3 ) .,Observation,Condition,C0013798,electrocardiogram,FALSE,FALSE,NA,NA,NA
22,NCT00923091,Exclusion,newly diagnosed subjects with a mean trough sesbp > 200 mmhg or mean trough sedbp > 115 mmhg or any subjects with bradycardia ( heart rate < 50 beats / min at rest documented by mean radial pulse rate [ pr ] or electrocardiogram [ ecg ] ) at screening ( visit 1 ) or immediately before taking period i study medication ( visit 3 ) .,Observation,Procedure,C1301725,documented,FALSE,FALSE,NA,NA,NA
22,NCT00923091,Exclusion,newly diagnosed subjects with a mean trough sesbp > 200 mmhg or mean trough sedbp > 115 mmhg or any subjects with bradycardia ( heart rate < 50 beats / min at rest documented by mean radial pulse rate [ pr ] or electrocardiogram [ ecg ] ) at screening ( visit 1 ) or immediately before taking period i study medication ( visit 3 ) .,Observation,Observation,C0428977,bradycardia,FALSE,FALSE,NA,greater 200 mmhg; greater 115 mmhg,NA
22,NCT00923091,Exclusion,newly diagnosed subjects with a mean trough sesbp > 200 mmhg or mean trough sedbp > 115 mmhg or any subjects with bradycardia ( heart rate < 50 beats / min at rest documented by mean radial pulse rate [ pr ] or electrocardiogram [ ecg ] ) at screening ( visit 1 ) or immediately before taking period i study medication ( visit 3 ) .,Observation,Observation,C0018810;C2197023;C2041121;C0488794,heart rate,FALSE,FALSE,NA,lower 50 beats/min,NA
22,NCT00923091,Exclusion,newly diagnosed subjects with a mean trough sesbp > 200 mmhg or mean trough sedbp > 115 mmhg or any subjects with bradycardia ( heart rate < 50 beats / min at rest documented by mean radial pulse rate [ pr ] or electrocardiogram [ ecg ] ) at screening ( visit 1 ) or immediately before taking period i study medication ( visit 3 ) .,Observation,Other,C1521726;C2365506;C0034833;C3484362,pr,FALSE,FALSE,NA,NA,NA
22,NCT00923091,Exclusion,newly diagnosed subjects with a mean trough sesbp > 200 mmhg or mean trough sedbp > 115 mmhg or any subjects with bradycardia ( heart rate < 50 beats / min at rest documented by mean radial pulse rate [ pr ] or electrocardiogram [ ecg ] ) at screening ( visit 1 ) or immediately before taking period i study medication ( visit 3 ) .,Observation,Other,C1623258;C0018064,ecg,FALSE,FALSE,NA,NA,NA
23,NCT00923091,Exclusion,subjects already taking four or more antihypertensive medications .,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
24,NCT00923091,Exclusion,subjects with a mean trough sesbp > 145 mmhg or mean trough sedbp > 95 mmhg while taking three antihypertensive medications .,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,greater 145 mmhg; greater 95 mmhg,NA
25,NCT00923091,Exclusion,subjects with a mean trough sesbp > 160 mmhg or mean trough sedbp > 100 mmhg while taking two antihypertensive medications .,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,greater 160 mmhg; greater 100 mmhg,NA
26,NCT00923091,Exclusion,subjects with a mean trough sesbp > 180 mmhg or mean trough sedbp > 110 mmhg while taking one antihypertensive medication .,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,greater 180 mmhg; greater 110 mmhg,NA
27,NCT00923091,Exclusion,subjects with electrocardiogram evidence of 2 nd or 3 rd degree atrio ventricular ( av ) block ; atrial fibrillation ; or other cardiac arrhythmia ( requiring treatment ) .,Condition Occurrence,Condition,C0013798,electrocardiogram,FALSE,FALSE,NA,NA,NA
27,NCT00923091,Exclusion,subjects with electrocardiogram evidence of 2 nd or 3 rd degree atrio ventricular ( av ) block ; atrial fibrillation ; or other cardiac arrhythmia ( requiring treatment ) .,Condition Occurrence,Condition,C0004245,av block,FALSE,FALSE,NA,NA,NA
27,NCT00923091,Exclusion,subjects with electrocardiogram evidence of 2 nd or 3 rd degree atrio ventricular ( av ) block ; atrial fibrillation ; or other cardiac arrhythmia ( requiring treatment ) .,Condition Occurrence,Condition,C0003811;C1560249,cardiac arrhythmia,FALSE,FALSE,NA,NA,NA
27,NCT00923091,Exclusion,subjects with electrocardiogram evidence of 2 nd or 3 rd degree atrio ventricular ( av ) block ; atrial fibrillation ; or other cardiac arrhythmia ( requiring treatment ) .,Condition Occurrence,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
27,NCT00923091,Exclusion,subjects with electrocardiogram evidence of 2 nd or 3 rd degree atrio ventricular ( av ) block ; atrial fibrillation ; or other cardiac arrhythmia ( requiring treatment ) .,Condition Occurrence,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
28,NCT00923091,Exclusion,subjects with severe heart failure ( new york heart association stage iii- ; clinically significant aortic valve stenosis or mitral valve stenosis ; uncorrected coarctation of the aorta ; obstruction of cardiac outflow ( obstructive cardiomyopathy ; hypertrophic cardiomyopathy ) or symptomatic coronary disease .,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
28,NCT00923091,Exclusion,subjects with severe heart failure ( new york heart association stage iii- ; clinically significant aortic valve stenosis or mitral valve stenosis ; uncorrected coarctation of the aorta ; obstruction of cardiac outflow ( obstructive cardiomyopathy ; hypertrophic cardiomyopathy ) or symptomatic coronary disease .,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
28,NCT00923091,Exclusion,subjects with severe heart failure ( new york heart association stage iii- ; clinically significant aortic valve stenosis or mitral valve stenosis ; uncorrected coarctation of the aorta ; obstruction of cardiac outflow ( obstructive cardiomyopathy ; hypertrophic cardiomyopathy ) or symptomatic coronary disease .,Condition Occurrence,Condition,C0003507;C3542024,aortic valve stenosis,FALSE,FALSE,NA,NA,NA
28,NCT00923091,Exclusion,subjects with severe heart failure ( new york heart association stage iii- ; clinically significant aortic valve stenosis or mitral valve stenosis ; uncorrected coarctation of the aorta ; obstruction of cardiac outflow ( obstructive cardiomyopathy ; hypertrophic cardiomyopathy ) or symptomatic coronary disease .,Condition Occurrence,Condition,C0026269;C0264766,mitral valve stenosis,FALSE,FALSE,NA,NA,NA
28,NCT00923091,Exclusion,subjects with severe heart failure ( new york heart association stage iii- ; clinically significant aortic valve stenosis or mitral valve stenosis ; uncorrected coarctation of the aorta ; obstruction of cardiac outflow ( obstructive cardiomyopathy ; hypertrophic cardiomyopathy ) or symptomatic coronary disease .,Condition Occurrence,Condition,C0332886,coarctation,FALSE,FALSE,NA,NA,NA
28,NCT00923091,Exclusion,subjects with severe heart failure ( new york heart association stage iii- ; clinically significant aortic valve stenosis or mitral valve stenosis ; uncorrected coarctation of the aorta ; obstruction of cardiac outflow ( obstructive cardiomyopathy ; hypertrophic cardiomyopathy ) or symptomatic coronary disease .,Condition Occurrence,Condition,C0596118,aorta obstruction,FALSE,FALSE,NA,NA,NA
28,NCT00923091,Exclusion,subjects with severe heart failure ( new york heart association stage iii- ; clinically significant aortic valve stenosis or mitral valve stenosis ; uncorrected coarctation of the aorta ; obstruction of cardiac outflow ( obstructive cardiomyopathy ; hypertrophic cardiomyopathy ) or symptomatic coronary disease .,Condition Occurrence,Condition,C0007194,obstructive cardiomyopathy,FALSE,FALSE,NA,NA,NA
28,NCT00923091,Exclusion,subjects with severe heart failure ( new york heart association stage iii- ; clinically significant aortic valve stenosis or mitral valve stenosis ; uncorrected coarctation of the aorta ; obstruction of cardiac outflow ( obstructive cardiomyopathy ; hypertrophic cardiomyopathy ) or symptomatic coronary disease .,Condition Occurrence,Condition,C0007194;C0340425,hypertrophic cardiomyopathy,FALSE,FALSE,NA,NA,NA
28,NCT00923091,Exclusion,subjects with severe heart failure ( new york heart association stage iii- ; clinically significant aortic valve stenosis or mitral valve stenosis ; uncorrected coarctation of the aorta ; obstruction of cardiac outflow ( obstructive cardiomyopathy ; hypertrophic cardiomyopathy ) or symptomatic coronary disease .,Condition Occurrence,Condition,C0010068,coronary disease,FALSE,FALSE,NA,NA,NA
28,NCT00923091,Exclusion,subjects with severe heart failure ( new york heart association stage iii- ; clinically significant aortic valve stenosis or mitral valve stenosis ; uncorrected coarctation of the aorta ; obstruction of cardiac outflow ( obstructive cardiomyopathy ; hypertrophic cardiomyopathy ) or symptomatic coronary disease .,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
28,NCT00923091,Exclusion,subjects with severe heart failure ( new york heart association stage iii- ; clinically significant aortic valve stenosis or mitral valve stenosis ; uncorrected coarctation of the aorta ; obstruction of cardiac outflow ( obstructive cardiomyopathy ; hypertrophic cardiomyopathy ) or symptomatic coronary disease .,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii-,FALSE,FALSE,NA,NA,NA
29,NCT00923091,Exclusion,subjects with clinical evidence of renal disease including reno-vascular occlusive disease ; nephrectomy or renal transplant ; bilateral renal artery stenosis ; unilateral renal artery stenosis in a solitary kidney ; or severe renal impairment as evidenced by crcl of < 30 ml / min calculated using the cockcroft formula and gault formula .,Condition Occurrence,Condition,C0022658,renal disease,FALSE,FALSE,NA,NA,NA
29,NCT00923091,Exclusion,subjects with clinical evidence of renal disease including reno-vascular occlusive disease ; nephrectomy or renal transplant ; bilateral renal artery stenosis ; unilateral renal artery stenosis in a solitary kidney ; or severe renal impairment as evidenced by crcl of < 30 ml / min calculated using the cockcroft formula and gault formula .,Condition Occurrence,Condition,C0268790,reno-vascular,FALSE,FALSE,NA,NA,NA
29,NCT00923091,Exclusion,subjects with clinical evidence of renal disease including reno-vascular occlusive disease ; nephrectomy or renal transplant ; bilateral renal artery stenosis ; unilateral renal artery stenosis in a solitary kidney ; or severe renal impairment as evidenced by crcl of < 30 ml / min calculated using the cockcroft formula and gault formula .,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
29,NCT00923091,Exclusion,subjects with clinical evidence of renal disease including reno-vascular occlusive disease ; nephrectomy or renal transplant ; bilateral renal artery stenosis ; unilateral renal artery stenosis in a solitary kidney ; or severe renal impairment as evidenced by crcl of < 30 ml / min calculated using the cockcroft formula and gault formula .,Condition Occurrence,Condition,C0856759,unilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
29,NCT00923091,Exclusion,subjects with clinical evidence of renal disease including reno-vascular occlusive disease ; nephrectomy or renal transplant ; bilateral renal artery stenosis ; unilateral renal artery stenosis in a solitary kidney ; or severe renal impairment as evidenced by crcl of < 30 ml / min calculated using the cockcroft formula and gault formula .,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
29,NCT00923091,Exclusion,subjects with clinical evidence of renal disease including reno-vascular occlusive disease ; nephrectomy or renal transplant ; bilateral renal artery stenosis ; unilateral renal artery stenosis in a solitary kidney ; or severe renal impairment as evidenced by crcl of < 30 ml / min calculated using the cockcroft formula and gault formula .,Condition Occurrence,Condition,C1565489;C0035078,renal impairment,FALSE,FALSE,NA,NA,NA
29,NCT00923091,Exclusion,subjects with clinical evidence of renal disease including reno-vascular occlusive disease ; nephrectomy or renal transplant ; bilateral renal artery stenosis ; unilateral renal artery stenosis in a solitary kidney ; or severe renal impairment as evidenced by crcl of < 30 ml / min calculated using the cockcroft formula and gault formula .,Condition Occurrence,Condition,C1846718,crcl,FALSE,FALSE,NA,lower 30 ml/min,NA
29,NCT00923091,Exclusion,subjects with clinical evidence of renal disease including reno-vascular occlusive disease ; nephrectomy or renal transplant ; bilateral renal artery stenosis ; unilateral renal artery stenosis in a solitary kidney ; or severe renal impairment as evidenced by crcl of < 30 ml / min calculated using the cockcroft formula and gault formula .,Condition Occurrence,Procedure,C0022671,renal transplant,FALSE,FALSE,NA,NA,NA
29,NCT00923091,Exclusion,subjects with clinical evidence of renal disease including reno-vascular occlusive disease ; nephrectomy or renal transplant ; bilateral renal artery stenosis ; unilateral renal artery stenosis in a solitary kidney ; or severe renal impairment as evidenced by crcl of < 30 ml / min calculated using the cockcroft formula and gault formula .,Condition Occurrence,Procedure,C0027695;C0176996,nephrectomy,FALSE,FALSE,NA,NA,NA
29,NCT00923091,Exclusion,subjects with clinical evidence of renal disease including reno-vascular occlusive disease ; nephrectomy or renal transplant ; bilateral renal artery stenosis ; unilateral renal artery stenosis in a solitary kidney ; or severe renal impairment as evidenced by crcl of < 30 ml / min calculated using the cockcroft formula and gault formula .,Condition Occurrence,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
29,NCT00923091,Exclusion,subjects with clinical evidence of renal disease including reno-vascular occlusive disease ; nephrectomy or renal transplant ; bilateral renal artery stenosis ; unilateral renal artery stenosis in a solitary kidney ; or severe renal impairment as evidenced by crcl of < 30 ml / min calculated using the cockcroft formula and gault formula .,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
29,NCT00923091,Exclusion,subjects with clinical evidence of renal disease including reno-vascular occlusive disease ; nephrectomy or renal transplant ; bilateral renal artery stenosis ; unilateral renal artery stenosis in a solitary kidney ; or severe renal impairment as evidenced by crcl of < 30 ml / min calculated using the cockcroft formula and gault formula .,Condition Occurrence,Other,C1705501;C0489829,formula,FALSE,FALSE,NA,NA,NA
29,NCT00923091,Exclusion,subjects with clinical evidence of renal disease including reno-vascular occlusive disease ; nephrectomy or renal transplant ; bilateral renal artery stenosis ; unilateral renal artery stenosis in a solitary kidney ; or severe renal impairment as evidenced by crcl of < 30 ml / min calculated using the cockcroft formula and gault formula .,Condition Occurrence,Other,C1705501;C0489829,formula,FALSE,FALSE,NA,NA,NA
30,NCT00923091,Exclusion,subjects with clinically relevant hepatic impairment .,Condition Occurrence,Condition,C0948807,hepatic impairment,FALSE,FALSE,NA,NA,NA
31,NCT00923091,Exclusion,subjects with biliary obstruction .,Condition Occurrence,Condition,C0400979,biliary obstruction,FALSE,FALSE,NA,NA,NA
32,NCT00923091,Exclusion,subjects with uncontrolled type 1 diabetes or type 2 diabetesdefined as hba1c > 9.0 %,Drug Exposure,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
32,NCT00923091,Exclusion,subjects with uncontrolled type 1 diabetes or type 2 diabetesdefined as hba1c > 9.0 %,Drug Exposure,Observation,C0202054,hba1c,FALSE,FALSE,NA,NA,greater 9.0 %
32,NCT00923091,Exclusion,subjects with uncontrolled type 1 diabetes or type 2 diabetesdefined as hba1c > 9.0 %,Drug Exposure,Other,C1552651,type,FALSE,FALSE,NA,NA,NA
33,NCT00923091,Exclusion,diabetics must have documentation of hba1c within 6 months of the screening visit ; or must have their hba1c assessed prior to randomisation,Observation,Observation,C0202054,hba1c,FALSE,FALSE,lower 6 months,NA,NA
33,NCT00923091,Exclusion,diabetics must have documentation of hba1c within 6 months of the screening visit ; or must have their hba1c assessed prior to randomisation,Observation,Observation,C0202054,hba1c,FALSE,FALSE,NA,NA,NA
34,NCT00923091,Exclusion,note : subjects with type 1 diabetes or type 2 diabetescontrolled with insulin ; diet or oral hypoglycaemic agents on a stable dose for at least 30 days may be included .,Other,Condition,C0011854,type 1 diabetes,FALSE,TRUE,NA,NA,NA
34,NCT00923091,Exclusion,note : subjects with type 1 diabetes or type 2 diabetescontrolled with insulin ; diet or oral hypoglycaemic agents on a stable dose for at least 30 days may be included .,Other,Drug,C0359086,oral hypoglycaemic,FALSE,TRUE,NA,NA,NA
34,NCT00923091,Exclusion,note : subjects with type 1 diabetes or type 2 diabetescontrolled with insulin ; diet or oral hypoglycaemic agents on a stable dose for at least 30 days may be included .,Other,Observation,C0021641;C0202098;C1533581;C1145751;C1579433;C2739803,insulin,FALSE,TRUE,NA,NA,NA
34,NCT00923091,Exclusion,note : subjects with type 1 diabetes or type 2 diabetescontrolled with insulin ; diet or oral hypoglycaemic agents on a stable dose for at least 30 days may be included .,Other,Other,C1317574;C1316572,note,FALSE,TRUE,NA,NA,NA
34,NCT00923091,Exclusion,note : subjects with type 1 diabetes or type 2 diabetescontrolled with insulin ; diet or oral hypoglycaemic agents on a stable dose for at least 30 days may be included .,Other,Other,C1552651,type,FALSE,TRUE,NA,NA,NA
34,NCT00923091,Exclusion,note : subjects with type 1 diabetes or type 2 diabetescontrolled with insulin ; diet or oral hypoglycaemic agents on a stable dose for at least 30 days may be included .,Other,Other,C0012159;C1519433;C1561465;C1550559;C1549512,diet,FALSE,TRUE,NA,NA,NA
34,NCT00923091,Exclusion,note : subjects with type 1 diabetes or type 2 diabetescontrolled with insulin ; diet or oral hypoglycaemic agents on a stable dose for at least 30 days may be included .,Other,Other,C1547311,stable,FALSE,TRUE,greater_equal 30 days,NA,NA
35,NCT00923091,Exclusion,subjects with a history of a wasting disease ( eg cancer ) ; autoimmune diseases ; connective tissue diseases ; major allergies or angioneurotic oedema .,Condition Occurrence,Condition,C0043046,wasting disease,FALSE,FALSE,NA,NA,NA
35,NCT00923091,Exclusion,subjects with a history of a wasting disease ( eg cancer ) ; autoimmune diseases ; connective tissue diseases ; major allergies or angioneurotic oedema .,Condition Occurrence,Condition,C0004364,autoimmune diseases,FALSE,FALSE,NA,NA,NA
35,NCT00923091,Exclusion,subjects with a history of a wasting disease ( eg cancer ) ; autoimmune diseases ; connective tissue diseases ; major allergies or angioneurotic oedema .,Condition Occurrence,Condition,C0002994,angioneurotic oedema,FALSE,FALSE,NA,NA,NA
35,NCT00923091,Exclusion,subjects with a history of a wasting disease ( eg cancer ) ; autoimmune diseases ; connective tissue diseases ; major allergies or angioneurotic oedema .,Condition Occurrence,Condition,C0020517,allergies,FALSE,FALSE,NA,NA,NA
35,NCT00923091,Exclusion,subjects with a history of a wasting disease ( eg cancer ) ; autoimmune diseases ; connective tissue diseases ; major allergies or angioneurotic oedema .,Condition Occurrence,Condition,C0009782,connective tissue diseases,FALSE,FALSE,NA,NA,NA
35,NCT00923091,Exclusion,subjects with a history of a wasting disease ( eg cancer ) ; autoimmune diseases ; connective tissue diseases ; major allergies or angioneurotic oedema .,Condition Occurrence,Other,C0260515;C2707253,cancer,FALSE,FALSE,NA,NA,NA
36,NCT00923091,Exclusion,subjects who require or are taking any concomitant medication which may interfere with the objectives of the study .,Other,NA,NA,NA,NA,NA,NA,NA,NA
37,NCT00923091,Exclusion,subjects on beta blockers or calcium channel blockers ( ccbs ) for both hypertension and either ischemia ; post-mi prophylaxis or tachyarrhythmias .,Drug Exposure,Condition,C0022116,ischemia,FALSE,FALSE,NA,NA,NA
37,NCT00923091,Exclusion,subjects on beta blockers or calcium channel blockers ( ccbs ) for both hypertension and either ischemia ; post-mi prophylaxis or tachyarrhythmias .,Drug Exposure,Drug,C0001645,beta blockers,FALSE,FALSE,NA,NA,NA
37,NCT00923091,Exclusion,subjects on beta blockers or calcium channel blockers ( ccbs ) for both hypertension and either ischemia ; post-mi prophylaxis or tachyarrhythmias .,Drug Exposure,Drug,C0006684,calcium channel blockers,FALSE,FALSE,NA,NA,NA
37,NCT00923091,Exclusion,subjects on beta blockers or calcium channel blockers ( ccbs ) for both hypertension and either ischemia ; post-mi prophylaxis or tachyarrhythmias .,Drug Exposure,Drug,C0591987,post-mi,FALSE,FALSE,NA,NA,NA
37,NCT00923091,Exclusion,subjects on beta blockers or calcium channel blockers ( ccbs ) for both hypertension and either ischemia ; post-mi prophylaxis or tachyarrhythmias .,Drug Exposure,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
38,NCT00923091,Exclusion,subjects with known malabsorption syndromes .,Condition Occurrence,Condition,C0024523,malabsorption syndromes,FALSE,FALSE,NA,NA,NA
39,NCT00923091,Exclusion,subjects with psychiatric problems or emotional problems ; which would invalidate the giving of informed consent or limit the ability of the subject to comply with study requirements .,Condition Occurrence,Condition,C0677660,emotional problems,FALSE,FALSE,NA,NA,NA
39,NCT00923091,Exclusion,subjects with psychiatric problems or emotional problems ; which would invalidate the giving of informed consent or limit the ability of the subject to comply with study requirements .,Condition Occurrence,Other,C1548428;C1561580,psychiatric,FALSE,FALSE,NA,NA,NA
40,NCT00923091,Exclusion,subjects with a history of alcohol or drug abuse .,Drug Exposure,Condition,C0013146,drug abuse,FALSE,FALSE,NA,NA,NA
40,NCT00923091,Exclusion,subjects with a history of alcohol or drug abuse .,Drug Exposure,Other,C0001975;C0001962;C1547288,alcohol,FALSE,FALSE,NA,NA,NA
41,NCT00923091,Exclusion,subjects who have received any investigational agent within 30 days prior to screening .,Drug Exposure,Drug,C0013230,investigational agent,FALSE,FALSE,lower 30 days,NA,NA
42,NCT00923091,Exclusion,subjects who are unwilling or unable to provide informed consent or to participate satisfactorily for the entire study .,Other,NA,NA,NA,NA,NA,NA,NA,NA
43,NCT00923091,Exclusion,subjects with malignancy during the past 2 years excluding squamous cell carcinoma or basal cell carcinoma of the skin .,Condition Occurrence,Condition,C0006826;C1306459,malignancy,FALSE,FALSE,lower_equal 2 past years,NA,NA
43,NCT00923091,Exclusion,subjects with malignancy during the past 2 years excluding squamous cell carcinoma or basal cell carcinoma of the skin .,Condition Occurrence,Condition,C0007137;C1302853,squamous cell carcinoma,TRUE,FALSE,NA,NA,NA
43,NCT00923091,Exclusion,subjects with malignancy during the past 2 years excluding squamous cell carcinoma or basal cell carcinoma of the skin .,Condition Occurrence,Condition,C0007117,basal cell carcinoma of the skin,TRUE,FALSE,NA,NA,NA
44,NCT00923091,Exclusion,subjects with signs or symptoms which could exacerbate the occurrence of hypotension such as volume and salt depletion .,Condition Occurrence,Condition,C0020649;C3163620,hypotension,FALSE,FALSE,NA,NA,NA
44,NCT00923091,Exclusion,subjects with signs or symptoms which could exacerbate the occurrence of hypotension such as volume and salt depletion .,Condition Occurrence,Condition,C0235425,salt depletion,FALSE,FALSE,NA,NA,NA
44,NCT00923091,Exclusion,subjects with signs or symptoms which could exacerbate the occurrence of hypotension such as volume and salt depletion .,Condition Occurrence,Observation,C1705102;C2700258,volume,FALSE,FALSE,NA,NA,NA
45,NCT00923091,Exclusion,subjects with any medical condition ; which in the judgment of the investigator would jeopardise the evaluation of efficacy or safety or constitute a significant safety risk to the subject,Other,Other,C1561579;C1561578,medical,FALSE,FALSE,NA,NA,NA
1,NCT00926289,Inclusion,ability to provide written informed consent in accordance with good clinical practice and local legislation ;,Other,Other,C2986419,good clinical practice,FALSE,FALSE,NA,NA,NA
1,NCT00926289,Inclusion,ability to provide written informed consent in accordance with good clinical practice and local legislation ;,Other,Other,C0600657,legislation,FALSE,FALSE,NA,NA,NA
2,NCT00926289,Inclusion,age 18 years or older ;,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 18 years,NA,NA
3,NCT00926289,Inclusion,patients with grade 2 or grade 3 hypertension as defined sbp > = 160 mmhg and dbp > = 100 mmhg at randomization,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 160 mmhg; greater_equal 100 mmhg,NA
3,NCT00926289,Inclusion,patients with grade 2 or grade 3 hypertension as defined sbp > = 160 mmhg and dbp > = 100 mmhg at randomization,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
4,NCT00926289,Inclusion,ability to stop any current antihypertensive therapy without unacceptable risk to the patient ( investigator discretion ),Drug Exposure,Drug,C0723457,stop,FALSE,FALSE,NA,NA,NA
4,NCT00926289,Inclusion,ability to stop any current antihypertensive therapy without unacceptable risk to the patient ( investigator discretion ),Drug Exposure,Procedure,C0585941,antihypertensive therapy,FALSE,FALSE,NA,NA,NA
5,NCT00926289,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to signing informed consent ) who,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
5,NCT00926289,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to signing informed consent ) who,Condition Occurrence,Condition,C1096235,pre-menopausal,FALSE,FALSE,NA,NA,NA
5,NCT00926289,Exclusion,pre-menopausal women ( last menstruation < = 1 year prior to signing informed consent ) who,Condition Occurrence,Condition,C0025344;C2129647,menstruation,FALSE,FALSE,lower_equal 1 year,NA,NA
6,NCT00926289,Exclusion,are not surgically sterile,Other,NA,NA,NA,NA,NA,NA,NA,NA
7,NCT00926289,Exclusion,or b ) are nursing ; or c ) are pregnant ; or d ) are of childbearing potential and are not practicing acceptable methods of birth control ; or do not plan to continue practicing an acceptable method throughout the trial,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
7,NCT00926289,Exclusion,or b ) are nursing ; or c ) are pregnant ; or d ) are of childbearing potential and are not practicing acceptable methods of birth control ; or do not plan to continue practicing an acceptable method throughout the trial,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
7,NCT00926289,Exclusion,or b ) are nursing ; or c ) are pregnant ; or d ) are of childbearing potential and are not practicing acceptable methods of birth control ; or do not plan to continue practicing an acceptable method throughout the trial,Condition Occurrence,Observation,C3831118,childbearing potential,FALSE,FALSE,NA,NA,NA
7,NCT00926289,Exclusion,or b ) are nursing ; or c ) are pregnant ; or d ) are of childbearing potential and are not practicing acceptable methods of birth control ; or do not plan to continue practicing an acceptable method throughout the trial,Condition Occurrence,Other,C0025663,methods,TRUE,FALSE,NA,NA,NA
7,NCT00926289,Exclusion,or b ) are nursing ; or c ) are pregnant ; or d ) are of childbearing potential and are not practicing acceptable methods of birth control ; or do not plan to continue practicing an acceptable method throughout the trial,Condition Occurrence,Other,C0700589;C2703065,birth control,TRUE,FALSE,NA,NA,NA
7,NCT00926289,Exclusion,or b ) are nursing ; or c ) are pregnant ; or d ) are of childbearing potential and are not practicing acceptable methods of birth control ; or do not plan to continue practicing an acceptable method throughout the trial,Condition Occurrence,Other,C2827714;C0871511;C2828387,method,FALSE,FALSE,NA,NA,NA
8,NCT00926289,Exclusion,the only acceptable methods of birth control are : intra-uterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives ; estrogen patch hormonal birth control should have been in use for at least three months before the study and continue at least until the next menstrual period after completing the study .,Drug Exposure,Condition,C2129647;C0025344,menstrual period,FALSE,FALSE,NA,NA,NA
8,NCT00926289,Exclusion,the only acceptable methods of birth control are : intra-uterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives ; estrogen patch hormonal birth control should have been in use for at least three months before the study and continue at least until the next menstrual period after completing the study .,Drug Exposure,Drug,C1706306,iud,FALSE,FALSE,NA,NA,NA
8,NCT00926289,Exclusion,the only acceptable methods of birth control are : intra-uterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives ; estrogen patch hormonal birth control should have been in use for at least three months before the study and continue at least until the next menstrual period after completing the study .,Drug Exposure,Drug,C0086466;C1272936,injectable,FALSE,FALSE,NA,NA,NA
8,NCT00926289,Exclusion,the only acceptable methods of birth control are : intra-uterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives ; estrogen patch hormonal birth control should have been in use for at least three months before the study and continue at least until the next menstrual period after completing the study .,Drug Exposure,Drug,C0445403;C1707974;C1533128,patch,FALSE,FALSE,NA,NA,NA
8,NCT00926289,Exclusion,the only acceptable methods of birth control are : intra-uterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives ; estrogen patch hormonal birth control should have been in use for at least three months before the study and continue at least until the next menstrual period after completing the study .,Drug Exposure,Other,C0025663,methods,FALSE,FALSE,NA,NA,NA
8,NCT00926289,Exclusion,the only acceptable methods of birth control are : intra-uterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives ; estrogen patch hormonal birth control should have been in use for at least three months before the study and continue at least until the next menstrual period after completing the study .,Drug Exposure,Other,C0700589;C2703065,birth control,FALSE,FALSE,NA,NA,NA
8,NCT00926289,Exclusion,the only acceptable methods of birth control are : intra-uterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives ; estrogen patch hormonal birth control should have been in use for at least three months before the study and continue at least until the next menstrual period after completing the study .,Drug Exposure,Other,C0009905;C0274536;C0481121;C1548892,oral contraceptives,FALSE,FALSE,NA,NA,NA
8,NCT00926289,Exclusion,the only acceptable methods of birth control are : intra-uterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives ; estrogen patch hormonal birth control should have been in use for at least three months before the study and continue at least until the next menstrual period after completing the study .,Drug Exposure,Other,C0014939;C0202006;C2936882,estrogen,FALSE,FALSE,NA,NA,NA
8,NCT00926289,Exclusion,the only acceptable methods of birth control are : intra-uterine device ( iud ) ; oral contraceptives ; implantable contraceptives or injectable contraceptives ; estrogen patch hormonal birth control should have been in use for at least three months before the study and continue at least until the next menstrual period after completing the study .,Drug Exposure,Other,C0700589;C2703065,birth control,FALSE,FALSE,NA,NA,NA
9,NCT00926289,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 m .,Drug Exposure,Condition,C0555008,night shift workers,FALSE,FALSE,NA,NA,NA
9,NCT00926289,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 m .,Drug Exposure,Drug,C1654656,daytime,FALSE,FALSE,NA,equal 4,equal 00 m
9,NCT00926289,Exclusion,night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4 : 00 m .,Drug Exposure,Other,C0037313;C0723362,sleep,FALSE,FALSE,NA,NA,NA
10,NCT00926289,Exclusion,known or suspected secondary hypertension ( eg ; renal artery stenosis orphaeochromocytoma ),Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
10,NCT00926289,Exclusion,known or suspected secondary hypertension ( eg ; renal artery stenosis orphaeochromocytoma ),Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
11,NCT00926289,Exclusion,mean in-clinic seated cuff sbp > = 200 mmhg or dbp > = 120 mmhg,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
11,NCT00926289,Exclusion,mean in-clinic seated cuff sbp > = 200 mmhg or dbp > = 120 mmhg,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 200 mmhg; greater_equal 120 mmhg,NA
11,NCT00926289,Exclusion,mean in-clinic seated cuff sbp > = 200 mmhg or dbp > = 120 mmhg,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 120 mmhg,NA
12,NCT00926289,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance of < 30 ml / min or clinical markers of severe renal impairment .,Observation,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
12,NCT00926289,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance of < 30 ml / min or clinical markers of severe renal impairment .,Observation,Condition,C1565489;C0035078,renal impairment,FALSE,FALSE,NA,NA,NA
12,NCT00926289,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance of < 30 ml / min or clinical markers of severe renal impairment .,Observation,Observation,C1697786;C1571737,laboratory,FALSE,FALSE,NA,NA,NA
12,NCT00926289,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance of < 30 ml / min or clinical markers of severe renal impairment .,Observation,Observation,C0201976;C0600061,serum creatinine,FALSE,FALSE,NA,greater 265 umol/l,greater 3.0 mg/dl
12,NCT00926289,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance of < 30 ml / min or clinical markers of severe renal impairment .,Observation,Observation,C0373595;C0812399,creatinine clearance,FALSE,FALSE,NA,lower 30 ml/min,NA
12,NCT00926289,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance of < 30 ml / min or clinical markers of severe renal impairment .,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
12,NCT00926289,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance of < 30 ml / min or clinical markers of severe renal impairment .,Observation,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
12,NCT00926289,Exclusion,renal dysfunction as defined by the following laboratory parameters : serum creatinine > 3.0 mg / dl ( or > 265 umol / l ) or known creatinine clearance of < 30 ml / min or clinical markers of severe renal impairment .,Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
13,NCT00926289,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney,Condition Occurrence,Condition,C0856760,bilateral renal artery stenosis,FALSE,FALSE,NA,NA,NA
13,NCT00926289,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
13,NCT00926289,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
13,NCT00926289,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney,Condition Occurrence,Condition,C0478647,transplant,FALSE,FALSE,NA,NA,NA
13,NCT00926289,Exclusion,bilateral renal artery stenosis ; renal artery stenosis in a solitary kidney ; post-renal transplant patients or patients with only one kidney,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
14,NCT00926289,Exclusion,clinically relevant hypokalemia or hyperkalemia ( ie ; < 3.5 mmol / l or > 5.5 mmol / l ; may be rechecked for suspected error in result ),Observation,Condition,C0020621,hypokalemia,FALSE,FALSE,NA,lower 3.5 mmol/l; greater 5.5 mmol/l,NA
14,NCT00926289,Exclusion,clinically relevant hypokalemia or hyperkalemia ( ie ; < 3.5 mmol / l or > 5.5 mmol / l ; may be rechecked for suspected error in result ),Observation,Condition,C0020461,hyperkalemia,FALSE,FALSE,NA,lower 3.5 mmol/l; greater 5.5 mmol/l,NA
15,NCT00926289,Exclusion,uncorrected sodium or volume depletion,Drug Exposure,Condition,C0546884,volume depletion,FALSE,FALSE,NA,NA,NA
15,NCT00926289,Exclusion,uncorrected sodium or volume depletion,Drug Exposure,Other,C0037473;C0337443;C0037570;C3541959,sodium,FALSE,FALSE,NA,NA,NA
16,NCT00926289,Exclusion,primary aldosteronism .,Condition Occurrence,Condition,C1384514,primary aldosteronism,FALSE,FALSE,NA,NA,NA
17,NCT00926289,Exclusion,hereditary fructose intolerance,Condition Occurrence,Condition,C0016751,hereditary fructose intolerance,FALSE,FALSE,NA,NA,NA
18,NCT00926289,Exclusion,biliary obstructive disorders ( eg ; cholestasis ) or hepatic insufficiency,Condition Occurrence,Condition,C0008370,cholestasis,FALSE,FALSE,NA,NA,NA
18,NCT00926289,Exclusion,biliary obstructive disorders ( eg ; cholestasis ) or hepatic insufficiency,Condition Occurrence,Condition,C1306571,hepatic insufficiency,FALSE,FALSE,NA,NA,NA
19,NCT00926289,Exclusion,congestive heart failure new york heart association functional class congestive heart failure iii-iv ( refer to appendix 10,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
19,NCT00926289,Exclusion,congestive heart failure new york heart association functional class congestive heart failure iii-iv ( refer to appendix 10,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
19,NCT00926289,Exclusion,congestive heart failure new york heart association functional class congestive heart failure iii-iv ( refer to appendix 10,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
19,NCT00926289,Exclusion,congestive heart failure new york heart association functional class congestive heart failure iii-iv ( refer to appendix 10,Condition Occurrence,Other,C0456387;C0489477,class,FALSE,FALSE,NA,NA,NA
19,NCT00926289,Exclusion,congestive heart failure new york heart association functional class congestive heart failure iii-iv ( refer to appendix 10,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii,FALSE,FALSE,NA,NA,NA
20,NCT00926289,Exclusion,contra-indication to a placebo run-in period ( eg ; stroke with-in the past 6 months ; myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past 3 months prior to start of run in period ),Condition Occurrence,Condition,C0002965,unstable angina,FALSE,FALSE,lower 3 past months,NA,NA
20,NCT00926289,Exclusion,contra-indication to a placebo run-in period ( eg ; stroke with-in the past 6 months ; myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past 3 months prior to start of run in period ),Condition Occurrence,Drug,C1696465,placebo,FALSE,FALSE,equal 6 past months,NA,NA
20,NCT00926289,Exclusion,contra-indication to a placebo run-in period ( eg ; stroke with-in the past 6 months ; myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past 3 months prior to start of run in period ),Condition Occurrence,Procedure,C0010055,coronary artery bypass graft,FALSE,FALSE,lower 3 past months,NA,NA
20,NCT00926289,Exclusion,contra-indication to a placebo run-in period ( eg ; stroke with-in the past 6 months ; myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past 3 months prior to start of run in period ),Condition Occurrence,Procedure,C2936173,percutaneous transluminal coronary angioplasty,FALSE,FALSE,lower 3 past months,NA,NA
20,NCT00926289,Exclusion,contra-indication to a placebo run-in period ( eg ; stroke with-in the past 6 months ; myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past 3 months prior to start of run in period ),Condition Occurrence,Procedure,C0018821,cardiac surgery,FALSE,FALSE,lower 3 past months,NA,NA
20,NCT00926289,Exclusion,contra-indication to a placebo run-in period ( eg ; stroke with-in the past 6 months ; myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past 3 months prior to start of run in period ),Condition Occurrence,Other,C1301624;C1547316,contra-indication,FALSE,FALSE,NA,NA,NA
20,NCT00926289,Exclusion,contra-indication to a placebo run-in period ( eg ; stroke with-in the past 6 months ; myocardial infarction ; cardiac surgery ; percutaneous transluminal coronary angioplasty ; unstable angina or coronary artery bypass graft within the past 3 months prior to start of run in period ),Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,lower 3 past months,NA,NA
21,NCT00926289,Exclusion,clinically significant ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0042514;C1963247;C2108113,ventricular tachycardia,FALSE,FALSE,NA,NA,NA
21,NCT00926289,Exclusion,clinically significant ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0004239;C1963068,atrial flutter,FALSE,FALSE,NA,NA,NA
21,NCT00926289,Exclusion,clinically significant ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Condition,C0003811,cardiac arrhythmias,FALSE,FALSE,NA,NA,NA
21,NCT00926289,Exclusion,clinically significant ventricular tachycardia ; atrial fibrillation ; atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator,Condition Occurrence,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
22,NCT00926289,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0007194,hypertrophic obstructive cardiomyopathy,FALSE,FALSE,NA,NA,NA
22,NCT00926289,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C1956346;C0010068;C0010054,coronary artery disease,FALSE,FALSE,NA,NA,NA
22,NCT00926289,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0003507,aortic stenosis,FALSE,FALSE,NA,NA,NA
22,NCT00926289,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0003501;C1269005,aortic valve,FALSE,FALSE,NA,NA,NA
22,NCT00926289,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Condition,C0026264;C1269004,mitral valve,FALSE,FALSE,NA,NA,NA
22,NCT00926289,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Observation,C1261287;C0947637;C0009814,stenosis,FALSE,FALSE,NA,NA,NA
22,NCT00926289,Exclusion,hypertrophic obstructive cardiomyopathy ; severe obstructive coronary artery disease ; aortic stenosis ; hemodynamically relevant stenosis of the aortic valve or mitral valve,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
23,NCT00926289,Exclusion,patients whose diabetes has not been stable and controlled for at least the past 3 months as defined by an glycosylated hemoglobin > = 10 %,Other,Condition,C0011849;C0011847,diabetes,FALSE,FALSE,NA,NA,NA
23,NCT00926289,Exclusion,patients whose diabetes has not been stable and controlled for at least the past 3 months as defined by an glycosylated hemoglobin > = 10 %,Other,Observation,C0017853;C0373638;C0202054,glycosylated hemoglobin,FALSE,FALSE,NA,NA,greater_equal 10 %
23,NCT00926289,Exclusion,patients whose diabetes has not been stable and controlled for at least the past 3 months as defined by an glycosylated hemoglobin > = 10 %,Other,Other,C1547311,stable,TRUE,FALSE,greater_equal 3 past months,NA,NA
23,NCT00926289,Exclusion,patients whose diabetes has not been stable and controlled for at least the past 3 months as defined by an glycosylated hemoglobin > = 10 %,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
24,NCT00926289,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or angiotensin-ii receptor antagonists,Drug Exposure,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
24,NCT00926289,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or angiotensin-ii receptor antagonists,Drug Exposure,Drug,C0003015,ace inhibitors,FALSE,FALSE,NA,NA,NA
24,NCT00926289,Exclusion,patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or angiotensin-ii receptor antagonists,Drug Exposure,Other,C0373546;C0003009,angiotensin-ii,FALSE,FALSE,NA,NA,NA
25,NCT00926289,Exclusion,history of drug or alcohol dependency within 6 months prior to signing the informed consent form,Condition Occurrence,Condition,C0001973,alcohol dependency,FALSE,FALSE,lower 6 months,NA,NA
25,NCT00926289,Exclusion,history of drug or alcohol dependency within 6 months prior to signing the informed consent form,Condition Occurrence,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,lower 6 months,NA,NA
25,NCT00926289,Exclusion,history of drug or alcohol dependency within 6 months prior to signing the informed consent form,Condition Occurrence,Other,C0009797,informed consent form,FALSE,FALSE,NA,NA,NA
26,NCT00926289,Exclusion,concomitant administration of any medications known to affect blood pressure ; except medications allowed by the protocol,Observation,Procedure,C2237113,affect,FALSE,FALSE,NA,NA,NA
26,NCT00926289,Exclusion,concomitant administration of any medications known to affect blood pressure ; except medications allowed by the protocol,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,NA,NA
27,NCT00926289,Exclusion,any investigational drug therapy within 1 month of signing the informed consent,Drug Exposure,Drug,C0013230,investigational drug,FALSE,FALSE,lower 1 month,NA,NA
28,NCT00926289,Exclusion,known hypersensitivity to any component of the trial drugs ( telmisartan ; hydrochlorothiazide ; or placebo ) ; history of non-compliance or inability to comply with prescribed medications or protocol procedures ( less than 80 % or more than 120 % ; especially during run-in ),Drug Exposure,Condition,C0376405,non-compliance,FALSE,FALSE,NA,NA,NA
28,NCT00926289,Exclusion,known hypersensitivity to any component of the trial drugs ( telmisartan ; hydrochlorothiazide ; or placebo ) ; history of non-compliance or inability to comply with prescribed medications or protocol procedures ( less than 80 % or more than 120 % ; especially during run-in ),Drug Exposure,Drug,C0248719,telmisartan,FALSE,FALSE,NA,NA,NA
28,NCT00926289,Exclusion,known hypersensitivity to any component of the trial drugs ( telmisartan ; hydrochlorothiazide ; or placebo ) ; history of non-compliance or inability to comply with prescribed medications or protocol procedures ( less than 80 % or more than 120 % ; especially during run-in ),Drug Exposure,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,NA
28,NCT00926289,Exclusion,known hypersensitivity to any component of the trial drugs ( telmisartan ; hydrochlorothiazide ; or placebo ) ; history of non-compliance or inability to comply with prescribed medications or protocol procedures ( less than 80 % or more than 120 % ; especially during run-in ),Drug Exposure,Drug,C0020261,hydrochlorothiazide,FALSE,FALSE,NA,NA,NA
28,NCT00926289,Exclusion,known hypersensitivity to any component of the trial drugs ( telmisartan ; hydrochlorothiazide ; or placebo ) ; history of non-compliance or inability to comply with prescribed medications or protocol procedures ( less than 80 % or more than 120 % ; especially during run-in ),Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
28,NCT00926289,Exclusion,known hypersensitivity to any component of the trial drugs ( telmisartan ; hydrochlorothiazide ; or placebo ) ; history of non-compliance or inability to comply with prescribed medications or protocol procedures ( less than 80 % or more than 120 % ; especially during run-in ),Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
28,NCT00926289,Exclusion,known hypersensitivity to any component of the trial drugs ( telmisartan ; hydrochlorothiazide ; or placebo ) ; history of non-compliance or inability to comply with prescribed medications or protocol procedures ( less than 80 % or more than 120 % ; especially during run-in ),Drug Exposure,Observation,C3202967;C3166216,prescribed medications,FALSE,FALSE,NA,NA,lower 80 %; greater 120 %
29,NCT00926289,Exclusion,any other clinical condition which ; in the opinion of the investigator ; would not allow safe completion of the protocol and safe administration of the trial medication,Other,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
3,NCT00926289,Inclusion,patients with grade 2 or grade 3 hypertension as defined sbp > = 160 mmhg and dbp > = 100 mmhg at randomization,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
3,NCT00926289,Inclusion,patients with grade 2 or grade 3 hypertension as defined sbp > = 160 mmhg and dbp > = 100 mmhg at randomization,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 100 mmhg,NA
1,NCT00927394,Inclusion,patients who are eligible and able to participate in the study ; and who give written informed consent before any assessment is performed .,Procedure,Other,C0542573;C0549068;C0870300;C0549070;C0549071;C0549072;C0549073;C0549074;C0028708;C0549075;C0549076;C0549077;C0549078;C0549079;C0549080;C0679207,assessment,FALSE,FALSE,NA,NA,NA
3,NCT00927394,Inclusion,patients with type 2 diabetes mellitus with an hba1c < = 9 % at visit 1 and on a stable anti-diabetic regimen not including insulin or stable diet and exercise for at least 4 weeks prior to visit 1 .,Procedure,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
3,NCT00927394,Inclusion,patients with type 2 diabetes mellitus with an hba1c < = 9 % at visit 1 and on a stable anti-diabetic regimen not including insulin or stable diet and exercise for at least 4 weeks prior to visit 1 .,Procedure,Drug,C0935929,anti-diabetic,FALSE,FALSE,NA,NA,NA
3,NCT00927394,Inclusion,patients with type 2 diabetes mellitus with an hba1c < = 9 % at visit 1 and on a stable anti-diabetic regimen not including insulin or stable diet and exercise for at least 4 weeks prior to visit 1 .,Procedure,Procedure,C0040808,regimen,FALSE,FALSE,NA,NA,NA
3,NCT00927394,Inclusion,patients with type 2 diabetes mellitus with an hba1c < = 9 % at visit 1 and on a stable anti-diabetic regimen not including insulin or stable diet and exercise for at least 4 weeks prior to visit 1 .,Procedure,Procedure,C1522704,exercise,FALSE,FALSE,greater_equal 4 weeks,NA,NA
3,NCT00927394,Inclusion,patients with type 2 diabetes mellitus with an hba1c < = 9 % at visit 1 and on a stable anti-diabetic regimen not including insulin or stable diet and exercise for at least 4 weeks prior to visit 1 .,Procedure,Observation,C0202054,hba1c,FALSE,FALSE,NA,NA,lower_equal 9 %
3,NCT00927394,Inclusion,patients with type 2 diabetes mellitus with an hba1c < = 9 % at visit 1 and on a stable anti-diabetic regimen not including insulin or stable diet and exercise for at least 4 weeks prior to visit 1 .,Procedure,Observation,C0021641;C0202098;C1533581;C1145751;C1579433;C2739803,insulin,TRUE,FALSE,NA,NA,NA
3,NCT00927394,Inclusion,patients with type 2 diabetes mellitus with an hba1c < = 9 % at visit 1 and on a stable anti-diabetic regimen not including insulin or stable diet and exercise for at least 4 weeks prior to visit 1 .,Procedure,Other,C1547311,stable,FALSE,FALSE,NA,NA,NA
3,NCT00927394,Inclusion,patients with type 2 diabetes mellitus with an hba1c < = 9 % at visit 1 and on a stable anti-diabetic regimen not including insulin or stable diet and exercise for at least 4 weeks prior to visit 1 .,Procedure,Other,C1547311,stable,TRUE,FALSE,NA,NA,NA
3,NCT00927394,Inclusion,patients with type 2 diabetes mellitus with an hba1c < = 9 % at visit 1 and on a stable anti-diabetic regimen not including insulin or stable diet and exercise for at least 4 weeks prior to visit 1 .,Procedure,Other,C0012159;C1519433;C1561465;C1550559;C1549512,diet,TRUE,FALSE,greater_equal 4 weeks,NA,NA
4,NCT00927394,Inclusion,cohort 1 :,Person,Person,C0599755,cohort,FALSE,FALSE,NA,NA,NA
5,NCT00927394,Inclusion,patients with stage 2 systolic hypertension ; defined as having a mssbp > = 160 mmhg and < 200 mmhg at visit 5 ( randomization ) .,Observation,Condition,C0221155,systolic hypertension,FALSE,FALSE,NA,greater_equal 160 mmhg; lower 200 mmhg,NA
5,NCT00927394,Inclusion,patients with stage 2 systolic hypertension ; defined as having a mssbp > = 160 mmhg and < 200 mmhg at visit 5 ( randomization ) .,Observation,Other,C3539106,defined,FALSE,FALSE,NA,greater_equal 160 mmhg; lower 200 mmhg,NA
6,NCT00927394,Inclusion,patients who have been newly diagnosed with hypertension or who have not received antihypertensive medication for at least 4 weeks ( 28 days ) prior to visit 1 must have mssbp > = 160 mmhg and < 200 mmhg at visit 1 ; otherwise ; they will be considered screen failures .,Observation,Drug,C0003364,antihypertensive,TRUE,FALSE,greater_equal 4 weeks,greater_equal 160 mmhg; lower 200 mmhg,NA
2,NCT00927394,Inclusion,men or women 18 years and older .,Person,Person,C0025266,men,FALSE,FALSE,greater_equal 18 years,NA,NA
2,NCT00927394,Inclusion,men or women 18 years and older .,Person,Person,C0086287,women,FALSE,FALSE,greater_equal 18 years,NA,NA
6,NCT00927394,Inclusion,patients who have been newly diagnosed with hypertension or who have not received antihypertensive medication for at least 4 weeks ( 28 days ) prior to visit 1 must have mssbp > = 160 mmhg and < 200 mmhg at visit 1 ; otherwise ; they will be considered screen failures .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
6,NCT00927394,Inclusion,patients who have been newly diagnosed with hypertension or who have not received antihypertensive medication for at least 4 weeks ( 28 days ) prior to visit 1 must have mssbp > = 160 mmhg and < 200 mmhg at visit 1 ; otherwise ; they will be considered screen failures .,Observation,Observation,C0430054;C0199230,screen,FALSE,FALSE,NA,NA,NA
7,NCT00927394,Inclusion,patients receiving antihypertensive medication must have a mssbp of > = 150 mmhg and < 200 mmhg at study visit 1 ; otherwise they will be considered screen failures .,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,greater_equal 150 mmhg; lower 200 mmhg,NA
7,NCT00927394,Inclusion,patients receiving antihypertensive medication must have a mssbp of > = 150 mmhg and < 200 mmhg at study visit 1 ; otherwise they will be considered screen failures .,Observation,Observation,C0430054;C0199230,screen,FALSE,FALSE,NA,NA,NA
8,NCT00927394,Inclusion,cohort 2 :,Person,Person,C0599755,cohort,FALSE,FALSE,NA,NA,NA
9,NCT00927394,Inclusion,patients must also have had a mean 8 - hour daytime ambulatory systolic blood pressure ( asbp ) > = 140 mmhg and mean 8 - hour daytime ambulatory diastolic blood pressure ( adbp ) > = 90 mmhg at visit 5 ( randomization ) .,Observation,Drug,C1654656,daytime,FALSE,FALSE,equal 8 hour,NA,NA
9,NCT00927394,Inclusion,patients must also have had a mean 8 - hour daytime ambulatory systolic blood pressure ( asbp ) > = 140 mmhg and mean 8 - hour daytime ambulatory diastolic blood pressure ( adbp ) > = 90 mmhg at visit 5 ( randomization ) .,Observation,Drug,C1654656,daytime,FALSE,FALSE,equal 8 hour,NA,NA
9,NCT00927394,Inclusion,patients must also have had a mean 8 - hour daytime ambulatory systolic blood pressure ( asbp ) > = 140 mmhg and mean 8 - hour daytime ambulatory diastolic blood pressure ( adbp ) > = 90 mmhg at visit 5 ( randomization ) .,Observation,Drug,C0168370,adbp,FALSE,FALSE,NA,greater_equal 90 mmhg,NA
9,NCT00927394,Inclusion,patients must also have had a mean 8 - hour daytime ambulatory systolic blood pressure ( asbp ) > = 140 mmhg and mean 8 - hour daytime ambulatory diastolic blood pressure ( adbp ) > = 90 mmhg at visit 5 ( randomization ) .,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater_equal 140 mmhg,NA
9,NCT00927394,Inclusion,patients must also have had a mean 8 - hour daytime ambulatory systolic blood pressure ( asbp ) > = 140 mmhg and mean 8 - hour daytime ambulatory diastolic blood pressure ( adbp ) > = 90 mmhg at visit 5 ( randomization ) .,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,NA,NA
9,NCT00927394,Inclusion,patients must also have had a mean 8 - hour daytime ambulatory systolic blood pressure ( asbp ) > = 140 mmhg and mean 8 - hour daytime ambulatory diastolic blood pressure ( adbp ) > = 90 mmhg at visit 5 ( randomization ) .,Observation,Other,C1561560;C1547135,ambulatory,FALSE,FALSE,NA,NA,NA
9,NCT00927394,Inclusion,patients must also have had a mean 8 - hour daytime ambulatory systolic blood pressure ( asbp ) > = 140 mmhg and mean 8 - hour daytime ambulatory diastolic blood pressure ( adbp ) > = 90 mmhg at visit 5 ( randomization ) .,Observation,Other,C1561560;C1547135,ambulatory,FALSE,FALSE,NA,NA,NA
10,NCT00927394,Inclusion,hypertensive patients with mssbp > = 150 mmhg and but < 200 mmhg and msdbp > = 95 but < 120 mmhg at visit 5 ( randomization ) .,Observation,Condition,C0857121,hypertensive,FALSE,FALSE,NA,greater_equal 150 mmhg; lower 200 mmhg; greater_equal 95 ; lower 120 mmhg,NA
11,NCT00927394,Inclusion,patients who had been newly diagnosed with hypertension or who had not received antihypertensive medication for at least 4 weeks ( 28 days ) prior to visit 1 must have had mssbp > = 150 mmhg but < 200 mmhg and msdbp > = 95 but < 120 mmhg at visit 1 ; otherwise ; they were considered screen failures .,Observation,Drug,C0003364,antihypertensive,TRUE,FALSE,greater_equal 4 weeks,greater_equal 150 mmhg; lower 200 mmhg; greater_equal 95 ; lower 120 mmhg,NA
11,NCT00927394,Inclusion,patients who had been newly diagnosed with hypertension or who had not received antihypertensive medication for at least 4 weeks ( 28 days ) prior to visit 1 must have had mssbp > = 150 mmhg but < 200 mmhg and msdbp > = 95 but < 120 mmhg at visit 1 ; otherwise ; they were considered screen failures .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
11,NCT00927394,Inclusion,patients who had been newly diagnosed with hypertension or who had not received antihypertensive medication for at least 4 weeks ( 28 days ) prior to visit 1 must have had mssbp > = 150 mmhg but < 200 mmhg and msdbp > = 95 but < 120 mmhg at visit 1 ; otherwise ; they were considered screen failures .,Observation,Observation,C0430054;C0199230,screen,FALSE,FALSE,NA,NA,NA
12,NCT00927394,Exclusion,office blood pressure measured by cuff ( mssbp > = 200 mmhg or msdbp > = 120 mmhg ) .,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,greater_equal 200 mmhg; greater_equal 120 mmhg,NA
12,NCT00927394,Exclusion,office blood pressure measured by cuff ( mssbp > = 200 mmhg or msdbp > = 120 mmhg ) .,Observation,Procedure,C2224281;C1314130,blood pressure measured,FALSE,FALSE,NA,NA,NA
13,NCT00927394,Exclusion,history or evidence of secondary hypertension of any etiology .,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
14,NCT00927394,Exclusion,refractory hypertension ; defined as having uncontrolled bp ( > = 140 / 90 mmhg ) while receiving 3 antihypertensive medications at the maximum approved dose of each drug ; one of which must be a diuretic .,Observation,Condition,C0860493,refractory hypertension,FALSE,FALSE,NA,NA,NA
14,NCT00927394,Exclusion,refractory hypertension ; defined as having uncontrolled bp ( > = 140 / 90 mmhg ) while receiving 3 antihypertensive medications at the maximum approved dose of each drug ; one of which must be a diuretic .,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,equal 3,NA
14,NCT00927394,Exclusion,refractory hypertension ; defined as having uncontrolled bp ( > = 140 / 90 mmhg ) while receiving 3 antihypertensive medications at the maximum approved dose of each drug ; one of which must be a diuretic .,Observation,Drug,C0012798,diuretic,FALSE,FALSE,NA,NA,NA
14,NCT00927394,Exclusion,refractory hypertension ; defined as having uncontrolled bp ( > = 140 / 90 mmhg ) while receiving 3 antihypertensive medications at the maximum approved dose of each drug ; one of which must be a diuretic .,Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,greater_equal 140 mmhg; greater_equal 90 mmhg,NA
14,NCT00927394,Exclusion,refractory hypertension ; defined as having uncontrolled bp ( > = 140 / 90 mmhg ) while receiving 3 antihypertensive medications at the maximum approved dose of each drug ; one of which must be a diuretic .,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
14,NCT00927394,Exclusion,refractory hypertension ; defined as having uncontrolled bp ( > = 140 / 90 mmhg ) while receiving 3 antihypertensive medications at the maximum approved dose of each drug ; one of which must be a diuretic .,Observation,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
15,NCT00927394,Exclusion,patients treated with more than 3 antihypertensive medications ( each component of a combination drug counts individually ) .,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,greater 3,NA
15,NCT00927394,Exclusion,patients treated with more than 3 antihypertensive medications ( each component of a combination drug counts individually ) .,Drug Exposure,Drug,C0013162,combination drug,FALSE,FALSE,NA,NA,NA
16,NCT00927394,Exclusion,type 2 diabetes mellitus currently requiring insulin treatment .,Condition Occurrence,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
16,NCT00927394,Exclusion,type 2 diabetes mellitus currently requiring insulin treatment .,Condition Occurrence,Procedure,C0745343,insulin treatment,FALSE,FALSE,NA,NA,NA
17,NCT00927394,Exclusion,modification of diet in renal disease ( mdrd ) estimated glomerular filtration rate ( egfr ) < 60 ml / min / 1.73 m2,Observation,Condition,C0022658,renal disease,FALSE,FALSE,NA,NA,NA
17,NCT00927394,Exclusion,modification of diet in renal disease ( mdrd ) estimated glomerular filtration rate ( egfr ) < 60 ml / min / 1.73 m2,Observation,Observation,C0034802;C1150617,egfr,FALSE,FALSE,NA,lower 60 ml/min; equal 1.73 m2,NA
17,NCT00927394,Exclusion,modification of diet in renal disease ( mdrd ) estimated glomerular filtration rate ( egfr ) < 60 ml / min / 1.73 m2,Observation,Other,C0012159;C1519433;C1561465;C1550559;C1549512,diet,FALSE,FALSE,NA,NA,NA
17,NCT00927394,Exclusion,modification of diet in renal disease ( mdrd ) estimated glomerular filtration rate ( egfr ) < 60 ml / min / 1.73 m2,Observation,Other,C0017654;C1561549,glomerular filtration rate,FALSE,FALSE,NA,NA,NA
18,NCT00927394,Exclusion,serum sodium less than lower limit of normal potassium ; serum potassium < 3.5 meq / l or > = 5.3 meq / l at visit 1 .,Observation,Condition,C0860869,normal potassium,FALSE,FALSE,NA,lower 3.5 ; greater_equal 5.3,NA
18,NCT00927394,Exclusion,serum sodium less than lower limit of normal potassium ; serum potassium < 3.5 meq / l or > = 5.3 meq / l at visit 1 .,Observation,Observation,C0523891;C0587356,serum sodium,FALSE,FALSE,NA,NA,NA
18,NCT00927394,Exclusion,serum sodium less than lower limit of normal potassium ; serum potassium < 3.5 meq / l or > = 5.3 meq / l at visit 1 .,Observation,Observation,C1548802,lower,FALSE,FALSE,NA,NA,NA
18,NCT00927394,Exclusion,serum sodium less than lower limit of normal potassium ; serum potassium < 3.5 meq / l or > = 5.3 meq / l at visit 1 .,Observation,Observation,C0302353;C0543465,serum potassium,FALSE,FALSE,NA,lower 3.5 ; greater_equal 5.3,NA
19,NCT00927394,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy .,Condition Occurrence,Condition,C0152132,hypertensive retinopathy,FALSE,FALSE,NA,NA,NA
19,NCT00927394,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy .,Condition Occurrence,Other,C0439070;C2337640;C3496532,iii,FALSE,FALSE,NA,NA,NA
19,NCT00927394,Exclusion,known keith-wagener grade iii or grade iv hypertensive retinopathy .,Condition Occurrence,Other,C0677510;C0021440;C3496001,iv,FALSE,FALSE,NA,NA,NA
20,NCT00927394,Exclusion,cohort 1 :,Person,Person,C0599755,cohort,FALSE,FALSE,NA,NA,NA
21,NCT00927394,Exclusion,patients with known diabetic retinopathy ( eg ; having a history of laser therapy for diabetic retinopathy ) or diabetic neuropathy ( eg ; receiving medication for diabetic neuropathy ) .,Condition Occurrence,Condition,C0011884,diabetic retinopathy,FALSE,FALSE,NA,NA,NA
21,NCT00927394,Exclusion,patients with known diabetic retinopathy ( eg ; having a history of laser therapy for diabetic retinopathy ) or diabetic neuropathy ( eg ; receiving medication for diabetic neuropathy ) .,Condition Occurrence,Condition,C0011884,diabetic retinopathy,FALSE,FALSE,NA,NA,NA
21,NCT00927394,Exclusion,patients with known diabetic retinopathy ( eg ; having a history of laser therapy for diabetic retinopathy ) or diabetic neuropathy ( eg ; receiving medication for diabetic neuropathy ) .,Condition Occurrence,Condition,C0011882,diabetic neuropathy,FALSE,FALSE,NA,NA,NA
21,NCT00927394,Exclusion,patients with known diabetic retinopathy ( eg ; having a history of laser therapy for diabetic retinopathy ) or diabetic neuropathy ( eg ; receiving medication for diabetic neuropathy ) .,Condition Occurrence,Condition,C0011882,diabetic neuropathy,FALSE,FALSE,NA,NA,NA
21,NCT00927394,Exclusion,patients with known diabetic retinopathy ( eg ; having a history of laser therapy for diabetic retinopathy ) or diabetic neuropathy ( eg ; receiving medication for diabetic neuropathy ) .,Condition Occurrence,Procedure,C1955835;C0279027,laser therapy,FALSE,FALSE,NA,NA,NA
22,NCT00927394,Exclusion,cohort 2 :,Person,Person,C0599755,cohort,FALSE,FALSE,NA,NA,NA
23,NCT00927394,Exclusion,patients with known diabetic retinopathy or diabetic neuropathy or having a history of treatment for either .,Condition Occurrence,Condition,C0011884,diabetic retinopathy,FALSE,FALSE,NA,NA,NA
23,NCT00927394,Exclusion,patients with known diabetic retinopathy or diabetic neuropathy or having a history of treatment for either .,Condition Occurrence,Condition,C0011882,diabetic neuropathy,FALSE,FALSE,NA,NA,NA
24,NCT00927394,Exclusion,other protocol-defined inclusiopplied,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00931710,Inclusion,male or female outpatient of 18 years of age or greater,Person,Person,C0025266;C1706429,male,FALSE,FALSE,equal 18 years,NA,NA
1,NCT00931710,Inclusion,male or female outpatient of 18 years of age or greater,Person,Person,C0086287,female,FALSE,FALSE,equal 18 years,NA,NA
2,NCT00931710,Inclusion,stage 2 systolic hypertension defined as office mean sitting systolic blood pressure ( mssbp ) greater than or equal to 160 and < 200 mmhg at randomization,Observation,Condition,C0221155,systolic hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00931710,Inclusion,stage 2 systolic hypertension defined as office mean sitting systolic blood pressure ( mssbp ) greater than or equal to 160 and < 200 mmhg at randomization,Observation,Condition,C1319893,sitting systolic blood pressure,FALSE,FALSE,NA,greater_equal 160 mmhg; lower 200 mmhg,NA
2,NCT00931710,Inclusion,stage 2 systolic hypertension defined as office mean sitting systolic blood pressure ( mssbp ) greater than or equal to 160 and < 200 mmhg at randomization,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
3,NCT00931710,Inclusion,patients who were able to participate in the study ; and who gave written informed consent before any study assessment was performed .,Observation,Other,C0542573;C0549068;C0870300;C0549070;C0549071;C0549072;C0549073;C0549074;C0028708;C0549075;C0549076;C0549077;C0549078;C0549079;C0549080;C0679207,assessment,FALSE,FALSE,NA,NA,NA
4,NCT00931710,Exclusion,office systolic blood pressure > 200 or mean sitting diastolic blood pressure ( msdbp ) greater than or equal to 110 mmhg at visit 1 .,Observation,Condition,C1319894,sitting diastolic blood pressure,FALSE,FALSE,NA,greater_equal 110 mmhg,NA
4,NCT00931710,Exclusion,office systolic blood pressure > 200 or mean sitting diastolic blood pressure ( msdbp ) greater than or equal to 110 mmhg at visit 1 .,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,greater 200,NA
5,NCT00931710,Exclusion,use of four 4 or more antihypertensive medications within 30 days of visit 1 .,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,lower 30 days,greater_equal 4,NA
6,NCT00931710,Exclusion,refractory hypertension ; defined as blood pressure > 140 / 90 mmhg while taking three 3 drugs at the maximum dose of each drug ; one of which must be a diuretic,Observation,Condition,C0860493,refractory hypertension,FALSE,FALSE,NA,NA,NA
6,NCT00931710,Exclusion,refractory hypertension ; defined as blood pressure > 140 / 90 mmhg while taking three 3 drugs at the maximum dose of each drug ; one of which must be a diuretic,Observation,Drug,C0012798,diuretic,FALSE,FALSE,NA,NA,NA
6,NCT00931710,Exclusion,refractory hypertension ; defined as blood pressure > 140 / 90 mmhg while taking three 3 drugs at the maximum dose of each drug ; one of which must be a diuretic,Observation,Procedure,C3687832,drugs,FALSE,FALSE,NA,equal 3,NA
6,NCT00931710,Exclusion,refractory hypertension ; defined as blood pressure > 140 / 90 mmhg while taking three 3 drugs at the maximum dose of each drug ; one of which must be a diuretic,Observation,Observation,C0005823;C0005824;C1272641;C1271104,blood pressure,FALSE,FALSE,NA,greater 140 mmhg; greater 90 mmhg,NA
6,NCT00931710,Exclusion,refractory hypertension ; defined as blood pressure > 140 / 90 mmhg while taking three 3 drugs at the maximum dose of each drug ; one of which must be a diuretic,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
6,NCT00931710,Exclusion,refractory hypertension ; defined as blood pressure > 140 / 90 mmhg while taking three 3 drugs at the maximum dose of each drug ; one of which must be a diuretic,Observation,Other,C0013227;C1254351;C0740721,drug,FALSE,FALSE,NA,NA,NA
7,NCT00931710,Exclusion,( therapy with a fixed-dose combination of two active medications represents two drugs ) .,Drug Exposure,Condition,C2827483,fixed,FALSE,FALSE,NA,NA,NA
7,NCT00931710,Exclusion,( therapy with a fixed-dose combination of two active medications represents two drugs ) .,Drug Exposure,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
7,NCT00931710,Exclusion,( therapy with a fixed-dose combination of two active medications represents two drugs ) .,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
8,NCT00931710,Exclusion,inability to safely discontinue all antihypertensive medications for 1 - 2 weeks prior to randomization .,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,greater_equal 1 weeks; lower_equal 2 weeks,NA,NA
8,NCT00931710,Exclusion,inability to safely discontinue all antihypertensive medications for 1 - 2 weeks prior to randomization .,Drug Exposure,Other,C1706472,discontinue,FALSE,FALSE,NA,NA,NA
9,NCT00931710,Exclusion,other protocol-defined inclusion / may apply,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT00942994,Inclusion,patients who are newly diagnosed or have a history of hypertension ; who are eligible and able to participate in the study ; and who give written informed consent before any assessment is performed .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
1,NCT00942994,Inclusion,patients who are newly diagnosed or have a history of hypertension ; who are eligible and able to participate in the study ; and who give written informed consent before any assessment is performed .,Observation,Other,C0542573;C0549068;C0870300;C0549070;C0549071;C0549072;C0549073;C0549074;C0028708;C0549075;C0549076;C0549077;C0549078;C0549079;C0549080;C0679207,assessment,FALSE,FALSE,NA,NA,NA
2,NCT00942994,Inclusion,men or women 18 years and older of minority background,Person,Person,C0025266,men,FALSE,FALSE,greater_equal 18 years,NA,NA
2,NCT00942994,Inclusion,men or women 18 years and older of minority background,Person,Person,C0086287,women,FALSE,FALSE,greater_equal 18 years,NA,NA
2,NCT00942994,Inclusion,men or women 18 years and older of minority background,Person,Person,C0026192,minority,FALSE,FALSE,NA,NA,NA
3,NCT00942994,Inclusion,self-identified .,Condition Occurrence,Condition,C1550043,identified,FALSE,FALSE,NA,NA,NA
4,NCT00942994,Inclusion,patients with stage 2 hypertension defined as mssbp > = 160 mmhg and < 200 mmhg at visit 5 ( randomization ) .,Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
4,NCT00942994,Inclusion,patients with stage 2 hypertension defined as mssbp > = 160 mmhg and < 200 mmhg at visit 5 ( randomization ) .,Observation,Other,C3539106,defined,FALSE,FALSE,NA,greater_equal 160 mmhg; lower 200 mmhg,NA
5,NCT00942994,Exclusion,patients with msdbp > = 110 mmhg or mssbp > = 200 mmhg as measured by office cuff at any visit .,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
5,NCT00942994,Exclusion,patients with msdbp > = 110 mmhg or mssbp > = 200 mmhg as measured by office cuff at any visit .,Observation,Observation,C3541902,measured,FALSE,FALSE,NA,greater_equal 110 mmhg; greater_equal 200 mmhg,NA
6,NCT00942994,Exclusion,patients on 4 or more antihypertensive medications .,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,greater_equal 4,NA
7,NCT00942994,Exclusion,patients with uncontrolled hypertension ( mssbp > 180 mmhg ) taking more than 1 antihypertensive medication at visit,Observation,Condition,C1868885,uncontrolled hypertension,FALSE,FALSE,NA,greater 180 mmhg,NA
7,NCT00942994,Exclusion,patients with uncontrolled hypertension ( mssbp > 180 mmhg ) taking more than 1 antihypertensive medication at visit,Observation,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,greater 1,NA
1,NCT00949884,Inclusion,males or females aged > 18 years who are not institutionalized and have signed informed consent .,Person,Person,C0025266,males,FALSE,FALSE,NA,NA,NA
1,NCT00949884,Inclusion,males or females aged > 18 years who are not institutionalized and have signed informed consent .,Person,Person,C0086287,females,FALSE,FALSE,NA,NA,NA
1,NCT00949884,Inclusion,males or females aged > 18 years who are not institutionalized and have signed informed consent .,Person,Person,C0001792,aged,FALSE,FALSE,greater 18 years,NA,NA
1,NCT00949884,Inclusion,males or females aged > 18 years who are not institutionalized and have signed informed consent .,Person,Condition,C0562359,institutionalized,TRUE,FALSE,NA,NA,NA
1,NCT00949884,Inclusion,males or females aged > 18 years who are not institutionalized and have signed informed consent .,Person,Other,C1519316,signed,TRUE,FALSE,NA,NA,NA
2,NCT00949884,Inclusion,mean cuff seated diastolic blood pressure ( bp ) must be > 95 mmhg and < 115 mmhg and a mean cuff seated systolic bp must be < 180 mmhg when measured at two consecutive qualification study visits during the placebo run-in phase .,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
2,NCT00949884,Inclusion,mean cuff seated diastolic blood pressure ( bp ) must be > 95 mmhg and < 115 mmhg and a mean cuff seated systolic bp must be < 180 mmhg when measured at two consecutive qualification study visits during the placebo run-in phase .,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
2,NCT00949884,Inclusion,mean cuff seated diastolic blood pressure ( bp ) must be > 95 mmhg and < 115 mmhg and a mean cuff seated systolic bp must be < 180 mmhg when measured at two consecutive qualification study visits during the placebo run-in phase .,Observation,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,NA
2,NCT00949884,Inclusion,mean cuff seated diastolic blood pressure ( bp ) must be > 95 mmhg and < 115 mmhg and a mean cuff seated systolic bp must be < 180 mmhg when measured at two consecutive qualification study visits during the placebo run-in phase .,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,NA,NA
2,NCT00949884,Inclusion,mean cuff seated diastolic blood pressure ( bp ) must be > 95 mmhg and < 115 mmhg and a mean cuff seated systolic bp must be < 180 mmhg when measured at two consecutive qualification study visits during the placebo run-in phase .,Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,greater 95 mmhg; lower 115 mmhg,NA
2,NCT00949884,Inclusion,mean cuff seated diastolic blood pressure ( bp ) must be > 95 mmhg and < 115 mmhg and a mean cuff seated systolic bp must be < 180 mmhg when measured at two consecutive qualification study visits during the placebo run-in phase .,Observation,Observation,C0871470,systolic bp,FALSE,FALSE,NA,lower 180 mmhg,NA
2,NCT00949884,Inclusion,mean cuff seated diastolic blood pressure ( bp ) must be > 95 mmhg and < 115 mmhg and a mean cuff seated systolic bp must be < 180 mmhg when measured at two consecutive qualification study visits during the placebo run-in phase .,Observation,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
3,NCT00949884,Inclusion,the difference in mean cuff seated diastolic bp must be < 7 mmhg between two consecutive qualification study visits during the placebo run-in phase .,Observation,Condition,C3668885;C1550244,cuff,FALSE,FALSE,NA,NA,NA
3,NCT00949884,Inclusion,the difference in mean cuff seated diastolic bp must be < 7 mmhg between two consecutive qualification study visits during the placebo run-in phase .,Observation,Drug,C1696465,placebo,FALSE,FALSE,NA,NA,NA
3,NCT00949884,Inclusion,the difference in mean cuff seated diastolic bp must be < 7 mmhg between two consecutive qualification study visits during the placebo run-in phase .,Observation,Observation,C0428883,diastolic bp,FALSE,FALSE,NA,lower 7 mmhg,NA
4,NCT00949884,Exclusion,subjects with type 2 diabetes mellitus with an hba1c > = 9.5 % at screening .,Condition Occurrence,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
4,NCT00949884,Exclusion,subjects with type 2 diabetes mellitus with an hba1c > = 9.5 % at screening .,Condition Occurrence,Observation,C0202054,hba1c,FALSE,FALSE,NA,NA,greater_equal 9.5 %
5,NCT00949884,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of olmesartan medoxomil and losartan potassium ; including cardiovascular ; renal ( including the absence of one kidney ) ; pulmonary ; hepatic ; gastrointestinal ( including clinically significant malabsorption ) ; endocrine / metabolic ( with the exception of non-insulin ; dependent type 2 diabetes mellitus with hba1c < 9.55 % at screening ) ; hematologic / oncologic ( including an active malignancy other than basal cell carcinoma ) ; neurologic and psychiatric diseases .,Condition Occurrence,Condition,C0205054,hepatic,FALSE,FALSE,NA,NA,NA
5,NCT00949884,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of olmesartan medoxomil and losartan potassium ; including cardiovascular ; renal ( including the absence of one kidney ) ; pulmonary ; hepatic ; gastrointestinal ( including clinically significant malabsorption ) ; endocrine / metabolic ( with the exception of non-insulin ; dependent type 2 diabetes mellitus with hba1c < 9.55 % at screening ) ; hematologic / oncologic ( including an active malignancy other than basal cell carcinoma ) ; neurologic and psychiatric diseases .,Condition Occurrence,Condition,C1559265,gastrointestinal,FALSE,FALSE,NA,NA,NA
5,NCT00949884,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of olmesartan medoxomil and losartan potassium ; including cardiovascular ; renal ( including the absence of one kidney ) ; pulmonary ; hepatic ; gastrointestinal ( including clinically significant malabsorption ) ; endocrine / metabolic ( with the exception of non-insulin ; dependent type 2 diabetes mellitus with hba1c < 9.55 % at screening ) ; hematologic / oncologic ( including an active malignancy other than basal cell carcinoma ) ; neurologic and psychiatric diseases .,Condition Occurrence,Condition,C0011860,type 2 diabetes,FALSE,FALSE,NA,NA,NA
5,NCT00949884,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of olmesartan medoxomil and losartan potassium ; including cardiovascular ; renal ( including the absence of one kidney ) ; pulmonary ; hepatic ; gastrointestinal ( including clinically significant malabsorption ) ; endocrine / metabolic ( with the exception of non-insulin ; dependent type 2 diabetes mellitus with hba1c < 9.55 % at screening ) ; hematologic / oncologic ( including an active malignancy other than basal cell carcinoma ) ; neurologic and psychiatric diseases .,Condition Occurrence,Condition,C0006826;C1306459,malignancy,FALSE,FALSE,NA,NA,NA
5,NCT00949884,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of olmesartan medoxomil and losartan potassium ; including cardiovascular ; renal ( including the absence of one kidney ) ; pulmonary ; hepatic ; gastrointestinal ( including clinically significant malabsorption ) ; endocrine / metabolic ( with the exception of non-insulin ; dependent type 2 diabetes mellitus with hba1c < 9.55 % at screening ) ; hematologic / oncologic ( including an active malignancy other than basal cell carcinoma ) ; neurologic and psychiatric diseases .,Condition Occurrence,Drug,C0386393,olmesartan medoxomil,FALSE,FALSE,NA,NA,NA
5,NCT00949884,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of olmesartan medoxomil and losartan potassium ; including cardiovascular ; renal ( including the absence of one kidney ) ; pulmonary ; hepatic ; gastrointestinal ( including clinically significant malabsorption ) ; endocrine / metabolic ( with the exception of non-insulin ; dependent type 2 diabetes mellitus with hba1c < 9.55 % at screening ) ; hematologic / oncologic ( including an active malignancy other than basal cell carcinoma ) ; neurologic and psychiatric diseases .,Condition Occurrence,Drug,C0700492,losartan potassium,FALSE,FALSE,NA,NA,NA
5,NCT00949884,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of olmesartan medoxomil and losartan potassium ; including cardiovascular ; renal ( including the absence of one kidney ) ; pulmonary ; hepatic ; gastrointestinal ( including clinically significant malabsorption ) ; endocrine / metabolic ( with the exception of non-insulin ; dependent type 2 diabetes mellitus with hba1c < 9.55 % at screening ) ; hematologic / oncologic ( including an active malignancy other than basal cell carcinoma ) ; neurologic and psychiatric diseases .,Condition Occurrence,Drug,C0718247,active,FALSE,FALSE,NA,NA,NA
5,NCT00949884,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of olmesartan medoxomil and losartan potassium ; including cardiovascular ; renal ( including the absence of one kidney ) ; pulmonary ; hepatic ; gastrointestinal ( including clinically significant malabsorption ) ; endocrine / metabolic ( with the exception of non-insulin ; dependent type 2 diabetes mellitus with hba1c < 9.55 % at screening ) ; hematologic / oncologic ( including an active malignancy other than basal cell carcinoma ) ; neurologic and psychiatric diseases .,Condition Occurrence,Observation,C0021641;C0202098;C1533581;C1145751;C1579433;C2739803,insulin,FALSE,FALSE,NA,NA,NA
5,NCT00949884,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of olmesartan medoxomil and losartan potassium ; including cardiovascular ; renal ( including the absence of one kidney ) ; pulmonary ; hepatic ; gastrointestinal ( including clinically significant malabsorption ) ; endocrine / metabolic ( with the exception of non-insulin ; dependent type 2 diabetes mellitus with hba1c < 9.55 % at screening ) ; hematologic / oncologic ( including an active malignancy other than basal cell carcinoma ) ; neurologic and psychiatric diseases .,Condition Occurrence,Observation,C0202054,hba1c,FALSE,FALSE,NA,NA,lower 9.55 %
5,NCT00949884,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of olmesartan medoxomil and losartan potassium ; including cardiovascular ; renal ( including the absence of one kidney ) ; pulmonary ; hepatic ; gastrointestinal ( including clinically significant malabsorption ) ; endocrine / metabolic ( with the exception of non-insulin ; dependent type 2 diabetes mellitus with hba1c < 9.55 % at screening ) ; hematologic / oncologic ( including an active malignancy other than basal cell carcinoma ) ; neurologic and psychiatric diseases .,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,TRUE,FALSE,NA,NA,NA
5,NCT00949884,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of olmesartan medoxomil and losartan potassium ; including cardiovascular ; renal ( including the absence of one kidney ) ; pulmonary ; hepatic ; gastrointestinal ( including clinically significant malabsorption ) ; endocrine / metabolic ( with the exception of non-insulin ; dependent type 2 diabetes mellitus with hba1c < 9.55 % at screening ) ; hematologic / oncologic ( including an active malignancy other than basal cell carcinoma ) ; neurologic and psychiatric diseases .,Condition Occurrence,Other,C1524026;C2707259,metabolic,FALSE,FALSE,NA,NA,NA
5,NCT00949884,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of olmesartan medoxomil and losartan potassium ; including cardiovascular ; renal ( including the absence of one kidney ) ; pulmonary ; hepatic ; gastrointestinal ( including clinically significant malabsorption ) ; endocrine / metabolic ( with the exception of non-insulin ; dependent type 2 diabetes mellitus with hba1c < 9.55 % at screening ) ; hematologic / oncologic ( including an active malignancy other than basal cell carcinoma ) ; neurologic and psychiatric diseases .,Condition Occurrence,Other,C0007117;C3540686;C1547219,basal cell carcinoma,TRUE,FALSE,NA,NA,NA
5,NCT00949884,Exclusion,subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of olmesartan medoxomil and losartan potassium ; including cardiovascular ; renal ( including the absence of one kidney ) ; pulmonary ; hepatic ; gastrointestinal ( including clinically significant malabsorption ) ; endocrine / metabolic ( with the exception of non-insulin ; dependent type 2 diabetes mellitus with hba1c < 9.55 % at screening ) ; hematologic / oncologic ( including an active malignancy other than basal cell carcinoma ) ; neurologic and psychiatric diseases .,Condition Occurrence,Other,C1548428;C1561580,psychiatric,TRUE,FALSE,NA,NA,NA
6,NCT00949884,Exclusion,subjects with a history of myocardial infarction ; angina ; coronary angioplasty ; bypass surgery or heart failure within the last 12 months .,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,lower 12 last months,NA,NA
6,NCT00949884,Exclusion,subjects with a history of myocardial infarction ; angina ; coronary angioplasty ; bypass surgery or heart failure within the last 12 months .,Condition Occurrence,Procedure,C1536078,bypass surgery,FALSE,FALSE,lower 12 last months,NA,NA
6,NCT00949884,Exclusion,subjects with a history of myocardial infarction ; angina ; coronary angioplasty ; bypass surgery or heart failure within the last 12 months .,Condition Occurrence,Procedure,C0190211;C0002997,coronary angioplasty,FALSE,FALSE,lower 12 last months,NA,NA
6,NCT00949884,Exclusion,subjects with a history of myocardial infarction ; angina ; coronary angioplasty ; bypass surgery or heart failure within the last 12 months .,Condition Occurrence,Other,C0027051;C2926063;C0428953,myocardial infarction,FALSE,FALSE,lower 12 last months,NA,NA
6,NCT00949884,Exclusion,subjects with a history of myocardial infarction ; angina ; coronary angioplasty ; bypass surgery or heart failure within the last 12 months .,Condition Occurrence,Other,C0002962;C2024883;C2926611,angina,FALSE,FALSE,lower 12 last months,NA,NA
7,NCT00949884,Exclusion,subjects with any history of new york heart association class iii or class iv congestive heart failure ( chf ),Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
7,NCT00949884,Exclusion,subjects with any history of new york heart association class iii or class iv congestive heart failure ( chf ),Condition Occurrence,Condition,C0018802,congestive heart failure chf,FALSE,FALSE,NA,NA,NA
7,NCT00949884,Exclusion,subjects with any history of new york heart association class iii or class iv congestive heart failure ( chf ),Condition Occurrence,Other,C0441887;C2698969,class iii,FALSE,FALSE,NA,NA,NA
7,NCT00949884,Exclusion,subjects with any history of new york heart association class iii or class iv congestive heart failure ( chf ),Condition Occurrence,Other,C0441888;C2698970,class iv,FALSE,FALSE,NA,NA,NA
8,NCT00949884,Exclusion,a history of new york heart association class i or class ii chf may be exclusionary at the discretion of the investigator .,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
8,NCT00949884,Exclusion,a history of new york heart association class i or class ii chf may be exclusionary at the discretion of the investigator .,Condition Occurrence,Condition,C2698967,class i,FALSE,FALSE,NA,NA,NA
8,NCT00949884,Exclusion,a history of new york heart association class i or class ii chf may be exclusionary at the discretion of the investigator .,Condition Occurrence,Condition,C0018802,chf,FALSE,FALSE,NA,NA,NA
8,NCT00949884,Exclusion,a history of new york heart association class i or class ii chf may be exclusionary at the discretion of the investigator .,Condition Occurrence,Other,C0441886;C2698968,class ii,FALSE,FALSE,NA,NA,NA
9,NCT00949884,Exclusion,subjects with a history of cerebrovascular accident or transient ischemic attack within the last 1 year .,Condition Occurrence,Condition,C0038454,cerebrovascular accident,FALSE,FALSE,lower 1 last year,NA,NA
9,NCT00949884,Exclusion,subjects with a history of cerebrovascular accident or transient ischemic attack within the last 1 year .,Condition Occurrence,Condition,C0007787,transient ischemic attack,FALSE,FALSE,lower 1 last year,NA,NA
10,NCT00949884,Exclusion,subjects with clinically significant cardiac conduction defects ; including second degree or third degree atrioventricular ( av ) block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation ; atrial flutter ; an accessory bypass tract ; or any arrhythmia requiring medication,Condition Occurrence,Condition,C0264886,cardiac conduction defects,FALSE,FALSE,NA,NA,NA
10,NCT00949884,Exclusion,subjects with clinically significant cardiac conduction defects ; including second degree or third degree atrioventricular ( av ) block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation ; atrial flutter ; an accessory bypass tract ; or any arrhythmia requiring medication,Condition Occurrence,Condition,C0004245,av block,FALSE,FALSE,NA,NA,NA
10,NCT00949884,Exclusion,subjects with clinically significant cardiac conduction defects ; including second degree or third degree atrioventricular ( av ) block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation ; atrial flutter ; an accessory bypass tract ; or any arrhythmia requiring medication,Condition Occurrence,Condition,C0004239;C1963068,atrial flutter,FALSE,FALSE,NA,NA,NA
10,NCT00949884,Exclusion,subjects with clinically significant cardiac conduction defects ; including second degree or third degree atrioventricular ( av ) block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation ; atrial flutter ; an accessory bypass tract ; or any arrhythmia requiring medication,Condition Occurrence,Condition,C0037052;C1963235,sick sinus syndrome,FALSE,FALSE,NA,NA,NA
10,NCT00949884,Exclusion,subjects with clinically significant cardiac conduction defects ; including second degree or third degree atrioventricular ( av ) block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation ; atrial flutter ; an accessory bypass tract ; or any arrhythmia requiring medication,Condition Occurrence,Condition,C0023211,left bundle branch block,FALSE,FALSE,NA,NA,NA
10,NCT00949884,Exclusion,subjects with clinically significant cardiac conduction defects ; including second degree or third degree atrioventricular ( av ) block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation ; atrial flutter ; an accessory bypass tract ; or any arrhythmia requiring medication,Condition Occurrence,Condition,C1185740,tract,FALSE,FALSE,NA,NA,NA
10,NCT00949884,Exclusion,subjects with clinically significant cardiac conduction defects ; including second degree or third degree atrioventricular ( av ) block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation ; atrial flutter ; an accessory bypass tract ; or any arrhythmia requiring medication,Condition Occurrence,Condition,C0003811,arrhythmia,FALSE,FALSE,NA,NA,NA
10,NCT00949884,Exclusion,subjects with clinically significant cardiac conduction defects ; including second degree or third degree atrioventricular ( av ) block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation ; atrial flutter ; an accessory bypass tract ; or any arrhythmia requiring medication,Condition Occurrence,Procedure,C0741847,bypass,FALSE,FALSE,NA,NA,NA
10,NCT00949884,Exclusion,subjects with clinically significant cardiac conduction defects ; including second degree or third degree atrioventricular ( av ) block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation ; atrial flutter ; an accessory bypass tract ; or any arrhythmia requiring medication,Condition Occurrence,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
10,NCT00949884,Exclusion,subjects with clinically significant cardiac conduction defects ; including second degree or third degree atrioventricular ( av ) block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation ; atrial flutter ; an accessory bypass tract ; or any arrhythmia requiring medication,Condition Occurrence,Observation,C0542560,degree,FALSE,FALSE,NA,NA,NA
10,NCT00949884,Exclusion,subjects with clinically significant cardiac conduction defects ; including second degree or third degree atrioventricular ( av ) block ; left bundle branch block ; sick sinus syndrome ; atrial fibrillation ; atrial flutter ; an accessory bypass tract ; or any arrhythmia requiring medication,Condition Occurrence,Other,C0004238;C1963067;C2926591,atrial fibrillation,FALSE,FALSE,NA,NA,NA
1,NCT00956644,Inclusion,established essential hypertension,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00956644,Inclusion,treated with amlodipine 5 mg monotherapy for at least 4 weeks,Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,greater_equal 4 weeks,NA,equal 5 mg
3,NCT00956644,Inclusion,with uncontrolled bp defined as mean sbp = or > 145 mmhg assessed by obpm,Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,NA,NA
3,NCT00956644,Inclusion,with uncontrolled bp defined as mean sbp = or > 145 mmhg assessed by obpm,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 145 mmhg,NA
3,NCT00956644,Inclusion,with uncontrolled bp defined as mean sbp = or > 145 mmhg assessed by obpm,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
4,NCT00956644,Inclusion,signed written inform consent obtained prior to inclusion in the study,Other,Other,C1519316,signed,FALSE,FALSE,NA,NA,NA
5,NCT00956644,Inclusion,randomisation criteria :,Other,NA,NA,NA,NA,NA,NA,NA,NA
6,NCT00956644,Inclusion,mean sbp = or > 135 mmhg assessed by hbpm,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 135 mmhg,NA
7,NCT00956644,Inclusion,good compliance with the hbpm protocol defined as at least 12 correct measurements performed over the last 6 days of the first period of measurements,Observation,Other,C3539106,defined,FALSE,FALSE,greater 6 last days,greater_equal 12 correct measurements,NA
8,NCT00956644,Inclusion,creatinine clearance = or > 30 ml / min ; determined by cockroft formula,Observation,Observation,C0373595;C0812399,creatinine clearance,FALSE,FALSE,NA,greater_equal 30 ml/min,NA
8,NCT00956644,Inclusion,creatinine clearance = or > 30 ml / min ; determined by cockroft formula,Observation,Other,C1705501;C0489829,formula,FALSE,FALSE,NA,NA,NA
9,NCT00956644,Exclusion,mean sbp = or > 180 mm hg or mean dbp = or > 110 mm hg measured at doctor office at visit 1,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 180 mm hg,NA
9,NCT00956644,Exclusion,mean sbp = or > 180 mm hg or mean dbp = or > 110 mm hg measured at doctor office at visit 1,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 110 mm hg,NA
9,NCT00956644,Exclusion,mean sbp = or > 180 mm hg or mean dbp = or > 110 mm hg measured at doctor office at visit 1,Observation,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
10,NCT00956644,Exclusion,known or suspected causes of secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
11,NCT00956644,Exclusion,patients with bilateral artery stenosis ; renal artery stenosis in a solitary kidney ; renal transplant or only one functioning kidney,Condition Occurrence,Condition,C0038449,artery stenosis,FALSE,FALSE,NA,NA,NA
11,NCT00956644,Exclusion,patients with bilateral artery stenosis ; renal artery stenosis in a solitary kidney ; renal transplant or only one functioning kidney,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
11,NCT00956644,Exclusion,patients with bilateral artery stenosis ; renal artery stenosis in a solitary kidney ; renal transplant or only one functioning kidney,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
11,NCT00956644,Exclusion,patients with bilateral artery stenosis ; renal artery stenosis in a solitary kidney ; renal transplant or only one functioning kidney,Condition Occurrence,Procedure,C0022671,renal transplant,FALSE,FALSE,NA,NA,NA
11,NCT00956644,Exclusion,patients with bilateral artery stenosis ; renal artery stenosis in a solitary kidney ; renal transplant or only one functioning kidney,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
12,NCT00956644,Exclusion,know contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination or history of angioedema related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
12,NCT00956644,Exclusion,know contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination or history of angioedema related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Condition,C0445223,related,FALSE,FALSE,NA,NA,NA
12,NCT00956644,Exclusion,know contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination or history of angioedema related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,NA
12,NCT00956644,Exclusion,know contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination or history of angioedema related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Drug,C0288171,irbesartan,FALSE,FALSE,NA,NA,NA
12,NCT00956644,Exclusion,know contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination or history of angioedema related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Drug,C0521942,angiotensin ii receptor antagonist,FALSE,FALSE,NA,NA,NA
12,NCT00956644,Exclusion,know contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination or history of angioedema related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
12,NCT00956644,Exclusion,know contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination or history of angioedema related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
13,NCT00956644,Exclusion,known type 1 diabetes,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
14,NCT00956644,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history or hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Condition,C0948807,hepatic impairment,FALSE,FALSE,NA,NA,NA
14,NCT00956644,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history or hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Condition,C0019151,hepatic encephalopathy,FALSE,FALSE,NA,NA,NA
14,NCT00956644,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history or hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Condition,C0014867,esophageal varices,FALSE,FALSE,NA,NA,NA
14,NCT00956644,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history or hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Procedure,C0032716,portocaval shunt,FALSE,FALSE,NA,NA,NA
14,NCT00956644,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history or hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Observation,C0001899;C0201836,alanine aminotransferase,FALSE,FALSE,NA,NA,NA
14,NCT00956644,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history or hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Observation,C1140170;C2257651,alt,FALSE,FALSE,NA,NA,NA
14,NCT00956644,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history or hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Observation,C0004002;C0201899,aspartate aminotransferase,FALSE,FALSE,NA,NA,NA
14,NCT00956644,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history or hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Observation,C0004002,ast,FALSE,FALSE,NA,NA,greater 5 times the upper limit of normal
14,NCT00956644,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history or hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
15,NCT00956644,Exclusion,known severe renal impairment ( creatinine clearance < 30 ml / mn ),Drug Exposure,Condition,C1565489;C0035078,renal impairment,FALSE,FALSE,NA,NA,NA
15,NCT00956644,Exclusion,known severe renal impairment ( creatinine clearance < 30 ml / mn ),Drug Exposure,Drug,C2348271,mn,FALSE,FALSE,NA,NA,NA
15,NCT00956644,Exclusion,known severe renal impairment ( creatinine clearance < 30 ml / mn ),Drug Exposure,Observation,C0373595;C0812399,creatinine clearance,FALSE,FALSE,NA,NA,lower 30 ml
15,NCT00956644,Exclusion,known severe renal impairment ( creatinine clearance < 30 ml / mn ),Drug Exposure,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
16,NCT00956644,Exclusion,concomitant use of any other antihypertensive treatment,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
17,NCT00956644,Exclusion,administration of any other investigational drug within 30 days before inclusion,Drug Exposure,Drug,C0013230,investigational drug,FALSE,FALSE,lower 30 days,NA,NA
18,NCT00956644,Exclusion,inability to obtain a valid automatic bp measurement recording,Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,NA,NA
19,NCT00956644,Exclusion,presence of any severe medical condition or psychological condition that ; in the opinion of the investigator ; indicate that participation in the study is not in the best interest of the patient,Condition Occurrence,Condition,C1306597,psychological,FALSE,FALSE,NA,NA,NA
19,NCT00956644,Exclusion,presence of any severe medical condition or psychological condition that ; in the opinion of the investigator ; indicate that participation in the study is not in the best interest of the patient,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
19,NCT00956644,Exclusion,presence of any severe medical condition or psychological condition that ; in the opinion of the investigator ; indicate that participation in the study is not in the best interest of the patient,Condition Occurrence,Other,C1561579;C1561578,medical,FALSE,FALSE,NA,NA,NA
20,NCT00956644,Exclusion,presence of any other conditions ( eg : geographical ; social ; etc ) that would restrict or limit the patient participation for the duration of the study,Procedure,Procedure,C0030699,patient participation,FALSE,FALSE,NA,NA,NA
21,NCT00956644,Exclusion,pregnant or breast feeding women,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
21,NCT00956644,Exclusion,pregnant or breast feeding women,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
21,NCT00956644,Exclusion,pregnant or breast feeding women,Condition Occurrence,Condition,C0006147;C1623040;C1623041,breast feeding,FALSE,FALSE,NA,NA,NA
22,NCT00956644,Exclusion,women of childbearing potential unable or unwilling to use an acceptable method to avoid pregnancy for the entire study period,Observation,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
22,NCT00956644,Exclusion,women of childbearing potential unable or unwilling to use an acceptable method to avoid pregnancy for the entire study period,Observation,Observation,C3831118,childbearing potential,FALSE,FALSE,NA,NA,NA
22,NCT00956644,Exclusion,women of childbearing potential unable or unwilling to use an acceptable method to avoid pregnancy for the entire study period,Observation,Other,C2827714;C0871511;C2828387,method,FALSE,FALSE,NA,NA,NA
22,NCT00956644,Exclusion,women of childbearing potential unable or unwilling to use an acceptable method to avoid pregnancy for the entire study period,Observation,Other,C0032961;C3484365,pregnancy,FALSE,FALSE,NA,NA,NA
23,NCT00956644,Exclusion,the above information is not intended to contain all considerations relevant to a patient potential participation in a clinical trial,Other,Other,C1096775,clinical trial,FALSE,FALSE,NA,NA,NA
1,NCT00957554,Inclusion,established essential hypertension,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
2,NCT00957554,Inclusion,treated with irbesartan 150 mg monotherapy for at least 4 weeks,Drug Exposure,Drug,C0288171,irbesartan,FALSE,FALSE,greater_equal 4 weeks,NA,equal 150 mg
3,NCT00957554,Inclusion,with uncontrolled bp defined as mean sbp = or > 145 mmhg assessed by obpm,Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,NA,NA
3,NCT00957554,Inclusion,with uncontrolled bp defined as mean sbp = or > 145 mmhg assessed by obpm,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 145 mmhg,NA
3,NCT00957554,Inclusion,with uncontrolled bp defined as mean sbp = or > 145 mmhg assessed by obpm,Observation,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
4,NCT00957554,Inclusion,signed written inform consent obtained prior to inclusion in the study,Other,Other,C1519316,signed,FALSE,FALSE,NA,NA,NA
5,NCT00957554,Inclusion,randomisation criteria :,Other,NA,NA,NA,NA,NA,NA,NA,NA
6,NCT00957554,Inclusion,mean sbp = or > 135 mmhg assessed by hbpm,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 135 mmhg,NA
7,NCT00957554,Inclusion,good compliance with the hbpm protocol defined as at least 12 correct measurements performed over the last 6 days of the first period of measurements,Observation,Other,C3539106,defined,FALSE,FALSE,greater 6 last days,greater_equal 12 correct measurements,NA
8,NCT00957554,Inclusion,creatinine clearance = or > 30 ml / min determined ny cockroft formula,Observation,Observation,C0373595;C0812399,creatinine clearance,FALSE,FALSE,NA,greater_equal 30 ml/min,NA
8,NCT00957554,Inclusion,creatinine clearance = or > 30 ml / min determined ny cockroft formula,Observation,Other,C1879958,ny,FALSE,FALSE,NA,NA,NA
8,NCT00957554,Inclusion,creatinine clearance = or > 30 ml / min determined ny cockroft formula,Observation,Other,C1705501;C0489829,formula,FALSE,FALSE,NA,NA,NA
9,NCT00957554,Exclusion,mean sbp = or > 180 mmhg or mean dbp = or > 110 mmhg measured at doctor office at visit 1,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,greater_equal 180 mmhg,NA
9,NCT00957554,Exclusion,mean sbp = or > 180 mmhg or mean dbp = or > 110 mmhg measured at doctor office at visit 1,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 110 mmhg,NA
9,NCT00957554,Exclusion,mean sbp = or > 180 mmhg or mean dbp = or > 110 mmhg measured at doctor office at visit 1,Observation,Observation,C3541902,measured,FALSE,FALSE,NA,NA,NA
10,NCT00957554,Exclusion,known or suspected causes of secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
11,NCT00957554,Exclusion,patients with bilateral artery stenosis ; renal artery stenosis in a solitary kidney ; renal transplant or only has one functioning kidney,Condition Occurrence,Condition,C0038449,artery stenosis,FALSE,FALSE,NA,NA,NA
11,NCT00957554,Exclusion,patients with bilateral artery stenosis ; renal artery stenosis in a solitary kidney ; renal transplant or only has one functioning kidney,Condition Occurrence,Condition,C0035067,renal artery stenosis,FALSE,FALSE,NA,NA,NA
11,NCT00957554,Exclusion,patients with bilateral artery stenosis ; renal artery stenosis in a solitary kidney ; renal transplant or only has one functioning kidney,Condition Occurrence,Condition,C0266294,solitary kidney,FALSE,FALSE,NA,NA,NA
11,NCT00957554,Exclusion,patients with bilateral artery stenosis ; renal artery stenosis in a solitary kidney ; renal transplant or only has one functioning kidney,Condition Occurrence,Procedure,C0022671,renal transplant,FALSE,FALSE,NA,NA,NA
11,NCT00957554,Exclusion,patients with bilateral artery stenosis ; renal artery stenosis in a solitary kidney ; renal transplant or only has one functioning kidney,Condition Occurrence,Other,C0496892;C0496927;C0869841;C0022646;C0812426;C1278978,kidney,FALSE,FALSE,NA,NA,NA
12,NCT00957554,Exclusion,know contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination or history of angioedema related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Condition,C0002994,angioedema,FALSE,FALSE,NA,NA,NA
12,NCT00957554,Exclusion,know contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination or history of angioedema related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Condition,C0445223,related,FALSE,FALSE,NA,NA,NA
12,NCT00957554,Exclusion,know contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination or history of angioedema related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Drug,C0051696,amlodipine,FALSE,FALSE,NA,NA,NA
12,NCT00957554,Exclusion,know contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination or history of angioedema related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Drug,C0288171,irbesartan,FALSE,FALSE,NA,NA,NA
12,NCT00957554,Exclusion,know contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination or history of angioedema related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Drug,C0521942,angiotensin ii receptor antagonist,FALSE,FALSE,NA,NA,NA
12,NCT00957554,Exclusion,know contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination or history of angioedema related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Procedure,C3687832,drugs,FALSE,FALSE,NA,NA,NA
12,NCT00957554,Exclusion,know contraindications or hypersensitivity to either amlodipine or irbesartan or to the combination or history of angioedema related to the administration of an angiotensin ii receptor antagonist or any combination of the drugs used,Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
13,NCT00957554,Exclusion,know type 1 diabetes,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
14,NCT00957554,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history of hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Condition,C0948807,hepatic impairment,FALSE,FALSE,NA,NA,NA
14,NCT00957554,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history of hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Condition,C0019151,hepatic encephalopathy,FALSE,FALSE,NA,NA,NA
14,NCT00957554,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history of hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Condition,C0014867,esophageal varices,FALSE,FALSE,NA,NA,NA
14,NCT00957554,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history of hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Procedure,C0032716,portocaval shunt,FALSE,FALSE,NA,NA,NA
14,NCT00957554,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history of hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Observation,C0001899;C0201836,alanine aminotransferase,FALSE,FALSE,NA,NA,NA
14,NCT00957554,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history of hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Observation,C1140170;C2257651,alt,FALSE,FALSE,NA,NA,NA
14,NCT00957554,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history of hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Observation,C0004002;C0201899,aspartate aminotransferase,FALSE,FALSE,NA,NA,NA
14,NCT00957554,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history of hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Observation,C0004002,ast,FALSE,FALSE,NA,NA,greater 5 times the upper limit of normal
14,NCT00957554,Exclusion,know severe hepatic impairment alanine aminotransferase ( alt ) or aspartate aminotransferase ( ast ) > 5 times the upper limit of normal or history of hepatic encephalopathy ; esophageal varices ; or portocaval shunt,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
15,NCT00957554,Exclusion,know severe renal impairment ( creatinine clearance < 30 ml / mn ),Drug Exposure,Condition,C1565489;C0035078,renal impairment,FALSE,FALSE,NA,NA,NA
15,NCT00957554,Exclusion,know severe renal impairment ( creatinine clearance < 30 ml / mn ),Drug Exposure,Drug,C2348271,mn,FALSE,FALSE,NA,NA,NA
15,NCT00957554,Exclusion,know severe renal impairment ( creatinine clearance < 30 ml / mn ),Drug Exposure,Observation,C0373595;C0812399,creatinine clearance,FALSE,FALSE,NA,NA,lower 30 ml
15,NCT00957554,Exclusion,know severe renal impairment ( creatinine clearance < 30 ml / mn ),Drug Exposure,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
16,NCT00957554,Exclusion,concomitant use of any other antihypertensive treatment,Drug Exposure,Drug,C0003364,antihypertensive,FALSE,FALSE,NA,NA,NA
17,NCT00957554,Exclusion,administration of any other investigational drug within 30 days before inclusion,Drug Exposure,Drug,C0013230,investigational drug,FALSE,FALSE,lower 30 days,NA,NA
18,NCT00957554,Exclusion,inability to obtain a valid automatic bp measurement recording,Observation,Observation,C0005824;C0005823,bp,FALSE,FALSE,NA,NA,NA
19,NCT00957554,Exclusion,presence of any severe medical condition or psychological condition that ; in the opinion of the investigator ; indicate that participation in the study is not in the best interest of of the patient,Condition Occurrence,Condition,C1306597,psychological,FALSE,FALSE,NA,NA,NA
19,NCT00957554,Exclusion,presence of any severe medical condition or psychological condition that ; in the opinion of the investigator ; indicate that participation in the study is not in the best interest of of the patient,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
19,NCT00957554,Exclusion,presence of any severe medical condition or psychological condition that ; in the opinion of the investigator ; indicate that participation in the study is not in the best interest of of the patient,Condition Occurrence,Other,C1561579;C1561578,medical,FALSE,FALSE,NA,NA,NA
20,NCT00957554,Exclusion,presence of any other conditions ( eg : geographical ; social ; etc ) that would restrict or limit the patient participation for the duration of the study,Procedure,Procedure,C0030699,patient participation,FALSE,FALSE,NA,NA,NA
21,NCT00957554,Exclusion,pregnant or breast feeding women,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
21,NCT00957554,Exclusion,pregnant or breast feeding women,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
21,NCT00957554,Exclusion,pregnant or breast feeding women,Condition Occurrence,Condition,C0006147;C1623040;C1623041,breast feeding,FALSE,FALSE,NA,NA,NA
22,NCT00957554,Exclusion,women of childbearing potential unable or unwilling to use an acceptable method to avoid pregnancy for the entire study period,Observation,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
22,NCT00957554,Exclusion,women of childbearing potential unable or unwilling to use an acceptable method to avoid pregnancy for the entire study period,Observation,Observation,C3831118,childbearing potential,FALSE,FALSE,NA,NA,NA
22,NCT00957554,Exclusion,women of childbearing potential unable or unwilling to use an acceptable method to avoid pregnancy for the entire study period,Observation,Other,C2827714;C0871511;C2828387,method,FALSE,FALSE,NA,NA,NA
22,NCT00957554,Exclusion,women of childbearing potential unable or unwilling to use an acceptable method to avoid pregnancy for the entire study period,Observation,Other,C0032961;C3484365,pregnancy,FALSE,FALSE,NA,NA,NA
23,NCT00957554,Exclusion,the above information is not intended to contain all considerations relevant to a patient potential participation in a clinical trial,Other,Other,C1096775,clinical trial,FALSE,FALSE,NA,NA,NA
1,NCT01237223,Inclusion,patients with essential hypertension ( msdbp > = 95 mmhg and < 110 mmhg and mssbp > = 140 mmhg ),Observation,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,greater_equal 95 mmhg; lower 110 mmhg; greater_equal 140 mmhg,NA
2,NCT01237223,Inclusion,outpatients,Other,NA,NA,NA,NA,NA,NA,NA,NA
3,NCT01237223,Exclusion,severe hypertension ( msdbp > = 110 mmhg or mssbp > = 180 mmhg ),Observation,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,greater_equal 110 mmhg; greater_equal 180 mmhg,NA
3,NCT01237223,Exclusion,severe hypertension ( msdbp > = 110 mmhg or mssbp > = 180 mmhg ),Observation,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
4,NCT01237223,Exclusion,history of allergy or hypersensitivity to renin inhibitors ; calcium channel blockers,Drug Exposure,Condition,C2917241,renin inhibitors,FALSE,FALSE,NA,NA,NA
4,NCT01237223,Exclusion,history of allergy or hypersensitivity to renin inhibitors ; calcium channel blockers,Drug Exposure,Drug,C0006684,calcium channel blockers,FALSE,FALSE,NA,NA,NA
4,NCT01237223,Exclusion,history of allergy or hypersensitivity to renin inhibitors ; calcium channel blockers,Drug Exposure,Observation,C0020517;C0520946,hypersensitivity,FALSE,FALSE,NA,NA,NA
4,NCT01237223,Exclusion,history of allergy or hypersensitivity to renin inhibitors ; calcium channel blockers,Drug Exposure,Other,C0489531;C0718579;C3542994;C3539909;C1314973;C1547315;C1611280,allergy,FALSE,FALSE,NA,NA,NA
5,NCT01237223,Exclusion,history or evidence of a secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
6,NCT01237223,Exclusion,other protocol-defined inclusiopplied,Other,Other,C3539106,defined,FALSE,FALSE,NA,NA,NA
1,NCT01508026,Inclusion,male or female outpatients of age 18 years or above,Person,Person,C0025266;C1706429,male,FALSE,FALSE,NA,NA,NA
1,NCT01508026,Inclusion,male or female outpatients of age 18 years or above,Person,Person,C0086287,female,FALSE,FALSE,NA,NA,NA
1,NCT01508026,Inclusion,male or female outpatients of age 18 years or above,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 18 years,NA,NA
2,NCT01508026,Inclusion,patients diagnosed with stage 1 or stage 2 essential hypertension,Condition Occurrence,Condition,C0085580,essential hypertension,FALSE,FALSE,NA,NA,NA
3,NCT01508026,Inclusion,normal physical examination findings ; electrocardiogram ( ecg ) results and chest x-ray,Observation,Condition,C0013798,electrocardiogram,FALSE,FALSE,NA,NA,NA
3,NCT01508026,Inclusion,normal physical examination findings ; electrocardiogram ( ecg ) results and chest x-ray,Observation,Procedure,C0031809,physical examination,FALSE,FALSE,NA,NA,NA
3,NCT01508026,Inclusion,normal physical examination findings ; electrocardiogram ( ecg ) results and chest x-ray,Observation,Observation,C0039985;C1114557;C3665494,chest x-ray,FALSE,FALSE,NA,NA,NA
3,NCT01508026,Inclusion,normal physical examination findings ; electrocardiogram ( ecg ) results and chest x-ray,Observation,Other,C2926606;C3539655,findings,FALSE,FALSE,NA,NA,NA
3,NCT01508026,Inclusion,normal physical examination findings ; electrocardiogram ( ecg ) results and chest x-ray,Observation,Other,C1623258;C0018064,ecg,FALSE,FALSE,NA,NA,NA
4,NCT01508026,Inclusion,or abnormal findings judged by the investigator to be not clinically significant,Other,Other,C2699333,abnormal,FALSE,FALSE,NA,NA,NA
4,NCT01508026,Inclusion,or abnormal findings judged by the investigator to be not clinically significant,Other,Other,C2926606;C3539655,findings,FALSE,FALSE,NA,NA,NA
5,NCT01508026,Exclusion,secondary hypertension or severe hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
5,NCT01508026,Exclusion,secondary hypertension or severe hypertension,Condition Occurrence,Observation,C0020538;C1963138,hypertension,FALSE,FALSE,NA,NA,NA
5,NCT01508026,Exclusion,secondary hypertension or severe hypertension,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
6,NCT01508026,Exclusion,clinically significant cardiovascular disease or heart failure,Condition Occurrence,Condition,C0007222,cardiovascular disease,FALSE,FALSE,NA,NA,NA
6,NCT01508026,Exclusion,clinically significant cardiovascular disease or heart failure,Condition Occurrence,Condition,C0018801;C0018802,heart failure,FALSE,FALSE,NA,NA,NA
7,NCT01508026,Exclusion,clinical significant respiratory disease that would prohibit the use of a beta blocker,Drug Exposure,Condition,C0035242;C0035204,respiratory disease,FALSE,FALSE,NA,NA,NA
7,NCT01508026,Exclusion,clinical significant respiratory disease that would prohibit the use of a beta blocker,Drug Exposure,Drug,C0138547,prohibit,FALSE,FALSE,NA,NA,NA
7,NCT01508026,Exclusion,clinical significant respiratory disease that would prohibit the use of a beta blocker,Drug Exposure,Drug,C0001645,beta blocker,FALSE,FALSE,NA,NA,NA
7,NCT01508026,Exclusion,clinical significant respiratory disease that would prohibit the use of a beta blocker,Drug Exposure,Other,C3272565;C1555900;C1608518;C1611832,clinical,FALSE,FALSE,NA,NA,NA
8,NCT01508026,Exclusion,a medical contraindication to discontinuing a current antihypertensive therapy,Condition Occurrence,Condition,C1301624,medical contraindication,FALSE,FALSE,NA,NA,NA
8,NCT01508026,Exclusion,a medical contraindication to discontinuing a current antihypertensive therapy,Condition Occurrence,Procedure,C0585941,antihypertensive therapy,FALSE,FALSE,NA,NA,NA
9,NCT01508026,Exclusion,history of type 1 diabetes mellitus,Condition Occurrence,Condition,C0011854,type 1 diabetes,FALSE,FALSE,NA,NA,NA
10,NCT01508026,Exclusion,history of severe mental illness except mild depression,Condition Occurrence,Condition,C0004936;C0455498,mental illness,FALSE,FALSE,NA,NA,NA
10,NCT01508026,Exclusion,history of severe mental illness except mild depression,Condition Occurrence,Condition,C0588006,mild depression,TRUE,FALSE,NA,NA,NA
10,NCT01508026,Exclusion,history of severe mental illness except mild depression,Condition Occurrence,Other,C1547231;C1547227;C1561581,severe,FALSE,FALSE,NA,NA,NA
1,NCT01975246,Inclusion,essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs and mean seated diastolic blood pressure ( dbp ) must be > = 90 and < = 114 mmhg and mean seated systolic blood pressure ( sbp ) must be = < 200 mmhg,Observation,Condition,C0857121,hypertensive,FALSE,FALSE,NA,equal 2,NA
1,NCT01975246,Inclusion,essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs and mean seated diastolic blood pressure ( dbp ) must be > = 90 and < = 114 mmhg and mean seated systolic blood pressure ( sbp ) must be = < 200 mmhg,Observation,Drug,C0003364,antihypertensive drugs,FALSE,FALSE,NA,equal 3,NA
1,NCT01975246,Inclusion,essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs and mean seated diastolic blood pressure ( dbp ) must be > = 90 and < = 114 mmhg and mean seated systolic blood pressure ( sbp ) must be = < 200 mmhg,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,NA,NA
1,NCT01975246,Inclusion,essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs and mean seated diastolic blood pressure ( dbp ) must be > = 90 and < = 114 mmhg and mean seated systolic blood pressure ( sbp ) must be = < 200 mmhg,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 90 mmhg; lower_equal 114 mmhg,NA
1,NCT01975246,Inclusion,essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs and mean seated diastolic blood pressure ( dbp ) must be > = 90 and < = 114 mmhg and mean seated systolic blood pressure ( sbp ) must be = < 200 mmhg,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,NA,NA
1,NCT01975246,Inclusion,essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs and mean seated diastolic blood pressure ( dbp ) must be > = 90 and < = 114 mmhg and mean seated systolic blood pressure ( sbp ) must be = < 200 mmhg,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,lower_equal 200 mmhg,NA
2,NCT01975246,Inclusion,able to stop all current antihypertensive drugs ( other than study medication ) from visit 1 b through the end of the trial without risk to the patient based on the investigator opinion,Drug Exposure,Drug,C0723457,stop,FALSE,FALSE,NA,NA,NA
2,NCT01975246,Inclusion,able to stop all current antihypertensive drugs ( other than study medication ) from visit 1 b through the end of the trial without risk to the patient based on the investigator opinion,Drug Exposure,Drug,C0003364,antihypertensive drugs,FALSE,FALSE,NA,NA,NA
3,NCT01975246,Inclusion,age 20 years or older,Person,Person,C0001779,age,FALSE,FALSE,greater_equal 20 years,NA,NA
4,NCT01975246,Exclusion,patients with known or suspected secondary hypertension,Condition Occurrence,Condition,C0155616,secondary hypertension,FALSE,FALSE,NA,NA,NA
5,NCT01975246,Exclusion,patients with clinically relevant cardiac arrhythmia,Condition Occurrence,Condition,C0003811;C1560249,cardiac arrhythmia,FALSE,FALSE,NA,NA,NA
6,NCT01975246,Exclusion,congestive heart failure with new york heart association ( nyha ) functional class iii - class iv,Condition Occurrence,Condition,C0018802,congestive heart failure,FALSE,FALSE,NA,NA,NA
6,NCT01975246,Exclusion,congestive heart failure with new york heart association ( nyha ) functional class iii - class iv,Condition Occurrence,Condition,C0018787;C0153500;C0153957;C0795691;C1281570,heart,FALSE,FALSE,NA,NA,NA
6,NCT01975246,Exclusion,congestive heart failure with new york heart association ( nyha ) functional class iii - class iv,Condition Occurrence,Other,C0441887;C2698969,class iii,FALSE,FALSE,NA,NA,NA
6,NCT01975246,Exclusion,congestive heart failure with new york heart association ( nyha ) functional class iii - class iv,Condition Occurrence,Other,C0441888;C2698970,class iv,FALSE,FALSE,NA,NA,NA
7,NCT01975246,Exclusion,patients with recent cardiovascular events,Condition Occurrence,Condition,C1320716,cardiovascular events,FALSE,FALSE,NA,NA,NA
8,NCT01975246,Exclusion,patients with recent stroke events,Other,NA,NA,NA,NA,NA,NA,NA,NA
9,NCT01975246,Exclusion,patients with a history of sudden deterioration of renal function with angiotensin ii receptor blockers or angiotensin converting enzyme inhibitors,Drug Exposure,Drug,C0003015,angiotensin converting enzyme inhibitors,FALSE,FALSE,NA,NA,NA
9,NCT01975246,Exclusion,patients with a history of sudden deterioration of renal function with angiotensin ii receptor blockers or angiotensin converting enzyme inhibitors,Drug Exposure,Other,C0232804;C0022662,renal function,FALSE,FALSE,NA,NA,NA
9,NCT01975246,Exclusion,patients with a history of sudden deterioration of renal function with angiotensin ii receptor blockers or angiotensin converting enzyme inhibitors,Drug Exposure,Other,C2757003;C0521942,angiotensin ii receptor blockers,FALSE,FALSE,NA,NA,NA
10,NCT01975246,Exclusion,or patients with post-renal transplant or post-nephrectomy,Condition Occurrence,Condition,C0478647,transplant,FALSE,FALSE,NA,NA,NA
10,NCT01975246,Exclusion,or patients with post-renal transplant or post-nephrectomy,Condition Occurrence,Procedure,C0027695;C0176996,nephrectomy,FALSE,FALSE,NA,NA,NA
11,NCT01975246,Exclusion,patients with hepatic dysfunction or renal dysfunction,Condition Occurrence,Condition,C0086565,hepatic dysfunction,FALSE,FALSE,NA,NA,NA
11,NCT01975246,Exclusion,patients with hepatic dysfunction or renal dysfunction,Condition Occurrence,Condition,C3279454,renal dysfunction,FALSE,FALSE,NA,NA,NA
12,NCT01975246,Exclusion,pre-menopausal women who are nursing or pregnant,Condition Occurrence,Person,C0086287,women,FALSE,FALSE,NA,NA,NA
12,NCT01975246,Exclusion,pre-menopausal women who are nursing or pregnant,Condition Occurrence,Condition,C1096235,pre-menopausal,FALSE,FALSE,NA,NA,NA
12,NCT01975246,Exclusion,pre-menopausal women who are nursing or pregnant,Condition Occurrence,Condition,C0006147,nursing,FALSE,FALSE,NA,NA,NA
12,NCT01975246,Exclusion,pre-menopausal women who are nursing or pregnant,Condition Occurrence,Condition,C0549206,pregnant,FALSE,FALSE,NA,NA,NA
1,NCT02269176,Inclusion,mild to moderate primary hypertension ; the mean sitting valley value of diastolic blood pressure ( dbp ) > = 95 and < 110 mmhg ; and the mean sitting valley value of systolic blood pressure ( sbp ) < 180 mmhg,Observation,Condition,C0085580,primary hypertension,FALSE,FALSE,NA,NA,NA
1,NCT02269176,Inclusion,mild to moderate primary hypertension ; the mean sitting valley value of diastolic blood pressure ( dbp ) > = 95 and < 110 mmhg ; and the mean sitting valley value of systolic blood pressure ( sbp ) < 180 mmhg,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
1,NCT02269176,Inclusion,mild to moderate primary hypertension ; the mean sitting valley value of diastolic blood pressure ( dbp ) > = 95 and < 110 mmhg ; and the mean sitting valley value of systolic blood pressure ( sbp ) < 180 mmhg,Observation,Condition,C0277814;C2584297,sitting,FALSE,FALSE,NA,NA,NA
1,NCT02269176,Inclusion,mild to moderate primary hypertension ; the mean sitting valley value of diastolic blood pressure ( dbp ) > = 95 and < 110 mmhg ; and the mean sitting valley value of systolic blood pressure ( sbp ) < 180 mmhg,Observation,Observation,C0428883;C1305849;C0488052,diastolic blood pressure,FALSE,FALSE,NA,NA,NA
1,NCT02269176,Inclusion,mild to moderate primary hypertension ; the mean sitting valley value of diastolic blood pressure ( dbp ) > = 95 and < 110 mmhg ; and the mean sitting valley value of systolic blood pressure ( sbp ) < 180 mmhg,Observation,Observation,C1305849,dbp,FALSE,FALSE,NA,greater_equal 95 mmhg; lower 110 mmhg,NA
1,NCT02269176,Inclusion,mild to moderate primary hypertension ; the mean sitting valley value of diastolic blood pressure ( dbp ) > = 95 and < 110 mmhg ; and the mean sitting valley value of systolic blood pressure ( sbp ) < 180 mmhg,Observation,Observation,C0871470;C1306620;C0488055,systolic blood pressure,FALSE,FALSE,NA,NA,NA
1,NCT02269176,Inclusion,mild to moderate primary hypertension ; the mean sitting valley value of diastolic blood pressure ( dbp ) > = 95 and < 110 mmhg ; and the mean sitting valley value of systolic blood pressure ( sbp ) < 180 mmhg,Observation,Observation,C1306620,sbp,FALSE,FALSE,NA,lower 180 mmhg,NA
1,NCT02269176,Inclusion,mild to moderate primary hypertension ; the mean sitting valley value of diastolic blood pressure ( dbp ) > = 95 and < 110 mmhg ; and the mean sitting valley value of systolic blood pressure ( sbp ) < 180 mmhg,Observation,Other,C1547225,mild,FALSE,FALSE,NA,NA,NA
1,NCT02269176,Inclusion,mild to moderate primary hypertension ; the mean sitting valley value of diastolic blood pressure ( dbp ) > = 95 and < 110 mmhg ; and the mean sitting valley value of systolic blood pressure ( sbp ) < 180 mmhg,Observation,Other,C1547226,moderate,FALSE,FALSE,NA,NA,NA
